PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Palosuo, K; Alenius, H; Varjonen, E; Koivuluhta, M; Mikkola, J; Keskinen, H; Kalkkinen, N; Reunala, T				Palosuo, K; Alenius, H; Varjonen, E; Koivuluhta, M; Mikkola, J; Keskinen, H; Kalkkinen, N; Reunala, T			A novel wheat gliadin as a cause of exercise-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						wheat; food hypersensitivity; anaphylaxis; urticaria; IgE antibody; enzyme-linked immunosorbent assay	BAKERS ASTHMA; CELIAC-DISEASE; INDUCED URTICARIA; LATEX ALLERGEN; MAJOR ALLERGEN; FOOD; FLOUR; BINDING; BARLEY; IGE	Background: Food-dependent, exercise-induced anaphylaxis is a severe form of allergy; the reaction is caused by ingestion of a specific food before exercise. This disorder often escapes diagnosis because neither the ingested food nor the exercise alone induces the symptoms. Objective: The aim of the study was to characterize the allergens involved in wheat-dependent, exercise-induced anaphylaxis and to describe the clinical outcome in a series of 18 adult patients. Methods: All 18 patients had experienced recurrent episodes of generalized urticaria during exercise, 17 patients in association with collapse and 15 patients with an anaphylactic reaction. The symptoms appeared only when the patients had eaten food containing wheat before exercise. Wheat allergens were detected by immunoblotting, purified by gel filtration and reversed-phase chromatography, and subjected to N-terminal sequencing. The IgE-binding ability of the purified proteins was studied by ELISA, and their in vivo reactivity was studied by skin prick testing. Results: IgE antibodies from pooled patient sera were bound to 65-kd and 40-kd wheat proteins in immunoblotting, The 65-kd allergen was a previously undescribed wheat protein, showing 61% sequence identity to gamma-gliadin, whereas the 40-kd allergen had 100% identity to alpha-gliadin, In ELISA, all 18 patients showed elevated IgE levels to the novel gamma-like gliadin, and 13 of the patients showed elevated IgE levels to the alpha-gliadin. None of the 54 control subjects with wheat allergy, urticaria, or coeliac disease had IgE antibodies to the gamma-like gliadin. The in vivo reactivity of the gamma-like gliadin was verified by positive skin prick test responses in all of the 15 patients who were tested. During the follow-up on a gluten-free or wheat-free diet, 3 patients experienced reactions after having unknowingly eaten wheat before exercise, but all the other : patients who were adhering to the diet remained symptom-free. Conclusion: This study shows that wheat is a frequent cause of food-dependent, exercise-induced anaphylaxis and suggests that the major allergen is a previously undescribed gamma-like gliadin. For screening of this life-threatening allergy, me recommend skin prick testing with crude gliadin and we recommend a gluten-free diet for treatment.	Univ Hosp Skin & Allerg Dis, Dept Dermatol, FIN-00250 Helsinki, Finland; Univ Helsinki, Dept Dermatol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Finnish Inst Occupat Hlth, Helsinki, Finland	University of Helsinki; University of Helsinki; Finland National Institute for Health & Welfare; Finnish Institute of Occupational Health	Palosuo, K (corresponding author), Univ Hosp Skin & Allerg Dis, Dept Dermatol, Meilahdentie 2, FIN-00250 Helsinki, Finland.		Kalkkinen, Nisse EJ/B-3923-2010	Alenius, Harri/0000-0003-0106-8923				Alenius H, 1996, INT ARCH ALLERGY IMM, V109, P362, DOI 10.1159/000237264; Alenius H, 1996, J IMMUNOL, V156, P1618; ARMENTIA A, 1993, CLIN EXP ALLERGY, V23, P410, DOI 10.1111/j.1365-2222.1993.tb00347.x; ARMENTIA A, 1990, ANN ALLERGY, V65, P149; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; EWEN P, 1996, BRIT MED J, V312, P1074; FRANKEN J, 1994, INT ARCH ALLERGY IMM, V104, P171, DOI 10.1159/000236726; GarciaCasado G, 1996, CLIN EXP ALLERGY, V26, P428, DOI 10.1046/j.1365-2222.1996.d01-326.x; GOMEZ L, 1990, FEBS LETT, V261, P85, DOI 10.1016/0014-5793(90)80642-V; Guinnepain MT, 1996, ANN ALLERG ASTHMA IM, V77, P491, DOI 10.1016/S1081-1206(10)63357-1; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P1101; JUJI F, 1994, ANN ALLERGY, V72, P452; KATSUNUMA T, 1992, ANN ALLERGY, V68, P184; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; KIVITY S, 1988, J ALLERGY CLIN IMMUN, V81, P1155, DOI 10.1016/0091-6749(88)90884-6; KUSHIMOTO H, 1985, ARCH DERMATOL, V121, P355, DOI 10.1001/archderm.121.3.355; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1111/j.1365-2222.1996.tb00537.x; ROMANO A, 1995, ALLERGY, V50, P817, DOI 10.1111/j.1398-9995.1995.tb05055.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SanchezMonge R, 1997, CLIN EXP ALLERGY, V27, P1130, DOI 10.1046/j.1365-2222.1997.1340945.x; Sandiford CP, 1997, CLIN EXP ALLERGY, V27, P1120, DOI 10.1046/j.1365-2222.1997.1310936.x; SAVILAHTI E, 1983, LANCET, V1, P320; Savolainen J, 1997, CLIN EXP ALLERGY, V27, P1111, DOI 10.1046/j.1365-2222.1997.1300937.x; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P479, DOI 10.1016/S0091-6749(85)80021-X; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; Varjonen E, 1997, CLIN EXP ALLERGY, V27, P162, DOI 10.1046/j.1365-2222.1997.d01-481.x; VARJONEN E, 1994, CLIN EXP ALLERGY, V24, P481, DOI 10.1111/j.1365-2222.1994.tb00938.x; Volcheck GW, 1997, MAYO CLIN PROC, V72, P140, DOI 10.4065/72.2.140; WALSH BJ, 1985, J ALLERGY CLIN IMMUN, V76, P23, DOI 10.1016/0091-6749(85)90799-7	33	181	188	0	16	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				912	917		10.1016/S0091-6749(99)70438-0	http://dx.doi.org/10.1016/S0091-6749(99)70438-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329828				2022-12-18	WOS:000080470200029
J	Juniper, EF; Guyatt, GH; Griffith, LE; Ferrie, PJ				Juniper, EF; Guyatt, GH; Griffith, LE; Ferrie, PJ			Interpretation of rhinoconjunctivitis quality of life questionnaire data	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							OF-LIFE; CLINICAL-TRIALS		MCMASTER UNIV,FAC HLTH SCI,DEPT MED,HAMILTON,ON L8N 3Z5,CANADA	McMaster University	Juniper, EF (corresponding author), MCMASTER UNIV,MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,RM 2C11,1200 MAIN ST,HAMILTON,ON L8N 3Z5,CANADA.							JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; JUNIPER EF, UNPUB CAN MED ASS J	5	181	185	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					843	845		10.1016/S0091-6749(96)70135-5	http://dx.doi.org/10.1016/S0091-6749(96)70135-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876562				2022-12-18	WOS:A1996VM66500019
J	Akinbami, LJ; Moorman, JE; Simon, AE; Schoendorf, KC				Akinbami, Lara J.; Moorman, Jeanne E.; Simon, Alan E.; Schoendorf, Kenneth C.			Trends in racial disparities for asthma outcomes among children 0 to 17 years, 2001-2010	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; child; race; disparities; prevalence; emergency room; hospitalization; mortality; epidemiology	CHILDHOOD ASTHMA; MEDICATION USE; CARE	Background: Racial disparities in childhood asthma have been a long-standing target for intervention, especially disparities in hospitalization and mortality. Objectives: Describe trends in racial disparities in asthma outcomes using both traditional population-based rates and at-risk rates (based on the estimated number of children with asthma) to account for prevalence differences between race groups. Methods: Estimates of asthma prevalence and outcomes (emergency department [ED] visits, hospitalizations, and deaths) were calculated from national data for 2001 to 2010 for black and white children. Trends were calculated using weighted loglinear regression, and changes in racial disparities over time were assessed using Joinpoint. Results: Disparities in asthma prevalence between black and white children increased from 2001 to 2010; at the end of this period, black children were twice as likely as white children to have asthma. Population-based rates showed that disparities in asthma outcomes remained stable (ED visits and hospitalizations) or increased (asthma attack prevalence, deaths). In contrast, analysis with at-risk rates, which account for differences in asthma prevalence, showed that disparities in asthma outcomes remained stable (deaths), decreased (ED visits, hospitalizations), or did not exist (asthma attack prevalence). Conclusions: Using at-risk rates to assess racial disparities in asthma outcomes accounts for prevalence differences between black and white children, and adds another perspective to the population-based examination of asthma disparities. An at-risk rate analysis shows that among children with asthma, there is no disparity for asthma attack prevalence and that progress has been made in decreasing disparities in asthma ED visit and hospitalization rates.	[Akinbami, Lara J.; Simon, Alan E.; Schoendorf, Kenneth C.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Infant, Child & Womens Hlth Stat Branch, Hyattsville, MD 20782 USA; [Akinbami, Lara J.; Schoendorf, Kenneth C.] US PHS, Rockville, MD USA; [Moorman, Jeanne E.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); United States Public Health Service; Centers for Disease Control & Prevention - USA	Akinbami, LJ (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Infant, Child & Womens Hlth Stat Branch, 3311 Toledo Rd, Hyattsville, MD 20782 USA.	lea8@cdc.gov		Akinbami, Lara/0000-0001-6876-6262	Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Agency for Healthcare Research and Quality, 2013, AHRQ PUBL; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Bai Y, 2007, J HEALTH CARE POOR U, V18, P54, DOI 10.1353/hpu.2007.0001; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Crocker D, 2009, CHEST, V136, P1063, DOI 10.1378/chest.09-0013; Division of Cancer Control and Population Sciences SRPaArP, 2013, HLTH DISP CALC VERS; Division of Health Care Statistics NCHS, 2013, AMB HLTH CAR DAT QUE; Division of Health Care Statistics NCHS, 2012, 2010 NHAMCS MICR FIL; Division of Health Care Statistics NCHS, 2013, NAT HOSP DISCH SURV; Federico MJ, 2005, CHEST, V127, P571, DOI 10.1378/chest.127.2.571; Finkelstein JA, 2002, ARCH PEDIAT ADOL MED, V156, P562, DOI 10.1001/archpedi.156.6.562; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Halterman JS, 2001, AMBUL PEDIATR, V1, P275, DOI 10.1367/1539-4409(2001)001<0275:MUAHCC>2.0.CO;2; Harper S, 2008, AM J EPIDEMIOL, V167, P889, DOI 10.1093/aje/kwn016; Joseph CLM, 2006, J ALLERGY CLIN IMMUN, V117, P233, DOI 10.1016/j.jaci.2005.11.004; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Kim HJ, 2004, BIOMETRICS, V60, P1005, DOI 10.1111/j.0006-341X.2004.00256.x; Kit BK, 2012, PEDIATRICS, V129, P62, DOI 10.1542/peds.2011-1513; Kopel SJ, 2010, BIOL PSYCHOL, V84, P135, DOI 10.1016/j.biopsycho.2009.11.007; Kozak L J, 1995, Adv Data, P1; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; McConnochie KM, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e75; Murphy SL, 2013, 614 NAT CTR HLTH STA; National Cancer Institute, 2010, JOINP REGR PROGR; National Cancer Institute, 2013, JOINP DOC AV ANN PER; National Center for Health Statistics, 2013, 2012 NAT HLTH INT SU; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287, DOI 10.1001/archpedi.154.3.287; President's Task Force on Environmental Health Risks and Safety Risks to Children, 2012, COORD FED ACT PLAN R; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P654, DOI 10.1016/j.jaci.2014.01.012; U.S. Department of Health and Human Services, 2011, HHS ACT PLAN RED RAC; US Department of Health & Human Services, 2011, NAT STAK STRAT ACH H; Williams DR, 2009, PEDIATRICS, V123, pS174, DOI 10.1542/peds.2008-2233H; Yoos HL, 2003, J ASTHMA, V40, P27, DOI 10.1081/JAS-120017204	34	180	180	2	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					547	+		10.1016/j.jaci.2014.05.037	http://dx.doi.org/10.1016/j.jaci.2014.05.037			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25091437	Green Accepted			2022-12-18	WOS:000341372400005
J	Snelgrove, RJ; Gregory, LG; Peiro, T; Akthar, S; Campbell, GA; Walker, SA; Lloyd, CM				Snelgrove, Robert J.; Gregory, Lisa G.; Peiro, Teresa; Akthar, Samia; Campbell, Gaynor A.; Walker, Simone A.; Lloyd, Clare M.			Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alternaria alternata; allergic airway disease; asthma exacerbation; protease; IL-33	ALLERGIC INFLAMMATION; AIRWAY INFLAMMATION; FUNGAL SPORES; RISK-FACTOR; MAST-CELL; IL-33; RECEPTOR; SEVERITY; EXPOSURE; INNATE	Background: The fungal allergen Alternaria alternata is implicated in severe asthma and rapid onset life-threatening exacerbations of disease. However, the mechanisms that underlie this severe pathogenicity remain unclear. Objective: We sought to investigate the mechanism whereby Alternaria was capable of initiating severe, rapid onset allergic inflammation. Methods: IL-33 levels were quantified in wild-type and ST2(-/-) mice that lacked the IL-33 receptor given inhaled house dust mite, cat dander, or Alternaria, and the effect of inhibiting allergen-specific protease activities on IL-33 levels was assessed. An exacerbation model of allergic airway disease was established whereby mice were sensitized with house dust mite before subsequently being challenged with Alternaria (with or without serine protease activity), and inflammation, remodeling, and lung function assessed 24 hours later. Results: Alternaria, but not other common aeroallergens, possessed intrinsic serine protease activity that elicited the rapid release of IL-33 into the airways of mice through a mechanism that was dependent upon the activation of protease activated receptor-2 and adenosine triphosphate signaling. The unique capacity of Alternaria to drive this early IL-33 release resulted in a greater pulmonary inflammation by 24 hours after challenge relative to the common aeroallergen house dust mite. Furthermore, this Alternaria serine protease-IL-33 axis triggered a rapid, augmented inflammation, mucus release, and loss of lung function in our exacerbation model. Conclusion: Alternaria-specific serine protease activity causes rapid IL-33 release, which underlies the development of a robust T(H)2 inflammation and exacerbation of allergic airway disease.	[Snelgrove, Robert J.; Gregory, Lisa G.; Peiro, Teresa; Akthar, Samia; Campbell, Gaynor A.; Walker, Simone A.; Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England	Imperial College London	Lloyd, CM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England.	c.lloyd@imperial.ac.uk		Gregory, Lisa/0000-0003-2199-5417; Lloyd, Clare/0000-0001-8977-6726; Peiro, Teresa/0000-0002-5704-8537	Welcome Trust [086718/Z/08/Z, 095707/Z/11/Z]; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish	Welcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	This work was supported by the Welcome Trust (grants 086718/Z/08/Z and 095707/Z/11/Z).	Agarwal R, 2011, CURR ALLERGY ASTHM R, V11, P403, DOI 10.1007/s11882-011-0217-4; Alves JC, 2010, NAT MED, V16, P708, DOI 10.1038/nm.2156; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Boitano S, 2011, AM J PHYSIOL-LUNG C, V300, pL605, DOI 10.1152/ajplung.00359.2010; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Cayrol C, 2009, P NATL ACAD SCI USA, V106, P9021, DOI 10.1073/pnas.0812690106; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Dales RE, 2000, AM J RESP CRIT CARE, V162, P2087, DOI 10.1164/ajrccm.162.6.2001020; Dales RE, 2003, CHEST, V123, P745, DOI 10.1378/chest.123.3.745; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622, DOI 10.2307/3433608; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633, DOI 10.1164/ajrccm.154.3.8810598; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; Enoksson M, 2013, BLOOD, V121, P530, DOI 10.1182/blood-2012-05-434209; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Gregory LG, 2009, CLIN EXP ALLERGY, V39, P1597, DOI 10.1111/j.1365-2222.2009.03302.x; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hoshino K, 1999, J EXP MED, V190, P1541, DOI 10.1084/jem.190.10.1541; Hueber AJ, 2011, EUR J IMMUNOL, V41, P2229, DOI 10.1002/eji.201041360; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Kearley J, 2009, AM J RESP CRIT CARE, V179, P772, DOI 10.1164/rccm.200805-666OC; Kelly EA, 2003, CURR OPIN PULM MED, V9, P28, DOI 10.1097/00063198-200301000-00005; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Le HT, 2012, J IMMUNOL, V189, P287, DOI 10.4049/jimmunol.1103564; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Liu XJ, 2009, BIOCHEM BIOPH RES CO, V386, P181, DOI 10.1016/j.bbrc.2009.06.008; Lloyd CM, 2010, CURR OPIN IMMUNOL, V22, P800, DOI 10.1016/j.coi.2010.10.006; LOPEZ M, 1985, CLIN REV ALLERG, V3, P183, DOI 10.1007/BF02992982; Mattos W, 2002, CHEST, V122, P1543, DOI 10.1378/chest.122.5.1543; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; Millien VO, 2013, SCIENCE, V341, P792, DOI 10.1126/science.1240342; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Nakayama M, 2013, SCI REP-UK, V3, DOI 10.1038/srep02960; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; O'Driscoll B Ronan, 2005, BMC Pulm Med, V5, P4, DOI 10.1186/1471-2466-5-4; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Porter P, 2009, MUCOSAL IMMUNOL, V2, P504, DOI 10.1038/mi.2009.102; Porter PC, 2011, BBA-GEN SUBJECTS, V1810, P1059, DOI 10.1016/j.bbagen.2011.04.019; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Pulimood TB, 2007, J ALLERGY CLIN IMMUN, V120, P610, DOI 10.1016/j.jaci.2007.04.045; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Smith DE, 2010, CLIN EXP ALLERGY, V40, P200, DOI 10.1111/j.1365-2222.2009.03384.x; Sugimoto K, 2012, J CLIN INVEST, V122, P748, DOI 10.1172/JCI58815; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Verri WA, 2010, ANN RHEUM DIS, V69, P1697, DOI 10.1136/ard.2009.122655; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; Williams Julie C, 2011, J Signal Transduct, V2011, P415195, DOI 10.1155/2011/415195; Yang ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059441; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	57	180	183	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					583	+		10.1016/j.jaci.2014.02.002	http://dx.doi.org/10.1016/j.jaci.2014.02.002			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24636086	hybrid, Green Published			2022-12-18	WOS:000341372400010
J	Jia, CE; Zhang, HP; Lv, Y; Liang, R; Jiang, YQ; Powell, H; Fu, JJ; Wang, L; Gibson, PG; Wang, G				Jia, Chun E.; Zhang, Hong Ping; Lv, Yan; Liang, Rui; Jiang, Yun Qiu; Powell, Heather; Fu, Juan Juan; Wang, Lei; Gibson, Peter Gerard; Wang, Gang			The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Global Initiative for Asthma; National Asthma Education and Prevention Program; Asthma Control Test; Asthma Control Questionnaire; diagnostic performance; meta-analysis	DIAGNOSTIC-TEST ACCURACY; CONTROL TEST ACT; HEALTH-CARE; VALIDITY; RELIABILITY; VALIDATION; QUALITY; VERSION; POINTS; WELL	Background: Currently, the cornerstone of asthma management is the achievement and maintenance of optimal asthma control, but the diagnostic performances of the Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ) have not been evaluated systematically. Objective: We explored the diagnostic performances of and statistically compared the ACT and ACQ. Methods: Studies that examined the accuracy of the ACT, ACQ, or both in the assessment of asthma control were found by searching PubMed, CENTRAL, Web of Science, Ovid, and Embase. Summary estimates of sensitivity, specificity, and diagnostic odds ratios for the different levels of asthma control were determined by using bivariate random-effects models and hierarchical summary receiver operating characteristic models. Results: Twenty-one studies with 11,141 subjects assessed with the ACT and 12,483 assessed with the ACQ were identified. The ACT had good diagnostic accuracy for assessment of controlled and not well-controlled asthma, and the ACQ (ACQ-7 and ACQ-6) had good diagnostic accuracy for assessment of not well-controlled asthma at prespecified cutoff points. The ACT and ACQ had significant differences in the assessment of controlled and not well-controlled asthma after adjusting for potential factors (P = .001 and P = .015). For assessment of uncontrolled asthma, the ACT had poor accuracy, with a hierarchical summary receiver operating characteristic area under the curve of 0.69, and the cutoff point for the ACQ has not been established. Conclusion: The ACT is preferable to the ACQ in clinical practice, and the ACQ requires further cross-validation. Moreover, neither the ACT nor the ACQ is useful for the assessment of uncontrolled asthma. (J Allergy Clin Immunol 2013;131:695-703.)	[Jia, Chun E.; Zhang, Hong Ping; Lv, Yan; Liang, Rui; Jiang, Yun Qiu; Fu, Juan Juan; Wang, Lei; Wang, Gang] Sichuan Univ, Pneumol Grp, Dept Integrated Tradit Chinese & Western Med, West China Hosp, Chengdu 610041, Peoples R China; [Wang, Gang] Sichuan Univ, Regenerat Med Res Ctr, West China Hosp, Chengdu 610041, Peoples R China; [Powell, Heather; Fu, Juan Juan; Gibson, Peter Gerard; Wang, Gang] Univ Newcastle, Ctr Asthma & Resp Dis, Dept Resp & Sleep Med, John Hunter Hosp,Hunter Med Res Inst, New Lambton, Australia	Sichuan University; Sichuan University; Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle	Wang, G (corresponding author), Sichuan Univ, Pneumol Grp, Dept Integrated Tradit Chinese & Western Med, West China Hosp, Chengdu 610041, Peoples R China.	wcums-respiration@hotmail.com	gibson, peter/G-6194-2014	gibson, peter/0000-0001-5865-489X; Fu, Juan-juan/0000-0002-7957-1409	National Natural Science Foundation of China [30971326, 30901907]; Sichuan Youth Science and Technology Foundation [2010JQ0008]; Youth Science Funding of Sichuan University [2011SCU04B17]; APSR Research/Training Fellowship	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Youth Science and Technology Foundation; Youth Science Funding of Sichuan University; APSR Research/Training Fellowship	Supported by the National Natural Science Foundation of China (30971326 and 30901907), the Sichuan Youth Science and Technology Foundation (2010JQ0008), and Youth Science Funding of Sichuan University (2011SCU04B17).; G. Wang has received grants from the National Natural Science Foundation of China, the Sichuan Youth Science and Technology Foundation, Youth Science Funding of Sichuan University; and has received an APSR Research/Training Fellowship (2011) and a scholarship as visiting Associated Professor at the University of Newcastle, Australia. The rest of the authors declare that they have no relevant conflicts of interest.	Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.3.CO;2-X; Arends LR, 2008, MED DECIS MAKING, V28, P621, DOI 10.1177/0272989X08319957; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Cloutier MM, 2012, J ALLERGY CLIN IMMUN, V129, pS24, DOI 10.1016/j.jaci.2011.12.980; Deeks JJ, 2001, BRIT MED J, V323, P157, DOI 10.1136/bmj.323.7305.157; Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016; Roxo JPF, 2010, J BRAS PNEUMOL, V36, P159, DOI 10.1590/S1806-37132010000200002; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Grammatopoulou EP, 2011, J ASTHMA, V48, P57, DOI 10.3109/02770903.2010.529222; Alvarez-Gutierrez FJ, 2010, ARCH BRONCONEUMOL, V46, P370, DOI 10.1016/j.arbres.2010.04.003; Jones CM, 2005, ANN THORAC SURG, V79, P16, DOI 10.1016/j.athoracsur.2004.09.040; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Khalili B, 2008, ANN ALLERG ASTHMA IM, V101, P124, DOI 10.1016/S1081-1206(10)60199-8; Ko FWS, 2012, RESPIROLOGY, V17, P370, DOI 10.1111/j.1440-1843.2011.02105.x; Ko FWS, 2009, RESPIROLOGY, V14, P559, DOI 10.1111/j.1440-1843.2009.01514.x; Korn S, 2011, ANN ALLERG ASTHMA IM, V107, P474, DOI 10.1016/j.anai.2011.09.001; Laforest L, 2005, ALLERGY, V60, P1505, DOI 10.1111/j.1398-9995.2005.00923.x; Lai CKW, 2011, RESPIROLOGY, V16, P688, DOI 10.1111/j.1440-1843.2011.01954.x; Leite Mylene, 2008, J. bras. pneumol., V34, P756, DOI 10.1590/S1806-37132008001000002; Meltzer EO, 2011, J ALLERGY CLIN IMMUN, V127, P167, DOI 10.1016/j.jaci.2010.08.042; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; O'Byrne PM, 2010, EUR RESPIR J, V36, P269, DOI 10.1183/09031936.00124009; Olaguibel J, 2010, ALLERGY, V65, P214; Pereira, 2002, J PNEUMOL, V28; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reitsma JB, 2005, J CLIN EPIDEMIOL, V58, P982, DOI 10.1016/j.jclinepi.2005.02.022; Rutter CM, 2001, STAT MED, V20, P2865, DOI 10.1002/sim.942; Sastre J, 2010, J ASTHMA, V47, P865, DOI 10.3109/02770903.2010.491149; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2007, AM J MANAG CARE, V13, P661; Schatz M, 2007, J ALLERGY CLIN IMMUN, V119, P336, DOI 10.1016/j.jaci.2006.08.042; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Thomas Mike, 2009, Prim Care Respir J, V18, P41, DOI 10.4104/pcrj.2009.00010; van den Nieuwenhof L, 2006, FAM PRACT, V23, P674, DOI 10.1093/fampra/cml041; Vega JM, 2007, J ASTHMA, V44, P867, DOI 10.1080/02770900701752615; Nguyen VN, 2012, PRIM CARE RESP J, V21, P85, DOI 10.4104/pcrj.2011.00093; Wallenstein GV, 2007, CURR MED RES OPIN, V23, P369, DOI 10.1185/030079906X167426; We HH, 2012, CHINESE MED J-PEKING, V125, P2986, DOI 10.3760/cma.j.issn.0366-6999.2012.17.005; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; Willis BH, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-27; Zhou X, 2009, CHEST, V135, P904, DOI 10.1378/chest.08-0967; Zhou X, 2007, CHINESE MED J-PEKING, V120, P1037, DOI 10.1097/00029330-200706020-00002	44	180	188	0	49	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					695	703		10.1016/j.jaci.2012.08.023	http://dx.doi.org/10.1016/j.jaci.2012.08.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23058645				2022-12-18	WOS:000315587800009
J	Hata, TR; Kotol, P; Jackson, M; Nguyen, M; Paik, A; Udall, D; Kanada, K; Yomasaki, K; Alexandrescu, D; Gallo, RL				Hata, Tissa R.; Kotol, Paul; Jackson, Michelle; Nguyen, Meggie; Paik, Aimee; Udall, Don; Kanada, Kimi; Yomasaki, Kenshi; Alexandrescu, Doru; Gallo, Richarcl L.			Administration of oral vitamin D induces cathelicidin production in atopic individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTIMICROBIAL PEPTIDES		[Hata, Tissa R.; Kotol, Paul; Jackson, Michelle; Nguyen, Meggie; Paik, Aimee; Udall, Don; Kanada, Kimi; Yomasaki, Kenshi; Alexandrescu, Doru; Gallo, Richarcl L.] Univ Calif San Diego, Div Dermatol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Hata, TR (corresponding author), Univ Calif San Diego, Div Dermatol, La Jolla, CA 92093 USA.	thata@ucsd.edu	Gallo, Richard L/A-8931-2009; Yamasaki, Kenshi/C-8905-2018	Gallo, Richard L/0000-0002-1401-7861; Yamasaki, Kenshi/0000-0002-5495-4956	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI052453, R01AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052728] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI052453-07, R01 AI052453-08, R01 AI052453, R37 AI052453] Funding Source: Medline; NIAMS NIH HHS [R01 AR052728-04, R01 AR052728] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V117, pS475, DOI 10.1016/j.jaci.2005.10.018; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Larsen FS, 2002, IMMUNOL ALLERGY CLIN, V22, P1, DOI 10.1016/S0889-8561(03)00066-3; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Vieth R, 2001, AM J CLIN NUTR, V73, P288	8	180	186	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					829	831		10.1016/j.jaci.2008.08.020	http://dx.doi.org/10.1016/j.jaci.2008.08.020			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	19014773	Green Accepted			2022-12-18	WOS:000259989000032
J	van der Hulst, AE; Klip, H; Brand, PLP				van der Hulst, Annelies E.; Klip, Helen; Brand, Paul L. P.			Risk of developing asthma in young children with atopic eczema: A systematic review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopic eczenw; atopic dermatitis. asthma; wheeze; atopic march	ALLERGIC AIRWAY DISEASE; TERM-FOLLOW-UP; INFANTILE ECZEMA; NATURAL COURSE; DERMATITIS; SENSITIZATION; LIFE; PROGNOSIS; AGE; HYPERRESPONSIVENESS	Background: It is commonly believed that the majority of infants and young children with early atopic eczema will develop asthma in later childhood. This belief is mainly based on cross-sectional population studies. Recent evidence suggests a more complex relationship between early eczema and asthma. Objective: This systematic review was conducted to assess the risk of developing asthma in children with atopic eczema during the first 4 years of life. Methods: A sensitive search was performed to identify all prospective cohort studies on the topic. By pooling the eligible reports, we calculated the risk of developing asthma at 6 years of age or older in children with atopic eczema in the first 4 Nears of life. Results: Thirteen prospective cohort studies were included, with 4 representing birth cohort studies and 9 representing eczema cohort studies. The pooled odds ratio for the risk of asthma after eczema, compared with children without eczema, in birth cohort studies was 2.14 (95% CI, 1.67-2.75). The prevalence of asthma at the age of 6 years in eczema cohort studies was 35.8% (95% CI, 32.2% to 39.9%) for inpatients and 29.5% (95% CI, 28.2% to 32.7%) for a combined group of inpatients and outpatients. Conclusion: Although there is an increased risk of developing asthma after eczema in early childhood, only I in every 3 children with eczema develops asthma during later childhood. This is lower than previously assumed. Clinical implications: Our results may have important consequences for counseling patients with atopic eczema and their parents.	Isala Kliniken, Isala Acad, Dept Epidemiol & Biostat, NL-8000 GK Zwolle, Netherlands	Isala Clinics	Brand, PLP (corresponding author), Isala Kliniken, Princess Amalia Childrens Clin, Dr Van Heesweg 2,POB 10400, NL-8000 GK Zwolle, Netherlands.	p.l.p.brand@isala.nl	Brand, Paul/ABB-3693-2021					Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; BURROWS D, 1960, BMJ-BRIT MED J, V5202, P825; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FINN OA, 1955, BRIT MED J, V4916, P772; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hays T, 2005, ARCH PEDIAT ADOL MED, V159, P810, DOI 10.1001/archpedi.159.9.810; HOLGATE ST, 2002, ALLERGY; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; KISSLING S, 1993, HAUTARZT, V44, P569; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; LINNA O, 1992, ACTA PAEDIATR, V81, P1013, DOI 10.1111/j.1651-2227.1992.tb12165.x; Liu AH, 2003, PEDIAT ALLERGY, P10; LUENG DYM, 2004, NELSON TXB PEDIATR, P774; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MEENAN FO, 1959, IRISH J MED SCI, V172, P79; MUSGROVE K, 1976, BRIT J DERMATOL, V95, P365, DOI 10.1111/j.1365-2133.1976.tb00837.x; Novembre E, 2001, ALLERGY, V56, P452, DOI 10.1034/j.1398-9995.2001.056005452.x; PASTERNACK B, 1965, J PEDIATR-US, V66, P164; PURDY MJ, 1953, BRIT MED J, V1, P1366, DOI 10.1136/bmj.1.4824.1366; QUEILLEROUSSEL C, 1985, ACTA DERM-VENEREOL, V114, P87; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Ricci G, 2006, J AM ACAD DERMATOL, V55, P765, DOI 10.1016/j.jaad.2006.04.064; RYSTEDT I, 1985, ACTA DERM-VENEREOL, P117; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; STIFLER WC, 1965, J PEDIATR-US, V66, P166; VANHECKE E, 1981, DERMATOLOGICA, V163, P370, DOI 10.1159/000250188; VOWLES M, 1955, BRIT J DERMATOL, V67, P53, DOI 10.1111/j.1365-2133.1955.tb12687.x; Wuthrich B, 2002, ALLERGY, V57, P267, DOI 10.1034/j.1398-9995.2002.1n3572.x; [No title captured]	37	180	188	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					565	569		10.1016/j.jaci.2007.05.042	http://dx.doi.org/10.1016/j.jaci.2007.05.042			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17655920				2022-12-18	WOS:000249505400014
J	Brightling, CE; Symon, FA; Birring, SS; Bradding, P; Pavord, ID; Wardlaw, AJ				Brightling, CE; Symon, FA; Birring, SS; Bradding, P; Pavord, ID; Wardlaw, AJ			T(H)2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)2 cells; asthma; eosinophilic bronchitis; eosinophils	INDUCED SPUTUM; CHRONIC COUGH; MAST-CELL; BLOOD; INTERLEUKIN-4; PROFILE; CD8(+); IL-5	Background: Asthma is characterized by variable airflow obstruction and airway hyperresponsiveness in association with airway inflammation under the influence of T(H)2 cytokines. Eosinophilic bronchitis has similar immunopathology to asthma but without disordered airway physiology. Whether eosinophilic bronchitis is associated with increased expression of T(H)2 cytokines is unknown. Objective: We sought to assess the expression of T(H)2 cytokines in eosinophilic bronchitis. Methods: Expression of activation markers and chemokine receptors from blood and bronchoalveolar lavage (BAL) fluid T cells and the T(H)2 cytokine expression from these T cells and bronchial mucosa biopsy specimens were assessed from subjects with eosinophilic bronchitis, subjects with asthma, and healthy control subjects. Results: The proportion of resting (stimulated) CD4 BAL fluid T cells expressing intracellular IL-4 was significantly higher in the subjects with eosinophilic bronchitis 7.2% (11.4%) and subjects with asthma 5.3% (5.5%) than in healthy control subjects 2.8% (3.9%) (P = .03). The number of IL-4(+) (P < .001) and IL5+ (P = .003) cells per square millimeter of bronchial submucosa was significantly higher in the disease groups than in the healthy control subjects. Expression of intracellular IFN-gamma was significantly higher in stimulated blood CD8 T cells from subjects with eosinophilic bronchitis (24%) and asthma (17%) than in the healthy control subjects (5 %; P = .003). There were no between-group differences in expression of IFN-gamma in the BAL fluid T cells or in the bronchial submucosa and no differences in expression of activation markers or chemokine receptors. Conclusion: These findings support the concept of asthma as a disease associated with activation of TH2 lymphocytes in the airway and provide evidence that these cytokines play a role in the development of airway inflammation in eosinophilic bronchitis but suggest that the release of TH2 cytokines is not sufficient for the elaboration of disordered airway physiology in Asthma.	Univ Hosp Leicester, Div Resp Med, Inst Lung Hlth, Leicester LE3 9QP, Leics, England; Leicester Warwick Med Sch, Div Resp Med, Inst Lung Hlth, Leicester LE3 9QP, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; University of Leicester	Wardlaw, AJ (corresponding author), Univ Hosp Leicester, Div Resp Med, Inst Lung Hlth, Clin Sci Wing,Groby Rd, Leicester LE3 9QP, Leics, England.		Birring, Surinder/GWU-6967-2022	Bradding, Peter/0000-0001-8403-0319; Pavord, Ian/0000-0002-4288-5973; Wardlaw, Andrew/0000-0001-6583-0791; brightling, chris/0000-0002-9345-4903				Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Brichtling CE, 2000, AM J RESP CRIT CARE, V162, P878, DOI 10.1164/ajrccm.162.3.9909064; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; GIBSON PG, 1989, LANCET, V1, P1346; Gibson PG, 1998, J ALLERGY CLIN IMMUN, V101, P320, DOI 10.1016/S0091-6749(98)70242-8; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Juniper E, 1994, HISTAMINE METHACHOLI; Kay AB, 1996, AM J RESP CRIT CARE, V154, pS66, DOI 10.1164/ajrccm/154.2_Pt_2.S66; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; Krug N, 2001, AM J RESP CELL MOL, V25, P125, DOI 10.1165/ajrcmb.25.1.4194; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; Moller GM, 1996, AM J RESP CELL MOL, V14, P439; NONAKA M, 1995, J IMMUNOL, V155, P3234; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 2000, BRIT MED BULL, V56, P956, DOI 10.1258/0007142001903625; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Till SJ, 1998, AM J RESP CRIT CARE, V158, P404, DOI 10.1164/ajrccm.158.2.9705007; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; Wardlaw AJ, 2000, BRIT MED BULL, V56, P985, DOI 10.1258/0007142001903490; Woltmann G, 2000, BLOOD, V95, P3146	28	180	190	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					899	905		10.1067/mai.2002.129698	http://dx.doi.org/10.1067/mai.2002.129698			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464957				2022-12-18	WOS:000179777400013
J	van Schaik, SM; Tristram, DA; Nagpal, IS; Hintz, KM; Welliver, RC; Welliver, RC				van Schaik, SM; Tristram, DA; Nagpal, IS; Hintz, KM; Welliver, RC; Welliver, RC			Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchiolitis; virus-induced wheezing; IFN-gamma; respiratory syncytial virus; leukotrienes; asthma	RESPIRATORY SYNCYTIAL VIRUS; LEUKOCYTE HISTAMINE-RELEASE; CYTOKINE PRODUCTION; INFECTION; BRONCHIOLITIS; INFANTS; CELL; IGE; INTERFERON; CHILDREN	Background: An imbalance of production of T-helper lymphocyte cytokines, favoring overproduction of IL-4, is believed to be important in the pathogenesis of allergic asthma. However, less is known about the cytokine response in virus-induced wheezing, which is a major cause of morbidity in asthma. Objective: We undertook this study to determine the magnitude of IFN-gamma, IL-4 and IL-10, and leukotriene (LT) responses in infants and children with virus-induced wheezing, Methods: We measured the concentrations of IFN-gamma, IL-4 and IL-10, and cysteinyl LTs in respiratory secretions of 82 infants and young children during acute episodes of virus-induced wheezing. Control subjects were 47 infants and children with uncomplicated upper respiratory infections and 18 normal healthy infants. Results: Ratios of IFN-gamma to IL-4 were higher (due to increased quantities of IFN-gamma) in subjects with wheezing than in those with upper respiratory infection alone (P =.003). Quantities of LTs were also increased in wheezing subjects in comparison with those with upper respiratory infections (P =.003), There was a significant correlation between measured concentrations of IFN-gamma and LTs (correlation coefficient = .451, P =.007), Quantities of IL-4 were slightly suppressed in the wheezing groups. Conclusions: An imbalance favoring overproduction of IFN-gamma appears to be associated temporarily with virus-induced wheezing. A possible mechanism is the enhanced release of LTs from eosinophils or mast cells after sensitization by IFN-gamma.	Childrens Hosp, Div Infect Dis, Buffalo, NY 14222 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Pediat, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Welliver, RC (corresponding author), Childrens Hosp, Div Infect Dis, 219 Bryant St, Buffalo, NY 14222 USA.		van Schaik, Sandrijn M/H-9078-2019		NHLBI NIH HHS [HL-49971] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049971] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUSSE WW, 1983, J ALLERGY CLIN IMMUN, V71, P382, DOI 10.1016/0091-6749(83)90066-0; CHONMAITREE T, 1988, J INFECT DIS, V157, P127, DOI 10.1093/infdis/157.1.127; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Garofalo R, 1994, Pediatr Allergy Immunol, V5, P111, DOI 10.1111/j.1399-3038.1994.tb00227.x; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; GURWITZ D, 1981, J PEDIATR-US, V98, P551, DOI 10.1016/S0022-3476(81)80758-5; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Renzi PM, 1997, J PEDIATR-US, V130, P584, DOI 10.1016/S0022-3476(97)70243-9; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050; SAITO H, 1988, INT ARCH ALLER A IMM, V87, P286, DOI 10.1159/000234687; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Takafuji S, 1996, J IMMUNOL, V156, P3980; VALERIUS T, 1990, J IMMUNOL, V145, P2950; VOLOVITZ B, 1988, PEDIATR RES, V24, P504, DOI 10.1203/00006450-198810000-00018; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1982, J PEDIATR-US, V101, P889, DOI 10.1016/S0022-3476(82)80005-X	22	180	182	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					630	636		10.1016/S0091-6749(99)70235-6	http://dx.doi.org/10.1016/S0091-6749(99)70235-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200012				2022-12-18	WOS:000079723900016
J	CARTIER, A; MALO, JL; FOREST, F; LAFRANCE, M; PINEAU, L; STAUBIN, JJ; DUBOIS, JY				CARTIER, A; MALO, JL; FOREST, F; LAFRANCE, M; PINEAU, L; STAUBIN, JJ; DUBOIS, JY			OCCUPATIONAL ASTHMA IN SNOW CRAB-PROCESSING WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOTEL DIEU, CTR SANTE ARCHIPEL ILES MADELEINE, GASPE, NB, CANADA; HOTEL DIEU, DEPT SANTE COMMUN, GASPE, NB, CANADA	Laval University; Laval University	CARTIER, A (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, MONTREAL H4J 1C5, QUEBEC, CANADA.							[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BERNSTEIN IL, 1981, CLIN CHEST MED, V2, P255; BURGE PS, 1979, THORAX, V34, P308, DOI 10.1136/thx.34.3.308; BURGE PS, 1979, THORAX, V34, P317, DOI 10.1136/thx.34.3.317; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; BUTCHER BT, 1982, J ALLERGY CLIN IMMUN, V70, P231, DOI 10.1016/0091-6749(82)90058-6; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1980, J ALLERGY CLIN IMMUN, V66, P458, DOI 10.1016/0091-6749(80)90006-8; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DROSZCZ W, 1981, INT ARCH OCC ENV HEA, V49, P13, DOI 10.1007/BF00380804; GADDIE J, 1980, LANCET, V2, P1350; JYO T, 1974, ALLERG IMMUNOL, V21, P425; MALO JL, 1982, J ALLERGY CLIN IMMUN, V69, P55, DOI 10.1016/0091-6749(82)90088-4; NAKASHIMA T, 1969, HIROSHIMA J MED SCI, V18, P141; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; ORFORD RR, 1976, THESIS U WASHINGTON; PARKES WR, 1982, OCCUPATIONAL LUNG DI, P415; SIMANI AS, 1974, LAB INVEST, V31, P75; SOKAL RR, 1981, BIOMETRY, P735; 1982, MORBIDITY MORTALITY, V31, P95	24	180	181	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					261	269		10.1016/0091-6749(84)90256-2	http://dx.doi.org/10.1016/0091-6749(84)90256-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TJ808	6470360				2022-12-18	WOS:A1984TJ80800008
J	STEVENSON, DD				STEVENSON, DD			DIAGNOSIS, PREVENTION, AND TREATMENT OF ADVERSE REACTIONS TO ASPIRIN AND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											STEVENSON, DD (corresponding author), SCRIPPS CLIN & RES FDN,DIV ALLERGY & IMMUNOL,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; CHRISTIANSEN S, COMMUNICATION; DANKNER RE, 1983, AM REV RESPIR DIS, V128, P953; FARR RS, 1970, J ALLERGY, V45, P321, DOI 10.1016/0021-8707(70)90040-7; KALLOS P, 1980, PSEUDOALLERGIC REACT, V1, P49; LUMRY W R, 1982, Journal of Allergy and Clinical Immunology, V69, P93; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; MATHISON DA, 1979, J ALLERGY CLIN IMMUN, V64, P669, DOI 10.1016/0091-6749(79)90036-8; MATHISON DA, 1982, J ALLERGY CLIN IMMUN, V68, P135; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MOOREROB.M, 1967, BRIT MED J, V4, P262, DOI 10.1136/bmj.4.5574.262; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1982, PSEUDOALLERGIC REACT, V3, P133; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANSELOW NA, 1967, ANN INTERN MED, V66, P567; WARREN RP, 1960, BRIT J DERMATOL, V72, P350; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0	23	180	180	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					617	622		10.1016/0091-6749(84)90115-5	http://dx.doi.org/10.1016/0091-6749(84)90115-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6436354				2022-12-18	WOS:A1984TQ16300012
J	Kimura, H; Francisco, D; Conway, M; Martinez, FD; Vercelli, D; Polverino, F; Billheimer, D; Kraft, M				Kimura, Hiroki; Francisco, Dave; Conway, Michelle; Martinez, Fernando D.; Vercelli, Donata; Polverino, Francesca; Billheimer, Dean; Kraft, Monica			Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; IL-13; ACE2; TMPRSS2; nasal epithelial cells; airway epithelial cells; COVID-19; SARS-CoV-2; type 2 inflammation	CORONAVIRUS RECEPTOR; FUNCTIONAL RECEPTOR; SARS CORONAVIRUS; INFLUENZA-VIRUS; EXPRESSION; ANGIOTENSIN-(1-7); ASTHMA	Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically changed our world, country, communities, and families. There is controversy regarding risk factors for severe COVID-19 disease. It has been suggested that asthma and allergy are not highly represented as comorbid conditions associated with COVID-19. Objective: Our aim was to extend our work in IL-13 biology to determine whether airway epithelial cell expression of 2 key mediators critical for SARS-CoV-2 infection, namely, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2), are modulated by IL-13. Methods: We determined effects of IL-13 treatment on ACE2 and TMPRSS2 expression ex vivo in primary airway epithelial cells from participants with and without type 2 asthma obtained by bronchoscopy. We also examined expression of ACE2 and TMPRSS2 in 2 data sets containing gene expression data from nasal and airway epithelial cells from children and adults with asthma and allergic rhinitis. Results: IL-13 significantly reduced ACE2 and increased TMPRSS2 expression ex vivo in airway epithelial cells. In 2 independent data sets, ACE2 expression was significantly reduced and TMPRSS2 expression was significantly increased in the nasal and airway epithelial cells in type 2 asthma and allergic rhinitis. ACE2 expression was significantly negatively associated with type 2 cytokines, whereas TMPRSS2 expression was significantly positively associated with type 2 cytokines. Conclusion: IL-13 modulates ACE2 and TMPRSS2 expression in airway epithelial cells in asthma and atopy. This deserves further study with regard to any effects that asthma and atopy may render in the setting of COVID-19 infection.	[Kimura, Hiroki; Francisco, Dave; Conway, Michelle; Polverino, Francesca; Kraft, Monica] Univ Arizona Hlth Sci, Coll Med Tucson, Dept Med, Tucson, AZ USA; [Martinez, Fernando D.; Vercelli, Donata] Univ Arizona Hlth Sci, Coll Med Tucson, Asthma & Airway Dis Res Ctr, Tucson, AZ USA; [Billheimer, Dean] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Dept Epidemiol & Biostat, Tucson, AZ USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Arizona	Kraft, M (corresponding author), Coll Med, 1501 North Campbell Ave,Off 6334, Tucson, AZ 85724 USA.	kraftm@email.arizona.edu	Polverino, Francesca/AAL-7997-2020; Polverino, Francesca/F-3816-2017	Francisco, Dave/0000-0003-1206-7424; Polverino, Francesca/0000-0001-9686-5698	National Institutes of Health [U19AI125357]; Arizona Bioscience Research Grant; MSD Life Science Foundation; Public Interest Incorporated Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Arizona Bioscience Research Grant; MSD Life Science Foundation; Public Interest Incorporated Foundation	Supported by a National Institutes of Health Funding (grant U19AI125357); an Arizona Bioscience Research Grant (to M.K.); and the MSD Life Science Foundation, Public Interest Incorporated Foundation (to H.K.).	[Anonymous], 2020, NY TIMES; Balakumar P, 2014, CELL SIGNAL, V26, P2147, DOI 10.1016/j.cellsig.2014.06.011; Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163; Bertram S, 2013, J VIROL, V87, P6150, DOI 10.1128/JVI.03372-12; Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876; Bertram S, 2010, J VIROL, V84, P10016, DOI 10.1128/JVI.00239-10; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; de Lang A, 2006, VIROLOGY, V353, P474, DOI 10.1016/j.virol.2006.06.011; Dong X, ALLERGY, DOI [10.1111/all., DOI 10.1111/ALL]; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Giovannini-Chami L, 2012, EUR RESPIR J, V39, P1197, DOI 10.1183/09031936.00070511; Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102; HoLmann M, 2020, CELL, V181, DOI [10.1016/ j.cell.2020.02.052, 10.1016/j.cell.2020.02.052, DOI 10.1016/J.CELL.2020.02.052]; Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Kraft M, 2008, EUR RESPIR J, V31, P43, DOI 10.1183/09031936.00103307; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Limburg H, 2019, J VIROL, V93, DOI 10.1128/JVI.00649-19; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021; Magalhaes GS, 2015, BRIT J PHARMACOL, V172, P2330, DOI 10.1111/bph.13057; Matsuyama S, 2020, BIORXIV, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Park SW, 2009, AM J RESP CRIT CARE, V180, P603, DOI 10.1164/rccm.200811-1768OC; PIERUZZI F, 1995, CIRCULATION, V92, P3105, DOI 10.1161/01.CIR.92.10.3105; Sakai K, 2015, J VIROL, V89, P5154, DOI 10.1128/JVI.00124-15; Sakai K, 2014, J VIROL, V88, P5608, DOI 10.1128/JVI.03677-13; Saraya T, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00226; US Centers for Disease Control and Prevention, PEOPLE WHO ARE HIGHE; Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238	37	179	184	3	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					80	+		10.1016/j.jaci.2020.05.004	http://dx.doi.org/10.1016/j.jaci.2020.05.004			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32422146	Green Published, Bronze			2022-12-18	WOS:000579170500017
J	Kloepfer, KM; Lee, WM; Pappas, TE; Kang, TJ; Vrtis, RF; Evans, MD; Gangnon, RE; Bochkov, YA; Jackson, DJ; Lemanske, RF; Gern, JE				Kloepfer, Kirsten M.; Lee, Wai Ming; Pappas, Tressa E.; Kang, Theresa J.; Vrtis, Rose F.; Evans, Michael D.; Gangnon, Ronald E.; Bochkov, Yury A.; Jackson, Daniel J.; Lemanske, Robert F., Jr.; Gern, James E.			Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinovirus; bacteria; asthma	STREPTOCOCCUS-PNEUMONIAE; MORAXELLA-CATARRHALIS; INFLUENZA-VIRUS; YOUNG-CHILDREN; AIRWAY; PCR	Background: Detection of either viral or bacterial pathogens is associated with wheezing in children; however, the influence of both bacteria and viruses on illness symptoms has not been described. Objective: We evaluated bacterial detection during the peak rhinovirus season in children with and without asthma to determine whether an association exists between bacterial infection and the severity of rhinovirus- induced illnesses. Methods: Three hundred eight children (166 with asthma and 142 without asthma) aged 4 to 12 years provided 5 consecutive weekly nasal samples during September and scored cold and asthma symptoms daily. Viral diagnostics and quantitative PCR for Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis were performed on all nasal samples. Results: Detection rates were 53%, 17%, and 11% for H influenzae, S pneumoniae, and M catarrhalis, respectively, with detection of rhinovirus increasing the risk of detecting bacteria within the same sample (odds ratio [OR], 2.0; 95% CI, 1.4-2.7; P <.0001) or the following week (OR, 1.6; 95% CI, 1.1-2.4; P =.02). In the absence of rhinovirus, S pneumoniae was associated with increased cold symptoms (mean, 2.7 [95% CI, 2.0-3.5] vs 1.8 [95% CI, 1.5-2.2]; P =.006) and moderate asthma exacerbations (18% [95% CI, 12% to 27%] vs 9.2% [95% CI, 6.7% to 12%]; P =.006). In the presence of rhinovirus, S pneumoniae was associated with increased moderate asthma exacerbations (22% [95% CI, 16% to 29%] vs 15% [95% CI, 11% to 20%]; P =.01). Furthermore, M catarrhalis detected alongside rhinovirus increased the likelihood of experiencing cold symptoms, asthma symptoms, or both compared with isolated detection of rhinovirus (OR, 2.0 [95% CI, 1.0-4.1]; P =.04). Regardless of rhinovirus status, H influenzae was not associated with respiratory symptoms. Conclusion: Rhinovirus infection enhances detection of specific bacterial pathogens in children with and without asthma. Furthermore, these findings suggest that M catarrhalis and S pneumoniae contribute to the severity of respiratory tract illnesses, including asthma exacerbations.	[Kloepfer, Kirsten M.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Lee, Wai Ming; Pappas, Tressa E.; Kang, Theresa J.; Bochkov, Yury A.; Jackson, Daniel J.; Lemanske, Robert F., Jr.; Gern, James E.] Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; [Vrtis, Rose F.; Jackson, Daniel J.; Lemanske, Robert F., Jr.; Gern, James E.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA; [Evans, Michael D.; Gangnon, Ronald E.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA	Indiana University System; Indiana University Bloomington; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kloepfer, KM (corresponding author), 705 Riley Hosp Dr,RI 2606, Indianapolis, IN 46202 USA.	kloepfer@iu.edu		Evans, Michael/0000-0001-7449-3993; Gangnon, Ronald/0000-0003-2587-6714; Bochkov, Yury/0000-0003-2618-4496	National Institutes of Health (NIH) [U19 AI070503-01, P01 HL070831]; Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, NIH [1UL1RR025011];  [T32AI007635]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD068371] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000428, UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070503, T32AI007635, U19AI104317] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, NIH; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The following National Institutes of Health (NIH) grants supported this research: U19 AI070503-01 (RhinoGen); P01 HL070831 (Childhood Origins of Asthma); 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, NIH; and T32AI007635 (University of Wisconsin Allergy Research Training program).	Abdeldaim GMK, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-310; Abdeldaim GMK, 2009, DIAGN MICR INFEC DIS, V64, P366, DOI 10.1016/j.diagmicrobio.2009.03.030; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Cardenas PA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046803; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; COLLAZOS J, 1992, EUR J CLIN MICROBIOL, V11, P237, DOI 10.1007/BF02098086; De Schutter I, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-83; Dowell SF, 2003, EMERG INFECT DIS, V9, P573, DOI 10.3201/eid0905.020556; GRAY BM, 1982, AM J EPIDEMIOL, V116, P692, DOI 10.1093/oxfordjournals.aje.a113452; Greiner O, 2003, J CLIN MICROBIOL, V41, P1386, DOI 10.1128/JCM.41.4.1386-1390.2003; HARFORD CG, 1949, J EXP MED, V89, P53, DOI 10.1084/jem.89.1.53; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kloepfer KM, 2012, AM J RESP CRIT CARE, V185, P1275, DOI 10.1164/rccm.201109-1635OC; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; LOURIA DB, 1959, J CLIN INVEST, V38, P213, DOI 10.1172/JCI103789; McCullers JA, 2002, J INFECT DIS, V186, P341, DOI 10.1086/341462; McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Peltola V, 2011, PEDIATR INFECT DIS J, V30, P456, DOI 10.1097/INF.0b013e318208ee82; Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; Short KR, 2013, INFECT IMMUN, V81, P645, DOI 10.1128/IAI.01278-12	28	179	187	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1301	U504		10.1016/j.jaci.2014.02.030	http://dx.doi.org/10.1016/j.jaci.2014.02.030			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24698319	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000335450700009
J	Oyoshi, MK; Murphy, GF; Geha, RS				Oyoshi, Michiko K.; Murphy, George F.; Geha, Raif S.			Filaggrin-deficient mice exhibit T(H)17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ft/ft mice; filaggrin; atopic dermatitis; IL-17; skin; allergen	OF-FUNCTION MUTATIONS; ATOPIC-DERMATITIS; FLAKY TAIL; EXPRESSION; MOUSE; CELLS; MODEL; GAMMA; INTERLEUKIN-17; EXPOSURE	Background: Filaggrin is important for skin barrier function and is mutated in 15% to 20% of patients with atopic dermatitis. Objective: To examine whether filaggrin deficiency predisposes to skin inflammation and epicutaneous sensitization with protein antigen. Methods: Skin histology in filaggrin-deficient flaky tail (ft)/ft mice and wild-type controls was assessed by Hematoxylin and Eosin (H&E) staining and immunohistochemistry. Cytokine mRNA expression was examined by quantitative RT-PCR. Serum antibody levels and splenocyte secretion of cytokines were measured by ELISA. Results: The ft/ft mice developed eczematous skin lesions after age 28 weeks and a progressive increase in serum IgE and IgG(1) levels. Normal-appearing skin from 8-week-old ft/ft mice had epidermal thickening and increased dermal infiltration with CD4(+) cells and expression of mRNA for IL-17, IL-6, and IL-23, but not IL-4, IL-13, or IFN-gamma. Lesional skin of 32-week-old ft/ft mice exhibited qualitatively similar, but more pronounced, changes, and elevated IL-4 mRNA levels. Epicutaneous application of ovalbumin to shaved skin of 8-week-old ft/ft mice, but not WT mice, resulted in increased epidermal thickening, dermal infiltration by CD4(+) cells but not eosinophils, and expression of IL-17, IL-6, IL-23, IL-4, and IFN-gamma, but not IL-5 or IL-13, mRNA. Splenocytes from epicutaneously sensitized ft/ft mice, but not controls, secreted cytokines in response to ovalbumin stimulation, and their sera, but not those of controls, contained ovalbumin-specific IgE and IgG1 antibodies. Conclusion: Filaggrin-deficient mice exhibit T(H)17-dominated skin inflammation and eczematous changes with age, and are permissive to epicutaneous sensitization with protein antigen. (J Allergy Clin Immunol 2009;124:485-93.)	[Oyoshi, Michiko K.; Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Oyoshi, Michiko K.; Geha, Raif S.] Dept Pediat, Boston, MA USA; [Murphy, George F.] Brigham & Womens Hosp, Div Dermatopathol, Boston, MA 02115 USA; [Murphy, George F.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 1 Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu			Atopic Dermatitis and Vaccinia Immunization Network [NO1 AI 40030]; USPHS [AR-047417]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER	Atopic Dermatitis and Vaccinia Immunization Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Atopic Dermatitis and Vaccinia Immunization Network, contract NO1 AI 40030, and USPHS grant AR-047417.	Alenius H, 2002, J ALLERGY CLIN IMMUN, V109, P106, DOI 10.1067/mai.2002.120553; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Gerosa F, 2008, J EXP MED, V205, P1447, DOI 10.1084/jem.20071450; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Jin HL, 2009, J CLIN INVEST, V119, P47, DOI 10.1172/JCI32310; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kostka SL, 2009, J IMMUNOL, V182, P3039, DOI 10.4049/jimmunol.0713598; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; LANE PW, 1972, J HERED, V63, P135, DOI 10.1093/oxfordjournals.jhered.a108252; Larsen JM, 2009, J ALLERGY CLIN IMMUN, V123, P486, DOI 10.1016/j.jaci.2008.09.036; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Makino T, 2003, J HISTOCHEM CYTOCHEM, V51, P485, DOI 10.1177/002215540305100410; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Matsumoto M, 2000, J DERMATOL SCI, V23, P178, DOI 10.1016/S0923-1811(00)00073-6; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Piskin G, 2006, J IMMUNOL, V176, P1908, DOI 10.4049/jimmunol.176.3.1908; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Rawlings A.V., 2004, DERMATOL THER, V17, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Smith Walter, 1999, International Journal of Cosmetic Science, V21, P99, DOI 10.1046/j.1467-2494.1999.196562.x; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Takatsu K, 2008, CURR OPIN IMMUNOL, V20, P288, DOI 10.1016/j.coi.2008.04.001; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Woodward AL, 2001, J ALLERGY CLIN IMMUN, V107, P359, DOI 10.1067/mai.2001.112695; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519	36	179	184	4	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					485	U145		10.1016/j.jaci.2009.05.042	http://dx.doi.org/10.1016/j.jaci.2009.05.042			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19665780	Green Accepted			2022-12-18	WOS:000274315900013
J	Celedon, JC; Milton, DK; Ramsey, CD; Litonjua, AA; Ryan, L; Platts-Mills, TAE; Gold, DR				Celedon, Juan C.; Milton, Donald K.; Ramsey, Clare D.; Litonjua, Augusto A.; Ryan, Louise; Platts-Mills, Thomas A. E.; Gold, Diane R.			Exposure to dust mite allergen and endotoxin in early life and asthma and atopy in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; dust mite; wheeze; atopy; asthma	DAY-CARE ATTENDANCE; 1ST YEAR; LIMULUS ASSAY; WHEEZE; RISK; HISTORY; INFANCY; SENSITIZATION; CHILDREN; ECZEMA	Background: There has been no longitudinal study of the relation between concurrent exposure to dust mite allergen and endotoxin in early life and asthma and atopy at school age. Objectives: To examine the relation between exposure to dust mite allergen and endotoxin at age 2 to 3 months and asthma, wheeze, and atopy in high-risk children. Methods: Birth cohort study of 440 children with parental history of atopy in the Boston metropolitan area. Results: In multivariate analyses, early exposure to high levels of dust mite allergen (>= 10 mu g/g) was associated with increased risks of asthma at age 7 years (odds ratio [OR], 3.0; 95% CI, 1.1-7.9) and late-onset wheeze (OR, 5.0; 95% Cl, 1.5-16.4). Exposure to endotoxin levels above the lowest quartile at age 2 to 3 months was associated with reduced odds of atopy at school age (OR, 0.5; 95% CI, 0.2-0.9). In contrast with its inverse association with atopy, endotoxin exposure in early life was associated with an increased risk of any wheeze between ages I and 7 years that did not change significantly with time (hazard ratio for each quartile increment in endotoxin levels, 1.23; 95% CI, 1.07-1.43). Conclusion: Among children at risk of atopy, early exposure to high levels of dust mite allergen is associated with increased risks of asthma and late-onset wheeze. In these children, endotoxin exposure is associated with a reduced risk of atopy but an increased risk of wheeze. Clinical implications: Early endotoxin exposure may be a protective factor against atopy but a risk factor for wheeze in high-risk children.	Channing Labs, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Massachusetts, Sch Hlth & Environm, Dept Work Environm, Lowell, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Virginia, Dept Med, Asthma & Allergy Ctr, Charlottesville, VA 22903 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Lowell; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; University of Virginia	Celedon, JC (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu	Milton, Donald K/G-3286-2010; Ryan, Louise M/A-4562-2009	Milton, Donald K/0000-0002-0550-7834; Ryan, Louise M/0000-0001-5957-2490; Litonjua, Augusto/0000-0003-0422-5875; Platts-Mills, Thomas/0000-0002-1263-329X	NHLBI NIH HHS [K01 HL004370, R01 HL079966, R01 HL073373, HL079966, HL073373, HL04370] Funding Source: Medline; NIAID NIH HHS [R01 AI035786-10, R01 AI035786] Funding Source: Medline; NIEHS NIH HHS [R01 ES007036, ES35786, R56 ES007036, ES07036] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL004370, R01HL079966, R01HL073373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007036, R56ES007036] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham JH, 2005, J ALLERGY CLIN IMMUN, V116, P431, DOI 10.1016/j.jaci.2005.05.015; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e77; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536, DOI 10.1164/ajrccm.157.5.9708011; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LE JM, 1986, J IMMUNOL, V136, P4525; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Michel O, 2003, J ENDOTOXIN RES, V9, P293, DOI 10.1179/096805103225002539; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; Polk S, 2004, AM J RESP CRIT CARE, V170, P273, DOI 10.1164/rccm.200310-1348OC; Raby BA, 2004, PEDIATRICS, V114, pE327, DOI 10.1542/peds.2003-0838-L; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Therneau TM, 2000, STAT BIOL HEALTH; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Wahl SM, 2004, CURR OPIN IMMUNOL, V16, P768, DOI 10.1016/j.coi.2004.09.006	38	179	185	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					144	149		10.1016/j.jaci.2007.03.037	http://dx.doi.org/10.1016/j.jaci.2007.03.037			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17507083	Green Accepted			2022-12-18	WOS:000248066400021
J	Simpson, A; Soderstrom, L; Ahistedt, S; Murray, CS; Woodcock, A; Custovic, A				Simpson, A; Soderstrom, L; Ahistedt, S; Murray, CS; Woodcock, A; Custovic, A			IgE antibody quantification and the probability of wheeze in preschool children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE antibody; quantitative assay; wheeze; specific airway resistance	FOOD ALLERGY; BRONCHIAL RESPONSIVENESS; INDIVIDUAL ALLERGENS; AIRWAY-RESISTANCE; MANCHESTER ASTHMA; RISK-FACTORS; EARLY-LIFE; SENSITIZATION; DIAGNOSIS; SYMPTOMS	Background: IgE-mediated sensitization is usually considered a dichotomous variable (either sensitized or not). Quantitative IgE antibody analysis may better predict the expression of wheeze. Objective: Within the context of a population-based birth cohort, we investigated the association among wheeze, lung function, and specific IgE antibody levels. Methods: Children (n = 521) were followed to age 5 years with repeated questionnaires, skin testing, and measurement of lung function (specific airway resistance) and specific serum IgE (ImmunoCAP). Results: Using specific IgE as a continuous variable, the risk of current wheeze increased significantly with increasing IgE to mite, cat, and dog (P < .0001). When IgE levels to these 3 allergens were summed, the probability of current wheeze increased 1.33-fold (95% CI, 1.21-1.47; P < .0001) per logarithmic unit increase, corresponding to an odds ratio of 3.1 at 10 and 4.25 at 30 kU(A)/L (kilo units of Allergen per liter). Similarly, increasing sum of mite-specific, cat-specific, and dog-specific IgE was associated with reduced lung function (P = .004). Among sensitized children (n = 184), the sum of mite, cat, and dog IgE was the strongest associate of current wheeze (odds ratio, 1.28; 95% CI, 1.13-1.46; P < .001), corresponding to an odds ratio of 2.56 at 10 and 3.32 at 30 kUA/L. There was no association between current wheeze and the size of skin test wheal. Furthermore, the sum of IgE to mite, cat, and dog at age 3 years increased the risk of persistent wheeze by age 5 years (2.15-fold/logarithmic unit increase in the specific IgE). Conclusion: IgE-mediated sensitization is not an all or nothing phenomenon. The probability of wheeze and reduced lung function increases with increasing specific IgE antibody levels.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England; Pharmacia Diagnost AB, S-75182 Uppsala, Sweden; Karolinska Inst, Ctr Allergy Res, Inst Environm Med, S-10401 Stockholm, Sweden	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Pfizer; Pharmacia Corporation; Karolinska Institutet	Simpson, A (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.	a.simpson@fs1.with.man.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Soderstrom, Lars/0000-0002-6474-6501; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666; Murray, Clare/0000-0002-8961-8055				Broadfield E, 2002, J ALLERGY CLIN IMMUN, V109, P969, DOI 10.1067/mai.2002.124772; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; Chinn S, 1996, EUR J EPIDEMIOL, V12, P155, DOI 10.1007/BF00145501; Chinn S, 1998, THORAX, V53, P662, DOI 10.1136/thx.53.8.662; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; DAB I, 1976, PEDIATR RES, V10, P996, DOI 10.1203/00006450-197612000-00009; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Hamilton RG, 2004, J ALLERGY CLIN IMMUN, V114, P213, DOI 10.1016/j.jaci.2004.06.046; Klug B, 1997, EUR RESPIR J, V10, P1599, DOI 10.1183/09031936.97.10071599; LIAPPIS N, 1999, CLIN LAB, V45, P229; Litonjua AA, 1997, AM J RESP CRIT CARE, V156, P23, DOI 10.1164/ajrccm.156.1.9608072; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; PEARCE N, 1993, EUR RESPIR J, V6, P1455; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Wickman M, 2004, ALLERGY, V59, P30, DOI 10.1111/j.1398-9995.2004.00572.x; Wickman M, 2003, PEDIATR ALLERGY IMMU, V14, P441, DOI 10.1046/j.0905-6157.2003.00079.x; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Yman L, 2001, ALLERGY, V56, P70, DOI 10.1111/j.1398-9995.2001.00921.x; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041	29	179	184	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					744	749		10.1016/j.jaci.2005.06.032	http://dx.doi.org/10.1016/j.jaci.2005.06.032			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210045				2022-12-18	WOS:000235686600004
J	Roberts, G; Patel, N; Levi-Schaffer, F; Habibi, P; Lack, G				Roberts, G; Patel, N; Levi-Schaffer, F; Habibi, P; Lack, G			Food allergy as a risk factor for life-threatening asthma in childhood: A case-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; life-threatening asthma; lung function	HAY-FEVER; SENSITIZATION; CHILDREN; DEATHS; TRENDS; ASSOCIATION; ANAPHYLAXIS; MORTALITY; ENGLAND; PEANUT	Background: No objective clinical risk factors exist for pediatric life-threatening asthma. Objectives: In this study, we address whether persistent food allergy and degree of atopy are risk factors for life-threatening asthma. Methods: By use of a case-controlled design, children (1-16 years) ventilated for an exacerbation of asthma were enrolled. Each case was matched by sex, age, and ethnicity, with 2 controls who had attended with a non-life-threatening exacerbation. All subjects were assessed by means of a questionnaire, spirometry, and skin prick or RAST testing. The data were analyzed by conditional logistic regression. Results: Nineteen cases and 38 controls were enrolled. Compared with controls, cases were found to have the following risk factors: food allergy (odds ratio, 8.58; 95% CI, 1.85-39.71), multiple allergic diagnoses (4.42; 1.17-16.71), early onset of asthma (6.48; 1.36-30.85), and frequent admissions (14.2; 1.77-113.59). After regression analysis, only frequent admission with asthma (9.85; 1.04-93.27) and food allergy (5.89; 1.06-32.61) were independently associated with life-threatening asthma. Half the cases had food allergy compared with only 10% of controls. Conclusion: This study demonstrates that poorly controlled asthma and food allergy are significant risk factors for life-threatening asthma. More intensive management of this high-risk group of children might help to reduce future morbidity and mortality.	St Marys Hosp, Dept Paediat Allergy & Clin Immunol, London W2 1NY, England; Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel	Imperial College London; Hebrew University of Jerusalem	Lack, G (corresponding author), St Marys Hosp, Dept Paediat Allergy & Clin Immunol, Ground Floor Salton House,Praed St, London W2 1NY, England.			Lack, Gideon/0000-0001-7350-4021; Levi-Schaffer, Francesca/0000-0003-0620-2810; Roberts, Graham/0000-0003-2252-1248				Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Austin JB, 1999, ARCH DIS CHILD, V81, P225, DOI 10.1136/adc.81.3.225; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOUSQUET J, 1992, PEDIATR ALLERGY IMMU, V3, P206; Campbell MJ, 1997, BRIT MED J, V314, P1439, DOI 10.1136/bmj.314.7092.1439; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; ERNST P, 1993, AM REV RESPIR DIS, V148, P75, DOI 10.1164/ajrccm/148.1.75; Fallon PG, 2001, J IMMUNOL, V166, P2712, DOI 10.4049/jimmunol.166.4.2712; Garrett JE, 1996, THORAX, V51, P1093, DOI 10.1136/thx.51.11.1093; Hashimoto S, 2001, J ALLERGY CLIN IMMUN, V107, P1001, DOI 10.1067/mai.2001.114702; Hessel PA, 1999, ANN ALLERG ASTHMA IM, V83, P362, DOI 10.1016/S1081-1206(10)62832-3; Holgate ST, 1997, LANCET, V350, P5; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Jalaludin BB, 1999, AUST NZ J PUBL HEAL, V23, P595, DOI 10.1111/j.1467-842X.1999.tb01543.x; JARVIS D, 1997, ALLERGY ALLERGIC DIS; KHOT A, 1984, BRIT MED J, V289, P235, DOI 10.1136/bmj.289.6439.235; KRAVIS LP, 1987, J ALLERGY CLIN IMMUN, V80, P467, DOI 10.1016/0091-6749(87)90077-7; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; LESON S, 1995, J ASTHMA, V32, P285, DOI 10.3109/02770909509044836; LESON S, 1995, J ASTHMA, V32, P279; MAO Y, 1990, CAN J PUBLIC HEALTH, V81, P226; MILES J, 1995, CLIN EXP ALLERGY, V25, P1074; MILLER BD, 1989, AM J DIS CHILD, V143, P1294, DOI 10.1001/archpedi.1989.02150230052022; Moore BB, 2001, ANN ALLERG ASTHMA IM, V86, P190, DOI 10.1016/S1081-1206(10)62690-7; NAVARRO RL, 1993, BIOCYCLE, V34, P76; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Roberts G, 2002, ALLERGY, V57, P713, DOI 10.1034/j.1398-9995.2002.03366.x; ROBERTSON CF, 1990, MED J AUSTRALIA, V152, P511, DOI 10.5694/j.1326-5377.1990.tb125350.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; SCHWARTZ J, 1995, AM J RESP CRIT CARE, V152, P2176, DOI 10.1164/ajrccm.152.6.8520794; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P949, DOI 10.1111/j.1365-2222.1993.tb00280.x; Sicherer SH, 1998, IMMUNOL ALLERGY CLIN, V18, P49, DOI 10.1016/S0889-8561(05)70346-5; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; STRUNK RC, 1998, FATAL ASTHMA; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; WESTERMAN DE, 1979, AM J MED, V66, P565, DOI 10.1016/0002-9343(79)91165-3	40	179	188	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					168	174		10.1067/mai.2003.1569	http://dx.doi.org/10.1067/mai.2003.1569			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847494				2022-12-18	WOS:000184010600025
J	Montuschi, P; Barnes, PJ				Montuschi, P; Barnes, PJ			Exhaled leukotrienes and prostaglandins in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						leukotrienes; prostaglandins; exhaled breath condensate; nitric oxide; asthma; airway inflammation; noninvasive markers	OXIDATIVE STRESS; NITRIC-OXIDE; 8-ISOPROSTANE; INFLAMMATION; CONDENSATE; RESPONSES; E-4	Background: Most of the studies investigating the role of leukotrienes (LTs) and prostaglandins (PGs) in asthma have used invasive (eg, bronchoalveolar lavage fluid) or semi-invasive leg, sputum induction) techniques. Others have measured eicosanoids in plasma or urine, probably reflecting systemic rather than lung inflammation. Collection of exhaled breath condensate (EBC) is a noninvasive method to collect airway secretions. Objective: We sought to investigate whether eicosanoids are measurable in EBC, to show possible differences in their concentrations in asthmatic patients and healthy subjects, and to investigate whether exhaled eicosanoids correlate with exhaled nitric oxide (NO), a marker of airway inflammation. Methods: Twelve healthy nonsmokers and 15 steroid-naive patients with mild asthma were studied. Subjects attended on one occasion for pulmonary function tests, collection of EBC, and exhaled NO measurements. Exhaled LTB4-like immunoreactivity, LTE4-like immunoreactivity, PGE(2)-like immunoreactivity, PGD(2)-methoxime, PGF(2alpha)-like immunoreactivity, and thromboxane B-2-like immunoreactivity were measured by means of enzyme immunoassays. Results: LTE4-like immunoreactivity and LTB4-like immunoreactivity were detectable in EBC in healthy subjects, and their levels in asthmatic patients were increased about 3-fold (P < .0001) and 2-fold (P < .0005), respectively. Exhaled NO was increased in asthmatic patients compared with healthy subjects (P < .0001). There was a correlation between exhaled LTB4 and exhaled NO (r = 0.56, P < .04) in patients with asthma. When measurable, prostanoid levels were similar in asthmatic patients and control subjects. Conclusions: Exhaled LTE4 and LTB4 are increased in steroid-naive patients with mild asthma. EBC may be proved to be a novel method to monitor airway inflammation in asthma.	Univ Cattolica Sacro Cuore, Dept Pharmacol, Sch Med, I-00168 Rome, Italy; Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll, Sch Med, London, England	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Imperial College London	Montuschi, P (corresponding author), Univ Cattolica Sacro Cuore, Dept Pharmacol, Sch Med, Lgo F Vito 1, I-00168 Rome, Italy.			Barnes, Peter/0000-0002-5122-4018; MONTUSCHI, Paolo/0000-0001-5589-1750				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ANTEZAK A, 2001, AM J RESP CRIT CARE, V163, pA48; ASANO K, 1995, J ALLERGY CLIN IMMUN, V96, P643, DOI 10.1016/S0091-6749(95)70263-6; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Busse WW, 1998, AM J RESP CRIT CARE, V157, pS210, DOI 10.1164/ajrccm.157.6.mar-1; Chavis C, 1997, ALLERGY, V52, P589, DOI 10.1111/j.1398-9995.1997.tb02606.x; CHINN S, 1991, THORAX, V46, P454, DOI 10.1136/thx.46.6.454; Deykin A, 2000, AM J RESP CRIT CARE, V162, P1685, DOI 10.1164/ajrccm.162.5.9911081; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273, DOI 10.1164/ajrccm.162.4.9912064; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kumlin M, 2000, AM J RESP CRIT CARE, V161, pS102, DOI 10.1164/ajrccm.161.supplement_1.ltta-20; Leff AR, 2000, AM J RESP CRIT CARE, V161, pS125, DOI 10.1164/ajrccm.161.supplement_1.ltta-25; MATHE AA, 1975, AM REV RESPIR DIS, V111, P313; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216, DOI 10.1164/ajrccm.160.1.9809140; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Nightingale JA, 1998, THORAX, V53, P87, DOI 10.1136/thx.53.2.87; *NIH NAT HEART LUN, 1997, PUBL; NOVERAL JP, 1992, AM J PHYSIOL, V263, pL555, DOI 10.1152/ajplung.1992.263.5.L555; O'Byrne PM, 2000, AM J RESP CRIT CARE, V161, pS186, DOI 10.1164/ajrccm.161.supplement_2.a1q4-8; Pavord ID, 1999, AM J RESP CRIT CARE, V160, P1905, DOI 10.1164/ajrccm.160.6.9903114; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; SEGGEV JS, 1991, CHEST, V99, P289, DOI 10.1378/chest.99.2.289; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802	29	179	185	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					615	620		10.1067/mai.2002.122461	http://dx.doi.org/10.1067/mai.2002.122461			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941309				2022-12-18	WOS:000175132600007
J	Mekori, YA; Metcalfe, DD				Mekori, YA; Metcalfe, DD			Mast cell-T cell interactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cell; T cell; adhesion; antigen presentation; chemotaxis; cytokines; degranulation; migration	FC-EPSILON-RI; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; INTERCELLULAR-ADHESION MOLECULE-1; LYMPHOCYTE CHEMOATTRACTANT FACTOR; MESSENGER-RNA EXPRESSION; CYTOKINE PRODUCTION; LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; IGE SYNTHESIS; IN-VIVO	In addition to being a major effector cell in the elicitation of allergic inflammation, mast cells have been found to be activated in various T cell-mediated inflammatory processes and to reside in close physical proximity to T cells, Such observations and the wide spectrum of mediators produced and secreted by mast cells have led investigators to propose a functional relationship between these 2 cell populations. Indeed, mast cell activation has been reported to induce T-cell migration either directly by the release of chemotactic factors, such as lymphotactin or IL-16, or indirectly by the induction of adhesion molecule expression on endothelial cells, Mast cells are also able to present antigens to T cells, resulting in their activation in either an MHC class I- or class II-restricted and costimulatory molecule-dependent fashion. Adhesion molecule-dependent intercellular contact or MHC class II cognate interactions between T cells and mast cells result in the release of both granule-associated mediators and cytokines from the latter, Also, T cell-derived mediators, such as beta-chemokines, directly induce mast cell degranulation, On the other hand, mast cell-derived cytokines, such as IL-4, have been found to polarize T cells to preferentially differentiate into the T-H2 subset. Thus T cell-mast fell interactions are bidirectional, fulfilling regulatory and/or modulatory roles affecting various aspects of the immune response.	Tel Aviv Univ, Sackler Sch Med, Kefar Sava, Israel; NIAID, Lab Allerg Dis, NIH, Bethesda, MD USA; Meir Hosp, Dept Med B, Allergy Clin Immunol Unit, IL-44281 Kefar Sava, Israel	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tel Aviv University; Sackler Faculty of Medicine	Mekori, YA (corresponding author), Meir Hosp, Dept Med B, Allergy Clin Immunol Unit, IL-44281 Kefar Sava, Israel.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000513, Z01AI000513] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1994, J IMMUNOL, V152, P1298; ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; ALBER G, 1992, J IMMUNOL, V149, P2428; BELLINI A, 1993, J ALLERGY CLIN IMMUN, V92, P412, DOI 10.1016/0091-6749(93)90120-5; Bhattacharyya SP, 1998, J LEUKOCYTE BIOL, V63, P337, DOI 10.1002/jlb.63.3.337; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BRADDING P, 1993, J IMMUNOL, V151, P3853; CENTER DM, 1983, J ALLERGY CLIN IMMUN, V71, P29, DOI 10.1016/0091-6749(83)90543-2; CHEN XJ, 1994, IMMUNOLOGY, V83, P595; Columbo M, 1996, CLIN IMMUNOL IMMUNOP, V81, P68, DOI 10.1006/clin.1996.0159; Compton SJ, 1998, J IMMUNOL, V161, P1939; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; FOX CC, 1994, CELL IMMUNOL, V158, P253, DOI 10.1006/cimm.1994.1272; Frandji P, 1996, EUR J IMMUNOL, V26, P2517, DOI 10.1002/eji.1830261036; FRANDJI P, 1993, J IMMUNOL, V151, P6318; Frandji P, 1998, EUR J IMMUNOL, V28, P844, DOI 10.1002/(SICI)1521-4141(199803)28:03<844::AID-IMMU844>3.3.CO;2-W; FRIEDMAN MM, 1985, J ALLERGY CLIN IMMUN, V76, P70, DOI 10.1016/0091-6749(85)90807-3; GABOURY JP, 1995, J IMMUNOL, V154, P804; Galli SJ, 1997, J EXP MED, V186, P343, DOI 10.1084/jem.186.3.343; GALLI SJ, 1991, CURR OPIN IMMUNOL, V3, P865, DOI 10.1016/S0952-7915(05)80005-6; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Geba GP, 1996, J IMMUNOL, V157, P557; GRUBER BL, 1994, J IMMUNOL, V152, P5860; GRUBER BL, 1995, BLOOD, V86, P2488; HERSHKOVIZ R, 1994, J LEUKOCYTE BIOL, V56, P495, DOI 10.1002/jlb.56.4.495; HUELS C, 1995, INT IMMUNOL, V7, P525, DOI 10.1093/intimm/7.4.525; Inamura N, 1998, J IMMUNOL, V160, P4026; KIRSHNASAWAMY G, 1997, J INTERFERON CYTOKIN, V17, P167; KUBES P, 1994, J IMMUNOL, V152, P3570; LABERGE S, 1995, J IMMUNOL, V155, P2902; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; Leung DYM, 1997, PEDIATR RES, V42, P559, DOI 10.1203/00006450-199711000-00001; LEVISCHAFFER F, 1991, IMMUNOLOGY, V72, P174; Love KS, 1996, CELL IMMUNOL, V170, P85, DOI 10.1006/cimm.1996.0137; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Malaviya R, 1996, J IMMUNOL, V156, P1490; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; MATSUURA N, 1989, J EXP MED, V170, P1421, DOI 10.1084/jem.170.4.1421; Mecheri S, 1997, IMMUNOL TODAY, V18, P212; MEKORI YA, 1994, J IMMUNOL, V153, P2194; MENG H, 1995, J CELL PHYSIOL, V165, P40, DOI 10.1002/jcp.1041650106; MENG H, 1995, J INVEST DERMATOL, V105, P789, DOI 10.1111/1523-1747.ep12326075; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; MOLLER A, 1993, J IMMUNOL, V151, P3261; Nilsson G, 1996, J IMMUNOL, V157, P1693; NILSSON G, 1994, J IMMUNOL, V153, P3717; Oh CK, 1996, BIOCHEM BIOPH RES CO, V221, P510, DOI 10.1006/bbrc.1996.0627; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Petersen LJ, 1996, J ALLERGY CLIN IMMUN, V98, P790, DOI 10.1016/S0091-6749(96)70128-8; PFEIFER JD, 1987, J EXP MED, V166, P1464, DOI 10.1084/jem.166.5.1464; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Rumsaeng V, 1997, J IMMUNOL, V158, P1353; Rumsaeng V, 1997, J IMMUNOL, V159, P2904; Smith TJ, 1996, IMMUNOL TODAY, V17, P60, DOI 10.1016/0167-5699(96)80580-9; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SVETIC A, 1993, J IMMUNOL, V150, P3434; TAUB D, 1995, J IMMUNOL, V154, P233; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; VANSEVENTER GA, 1992, J IMMUNOL, V149, P3872; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; Wang HW, 1998, J CLIN INVEST, V102, P1617, DOI 10.1172/JCI3704; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; Wershil BK, 1996, GASTROENTEROLOGY, V110, P1482, DOI 10.1053/gast.1996.v110.pm8613053; WHERSHIL BK, 1991, J CLIN INVEST, V87, P446	67	179	185	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				517	523		10.1016/S0091-6749(99)70316-7	http://dx.doi.org/10.1016/S0091-6749(99)70316-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482820	Bronze			2022-12-18	WOS:000082870000008
J	Almqvist, C; Larsson, PH; Egmar, AC; Hedren, M; Malmberg, P; Wickman, M				Almqvist, C; Larsson, PH; Egmar, AC; Hedren, M; Malmberg, P; Wickman, M			School as a risk environment for children allergic to cats and a site for transfer of cat allergen to homes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; cat; Fel d 1; school; environment; air sampling; clothes; pets; transfer	FEL-D-I; F-I; DOG; EXPOSURE; ASTHMA; SENSITIZATION; DUST; MITE; SCHOOLCHILDREN; DEPOSITION	Background: Many children are allergic to furred pets and avoid direct pet contact. The school may be a site of indirect exposure to pet allergens, which may induce or maintain symptoms of allergic diseases. Objective: We sought to investigate airborne levels of cat allergen (Fel d 1) at schools and in homes with or without cats and to study clothes as a route for dissemination of allergens between homes and school. Methods: Airborne fat allergen was collected with personal samplers from (1) children attending classes with many >25%) or few (<10%) cat owners and (2) homes with or without eats. A recently developed amplified ELISA assay, which detects low levels of airborne cat allergen in pet-free environments, was used. Dust samples were collected from clothes and mattresses. Results: There was a 5-fold difference in the median levels of airborne cat allergen between classes with many and few eat owners (2.94 vs 0.59 ng/m(3); P < .001). The median airborne cat allergen concentration in classes with many cat owners was significantly higher than that found in the homes of non-fat owners (P < .001) but lower than that found in homes with eats (P < .001). Allergen levels in non-cat owners' clothes increased after a school day (P < .001), Non-cat owners in classes with many cat owners had higher levels of mattress-bound cat allergen (P = .01). Conclusion: The results indicate significant exposure to fat allergen at school, Allergen is spread through clothing from homes with cats to classrooms. There the allergen is dispersed in air and contaminates the clothes of children without cats. The allergen levels in non-cat owners' homes correlate with exposure to cat allergen at school.	Karolinska Hosp, Dept Environm Hlth, S-17176 Stockholm, Sweden; Karolinska Inst, Astrid Lindgren Childrens Hosp, Dept Woman & Child Hlth, S-10401 Stockholm, Sweden; Natl Inst Working Life, Stockholm, Sweden; Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; Karolinska Hosp, Dept Clin Immunol & Transfus Med, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Almqvist, C (corresponding author), Karolinska Hosp, Dept Environm Hlth, Norrbacka Bldg,Level 3, S-17176 Stockholm, Sweden.			Egmar, Ann-Charlotte/0000-0003-2504-343X				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; Bollinger ME, 1998, J ALLERGY CLIN IMMUN, V101, P124, DOI 10.1016/S0091-6749(98)70203-9; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Egmar AC, 1998, PEDIATR ALLERGY IMMU, V9, P31, DOI 10.1111/j.1399-3038.1998.tb00297.x; Egmar AC, 1998, ALLERGY, V53, P957, DOI 10.1111/j.1398-9995.1998.tb03796.x; ENBERG RN, 1993, ANN ALLERGY, V70, P471; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; Roquet A, 1998, APMIS, V106, P293, DOI 10.1111/j.1699-0463.1998.tb01349.x; SAKAGUCHI M, 1993, J ALLERGY CLIN IMMUN, V92, P797, DOI 10.1016/0091-6749(93)90056-L; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner J, 1990, PEDIATR ALLERGY IMMU, V1, P79; WICKMAN M, 1992, PEDIATRIC ALLERGY IM, V3, P128; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOODCOCK A, 1995, J ALLERGY CLIN IMMUN, V95, P326	26	179	181	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1012	1017		10.1016/S0091-6749(99)70172-7	http://dx.doi.org/10.1016/S0091-6749(99)70172-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359879				2022-12-18	WOS:000080929500006
J	BRODER, I; HIGGINS, MW; MATHEWS, KP; KELLER, JB				BRODER, I; HIGGINS, MW; MATHEWS, KP; KELLER, JB			EPIDEMIOLOGY OF ASTHMA AND ALLERGIC RHINITIS IN A TOTAL COMMUNITY, TECUMSEH, MICHIGAN .3. SECOND SURVEY OF COMMUNITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,DEPT INTERN MED,ANN ARBOR,MI 48104; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								ALANKO K, 1970, SCAND J RESPIR DIS, P1; ANDERSON DO, 1965, CAN MED ASSOC J, V92, P1007; BRODER I, 1962, J ALLERGY, V33, P513, DOI 10.1016/0021-8707(62)90019-9; BRODER I, IN PRESS; EPSTEIN FH, 1965, AM J EPIDEMIOL, V81, P307, DOI 10.1093/oxfordjournals.aje.a120517; EPSTEIN FH, 1970, ARCH ENVIRON HEALTH, V21, P402, DOI 10.1080/00039896.1970.10667258; FERRIS BG, 1962, AM REV RESPIR DIS, V86, P165; FREEMAN GL, 1969, AM J DIS CHILD, V118, P886, DOI 10.1001/archpedi.1969.02100040888012; FRY J, 1961, BRIT MED J, V1, P227, DOI 10.1136/bmj.1.5221.227; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HIGGINS MW, UNPUBLISHED DATA; HUHTI E, 1965, ACTA TUBERC SCAN S61, P1; MATERNOWSKI CJ, 1962, J ALLERGY, V33, P130; MUELLER RE, 1971, AM REV RESPIR DIS, V103, P209; NAPIER JA, 1970, COMMUNITY EPIDEMIOLO, pCH2; PEARSON R S B, 1958, Acta Allergol, V12, P277; PORTER R, 1971, 38 CIBA F STUD GROUP; Selander PER, 1960, ACTA PAEDIATR, V49, P265; SMITH JM, 1961, BRIT MED J, V1, P711, DOI 10.1136/bmj.1.5227.711; SMITH JM, 1965, AM REV RESPIR DIS, V92, P16; SMITH JM, 1965, AM REV RESPIR DIS, V92, P31; WALTHER T, 1955, ASTHMA NORWEGIAN CHI; WASHBURN TC, 1965, PEDIATRICS, V35, P57; WILLIAMS D A, 1958, Acta Allergol, V12, P376, DOI 10.1111/j.1398-9995.1958.tb04007.x; WILLIAMS EO, 1949, BMJ-BRIT MED J, V2, P897, DOI 10.1136/bmj.2.4633.897	25	179	179	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	3					127	138		10.1016/0091-6749(74)90001-3	http://dx.doi.org/10.1016/0091-6749(74)90001-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S3550	4813888				2022-12-18	WOS:A1974S355000001
J	Lindsley, AW; Schwartz, JT; Rothenberg, ME				Lindsley, Andrew W.; Schwartz, Justin T.; Rothenberg, Marc E.			Eosinophil responses during COVID-19 infections and coronavirus vaccination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Coronavirus; COVID-19; eosinophils; immunopathology; immunopotentiation; SARS; vaccines	ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING DOMAIN; SARS-COV; ANTIVIRAL IMMUNITY; SEVERE ASTHMA; MICE; CHILDREN; SPIKE; ACTIVATION; PROTECTION	Eosinophils are circulating and tissue-resident leukocytes that have potent proinflammatory effects in a number of diseases. Recently, eosinophils have been shown to have various other functions, including immunoregulation and antiviral activity. Eosinophil levels vary dramatically in a number of clinical settings, especially following eosinophil-targeted therapy, which is now available to selectively deplete these cells. There are key coronavirus disease 2019 (COVID-19)-related questions concerning eosinophils whose answers affect recommended prevention and care. First, do patients with eosinophiliaassociated diseases have an altered course of COVID-19? Second, do patients with eosinopenia (now intentionally induced by biological drugs) have unique COVID-19 susceptibility and/or disease course? This is a particularly relevant question because eosinopenia is associated with acute respiratory deterioration during infection with the severe acute respiratory syndrome coronavirus 2, the causative agent of COVID-19. Third, do eosinophils contribute to the lung pathology induced during COVID-19 and will they contribute to immunopotentiation potentially associated with emerging COVID-19 vaccines? Herein, we address these timely questions and project considerations during the emerging COVID-19 pandemic.	[Lindsley, Andrew W.; Schwartz, Justin T.; Rothenberg, Marc E.] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	Lin, Chen/AFV-2163-2022	Schwartz, Justin/0000-0001-6472-5877	CURED Foundation	CURED Foundation	Dr Rothenberg thanks the CURED Foundation and Dave and Denise Bunning Fund for kind donations, and the authors thank Shawna Hottinger for editorial assistance.	Arden KE, 2010, J MED VIROL, V82, P1458, DOI 10.1002/jmv.21819; Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]; BASS DA, 1975, J CLIN INVEST, V56, P870, DOI 10.1172/JCI108166; Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101; Bjerregaard A, 2017, CLIN EXP ALLERGY, V47, P1007, DOI 10.1111/cea.12935; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101; Burris D, 2019, J ALLER CL IMM-PRACT, V7, P2750, DOI 10.1016/j.jaip.2019.05.011; Busse W, 2019, J ALLERGY CLIN IMMUN, V143, P190, DOI 10.1016/j.jaci.2018.08.031; Busse WW, 2019, LANCET RESP MED, V7, P46, DOI 10.1016/S2213-2600(18)30406-5; Butterfield JH, 2007, IMMUNOL ALLERGY CLIN, V27, P493, DOI 10.1016/j.iac.2007.06.003; Castilow EM, 2007, IMMUNOL RES, V39, P225, DOI 10.1007/s12026-007-0071-6; Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6; Clark CM, 2017, CURR CLIN MICROBIOL, V4, P202, DOI 10.1007/s40588-017-0074-6; Clay C, 2012, J VIROL, V86, P4234, DOI 10.1128/JVI.06791-11; Davoine F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00570; DELPOZO V, 1992, EUR J IMMUNOL, V22, P1919; Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525; Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322; Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P3358, DOI 10.1093/nar/26.14.3358; Drake MG, 2016, AM J RESP CELL MOL, V55, P387, DOI 10.1165/rcmb.2015-0405OC; Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031; Du LY, 2010, VIRAL IMMUNOL, V23, P211, DOI 10.1089/vim.2009.0090; Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC; Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Flores-Torres AS, 2019, VIRAL IMMUNOL, V32, P198, DOI 10.1089/vim.2018.0150; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Haagmans BL, 2005, 10 INT NID S COL SPR; Handzel ZT, 1998, J IMMUNOL, V160, P1279; Hassani M, 2020, J LEUKOCYTE BIOL, V108, P1665, DOI 10.1002/JLB.1AB1219-493R; Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14; Ishii K, 2009, MICROBIOL IMMUNOL, V53, P75, DOI 10.1111/j.1348-0421.2008.00097.x; Iwata-Yoshikawa N, 2014, J VIROL, V88, P8597, DOI 10.1128/JVI.00983-14; Jackson DJ, 2020, DRUG SAFETY, V43, P409, DOI 10.1007/s40264-020-00926-3; Jiang SB, 2012, EXPERT REV VACCINES, V11, P1405, DOI [10.1586/ERV.12.126, 10.1586/erv.12.126]; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Juhn YJ, 2014, J ALLERGY CLIN IMMUN, V134, P247, DOI 10.1016/j.jaci.2014.04.024; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; Katial RK, 2017, J ALLER CL IMM-PRACT, V5, pS1, DOI 10.1016/j.jaip.2016.11.029; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Laidlaw TM, 2020, ANN ALLERG ASTHMA IM, V124, P326, DOI 10.1016/j.anai.2019.12.001; Lavoignet CE, 2019, EUR J CLIN MICROBIOL, V38, P1523, DOI 10.1007/s10096-019-03583-2; Li X, J ALLERGY CLIN IMMUN, DOI [10.1016/j.jaci.2020.04., DOI 10.1016/J.JACI.2020.04.]; Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013; Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002; Lugogo N, 2016, CLIN THER, V38, P2058, DOI 10.1016/j.clinthera.2016.07.010; Malinczak CA, 2019, MUCOSAL IMMUNOL, V12, P969, DOI 10.1038/s41385-019-0171-3; Mansson A, 2010, INT ARCH ALLERGY IMM, V151, P118, DOI 10.1159/000236001; Mo P, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa270., DOI 10.1093/CID/CIAA270, 10.1093/cid/ciaa270]; Nagase H, 2003, J IMMUNOL, V171, P3977, DOI 10.4049/jimmunol.171.8.3977; Phipps S, 2007, BLOOD, V110, P1578, DOI 10.1182/blood-2007-01-071340; Pineros YSS, 2019, AM J RESP CRIT CARE, V199, P508, DOI 10.1164/rccm.201803-0461OC; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Qiu MF, 2005, MICROBES INFECT, V7, P882, DOI 10.1016/j.micinf.2005.02.006; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Samarasinghe AE, 2017, J IMMUNOL, V198, P3214, DOI 10.4049/jimmunol.1600787; Schwartz JT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01944; Silveira JS, 2019, ASIA PAC ALLERGY, V9, DOI 10.5415/apallergy.2019.9.e32; Su YC, 2015, J VIROL, V89, P1564, DOI 10.1128/JVI.01536-14; Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004; Weller PF, 2017, NAT REV IMMUNOL, V17, P746, DOI 10.1038/nri.2017.95; Winthrop KL, 2018, CLIN MICROBIOL INFEC, V24, pS21, DOI 10.1016/j.cmi.2018.02.002; Wong CK, 2007, AM J RESP CELL MOL, V37, P85, DOI 10.1165/rcmb.2006-0457OC; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337; Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196; Yousefi S, 2018, J LEUKOCYTE BIOL, V104, P205, DOI 10.1002/JLB.3AB1117-455R; Zhang JJ, 2020, ALLERGY, V75, P1809, DOI 10.1111/all.14316; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	77	178	183	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					1	7		10.1016/j.jaci.2020.04.021	http://dx.doi.org/10.1016/j.jaci.2020.04.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32344056	Green Published, Bronze			2022-12-18	WOS:000579170500001
J	Hastie, AT; Moore, WC; Li, HS; Rector, BM; Ortega, VE; Pascual, RM; Peters, SP; Meyers, DA; Bleecker, ER				Hastie, Annette T.; Moore, Wendy C.; Li, Huashi; Rector, Brian M.; Ortega, Victor E.; Pascual, Rodolfo M.; Peters, Stephen P.; Meyers, Deborah A.; Bleecker, Eugene R.		Natl Heart Lung Blood Inst Severe	Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma phenotypes; sputum eosinophils and neutrophils; inflammatory biomarker surrogates; TH2 biomarkers; fraction of exhaled nitric oxide	EXHALED NITRIC-OXIDE; BREATH CONDENSATE PH; AIRWAY INFLAMMATION; CELL COUNTS; MILD; ADULTS; IDENTIFICATION; SUBTYPES; MARKERS; LUNG	Background: Sputum eosinophil percentages are a strong predictor of airway inflammation and exacerbations and aid asthma management, whereas sputum neutrophil percentages indicate a different severe asthma phenotype that is potentially less responsive to T(H)2-targeted therapy. Variables, such as blood eosinophil counts, total IgE levels, fraction of exhaled nitric oxide (FENO) levels, or FEV1 percent predicted, might predict airway eosinophil percentages, whereas age, FEV1 percent predicted, or blood neutrophil counts might predict sputum neutrophil percentages. Availability and ease of measurement are useful characteristics, but accuracy in predicting airway eosinophil and neutrophil percentages either individually or combined is not established. Objectives: We sought to determine whether blood eosinophil counts, FENO levels, and IgE levels accurately predict sputum eosinophil percentages and whether age, FEV1 percent predicted, and blood neutrophil counts accurately predict sputum neutrophil percentages. Methods: Subjects in the Wake Forest Severe Asthma Research Program (n = 328) were characterized by blood and sputum cell counts, health care use, lung function, FENO levels, and IgE levels. Multiple analytic techniques were used. Results: Despite significant association with sputum eosinophil percentages, blood eosinophil counts, FENO levels, and total IgE levels did not accurately predict sputum eosinophil percentages, and combinations of these variables did not improve prediction. Age, FEV1 percent predicted, and blood neutrophil counts were similarly unsatisfactory for the prediction of sputum neutrophil percentages. Factor analysis and stepwise selection found FENO levels, IgE levels, and FEV1 percent predicted, but not blood eosinophil counts, correctly predicted 69% of sputum eosinophil percentages of less than 2% or 2% and greater. Likewise, age, asthma duration, and blood neutrophil counts correctly predicted 64% of sputum neutrophil percentages of less than 40% or 40% and greater. A model to predict both sputum eosinophil and neutrophil percentages accurately assigned only 41% of samples. Conclusion: Despite statistically significant associations, FENO levels, IgE levels, blood eosinophil and neutrophil counts, FEV1 percent predicted, and age are poor surrogates, both separately and combined, for accurately predicting sputum eosinophil and neutrophil percentages.	[Hastie, Annette T.; Moore, Wendy C.; Li, Huashi; Rector, Brian M.; Ortega, Victor E.; Pascual, Rodolfo M.; Peters, Stephen P.; Meyers, Deborah A.; Bleecker, Eugene R.; Natl Heart Lung Blood Inst Severe] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27157 USA	Wake Forest University	Hastie, AT (corresponding author), Wake Forest Sch Med, Ctr Genom & Personalized Med Res, NRC G70, Winston Salem, NC 27157 USA.	ahastie@wakehealth.edu			National Heart, Lung, and Blood Institute Severe Asthma Research Program [HL69167, U10HL109164, RC2HL101487]; National Heart, Lung, and Blood Institute (NHLBI); Actelion; National Institutes of Health (NIH)/NHLBI; Merck; Integrity CE; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109164, RC2HL101487, R01HL069167] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute Severe Asthma Research Program; National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Actelion; National Institutes of Health (NIH)/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Merck(Merck & Company); Integrity CE; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the National Heart, Lung, and Blood Institute Severe Asthma Research Program Awards HL69167, U10HL109164, and RC2HL101487.; Disclosure of potential conflict of interest: A. T. Hastie, W. C. Moore, B. M Rector, and D. A. Meyers have received grants from the National Heart, Lung, and Blood Institute (NHLBI). R. M. Pascual has consultant arrangements with United Therapeutics and has received grants from Actelion. S. P. Peters has received a grant and travel support from the National Institutes of Health (NIH)/NHLBI; has served on advisory boards for AstraZeneca, Aerocrine, Merck, Targacept, and TEVA; has received payment for lectures from Merck and Integrity CE; and has received royalties from UpToDate. E. R. Bleecker has received grants and travel support from the NIH/NHLBI. The rest of the authors declare that they have no relevant conflicts of interest.	Balbi B, 2007, EUR RESPIR J, V30, P769, DOI 10.1183/09031936.00112306; Barnes PJ, 2010, CHEST, V138, P682, DOI 10.1378/chest.09-2090; Bartoli ML, 2004, RESP MED, V98, P184, DOI 10.1016/j.rmed.2003.09.012; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Black PN, 2001, AM J RESP CRIT CARE, V164, P536, DOI 10.1164/ajrccm.164.4.2011040; Boulet LP, 2006, CHEST, V129, P661, DOI 10.1378/chest.129.3.661; Calhoun WJ, 2012, JAMA-J AM MED ASSOC, V308, P987, DOI 10.1001/2012.jama.10893; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cowan DC, 2010, THORAX, V65, P384, DOI 10.1136/thx.2009.126722; Deykin A, 2005, J ALLERGY CLIN IMMUN, V115, P720, DOI 10.1016/j.jaci.2004.12.1129; Dottorini T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022319; Ducharme ME, 2011, RESP MED, V105, P1284, DOI 10.1016/j.rmed.2011.04.006; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Gruchalla RS, 2009, J ALLERGY CLIN IMMUN, V124, P213, DOI 10.1016/j.jaci.2009.05.036; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hillas G, 2011, RESPIROLOGY, V16, P811, DOI 10.1111/j.1440-1843.2011.01984.x; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Kuhl K, 2012, CURR OPIN PULM MED, V18, P1, DOI 10.1097/MCP.0b013e32834deebb; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Lim S, 2000, THORAX, V55, P184, DOI 10.1136/thorax.55.3.184; Lim S, 2001, AM J RESP CRIT CARE, V164, P273, DOI 10.1164/ajrccm.164.2.2006043; Little SA, 2002, AM J MED, V112, P446, DOI 10.1016/S0002-9343(02)01047-1; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Maneechotesuwan K, 2007, CHEST, V132, P98, DOI 10.1378/chest.06-2982; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nadif R, 2009, THORAX, V64, P374, DOI 10.1136/thx.2008.103069; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Nair P, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.032; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nightingale JA, 1999, THORAX, V54, P1061, DOI 10.1136/thx.54.12.1061; Paone G, 2011, DIS MARKERS, V31, P91, DOI [10.1155/2011/139493, 10.3233/DMA-2011-0807]; Petsky HL, 2012, THORAX, V67, P199, DOI 10.1136/thx.2010.135574; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Sato S, 2008, RESP MED, V102, P1452, DOI 10.1016/j.rmed.2008.04.018; Schleich FN, 2010, THORAX, V65, P1039, DOI 10.1136/thx.2009.124925; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; Thomas RA, 2004, CHEST, V126, P1811, DOI 10.1016/S0012-3692(15)31427-6; Tseliou E, 2010, CHEST, V138, P107, DOI 10.1378/chest.09-1257; Uddin M, 2010, THORAX, V65, P684, DOI 10.1136/thx.2009.120741; Wang YH, 2011, CURR ALLERGY ASTHM R, V11, P388, DOI 10.1007/s11882-011-0210-y; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Woodruff PG, 2001, J ALLERGY CLIN IMMUN, V108, P753, DOI 10.1067/mai.2001.119411; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yap E, 2011, INTERN MED J, V43, P46	69	178	182	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					72	U150		10.1016/j.jaci.2013.03.044	http://dx.doi.org/10.1016/j.jaci.2013.03.044			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23706399	Green Accepted			2022-12-18	WOS:000321052300009
J	Rondon, C; Campo, P; Togias, A; Fokkens, WJ; Durham, SR; Powe, DG; Mullol, J; Blanca, M				Rondon, Carmen; Campo, Paloma; Togias, Alkis; Fokkens, Wytske J.; Durham, Stephen R.; Powe, Desmond G.; Mullol, Joaquim; Blanca, Miguel			Local allergic rhinitis: Concept, pathophysiology, and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; eosinophil cationic protein; entopy; local allergic rhinitis; local specific IgE; nasal polyps; nonallergic rhinitis; nasal allergen provocation test; tryptase	IDIOPATHIC RHINITIS; PROVOCATION TEST; IGE ANTIBODIES; MESSENGER-RNA; ABSENCE; CELLS; PTERONYSSINUS; CHALLENGES; DISEASE; MUCOSA	Local allergic rhinitis (LAR) is a localized nasal allergic response in the absence of systemic atopy characterized by local production of specific IgE (sIgE) antibodies, a T(H)2 pattern of mucosal cell infiltration during natural exposure to aeroallergens, and a positive nasal allergen provocation test response with release of inflammatory mediators (tryptase and eosinophil cationic protein). Although the prevalence remains to be established, a number of patients previously given a diagnosis of nonallergic rhinitis or idiopathic rhinitis are now being classified as having LAR. Culprit allergens responsible include house dust mite, grass and olive pollens, and many others. For the diagnosis of LAR, neither skin prick testing nor determination of the presence of serum sIgE antibodies is useful, and a nasal allergen provocation test is needed to identify the culprit allergen or allergens. In a certain proportion of cases, local sIgE can be detected, and conjunctivitis, asthma, or both can be associated. Whether patients with LAR will have systemic atopy in the future is a matter of debate. Further studies are needed for examine the prevalence of this phenomenon in different areas, to improve the diagnostic methods to better identify these patients, and to develop therapeutic approaches, including the use of immunotherapy. (J Allergy Clin Immunol 2012;129:1460-7.)	[Rondon, Carmen; Campo, Paloma; Blanca, Miguel] Carlos Haya Hosp, Allergy Serv, Malaga, Spain; [Togias, Alkis] NIAID, Asthma Allergy & Inflammat Branch, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Fokkens, Wytske J.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands; [Durham, Stephen R.] Imperial Coll Sch Med, Natl Heart & Lung Inst, London, England; [Powe, Desmond G.] Nottingham Trent Univ, John Van Geest Canc Res Ctr, Nottingham, England; [Powe, Desmond G.] Nottingham Trent Univ, Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Dept Cellular Pathol, Nottingham, England; [Mullol, Joaquim] CIBERES, Hosp Clin IDIBAPS, ENT Dept, Rhinol Unit, Barcelona, Spain; [Mullol, Joaquim] CIBERES, Hosp Clin IDIBAPS, ENT Dept, Smell Clin, Barcelona, Spain	Hospital Carlos Haya; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Amsterdam; Academic Medical Center Amsterdam; Imperial College London; Nottingham Trent University; Nottingham Trent University; Nottingham University Hospital NHS Trust; University of Nottingham; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Rondon, C (corresponding author), Hosp Civil, Lab Invest, Pabellon 5,Plaza Hosp Civil, Malaga 29009, Spain.	carmenrs61@gmail.com	Fokkens, Wytske WJ/ABF-2185-2020	RONDON SEGOVIA, CARMEN/0000-0003-0976-3402	GlaxoSmithKline; Medtronic; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish	GlaxoSmithKline(GlaxoSmithKline); Medtronic(Medtronic); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	W. J. Fokkens has received research support from GlaxoSmithKline and Medtronic and has served as an advisor to GlaxoSmith Kline, MSD, and Stallergenes. The rest of the authors declare that they have no relevant conflicts of interest.	BLOM HM, 1995, EUR ARCH OTO-RHINO-L, V252, pS33, DOI 10.1007/BF02484432; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Campo P, 2011, J ALLERGY CLIN IMMUN, V127, pAB6, DOI 10.1016/j.jaci.2010.12.038; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; HUGGINS KG, 1975, LANCET, V2, P148; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Lopez S, 2010, CLIN EXP ALLERGY, V40, P1007, DOI 10.1111/j.1365-2222.2010.03492.x; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; Powe DG, 2010, J ALLERGY CLIN IMMUN, V125, P139, DOI 10.1016/j.jaci.2009.07.025; Powe DG, 2004, ALLERGY, V59, P204, DOI 10.1046/j.1398-9995.2003.00315.x; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; Rondon C, 2008, ALLERGY, V63, P1352, DOI 10.1111/j.1398-9995.2008.01695.x; Rondon C, 2010, J INVEST ALLERG CLIN, V20, P364; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Rondon C, 2011, J ALLERGY CLIN IMMUN, V128, P1192, DOI 10.1016/j.jaci.2011.06.012; Rondon C, 2011, J ALLERGY CLIN IMMUN, V127, P1069, DOI 10.1016/j.jaci.2010.12.013; Rondon C, 2009, J ALLERGY CLIN IMMUN, V124, P1005, DOI 10.1016/j.jaci.2009.07.018; Rondon C, 2009, J ALLERGY CLIN IMMUN, V123, P1098, DOI 10.1016/j.jaci.2009.02.018; Sabirov A, 2008, LARYNGOSCOPE, V118, P4, DOI 10.1097/MLG.0b013e3181567a7a; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; van Rijswijk JB, 2003, RHINOLOGY, V41, P25; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Wedback A, 2005, RHINOLOGY, V43, P86	26	178	191	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1460	1467		10.1016/j.jaci.2012.02.032	http://dx.doi.org/10.1016/j.jaci.2012.02.032			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22516477				2022-12-18	WOS:000304764600004
J	Zuraw, B; Cicardi, M; Levy, RJ; Nuijens, JH; Relan, A; Visscher, S; Haase, G; Kaufman, L; Hack, CE				Zuraw, Bruce; Cicardi, Marco; Levy, Robyn J.; Nuijens, Jan H.; Relan, Anurag; Visscher, Sonja; Haase, Gerald; Kaufman, Leonard; Hack, C. Erik			Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HAE; angioedema; attack; recombinant human C1-inhibitor; efficacy; safety	C1 INHIBITOR CONCENTRATE; LARYNGEAL EDEMA; ABDOMINAL-PAIN	Background: Hereditary angioedema (HAE) results from a genetic deficiency of C1-inhibitor. Two similar independent, randomized, saline controlled, double-blind studies were conducted to evaluate the efficacy and safety of recombinant human C1-inhibitor (rhC1INH) as a treatment of acute angioedema attacks in patients with HAE. Objective: Analysis of pooled study results. Methods: Patients with an eligible attack were randomized to a single intravenous dose of rhC1INH or saline. Efficacy was assessed by using patient-reported visual analog scale outcomes, and safety was assessed by using adverse events and immunogenicity of rhC1INH. Results: rhC1INH at 100 (n = 29) and 50 (n = 12) U/kg body weight resulted in a significant reduction for both the primary endpoint time to the beginning of relief of symptoms compared with saline (n 5 29): median, 66 (95% CI, 61-122) minutes, 122 (72-136) minutes, and 495 (245-520) minutes, P < .001 and P = .013, respectively; and for the secondary endpoint time to minimal symptoms, median, 266 (242-490) minutes, 247 (243484) minutes, and 1210 (970-1500) minutes, P < .001 and P = .001, respectively. Therapeutic failure occurred in 59% (17/29) of the saline group compared with 0% (0/12) of the 50 U/kg group and 10% (3/29) of the 100 U/kg group. Treatment-emergent adverse events were unremarkable and tended to be reported more frequently in the saline group. No postexposure antibody responses against rhC1INH or host-related impurities were observed. Conclusion: Administration of rhC1INH at 100 or 50 U/kg was highly effective as a treatment of acute attacks in patients with HAE and appeared to be safe and well tolerated. (J Allergy Clin Immunol 2010;126:821-7.)	[Nuijens, Jan H.; Relan, Anurag; Visscher, Sonja] Pharming Technol BV, NL-2333 CR Leiden, Netherlands; [Zuraw, Bruce] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Zuraw, Bruce] San Diego VA Healthcare, La Jolla, CA USA; [Cicardi, Marco] Univ Milan, Dept Sci Med Luigi Sacco, Osped L Sacco, Milan, Italy; [Levy, Robyn J.] Family Allergy & Asthma Ctr PC, Atlanta, GA USA; [Haase, Gerald] Haase Consultancy Serv Ltd, London, England; [Kaufman, Leonard] Veeda Clin Res, Brussels, Belgium; [Hack, C. Erik] Univ Med Ctr Utrecht, Dept Dermatol Allergol & Rheumatol, Utrecht, Netherlands	University of California System; University of California San Diego; University of Milan; Luigi Sacco Hospital; Utrecht University; Utrecht University Medical Center	Relan, A (corresponding author), Pharming Technol BV, Darwinweg 24, NL-2333 CR Leiden, Netherlands.	a.relan@pharming.com	cicardi, marco/K-9219-2016; Relan, Anurag/AAA-7372-2022; Levi, Marcel/AAZ-8559-2020	cicardi, marco/0000-0003-1251-225X; Relan, Anurag/0000-0002-5521-4538; Zuraw, Bruce/0000-0003-0640-6768	Pharming Technologies BV, Leiden, The Netherlands; US Food and Drug Administration Office of Orphan Products Development [1-R01-FD-R 03086-01]; Pharming; Dyax; Jerini-Shire; ViroPharma; CSL Behring; Dyax Corp; Lev Pharma	Pharming Technologies BV, Leiden, The Netherlands(Netherlands Government); US Food and Drug Administration Office of Orphan Products Development; Pharming; Dyax; Jerini-Shire; ViroPharma; CSL Behring; Dyax Corp; Lev Pharma	Supported by Pharming Technologies BV, Leiden, The Netherlands. Additional funding for the North American study was provided by US Food and Drug Administration Office of Orphan Products Development grant 1-R01-FD-R 03086-01.; Disclosure of potential conflict of interest: B. Zuraw is a consultant for ViroPharma, CSL Behring, and Shire; has received research support from Pharming; and is an advisor for the HAE Association. M. Cicardi has received honoraria from Dyax, Jerini-Shire, and ViroPharma and is a consultant for Dyax. R. J. Levy is a medical consultant for CSL Behring, Dyax Corp, and Jerini and has received research support from CSL Behring, Dyax Corp, and Lev Pharma. G. Haase has received independent consulting fees from Pharming Technologies BV.L. Kaufman is a consultant for Pharming and has served as an expert witness on the topic of statistical analysis. C. E. Hack has received a consultancy fee from Pharming Technologies BV. The rest of the authors have declared that they have no conflict of interest.	AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Bork K, 2008, ALLERGY, V63, P751, DOI 10.1111/j.1398-9995.2007.01577.x; Bork K, 2000, MAYO CLIN PROC, V75, P349, DOI 10.4065/75.4.349; Bork K, 2005, TRANSFUSION, V45, P1774, DOI 10.1111/j.1537-2995.2005.00602.x; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; Bowen T, 2004, J ALLERGY CLIN IMMUN, V114, P629, DOI 10.1016/j.jaci.2004.06.043; Bygum A, 2009, BRIT J DERMATOL, V161, P1153, DOI 10.1111/j.1365-2133.2009.09366.x; Choi G, 2007, TRANSFUSION, V47, P1028, DOI 10.1111/j.1537-2995.2007.01239.x; Cicardi M, 2007, EXPERT OPIN PHARMACO, V8, P3173, DOI 10.1517/14656566.8.18.3173; Craig TJ, 2009, J ALLERGY CLIN IMMUN, V124, P801, DOI 10.1016/j.jaci.2009.07.017; European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP), REFL PAP REG GUID US; FDA Ctr Drug Evaluation Res, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-79; Food and Drug Administration, 2009, GUID IND PAT REP OUT; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; Gallagher EJ, 2002, AM J EMERG MED, V20, P287, DOI 10.1053/ajem.2002.33778; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Kunschak M, 1998, TRANSFUSION, V38, P540, DOI 10.1046/j.1537-2995.1998.38698326333.x; Martinez-Saguer I, 2010, TRANSFUSION, V50, P354, DOI 10.1111/j.1537-2995.2009.02394.x; NUIJENS J, 2008, J ALLERGY CLIN IMM S, V115, P202; NUIJENS JH, 2004, J ALLERGY CLIN IMMUN, V114, pS100; NUIJENS JH, OPEN LABEL STUDIES R; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Nzeako UC, 2001, ARCH INTERN MED, V161, P2417, DOI 10.1001/archinte.161.20.2417; Pappalardo E, 2008, MOL IMMUNOL, V45, P3536, DOI 10.1016/j.molimm.2008.05.007; Prematta Michael J, 2008, Ther Clin Risk Manag, V4, P975; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; van Doorn MBA, 2005, J ALLERGY CLIN IMMUN, V116, P876, DOI 10.1016/j.jaci.2005.05.019; Wagenaar-Bos IGA, 2008, J IMMUNOL METHODS, V338, P14, DOI 10.1016/j.jim.2008.06.004; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977; Zuraw BL, 2010, NEW ENGL J MED, V363, P513, DOI 10.1056/NEJMoa0805538	34	178	182	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					821	U229		10.1016/j.jaci.2010.07.021	http://dx.doi.org/10.1016/j.jaci.2010.07.021			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920772				2022-12-18	WOS:000282510000021
J	von Berg, A; Filipiak-Pittroff, B; Kraemer, U; Link, E; Bollrath, C; Brockow, I; Koletzko, S; Armin, G; Heinrich, J; Wichmann, HE; Bauer, CP; Reinhardt, D; Berdel, D				von Berg, Andrea; Filipiak-Pittroff, Birgit; Kraemer, Ursula; Link, Elke; Bollrath, Christina; Brockow, Inken; Koletzko, Sibylle; Gruebl, Armin; Heinrich, Joachim; Wichmann, H. -Erich; Bauer, Carl-P.; Reinhardt, Dietrich; Berdel, Dietrich		GINIplus study grp	Preventive effect of hydrolyzed infant formulas persists until age 6 years: Long-term results from the German Infant Nutritional Intervention Study (GINI)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birth cohort; long-term allergy prevention; hydrolysates; double-blind randomized trial	FOOD-ALLERGEN AVOIDANCE; DIETARY PREVENTION; SMALL CHILDREN; CHILDHOOD; ASTHMA; ATOPY; RECOMMENDATIONS; COMMITTEE; EXPOSURE; DISEASES	Background: The long-term effect of nutritional intervention with hydrolyzed infant formulas on allergy development has not been sufficiently evaluated. Objective: We performed a follow-up of the German Infant Nutritional Intervention study until 6 years of life to investigate the long-term allergy-preventive effect of 3 hydrolyzed infant formulas compared with cow's milk formula (CMF) in a randomized, double-blind trial. Methods: Between 1995 and 1998, 2252 newborns with atopic heredity were randomly assigned at birth to receive one of 4 blinded formulas: partially or extensively hydrolyzed whey formula, extensively hydrolyzed casein formula, or CMF as milk substitute for the first 4 months when breast-feeding was insufficient. The cohort was followed from birth until 6 years of age with yearly questionnaires. Outcomes were physician-diagnosed allergic diseases (atopic dermatitis, food allergy, allergic urticaria, asthma, and hay fever/allergic rhinitis). Log-binomial regression modeled with generalized estimation equations was used for the statistical analysis. Results: In the intent-to-treat analysis the relative risk of a physician's diagnosis of allergic manifestation (AM) compared with CMF was 0.82 (95% CI, 0.70-0.96) for partially hydrolyzed whey formula, 0.90 (95% CI, 0.78-1.04) for extensively hydrolyzed whey formula, and 0.80 (95% CI, 0.69-0.93) for extensively hydrolyzed casein formula. The corresponding figures for atopic eczema were 0.79 (95% CI, 0.64-0.97), 0.92 (95% CI, 0.76-1.11), and 0.71 (95% CI, 0.58-0.88), respectively. In the per-protocol analysis all effects were stronger and significant. No significant effect on other AMs was found. Conclusion: The data confirm a long-term allergy-preventive effect of hydrolyzed infant formulas on AM and atopic eczema until 6 years of age.	[von Berg, Andrea; Filipiak-Pittroff, Birgit; Bollrath, Christina; Berdel, Dietrich] Marien Hosp, Dept Pediat, Wesel, Germany; [Kraemer, Ursula; Link, Elke] Univ Dusseldorf, Inst Umweltmed Forschung, Dusseldorf, Germany; [Brockow, Inken; Heinrich, Joachim; Wichmann, H. -Erich] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany; [Koletzko, Sibylle; Reinhardt, Dietrich] Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; [Brockow, Inken; Gruebl, Armin; Bauer, Carl-P.] Tech Univ Munich, Dept Pediat, D-8000 Munich, Germany; [Bauer, Carl-P.] LVA Oberbayern, Munich, Germany; [Wichmann, H. -Erich] Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany	St. Marien Hospital; Heinrich Heine University Dusseldorf; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Technical University of Munich; University of Munich	von Berg, A (corresponding author), Marien Hosp, Dept Pediat, Pastor Janssen Str 8-38, Wesel, Germany.	vonberg@marien-hospital-wesel.de	Heinrich, Joachim/N-1720-2013; Wichmann, Heinz Erich/AAA-5695-2022	Heinrich, Joachim/0000-0002-9620-1629; 				American Academy of Pediatrics Committee on Nutrition, 2000, PEDIATRICS, V106, P236; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Brand PLP, 2007, PEDIAT ALLERG IMM-UK, V18, P475, DOI 10.1111/j.1399-3038.2007.00541.x; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Hays T, 2005, ARCH PEDIAT ADOL MED, V159, P810, DOI 10.1001/archpedi.159.9.810; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P103, DOI 10.1046/j.1399-3038.2003.00129.x; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4, DOI 10.1136/adc.77.1.4; Osborn DA, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003664; Schoetzau A, 2002, ARCH DIS CHILD, V86, P180, DOI 10.1136/adc.86.3.180; Schoetzau A, 2001, EUR J PEDIATR, V160, P323, DOI 10.1007/PL00008442; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; van Schayck OCP, 2007, J ALLERGY CLIN IMMUN, V119, P1323, DOI 10.1016/j.jaci.2007.02.024; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/BF02029362; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Zeiger RS, 2003, PEDIATRICS, V111, P1662; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	28	178	188	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1442	1447		10.1016/j.jaci.2008.04.021	http://dx.doi.org/10.1016/j.jaci.2008.04.021			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18539195	Bronze			2022-12-18	WOS:000256771700021
J	Amin, HS; Liss, GM; Bernstein, DI				Amin, HS; Liss, GM; Bernstein, DI			Evaluation of near-fatal reactions to allergen immunotherapy injections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; anaphylaxis; near-fatal reactions; asthma; epinephrine	SYSTEMIC REACTIONS; CHILDREN; SAFETY	Background: The overall incidence of near-fatal reactions (NFRs) after immunotherapy injections is unknown. Investigation of NFRs might identify preventive strategies that could avert fatal immunotherapy reactions. Objective: We sought to determine the incidence and characteristics of NFRs to allergen immunotherapy. Methods: In a brief survey of fatal reactions (FRs) and NFRs administered to practicing allergists, 273 of 646 respondents reported NFRs after immunotherapy injections; a NFR was defined as respiratory compromise, hypotension, or both requiring emergency epinephrine. Respondents were mailed a 105-item questionnaire regarding the details of NFRs and circumstances of these events. Results: During the period from 1990 through 2001, the incidence of unconfirmed NFRs was estimated at 23 per year (5.4 events per million injections). There were 68 confirmed NFRs on the basis of responses to the long survey, with a mean case incidence of 4.7 per year or I NFR per million injections. Asthma was present in 46% of near-fatal reactors and in 88% of fatal reactors identified in this study. Hypotension was reported in 80% and respiratory failure occurred in 10% of NFRs and exclusively in asthmatic subjects. Epinephrine was delayed or not administered in 6% of NFRs versus 30% of reported FRs (OR, 7.3; 95% Cl, 1.4-39.8; P = .01). Conclusions: Confirmed NFRs were 2.5 times more frequent than FRs. Favorable outcomes of NFRs when compared with FRs could be related to lower asthma prevalence and appropriate management of life-threatening anaphylaxis.	Univ Cincinnati, Div Immunol & Allergy, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Toronto, Dept Publ Hlth Sci, Gage Occupat & Environm Hlth Unit, Toronto, ON, Canada	University System of Ohio; University of Cincinnati; University of Toronto	Bernstein, DI (corresponding author), Univ Cincinnati, Div Immunol & Allergy, Dept Internal Med, POB 670563, Cincinnati, OH 45267 USA.	bernstdd@ucmail.uc.edu						Aaronson DW, 2004, J ALLERGY CLIN IMMUN, V113, P1117, DOI 10.1016/j.jaci.2004.01.756; Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; ALTINTAS D, 1969, ALLERGOL IMMUNOPATH, V27, P309; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; BOUSQUET J, 1994, DRUG SAFETY, V10, P5, DOI 10.2165/00002018-199410010-00002; Cantani A, 1997, J INVEST ALLERG CLIN, V7, P90; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; FREW AJ, 1993, BRIT MED J, V307, P919, DOI 10.1136/bmj.307.6909.919; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; GREENBERG MA, 1988, J ALLERGY CLIN IMMUN, V82, P287, DOI 10.1016/0091-6749(88)91013-5; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; Hughes G, 1999, BRIT MED J, V319, P1; Li JT, 2003, ANN ALLERG ASTHMA IM, V90, P1, DOI 10.1016/S1081-1206(10)63600-9; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; National Heart LaBI, 1997, LIPPINCOTT HLTH PROM, V2, P8; Nicklas RA, 1996, J ALLERGY CLIN IMMUN, V98, P1001, DOI 10.1016/S0091-6749(96)80183-7; OSTERGAARD PA, 1986, ALLERGY, V41, P588; Pifferi M, 2002, ALLERGY, V57, P785, DOI 10.1034/j.1398-9995.2002.23498.x; Ragusa FV, 1997, J INVEST ALLERG CLIN, V7, P151; RAGUSA VF, 2004, ALLERGY IMMUNOL PARI, V36, P52; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3	22	178	193	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					169	175		10.1016/j.jaci.2005.10.010	http://dx.doi.org/10.1016/j.jaci.2005.10.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387602				2022-12-18	WOS:000235687100027
J	Bush, RK; Portnoy, JM				Bush, RK; Portnoy, JM			The role and abatement of fungal allergens in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fungi; allergic disease; asthma; environment; exposure; abatement	NUTRITION EXAMINATION SURVEY; MAJOR ALTERNARIA ALLERGEN; SICK BUILDING SYNDROME; 2ND NATIONAL-HEALTH; SCHOOL-AGE-CHILDREN; DUST MITE; INDOOR AIR; RESIDENTIAL CHARACTERISTICS; ENVIRONMENTAL-FACTORS; RESPIRATORY SYMPTOMS	Sensitivity to a variety of fungi is known to be a factor in allergic rhinitis and asthma. In this review methods for measuring exposure to fungi in the indoor environment are evaluated. A variety of markers for the presence of fungi are also described in addition to their known relationship to either toxic or adverse immunologic effects. Key studies documenting the clinical effects of different types of fungi are also reviewed, as well as a description of abatement methods that either have been successful or need further investigation. Although many studies have shown an association between exposure to fungi and allergic disease, in many cases a direct cause-and-effect relationship has not been established. Improved knowledge of the epidemiology and mechanisms behind fungal-induced human disease will hopefully establish this causal link and suggest methods for reducing morbidity.	Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Dept Med, Madison, WI 53705 USA; Childrens Mercy Hosp, Sect Allergy Immunol, Kansas City, MO 64108 USA	University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; Children's Mercy Hospital	Bush, RK (corresponding author), Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Dept Med, 2500 OVerlook Terrace, Madison, WI 53705 USA.							AAS K, 1980, ALLERGY, V35, P443, DOI 10.1111/j.1398-9995.1980.tb01791.x; Abe K, 1996, APPL ENVIRON MICROB, V62, P959, DOI 10.1128/AEM.62.3.959-963.1996; Aden E, 1999, J ALLERGY CLIN IMMUN, V104, P128, DOI 10.1016/S0091-6749(99)70124-7; Ahearn DG, 1997, CURR MICROBIOL, V35, P305, DOI 10.1007/s002849900259; ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; Banerjee B, 1998, IMMUNOL ALLERGY CLIN, V18, P601, DOI 10.1016/S0889-8561(05)70024-2; Bardana EJ, 1997, ANN ALLERG ASTHMA IM, V79, P283, DOI 10.1016/S1081-1206(10)63017-7; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; Breitenbach M, 1997, INT ARCH ALLERGY IMM, V113, P114, DOI 10.1159/000237521; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BURGE HA, 1992, CLIN REV ALLERG, V10, P153; BURGE HA, 1976, J ALLERGY CLIN IMMUN, V58, P491, DOI 10.1016/0091-6749(76)90193-7; BURGE HA, 1982, J ALLERGY CLIN IMMUN, V70, P101, DOI 10.1016/0091-6749(82)90236-6; Burr ML, 1999, CLIN EXP ALLERGY, V29, P1442; Bush RK, 1999, J ALLERGY CLIN IMMUN, V104, P665, DOI 10.1016/S0091-6749(99)70340-4; BUSH RK, 2001, ENV ASTHMA, P69; Chapman JA, 1999, ALLERGY ASTHMA PROC, V20, P289, DOI 10.2500/108854199778251889; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; Codina R, 1998, J ALLERGY CLIN IMMUN, V102, P318, DOI 10.1016/S0091-6749(98)70102-2; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; CROFT W, 1986, ATMOS ENVIRON, V20, P249; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633, DOI 10.1164/ajrccm.154.3.8810598; Dharmage S, 1999, INDOOR AIR, V9, P188, DOI 10.1111/j.1600-0668.1999.t01-1-00005.x; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P1481, DOI 10.1046/j.1365-2222.1999.00640.x; Dill I, 1996, PEDIAT ALLERG IMM-UK, V7, P151, DOI 10.1111/j.1399-3038.1996.tb00123.x; Dillon HK, 1999, ENVIRON HEALTH PERSP, V107, P473, DOI 10.1289/ehp.99107s3473; Dotterud LK, 1995, PEDIATR ALLERGY IMMU, V6, P181, DOI 10.1111/j.1399-3038.1995.tb00282.x; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; *EPA, 1999, 402F99005 EPA; Esch RE, 1997, METHODS, V13, P2, DOI 10.1006/meth.1997.0491; Fischer G, 1999, CHEMOSPHERE, V39, P795, DOI 10.1016/S0045-6535(99)00015-6; FOX RW, 1994, J ALLERGY CLIN IMMUN, V94, P413, DOI 10.1053/ai.1994.v94.a56025; FRANKLAND AW, 1973, NATURE, V245, P336, DOI 10.1038/245336a0; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459, DOI 10.1046/j.1365-2222.1998.00255.x; GARRISON RA, 1993, ANN ALLERGY, V71, P548; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gorny RL, 1999, ANN AGR ENV MED, V6, P105; Gravesen S, 1999, ENVIRON HEALTH PERSP, V107, P505, DOI 10.1289/ehp.99107s3505; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786, DOI 10.1164/ajrccm.151.6.7767521; HOMER W, 1994, FUNGI IMMUNOL ALLERG, V3, P551; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; KAUFFMAN HF, 1995, AM J RESP CRIT CARE, V151, P2109, DOI 10.1164/ajrccm.151.6.7767565; Kenny LC, 1999, ANN OCCUP HYG, V43, P393, DOI 10.1016/S0003-4878(99)00042-3; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; Levetin E., 1995, Aerobiologia, V11, P27, DOI 10.1007/BF02136141; LEVETIN E, 1995, BIOAEROSOLS, P108; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72, DOI 10.1080/00039899709603804; Li DW, 1995, MYCOPATHOLOGIA, V131, P149, DOI 10.1007/BF01102894; LOPEZ M, 1985, CLIN REV ALLERG, V3, P183, DOI 10.1007/BF02992982; MALONEY MJ, 1987, ANN ALLERGY, V59, P192; McGrath JJ, 1999, CURR MICROBIOL, V38, P33, DOI 10.1007/PL00006768; Miller JD, 1997, AM IND HYG ASSOC J, V58, P39, DOI 10.1080/15428119791013062; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PARIS S, 1991, J ALLERGY CLIN IMMUN, V88, P902, DOI 10.1016/0091-6749(91)90247-L; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; Pieckova E, 1999, ANN AGR ENV MED, V6, P1; Pirhonen I, 1996, EUR RESPIR J, V9, P2618, DOI 10.1183/09031936.96.09122618; Platts-Mills T A, 1986, Allerg Immunol (Paris), V18, P17; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1983, MONOGR ALLERGY, V18, P153; PLATTSMILLS TAE, 1990, TOXICOL IND HEALTH, V6, P197, DOI 10.1177/074823379000600201; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; PORTNOY J, 1990, ANN ALLERGY, V65, P109; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P773, DOI 10.1016/0091-6749(93)90197-N; Portnoy J, 1998, ANN ALLERG ASTHMA IM, V81, P59; PRAHL P, 1992, ALLERGY, V47, P362, DOI 10.1111/j.1398-9995.1992.tb02072.x; Rao CY, 1996, J AIR WASTE MANAGE, V46, P899, DOI 10.1080/10473289.1996.10467526; REISMAN RE, 1990, J ALLERGY CLIN IMMUN, V85, P1050, DOI 10.1016/0091-6749(90)90050-E; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; Rylander R, 1999, ENVIRON HEALTH PERSP, V107, P501, DOI 10.1289/ehp.99107s3501; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SAMSON RA, 1992, J MED VET MYCOL, V30, P9; Shen HD, 1998, INT ARCH ALLERGY IMM, V116, P29, DOI 10.1159/000023921; Shen HD, 1997, CLIN EXP ALLERGY, V27, P682, DOI 10.1111/j.1365-2222.1997.tb01197.x; SMEDJE G, 1996, 7 INT C IND AIR QUAL, P611; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P305, DOI 10.1016/0091-6749(80)90160-8; SOLOMON WR, 1976, J ALLERGY CLIN IMMUN, V57, P46, DOI 10.1016/0091-6749(76)90078-6; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P229; SOLOMON WR, 1998, ALLERGY PRINCIPLES P, P367; Takahashi T, 1997, MYCOPATHOLOGIA, V139, P23, DOI 10.1023/A:1006831111595; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Tariq SM, 1996, CLIN EXP ALLERGY, V26, P794, DOI 10.1111/j.1365-2222.1996.tb00610.x; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; VERHOEFF AP, 1990, ALLERGY, V45, P275, DOI 10.1111/j.1398-9995.1990.tb00496.x; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544, DOI 10.1016/S1081-1206(10)63214-0; Vijay HM, 1999, ALLERGENS ALLERGEN I, P133; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V57, P293, DOI 10.1016/0091-6749(76)90085-3	94	178	190	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3		S			S430	S440		10.1067/mai.2001.113669	http://dx.doi.org/10.1067/mai.2001.113669			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	418KR	11242604				2022-12-18	WOS:000167891800005
J	MURRAY, AB; MORRISON, BJ				MURRAY, AB; MORRISON, BJ			THE EFFECT OF CIGARETTE-SMOKE FROM THE MOTHER ON BRONCHIAL RESPONSIVENESS AND SEVERITY OF SYMPTOMS IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA,DEPT PEDIAT,DIV ALLERGY,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia								BURROWS B, 1983, CHEST, V84, P657, DOI 10.1378/chest.84.6.657; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P72; GERRARD JW, 1980, ANN ALLERGY, V44, P261; GERRARD JW, 1980, AM REV RESPIR DIS, V122, P577; GORTMAKER SL, 1982, AM J PUBLIC HEALTH, V72, P574, DOI 10.2105/AJPH.72.6.574; HASSELBLAD V, 1981, AM REV RESPIR DIS, V123, P479; Holt P G, 1984, Eur J Respir Dis Suppl, V133, P109; KJELLMAN NIM, 1981, LANCET, V1, P993; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; Lebowitz M, 1982, ENVIRON INT, V8, P371; LEBOWITZ MD, 1976, CHEST, V69, P48, DOI 10.1378/chest.69.1.48; LEHRER SB, 1984, J ALLERGY CLIN IMMUN, V73, P240, DOI 10.1016/S0091-6749(84)80014-7; MALO JL, 1982, J APPL PHYSIOL, V52, P1464, DOI 10.1152/jappl.1982.52.6.1464; MURRAY AB, 1983, CAN MED ASSOC J, V129, P828; MURRAY AB, 1981, J ALLERGY CLIN IMMUN, V68, P119, DOI 10.1016/0091-6749(81)90169-X; POLGAR G, 1971, STANDARD VALUES PULM, P179; SCHILLING RSF, 1977, AM J EPIDEMIOL, V106, P274, DOI 10.1093/oxfordjournals.aje.a112463; TAGER IB, 1979, AM J EPIDEMIOL, V110, P15, DOI 10.1093/oxfordjournals.aje.a112783; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; VEDAL S, 1984, AM REV RESPIR DIS, V130, P187; WEISS ST, 1983, AM REV RESPIR DIS, V128, P933; WEISS ST, 1980, AM REV RESPIR DIS, V122, P697, DOI 10.1164/arrd.1980.122.5.697	24	178	181	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					575	581		10.1016/0091-6749(86)90348-9	http://dx.doi.org/10.1016/0091-6749(86)90348-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	3958385	Bronze			2022-12-18	WOS:A1986A938100008
J	CASALE, TB; BOWMAN, S; KALINER, M				CASALE, TB; BOWMAN, S; KALINER, M			INDUCTION OF HUMAN CUTANEOUS MAST-CELL DE-GRANULATION BY OPIATES AND ENDOGENOUS OPIOID-PEPTIDES - EVIDENCE FOR OPIATE AND NONOPIATE RECEPTOR PARTICIPATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CASALE, TB (corresponding author), NIAID, CLIN INVEST LAB, ALLERG DIS SECT, BLDG 10, RM 11C207, BETHESDA, MD 20205 USA.		Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				ADAM HM, 1950, Q J EXP PHYSIOL CMS, V35, P281, DOI 10.1113/expphysiol.1950.sp000954; Beaven M A, 1978, Monogr Allergy, V13, P1; BEAVEN MA, 1981, ANESTHESIOLOGY, V55, P3, DOI 10.1097/00000542-198107000-00002; CHANG KJ, 1981, FED PROC, V40, P2729; COLLDAHL H, 1971, ACTA ALLERGOL, V26, P409, DOI 10.1111/j.1398-9995.1971.tb01400.x; COX BM, 1982, LIFE SCI, V31, P1645, DOI 10.1016/0024-3205(82)90179-5; DUNHILL RS, 1978, ALLERGY PRINCIPLES P, P678; ELLIS HV, 1970, J PHARMACOL EXP THER, V175, P627; FELDBERG W, 1951, J PHYSIOL-LONDON, V114, P490, DOI 10.1113/jphysiol.1951.sp004639; GILMAN SC, 1982, P NATL ACAD SCI-BIOL, V79, P4226, DOI 10.1073/pnas.79.13.4226; HAWK JLM, 1980, BRIT J CLIN PHARMACO, V9, P183, DOI 10.1111/j.1365-2125.1980.tb05831.x; HAZUM E, 1979, SCIENCE, V205, P1033, DOI 10.1126/science.224457; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; IKEDA K, 1975, PROSTAG OTH LIPID M, V10, P747, DOI 10.1016/0090-6980(75)90003-9; JAFFE JH, 1980, PHARMACOL BASIS THER, P494; KALINER M, 1976, TXB IMMUNOPATHOLOGY, P387; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; LI CH, 1976, P NATL ACAD SCI USA, V73, P1145, DOI 10.1073/pnas.73.4.1145; MITCHELL RG, 1956, BRIT J PHARM CHEMOTH, V11, P462, DOI 10.1111/j.1476-5381.1956.tb00018.x; MORRISON DC, 1978, IMMEDIATE HYPERSENSI, P431; MYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305, DOI 10.1016/0091-6749(81)90026-9; PARRATT JR, 1957, J PHYSIOL-LONDON, V137, P179, DOI 10.1113/jphysiol.1957.sp005805; PATON WDM, 1957, PHARMACOL REV, V9, P269; PHILBIN DM, 1981, ANESTHESIOLOGY, V55, P292, DOI 10.1097/00000542-198109000-00019; ROWLEY DA, 1964, BRIT J EXP PATHOL, V45, P56; SAMUELSSON B, 1981, INT ARCH ALLER A IMM, V66, P98, DOI 10.1159/000232880; SELYE H, 1965, MAST CELLS, P144; SIMON EJ, 1978, ANNU REV PHARMACOL, V18, P371, DOI 10.1146/annurev.pa.18.040178.002103; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302	32	178	183	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	6					775	781		10.1016/0091-6749(84)90447-0	http://dx.doi.org/10.1016/0091-6749(84)90447-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SV829	6327790				2022-12-18	WOS:A1984SV82900003
J	Steelant, B; Farre, R; Wawrzyniak, P; Belmans, J; Dekimpe, E; Vanheel, H; Van Gerven, L; Krohn, IK; Bullens, DMA; Ceuppens, JL; Akdis, CA; Boeckxstaens, G; Seys, SF; Hellings, PW				Steelant, Brecht; Farre, Ricard; Wawrzyniak, Paulina; Belmans, Jochen; Dekimpe, Emily; Vanheel, Hanne; Van Gerven, Laura; Krohn, Inge Kortekaas; Bullens, Dominique M. A.; Ceuppens, Jan L.; Akdis, Cezmi A.; Boeckxstaens, Guy; Seys, Sven F.; Hellings, Peter W.			Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; tight junctions; fluticasone propionate; IL-4; leak pathway; epithelial resistance; epithelial permeability	EPITHELIAL-CELLS; CHRONIC RHINOSINUSITIS; TIGHT; IMMUNOTHERAPY; INFLAMMATION; INTERFACE; JUNCTIONS; EXPOSURE; INNATE; IMPACT	Background: Tight junction (TJ) defects have recently been associated with asthma and chronic rhinosinusitis. The expression, function, and regulation of nasal epithelial TJs remain unknown in patients with allergic rhinitis (AR). Objective: We investigated the expression, function, and regulation of TJs in the nasal epithelium of patients with house dust mite (HDM)-induced AR and in an HDM-induced murine model of allergic airway disease. Methods: Air-liquid interface cultures of primary nasal epithelial cells of control subjects and patients with HDM-induced AR were used for measuring transepithelial resistance and passage to fluorescein isothiocyanate-dextran 4 kDa (FD4). Ex vivo transtissue resistance and FD4 permeability of nasal mucosal explants were measured. TJ expression was evaluated by using real-time quantitative PCR and immunofluorescence. In addition, the effects of IL-4, IFN-gamma, and fluticasone propionate (FP) on nasal epithelial cells were investigated in vitro. An HDM murine model was used to study the effects of allergic inflammation and FP treatment on transmucosal passage of FD4 in vivo. Results: A decreased resistance in vitro and ex vivo was found in patients with HDM-induced AR, with increased FD4 permeability and reduced occludin and zonula occludens-1 expression. AR symptoms correlated inversely with resistance in patients with HDM-induced AR. In vitro IL-4 decreased transepithelial resistance and increased FD4 permeability, whereas IFN-gamma had no effect. FP prevented IL-4-induced barrier dysfunction in vitro. In an HDM murine model FP prevented the allergen-induced increased mucosal permeability. Conclusion: We found impaired nasal epithelial barrier function in patients with HDM-induced AR, with lower occludin and zonula occludens-1 expression. IL-4 disrupted epithelial integrity in vitro, and FP restored barrier function. Better understanding of nasal barrier regulation might lead to a better understanding and treatment of AR.	[Steelant, Brecht; Dekimpe, Emily; Van Gerven, Laura; Krohn, Inge Kortekaas; Ceuppens, Jan L.; Seys, Sven F.; Hellings, Peter W.] Katholieke Univ Leuven, Dept Microbiol & Immunol, Clin Immunol, Kapucijnenvoer 33, B-3000 Leuven, Belgium; [Belmans, Jochen; Bullens, Dominique M. A.] Katholieke Univ Leuven, Dept Microbiol & Immunol, Pediat Immunol, Kapucijnenvoer 33, B-3000 Leuven, Belgium; [Farre, Ricard; Vanheel, Hanne; Boeckxstaens, Guy] Katholieke Univ Leuven, Translat Res Gastro Intestinal Disorders, Kapucijnenvoer 33, B-3000 Leuven, Belgium; [Wawrzyniak, Paulina; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Dekimpe, Emily; Van Gerven, Laura; Hellings, Peter W.] Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Leuven, Belgium; [Hellings, Peter W.] Univ Hosp Ghent, Dept Otorhinolaryngol, Ghent, Belgium; [Hellings, Peter W.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands	KU Leuven; KU Leuven; KU Leuven; Swiss Institute of Allergy & Asthma Research; University of Zurich; KU Leuven; University Hospital Leuven; Ghent University; Ghent University Hospital; University of Amsterdam	Hellings, PW (corresponding author), Katholieke Univ Leuven, Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Kapucijnenvoer 33, B-3000 Leuven, Belgium.	Peter.hellings@med.kuleuven.be	Wawrzyniak, Paulina/AAG-3548-2019; Wawrzyniak, Paulina/HCG-8924-2022; Akdis, Cezmi/AAV-4844-2020; Farre, Ricard/M-9275-2013; Boeckxstaens, Guy/AAP-2502-2020; Farre, Ricard/O-4549-2016; Steelant, Brecht/H-8335-2018; Hellings, Peter W/I-4068-2018; Van Gerven, Laura/ABG-5800-2021; Belmans, Jochen/I-3778-2018; Wawrzyniak, Paulina/AAD-7265-2020; Bullens, Dominique M A/T-6211-2017	Akdis, Cezmi/0000-0001-8020-019X; Farre, Ricard/0000-0001-7158-171X; Farre, Ricard/0000-0001-7158-171X; Steelant, Brecht/0000-0002-0358-9362; Hellings, Peter W/0000-0001-6898-688X; Van Gerven, Laura/0000-0002-5325-7956; Belmans, Jochen/0000-0002-3239-9090; Wawrzyniak, Paulina/0000-0001-9641-2103; Bullens, Dominique M A/0000-0002-4595-9579; Kortekaas Krohn, Inge/0000-0003-3649-1131; Seys, Sven/0000-0002-4399-9892; Ceuppens, Jan/0000-0003-4502-2679	Belgian Federal Government [IUAP P6/28]; IWT (TBM project) [130260]; research council of the KU Leuven [GOA 2009/07, 14/011]; Fund of Scientific Research (FWO), Flanders, Belgium	Belgian Federal Government; IWT (TBM project); research council of the KU Leuven(KU Leuven); Fund of Scientific Research (FWO), Flanders, Belgium(FWO)	The authors' laboratories are supported by grants from the Belgian Federal Government (IUAP P6/28), IWT (TBM project 130260), and the research council of the KU Leuven (GOA 2009/07 and 14/011). P.W.H. and D.M.A.B. are recipients of a senior researcher fellowship from the Fund of Scientific Research (FWO), Flanders, Belgium.	Ahdieh M, 2001, AM J PHYSIOL-CELL PH, V281, pC2029, DOI 10.1152/ajpcell.2001.281.6.C2029; Bobic S, 2010, RHINOLOGY, V48, P401, DOI 10.4193/Rhino10.033; Boivin MA, 2007, AM J PHYSIOL-GASTR L, V292, pG590, DOI 10.1152/ajpgi.00252.2006; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet PJ, 2010, J ALLERGY CLIN IMMUN, V126, P666, DOI 10.1016/j.jaci.2010.06.034; Braido F, 2014, RHINOLOGY, V52, P66, DOI [10.4193/Rhin13.040, 10.4193/Rhino13.040]; Bruewer M, 2005, FASEB J, V19, P923, DOI 10.1096/fj.04-3260com; Capaldo CT, 2009, BBA-BIOMEMBRANES, V1788, P864, DOI 10.1016/j.bbamem.2008.08.027; Chiba Y, 2010, PHARMACOL RES, V61, P188, DOI 10.1016/j.phrs.2009.10.003; Cornelis M, 2014, RHINOLOGY, V52, P72, DOI 10.4193/Rhin; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773; Dimova S, 2005, TOXICOL IN VITRO, V19, P107, DOI 10.1016/j.tiv.2004.07.003; Fischer A, 2014, AM J PHYSIOL-GASTR L, V306, pG218, DOI 10.1152/ajpgi.00095.2013; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Golebski K, 2013, ALLERGY, V68, P152, DOI 10.1111/all.12080; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hellings PW, 2013, ALLERGY, V68, P1, DOI 10.1111/all.12040; Henriquez OA, 2013, INT FORUM ALLERGY RH, V3, P630, DOI 10.1002/alr.21168; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Hox V, 2011, TOXICOL LETT, V204, P101, DOI 10.1016/j.toxlet.2011.04.017; Jacquet A, 2011, CLIN EXP ALLERGY, V41, P305, DOI 10.1111/j.1365-2222.2010.03661.x; Kast JI, 2012, J ALLERGY CLIN IMMUN, V130, P544, DOI 10.1016/j.jaci.2012.04.044; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kubo T, 2015, J ALLERGY CLIN IMMUN, V136, P1413, DOI 10.1016/j.jaci.2015.05.006; Mattila Pirkko, 2011, Clin Transl Allergy, V1, P5, DOI 10.1186/2045-7022-1-5; Petalas K, 2013, RHINOLOGY, V51, P99, DOI [10.4193/Rhino12.086, 10.4193/Rhin12.86]; Prokopakis EP, 2014, RHINOLOGY, V52, P3, DOI [10.4193/Rhin13.049, 10.4193/Rhino13.049]; Salim SY, 2011, INFLAMM BOWEL DIS, V17, P362, DOI 10.1002/ibd.21403; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Sekiyama A, 2012, INT IMMUNOPHARMACOL, V12, P350, DOI 10.1016/j.intimp.2011.12.006; Seys SF, 2013, CLIN EXP ALLERGY, V43, P1009, DOI 10.1111/cea.12125; Shen L, 2011, ANNU REV PHYSIOL, V73, P283, DOI 10.1146/annurev-physiol-012110-142150; Sin Betul, 2011, Proc Am Thorac Soc, V8, P106, DOI 10.1513/pats.201008-057RN; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Suenaert P, 2010, INFLAMM BOWEL DIS, V16, P1322, DOI 10.1002/ibd.21211; Takano K, 2005, J HISTOCHEM CYTOCHEM, V53, P611, DOI 10.1369/jhc.4A6539.2005; Van Gerven L, 2012, RHINOLOGY, V50, P227, DOI [10.4193/Rhino11.152, 10.4193/Rhino.11.152]; Van Gerven L, 2014, J ALLERGY CLIN IMMUN, V133, P1332, DOI 10.1016/j.jaci.2013.08.026; Vanheel H, 2014, GUT, V63, P262, DOI 10.1136/gutjnl-2012-303857; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Yoon YH, 2014, RHINOLOGY, V52, P390, DOI [10.4193/Rhin13.154, 10.4193/Rhino13.154]	41	177	189	4	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1043	+		10.1016/j.jaci.2015.10.050	http://dx.doi.org/10.1016/j.jaci.2015.10.050			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26846377	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000373351200010
J	Brandt, EB; Kovacic, MB; Lee, GB; Gibson, AM; Acciani, TH; Le Cras, TD; Ryan, PH; Budelsky, AL; Hershey, GKK				Brandt, Eric B.; Kovacic, Melinda Butsch; Lee, Gerald B.; Gibson, Aaron M.; Acciani, Thomas H.; Le Cras, Timothy D.; Ryan, Patrick H.; Budelsky, Alison L.; Hershey, Gurjit K. Khurana			Diesel exhaust particle induction of IL-17A contributes to severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; house dust mite; diesel exhaust particle; IL-17A; regulatory T cell	AIR-POLLUTION; T(H)17 CELLS; T-CELLS; INFLAMMATION; EXPOSURE; HYPERRESPONSIVENESS; DIFFERENTIATION; INTERLEUKIN-17; PROMOTE; MODELS	Background: IL-17A has been implicated in severe forms of asthma. However, the factors that promote IL-17A production during the pathogenesis of severe asthma remain undefined. Diesel exhaust particles (DEPs) are a major component of traffic-related air pollution and are implicated in asthma pathogenesis and exacerbation. Objective: We sought to determine the mechanism by which DEP exposure affects asthma severity using human and mouse studies. Methods: BALB/c mice were challenged with DEPs with or without house dust mite (HDM) extract. Airway inflammation and function, bronchoalveolar lavage fluid cytokine levels, and flow cytometry of lung T cells were assessed. The effect of DEP exposure on the frequency of asthma symptoms and serum cytokine levels was determined in children with allergic asthma. Results: In mice exposure to DEPs alone did not induce asthma. DEP and HDM coexposure markedly enhanced airway hyperresponsiveness compared with HDM exposure alone and generated a mixed T(H)2 and T(H)17 response, including IL-13(+)IL-17A(+) double-producing T cells. IL-17A neutralization prevented DEP-induced exacerbation of airway hyperresponsiveness. Among 235 high DEP-exposed children with allergic asthma, 32.2% had more frequent asthma symptoms over a 12-month period compared with only 14.2% in the low DEP-exposed group (P = .002). Additionally, high DEP-exposed children with allergic asthma had nearly 6 times higher serum IL-17A levels compared with low DEP-exposed children. Conclusions: Expansion of T(H)17 cells contributes to DEP-mediated exacerbation of allergic asthma. Neutralization of IL-17A might be a useful potential therapeutic strategy to counteract the asthma-promoting effects of traffic-related air pollution, especially in highly exposed patients with severe allergic asthma.	[Brandt, Eric B.; Kovacic, Melinda Butsch; Lee, Gerald B.; Gibson, Aaron M.; Hershey, Gurjit K. Khurana] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45221 USA; [Acciani, Thomas H.; Le Cras, Timothy D.] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH 45221 USA; [Ryan, Patrick H.] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Div Epidemiol & Biostat, Cincinnati, OH 45221 USA; [Budelsky, Alison L.] Amgen Inc, Dept Inflammat Res, Seattle, WA USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Amgen	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org	Lee, Gwo-Bin Vincent/D-3032-2012; Ryan, Patrick H/L-7062-2015; Ryan, Patrick/HDO-1133-2022	Lee, Gwo-Bin Vincent/0000-0001-6910-9133; Khurana Hershey, Gurjit/0000-0001-6663-977X; Brandt, Eric/0000-0003-0617-4100; Le Cras, Timothy/0000-0001-8538-2703	National Institute of Environmental Health Sciences (NIEHS) [T32 ES010957]; National Heart, Lung, and Blood Institute (NHLBI) [R01HL097135]; NIEHS [R21016830]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES010957, R21ES016830] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institute of Environmental Health Sciences (NIEHS) grant T32 ES010957 (to E.B.B.); National Heart, Lung, and Blood Institute (NHLBI) grant R01HL097135 (to G.K.K.H. and T.D.L.C.); and NIEHS grant R21016830 (to M.B.K.).	Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Alessandrini F, 2006, J ALLERGY CLIN IMMUN, V117, P824, DOI 10.1016/j.jaci.2005.11.046; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Braback L, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-17; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; Cosmi L, 2011, ALLERGY, V66, P989, DOI 10.1111/j.1398-9995.2011.02576.x; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Delfino RJ, 2009, AM J RESP CRIT CARE, V180, P1037, DOI 10.1164/rccm.200908-1285ED; Gandhi R, 2010, NAT IMMUNOL, V11, P846, DOI 10.1038/ni.1915; Halwani R, 2013, CHEST, V143, P494, DOI 10.1378/chest.12-0598; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hirota JA, 2012, J ALLERGY CLIN IMMUN, V129, P1116, DOI 10.1016/j.jaci.2011.11.033; Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kovacic MB, 2012, PEDIAT ALLER IMM PUL, V25, P104, DOI 10.1089/ped.2011.0116; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Li N, 2010, AM J PHYSIOL-LUNG C, V299, pL374, DOI 10.1152/ajplung.00115.2010; Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Maes T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-7; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Pappu R, 2012, TRENDS IMMUNOL, V33, P343, DOI 10.1016/j.it.2012.02.008; Provoost S, 2011, J IMMUNOL, V187, P3331, DOI 10.4049/jimmunol.1004062; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Quintana FJ, 2012, NAT IMMUNOL, V13, P770, DOI 10.1038/ni.2363; Raymond M, 2011, J ALLERGY CLIN IMMUN, V128, P192, DOI 10.1016/j.jaci.2011.04.029; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Riedl Marc A, 2012, Res Rep Health Eff Inst, P5; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Ryan PH, 2009, AM J RESP CRIT CARE, V180, P1068, DOI 10.1164/rccm.200808-1307OC; Saber AT, 2006, PART FIBRE TOXICOL, V3, DOI 10.1186/1743-8977-3-4; Saunders V, 2010, ENVIRON HEALTH PERSP, V118, P640, DOI 10.1289/ehp.0901461; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Stevens T, 2009, TOXICOL SCI, V107, P522, DOI 10.1093/toxsci/kfn248; Totlandsdal AI, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-41; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Zhang Junfeng Jim, 2009, Res Rep Health Eff Inst, P5	43	177	185	2	44	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1194	+		10.1016/j.jaci.2013.06.048	http://dx.doi.org/10.1016/j.jaci.2013.06.048			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24060272	Bronze, Green Accepted			2022-12-18	WOS:000326235600022
J	Senti, G; Crameri, R; Kuster, D; Johansen, P; Martinez-Gomez, JM; Graf, N; Steiner, M; Hothorn, LA; Gronlund, H; Tivig, C; Zaleska, A; Soyer, O; van Hage, M; Akdis, CA; Akdis, M; Rose, H; Kundig, TM				Senti, Gabriela; Crameri, Reto; Kuster, Daniela; Johansen, Pal; Martinez-Gomez, Julia M.; Graf, Nicole; Steiner, Martin; Hothorn, Ludwig A.; Gronlund, Hans; Tivig, Christine; Zaleska, Anna; Soyer, Ozge; van Hage, Marianne; Akdis, Cezmi A.; Akdis, Muebeccel; Rose, Horst; Kuendig, Thomas M.			Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intralymphatic; cat dander allergy; immunotherapy; tolerance; vaccination; Fel d 1	INTRA-LYMPHATIC INFUSION; NODE IMMUNIZATION; POSITION PAPER; TUMOR-CELLS; ANTIGEN; PROTEIN; ASTHMA; SENSITIZATION; TRANSDUCTION; VACCINATION	Background: Subcutaneous allergen-specific immunotherapy frequently causes allergic side effects and requires 30 to 80 injections over 3 to 5 years. Objective: We sought to improve immunotherapy by using intralymphatic allergen administration (intralymphatic immunotherapy [ILIT]) and by targeting allergen to the MHC class II pathway. Methods: Recombinant major cat dander allergen Fel d 1 was fused to a translocation sequence (TAT) and to part of the human invariant chain, generating a modular antigen transporter (MAT) vaccine (MAT-Fel d 1). In a randomized double-blind trial ILIT with MAT-Fel d 1 in alum was compared with ILIT with placebo (saline in alum) in allergic patients (ClinicalTrials.gov NCT00718679). Results: ILIT with MAT-Fel d 1 elicited no adverse events. After 3 placebo injections within 2 months, nasal tolerance increased less than 3-fold, whereas 3 intralymphatic injections with MAT-Fel d 1 increased nasal tolerance 74-fold (P < .001 vs placebo). ILIT with MAT-Fel d 1 stimulated regulatory T-cell responses (P = .026 vs placebo) and increased cat dander-specific IgG(4) levels by 5.66-fold (P = .003). The IgG(4) response positively correlated with IL-10 production (P < .001). Conclusion: In a first-in-human clinical study ILIT with MAT-Fel d 1 was safe and induced allergen tolerance after 3 injections. (J Allergy Clin Immunol 2012;129:1290-6.)	[Johansen, Pal; Martinez-Gomez, Julia M.; Kuendig, Thomas M.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Senti, Gabriela; Kuster, Daniela; Graf, Nicole; Tivig, Christine] Univ Zurich Hosp, Clin Trials Ctr, CH-8091 Zurich, Switzerland; [Crameri, Reto; Zaleska, Anna; Soyer, Ozge; Akdis, Cezmi A.; Akdis, Muebeccel] Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Steiner, Martin; Rose, Horst] ImVisioN GmbH, Hannover, Germany; [Hothorn, Ludwig A.] Leibniz Univ Hannover, Inst Biostat, Hannover, Germany; [Gronlund, Hans; van Hage, Marianne] Karolinska Univ Hosp Solna, Dept Med, Clin Immunol & Allergy Unit, Stockholm, Sweden	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Swiss Institute of Allergy & Asthma Research; Leibniz University Hannover; Karolinska Institutet; Karolinska University Hospital	Kundig, TM (corresponding author), Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.	thomas.kuendig@usz.ch	Senti, Gabriela/Y-1019-2019; Akdis, Cezmi/AAV-4844-2020; van Hage, Marianne/A-9678-2017; Johansen, Pål/A-1403-2013	Senti, Gabriela/0000-0002-9066-8383; Akdis, Cezmi/0000-0001-8020-019X; van Hage, Marianne/0000-0003-3091-1596; Johansen, Pål/0000-0002-5055-6299; Gronlund, Hans/0000-0003-4882-7624; Zaleska, Anna/0000-0002-7513-8042	ImVisioN Therapeutics AG; Swiss National Science Foundation; ImVisioN GmbH; Center for Clinical Research, University Hospital Zurich; Novartis; PREDICTA; MeDALL; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research and Education; Swiss National Foundation; European Union	ImVisioN Therapeutics AG; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); ImVisioN GmbH; Center for Clinical Research, University Hospital Zurich; Novartis(Novartis); PREDICTA; MeDALL; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research and Education; Swiss National Foundation(Swiss National Science Foundation (SNSF)); European Union(European Commission)	Supported by ImVisioN Therapeutics AG and the Swiss National Science Foundation. H. R. and M. S. are employees of ImVisioN Therapeutics AG. T. M. K., R. C., and H. G. are scientific advisors for and receive travel expenses from ImVisioN GmbH.; Disclosure of potential conflict of interest: M. Steiner and H. Rose are employed by ImVisioN GmbH. L. A. Hothorn has received research support from ImVisioN GmbH and the Center for Clinical Research, University Hospital Zurich. C. A. Akdis receives research support from Novartis, PREDICTA, the Swiss National Science Foundation, MeDALL, the Global Allergy and Asthma European Network, and the Christine Kuhne Center for Allergy Research and Education; has consulted for Actelion, Aventis, Stallergenes, and Allergopharma; is President of the European Academy of Allergy and Clinical Immunology; is a fellow and interest group member of the American Academy of Allergy, Asthma & Immunology; is a former committee member of the Global Allergy and Asthma European Network; and is director of the Christine Kuhne Center for Allergy Research and Education. M. Akdis has received research support from the Swiss National Foundation and the European Union. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Ali FR, 2004, AM J RESP CRIT CARE, V169, P20, DOI 10.1164/rccm.200305-690OC; [Anonymous], 1989, ALLERGY S10, V10, P1; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BOUSQUET J, 1986, ANN ALLERGY, V56, P456; Calderon MA, 2011, ALLERGY, V66, P1345, DOI 10.1111/j.1398-9995.2011.02669.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Cox L, 2010, CURR MED RES OPIN, V26, P2723, DOI 10.1185/03007995.2010.528647; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Crameri R, 2007, ALLERGY, V62, P197, DOI 10.1111/j.1398-9995.2006.01292.x; DEMOLY P, 1991, J ALLERGY CLIN IMMUN, V88, P758, DOI 10.1016/0091-6749(91)90183-O; Dreborg S, 2001, ALLERGY, V56, P359, DOI 10.1034/j.1398-9995.2001.056005359.x; Fittipaldi A, 2005, ADV DRUG DELIVER REV, V57, P597, DOI 10.1016/j.addr.2004.10.011; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002; Hedlin G, 1995, J ALLERGY CLIN IMMUN, V96, P879, DOI 10.1016/S0091-6749(95)70223-7; Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; Johansen P, 2005, CLIN EXP ALLERGY, V35, P1591, DOI 10.1111/j.1365-2222.2005.02384.x; Johansen P, 2005, EUR J IMMUNOL, V35, P568, DOI 10.1002/eji.200425599; JUILLARD GJF, 1983, FED PROC, V42, P441; JUILLARD GJF, 1977, CANCER, V39, P126, DOI 10.1002/1097-0142(197701)39:1<126::AID-CNCR2820390122>3.0.CO;2-5; JUILLARD GJF, 1976, INT J RADIAT ONCOL, V1, P497, DOI 10.1016/0360-3016(76)90017-1; JUILLARD GJF, 1978, CANCER, V41, P2215, DOI 10.1002/1097-0142(197806)41:6<2215::AID-CNCR2820410622>3.0.CO;2-X; Juniper EF, 2000, CLIN EXP ALLERGY, V30, P132; Klavinskis LS, 1996, J IMMUNOL, V157, P2521; Kreiter S, 2010, CANCER RES, V70, P9031, DOI 10.1158/0008-5472.CAN-10-0699; KUNDIG TM, 1995, SCIENCE, V268, P1343, DOI 10.1126/science.7761853; Landolt GA, 2010, VET REC, V167, P302, DOI 10.1136/vr.c3891; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; LEHNER T, 1994, J IMMUNOL, V153, P1858; Malm L, 2000, RHINOLOGY, V38, P1; Maloy KJ, 2001, P NATL ACAD SCI USA, V98, P3299, DOI 10.1073/pnas.051630798; Martinez-Gomez JM, 2009, ALLERGY, V64, P172, DOI 10.1111/j.1398-9995.2008.01812.x; Martinez-Gomez JM, 2009, INT ARCH ALLERGY IMM, V150, P59, DOI 10.1159/000210381; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; NILSSON BO, 1987, J IMMUNOL METHODS, V99, P67; Pfaar O, 2009, CURR OPIN ALLERGY CL, V9, P208, DOI 10.1097/ACI.0b013e32832aef57; Rhyner C, 2007, BIOCHEM SOC T, V35, P833, DOI 10.1042/BST0350833; Riechelmann H, 2003, LARYNGO RHINO OTOL, V82, P183, DOI 10.1055/s-2003-38411; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Senti G, 2011, CURR TOP MICROBIOL, V352, P71, DOI 10.1007/82_2011_133; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; SIGEL MB, 1983, METHOD ENZYMOL, V93, P3; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; SUSSMAN GL, 1982, ANN ALLERGY, V48, P75; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P888, DOI 10.1016/0091-6749(89)90102-4; von Beust BR, 2005, EUR J IMMUNOL, V35, P1869, DOI 10.1002/eji.200526124	55	177	189	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1290	1296		10.1016/j.jaci.2012.02.026	http://dx.doi.org/10.1016/j.jaci.2012.02.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22464647	Bronze			2022-12-18	WOS:000303418000017
J	Beck, LA; Boguniewicz, M; Hata, T; Schneider, LC; Hanifin, J; Gallo, R; Paller, AS; Lieff, S; Reese, J; Zaccaro, D; Milgrom, H; Barnes, KC; Leung, DYM				Beck, Lisa A.; Boguniewicz, Mark; Hata, Tissa; Schneider, Lynda C.; Hanifin, Jon; Gallo, Rich; Paller, Amy S.; Lieff, Susi; Reese, Jamie; Zaccaro, Daniel; Milgrom, Henry; Barnes, Kathleen C.; Leung, Donald Y. M.			Phenotype of atopic dermatitis subjects with a history of eczema herpeticum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; herpes simplex virus; eczema herpeticum; eczema vaccinatum; biomarkers; Staphylococcus aureus	ACTIVATION-REGULATED CHEMOKINE; INNATE IMMUNE-RESPONSE; ANTIMICROBIAL PEPTIDES; VACCINIA VIRUS; TH2 CYTOKINES; SERUM THYMUS; FOOD ALLERGY; SKIN; EXPRESSION; DISEASE	Background: A subset of subjects with atopic dermatitis (AD) are susceptible to serious infections with herpes simplex virus, called eczema herpeticum, or vaccina virus, called eczema vaccinatum. Objective: This National Institute of Allergy and Infectious Diseases-funded multicenter study was performed to establish a database of clinical information and biologic samples on subjects with AD with and without a history of eczema herpeticum (ADEH(+) and ADEH(-) subjects, respectively) and healthy control subjects. Careful phenotyping of AD subsets might suggest mechanisms responsible for disseminated viral infections and help identify at-risk individuals. Methods: We analyzed the data from 901 subjects (ADEH(+) subjects, n = 134; ADEH(-) subjects, n = 419; healthy control subjects, n = 348) enrolled between May 11, 2006, and September 16, 2008, at 7 US medical centers. Results: ADEH(+) subjects had more severe disease based on scoring systems (Eczema Area and Severity Index and Rajka-Langeland score), body surface area affected, and biomarkers (circulating eosinophil counts and serum IgE, thymus and activation-regulated chemokine, and cutaneous T cell-attracting chemokine) than ADEH(-) subjects (P < .001). ADEH(+) subjects were also more likely to have a history of food allergy (69% vs 40%, P < .001) or asthma (64% vs 44%, P < .001) and were more commonly sensitized to many common allergens (P < .001). Cutaneous infections with Staphylococcus aureus or molluscum contagiosum virus were more common in ADEH(+) subjects (78% and 8%, respectively) than in ADEH(-) subjects (29% and 2%, respectively; P < .001). Conclusion: Subjects with AD in whom eczema herpeticum develops have more severe T(H)2-polarized disease with greater allergen sensitization and more commonly have a history of food allergy, asthma, or both. They are also much more likely to experience cutaneous infections with S aureus or molluscum contagiosum. (J Allergy Clin Immunol 2009;124:260-9.)	[Beck, Lisa A.] Univ Rochester, Dept Dermatol, Med Ctr, Rochester, NY 14642 USA; [Boguniewicz, Mark; Milgrom, Henry; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Hata, Tissa; Gallo, Rich] Univ Calif San Diego, Div Dermatol, San Diego, CA 92103 USA; [Schneider, Lynda C.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Hanifin, Jon] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Lieff, Susi; Reese, Jamie; Zaccaro, Daniel] Rho Inc, Chapel Hill, NC USA; [Barnes, Kathleen C.] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; [Paller, Amy S.] Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA; [Paller, Amy S.] Childrens Mem Hosp, Dept Dermatol, Chicago, IL 60614 USA	University of Rochester; National Jewish Health; University of California System; University of California San Diego; Harvard University; Boston Children's Hospital; Oregon Health & Science University; Rho; Johns Hopkins University; Johns Hopkins Medicine; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago	Beck, LA (corresponding author), Univ Rochester, Dept Dermatol, Med Ctr, 601 Elmwood Ave,Box 697, Rochester, NY 14642 USA.	Lisa_Beck@URMC.ROCHESTER.EDU	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Paller, Amy/0000-0001-6187-6549	National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis and Vaccinia Network [N01 AI40029, NO1 AI40033]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis and Vaccinia Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis and Vaccinia Network contract N01 AI40029 and NO1 AI40033. Partial funding also provided by Mary Beryl Patch Turnbull Scholar Program.	Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; BORK K, 1988, J AM ACAD DERMATOL, V19, P1024, DOI 10.1016/S0190-9622(88)70267-4; Bremmer SE, 2008, J AM ACAD DERMATOL, V59, P72, DOI 10.1016/j.jaad.2008.03.029; CHRISTOPHERS E, 1987, ARCH DERMATOL RES, V279, pS48, DOI 10.1007/BF00585919; Eichenfield Lawrence F, 2003, J Am Acad Dermatol, V49, P1088, DOI 10.1016/S0190-9622(03)02539-8; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Gordon YJ, 2005, CURR EYE RES, V30, P385, DOI 10.1080/02713680590934111; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P1117, DOI 10.1067/mai.2000.105804; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Kakinuma T, 2003, J ALLERGY CLIN IMMUN, V111, P592, DOI 10.1067/mai.2003.114; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim BE, 2007, J ALLERGY CLIN IMMUN, V119, P457, DOI 10.1016/j.jaci.2006.10.005; Kimata H, 1999, ANN ALLERG ASTHMA IM, V82, P293, DOI 10.1016/S1081-1206(10)62611-7; MATRICARDI PM, 1990, CLIN EXP ALLERGY, V20, P151, DOI 10.1111/j.1365-2222.1990.tb02660.x; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Peng WM, 2007, J INVEST DERMATOL, V127, P1261, DOI 10.1038/sj.jid.5700657; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Sampson HA, 2003, CLIN DERMATOL, V21, P183, DOI 10.1016/S0738-081X(02)00363-2; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Tschopp JM, 1998, ALLERGY, V53, P608, DOI 10.1111/j.1398-9995.1998.tb03937.x; Uchida T, 2002, INT IMMUNOL, V14, P1431, DOI 10.1093/intimm/dxf109; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Vora S, 2008, CLIN INFECT DIS, V46, P1555, DOI 10.1086/587668; Wetzel S, 2004, HAUTARZT, V55, P646, DOI 10.1007/s00105-004-0744-1; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X; Wuthrich B, 1996, INT ARCH ALLERGY IMM, V111, P396, DOI 10.1159/000237398; Xu FJ, 2006, JAMA-J AM MED ASSOC, V296, P964, DOI 10.1001/jama.296.8.964	37	177	184	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					260	269		10.1016/j.jaci.2009.05.020	http://dx.doi.org/10.1016/j.jaci.2009.05.020			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19541356	Green Accepted			2022-12-18	WOS:000268860400012
J	O'Connor, GT; Neas, L; Vaughn, B; Kattan, M; Mitchell, H; Crain, EF; Evans, R; Gruchalla, R; Morgan, W; Stout, J; Adams, GK; Lippmann, M				O'Connor, George T.; Neas, Lucas; Vaughn, Benjamin; Kattan, Meyer; Mitchell, Herman; Crain, Ellen F.; Evans, Richard, III; Gruchalla, Rebecca; Morgan, Wayne; Stout, James; Adams, G. Kenneth; Lippmann, Morton			Acute respiratory health effects of air pollution on children with asthma in US inner cities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nitrogen dioxide; ozone; sulfur dioxide; carbon monoxide; fine particle emissions; asthma in children	PEAK EXPIRATORY FLOW; FINE PARTICLES; DAILY MORTALITY; ENVIRONMENTAL INTERVENTION; HOSPITAL ADMISSIONS; SYMPTOM SEVERITY; MEDICATION USE; URBAN AIR; PARTICULATE; ASSOCIATION	Background: Children with asthma in inner-city communities may be particularly vulnerable to adverse effects of air pollution because of their airways disease and exposure to relatively high levels of motor vehicle emissions. Objective: To investigate the association between fluctuations in outdoor air pollution and asthma morbidity among inner-city children with asthma. Methods: We analyzed data from 861 children with persistent asthma in 7 US urban communities who performed 2-week periods of twice-daily pulmonary function testing every 6 months for 2 years. Asthma symptom data were collected every 2 months. Daily pollution measurements were obtained from the Aerometric Information Retrieval System. The relationship of lung function and symptoms to fluctuations in pollutant concentrations was examined by using mixed models. Results: Almost all pollutant concentrations measured were below the National Ambient Air Quality Standards. In single-pollutant models, higher 5-day average concentrations of NO2, sulfur dioxide, and particles smaller than 2.5 mu m were associated with significantly lower pulmonary function. Higher pollutant levels were independently associated with reduced lung function in a 3-pollutant model. Higher concentrations of NO2 and particles smaller than 2.5 mu m were associated with asthma-related missed school days, and higher NO2 concentrations were associated with asthma symptoms. Conclusion: Among inner-city children with asthma, short-term increases in air pollutant concentrations below the National Ambient Air Quality Standards were associated with adverse respiratory health effects. The associations with NO2 suggest that motor vehicle emissions may be causing excess morbidity in this population.	[O'Connor, George T.] Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; [Neas, Lucas; Mitchell, Herman] US EPA, Res Triangle Pk, NC 27711 USA; [Vaughn, Benjamin] Rho Fed Syst Div Inc, Chapel Hill, NC USA; [Kattan, Meyer] Mt Sinai Sch Med, Dept Pediat, New York, NY USA; [Crain, Ellen F.] Albert Einstein Coll Med, Dept Pediat Emergency Med, Jacobi Med Ctr, Bronx, NY 10467 USA; [Evans, Richard, III] Northwestern Univ, Sch Med, Dept Pediat & Med, Chicago, IL 60611 USA; [Gruchalla, Rebecca] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA; [Gruchalla, Rebecca] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Morgan, Wayne] Univ Arizona, Coll Med, Resp Sci Ctr, Tucson, AZ 85721 USA; [Stout, James] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Adams, G. Kenneth] Natl Inst Allergy & Infect Dis, Bethesda, MD USA; [Lippmann, Morton] NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY USA	Boston University; United States Environmental Protection Agency; Icahn School of Medicine at Mount Sinai; Jacobi Medical Center; Yeshiva University; Albert Einstein College of Medicine; Northwestern University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Arizona; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); New York University	O'Connor, GT (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Dept Med, 715 Albany St,Room 304, Boston, MA 02118 USA.	goconnor@bu.edu	Neas, Lucas/J-9378-2012	Neas, Lucas/0000-0002-9377-8334; O'Connor, George/0000-0002-6476-3926	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI039776, U01AI039785, U01AI039901, U01AI039900, U01AI039761, U01AI039789, U01AI039769, U01AI039902] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00533] Funding Source: Medline; NIAID NIH HHS [AI-39769, AI-39776, AI-39785, AI-39789, AI-39902, AI-39901, AI-39900, AI-39761] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Belanger K, 2006, AM J RESP CRIT CARE, V173, P297, DOI 10.1164/rccm.200408-1123OC; Burnett RT, 2000, INHAL TOXICOL, V12, P15, DOI 10.1080/089583700750019495; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.2307/3434265; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; Ito K, 2005, J EXPO ANAL ENV EPID, V15, P172, DOI 10.1038/sj.jea.7500386; Krewski D, 2007, J TOXICOL ENV HEAL A, V70, P275, DOI 10.1080/15287390600884859; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; Neas LM, 1999, EPIDEMIOLOGY, V10, P550, DOI 10.1097/00001648-199909000-00015; NEAS LM, 1995, AM J EPIDEMIOL, V141, P111, DOI 10.1093/oxfordjournals.aje.a117399; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; Phalen R. F, 2002, PARTICULATE AIR POLL; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123, DOI 10.1164/ajrccm/145.5.1123; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300, DOI 10.1164/ajrccm.154.2.8756798; Sarnat JA, 2000, J AIR WASTE MANAGE, V50, P1184, DOI 10.1080/10473289.2000.10464165; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Sinclair AH, 2004, J AIR WASTE MANAGE, V54, P1212, DOI 10.1080/10473289.2004.10470979; Slaughter JC, 2003, ANN ALLERG ASTHMA IM, V91, P346, DOI 10.1016/S1081-1206(10)61681-X; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313, DOI 10.1164/ajrccm/137.2.313; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654, DOI 10.1164/ajrccm.155.2.9032209; Tiittanen P, 1999, EUR RESPIR J, V13, P266, DOI 10.1034/j.1399-3003.1999.13b08.x; U. S. Environmental Protection Agency, 2004, EPA600P99002AF; *US ENV PROT AG, TECHN TRANSF NETW AI; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/ajrccm.164.12.2106126; Ward DJ, 2004, OCCUP ENVIRON MED, V61, DOI 10.1136/oem.2003.007088; Ward DJ, 2002, THORAX, V57, P489, DOI 10.1136/thorax.57.6.489; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P1071, DOI 10.2307/3434961	44	177	189	1	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1133	1139		10.1016/j.jaci.2008.02.020	http://dx.doi.org/10.1016/j.jaci.2008.02.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18405952	Green Submitted, Bronze			2022-12-18	WOS:000255961700009
J	Bacchetta, R; Gambineri, E; Roncarolo, MG				Bacchetta, Rosa; Gambineri, Eleonora; Roncarolo, Maria-Grazia			Role of regulatory T cells and FOXP3 in human diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						tolerance; immune regulation; transcription factors; FOXP3; genetic autoimmunity	DEFECTIVE SUPPRESSOR FUNCTION; CYTOKINE GENE-EXPRESSION; TRANSCRIPTION FACTOR; INTERLEUKIN (IL)-2; PERIPHERAL-BLOOD; CUTTING EDGE; TYPE-1; EFFECTOR; LINEAGE; IL-2	Immune regulation and tolerance are specific functions of the immune system, meaning at prevention or limitation of effector immune responses against inner and external insults. Regulatory T (Treg) cells are crucial players in this immune balance network. Research over the last 10 years has significantly contributed to. characterizing Treg cell features, their mechanisms of function, and their role in human pathologies. The discovery or FOXP3 as an essential transcription factor not only for differentiation and function of naturally occurring Treg cells but also for regulation of intracellular molecules related to effector T-cell responses has provided new insights into the pathogenesis of immune-mediated diseases. Interestingly, there is increasing evidence that the individual signature of genes relevant for immune regulation definitely influences the final outcome of an immune response.	San Raffaele Telethon Inst Gene Therapy, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, Milan, Italy; Univ Florence, Anna Meyer Univ Childrens Hosp, Dept Pediat, I-50121 Florence, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; University of Florence	Roncarolo, MG (corresponding author), San Raffaele Telethon Inst Gene Therapy, Via Olgettina 58, I-20132 Milan, Italy.	rosa.bacchetta@hsr.it; m.roncarolo@hsr.it	Gambineri, Eleonora/J-8747-2016	Gambineri, Eleonora/0000-0002-4676-6541; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Allakhverdi Z, 2006, J ALLERGY CLIN IMMUN, V118, P1342, DOI 10.1016/j.jaci.2006.07.034; Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014; Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685; Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; Banham AH, 2006, EUR J IMMUNOL, V36, P2832, DOI 10.1002/eji.200636459; BATTAGLIA M, 2007, IN PRESS; Battaglia Manuela, 2006, Inflammation & Allergy Drug Targets, V5, P157, DOI 10.2174/187152806778256052; Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; BORSELLINO G, 2007, BLOOD           0420; Brusko TM, 2005, DIABETES, V54, P1407, DOI 10.2337/diabetes.54.5.1407; Campbell DJ, 2007, NAT REV IMMUNOL, V7, P305, DOI 10.1038/nri2061; CARSON DB, 2007, ANN NY ACAD SCI, V1103, P167; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; Chatenoud L, 2006, J CLIN INVEST, V116, P2325, DOI 10.1172/JCI29748; Crellin NK, 2007, BLOOD, V109, P2014, DOI 10.1182/blood-2006-07-035279; Davidson TS, 2007, J IMMUNOL, V178, P4022, DOI 10.4049/jimmunol.178.7.4022; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Garin MI, 2007, BLOOD, V109, P2058, DOI 10.1182/blood-2006-04-016451; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Holscher Christoph, 2005, Curr Opin Investig Drugs, V6, P489; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim JM, 2006, IMMUNOL REV, V212, P86, DOI 10.1111/j.0105-2896.2006.00426.x; Kleinewietfeld M, 2005, BLOOD, V105, P2877, DOI 10.1182/blood-2004-07-2505; Kriegel MA, 2004, J EXP MED, V199, P1285, DOI 10.1084/jem.20032158; Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI200213605; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Lee JH, 2007, CLIN EXP IMMUNOL, V148, P53, DOI 10.1111/j.1365-2249.2007.03329.x; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Lindley S, 2005, DIABETES, V54, P92, DOI 10.2337/diabetes.54.1.92; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; Marazuela M, 2006, J CLIN ENDOCR METAB, V91, P3639, DOI 10.1210/jc.2005-2337; Miyara M, 2006, J EXP MED, V203, P359, DOI 10.1084/jem.20050648; Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Mottonen M, 2005, CLIN EXP IMMUNOL, V140, P360, DOI 10.1111/j.1365-2249.2005.02754.x; Nakamura K, 2006, WORLD J GASTROENTERO, V12, P4628, DOI 10.3748/wjg.v12.i29.4628; Nomura T, 2007, NAT IMMUNOL, V8, P333, DOI 10.1038/ni0407-333; Ochs HD, 2005, IMMUNOL REV, V203, P156, DOI 10.1111/j.0105-2896.2005.00231.x; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pearce SHS, 2006, TRENDS MOL MED, V12, P90, DOI 10.1016/j.molmed.2005.12.005; Peluso I, 2007, J IMMUNOL, V178, P732, DOI 10.4049/jimmunol.178.2.732; Putheti P, 2004, J CLIN IMMUNOL, V24, P155, DOI 10.1023/B:JOCI.0000019780.93817.82; Putnam AL, 2005, J AUTOIMMUN, V24, P55, DOI 10.1016/j.jaut.2004.11.004; Ramsdell F, 2003, CURR OPIN IMMUNOL, V15, P718, DOI 10.1016/j.coi.2003.09.008; Ravelli A, 2007, LANCET, V369, P767, DOI 10.1016/S0140-6736(07)60363-8; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Ryan KR, 2005, J ALLERGY CLIN IMMUN, V116, P1158, DOI 10.1016/j.jaci.2005.08.036; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Schneider MA, 2007, J EXP MED, V204, P735, DOI 10.1084/jem.20061405; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Sharfe N, 1997, J CLIN INVEST, V100, P3036, DOI 10.1172/JCI119858; Shevach EM, 2006, IMMUNITY, V25, P195, DOI 10.1016/j.immuni.2006.08.003; Shi HZ, 2004, CLIN IMMUNOL, V113, P172, DOI 10.1016/j.clim.2004.06.009; Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005; Stockinger B, 2007, IMMUNITY, V26, P278, DOI 10.1016/j.immuni.2007.03.001; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tang QZ, 2006, IMMUNOL REV, V212, P217, DOI 10.1111/j.0105-2896.2006.00421.x; Torgerson TR, 2006, SPRINGER SEMIN IMMUN, V28, P63, DOI 10.1007/s00281-006-0041-4; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; van Amelsfort JMR, 2004, ARTHRITIS RHEUM, V50, P2775, DOI 10.1002/art.20499; van Amelsfort JMR, 2007, ARTHRITIS RHEUM, V56, P732, DOI 10.1002/art.22414; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Walker MR, 2005, P NATL ACAD SCI USA, V102, P4103, DOI 10.1073/pnas.0407691102; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Wraith DC, 2006, EUR J IMMUNOL, V36, P2844, DOI 10.1002/eji.200636760; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Yu QT, 2007, INFLAMM BOWEL DIS, V13, P191, DOI 10.1002/ibd.20053; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547; Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747	89	177	190	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					227	235		10.1016/j.jaci.2007.06.023	http://dx.doi.org/10.1016/j.jaci.2007.06.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17666212				2022-12-18	WOS:000248654900001
J	Kuperman, DA; Lewis, CC; Woodruff, PG; Rodriguez, MW; Yang, YH; Dolganov, GM; Fahy, JV; Erle, DJ				Kuperman, DA; Lewis, CC; Woodruff, PG; Rodriguez, MW; Yang, YH; Dolganov, GM; Fahy, JV; Erle, DJ			Dissecting asthma using focused transgenic modeling and functional genomics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IL-13; calcium-activated chloride channel; trefoil factor; 15-lipoxygenase; intelectin	MUCUS OVERPRODUCTION; INCREASED EXPRESSION; EPITHELIAL-CELLS; GENE-EXPRESSION; MICROARRAY DATA; AIRWAY; IL-13; ACID; INFLAMMATION; INTERLEUKIN-13	Background: Asthma functional genomics studies are challenging because it is difficult to relate gene expression changes to specific disease mechanisms or pathophysiologic features. Use of simplified model systems might help to address this problem. One such model is the IL-13/Epi (IL-13-overexpressing transgenic mice with STAT6 expression limited to epithelial cells) focused transgenic mouse, which isolates the effects of a single mediator, IL-13, on a single cell type, the airway epithelial cell. These mice develop airway hyperreactivity and mucus overproduction but not airway inflammation. Objective: To identify how effects of IL-13 on airway epithelial cells contribute to gene expression changes in murine asthma models and determine whether similar changes are seen in people with asthma. Methods: We analyzed gene expression in ovalbumin allergic mice, IL-13-overexpressing mice, and IL-13/Epi mice with microarrays. We analyzed the expression of human orthologues of genes identified in the mouse studies in airway epithelial cells from subjects with asthma and control subjects. Results: In comparison with the other 2 models, IL-13/Epi mice had a remarkably small subset of gene expression changes. Human orthologues; of some genes identified as increased in the mouse models were more highly expressed in airway epithelial cells from subjects with asthma than in controls. These included calcium-activated chloride channel 1, 15-lipoxygenase, trefoil factor 2, and intelectin. Conclusion: The combination of focused transgenic models, DNA microarray analyses, and translational studies provides a powerful approach for analyzing the contributions of specific mediators and cell types and for focusing attention on a limited number of genes associated with specific pathophysiologic aspects of asthma.	Univ Calif San Francisco, Dept Med, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Lung Biol Ctr, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Pulm & Crit Care Med, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Immunol, Sch Med, San Francisco, CA 94143 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, Chicago, IL USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Northwestern University; Feinberg School of Medicine	Erle, DJ (corresponding author), Univ Calif San Francisco, Dept Med, Sch Med, Box 2922, San Francisco, CA 94143 USA.	erle@itsa.ucsf.edu	Yang, Jean YH/D-2920-2015	Yang, Jean YH/0000-0002-5271-2603; Erle, David/0000-0002-2171-0648	NHLBI NIH HHS [HL72301, HL56835] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072301] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Barczak A, 2003, GENOME RES, V13, P1775, DOI 10.1101/gr.1048803; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CLAMAN DM, 1994, J ALLERGY CLIN IMMUN, V94, P861, DOI 10.1016/0091-6749(94)90154-6; COPAS JL, 1982, PROSTA LEUKOTR MED, V8, P105, DOI 10.1016/S0262-1746(82)80002-4; Diaz E, 2003, P NATL ACAD SCI USA, V100, P5491, DOI 10.1073/pnas.0831080100; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; Farrell JJ, 2002, J CLIN INVEST, V109, P193, DOI 10.1172/JCI200212529; GE YC, 2003, TEST, V12, P1, DOI DOI 10.1007/BF02595811; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hoshino M, 2002, AM J RESP CRIT CARE, V165, P1132, DOI 10.1164/ajrccm.165.8.2107068; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Jin W, 2001, NAT GENET, V29, P389, DOI 10.1038/ng766; JOHNSON HG, 1985, AM REV RESPIR DIS, V131, P917; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; LAI CKW, 1990, AM REV RESPIR DIS, V141, P1423; Laprise C, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-21; Lonnstedt I, 2002, STAT SINICA, V12, P31; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nikolaidis NM, 2003, AM J RESP CELL MOL, V29, P458, DOI 10.1165/rcmb.2002-0309OC; Oertel M, 2001, AM J RESP CELL MOL, V25, P418, DOI 10.1165/ajrcmb.25.4.4429; Sharma P, 1998, AM J RESP CELL MOL, V19, P30, DOI 10.1165/ajrcmb.19.1.3054; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; Tsuji S, 2001, J BIOL CHEM, V276, P23456, DOI 10.1074/jbc.M103162200; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Westfall P.H., 1993, RESAMPLING BASED MUL; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou YH, 2002, NOVART FDN SYMP, V248, P150; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912; Zou J, 2002, GENOME BIOL, V3	36	177	186	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					305	311		10.1016/j.jaci.2005.03.024	http://dx.doi.org/10.1016/j.jaci.2005.03.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083784				2022-12-18	WOS:000235686400011
J	Pappalardo, E; Cicardi, M; Duponchel, C; Carugati, A; Choquet, S; Agostoni, A; Tosi, M				Pappalardo, E; Cicardi, M; Duponchel, C; Carugati, A; Choquet, S; Agostoni, A; Tosi, M			Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						de novo mutations; de novo deletions; angioedema; genetics; epidemiology; complement; DNA mutational analysis; genetic variation; fluorescence-assisted mismatch analysis; gene deletions; Alu repeats	HEREDITARY ANGIONEUROTIC-EDEMA; ACQUIRED C1-INHIBITOR DEFICIENCY; HUMAN C1BAR INHIBITOR; C1 INHIBITOR; AUTOANTIBODY; DISORDERS; REPEAT	Background: Cases of angioedema with no family history but with functionally low levels of C1 inhibitor and recurrent attacks are often observed. Clinical and biochemical data do not distinguish these cases from proven inherited forms of hereditary angioedema. Objective: We sought to test the hypothesis of de novo mutations in patients affected by angioedema without a family history of the disease. Methods: Among 137 independent kindreds followed for hereditary angioedema, 45 (32.8%) patients with early onset of the disease were registered as sporadic cases. Nineteen patients with unaffected parents were screened for point mutations and microdeletions-insertions by using fluorescence-assisted mismatch analysis. The biologic paternity of these patients was verified by determining their alleles at 4 microsatellite loci. Gross deletions were detected with Southern blot analysis, Results: C1 inhibitor plasma levels measured in both parents of 24 sporadic patients were normal in all but 3 patients. Among the 19 patients studied at the DNA level, 9 de novo single nucleotide substitutions and 6 de novo microdeletions were found. De novo exon deletions mere detected in 3 additional patients,vith Southern blot analysis. Conclusions: De novo Clinhibitor mutations and exon deletions account for at least 25% of all unrelated cases of angioedema. This finding has implications relevant to the genetic epidemiology and genetic counseling of this disease. The observation that 5 of the 9 de novo point mutations reproduce previously reported changes underlines the presence of multiple hot spots, two of which contain a CpG dinucleotide.	Inst Pasteur, Dept Immunol, INSERM U276, Unite Immunogenet, F-75724 Paris 15, France; Univ Milan, Maggiore Hosp, IRCCS, Dept Internal Med, Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Tosi, M (corresponding author), Inst Pasteur, Dept Immunol, INSERM U276, Unite Immunogenet, 25 Rue Dr Roux, F-75724 Paris 15, France.		cicardi, marco/K-9219-2016	cicardi, marco/0000-0003-1251-225X	Telethon [E.C0469] Funding Source: Medline	Telethon(Fondazione Telethon)		AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; ARIGA T, 1990, GENOMICS, V8, P607, DOI 10.1016/0888-7543(90)90246-Q; ARIGA T, 1993, CLIN IMMUNOL IMMUNOP, V69, P103, DOI 10.1006/clin.1993.1156; BISSLER JJ, 1994, P NATL ACAD SCI USA, V91, P9622, DOI 10.1073/pnas.91.20.9622; BISSLER JJ, 1994, HUM GENET, V93, P265, DOI 10.1007/BF00212020; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; BRICKMAN CM, 1986, J ALLERGY CLIN IMMUN, V77, P749, DOI 10.1016/0091-6749(86)90424-0; Cicardi M, 1996, CLIN EXP IMMUNOL, V106, P475, DOI 10.1046/j.1365-2249.1996.d01-866.x; Crow JF, 1997, P NATL ACAD SCI USA, V94, P8380, DOI 10.1073/pnas.94.16.8380; FRANGI D, 1992, FEBS LETT, V301, P34, DOI 10.1016/0014-5793(92)80204-T; FRANK MM, 1993, COMPLEMENT HLTH DIS, P229; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; JACKSON J, 1986, NATURE, V323, P722, DOI 10.1038/323722a0; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SKRIVER K, 1989, J BIOL CHEM, V264, P3066; STOPPALYONNET D, 1991, AM J HUM GENET, V49, P1055; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; Tosi M, 1998, IMMUNOBIOLOGY, V199, P358, DOI 10.1016/S0171-2985(98)80040-5; TOSI M, 1989, J MOL BIOL, V208, P709, DOI 10.1016/0022-2836(89)90161-7; Verpy E, 1996, AM J HUM GENET, V59, P308; VERPY E, 1994, P NATL ACAD SCI USA, V91, P1873, DOI 10.1073/pnas.91.5.1873; Zuraw BL, 2000, J ALLERGY CLIN IMMUN, V105, P541, DOI 10.1067/mai.2000.104780	23	177	184	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1147	1154		10.1067/mai.2000.110471	http://dx.doi.org/10.1067/mai.2000.110471			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112899				2022-12-18	WOS:000165930300018
J	DOHI, M; SUKO, M; SUGIYAMA, H; YAMASHITA, N; TADOKORO, K; JUJI, F; OKUDAIRA, H; SANO, Y; ITO, K; MIYAMOTO, T				DOHI, M; SUKO, M; SUGIYAMA, H; YAMASHITA, N; TADOKORO, K; JUJI, F; OKUDAIRA, H; SANO, Y; ITO, K; MIYAMOTO, T			FOOD-DEPENDENT, EXERCISE-INDUCED ANAPHYLAXIS - A STUDY ON 11 JAPANESE CASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHOLINERGIC URTICARIA; PHYSICAL ALLERGY; ANGIOEDEMA; FORM	Eleven patients with food-dependent, exercise-induced anaphylaxis were studied. Seven patients experienced anaphylactic symptoms only after eating certain foods, such as shellfish, wheat, and grape before exercise. In the remaining four patients, no specific food could be identified, but the act of eating itself predisposed to anaphylaxis. Their anaphylactic symptoms were all clearly distinguished from cholinergic urticaria by history. Patients who developed anaphylactic symptoms before 20 years of age (N = 7) were atopic themselves or had atopic first-degree relatives. Six patients had increased serum IgE levels, and IgE antibodies against the causative food allergens were detected by the skin prick test or RAST in four cases. In contrast, patients who developed the symptoms after 30 years of age (N = 4) appeared to have a less atopic background, and IgE levels were within normal range except in one case. Three of four patients in the latter group developed symptoms after ingesting food made of wheat followed by exercise. All patients were sensitive to wheat as determined by the skin prick test. In six of 11 patients, a considerable rise in plasma histamine concentration was observed after exercise challenge with treadmill alone, and food intake followed by exercise induced a further increase in one patient.	DO AI MEM HOSP,DEPT ALLERGY & RESP DIS,TOKYO,JAPAN		DOHI, M (corresponding author), UNIV TOKYO,FAC MED,DEPT MED & PHYS THERAPY,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.							AKUTSU I, 1989, Japanese Journal of Allergology, V38, P277; BRUCE R A, 1963, Pediatrics, V32, P742; CASALE TB, 1988, J ALLERGY CLIN IMMUN, V82, P758, DOI 10.1016/0091-6749(88)90076-0; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P299, DOI 10.1016/0091-6749(76)90135-4; CIRILLO A, 1986, ALLERGOL IMMUNOPATH, V14, P419; GRANT JA, 1985, ANN ALLERGY, V54, P35; JUHLIN L, 1961, JAMA-J AM MED ASSOC, V177, P371, DOI 10.1001/jama.1961.73040320001004; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P319, DOI 10.1016/0091-6749(81)90158-5; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; KIVITY S, 1988, J ALLERGY CLIN IMMUN, V81, P1155, DOI 10.1016/0091-6749(88)90884-6; KUSHIMOTO H, 1985, ARCH DERMATOL, V121, P355, DOI 10.1001/archderm.121.3.355; LEWIS J, 1981, J ALLERGY CLIN IMMUN, V68, P432, DOI 10.1016/0091-6749(81)90197-4; LONGLEY S, 1987, ANN ALLERGY, V58, P257; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MCNEIL D, 1988, ANN ALLERGY, V61, P440; Miyake T., 1988, J JPN PED SOC, V92, P1328; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V71, P498, DOI 10.1016/0091-6749(83)90468-2; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P479, DOI 10.1016/S0091-6749(85)80021-X; SHEFFER AL, 1984, J ALLERGY CLIN IMMUN, V73, P699, DOI 10.1016/0091-6749(84)90309-9; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SHEFFER AL, 1988, NEW ENGL REG ALLERGY, V9, P215; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SILVERSTEIN S R, 1986, Journal of Emergency Medicine, V4, P195, DOI 10.1016/0736-4679(86)90040-5; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; WADE JP, 1989, PROGR CLIN BIOL RES, P175	26	177	182	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				34	40		10.1016/0091-6749(91)90210-F	http://dx.doi.org/10.1016/0091-6749(91)90210-F			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991921				2022-12-18	WOS:A1991EX98500005
J	HOPP, RJ; BEWTRA, A; NAIR, NM; TOWNLEY, RG				HOPP, RJ; BEWTRA, A; NAIR, NM; TOWNLEY, RG			THE EFFECT OF AGE ON METHACHOLINE RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,CTR ALLERG DIS,2500 CALIF,OMAHA,NE 68178	Creighton University			Hopp, Russell/K-4578-2019					BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; SHAPIRO GG, 1982, J ALLERGY CLIN IMMUN, V69, P365, DOI 10.1016/0091-6749(82)90147-6; SIMONSSO BG, 1965, ACTA ALLERGOL, V20, P325, DOI 10.1111/j.1398-9995.1965.tb03068.x; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; WEISS ST, 1983, AM REV RESPIR DIS, V128, P933; 1971, 1ST P NAT HEART LUNG	12	177	177	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					609	613		10.1016/0091-6749(85)90783-3	http://dx.doi.org/10.1016/0091-6749(85)90783-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	3902938				2022-12-18	WOS:A1985ATH6600014
J	Chhiba, KD; Patel, GB; Vu, THT; Chen, MM; Guo, A; Kudlaty, E; Mai, Q; Yeh, C; Muhammad, LN; Harris, KE; Bochner, BS; Grammer, LC; Greenberger, PA; Kalhan, R; Kuang, FL; Saltoun, CA; Schleimer, RP; Stevens, WW; Peters, AT				Chhiba, Krishan D.; Patel, Gayatri B.; Vu, Thanh Huyen T.; Chen, Michael M.; Guo, Amina; Kudlaty, Elizabeth; Mai, Quan; Yeh, Chen; Muhammad, Lutfiyya N.; Harris, Kathleen E.; Bochner, Bruce S.; Grammer, Leslie C.; Greenberger, Paul A.; Kalhan, Ravi; Kuang, Fei Li; Saltoun, Carol A.; Schleimer, Robert P.; Stevens, Whitney W.; Peters, Anju T.			Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; asthma; risk factors; morbidity; severity; corticosteroid; long-acting beta-agonist; allergic rhinitis; rhinosinusitis	COMORBIDITIES	Background: The Centers for Disease Control and Prevention advises that patients with moderate to severe asthma belong to a high-risk group that is susceptible to severe coronavirus disease 2019 (COVID-19). However, the association between asthma and COVID-19 has not been well-established. Objective: The primary objective was to determine the prevalence of asthma among patients with COVID-19 in a major US health system. We assessed the clinical characteristics and comorbidities in asthmatic and nonasthmatic patients with COVID-19. We also determined the risk of hospitalization associated with asthma and/or inhaled corticosteroid use. Methods: Medical records of patients with COVID-19 were searched by a computer algorithm (March 1 to April 15, 2020), and chart review was used to validate the diagnosis of asthma and medications prescribed for asthma. All patients had PCR-confirmed COVID-19. Demographic and clinical features were characterized. Regression models were used to assess the associations between asthma and corticosteroid use and the risk of COVID-19 related hospitalization. Results: Of 1526 patients identified with COVID-19, 220 (14%) were classified as having asthma. Asthma was not associated with an increased risk of hospitalization (relative risk, 0.96; 95% CI, 0.77-1.19) after adjusting for age, sex, and comorbidities. The ongoing use of inhaled corticosteroids did not increase the risk of hospitalization in a similar adjusted model (relative risk, 1.39; 95% CI, 0.90-2.15). Conclusions: Despite a substantial prevalence of asthma in our COVID-19 cohort, asthma was not associated with an increased risk of hospitalization. Similarly, the use of inhaled corticosteroids with or without systemic corticosteroids was not associated with COVID-19 related hospitalization.	[Vu, Thanh Huyen T.] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, Chicago, IL 60611 USA; [Vu, Thanh Huyen T.] Northwestern Univ, Feinberg Sch Med, Div Epidemiol, Dept Prevent Med, Chicago, IL 60611 USA; [Mai, Quan] Northwestern Univ, Feinberg Sch Med, Dept Feinberg Informat & Technol, Chicago, IL 60611 USA; [Yeh, Chen; Muhammad, Lutfiyya N.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Div Biostat, Chicago, IL 60611 USA; [Kalhan, Ravi] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Pulm & Crit Care, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Peters, AT (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA.	anjupeters@northwestern.edu	Yeh, Chen/AAY-2864-2020	Yeh, Chen/0000-0003-1320-3870; Muhammad, Lutfiyya NaQiyba/0000-0001-8655-1484	Chronic Rhinosinusitis Integrative Studies Program 2 [NIH P01AI145818]; Ernest Bazley Foundation	Chronic Rhinosinusitis Integrative Studies Program 2; Ernest Bazley Foundation	This work was supported by the Chronic Rhinosinusitis Integrative Studies Program 2 (grant no. NIH P01AI145818) and the Ernest Bazley Foundation.	Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Cazzola M, 2011, EUR RESPIR J, V38, P42, DOI 10.1183/09031936.00140310; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chicago Department of Public Health Chicago Health Atlas, 2018, ASTHM AD WHO HAV BEE; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Halpin DMG, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01009-2020; Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3; Hekking PP, 2018, J ALLER CL IMM-PRACT, V6, P108, DOI 10.1016/j.jaip.2017.06.008; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Johnston Sebastian L, 2005, Proc Am Thorac Soc, V2, P150, DOI 10.1513/pats.200502-018AW; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Matsuyama S, 2020, BIORXIV, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]; Myers LC, 2020, JAMA-J AM MED ASSOC, V323, P2195, DOI 10.1001/jama.2020.7202; NHIS Centers for Disease Control and Prevention, 2020, MOST REC NAT ASTHM D; Peters MC, 2020, AM J RESP CRIT CARE, V202, P83, DOI 10.1164/rccm.202003-0821OC; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Sears MR, 2008, J ALLERGY CLIN IMMUN, V122, P662, DOI 10.1016/j.jaci.2008.08.003; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1056/NEJMc2004973, 10.1101/2020.03.09.20033217]; Velavan TP, 2020, INT J INFECT DIS, V95, P304, DOI 10.1016/j.ijid.2020.04.061; Wai-san Ko F, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1181-0; Wark PAB, 2013, RESPIROLOGY, V18, P996, DOI 10.1111/resp.12099; Zheng XY, 2018, ARCH VIROL, V163, P845, DOI 10.1007/s00705-017-3700-y; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhou Y, 2020, J ALLER CL IMM-PRACT, V8, P2814, DOI 10.1016/j.jaip.2020.04.041	28	176	178	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					307	+		10.1016/j.jaci.2020.06.010	http://dx.doi.org/10.1016/j.jaci.2020.06.010			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32554082	Green Published, Bronze			2022-12-18	WOS:000558835000015
J	Mosbech, H; Deckelmann, R; de Blay, F; Pastorello, EA; Trebas-Pietras, E; Andres, LP; Malcus, I; Ljorring, C; Canonica, GW				Mosbech, Holger; Deckelmann, Regina; de Blay, Frederic; Pastorello, Elide Anna; Trebas-Pietras, Ewa; Andres, Luis Prieto; Malcus, Inga; Ljorring, Christian; Canonica, Giorgio Walter			Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; asthma control; house dust mite; immunotherapy; allergy immunotherapy; SLIT-tablet; respiratory allergic disease; inhaled corticosteroid; SQ	GRASS ALLERGEN TABLETS; POLLEN-INDUCED RHINOCONJUNCTIVITIS; TERM CLINICAL-EFFICACY; SAFETY; RHINITIS; CHILDREN; QUESTIONNAIRE; IMPACT	Background: Investigations meeting current standards are limited for the effect of house dust mite (HDM) allergy immunotherapy in asthmatic patients. Objective: This trial investigated the efficacy and safety of a standardized quality (SQ; allergen standardization method proprietary to the trial sponsor) HDM SLIT-tablet (ALK, Horsholm, Denmark) in adults and adolescents with HDM respiratory allergic disease. This publication reports the results of the endpoints related to asthma. Methods: Six hundred four subjects 14 years or older with HDM allergic rhinitis and mild-to-moderate asthma were randomized 1: 1: 1: 1 to double-blind daily treatment with one of 3 active doses (1, 3, or 6 SQ-HDM) or placebo. Their use of inhaled corticosteroid (ICS) was standardized and adjusted at baseline and the end of treatment to the lowest dose providing asthma control. The primary end point was a reduction in ICS dose from the individual subject's baseline dose after 1 year of treatment. Results: The primary analysis revealed a mean difference between 6 SQ-HDM and placebo in the reduction in daily ICS dose of 81 mg (P = .004). Relative mean and median reductions were 42% and 50% for 6 SQ-HDM and 15% and 25% for placebo, respectively. No statistically significant differences were observed for the other assessed asthma parameters, reflecting the intended controlled status of the trial subjects. The most common adverse events were local reactions in the mouth. The rate and severity of adverse events were higher for 3 and 6 SQ-HDM than for 1 SQ-HDM and placebo. Conclusion: Efficacy in mild-to-moderate asthma of 6 SQ-HDM relative to placebo was demonstrated by a moderate statistically significant reduction in the ICS dose required to maintain asthma control. All active doses were well tolerated.	[Mosbech, Holger] Univ Copenhagen, Gentofte Hosp, Allergy Unit, DK-1168 Copenhagen, Denmark; [Deckelmann, Regina] SALVUS UG Ctr Clin Trials, Leipzig, Germany; [de Blay, Frederic] Univ Strasbourg, Strasbourg Univ Hosp, Federat Translat Med, Chest Dis Dept, Strasbourg, France; [Pastorello, Elide Anna] Ospedale Niguarda Ca Granda, Milan, Italy; [Andres, Luis Prieto] Univ Valencia, E-46003 Valencia, Spain; [Ljorring, Christian] ALK, Horsholm, Denmark; [Canonica, Giorgio Walter] Univ Genoa, I-16126 Genoa, Italy	University of Copenhagen; Herlev & Gentofte Hospital; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Ospedale Niguarda Ca' Granda; University of Valencia; University of Genoa	Mosbech, H (corresponding author), Univ Copenhagen, Gentofte Hosp, Allergy Unit, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark.	hmos0006@geh.regionh.dk	canonica, giorgio walter/ABF-2037-2020; PASTORELLO, ELIDE ANNA/E-3897-2017	canonica, giorgio walter/0000-0001-8467-2557; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783	ALK-Abello, Horsholm, Denmark	ALK-Abello, Horsholm, Denmark	Sponsored by ALK-Abello, Horsholm, Denmark, who assumes overall responsibility for the trial and has been involved in both trial design and conduct.	Adult Treatment Panel III, 2002, NIH PUBL, V02-5215, P1; [Anonymous], 1997, ICH HARM TRIP GUID T; [Anonymous], 1983, B EUROP PHYSIOPAT S5, V19; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V128, P430, DOI 10.1016/j.jaci.2011.04.053; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Blumberga G, 2006, ALLERGY, V61, P843, DOI 10.1111/j.1398-9995.2006.01088.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calderon MA, 2012, J ALLERGY CLIN IMMUN, V129, P929, DOI 10.1016/j.jaci.2011.11.019; Canonica GW, 2009, WORLD ALLERGY ORGAN, V2, P233, DOI 10.1097/WOX.0b013e3181c6c379; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; Corzo JL, 2014, J INVESTIG IN PRESS; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Didier A, 2011, J ALLERGY CLIN IMMUN, V128, P559, DOI 10.1016/j.jaci.2011.06.022; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; GINA, 2010, GLOB STRAT ASTHM MAN; GINA Executive Committee, 2011, GLOB IN ASTHM GLOB S; Global Initiative for Asthma (GINA), GLOB STRAT ASTH MAN; Ibanez MD, 2007, PEDIAT ALLERG IMM-UK, V18, P516, DOI 10.1111/j.1399-3038.2007.00556.x; ICH, 1996, ICH HARM TRIP GUID T; International Conference on Harmonization (ICH), 1998, ICH HARM TRIP GUID T; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kette F, 2011, J ALLERGY CLIN IMMUN, V128, P430, DOI 10.1016/j.jaci.2011.04.048; Knudsen TB, 2009, J ASTHMA, V46, P91, DOI 10.1080/02770900802524657; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; Malling HJ, 2009, CLIN EXP ALLERGY, V39, P387, DOI 10.1111/j.1365-2222.2008.03152.x; Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Walker S, 2006, ANTIIGE CHRONIC ASTH; Zielen S, 2010, J ALLERGY CLIN IMMUN, V126, P942, DOI 10.1016/j.jaci.2010.06.002; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	46	176	180	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					568	+		10.1016/j.jaci.2014.03.019	http://dx.doi.org/10.1016/j.jaci.2014.03.019			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24797423				2022-12-18	WOS:000341372400008
J	Nelson, HS; Nolte, H; Creticos, P; Maloney, J; Wu, JM; Bernstein, DI				Nelson, Harold S.; Nolte, Hendrik; Creticos, Peter; Maloney, Jennifer; Wu, Jiangming; Bernstein, David I.			Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy immunotherapy tablet; allergic rhinoconjunctivitis; specific immunotherapy; grass pollen; sublingual immunotherapy	TERM CLINICAL-EFFICACY; SUBLINGUAL IMMUNOTHERAPY; DOUBLE-BLIND; FATAL REACTIONS; ASTHMA; RHINOCONJUNCTIVITIS; RHINITIS; METAANALYSIS; INJECTIONS; CHILDREN	Background: Immunotherapy for allergic rhinoconjunctivitis (ARC) in North America is generally administered subcutaneously, but alternative formulations might be safer and more convenient. Trials of sublingual formulations in North America are needed to confirm European efficacy and safety data. Objective: We sought to investigate the efficacy and safety of timothy grass allergy immunotherapy tablet (AIT) treatment in North American subjects with ARC. Methods: Four hundred thirty-nine adults with grass pollen-induced ARC with or without asthma were randomized to once-daily 2,800 bioequivalent allergen units of standardized grass AIT (oral lyophilisate, Phleum pratense, 75,000 standardized quality tablet, containing approximately 15 mu g of Phl p 5) or placebo approximately 16 weeks before the 2009 grass pollen season (GPS). The primary end point was the average total combined score of the daily symptom score and the daily medication score during the GPS. Rhinoconjunctivitis Quality of Life Questionnaire with standardized activities (RQLQ[S]) scores, Phl p 5-specific IgG4 levels, and IgE-blocking factor levels were additional end points. Adverse events (AEs) were monitored for safety. Results: Relative to placebo, grass AIT treatment improved total combined scores by 20% (P = .005), daily symptom scores by 18% (P = .02), and RQLQ(S) scores by 17% (P = .02). Daily medication scores were improved by 26% and trended toward significance (P = .08). Phl p 5-specific IgG4 and IgE-blocking factor levels were higher after grass AIT treatment compared with those after placebo at the end of the GPS (P < .001). Grass AIT treatment was safe and well tolerated. The majority of AEs were transient mild local reactions with no investigator-diagnosed grass AIT-related serious AEs or reports of anaphylactic shock/respiratory compromise. In the grass AIT group, 1 subject received epinephrine after experiencing a possible grade 1 systemic reaction (local site reactions, chest discomfort, and rash). Conclusions: Timothy grass AIT treatment (cross-reactive with related Pooideae grasses) was demonstrated to be effective, generally safe, and well tolerated in North American adults with grass pollen-induced ARC. (J Allergy Clin Immunol 2011;127:72-80.)	[Nelson, Harold S.] Natl Jewish Hlth, Div Allergy & Immunol, Dept Med, Denver, CO 80206 USA; [Nolte, Hendrik; Maloney, Jennifer; Wu, Jiangming] Merck Res Labs, Kenilworth, NJ USA; [Nolte, Hendrik] Bispebjerg Copenhagen Univ Hosp, Resp Res Unit, Copenhagen, Denmark; [Creticos, Peter] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Maloney, Jennifer] Mt Sinai Sch Med, Dept Pediat, New York, NY USA; [Bernstein, David I.] Univ Cincinnati, Div Allergy & Immunol, Dept Med, Cincinnati, OH 45221 USA	National Jewish Health; Merck & Company; University of Copenhagen; Johns Hopkins University; Icahn School of Medicine at Mount Sinai; University System of Ohio; University of Cincinnati	Nelson, HS (corresponding author), Natl Jewish Hlth, Div Allergy & Immunol, Dept Med, 1400 Jackson St,Room B104, Denver, CO 80206 USA.	nelsonh@njhealth.org			ALK-Abello; Merck/Schering-Plough; Greer Labs; GlaxoSmithKline; Stallergenes; Merck; Merck Co.	ALK-Abello; Merck/Schering-Plough(Merck & CompanySchering Plough Corporation); Greer Labs; GlaxoSmithKline(GlaxoSmithKline); Stallergenes; Merck(Merck & Company); Merck Co.(Merck & Company)	Supported by Merck & Co.; H. S. Nelson has consulted for Genentech/Novartis, Merck, Sepracor, Forest Labs, Pfizer, Planet Biopharmaceuticals, GlaxoSmithKline, AstraZeneca, Abbott Laboratories, DBV Technologies, and Vectura and has received research support from ALK-Abello. P. Creticos has consulted for Greer Labs, Schering-Plough, Sanofi-Aventis, and Stallergenes; has received research support from Merck/Schering-Plough, Greer Labs, GlaxoSmithKline, and Stallergenes; and is a member of the American Academy of Allergy, Asthma & Immunology (AAAAI) Immunotherapy Committee. H. Nolte is an employee of Merck. J. Maloney is an employee of Merck. J. Wu is an employee of Merck D. I. Bernstein has served on advisory boards for ALK America and Merck; has received research support from Merck; and is a member of the AAAAI Immunotherapy Committee.	Abramson MJ, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001186, DOI 10.1002/14651858.CD001186]; Acquistapace F, 2009, PEDIAT ALLERG IMM-UK, V20, P660, DOI 10.1111/j.1399-3038.2009.00860.x; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; [Anonymous], 2009, GUID CLIN DEV PROD S; Bernstein DI, 2010, ANN ALLERG ASTHMA IM, V104, P530, DOI 10.1016/j.anai.2010.04.008; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Blaiss MS, 2007, ALLERGY ASTHMA PROC, V28, P393, DOI 10.2500/aap.2007.28.3013; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Calderon M, 2006, J INVEST ALLERG CLIN, V16, P338; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Cox L, 2008, ALLERGY ASTHMA PROC, V29, P580, DOI 10.2500/aap.2008.29.3162; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Esch RE, 2008, ANN ALLERG ASTHMA IM, V100, P475, DOI 10.1016/S1081-1206(10)60474-7; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Galant S, 1998, ANN ALLERG ASTHMA IM, V81, P203, DOI 10.1016/S1081-1206(10)62813-X; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; Marogna M, 2008, ANN ALLERG ASTHMA IM, V101, P206, DOI 10.1016/S1081-1206(10)60211-6; MARTIN BG, 1985, ANN ALLERGY, V54, P99; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Nelson HS, 2007, J ALLERGY CLIN IMMUN, V119, P769, DOI 10.1016/j.jaci.2007.01.036; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Ross RN, 2000, CLIN THER, V22, P329, DOI 10.1016/S0149-2918(00)80037-5; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Skoner D, 2010, J ALLERGY CLIN IMMUN, V125, P660, DOI 10.1016/j.jaci.2009.12.931; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425, DOI 10.1016/S1081-1206(10)61509-8; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wu LYF, 1999, ANN ALLERG ASTHMA IM, V83, P137, DOI 10.1016/S1081-1206(10)62625-7	40	176	177	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					72	U138		10.1016/j.jaci.2010.11.035	http://dx.doi.org/10.1016/j.jaci.2010.11.035			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211643	Bronze			2022-12-18	WOS:000285917300011
J	Roufosse, F; Weller, PF				Roufosse, Florence; Weller, Peter F.			Practical approach to the patient with hypereosinophilia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; hypereosinophilic syndromes; FIPILI-PDGFRA	EOSINOPHILIA; VARIANT	Markedly increased blood eosinophilia (ie, >= 1.5 x 10(9)/L), whether discovered fortuitously or found with signs and symptoms of associated organ involvement, commands diagnostic evaluation and often therapeutic interventions. This degree of hypereosinophilia is often but not uniformly associated with eosinophilic infiltration of tissues that can potentially lead to irreversible, life-threatening organ damage. Initial approaches focus on ascertaining that eosinophilia is not secondary to other underlying disease processes, including helminthic parasite infections, varied types of adverse reactions to medications, and other eosinophil-associated syndromes, such as eosinophilic gastroenteritides, eosinophilic pneumonias, and Churg-Strauss syndrome vasculitis. If evaluations exclude eosinophilia attributable to secondary causes or other eosinophil-related syndromes or organ-specific diseases, attention must be directed to considerations of varied other forms of the hypereosinophilic syndromes, which include myeloproliferative variants, lymphocytic variants, and many of still unknown causes. Cognizant of the capacities of eosinophils to mediate tissue damage, the varied causes for hypereosinophilia are considered, and a contemporary stepwise practical approach to the diagnosis and treatment of patients with hypereosinophilia is presented. (J Allergy Clin Immunol 2010;126:39-44.)	[Weller, Peter F.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Infect Dis,Dept Med, Boston, MA 02215 USA; [Weller, Peter F.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Allergy & Inflammat, Boston, MA 02215 USA; [Roufosse, Florence] Univ Libre Bruxelles, Erasme Hosp, Dept Internal Med, Brussels, Belgium; [Roufosse, Florence] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles	Weller, PF (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Infect Dis,Dept Med, CLS 943,330 Brookline Ave, Boston, MA 02215 USA.	pweller@bidmc.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020241] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI020241, R01 AI020241-26, R01 AI020241-27] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ackerman SJ, 2007, IMMUNOL ALLERGY CLIN, V27, P357, DOI 10.1016/j.iac.2007.07.004; Bain BJ, 2007, IMMUNOL ALLERGY CLIN, V27, P377, DOI 10.1016/j.iac.2007.06.001; Blanchard C, 2009, ADV IMMUNOL, V101, P81, DOI 10.1016/S0065-2776(08)01003-1; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Klion A, 2009, ANNU REV MED, V60, P293, DOI 10.1146/annurev.med.60.062107.090340; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Roufosse F, 2007, IMMUNOL ALLERGY CLIN, V27, P389, DOI 10.1016/j.iac.2007.07.002; Simon HU, 2010, J ALLERGY CLIN IMMUN, V126, P45, DOI 10.1016/j.jaci.2010.03.042; Spencer LA, 2009, J LEUKOCYTE BIOL, V85, P117, DOI 10.1189/jlb.0108058; Tefferi A, 2010, MAYO CLIN PROC, V85, P158, DOI 10.4065/mcp.2009.0503; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262	13	176	190	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					39	44		10.1016/j.jaci.2010.04.011	http://dx.doi.org/10.1016/j.jaci.2010.04.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20538328	Green Accepted, Green Published			2022-12-18	WOS:000280061800007
J	Christensen, LH; Holm, J; Lund, G; Riise, E; Lund, K				Christensen, Lars Harder; Holm, Jens; Lund, Gitte; Riise, Erik; Lund, Kaare			Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; recombinant IgE; human IgE; chimeric IgE; antibody; affinity; epitope; allergen; Der p 2; effector cell degranulation; basophil activation test; basophils; diagnosis	HUMAN BASOPHIL ACTIVATION; HISTAMINE-RELEASE; CROSS-REACTIVITY; LEUKEMIA-CELLS; MITE ALLERGEN; ANTI-IGE; AFFINITY; IMMUNOASSAY; EXPRESSION; EPITOPES	Background: On cross-linking of receptor-bound IgE antibodies by allergens, effector cells (basophils and mast cells) involved in type I allergic reactions degranulate and release the potent chemical mediators stored inside their granules. Total and allergen-specific IgE concentrations, IgE affinity for allergen, and IgE clonality are all distinct properties of allergic patients' IgE repertoires. However, the inability to isolate individual IgE antibodies from allergic patients' sera presents a major barrier to understanding the importance of patient-specific IgE repertoires for the manifestation and severity of allergic symptoms. Objective: We sought to investigate how individual properties of an IgE repertoire affect effector cell degranulation. Methods: A panel of recombinant IgE (rIgE) antibodies specific for the major house dust mite allergen Der p 2 was developed and characterized in regard to Der p 2 affinity, as well as Der p 2 epitope specificity, by using surface plasmon resonance technology. Human basophils were sensitized with different combinations of rIgEs, and degranulation responses were measured by means of flow cytometry after challenge with Der p 2. Results: A total of 31 Der p 2-specific rIgEs were produced. They bound a total of 9 different Der p 2 epitopes in the affinity range (KD value) of 0.0358 to 291 nM. Factors increasing human basophil degranulation were increased total IgE concentrations, increased concentrations of allergen-specific IgE relative to non-allergen-specific IgE, more even concentration of individual allergen-specific IgE clones, increased IgE affinity for allergen, and increased number of allergen epitopes recognized by the IgE repertoire (increased IgE clonality). Conclusion: This study demonstrates how distinct properties of the IgE repertoire, such as total and allergen-specific IgE antibody concentration, IgE affinity, and IgE clonality, affect effector cell degranulation.	[Christensen, Lars Harder; Holm, Jens; Lund, Gitte; Lund, Kaare] ALK Abello AS, Dept Expt Immunol, DK-2970 Horsholm, Denmark; [Christensen, Lars Harder; Riise, Erik] Univ Copenhagen, Fac Pharmaceut Sci, Antibody Technol Grp, Copenhagen, Denmark	ALK-Abello AS; University of Copenhagen	Christensen, LH (corresponding author), ALK Abello AS, Dept Expt Immunol, Boge Alle 6-8, DK-2970 Horsholm, Denmark.	lars-harder@hotmail.com		Lund, Gitte/0000-0003-2221-7465; Harder Christensen, Lars/0000-0003-4230-7820				Aalberse RC, 2001, ALLERGY, V56, P27, DOI 10.1034/j.1398-9995.2001.00909.x; Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; COLLINS AM, 1995, INT ARCH ALLERGY IMM, V107, P547, DOI 10.1159/000237098; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; FEWTRELL C, 1980, J IMMUNOL, V125, P701; Gieras A, 2007, J ALLERGY CLIN IMMUN, V119, P384, DOI 10.1016/j.jaci.2006.09.034; Hahn EL, 2005, IMMUNOL ALLERGY CLIN, V25, P231, DOI 10.1016/j.iac.2005.02.004; HEALICON RM, 1986, IMMUNOLOGY, V57, P611; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Johansson SGO, 2006, ALLERGY, V61, P1216, DOI 10.1111/j.1398-9995.2006.01172.x; KAGEYSOBOTKA A, 1981, J IMMUNOL, V127, P2285; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Marchand F, 2003, ALLERGY, V58, P1037, DOI 10.1034/j.1398-9995.2003.00251.x; Mita H, 2000, CLIN EXP ALLERGY, V30, P1582, DOI 10.1046/j.1365-2222.2000.00921.x; Norderhaug L, 1997, J IMMUNOL METHODS, V204, P77, DOI 10.1016/S0022-1759(97)00034-3; Nott A, 2003, RNA, V9, P607, DOI 10.1261/rna.5250403; Persson H, 2007, MOL IMMUNOL, V44, P2729, DOI 10.1016/j.molimm.2006.11.024; Pierson-Mullany LK, 2002, CLIN EXP ALLERGY, V32, P107, DOI 10.1046/j.0022-0477.2001.01244.x; PRUZANSKY JJ, 1988, IMMUNOLOGY, V64, P307; Romano A, 2007, CURR OPIN ALLERGY CL, V7, P299, DOI 10.1097/ACI.0b013e328216f4d4; Sainte-Laudy J, 1998, INFLAMM RES, V47, P401, DOI 10.1007/s000110050351; Schroeder JT, 2001, ADV IMMUNOL, V77, P93, DOI 10.1016/S0065-2776(01)77015-0; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021	28	176	179	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					298	304		10.1016/j.jaci.2008.05.026	http://dx.doi.org/10.1016/j.jaci.2008.05.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18572230				2022-12-18	WOS:000258426300013
J	Untersmayr, E; Jensen-Jarolim, E				Untersmayr, Eva; Jensen-Jarolim, Erika			The role of protein digestibility and antacids on food allergy outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						food allergy; gastric digestion; acid-suppression medication; digestion assay; simulated gastric fluid	PROTON PUMP INHIBITORS; GASTROESOPHAGEAL-REFLUX DISEASE; SIMULATED INTESTINAL FLUID; ACID SUPPRESSING TREATMENT; B-CELL EPITOPES; ORAL TOLERANCE; NONALLERGENIC PROTEINS; HELICOBACTER-PYLORI; SIZE DISTRIBUTION; DIETARY ANTIGENS	Digestion assays with simulated gastric fluid have been introduced for characterization of food proteins to imitate the effect of stomach proteolysis on dietary compounds in vitro. By using these tests, dietary proteins can be categorized as digestion-resistant class 1 (true allergens triggering direct oral sensitization) or as labile class 2 allergens (nonsensitizing elicitors). Thus the results of these digestion assays mirror situations of intact gastric proteolysis. Alterations in the gastric milieu are frequently experienced during a lifetime either physiologically in the very young and the elderly or as a result of gastrointestinal pathologies. Additionally, acid-suppression medications are frequently used for treatment of dyspeptic disorders. By increasing the gastric pH, they interfere substantially with the digestive function of the stomach, leading to persistence of labile food protein during gastric transit. Indeed, both murine and human studies reveal that antiulcer medication increases the risk of food allergy induction. Gastric digestion substantially decreases the potential of food proteins to bind IgE, which increases the threshold dose of allergens required to elicit symptoms in patients with food allergy. Thus antiulcer agents impeding gastric protein digestion have a major effect on the sensitization and effector phase of food allergy.	[Untersmayr, Eva; Jensen-Jarolim, Erika] Med Univ Vienna, Ctr Physiol Pathophysiol & Immunol, Dept Pathophysiol, A-1090 Vienna, Austria	Medical University of Vienna	Untersmayr, E (corresponding author), Med Univ Vienna, Ctr Physiol Pathophysiol & Immunol, Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	eva.untersmayr@meduniwien.ac.at	Untersmayr, Eva/GRY-4470-2022; Eckhardt, Erik/G-1567-2010; Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765; Untersmayr, Eva/0000-0002-1963-499X	Austrian Science Fund FWF [F 1808, H 220] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Aalberse RC, 1997, ENVIRON TOXICOL PHAR, V4, P55, DOI 10.1016/S1382-6689(97)10042-4; Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; AGUNOD M, 1969, AM J DIG DIS, V14, P400, DOI 10.1007/BF02239360; Aihara T, 2003, PHARMACOL THERAPEUT, V98, P109, DOI 10.1016/S0163-7258(03)00015-9; Alcorn J, 2003, ADV DRUG DELIVER REV, V55, P667, DOI 10.1016/S0169-409X(03)00030-9; ALJANABI J, 1972, J BIOL CHEM, V247, P4628; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; AVERY GB, 1966, PEDIATRICS, V37, P1005; Bannon GA, 2004, CURR ALLERGY ASTHM R, V4, P43, DOI 10.1007/s11882-004-0042-0; Barone KS, 2000, CELL IMMUNOL, V199, P65, DOI 10.1006/cimm.1999.1603; Bashford JNR, 1998, BRIT MED J, V317, P452; Bland PW, 1998, GUT, V42, P455, DOI 10.1136/gut.42.4.455; Blumberg RS, 1999, IMMUNOL LETT, V69, P7, DOI 10.1016/S0165-2478(99)00093-0; Boutet R, 1999, ALIMENT PHARM THERAP, V13, P813, DOI 10.1046/j.1365-2036.1999.00524.x; Brandtzaeg P, 1997, ENVIRON TOXICOL PHAR, V4, P9, DOI 10.1016/S1382-6689(97)10036-9; Brandtzaeg P, 2002, ANN NY ACAD SCI, V964, P13; Brandtzaeg P, 1996, ANN NY ACAD SCI, V778, P1, DOI 10.1111/j.1749-6632.1996.tb21110.x; Brewer JM, 1999, J IMMUNOL, V163, P6448; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Brunner M, 1928, ARCH INTERN MED, V42, P172, DOI 10.1001/archinte.1928.00130200024002; Brunner R, 2007, CLIN EXP ALLERGY, V37, P1566, DOI 10.1111/j.1365-2222.2007.02813.x; BUDAGOVSKAYA V N, 1984, Voprosy Pitaniya, P30; Burnett GR, 2002, BIOCHEM SOC T, V30, P916, DOI 10.1042/BST0300916; Carreno I, 2005, FOOD DRUG LAW J, V60, P375; Chen TJ, 2003, WORLD J GASTROENTERO, V9, P1365, DOI 10.3748/wjg.v9.i6.1365; *DAN MED AG, STAT REG PHARM; DAVIES D, 1930, BMJ-BRIT MED J, V1, P1; De Lazzari F, 1994, Minerva Gastroenterol Dietol, V40, P1; DELAZZARI F, 1994, ITAL J GASTROENTEROL, V26, P7; Deplancke B, 2001, AM J CLIN NUTR, V73, p1131S; DEREN JS, 1971, AM J CLIN NUTR, V24, P144; DEWITTE TJ, 1979, ANN RHEUM DIS, V38, P14, DOI 10.1136/ard.38.1.14; Dirks CG, 2005, J ALLERGY CLIN IMMUN, V115, P1321, DOI 10.1016/j.jaci.2005.03.027; EBERS DW, 1956, PEDIATRICS, V18, P800; Eiwegger T, 2006, CLIN EXP ALLERGY, V36, P1281, DOI 10.1111/j.1365-2222.2006.02565.x; ERICKSON RH, 1990, ANNU REV MED, V41, P133; ETHERINGTON DJ, 1970, BIOCHEM J, V118, P587, DOI 10.1042/bj1180587; EULER AR, 1977, GASTROENTEROLOGY, V72, P1271; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Faria Ana M. C., 2006, Inflammation & Allergy Drug Targets, V5, P179; Fu TJ, 2002, ANN NY ACAD SCI, V964, P99; Fu TT, 2002, J AGR FOOD CHEM, V50, P7154, DOI 10.1021/jf020599h; Ganglberger E, 2000, FASEB J, V14, P2177, DOI 10.1096/fj.99-1000com; Gold BD, 2004, ALIMENT PHARM THERAP, V19, P22, DOI 10.1111/j.0953-0673.2004.01832.x; Gold Benjamin D, 2007, J Fam Pract, V56, pS1; Gold BD, 2007, J PEDIATR GASTR NUTR, V45, P520, DOI 10.1097/MPG.0b013e318148c17c; GRAY GM, 1971, GASTROENTEROLOGY, V61, P535; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Gullotta R, 1997, ITAL J GASTROENTEROL, V29, P325; Hantusch B, 2004, J ALLERGY CLIN IMMUN, V114, P1294, DOI 10.1016/j.jaci.2004.06.048; Hefle SL, 1996, CRIT REV FOOD SCI, V36, pS69, DOI 10.1080/10408399609527760; Heikkinen M, 1996, SCAND J GASTROENTERO, V31, P648, DOI 10.3109/00365529609009144; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; HOSKING DJ, 1975, BMJ-BRIT MED J, V2, P588, DOI 10.1136/bmj.2.5971.588; HOWITZ J, 1971, LANCET, V1, P1331; HUSBY S, 1985, SCAND J IMMUNOL, V22, P83, DOI 10.1111/j.1365-3083.1985.tb01862.x; HUSBY S, 1987, GUT, V28, P1062, DOI 10.1136/gut.28.9.1062; INGLIS TJJ, 1993, LANCET, V341, P911, DOI 10.1016/0140-6736(93)91208-4; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Jensen-Jarolim E, 2006, IMMUNOL LETT, V102, P118, DOI 10.1016/j.imlet.2005.07.009; Jensen-Jarolim E, 2005, WIEN KLIN WOCHENSCHR, V117, P437, DOI 10.1007/s00508-005-0397-9; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; Kay L, 1994, Scand J Gastroenterol, V29, P2; Khan AR, 1998, PROTEIN SCI, V7, P815; Kimura T, 2002, BIOL PHARM BULL, V25, P149, DOI 10.1248/bpb.25.149; Laheij RJF, 2004, JAMA-J AM MED ASSOC, V292, P1955, DOI 10.1001/jama.292.16.1955; Lassen A, 2004, ALIMENT PHARM THERAP, V20, P577, DOI 10.1111/j.1365-2036.2004.02120.x; Lauerma AI, 2001, ALLERGY, V56, P580, DOI 10.1034/j.1398-9995.2001.056006580.x; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; Lehrer SB, 2002, ANN NY ACAD SCI, V964, P69; Leonard J, 2007, AM J GASTROENTEROL, V102, P2047, DOI 10.1111/j.1572-0241.2007.01275.x; Liutu M, 2001, INT ARCH ALLERGY IMM, V126, P213, DOI 10.1159/000049516; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; Maier I, 2006, J CHROMATOGR B, V841, P160, DOI 10.1016/j.jchromb.2006.06.040; Mancin O, 1988, Minerva Dietol Gastroenterol, V34, P171; Marshall JK, 2002, CAN MED ASSOC J, V166, P1655; Martinsen TC, 2005, BASIC CLIN PHARMACOL, V96, P94, DOI 10.1111/j.1742-7843.2005.pto960202.x; Mayer L, 2003, PEDIATRICS, V111, P1595; MCCARTHY DM, 1991, NEW ENGL J MED, V325, P1017; MCCULLAGH M, 1994, BRIT MED J, V308, P1238, DOI 10.1136/bmj.308.6938.1238; MCPHIE P, 1972, J BIOL CHEM, V247, P4277; MICHAEL JG, 1989, IMMUNOL INVEST, V18, P1049, DOI 10.3109/08820138909030606; Miller R. A., 1941, ARCH DIS CHILDHOOD, V16, P22; Moreno FJ, 2005, J AGR FOOD CHEM, V53, P9810, DOI 10.1021/jf0515227; Nardino RJ, 2000, AM J GASTROENTEROL, V95, P3118; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; OKA T, 1970, FEBS LETT, V10, P222, DOI 10.1016/0014-5793(70)80633-0; PAGANELLI R, 1980, J IMMUNOL METHODS, V37, P333, DOI 10.1016/0022-1759(80)90319-1; Permin H, 2000, INFLAMM RES, V49, pS29; PRICHARD PJ, 1985, GASTROENTEROLOGY, V88, P64, DOI 10.1016/S0016-5085(85)80133-5; Richardson P, 1998, DRUGS, V56, P307, DOI 10.2165/00003495-199856030-00002; Richter C, 1998, BIOCHEM J, V335, P481, DOI 10.1042/bj3350481; Richter JE, 2005, ALIMENT PHARM THER, V22, P749, DOI 10.1111/j.1365-2036.2005.02654.x; Roberts Graham, 2003, Paediatr Respir Rev, V4, P205, DOI 10.1016/S1526-0542(03)00058-7; RYDER SD, 1994, BRIT MED J, V308, P827, DOI 10.1136/bmj.308.6932.827; SAMLOFF IM, 1989, GASTROENTEROLOGY, V96, P586, DOI 10.1016/S0016-5085(89)80054-X; Sampson HA, 1996, PEDIAT ALLERG IMM-UK, V7, P42, DOI 10.1111/j.1399-3038.1996.tb00394.x; Sampson HA, 2000, BRIT MED BULL, V56, P925, DOI 10.1258/0007142001903607; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Schimek EM, 2005, J ALLERGY CLIN IMMUN, V116, P1327, DOI 10.1016/j.jaci.2005.09.007; Scholl I, 2007, FASEB J, V21, P1264, DOI 10.1096/fj.06-7223com; Scholl I, 2005, J IMMUNOL, V175, P6645, DOI 10.4049/jimmunol.175.10.6645; Scholl L, 2005, AM J CLIN NUTR, V81, P154; Schubert ML, 2007, CURR OPIN GASTROEN, V23, P595, DOI 10.1097/MOG.0b013e3282f03462; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; SLEISENGER MH, 1979, NEW ENGL J MED, V300, P659, DOI 10.1056/NEJM197903223001207; Sloane D, 2001, ALLERGY ASTHMA PROC, V22, P321; Smit DV, 2005, J EMERG MED, V28, P381, DOI 10.1016/j.jemermed.2004.11.028; Sunku B, 2000, J Am Osteopath Assoc, V100, pS11; Szalai K, 2008, MOL IMMUNOL, V45, P1308, DOI 10.1016/j.molimm.2007.09.012; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P1259; Talley NJ, 1998, GASTROENTEROLOGY, V114, P582, DOI 10.1016/S0016-5085(98)70542-6; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Taylor SL, 2003, J AGR FOOD CHEM, V51, P5183, DOI 10.1021/jf030375e; Taylor SL, 2001, J ALLERGY CLIN IMMUN, V107, P765, DOI 10.1067/mai.2001.114241; Tolia V, 2003, DIGEST DIS SCI, V48, P1723, DOI 10.1023/A:1025486710231; Tolia V, 2002, J PEDIATR GASTR NUTR, V35, pS300, DOI 10.1097/00005176-200211004-00002; TROUT GE, 1969, BIOCHEMISTRY-US, V8, P4183, DOI 10.1021/bi00838a041; Untersmayr E, 2006, MOL IMMUNOL, V43, P1454, DOI 10.1016/j.molimm.2005.07.038; Untersmayr E, 2005, FASEB J, V19, P656, DOI 10.1096/fj.04-3170fje; Untersmayr E, 2005, J ALLERGY CLIN IMMUN, V115, P377, DOI 10.1016/j.jaci.2004.10.029; Untersmayr E, 2004, INT ARCH ALLERGY IMM, V135, P1, DOI 10.1159/000080035; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; UNTERSMAYR E, 2007, FOOD ALLERGY CHILDHO, P52; Untersmayr E, 2008, MECH AGEING DEV, V129, P120, DOI 10.1016/j.mad.2007.10.015; Untersmayr E, 2007, J ALLERGY CLIN IMMUN, V119, P711, DOI 10.1016/j.jaci.2006.10.039; van Zyl J, 2004, DIGESTION, V70, P61, DOI 10.1159/000080130; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Vieths S, 1999, EUR FOOD RES TECHNOL, V209, P379, DOI 10.1007/s002170050513; Waldum Helge L, 2002, Expert Opin Drug Saf, V1, P29; Wang JL, 2007, CLIN EXP ALLERGY, V37, P651, DOI 10.1111/j.1365-2222.2007.02682.x; WARNDORFF DK, 1989, J ROY COLL GEN PRACT, V39, P499; Westbrook JI, 2001, BRIT MED J, V323, P1338, DOI 10.1136/bmj.323.7325.1338; Westbrook JI, 2000, SCAND J GASTROENTERO, V35, P227; Williams C, 2001, BEST PRACT RES CL GA, V15, P511, DOI 10.1053/bega.2001.0191; Yagami T, 2000, J ALLERGY CLIN IMMUN, V106, P752, DOI 10.1067/mai.2000.109171; York IA, 1999, IMMUNOL REV, V172, P49, DOI 10.1111/j.1600-065X.1999.tb01355.x; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8; Zink DA, 2005, ALIMENT PHARM THERAP, V21, P1203, DOI 10.1111/j.1365-2036.2005.02454.x; EVALUATION GENETICAL; FOOD SAFETY REGULATI	147	176	178	1	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1301	1308		10.1016/j.jaci.2008.04.025	http://dx.doi.org/10.1016/j.jaci.2008.04.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18539189	Green Accepted, Bronze			2022-12-18	WOS:000256771700001
J	Wensing, M; Penninks, AH; Hefle, SL; Koppelman, SJ; Bruijnzeel-Koomen, CAFM; Knulst, AC				Wensing, M; Penninks, AH; Hefle, SL; Koppelman, SJ; Bruijnzeel-Koomen, CAFM; Knulst, AC			The distribution of individual threshold doses eliciting allergic reactions in a population with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; double-blind; placebo-controlled food challenge; peanut allergy; threshold dose	ATOPIC-DERMATITIS; NATURAL-HISTORY; DOUBLE-BLIND; FOOD; IDENTIFICATION; CHILDREN; CHALLENGES; PREVALENCE; RESOLUTION	Background: Hidden peanut in consumer products can endanger patients with peanut allergy. Individual threshold doses for eliciting allergic reactions need to be elucidated to assess the risks for development of allergic reactions after accidental is ingestion of peanut in a population with peanut allergy. Objective: We sought to determine the distribution of individual threshold doses in a population with peanut allergy and to correlate these thresholds to the severity of peanut-induced symptoms. Methods: Twenty-six adult patients with a convincing history of peanut-related symptoms, a specific IgE level of 0.7 kU/L or greater, or a positive skin prick test response of 2+ or greater to peanut were included. These patients underwent double-blind, placebo-controlled food challenges with increasing doses of peanut. A threshold dose could be established when objective or repetitive subjective reactions occurred after active doses. Results: All patients had subjective oral symptoms (n = 26), prior subjective gastrointestinal symptoms (n = 14), or objective symptoms (n = 5). Reactions started within 30 minutes after ingestion of peanut, but in 2 patients additional symptoms were delayed by 1 to 2 hours. Threshold doses for allergic reactions ranged from a dose as low as 100 mug up to 1 g of peanut protein. Fifty percent of the study population (95% CI, 30%-70%) already had an allergic reaction after ingestion of 3 mg of peanut protein. Patients with severe symptoms had lower threshold doses compared with those of patients with mild symptoms (P = .027). Conclusions: A substantial part of a population with peanut allergy will react to very low amounts of peanut, requiring accurate declaration of peanut content in consumer products. This is even more important because patients with severe reactions react to lower doses than patients with mild symptoms.	Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3584 CX Utrecht, Netherlands; TNO, Nutr & Food Res Inst, NL-3700 AJ Zeist, Netherlands; Univ Nebraska, Lincoln, NE 68583 USA	Utrecht University; Netherlands Organization Applied Science Research; University of Nebraska System; University of Nebraska Lincoln	Wensing, M (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol & Allergol, G02-124,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.							BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; Bousquet J, 1998, ALLERGY, V53, P3, DOI 10.1111/j.1398-9995.1998.tb04987.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; Cunniff AP., 1995, OFFICIAL METHODS ANA, P7; CUNNIFFE P, 1995, OFFICIAL METHODS ANA, P23; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; HANSEN TK, 1992, ALLERGY, V47, P610, DOI 10.1111/j.1398-9995.1992.tb02383.x; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Hourihane JOB, 2001, ALLERGY, V56, P86, DOI 10.1034/j.1398-9995.2001.00926.x; Kemp SF, 1996, JAMA-J AM MED ASSOC, V275, P1636, DOI 10.1001/jama.275.21.1636; Madsen C, 2001, ALLERGY, V56, P91, DOI 10.1034/j.1398-9995.2001.00927.x; McKenna C, 1997, ANN ALLERG ASTHMA IM, V79, P234, DOI 10.1016/S1081-1206(10)63008-6; Mueller H L, 1966, J Asthma Res, V3, P331; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; SAMPSON HA, 1988, ANN ALLERGY, V60, P262; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Spergel JM, 2000, ANN ALLERG ASTHMA IM, V85, P473, DOI 10.1016/S1081-1206(10)62574-4	28	176	179	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					915	920		10.1067/mai.2002.129235	http://dx.doi.org/10.1067/mai.2002.129235			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464959				2022-12-18	WOS:000179777400015
J	Palosuo, K; Varjonen, E; Kekki, OM; Klemola, T; Kalkkinen, N; Alenius, H; Reunala, T				Palosuo, K; Varjonen, E; Kekki, OM; Klemola, T; Kalkkinen, N; Alenius, H; Reunala, T			Wheat omega-5 gliadin is a major allergen in children with immediate allergy to ingested wheat	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						wheat; gliadin; food hypersensitivity; IgE antibody; allergens; enzyme-linked immunosorbent assay	ALPHA-AMYLASE INHIBITOR; ORAL FOOD CHALLENGES; DOUBLE-BLIND; SKIN-PRICK; IGE; IDENTIFICATION; COMPONENTS; EVOLUTION; PROTEINS; SECALINS	Background: Sensitization to wheat by ingestion can lead to food allergy symptoms and wheat-dependent, exercise-induced anaphylaxis. Sensitization by inhalation causes bakers' asthma and rhinitis. Wheat allergens have been characterized at the molecular level in bakers' asthma and in wheat-dependent, exercise-induced anaphylaxis, in which omega -5 gliadin (Tri a 19) is a major allergen. However, little information is available regarding allergens responsible for hypersensitivity reactions to ingested wheat in children. Objective: The aim of this study was to examine whether children with allergy to ingested wheat have IgE antibodies to omega -5 gliadin. Methods: Sera were obtained from 40 children (mean age, 2.5 years; range, 0.7-8.2 years) with suspected wheat allergy who presented with atopic dermatitis and/or gastrointestinal and/or respiratory symptoms. Wheat allergy was diagnosed with open or double-blinded, placebo-controlled oral wheat challenge. Wheat omega -5 gliadin was purified by reversed-phase chromatography, and serum IgE antibodies to omega -5 gliadin were measured by means of ELISA. In vivo reactivity was studied by skin prick testing. Control sera were obtained from 22 children with no evidence of food allergies. Results: In oral wheat challenge, 19 children (48%) reacted with immediate and 8 children (20%) with delayed hypersensitivity, symptoms. Sixteen (84%) of the children with immediate symptoms had IgE antibodies to purified omega -5 gliadin in ELISA. In contrast, IgE antibodies to omega -5 gliadin were not detected in any of the children with delayed or negative challenge test results or in the control children. The diagnostic specificity and positive predictive value of omega -5 gliadin ELISA were each 100% for immediate challenge reactions. Skin prick testing with w-5 gliadin was positive in 6 of 7 children with immediate challenge symptoms and negative in 2 children with delayed challenge symptoms. Conclusion: The results of this study show that omega -5 gliadin is a significant allergen in young children with immediate allergic reactions to ingested wheat. IgE testing with omega -5 gliadin could be used to reduce the need for oral wheat challenges in children.	Finnish Inst Occupat Hlth, Lab Immunotoxicol, Helsinki 00250, Finland; Univ Helsinki, Dept Dermatol, Helsinki, Finland; Hosp Skin & Allerg Dis, Helsinki, Finland; Univ Tampere, Dept Dermatol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Univ Helsinki, Inst Biotechnol, Helsinki, Finland	Finnish Institute of Occupational Health; University of Helsinki; Tampere University; Tampere University; Tampere University Hospital; University of Helsinki	Palosuo, K (corresponding author), Finnish Inst Occupat Hlth, Lab Immunotoxicol, Topeliuksenkatu 41 B, Helsinki 00250, Finland.		Kalkkinen, Nisse EJ/B-3923-2010	Alenius, Harri/0000-0003-0106-8923				Alenius H, 1996, INT ARCH ALLERGY IMM, V109, P362, DOI 10.1159/000237264; Baur X, 1998, ALLERGY, V53, P562, DOI 10.1111/j.1398-9995.1998.tb03931.x; Bengtsson U, 1996, GUT, V39, P130, DOI 10.1136/gut.39.1.130; BIETZ JA, 1982, BIOCHEM GENET, V20, P1039, DOI 10.1007/BF00498931; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; FRANKEN J, 1994, INT ARCH ALLERGY IMM, V104, P171, DOI 10.1159/000236726; James JM, 1997, J ALLERGY CLIN IMMUN, V99, P239, DOI 10.1016/S0091-6749(97)70103-9; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; KASARDA DD, 1983, BIOCHIM BIOPHYS ACTA, V747, P138, DOI 10.1016/0167-4838(83)90132-2; Majamaa H, 1999, ALLERGY, V54, P851, DOI 10.1034/j.1398-9995.1999.00081.x; Miflin B. J., 1983, Seed proteins, P255; Palosuo K, 1999, J ALLERGY CLIN IMMUN, V103, P912, DOI 10.1016/S0091-6749(99)70438-0; Palosuo K, 2001, CLIN EXP ALLERGY, V31, P466, DOI 10.1046/j.1365-2222.2001.01023.x; POSCH A, 1995, ELECTROPHORESIS, V16, P1115, DOI 10.1002/elps.11501601188; RASANEN L, 1994, ALLERGY, V49, P871, DOI 10.1111/j.1398-9995.1994.tb00790.x; Reibel S, 2000, ALLERGY, V55, P940, DOI 10.1034/j.1398-9995.2000.00689.x; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SanchezMonge R, 1997, CLIN EXP ALLERGY, V27, P1130, DOI 10.1046/j.1365-2222.1997.1340945.x; Sandiford CP, 1997, CLIN EXP ALLERGY, V27, P1120, DOI 10.1046/j.1365-2222.1997.1310936.x; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; SUTTON R, 1982, CLIN ALLERGY, V12, P63, DOI 10.1111/j.1365-2222.1982.tb03127.x; Varjonen E, 1997, CLIN EXP ALLERGY, V27, P162, DOI 10.1046/j.1365-2222.1997.d01-481.x; VARJONEN E, 1995, CLIN EXP ALLERGY, V25, P1100, DOI 10.1111/j.1365-2222.1995.tb03257.x; Varjonen E, 2000, ALLERGY, V55, P386, DOI 10.1034/j.1398-9995.2000.00451.x; WALSH BJ, 1985, J ALLERGY CLIN IMMUN, V76, P23, DOI 10.1016/0091-6749(85)90799-7; Weiss W, 1997, ELECTROPHORESIS, V18, P826, DOI 10.1002/elps.1150180529	32	176	191	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					634	638		10.1067/mai.2001.118602	http://dx.doi.org/10.1067/mai.2001.118602			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590393	Bronze			2022-12-18	WOS:000171760300026
J	BENTLEY, AM; DURHAM, SR; ROBINSON, DS; MENZ, G; STORZ, C; CROMWELL, O; KAY, AB; WARDLAW, AJ				BENTLEY, AM; DURHAM, SR; ROBINSON, DS; MENZ, G; STORZ, C; CROMWELL, O; KAY, AB; WARDLAW, AJ			EXPRESSION OF ENDOTHELIAL AND LEUKOCYTE ADHESION MOLECULES INTERCELLULAR-ADHESION MOLECULE-1, E-SELECTIN, AND VASCULAR CELL-ADHESION MOLECULE-1 IN THE BRONCHIAL-MUCOSA IN STEADY-STATE AND ALLERGEN-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADHESION; BRONCHIAL BIOPSY SPECIMENS; ASTHMA; INTEGRINS; ENDOTHELIUM; EPITHELIUM; LEUKOCYTES; EOSINOPHILS; LYMPHOCYTES	TUMOR-NECROSIS-FACTOR; T-CELLS; ACTIVATED EOSINOPHILS; LYMPHOCYTES-T; ATOPIC ASTHMA; IFN-GAMMA; ICAM-1; NEUTROPHILS; DISTINCT; IL-1	Background. Interactions between cell adhesion molecules and their ligands are an integral part of inflammatory processes and may have direct relevance to the pathology of asthma. Methods: Immunostaining with antibodies to cell adhesion molecules was performed on bronchial biopsy specimens from persons with intrinsic and extrinsic asthma, normal nonasthmatic control subjects, and patients with asthma after allergen challenge. Results: There was constitutive expression of intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular celt adhesion molecule-1 (VCAM-1) in patients with intrinsic and extrinsic asthma and in control subjects. Compared with control subjects, ICAM-1 and E-selectin staining in the submucosa was greater in the intrinsic asthmatic group for intensity (p < 0.02, p < 0.05) and extent (p < 0.01, p < 0.05) of staining, respectively. No differences were observed between patients with extrinsic asthma and normal control subjects, and VCAM-1 expression did not differ among the groups. Epithelial expression of ICAM-1 was more frequent in patients with asthma compared with normal control subjects (p< 0.05). Compared with diluent challenge, bronchial biopsy specimens obtained 24 hours after allergen challenge revealed no significant differences in intensity or extent of staining for ICAM-1, E-selectin, or VCAM-1. After allergen challenge, the intensity and extent of both VCAM-1 and ICAM-1 expression correlated significantly with the number of eosinophils (cells positive for major basic protein). Epithelial ICAM-1 expression was more frequently observed after allergen challenge than after diluent challenge (p< 0.02). Conclusions: The data suggest a complex pattern of regulation for ICAM-1, E-selectin, and VCAM-1 in vivo, where they may reflect the degree of ongoing inflammation in asthma.	NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND; HOCHGEBIRGSKLIN DAVOS WOLFGANG,DAVOS,SWITZERLAND	Imperial College London				Wardlaw, Andrew/0000-0001-6583-0791; Bentley, Andrew/0000-0002-6883-9246				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ADAMS DH, 1989, LANCET, V2, P1122; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CROMWELL O, 1986, HDB EXPT IMMUNOLOGY, V4; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUSTIN ML, 1986, J IMMUNOL, V137, P245; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FREW AJ, 1988, J IMMUNOL, V141, P4158; GRABER N, 1990, J IMMUNOL, V145, P819; KOCH AE, 1991, LAB INVEST, V64, P313; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MASON DY, 1978, J CLIN PATHOL, V31, P454, DOI 10.1136/jcp.31.5.454; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P265, DOI 10.1111/j.1365-2222.1992.tb03082.x; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POBER JS, 1986, J IMMUNOL, V136, P1680; POBER JS, 1986, J IMMUNOL, V137, P1893; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STURGESS RP, 1990, CLIN EXP IMMUNOL, V82, P489; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; THORNHILL MH, 1990, J IMMUNOL, V145, P865; THORNHILL MH, 1991, J IMMUNOL, V146, P592; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; WALSH GM, 1991, J IMMUNOL, V146, P3419; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELLICOME SM, 1990, J IMMUNOL, V144, P2558	38	176	180	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					857	868		10.1016/0091-6749(93)90064-M	http://dx.doi.org/10.1016/0091-6749(93)90064-M			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	7505008				2022-12-18	WOS:A1993ML89300012
J	CARTIER, A; GRAMMER, L; MALO, JL; LAGIER, F; GHEZZO, H; HARRIS, K; PATTERSON, R				CARTIER, A; GRAMMER, L; MALO, JL; LAGIER, F; GHEZZO, H; HARRIS, K; PATTERSON, R			SPECIFIC SERUM ANTIBODIES AGAINST ISOCYANATES - ASSOCIATION WITH OCCUPATIONAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA; NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY IMMUNOL SECT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, OCCUPAT MED SECT, CHICAGO, IL 60611 USA	Universite de Montreal; Northwestern University; Northwestern University				Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P1185, DOI 10.1016/0091-6749(86)90270-8; CHANG KC, 1984, CLIN ALLERGY, V14, P329, DOI 10.1111/j.1365-2222.1984.tb02213.x; CHEN SE, 1982, J ALLERGY CLIN IMMUN, V70, P383, DOI 10.1016/0091-6749(82)90029-X; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DANKS JM, 1981, CLIN ALLERGY, V11, P161, DOI 10.1111/j.1365-2222.1981.tb01580.x; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P223, DOI 10.1016/0091-6749(77)90134-8; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; GERVAIS P, 1986, 12 P INT C ALL CLIN, P480; HOMBURGER HA, 1986, J ALLERGY CLIN IMMUN, V77, P427, DOI 10.1016/0091-6749(86)90176-4; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LENKEI R, 1977, J IMMUNOL METHODS, V16, P23, DOI 10.1016/0022-1759(77)90036-9; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; MUSK AW, 1988, AM J IND MED, V13, P331, DOI 10.1002/ajim.4700130304; PAGGIARO PL, 1983, CLIN ALLERGY, V13, P75, DOI 10.1111/j.1365-2222.1983.tb02570.x; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V71, P604, DOI 10.1016/0091-6749(83)90443-8; PATTERSON R, 1987, INT ARCH ALLER A IMM, V84, P93, DOI 10.1159/000234404; PAULI G, 1986, B EUR PHYSIOPATH RES, V22, P399; PAULI G, 1977, CLIN ALLERGY, V7, P337, DOI 10.1111/j.1365-2222.1977.tb01461.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEZZINI A, 1984, CLIN ALLERGY, V14, P453, DOI 10.1111/j.1365-2222.1984.tb02229.x; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P232; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WELINDER H, 1988, CLIN ALLERGY, V18, P85, DOI 10.1111/j.1365-2222.1988.tb02847.x; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	33	176	177	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				507	514		10.1016/0091-6749(89)90364-3	http://dx.doi.org/10.1016/0091-6749(89)90364-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2794294				2022-12-18	WOS:A1989AW76000012
J	Chang, TW; Chen, C; Lin, CJ; Metz, M; Church, MK; Maurer, M				Chang, Tse Wen; Chen, Christina; Lin, Chien-Jen; Metz, Martin; Church, Martin K.; Maurer, Marcus			The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic urticaria; omalizumab; IgE; FceRI; autoantibodies; mast cells; activation/release threshold; IgE-FceRI-mast cell axis	CHRONIC IDIOPATHIC URTICARIA; CHRONIC AUTOIMMUNE URTICARIA; MAST-CELL SURVIVAL; ANTI-IGE THERAPY; FC-EPSILON-RI; DOSE OMALIZUMAB; THYROID AUTOIMMUNITY; IMMUNOGLOBULIN-E; EFFICACY; ANTIBODIES	In patients given a diagnosis of chronic spontaneous urticaria (CSU), there are no obvious external triggers, and the factors that initiate the clinical symptoms of wheal, flare, and itch arise from within the patient. Most patients with CSU have an autoimmune cause: some patients produce IgE autoantibodies against autoantigens, such as thyroperoxidase or double-stranded DNA, whereas other patients make IgG autoantibodies against FceRI, IgE, or both, which might chronically activate mast cells and basophils. In the remainder of patients with CSU, the nature of the abnormalities has not yet been identified. Accumulating evidence has shown that IgE, by binding to FceRI on mast cells without FceRI cross-linking, can promote the proliferation and survival of mast cells and thus maintain and expand the pool of mast cells. IgE and FceRI engagement can also decrease the release threshold of mast cells and increase their sensitivity to various stimuli through either FceRI or other receptors for the degranulation process. Furthermore, IgE-FceRI engagement potentiates the ability of mast cells to store and synthesize de novo inflammatory mediators and cytokines. Administration of omalizumab, by virtue of its ability to deplete IgE, attenuates the multiple effects of IgE to maintain and enhance mast cell activities and hence reduces the ability of mast cells to manifest inflammatory mechanisms in patients with CSU.	[Chang, Tse Wen; Chen, Christina; Lin, Chien-Jen] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Metz, Martin; Church, Martin K.; Maurer, Marcus] Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany	Academia Sinica - Taiwan; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Church, MK (corresponding author), Charite, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany.	mkc@soton.ac.uk	Chang, Tse Wen/H-5955-2011; Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020	Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X	Nation Science Council Taiwan [NSC-2320-B-001-005]; Novartis; Switzerland; Genentech	Nation Science Council Taiwan; Novartis(Novartis); Switzerland; Genentech(Roche HoldingGenentech)	T. W. Chang has received research support grant no. NSC-2320-B-001-005 from Nation Science Council Taiwan. M. Metz has consultant arrangements with and has received research support and honoraria for lectures from Novartis, Switzerland. M. K. Church has received payment for lectures from Novartis, Switzerland. M. Maurer has received honoraria for lectures and consulting, and funding for research from Novartis, Switzerland and Genentech. The rest of the authors declare that they have no relevant conflicts of interest.	Al-Ahmad M, 2010, ANN SAUDI MED, V30, P478, DOI 10.4103/0256-4947.70567; Altrichter S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014794; Alysandratos KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048934; Arkwright PD, 2009, J ALLERGY CLIN IMMUN, V123, P510, DOI 10.1016/j.jaci.2008.11.043; Armengot-Carbo M, 2013, DERMATOL THER, V26, P257, DOI 10.1111/j.1529-8019.2013.01549.x; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Asero R, 2005, CLIN EXP DERMATOL, V30, P582, DOI 10.1111/j.1365-2230.2005.01799.x; BENYON RC, 1989, CLIN EXP ALLERGY, V19, P375, DOI 10.1111/j.1365-2222.1989.tb02402.x; Bernstein JA, 2002, ANN ALLERG ASTHMA IM, V89, P212, DOI 10.1016/S1081-1206(10)61941-2; Boyce JA, 2006, J ALLERGY CLIN IMMUN, V117, P1415, DOI 10.1016/j.jaci.2006.04.003; Buyukozturk S, 2012, J DERMATOL, V39, P439, DOI 10.1111/j.1346-8138.2011.01473.x; Chakravarty SD, 2011, J ALLERGY CLIN IMMUN, V128, P1354, DOI 10.1016/j.jaci.2011.08.023; Chan Marcia A, 2013, Clin Transl Allergy, V3, P29, DOI 10.1186/2045-7022-3-29; Chang TW, 2007, ADV IMMUNOL, V93, P63, DOI 10.1016/S0065-2776(06)93002-8; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Chang TW, 2006, J ALLERGY CLIN IMMUN, V117, P1203, DOI 10.1016/j.jaci.2006.04.005; Confino-Cohen R, 2012, J ALLERGY CLIN IMMUN, V129, P1307, DOI 10.1016/j.jaci.2012.01.043; DAVIS FM, 1993, SPRINGER SEMIN IMMUN, V15, P51; Ferrer M, 2011, J ALLERGY CLIN IMMUN, V127, P1300, DOI 10.1016/j.jaci.2010.12.1085; Godse KV, 2008, INDIAN J DERMATOL VE, V74, P157, DOI 10.4103/0378-6323.39708; Godse Kiran V, 2011, Indian J Dermatol, V56, P444, DOI 10.4103/0019-5154.84737; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; Groffik A, 2011, ALLERGY, V66, P303, DOI 10.1111/j.1398-9995.2010.02472.x; Guzelbey O, 2008, ALLERGY, V63, P1563, DOI 10.1111/j.1398-9995.2008.01879.x; Hatada Y, 2013, INT ARCH ALLERGY IMM, V161, P154, DOI 10.1159/000350388; Hsu CL, 2010, INT IMMUNOPHARMACOL, V10, P533, DOI 10.1016/j.intimp.2010.02.001; Iemoli E, 2010, J INVEST ALLERG CLIN, V20, P252; Ivyanskiy I, 2012, CASE REP DERMATOL, V4, P19, DOI 10.1159/000336205; Jayapal M, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-210; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; Kashiwakura JI, 2012, ALLERGY ASTHMA IMMUN, V4, P332, DOI 10.4168/aair.2012.4.6.332; Kawakami T, 2005, J IMMUNOL, V175, P4167, DOI 10.4049/jimmunol.175.7.4167; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; Konstantinou GN, 2009, ALLERGY, V64, P1256, DOI 10.1111/j.1398-9995.2009.02132.x; Labrador-Horrillo M, 2013, EXPERT OPIN BIOL TH, V13, P1225, DOI 10.1517/14712598.2013.822484; Lefevre AC, 2013, ANN DERMATOL, V25, P242, DOI 10.5021/ad.2013.25.2.242; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; Lowe PJ, 2011, BRIT J CLIN PHARMACO, V72, P306, DOI 10.1111/j.1365-2125.2011.03962.x; Magerl M, 2010, J ALLERGY CLIN IMMUN, V126, P665, DOI 10.1016/j.jaci.2010.05.047; Maspero JF, 2009, ARCH ARGENT PEDIATR, V107, P452, DOI 10.1590/S0325-00752009000500014; MATHEWS KP, 1985, DRUGS, V30, P552, DOI 10.2165/00003495-198530060-00006; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Maurer M, 2011, J ALLERGY CLIN IMMUN, V128, P202, DOI 10.1016/j.jaci.2011.04.038; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Metz M, 2008, ALLERGY, V63, P247, DOI 10.1111/j.1398-9995.2007.01591.x; Metz M, 2014, J DERMATOL SCI, V73, P57, DOI 10.1016/j.jdermsci.2013.08.011; Rabe KF, 2011, ALLERGY, V66, P1142, DOI 10.1111/j.1398-9995.2011.02617.x; READ GW, 1986, J PHARMACOL EXP THER, V237, P357; Romano C, 2010, ANN ALLERG ASTHMA IM, V104, P95, DOI 10.1016/j.anai.2009.11.017; Sabroe RA, 1999, J AM ACAD DERMATOL, V40, P443, DOI 10.1016/S0190-9622(99)70495-0; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Sands MF, 2007, J ALLERGY CLIN IMMUN, V120, P979, DOI 10.1016/j.jaci.2007.07.041; Slavin RG, 2009, J ALLERGY CLIN IMMUN, V123, P107, DOI 10.1016/j.jaci.2008.09.050; Song CH, 2013, ANN ALLERG ASTHMA IM, V110, P113, DOI 10.1016/j.anai.2012.11.022; Spector SL, 2007, ANN ALLERG ASTHMA IM, V99, P190, DOI 10.1016/S1081-1206(10)60644-8; STAMPFLI MR, 1994, EUR J IMMUNOL, V24, P2161, DOI 10.1002/eji.1830240934; Staubach P, 2011, ACTA DERM-VENEREOL, V91, P557, DOI 10.2340/00015555-1109; Staubach P, 2009, MYCOSES, V52, P334, DOI 10.1111/j.1439-0507.2008.01601.x; Vestergaard C, 2010, ACTA DERM-VENEREOL, V90, P443, DOI 10.2340/00015555-0884; dos Santos RV, 2014, BRIT J DERMATOL, V170, P469, DOI 10.1111/bjd.12628; Viswanathan RK, 2013, ALLERGY ASTHMA PROC, V34, P446, DOI 10.2500/aap.2013.34.3694; Wan KS, 2013, ENDOCR RES, V38, P85, DOI 10.3109/07435800.2012.714432; Zauli D, 2001, ALLERGY ASTHMA PROC, V22, P93, DOI 10.2500/108854101778250625; Zuberbier T, 2009, ALLERGY, V64, P1427, DOI 10.1111/j.1398-9995.2009.02178.x; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x	69	175	189	0	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					337	+		10.1016/j.jaci.2014.04.036	http://dx.doi.org/10.1016/j.jaci.2014.04.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	24948369				2022-12-18	WOS:000349372300004
J	Kulshreshtha, A; Ahmad, T; Agrawal, A; Ghosh, B				Kulshreshtha, Ankur; Ahmad, Tanveer; Agrawal, Anurag; Ghosh, Balaram			Proinflammatory role of epithelial cell-derived exosomes in allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergy; exosomes; epithelial cells; IL-13; monocytes	IMMUNE-RESPONSES; MEMBRANE-VESICLES; SUPPRESSOR-CELLS; DENDRITIC CELLS; IN-VITRO; T-CELLS; MACROPHAGES; ACTIVATION; MICRORNAS; MECHANISM	Background: Exosomes are nanovesicles involved in intercellular communication. Their roles in various diseases are often contextual, depending on the cell type producing them. Although few studies hint toward the proinflammatory role of bronchoalveolar lavage fluid-derived exosomes in asthmatic progression, the cell types in lungs associated with exosome-mediated crosstalk and their resultant effects remain unexplored. Objective: It is well established that exosome-mediated cellular communication can influence disease phenotypes. This study explores exosome-mediated cellular crosstalk between structural and immune cells in asthma pathogenesis. Methods: Exosomes were isolated and detected from bronchoalveolar lavage fluid of control and asthmatic mice and were quantified by using a bead-based assay. Involvement of epithelial cells and macrophages were established by using immunohistochemical techniques in lung tissue sections. The role of IL-13 in exosome production was ascertained by using various in vitro and in vivo techniques. Exosome secretion was blocked in in vitro and in vivo settings by using a chemical inhibitor, and the effects on various asthmatic features were studied. Results: Using combinatorial in vitro and in vivo approaches, we found that exosome secretion and production of exosome-associated proteins are higher in lungs of asthmatic mice compared with that seen in sham mice. Asthma is marked by enhanced secretion of exosomes by epithelial cells, but not macrophages, under the influence of IL-13. These epithelial cell exosomes induce proliferation and chemotaxis of undifferentiated macrophages. On the other hand, GW4869, which inhibited exosome production, resulted in a reduced population of proliferating monocytes and alleviation of various asthmatic features. Conclusion: Under the influence of IL-13, epithelial cell-derived exosomes can induce enhanced proliferation and chemotaxis of undifferentiated macrophages in the lungs during asthmatic inflammatory conditions. (J Allergy Clin Immunol 2013;131:1194-203.)	[Ghosh, Balaram] CSIR Inst Genom & Integrat Biol, Immunogenet Mol Lab, Delhi 110007, India; CSIR Inst Genom & Integrat Biol, Ctr Excellence Translat Res Asthma & Lung Dis, Delhi 110007, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB)	Ghosh, B (corresponding author), CSIR Inst Genom & Integrat Biol, Immunogenet Mol Lab, Mall Rd, Delhi 110007, India.	bghosh@igib.res.in	KULSHRESHTHA, ANKUR/AFP-2527-2022; Agrawal, Anurag/GZL-5821-2022	KULSHRESHTHA, ANKUR/0000-0001-5139-6744; Agrawal, Anurag/0000-0002-0340-5252; Ahmad, Tanveer/0000-0002-8384-5273	Council of Scientific and Industrial Research (CSIR), India [NWP0033, MLP5501]; Council of Scientific and Industrial Research	Council of Scientific and Industrial Research (CSIR), India(Council of Scientific & Industrial Research (CSIR) - India); Council of Scientific and Industrial Research(Council of Scientific & Industrial Research (CSIR) - India)	Supported by grants from the Council of Scientific and Industrial Research (CSIR), India (Task Force Project NWP0033, MLP5501).; A. Kulshreshtha has received grants from the Council of Scientific and Industrial Research and has received travel support from the Department of Science and Technology, Government of India. A. Agrawal has received grants from the Council of Scientific and Industrial Research. The rest of the authors declare that they have no relevant conflicts of interest.	Abusamra AJ, 2005, BLOOD CELL MOL DIS, V35, P169, DOI 10.1016/j.bcmd.2005.07.001; Ahmad T, 2012, AM J RESP CELL MOL, V47, P1, DOI 10.1165/rcmb.2011-0203OC; Ahmad T, 2011, AM J RESP CELL MOL, V44, P531, DOI 10.1165/rcmb.2010-0041OC; Anand PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010136; Atay S, 2011, AM J REPROD IMMUNOL, V66, P259, DOI 10.1111/j.1600-0897.2011.00995.x; Bhatnagar S, 2007, BLOOD, V110, P3234, DOI 10.1182/blood-2007-03-079152; Biton M, 2011, NAT IMMUNOL, V12, P239, DOI 10.1038/ni.1994; Bolasco G, 2011, AM J PHYSIOL-CELL PH, V300, pC466, DOI 10.1152/ajpcell.00446.2010; Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049; Chen TY, 2011, J IMMUNOL, V186, P2219, DOI 10.4049/jimmunol.1002991; Clayton A, 2008, J IMMUNOL, V180, P7249, DOI 10.4049/jimmunol.180.11.7249; Clayton A, 2007, CANCER RES, V67, P7458, DOI 10.1158/0008-5472.CAN-06-3456; Esser J, 2010, J ALLERGY CLIN IMMUN, V126, P1032, DOI 10.1016/j.jaci.2010.06.039; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Higginbotham JN, 2011, CURR BIOL, V21, P779, DOI 10.1016/j.cub.2011.03.043; Hong SW, 2011, ALLERGY, V66, P351, DOI 10.1111/j.1398-9995.2010.02483.x; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Kim JW, 2005, CLIN CANCER RES, V11, P1010; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200; Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x; Liu CR, 2007, BLOOD, V109, P4336, DOI 10.1182/blood-2006-09-046201; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Mabalirajan U, 2008, J IMMUNOL, V181, P3540, DOI 10.4049/jimmunol.181.5.3540; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Qazi KR, 2010, THORAX, V65, P1016, DOI 10.1136/thx.2009.132027; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Savina A, 2003, J BIOL CHEM, V278, P20083, DOI 10.1074/jbc.M301642200; Sheng HM, 2011, J IMMUNOL, V187, P1591, DOI 10.4049/jimmunol.1100231; Silverman JM, 2010, J IMMUNOL, V185, P5011, DOI 10.4049/jimmunol.1000541; Singh PP, 2012, J IMMUNOL, V189, P777, DOI 10.4049/jimmunol.1103638; Singh PP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018564; Siracusa MC, 2008, J LEUKOCYTE BIOL, V84, P1422, DOI 10.1189/jlb.0308199; Skokos D, 2003, J IMMUNOL, V170, P3037, DOI 10.4049/jimmunol.170.6.3037; Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Balkom BWM, 2011, KIDNEY INT, V80, P1138, DOI 10.1038/ki.2011.292; Van Niel G, 2003, GUT, V52, P1690, DOI 10.1136/gut.52.12.1690; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wiley RD, 2006, P NATL ACAD SCI USA, V103, P738, DOI 10.1073/pnas.0507995103; Willart M, 2011, CURR OPIN IMMUNOL, V23, P772, DOI 10.1016/j.coi.2011.09.008; Zhang HG, 2006, J IMMUNOL, V176, P7385, DOI 10.4049/jimmunol.176.12.7385; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	51	175	184	4	47	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1194	+		10.1016/j.jaci.2012.12.1565	http://dx.doi.org/10.1016/j.jaci.2012.12.1565			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23414598				2022-12-18	WOS:000317187200030
J	Aceves, SS; Chen, D; Newbury, RO; Dohil, R; Bastian, JF; Broide, DH				Aceves, Seema S.; Chen, Diana; Newbury, Robert O.; Dohil, Ranjan; Bastian, John F.; Broide, David H.			Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-beta 1, and increase esophageal smooth muscle contraction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; mast cell; TGF-beta 1; smooth muscle; pediatric; topical corticosteroids; tryptase; chymase; eosinophil; remodeling	CHILDREN; RESOLUTION; ADULTS	Background: Increased numbers of mast cells are present in the esophageal epithelium in patients with eosinophilic esophagitis (EE). However, mast cell infiltration into the esophageal lamina propria (LP) and smooth muscle (SM) and the effects of their products on SM function has not been determined. Objective: We investigated mast cell localization and characterization in esophageal SM, the functional significance of mast cell TGF-beta 1 expression to contraction of human esophageal smooth muscle (HESM) cells in vitro, and the effect of topical corticosteroids on the number of tryptase-positive (MCT) and chymase-positive (MCC) mast cells in patients with EE. Methods: MCT- and MCC-positive mast cell numbers were quantitated in the epithelium, the LP before and after topical corticosteroid therapy, and the muscularis mucosa in patients with EE and control subjects by using immunohistology. Double immunofluorescence was used to assess mast cell production of TGF-beta 1. The ability of TGF-beta 1 to influence HESM cell contractility was assessed in vitro. Results: In the SM in patients with EE, significantly increased numbers of MCT- and TGF-beta 1-positive cells (but only low levels of eosinophils) were detected compared with those seen in control subjects. MCT expressed TGF-beta 1, which increased the contractility of cultured primary HESM cells in vitro. Topical corticosteroid therapy in patients with EE significantly reduced epithelial MCT numbers but not LP tryptase-chymase-positive mast cell numbers. Conclusions: MCT numbers, rather than eosinophil numbers, are increased in the SM in patients with EE, express TGF-beta 1, and increase the contractility of HESM cells in vitro. As such, mast cells localized to SM in patients with EE might modulate esophageal contractility. (J Allergy Clin Immunol 2010;126:1198-204.)	[Aceves, Seema S.; Chen, Diana; Bastian, John F.; Broide, David H.] Univ Calif San Diego, Div Allergy & Immunol, San Diego, CA 92103 USA; [Newbury, Robert O.] Univ Calif San Diego, Div Pathol, San Diego, CA 92103 USA; [Dohil, Ranjan] Univ Calif San Diego, Div Gastroenterol, San Diego, CA 92103 USA; [Aceves, Seema S.; Newbury, Robert O.; Dohil, Ranjan; Bastian, John F.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Aceves, Seema S.; Chen, Diana; Broide, David H.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Aceves, Seema S.; Chen, Diana; Broide, David H.] Rady Childrens Hosp, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego	Aceves, SS (corresponding author), 3020 Childrens Way,MC 5114, San Diego, CA 92123 USA.	saceves@ucsd.edu		Broide, David/0000-0001-8405-9090	American Academy of Allergy, Asthma Immunology; American Partnership for Eosinophilic Disorder HOPE; National Institutes of Health [AI38435, AI70535, AI72115]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070535, R01AI072115] Funding Source: NIH RePORTER	American Academy of Allergy, Asthma Immunology; American Partnership for Eosinophilic Disorder HOPE; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the American Academy of Allergy, Asthma & Immunology Women in Allergy Award Junior Faculty Award (S. S. A.); the American Partnership for Eosinophilic Disorder HOPE Junior Faculty Award (S. S. A.); and National Institutes of Health grants AI38435, AI70535, and AI72115 (D. H. B.).	Aceves SS, 2010, ALLERGY, V65, P109, DOI 10.1111/j.1398-9995.2009.02142.x; Aceves SS, 2009, ANN ALLERG ASTHMA IM, V103, P401, DOI 10.1016/S1081-1206(10)60359-6; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Da Silva CA, 2006, CLIN EXP ALLERGY, V36, P317; Fox VL, 2003, GASTROINTEST ENDOSC, V57, P30, DOI 10.1067/mge.2003.33; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Kambe N, 2001, BLOOD, V97, P2045, DOI 10.1182/blood.V97.7.2045; Kirsch R, 2007, J PEDIATR GASTR NUTR, V44, P20, DOI 10.1097/MPG.0b013e31802c0d06; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Korsapati H, 2009, GUT, V58, P1056, DOI 10.1136/gut.2008.168146; Kraft M, 2003, CHEST, V124, P42, DOI 10.1378/chest.124.1.42; Lucendo AJ, 2007, ENDOSCOPY, V39, P765, DOI 10.1055/s-2007-966738; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Nurko S, 2009, AM J GASTROENTEROL, V104, P3050, DOI 10.1038/ajg.2009.543; Remedios M, 2006, GASTROINTEST ENDOSC, V63, P3, DOI 10.1016/j.gie.2005.07.049; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Teitelbaum JE, 2002, GASTROENTEROLOGY, V122, P1216, DOI 10.1053/gast.2002.32998; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Wenzel SE, 2006, AM J RESP CRIT CARE, V174, P364, DOI 10.1164/rccm.200606-755ED; Woodman L, 2008, J IMMUNOL, V181, P5001, DOI 10.4049/jimmunol.181.7.5001	25	175	178	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1198	U200		10.1016/j.jaci.2010.08.050	http://dx.doi.org/10.1016/j.jaci.2010.08.050			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21047675				2022-12-18	WOS:000284947800018
J	Ando, H; Moverare, R; Kondo, Y; Tsuge, I; Tanaka, A; Borres, MP; Urisu, A				Ando, Hitoshi; Moverare, Robert; Kondo, Yasuto; Tsuge, Ikuya; Tanaka, Akira; Borres, Magnus P.; Urisu, Atsuo			Utility of ovomucoid-specific IgE concentrations in predicting symptomatic egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						egg hypersensitivity; specific IgE; egg white; ovalbumin; ovomucoid; food challenge	IMMUNOGLOBULIN-E LEVELS; FOOD HYPERSENSITIVITY; BINDING ACTIVITY; CHILDREN; SENSITIZATION; PREVALENCE; POPULATION; TOLERANCE; DIAGNOSIS; AGE	Background: Children with allergy to raw egg white might tolerate low amounts of heated egg. Ovomucoid-specific IgE antibodies have been suggested to be predictors of whether children could tolerate heat-treated egg. Objective: The aim was to evaluate the clinical usefulness and added diagnostic value of measurements of IgE antibodies to egg white, ovalbumin, and ovomucoid in children with egg allergy. Methods: One hundred eight patients (median age, 34.5 months) with suspected egg allergy underwent double-blind, placebo-controlled food challenges with raw and heated egg. The outcomes of the challenges were related to the serum concentration of specific IgE antibodies and total IgE by using ImmunoCAP. Results: Reactions to heated egg white were observed in 38 patients (considered allergic to raw and heated egg), 29 patients reacted to only raw egg white, and 41 patients were tolerant. Correlation was observed between the serologic parameters studied. Receiver operating characteristic analysis showed that egg white ImmunoCAP was useful in the diagnosis of allergy to raw egg white. The positive decision point, based on 95% clinical specificity, was 7.4 kU(A)/L, and the negative decision point, based on 95% clinical sensitivity, was 0.6 kU(A)/L. For reaction to heated egg white, ovomucoid ImmunoCAP was superior. The positive decision point was 10.8 kU(A)/L, and the negative decision point was 1.2 kU(A)/L. Conclusions: Quantitative measurements of specific IgE antibodies to both egg white and ovomucoid and the evaluation against the suggested positive and negative decision points for specific IgE will be useful in the diagnosis of egg allergy.	[Urisu, Atsuo] Fujita Hlth Univ, Teaching Hosp 2, Dept Pediat, Nakagawa Ku, Nagoya, Aichi, Japan; [Ando, Hitoshi] Toyokawa City Hosp, Dept Pediat, Toyokawa, Japan; [Moverare, Robert; Borres, Magnus P.] Phadia AB, Uppsala, Sweden; [Moverare, Robert] Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; [Kondo, Yasuto; Tsuge, Ikuya] Fujita Hlth Univ, Sch Med, Dept Pediat, Toyoake, Aichi 47011, Japan; [Tanaka, Akira] Phadia KK, Tokyo, Japan; [Borres, Magnus P.] Univ Gothenburg, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden	Fujita Health University; Thermo Fisher Scientific; Phadia; Uppsala University; Fujita Health University; University of Gothenburg	Urisu, A (corresponding author), Fujita Hlth Univ, Teaching Hosp 2, Dept Pediat, Nakagawa Ku, 3-6-10 Otobashi, Nagoya, Aichi, Japan.	urisu@fujita-hu.ac.jp			Ministry of Health, Labour. and Welfare of Japan	Ministry of Health, Labour. and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	Supported by Health and Labour Science Research Grants from the Ministry of Health, Labour. and Welfare of Japan.	Benhamou AH, 2008, PEDIATR ALLERGY IMMU, V19, P173, DOI 10.1111/j.1399-3038.2007.00602.x; BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; BOCK SA, 1987, PEDIATRICS, V79, P683; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Cooke SK, 1997, J IMMUNOL, V159, P2026; Des Roches A, 2006, ALLERGY, V61, P1487, DOI 10.1111/j.1398-9995.2006.01200.x; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Garcia C, 2007, ALLERGOL IMMUNOPATH, V35, P15, DOI 10.1157/13099090; GARIQ SM, 2000, PEDIATR ALLERGY IMMU, V11, P162; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P421, DOI 10.1111/j.1399-3038.2004.00178.x; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; Kemp AS, 2007, PEDIAT ALLERG IMM-UK, V18, P696, DOI 10.1111/j.1399-3038.2007.00679.x; Knight AK, 2006, J ALLERGY CLIN IMMUN, V117, P842, DOI 10.1016/j.jaci.2005.12.1304; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Niggemann B, 2006, ALLERGY, V61, P808, DOI 10.1111/j.1398-9995.2006.01066.x; Osterballe M, 2005, PEDIAT ALLERG IMM-UK, V16, P567, DOI 10.1111/j.1399-3038.2005.00251.x; Roberts G, 2007, PEDIAT ALLERG IMM-UK, V18, P543, DOI 10.1111/j.1399-3038.2007.00609.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Sopo SM, 2007, PEDIATR ALLERGY IMMU, V18, P575, DOI 10.1111/j.1399-3038.2007.00595.x; Urisu A, 1999, INT ARCH ALLERGY IMM, V120, P192, DOI 10.1159/000024267; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; Venter C, 2006, J ALLERGY CLIN IMMUN, V117, P1118, DOI 10.1016/j.jaci.2005.12.1352; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1076, DOI 10.1016/j.jaci.2005.02.014; Yamada K, 2000, ALLERGY, V55, P565, DOI 10.1034/j.1398-9995.2000.00430.x; ZWEIG MH, 1993, CLIN CHEM, V39, P561	29	175	182	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					583	588		10.1016/j.jaci.2008.06.016	http://dx.doi.org/10.1016/j.jaci.2008.06.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18692888				2022-12-18	WOS:000259234000022
J	Wills-Karp, M				Wills-Karp, M			IL-12/IL-13 axis in allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; cytokine; T-cell differentiation	INDUCED AIRWAY HYPERRESPONSIVENESS; T-CELLS; INTERLEUKIN-4 RECEPTOR; IFN-GAMMA; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; IL-12 PRODUCTION; IMMUNOGLOBULIN-E; ATOPIC ASTHMA; MESSENGER-RNA	Allergic airway diseases are associated with skewed T(H)2 cytokine production, although the underlying cause of this aberrant immune response is not well understood. Recently, 2 double-digit cytokines, IL-12 and IL-13, have been proposed to play pivotal roles in the T(H)2-polarized immune response to inhaled allergens. IL-12 is a critical determinant of T(H)1-mediated immune responses, and it has been shown that deficiency In this cytokine can lead to T(H)2-polarized immune responses. IL-13, on the other hand, has recently been shown to be a critical mediator of the effector arm of the allergic response. Overproduction of this cytokine has been shown to Induce many common features of the allergic diathesis, such as airway hyperresponsiveness, eosinophilic inflammation, IgE production, mucus hypersecretion, and subepithelial fibrosis, Substantial evidence suggests that an imbalance in the production of these 2 critical immunoregulatory cytokines occurs in the lungs of atopic and asthmatic individuals, such that IL-13 is overproduced, and IL-12 production is Impaired. As a result of this imbalance, IL-13 production may go unchecked and induce the classical allergic phenotype. Although it is not entirely clear what tips the balance between these 2 cytokines, genetic studies suggest that this could indeed be a primary event. Interestingly, the genes encoding both of these cytokines reside within the chromosomal regions on 5q, which have been associated with asthma in many populations. Although no evidence exists to date to support an association between asthma and polymorphisms in the IL12 gene, evidence is accumulating that supports an association between genetic alterations in the ILI3 gene and atopy and asthma. From these observations, we can conclude that an imbalance In the IL-12/IL-13 axis may contribute to the development of allergic diseases, such as asthma, Studies to more fully examine the yin-yang relationship between these 2 critical immunoregulatory cytokines are clearly warranted.	Childrens Hosp, Med Ctr, Dept Pediat, Div Immunobiol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Wills-Karp, M (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Immunobiol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.							Agarwal SK, 2000, J ALLERGY CLIN IMMUN, V105, P91, DOI 10.1016/S0091-6749(00)90183-0; Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Blotta MH, 1997, J IMMUNOL, V158, P5589; Bodey KJ, 1999, ALLERGY, V54, P1083, DOI 10.1034/j.1398-9995.1999.00889.x; Brusselle GG, 1997, AM J RESP CELL MOL, V17, P767, DOI 10.1165/ajrcmb.17.6.2820; Chen H, 1999, AM J RESP CRIT CARE, V159, pA399; Chou CC, 1999, ANN ALLERG ASTHMA IM, V82, P479, DOI 10.1016/S1081-1206(10)62725-1; Cohn L, 1998, J IMMUNOL, V161, P3813; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; DANDREA A, 1995, J EXP MED, V181, P537, DOI 10.1084/jem.181.2.537; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; Franchimont D, 2000, J IMMUNOL, V164, P1768, DOI 10.4049/jimmunol.164.4.1768; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Graber P, 1998, EUR J IMMUNOL, V28, P4286, DOI 10.1002/(SICI)1521-4141(199812)28:12<4286::AID-IMMU4286>3.0.CO;2-H; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Hogan SP, 1998, J IMMUNOL, V161, P1501; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Keane-Myers A, 1998, J IMMUNOL, V161, P919; Kim TS, 1997, J IMMUNOL, V158, P4137; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; Kroegel C, 1996, EUR RESPIR J, V9, P899, DOI 10.1183/09031936.96.09050899; Kruse S, 1999, IMMUNOLOGY, V96, P365; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuznetsov VA, 1999, BIOPHYS J, V77, P154, DOI 10.1016/S0006-3495(99)76879-7; Li L, 1999, J IMMUNOL, V162, P2477; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSHALL JD, 1995, J IMMUNOL, V155, P111; Matasic R, 1999, J LEUKOCYTE BIOL, V66, P909, DOI 10.1002/jlb.66.6.909; Matsui E, 1999, BIOCHEM BIOPH RES CO, V266, P551, DOI 10.1006/bbrc.1999.1859; Meyaard L, 1996, J IMMUNOL, V156, P2776; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Pravica V, 2000, EUR J IMMUNOGENET, V27, P35, DOI 10.1046/j.1365-2370.2000.00190.x; Prieto J, 2000, RESP MED, V94, P806, DOI 10.1053/rmed.2000.0826; Purello-D'Ambrosio F, 1999, J INVEST ALLERG CLIN, V9, P262; Sur S, 1996, J IMMUNOL, V157, P4173; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Tang C, 1999, EUR RESPIR J, V14, P106, DOI 10.1034/j.1399-3003.1999.14a18.x; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; Vieira PL, 1998, J IMMUNOL, V161, P5245; Wang HY, 1999, J IMMUNOL, V162, P4385; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wright ED, 1999, CLIN EXP ALLERGY, V29, P1320; Wu CY, 1998, J IMMUNOL, V161, P2723; Ying S, 1997, J IMMUNOL, V158, P5050; Zhao LL, 2000, ALLERGY, V55, P749, DOI 10.1034/j.1398-9995.2000.00583.x; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	68	175	185	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					9	18		10.1067/mai.2001.112265	http://dx.doi.org/10.1067/mai.2001.112265			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149983	Bronze			2022-12-18	WOS:000166533300002
J	Phipatanakul, W; Eggleston, PA; Wright, EC; Wood, RA				Phipatanakul, W; Eggleston, PA; Wright, EC; Wood, RA		Natl Cooperative Inner City Asthma	Mouse allergen. II. The relationship of mouse allergen exposure to mouse sensitization and asthma morbidity in inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mouse allergen; indoor allergens; inner-city asthma; sensitization; asthma morbidity	DER-P-I; MITE; RISK; CHILDHOOD; CAT	Background: Although mouse allergen is known to cause occupational asthma in laboratory workers, its potential significance in home environments has never been studied. Objective: This study was designed to define the prevalence of mouse sensitivity and its relationship to mouse allergen exposure and disease activity in inner-city children with asthma, Methods: A subset Of 499 subjects from the National Cooperative Inner-City Asthma Study had dust samples adequate for mouse allergen analysis, as well as valid puncture skin test (PST) results, Data were analyzed to relate mouse allergen exposure and other risk factors to mouse sensitization and asthma morbidity, Results: Eighty-nine (18%) of the 499 children had a positive mouse skin test response, Children whose homes had mouse allergen levels above the median (1.60 mug/g) in the kitchen had a significantly higher rate of mouse sensitization (23% vs 11%, P = .007). Atopy was also significantly related to mouse sensitization, with 40% of those with more than 4 positive PST responses having mouse sensitivity compared with 4% of those with no other positive PST responses (P < .0001). When atopy and exposure were considered together, 53% of those with more than 4 positive PST responses and allergen levels above the median had a positive PST response to mouse allergen compared with 22% of those with more than 4 positive PST responses and allergen levels below the median (P < .0001). The relationship among mouse allergen exposure, sensitization, and any measures of asthma morbidity was not statistically significant, Conclusions: Mouse allergen may be an important indoor allergen in inner-city children with asthma, with exposure and atopy contributing to mouse sensitization.	Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat,Div Allergy & Immunol, Boston, MA USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD USA; New England Res Inst, Watertown, MA 02172 USA; Albert Einstein Sch Med, Bronx, NY USA; Childrens Mem Hosp, Chicago, IL 60614 USA; Cook Cty Hosp, Chicago, IL 60612 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Henry Ford Hosp, Detroit, MI 48202 USA; Wayne State Univ, Med Ctr, Detroit, MI 48202 USA; Mt Sinai Sch Med, New York, NY USA; Washington Univ, Sch Med, St Louis, MO USA; St Louis Univ, Sch Med, St Louis, MO USA; Howard Univ, Washington, DC 20059 USA; NIAID, Program Off, Bethesda, MD 20892 USA; Ctr Occupat Environm Hlth, Irvine, CA USA; New England Res Inst, Watertown, MA 02172 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Johns Hopkins University; HealthCore, Inc; Yeshiva University; Ann & Robert H. Lurie Children's Hospital of Chicago; John H Stroger Junior Hospital Cook County; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Henry Ford Health System; Henry Ford Hospital; Detroit Medical Center; Wayne State University; Icahn School of Medicine at Mount Sinai; Washington University (WUSTL); Saint Louis University; Howard University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); HealthCore, Inc	Wood, RA (corresponding author), Johns Hopkins Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.				NIAID NIH HHS [AI07007] Funding Source: Medline; NIEHS NIH HHS [ES09606] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009606] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUNYER J, 1997, EUR RESPIR J, V10, P2490; BERKOWITZ RB, 1992, J ALLERGY CLIN IMMUN, V90, P979, DOI 10.1016/0091-6749(92)90471-D; BIRKHEAD G, 1989, J ALLERGY CLIN IMMUN, V84, P484, DOI 10.1016/0091-6749(89)90361-8; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; KUHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408, DOI 10.1136/adc.73.5.408; Mitchell H, 1997, PEDIATR PULM, V24, P237; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Phipatanakul W, 1999, J ALLERGY CLIN IMMUN, V103, pS235; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PLATTSMILLS TAE, 1990, ALLERGY PROC, V11, P269, DOI 10.2500/108854190778879729; POLLART S, 1995, J ALLERGY CLIN IMMUN, V87, P505; RONCHETTI R, 1992, ARCH DIS CHILD, V67, P496, DOI 10.1136/adc.67.4.496; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L	23	175	176	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1075	1080						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112889				2022-12-18	WOS:000165930300008
J	ARSHAD, SH; HIDE, DW				ARSHAD, SH; HIDE, DW			EFFECT OF ENVIRONMENTAL-FACTORS ON THE DEVELOPMENT OF ALLERGIC DISORDERS IN INFANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ENVIRONMENTAL FACTORS; MATERNAL SMOKING; SEASON OF BIRTH; ASTHMA; ALLERGIC DISORDERS	IMMEDIATE HYPERSENSITIVITY; RESPIRATORY ILLNESS; PARENTAL SMOKING; 1ST YEAR; BREAST; ASTHMA; DEPENDENCE; SYMPTOMS; CHILDREN; MOTHER	A total of 1167 infants were followed for 1 year in a population-based prospective study to assess the effect of environmental factors on the development of allergic disorders. Some of these environmental factors are interdependent. Mothers who formula fed their infants smoked more often (p < 0.001) and tended to belong to lower social classes (p < 0.01). Logistic regression analysis was performed to adjust for these confounding variables. Maternal smoking adversely affected the prevalence of asthma (p = 0.003) defined as three or more separate episodes of wheezing and total allergy (p = 0.02). Infants in lower socioeconomic groups developed asthma significantly more often (p = 0.03) than infants born in higher socioeconomic groups. There was a nonsignificant trend for infants born in summer to develop asthma more than infants born in winter (p = 0.08). No effect of these factors was observed on eczema, food intolerance, or on the subgroup of infants with definite allergy (clinical disorder with positive skin prick test [SPT]). Exposure to animal dander did not influence the prevalence of clinical disorder, but positive SPT reaction to cat dander was more prevalent in infants who were exposed to cats and/or dogs (p = 0.04). Positive SPT to house dust mite occurred significantly more often in infants who were formula fed (p = 0.05). The environmental factors had a profound effect on the prevalence of asthma but not on other allergic disorders.	ST MARYS HOSP,CLIN ALLERGY RES UNIT,NEWPORT PO30 5TG,WIGHT,ENGLAND									ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BJORKSTEN F, 1976, CLIN ALLERGY, V6, P165, DOI 10.1111/j.1365-2222.1976.tb01894.x; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; BURR ML, 1983, ARCH DIS CHILD, V58, P561, DOI 10.1136/adc.58.7.561; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; FERGUSSON DM, 1980, ARCH DIS CHILD, V55, P358, DOI 10.1136/adc.55.5.358; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HARLAP S, 1974, LANCET, V1, P529; HIDE DW, 1991, CLIN EXP ALLERGY, V21, P739, DOI 10.1111/j.1365-2222.1991.tb03204.x; HIDE DW, 1981, ARCH DIS CHILD, V56, P172, DOI 10.1136/adc.56.3.172; KERSHAW CR, 1987, J ROY SOC MED, V80, P683, DOI 10.1177/014107688708001108; MERRETT TG, 1988, ANN ALLERGY, V61, P13; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; MURRAY AB, 1990, J ALLERGY CLIN IMMUN, V86, P732, DOI 10.1016/S0091-6749(05)80177-0; PARK ES, 1986, ARCH DIS CHILD, V61, P642, DOI 10.1136/adc.61.7.642; PEDREIRA FA, 1985, PEDIATRICS, V75, P594; SMITH JM, 1979, CLIN ALLERGY, V9, P153, DOI 10.1111/j.1365-2222.1979.tb01536.x; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WILSON NM, 1989, ARCH DIS CHILD, V64, P1194, DOI 10.1136/adc.64.8.1194; WRIGHT AL, 1989, BRIT MED J, V299, P946, DOI 10.1136/bmj.299.6705.946	24	175	176	0	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					235	241		10.1016/0091-6749(92)90077-F	http://dx.doi.org/10.1016/0091-6749(92)90077-F			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1500628	Bronze			2022-12-18	WOS:A1992JJ42300014
J	Sicherer, SH; Wood, RA; Vickery, BP; Jones, SM; Liu, AH; Fleischer, DM; Dawson, P; Mayer, L; Burks, AW; Grishin, A; Stablein, D; Sampson, HA				Sicherer, Scott H.; Wood, Robert A.; Vickery, Brian P.; Jones, Stacie M.; Liu, Andrew H.; Fleischer, David M.; Dawson, Peter; Mayer, Lloyd; Burks, A. Wesley; Grishin, Alexander; Stablein, Donald; Sampson, Hugh A.			The natural history of egg allergy in an observational cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Egg allergy; natural history; food allergy; IgE	FOOD ALLERGY; ATOPIC-DERMATITIS; MILK ALLERGY; COWS MILK; CHILDREN; PREVALENCE; IGE; INFANTS; ASTHMA; PREDICTION	Background: There are few studies on the natural history of egg allergy, and most are single-site and nonlongitudinal and have not identified early predictors of outcomes. Objective: We sought to describe the natural course of egg allergy and to identify early prognostic markers. Methods: Children age 3 to 15 months were enrolled in a multicenter observational study with either (1) a convincing history of an immediate allergic reaction to egg, milk, or both with a positive skin prick test (SPT) response to the trigger food and/or (2) moderate-to-severe atopic dermatitis and a positive SPT response to egg or milk. Children enrolled with a clinical history of egg allergy were followed longitudinally, and resolution was established based on successful ingestion. Results: The cohort with egg allergy consists of 213 children followed to a median age of 74 months. Egg allergy resolved in 105 (49.3%) children at a median age of 72 months. Factors that were most predictive of resolution included the following: initial reaction characteristics (isolated urticaria/angioedema vs other presentations), baseline egg-specific IgE level, egg SPT wheal size, atopic dermatitis severity, IgG(4) level, and IL-4 response (all P<.05). Numerous additional baseline clinical and demographic factors and laboratory assessments were not associated with resolution. Multivariate analysis identified baseline egg-specific IgE levels and initial reaction characteristics as strongly associated with resolution; a calculator to estimate resolution probabilities using these variables was established. Conclusions: In this cohort of infants with egg allergy, approximately one half had resolved over 74 months of follow-up. Baseline egg-specific IgE levels and initial reaction characteristics were important predictors of the likelihood of resolution.	[Sicherer, Scott H.; Mayer, Lloyd; Grishin, Alexander; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Vickery, Brian P.; Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA; [Liu, Andrew H.; Fleischer, David M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Dawson, Peter; Stablein, Donald] EMMES Corp, Rockville, MD USA	Icahn School of Medicine at Mount Sinai; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; National Jewish Health; Emmes Corporation	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,One Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu		Vickery, Brian/0000-0002-7243-5543	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [U19AI066738, U01AI066560]; National Center for Research Resources (NCRR), a component of the NIH [UL1 TR-000154, UL1 TR-000067, UL1 TR-000039, UL1 TR-000083, UL1 TR-000424]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, UL1TR000154, UL1TR000039, UL1TR001079, UL1TR000067, UL1TR000424, UL1TR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738, U01AI066560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK072201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [DP4GM096850] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR), a component of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grant U19AI066738 and U01AI066560. The project was also supported by grants UL1 TR-000154 (National Jewish), UL1 TR-000067 (Mount Sinai), UL1 TR-000039 (Arkansas), UL1 TR-000083 (University of North Carolina) and UL1 TR-000424 (Johns Hopkins) from the National Center for Research Resources (NCRR), a component of the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.	Baker SS, 2000, PEDIATRICS, V106, P346; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Chapman JA, 2006, ANN ALLERG ASTHMA IM, V96, pS1, DOI 10.1016/S1081-1206(10)60926-X; Clark A, 2011, CLIN EXP ALLERGY, V41, P706, DOI 10.1111/j.1365-2222.2011.03697.x; Clark TG, 2003, BRIT J CANCER, V89, P232, DOI 10.1038/sj.bjc.6601118; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; FORD RPK, 1982, ARCH DIS CHILD, V57, P649, DOI 10.1136/adc.57.9.649; Gaffin JM, 2011, CLIN PEDIATR, V50, P133, DOI 10.1177/0009922810384720; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; HILL DJ, 1993, CLIN EXP ALLERGY, V23, P124, DOI 10.1111/j.1365-2222.1993.tb00307.x; Kulig M, 1998, CLIN EXP ALLERGY, V28, P1397, DOI 10.1046/j.1365-2222.1998.00439.x; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V130, P473, DOI 10.1016/j.jaci.2012.06.006; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1, DOI 10.1016/S1081-1206(10)61385-3; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Noma T, 1996, CLIN EXP ALLERGY, V26, P1298, DOI 10.1111/j.1365-2222.1996.tb00527.x; Okamoto S, 2012, ALLERGY ASTHMA CL IM, V8, DOI 10.1186/1710-1492-8-9; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Soderstrom L, 2011, ALLERGY, V66, P1058, DOI 10.1111/j.1398-9995.2011.02578.x; Todd DG, 2007, PEDIATRICS, V120, P1304, DOI 10.1542/peds.2007-0350; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060	36	174	178	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					492	+		10.1016/j.jaci.2013.12.1041	http://dx.doi.org/10.1016/j.jaci.2013.12.1041			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24636473	Green Accepted, Green Published			2022-12-18	WOS:000332397100025
J	Schmitt, J; Langan, S; Deckert, S; Svensson, A; von Kobyletzki, L; Thomas, K; Spuls, P				Schmitt, Jochen; Langan, Sinead; Deckert, Stefanie; Svensson, Ake; von Kobyletzki, Laura; Thomas, Kim; Spuls, Phyllis		Harmonising Outcome Measures Atopi	Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; evidence-based medicine; systematic review; severity of illness index; reliability; validity; responsiveness	PATIENT-ORIENTED SCORAD; OBJECTIVE SEVERITY ASSESSMENT; ADMINISTERED ECZEMA AREA; BODY-SURFACE AREA; QUALITY-OF-LIFE; METHODOLOGICAL QUALITY; DISEASE-ACTIVITY; COSMIN CHECKLIST; OUTCOME MEASURES; SCORING SYSTEM	Background: Clinical signs are a core outcome domain for atopic dermatitis (AD) trials. The current lack of standardization of outcome measures in AD trials hampers evidence-based communication. Objective: We sought to provide evidence-based recommendations for the measurement of clinical signs in AD trials and to inform the Harmonising Outcome Measures for Atopic Dermatitis Initiative. Methods: We conducted a systematic review on measurement properties of outcome measurements for clinical signs of AD. We systematically searched MEDLINE and Embase (until October 1, 2012) for validation studies on instruments measuring the clinical signs of AD. Grading of the truth, discrimination, and feasibility of scales; methodological study quality; and recommendations were based on predefined criteria. Results: Sixteen eligible instruments were identified, of which 2 were best validated. The Eczema Area and Severity Index has adequate validity, responsiveness, internal consistency, intraobserver reliability, and intermediate interobserver reliability but unclear interpretability and feasibility. The Severity Scoring of Atopic Dermatitis Index (SCORAD) has adequate validity, responsiveness, interobserver reliability, and interpretability and unclear intraobserver reliability. Only the objective SCORAD (ie, the clinical signs domain of the SCORAD) is internally consistent. The Six Area, Six Sign Atopic Dermatitis Index severity score and Three Item Severity Score fulfill some quality criteria, but the performance in other required measurement properties is unclear. The Patient-oriented Eczema Measure is reliable and responsive but has inadequate content validity to assess clinical signs of AD. The remaining 11 scales have either (almost) not been validated or performed inadequately. Conclusions: The Eczema Area and Severity Index and SCORAD are the best instruments to assess the clinical signs of AD. The other 14 instruments identified are (currently) not recommended because of unclear or inadequate measurement properties.	[Schmitt, Jochen; Deckert, Stefanie] Univ Hosp Dresden, Ctr Evidence Based Healthcare, D-01307 Dresden, Germany; [Schmitt, Jochen] Tech Univ Dresden, Inst & Policlin Occupat & Social Med, D-01062 Dresden, Germany; [Langan, Sinead] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England; [Svensson, Ake] Lund Univ, Inst Clin Sci, Dept Dermatol, Malmo, Sweden; [von Kobyletzki, Laura] Karlstad Univ, Dept Publ Hlth Sci, Karlstad, Sweden; [Thomas, Kim] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2RD, England; [Spuls, Phyllis] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1105 AZ Amsterdam, Netherlands	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; University of London; London School of Hygiene & Tropical Medicine; Lund University; Karlstad University; University of Nottingham; University of Amsterdam; Academic Medical Center Amsterdam	Schmitt, J (corresponding author), Univ Hosp Dresden, Ctr Evidence Based Healthcare, Fetscherstr 74, D-01307 Dresden, Germany.	jochen.schmitt@uniklinikum-dresden.de	von Kobyletzki, Laura/AAN-7060-2021	Langan, Sinead/0000-0002-7022-7441; Deckert, MPH, Stefanie/0000-0002-4889-3632; Thomas, Kim/0000-0001-7785-7465; Spuls, Phyllis/0000-0002-6035-2863	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research funding scheme [RP-PG-0407-10177]; National Institute for Health Research [NIHR/CS/010/014, RP-PG-0407-10177] Funding Source: researchfish	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research funding scheme(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	This publication describes work conducted on behalf of the Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative, which is supported through an independent research grant funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research funding scheme (RP-PG-0407-10177). The views expressed in this publication are those of the author or authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.	Angelova-Fischer I, 2005, BRIT J DERMATOL, V153, P767, DOI 10.1111/j.1365-2133.2005.06697.x; BAHMER FA, 1992, ACTA DERM-VENEREOL, P32; BAHMER FA, 1991, ARCH DERMATOL, V127, P1239, DOI 10.1001/archderm.127.8.1239; Barbier N, 2004, BRIT J DERMATOL, V150, P96, DOI 10.1111/j.1365-2133.2004.05696.x; BerthJones J, 1996, BRIT J DERMATOL, V135, P25, DOI 10.1111/j.1365-2133.1996.tb00706.x; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boers M, 1998, J RHEUMATOL, V25, P198; Carel K, 2008, ANN ALLERG ASTHMA IM, V101, P500, DOI 10.1016/S1081-1206(10)60289-X; Carroll CL, 2005, PEDIATR DERMATOL, V22, P192, DOI 10.1111/j.1525-1470.2005.22303.x; Charman CR, 2005, ARCH DERMATOL, V141, P1146, DOI 10.1001/archderm.141.9.1146; Charman CR, 2004, ARCH DERMATOL, V140, P1513, DOI 10.1001/archderm.140.12.1513; Charman CR, 2002, BRIT J DERMATOL, V146, P1057, DOI 10.1046/j.1365-2133.2002.04644.x; Charman CR, 1999, BRIT J DERMATOL, V140, P109; Charman D, 1999, J Outcome Meas, V3, P21; Charman D P, 1999, J Outcome Meas, V3, P162; Cosickic Almira, 2010, Med Arh, V64, P178; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; Hachisuka J, 2009, INT J DERMATOL, V48, P374, DOI 10.1111/j.1365-4632.2009.03906.x; Haeck IM, 2012, J EUR ACAD DERMATOL, V26, P236, DOI 10.1111/j.1468-3083.2011.04043.x; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hon KLE, 2006, INT J DERMATOL, V45, P728, DOI 10.1111/j.1365-4632.2005.02703.x; Housman TS, 2002, BRIT J DERMATOL, V147, P1192, DOI 10.1046/j.1365-2133.2002.05031.x; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Mazzotti E, 2005, ITAL J DERMATOL VENE, V140, P389; Mazzotti E, 2008, ACTA DERM-VENEREOL, V88, P60, DOI 10.2340/00015555-0315; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Mokkink LB, 2010, QUAL LIFE RES, V19, P539, DOI 10.1007/s11136-010-9606-8; Mokkink LB, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-22; Murao Y, 2004, PEDIATR INT, V46, P330, DOI 10.1111/j.1442-200x.2004.01885.x; Orange AP, 1997, PEDIAT ALLERG IMM-UK, V8, P28, DOI 10.1111/j.1399-3038.1997.tb00139.x; Oranje AP, 2011, CURR PROBL DERMATOL, V41, P149, DOI 10.1159/000323308; PILL J, 1971, SOCIO ECON PLAN SCI, V5, P57, DOI 10.1016/0038-0121(71)90041-3; Pucci N, 2005, ALLERGY, V60, P113, DOI 10.1111/j.1398-9995.2004.00622.x; Rehal B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017520; Rullo VEV, 2008, ALLERGOL IMMUNOPATH, V36, P205, DOI 10.1016/S0301-0546(08)72551-5; Schafer T, 1997, BRIT J DERMATOL, V137, P558, DOI 10.1111/j.1365-2133.1997.tb03786.x; Schmitt J, 2010, Br J Dermatol, V163, P1166, DOI 10.1111/j.1365-2133.2010.10054.x; Schmitt J, 2011, CLIN EVID, V2011; Schmitt J, 2007, J ALLERGY CLIN IMMUN, V120, P1389, DOI 10.1016/j.jaci.2007.08.011; Schmitt J, 2007, ACTA DERM-VENEREOL, V87, P100, DOI 10.2340/00015555-0207; Schmitt J, 2012, ALLERGY, V67, P1111, DOI 10.1111/j.1398-9995.2012.02874.x; Schmitt J, 2011, J INVEST DERMATOL, V131, P623, DOI 10.1038/jid.2010.303; Schram ME, 2012, ALLERGY, V67, P99, DOI 10.1111/j.1398-9995.2011.02719.x; Shim WH, 2011, ANN ALLERG ASTHMA IM, V106, P540, DOI 10.1016/j.anai.2011.02.005; Silny Wojciech, 2005, Acta Dermatovenerol Croat, V13, P219; Sprikkelman AB, 1997, ALLERGY, V52, P944, DOI 10.1111/j.1398-9995.1997.tb01255.x; Stalder JF, 2011, ALLERGY, V66, P1114, DOI 10.1111/j.1398-9995.2011.02577.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Sugarman JL, 2003, ARCH DERMATOL, V139, P1417, DOI 10.1001/archderm.139.11.1417; Suh DC, 2007, J MANAGE CARE PHARM, V13, P778, DOI 10.18553/jmcp.2007.13.9.778; Terwee CB, 2012, QUAL LIFE RES, V21, P651, DOI 10.1007/s11136-011-9960-1; Terwee CB, 2009, QUAL LIFE RES, V18, P1115, DOI 10.1007/s11136-009-9528-5; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Terwee CB., 2011, MEASUREMENT MED; Tofte S., 1998, J EUR ACAD DERMAT S2, V11, pS197; Tremp M, 2011, DERMATOLOGY, V223, P68, DOI 10.1159/000330333; van Velsen SGA, 2010, PEDIATR DERMATOL, V27, P470, DOI 10.1111/j.1525-1470.2010.01285.x; VERWIMP JJM, 1995, EUR J CLIN NUTR, V49, pS39; Vourc'h-Jourdain M, 2009, DERMATOLOGY, V218, P246, DOI 10.1159/000193997; Weisshaar E, 2008, ACTA DERM-VENEREOL, V88, P234, DOI 10.2340/00015555-0432; Willemsen MG, 2009, DERMAT RES PRACT, V2009, DOI 10.1155/2009/357046; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; Wolkerstorfer A, 1999, ACTA DERM-VENEREOL, V79, P356; Yang HJ, 2010, ASIAN PAC J ALLERGY, V28, P130	66	174	183	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1337	1347		10.1016/j.jaci.2013.07.008	http://dx.doi.org/10.1016/j.jaci.2013.07.008			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	24035157				2022-12-18	WOS:000327538200013
J	Allen, KJ; Koplin, JJ; Ponsonby, AL; Gurrin, LC; Wake, M; Vuillermin, P; Martin, P; Matheson, M; Lowe, A; Robinson, M; Tey, D; Osborne, NJ; Dang, T; Tan, HTT; Thiele, L; Anderson, D; Czech, H; Sanjeevan, J; Zurzolo, G; Dwyer, T; Tang, MLK; Hill, D; Dharmage, SC				Allen, Katrina J.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Gurrin, Lyle C.; Wake, Melissa; Vuillermin, Peter; Martin, Pamela; Matheson, Melanie; Lowe, Adrian; Robinson, Marnie; Tey, Dean; Osborne, Nicholas J.; Thanh Dang; Tan, Hern-Tze Tina; Thiele, Leone; Anderson, Deborah; Czech, Helen; Sanjeevan, Jeeva; Zurzolo, Giovanni; Dwyer, Terence; Tang, Mimi L. K.; Hill, David; Dharmage, Shyamali C.			Vitamin D insufficiency is associated with challenge-proven food allergy in infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; food allergy; peanut allergy; egg allergy; population; oral food challenge; eczema; epigenetic	REGULATORY T-CELLS; UNITED-STATES; BIRTH COHORT; RISK-FACTORS; POPULATION; PREVALENCE; CHILDREN; LATITUDE; RADIATION; EXPOSURE	Background: Epidemiological evidence has shown that pediatric food allergy is more prevalent in regions further from the equator, suggesting that vitamin D insufficiency may play a role in this disease. Objective: To investigate the role of vitamin D status in infantile food allergy. Methods: A population sample of 5276 one-year-old infants underwent skin prick testing to peanut, egg, sesame, and cow's milk or shrimp. All those with a detectable wheal and a random sample of participants with negative skin prick test results attended a hospital-based food challenge clinic. Blood samples were available for 577 infants (344 with challenge-proven food allergy, 74 sensitized but tolerant to food challenge, 159 negative on skin prick test and food challenge). Serum 25-hydroxyvitamin D levels were measured by using liquid chromatography tandem mass spectrometry. Associations between serum 25-hydroxyvitamin D and food allergy were examined by using multiple logistic regression, adjusting for potential risk and confounding factors. Results: Infants of Australian-born parents, but not of parents born overseas, with vitamin D insufficiency (<= 50 nmol/L) were more likely to be peanut (adjusted odds ratio [aOR], 11.51; 95% CI, 2.01-65.79; P = .006) and/or egg (aOR, 3.79; 95% CI, 1.1912.08; P = .025) allergic than were those with adequate vitamin D levels independent of eczema status. Among those with Australian-born parents, infants with vitamin D insufficiency were more likely to have multiple food allergies (>= 2) rather than a single food allergy (aOR, 10.48; 95% CI, 1.60-68.61 vs aOR, 1.82; 95% CI, 0.38-8.77, respectively). Conclusions: These results provide the first direct evidence that vitamin D sufficiency may be an important protective factor for food allergy in the first year of life. (J Allergy Clin Immunol 2013; 131:1109-16.)	[Allen, Katrina J.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Gurrin, Lyle C.; Wake, Melissa; Vuillermin, Peter; Martin, Pamela; Lowe, Adrian; Osborne, Nicholas J.; Thanh Dang; Tan, Hern-Tze Tina; Thiele, Leone; Anderson, Deborah; Czech, Helen; Sanjeevan, Jeeva; Zurzolo, Giovanni; Dwyer, Terence; Tang, Mimi L. K.; Hill, David; Dharmage, Shyamali C.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Allen, Katrina J.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Wake, Melissa; Osborne, Nicholas J.; Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Allen, Katrina J.; Robinson, Marnie; Tey, Dean; Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Gurrin, Lyle C.; Matheson, Melanie; Lowe, Adrian; Osborne, Nicholas J.; Dharmage, Shyamali C.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3052, Australia; [Wake, Melissa] Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic 3052, Australia; [Vuillermin, Peter] Barwon Hlth, Child Hlth Res Unit, Geelong, Vic, Australia; [Vuillermin, Peter] Deakin Univ, Geelong, Vic 3217, Australia; [Osborne, Nicholas J.] Univ Exeter, Peninsula Coll Med & Dent, European Ctr Environm & Human Hlth, Exeter EX4 4QJ, Devon, England	Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; Deakin University; University of Exeter; University of Plymouth	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Tey, Dean/U-4525-2019; Allen, Katrina/I-4361-2018; Tang, Mimi/ABD-8350-2020; Osborne, Nicholas/D-2086-2011; Wake, Melissa/J-1396-2012; Matheson, Melanie C/O-4721-2015; Ponsonby, Anne-Louise/AAE-4351-2019; Dang, Thanh/AAK-1608-2021	Allen, Katrina/0000-0002-1921-4493; Tang, Mimi/0000-0002-3839-5293; Osborne, Nicholas/0000-0002-6700-2284; Wake, Melissa/0000-0001-7501-9257; Matheson, Melanie C/0000-0002-5822-3499; Dang, Thanh/0000-0003-2010-5582; Zurzolo, Giovanni/0000-0002-0623-9333; Ponsonby, Anne-Louise/0000-0002-6581-3657; Koplin, Jennifer/0000-0002-7576-5142; Zurzolo, Giovanni/0000-0003-0230-0691; Tan, Hern-Tze Tina/0000-0002-8289-7573; Lowe, Adrian/0000-0002-4691-8162; Gurrin, Lyle/0000-0001-7052-1969	National Health and Medical Research Council of Australia; Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program; National Health and Medical Research Council; European Regional Development Fund; European Social Fund Convergence Programme; Australian Egg Corporation	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); European Regional Development Fund(European Commission); European Social Fund Convergence Programme; Australian Egg Corporation(Australian Eggs)	This study was supported by funding from the National Health and Medical Research Council of Australia, the Ilhan Food Allergy Foundation, AnaphylaxiStop, the Charles and Sylvia Viertel Medical Research Foundation, and the Victorian Government's Operational Infrastructure Support Program.; Disclosure of potential conflict of interest: K. J. Allen is a Viertel Senior Medical Research Fellow and has received payment for lectures from Abbott, Wyeth, and Nutricia. J. J. Koplin is partly supported by a postdoctoral fellowship from a National Health and Medical Research Council Capacity Building Grant in Population Health. A.-L. Ponsonby, L. C. Gurrin, M. Wake, M. Matheson, A. Lowe, and S. C. Dharmage are supported by the National Health and Medical Research Council. D. Tey has received payment for lectures from Merck Sharp & Dohme, Abbott Nutrition, and Alphapharm. P. Martin and T. Dang are Australian Postgraduate Award PhD scholars, and H.-T. Tina Tan is a Malaysian Government PhD scholar. N. J. Osborne is supported by the European Regional Development Fund and the European Social Fund Convergence Programme, has received grants and travel support from the National Health and Medical Research Council, and has received grants from the Australian Egg Corporation. M. Tang is on the advisory board for the Nestle Nutrition Institute and Nutricia and has received speakers fees from Nutricia, Nestle Nutrition Institute, and Wyeth. The rest of the authors declare that they have no relevant conflicts of interest.	Armas LAG, 2007, J AM ACAD DERMATOL, V57, P588, DOI 10.1016/j.jaad.2007.03.004; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Keet CA, 2012, ALLERGY, V67, P775, DOI 10.1111/j.1398-9995.2012.02823.x; Kong J, 2008, AM J PHYSIOL-GASTR L, V294, pG208, DOI 10.1152/ajpgi.00398.2007; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Little R. J., 2019, STAT ANAL MISSING DA, V793; Liu X, 2011, ALLERGY, V66, P1442, DOI 10.1111/j.1398-9995.2011.02681.x; Lucas RM, 2011, NEUROLOGY, V76, P540, DOI 10.1212/WNL.0b013e31820af93d; Merewood A, 2012, J HUM LACT, V28, P159, DOI 10.1177/0890334411434802; Morley R, 2009, EUR J CLIN NUTR, V63, P802, DOI 10.1038/ejcn.2008.55; Mullins RJ, 2012, CURR ALLERGY ASTHM R, V12, P64, DOI 10.1007/s11882-011-0230-7; Mullins RJ, 2011, PEDIAT ALLERG IMM-UK, V22, P583, DOI 10.1111/j.1399-3038.2011.01151.x; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2012, J ALLERGY CLIN IMMUN, V129, P865, DOI 10.1016/j.jaci.2012.01.037; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Pink B, 2006, INTRO SOCIOECONOMIC; Saraiva GL, 2005, OSTEOPOROSIS INT, V16, P1649, DOI 10.1007/s00198-005-1895-3; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; Tan THT, 2012, CLIN EXP ALLERGY, V42, P20, DOI 10.1111/j.1365-2222.2011.03823.x; Thieden E, 2009, PHOTOCHEM PHOTOBIOL, V85, P1480, DOI 10.1111/j.1751-1097.2009.00612.x; U.S. Institute of Medicine, 2011, DIETARY REFERENCE IN; van der Mei IAF, 2007, ENVIRON HEALTH PERSP, V115, P1132, DOI 10.1289/ehp.9937; Vassallo MF, 2010, ALLERGY, V65, P1492, DOI 10.1111/j.1398-9995.2010.02384.x; Vassallo MF, 2010, J ALLERGY CLIN IMMUN, V126, P217, DOI 10.1016/j.jaci.2010.06.011; Vuillermin PJ, 2013, CLIN EXP ALLERGY, V43, P599, DOI 10.1111/cea.12048; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	33	174	185	1	49	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1109	+		10.1016/j.jaci.2013.01.017	http://dx.doi.org/10.1016/j.jaci.2013.01.017			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23453797	Green Submitted, hybrid			2022-12-18	WOS:000317187200021
J	Hatzler, L; Panetta, V; Lau, S; Wagner, P; Bergmann, RL; Illi, S; Bergmann, KE; Keil, T; Hofmaier, S; Rohrbach, A; Bauer, CP; Hoffman, U; Forster, J; Zepp, F; Schuster, A; Wahn, U; Matricardi, PM				Hatzler, Laura; Panetta, Valentina; Lau, Susanne; Wagner, Petra; Bergmann, Renate L.; Illi, Sabina; Bergmann, Karl E.; Keil, Thomas; Hofmaier, Stephanie; Rohrbach, Alexander; Bauer, Carl Peter; Hoffman, Ute; Forster, Johannes; Zepp, Fred; Schuster, Antje; Wahn, Ulrich; Matricardi, Paolo Maria			Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergenic molecules; allergic rhinitis; children; component-resolved diagnosis; component-resolved therapy; grass pollen; hay fever; immunoglobulin E; Phleum pratense; Phl p 1; prediction; timothy grass	GRASS-POLLEN ALLERGENS; IMMUNOTHERAPY; RHINITIS; CHILDHOOD; ASTHMA; PREVALENCE; DIAGNOSIS; EFFICACY; EXTRACT	Background: IgE sensitization against grass pollen is a cause of seasonal allergic rhinitis. Objective: We sought to investigate the evolution at the molecular level and the preclinical predictive value of IgE responses against grass pollen. Methods: The German Multicentre Allergy Study examined a birth cohort born in 1990. A questionnaire was administered yearly, and blood samples were collected at 1, 2, 3, 5, 6, 7, 10, and 13 years of age. Grass pollen-related seasonal allergic rhinitis (SARg) was diagnosed according to nasal symptoms in June/July. Serum IgE antibodies to Phleum pratense extract and 8 P pratense molecules were tested with immune-enzymatic singleplex and multiplex assays, respectively. Results: One hundred seventy-seven of the 820 examined children had SARg. A weak monomolecular/oligomolecular IgE response to P pratense was observed very frequently before SARg onset. These initial IgE responses increased in concentration and molecular complexity during the preclinical and clinical process. A typical progression of IgE sensitization was observed: Phl p 1 (initiator in >75% of cases); then Phl p 4 and Phl p 5; then Phl p 2, Phl p 6, and Phl p 11; and then Phl p 12 and Phl p 7. At age 3 years, IgE sensitization predicted SARg by age 12 years (positive predictive value, 68% [95% CI, 50% to 82%]; negative predictive value, 84% [95% CI, 80% to 87%]). At this preclinical prediction time, the number of recognized molecules and the serum levels of IgE to P pratense were significantly lower than at 3 or more years after SARg onset. Conclusions: The IgE response against grass pollen molecules can start years before disease onset as a weak monosensitization or oligosensitization phenomenon. It can increase in serum concentration and complexity through a "molecular spreading" process during preclinical and early clinical disease stages. Testing IgE sensitization at a preclinical stage facilitates prediction of seasonal allergic rhinitis at its molecular monosensitization or oligosensitization stage. (J Allergy Clin Immunol 2012; 130:894-901.)	[Hatzler, Laura; Panetta, Valentina; Lau, Susanne; Wagner, Petra; Hofmaier, Stephanie; Rohrbach, Alexander; Wahn, Ulrich; Matricardi, Paolo Maria] Charite Univ Med Ctr, Dept Paediat Pneumol & Immunol, Berlin, Germany; [Bergmann, Renate L.] Charite Univ Med Ctr, Dept Paediat & Obstet, Berlin, Germany; [Keil, Thomas] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Panetta, Valentina] Altrastatist Srl, Consultancy & Training, Biostat Off, Rome, Italy; [Illi, Sabina] LMU, Univ Childrens Hosp Munich, Dept Pulm & Allergy, Munich, Germany; [Bauer, Carl Peter; Hoffman, Ute] Tech Univ Munich, Dept Pediat, D-8000 Munich, Germany; [Bergmann, Karl E.] Robert Koch Inst, Berlin, Germany; [Forster, Johannes] St Josefs Hosp, Dept Pediat, Freiburg, Germany; [Zepp, Fred] Johannes Gutenberg Univ Med Ctr, Dept Pediat & Adolescent Med, Mainz, Germany; [Schuster, Antje] Univ Dusseldorf, Dept Pediat Cardiol & Pneumol, D-40225 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; Technical University of Munich; Robert Koch Institute; Johannes Gutenberg University of Mainz; Heinrich Heine University Dusseldorf	Matricardi, PM (corresponding author), Charite, Dept Paediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	paolo.matricardi@charite.de	Dramburg, Stephanie/AAM-8340-2020	Dramburg, Stephanie/0000-0002-9303-3260; Hatzler, Laura/0000-0001-8795-6205	Deutsche Forschungsgemeinschaft (DFG) [MA-4740/1-1]; German Ministry for Education and Research (Bundesministerium fur Bildung und Forschung) [07.015.633 ALE27, 01EE9405/5, 01EE9406]; German Research Foundation; SymbioPharm; Airsonett; Federal Office of Health in Berlin, Germany; German Ministry for Education and Research; German Ministry of Research and Education; Deutsche Forschung Gesellschaft (DFG); Thermo Fisher Scientific	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Ministry for Education and Research (Bundesministerium fur Bildung und Forschung)(Federal Ministry of Education & Research (BMBF)); German Research Foundation(German Research Foundation (DFG)); SymbioPharm; Airsonett; Federal Office of Health in Berlin, Germany; German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); German Ministry of Research and Education(Federal Ministry of Education & Research (BMBF)); Deutsche Forschung Gesellschaft (DFG)(German Research Foundation (DFG)); Thermo Fisher Scientific	Supported by Deutsche Forschungsgemeinschaft (DFG) MA-4740/1-1. The Multicentre Allergy Study cohort was supported by several grants from the German Ministry for Education and Research (Bundesministerium fur Bildung und Forschung; reference nos. 07.015.633 ALE27; 01EE9405/5; 01EE9406).; S. Lau has consulted for the Merck Drug monitoring committee; is employed by Charite; has received grants from the German Research Foundation, SymbioPharm, and Airsonett; and has received payment for lectures from AstraZeneca, Novartis, and SymbioPharm. K.E. Bergmann has received grants from and is employed by the Federal Office of Health in Berlin, Germany; has consulted for the European Union; and has received payment for lectures and development of education presentations from AOK Baden. T. Keil has received grants from the German Research Foundation. F. Zepp is a member of the board for GlaxoSmithKline, Novartis, Pfizer, and Sanofi Pasteur; has consulted for Novartis and GlaxoSmithKline; has received payment for lectures from GlaxoSmithKline and Novartis; and has received payment for development of educational presentations from Pfizer. A. Schuster has received grants from the German Ministry for Education and Research and has received payment for lectures from Thermo Fisher. U. Wahn has received grants from the German Ministry of Research and Education. P.M. Matricardi has received grants from the Deutsche Forschung Gesellschaft (DFG) and Thermo Fisher Scientific, has consultant arrangements with Allergopharma, and has received payment for lectures from Thermo Fisher Scientific. The rest of the authors declare that they have no relevant conflicts of interest.	Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bousquet J, 2010, ALLERGY, V65, P1212, DOI [10.1111/j.1398-9995.2010.02439.x, 10.1111/j.1398-9995.2010.02480.x]; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Chabre H, 2010, CLIN EXP ALLERGY, V40, P505, DOI 10.1111/j.1365-2222.2009.03380.x; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Eifan AO, 2011, CURR OPIN ALLERGY CL, V11, P586, DOI 10.1097/ACI.0b013e32834cb994; Focke M, 2008, CLIN EXP ALLERGY, V38, P1400, DOI 10.1111/j.1365-2222.2008.03031.x; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Johansen N, 2009, INT ARCH ALLERGY IMM, V150, P325, DOI 10.1159/000226233; Kellberger J, 2012, J ALLERGY CLIN IMMUN, V129, P397, DOI 10.1016/j.jaci.2011.08.016; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Matricardi PM, 2011, J ALLERGY CLIN IMMUN, V128, P791, DOI 10.1016/j.jaci.2011.03.049; Melioli G, 2012, PEDIAT ALLERG IMM-UK, V23, P433, DOI 10.1111/j.1399-3038.2011.01228.x; Melioli G, 2011, CLIN BIOCHEM, V44, P1005, DOI 10.1016/j.clinbiochem.2011.05.007; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; PETERSEN A, 1995, INT ARCH ALLERGY IMM, V108, P49, DOI 10.1159/000237117; Plaut M, 2005, NEW ENGL J MED, V353, P1934, DOI 10.1056/NEJMcp044141; Rossi RE, 2001, ALLERGY, V56, P1180, DOI 10.1034/j.1398-9995.2001.00258.x; Rudenko M, 2010, CLIN EXP ALLERGY, V40, P365, DOI 10.1111/j.1365-2222.2009.03432.x; Schafer T, 2007, ALLERGY, V62, P1282, DOI 10.1111/j.1398-9995.2007.01453.x; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Tripodi S, 2011, J ALLERGY CLIN IMMUN, V129, pe8; Tripodi S, 2012, J ALLERGY CLIN IMMUN, V129, P834, DOI 10.1016/j.jaci.2011.10.045; Valenta R, 2007, J INVEST ALLERG CLIN, V17, P36; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Weber RW, 2003, J ALLERGY CLIN IMMUN, V112, P229, DOI 10.1067/mai.2003.1683; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x	34	174	177	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					894	+		10.1016/j.jaci.2012.05.053	http://dx.doi.org/10.1016/j.jaci.2012.05.053			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22841010				2022-12-18	WOS:000309594800008
J	Nakajima, S; Igyarto, BZ; Honda, T; Egawa, G; Otsuka, A; Hara-Chikuma, M; Watanabe, N; Ziegler, SF; Tomura, M; Inaba, K; Miyachi, Y; Kaplan, DH; Kabashima, K				Nakajima, Saeko; Igyarto, Botond Z.; Honda, Tetsuya; Egawa, Gyohei; Otsuka, Atsushi; Hara-Chikuma, Mariko; Watanabe, Norihiko; Ziegler, Steven F.; Tomura, Michio; Inaba, Kayo; Miyachi, Yoshiki; Kaplan, Daniel H.; Kabashima, Kenji			Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Langerhans cell; TSLP; TSLP receptor; epicutaneous sensitization; protein antigen	LANGERIN(+) DENDRITIC CELLS; ATOPIC-DERMATITIS; ALLERGIC INFLAMMATION; TH1 CHEMOKINES; STEADY-STATE; OX40 LIGAND; T-CELLS; IN-VIVO; TSLP; SKIN	Background: The clarification of cutaneous dendritic cell subset and the role of thymic stromal lymphopoietin (TSLP) signaling in epicutaneous sensitization with protein antigens, as in the development of atopic dermatitis, is a crucial issue. Objectives: Because TSLP is highly expressed in the vicinity of Langerhans cells (LCs), we sought to clarify our hypothesis that LCs play an essential role in epicutaneous sensitization with protein antigens through TSLP signaling. Methods: By using Langerin-diphtheria toxin receptor knock-in mice and human Langerin-diphtheria toxin A transgenic mice, we prepared mice deficient in LCs. We also prepared mice deficient in TSLP receptors in LCs by using TSLP receptor-deficient mice with bone marrow chimeric technique. We applied these mice to an ovalbumin (OVA)-induced epicutaneous sensitization model. Results: Upon the epicutaneous application of OVA, conditional LC depletion attenuated the development of clinical manifestations as well as serum OVA-specific IgE increase, OVA-specific T-cell proliferation, and IL-4 mRNA expression in the draining lymph nodes. Consistently, even in the steady state, permanent LC depletion resulted in decreased serum IgE levels, suggesting that LCs mediate the T(H)2 local environment. In addition, mice deficient in TSLP receptors on LCs abrogated the induction of OVA-specific IgE levels upon epicutaneous OVA sensitization. Conclusion: LCs initiate epicutaneous sensitization with protein antigens and induce T(H)2-type immune responses via TSLP signaling. (J Allergy Clin Immunol 2012;129:1048-55.)	[Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, Kyoto 6068507, Japan; [Hara-Chikuma, Mariko; Watanabe, Norihiko; Tomura, Michio] Kyoto Univ, Grad Sch Med, Ctr Innovat Immunoregulat Technol & Therapeut, Kyoto 6068507, Japan; [Igyarto, Botond Z.; Kaplan, Daniel H.] Univ Minnesota, Dept Dermatol, Ctr Immunol, Minneapolis, MN 55455 USA; [Ziegler, Steven F.] Benaroya Res Inst, Program Immunol, Seattle, WA USA; [Inaba, Kayo] Kyoto Univ, Grad Sch Biostudies, Dept Anim Dev & Physiol, Kyoto 6068507, Japan	Kyoto University; Kyoto University; University of Minnesota System; University of Minnesota Twin Cities; Benaroya Research Institute; Kyoto University	Kabashima, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawara, Kyoto 6068507, Japan.	kaba@kuhp.kyoto-u.ac.jp	Kaplan, Daniel H/N-2779-2013; Nakajima, Saeko/AAB-1577-2021; Kabashima, Kenji/G-2521-2014	Kaplan, Daniel H/0000-0002-7851-7320; Igyarto, Botond/0000-0002-9770-800X; Kabashima, Kenji/0000-0002-0773-0554; Egawa, Gyohei/0000-0002-6101-4719; Otsuka, Atsushi/0000-0001-7365-947X; Nakajima, Saeko/0000-0003-0831-1447	Ministries of Education, Culture, Sports, Science and Technology; Japan Society for the Promotion of Science; NIH [AR056632]; American Skin Association; Dermatology Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056632] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [12J04619, 23590973] Funding Source: KAKEN	Ministries of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Skin Association; Dermatology Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by Grants-in-Aid for Scientific Research from the Ministries of Education, Culture, Sports, Science and Technology (to K.K.) and by a Grant-in-Aid from the Japan Society for the Promotion of Science Fellows (to S.N.). This work was also supported by a grant from the NIH (AR056632 to D.H.K.) and the American Skin Association. B.Z.I. was supported by a grant from the Dermatology Foundation.	Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bursch LS, 2007, J EXP MED, V204, P3147, DOI 10.1084/jem.20071966; Carpino N, 2004, MOL CELL BIOL, V24, P2584, DOI 10.1128/MCB.24.6.2584-2592.2004; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Egawa G, 2011, J INVEST DERMATOL, V131, P2178, DOI 10.1038/jid.2011.198; Elentner A, 2009, J CELL MOL MED, V13, P2658, DOI 10.1111/j.1582-4934.2009.00797.x; Ginhoux F, 2007, J EXP MED, V204, P3133, DOI 10.1084/jem.20071733; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Honda T, 2010, J ALLERGY CLIN IMMUN, V125, P1154, DOI 10.1016/j.jaci.2009.12.005; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kaplan DH, 2008, EUR J IMMUNOL, V38, P2369, DOI 10.1002/eji.200838397; Kaplan DH, 2010, TRENDS IMMUNOL, V31, P446, DOI 10.1016/j.it.2010.08.006; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Kitajima M, 2011, EUR J IMMUNOL, V41, P1862, DOI 10.1002/eji.201041195; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; LEUNG DYM, 1990, J ALLERGY CLIN IMMUN, V85, P927, DOI 10.1016/0091-6749(90)90079-J; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; Moniaga Catharina Sagita, 2011, Inflammation & Allergy Drug Targets, V10, P477; Mori T, 2008, J INVEST DERMATOL, V128, P1719, DOI 10.1038/jid.2008.5; Nakajima S, 2010, J IMMUNOL, V184, P5595, DOI 10.4049/jimmunol.0903260; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; Novak N, 2007, ADV EXP MED BIOL, V601, P97; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Poulin LF, 2007, J EXP MED, V204, P3119, DOI 10.1084/jem.20071724; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Shimada Y, 2004, J DERMATOL SCI, V34, P201, DOI 10.1016/j.jdermsci.2004.01.001; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	34	174	183	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1048	U564		10.1016/j.jaci.2012.01.063	http://dx.doi.org/10.1016/j.jaci.2012.01.063			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22385635	Green Accepted, Green Published			2022-12-18	WOS:000302144600021
J	Wood, LG; Garg, ML; Gibson, PG				Wood, Lisa G.; Garg, Manohar L.; Gibson, Peter G.			A high-fat challenge increases airway inflammation and impairs bronchodilator recovery in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dietary fat; fatty acids; neutrophils; Toll-like receptor 4; innate immunity; asthma; bronchodilator recovery; airway inflammation	FACTOR-KAPPA-B; TRANSCRIPTION FACTOR; PRESCHOOL-CHILDREN; INSULIN-RESISTANCE; MONONUCLEAR-CELLS; ACIDS; ACTIVATION; RISK; MEAL; DIET	Background: Dietary fat activates systemic innate immune responses, but the effect on airway responses is unknown. Objective: To examine effects of a high-fat versus low-fat meal on systemic and airway inflammation in asthma. Methods: Nonobese subjects with asthma were randomized to consume a high-fat (n = 19; 48% [49 g] fat) or low-fat (n = 18; 15% [3 g] fat) meal. Fourteen obese patients with asthma and 21 healthy controls also consumed a high-fat meal. Another group of patients with asthma consumed a high-trans (n = 5; 5.2 g trans fat) or nontrans (n = 5, <0.3 g trans fat) fatty acid meal. Lung function was measured at baseline (prebronchodilator) and 2, 3, and 4 hours after bronchodilator. Airway inflammation was assessed by using induced sputum cell counts and Toll-like receptor 4 mRNA expression by real-time PCR. Systemic inflammation was measured by ELISA quantification of plasma TNF-alpha, high-sensitivity C-reactive protein, and IL-6 concentrations. Results: In patients with asthma, at 4 hours postmeal, increases in sputum % neutrophils and Toll-like receptor 4 mRNA expression were higher and increases in FEV1/forced vital capacity (FVC) were lower in the high-fat versus low-fat groups. Changes in plasma fatty acids correlated with changes in sputum % neutrophils and were negatively associated with changes in % FEV1, % FVC, and FEV1/FVC. After the high-trans fatty acid meal, sputum % neutrophils were significantly higher than after the nontrans meal. Conclusion: A high-fat meal augments neutrophilic airway inflammation, with the effect dependent on the type of fat consumed. A high-fat meal also suppresses bronchodilator recovery in asthma. Modifying dietary fat intake may be useful in asthma. (J Allergy Clin Immunol 2011;127:1133-40.)	[Wood, Lisa G.; Gibson, Peter G.] Univ Newcastle, Hunter Med Res Inst, Ctr Asthma & Resp Dis, Newcastle, NSW 2308, Australia; [Garg, Manohar L.] Univ Newcastle, Nutraceut Res Grp, Sch Biomed Sci & Pharm, Newcastle, NSW 2308, Australia; [Gibson, Peter G.] John Hunter Hosp, Dept Resp & Sleep Med, Newcastle, NSW, Australia	Hunter Medical Research Institute; University of Newcastle; University of Newcastle; John Hunter Hospital	Wood, LG (corresponding author), John Hunter Hosp, Hunter Med Res Inst, Level 3, Newcastle, NSW, Australia.	lisa.wood@newcastle.edu.au	Wood, Lisa G/G-7068-2013; gibson, peter/G-6194-2014	gibson, peter/0000-0001-5865-489X; Garg, Manohar/0000-0003-0514-0865; Wood, Lisa/0000-0002-0941-9225	National Health and Medical Research Council of Australia; Hunter Medical Research Institute; National Health and Medical Research Council	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Hunter Medical Research Institute; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Supported by a National Health and Medical Research Council of Australia Project Grant and a Hunter Medical Research Institute project grant sponsored by the Piggott family.; Disclosure of potential conflict of interest: L. G. Wood has received honoraria from GlaxoSmithKline and has received research support from the National Health and Medical Research Council. M. L. Garg declares no conflicts of interest. P. G. Gibson has received honoraria from GlaxoSmithKline and Boehringer Ingelheim and has received research support from the National Health and Medical Research Council.	Ajuwon KM, 2005, J NUTR, V135, P1841, DOI 10.1093/jn/135.8.1841; Aljada A, 2004, AM J CLIN NUTR, V79, P682; Bellido C, 2004, AM J CLIN NUTR, V80, P1487, DOI 10.1093/ajcn/80.6.1487; Beuther DA, 2010, CURR OPIN PULM MED, V16, P64, DOI 10.1097/MCP.0b013e3283338fa7; Blackburn P, 2006, OBESITY, V14, P1747, DOI 10.1038/oby.2006.201; Blum S, 2006, ANN NUTR METAB, V50, P20, DOI 10.1159/000089560; Bodner C, 1999, EUR RESPIR J, V13, P22, DOI 10.1183/09031936.99.13102299; Chisty MNA, 2002, DRUG DEV IND PHARM, V28, P1221, DOI 10.1081/DDC-120015355; Cuevas AM, 2004, BIOL RES, V37, P225, DOI 10.4067/S0716-97602004000200008; Ghanim H, 2010, AM J CLIN NUTR, V91, P940, DOI 10.3945/ajcn.2009.28584; GINA Executive and Science Committees, 2007, UPD GINA REP GLOB ST; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kim F, 2007, CIRC RES, V100, P1589, DOI 10.1161/CIRCRESAHA.106.142851; Laerum BN, 2007, CLIN EXP ALLERGY, V37, P1616, DOI 10.1111/j.1365-2222.2007.02821.x; Lee JY, 2004, J BIOL CHEM, V279, P16971, DOI 10.1074/jbc.M312990200; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; Mozaffarian D, 2009, EUR J CLIN NUTR, V63, pS5, DOI 10.1038/sj.ejcn.1602973; Nagel G, 2005, EUR J CLIN NUTR, V59, P8, DOI 10.1038/sj.ejcn.1602025; Nagel G, 2010, THORAX, V65, P516, DOI 10.1136/thx.2009.128256; Nappo F, 2002, J AM COLL CARDIOL, V39, P1145, DOI 10.1016/S0735-1097(02)01741-2; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Patel C, 2007, J CLIN ENDOCR METAB, V92, P4476, DOI 10.1210/jc.2007-0778; Rosenkranz SK, 2010, EUR J APPL PHYSIOL, V109, P499, DOI 10.1007/s00421-010-1390-1; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; Sinha S, 2004, J BIOL CHEM, V279, P41294, DOI 10.1074/jbc.M406514200; Soutar A, 1997, THORAX, V52, P166, DOI 10.1136/thx.52.2.166; Strom K, 1996, Monaldi Arch Chest Dis, V51, P16; Tabak C, 2006, THORAX, V61, P1048, DOI 10.1136/thx.2005.043034; Unger RH, 2003, ENDOCRINOLOGY, V144, P5159, DOI 10.1210/en.2003-0870; van Oostrom AJHHM, 2003, J LIPID RES, V44, P576, DOI 10.1194/jlr.M200419-JLR200; Vogel RA, 1997, AM J CARDIOL, V79, P350, DOI 10.1016/S0002-9149(96)00760-6; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Weiland SK, 1999, LANCET, V353, P2040, DOI 10.1016/S0140-6736(99)01609-8; Wickens K, 2005, ALLERGY, V60, P1537, DOI 10.1111/j.1398-9995.2005.00945.x; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Wood LG, 2010, CLIN EXP ALLERGY, V40, P232, DOI 10.1111/j.1365-2222.2009.03371.x; Wood LG, 2003, AM J CLIN NUTR, V77, P150, DOI 10.1093/ajcn/77.1.150; Wood LG, 2010, AM THOR SOC INT C NE; Wood LG, 2009, PROG LIPID RES, V48, P27, DOI 10.1016/j.plipres.2008.10.001; Woods RK, 2004, THORAX, V59, P105, DOI 10.1136/thorax.2003.009498; Zhao L, 2007, J BIOL CHEM, V282, P11618, DOI 10.1074/jbc.M608644200	45	174	178	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1133	1140		10.1016/j.jaci.2011.01.036	http://dx.doi.org/10.1016/j.jaci.2011.01.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21377715	Green Submitted, Bronze			2022-12-18	WOS:000290018600006
J	Bork, K; Frank, J; Grundt, B; Schlattmann, P; Nussberger, J; Kreuz, W				Bork, Konrad; Frank, Jorge; Grundt, Boris; Schlattmann, Peter; Nussberger, Juerg; Kreuz, Wolfhart			Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						angioedema; hereditary angioedema; C1 inhibitor deficiency; bradykinin; bradykinin receplor-2 antagonist; Icatibant	C1 INHIBITOR; LARYNGEAL EDEMA; HOE-140; POTENT; ASPHYXIATION; EFFICACY; DANAZOL; PAIN	Background: In hereditary angioedema, bradykinin is assumed to be the most important mediator of edema formation. Objective: To assess whether the selective bradykinin receptor-2 antagonist Icatibant is effective in acute edema attacks of hereditary angioedema. Methods: In this uncontrolled pilot study, 15 patients with 20 attacks were treated with Icatibant. The attacks were analyzed by using a standardized and validated visual analog scale measurement and compared with historical data of untreated attacks. Plasma bradykinin concentration was measured before and 4 hours after intravenous Icatibant treatment. Results: Symptom intensity decreased within 4 hours after administration of Icatibant; the median time to onset of symptom relief was 1.50,1.42, and 1.13 hours in the intravenous groups and 0.58 and 0.45 hours in the subcutaneous groups, respectively. The median difference in the 10-cm visual analog scale 4 hours after start of treatment was 4.11 cm (95% CI, 1.72-6.07). Compared with untreated attacks, Icatibant treatment reduced the mean (SD) time to onset of symptom relief by 97% from 42 +/- 14 to 1.16 +/- 0.95 hours (all groups combined). Median bradykinin concentration was 7-fold above the norm during acute attacks at 48.5 pmol/L and decreased to 18.0 pmol/L 4 hours after Icatibant infusion or injection. Conclusion: Icatibant was effective in treating acute attacks of hereditary angioedema. Clinical implications: This is the first report demonstrating the clinical usefulness of antagonizing bradykinin binding to bradykinin receptor-2 in hereditary angioedema.	Johannes Gutenberg Univ Mainz, Dept Dermatol, D-6500 Mainz, Germany; Univ Hosp, Dept Dermatol, Maastricht, Netherlands; Charite, Inst Med Informat Biostat & Epidemiol, Berlin, Germany; CHU Vaudois, Dept Med, CH-1011 Lausanne, Switzerland; Goethe Univ Frankfurt, Ctr Pediat, D-6000 Frankfurt, Germany	Johannes Gutenberg University of Mainz; Maastricht University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Goethe University Frankfurt	Bork, K (corresponding author), Johannes Gutenberg Univ Mainz, Hautklin, Langenbeckstr 1, D-55131 Mainz, Germany.	bork@hautklinik.klinik.uni-mainz.de	Schlattmann, Peter/B-5289-2008; Bork, Konrad/AAE-4985-2022	Bork, Konrad/0000-0002-6084-4577				Akbary AM, 1996, IMMUNOPHARMACOLOGY, V33, P238, DOI 10.1016/0162-3109(96)00065-3; Altman DG, 1997, BRIT MED J, V314, P1874, DOI 10.1136/bmj.314.7098.1874; AUSTIN CE, 1994, BRIT J PHARMACOL, V111, P969, DOI 10.1111/j.1476-5381.1994.tb14835.x; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Bork K, 2006, AM J GASTROENTEROL, V101, P619, DOI 10.1111/j.1572-0241.2006.00492.x; Bork K, 2006, BRIT J DERMATOL, V154, P542, DOI 10.1111/j.1365-2133.2005.07048.x; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bork K, 2003, J AM DENT ASSOC, V134, P1088, DOI 10.14219/jada.archive.2003.0323; Bork K, 2000, MAYO CLIN PROC, V75, P349, DOI 10.4065/75.4.349; Bork K, 2003, TRANSFUS APHER SCI, V29, P235, DOI 10.1016/j.transci.2003.08.007; Bork K, 1999, LANCET, V353, P1066, DOI 10.1016/S0140-6736(99)00110-5; Bork K, 2002, J HEPATOL, V36, P707, DOI 10.1016/S0168-8278(02)00035-1; BORK K, 2004, J ALLERGY CLIN IMMUN, V114, P94; Bowen T, 2004, J ALLERGY CLIN IMMUN, V114, P629, DOI 10.1016/j.jaci.2004.06.043; Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2; COCKCROFT JR, 1994, BRIT J CLIN PHARMACO, V38, P317, DOI 10.1111/j.1365-2125.1994.tb04360.x; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; DROUET C, 2004, J ALLERGY CLIN IMMUN, V114, P66; Gainer JV, 1998, NEW ENGL J MED, V339, P1285, DOI 10.1056/NEJM199810293391804; Gallagher EJ, 2002, AM J EMERG MED, V20, P287, DOI 10.1053/ajem.2002.33778; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; Kunschak M, 1998, TRANSFUSION, V38, P540, DOI 10.1046/j.1537-2995.1998.38698326333.x; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321, DOI 10.1016/S0091-6749(99)70030-8; Osler W, 1888, AM J MED SCI, V95, P362; QUINCKE HI, 1882, UBER AKUTES UMSCHRIE, V1, P129; Squire IB, 2000, HYPERTENSION, V36, P132, DOI 10.1161/01.HYP.36.1.132; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Tosi M, 1998, IMMUNOBIOLOGY, V199, P358, DOI 10.1016/S0171-2985(98)80040-5; Turner P, 2001, J ALLERGY CLIN IMMUN, V107, P105, DOI 10.1067/mai.2001.111145; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; WIRTH K, 1991, BRIT J PHARMACOL, V102, P774, DOI 10.1111/j.1476-5381.1991.tb12249.x	35	174	182	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1497	1503		10.1016/j.jaci.2007.02.012	http://dx.doi.org/10.1016/j.jaci.2007.02.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17418383				2022-12-18	WOS:000247232800027
J	Srivastava, KD; Kattan, JD; Zou, ZM; Li, JH; Zhang, LB; Wallenstein, S; Goldfarb, J; Sampson, HA; Li, XM				Srivastava, KD; Kattan, JD; Zou, ZM; Li, JH; Zhang, LB; Wallenstein, S; Goldfarb, J; Sampson, HA; Li, XM			The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut anaphylaxis; Chinese herbal medicine formula; T(H)2 cytokine modulation	FOOD ALLERGY; IN-VITRO; RESPONSES; IGE; SENSITIZATION; PROTECTS	Background: Peanut allergy is potentially life threatening. There is no curative therapy for this disorder. We previously found that an herbal formula, food allergy herbal formula (FAHF)-1, blocked peanut-induced anaphylaxis in a marine model when challenged immediately posttherapy. Objective: To test whether FAHF-2, an improved herbal formula, from which 2 herbs, Zhi Fu Zi (Radix Lateralis Aconiti Carmichaeli Praeparata) and Xi Xin (Herbs Asari), were eliminated, is equally effective to FAHF-1, and if so, whether protection persists after therapy is discontinued. Methods: Mice allergic to peanut treated with FAHF-2 for 7 weeks were challenged 1, 3, or 5 weeks posttherapy. Anaphylactic scores, core body temperatures, vascular leakage, and plasma histamine levels after peanut challenge were determined. Serum peanut-specific antibody levels and splenocyte cytokine profiles were also measured. Results: After challenges, all sham-treated mice developed severe anaphylactic signs, significant decrease in rectal temperatures, significantly increased plasma histamine levels, and marked vascular leakage. In contrast, no sign of anaphylactic reactions, decrease in rectal temperatures, or elevation of plasma histamine levels was observed in FAHF-2-treated mice in 5 separate experiments. IgE levels were significantly reduced by FAHF-2 treatment and remained significantly lower as long as 5 weeks posttherapy. Splenocytes from FAHF-2-treated mice showed significantly reduced IL-4, IL-5, and IL-13, and enhanced IFN-gamma production to recall peanut stimulation in vitro. Conclusion: FAHF-2 treatment completely eliminated anaphylaxis in mice allergic to peanut challenged as long as 5 weeks posttherapy. This result was associated with downregulation of T(H)2 responses. FAHF-2 may be a potentially effective and safe therapy for peanut allergy.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Ctr Comparat Med & Surg, Clin Pathol Lab, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Li, XM (corresponding author), Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl, New York, NY 10029 USA.	xiu-min.li@mssm.edu						[Anonymous], CHINESE HERBAL MED M; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; BENSKY D, 1993, CHINESE HERBAL MED F, P466; BENSKY D, 1993, CHINESE HERBAL MED M, P297; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bielory L, 1999, J ASTHMA, V36, P1, DOI 10.3109/02770909909065150; Bischoff SC, 2000, INT ARCH ALLERGY IMM, V121, P270, DOI 10.1159/000024340; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brandtzaeg P, 2002, ANN NY ACAD SCI, V964, P13; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; Helm RM, 2002, ANN NY ACAD SCI, V964, P139; HOWARD M, 1983, ANNU REV IMMUNOL, V1, P307, DOI 10.1146/annurev.iy.01.040183.001515; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; Kowalski ML, 1998, ALLERGY, V53, P485, DOI 10.1111/j.1398-9995.1998.tb04085.x; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li Xiu-Min, 2004, Clin Allergy Immunol, V18, P663; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P660, DOI 10.1067/mai.2000.110102; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 1999, J IMMUNOL, V162, P3045; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2003, J ALLERGY CLIN IMMUN, V111, P1140, DOI 10.1067/mai.2003.1494; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Lorentz A, 1999, EUR J IMMUNOL, V29, P1496, DOI 10.1002/(SICI)1521-4141(199905)29:05<1496::AID-IMMU1496>3.0.CO;2-5; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Norman PS, 2004, J ALLERGY CLIN IMMUN, V113, P1013, DOI 10.1016/j.jaci.2004.03.020; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Saini SS, 1999, J IMMUNOL, V162, P5624; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Srivastava K, 2004, J ALLERGY CLIN IMMUN, V113, P268, DOI 10.1016/j.jaci.2003.10.062; *STAT PHARM COMM P, 2000, PHARM PEOPLE REP CHI; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Towers GHN, 2003, J ALLERGY CLIN IMMUN, V111, P1140, DOI 10.1067/mai.2003.1493; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Xiu S., 1986, EXPT METHOD PHARM	39	174	178	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					171	178		10.1016/j.jaci.2004.10.003	http://dx.doi.org/10.1016/j.jaci.2004.10.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637565	Bronze			2022-12-18	WOS:000226267000025
J	Fleischer, DM; Conover-Walker, MK; Christie, L; Burks, AW; Wood, RA				Fleischer, DM; Conover-Walker, MK; Christie, L; Burks, AW; Wood, RA			The natural progression of peanut allergy: Resolution and the possibility of recurrence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; food challenge; recurrence; RAST; food hypersensitivity	TREE NUT ALLERGY; PREVALENCE; ASSOCIATION; CHILDREN; HISTORY	Background: It was once thought that peanut allergy is a lifelong problem. We previously reported that about 20% of children outgrow their peanut allergy and that more than 60% of patients with a peanut-IgE level of 5 or less passed an oral challenge. Objective: The goal of this study was to further describe the natural progression of peanut allergy by reviewing patients who have undergone oral peanut challenges since the previous study. Methods: Patients with peanut-IgE levels of 5 or less were offered a peanut challenge. Those who passed were further evaluated by questionnaire to assess reintroduction of peanut into their diet and whether any recurrence has occurred. Results: Eighty-four patients were evaluated, and 80 underwent complete analysis. Fifty-five percent with peanut-IgE levels of 5 or less and 63% with peanut-IgE levels of 2 or less passed challenges, compared to 61% and 67%, respectively, in our previous study. The 4 additional patients passed peanut challenges in this study after previously failing. Three patients with initial anaphylactic reactions and 2 patients with initial peanut-IgE levels greater than 70 passed their challenge. Follow-up of those who passed in both studies showed that the majority of patients reintroduced peanut into their diet, but that continued label reading, infrequent/limited ingestion, and aversion to peanut were all common in this population. Two patients had suspected subsequent reactions to peanut after passing their challenge. Conclusions: Patients with a history of peanut allergy and peanut-IgE levels of 5 or less have at least a 50% chance of outgrowing their allergy. Recurrence of peanut allergy may occur but appears to be uncommon.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Arkansas Childrens Hosp, Little Rock, AR 72202 USA	Johns Hopkins University; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital	Wood, RA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102, 600 N Wolfe St, Baltimore, MD 21287 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007, K24AI001666] Funding Source: NIH RePORTER; NIAID NIH HHS [1 K24AI01666-03, T32 AI07007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Busse PJ, 2002, NEW ENGL J MED, V347, P1535, DOI 10.1056/NEJM200211073471921; Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, pS92, DOI 10.1016/S0091-6749(02)81378-1; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Spergel JM, 2000, ANN ALLERG ASTHMA IM, V85, P473, DOI 10.1016/S1081-1206(10)62574-4; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376	14	174	175	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					183	189		10.1067/mai.2003.1517	http://dx.doi.org/10.1067/mai.2003.1517			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847497				2022-12-18	WOS:000184010600028
J	Li, XM; Sampson, HA				Li, XM; Sampson, HA			FAHF-1 purporting to block peanut-induced anaphylaxis - Reply	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MURINE MODEL; MEDICINE; ALLERGY; ASTHMA		Mt Sinai Sch Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Li, XM (corresponding author), Mt Sinai Sch Med, New York, NY 10029 USA.							BENSKY D, 1993, CHINESE HERBAL MED M, P513; Claman HN, 2002, J ALLERGY CLIN IMMUN, V109, P1038, DOI 10.1067/mai.2002.125261; Keane FM, 1999, BRIT MED J, V318, P563, DOI 10.1136/bmj.318.7183.563; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P660, DOI 10.1067/mai.2000.110102; Li XM, 2002, J ALLERGY CLIN IMMUN, V109, pS155, DOI 10.1016/S0091-6749(02)81592-5; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; *STAT PHARM COMM P, 2000, PHARM PEOPL REP CHIN, P3; Towers GHN, 2003, J ALLERGY CLIN IMMUN, V111, P1140, DOI 10.1067/mai.2003.1493; TOWERS GHN, 2002, J ALLERGY CLIN IMMUN; Ziment I, 2000, J ALLERGY CLIN IMMUN, V106, P603, DOI 10.1067/mai.2000.109432	10	174	191	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1140	1141		10.1067/mai.2003.1494	http://dx.doi.org/10.1067/mai.2003.1494			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12592300	Bronze			2022-12-18	WOS:000182904500040
J	Ballow, M				Ballow, M			Primary immunodeficiency disorders: Antibody deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						primary immune deficiencies; antibody deficiencies; B-cell development and differentiation	COMMON VARIABLE IMMUNODEFICIENCY; X-LINKED AGAMMAGLOBULINEMIA; SELECTIVE IGA DEFICIENCY; INFLUENZAE TYPE-B; NODULAR LYMPHOID HYPERPLASIA; IMMUNOGLOBULIN-A DEFICIENCY; HYPER-IGM; TRANSIENT HYPOGAMMAGLOBULINEMIA; INTRAVENOUS IMMUNOGLOBULIN; IMMUNOLOGICAL FEATURES	As a group, antibody deficiencies represent the most common types of primary immune deficiencies in human subjects. Often symptoms do not appear until the latter part of the first year of life, as passively acquired IgG from the mother decreases to below protective levels. As with the T-cell immune deficiencies, the spectrum of antibody deficiencies is broad, ranging from the most severe type of antibody deficiency with totally absent B cells and Serum Igs to patients who have a selective antibody deficiency with normal serum Ig. In addition to the increased susceptibility to infections, a number of other disease processes (eg, autoimmunity and malignancies) can be involved in the clinical presentation. Fortunately, the availability of intravenous immune serum globulin has made the management of these patients more complete. Recently, molecular immunology has led to identification of the gene or genes involved in many of these antibody deficiencies. As discussed in this review, this has led to a better elucidation of the B-cell development and differentiation pathways and a more complete understanding of the pathogenesis of many of these antibody deficiencies.	SUNY Coll Buffalo, Childrens Hosp Buffalo, Sch Med & Biomed Sci,Dept Pediat, Allergy Clin Immunol & Pediat Rheumatol Div, Buffalo, NY 14222 USA	State University of New York (SUNY) System; Buffalo State College	Ballow, M (corresponding author), SUNY Coll Buffalo, Childrens Hosp Buffalo, Sch Med & Biomed Sci,Dept Pediat, Allergy Clin Immunol & Pediat Rheumatol Div, 219 Bryant St, Buffalo, NY 14222 USA.							AMBROSINO DM, 1987, NEW ENGL J MED, V316, P790, DOI 10.1056/NEJM198703263161306; AMBROSINO DM, 1988, J ALLERGY CLIN IMMUN, V81, P1175, DOI 10.1016/0091-6749(88)90887-1; AMBROSINO DM, 1985, J CLIN INVEST, V75, P1935, DOI 10.1172/JCI111909; AMENT ME, 1973, MEDICINE, V52, P227, DOI 10.1097/00005792-197305000-00004; AMMANN AJ, 1971, MEDICINE, V50, P223, DOI 10.1097/00005792-197105000-00004; ASHMAN RF, 1992, J CLIN IMMUNOL, V12, P406, DOI 10.1007/BF00918852; BACHMANN R, 1965, SCAND J CLIN LAB INV, V17, P316, DOI 10.3109/00365516509077057; BALLOW M, 1991, CLIN REV ALLERG, V10, P1; BJORKANDER J, 1987, J CLIN IMMUNOL, V7, P8, DOI 10.1007/BF00915419; BJORKANDER J, 1985, NEW ENGL J MED, V313, P720, DOI 10.1056/NEJM198509193131203; BRUTON OC, 1952, PEDIATRICS, V9, P722; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; CAMPANA D, 1990, J IMMUNOL, V145, P1675; Candotti F, 2000, PEDIATR CLIN N AM, V47, P1389, DOI 10.1016/S0031-3955(05)70277-7; CANO F, 1990, J ALLERGY CLIN IMMUN, V85, P510, DOI 10.1016/0091-6749(90)90163-X; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; CONLEY ME, 1985, J IMMUNOL, V134, P3070; Conley ME, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P285; CONLEY ME, 1986, J PEDIATR-US, V108, P915, DOI 10.1016/S0022-3476(86)80927-1; CONLEY ME, 1981, NEW ENGL J MED, V305, P495, DOI 10.1056/NEJM198108273050905; COOPER MD, 1972, AM J PATHOL, V69, P513; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Cunningham-Rundles C, 2001, CLIN IMMUNOL, V100, P181, DOI 10.1006/clim.2001.5052; Cunningham-Rundles C, 2001, J CLIN IMMUNOL, V21, P303, DOI 10.1023/A:1012241117984; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUNNINGHAMRUNDLES C, 1987, J CLIN IMMUNOL, V7, P294, DOI 10.1007/BF00915550; CUNNINGHAMRUNDLES C, 1988, IMMUNOL ALLERGY CLIN, V8, P17; Depiero A, 2001, J ALLERGY CLIN IMMUN, V107, P1051, DOI 10.1067/mai.2001.115094; EISENSTEIN EM, 1994, J IMMUNOL, V152, P5957; FACCHETTI F, 1995, J IMMUNOL, V154, P6624; FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099; FEARON ER, 1987, NEW ENGL J MED, V316, P427, DOI 10.1056/NEJM198702193160802; FERRANTE A, 1990, PEDIATR INFECT DIS J, V9, pS16; FILIPOVICH AH, 1991, EOS-RIV IMMUNOL, V11, P43; FUDENBERG H, 1971, PEDIATRICS, V47, P927; GANDHI A, 1993, ALLERGY PROC, V14, P37, DOI 10.2500/108854193778816833; GEHA RS, 1974, NEW ENGL J MED, V291, P1, DOI 10.1056/NEJM197407042910101; GOOD RA, 1960, AM J MED, V29, P804, DOI 10.1016/0002-9343(60)90114-5; GOTOFF SP, 1972, AM J DIS CHILD, V123, P53, DOI 10.1001/archpedi.1972.02110070103015; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; GRYBOSKI JD, 1968, PEDIATRICS, V42, P833; Hammarstrom L, 2000, CLIN EXP IMMUNOL, V120, P225, DOI 10.1046/j.1365-2249.2000.01131.x; Heneghan MA, 1997, J CLIN GASTROENTEROL, V25, P421, DOI 10.1097/00004836-199709000-00004; HERMANS PE, 1966, AM J MED, V40, P78, DOI 10.1016/0002-9343(66)90189-6; HERMANS PE, 1976, AM J MED, V61, P221, DOI 10.1016/0002-9343(76)90173-X; HERROD HG, 1989, J CLIN IMMUNOL, V9, P429, DOI 10.1007/BF00917109; INSEL RA, 1988, MONOGR ALLERGY, V23, P128; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; JANEWAY C, 1956, T ASSOC AM PHYSICIAN, V69, P63; JORUPRONSTROM C, 1989, INFECTION, V17, P301, DOI 10.1007/BF01650712; KRAAKMAN MEM, 1999, CLIN GENET, V48, P464; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9; Matsuuchi L, 2001, CURR OPIN IMMUNOL, V13, P270, DOI 10.1016/S0952-7915(00)00215-6; MCGEADY SJ, 1987, J PEDIATR-US, V110, P47, DOI 10.1016/S0022-3476(87)80286-X; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; Mechanic LJ, 1997, ANN INTERN MED, V127, P613, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00005; MIGONE N, 1984, P NATL ACAD SCI-BIOL, V81, P5811, DOI 10.1073/pnas.81.18.5811; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; Minegishi Y, 2000, CLIN IMMUNOL, V97, P203, DOI 10.1006/clim.2000.4956; MOHIUDDIN AA, 1991, J ALLERGY CLIN IMMUN, V87, P104, DOI 10.1016/0091-6749(91)90219-E; MORELL A, 1972, J IMMUNOL, V108, P195; MORELL A, 1990, PEDIATR INFECT DIS J, V9, pS4; NELL PA, 1972, PEDIATRICS, V49, P71; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; OLIVA A, 1995, J ALLERGY CLIN IMMUN, V96, P403, DOI 10.1016/S0091-6749(95)70060-9; ONEIL KM, 1988, J INFECT DIS, V157, P183, DOI 10.1093/infdis/157.1.183; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; OXELIUS VA, 1979, CLIN EXP IMMUNOL, V36, P112; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PAROLINI O, 1993, GENOMICS, V15, P342, DOI 10.1006/geno.1993.1066; PETERSON RD, 1964, LANCET, V1, P1189; Plebani A, 1986, Monogr Allergy, V20, P171; PROESMANS W, 1976, LANCET, V2, P804; Puck JM, 2000, CLIN IMMUNOL, V97, P191, DOI 10.1006/clim.2000.4973; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Quartier P, 1999, J PEDIATR-US, V134, P589, DOI 10.1016/S0022-3476(99)70246-5; REINHERZ EL, 1981, NEW ENGL J MED, V304, P811, DOI 10.1056/NEJM198104023041403; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; ROIFMAN CM, 1986, AM J MED, V80, P590, DOI 10.1016/0002-9343(86)90812-0; ROIFMAN CM, 1987, LANCET, V1, P1075; SCHAFFER F M, 1991, Immunodeficiency Reviews, V3, P15; SCHAFFER FM, 1989, P NATL ACAD SCI USA, V86, P8015, DOI 10.1073/pnas.86.20.8015; Schroeder HW, 2000, CLIN REV ALLERG IMMU, V19, P127, DOI 10.1385/CRIAI:19:2:127; SCHROEDER HW, 2001, CLIN IMMUNOLOGY PRIN; SCHUR PH, 1979, PEDIATR RES, V13, P181, DOI 10.1203/00006450-197903000-00010; SCHUR PH, 1970, NEW ENGL J MED, V283, P631, DOI 10.1056/NEJM197009172831205; SEAGER J, 1975, LANCET, V2, P632; SHACKELFORD PG, 1990, PEDIATR RES, V27, P16, DOI 10.1203/00006450-199001000-00004; SHAPIRO GG, 1991, PEDIATRICS, V87, P311; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; SNELLER MC, 1990, J IMMUNOL, V144, P3762; SODERSTROM T, 1987, INT ARCH ALLER A IMM, V82, P476, DOI 10.1159/000234258; STANLEY PJ, 1984, CLIN EXP IMMUNOL, V58, P703; STEWART J M, 1970, Journal of Medical Genetics, V7, P11, DOI 10.1136/jmg.7.1.11; STIEHM ER, 1966, PEDIATRICS, V37, P715; Stiehm ER, 1989, IMMUNOLOGIC DISORDER, P157; STROBER W, 1991, ANN ALLERGY, V66, P363; Thampakkul S, 2001, IMMUNOL ALLERGY CLIN, V21, P165, DOI 10.1016/S0889-8561(05)70198-3; TILLER TL, 1978, J PEDIATR-US, V92, P347, DOI 10.1016/S0022-3476(78)80417-X; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Vihinen M, 1998, NUCLEIC ACIDS RES, V26, P242, DOI 10.1093/nar/26.1.242; VOLANAKIS JE, 1992, J CLIN INVEST, V89, P1914, DOI 10.1172/JCI115797; Vorechovsky I, 1997, HUM MUTAT, V9, P418; VYAS GN, 1968, LANCET, V2, P312; WALDMANN TA, 1974, LANCET, V2, P609; Wienands J, 2000, IMMUNOBIOLOGY, V202, P120, DOI 10.1016/S0171-2985(00)80059-5; WILFERT CM, 1977, NEW ENGL J MED, V296, P1485, DOI 10.1056/NEJM197706302962601; WRIGHT PF, 1977, J PEDIATR-US, V91, P408, DOI 10.1016/S0022-3476(77)81309-7; Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003; YOUNT WJ, 1970, J CLIN INVEST, V49, P1957, DOI 10.1172/JCI106415; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	115	174	197	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					581	591		10.1067/mai.2002.122466	http://dx.doi.org/10.1067/mai.2002.122466			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941303				2022-12-18	WOS:000175132600001
J	Pizzichini, E; Pizzichini, MMM; Efthimiadis, A; Dolovich, J; Hargreave, FE				Pizzichini, E; Pizzichini, MMM; Efthimiadis, A; Dolovich, J; Hargreave, FE			Measuring airway inflammation in asthma: Eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						induced sputum; eosinophils; eosinophilic cationic protein; airway inflammation; asthma	BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE; COUNTS	Background: Airway eosinophilic inflammation is a characteristic feature of asthma. This can be assessed directly by measurement of eosinophils and eosinophilic cationic protein (ECP) in sputum or indirectly by measurement of the same markers in blood. We investigated the performance of these markers of airway eosinophilic inflammation in a population of patients with asthma compared with control subjects and the extent to which the markers differed. Methods: In a cross-sectional study, subject characteristics were documented on day 1 and induced sputum and blood samples were obtained on day 2. Nineteen patients with asthma and 20 control subjects (10 heathy subjects and 10 smokers with nonobstructive bronchitis) were consecutively enrolled in the study. Sputum (selected from saliva) and blood samples were processed by persons blind to the clinical details. Results are presented as median values (minimum-maximum); differences were measured by Mann-Whitney U test. The accuracy of the tests (sensitivity and specificity) was measured by plotting the data in receiver-operating characteristic (ROC) curves and comparing the areas under the curve for each marker. Results: Patients with asthma in comparison with control subjects had a higher proportion of sputum eosinophils (5.2% [0.2% to 93%] vs 0.3% [O% to 1.7%],p < 0.001), higher numbers of blood eosinophils (350.0 x 10(6)/L [144.0 to 1520.0 x 10(6)/L] vs 155.0 x 10(6)/L; [34.0 to 426.0 x 10(6)/L,], p = 0.003), and higher levels of ECP in sputum (1040.0 mu g/L [76.8 to 32,000.0 mu g/L] vs 455.3 mu g/L [54.4 to 1280.0 mu g/L], p = 0.001) but not in serum (25.0 mu g/L [5.6 to 52.4 mu g/L] vs 16.5 mu g/L [3.3 to 36.0 mu g/L],p = 0.08), Markers of airway inflammation in induced sputum and blood samples were correlated with clinical and physiologic variables. The area under the ROC curve showed that eosinophils in sputum (0.90) are significantly more accurate markers than blood eosinophils (0.72) and serum ECP (0.67) (p = 0.02). Although the area under the ROC curve for sputum ECP was greater than those for blood eosinophils and serum ECP, the differences could have occurred by chance (p greater than or equal to 0.1). Conclusion: We conclude that the proportion of eosinophils in sputum is a more accurate marker of asthmatic airway inflammation than the proportions of blood eosinophils or serum ECP.	ST JOSEPHS HOSP, FIRESTONE REG CHEST & ALLERGY UNIT, ASTHMA RES GRP, DEPT MED, HAMILTON, ON L8N 4A6, CANADA; ST JOSEPHS HOSP, FIRESTONE REG CHEST & ALLERGY UNIT, ASTHMA RES GRP, DEPT PEDIAT, HAMILTON, ON L8N 4A6, CANADA; MCMASTER UNIV, HAMILTON, ON, CANADA	McGill University; McMaster University; McGill University; McMaster University; McMaster University			Pizzichini, Emilio/L-2252-2014; Pizzichini, Marcia/K-5168-2013	Pizzichini, Emilio/0000-0001-7046-9996; Pizzichini, Marcia/0000-0001-7409-7536; Pizzichini, Marcia/0000-0001-6336-7203				ADOLPHSON CR, 1993, ALLERGY; ALTMAN DG, 1994, BRIT MED J, V309, P188, DOI 10.1136/bmj.309.6948.188; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DAHL R, 1993, ALLERGY, V48, P77, DOI 10.1111/j.1398-9995.1993.tb04704.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; EFTHIMIADIS A, 1997, IN PRESS EUR RESP J; Ernst P, 1996, CAN RESPIR J, V3, P89; FEATHER IH, 1995, ASTHMA RHINITIS, P347; FRETTE C, 1991, AM REV RESPIR DIS, V143, P987, DOI 10.1164/ajrccm/143.5_Pt_1.987; Gollash H., 1889, FORTSCHR MED, V7, P361; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; Juniper E, 1994, HISTAMINE METHACHOLI; KILLIAN KJ, 1993, EUR RESPIR J, V6, P1004; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; MARTIN TR, 1985, AM REV RESPIR DIS, V132, P254; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Pizzichini MMM, 1996, AM J RESP CRIT CARE, V154, P866, DOI 10.1164/ajrccm.154.4.8887576; PIZZICHINI MMM, 1997, IN PRESS AM J RESP C; POPOV T, 1994, CLIN EXP ALLERGY, V24, P778, DOI 10.1111/j.1365-2222.1994.tb00990.x; POPOV TA, 1995, EUR RESPIR J, V8, P559; SCADDING JG, 1983, ASTHMA, P2; SCHAUER U, 1995, ALLERGY, V50, P126; SUGAI T, 1992, CLIN EXP ALLERGY, V22, P275, DOI 10.1111/j.1365-2222.1992.tb03083.x; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; ULRIK CS, 1995, CLIN EXP ALLERGY, V25, P820, DOI 10.1111/j.1365-2222.1995.tb00024.x; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	35	174	178	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					539	544		10.1016/S0091-6749(97)70082-4	http://dx.doi.org/10.1016/S0091-6749(97)70082-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111500	Bronze			2022-12-18	WOS:A1997WU27400018
J	SWANSON, MC; BUBAK, ME; HUNT, LW; YUNGINGER, JW; WARNER, MA; REED, CE				SWANSON, MC; BUBAK, ME; HUNT, LW; YUNGINGER, JW; WARNER, MA; REED, CE			QUANTIFICATION OF OCCUPATIONAL LATEX AEROALLERGENS IN A MEDICAL-CENTER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX ALLERGY; GLOVE SENSITIVITY LATEX AEROALLERGEN; OCCUPATIONAL LATEX AEROALLERGEN; LATEX ALLERGEN AIR SAMPLING	PROTEINS; ANAPHYLAXIS; ANTIGENS	To determine the quantity, variability and mean aerodynamic diameter of latex aeroallergens in a large medical center we collected air samples from work sites by using area and personal breathing zone air samples, and we measured latex allergens by an inhibition assay with IgE antibodies from latex-sensitive individuals. Latex aeroallergen concentrations in 11 areas where powdered latex gloves were frequently used ranged from 13 to 208 ng/m(3), and in areas where powdered latex gloves were never or seldom used, concentrations ranged from 0.3 to 1.8 ng/m(3). Installation and use of a laminar flow glove changing station in one work area did not reduce latex aeroallergen levels. Large quantities of allergen were recovered from used laboratory coats and anesthesia scrub suits and from laboratory surfaces. Later allergen concentrations in personal breathing zone samplers worn by health care workers in areas where powdered gloves were frequently used ranged from 8 to 974 ng/m(3). Exposure likely occurs when gloves are changed and as a result of resuspension from reservoirs of powder in the room and clothing. Latex allergens were found in all particle sizes but were predominant in particles greater than 7 mu m in mass median aerodynamic diameter. Results of electrophoretic immunoblotting showed that the aeroallergens are primarily the higher molecular mass components of the latex glove proteins. Measures to control exposure can be monitored by both area and personal air sampling with this immunochemical approach. Use of gloves with low allergen content or powder-free gloves appears to be more effective than use of a laminar flow glove changing station in reducing aeroallergen levels.	MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT ANESTHESIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021255] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21255] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; CAMPBELL AR, 1989, AM REV RESPIR DIS, V140, P317, DOI 10.1164/ajrccm/140.2.317; CHAMBEYRON C, 1992, ALLERGY, V47, P92, DOI 10.1111/j.1398-9995.1992.tb05094.x; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIBACH HI, 1988, ALLERGY PRINCIPLES P, P1429; OWABY DR, 1991, AJR AM J ROENTGENOL, V156, P983; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SWANSON MC, 1992, AM IND HYG ASSOC J, V53, P1; SWANSON MC, 1990, AM REV RESPIR DIS, V141, P1578, DOI 10.1164/ajrccm/141.6.1578; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURJANMAA K, 1988, ACTA U TAMPERENSIS A, V254, P18; WARPINSKI JR, 1991, ALLERGY PROC, V12, P95, DOI 10.2500/108854191779011846; 1990, JAMA-J AM MED ASSOC, V264, P2863	17	174	177	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				445	451		10.1016/0091-6749(94)90199-6	http://dx.doi.org/10.1016/0091-6749(94)90199-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083449				2022-12-18	WOS:A1994PG90700002
J	DURHAM, SR; LEE, TH; CROMWELL, O; SHAW, RJ; MERRETT, TG; MERRETT, J; COOPER, P; KAY, AB				DURHAM, SR; LEE, TH; CROMWELL, O; SHAW, RJ; MERRETT, TG; MERRETT, J; COOPER, P; KAY, AB			IMMUNOLOGICAL STUDIES IN ALLERGEN-INDUCED LATE-PHASE ASTHMATIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,INST CARDIOTHORAC,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6HP,ENGLAND; BENENDEN CHEST HOSP,RAST ALLERGY UNIT,BENENDEN,KENT,ENGLAND; BROMPTON HOSP,DEPT PAEDIAT,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital; Royal Brompton Hospital				Lee, Tak/0000-0002-7554-4059				ALLEN DH, 1979, CHEST, V75, P235; ALTOUNYAN REC, 1969, DISODIUM CROMOGLYCAT, P47; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS PC, 1981, J ALLERGY CLIN IMMUN, V68, P286, DOI 10.1016/0091-6749(81)90153-6; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DORSCH W, 1982, J ALLERGY CLIN IMMUN, V70, P236, DOI 10.1016/0091-6749(82)90059-8; GWYNN CM, 1982, LANCET, V2, P1339; GWYNN CM, 1982, LANCET, V1, P254; HUTCHCROFT BJ, 1978, CLIN ALLERGY, V8, P59, DOI 10.1111/j.1365-2222.1978.tb00448.x; JANOFF A, 1965, J EXP MED, V122, P841, DOI 10.1084/jem.122.5.841; KAUFFMAN HF, 1983, CLIN ALLERGY, V13, P219, DOI 10.1111/j.1365-2222.1983.tb02591.x; KELLY MT, 1971, J CLIN INVEST, V50, P1044, DOI 10.1172/JCI106575; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1982, LANCET, V2, P1048; LEE TH, 1984, AM REV RESPIR DIS, V129, P409; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MERRETT J, 1983, CLIN ALLERGY, V13, P397, DOI 10.1111/j.1365-2222.1983.tb02615.x; MILFORDWARD A, 1980, TECHNIQUES CLIN IMMU; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; ODRISCOLL BRC, 1983, J ALLERGY CLIN IMMUN, V72, P695, DOI 10.1016/0091-6749(83)90632-2; PEPYS J, 1968, LANCET, V2, P134; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1968, ALLERGOLOGY INT C SE, V162, P221; PRICE JF, 1982, CLIN EXP IMMUNOL, V47, P587; RANADIVE NS, 1968, J EXP MED, V128, P605, DOI 10.1084/jem.128.4.605; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SCHERER J, 1968, LAB INVEST, V18, P196; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; WARNER JO, 1978, LANCET, V2, P912; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	43	174	174	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					49	60		10.1016/0091-6749(84)90086-1	http://dx.doi.org/10.1016/0091-6749(84)90086-1			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6736483	Bronze			2022-12-18	WOS:A1984SZ64800007
J	Dworski, R; Simon, HU; Hoskins, A; Yousefi, S				Dworski, Ryszard; Simon, Hans-Uwe; Hoskins, Aimee; Yousefi, Shida			Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic asthma; bronchoalveolar lavage fluid; biomarker; eosinophils; extracellular DNA traps; human; neutrophils	BRONCHIAL EPITHELIUM; INDUCED SPUTUM; CELLS; EXPRESSION; INTERLEUKIN-5; MEPOLIZUMAB; ACTIVATE; DAMAGE	Background: Asthma is a heterogeneous inflammatory airway disorder that involves eosinophilic and noneosinophilic phenotypes. Unlike in healthy lungs, eosinophils are often present in atopic asthmatic airways, although a subpopulation of asthmatic subjects predominantly experience neutrophilic inflammation. Recently, it has been demonstrated that eosinophils and neutrophils generate bactericidal extracellular traps consisting of DNA and cytotoxic granule proteins. Objective: We sought to explore whether living eosinophils and neutrophils infiltrating human atopic asthmatic airways actively form extracellular DNA traps in vivo. Methods: Quantitative analysis of eosinophils releasing DNA was performed in endobronchial biopsy specimens from 20 human subjects with mild atopic asthma at baseline and after local allergen challenge and 10 healthy subjects. DNA was stained with propidium iodine and major basic protein with specific antibody. Differential cell counts and cytokines/chemokines were assessed in bronchoalveolar lavage fluid. Results: Asthmatic airways were infiltrated with a significantly higher number of eosinophils than healthy airways (39.3 +/- 4.6 vs 0.4 +/- 0.9, P < .0001). All asthmatic subjects but only 1 control subject expressed eosinophils releasing DNA that colocalized with major basic protein (33.65 +/- 20.33 vs 0.3 +/- 0.9 per high-power field, P < .0001). Four asthmatic subjects mostly expressed neutrophilic inflammation and neutrophil DNA traps. Allergen challenge had no significant quantitative effect on eosinophil or neutrophil DNA traps. Airway eosinophils or DNA traps did not correlate with either bronchoalveolar lavage levels of IL-5, IFN-gamma, or eotaxin or the provoking doses of methacholine or allergen in asthmatic subjects. Conclusions: Extracellular DNA traps are generated by eosinophils and neutrophils in human atopic asthmatic airways in vivo. The mechanism and role of this new finding will necessitate further investigation. (J Allergy Clin Immunol 2011;127:1260-6.)	[Dworski, Ryszard] Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Sch Med, Nashville, TN 37232 USA; [Simon, Hans-Uwe; Yousefi, Shida] Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland	Vanderbilt University; University of Bern	Dworski, R (corresponding author), Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Sch Med, T-1218 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	ryszard.dworski@vanderbilt.edu; shida.yousefi@pki.unibe.ch	Yousefi, Shida/L-9689-2016; Simon, Hans-Uwe/AAU-5079-2020; Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-7410-2020	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736	National Institutes of Health [K23 HL080030-02, M01 RR 00095, CA102353]; Swiss National Science Foundation; NATIONAL CANCER INSTITUTE [R01CA102353] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL080030] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the National Institutes of Health (K23 HL080030-02, M01 RR 00095, and CA102353) and the Swiss National Science Foundation.	BRICKMANN V, 2004, SCIENCE, V303, P1532; CAMPBELL AM, 1993, AM REV RESPIR DIS, V147, P529, DOI 10.1164/ajrccm/147.3.529; Cockcroft DW, 2005, ALLERGY, V60, P56, DOI 10.1111/j.1398-9995.2004.00612.x; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Haldar P, 2007, J ALLERGY CLIN IMMUN, V119, P1043, DOI 10.1016/j.jaci.2007.02.042; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Imaoka H, 2009, AM J RESP CRIT CARE, V179; Jacobsen EA, 2007, J ALLERGY CLIN IMMUN, V119, P1313, DOI 10.1016/j.jaci.2007.03.043; Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MONTEFORT S, 1993, CLIN EXP ALLERGY, V23, P185, DOI 10.1111/j.1365-2222.1993.tb00880.x; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; *NAT ASTHM ED PREV, 2007, PUBL NIH; Pegorier S, 2006, J IMMUNOL, V177, P4861, DOI 10.4049/jimmunol.177.7.4861; Ravensberg AJ, 2005, J ALLERGY CLIN IMMUN, V115, P779, DOI 10.1016/j.jaci.2004.11.045; Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Saha S, 2009, THORAX, V64, P671, DOI 10.1136/thx.2008.108290; Simpson A, 2010, CLIN EXP ALLERGY, V40, P209, DOI 10.1111/j.1365-2222.2009.03391.x; Straumann A, 2010, GASTROENTEROLOGY, V139, P1526, DOI 10.1053/j.gastro.2010.07.048; von Kockritz-Blickwede M, 2009, J MOL MED, V87, P775, DOI 10.1007/s00109-009-0481-0; von Kockritz-Blickwede M, 2008, BLOOD, V111, P3070, DOI 10.1182/blood-2007-07-104018; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Yang D, 2008, J EXP MED, V205, P79, DOI 10.1084/jem.20062027; Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855	33	173	187	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1260	1266		10.1016/j.jaci.2010.12.1103	http://dx.doi.org/10.1016/j.jaci.2010.12.1103			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21315435	Green Accepted			2022-12-18	WOS:000290018600022
J	Blanchard, C; Stucke, EM; Rodriguez-Jimenez, B; Burwinkel, K; Collins, MH; Ahrens, A; Alexander, ES; Buckmeier, BK; Jameson, SC; Kaul, A; Franciosi, JP; Kushner, JP; Putnam, PE; Abonia, JP; Rothenberg, ME				Blanchard, Carine; Stucke, Emily M.; Rodriguez-Jimenez, Beatriz; Burwinkel, Karen; Collins, Margaret H.; Ahrens, Annette; Alexander, Eileen S.; Buckmeier, Bridget K.; Jameson, Sean C.; Kaul, Ajay; Franciosi, James P.; Kushner, Jonathan P.; Putnam, Philip E.; Abonia, J. Pablo; Rothenberg, Marc E.			A striking local esophageal cytokine expression profile in eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; eosinophils; cytokines; biomarkers; eotaxin-3/CCL26; allergy	EOTAXIN-3/CCL26 GENE-EXPRESSION; HISTOPATHOLOGIC VARIABILITY; IL-13; PATHOGENESIS; CHILDREN; THERAPY; DISEASE; ADULTS; CELLS	Background: Eosinophilic esophagitis (EE) is an emerging worldwide disease that mimics gastroesophageal reflux disease. Objective: Early studies have suggested that esophageal eosinophilia occurs in association with T(H)2 allergic responses, yet the local and systemic expression of relevant cytokines has not been well characterized. Methods: A human inflammatory cytokine and receptor PCR array containing 84 genes followed by PCR validation and multiplex arrays were used to quantify cytokine mRNA in esophageal biopsies and blood samples. Results: Esophageal transcripts of numerous chemokines (eg, chemokine [C-C motif] ligand [CCL] 1, CCL1, CCL23, CCL26 [eotaxin-3], chemokine [C-X-C motif] ligand [CXCL] 1, and CXCL2), cytokines (eg, IL13 and ATP-binding cassette, subfamily F, member 1), and cytokine receptors (eg, IL5 receptor, alpha) were induced at least 4-fold in individuals with EE. Analysis of esophageal biopsies (n = 288) revealed that eotaxin-3 mRNA level alone had 89% sensitivity for distinguishing individuals with and without EE. The presence of allergy was associated with significantly increased esophageal expression of IL4 and IL5 mRNA in patients with active EE. We identified 8 cytokines (IL-4, IL-13, IL-5, IL-6, IL-12p70, CD40 ligand, IL-1 alpha, and IL-17) whose blood levels retrospectively distinguished 12 patients without EE from 13 patients with EE with 100% specificity and 100% sensitivity. When applied to a blind, prospectively recruited group of 36 patients, the cytokine panel scoring system had a 79% positive predictive value, 68% negative predictive value, 61% sensitivity, and 83% specificity for identifying EE. Conclusion: Evidence is presented that IL13 and IL5 associate with eosinophil and eotaxin-3 levels, indicating the key role of adaptive T(H)2 immunity in regulating eotaxin-3-driven esophageal eosinophilia in the absence of a consistent systemic change in cytokines. (J Allergy Clin Immunol 2011;127:208-17.)	[Blanchard, Carine; Stucke, Emily M.; Rodriguez-Jimenez, Beatriz; Burwinkel, Karen; Ahrens, Annette; Buckmeier, Bridget K.; Jameson, Sean C.; Abonia, J. Pablo; Rothenberg, Marc E.] Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Collins, Margaret H.] Cincinnati Childrens Hosp, Med Ctr, Div Pathol & Lab Med, Cincinnati, OH 45229 USA; [Kaul, Ajay; Franciosi, James P.; Putnam, Philip E.] Cincinnati Childrens Hosp, Med Ctr, Div Gastroenterol Hepatol & Nutr, Dept Pediat, Cincinnati, OH 45229 USA; [Alexander, Eileen S.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Rodriguez-Jimenez, Beatriz] Hosp Clin San Carlos, Madrid, Spain	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Hospital Clinico San Carlos	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org		Abonia, Juan/0000-0003-3788-6485; Alexander, Eileen/0000-0002-6548-489X	Thrasher Research Fund [NR-0014]; APFED HOPE research grant; Pilot and Feasibility Program PHS [P30 DK0789392]; NIH [AI079874-01, AI070235, AI045898, DK076893]; Cincinnati Children's Translational Research Initiative; Food Allergy and Anaphylaxis Network; Campaign Urging Research for Eosinophilic Disorders (CURED); Buckeye Foundation; Food Allergy Project/Food Allergy Initiative; National Institutes of Health; American Partnership for Eosinophilic Disorders; Ception Therapeutics; Children's Digestive Health and Nutrition Foundation; Dana Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI045898, R21AI079874, R01AI083450, R01AI045898, U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392, R01DK076893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [Z01NR000014] Funding Source: NIH RePORTER	Thrasher Research Fund; APFED HOPE research grant; Pilot and Feasibility Program PHS; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cincinnati Children's Translational Research Initiative; Food Allergy and Anaphylaxis Network; Campaign Urging Research for Eosinophilic Disorders (CURED); Buckeye Foundation; Food Allergy Project/Food Allergy Initiative; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Partnership for Eosinophilic Disorders; Ception Therapeutics; Children's Digestive Health and Nutrition Foundation; Dana Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Supported in part by the Thrasher Research Fund NR-0014 (C. B.); the 2009 APFED HOPE research grant (C. B.); the Pilot and Feasibility Program PHS Grant P30 DK0789392 (C. B.); NIH AI079874-01 (C. B.), AI070235 (M. E. R.), AI045898 (M. E. R.), and DK076893 (M. E. R.); the Cincinnati Children's Translational Research Initiative grant (M. E. R); the Food Allergy and Anaphylaxis Network (M. E. R.); Campaign Urging Research for Eosinophilic Disorders (CURED) (M. E. R.); the Buckeye Foundation (M. E. R.); and the Food Allergy Project/Food Allergy Initiative (M. E. R).; C. Blanchard receives research support from the National Institutes of Health and the American Partnership for Eosinophilic Disorders. M. H. Collins has consultant arrangements with GlaxoSmithKline, Ception Therapeutics (Cephalon), and Meritage Pharma and is a member of the Medical Advisory Panel for the American Partnership for Eosinophilic Disorders. J. P. Abonia receives research support from the National Institutes of Health, Ception Therapeutics, and the Children's Digestive Health and Nutrition Foundation. M. E. Rothenberg is a speaker for Merck; has consultant arrangements with Merck, Centocor, Ception Therapeutics, Array Biopharma, Biocrystal Pharmaceuticals, Endo Pharmaceuticals, and Pieres AG; receives research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Dana Foundation; is on the Medical Advisory Board for the American Partnership for Eosinophilic Disorders; and is on the Executive Council for the International Eosinophil Society. The rest of the authors have declared that they have no conflict of interest.	Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Bhattacharya B, 2007, HUM PATHOL, V38, P1744, DOI 10.1016/j.humpath.2007.05.008; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2005, INT J BIOCHEM CELL B, V37, P2559, DOI 10.1016/j.biocel.2005.06.010; Blanchard Carine, 2008, Gastrointest Endosc Clin N Am, V18, P133, DOI 10.1016/j.giec.2007.09.016; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blanchard C, 2006, J ALLERGY CLIN IMMUN, V118, P1054, DOI 10.1016/j.jaci.2006.07.038; Bullock JZ, 2007, J PEDIATR GASTR NUTR, V45, P22, DOI 10.1097/MPG.0b013e318043c097; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gonsalves N, 2006, GASTROINTEST ENDOSC, V64, P313, DOI 10.1016/j.gie.2006.04.037; Gupta SK, 2006, J PEDIATR GASTR NUTR, V42, P22, DOI 10.1097/01.mpg.0000188740.38757.d2; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Liacouras Chris A, 2007, J Pediatr Gastroenterol Nutr, V45, P370; Lucendo AJ, 2008, AM J GASTROENTEROL, V103, P2184, DOI 10.1111/j.1572-0241.2008.01937.x; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; Novak H, 2007, J IMMUNOL, V178, P4335, DOI 10.4049/jimmunol.178.7.4335; Ozawa S, 2009, BIOMED RES-TOKYO, V30, P315, DOI 10.2220/biomedres.30.315; Ozawa S, 2009, CANCER SCI, V100, P2202, DOI 10.1111/j.1349-7006.2009.01281.x; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Shah AA, 2009, AM J GASTROENTEROL, V104, P716, DOI 10.1038/ajg.2008.117; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Yamazaki K, 2006, DIGEST DIS SCI, V51, P1934, DOI 10.1007/s10620-005-9048-2	28	173	192	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					208	U341		10.1016/j.jaci.2010.10.039	http://dx.doi.org/10.1016/j.jaci.2010.10.039			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211656	Green Accepted			2022-12-18	WOS:000285917300030
J	Nelson, HS; Chapman, KR; Pyke, SD; Johnson, M; Pritchard, JN				Nelson, HS; Chapman, KR; Pyke, SD; Johnson, M; Pritchard, JN			Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fluticasone propionate; salmeterol; synergy; asthma; Advair/Seretide; combination therapy	SALMETEROL/FLUTICASONE PROPIONATE; MU-G; COMBINATION THERAPY; ASTHMA CONTROL; BUDESONIDE; MODERATE; BETA(2)-AGONISTS; METAANALYSIS; FORMOTEROL; DEVICE	Background: The coadministration of long-acting inhaled beta(2)-agonists and inhaled corticosteroids is the most effective treatment for persistent asthma. Objective: This meta-analysis aimed to determine the efficacy of fluticasone propionate and salmeterol inhaled from a single inhaler (combination therapy) or from separate inhalers (concurrent therapy). Methods: Four similarly designed double-blind studies individually confirmed equivalence between combination and concurrent therapy on the basis of the primary efficacy measure (morning peak expiratory flow [PEF]). Each study showed a consistent trend in favor of combination therapy. Individual patient data from these studies were combined to provide overall estimates of treatment effect for morning PEF and other efficacy measures. Results: Fixed-effects meta-analysis showed a significant advantage for combination therapy compared with concurrent therapy in morning PEF (mean difference between groups in change from baseline over 12 weeks of 5.4 L/min; P = .006; 95% CI = 1.5-9.2). Logistic regression analysis showed that the odds of achieving a greater than 15 or greater than 30 L/min improvement with combination therapy were increased by approximately 40% compared with those after concurrent therapy (15 L/min: odds ratio = 1.42, P = .008, 95% CI = 1.1-1.8; 30 L/min: odds ratio = 1.40, P = .006, 95% CI = 1.1-1.8), representing an additional 7% to 9% and 5% to 14% more patients, respectively, on combination therapy responding compared with those on concurrent therapy. Conclusion: The meta-analysis indicates that the fluticasone propionate plus salmeterol combination offers the potential for increased clinical efficacy over concurrent use of the same doses of the same 2 drugs. After administration from a single inhaler, fluticasone propionate and salmeterol might codeposit in the airways. It is hypothesized that this codeposition offers an increased opportunity for synergistic interaction to occur.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Hlth Network, Asthma & Airway Ctr, Toronto, ON, Canada; GlaxoSmithKline, Greenford, Middx, England	National Jewish Health; University of Toronto; University Toronto Affiliates; University Health Network Toronto; GlaxoSmithKline	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.			Pritchard, John/0000-0003-1050-5996				Anenden V., 1998, European Respiratory Journal, V12, p157S; ASHURST IC, 1998, EUR RESPIR J, V15, pS93; Aubier M, 1999, RESP MED, V93, P876, DOI 10.1016/S0954-6111(99)90053-7; Baraniuk JN, 1997, AM J RESP CRIT CARE, V155, P704, DOI 10.1164/ajrccm.155.2.9032216; Barnes PJ, 2002, EUR RESPIR J, V19, P182, DOI 10.1183/09031936.02.00283202; Bateman ED, 1998, CLIN DRUG INVEST, V16, P193, DOI 10.2165/00044011-199816030-00003; Calhoun WJ, 2001, AM J RESP CRIT CARE, V164, P759, DOI 10.1164/ajrccm.164.5.2012124; Chapman K R, 1999, Can Respir J, V6, P45; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dowling RB, 1999, EUR RESPIR J, V14, P363, DOI 10.1034/j.1399-3003.1999.14b21.x; Frank C.J., 1999, ANAL APPL RAMAN SPEC, P224; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Jenkins C, 2000, RESP MED, V94, P715, DOI 10.1053/rmed.2000.0875; Johansson G, 2001, CLIN DRUG INVEST, V21, P633, DOI 10.2165/00044011-200121090-00005; Johnson M., 2002, CURR ALLERGY CLIN IM, V15, P16; JUNIPER EF, 1999, EUR RESPIR J, V14, pS370; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; Kirby S, 2001, EUR J CLIN PHARMACOL, V56, P781, DOI 10.1007/s002280000233; Korn SH, 2001, EUR RESPIR J, V17, P1070, DOI 10.1183/09031936.01.00073301; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; Malley T. R., 1998, European Respiratory Journal, V12, p8s; Matz J, 2001, J ALLERGY CLIN IMMUN, V107, P783, DOI 10.1067/mai.2001.114709; Michael Y, 2001, INT J PHARM, V221, P165, DOI 10.1016/S0378-5173(01)00678-0; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P1088, DOI 10.1067/mai.2000.110920; *NIH NAT HEART LUN, 1997, NIH PUBL; *NIH NAT HEART LUN, 2002, NIH PUBL; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117, DOI 10.1164/ajrccm.164.1.2006003; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Reese P. R., 1998, European Respiratory Journal, V12, p35S; Reese PR, 1999, J ALLERGY CLIN IMMUN, V103, pS69; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527, DOI 10.1164/ajrccm.161.2.9905091; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; SUECHU M, 1999, EUR RESPIR J, V14, pS124; USMANI O, 2002, AM J RESP CRIT CARE, V165, pA616; Van den Berg NJ, 2000, PEDIATR PULM, V30, P97, DOI 10.1002/1099-0496(200008)30:2<97::AID-PPUL4>3.0.CO;2-P; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Zetterstrom O, 2001, EUR RESPIR J, V18, P262, DOI 10.1183/09031936.01.00065801	40	173	184	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					29	36		10.1067/mai.2003.1558	http://dx.doi.org/10.1067/mai.2003.1558			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	14530795				2022-12-18	WOS:000184010600006
J	Wardlaw, AJ				Wardlaw, AJ			Molecular basis for selective eosinophil trafficking in asthma: A multistep paradigm	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						eosinophils; migration; adhesion; chemotaxis; asthma	CELL-ADHESION MOLECULE-1; MICROVASCULAR ENDOTHELIAL-CELLS; MONOCYTE CHEMOTACTIC PROTEIN-3; CHEMOKINE RECEPTOR CCR3; P-SELECTIN; ALLERGIC INFLAMMATION; TISSUE EOSINOPHILIA; ALPHA(4) INTEGRIN; BONE-MARROW; IN-VIVO	Asthma is characterized by a 50- to 100-fold increase in the number of eosinophils relative to neutrophils in the bronchial mucosa. This increase is not the result of a single molecular event but of the cumulative and sequential effects of several approximately 4-fold increases in selective eosinophil versus neutrophil migration, occurring at a number of stages in the Life cycle of the eosinophil, These steps include (1) effects on the bone marrow, mediated principally by IL-5, which result in a 4-fold increase in circulating eosinophils, (2) selective tethering of eosinophils to venular endothelium through the combined effects of P-selectin/P-selectin glycoprotein ligand 1 and very late activation antigen-4/vascular cell adhesion molecule-1, which has the potential for an up to 10-fold increase in eosinophil versus neutrophil adhesion, (3) selective chemotaxis under the influence of CC chemokines, and (4) prolonged survival, again mediated by IL-5, These events are integrated and directed by allergen-specific T(H)2 lymphocytes through the generation of IL-5, IL-4, and IL-13, The implications of this multistep process are that antagonists of IL-5, very late activation antigen-4, P-selectin glycoprotein ligand 1, and CCR3 as well as IL-4 and IL-13 each have the potential to markedly inhibit eosinophil recruitment in asthma.	Univ Leicester, Sch Med, Div Resp Med, Leicester, Leics, England	University of Leicester	Wardlaw, AJ (corresponding author), Glenfield Gen Hosp, Dept Resp Med, Groby Rd, Leicester LE3 9QP, Leics, England.			Wardlaw, Andrew/0000-0001-6583-0791				Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Beck LA, 1996, J ALLERGY CLIN IMMUN, V98, P766, DOI 10.1016/S0091-6749(96)70126-4; Blease K, 1998, AM J RESP CELL MOL, V18, P620, DOI 10.1165/ajrcmb.18.5.3052; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; Bochner BS, 1999, J ALLERGY CLIN IMMUN, V103, P527, DOI 10.1016/S0091-6749(99)70481-1; Bradding P, 1996, CLIN EXP ALLERGY, V26, P13, DOI 10.1111/j.1365-2222.1996.tb00051.x; Broide DH, 1998, AM J RESP CELL MOL, V18, P218, DOI 10.1165/ajrcmb.18.2.2829; Broide DH, 1998, BLOOD, V91, P2847, DOI 10.1182/blood.V91.8.2847.2847_2847_2856; BurkeGaffney A, 1996, BIOCHEM BIOPH RES CO, V227, P35, DOI 10.1006/bbrc.1996.1463; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chin JE, 1998, AM J RESP CELL MOL, V18, P158, DOI 10.1165/ajrcmb.18.2.2565m; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Coulin F, 1997, EUR J BIOCHEM, V248, P507, DOI 10.1111/j.1432-1033.1997.00507.x; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; Denburg JA, 1998, J ALLERGY CLIN IMMUN, V102, pS74, DOI 10.1016/S0091-6749(98)70034-X; DeSanctis GT, 1997, J APPL PHYSIOL, V83, P681, DOI 10.1152/jappl.1997.83.3.681; DiScipio RG, 1999, J IMMUNOL, V162, P1127; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747, DOI 10.1165/ajrcmb.19.5.3166; ERGER RA, 1995, AM J PHYSIOL-LUNG C, V268, pL117, DOI 10.1152/ajplung.1995.268.1.L117; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fukuda T, 1996, AM J RESP CELL MOL, V14, P84, DOI 10.1165/ajrcmb.14.1.8534490; Garlisi CG, 1999, AM J RESP CELL MOL, V20, P248, DOI 10.1165/ajrcmb.20.2.3327; Gerwin N, 1999, IMMUNITY, V10, P9, DOI 10.1016/S1074-7613(00)80002-3; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Grayson MH, 1998, J EXP MED, V188, P2187, DOI 10.1084/jem.188.11.2187; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hamilos DL, 1999, J ALLERGY CLIN IMMUN, V103, P79, DOI 10.1016/S0091-6749(99)70529-4; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Henriques GMO, 1996, BLOOD, V87, P5297, DOI 10.1182/blood.V87.12.5297.bloodjournal87125297; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; KAY AB, 1996, AM J CRIT CARE MED, V154, P566; Khew-Goodall Y, 1999, ARTERIOSCL THROM VAS, V19, P1421, DOI 10.1161/01.ATV.19.6.1421; Kitayama J, 1997, J IMMUNOL, V159, P3929; Kitayama J, 1998, J CLIN INVEST, V101, P2017, DOI 10.1172/JCI2688; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Li L, 1998, J IMMUNOL, V161, P3128; Li L, 1999, J IMMUNOL, V162, P2477; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461; Matsumoto K, 1997, J ALLERGY CLIN IMMUN, V99, P648, DOI 10.1016/S0091-6749(97)70027-7; McNulty CA, 1999, AM J RESP CELL MOL, V20, P1251, DOI 10.1165/ajrcmb.20.6.3531; Meagher LC, 1996, J IMMUNOL, V156, P4422; Minshall EM, 1998, AM J RESP CRIT CARE, V158, P951, DOI 10.1164/ajrccm.158.3.9709114; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Patel KD, 1999, J IMMUNOL, V162, P6209; Patel KD, 1998, BLOOD, V92, P3904, DOI 10.1182/blood.V92.10.3904.422k41_3904_3911; Patel VP, 1997, J EXP MED, V185, P1163, DOI 10.1084/jem.185.7.1163; Petering H, 1999, BLOOD, V93, P694, DOI 10.1182/blood.V93.2.694.402k31_694_702; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; Richards IM, 1996, AM J RESP CELL MOL, V15, P172, DOI 10.1165/ajrcmb.15.2.8703473; Robinson DS, 1999, AM J RESP CELL MOL, V20, P9, DOI 10.1165/ajrcmb.20.1.3449; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Sabroe I, 1999, J IMMUNOL, V162, P2946; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SEHMI R, 1991, J IMMUNOL, V147, P2276; SEHMI R, 1992, BLOOD, V79, P2952; SEHMI R, 1993, CLIN EXP ALLERGY, V23, P1027, DOI 10.1111/j.1365-2222.1993.tb00295.x; Shute JK, 1997, AM J RESP CRIT CARE, V155, P1877, DOI 10.1164/ajrccm.155.6.9196089; Simon HU, 1997, J IMMUNOL, V158, P3902; Sriramarao P, 1996, J IMMUNOL, V157, P4672; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; Stafford S, 1997, J IMMUNOL, V158, P4953; Strauss EC, 1999, INVEST OPHTH VIS SCI, V40, P1336; SYMON FA, 1994, J EXP MED, V180, P371, DOI 10.1084/jem.180.1.371; Symon FA, 1996, J IMMUNOL, V157, P1711; Taha RA, 1999, J ALLERGY CLIN IMMUN, V103, P476, DOI 10.1016/S0091-6749(99)70474-4; Teixeira MM, 1998, J IMMUNOL, V161, P2516; TERAN LM, AM J RESP CELL MOL B, V20, P777; Tsuyuki S, 1995, J CLIN INVEST, V96, P2924, DOI 10.1172/JCI118364; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Ulfman LH, 1999, J IMMUNOL, V163, P343; Wang J, 1998, J CLIN INVEST, V102, P1132, DOI 10.1172/JCI2686; Wardlaw A, 1998, ASTHMA: BASIC MECHANISMS AND CLINICAL MANAGEMENT, 3RD EDITION, P239, DOI 10.1016/B978-012079027-2/50095-2; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; WEBER M, 1995, J IMMUNOL, V154, P4166; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; WOLTMANN G, 1989, AM J RESP CRIT CARE, V159, pA20; Yamamoto H, 1998, J IMMUNOL, V161, P971; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; Yang Y, 1998, BLOOD, V92, P3912, DOI 10.1182/blood.V92.10.3912.422k23_3912_3923; Yao LB, 1996, J EXP MED, V184, P81, DOI 10.1084/jem.184.1.81; Zimmerman GA, 1997, J CLIN INVEST, V100, pS3	102	173	183	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					917	926		10.1016/S0091-6749(99)70069-2	http://dx.doi.org/10.1016/S0091-6749(99)70069-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550733	Bronze			2022-12-18	WOS:000083778400011
J	Weiler, JM; Layton, M; Hunt, M				Weiler, JM; Layton, M; Hunt, M			Asthma in United States Olympic athletes who participated in the 1996 Summer Games	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exercise-induced asthma; sports medicine	EXERCISE-INDUCED BRONCHOSPASM; PREVALENCE	Background: Asthma prevalence appears to he increasing in the general population. We sought to determine whether asthma prevalence has also increased in highly competitive athletes. Objective: Our aim was to determine how many United States Olympic athletes who were chosen to participate in the 1996 Summer Olympic Games had a past history of asthma or symptoms that suggested asthma or took asthma medications. Methods: We analyzed responses to questions that asked about allergic and respiratory diseases on the United States Olympic Committee (USOC) Medical History Questionnaire that was completed by all athletes who were chosen to represent the US at the 1996 Summer Olympic Games in Atlanta. Results: Of the 699 athletes who completed the questionnaire, 107 (15.3%) had a previous diagnosis of asthma, and 97 (13.9%,) recorded use of an asthma medication at some time in the past. One hundred seventeen (16.7%) reported use of an asthma medication, a diagnosis of asthma, or both (which was our basis for the diagnosis of asthma). Seventy-three (10.4%) of the athletes were currently taking an asthma medication at the time that they were processed in Atlanta or noted that they took asthma medications on a permanent or semipermanent basis and were considered to hale active asthma. Athletes who participated in cycling and mountain biking had the highest prevalence of having been told that they had asthma or had taken an asthma meditation in the past (50%). Frequency of active asthma varied from 45% of cyclists and mountain hikers to none of the divers and weight lifters. Only about 11 % of the athletes who participated in the 1984 Summer Olympic Games were reported to have had exercise-induced asthma on the basis of other criteria that may have been less restrictive, On the basis of these less restrictive criteria, more than 20% of the athletes who participated in the 1996 Olympic Games might have been considered to have had asthma. Conclusions: Asthma appeared to have been more prevalent in athletes who participated in the 1996 Summer Games than in the general population or in those who participated in the 1984 Summer Games. This study also suggests that asthma may influence the sport that an athlete chooses.	Univ Iowa, Iowa City, IA 52242 USA; US Olymp Comm, Colorado Springs, CO USA	University of Iowa	Weiler, JM (corresponding author), Univ Iowa, T307GH,200 Hawkins Dr, Iowa City, IA 52242 USA.							BIERMAN C W, 1975, Pediatrics, V56, P847; EVANS R, 1993, ALLERGY PRINCIPLES P, P1116; FITCH KD, 1984, J ALLERGY CLIN IMMUN, V73, P722, DOI 10.1016/0091-6749(84)90314-2; HUFTEL MA, 1991, J RESP DIS, V12, P1110; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; *NAT ASTHM ED PROG, 1991, PUBL NIH; PETER MM, 1997, ALLERGIC RESP DIS SP; RUPP NT, 1992, AM J DIS CHILD, V146, P941, DOI 10.1001/archpedi.1992.02160200063028; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; Weiler JM, 1996, ALLERGY ASTHMA PROC, V17, P315, DOI 10.2500/108854196778606437; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23	12	173	178	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					722	726		10.1016/S0091-6749(98)70010-7	http://dx.doi.org/10.1016/S0091-6749(98)70010-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819287	Bronze			2022-12-18	WOS:000077033400004
J	CZUPPON, AB; CHEN, Z; RENNERT, S; ENGELKE, T; MEYER, HE; HEBER, M; BAUR, X				CZUPPON, AB; CHEN, Z; RENNERT, S; ENGELKE, T; MEYER, HE; HEBER, M; BAUR, X			THE RUBBER ELONGATION-FACTOR OF RUBBER TREES (HEVEA-BRASILIENSIS) IS THE MAJOR ALLERGEN IN LATEX	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RUBBER ELONGATION FACTOR; LATEX ALLERGEN; LATEX GLOVES; AIRBORNE LATEX ALLERGEN	PURIFICATION; ANAPHYLAXIS	Background: Allergy to latex-containing articles is becoming more and more important because it can result in unexpected life-threatening anaphylactic reactions in sensitized individuals. Methods: A protein of 58 kd with an isoelectric point of 8.45 was purified from raw latex and from latex gloves and identified as the major allergen, completely blocking specific IgE antibodies in the serum of latex-sensitized subjects. The allergen is a noncovalent homotetramer molecule, in which the 14.6 kd monomer was identified, by amino acid composition and sequence homologies of tryptic peptides, to be the rubber elongation factor found in natural latex of the Malaysian rubber tree. Results: Competitive immunoinhibition tests showed that the starch powder covering the finished gloves is the airborne carrier of the allergen, resulting in bronchial asthma on inhalation. The purified allergen can induce allergic reactions in the nanogram range. Conclusion: The identification of the allergen (Hev b I) may help to eliminate it during the production of latex-based articles in the future.	RUHR UNIV BOCHUM,DEPT ALLERGOL,OCCUPAT MED RES INST,W-4630 BOCHUM,GERMANY; RUHR UNIV BOCHUM,DEPT PHYSIOL CHEM,W-4630 BOCHUM,GERMANY	Ruhr University Bochum; Ruhr University Bochum								AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; CHAMBEYRON C, 1992, ALLERGY, V47, P92, DOI 10.1111/j.1398-9995.1992.tb05094.x; CZUPPON AB, 1991, J ALLERGY CLIN IM S1, V1, P201; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; LIGHT DR, 1989, J BIOL CHEM, V264, P18589; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P226; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SWANSON MC, 1992, J ALLERGY CLIN IMMUN, V89, P227; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029; TURJANMAA K, 1987, CONTACT DERMATITIS, V21, P197	13	173	179	3	15	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					690	697		10.1016/0091-6749(93)90012-5	http://dx.doi.org/10.1016/0091-6749(93)90012-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227860	Bronze			2022-12-18	WOS:A1993MG98200010
J	BOUSQUET, J; CHANEZ, P; LACOSTE, JY; ENANDER, I; VENGE, P; PETERSON, C; AHLSTEDT, S; MICHEL, FB; GODARD, P				BOUSQUET, J; CHANEZ, P; LACOSTE, JY; ENANDER, I; VENGE, P; PETERSON, C; AHLSTEDT, S; MICHEL, FB; GODARD, P			INDIRECT EVIDENCE OF BRONCHIAL INFLAMMATION ASSESSED BY TITRATION OF INFLAMMATORY MEDIATORS IN BAL FLUID OF PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHIAL INFLAMMATION; BAL; MEDIATORS; ASTHMA	BRONCHOALVEOLAR LAVAGE FLUID; EOSINOPHIL CATIONIC PROTEIN; HUMAN MAST-CELLS; MAJOR BASIC-PROTEIN; ALVEOLAR MACROPHAGES; MILD ASTHMA; RESPIRATORY-DISEASES; HISTAMINE-RELEASE; HYALURONIC-ACID; TRYPTASE	Bronchial inflammation is a characteristic of asthma that may be examined indirectly by bronchoalveolar lavage (BAL). Nine normal individuals were compared with 38 age-matched adults with asthma of variable severity to appreciate the importance of cell activation in the severity of asthma. The severity of asthma was appreciated by the clinical score of Aas and the pulmonary function of the patients. FEV1 ranged between 35% and 130% of predicted. The indirect activation of eosinophils (EOSs), mast cells, fibroblasts, and neutrophils was examined by the titration of eosinophil cationic protein (ECP), tryptase, hyaluronan (HA), and myeloperoxidase (MPO) by radioimmunoassay in BAL fluid (BALF) and cytology of BALF. In the adults with asthma, there was a significantly increased number of EOSs and a significantly increased level of all mediators but MPO. MPO levels were increased in seven patients only; three of these patients were previously smokers. Only ECP and HA levels were significantly correlated with the severity of asthma. These results demonstrate EOSs, mast cells, and fibroblasts are activated in asthma, whereas the involvement of neutrophils is less clear. There was a significant correlation between ECP and HA levels, suggesting a common activation of EOSs and fibroblasts.	PHARMACIA AB,UPPSALA,SWEDEN; UNIV LUND HOSP,DEPT CLIN CHEM,S-22185 LUND,SWEDEN	Pfizer; Pharmacia Corporation; Lund University; Skane University Hospital	BOUSQUET, J (corresponding author), CHU MONTPELLIER,HOP AIGUELONGUE,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019	chanez, pascal/0000-0003-4059-0917				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BJERMER L, 1989, THORAX, V44, P126, DOI 10.1136/thx.44.2.126; BJERMER L, 1987, THORAX, V42, P933, DOI 10.1136/thx.42.12.933; BJERMER L, 1987, BRIT MED J, V295, P801; BOUSQET J, 1988, AIRWAYS NEURLA CONTR, V33, P119; BOUSQUET J, 1990, Journal of Allergy and Clinical Immunology, V85, P263; BOUSQUET J, IN PRESS INT ARCH AL; BOUSQUET J, 1991, NEW ENGL J MED, V373, P1033; BRANDT R, 1987, ACTA OTOLARYNGOL S, V442, P31; BUTTERFIELD JH, 1990, LAB INVEST, V62, P77; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; CRAIG SS, 1989, IMMUNOL RES, V8, P130, DOI 10.1007/BF02919075; DAHL DH, 1987, PULMONARY PAUTHOLOGY, P359; DAHL R, 1978, SCAND J RESPIR DIS, V59, P319; DAMATO G, 1983, EUR J RESPIR DIS, V64, P509; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENBURG JA, 1988, MAST CELL BASOPHIL D, P59; DUNHILL MS, 1987, PULMONARY PATHOLOGY, P61; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; Ellis AG, 1908, AM J MED SCI, V136, P407, DOI 10.1097/00000441-190809000-00009; ENANDER I, IN PRESS J IMMUNOL M; FICK RB, 1987, AM REV RESPIR DIS, V135, P1204; FILLEY WV, 1982, LANCET, V2, P11; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FREDENS K, 1985, NEW ENGL REG ALLERGY, V6, P346; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; FUGNER A, 1977, INT ARCH ALLER A IMM, V54, P78, DOI 10.1159/000231810; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689, DOI 10.1164/ajrccm/141.3.689; GERBER F, 1985, REV MAL RESPIR, V2, P313; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; GLEICH GJ, 1987, J ALLERGY CLIN IMMUN, V80, P512; GODARD P, 1989, J ALLERGY CLIN IMMUN, V83, P175; GODARD P, 1987, B EUR PHYSIOPATH RES, V23, P73; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; GODARD P, 1987, HIGHLIGHTS ASTHMOLOG, P186; GOLDSTEIN RA, 1985, AM REV RESPIR DIS, V132, P180; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HOGG JC, 1988, PATHOLOGY LUNG, P578; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; IRANI AA, 1988, P NATL ACAD SCI USA, V140, P3936; JONES KP, 1990, EUR RESPIR J, V3, P152; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KNUDSON RJ, 1977, AM REV RESPIR DIS, P115; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEBEL B, 1988, CLIN ALLERGY, V18, P605, DOI 10.1111/j.1365-2222.1988.tb02912.x; MARONE G, 1984, INT ARCH ALLER A IMM, V74, P356, DOI 10.1159/000233573; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MIAN N, 1986, BIOCHEM J, V237, P333, DOI 10.1042/bj2370333; MOLINA C, 1985, REV MAL RESPIR, V2, P1011; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NETTELBLADT O, 1989, LUNG CELL MOL PHYSL, V1, pL379; OHMAN JL, 1972, J ALLERGY CLIN IMMUN, V50, P151, DOI 10.1016/0091-6749(72)90046-2; OLOFSSON T, 1977, SCAND J HAEMATOL, V18, P73; OLSSON I, 1977, LAB INVEST, V36, P493; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1140; PETERSON CGB, 1988, EUR J HAEMATOL, V40, P415; PINCUS SH, 1987, BLOOD, V70, P572; POSTLETHWAITE AE, 1988, INFLAMMATION BASIC P, P577; POSTON R, 1991, J ALLERGY CLIN IMMUN, V8, P213; RANKIN JA, 1984, CHEST, V85, P723, DOI 10.1378/chest.85.6.723; RANKIN JA, 1989, J ALLERGY CLIN IMMUN, V83, P722, DOI 10.1016/0091-6749(89)90005-5; REED CE, 1970, J ALLERGY, V46, P90, DOI 10.1016/0021-8707(70)90076-6; REED CE, 1986, J ALLERGY CLIN IMMUN, V77, P537, DOI 10.1016/0091-6749(86)90342-8; REID LM, 1989, ROLE INFLAMMATORY PR, P36; RENNARD SJ, 1981, CRC REV, P115; REYNOLDS HY, 1974, J LAB CLIN MED, V84, P559; ROCHE WR, 1989, LANCET, V1, P520; SAURA S, 1978, BIOCHEM J, V173, P565; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1990, J IMMUNOL, V144, P2304; SODERBERG M, 1989, INT ARCH ALLER A IMM, V88, P373, DOI 10.1159/000234719; SPENCER H, 1985, PATHOLOGY LUNG, P755; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; The BAL Cooperative Group Steering Committee, 1990, AM REV RESPIR DIS, V141, pS169; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; TONNEL AB, 1983, LANCET, V1, P1406; TONNEL AB, 1987, ALLERGY INFLAMMATION, P139; VANCHERI C, 1989, AM J RESP CELL MOL, V1, P289, DOI 10.1165/ajrcmb/1.4.289; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WARDLAW AJ, 1986, CLIN ALLERGY, V16, P163, DOI 10.1111/j.1365-2222.1986.tb00760.x; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; WENZEL SE, 1978, AM REV RESPIR DIS, V173, P565; YUKAWA T, 1988, AM REV RESPIR DIS, V137, pA27; 1962, AM REV RESPIR DIS, V85, P762	90	173	176	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					649	660		10.1016/0091-6749(91)90159-L	http://dx.doi.org/10.1016/0091-6749(91)90159-L			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1918730				2022-12-18	WOS:A1991GL04900014
J	SIMONS, FER; MCMILLAN, JL; SIMONS, KJ				SIMONS, FER; MCMILLAN, JL; SIMONS, KJ			A DOUBLE-BLIND, SINGLE-DOSE, CROSSOVER COMPARISON OF CETIRIZINE, TERFENADINE, LORATADINE, ASTEMIZOLE, AND CHLORPHENIRAMINE VERSUS PLACEBO - SUPPRESSIVE EFFECTS ON HISTAMINE-INDUCED WHEALS AND FLARES DURING 24 HOURS IN NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,HLTH SCI CLIN RES CTR,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba								[Anonymous], 1980, PRINCIPLES PROCEDURE; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; COOK J, 1980, BRIT J PHARMACOL, V69, P579, DOI 10.1111/j.1476-5381.1980.tb07907.x; GENDREAUREID L, 1986, J ALLERGY CLIN IMMUN, V77, P335, DOI 10.1016/S0091-6749(86)80114-2; GHYS L, 1989, J INT MED RES, V17, P24, DOI 10.1177/030006058901700103; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; KONTOUFILI K, 1989, EUR J CLIN PHARMACOL, V36, P617, DOI 10.1007/BF00637746; LADURON PM, 1982, MOL PHARMACOL, V21, P294; MALLING HJ, 1987, ALLERGY, V42, P196, DOI 10.1111/j.1398-9995.1987.tb02200.x; MALO JL, 1990, J ALLERGY CLIN IMMUN, V85, P729, DOI 10.1016/0091-6749(90)90191-6; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; MULLER FO, 1988, EUR J CLIN PHARMACOL, V35, P319, DOI 10.1007/BF00558272; PECHADRE JC, 1988, EUR J CLIN PHARMACOL, V35, P255, DOI 10.1007/BF00558262; RIHOUX JP, 1987, ANN ALLERGY, V59, P235; RIHOUX JP, IN PRESS ANN ALLERGY; SHALL L, 1989, 14TH C EUR AC ALL CL, P14; SIMONS FER, 1989, J ALLERGY CLIN IMMUN, V84, P845, DOI 10.1016/0091-6749(89)90377-1; SKASSABROCIEK W, 1988, J ALLERGY CLIN IMMUN, V81, P175, DOI 10.1016/0091-6749(88)90262-X; VICHYANOND P, 1989, J ALLERGY CLIN IMMUN, V83, P1101, DOI 10.1016/0091-6749(89)90452-1; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8	20	173	177	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				540	547						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	1977781				2022-12-18	WOS:A1990EG45400014
J	RACHELEFSKY, GS; GOLDBERG, M; KATZ, RM; BORIS, G; GYEPES, MT; SHAPIRO, MJ; MICKEY, MR; FINEGOLD, SM; SIEGEL, SC				RACHELEFSKY, GS; GOLDBERG, M; KATZ, RM; BORIS, G; GYEPES, MT; SHAPIRO, MJ; MICKEY, MR; FINEGOLD, SM; SIEGEL, SC			SINUS DISEASE IN CHILDREN WITH RESPIRATORY ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOMATH,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								AXELSSON A, 1973, LARYNGOSCOPE, V83, P2003, DOI 10.1288/00005537-197312000-00011; AXELSSON A, 1972, ACTA OTO-LARYNGOL, V74, P118, DOI 10.3109/00016487209128430; BHATTACHARYYA TK, 1972, ACTA OTO-LARYNGOL, V74, P293, DOI 10.3109/00016487209128453; Bjonness H, 1973, Ther Umsch, V30, P452; BJORKWALL T, 1950, FINSKA LAK SALLSK HA, V93, P38; BJUGGREN G, 1953, Sven Lakartidn, V50, P953; DARCY F, 1974, IRISH MED J, V67, P456; DAWES JDK, 1966, BRIT MED J, V2, P843; DIXON W.J., 1975, BMDP BIOMEDICAL COMP; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FREDERICK J, 1974, NEW ENGL J MED, V290, P135, DOI 10.1056/NEJM197401172900304; HERZ G, 1977, CHEMOTHERAPY, V23, P50, DOI 10.1159/000221971; JAFFE BF, 1974, CLIN PEDIATR, V13, P944, DOI 10.1177/000992287401301106; KILGORE DE, 1976, OTOLARYNG CLIN N AM, V9, P601; KOGUTT MS, 1973, PEDIATRICS, V52, P122; MCLEAN DC, 1970, CLIN PEDIATR, V9, P342, DOI 10.1177/000992287000900611; NYLEN O, 1972, Scandinavian Journal of Infectious Diseases, V4, P43; SCHMID F, 1972, PADIAT PRAX, V15, P555; SMITH CH, 1964, CLIN PEDIATR, V3, P489, DOI 10.1177/000992286400300813; STIEHM ER, 1966, PEDIATRICS, V37, P715; Sutter V.L, 1975, WADSWORTH ANAEROBIC; [No title captured]	22	173	174	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	5					310	314		10.1016/0091-6749(78)90052-0	http://dx.doi.org/10.1016/0091-6749(78)90052-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EY714	641266	Bronze			2022-12-18	WOS:A1978EY71400006
J	Nowak-Wegrzyn, A; Katz, Y; Mehr, SS; Koletzko, S				Nowak-Wegrzyn, Anna; Katz, Yitzhak; Mehr, Sam Soheil; Koletzko, Sibylle			Non-IgE-mediated gastrointestinal food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food protein-induced enterocolitis syndrome; allergic proctocolitis; food protein-induced enteropathy; food allergy; non-IgE-mediated food allergy	PROTEIN-INDUCED ENTEROCOLITIS; BREAST-FED INFANTS; COWS MILK ALLERGY; CELIAC WHEAT SENSITIVITY; ATOPY PATCH TEST; DIFFERENTIAL-DIAGNOSIS; CLINICAL-FEATURES; CHANGING PATTERN; SYNDROME FPIES; BAKED MILK	Non-IgE-mediated gastrointestinal food-induced allergic disorders (non-IgE-GI-FAs) account for an unknown proportion of food allergies and include food protein-induced enterocolitis syndrome (FPIES), food protein-induced allergic proctocolitis (FPIAP), and food protein-induced enteropathy (FPE). Non-IgE-GI-FAs are separate clinical entities but have many overlapping clinical and histologic features among themselves and with eosinophilic gastroenteropathies. Over the past decade, FPIES has emerged as the most actively studied non-IgE-GI-FA, potentially because of acute and distinct clinical features. FPIAP remains among the common causes of rectal bleeding in infants, while classic infantile FPE is rarely diagnosed. The overall most common allergens are cow's milk and soy; in patients with FPIES, rice and oat are also common. The most prominent clinical features of FPIES are repetitive emesis, pallor, and lethargy; chronic FPIES can lead to failure to thrive. FPIAP manifests with bloody stools in well-appearing young breast-fed or formula-fed infants. Features of FPE are nonbloody diarrhea, malabsorption, protein-losing enteropathy, hypoalbuminemia, and failure to thrive. Non-IgE-GI-FAs have a favorable prognosis; the majority resolve by 1 year in patients with FPIAP, 1 to 3 years in patients with FPE, and 1 to 5 years in patients with FPIES, with significant differences regarding specific foods. There is an urgent need to better define the natural history of FPIES and the pathophysiology of non-IgE-GI-FAs to develop biomarkers and novel therapies.	[Nowak-Wegrzyn, Anna] Mt Sinai Sch Med, Jaffe Food Allergy Inst, Div Pediat Allergy, New York, NY 10029 USA; [Katz, Yitzhak] Tel Aviv Univ, Sackler Fac Med, Assaf Harofeh Med Ctr, Allergy & Immunol Inst,Dept Pediat, IL-69978 Tel Aviv, Israel; [Mehr, Sam Soheil] Childrens Hosp, Dept Allergy & Immunol, Westmead, NSW, Australia; [Koletzko, Sibylle] Univ Munich, Dr Von Hauner Childrens Hosp, Div Gastroenterol & Hepatol, Munich, Germany	Icahn School of Medicine at Mount Sinai; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; University of Sydney; University of Munich	Nowak-Wegrzyn, A (corresponding author), Mt Sinai Sch Med, Dept Pediat, Box 1198,One Gustave L Levy Pl, New York, NY 10029 USA.	anna.nowak-wegrzyn@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854; Mehr, Sam/0000-0003-2483-917X	Nestle; Thermo Fisher Scientific; National Institutes of Health; FARE; Nutricia; Boehringer Ingelheim; MSA; Merck; AbbVie; Danone; Mead Johnson; Thermo Fisher; EuroImmun; INOVA; R-Biopharm; Schar; Centocor; MSD; Vifor; Hipp; Falk; a050815	Nestle(Nestle SA); Thermo Fisher Scientific; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FARE; Nutricia(Danone Nutricia); Boehringer Ingelheim(Boehringer Ingelheim); MSA; Merck(Merck & Company); AbbVie(AbbVie); Danone(Danone Nutricia); Mead Johnson; Thermo Fisher; EuroImmun; INOVA; R-Biopharm; Schar; Centocor; MSD; Vifor; Hipp; Falk; a050815	A. Nowak-Wegrzyn has received compensation for board membership from Merck, consultancy fees from Nestle, and payment for delivering lectures from Thermo Fisher Scientific; she receives royalties from UpToDate, and has received compensation for travel and other meeting-related expenses from Nestle and Thermo Fisher; her institution has received or has grants pending from the National Institutes of Health, FARE, and Nutricia. S. Koletzko has received compensation for board membership from MSD, Nestle, Danone, Merck, and Nutricia; she has received consultancy fees from Boehringer Ingelheim, MSA, Merck, AbbVie, and Danone; her institution has received or has grants pending from Nestle, Mead Johnson, Thermo Fisher, EuroImmun, INOVA, R-Biopharm, and Schar; she has received payment for delivering lectures from Centocor, MSD, Danone, Merck, Vifor, Nestle, EuroImmun, Thermo Fisher, AbbVie, Schar, Hipp, and Falk; she has received compensation for travel and other meeting-related expenses from MSD. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Arvola T, 2006, PEDIATRICS, V117, pE760, DOI 10.1542/peds.2005-1069; Banzato C, 2013, EUR ANN ALLERGY CLIN, V45, P209; BORCHERS SD, 1992, J PEDIATR GASTR NUTR, V15, P321, DOI 10.1097/00005176-199210000-00016; Borrelli O, 2012, J PEDIATR-US, V161, P476, DOI 10.1016/j.jpeds.2012.03.002; Borrelli O, 2009, AM J GASTROENTEROL, V104, P454, DOI 10.1038/ajg.2008.109; Burks A W, 1994, Pediatr Allergy Immunol, V5, P40; Burks AW, 2011, PEDIATRICS, V128, P955, DOI 10.1542/peds.2011-0539; Carroccio A, 2013, AM J GASTROENTEROL, V108, P1845, DOI 10.1038/ajg.2013.353; Carroccio A, 2013, AM J GASTROENTEROL, V108, P825, DOI 10.1038/ajg.2013.58; Carroccio A, 2012, AM J GASTROENTEROL, V107, P1898, DOI 10.1038/ajg.2012.236; Caubet JC, 2014, J ALLERGY CLIN IMMUN, V134, P382, DOI 10.1016/j.jaci.2014.04.008; Caubet JC, 2011, J ALLERGY CLIN IMMUN, V128, P1386, DOI 10.1016/j.jaci.2011.07.011; Caubet JC, 2011, EXPERT REV CLIN IMMU, V7, P317, DOI [10.1586/eci.11.13, 10.1586/ECI.11.13]; Cavataio F, 1996, J PEDIATR-US, V128, P558, DOI 10.1016/S0022-3476(96)70370-0; Chung HL, 2002, J ALLERGY CLIN IMMUN, V109, P150, DOI 10.1067/mai.2002.120562; Dobson D, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004796.pub2; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Elizur A, 2012, PEDIAT ALLERG IMM-UK, V23, P766, DOI 10.1111/pai.12009; Fernandes BN, 2012, J ALLERGY CLIN IMMUN, V130, P1199, DOI 10.1016/j.jaci.2012.06.017; Fiocchi A, 2014, PEDIATRICS, V134, pE602, DOI 10.1542/peds.2013-2623; Fiocchi A, 2014, CURR OPIN ALLERGY CL, V14, P246, DOI 10.1097/ACI.0000000000000057; Fiocchi A, 2010, PEDIAT ALLERG IMM-UK, V21, P1, DOI [10.1111/j.1399-3038.2010.01068.x, 10.1097/WOX.0b013e3181defeb9]; Flinterman AE, 2006, ALLERGY, V61, P370, DOI 10.1111/j.1398-9995.2006.01018.x; Fogg MI, 2006, PEDIAT ALLERG IMM-UK, V17, P351, DOI 10.1111/j.1399-3038.2006.00418.x; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Fritscher-Ravens A, 2014, GASTROENTEROLOGY, V147, P1012, DOI 10.1053/j.gastro.2014.07.046; GOLDMAN H, 1986, AM J SURG PATHOL, V10, P75, DOI 10.1097/00000478-198602000-00001; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; GRYBOSKI JD, 1967, PEDIATRICS, V40, P354; Hall B, 2012, J PAEDIATR CHILD H, V48, P128, DOI 10.1111/j.1440-1754.2011.02061.x; Hayashi Daisuke, 2010, Arerugi, V59, P1628; Hill DJ, 2005, PEDIATRICS, V116, pE709, DOI 10.1542/peds.2005-0147; Hill DJ, 2000, J PEDIATR-US, V136, P641, DOI 10.1067/mpd.2000.104774; Holbrook T, 2013, J ALLERGY CLIN IMMUN, V132, P1219, DOI 10.1016/j.jaci.2013.06.021; Hsu P, 2013, J ALLERGY CLIN IMMUN, V131, P241, DOI 10.1016/j.jaci.2012.08.045; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Hwang JB, 2009, ARCH DIS CHILD, V94, P425, DOI 10.1136/adc.2008.143289; Hwang JB, 2009, ANN ALLERG ASTHMA IM, V103, P87, DOI 10.1016/S1081-1206(10)60154-8; Iacovou M, 2012, MATERN CHILD HLTH J, V16, P1319, DOI 10.1007/s10995-011-0842-5; IYNGKARAN N, 1978, ARCH DIS CHILD, V53, P150, DOI 10.1136/adc.53.2.150; Jarvinen KM, 2013, J ALLER CL IMM-PRACT, V1, P317, DOI 10.1016/j.jaip.2013.04.004; Jarvinen KM, 2012, ANN ALLERG ASTHMA IM, V109, P221, DOI 10.1016/j.anai.2012.06.020; JENKINS HR, 1984, ARCH DIS CHILD, V59, P326, DOI 10.1136/adc.59.4.326; Kalach N, 2013, CLIN CHEM LAB MED, V51, P351, DOI 10.1515/cclm-2012-0083; Katz Y, 2014, CURR OPIN ALLERGY CL, V14, P229, DOI 10.1097/ACI.0000000000000053; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, P647, DOI 10.1016/j.jaci.2010.12.1105; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Kokkonen J, 2001, J PEDIATR-US, V139, P797, DOI 10.1067/mpd.2001.118882; Koletzko S, 2012, J PEDIATR GASTR NUTR, V55, P221, DOI 10.1097/MPG.0b013e31825c9482; Konstantinou GN, 2014, PEDIAT ALLERG IMM-UK, V25, P651, DOI 10.1111/pai.12288; KUITUNEN P, 1975, ARCH DIS CHILD, V50, P351, DOI 10.1136/adc.50.5.351; LAKE AM, 1982, J PEDIATR-US, V101, P906, DOI 10.1016/S0022-3476(82)80008-5; Lake AM, 2000, J PEDIATR GASTR NUTR, V30, pS58, DOI 10.1097/00005176-200001001-00009; Latcham F, 2003, J PEDIATR-US, V143, P39, DOI 10.1016/S0022-3476(03)00193-8; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Leung J, 2013, J ALLERGY CLIN IMMUN, V132, P1215, DOI 10.1016/j.jaci.2013.08.017; Levy Y, 2003, PEDIAT ALLERG IMM-UK, V14, P325, DOI 10.1034/j.1399-3038.2003.00039.x; Lightdale JR, 2013, PEDIATRICS, V131, pE1684, DOI 10.1542/peds.2013-0421; Lin XP, 2002, J ALLERGY CLIN IMMUN, V109, P879, DOI 10.1067/mai.2002.123238; Lucarelli S, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-82; Ludman S, 2014, ANN ALLERG ASTHMA IM, V113, P290, DOI 10.1016/j.anai.2014.06.020; Maines E, 2013, PEDIAT ALLERG IMM-UK, V24, P509, DOI 10.1111/pai.12096; Maloney J, 2007, PEDIAT ALLERG IMM-UK, V18, P360, DOI 10.1111/j.1399-3038.2007.00561.x; Mane SK, 2014, EUR J PEDIATR, V173, P1545, DOI 10.1007/s00431-013-2051-2; Mehl A, 2012, CLIN EXP ALLERGY, V42, P1266, DOI 10.1111/j.1365-2222.2012.04046.x; Mehr SS, 2009, ARCH DIS CHILD, V94, P220, DOI 10.1136/adc.2008.145144; Mehr S, 2014, CURR OPIN ALLERGY CL, V14, P208, DOI 10.1097/ACI.0000000000000056; Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; Miller NB, 2014, JIMD REP, V12, P11, DOI 10.1007/8904_2013_238; Molnar K, 2013, WORLD J GASTROENTERO, V19, P3824, DOI 10.3748/wjg.v19.i24.3824; Monti G, 2011, J ALLERGY CLIN IMMUN, V127, P679, DOI 10.1016/j.jaci.2010.10.017; Morita H, 2013, J ALLERGY CLIN IMMUN, V131, P590, DOI 10.1016/j.jaci.2012.09.005; Muraro A, 2014, ALLERGY, V69, P1008, DOI 10.1111/all.12429; Nielsen RG, 2004, J PEDIATR GASTR NUTR, V39, P383, DOI 10.1097/00005176-200410000-00015; Nomura I, 2012, CURR ALLERGY ASTHM R, V12, P297, DOI 10.1007/s11882-012-0272-5; Nomura I, 2011, J ALLERGY CLIN IMMUN, V127, P685, DOI 10.1016/j.jaci.2011.01.019; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; POWELL GK, 1976, J PEDIATR-US, V88, P840, DOI 10.1016/S0022-3476(76)81128-6; Pumberger W, 2001, POSTGRAD MED J, V77, P252, DOI 10.1136/pmj.77.906.252; Ravelli A, 2008, AM J GASTROENTEROL, V103, P2605, DOI 10.1111/j.1572-0241.2008.02035.x; Ravelli AM, 2001, J PEDIATR GASTR NUTR, V32, P59, DOI 10.1097/00005176-200101000-00017; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Ruffner MA, 2013, J ALLER CL IMM-PRACT, V1, P343, DOI 10.1016/j.jaip.2013.05.011; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Savilahti E, 2000, J PEDIATR GASTR NUTR, V30, pS61, DOI 10.1097/00005176-200001001-00010; Schultz F, 2014, CURR OPIN ALLERGY CL, V14, P263, DOI 10.1097/ACI.0000000000000059; Serafini S, 2015, J ALLER CL IMM-PRACT, V3, P135, DOI 10.1016/j.jaip.2014.09.016; Shek LPC, 2005, ALLERGY, V60, P912, DOI 10.1111/j.1398-9995.2005.00705.x; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Sopo SM, 2013, ALLERGOL IMMUNOPATH, V41, P346, DOI 10.1016/j.aller.2012.06.008; Sopo SM, 2012, CLIN EXP ALLERGY, V42, P1257, DOI 10.1111/j.1365-2222.2012.04027.x; Sopo SM, 2014, INT ARCH ALLERGY IMM, V164, P137, DOI 10.1159/000363384; Sopo SM, 2014, INT ARCH ALLERGY IMM, V164, P40, DOI 10.1159/000362365; Sopo SM, 2014, CURR OPIN ALLERGY CL, V14, P240, DOI 10.1097/ACI.0000000000000058; Szajewska H, 2007, J PEDIATR GASTR NUTR, V45, P247, DOI 10.1097/MPG.0b013e31804c505b; Tan J, 2012, J ALLERGY CLIN IMMUN, V129, P873, DOI 10.1016/j.jaci.2011.12.1000; Tan JA, 2014, J ALLER CL IMM-PRACT, V2, P355, DOI 10.1016/j.jaip.2014.02.002; Turunen S, 2004, J PEDIATR-US, V145, P606, DOI 10.1016/j.jpeds.2004.06.067; Uhlig HH, 2014, GASTROENTEROLOGY, V147, P990, DOI 10.1053/j.gastro.2014.07.023; VANDENPLAS Y, 1994, J PEDIATR GASTR NUTR, V19, P240, DOI 10.1097/00005176-199408000-00016; Vandenplas Y, 2014, NAT REV GASTRO HEPAT, V11, P147, DOI 10.1038/nrgastro.2013.199; Venter C, 2014, CURR OPIN ALLERGY CL, V14, P255, DOI 10.1097/ACI.0000000000000054; Veres G, 2003, J PEDIATR GASTR NUTR, V37, P27, DOI 10.1097/00005176-200307000-00005; VERKASALO M, 1981, ACTA PAEDIATR SCAND, V70, P289, DOI 10.1111/j.1651-2227.1981.tb16554.x; VITORIA JC, 1990, ACTA PAEDIATR SCAND, V79, P566, DOI 10.1111/j.1651-2227.1990.tb11514.x; Wada T, 2014, PEDIAT ALLERG IMM-UK, V25, P617, DOI 10.1111/pai.12254; Wuthrich B, 2014, CHEM IMMUNOL ALLERGY, V100, P109, DOI 10.1159/000358616; Xanthakos SA, 2005, J PEDIATR GASTR NUTR, V41, P16, DOI 10.1097/01.MPG.0000161039.96200.F1; Yilmaz EA, 2014, PEDIAT ALLERG IMM-UK, V25, P296, DOI 10.1111/pai.12173; Zapatero Remon L, 2005, Allergol Immunopathol (Madr), V33, P312	116	172	184	0	67	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1114	1124		10.1016/j.jaci.2015.03.025	http://dx.doi.org/10.1016/j.jaci.2015.03.025			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25956013				2022-12-18	WOS:000353980700003
J	Gutzmer, R; Mommert, S; Gschwandtner, M; Zwingmann, K; Stark, H; Werfel, T				Gutzmer, Ralf; Mommert, Susanne; Gschwandtner, Maria; Zwingmann, Katja; Stark, Holger; Werfel, Thomas			The histamine H-4 receptor is functionally expressed on T(H)2 cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Histamine; T cells; H-4 receptor; IL-31	T-CELLS; ATOPIC-DERMATITIS; DENDRITIC CELLS; AIRWAY INFLAMMATION; SCRATCHING BEHAVIOR; IL-31; MICE; ACTIVATION; PRURITUS; ANTIHISTAMINES	Background: Histamine influences T-cell reactions via histamine receptors I and 2. The histamine receptor 4 (H4R) is the most recently identified histamine receptor and is also expressed on human CD4(+) T cells; however, its regulation and function are unclear. Objective: To investigate expression, regulation, and function of the H4R on human CD4(+) T cells. Methods: Histamine receptor 4 expression was studied by real-time quantitative RT-PCR and by flow cytometry. Effects of H4R stimulation on induction of the signal transduction molecules activator protein 1 (AP-1) and nuclear factor-kappa B (NF-kappa B) were determined by electrophoretic mobility shift assay and on cytokine production by RT-PCR and ELISA. Results: Histamine receptor 4 mRNA and protein were expressed by CD4(+) T cells and upregulated by IL-4. Its expression was higher on T(H)2 cells than T(H)1 cells and naive T-cells. H4R agonists (clobenpropit and 4-methylhistamine) induced AP-1 in T(H)2 cells but not in T(H)1 cells. This effect was blocked by the H4R antagonist JNJ7777120. H4R agonists upregulated IL-31 mRNA in PBMCs and T(H)2 cells, a cytokine that has been associated with T(H)2 cells and the induction of pruritus. IL-31 mRNA induction by H4R stimulation was pronounced in PBMCs from patients with atopic dermatitis. Expression of IL-4, IL-5, and IL-13 was not altered by the H4R. Conclusion: Human CD4(+) T cells express a functional H4R. The receptor is upregulated under T(H)2 conditions, and its stimulation leads to induction of AP-1 and IL-31. (J Allergy Clin Immunol 2009;123:619-25.)	[Gutzmer, Ralf; Mommert, Susanne; Gschwandtner, Maria; Zwingmann, Katja; Werfel, Thomas] Hannover Med Sch, Dept Immunodermatol & Allergy Res, D-30449 Hannover, Germany; [Stark, Holger] Goethe Univ Frankfurt, Inst Pharmaceut Chem, Frankfurt, Germany	Hannover Medical School; Goethe University Frankfurt	Gutzmer, R (corresponding author), Hannover Med Sch, Dept Immunodermatol & Allergy Res, Ricklinger Str 5, D-30449 Hannover, Germany.	gutzmer.ralf@mh-hannover.de	Stark, Holger/A-4235-2009; Werfel, Thomas/B-6921-2012	Stark, Holger/0000-0003-3336-1710; Gschwandtner, Maria/0000-0002-7944-7475	Deutsche Forschungsgemeinschaft [Gu434/5-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	Supported by grants from the Deutsche Forschungsgemeinschaft (DFG Gu434/5-1).	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Bell JK, 2004, BRIT J PHARMACOL, V142, P374, DOI 10.1038/sj.bjp.0705754; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Breuer K, 2000, ALLERGY, V55, P551, DOI 10.1034/j.1398-9995.2000.00432.x; Caron G, 2001, J IMMUNOL, V167, P3682, DOI 10.4049/jimmunol.167.7.3682; Dijkstra D, 2008, J INVEST DERMATOL, V128, P1696, DOI 10.1038/sj.jid.5701250; Dijkstra D, 2007, J ALLERGY CLIN IMMUN, V120, P300, DOI 10.1016/j.jaci.2007.03.024; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Dunford PJ, 2007, J ALLERGY CLIN IMMUN, V119, P176, DOI 10.1016/j.jaci.2006.08.034; Dunford PJ, 2006, J IMMUNOL, V176, P7062, DOI 10.4049/jimmunol.176.11.7062; Faith A, 2003, CLIN EXP ALLERGY, V33, P1209, DOI 10.1046/j.1365-2222.2003.01748.x; Gambichler T, 2008, BRIT J DERMATOL, V158, P1117, DOI 10.1111/j.1365-2133.2008.08498.x; Gutzmer R, 2002, J ALLERGY CLIN IMMUN, V109, P524, DOI 10.1067/mai.2002.121944; Gutzmer R, 2005, J IMMUNOL, V174, P5224, DOI 10.4049/jimmunol.174.9.5224; Hartenstein B, 2002, EMBO J, V21, P6321, DOI 10.1093/emboj/cdf648; Idzko M, 2002, J ALLERGY CLIN IMMUN, V109, P839, DOI 10.1067/mai.2002.124044; Jelinek I, 2007, INT IMMUNOL, V19, P51, DOI 10.1093/intimm/dxl121; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; Mazzoni A, 2006, J IMMUNOL, V177, P3577, DOI 10.4049/jimmunol.177.6.3577; Morgan RK, 2007, J IMMUNOL, V178, P8081, DOI 10.4049/jimmunol.178.12.8081; Morse KL, 2001, J PHARMACOL EXP THER, V296, P1058; Nakamura Yutaka, 2005, Current Drug Targets - Inflammation and Allergy, V4, P267, DOI 10.2174/1568010053586273; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Noubade R, 2007, J CLIN INVEST, V117, P3507, DOI 10.1172/JCI32792; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P421, DOI 10.1016/j.jaci.2008.05.047; Rossbach K, 2009, EXP DERMATOL, V18, P57, DOI 10.1111/j.1600-0625.2008.00762.x; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stander S, 2002, EXP DERMATOL, V11, P12, DOI 10.1034/j.1600-0625.2002.110102.x; Stark H, 2004, MINI-REV MED CHEM, V4, P965, DOI 10.2174/1389557043403107; Sugata Y, 2007, IMMUNOLOGY, V121, P266, DOI 10.1111/j.1365-2567.2007.02574.x; Takaoka A, 2006, EXP DERMATOL, V15, P161, DOI 10.1111/j.1600-0625.2006.00405.x; Thurmond RL, 2008, NAT REV DRUG DISCOV, V7, P41, DOI 10.1038/nrd2465; Zhu Y, 2001, MOL PHARMACOL, V59, P434, DOI 10.1124/mol.59.3.434	34	172	179	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					619	625		10.1016/j.jaci.2008.12.1110	http://dx.doi.org/10.1016/j.jaci.2008.12.1110			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19281909				2022-12-18	WOS:000264731200020
J	Pajno, GB; Caminiti, L; Vita, D; Barberio, G; Salzano, G; Lombardo, F; Canonica, GW; Passalacqua, G				Pajno, Giovanni B.; Caminiti, Lucia; Vita, Daniela; Barberio, Giovanni; Salzano, Giuseppina; Lombardo, Fortunato; Canonica, Giorgio Walter; Passalacqua, Giovanni			Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; house dust mites; sublingual immunotherapy	EFFICACY; STANDARDIZATION; MULTICENTER; ALLERGENS; ASTHMA	Background: Atopic dermatitis often has an allergic component, and immunotherapy may therefore prove beneficial. Objective: To assess the effect of sublingual immunotherapy (SLIT) in children with atopic dermatitis. Methods: Children age 5 to 16 years with atopic dermatitis (Scoring Atopic Dermatitis [SCORAD] > 7) and sensitization to dust mites alone, without food allergy or chronic asthma, were enrolled in a randomized, double-blind, placebo-controlled study and stratified according to disease severity. SLIT or placebo was given for 18 months in addition to standard therapy. SCORAD, visual analog scale, and rescue medication consumption were recorded at 3-month intervals. Results: Fifty-six children were enrolled, and 28 were allocated to SLIT. Forty-eight completed the study, with 2 dropouts in the active and 6 in the placebo group. The difference from baseline in the SCORAD was significant (P = .025) between the 2 groups starting from month 9. Similarly, there was a significant reduction in the use of medications only in the active group. A trend toward significance was seen for the visual analog score only in the active group versus baseline (P = .07). A significant difference in the considered parameters was found only in patients with a mild-moderate disease, whereas severe patients had only a marginal benefit. SLIT had to be discontinued in 2 patients because of exacerbation of dermatitis. Conclusion: Sublingual immunotherapy to dust mite improves mild-moderate atopic dermatitis. Clinical implications: Sublingual immunotherapy may represent an additional therapeutic tool for the treatment of extrinsic atopic dermatitis in properly selected children.	Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; Univ Messina, Dept Pediat, Allergy Unit, I-98100 Messina, Italy	University of Genoa; University of Messina	Passalacqua, G (corresponding author), Univ Genoa, Dept Internal Med, Padiglione Maragliano,Lgo R Benzi 10, I-16132 Genoa, Italy.	passalacqua@unige.it	canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557; Salzano, Giuseppina/0000-0003-2180-4510				Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Bindslev-Jensen C, 2001, ALLERGY, V56, P75, DOI 10.1111/j.1398-9995.2001.00922.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V118, P40, DOI 10.1016/j.jaci.2006.04.044; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Fonacier L, 2006, ANN ALLERG ASTHMA IM, V97, P117, DOI 10.1016/S1081-1206(10)61381-6; Galli E, 1994, Allergol Immunopathol (Madr), V22, P18; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; LEROY BP, 1993, J AM ACAD DERMATOL, V28, P232, DOI 10.1016/0190-9622(93)70033-P; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lue KH, 2006, PEDIAT ALLERG IMM-UK, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; Mastrandrea F, 2000, Allergol Immunopathol (Madr), V28, P54; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; NOWAK N, 2003, J ALLERGY CLIN IM S6, V112, pS128; Pacor Maria Luisa, 1994, Recenti Progressi in Medicina, V85, P273; Pajno GB, 2003, PEDIAT ALLERG IMM-UK, V14, P292, DOI 10.1034/j.1399-3038.2003.00060.x; Passalacqua G, 2006, CURR OPIN ALLERGY CL, V6, P449, DOI 10.1097/01.all.0000246617.41871.40; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Petrova S. Yu., 2001, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P33; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Werfel T, 1998, ALLERGY, V53, P731	30	172	180	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					164	170		10.1016/j.jaci.2007.04.008	http://dx.doi.org/10.1016/j.jaci.2007.04.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17543376				2022-12-18	WOS:000248066400024
J	Himly, M; Jahn-Schmid, B; Pittertschatscher, K; Bohle, B; Grubmayr, K; Ferreira, F; Ebner, H; Ebner, C				Himly, M; Jahn-Schmid, B; Pittertschatscher, K; Bohle, B; Grubmayr, K; Ferreira, F; Ebner, H; Ebner, C			IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adverse drug reaction; drug allergy; propyphenazone; IgE; anaphylaxis; ELISA	ASPIRIN	Background: Propyphenazone (1,2-dihydro-1,5-dimethyl-4-(1-methylethyl)-2-phenyl-3H-pyrazol-3-one; PP) is a nonsteroidal anti-inflammatory drug frequently used as mild analgesic medicament. It belongs to the chemical group of pyrazolones. Severe adverse reactions to PP are frequent and have generally been regarded as pseudoallergic or intolerance reactions. Presently, there are no useful in vitro test systems available for the detection of antibodies directed against analgesic drugs. Objective: The purpose of this study was to unequivocally demonstrate that IgE-mediated Type I allergy is the main mechanism leading to immediate-type adverse reactions to the analgesic drug PP. Methods: We investigated 53 young adult patients with adverse reactions to PP. All patients developed symptoms suggestive of IgE-mediated anaphylaxis within 30 minutes after intake of a painkiller containing PP. Patients were subjected to skin tests (prick test and intracutaneous test). In addition, a novel ELISA system was developed to prove the existence of specific IgE antibodies in patients' sera. Results: In 44 of 53 (83%) patients, skin tests showed typical wheal and flare reactions. Significant amounts of PP-specific serum IgE was detected in 31 of 53 (58%) of the serum samples. Moreover, in 7 of 9 patients with skin test negative results, PP-specific IgE could be detected. The assay was PP-specific because only PP, but no other pyrazolone derivative (antipyrine, aminophenazone, or metamizol), was able to inhibit IgE-binding in the system. Conclusion: Propyphenazone is a sensitizing agent in susceptible individuals and can elicit IgE-mediated anaphylaxis. By using skin tests and our ELISA system we were able to confirm Type I allergy in 51 of 53 (96%) patients in this study.	Univ Vienna, Inst Pathophysiol, A-1090 Vienna, Austria; Salzburg Univ, Inst Genet, A-5020 Salzburg, Austria; Salzburg Univ, Inst Chem, A-5020 Salzburg, Austria; Johannes Kepler Univ Linz, Inst Chem, A-4040 Linz, Austria	University of Vienna; Salzburg University; Salzburg University; Johannes Kepler University Linz	Ebner, C (corresponding author), Univ Vienna, Inst Pathophysiol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019; Himly, Martin/D-1568-2015	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Himly, Martin/0000-0001-5416-085X; Bohle, Barbara/0000-0002-5105-7985				Barbaud A, 2001, CONTACT DERMATITIS, V45, P321, DOI 10.1034/j.1600-0536.2001.450601.x; Corominas M., 1998, Clinical and Experimental Allergy, V28, P41; CZERNIAWSKAMYSIK G, 1981, ALLERGY, V36, P381, DOI 10.1111/j.1398-9995.1981.tb01842.x; Dekker JW, 1997, CLIN EXP ALLERGY, V27, P574, DOI 10.1046/j.1365-2222.1997.540848.x; Demoly P, 2001, CURR OPIN ALLERGY CL, V1, P305, DOI 10.1097/01.all.0000011031.16814.e0; Gruchalla R, 2000, J ALLERGY CLIN IMMUN, V105, pS637, DOI 10.1067/mai.2000.106156; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Pouyanne P, 2000, BRIT MED J, V320, P1036, DOI 10.1136/bmj.320.7241.1036; Quiralte J, 1997, ANN ALLERG ASTHMA IM, V78, P293, DOI 10.1016/S1081-1206(10)63184-5; Rubio-Martinez A, 1998, VOX SANG, V75, P257; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SCHNEIDER CH, 1987, ALLERGY, V42, P597, DOI 10.1111/j.1398-9995.1987.tb00390.x; TORRELO A, 1990, INT J DERMATOL, V29, P384, DOI 10.1111/j.1365-4362.1990.tb04775.x; VanDerKlauw MM, 1996, CLIN EXP ALLERGY, V26, P1355, DOI 10.1046/j.1365-2222.1996.d01-300.x; ZHU DX, 1992, ASIAN PAC J ALLERGY, V10, P95	15	172	176	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					882	888		10.1067/mai.2003.163	http://dx.doi.org/10.1067/mai.2003.163			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704373	Bronze			2022-12-18	WOS:000182258500033
J	YUNGINGER, JW; JONES, RT; FRANSWAY, AF; KELSO, JM; WARNER, MA; HUNT, LW				YUNGINGER, JW; JONES, RT; FRANSWAY, AF; KELSO, JM; WARNER, MA; HUNT, LW			EXTRACTABLE LATEX ALLERGENS AND PROTEINS IN DISPOSABLE MEDICAL GLOVES AND OTHER RUBBER PRODUCTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX; RUBBER; ALLERGENS; PROTEINS; DISPOSABLE GLOVES	ANTIGENS; PREVALENCE	Background: IgE-mediated sensitization to rubber proteins is being reported with increasing frequency in health care workers. To explore the relative importance of various sources of allergen exposure, we measured the total rubber allergen and protein levels in extracts of disposable rubber gloves and compared the allergen levels with those in extracts of other medical and consumer rubber products. Methods: Rubber allergens were measured by inhibition immunoassay with a rubber glove extract as the solid-phase allergen and pooled plasma from five rubber-sensitized health care workers as the IgE antibody source. Proteins were measured by Ninhydrin assay. Results: Among 71 lots of gloves tested, the extractable allergen and protein levels were significantly correlated and were appreciably higher in powdered gloves than in powder-free gloves. Allergen levels varied 3000-fold among gloves Fern different manufacturers and were higher in examination gloves than in surgical or chemotherapy gloves. Measurable allergen was found in 11 of 24 lots of ''hypoallergenic'' gloves tested. Allergen levels in toy balloons were comparable to those in powdered gloves; much lower allergen levels were measured in condoms and anesthesia rebreathing bags. Conclusions: The allergen content of disposable rubber gloves varies widely and is higher in powdered gloves than in powder-free gloves and higher in examination gloves than in surgical gloves. Hypoallergenic gloves may contain substantial amounts of IgE-binding proteins. Gloves and toy balloons appear to be more important sources of rubber allergens than the other rubber products tested	MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV ALLERG DIS,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT DERMATOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT ANESTHESIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905; USN HOSP,DEPT INTERNAL MED,DIV ALLERGY,SAN DIEGO,CA 92134; USN HOSP,DEPT CLIN INVEST,SAN DIEGO,CA 92134	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; United States Department of Defense; United States Navy; United States Department of Defense; United States Navy								ANDERSON MC, 1986, RAST INHIBITION PROC; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; BERKY ZT, 1992, JAMA-J AM MED ASSOC, V268, P2695; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; CARILLO T, 1986, CONTACT DERMATITIS, V15, P69; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; KORNIEWICZ DM, 1993, AM IND HYG ASSOC J, V54, P22, DOI 10.1080/15298669391354261; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; RICHMAN PG, 1988, J BIOL STAND, V16, P225, DOI 10.1016/0092-1157(88)90010-8; SEGGEV JS, 1990, ANN ALLERGY, V65, P152; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SWANSON MC, IN PRESS J ALLERGY C; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; Yunginger JW, 1992, MANUAL CLIN LAB IMMU, V4th, P678; 1987, MMWR S25, V36, pS1	19	172	178	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					836	842		10.1016/0091-6749(94)90374-3	http://dx.doi.org/10.1016/0091-6749(94)90374-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182224	Bronze			2022-12-18	WOS:A1994NL91900005
J	MONERETVAUTRIN, DA; BEAUDOUIN, E; WIDMER, S; MOUTON, C; KANNY, G; PRESTAT, F; KOHLER, C; FELDMANN, L				MONERETVAUTRIN, DA; BEAUDOUIN, E; WIDMER, S; MOUTON, C; KANNY, G; PRESTAT, F; KOHLER, C; FELDMANN, L			PROSPECTIVE-STUDY OF RISK-FACTORS IN NATURAL-RUBBER LATEX HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX ALLERGY; RISK FACTORS; SPINA BIFIDA; INTRAOPERATIVE ANAPHYLAXIS; ATOPY; EXPOSURE	CONTACT URTICARIA; INTRAOPERATIVE ANAPHYLAXIS; SURGICAL GLOVES; SPINA-BIFIDA; HOSPITAL PERSONNEL; ETHYLENE-OXIDE; BARIUM ENEMA; ALLERGY; SHOCK; ANTIGENS	Five hundred sixty-nine subjects routinely underwent skin prick tests for latent sensitization to latex The study of risk factors included skin tests to inhalant allergens to diagnose atopy, and a questionnaire aimed at revealing frequent exposure to latex such as the wearing of gloves, multiple surgical procedures, or urinary catheterization. The subjects were categorized into five groups. group I, subjects with no risk factor (n = 272); group II, nonatopic subjects exposed to later (n = 73); group III, atopic subjects not exposed (n = 180); group IV, exposed atopic subjects (n = 44); and group V, subjects with a history of intraoperative anaphylactic shock caused by latex (n = 13). Twenty-five subjects had spina bifida and were in either group II (14 subjects) or group IV (11 subjects). The questionnaire identified a probable allergy to latex in 18 subjects: 16 cases were confirmed by skin test, but responses were not informative in 23 patients who were sensitive to latex. Positive prick tests to latex were obtained in 0.37% of group I, 6.85% of group II, 9.44% of group III, and 36.36% of group IV. Of the children with spina bifida, 32 % had positive skin test results. As risk factors, atopy and exposure were synergistic. We recommend predictive prick tests not only in children with spina but also in any atopic subject or in any patient with a history of frequent exposure to latex. Latex could be considered a habitual allergen. The use of latex urinary catheters should be avoided in patients who are catheterized on a daily basis.	UNIV NANCY 1, HOP CENT, DEPT ANESTHESIE REANIMAT, F-54013 NANCY, FRANCE; UNIV NANCY 1, FAC MED NANCY, SERV INFORMAT, F-54013 NANCY, FRANCE	CHU de Nancy; Universite de Lorraine; Universite de Lorraine	MONERETVAUTRIN, DA (corresponding author), CHU NANCY, SERV MED D, RUE MORVAN, F-54511 VANDOEUVRE LES NANCY, FRANCE.		Kanny, Gisèle/AHA-8910-2022					ARCHER BL, 1960, BIOCHEM J, V75, P236, DOI 10.1042/bj0750236; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; BEAUDOUIN E, 1990, REV FR ALLERGOL, V30, P157, DOI 10.1016/S0335-7457(05)80230-8; BERNARD PM, 1987, MESURES STATISTIQUES, P120; BEUERS U, 1990, LANCET, V335, P1095, DOI 10.1016/0140-6736(90)92664-4; BRADLEY J, 1991, CAN J ANAESTH, V38, pA100; CALENDA E, 1991, ANESTH ANALG, V72, P845, DOI 10.1213/00000539-199106000-00034; FABRO L, 1989, HAUTARZT, V40, P208; FECZKO PJ, 1989, AM J ROENTGENOL, V153, P275, DOI 10.2214/ajr.153.2.275; GAY G, 1988, Allergie et Immunologie (Paris), V20, P379; GEIER J, 1990, Z HAUTKRANKHEITEN, V65, P267; GELFAND DW, 1991, AM J ROENTGENOL, V156, P1; GERBER AC, 1989, ANESTHESIOLOGY, V71, P800, DOI 10.1097/00000542-198911000-00031; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; LAURENT J, 1992, J ALLERGY CLIN IMMUN, V89, P779, DOI 10.1016/0091-6749(92)90389-J; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; Laxenaire MC, 1992, CURR OPIN ANESTHESIO, V5, P436; LEYNADIER F, 1988, PRESSE MED, V17, P390; LEYNADIER F, 1991, ALLERGY, V46, P619, DOI 10.1111/j.1398-9995.1991.tb00633.x; LEYNADIER F, 1989, REV FR ALLERGOL, V29, P99; MARCOS C, 1991, ANN ALLERGY, V67, P319; Mathey C, 1990, Cah Anesthesiol, V38, P568; MEEROPOL E, 1989, NEW ENGL J MED, V320, P1126; MEURICE JC, 1990, REV FR ALLERGOL, V30, P247, DOI 10.1016/S0335-7457(05)80265-5; MONERETVAUTRIN DA, 1990, LANCET, V335, P865, DOI 10.1016/0140-6736(90)90989-I; MONERETVAUTRIN DA, 1990, ANESTHESIOLOGY, V73, P556, DOI 10.1097/00000542-199009000-00032; MONERETVAUTRIN DA, 1991, CLIN REV ALLERG, V9, P249; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MOSTELLO LA, 1991, ANESTHESIOLOGY, V74, P391, DOI 10.1097/00000542-199102000-00047; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NACEY JN, 1985, BRIT J UROL, V57, P325, DOI 10.1111/j.1464-410X.1985.tb06354.x; NGUYEN DH, 1991, J UROLOGY, V146, P571, DOI 10.1016/S0022-5347(17)37858-8; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; PALMISANO BW, 1991, ANESTHESIOLOGY, V75, P238, DOI 10.1097/00000542-199108000-00011; PARAT S, 1990, ARCH FR PEDIATR, V47, P129; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; Sleth J C, 1990, Cah Anesthesiol, V38, P571; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; SWARTZ J, 1990, CAN J ANAESTH, V37, P589, DOI 10.1007/BF03006333; SWARTZ JS, 1990, CAN J ANAESTH, V37, P5131; TAYLOR JS, 1989, J AM ACAD DERMATOL, V21, P874, DOI 10.1016/S0190-9622(89)70271-1; TURJANMAA K, 1989, ALLERGY, V44, P181, DOI 10.1111/j.1398-9995.1989.tb02259.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029; WARPINSKI JR, 1991, ALLERGY PROC, V12, P95, DOI 10.2500/108854191779011846; WEISS ME, 1989, ANESTHESIOLOGY, V71, P483; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x; 1991, AM SOC ANESTHESIOLOG, V55	54	172	179	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					668	677		10.1016/0091-6749(93)90009-5	http://dx.doi.org/10.1016/0091-6749(93)90009-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227857				2022-12-18	WOS:A1993MG98200007
J	SAMPSON, HA				SAMPSON, HA			THE ROLE OF FOOD ALLERGY AND MEDIATOR RELEASE IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K07AI000830, R01AI024439] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-30] Funding Source: Medline; NIAID NIH HHS [AI00830, AI24439] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATHERTON DJ, 1983, CLIN EXP DERMATOL, V8, P227, DOI 10.1111/j.1365-2230.1983.tb01775.x; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BLAYLOCK WK, 1976, J ALLERGY CLIN IMMUN, V57, P62, DOI 10.1016/0091-6749(76)90080-4; BOLTZNITULESCU G, 1982, J IMMUNOL, V128, P2265; BROSTOFF J, 1979, LANCET, V1, P1268; BRUNNER M, 1928, ARCH INTERN MED, V42, P173; BRUYNZEELKOOMEN C, 1986, ARCH DERMATOL RES, V278, P199, DOI 10.1007/BF00412924; BURKS A, 1986, J ALLERGY CLIN IMMUN, V77, P184; CAPRON A, 1985, INT ARCH ALLER A IMM, V77, P107, DOI 10.1159/000233762; CAPRON M, 1984, J IMMUNOL, V132, P462; CHENOWITH DE, IMMUNOASSAYS CLIN LA, P443; CINES DB, 1986, J IMMUNOL, V136, P3433; Cohen MB, 1930, J IMMUNOL, V18, P419; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DORSCH W, 1981, J ALLERGY CLIN IMMUN, V67, P117, DOI 10.1016/0091-6749(81)90006-3; ENGMAN WF, 1936, MED CLIN N AM, V10, P651; FARBER HW, 1986, J IMMUNOL, V137, P2918; FERRERI NR, 1986, J IMMUNOL, V136, P4188; GERRARD JW, 1984, CLIN REV ALLERG, V2, P143; GLASER J, 1962, PEDIATRICS, V29, P835; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GLEICH GJ, 1986, 12 P INT C ALL CLIN, P124; GOETZL EJ, 1975, ARCH PATHOL, V99, P1; HANIFIN JM, 1986, CLIN REV ALLERG, V4, P43; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HANIFIN JM, 1981, COMPREHENSIVE IMMUNO, P301; Hill LW, 1935, ARCH DERMATOL SYPH, V32, P451, DOI 10.1001/archderm.1935.01470030093010; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; JAKOBSSON I, 1985, ACTA PAEDIATR SCAND, V74, P342, DOI 10.1111/j.1651-2227.1985.tb10981.x; JOHNSON EE, 1974, J ALLERGY CLIN IMMUN, V54, P94, DOI 10.1016/0091-6749(74)90037-2; JOHNSON HH, 1960, J INVEST DERMATOL, V34, P237, DOI 10.1038/jid.1960.38; JOSEPH M, 1986, 12 P INT C ALL CLIN, P135; JUHLIN L, 1967, ACTA DERM-VENEREOL, V42, P218; KAJOSAARI M, 1983, ACTA PAEDIATR SCAND, V72, P411, DOI 10.1111/j.1651-2227.1983.tb09738.x; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V57, P8; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEIFERMAN KM, 1986, J AM ACAD DERMATOL, V15, P513, DOI 10.1016/S0190-9622(86)70203-X; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; LEMANSKE RF, 1987, J ALLERGY CLIN IMMUN, V79, P32, DOI 10.1016/S0091-6749(87)80013-1; LEUNG DYM, 1986, CLIN REV ALLERG, V4, P67; LEUNG DYM, 1983, J IMMUNOL, V130, P1678; LEYDEN JJ, 1979, ARCH DERMATOL, V115, P311, DOI 10.1001/archderm.115.3.311; MACHTINGER S, 1986, J ALLERGY CLIN IMMUN, V77, P341, DOI 10.1016/S0091-6749(86)80115-4; MARONE G, 1986, J INVEST DERMATOL, V87, P19, DOI 10.1111/1523-1747.ep12523520; MAY CD, 1982, CLIN ALLERGY, V12, P229, DOI 10.1111/j.1365-2222.1982.tb02523.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; MCDONALD SM, 1987, J IMMUNOL, V139, P506; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MITCHELL EB, 1986, BRIT J DERMATOL, V114, P65, DOI 10.1111/j.1365-2133.1986.tb02780.x; MOROMTZ M, 1982, SURG GYNECOL OBSTET, V155, P737; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; OERTEL HL, 1981, J IMMUNOL, V127, P1398; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PAGANELLI R, 1979, LANCET, V1, P1270; PAGANELLI R, 1983, ARCH DIS CHILD, V58, P201, DOI 10.1136/adc.58.3.201; PASTERNACK B, 1965, J PEDIATR-US, V66, P164; RAJKA G, 1975, ATOPIC DERMATITIS, V3; ROGGE JL, 1976, ARCH DERMATOL, V112, P1391, DOI 10.1001/archderm.112.10.1391; RUZICKA T, 1987, J IMMUNOL, V138, P539; RUZICKA T, 1986, J INVEST DERMATOL, V86, P105, DOI 10.1111/1523-1747.ep12284061; SAARINEN UM, 1980, LANCET, V1, P166; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SAMPSON HA, 1985, J ALLERGY CLIN IMMUN, V75, P179, DOI 10.1016/0091-6749(85)90432-4; SAMPSON HA, 1987, J ALLERGY CLIN IMMUN, V79, P241; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOLOMON LM, 1986, CAN MED ASS J, V95, P978; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SPIEGELBERG HL, 1984, ADV IMMUNOL, V35, P61, DOI 10.1016/S0065-2776(08)60574-X; STIFLER WC, 1965, J PEDIATR-US, V66, P166; STUART CA, 1984, CLIN ALLERGY, V14, P533, DOI 10.1111/j.1365-2222.1984.tb02240.x; TALBOT S, 1984, Journal of Allergy and Clinical Immunology, V73, P147; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626; TONG AKF, 1986, CLIN REV ALLERG, V4, P27; TUFT L, 1950, J INVEST DERMATOL, V15, P333, DOI 10.1038/jid.1950.107; TUFT L, 1952, J ALLERGY, V23, P528, DOI 10.1016/0021-8707(52)90040-3; WARNER JA, 1986, J IMMUNOL, V136, P2583; WARNER JA, 1986, J IMMUNOL, V123, P626; Wilson SJ, 1935, AM J DIS CHILD, V50, P49, DOI 10.1001/archpedi.1935.01970070058005; WISE F, 1933, YB DERMATOLOGY SYPHI, P59; YODOI J, 1979, J IMMUNOL, V122, P2577; 1979, NIH79387 PUBL, P375	95	172	173	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					635	645		10.1016/0091-6749(88)91033-0	http://dx.doi.org/10.1016/0091-6749(88)91033-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3356844	Bronze			2022-12-18	WOS:A1988N065000002
J	STEVENSON, DD; PLESKOW, WW; SIMON, RA; MATHISON, DA; LUMRY, WR; SCHATZ, M; ZEIGER, RS				STEVENSON, DD; PLESKOW, WW; SIMON, RA; MATHISON, DA; LUMRY, WR; SCHATZ, M; ZEIGER, RS			ASPIRIN-SENSITIVE RHINOSINUSITIS ASTHMA - A DOUBLE-BLIND CROSSOVER STUDY OF TREATMENT WITH ASPIRIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAISER PERMANENTE MED CTR,DEPT ALLERGY & CLIN IMMUNOL,SAN DIEGO,CA	Kaiser Permanente	STEVENSON, DD (corresponding author), SCRIPPS CLIN & RES FDN,DEPT BASIC & CLIN RES,DIV ALLERGY & IMMUNOL 206WA,LA JOLLA,CA 92037, USA.			Zeiger, Robert/0000-0001-5788-5063	NCRR NIH HHS [RR-00833] Funding Source: Medline; NIAID NIH HHS [AI-10386] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIANCO S, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P129; FRIEDMAN WH, 1982, OTOLARYNG HEAD NECK, V90, P171, DOI 10.1177/019459988209000205; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V72, P580; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1982, INVOLVEMENT DRUGS CH, V3, P133; Widal M, 1922, PRESSE MED, V30, P189; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2	9	172	173	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					500	507		10.1016/0091-6749(84)90361-0	http://dx.doi.org/10.1016/0091-6749(84)90361-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM089	6368649	Bronze			2022-12-18	WOS:A1984SM08900012
J	CLAMAN, HN				CLAMAN, HN			HOW CORTICOSTEROIDS WORK	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,DIV CLIN IMMUNOL,CONTAINER 2309,4200 E 9TH AVE,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AVIADO DM, 1970, J CLIN PHARMACOL N D, V10, P3; AZARNOFF DL, 1973, MED CLIN N AM, V57; BALOW JE, 1973, J EXP MED, V137, P1031, DOI 10.1084/jem.137.4.1031; BAXTER JD, 1972, AM J MED, V53, P573, DOI 10.1016/0002-9343(72)90154-4; BORELLA L, 1972, J IMMUNOL, V109, P927; BUTLER WT, 1973, J CLIN INVEST, V52, P2629, DOI 10.1172/JCI107455; CAFFEY J, 1960, PEDIATRICS, V26, P762; CHAI H, 1973, J ALLERGY CLIN IMMUN, V51, P65, DOI 10.1016/S0091-6749(73)80001-6; CLAMAN HN, 1971, J LAB CLIN MED, V78, P499; CLAMAN HN, 1972, NEW ENGL J MED, V287, P388, DOI 10.1056/NEJM197208242870806; COBURG AJ, 1970, SURG GYNECOL OBSTETR, V131, P933; COHEN JJ, 1971, J EXP MED, V133, P1026, DOI 10.1084/jem.133.5.1026; COHEN JJ, 1972, J IMMUNOL, V108, P841; EISEN V, 1968, BRIT J PHARMACOL, V34, P169, DOI 10.1111/j.1476-5381.1968.tb07960.x; FAUCI AS, 1974, J CLIN INVEST, V53, P240, DOI 10.1172/JCI107544; FAUCI AS, 1974, FED PROC, V33, P750; FAUVE RM, 1967, J EXP MED, V125, P806; GERMUTH FG, 1968, JOHNS HOPKINS MED J, V122, P137; GREESON TP, 1973, J INVEST DERMATOL, V61, P242, DOI 10.1111/1523-1747.ep12676501; KALINER M, 1973, J EXP MED, V138, P1077, DOI 10.1084/jem.138.5.1077; LIBBY P, 1973, J CLIN INVEST, V52, P599, DOI 10.1172/JCI107221; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MENDELSOHN J, 1973, J CLIN INVEST, V52, P2129, DOI 10.1172/JCI107397; MOORHEAD JW, 1972, CELL IMMUNOL, V5, P74, DOI 10.1016/0008-8749(72)90085-8; NORTH RJ, 1971, J EXP MED, V134, P1485, DOI 10.1084/jem.134.6.1485; NOWELL PC, 1961, CANCER RES, V21, P1518; OLDS JW, 1974, INFECT IMMUN, V9, P524, DOI 10.1128/IAI.9.3.524-529.1974; PARKER CW, 1973, J CLIN INVEST, V52, P1342, DOI 10.1172/JCI107306; SCHREK R, 1961, P SOC EXP BIOL MED, V108, P328; THOMPSON J, 1970, Journal of Experimental Medicine, V131, P429, DOI 10.1084/jem.131.3.429; TUCHINDA M, 1972, INT ARCH ALLER A IMM, V42, P533, DOI 10.1159/000230634; WARD PA, 1966, J EXP MED, V124, P209, DOI 10.1084/jem.124.2.209; WEISSMAN.G, 1967, ANN NY ACAD SCI, V141, P326, DOI 10.1111/j.1749-6632.1967.tb34897.x; WESTON WL, 1973, J IMMUNOL, V110, P880; YU DTY, 1974, J CLIN INVEST, V53, P565, DOI 10.1172/JCI107591	35	172	172	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	3					145	151		10.1016/0091-6749(75)90010-X	http://dx.doi.org/10.1016/0091-6749(75)90010-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V8448	803519				2022-12-18	WOS:A1975V844800001
J	Gamez-Diaz, L; August, D; Stepensky, P; Revel-Vilk, S; Seidel, MG; Noriko, M; Morio, T; Worth, AJJ; Blessing, J; Van de Veerdonk, F; Feuchtinger, T; Kanariou, M; Schmitt-Graeff, A; Jung, S; Seneviratne, S; Burns, S; Belohradsky, BH; Rezaei, N; Bakhtiar, S; Speckmann, C; Jordan, M; Grimbacher, B				Gamez-Diaz, Laura; August, Dietrich; Stepensky, Polina; Revel-Vilk, Shoshana; Seidel, Markus G.; Noriko, Mitsuiki; Morio, Tomohiro; Worth, Austen J. J.; Blessing, Jacob; Van de Veerdonk, Frank; Feuchtinger, Tobias; Kanariou, Maria; Schmitt-Graeff, Annette; Jung, Sophie; Seneviratne, Suranjith; Burns, Siobhan; Belohradsky, Bernd H.; Rezaei, Nima; Bakhtiar, Shahrzad; Speckmann, Carsten; Jordan, Michael; Grimbacher, Bodo			The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LPS-responsive beige-like anchor protein; primary immunodeficiency; common variable Immunodeficiency; autoimmunity; hypogammaglobulinemia; enteropathy; lymphoproliferation	IMMUNE DYSREGULATION; CHILDHOOD; MUTATIONS; DISEASE	Background: LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. Objective: We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Methods: Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Results: Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents. Conclusion: This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management.	[Gamez-Diaz, Laura; August, Dietrich; Jung, Sophie; Speckmann, Carsten; Grimbacher, Bodo] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Speckmann, Carsten] Univ Med Ctr Freiburg, Ctr Pediat & Adolescent Med, Freiburg, Germany; [Stepensky, Polina; Revel-Vilk, Shoshana] Hadassah Hebrew Univ Hosp, Pediat Hematol Oncol & Bone Marrow Transplantat, Jerusalem, Israel; [Seidel, Markus G.] Med Univ Graz, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Graz, Austria; [Noriko, Mitsuiki; Morio, Tomohiro] Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Grad Sch Med & Dent Sci, Tokyo, Japan; [Worth, Austen J. J.] Great Ormond St Hosp Sick Children, Dept Immunol, London WC1N 3JH, England; [Blessing, Jacob; Jordan, Michael] Univ Cincinnati, Sch Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45221 USA; [Van de Veerdonk, Frank] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands; [Feuchtinger, Tobias] Univ Munich, Pediat Hematol Oncol & Stem Cell Transplantat, Dr von Hauner Univ Childrens Hosp, Munich, Germany; [Kanariou, Maria] Aghia Sophia Childrens Hosp, Dept Immunol, Athens, Greece; [Schmitt-Graeff, Annette] Univ Hosp Freiburg, Dept Pathol, Freiburg, Germany; [Seneviratne, Suranjith; Burns, Siobhan; Grimbacher, Bodo] Royal Free Hosp Fdn Trust, UCL Ctr Immunodeficiency, London, England; [Belohradsky, Bernd H.] Univ Childrens Hosp Munich, Div Immunol & Infect Dis, Munich, Germany; [Rezaei, Nima] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Childrens Med Ctr, Tehran, Iran; [Rezaei, Nima] Univ Tehran Med Sci, Dept Immunol, Sch Med, Tehran, Iran; [Bakhtiar, Shahrzad] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Div Stem Cell Transplantat & Immunol, Dept Children & Adolescents Med, D-60054 Frankfurt, Germany	University of Freiburg; University of Freiburg; Hebrew University of Jerusalem; Hadassah University Medical Center; Medical University of Graz; Tokyo Medical & Dental University (TMDU); University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Radboud University Nijmegen; University of Munich; The Aghia Sophia Children's Hospital; University of Freiburg; University of Munich; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Grimbacher, B (corresponding author), Engesserstr 4,Second Floor, D-79108 Freiburg, Germany.	bodo.grimbacher@uniklinik-freiburg.de	Rezaei, Nima/B-4245-2008; Jung, Sophie/AAA-5556-2021; van de Veerdonk, Frank L/C-7256-2008; Feuchtinger, Tobias/AAS-3869-2021; Netea, Mihai/N-5155-2014; Ba, Sha/HGB-9711-2022; Seidel, Markus G/N-9951-2017	Rezaei, Nima/0000-0002-3836-1827; Jung, Sophie/0000-0002-7925-1077; van de Veerdonk, Frank L/0000-0002-1121-4894; Feuchtinger, Tobias/0000-0002-8517-9681; Morio, Tomohiro/0000-0002-9259-1025; Burns, Siobhan/0000-0002-3356-9506; Seidel, Markus G/0000-0003-0981-8661; Speckmann, Carsten/0000-0002-6217-1556	Bundesministerium fur Bildung und Forschung (BMBF) [IFB/CCI: 01E01303, E-med SysINFLAME: 012X1306F, DZIF: 8000805-3, BMBF: 01GM1517C, BMBF PID-NET: 01GM1111B]	Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF))	Supported by Bundesministerium fur Bildung und Forschung (BMBF) grant nos. IFB/CCI: 01E01303, E-med SysINFLAME: 012X1306F, DZIF: 8000805-3, BMBF: 01GM1517C, and BMBF PID-NET: 01GM1111B.	Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Beck C, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2992; Burns SO, 2012, J ALLERGY CLIN IMMUN, V130, P1428, DOI 10.1016/j.jaci.2012.07.035; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Cullinane AR, 2013, TRAFFIC, V14, P749, DOI 10.1111/tra.12069; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Park JH, 2010, CLIN IMMUNOL, V134, P97, DOI 10.1016/j.clim.2009.10.002; Revel-Vilk S, 2015, CLIN IMMUNOL, V159, P84, DOI 10.1016/j.clim.2015.04.007; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Seidel MG, 2015, J ALLERGY CLIN IMMUN, V135, P1384, DOI 10.1016/j.jaci.2014.10.048; Serwas NK, 2015, INFLAMM BOWEL DIS, V21, P40, DOI 10.1097/MIB.0000000000000266; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7	14	171	179	2	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					223	230		10.1016/j.jaci.2015.09.025	http://dx.doi.org/10.1016/j.jaci.2015.09.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26768763	Green Published, Bronze			2022-12-18	WOS:000367724300014
J	Suarez-Farinas, M; Ungar, B; da Rosa, JC; Ewald, DA; Rozenblit, M; Gonzalez, J; Xu, H; Zheng, XZ; Peng, XY; Estrada, YD; Dillon, SR; Krueger, JG; Guttman-Yassky, E				Suarez-Farinas, Mayte; Ungar, Benjamin; da Rosa, Joel Correa; Ewald, David A.; Rozenblit, Mariya; Gonzalez, Juana; Xu, Hui; Zheng, Xiuzhong; Peng, Xiangyu; Estrada, Yeriel D.; Dillon, Stacey R.; Krueger, James G.; Guttman-Yassky, Emma			RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RNA-seq; microarrays; atopic dermatitis; lesional transcriptome	GENE-EXPRESSION; IL-36 CYTOKINES; SKIN; PSORIASIS; SEQ; IMMUNE; ACTIVATION; CYCLOSPORINE; CELLS; REGULATORS	Background: Genomic profiling of lesional and nonlesional skin of patients with atopic dermatitis (AD) using microarrays has led to increased understanding of AD and identification of novel therapeutic targets. However, the limitations of microarrays might decrease detection of AD genes. These limitations might be lessened with next-generation RNA sequencing (RNA-seq). Objective: We sought to define the lesional AD transcriptome using RNA-seq and compare it using microarrays performed on the same cohort. Methods: RNA-seq and microarrays were performed to identify differentially expressed genes (criteria: fold change, >= 2.0; false discovery rate <= 0.05) in lesional versus nonlesional skin from 18 patients with moderate-to-severe AD, with real-time PCR (RT-PCR) and immunohistochemistry used for validation. Results: Both platforms showed robust disease transcriptomes and correlated well with RT-PCR. The common AD transcriptome identified by using both techniques contained 217 genes, including inflammatory (S100A8/A9/A12, CXCL1, and 2'-5'-oligoadenylate synthetase-like [OASL]) and barrier (MKi67, keratin 16 [K16], and claudin 8 [CLDN8]) AD-related genes. Although fold change estimates determined by using RNA-seq showed somewhat better agreement with RT-PCR (intraclass correlation coefficient, 0.57 and 0.70 for microarrays and RNA-seq vs RT-PCR, respectively), bias was not eliminated. Among genes uniquely identified by using RNA-seq were triggering receptor expressed on myeloid cells 1 (TREM-1) signaling (eg, CCL2, CCL3, and single immunoglobulin domain IL1R1 related [SIGIRR]) and IL-36 isoform genes. TREM-1 is a surface receptor implicated in innate and adaptive immunity that amplifies infection-related inflammation. Conclusions: This is the first report of a lesional AD phenotype using RNA-seq and the first direct comparison between platforms in this disease. Both platforms robustly characterize the AD transcriptome. Through RNA-seq, we unraveled novel disease pathology, including increased expression of the novel TREM-1 pathway and the IL-36 cytokine in patients with AD.	[Suarez-Farinas, Mayte; Ungar, Benjamin; da Rosa, Joel Correa; Ewald, David A.; Rozenblit, Mariya; Gonzalez, Juana; Xu, Hui; Zheng, Xiuzhong; Peng, Xiangyu; Estrada, Yeriel D.; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA; [Ungar, Benjamin; Rozenblit, Mariya; Xu, Hui; Peng, Xiangyu; Estrada, Yeriel D.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Ungar, Benjamin; Rozenblit, Mariya; Xu, Hui; Peng, Xiangyu; Estrada, Yeriel D.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Ewald, David A.] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark; [Dillon, Stacey R.] ZymoGenetics, Seattle, WA USA	Rockefeller University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Technical University of Denmark; Zymogenet Inc.	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Da Rosa, Joel/AAU-1238-2020; Correa da Rosa, Joel/Q-4753-2017	Da Rosa, Joel/0000-0003-4221-1976; Correa da Rosa, Joel/0000-0003-4221-1976; Ungar, Benjamin/0000-0003-0882-8163; Rozenblit, Mariya/0000-0002-8874-6688; Ewald, David Adrian/0000-0001-6620-2738	National Center for Advancing Translational Sciences (NCATS), a National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program [UL1 TR000043]; Bristol-Myers Squibb; Danish Ministry of Higher Education and Science; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000043] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences (NCATS), a National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program; Bristol-Myers Squibb(Bristol-Myers Squibb); Danish Ministry of Higher Education and Science; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported in part by grant no. UL1 TR000043 from the National Center for Advancing Translational Sciences (NCATS), a National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. Also supported by a research grant to E.G.-Y. from Bristol-Myers Squibb. D.A.E is a joint PhD student of Leo Pharma and DTU and partly funded by the Danish Ministry of Higher Education and Science.	Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bleharski JR, 2003, J IMMUNOL, V170, P3812, DOI 10.4049/jimmunol.170.7.3812; Blumberg H, 2007, J EXP MED, V204, P2603, DOI 10.1084/jem.20070157; Blumberg H, 2010, J IMMUNOL, V185, P4354, DOI 10.4049/jimmunol.1000313; Carrier Y, 2011, J INVEST DERMATOL, V131, P2428, DOI 10.1038/jid.2011.234; Chamlin SL, 2010, IMMUNOL ALLERGY CLIN, V30, P281, DOI 10.1016/j.iac.2010.05.004; CHRISTOPHERS E, 1987, ARCH DERMATOL RES, V279, pS48, DOI 10.1007/BF00585919; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Czarnowicki T, 2014, J ALLER CL IMM-PRACT, V2, P371, DOI 10.1016/j.jaip.2014.03.006; Dohm JC, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn425; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Foster AM, 2014, J IMMUNOL, V192, P6053, DOI 10.4049/jimmunol.1301481; Frey S, 2013, ANN RHEUM DIS, V72, P1569, DOI 10.1136/annrheumdis-2012-202264; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gresnigt MS, 2013, SEMIN IMMUNOL, V25, P458, DOI 10.1016/j.smim.2013.11.003; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Horst SA, 2013, J INNATE IMMUN, V5, P581, DOI 10.1159/000348283; Hyder LA, 2013, J INVEST DERMATOL, V133, P1742, DOI 10.1038/jid.2013.68; Jabbari A, 2012, J INVEST DERMATOL, V132, P246, DOI 10.1038/jid.2011.267; Jones DC, 2012, BIOINFORMATICS, V28, P921, DOI 10.1093/bioinformatics/bts055; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Leung DYM, 2003, CURR OPIN PEDIATR, V15, P399, DOI 10.1097/00008480-200308000-00008; Li BS, 2014, J INVEST DERMATOL, V134, P1828, DOI 10.1038/jid.2014.28; Liu S, 2011, NUCLEIC ACIDS RES, V39, P578, DOI 10.1093/nar/gkq817; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Mutamba S, 2012, EUR J IMMUNOL, V42, P607, DOI 10.1002/eji.201142035; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Oku R, 2013, CYTOKINE, V61, P112, DOI 10.1016/j.cyto.2012.09.003; Roy NC, 2011, BRIEF FUNCT GENOMICS, V10, P135, DOI 10.1093/bfgp/elr005; Rozenblit M, 2014, J ALLERGY CLIN IMMUN, V134, P955, DOI 10.1016/j.jaci.2014.05.024; Russell CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/jimmunol.1301737; Shemer A, 2013, J ALLERGY CLIN IMMUN, V131, P577, DOI 10.1016/j.jaci.2012.11.010; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Swindell WR, 2014, PHYSIOL GENOMICS, V46, P533, DOI 10.1152/physiolgenomics.00022.2014; Tajima K, 2003, IMMUNOLOGY, V108, P321, DOI 10.1046/j.1365-2567.2003.01585.x; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tsuda K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031465; Ubagai T, 2014, INT J MED SCI, V11, P215, DOI 10.7150/ijms.7231; van der Fits L, 2011, J INVEST DERMATOL, V131, P762, DOI 10.1038/jid.2010.349; Vigne S, 2011, BLOOD, V118, P5813, DOI 10.1182/blood-2011-05-356873; Wang L, 2014, MOL IMMUNOL, V59, P163, DOI 10.1016/j.molimm.2014.02.004; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Yamada Y, 2014, BIOCHEM BIOPH RES CO, V443, P980, DOI 10.1016/j.bbrc.2013.12.078; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094	51	171	177	1	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1218	1227		10.1016/j.jaci.2015.03.003	http://dx.doi.org/10.1016/j.jaci.2015.03.003			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25840722				2022-12-18	WOS:000353980700015
J	Sharpe, RA; Bearman, N; Thornton, CR; Husk, K; Osborne, NJ				Sharpe, Richard A.; Bearman, Nick; Thornton, Christopher R.; Husk, Kerryn; Osborne, Nicholas J.			Indoor fungal diversity and asthma: A meta-analysis and systematic review of risk factors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Systematic review; damp; indoor fungi and allergic asthma	RELATIVE MOLDINESS INDEX; MOISTURE-RELATED PROBLEMS; AIRBORNE FUNGI; RESPIRATORY SYMPTOMS; CHILDHOOD ISAAC; HOUSEHOLD MOLD; OUTDOOR AIR; US HOMES; 1ST YEAR; ALLERGENS	Background: Indoor dampness increases the risk of indoor fungal growth. A complex interaction between occupant behaviors and the built environment are thought to affect indoor fungal concentrations and species diversity, which are believed to increase the risk of having asthma, exacerbation of asthma symptoms, or both. To date, no systematic review has investigated this relationship. Objective: This review aims to assess the relationship between exposure to indoor fungi identified to the genera or species level on asthma outcomes in children and adults. Methods: Ten databases were systematically searched on April 18, 2013, and limited to articles published since 1990. Reference lists were independently screened by 2 reviewers, and authors were contacted to identify relevant articles. Data were extracted from included studies meeting our eligibility criteria by 2 reviewers and quality assessed by using the Newcastle-Ottawa scale designed for assessment of case-control and cohort studies. Results: Cladosporium, Alternaria, Aspergillus, and Penicillium species were found to be present in higher concentrations in homes of asthmatic participants. Exposure to Penicillium, Aspergillus, and Cladosporium species were found to be associated with increased risk of reporting asthma symptoms by a limited number of studies. The presence of Cladosporium, Alternaria, Aspergillus, and Penicillium species increased the exacerbation of current asthma symptoms by 36% to 48% compared with those exposed to lower concentrations of these fungi, as shown by using random-effect estimates. Studies were of medium quality and showed medium-high heterogeneity, but evidence concerning the specific role of fungal species was limited. Conclusion: Longitudinal studies assessing increased exposure to indoor fungi before the development of asthma symptoms suggests that Penicillium, Aspergillus, and Cladosporium species pose a respiratory health risk in susceptible populations. Increased exacerbation of current asthma symptoms in children and adults were associated with increased levels of Penicillium, Aspergillus, Cladosporium, and Alternaria species, although further work should consider the role of fungal diversity and increased exposure to other fungal species.	[Sharpe, Richard A.; Bearman, Nick; Husk, Kerryn; Osborne, Nicholas J.] Univ Exeter, Sch Med, European Ctr Environm & Human Hlth, Truro TR1 3HD, Cornwall, England; [Bearman, Nick] Univ Liverpool, Dept Geog & Planning, Liverpool L69 3BX, Merseyside, England; [Thornton, Christopher R.] Univ Exeter, Coll Life & Environm Sci, Truro TR1 3HD, Cornwall, England; [Osborne, Nicholas J.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia	University of Exeter; University of Liverpool; University of Exeter; University of Melbourne	Osborne, NJ (corresponding author), Univ Exeter, Royal Cornwall Hosp, Knowledge Spa, European Ctr Environm & Human Hlth,Med Sch, Truro TR1 3HD, Cornwall, England.	n.j.osborne@exeter.ac.uk	Osborne, Nicholas/D-2086-2011	Osborne, Nicholas/0000-0002-6700-2284; Husk, Kerryn/0000-0001-5674-8673	European Social Fund Convergence Programme for Cornwall; Isles of Scilly; European Regional Development Fund Programme [202497, 500020]	European Social Fund Convergence Programme for Cornwall; Isles of Scilly; European Regional Development Fund Programme	R.A.S.'s PhD scholarship was funded by the European Social Fund Convergence Programme for Cornwall and the Isles of Scilly and was undertaken in collaboration with Coastline Housing (ESF Phase 1: 09099NCO5 and ESF Phase 2: 11200NCO5). The European Centre for Environment and Human Health (part of the University of Exeter Medical School) is partially financed by the European Regional Development Fund Programme 2007 to 2013 (ERDF Phase 1: 202497 and ERDF Phase 2: 500020) and European Social Fund Convergence Programme for Cornwall and the Isles of Scilly.	Adams RI, 2013, ISME J, V7, P1262, DOI 10.1038/ismej.2013.28; Agarwal R, 2011, MED MYCOL, V49, pS150, DOI 10.3109/13693786.2010.504752; Agbetile J, 2012, CLIN EXP ALLERGY, V42, P782, DOI 10.1111/j.1365-2222.2012.03987.x; [Anonymous], COCHR HDB; Araki A, 2012, SCI TOTAL ENVIRON, V423, P18, DOI 10.1016/j.scitotenv.2012.02.026; ARUNDEL AV, 1986, ENVIRON HEALTH PERSP, V65, P351, DOI 10.2307/3430203; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barnes CS, 2013, J ALLER CL IMM-PRACT, V1, P137, DOI 10.1016/j.jaip.2012.07.002; Blanc PD, 2013, ENVIRON RES, V122, P98, DOI 10.1016/j.envres.2013.01.002; Breitenbach M, 2008, INT ARCH ALLERGY IMM, V145, P58, DOI 10.1159/000107578; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Bundy KW, 2009, ANN ALLERG ASTHMA IM, V103, P26, DOI 10.1016/S1081-1206(10)60139-1; Chew GL, 2003, ALLERGY, V58, P13, DOI 10.1034/j.1398-9995.2003.00013.x; Cho SJ, 2008, J OCCUP ENVIRON HYG, V5, P780, DOI 10.1080/15459620802490267; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Crameri R, 2014, ALLERGY, V69, P176, DOI 10.1111/all.12325; Crawford C, 2009, AEROBIOLOGIA, V25, P147, DOI 10.1007/s10453-009-9120-z; Dales RE, 1999, MYCOPATHOLOGIA, V147, P21, DOI 10.1023/A:1007096704217; Denning DW, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-14; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dharmage S, 2001, AM J RESP CRIT CARE, V164, P65, DOI 10.1164/ajrccm.164.1.9911066; Environmental Protection Agency, PUBL HLTH CONS COST; Fairs A, 2010, J INVEST ALLERG CLIN, V20, P490; Fernandez-Rodriguez S, 2014, FUNGAL ECOL, V7, P16, DOI 10.1016/j.funeco.2013.11.004; Fisk WJ, 2007, INDOOR AIR, V17, P284, DOI 10.1111/j.1600-0668.2007.00475.x; Frankel M, 2012, APPL ENVIRON MICROB, V78, P8289, DOI 10.1128/AEM.02069-12; Gaffin JM, 2009, CURR OPIN ALLERGY CL, V9, P128, DOI 10.1097/ACI.0b013e32832678b0; Gent JF, 2012, ENVIRON RES, V118, P86, DOI 10.1016/j.envres.2012.07.005; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781, DOI 10.1289/ehp.021100781; Gravesen S, 1999, ENVIRON HEALTH PERSP, V107, P505, DOI 10.1289/ehp.99107s3505; Hayes D, 2013, CLIN RESPIR J, V7, P135, DOI 10.1111/j.1752-699X.2012.00294.x; Heederik D, 2012, J ALLERGY CLIN IMMUN, V130, P44, DOI 10.1016/j.jaci.2012.01.067; Herrera AB, 2011, BIOMEDICA, V31, P357, DOI 10.1590/S0120-41572011000300008; Holme J, 2010, INDOOR AIR, V20, P329, DOI 10.1111/j.1600-0668.2010.00658.x; Jaakkola JJK, 2005, ENVIRON HEALTH PERSP, V113, P357, DOI 10.1289/ehp.7242; Jaakkola MS, 2006, J ALLERGY CLIN IMMUN, V117, P642, DOI 10.1016/j.jaci.2005.11.003; Jaakkola MS, 2002, ENVIRON HEALTH PERSP, V110, P543, DOI 10.1289/ehp.02110543; Jones R, 2011, INDOOR AIR, V21, P156, DOI 10.1111/j.1600-0668.2010.00692.x; Larsson M, 2011, INT J ENVIRON HEAL R, V21, P237, DOI 10.1080/09603123.2010.533368; Laverge J, 2011, BUILD ENVIRON, V46, P1497, DOI 10.1016/j.buildenv.2011.01.023; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72, DOI 10.1080/00039899709603804; Matheson MC, 2005, CLIN EXP ALLERGY, V35, P907, DOI 10.1111/j.1365-2222.2005.02272.x; Matsuwaki Y, 2012, INT ARCH ALLERGY IMM, V158, P19, DOI 10.1159/000337756; Meheust D, 2014, CRIT REV MICROBIOL, V40, P248, DOI 10.3109/1040841X.2013.777687; Mendell MJ, 2011, ENVIRON HEALTH PERSP, V119, P748, DOI 10.1289/ehp.1002410; Meng J, 2012, CLIN EXP ALLERGY, V42, P1448, DOI 10.1111/j.1365-2222.2012.04001.x; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Nasser SM, 2009, CURR ALLERGY ASTHM R, V9, P384, DOI 10.1007/s11882-009-0056-8; Pashley CH, 2012, FUNGAL BIOL-UK, V116, P214, DOI 10.1016/j.funbio.2011.11.004; Pongracic JA, 2010, J ALLERGY CLIN IMMUN, V125, P593, DOI 10.1016/j.jaci.2009.10.036; Pulimood TB, 2007, J ALLERGY CLIN IMMUN, V120, P610, DOI 10.1016/j.jaci.2007.04.045; Quansah R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047526; Reponen T, 2013, ENVIRON RES, V124, P67, DOI 10.1016/j.envres.2013.04.003; Reponen T, 2012, J ALLERGY CLIN IMMUN, V130, P639, DOI 10.1016/j.jaci.2012.05.030; Rosenbaum PF, 2010, J EXPO SCI ENV EPID, V20, P503, DOI 10.1038/jes.2009.27; Salo PM, 2008, J ALLERGY CLIN IMMUN, V121, P678, DOI 10.1016/j.jaci.2007.12.1164; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Sharma R, 2011, ALLERGY RHINOL, V2, P21, DOI 10.2500/ar.2011.2.0005; Sharpe R, 2014, CLIN EXP ALLERGY, V44, P631, DOI 10.1111/cea.12281; STRACHAN DP, 1990, THORAX, V45, P382, DOI 10.1136/thx.45.5.382; Su HJ, 2001, ENVIRON RES, V85, P135, DOI 10.1006/enrs.2000.4113; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Turyk M, 2006, J ASTHMA, V43, P453, DOI 10.1080/02770900600758333; Vesper S, 2008, SCI TOTAL ENVIRON, V394, P192, DOI 10.1016/j.scitotenv.2008.01.031; Vesper S, 2007, J OCCUP ENVIRON MED, V49, P829, DOI 10.1097/JOM.0b013e3181255e98; Vesper S, 2011, J ENVIRON PUBLIC HEA, V2011, DOI 10.1155/2011/242457; Vesper S, 2011, CRIT REV MICROBIOL, V37, P15, DOI 10.3109/1040841X.2010.506177; Vesper SJ, 2006, J OCCUP ENVIRON MED, V48, P852, DOI 10.1097/01.jom.0000224736.52780.2f; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Weinmayr G, 2013, CLIN EXP ALLERGY, V43, P762, DOI 10.1111/cea.12107; Wilkinson P, 2007, LANCET, V370, P1175, DOI 10.1016/S0140-6736(07)61255-0; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	73	171	176	4	84	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					110	122		10.1016/j.jaci.2014.07.002	http://dx.doi.org/10.1016/j.jaci.2014.07.002			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25159468				2022-12-18	WOS:000347298200013
J	Alangari, A; Alsultan, A; Adly, N; Massaad, MJ; Kiani, IS; Aljebreen, A; Raddaoui, E; Almomen, AK; Al-Muhsen, S; Geha, RS; Alkuraya, FS				Alangari, Abdullah; Alsultan, Abdulrahman; Adly, Nouran; Massaad, Michel J.; Kiani, Iram Shakir; Aljebreen, Abdulrahman; Raddaoui, Emad; Almomen, Abdul-Kareem; Al-Muhsen, Saleh; Geha, Raif S.; Alkuraya, Fowzan S.			LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LPS-responsive beige-like anchor (LRBA); chronic diarrhea; common variable immunodeficiency; autoimmunity	COMMON VARIABLE IMMUNODEFICIENCY; ANTIBODY-DEFICIENCY SYNDROME; B-CELL; TACI	Background: Clinical immunology has traditionally relied on accurate phenotyping of the patient's immune dysfunction for the identification of a candidate gene or genes for sequencing and molecular confirmation. Although this is also true for other branches of medicine, the marked variability in immune-related phenotypes and the highly complex network of molecules that confer normal host immunity are challenges that clinical immunologists often face in their quest to establish a specific genetic diagnosis. Objective: We sought to identify the underlying genetic cause in a consanguineous family with chronic inflammatory bowel disease-like disorder and combined immunodeficiency. Methods: We performed exome sequencing followed by autozygome filtration. Results: A truncating mutation in LPS-responsive beige-like anchor (LRBA), which abolished protein expression, was identified as the most likely candidate variant in this family. Conclusion: The combined exome sequencing and autozygosity mapping approach is a powerful tool in the study of atypical immune dysfunctions. We identify LRBA as a novel immunodeficiency candidate gene the precise role of which in the immune system requires future studies. (J Allergy Clin Immunol 2012; 130:481-8.)	[Alangari, Abdullah; Alsultan, Abdulrahman; Al-Muhsen, Saleh; Alkuraya, Fowzan S.] King Saud Univ, Dept Pediat, King Khalid Univ Hosp, Riyadh, Saudi Arabia; [Kiani, Iram Shakir; Aljebreen, Abdulrahman; Almomen, Abdul-Kareem] King Saud Univ, Dept Internal Med, King Khalid Univ Hosp, Riyadh, Saudi Arabia; [Massaad, Michel J.; Raddaoui, Emad] King Saud Univ, Dept Pathol, King Khalid Univ Hosp, Riyadh, Saudi Arabia; King Saud Univ, Coll Med, Riyadh 11461, Saudi Arabia; [Alkuraya, Fowzan S.] King Faisal Specialist Hosp & Res Ctr, Dev Genet Unit, Dept Genet, Riyadh 11211, Saudi Arabia; [Geha, Raif S.] Harvard Univ, Sch Med, Boston, MA USA; [Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Alkuraya, Fowzan S.] Alfaisal Univ, Coll Med, Dept Anat & Cell Biol, Riyadh, Saudi Arabia	King Saud University; King Khalid University Hospital; King Saud University; King Khalid University Hospital; King Saud University; King Khalid University Hospital; King Saud University; King Faisal Specialist Hospital & Research Center; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Alfaisal University	Alkuraya, FS (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dev Genet Unit, Dept Genet, MBC 03,POB 3354, Riyadh 11211, Saudi Arabia.	falkuraya@kfshrc.edu.sa	Al-muhsen, saleh/E-9315-2014; Alkuraya, Fowzan S./A-1542-2009	Al-muhsen, saleh/0000-0003-3698-9968; Alkuraya, Fowzan S./0000-0003-4158-341X; Alsultan, Abdulrahman/0000-0001-5577-3228	KFSHRC; National Institutes of Health [AI-076210, AI094017]; Perkin-Elmer Foundation; Dubai-Harvard Foundation for Medical Research; Research Center at King Faisal Specialist Hospital & Research Centre; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, R03AI094017] Funding Source: NIH RePORTER	KFSHRC; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Perkin-Elmer Foundation; Dubai-Harvard Foundation for Medical Research; Research Center at King Faisal Specialist Hospital & Research Centre; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by an intramural fund from KFSHRC (to F.S.A.), National Institutes of Health grants AI-076210 and AI094017 (to R.S.G.), the Perkin-Elmer Foundation (to R.S.G.), and the Dubai-Harvard Foundation for Medical Research (to R.S.G. and F.S.A.).; N. Adly has received grants from and is employed by the Research Center at King Faisal Specialist Hospital & Research Centre. R. S. Geha has received grants from the National Institutes of Health, is employed by Children's Hospital Boston, has patents for Quickchange and Stratogene, and receives royalties for the book Pediatric Allergy Cases in Immunology. F. S. Alkuraya has received grants from the Dubai Harvard Foundation for Medical Research. The rest of the authors declare that they have no relevant conflicts of interest.	Agarwal S, 2011, INFLAMM BOWEL DIS, V17, P251, DOI 10.1002/ibd.21376; Al-Herz W, 2011, FRONT PRIMARY IMMUNO, V2, P1; Alkuraya FS, 2010, GENET MED, V12, P765, DOI 10.1097/GIM.0b013e3181fbfcc4; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Carr IM, 2006, HUM MUTAT, V27, P1041, DOI 10.1002/humu.20383; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Cunningham-Rundles C, IMMUNOL RES; de Souza N, 2007, DEVELOPMENT, V134, P691, DOI 10.1242/dev.02767; Fischer A, 2007, IMMUNITY, V27, P835, DOI 10.1016/j.immuni.2007.11.012; FISCHER MB, 1994, BLOOD, V84, P4234, DOI 10.1182/blood.V84.12.4234.bloodjournal84124234; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Huizing M, 2008, ANNU REV GENOM HUM G, V9, P359, DOI 10.1146/annurev.genom.9.081307.164303; Kaplan J, 2008, CURR OPIN HEMATOL, V15, P22, DOI 10.1097/MOH.0b013e3282f2bcce; Kuijpers TW, 2010, J CLIN INVEST, V120, P214, DOI 10.1172/JCI40231; Moratto D, 2006, CLIN IMMUNOL, V121, P203, DOI 10.1016/j.clim.2006.07.003; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Park JH, 2011, ANN NY ACAD SCI, V1246, P41, DOI 10.1111/j.1749-6632.2011.06338.x; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2012, ANN NY ACAD SCI, V1250, P41, DOI 10.1111/j.1749-6632.2011.06377.x; STAGG AJ, 1994, CLIN EXP IMMUNOL, V96, P48; Thiel J, 2012, J ALLERGY CLIN IMMUN, V129, P801, DOI 10.1016/j.jaci.2011.09.027; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567; Wang JW, 2001, J IMMUNOL, V166, P4586, DOI 10.4049/jimmunol.166.7.4586; Ward Diane McVey, 2002, Current Molecular Medicine (Hilversum), V2, P469, DOI 10.2174/1566524023362339; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Yuseff MI, 2009, TRAFFIC, V10, P629, DOI 10.1111/j.1600-0854.2009.00913.x; Zarzour W, 2005, MOL GENET METAB, V85, P125, DOI 10.1016/j.ymgme.2005.02.011	30	171	182	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					481	+		10.1016/j.jaci.2012.05.043	http://dx.doi.org/10.1016/j.jaci.2012.05.043			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22721650	Green Accepted			2022-12-18	WOS:000307002200031
J	Salo, PM; Arbes, SJ; Sever, M; Jaramillo, R; Cohn, RD; London, SJ; Zeldin, DC				Salo, Paivi M.; Arbes, Samuel J., Jr.; Sever, Michelle; Jaramillo, Renee; Cohn, Richard D.; London, Stephanie J.; Zeldin, Darryl C.			Exposure to Alternaria alternata in US homes is associated with asthma symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alternaria alternata; fungal allergen; antigen; indoor; exposure; asthma; allergy	FUNGAL ALLERGENS; NATIONAL-HEALTH; AIRBORNE FUNGI; RISK-FACTOR; INDOOR; OUTDOOR; SPORES; CHILDREN; SENSITIZATION; AEROALLERGEN	Background: Exposure to the fungus Alternaria alternata is a risk factor for asthma. Few studies have examined Alternaria exposures in indoor environments. Objective: We examined whether exposure to A alternata in US homes was associated with asthma-related outcomes. Methods: The data for this study were collected as part of the National Survey of Lead and Allergens in Housing. This cross-sectional study surveyed a nationally representative sample of 831 housing units inhabited by 2456 individuals in 75 different locations throughout the United States. An interviewer-administered questionnaire obtained information on demographics, household characteristics, and occupants' health status. Exposure to A alternata was assessed by measuring concentrations of A alternata antigens in vacuumed dust samples using a polyclonal anti-A alternata antibody assay. Dust samples were collected from a bed, a sofa, or a chair, and from bedroom, living room, and kitchen floors. Results: Lifetime prevalence of doctor-diagnosed asthma was 11.2%, and 6.9% of the study subjects reported active asthma symptoms in the past 12 months. The prevalence of current symptomatic asthma increased with increasing Alternaria concentrations in US homes; higher levels of A alternata antigens increased the odds of having asthma symptoms in the past year (relative to the lowest tertile, adjusted odds ratio was 1.52, 95% CI, 0.90-2.55 for the 2nd tertile; and 1.84, 95% Cl, 1.18-2.85 for the 3rd tertile). Conclusion: Exposure to A alternata in US homes is associated with active asthma symptoms. Clinical implications: Measures that reduce indoor exposure to A alternata may help control asthma exacerbations.	NIH, NIEHS, Res Triangle Pk, NC 27709 USA; Constella Grp LLC, Durham, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Zeldin, DC (corresponding author), NIH, NIEHS, 111 Alexander Dr,Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018; London, Stephanie/C-3734-2019	Zeldin, Darryl C/0000-0002-2087-7307; London, Stephanie/0000-0003-4911-5290; Sever, Michelle/0000-0002-2435-1214	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025041] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES025041-10] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andersson M, 2003, PEDIAT ALLERG IMM-UK, V14, P100, DOI 10.1034/j.1399-3038.2003.00031.x; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P133, DOI 10.1016/j.jaci.2005.04.022; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Barnes C, 2001, ANN ALLERG ASTHMA IM, V86, P517, DOI 10.1016/S1081-1206(10)62899-2; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; Berger WE, 2003, ANN ALLERG ASTHMA IM, V90, P7, DOI 10.1016/S1081-1206(10)61653-5; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Britton J, 1998, CLIN EXP ALLERGY, V28, P2; Burge HA, 2000, ENVIRON HEALTH PERSP, V108, P653, DOI 10.2307/3454401; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Bush RK, 2001, J ALLERGY CLIN IMMUN, V107, pS430, DOI 10.1067/mai.2001.113669; *CDCP, 2005, ASTHM NAT HLTH INT S; Chapman MD, 2000, CLIN REV ALLERG IMMU, V18, P285, DOI 10.1385/CRIAI:18:3:285; *COMM ASS ASTHM IN, 2000, CLEAR AIR ASTHM IND, P105; Corden J.M., 2001, AEROBIOLOGIA, V17, P127, DOI [10.1023/A, DOI 10.1023/A:1010876917512, 10.1023/A:1010876917512]; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622, DOI 10.2307/3433608; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P1481, DOI 10.1046/j.1365-2222.1999.00640.x; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459, DOI 10.1046/j.1365-2222.1998.00255.x; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Green BJ, 2005, J ALLERGY CLIN IMMUN, V115, P1043, DOI 10.1016/j.jaci.2005.02.009; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P271, DOI 10.2500/108854198778557728; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; Instanes C, 2004, CLIN EXP ALLERGY, V34, P1634, DOI 10.1111/j.1365-2222.2004.02076.x; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Leech JA, 2002, J EXPO ANAL ENV EPID, V12, P427, DOI 10.1038/sj.jea.7500244; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; Mitakakis TZ, 2000, CLIN EXP ALLERGY, V30, P1733, DOI 10.1046/j.1365-2222.2000.00966.x; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; O'Connor GT, 2004, J ALLERGY CLIN IMMUN, V114, P599, DOI 10.1016/j.jaci.2004.05.064; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; Platts-Mills TAE, 2004, J ALLERGY CLIN IMMUN, V113, P388, DOI 10.1016/j.jaci.2003.12.027; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P773, DOI 10.1016/0091-6749(93)90197-N; Portnoy JM, 2005, ANN ALLERG ASTHMA IM, V94, P313, DOI 10.1016/S1081-1206(10)60982-9; Portnoy JM, 2004, J ALLERGY CLIN IMMUN, V113, P189, DOI 10.1016/j.jaci.2003.11.021; Ren P, 1999, J EXPO ANAL ENV EPID, V9, P560, DOI 10.1038/sj.jea.7500061; Salo PM, 2005, J ALLERGY CLIN IMMUN, V116, P623, DOI 10.1016/j.jaci.2005.05.030; Schmechel D, 2005, INDOOR AIR, V15, P11, DOI 10.1111/j.1600-0668.2005.00340.x; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; Stark PC, 2005, ENVIRON HEALTH PERSP, V113, P1405, DOI 10.1289/ehp.7844; Sterling DA, 1998, ANN ALLERG ASTHMA IM, V80, P279, DOI 10.1016/S1081-1206(10)62971-7; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527, DOI 10.1289/ehp.02110527	47	171	177	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					892	898		10.1016/j.jaci.2006.07.037	http://dx.doi.org/10.1016/j.jaci.2006.07.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030243	Green Accepted			2022-12-18	WOS:000241434200017
J	Sicherer, SH				Sicherer, SH			Food protein-induced enterocolitis syndrome: Case presentations and management lessons	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; food protein-induced enterocolitis syndrome	COWS MILK ALLERGY; EPITHELIAL BARRIER FUNCTION; NECROSIS-FACTOR-ALPHA; ATOPY PATCH TEST; GASTROINTESTINAL MANIFESTATIONS; CLINICAL-FEATURES; SKIN PRICK; TNF-ALPHA; INFANTS; SOY	Enterocolitis induced in infants by cow's milk and/or soy protein has been recognized for decades. Symptoms typically begin in the first month of life in association with failure to thrive and may progress to acidemia and shock. Symptoms resolve after the causal protein is removed from the diet but recur with a characteristic symptom pattern on re-exposure. Approximately 2 hours after reintroduction of the protein, vomiting ensues, followed by an elevation of the peripheral blood polymorphonuclear leukocyte count, diarrhea, and possibly lethargy and hypotension. The disorder is generally not associated with detectable food-specific IgE antibody. There are increasing reports of additional causal foods, prolonged clinical courses, and onset outside of early infancy, leading to description of a food protein-induced enterocolitis syndrome. The disorder poses numerous diagnostic and therapeutic challenges. The purpose of this report is to delineate the characteristic clinical features and review the possible pathophysiologic basis to frame a rational strategy toward management.	Mt Sinai Sch Med, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, New York, NY USA	Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), Mt Sinai Hosp, Jaffe Food Allergy Inst, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu						Benlounes N, 1996, J ALLERGY CLIN IMMUN, V98, P781, DOI 10.1016/S0091-6749(96)70127-6; Benlounes N, 1999, J ALLERGY CLIN IMMUN, V104, P863, DOI 10.1016/S0091-6749(99)70300-3; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Burks A W, 1994, Pediatr Allergy Immunol, V5, P40; Busse PJ, 2000, J ALLERGY CLIN IMMUN, V105, pS129, DOI 10.1016/S0091-6749(00)90815-7; Chung HL, 2002, J ALLERGY CLIN IMMUN, V109, P150, DOI 10.1067/mai.2002.120562; COELLORAMIREZ P, 1984, J PEDIATR GASTR NUTR, V3, P215, DOI 10.1097/00005176-198403000-00008; de Boissieu D, 2003, J PEDIATR-US, V142, P203, DOI 10.1067/mpd.2003.92; FONTAINE JL, 1975, ARCH DIS CHILD, V50, P357, DOI 10.1136/adc.50.5.357; GOLDMAN H, 1986, AM J SURG PATHOL, V10, P75, DOI 10.1097/00000478-198602000-00001; GRYBOSKI JD, 1967, PEDIATRICS, V40, P354; HALPIN TC, 1977, J PEDIATR-US, V91, P404, DOI 10.1016/S0022-3476(77)81308-5; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514, DOI 10.1016/0016-5085(94)90405-7; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Jarvinen KM, 1999, J PEDIATR-US, V135, P506, DOI 10.1016/S0022-3476(99)70175-7; JENKINS HR, 1984, ARCH DIS CHILD, V59, P326, DOI 10.1136/adc.59.4.326; Kapel N, 1999, CLIN CHEM LAB MED, V37, P29, DOI 10.1515/CCLM.1999.004; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V92, P909, DOI 10.1016/0091-6749(93)90069-R; Levy Y, 2003, PEDIAT ALLERG IMM-UK, V14, P325, DOI 10.1034/j.1399-3038.2003.00039.x; Li XM, 2003, J ALLERGY CLIN IMMUN, V111, P1140, DOI 10.1067/mai.2003.1494; Lin XP, 2002, J ALLERGY CLIN IMMUN, V109, P879, DOI 10.1067/mai.2002.123238; Majamaa H, 2001, CLIN EXP ALLERGY, V31, P590, DOI 10.1046/j.1365-2222.2001.01035.x; MCDONALD PJ, 1984, PEDIATR RES, V18, P751, DOI 10.1203/00006450-198408000-00016; MURRAY KF, 1993, J PEDIATR-US, V122, P90, DOI 10.1016/S0022-3476(05)83495-X; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Perackis K, 2003, J ALLERGY CLIN IMMUN, V112, P625, DOI 10.1067/mai.2003.1656; Planchon S, 1999, J CELL PHYSIOL, V181, P55, DOI 10.1002/(SICI)1097-4652(199910)181:1<55::AID-JCP6>3.3.CO;2-D; PLANCHON SM, 1994, J IMMUNOL, V153, P5730; POWELL G K, 1986, Comprehensive Therapy, V12, P28; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; POWELL GK, 1976, J PEDIATR-US, V88, P840, DOI 10.1016/S0022-3476(76)81128-6; Rubin MI, 1940, AM J MED SCI, V200, P385, DOI 10.1097/00000441-194009000-00014; Sampson HA, 2000, J PEDIATR GASTR NUTR, V30, pS87, DOI 10.1097/00005176-200001001-00013; Sicherer SH, 2003, PEDIATRICS, V111, P1609; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x; Sicherer SH, 2000, J PEDIATR GASTR NUTR, V30, pS45, DOI 10.1097/00005176-200001001-00007; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; VANDENPLAS Y, 1994, J PEDIATR GASTR NUTR, V19, P240, DOI 10.1097/00005176-199408000-00016; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; VITORIA JC, 1982, ARCH DIS CHILD, V57, P44	44	171	183	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					149	156		10.1016/j.jaci.2004.09.033	http://dx.doi.org/10.1016/j.jaci.2004.09.033			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637562				2022-12-18	WOS:000226267000022
J	Pastorello, EA; Vieths, S; Pravettoni, V; Farioli, L; Trambaioli, C; Fortunato, D; Luttkopf, D; Calamari, M; Ansaloni, R; Scibilia, J; Ballmer-Weber, BK; Poulsen, LK; Wutrich, B; Hansen, KS; Robino, AM; Ortolani, C; Conti, A				Pastorello, EA; Vieths, S; Pravettoni, V; Farioli, L; Trambaioli, C; Fortunato, D; Luttkopf, D; Calamari, M; Ansaloni, R; Scibilia, J; Ballmer-Weber, BK; Poulsen, LK; Wutrich, B; Hansen, KS; Robino, AM; Ortolani, C; Conti, A			Identification of hazelnut major allergens in sensitive patients with positive double-blind, placebo-controlled food challenge results	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; hazelnut; immunoblotting; major allergen	CROSS-REACTIVITY; NUT ALLERGY; TREE POLLEN; PROTEIN; HYPERSENSITIVITY; ANAPHYLAXIS; EXTRACTS; PEANUT	Background: The hazelnut major allergens identified to date are an 18-kd protein homologous to Bet v 1 and a 14-kd allergen homologous to Bet v 2. No studies have reported hazelnut allergens recognized in patients with positive double-blind, placebo-controlled food challenge (DBPCFC) results or in patients allergic to hazelnut but not to birch. Objective: We characterized the hazelnut allergens by studying the IgE reactivity of 65 patients with positive DBPCFC results and 7 patients with severe anaphylaxis to hazelnut. Methods: Hazelnut allergens were identified by means of SDS-PAGE and IgE immunoblotting. Further characterization was done with amino acid sequencing, evaluation of the IgE-binding properties of raw and roasted hazelnut with enzyme allergosorbent test inhibition, assessment of cross-reactivity with different allergens by means of immunoblotting inhibition, and purification by means of HPLC. Results: All the sera from the patients with positive DBPCFC results recognized an 18- and a 47-kd allergen; other major allergens were at molecular weights of 32 and 35 kd. Binding to the 18-kd band was inhibited by birch extract, indicating its homology with the birch major allergen, and abolished in roasted hazelnut. The 47-kd allergen is a sucrose-binding protein, the 35-kd allergen is a legumin, and the 32-kd allergen is a 2S albumin. Patients with severe anaphylactic reactions to hazelnut showed specific IgE reactivity to a 9-kd allergen, totally inhibited by purified peach lipid-transfer protein (LTP), which was heat stable and, when purified, corresponded to an LTP. Conclusions: The major allergen of hazelnut is an 18-kd protein homologous to Bet v 1, and the 9-kd allergen is presumably an LTP. Other major allergens have molecular weights of 47, 32, and 35 kd.	Osped Maggiore, IRCCS, Div Gen Med 3, Allergy Ctr, Milan, Italy; Paul Ehrlich Inst, Dept Allergol, D-6070 Langen, Germany; Ist Clin Perfezionamento, CEMOC, UOOML, Milan, Italy; CNR, Turin, Italy; Osped Niguarda Ca Granda, Bizzozzero Div, Milan, Italy; Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Natl Univ Hosp Copenhagen, Copenhagen, Denmark	IRCCS Ca Granda Ospedale Maggiore Policlinico; Paul Ehrlich Institute; Consiglio Nazionale delle Ricerche (CNR); IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Zurich; University Zurich Hospital; Rigshospitalet; University of Copenhagen	Pastorello, EA (corresponding author), Div Gen Med 3, Padiglione Granelli,Via Francesco Sforza 35, I-20122 Milan, Italy.		SCIBILIA, GIUSEPPE/AAC-9673-2022; Poulsen, Lars K/J-3065-2019; PASTORELLO, ELIDE ANNA/E-3897-2017	SCIBILIA, GIUSEPPE/0000-0002-5452-4024; Poulsen, Lars K/0000-0002-1730-847X; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; Brenna O, 2000, J AGR FOOD CHEM, V48, P493, DOI 10.1021/jf9906681; Caballero T, 1997, CLIN EXP ALLERGY, V27, P1203; Castillo J, 2000, EUR J BIOCHEM, V267, P2156, DOI 10.1046/j.1432-1327.2000.01229.x; Ewan PW, 1996, BRIT MED J, V312, P1074; Helm RM, 2000, INT ARCH ALLERGY IMM, V123, P205, DOI 10.1159/000024445; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; IPSEN H, 1991, MOL IMMUNOL, V28, P1279, DOI 10.1016/0161-5890(91)90015-C; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Muller U, 2000, EUR FOOD RES TECHNOL, V212, P2, DOI 10.1007/s002170000245; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pastorello EA, 2001, J CHROMATOGR B, V756, P11, DOI 10.1016/S0378-4347(01)00067-6; PASTORELLO EA, 1994, J ALLERGY CLIN I S46, V53, P55; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1111/j.1365-2222.1996.tb00537.x; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V82, P718, DOI 10.1016/0091-6749(88)90070-X; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Stewart AG, 1996, QJM-MON J ASSOC PHYS, V89, P859, DOI 10.1093/qjmed/89.11.859; Teuber SS, 1999, J ALLERGY CLIN IMMUN, V103, P1180, DOI 10.1016/S0091-6749(99)70196-X; VIETHS S, 2000, ARBEITEN P EHRLICH I, V93, P159; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1	24	171	181	0	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					563	570		10.1067/mai.2002.121946	http://dx.doi.org/10.1067/mai.2002.121946			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11898007				2022-12-18	WOS:000174586400027
J	Santos, ABR; Chapman, MD; Aalberse, RC; Vailes, LD; Ferriani, VPL; Oliver, C; Rizzo, MC; Naspitz, CK; Arruda, LK				Santos, ABR; Chapman, MD; Aalberse, RC; Vailes, LD; Ferriani, VPL; Oliver, C; Rizzo, MC; Naspitz, CK; Arruda, LK			Cockroach allergens and asthma in Brazil: Identification of tropomyosin as a major allergen with potential cross-reactivity with mite and shrimp allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach; tropomyosin; asthma; mites; shrimp; allergy; Periplaneta americana	AMERICAN PERIPLANETA-AMERICANA; IGE ANTIBODY-RESPONSES; HIGH-LEVEL EXPRESSION; INNER-CITY CHILDREN; HOUSE-DUST-MITE; BLATTELLA-GERMANICA; RISK-FACTORS; HYPERSENSITIVITY; EXPOSURE; CLONING	Background: Cockroaches produce several proteins that induce IgE antibody responses. Although cockroaches are abundant in warm and humid areas, sensitization to cockroach allergens has not been investigated in Brazil. Objective: The aims of this study were to investigate the frequency of cockroach allergy among patients with asthma, rhinitis, or both in Brazil and to identify American cockroach allergens. Methods: Skin tests using cockroach extracts were performed on children and young adults with asthma, rhinitis, or both. A Periplaneta americana complementary (c)DNA library was screened by using IgE antibodies from Brazilian patients allergic to cockroaches. Reactivity of an mAb directed to Dermatophagoides pteronyssinus tropomyosin against cockroach tissue was examined by immunofluorescence. Results: Cockroach allergy was present in 55% and 79% of the patients, as determined by using skin prick tests alone or combined prick and intradermal tests, respectively. Five cDNA clones reacted with IgE antibody and contained the same sequence. A representative clone (1300 bp), pa12, coded for a protein that reacted with 50% of the sera from patients allergic to cockroaches on plaque immunoassay and showed a high degree of homology to tropomyosins, particularly those from invertebrates. P americana tropomyosin showed 80%, 81%, and 82% sequence identity to tropomyosins from D pteronyssinus, D farinae, and shrimp, respectively, which have been previously defined as important allergens. An mAb directed against D pteronyssinus tropomyosin, which also recognizes shrimp tropomyosin, showed binding to cockroach striated muscle. Conclusion: Our results support the recommendation that cockroach extracts should be routinely used for the evaluation of patients with asthma, rhinitis, or both in Brazil. The identification of P americana tropomyosin as an important allergen Hill make it possible to investigate cross-reactivity among cockroaches, mites, and food derived from invertebrates.	Univ Sao Paulo, Sch Med Ribeirao Preto, Fac Med Ribeirao Preto, Dept Immunol, BR-14049900 Ribeirao Preto, SP, Brazil; Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pediat, BR-14049900 Ribeirao Preto, SP, Brazil; Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Morphol, BR-14049900 Ribeirao Preto, SP, Brazil; Univ Fed Sao Paulo, Paulista Sch Med, Div Pediat Allergy Clin Immunol & Rheumatol, Sao Paulo, Brazil; Netherlands Red Cross, Blood Transfus Serv, Cent Labs, Amsterdam, Netherlands; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); University of Virginia	Arruda, LK (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Fac Med Ribeirao Preto, Dept Immunol, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.		Rizzo, Maria/HGD-6576-2022; Arruda, L. Karla/D-5845-2013; Ferriani, Virginia PL/E-2209-2012	Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, U19AI034607, R01AI032557] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34607, AI 32557] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; Arruda LK, 1997, AM J RESP CRIT CARE, V155, P343, DOI 10.1164/ajrccm.155.1.9001334; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Chapman MD, 1996, ALLERGY ALLERGIC DIS, P942; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)70307-5; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; MELEN E, IN PRESS J ALLERGY C; MENDOZA J, 1970, ANN ALLERGY, V28, P159; MENON P, 1991, ANN ALLERGY, V67, P573; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Reese G, 1997, INT ARCH ALLERGY IMM, V113, P240, DOI 10.1159/000237558; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SHANTI KN, 1993, J IMMUNOL, V151, P5354; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274, DOI 10.1016/S0091-6749(98)70393-8; vanRee R, 1996, ALLERGY, V51, P387, DOI 10.1111/j.1398-9995.1996.tb00147.x; vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56, DOI 10.1159/000236803; Wu CH, 1996, J BIOL CHEM, V271, P17937, DOI 10.1074/jbc.271.30.17937; WU CH, 1995, J ALLERGY CLIN IMMUN, V96, P352, DOI 10.1016/S0091-6749(95)70054-4	41	171	191	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				329	337		10.1016/S0091-6749(99)70375-1	http://dx.doi.org/10.1016/S0091-6749(99)70375-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452753				2022-12-18	WOS:000082364800024
J	Mari, A; Iacovacci, P; Afferni, C; Barletta, B; Tinghino, R; Di Felice, G; Pini, C				Mari, A; Iacovacci, P; Afferni, C; Barletta, B; Tinghino, R; Di Felice, G; Pini, C			Specific IgE to cross-reactive carbohydrate determinants strongly affect the in vitro diagnosis of allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; allergy; carbohydrates; cross-reactions; diagnosis; epitopes; glycoproteins; IgE; skin tests	MAJOR ALLERGEN; GRASS-POLLEN; ANTIBODY-ASSAYS; SKIN-TEST; EPITOPES; GLYCANS; MOIETY; GLYCOPROTEINS; BROMELAIN; COMMON	Background: Cross-reacting carbohydrate determinants (CCDs) are antigenic structures shared by allergenic components from taxonomically distant sources. The case history of a patient with a great discrepancy between skin test and specific IgE results led us to investigate the role of these determinants in his specific case and in an allergic population. Objective: We sought to determine the role of CCDs in causing false-positive and clinically irrelevant results in in vitro tests. Methods: The involvement of CCDs was studied by specific IgE inhibition by using glycoproteins with a known carbohydrate structure. Direct and inhibition assays were performed by commercially available systems, in-house ELISA, and the immunoblotting technique. The binding to the periodate-oxidated carbohydrate structure of glycoproteins and allergenic extracts was also evaluated. A comparative study between skin test and specific IgE responses to the antigens studied was carried out in 428 consecutive allergic subjects. Results: All the tests performed suggested that cross-reacting carbohydrate epitopes were the cause of false-positive specific IgE results in one of the commercial systems and the high reactivity in all the solid-phase in vitro tests. None of the crossreacting carbohydrate allergens yielded a positive skin test response. Periodate treatment caused variable degrees of reduction of IgE binding to the different antigens studied, indicating that CCDs played a different role in each of them. About 41% of patients allergic to pollen had specific IgE for a glycoprotein, without a positive skin test response to the same molecule. Conclusions: CCDs must be taken into account when evaluating the clinical relevance of positive results in in vitro specific IgE assays, at least in the diagnosis of patients with pollen allergy, Commercial systems should be carefully assessed for the ability to detect specific IgE for carbohydrate determinants to avoid false-positive or clinically irrelevant results.	Ist Super Sanita, Dept Immunol, I-00161 Rome, Italy; Natl Hlth Serv, Allergy Unit, Rome, Italy	Istituto Superiore di Sanita (ISS)	Mari, A (corresponding author), Ist Super Sanita, Dept Immunol, Viale Regina Elena 299, I-00161 Rome, Italy.		BARLETTA, BIANCA/B-9980-2016; Di Felice, Gabriella/B-9985-2016; AFFERNI, CLAUDIA/B-9978-2016	Di Felice, Gabriella/0000-0001-7387-9683; AFFERNI, CLAUDIA/0000-0002-8567-7365				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; Barletta B, 1998, ALLERGY, V53, P586, DOI 10.1111/j.1398-9995.1998.tb03934.x; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; BINDSLEVJENSEN C, 1997, FOOD ALLERGY ADVERSE, P137; DANDREA G, 1988, GLYCOCONJUGATE J, V5, P151, DOI 10.1007/BF01061204; DE CESARE F, 1993, ALLERGY, V48, P248; DEBLAY F, 1993, J ALLERGY CLIN IMMUN, V92, P255, DOI 10.1016/0091-6749(93)90169-G; ELSHAMI AS, 1989, ADV BIOSCI, V74, P191; *EUR DEP QUAL MED, 1997, EUR PHARM, P356; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; Fuchs T, 1997, J ALLERGY CLIN IMMUN, V100, P356, DOI 10.1016/S0091-6749(97)70249-5; GAILHOFER G, 1988, CLIN ALLERGY, V18, P445, DOI 10.1111/j.1365-2222.1988.tb02894.x; Iacovacci P, 1998, J ALLERGY CLIN IMMUN, V101, P755, DOI 10.1016/S0091-6749(98)70304-5; ISHIHARA H, 1979, J BIOL CHEM, V254, P715; KLEINETEBBE J, 1992, CLIN EXP ALLERGY, V22, P475, DOI 10.1111/j.1365-2222.1992.tb00150.x; Mari A, 1996, J ALLERGY CLIN IMMUN, V98, P21, DOI 10.1016/S0091-6749(96)70222-1; MUCCI N, 1992, ALLERGY, V47, P424, DOI 10.1111/j.1398-9995.1992.tb02083.x; Muller U, 1997, CLIN EXP ALLERGY, V27, P915, DOI 10.1111/j.1365-2222.1997.tb01233.x; NILSEN BM, 1991, J BIOL CHEM, V266, P2660; Ogawa H, 1996, GLYCOCONJUGATE J, V13, P555, DOI 10.1007/BF00731443; Ohsuga H, 1996, J BIOL CHEM, V271, P26653, DOI 10.1074/jbc.271.43.26653; OLIVIERI V, 1993, J IMMUNOL METHODS, V157, P65, DOI 10.1016/0022-1759(93)90071-E; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; Pike RN, 1997, INT ARCH ALLERGY IMM, V112, P412, DOI 10.1159/000237489; SALKIE ML, 1994, CLIN BIOCHEM, V27, P343, DOI 10.1016/0009-9120(94)90038-8; Schafer T, 1996, ALLERGY, V51, P372; Smith PM, 1996, J ALLERGY CLIN IMMUN, V98, P331, DOI 10.1016/S0091-6749(96)70158-6; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P22, DOI 10.1016/0091-6749(94)90229-1; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VANKUIK JA, 1986, GLYCOCONJUGATE J, V3, P27, DOI 10.1007/BF01108609; Vieths S., 1994, Food and Agricultural Immunology, V6, P453, DOI 10.1080/09540109409354857; WIDE L, 1967, LANCET, V2, P1105; Witteman AM, 1996, J ALLERGY CLIN IMMUN, V97, P16, DOI 10.1016/S0091-6749(96)70278-6; Yang BY, 1996, CARBOHYD RES, V287, P203, DOI 10.1016/0008-6215(96)00073-0	40	171	181	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1005	1011		10.1016/S0091-6749(99)70171-5	http://dx.doi.org/10.1016/S0091-6749(99)70171-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359878				2022-12-18	WOS:000080929500005
J	Krueger, JG; Ferris, LK; Menter, A; Wagner, F; White, A; Visvanathan, S; Lalovic, B; Aslanyan, S; Wang, EEL; Hall, D; Solinger, A; Padula, S; Scholl, P				Krueger, James G.; Ferris, Laura K.; Menter, Alan; Wagner, Frank; White, Alexander; Visvanathan, Sudha; Lalovic, Bojan; Aslanyan, Stella; Wang, Elaine E. L.; Hall, David; Solinger, Alan; Padula, Steven; Scholl, Paul			Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-23A; mAb; psoriasis; pharmacokinetics; biomarkers; single dose; randomized	MONOCLONAL-ANTIBODY; GLOBAL ASSESSMENT; PLAQUE PSORIASIS; ASSOCIATION; GUIDELINES; THERAPY; IL-23; INDEX; AREA	Background: IL-23 is associated with plaque psoriasis susceptibility and pathogenesis. BI 655066 is a fully human IgG(1) mAb specific for the IL-23 p19 subunit. Objective: This first-in-human proof-of-concept study evaluated the clinical and biological effects of BI 655066 in patients with moderate-to-severe plaque psoriasis. Methods: We performed a single-rising-dose, multicenter, randomized, double-blind, placebo-controlled, within-dose cohort phase I trial. Patients received 0.01, 0.05, 0.25, 1, 3, or 5 mg/kg BI 655066 intravenously, 0.25 or 1 mg/kg BI 655066 subcutaneously, or matched placebo. The primary objective was safety evaluation. Results: Thirty-nine patients received single-dose BI 655066 intravenously (n = 18) or subcutaneously (n = 13) or placebo (n = 8). Adverse events were reported with similar frequency in the BI 655066 and placebo groups. Four serious adverse events (not considered treatment related) were reported among BI 655066-treated patients. BI 655066 was associated with clinical improvement from week 2 and maintained for up to 66 weeks after treatment. At week 12, 75%, 90%, and 100% decreases in the Psoriasis Area and Severity Index were achieved by 87%, 58%, and 16% of BI 655066-treated patients (any dose), respectively, versus none receiving placebo. BI 655066 treatment resulted in reduced expression of lesional skin genes associated with IL-23/IL-17 signaling pathways and normalization of psoriatic lesion gene expression profiles to a profile approaching that of nonlesional skin. Significant correlation between treatment-associated molecular changes and psoriasis area and severity index improvement was observed (r = 0.73, P = 2 x 10(-6)). Conclusions: BI 655066 was well tolerated and associated with rapid, substantial, and durable clinical improvement in patients with moderate-to-severe psoriasis, supporting a central role for IL-23 in psoriasis pathogenesis.	[Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, New York, NY 10065 USA; [Ferris, Laura K.] UPMC, Dept Dermatol, Pittsburgh, PA USA; [Menter, Alan] Baylor Res Inst, Dallas, TX USA; [Wagner, Frank] Charite Res Org, Berlin, Germany; [White, Alexander] Progress Med Res, Port Orange, FL USA; [Visvanathan, Sudha; Lalovic, Bojan; Aslanyan, Stella; Wang, Elaine E. L.; Hall, David; Solinger, Alan; Scholl, Paul] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; [Padula, Steven] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany	Rockefeller University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor Scott & White Health; Baylor University Medical Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Boehringer Ingelheim; Boehringer Ingelheim	Krueger, JG (corresponding author), Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10065 USA.	James.Krueger@rockefeller.edu	Gacenga, Francis/K-5233-2012; Toleman, Mark/H-5574-2011	Gacenga, Francis/0000-0003-3021-1012; Toleman, Mark/0000-0002-9497-0512	Boehringer Ingelheim	Boehringer Ingelheim(Boehringer Ingelheim)	Supported by Boehringer Ingelheim.	[Anonymous], PSOR REP SECR; Brezinski EA, 2014, SEMIN CUTAN MED SURG, V33, P91, DOI 10.12788/j.sder.0086; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Chiricozzi A, 2014, EXPERT OPIN THER TAR, V18, P513, DOI 10.1517/14728222.2014.889686; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; FREDRIKSSON T, 1979, DERMATOLOGICA, V158, P60, DOI 10.1159/000250744; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; Langley RG, 2004, J AM ACAD DERMATOL, V51, P563, DOI 10.1016/j.jaad.2004.04.012; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Li BS, 2014, J INVEST DERMATOL, V134, P1828, DOI 10.1038/jid.2014.28; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Mehta NN, 2011, AM J MED, V124, DOI 10.1016/j.amjmed.2011.03.028; Menter A, 2008, J AM ACAD DERMATOL, V58, P826, DOI 10.1016/j.jaad.2008.02.039; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Papp KA, 2013, BRIT J DERMATOL, V168, P844, DOI 10.1111/bjd.12214; Papp KA, 2013, BRIT J DERMATOL, V168, P412, DOI 10.1111/bjd.12110; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Pfohler C, 2013, CURR RHEUMATOL REV, V9, P2, DOI 10.2174/1573397111309010002; Ramirez-Fort MK, 2013, CLIN EXP RHEUMATOL, V31, pS63; Robinson A, 2012, J AM ACAD DERMATOL, V66, P369, DOI 10.1016/j.jaad.2011.01.022; Ryan C, 2011, JAMA-J AM MED ASSOC, V306, P864, DOI 10.1001/jama.2011.1211; Smith CH, 2005, BRIT J DERMATOL, V153, P486, DOI 10.1111/j.1365-2133.2005.06893.x; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Stern RS, 2004, J INVEST DERM SYMP P, V9, P136, DOI 10.1046/j.1087-0024.2003.09102.x; Zaba LC, 2009, J INVEST DERMATOL, V129, P79, DOI 10.1038/jid.2008.194	28	170	185	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					116	U231		10.1016/j.jaci.2015.01.018	http://dx.doi.org/10.1016/j.jaci.2015.01.018			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25769911				2022-12-18	WOS:000357542200013
J	Engelhardt, KR; Shah, N; Faizura-Yeop, I; Uygun, DFK; Frede, N; Muise, AM; Shteyer, E; Filiz, S; Chee, R; Elawad, M; Hartmann, B; Arkwright, PD; Dvorak, C; Klein, C; Puck, JM; Grimbacher, B; Glocker, EO				Engelhardt, Karin R.; Shah, Neil; Faizura-Yeop, Intan; Uygun, Dilara F. Kocacik; Frede, Natalie; Muise, Aleixo M.; Shteyer, Eyal; Filiz, Serkan; Chee, Ronnie; Elawad, Mamoun; Hartmann, Britta; Arkwright, Peter D.; Dvorak, Christopher; Klein, Christoph; Puck, Jennifer M.; Grimbacher, Bodo; Glocker, Erik-Oliver			Clinical outcome in IL-10-and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-10; IL-10 receptor; enterocolitis; mutations; colectomy; hematopoietic stem cell transplantation	INFLAMMATORY-BOWEL-DISEASE; INTERLEUKIN-10 RECEPTOR; CROHNS-DISEASE; MUTATIONS; CYTOKINE; COMPLEX; IMMUNODEFICIENCY; FAMILY; GENE	Background: Inherited deficiencies of IL-10 or IL-10 receptor (IL-10R) lead to immune dysregulation with life-threatening early-onset enterocolitis. Objectives: We sought to gather clinical data of IL-10/IL-10R-deficient patients and devise guidelines for diagnosis and management, including hematopoietic stem cell transplantation (HSCT). Methods: We enrolled 40 patients with early-onset enterocolitis and screened for mutations in IL10/IL10R using genetic studies, functional studies, or both of the IL-10 signaling pathway. Medical records of IL-10/IL-10R-deficient patients were reviewed and compiled. Results: Of 40 patients, we identified 7 with novel mutations, predominantly in consanguineous families with more than 1 affected member. IL-10/IL-10R-deficient patients had intractable enterocolitis, perianal disease, and fistula formation. HSCT was carried out in 2 patients with IL-10 deficiency and 1 patient with IL-10R a chain deficiency and proved to be an effective therapy, leading to rapid improvement of clinical symptoms and quality of life. Conclusion: Because the defect in patients with IL-10/IL-10R deficiency resides in hematopoietic lineage cells and their colitis is resistant to standard immunosuppressive therapy, HSCT should be considered early as a potentially curative therapeutic option. (J Allergy Clin Immunol 2013; 131:825-30.)	[Engelhardt, Karin R.; Chee, Ronnie; Grimbacher, Bodo] UCL, Dept Immunol, Sch Med, London, England; [Engelhardt, Karin R.; Frede, Natalie; Grimbacher, Bodo] Univ Med Ctr Freiburg, CCI, D-79104 Freiburg, Germany; [Engelhardt, Karin R.; Frede, Natalie; Grimbacher, Bodo] Univ Freiburg, Freiburg, Germany; [Shah, Neil; Faizura-Yeop, Intan; Elawad, Mamoun] UCL, Dept Pediat Gastroenterol, Great Ormond St Hosp, London, England; [Uygun, Dilara F. Kocacik; Filiz, Serkan] Akdeniz Univ, Sch Med, Pediat Immunol & Allergy Dept, TR-07058 Antalya, Turkey; [Muise, Aleixo M.] Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, Dept Pediat, Cell Biol Program, Toronto, ON, Canada; [Muise, Aleixo M.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Shteyer, Eyal] Hadassah Hebrew Univ, Dept Pediat, Pediat Gastroenterol Unit, Med Ctr, Jerusalem, Israel; [Hartmann, Britta] Univ Med Ctr Freiburg, Inst Human Genet, D-79104 Freiburg, Germany; [Arkwright, Peter D.] Univ Manchester, Royal Manchester Childrens Hosp, Manchester M13 9PL, Lancs, England; [Dvorak, Christopher; Puck, Jennifer M.] Univ Calif San Francisco, Div Allergy Immunol & Blood & Marrow Transplantat, Dept Pediat, San Francisco, CA 94143 USA; [Klein, Christoph] Dr von Haunersches Kinderspital, Univ Childrens Hosp Munich, Munich, Germany; [Glocker, Erik-Oliver] Univ Med Ctr Freiburg, Inst Med Microbiol & Hyg, D-79104 Freiburg, Germany	University of London; University College London; UCL Medical School; University of Freiburg; University of Freiburg; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Akdeniz University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Freiburg; Royal Manchester Children's Hospital; University of Manchester; University of California System; University of California San Francisco; University of Munich; University of Freiburg	Glocker, EO (corresponding author), Univ Med Ctr Freiburg, Inst Med Microbiol & Hyg, Hermann Herder Str 11, D-79104 Freiburg, Germany.	erik-oliver.glocker@uniklinik-freiburg.de	Dvorak, Christopher C/AAX-1630-2020; Arkwright, Peter/C-5149-2012	Dvorak, Christopher C/0000-0002-6146-3952; Arkwright, Peter/0000-0002-7411-5375	NEOPICS; Canadian National Early Onset Pediatric Cohort Study; European Commission Marie Curie Excellence program [MEXT-CT-2006-042316]; EURO-PADNet; Marie Curie Actions CIG [294253]; USA National Institutes of Health/NCRR UCSF-CTSI [UL1 RR024131]; UCSF Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies; German Federal Ministry of Education and Research [BMBF 01 EO0803]; Care-for-Rare Foundation; National Institutes of Health; European Community 6th Programme; European Community 7th Programme; Marie Curie Excellence grant; German Federal Ministry of Education and Research; European Commission/Marie-Curie Actions; Great Ormond Street Hospital Childrens Charity [V1204] Funding Source: researchfish; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER	NEOPICS; Canadian National Early Onset Pediatric Cohort Study; European Commission Marie Curie Excellence program(European Commission); EURO-PADNet; Marie Curie Actions CIG; USA National Institutes of Health/NCRR UCSF-CTSI; UCSF Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Care-for-Rare Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Community 6th Programme; European Community 7th Programme; Marie Curie Excellence grant(European Commission); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); European Commission/Marie-Curie Actions(European Commission); Great Ormond Street Hospital Childrens Charity; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by NEOPICS, the Canadian National Early Onset Pediatric Cohort Study (to A. M. M.), grants from the European Commission Marie Curie Excellence program (MEXT-CT-2006-042316, to B.G.), EURO-PADNet (to B.G.), Marie Curie Actions CIG (294253, to E.-O.G.), the USA National Institutes of Health/NCRR UCSF-CTSI (grant no. UL1 RR024131), the UCSF Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies (to J.M.P.), and the German Federal Ministry of Education and Research (BMBF 01 EO0803).; Disclosure of potential conflict of interest: K. R. Engelhardt has received a grant from the German Federal Ministry of Education and Research (BMBF 01 EO0803). C. Klein has received a grant from the Care-for-Rare Foundation. J. M. Puck has received a grant from the National Institutes of Health. B. Grimbacher has received a grant from the European Community 6th and 7th Framework Programmes, a Marie Curie Excellence grant, and a grant from the German Federal Ministry of Education and Research. E.-O. Glocker has received a Career Integration grant from the European Commission/Marie-Curie Actions. The rest of the authors declare that they have no relevant conflicts of interest.	Begue B, 2011, AM J GASTROENTEROL, V106, P1544, DOI 10.1038/ajg.2011.112; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Cheng LE, 2009, CLIN IMMUNOL, V132, P124, DOI 10.1016/j.clim.2009.03.514; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Commins S, 2008, J ALLERGY CLIN IMMUN, V121, P1108, DOI 10.1016/j.jaci.2008.02.026; den Dunnen JT, 2000, HUM MUTAT, V15, P7; Donnelly RP, 2004, J LEUKOCYTE BIOL, V76, P314, DOI 10.1189/jlb.0204117; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Glocker EO, 2010, LANCET, V376, P1272, DOI 10.1016/S0140-6736(10)61008-2; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Kotlarz D, 2012, GASTROENTEROLOGY, V143, P347, DOI 10.1053/j.gastro.2012.04.045; Mao H, 2012, GENES IMMUN, V13, P437, DOI 10.1038/gene.2012.8; Marks DJB, 2009, AM J GASTROENTEROL, V104, P117, DOI 10.1038/ajg.2008.72; Marsh RA, 2010, BLOOD, V116, P1079, DOI 10.1182/blood-2010-01-256099; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moraes-Vasconcelos D, 2008, J CLIN IMMUNOL, V28, pS11, DOI 10.1007/s10875-008-9176-5; Moran CJ, 2012, INFLAMM BOWEL DIS, DOI 10.1002/ibd.22974; Muise AM, 2012, GUT, V61, P1028, DOI 10.1136/gutjnl-2011-300078; O'Shea JJ, 2008, IMMUNITY, V28, P477, DOI 10.1016/j.immuni.2008.03.002; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; Schmid JP, 2011, BLOOD, V117, P1522, DOI 10.1182/blood-2010-07-298372; Thrasher AJ, 2010, NAT REV IMMUNOL, V10, P182, DOI 10.1038/nri2724; Torgerson TR, 2007, J ALLERGY CLIN IMMUN, V120, P744, DOI 10.1016/j.jaci.2007.08.044; Warnatz K, 2008, CYTOM PART B-CLIN CY, V74B, P261, DOI 10.1002/cyto.b.20432; Wolk K, 2006, CYTOKINE GROWTH F R, V17, P367, DOI 10.1016/j.cytogfr.2006.09.001	27	170	176	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					825	+		10.1016/j.jaci.2012.09.025	http://dx.doi.org/10.1016/j.jaci.2012.09.025			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23158016				2022-12-18	WOS:000315587800026
J	Caballero, T; Farkas, H; Bouillet, L; Bowen, T; Gompel, A; Fagerberg, C; Bjokander, J; Bork, K; Bygum, A; Cicardi, M; de Carolis, C; Frank, M; Gooi, JHC; Longhurst, H; Martinez-Saguer, I; Nielsen, EW; Obtulowitz, K; Perricone, R; Prior, N				Caballero, Teresa; Farkas, Henriette; Bouillet, Laurence; Bowen, Tom; Gompel, Anne; Fagerberg, Christina; Bjokander, Janne; Bork, Konrad; Bygum, Anette; Cicardi, Marco; de Carolis, Caterina; Frank, Michael; Gooi, Jimmy H. C.; Longhurst, Hilary; Martinez-Saguer, Inmaculada; Nielsen, Erik Waage; Obtulowitz, Krystina; Perricone, Roberto; Prior, Nieves			International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Angioedema; breast cancer; C1 inhibitor deficiency; contraception; delivery; fertility; genetic counseling; hereditary angioedema; pregnancy; treatment	HORMONE REPLACEMENT THERAPY; PREIMPLANTATION GENETIC DIAGNOSIS; HUMAN C1-INHIBITOR CONCENTRATE; RECOMBINANT HUMAN C1-INHIBITOR; UPPER AIRWAY-OBSTRUCTION; FRESH-FROZEN PLASMA; LONG-TERM TREATMENT; ANGIONEUROTIC-EDEMA; ESTERASE INHIBITOR; FACTOR-XII	Background: There are a limited number of publications on the management of gynecologic/obstetric events in female patients with hereditary angioedema caused by C1 inhibitor deficiency (HAE-C1-INH). Objective: We sought to elaborate guidelines for optimizing the management of gynecologic/obstetric events in female patients with HAE-C1-INH. Methods: A roundtable discussion took place at the 6th C1 Inhibitor Deficiency Workshop (May 2009, Budapest, Hungary). A review of related literature in English was performed. Results: Contraception: Estrogens should be avoided. Barrier methods, intrauterine devices, and progestins can be used. Pregnancy: Attenuated androgens are contraindicated and should be discontinued before attempting conception. Plasma-derived human C1 inhibitor concentrate (pdhC1INH) is preferred for acute treatment, short-term prophylaxis, or long-term prophylaxis. Tranexamic acid or virally inactivated fresh frozen plasma can be used for long-term prophylaxis if human plasma-derived C1-INH is not available. No safety data are available on icatibant, ecallantide, or recombinant human C1-INH (rhC1INH). Parturition: Complications during vaginaldelivery are rare. Prophylaxis before labor and delivery might not be clinically indicated, but pdhC1INH therapeutic doses (20 U/kg) should be available. Nevertheless, each case should be treated based on HAE-C1-INH symptoms during pregnancy and previous labors. pdhC1INH prophylaxis is advised before forceps or vacuum extraction or cesarean section. Regional anesthesia is preferred to endotracheal intubation. Breast cancer: Attenuated androgens should be avoided. Antiestrogens can worsen angioedema symptoms. In these cases anastrozole might be an alternative. Other issues addressed include special features of HAE-C1-INH treatment in female patients, genetic counseling, infertility, abortion, lactation, menopause treatment, and endometrial cancer. Conclusions: A consensus for the management of female patients with HAE-C1-INH is presented. (J Allergy Clin Immunol 2012;129:308-20.)	[Caballero, Teresa; Prior, Nieves] Hosp La Paz Hlth Res Inst IdiPaz, Serv Alergia, Biomed Res Network Rare Dis CIBERER U754, Madrid, Spain; [Farkas, Henriette] Semmelweis Univ, Fac Med, Dept Internal Med 3, Budapest, Hungary; [Bouillet, Laurence] Grenoble Univ Hosp, Dept Internal Med, Grenoble, France; [Bowen, Tom] Univ Calgary, Dept Med & Pediat, Calgary, AB T2N 1N4, Canada; [Gompel, Anne] Univ Paris 05, APHP, Unite Gynecol Endocrinienne, Paris, France; [Fagerberg, Christina] Odense Univ Hosp, Dept Clin Genet, Odense, Denmark; [Bjokander, Janne] Cty Hosp Ryhov, Dept Internal Med, Jonkoping, Sweden; [Bork, Konrad] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Hosp Johannes Gutenberg, Mainz, Germany; [Bygum, Anette] Odense Univ Hosp, Dept Dermatol, Odense, Denmark; [Bygum, Anette] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [Cicardi, Marco] Dipartamento Sci Clin Luigi Sacco, Milan, Italy; [de Carolis, Caterina] Azienda Osped San Giovanni Addolorata, Rome, Italy; [Frank, Michael] Duke Univ, Med Ctr, Durham, NC USA; [Gooi, Jimmy H. C.] St James Univ Hosp, Dept Immunol, Leeds, W Yorkshire, England; [Longhurst, Hilary] Barts & London NHS Trust, Dept Immunol, London, England; [Martinez-Saguer, Inmaculada] Goethe Univ Frankfurt, Frankfurt, Germany; [Nielsen, Erik Waage] Norland Hosp, Dept Anesthesiol, Bodo, Norway; [Obtulowitz, Krystina] Jagiellonian Univ Hosp, Krakow, Poland; [Perricone, Roberto] Univ Roma Tor Vergata, Dept Internal Med, Rome, Italy	CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Semmelweis University; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of Calgary; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Southern Denmark; Odense University Hospital; Johannes Gutenberg University of Mainz; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Milan; Luigi Sacco Hospital; Duke University; Saint James's University Hospital; Barts Health NHS Trust; Goethe University Frankfurt; Jagiellonian University; Collegium Medicum Jagiellonian University; University of Rome Tor Vergata	Caballero, T (corresponding author), Hosp Univ La Paz, Serv Alergia, Paseo Castellana 261, Madrid 28046, Spain.	mteresa.caballero@idipaz.es	cicardi, marco/K-9219-2016; Caballero, Teresa/H-6454-2014; Caballero, Teresa/AAU-3982-2020; Gompel, Anne/AAV-3132-2020; Bork, Konrad/AAE-4985-2022	cicardi, marco/0000-0003-1251-225X; Caballero, Teresa/0000-0003-3005-9858; Caballero, Teresa/0000-0003-3005-9858; Bork, Konrad/0000-0002-6084-4577; Perricone, Roberto/0000-0002-2368-9766; De Carolis, Caterina/0000-0002-6597-6253; Farkas, Henriette/0000-0003-2929-1721; Bygum, Anette/0000-0002-3004-0180; Fagerberg, Christina Ringmann/0000-0002-5206-4327	CSL Behring; Pharming NV; Shire; Sanquin; Viropharma Pharmaceuticals; HAE International; Hospital La Paz Health Research Institute (IdiPaz); HAEi (International Patient Organization for C1 Inhibitor Deficiencies); Shire HGT; Jerini AG; Viropharma; Shire/Jerini AG; Jerini;  [PREHAEAT QLG1-CT-2002-01359]	CSL Behring; Pharming NV; Shire; Sanquin; Viropharma Pharmaceuticals; HAE International; Hospital La Paz Health Research Institute (IdiPaz); HAEi (International Patient Organization for C1 Inhibitor Deficiencies); Shire HGT; Jerini AG; Viropharma; Shire/Jerini AG; Jerini; 	The 2009 International Consensus for Gynecological and Obstetric Management of Female Patients with Hereditary Angioedema Caused by C1 Inhibitor Deficiency (HAE-C1-INH) was arrived at during the 6th C1 Inhibitor Deficiency Workshop, which was held on May 24-25, 2009, Budapest, Hungary. This meeting was funded by unrestricted educational grants from CSL Behring, Pharming NV, Shire, Sanquin, and Viropharma Pharmaceuticals. This consensus has been partially supported by the grant PREHAEAT QLG1-CT-2002-01359. HAE International provided financial support but did not have any input or provide comments on the manuscript. Publication of this manuscript is sponsored by Hospital La Paz Health Research Institute (IdiPaz) and HAEi (International Patient Organization for C1 Inhibitor Deficiencies). T. Caballero is a researcher with the Hospital La Paz Health Research Institute (IdiPaz) program for promoting research activities (2009).; T. Caballero has received a travel grant from CSL Behring and Shire HGT, has consultant arrangements with Shire HGT and Viropharma, is on the speakers' bureau for Shire HGT and Viropharma, and receives research support from Shire HGT and Jerini AG. H. Farkas receives travel grants from CSL Behring, Pharming NV, Viropharma, and Shire/Jerini AG and receives consultancy fees from CSL Behring, Pharming NV, Viropharma, and Shire/Jerini AG. L. Bouillet has consultant arrangements with Shire, Behring, and Viropharma. T. Bowen receives speaking honoraria and consultancy fees from Shire and has received a travel grant from CSL Behring. A. Gompel is on the advisory board of Shire France. J. Bjokander has consultant arrangements with Shire and is on the advisory boards for CSL Behring and the Swedish Patient Organization HAE. K. Bork has consultant arrangements with CSL Behring, Shire, and Viropharma. A. Bygum receives speakers' fees from Jerini/Shire, receives research support from Jerini, has consultant arrangements with Viropharma and CSL Behring, and is an advisor for the HAE Danish Patient Organization. M. Cicardi has consultant arrangements with Jerini/Shire, Dyax, and Pharming. M. Frank has consultant arrangements with Shire, Viropharma, CSL Behring, Dyax, and Alexion. H. Longhurst has received research support from CSL Behring and Shire, is a medical advisor for CSL Behring and Shire, is on the speakers' bureau for CSL Behring and Shire, and has received travel grants from Viropharma. N. Prior has received a travel grant from CSL-Behring, speaking honoraria from Shire HGT, and research support from Jerini AG. The rest of the authors declare that they have no relevant conflicts of interest.	Aboulghar M, 2009, HUM REPROD UPDATE, V15, P265, DOI 10.1093/humupd/dmp003; AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; ALEN M, 1985, MED SCI SPORT EXER, V17, P354; Amar L, 2004, BRIT J DERMATOL, V151, P713, DOI 10.1111/j.1365-2133.2004.06152.x; [Anonymous], 2010, MED LETT DRUGS THER, V52, P54; [Anonymous], 2009, KALB EC PACK INS; [Anonymous], 2009, FIR IC AC PACK INS; [Anonymous], 1989, GUID CLIN PREV SERV, P24; Aribarg A, 1996, J Med Assoc Thai, V79, P624; ATKINSON JC, 1991, J ORAL PATHOL MED, V20, P139, DOI 10.1111/j.1600-0714.1991.tb00908.x; Baker J, 2010, WAO INT SCI C DEC 5; Banerji A, 2008, ANN ALLERG ASTHMA IM, V100, pS19, DOI 10.1016/S1081-1206(10)60582-0; BARBIERI RL, 1982, FERTIL STERIL, V37, P737; Bas M, 2006, ALLERGY, V61, P1490, DOI 10.1111/j.1398-9995.2006.01197.x; Bautista-Llacer R, 2010, REPROD BIOMED ONLINE, V21, P658, DOI 10.1016/j.rbmo.2010.05.016; Bellver J, 2009, FERTIL STERIL, V92, P1803, DOI 10.1016/j.fertnstert.2009.06.033; BERGLUND F, 1984, ACTA OBSTET GYN SCAN, P1; Bernstein JA, 2010, EXPERT REV CLIN IMMU, V6, P29, DOI 10.1586/ECI.09.60; BLOHME G, 1972, ACTA MED SCAND, V191, P209; BOCKERS M, 1987, DEUT MED WOCHENSCHR, V112, P507, DOI 10.1055/s-2008-1068085; Bork K, 2003, AM J MED, V114, P294, DOI 10.1016/S0002-9343(02)01526-7; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Bork K, 2000, MAYO CLIN PROC, V75, P349, DOI 10.4065/75.4.349; Bork K, 2005, TRANSFUSION, V45, P1774, DOI 10.1111/j.1537-2995.2005.00602.x; Bork K, 2003, ARCH INTERN MED, V163, P1229, DOI 10.1001/archinte.163.10.1229; Bork K, 2003, TRANSFUS APHER SCI, V29, P235, DOI 10.1016/j.transci.2003.08.007; Bork K, 1999, LANCET, V353, P1066, DOI 10.1016/S0140-6736(99)00110-5; Bork K, 2002, J HEPATOL, V36, P707, DOI 10.1016/S0168-8278(02)00035-1; Bork K, 2008, ANN ALLERG ASTHMA IM, V100, P153, DOI 10.1016/S1081-1206(10)60424-3; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; BORRADORI L, 1990, DERMATOLOGICA, V181, P78, DOI 10.1159/000247874; Borry P, 2009, EUR J HUM GENET, V17, P711, DOI [10.1038/ejhg.2009.25, 10.1038/ejhg.2009.26]; Bouillet L, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.034; BOULOS AN, 1994, BRIT J OBSTET GYNAEC, V101, P1094, DOI 10.1111/j.1471-0528.1994.tb13594.x; Bowen T, 2003, TRANSFUS APHER SCI, V29, P205, DOI 10.1016/j.transci.2003.08.009; Bowen T, 2008, ANN ALLERG ASTHMA IM, V100, pS30, DOI 10.1016/S1081-1206(10)60584-4; Bowen Tom, 2010, Allergy Asthma Clin Immunol, V6, P24, DOI 10.1186/1710-1492-6-24; Brown J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000194.pub2; Bygum A, 2009, BRIT J DERMATOL, V161, P1153, DOI 10.1111/j.1365-2133.2009.09366.x; CAMPBELL SJ, 1993, BRIT J OBSTET GYNAEC, V100, P79, DOI 10.1111/j.1471-0528.1993.tb12956.x; Chabbert-Buffet N, 2011, CONTRACEPTION, V83, P229, DOI 10.1016/j.contraception.2010.08.012; Chan WS, 2009, CURR OPIN OBSTET GYN, V21, P207, DOI 10.1097/GCO.0b013e328329c2b8; CHAPPATTE O, 1988, BRIT J OBSTET GYNAEC, V95, P938, DOI 10.1111/j.1471-0528.1988.tb06585.x; CHEN LM, 1992, BIOCHIM BIOPHYS ACTA, V1131, P145, DOI 10.1016/0167-4781(92)90069-C; CHHIBBER G, 1990, J LAB CLIN MED, V115, P112; Chi C, 2009, ACTA OBSTET GYN SCAN, V88, P1095, DOI 10.1080/00016340903144238; Chinniah N, 2009, AUST NZ J OBSTET GYN, V49, P2, DOI 10.1111/j.1479-828X.2008.00945.x; Choi G, 2007, TRANSFUSION, V47, P1028, DOI 10.1111/j.1537-2995.2007.01239.x; Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2; CICARDI M, 1991, J ALLERGY CLIN IMMUN, V87, P768, DOI 10.1016/0091-6749(91)90120-D; Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510; Cicardi M, 2010, NEW ENGL J MED, V363, P532, DOI 10.1056/NEJMoa0906393; CICARDI M, 1983, J ALLERGY CLIN IMMUN, V72, P294, DOI 10.1016/0091-6749(83)90034-9; Cicardi M, 2010, NEW ENGL J MED, V363, P523, DOI 10.1056/NEJMoa0905079; Cimbollek S, 2007, 5 C1 INH DEF WORKSH; Citarella F, 1996, STEROIDS, V61, P270, DOI 10.1016/0039-128X(96)00037-2; COHEN AJ, 1992, J ALLERGY CLIN IMMUN, V90, P412, DOI 10.1016/S0091-6749(05)80025-9; Conard J, 2004, CONTRACEPTION, V70, P437, DOI 10.1016/j.contraception.2004.07.009; COX M, 1995, ANAESTHESIA, V50, P547, DOI 10.1111/j.1365-2044.1995.tb06050.x; Craig TJ, 2009, J ALLERGY CLIN IMMUN, V124, P801, DOI 10.1016/j.jaci.2009.07.017; Crampon D, 1998, J HEPATOL, V29, P1035, DOI 10.1016/S0168-8278(98)80140-2; Cruden NLM, 2008, EXPERT OPIN PHARMACO, V9, P2383, DOI [10.1517/14656566.9.13.2383, 10.1517/14656566.9.13.2383 ]; Cugno M, 2003, INT IMMUNOPHARMACOL, V3, P311, DOI 10.1016/S1567-5769(02)00162-5; CUMMING DC, 1990, CLEV CLIN J MED, V57, P285, DOI 10.3949/ccjm.57.3.285; CUMMING DC, 1982, JAMA-J AM MED ASSOC, V247, P1295, DOI 10.1001/jama.247.9.1295; CUNNINGHAM DS, 1991, J REPROD MED, V36, P312; Czaller I, 2010, EUR J OBSTET GYN R B, V152, P44, DOI 10.1016/j.ejogrb.2010.05.008; Davis AE, 2005, CLIN IMMUNOL, V114, P3, DOI 10.1016/j.clim.2004.05.007; DAVIS CA, 1979, PEDIATR RES, V13, P1043, DOI 10.1203/00006450-197909000-00019; De Serres J, 2003, TRANSFUS APHER SCI, V29, P247, DOI 10.1016/j.transci.2003.08.006; Dmowski W P, 1987, Contrib Gynecol Obstet, V16, P220; DMOWSKI WP, 1988, CLIN OBSTET GYNECOL, V31, P829, DOI 10.1097/00003081-198812000-00009; DONALDSON VH, 1966, PEDIATRICS, V37, P1017; DONALDSON VH, 1983, NEW ENGL J MED, V308, P1094, DOI 10.1056/NEJM198305053081810; DUCK SC, 1981, FERTIL STERIL, V35, P230; Dunn CJ, 1999, DRUGS, V57, P1005, DOI 10.2165/00003495-199957060-00017; Ebert A, 1992, Zentralbl Gynakol, V114, P519; European Medicines Agency, EMEA3504572008; European Medicines Agency, 2010, EMA4317172010; Farkas H, 2007, J ALLERGY CLIN IMMUN, V120, P941, DOI 10.1016/j.jaci.2007.06.026; Farkas H, 2007, PEDIATRICS, V120, pE713, DOI 10.1542/peds.2006-3303; Farkas H, 2010, EUR J CLIN PHARMACOL, V66, P419, DOI 10.1007/s00228-009-0771-z; Fechner S, 2007, FERTIL STERIL, V88, P1029, DOI 10.1016/j.fertnstert.2006.11.153; Fletcher A, 1998, POSTGRAD MED J, V74, P41, DOI 10.1136/pgmj.74.867.41; Frank MM, 2008, J ALLERGY CLIN IMMUN, V121, pS398, DOI 10.1016/j.jaci.2007.07.057; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; Galan HL, 1996, J REPROD MED, V41, P541; Gallagher PE, 1999, HYPERTENSION, V33, P323, DOI 10.1161/01.HYP.33.1.323; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Golan A, 2009, REPROD BIOMED ONLINE, V19, P28, DOI 10.1016/S1472-6483(10)60042-9; Gompel A, 1995, Rev Prat, V45, P2431; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; Gooi JHC, 2009, 6 C1 INH DEF WORKSH; GORDON EM, 1985, BLOOD, V66, P602; GORDON EM, 1988, J LAB CLIN MED, V111, P52; GORDON EM, 1980, J LAB CLIN MED, V96, P762; Gorman PJ, 2008, CAN FAM PHYSICIAN, V54, P365; Hardie J, 1990, J Can Dent Assoc, V56, P1096; HARDY F, 1990, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V19, P65; Heusse JL, 2008, ANN CHIR PLAST ESTH, V53, P289, DOI 10.1016/j.anplas.2007.05.011; HOEM NO, 1991, THROMB RES, V64, P427, DOI 10.1016/0049-3848(91)90343-U; HOPKINSON RB, 1979, ANAESTHESIA, V34, P183, DOI 10.1111/j.1365-2044.1979.tb06276.x; HOSEA SW, 1980, DRUGS, V19, P370, DOI 10.2165/00003495-198019050-00007; HOSEA SW, 1980, ANN INTERN MED, V93, P809, DOI 10.7326/0003-4819-93-6-809; Hsieh FH, 2002, ALLERGY ASTHMA PROC, V23, P157; Humaidan P, 2010, FERTIL STERIL, V94, P389, DOI 10.1016/j.fertnstert.2010.03.028; Ishihara H, 2003, FERTIL STERIL, V79, P735, DOI 10.1016/S0015-0282(02)04813-6; Kalmar L, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9202; Krause K, 2010, J DTSCH DERMATOL GES, V8, P272, DOI 10.1111/j.1610-0387.2009.07215.x; Krogh CME, 1993, COMPENDIUM PHARM SPE, P311; KULLANDE.S, 1970, ACTA OBSTET GYN SCAN, V49, P241, DOI 10.3109/00016347009157244; Lacey JV, 2000, GYNECOL ONCOL, V77, P149, DOI 10.1006/gyno.2000.5731; LAURENT J, 1987, PRESSE MED, V16, P2132; Levy JH, 2006, EXPERT OPIN INV DRUG, V15, P1077, DOI 10.1517/13543784.15.9.1077; LOGAN RA, 1984, J ROY SOC MED, V77, P1046, DOI 10.1177/014107688407701213; Longhurst H, 2008, CURR OPIN INVEST DR, V9, P310; Longhurst Hilary J, 2010, Allergy Asthma Clin Immunol, V6, P22, DOI 10.1186/1710-1492-6-22; Longhurst HJ, 2005, INT J CLIN PRACT, V59, P594, DOI 10.1111/j.1742-1241.2005.00352.x; Loprinzi CL, 2006, J CLIN ONCOL, V24, P1409, DOI 10.1200/JCO.2005.04.7324; Madsen JS, 2003, J THROMB HAEMOST, V1, P1984, DOI 10.1046/j.1538-7836.2003.00362.x; Manikkam M, 2004, ENDOCRINOLOGY, V145, P790, DOI 10.1210/en.2003-0478; Martinez-Saguer I, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.03.003; MATSUMOTO AM, 1990, J CLIN ENDOCR METAB, V70, P282, DOI 10.1210/jcem-70-1-282; McGlinchey PG, 2000, ULSTER MED J, V69, P54; McGlinchey PG, 2000, AM J MED SCI, V320, P212, DOI 10.1097/00000441-200009000-00014; Murakami K, 2006, FERTIL STERIL, V86, P291, DOI 10.1016/j.fertnstert.2005.12.074; Murone C, 1999, ENDOCRINOLOGY, V140, P3372, DOI 10.1210/en.140.7.3372; Nelson HD, 2008, LANCET, V371, P760, DOI 10.1016/S0140-6736(08)60346-3; Nielsen EW, 1996, J INTERN MED, V239, P119, DOI 10.1046/j.1365-2796.1996.418764000.x; NIELSEN EW, 1994, PEDIATR RES, V35, P184, DOI 10.1203/00006450-199402000-00012; Nogawa N, 2001, MENOPAUSE, V8, P210, DOI 10.1097/00042192-200105000-00011; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321, DOI 10.1016/S0091-6749(99)70030-8; Obtulowicz K, 2009, 6 C1 INH DEF WORKSH; OGSTON D, 1981, THROMB RES, V23, P453, DOI 10.1016/0049-3848(81)90206-1; Ott HW, 2007, CLIN ENDOCRINOL, V66, P180, DOI 10.1111/j.1365-2265.2006.02704.x; Pappalardo E, 2008, MOL IMMUNOL, V45, P3536, DOI 10.1016/j.molimm.2008.05.007; PELISSIER C, 1994, CONTRACEPT FERTIL S, V22, P37; PELISSIER C, 1987, CONTRACEPT FERTIL S, V15, P45; PERRICONE R, 1992, CLIN EXP IMMUNOL, V90, P401; Perricone R, 2000, SCAND J IMMUNOL, V51, P104; PICHLER WJ, 1989, ANN ALLERGY, V63, P301; PILBRANT A, 1981, EUR J CLIN PHARMACOL, V20, P65, DOI 10.1007/BF00554669; POSTNIKOFF IM, 1979, J FORENSIC SCI, V24, P473; POTTS GO, 1980, DRUGS, V19, P321, DOI 10.2165/00003495-198019050-00001; Prematta M, 2007, ANN ALLERG ASTHMA IM, V98, P383, DOI 10.1016/S1081-1206(10)60886-1; Prematta Michael J, 2008, Ther Clin Risk Manag, V4, P975; Prior JC, 2010, ENDOCR REV S1, V31, pS19; Raychaudhuri K, 1997, BRIT J HOSP MED, V58, P287; RESCHINI E, 1985, LANCET, V1, P1226; ROACH B, 1981, AM J DIS CHILD, V135, P918, DOI 10.1001/archpedi.1981.02130340030011; Roche O, 2005, ANN ALLERG ASTHMA IM, V94, P498, DOI 10.1016/S1081-1206(10)61121-0; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; Rousset-Jablonski C, 2009, ANN ONCOL, V20, P1281, DOI 10.1093/annonc/mdp295; RYBO G, 1991, THER ADV, V4, P1; Sanhueza PI, 2008, FERTIL STERIL, V90, DOI 10.1016/j.fertnstert.2008.01.032; Sathishkumar K, 2009, BIOL REPROD, V81, P250; Schindler AE, 2003, MATURITAS, V46, pS31, DOI 10.1016/j.maturitas.2003.09.016; Schneider L, 2007, J ALLERGY CLIN IMMUN, V120, P416, DOI 10.1016/j.jaci.2007.04.028; Shahidi NT, 2001, CLIN THER, V23, P1355, DOI 10.1016/S0149-2918(01)80114-4; SHEFFER AL, 1987, J ALLERGY CLIN IMMUN, V80, P855, DOI 10.1016/S0091-6749(87)80277-4; SHEFFER AL, 1981, J ALLERGY CLIN IMMUN, V68, P181, DOI 10.1016/0091-6749(81)90181-0; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; SIM TC, 1990, AM J MED, V88, P656, DOI 10.1016/0002-9343(90)90535-L; Sloane DE, 2007, J ALLERGY CLIN IMMUN, V120, P654, DOI 10.1016/j.jaci.2007.06.037; STILLER RJ, 1984, OBSTET GYNECOL, V64, P133; Sundberg K, 1997, LANCET, V350, P697, DOI 10.1016/S0140-6736(97)02449-5; Szema AM, 2009, ALLERGY ASTHMA PROC, V30, P338, DOI 10.2500/aap.2009.30.3225; Teede HJ, 2000, ARTERIOSCL THROM VAS, V20, P1404, DOI 10.1161/01.ATV.20.5.1404; Terpstra FG, 2007, BIOLOGICALS, V35, P173, DOI 10.1016/j.biologicals.2006.08.005; Verpoest W, 2009, HUM REPROD, V24, P2951, DOI 10.1093/humrep/dep272; Visy B, 2004, CLIN ENDOCRINOL, V60, P508, DOI 10.1111/j.1365-2265.2004.02009.x; WALKER JE, 1982, BRIT J OBSTET GYNAEC, V89, P208, DOI 10.1111/j.1471-0528.1982.tb03615.x; Walzman M, 1982, Arch Toxicol Suppl, V5, P214; WAUTIER JL, 1986, PRESSE MED, V15, P2023; Weiler CR, 2006, MAYO CLIN PROC, V81, P958, DOI 10.4065/81.7.958; Wessler S, 1992, Ann Epidemiol, V2, P439; Winnewisser J, 1997, J INTERN MED, V241, P39, DOI 10.1046/j.1365-2796.1997.76893000.x; Yip J, 1992, Australas J Dermatol, V33, P35, DOI 10.1111/j.1440-0960.1992.tb00050.x; Zuraw B, 2010, J ALLERGY CLIN IMMUN, V126, P821, DOI 10.1016/j.jaci.2010.07.021; Zuraw BL, 2010, NEW ENGL J MED, V363, P513, DOI 10.1056/NEJMoa0805538; ZURLO JJ, 1990, FERTIL STERIL, V54, P64	184	170	178	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					308	320		10.1016/j.jaci.2011.11.025	http://dx.doi.org/10.1016/j.jaci.2011.11.025			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22197274				2022-12-18	WOS:000299951700003
J	Letourneau, S; Krieg, C; Pantaleo, G; Boyman, O				Letourneau, Sven; Krieg, Carsten; Pantaleo, Giuseppe; Boyman, Onur			IL-2-and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-2; CD25; T-cell homeostasis; CD8 T cell; regulatory T cell; T(H)1; T(H)2; T(H)17; cytokine deprivation	RECEPTOR ALPHA-CHAIN; BETA-CHAIN; TH2 DIFFERENTIATION; DENDRITIC CELLS; CUTTING EDGE; IN-VIVO; INTERLEUKIN-2; MEMORY; LYMPHOCYTES; EXPRESSION	IL-2 plays a pivotal role in regulating the adaptive immune system by controlling the survival and proliferation of regulatory T (Treg) cells, which are required for the maintenance of immune tolerance. Moreover, IL-2 is implicated in the differentiation and homeostasis of effector T-cell subsets, including T(H)1, T(H)2, T(H)17, and memory CD8(+) T cells. The IL-2 receptor is composed of 3 distinct subunits, namely the alpha (CD25), beta (CD122), and gamma (gamma c) chains. Of crucial importance for the delivery of IL-2 signals to Treg cells is the expression of CD25, which, along with CD122 and gamma c, confers high affinity binding to IL-2. Notably, recent findings suggest a novel role for CD25, whereby CD25 molecules on Treg cells and possibly other cells are capable of influencing T-cell homeostasis by means of IL-2 deprivation. This review explores these findings and integrates them into our current understanding of T-cell homeostasis. (J Allergy Clin Immunol 2009;123:758-62.)	[Letourneau, Sven; Krieg, Carsten; Pantaleo, Giuseppe; Boyman, Onur] Univ Lausanne, CHU Vaudois, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland; [Pantaleo, Giuseppe] Swiss Vaccine Res Inst, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Boyman, O (corresponding author), Univ Lausanne, CHU Vaudois, Div Immunol & Allergy, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	onur.boyman@chuv.ch	Pantaleo, Giuseppe/K-6163-2016; Krieg, Carsten/ABA-6734-2020	Krieg, Carsten/0000-0002-5145-7591; Boyman, Onur/0000-0001-8279-5545				Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; ARDAVIN C, 1992, EUR J IMMUNOL, V22, P859, DOI 10.1002/eji.1830220334; Bachmann MF, 2007, EUR J IMMUNOL, V37, P1502, DOI 10.1002/eji.200637023; Blattman JN, 2003, NAT MED, V9, P540, DOI 10.1038/nm866; Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927; Boyman O, 2007, CURR OPIN IMMUNOL, V19, P320, DOI 10.1016/j.coi.2007.04.015; Cho JH, 2007, J EXP MED, V204, P1787, DOI 10.1084/jem.20070740; Cote-Sierra J, 2004, P NATL ACAD SCI USA, V101, P3880, DOI 10.1073/pnas.0400339101; Dooms H, 2004, J IMMUNOL, V172, P5973, DOI 10.4049/jimmunol.172.10.5973; Dooms H, 2007, J EXP MED, V204, P547, DOI 10.1084/jem.20062381; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Gruss HJ, 1996, J IMMUNOL, V157, P851; HANKE T, 1994, J EXP MED, V180, P1629, DOI 10.1084/jem.180.5.1629; Harari A, 2006, IMMUNOL REV, V211, P236, DOI 10.1111/j.0105-2896.2006.00395.x; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Kamimura D, 2007, J EXP MED, V204, P1803, DOI 10.1084/jem.20070543; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; Kryczek I, 2007, J IMMUNOL, V179, P1423, DOI 10.4049/jimmunol.179.3.1423; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Liao W, 2008, NAT IMMUNOL, V9, P1288, DOI 10.1038/ni.1656; Malchow D, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-31; Mnasria K, 2008, J LEUKOCYTE BIOL, V84, P460, DOI 10.1189/jlb.1007712; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; PLAISANCE S, 1993, INT IMMUNOL, V5, P843; Reya T, 1996, BLOOD, V87, P190, DOI 10.1182/blood.V87.1.190.bloodjournal871190; Sarkar S, 2008, J EXP MED, V205, P625, DOI 10.1084/jem.20071641; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Sharfe N, 1997, P NATL ACAD SCI USA, V94, P3168, DOI 10.1073/pnas.94.7.3168; Sharma R, 2007, J IMMUNOL, V178, P1251, DOI 10.4049/jimmunol.178.3.1251; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Van Parijs L, 1998, SCIENCE, V280, P243; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Williams MA, 2006, NATURE, V441, P890, DOI 10.1038/nature04790; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304	35	170	195	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					758	762		10.1016/j.jaci.2009.02.011	http://dx.doi.org/10.1016/j.jaci.2009.02.011			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348914	Bronze			2022-12-18	WOS:000265058600003
J	von Mutius, E				von Mutius, Erika			Gene-environment interactions in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; genes; environment; interactions	GLUTATHIONE-S-TRANSFERASE; TOBACCO-SMOKE; AIR-POLLUTION; BRONCHIAL HYPERRESPONSIVENESS; ORMDL3 EXPRESSION; MATERNAL SMOKING; IMMUNOGLOBULIN-E; PASSIVE SMOKING; EARLY-LIFE; EXPOSURE	Asthma is a complex disease, and its incidence is determined by an intricate interplay of genetic and environmental factors. The Identification of novel genes for asthma suggests that many genes with small effect,; rather than few genes with strong effects contribute to the development of asthma. These genetic effects may in part differ with respect to a subject's environmental exposures, although some genes may also exert their effect independently of the environment. Whereas the geneticist uses highly advanced, rapid, comprehensive technologies to assess even subtle changes in the human genome, the researcher interested in environmental exposures is often confronted with crude information obtained from questionnaires or interviews. There is thus substantial need to develop better tools for individual exposure assessment in all relevant environmental fields. Despite these limitations, a number of important gene-environment interactions have been identified. These interactions point to the biology of environmental exposures as the involved genetic variation is suggestive of certain underlying mechanisms. Furthermore, the identification of subjects who are particularly susceptible to environmental hazards through genetic analyses helps to estimate better the strength of effect of environmental exposures. Finally, the analysis of gene-environment interactions may result in a reconciliation of seemingly contradictory findings from studies not taking environmental exposures into account. (J Allergy Clin Immunol 2009;123:3-11.)	Univ Childrens Hosp, D-80337 Munich, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich	von Mutius, E (corresponding author), Univ Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Erika.von.Mutius@med.uni-muenchen.de		von Mutius, Erika/0000-0002-8893-4515				Alexandrov K, 2002, CARCINOGENESIS, V23, P1969, DOI 10.1093/carcin/23.12.1969; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860, DOI 10.1164/ajrccm.164.10.2010138; Atkinson RW, 2004, AM J RESP CRIT CARE, V169, P1257, DOI 10.1164/ajrccm.169.11.960; Bergamaschi E, 2001, AM J RESP CRIT CARE, V163, P1426, DOI 10.1164/ajrccm.163.6.2006056; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bottema RWB, 2008, EUR RESPIR J, V32, P593, DOI 10.1183/09031936.00162407; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; CALIGARI PDS, 1975, PROC R SOC SER B-BIO, V191, P387, DOI 10.1098/rspb.1975.0135; Cameron L, 2006, J IMMUNOL, V177, P8633, DOI 10.4049/jimmunol.177.12.8633; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; Christiani DC, 2008, OCCUP ENVIRON MED, V65, P430, DOI 10.1136/oem.2007.033977; CHRISTIANI DC, 2008, OCCUP ENVIRON MED, V65, P397; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; Dizier MH, 2007, EUR J HUM GENET, V15, P810, DOI 10.1038/sj.ejhg.5201830; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Eder W, 2006, ALLERGY, V61, P1117, DOI 10.1111/j.1398-9995.2006.01128.x; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Evans GS, 2008, J APPL TOXICOL, V28, P1, DOI 10.1002/jat.1294; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Guo SW, 2000, HUM HERED, V50, P286, DOI 10.1159/000022931; Hawkins Gregory A., 2008, V448, P359, DOI 10.1007/978-1-59745-205-2_11; Hawkins GA, 2008, PHARMACOGENOMICS, V9, P349, DOI 10.2217/14622416.9.3.349; Hawkins GA, 2006, AM J RESP CRIT CARE, V174, P1101, DOI 10.1164/rccm.200509-1405OC; Hersh CP, 2007, AM J RESP CRIT CARE, V176, P849, DOI 10.1164/rccm.200704-592OC; Hirota T, 2008, J ALLERGY CLIN IMMUN, V121, P769, DOI 10.1016/j.jaci.2007.09.038; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jones MG, 2008, CURR OPIN ALLERGY CL, V8, P110, DOI 10.1097/ACI.0b013e3282f4b5f1; Jusufagic AS, 2006, CURR ALLERGY ASTHM R, V6, P521, DOI 10.1007/s11882-006-0031-6; Kabesch M, 2006, TOXICOL LETT, V162, P43, DOI 10.1016/j.toxlet.2005.10.009; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; Karjalainen J, 2003, CLIN EXP ALLERGY, V33, P78, DOI 10.1046/j.1365-2222.2003.01577.x; Kurz T, 2004, CURR OPIN ALLERGY CL, V4, P335, DOI 10.1097/00130832-200410000-00002; Lee YL, 2007, ALLERGY, V62, P641, DOI 10.1111/j.1398-9995.2007.01380.x; Leynaert B, 2006, J ALLERGY CLIN IMMUN, V118, P658, DOI 10.1016/j.jaci.2006.06.015; Li YF, 2008, ENVIRON HEALTH PERSP, V116, P409, DOI 10.1289/ehp.10655; Litonjua AA, 2006, CURR OPIN PULM MED, V12, P12, DOI 10.1097/01.mcp.0000198068.50457.95; London Stephanie J, 2007, Proc Am Thorac Soc, V4, P217, DOI 10.1513/pats.200701-031AW; Madore AM, 2008, HUM GENET, V123, P93, DOI 10.1007/s00439-007-0444-x; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ortega VE, 2007, IMMUNOL ALLERGY CLIN, V27, P665, DOI 10.1016/j.iac.2007.09.007; Palmer CNA, 2006, PEDIATRICS, V118, P710, DOI 10.1542/peds.2005-3030; Payne Donald, 2004, Paediatr Respir Rev, V5, P116, DOI 10.1016/j.prrv.2004.01.006; Ramadas RA, 2007, EUR RESPIR J, V29, P502, DOI 10.1183/09031936.00029506; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Sadeghnejad A, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-2; Saglani S, 2007, CURR OPIN ALLERGY CL, V7, P83; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Smit LAM, 2007, CLIN EXP ALLERGY, V37, P1602, DOI 10.1111/j.1365-2222.2007.02831.x; Szefler SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1043, DOI 10.1016/j.jaci.2007.08.063; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Taylor DR, 2007, EXPERT OPIN PHARMACO, V8, P3195, DOI 10.1517/14656566.8.18.3195; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404, DOI 10.1164/ajrccm.163.6.2001101; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648; Wong GWK, 2008, PEDIATR PULM, V43, P107, DOI 10.1002/ppul.20755; Wu H, 2007, ENVIRON HEALTH PERSP, V115, P616, DOI 10.1289/ehp.9740; Yang IA, 2005, AM J RESP CRIT CARE, V171, P171, DOI 10.1164/rccm.200402-194OC; Yang IA, 2007, CURR OPIN ALLERGY CL, V7, P75, DOI 10.1097/ACI.0b013e328012ce39	78	170	171	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					3	11		10.1016/j.jaci.2008.10.046	http://dx.doi.org/10.1016/j.jaci.2008.10.046			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130922	Bronze			2022-12-18	WOS:000262793900002
J	Al-Muhsen, S; Casanova, JL				Al-Muhsen, Saleh; Casanova, Jean-Laurent			The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						MSMD; genetic heterogeneity; IL-12B; IL-12RB1; IFNGR1; IFNGR2; STAT1; NEMO; Middle East	INTERFERON-GAMMA-RECEPTOR; BACILLE CALMETTE-GUERIN; INHERITED INTERLEUKIN-12 DEFICIENCY; PRIMARY-IMMUNODEFICIENCY-DISEASES; DISSEMINATED BCG INFECTION; STEM-CELL TRANSPLANTATION; AVIUM COMPLEX INFECTION; SMALL DELETION HOTSPOT; IFN-GAMMA; CONSANGUINEOUS MARRIAGES	Primary immunodeficiencies (PIDs) were long thought to be exclusively recessive traits - autosomal recessive (AR) in most cases, with a Few X-linked recessive (XR) diseases. In recent years, autosomal dominant (AD), mitochondrial, polygenic, and even somatic PIDs have been described. However, AR remains the most frequent inheritance pattern among recently described PIDs. Some PIDs have been shown to be genetically heterogeneous. Mendelian susceptibility to mycobacterial diseases (MSMD) displays a high level of genetic heterogeneity. There are 6 MSMD-causing genes, including 1 X-linked gene (nuclear factor-kappa B-essential modulator [NEMO]) and 5 autosomal genes (IFN-gamma receptor 1 [IFNGR1], IFN-gamma receptor 2 [IFNGR2], signal transducer and activator of transcription 1[STAT1], IL-12 p40 subunit [IL12P40], and IL-12 receptor beta-subunit [IL12RB1]). The X-linked trait is XR; STAT1 deficiency is AD; the IFNGR2, IL12P0 subunit, and IL12RB1 deficiencies are AR; and IFNGR1 deficiency may be AD or AR. Two of the AR traits (IFNGR1, IFNGR2) may be subdivided into complete and partial deficiencies, and 3 AR complete deficiencies (IFNGR1, IFNGR2, IL12RB1) may be subdivided into disorders with and without cell surface expression. Finally, there are 2 types of AD STAT1 deficiency, depending on whether the mutation impairs phosphorylation or DNA binding. Thirteen genetic disorders conferring MSMD have been described, involving 1 XR, 3 AD (2 genes), and 9 AR traits (4 genes). However, no genetic etiology has yet been identified for about half of all patients with MSMD. We expect to identify new XR and AD causes of MSMD, but new AR etiologies of MSMD are also likely to be discovered. The investigation of children from areas in which consanguineous marriages are common will probably facilitate the description of many more AR traits. (J Allergy Clin Immunol 2008;122:1043-51.)	[Al-Muhsen, Saleh; Casanova, Jean-Laurent] King Saud Univ, Coll Med, Dept Pediat, Riyadh 11211, Saudi Arabia; [Al-Muhsen, Saleh] King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; [Casanova, Jean-Laurent] Inst Natl Sante & Rech Med, U550, Lab Human Genet Infect Dis, Paris, France; [Casanova, Jean-Laurent] Hop Necker Enfants Malad, Pediat Immunol Hematol Unit, Paris, France; [Casanova, Jean-Laurent] Univ Paris 05, Necker Med Sch, Paris, France	King Saud University; King Faisal Specialist Hospital & Research Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Al-Muhsen, S (corresponding author), King Saud Univ, Coll Med, Dept Pediat, POB 3354,MBC 58, Riyadh 11211, Saudi Arabia.	almuhsen@ksu.edu.sa	Casanova, Jean-Laurent/I-3418-2017; Al-muhsen, saleh/E-9315-2014	Al-muhsen, saleh/0000-0003-3698-9968; Casanova, Jean-Laurent/0000-0002-7782-4169				Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Alcais A, 2005, J EXP MED, V202, P1617, DOI 10.1084/jem.20052302; Allende LM, 2001, CLIN DIAGN LAB IMMUN, V8, P133, DOI 10.1128/CDLI.8.1.133-137.2001; Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; Altare F, 1998, AM J HUM GENET, V62, P723, DOI 10.1086/301750; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Altare F, 2001, J INFECT DIS, V184, P231, DOI 10.1086/321999; Arend SM, 2001, NETH J MED, V59, P140, DOI 10.1016/S0300-2977(01)00152-8; Bener A, 2007, MED PRIN PRACT, V16, P262, DOI 10.1159/000102147; Bustamante J, 2008, IMMUNOL ALLERGY CLIN, V28, P235, DOI 10.1016/j.iac.2008.01.009; Bustamante J, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.043406; Camcioglu Y, 2004, J PEDIATR-US, V144, P519, DOI 10.1016/j.jpeds.2003.11.012; Caragol I, 2003, CLIN INFECT DIS, V37, P302, DOI 10.1086/375587; Casanova JL, 2008, J INTERN MED, V264, P115, DOI 10.1111/j.1365-2796.2008.01971.x; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; Casanova JL, 2005, J ALLERGY CLIN IMMUN, V116, P426, DOI 10.1016/j.jaci.2005.03.053; CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; Casanova JL, 1996, PEDIATRICS, V98, P774; Chantrain CF, 2006, BONE MARROW TRANSPL, V38, P75, DOI 10.1038/sj.bmt.1705399; Chapgier A, 2006, PLOS GENET, V2, P1193, DOI 10.1371/journal.pgen.0020131; Chapgier A, 2006, J IMMUNOL, V176, P5078, DOI 10.4049/jimmunol.176.8.5078; Conley ME, 2005, IMMUNOL REV, V203, P5, DOI 10.1111/j.0105-2896.2005.00237.x; Cunningham JA, 2000, INT J TUBERC LUNG D, V4, P791; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; de Jong R, 1998, SCIENCE, V280, P1435; de Moraes-Vasconcelos D, 2005, CLIN INFECT DIS, V41, pE31, DOI 10.1086/432119; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Doffinger R, 2000, J INFECT DIS, V181, P379, DOI 10.1086/315197; Dorman SE, 2000, CYTOKINE GROWTH F R, V11, P321, DOI 10.1016/S1359-6101(00)00010-1; Dorman SE, 1999, J PEDIATR-US, V135, P640, DOI 10.1016/S0022-3476(99)70064-8; Dorman SE, 2004, LANCET, V364, P2113, DOI 10.1016/S0140-6736(04)17552-1; Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Elloumi-Zghal H, 2002, J INFECT DIS, V185, P1468, DOI 10.1086/340510; Emile JF, 1997, J PATHOL, V181, P25, DOI 10.1002/(SICI)1096-9896(199701)181:1<25::AID-PATH747>3.0.CO;2-Z; Feinberg J, 2004, EUR J IMMUNOL, V34, P3276, DOI 10.1002/eji.200425221; Fieschi C, 2004, BLOOD, V104, P2095, DOI 10.1182/blood-2004-02-0584; Fieschi C, 2003, EUR J IMMUNOL, V33, P1461, DOI 10.1002/eji.200324038; Fieschi C, 2003, J EXP MED, V197, P527, DOI 10.1084/jem.20021769; Fieschi C, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.4.e48; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20060085; Fischer A, 2007, IMMUNITY, V27, P835, DOI 10.1016/j.immuni.2007.11.012; Frucht DM, 1999, CLIN IMMUNOL, V91, P234, DOI 10.1006/clim.1999.4688; Frucht DM, 1996, J IMMUNOL, V157, P411; Frucht DM, 2001, TRENDS IMMUNOL, V22, P556, DOI 10.1016/S1471-4906(01)02005-1; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; GIBLETT ER, 1972, LANCET, V2, P1067; Hamamy HA, 2007, SAUDI MED J, V28, P1015; Hammy H, 2007, COMMUNITY GENET, V10, P52, DOI 10.1159/000096282; Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; Holland SM, 1998, J INFECT DIS, V178, P1095, DOI 10.1086/515670; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Jouanguy E, 2000, J CLIN INVEST, V105, P1429, DOI 10.1172/JCI9166; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Jouanguy E, 1999, NAT GENET, V21, P370, DOI 10.1038/7701; Kanaan ZM, 2008, GENET TEST, V12, P367, DOI 10.1089/gte.2007.0093; Kerkeni E, 2007, CROAT MED J, V48, P701; Koc I, 2008, J BIOSOC SCI, V40, P137, DOI 10.1017/S002193200700226X; Koscielniak E, 2003, PEDIATR INFECT DIS J, V22, P378; Ku CL, 2007, J MED GENET, V44, P16, DOI 10.1136/jmg.2006.044446; Ku CL, 2005, PEDIATRICS, V115, pE615, DOI 10.1542/peds.2004-1754; Lawrence T, 2005, CURR OPIN HEMATOL, V12, P22, DOI 10.1097/01.moh.0000149609.37309.0a; LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4; Lichtenauer-Kaligis EGR, 2003, EUR J IMMUNOL, V33, P59, DOI 10.1002/immu.200390008; MacLennan C, 2004, J INFECT DIS, V190, P1755, DOI 10.1086/425021; Mansouri D, 2005, EUR J PEDIATR, V164, P753, DOI 10.1007/s00431-005-1689-9; Marodi L, 2007, NAT REV IMMUNOL, V7, P851, DOI 10.1038/nri2195; MI ASA, 2008, ANN SAUDI MED, V28, P169; NEDOROST ST, 1991, INT J DERMATOL, V30, P491, DOI 10.1111/j.1365-4362.1991.tb04869.x; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Noordzij JG, 2007, J CLIN IMMUNOL, V27, P490, DOI 10.1007/s10875-007-9097-8; OCHS HD, 2007, PRIMARY IMMUNODEFICI; Ozbek N, 2005, CLIN INFECT DIS, V40, pE55, DOI 10.1086/427879; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Picard C, 2002, AM J HUM GENET, V70, P336, DOI 10.1086/338625; PierreAudigier C, 1997, CLIN INFECT DIS, V24, P982, DOI 10.1093/clinids/24.5.982; Puel A, 2006, AM J HUM GENET, V78, P691, DOI 10.1086/501532; Remiszewski P, 2006, RESPIRATION, V73, P375, DOI 10.1159/000088682; Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153; Rezaei N, 2006, AM J REPROD IMMUNOL, V56, P145, DOI 10.1111/j.1600-0897.2006.00409.x; Roesler J, 2004, J PEDIATR-US, V145, P806, DOI 10.1016/j.jpeds.2004.08.021; Roesler J, 1999, EXP HEMATOL, V27, P1368, DOI 10.1016/S0301-472X(99)00077-6; Rosenzweig S, 2002, CLIN IMMUNOL, V102, P25, DOI 10.1006/clim.2001.5135; Rosenzweig SD, 2004, J IMMUNOL, V173, P4000, DOI 10.4049/jimmunol.173.6.4000; Rottman M, 2008, PLOS MED, V5, P152, DOI 10.1371/journal.pmed.0050026; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sanal O, 2007, PEDIATR INFECT DIS J, V26, P366, DOI 10.1097/01.inf.0000258696.64507.0f; Sasaki Y, 2002, J INFECT DIS, V185, P706, DOI 10.1086/339011; Sharkia R, 2008, AM J HUM BIOL, V20, P72, DOI 10.1002/ajhb.20678; Smahi A, 2000, NATURE, V405, P466; Smyth AE, 2006, EUR J PEDIATR, V165, P71, DOI 10.1007/s00431-005-1739-3; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Villella A, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.4.e47; Vogt G, 2005, NAT GENET, V37, P692, DOI 10.1038/ng1581; Vogt G, 2008, J EXP MED, V205, P1729, DOI 10.1084/jem.20071987; Zerbe CS, 2005, CLIN INFECT DIS, V41, pE38, DOI 10.1086/432120; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	104	170	176	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1043	1051		10.1016/j.jaci.2008.10.037	http://dx.doi.org/10.1016/j.jaci.2008.10.037			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	19084105				2022-12-18	WOS:000261711800001
J	Ross, MP; Ferguson, M; Street, D; Klontz, K; Schroeder, T; Luccioli, S				Ross, Marianne Phelan; Ferguson, Martine; Street, Debra; Klontz, Karl; Schroeder, Tom; Luccioli, Stefano			Analysis of food-allergic and anaphylactic events in the national electronic injury surveillance system	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; food allergy; emergency department; surveillance/epidemiology	EMERGENCY-DEPARTMENT VISITS; NATURAL-HISTORY; CHILDREN	Background: The National Electronic Injury Surveillance System (NEISS) captures a nationally representative probability sample from hospital emergency departments (EDs) in the United States. Objective: Emergency department data from NEISS were analyzed to assess the magnitude and severity of adverse events attributable to food allergies. Methods: Emergency department events describing food-related allergic symptomatology were identified from 34 participating EDs from August 1 to September 30, 2003. Results: Extrapolation of NEISS event data predicts a total of 20,821 hospital ED visits, 2333 visits for anaphylaxis, and 520 hospitalizations caused by food allergy in the United States during the 2-month study period. The median age was 26 years; 24% of visits involved children <= 5 years old. Shellfish was the most frequently implicated food in persons >= 6 years old, whereas children <= 5 years old experienced more events from eggs, fruit, peanuts, and tree nuts. There were no reported deaths. Review of medical records found that only 19% of patients received epinephrine, and, using criteria established by a 2005 anaphylaxis symposium, 57% of likely anaphylactic events did not have an ED diagnosis of anaphylaxis. Conclusion: Analysis of NEISS data may be a useful tool for assessing the magnitude and severity of food-allergic events. A criteria-based review of medical records suggests underdiagnosis of anaphylactic events in EDs.	[Ross, Marianne Phelan; Ferguson, Martine; Street, Debra; Klontz, Karl; Luccioli, Stefano] Food Drug Adm, Ctr Food Safety & Appl Nutr, College Pk, MD 20740 USA; [Schroeder, Tom] US Consumer Prod Safety Commiss, Bethesda, MD USA	US Food & Drug Administration (FDA)	Ross, MP (corresponding author), Food Drug Adm, Ctr Food Safety & Appl Nutr, 5100 Paint Branch Pkwy, College Pk, MD 20740 USA.	Marianne.Ross@fda.hhs.gov						AULT K, 2001, UPDATED NEISS WEIGHT; BISHOP JM, 1990, J PEDIATR-US, V116, P862, DOI 10.1016/S0022-3476(05)80641-9; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Braganza SC, 2006, ARCH DIS CHILD, V91, P159, DOI 10.1136/adc.2004.069914; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; LIEBERMAN P, 2005, J ALLERGY CLIN IMMUN, V115, pS483, DOI DOI 10.1016/J.JACI.2005.01.010; MONERETVAUTRIN DA, 2004, ALLERG IMMUNOL PARIS, V36, P46; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Quinlan KP, 1999, ANN EMERG MED, V34, P637, DOI 10.1016/S0196-0644(99)70166-6; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Section on Breastfeeding, 2012, Pediatrics, V129, pe827, DOI 10.1542/peds.2011-3552; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; SMITH LJ, 1997, FOOD ALLERGY ADVERSE, P431; *US FDA, 2006, APPR EST THRESH MAJ; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011; Wood RA, 2003, PEDIATRICS, V111, P1631; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	25	170	175	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					166	171		10.1016/j.jaci.2007.10.012	http://dx.doi.org/10.1016/j.jaci.2007.10.012			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206508	Bronze			2022-12-18	WOS:000252372000024
J	Weiler, JM; Bonini, S; Coifman, R; Craig, T; Delgado, L; Capao-Filipe, M; Passali, D; Randolph, C; Storms, W				Weiler, John M.; Bonini, Sergio; Coifman, Robert; Craig, Timothy; Delgado, Luis; Capao-Filipe, Miguel; Passali, Desiderio; Randolph, Christopher; Storms, William			American Academy of Allergy, Asthma & Immunology Work Group Report: Exercise-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; exercise; athlete; sports; medicine; anaphylaxis	VOCAL CORD DYSFUNCTION; CROSS-COUNTRY SKIERS; EUCAPNIC VOLUNTARY HYPERPNEA; PEAK FLOW METERS; INDUCED BRONCHOSPASM; INDUCED BRONCHOCONSTRICTION; BRONCHIAL HYPERRESPONSIVENESS; AIRWAY INFLAMMATION; PULMONARY-FUNCTION; 5-LIPOXYGENASE INHIBITOR		Amer Acad Allergy Asthma & Immunol, Milwaukee, WI 53202 USA		Weiler, JM (corresponding author), Amer Acad Allergy Asthma & Immunol, 611 E Wells St, Milwaukee, WI 53202 USA.		Bonini, Sergio/T-6594-2019; Delgado, Luis/L-8035-2013; Coifman, Robert/F-6647-2015	Bonini, Sergio/0000-0003-0079-3031; Delgado, Luis/0000-0003-2375-9071; Coifman, Robert/0000-0002-8472-3374; Passali, Desiderio/0000-0002-4791-012X				Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; Anderson SD, 2003, CLIN REV ALLERG IMMU, V24, P27, DOI 10.1385/CRIAI:24:1:27; Anderson SD, 2003, J ALLERGY CLIN IMMUN, V111, P45, DOI 10.1067/mai.2003.1; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; [Anonymous], 2003, NIH PUBL; BARDAGI S, 1993, AM REV RESPIR DIS, V147, P1112, DOI 10.1164/ajrccm/147.5.1112; Becklake M, 2003, AM J RESP CRIT CARE, V167, P466; Benckhuijsen J, 1996, PEDIATR PULM, V22, P147, DOI 10.1002/(SICI)1099-0496(199609)22:3<147::AID-PPUL2>3.0.CO;2-M; BITTLEMAN DB, 1994, CHEST, V106, P615, DOI 10.1378/chest.106.2.615; Bjornsdottir US, 2000, ANN ALLERG ASTHMA IM, V85, P387; Bonini S, 2005, ALLERGY, V60, P548, DOI 10.1111/j.1398-9995.2005.00838.x; Bonini S, 2001, ANN ALLERG ASTHMA IM, V87, P48, DOI 10.1016/S1081-1206(10)62341-1; Brannan JD, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-144; BRUDNO DS, 1994, ANN ALLERGY, V73, P227; Capao-Filipe M, 2003, ALLERGY, V58, P1196, DOI 10.1046/j.0105-4538.2003.00309.x; Chemery L, 2002, REV MAL RESPIR, V19, P641; Cockcroft DW, 2003, CLIN REV ALLERG IMMU, V24, P19, DOI 10.1385/CRIAI:24:1:19; Connolly CK, 2004, THORAX, V59, P82; Cooper S, 2004, THORAX, V59, P50; COOPER S, 2004, THORAX S3, V59, pP24; Coreno A, 2000, J ALLERGY CLIN IMMUN, V106, P500; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; EGGLESTON PA, 1984, J ALLERGY CLIN IMMUN, V73, P666, DOI 10.1016/0091-6749(84)90302-6; Fahey JT, 2005, PEDIATR PULM, V39, P51, DOI 10.1002/ppul.20076; Ferrari M, 2000, RESPIRATION, V67, P510, DOI 10.1159/000067465; Ferrari M, 2002, RESPIRATION, V69, P509, DOI 10.1159/000066458; Filipe JAC, 2003, AUTON NEUROSCI-BASIC, V104, P66, DOI 10.1016/S1566-0702(02)00268-0; Fisher LH, 2005, CLIN REV ALLERG IMMU, V29, P151, DOI 10.1385/CRIAI:29:2:151; Fonseca JA, 2005, CHEST, V128, P1258, DOI 10.1378/chest.128.3.1258; Ford CN, 2005, JAMA-J AM MED ASSOC, V294, P1534, DOI 10.1001/jama.294.12.1534; Gardner WN, 2004, AM J RESP CRIT CARE, V170, P105, DOI 10.1164/rccm.2405003; Gessler EM, 2002, AM J OTOLARYNG, V23, P386, DOI 10.1053/ajot.2002.126322; Godfrey S, 1974, EXERCISE TESTING CHI; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Hammerman SI, 2002, ANN ALLERG ASTHMA IM, V88, P380, DOI 10.1016/S1081-1206(10)62368-X; Hammo AH, 1999, ANN ALLERG ASTHMA IM, V82, P574, DOI 10.1016/S1081-1206(10)63169-9; Hancox RJ, 2002, AM J RESP CRIT CARE, V165, P1068, DOI 10.1164/ajrccm.165.8.200111-091bc; Hashimoto S, 2000, AM J RESP CRIT CARE, V162, P1075, DOI 10.1164/ajrccm.162.3.9911099; Helenius I, 2000, J ALLERGY CLIN IMMUN, V106, P444, DOI 10.1067/mai.2000.107749; Helenius I, 2005, SPORTS MED, V35, P565, DOI 10.2165/00007256-200535070-00002; Helenius I, 2002, J ALLERGY CLIN IMMUN, V109, P962, DOI 10.1067/mai.2002.124769; Hermansen CL, 2004, POSTGRAD MED, V115, P15, DOI 10.3810/pgm.2004.06.1541; Holzer K, 2004, CLIN J SPORT MED, V14, P134, DOI 10.1097/00042752-200405000-00005; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Jack S, 2004, AM J RESP CRIT CARE, V170, P118, DOI 10.1164/rccm.200207-720OC; JONES RS, 1962, BRIT J DIS CHEST, V56, P78, DOI 10.1016/S0007-0971(62)80005-9; Joos GF, 2003, EUR RESPIR J, V22, P718, DOI 10.1183/09031936.03.00000003; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; Katelaris CH, 2000, J ALLERGY CLIN IMMUN, V106, P260, DOI 10.1067/mai.2000.108603; Katelaris CH, 2003, SPORTS MED, V33, P401, DOI 10.2165/00007256-200333060-00002; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; Langdeau JB, 2001, SPORTS MED, V31, P601, DOI 10.2165/00007256-200131080-00005; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Mandell DL, 2003, INT J PEDIATR OTORHI, V67, P999, DOI 10.1016/S0165-5876(03)00178-2; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; McFadden ER, 1999, AM J RESP CRIT CARE, V160, P221, DOI 10.1164/ajrccm.160.1.9810055; McFadden ER, 1999, EXERCISE INDUCED AST; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; Miller MG, 2005, J ATHL TRAINING, V40, P224; Morris MJ, 1999, CHEST, V116, P1676, DOI 10.1378/chest.116.6.1676; Nazir Z, 2005, RESP MED, V99, P592, DOI 10.1016/j.rmed.2004.10.015; Palosuo K, 2003, J ALLERGY CLIN IMMUN, V111, P1386, DOI 10.1067/mai.2003.1498; Patel NJ, 2004, OTOLARYNG HEAD NECK, V130, P686, DOI 10.1016/j.otohns.2004.01.003; Perkins PJ, 2002, CHEST, V122, P1988, DOI 10.1378/chest.122.6.1988; Powell DM, 2000, ARCH OTOLARYNGOL, V126, P29, DOI 10.1001/archotol.126.1.29; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; RANDOLPH C, 1991, Journal of Allergy and Clinical Immunology, V87, P341, DOI 10.1016/0091-6749(91)92087-H; Reibman J, 2005, ENVIRON HEALTH PERSP, V113, P406, DOI 10.1289/ehp.7375; Rundell KW, 2004, CHEST, V125, P909, DOI 10.1378/chest.125.3.909; Rundell KW, 2004, MED SCI SPORT EXER, V36, P405, DOI 10.1249/01.MSS.0000117118.77267.BF; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2003, CHEST, V123, P468, DOI 10.1378/chest.123.2.468; Rundell KW, 2002, SPORTS MED, V32, P583, DOI 10.2165/00007256-200232090-00004; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; RUPP NT, 1992, AM J DIS CHILD, V146, P941, DOI 10.1001/archpedi.1992.02160200063028; Rupp NT, 1996, PHYSICIAN SPORTSMED, V24, P77, DOI 10.3810/psm.1996.01.1213; RUPP NT, 1993, ANN ALLERGY, V70, P339; Sadeh J, 2003, AM J RESP CRIT CARE, V168, P1146, DOI 10.1164/rccm.2309007; SCADDING JG, 1977, ASTHMA, P1; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; Sinha T, 2003, AM FAM PHYSICIAN, V67, P769; SMITH CM, 1990, EUR RESPIR J, V3, P144; Storms WW, 2003, MED SCI SPORT EXER, V35, P1464, DOI 10.1249/01.MSS.0000084533.75912.B4; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597, DOI 10.1164/ajrccm.158.2.9711012; Tan RA, 2002, ANN ALLERG ASTHMA IM, V89, P226, DOI 10.1016/S1081-1206(10)61948-5; Thickett KM, 2002, EUR RESPIR J, V19, P827, DOI 10.1183/09031936.02.00232802; Thole RT, 2001, MED SCI SPORT EXER, V33, P1641, DOI 10.1097/00005768-200110000-00005; Verges S, 2005, CHEST, V127, P1935, DOI 10.1378/chest.127.6.1935; Verges S, 2004, SCAND J MED SCI SPOR, V14, P381, DOI 10.1111/j.1600-0838.2004.00383.x; Vilsvik J, 2001, RESP MED, V95, P769, DOI 10.1053/rmed.2001.1183; VOY RO, 1984, MED SCI SPORTS EXERC, V18, P328; Weiler JM, 2005, CLIN REV ALLERG IMMU, V29, P139, DOI 10.1385/CRIAI:29:2:139; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; Weiler JM, 1996, ALLERGY ASTHMA PROC, V17, P315, DOI 10.2500/108854196778606437; Weiler JM, 2003, J ALLERGY CLIN IMMUN, V111, P36, DOI 10.1067/mai.2003.113; Weiler JM, 2000, J ALLERGY CLIN IMMUN, V106, P267, DOI 10.1067/mai.2000.108605; Wenzel SE, 2004, AM J RESP CRIT CARE, V170, P579, DOI 10.1164/rccm.2407005; WIENS L, 1992, PEDIATRICS, V90, P350; Yates DH, 1997, AM J RESP CRIT CARE, V156, P988, DOI 10.1164/ajrccm.156.3.9610051	102	170	177	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1349	1358		10.1016/j.jaci.2007.02.041	http://dx.doi.org/10.1016/j.jaci.2007.02.041			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17433829	Bronze			2022-12-18	WOS:000247232800009
J	Guttman-Yassky, E; Lowes, MA; Fuentes-Duculan, J; Whynot, J; Novitskaya, I; Cardinale, I; Haider, A; Khatcherian, A; Carucci, JA; Bergman, R; Krueger, JG				Guttman-Yassky, Emma; Lowes, Michelle A.; Fuentes-Duculan, Judilyn; Whynot, Julia; Novitskaya, Inna; Cardinale, Irma; Haider, Asifa; Khatcherian, Artemis; Carucci, John A.; Bergman, Reuven; Krueger, James G.			Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; psoriasis; myeloid DCs; inflammatory dendritic epidermal cells; plasmacytoid DCs; TIP-DCs	SKIN DISEASES; LESIONAL SKIN; EXPRESSION; SUBSETS; INNATE; RANTES; ECZEMA; TSLP; CCR3	Background: Atopic dermatitis (AD) and psoriasis represent contrasting poles of the T-H(1) versus T-H(2) paradigm. Both diseases have been associated with increased numbers of dendritic cells (DCs) in the skin, but the similarities and differences in DC populations need to be established. Objective: We aimed to characterize the specific DC subsets, as well as chemokine and cytokine environment in chronic AD compared with psoriasis. Methods: Skin biopsies were obtained from patients with acute exacerbation of chronic AD (n = 18), psoriasis (n = 15), and healthy volunteers (n = 15) for microarray analysis, RT-PCR, immunohistochemistry, and double-label immunofluorescence. Results: Myeloid DCs upregulate CCL17 and CCL18 in AD, as opposed to TNF-a and inducible nitric oxide synthase (iNOS) in psoriasis. In our study, we identified cells phenotypically identical to the inflammatory dendritic epidermal cells in the dermis in both diseases, although to a lesser extent in psoriasis. We found substantially higher numbers of dermal CCL22 producing plasmacytoid DCs in AD. The thymic stromal lymphopoietin receptor showed significantly higher expression in AD, whereas the thymic stromal lymphopoietin ligand was upregulated more in psoriasis. Conclusion: There are major differences in myeloid and plasmacytoid subsets of cutaneous DCs and the chemokine/ cytokine environment between AD and psoriasis. Distinct subsets within the CD11c(+) population may influence polarization through the production of regulatory mediators, including NOS, TNF, CCL17, and CCL18. Plasmacytoid DCs may also influence TH2 polarization, having a more important role in AD than previously appreciated. Clinical implications: Dermal inflammatory dendritic cells in AD and TNF and iNOS-producing DCs in psoriasis, and/or their regulatory products, may be potential targets for future therapeutic interventions.	Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Sect Mohs Microg & Dermatol Surg, Ithaca, NY 14853 USA; Rambam Med Ctr, Dept Dermatol, Haifa, Israel; Technion Israel Inst Technol, Haifa, Israel	Rockefeller University; Cornell University; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Krueger, JG (corresponding author), Rockefeller Univ, Invest Dermatol Lab, Box 178,1230 York Ave, New York, NY 10021 USA.	jgk@rockefeller.edu	Lowes, Michelle A/G-9585-2016	Lowes, Michelle A/0000-0003-4256-478X; carucci, john/0000-0001-6817-9439	NCRR NIH HHS [UL1RR024143] Funding Source: Medline; NIAMS NIH HHS [K23 AR052404-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR052404] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Angel CE, 2006, J IMMUNOL, V176, P5730, DOI 10.4049/jimmunol.176.10.5730; de Jongh GJ, 2005, J INVEST DERMATOL, V125, P1163, DOI 10.1111/j.0022-202X.2005.23935.x; Gilliet M, 2004, ARCH DERMATOL, V140, P1490, DOI 10.1001/archderm.140.12.1490; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Kato Y, 2006, INT ARCH ALLERGY IMM, V139, P245, DOI 10.1159/000091170; Krueger JG, 2002, J AM ACAD DERMATOL, V46, P1, DOI 10.1067/mjd.2002.120568; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Novak N, 2005, J AM ACAD DERMATOL, V53, pS171, DOI 10.1016/j.jaad.2005.04.060; Ong PY, 2006, CURR ALLERGY ASTHM R, V6, P384, DOI 10.1007/s11882-996-0008-5; Park CW, 2005, BRIT J DERMATOL, V152, P1173, DOI 10.1111/j.1365-2133.2005.06474.x; Penna G, 2002, HUM IMMUNOL, V63, P1164, DOI 10.1016/S0198-8859(02)00755-3; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stary G, 2005, INT ARCH ALLERGY IMM, V138, P278, DOI 10.1159/000088865; Tanaka K, 2006, INT J IMMUNOGENET, V33, P423, DOI 10.1111/j.1744-313X.2006.00635.x; Watanabe N, 2005, BLOOD, V105, P4749, DOI 10.1182/blood-2004-09-3622; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou XH, 2003, PHYSIOL GENOMICS, V13, P69, DOI 10.1152/physiolgenomics.00157.2002	29	170	184	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1210	1217		10.1016/j.jaci.2007.03.006	http://dx.doi.org/10.1016/j.jaci.2007.03.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17472813				2022-12-18	WOS:000246427200024
J	Takhar, P; Corrigan, CJ; Smurthwaite, L; O'Connor, BJ; Durham, SR; Lee, TH; Gould, HJ				Takhar, Pooja; Corrigan, Christopher J.; Smurthwaite, Lyn; O'Connor, Brian J.; Durham, Stephen R.; Lee, Tak H.; Gould, Hannah J.			Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; class switch recombination; asthma; mucosa	INDUCED CYTIDINE DEAMINASE; IL-5 MESSENGER-RNA; HUMAN B-CELLS; NASAL-MUCOSA; ALLERGIC INFLAMMATION; EXPRESSION; BIOPSIES; HYPERMUTATION; TRANSCRIPTS; RHINITIS	Background: Class switching from IgM/IgG/IgA to IgE is required for B cells to express IgE. This requires class switch recombination in the Ig heavy-chain gene locus. It is generally believed that class switch recombination occurs in lymphoid tissue, but it was recently shown that class switching to IgE occurs in the nasal mucosa in allergic rhinitis. Objective: We aimed to determine whether class switching to IgE also occurs in the bronchial mucosa in asthma, and to look for possible differences/similarities between atopic and nonatopic asthma. Methods: We have used RT-PCR to examine epsilon immunoglobulin heavy-chain germline gene transcripts (GLTs; epsilon GLTs), epsilon circle transcripts (CTs; I epsilon-C mu CT or I epsilon-C gamma CT), and mRNA encoding the heavy chain of IgE (c mRNA) and activation-induced cytidine deaminase (AID) in bronchial biopsies from atopic patients with asthma, nonatopic patients with asthma, atopic controls without asthma, and nonatopic controls without asthma (10 subjects in each group). Results: The epsilon GLT and AID mRNA were detectable in the bronchial mucosa of subjects in all 4 groups. In contrast, I epsilon-C mu, CT, I epsilon-C gamma CT, and r mRNA were detectable in the bronchial mucosa of the majority of both atopic and nonatopic patients with asthma, but rarely in the controls without asthma. Conclusion: The bronchial mucosa is a site primed in all individuals for class switching to IgE, because of B-cell expression of epsilon GLT and AID mRNA. However, it is only in patients with asthma, regardless of atopic status, that class switching to IgE occurs. Clinical implications: Our findings reveal prospects for local targeting of the Ig class switch mechanism in the management of atopic and nonatopic asthma.	Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; Kings Coll London, Div Asthma Allergy & Lung Biol, London SE1 1UL, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; Asthma UK Ctr Allerg Mech Asthma, MRC, London, England	University of London; King's College London; University of London; King's College London; Imperial College London; University of London; King's College London	Gould, HJ (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	hannah.gould@kcl.ac.uk	Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Gould, Hannah/0000-0003-0411-688X; Corrigan, Chris/0000-0002-0706-6534	Medical Research Council [G0200485, G0501494] Funding Source: Medline; MRC [G0501494, G0200485] Funding Source: UKRI; Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; Corrigan C, 2004, CURR OPIN ALLERGY CL, V4, P53, DOI 10.1097/01.all.0000113679.18759.71; Fear DJ, 2004, J IMMUNOL, V173, P4529, DOI 10.4049/jimmunol.173.7.4529; GODARD P, 1997, CLIN ASTHMA REV, V1, P19; Gould HJ, 2006, TRENDS IMMUNOL, V27, P446, DOI 10.1016/j.it.2006.08.007; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Jayaratnam A, 2005, CLIN EXP ALLERGY, V35, P835, DOI 10.1111/j.1365-2222.2005.02283.x; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339; Ying S, 1997, J IMMUNOL, V158, P3539; Zhou C, 2003, J IMMUNOL, V170, P1887, DOI 10.4049/jimmunol.170.4.1887	22	170	177	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					213	218		10.1016/j.jaci.2006.09.045	http://dx.doi.org/10.1016/j.jaci.2006.09.045			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208604				2022-12-18	WOS:000243622200030
J	Lin, W; Truong, N; Grossman, WJ; Haribhai, D; Williams, CB; Wang, JF; Martin, MG; Chatila, TA				Lin, W; Truong, N; Grossman, WJ; Haribhai, D; Williams, CB; Wang, JF; Martin, MG; Chatila, TA			Allergic dysregulation and hyperimmuno-globulinemia E in Foxp3 mutant mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Foxp3; dysregulation polyendocrinopathy enteropathy-X-linked; allergic inflammation; regulatory T cells; signal transducer and activator of transcription 6	REGULATORY T-CELLS; GERMINAL-CENTER FORMATION; TGF-BETA; TH2 CELLS; INFLAMMATION; ENTEROPATHY; EXPRESSION; TOLERANCE; SCURFIN; DISEASE	Background: Regulatory T cells have been proposed to play an important role in regulating allergic inflammation. The transcription factor Foxp3 is a master switch gene that controls the development and function of natural and adaptive CD4(+)CD25(+) regulatory T (T-R) cells. In human subjects loss-of-function Foxp3 mutations trigger lymphoproliferation, autoimmunity, and intense allergic inflammation in a disease termed immune dysregulation polyendocrinopathy enteropathy-X-linked syndrome. Objective: We sought to examine the evolution and attributes of allergic inflammation in mice with a targeted loss-of-function mutation in the murine Foxp3 gene that recapitulates a known disease-causing human Foxp3 mutation. Methods: Foxp3 mutant mice were generated by means of knock-in mutagenesis and were analyzed for histologic, immunologic, and hematologic abnormalities. The role of signal transducer and activator of transcription 6 (Stat6) in disease pathogenesis was analyzed by using Stat6 and Foxp3 double-mutant mice. Results: Foxp3 mutant mice developed an intense multiorgan inflammatory response associated with allergic airway inflammation, a striking hyperimmunoglobulinemia E, eosinophilia, and dysregulated T(H)1 and T(H)2 cytokine production in the absence of overt T(H)2 skewing. Concurrent Stat6 deficiency reversed the hyperimmunoglobulinemia E and eosinophilia and delayed mortality, which is consistent with a pathogenic role for allergic inflammation in Foxp3 deficiency. Conclusion: Allergic dysregulation is a common and fundamental consequence of loss of CD4(+)CD25(+) T-R cells caused by Foxp3 deficiency in different species. Abnormalities affecting TR cells might contribute to a variety of allergic diseases.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Immunol Allergy & Rheumatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Nutr, Dept Pediat, Los Angeles, CA 90095 USA; Med Coll Wisconsin, Div Pediat Hematol Oncol, Blood & Marrow Transplant Program, Dept Pediat, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Div Rheumatol, Dept Pediat, Milwaukee, WI 53226 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Medical College of Wisconsin; Medical College of Wisconsin	Chatila, TA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Immunol Allergy & Rheumatol, MDCC 12-430,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	tchatila@mednet.ucla.edu		Williams, Calvin/0000-0002-5492-8475; Chatila, Talal/0000-0001-7439-2762	NIAID NIH HHS [R01 AI047154, R01 AI-47154] Funding Source: Medline; NIDDK NIH HHS [R21DK060235] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK060235] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bour-Jordan H, 2003, NAT IMMUNOL, V4, P182, DOI 10.1038/ni884; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chakir H, 2003, J IMMUNOL METHODS, V278, P157, DOI 10.1016/S0022-1759(03)00200-X; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; de Lafaille MAC, 2004, J IMMUNOL, V173, P7259, DOI 10.4049/jimmunol.173.12.7259; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; GODFREY VL, 1991, AM J PATHOL, V138, P1379; Hadeiba H, 2003, J IMMUNOL, V170, P5502, DOI 10.4049/jimmunol.170.11.5502; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Jaffar Z, 2004, J IMMUNOL, V172, P3842, DOI 10.4049/jimmunol.172.6.3842; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kusunoki T, 2003, J ALLERGY CLIN IMMUN, V111, P136, DOI 10.1067/mai.2003.29; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LYON MF, 1990, P NATL ACAD SCI USA, V87, P2433, DOI 10.1073/pnas.87.7.2433; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Randolph DA, 1999, J IMMUNOL, V162, P2375; Ritz SA, 2004, CLIN EXP IMMUNOL, V138, P213, DOI 10.1111/j.1365-2249.2004.02618.x; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Stassen M, 2004, J IMMUNOL, V173, P267, DOI 10.4049/jimmunol.173.1.267; Suto A, 2001, AM J RESP CRIT CARE, V164, P680, DOI 10.1164/ajrccm.164.4.2010170; Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161	32	170	185	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1106	1115		10.1016/j.jaci.2005.08.046	http://dx.doi.org/10.1016/j.jaci.2005.08.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275384				2022-12-18	WOS:000235686700025
J	SLATER, JE				SLATER, JE			LATEX ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							RUBBER ELONGATION-FACTOR; CONTACT URTICARIA; SURGICAL GLOVES; NATURAL-RUBBER; SPINA-BIFIDA; HEVEA-BRASILIENSIS; SYSTEMIC REACTIONS; IMMEDIATE ALLERGY; CROSS-REACTIVITY; IGE ANTIBODIES		GEORGE WASHINGTON UNIV, CTR MOLEC MECHANISMS DIS RES, CHILDRENS RES INST, WASHINGTON, DC USA; GEORGE WASHINGTON UNIV, CHILDRENS NATL MED CTR, MED CTR, DEPT PEDIAT, WASHINGTON, DC USA	George Washington University; Children's National Health System; George Washington University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI029428] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29428-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABAZIZ NA, 1993, LATEX PROTEIN WORKSH; AHLROTH M, 1993, J ALLERGY CLIN IMMUN, V91, P242; ALENIUS H, 1991, INT ARCH ALLER A IMM, V96, P376, DOI 10.1159/000235525; ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; ALENIUS H, 1992, ALLERGY PROC, V13, P75, DOI 10.2500/108854192778878863; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; BER DJ, 1992, ALLERGY PROC, V13, P71, DOI 10.2500/108854192778878908; Berky Zoltan T., 1992, JAMA (Journal of the American Medical Association), V268, P2695, DOI 10.1001/jama.268.19.2695; BEUERS U, 1990, LANCET, V335, P1095, DOI 10.1016/0140-6736(90)92664-4; BONNEKOH B, 1992, JAMA-J AM MED ASSOC, V267, P2603, DOI 10.1001/jama.267.19.2603; BOYLE KT, 1992, J ALLERGY CLIN IMMUN, V89, P224; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; CHAMBEYRON C, 1992, ALLERGY, V47, P92, DOI 10.1111/j.1398-9995.1992.tb05094.x; CHAROUS BL, 1993, J ALLERGY CLIN IMMUN, V91, P243; CHEN MD, 1992, AM J OBSTET GYNECOL, V166, P968, DOI 10.1016/0002-9378(92)91373-I; D'Auzac J., 1989, PHYSL RUBBER TREE LA; DALRYMPLE S. J., 1992, RUBBER DEV, V45, P51; DASCHNER FD, 1988, INFECT CONT HOSP EP, V9, P184, DOI 10.1086/645828; DECORRES LF, 1993, ANN ALLERGY, V70, P35; DEGROOTKOSOLCHAROEN J, 1989, AM J INFECT CONTROL, V17, P196, DOI 10.1016/0196-6553(89)90128-4; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; Dillard SF, 1992, INT LATEX C SENSITIV, P23; FUCHS T, 1992, ALLERGY PROC, V13, P61, DOI 10.2500/108854192778878881; FUCHS T, 1991, Journal of Allergy and Clinical Immunology, V87, P269, DOI 10.1016/0091-6749(91)91800-9; GELFAND DW, 1991, AM J ROENTGENOL, V156, P1; GERBER AC, 1989, ANESTHESIOLOGY, V71, P800, DOI 10.1097/00000542-198911000-00031; Grimm A., 1927, KLIN WOCHENSCHR, V6, P1479, DOI 10.1007/BF017185344.; HALSEY JF, 1992, INT LATEX C SENSITIV, P27; HALSEY JF, 1992, INT LAT C SENS LAT M, P24; HAMILTON RG, 1993, J ALLERGY CLIN IMMUN, V91, P241; HASHIM MYA, 1993, LATEX PROTEIN WORKSH; HOLZMAN RS, 1993, ANESTH ANALG, V76, P635; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; JOHNSON RM, 1992, INT LATEX C, P68; KARATHANASIS P, 1993, J ALLERGY CLIN IMMUN, V91, P272; Kekwick RGO, 1989, PHYSL RUBBER TREE LA, P145; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KETTERING J, 1993, CONTRACEPTION, V47, P559, DOI 10.1016/0010-7824(93)90023-Z; KUMAR A, 1992, INT LATEX C, P53; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V91, P1128, DOI 10.1016/0091-6749(93)90314-6; KURUP VP, 1992, ALLERGY PROC, V13, P329, DOI 10.2500/108854192778816915; KWITTKEN PL, 1992, ALLERGY PROC, V13, P123, DOI 10.2500/108854192778878782; LAGIER F, 1990, LANCET, V336, P516, DOI 10.1016/0140-6736(90)92076-T; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; LAURENT J, 1992, J ALLERGY CLIN IMMUN, V89, P779, DOI 10.1016/0091-6749(92)90389-J; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; LEYNADIER F, 1991, ALLERGY, V46, P619, DOI 10.1111/j.1398-9995.1991.tb00633.x; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; LIGHT DR, 1989, J BIOL CHEM, V264, P18598; LIGHT DR, 1989, J BIOL CHEM, V264, P18589; LOSADA E, 1992, ALLERGY PROC, V13, P115, DOI 10.2500/108854192778878773; MAKINEN-KILJUNEN S, 1991, Journal of Allergy and Clinical Immunology, V87, P270, DOI 10.1016/0091-6749(91)91807-6; MAKINENKILJUNEN S, 1992, LANCET, V339, P1608, DOI 10.1016/0140-6736(92)91872-6; MAKINENKILJUNEN S, 1992, J ALLERGY CLIN IMMUN, V90, P230, DOI 10.1016/0091-6749(92)90076-E; MAKINENKILJUNEN S, 1993, J ALLERGY CLIN IMMUN, V91, P242; MCCULLOUGH J, 1993, J ALLERGY CLIN IMMUN, V91, P242; MEEROPOL E, 1993, J PEDIATR ORTHOPED, V13, P1, DOI 10.1097/01241398-199301000-00001; MEEROPOL E, 1990, NEW ENGL J MED, V323, P1072; MELTON AL, 1992, INT LATEX C, P26; MONERETVAUTRIN DA, 1991, ANESTHESIOLOGY, V74, P391, DOI 10.1097/00000542-199102000-00048; MONERETVAUTRIN DA, 1990, ANESTHESIOLOGY, V73, P556, DOI 10.1097/00000542-199009000-00032; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OEI HD, 1992, ALLERGY PROC, V13, P121, DOI 10.2500/108854192778878809; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; PECQUET C, 1990, J AM ACAD DERMATOL, V22, P631, DOI 10.1016/0190-9622(90)70086-W; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; SETLOCK MA, 1993, ANESTH ANALG, V76, P650; SHIELD SW, 1992, ALLERGY PROC, V13, P129, DOI 10.2500/108854192778878827; SILER D, 1992, INT LATEX C SENSITIV, P46; SILVERMAN HI, 1989, NEW ENGL J MED, V321, P837; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1990, ANN ALLERGY, V65, P411; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V93, P825, DOI 10.1016/0091-6749(94)90372-7; SLATER JE, 1992, ANN ALLERGY, V68, P203; SOCKIN SM, 1991, J ALLERGY CLIN IMMUN, V37, P269; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; STCYR DR, 1982, ENCY CHEM TECHNOLOGY, P468; Stern G, 1927, KLIN WOCHENSCHR, V6, P1096; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; SWANSON MC, 1992, J ALLERGY CLIN IMMUN, V89, P227; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TAYLOR JS, 1989, J AM ACAD DERMATOL, V21, P874, DOI 10.1016/S0190-9622(89)70271-1; TOMAZIC VI, 1992, INT LATEX C, P50; TOMAZIC VJ, 1992, INT LATEX C, P37; TOSI LL, 1993, J PEDIATR ORTHOPED, V13, P709, DOI 10.1097/01241398-199311000-00003; TURJANMAA K, 1989, ALLERGY, V44, P181, DOI 10.1111/j.1398-9995.1989.tb02259.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1989, CONTACT DERMATITIS, V20, P360, DOI 10.1111/j.1600-0536.1989.tb03173.x; TURJANMAA K, 1990, LANCET, V336, P1588, DOI 10.1016/0140-6736(90)93372-V; TURJANMAA K, 1993, J ALLERGY CLIN IMMUN, V91, P270; TURJANMAA K, 1988, BRIT MED J, V297, P1020; WARPINSKI J R, 1990, Annals of Allergy, V64, P70; WARPINSKI JR, 1991, ALLERGY PROC, V12, P95, DOI 10.2500/108854191779011846; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x; YOUNG MC, 1992, J ALLERGY CLIN IMMUN, V89, P226; YUNGINGER JW, 1993, J ALLERGY CLIN IMMUN, V91, P241; 1990, FED REGISTER, V55, P51254; 1993, J ALLERGY CLIN IMMUN, V92, P16; 1992, LATEX ALLERGY PRECAU; 1993, FACTS CONDOMS THEIR; 1987, MMWR-MORBID M    S2S, V36, pS2	113	170	175	3	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					139	149		10.1016/0091-6749(94)90031-0	http://dx.doi.org/10.1016/0091-6749(94)90031-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064066				2022-12-18	WOS:A1994PC92600002
J	VANSCHAYCK, CP; GRAAFSMA, SJ; VISCH, MB; DOMPELING, E; VANWEEL, C; VANHERWAARDEN, CLA				VANSCHAYCK, CP; GRAAFSMA, SJ; VISCH, MB; DOMPELING, E; VANWEEL, C; VANHERWAARDEN, CLA			INCREASED BRONCHIAL HYPERRESPONSIVENESS AFTER INHALING SALBUTAMOL DURING 1-YEAR IS NOT CAUSED BY SUBSENSITIZATION TO SALBUTAMOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CATHOLIC UNIV NIJMEGEN,DEPT INTERNAL MED,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,DEPT PULM DIS,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen	VANSCHAYCK, CP (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT FAMILY MED,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CONOLLY ME, 1982, J ALLERGY CLIN IMMUN, V70, P423, DOI 10.1016/0091-6749(82)90004-5; CONOLLY ME, 1977, BRIT J PHARMACOL, V59, P17, DOI 10.1111/j.1476-5381.1977.tb06971.x; CRANE J, 1989, LANCET, V1, P917; FARBER MO, 1984, AM REV RESPIR DIS, V129, P1014; GRAAFSMA SJ, 1988, J RECEPTOR RES, V8, P773, DOI 10.3109/10799898809049025; HARVEY JE, 1981, CLIN SCI, V60, P579, DOI 10.1042/cs0600579; HOLGATE ST, 1977, LANCET, V2, P375; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LIPWORTH BJ, 1989, AM REV RESPIR DIS, V140, P586, DOI 10.1164/ajrccm/140.3.586; MITCHELL EA, 1989, THORAX, V44, P81, DOI 10.1136/thx.44.2.81; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; PRIDE NB, 1984, THORAX, V39, P81; QUANJER PLH, 1983, B EUROP PHYSIOPAT S5, V19, P7; SANJAR S, 1988, LANCET, V2, P160; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; SLY RM, 1989, J ALLERGY CLIN IMMUN, V84, P421, DOI 10.1016/0091-6749(89)90351-5; STERK PJ, 1989, EUR RESPIR J, V2, P267; van Schayck C P, 1989, Scand J Prim Health Care, V7, P137, DOI 10.3109/02813438909087230; VATHENEN AS, 1988, LANCET, V1, P554; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; 1987, AM REV RESPIR DIS, V136, P225; 1985, J ALLERGY CLIN IMMUN, V75, P443	25	170	171	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					793	800		10.1016/S0091-6749(05)80185-X	http://dx.doi.org/10.1016/S0091-6749(05)80185-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	1977787				2022-12-18	WOS:A1990EJ63100013
J	BOUSQUET, J; CHANEZ, P; CHANAL, I; MICHEL, FB				BOUSQUET, J; CHANEZ, P; CHANAL, I; MICHEL, FB			COMPARISON BETWEEN RAST AND PHARMACIA CAP SYSTEM - A NEW AUTOMATED SPECIFIC IGE ASSAY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BOUSQUET, J (corresponding author), HOP AIGUELONGUE,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019	chanez, pascal/0000-0003-4059-0917				AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; AXEN R, 1971, EUR J BIOCHEM, V18, P351; AXEN R, 1988, P CLIN WORKSH IGE AN, P3; BERG T, 1976, INT ARCH ALLER A IMM, V51, P471, DOI 10.1159/000231621; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; CHANAL I, 1988, J ALLERGY CLIN IMMUN, V82, P878, DOI 10.1016/0091-6749(88)90093-0; CRIMI E, 1988, ANN ALLERGY, V61, P371; DEFILIPPI I, 1981, ANN ALLERGY, V46, P249; ERIKSSON NE, 1976, INT ARCH ALLER A IMM, V52, P335, DOI 10.1159/000231700; Galen RS, 1975, PREDICT VALUE EFFIC; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P346, DOI 10.1016/0091-6749(75)90006-8; GUEANT JL, 1989, ALLERGY, V44, P204, DOI 10.1111/j.1398-9995.1989.tb02263.x; HOFFMAN DR, 1980, ANN ALLERGY, V45, P343; HOMBURGER HA, 1988, ALLERGY PRINCIPLES P, P402; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; KEMENY DM, 1983, RECENT DEV RAST OTHE; KNAUER KA, 1983, ALLERGY PRINCIPLES P, P673; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; PECOUD A, 1982, CLIN ALLERGY, V12, P75, DOI 10.1111/j.1365-2222.1982.tb03128.x; PECOUD A, 1986, ALLERGY, V41, P243, DOI 10.1111/j.1398-9995.1986.tb02024.x; SCHRODER H, 1985, ALLERGY S4, V40, P14; SCHRODER H, 1980, 1ST P P EHRL SEM REG, P139; SELTZER JM, 1985, ANN ALLERGY, V54, P25; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	31	170	172	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					1039	1043		10.1016/0091-6749(90)90048-9	http://dx.doi.org/10.1016/0091-6749(90)90048-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	2191989				2022-12-18	WOS:A1990DK50900009
J	BIENENSTOCK, J; BEFUS, AD; PEARCE, F; DENBURG, J; GOODACRE, R				BIENENSTOCK, J; BEFUS, AD; PEARCE, F; DENBURG, J; GOODACRE, R			MAST-CELL HETEROGENEITY - DERIVATION AND FUNCTION, WITH EMPHASIS ON THE INTESTINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8N 3Z5,ONTARIO,CANADA; UNIV LONDON UNIV COLL,DEPT CHEM,LONDON WC1E 6BT,ENGLAND	McMaster University; University of London; University College London	BIENENSTOCK, J (corresponding author), MCMASTER UNIV,MED CTR,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA.		Befus, Dean/C-5561-2009	Befus, Dean/0000-0002-1611-2897				ALLAN RN, 1982, BRIT MED J, V284, P70, DOI 10.1136/bmj.284.6309.70; ASKENASE PW, 1980, J EXP MED, V152, P1358, DOI 10.1084/jem.152.5.1358; ASKENASE PW, 1980, SPRINGER SEMIN IMMUN, V2, P417, DOI 10.1007/BF01857177; AUSTEN K F, 1978, Journal of Immunology, V121, P793; BEFUS AD, 1979, IMMUNOLOGY, V38, P95; BEFUS AD, 1982, J IMMUNOL, V128, P2475; BEFUS AD, 1982, PROG ALLERGY, V31, P76; BEFUS AD, ADV EXP MED BIOL; BEFUS AD, 1980, MUCOSAL IMMUNE SYSTE; BEFUS AD, 1979, MAST CELL ITS ROLE H, P702; BROSTOFF J, 1979, LANCET, V1, P1268; BYARS NE, 1980, AGENTS ACTIONS, V10, P252, DOI 10.1007/BF02025944; CAPRON M, 1978, EUR J IMMUNOL, V8, P127, DOI 10.1002/eji.1830080211; CODE CF, 1977, NEW ENGL J MED, V296, P1459, DOI 10.1056/NEJM197706232962510; COLLAN Y, 1972, SCAND J GASTROENTERO, V7, P1; DENBURG JA, 1980, IMMUNOLOGY, V41, P195; DOLOVICH J, 1974, CAN MED ASSOC J, V111, P684; Enerback L., 1981, MONOGR ALLERGY, V17, P222; FARRAM E, 1980, CELL IMMUNOL, V55, P294, DOI 10.1016/0008-8749(80)90162-8; GINSBURG H, 1981, INT ARCH ALLER A IMM, V66, P447, DOI 10.1159/000232853; GUYGRAND D, 1978, J EXP MED, V148, P1661, DOI 10.1084/jem.148.6.1661; GUYGRAND D, 1981, RECENT ADV MUCOSAL I; HEAP BJ, 1973, J ANAT, V115, P315; IHLE JN, 1982, IMMUNOL REV, V63, P5, DOI 10.1111/j.1600-065X.1982.tb00409.x; KALINER MA, 1980, J ALLERGY CLIN IMMUN, V66, P1, DOI 10.1016/0091-6749(80)90131-1; KELLER R, 1976, EXPERIENTIA, V32, P172; KENT JF, 1966, ANAT RECORD, V156, P439, DOI 10.1002/ar.1091560408; KITAMURA Y, 1981, NATURE, V291, P159, DOI 10.1038/291159a0; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; KITAMURA Y, 1981, NATURE, V294, P290, DOI 10.1038/294290b0; KLEBANOFF SJ, 1980, EOSINOPHIL HLTH DISE, P99; LLOYD G, 1975, GUT, V16, P861, DOI 10.1136/gut.16.11.861; MACDONALD TT, 1980, EXP PARASITOL, V49, P9, DOI 10.1016/0014-4894(80)90050-8; MAYRHOFER G, 1979, IMMUNOLOGY, V37, P145; MAYRHOFER G, 1980, BLOOD, V55, P532; MILLER HRP, 1980, BIOL CELLULAIRE, V39, P229; MILLER HRP, 1971, LAB INVEST, V24, P339; MURRAY M, 1968, LAB INVEST, V19, P222; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NAGAO K, 1981, SCIENCE, V212, P333, DOI 10.1126/science.7209531; NAWA Y, 1979, CELL IMMUNOL, V42, P225, DOI 10.1016/0008-8749(79)90188-6; PEARCE FL, 1982, J IMMUNOL, V128, P2481; RANLOV P, 1972, SCAND J GASTROENTERO, V7, P471, DOI 10.3109/00365527209180772; RAO SN, 1973, J PATHOL, V109, P79, DOI 10.1002/path.1711090109; RAZIN E, 1981, P NATL ACAD SCI-BIOL, V78, P2559, DOI 10.1073/pnas.78.4.2559; RUDZIK O, 1974, LAB INVEST, V30, P260; RUITENBER EJ, 1976, NATURE, V264, P258, DOI 10.1038/264258a0; RUITENBERG EJ, 1979, BRIT J EXP PATHOL, V60, P246; SAAVEDRADELGADO AM, DEMONSTRATION ALTERA; SAAVEDRADELGADO AM, AGENTS ACTIONS; SCHRADER JW, 1981, J IMMUNOL, V126, P452; Selye H, 1965, MAST CELLS; SEVERSON AR, 1969, BRIT J EXP PATHOL, V50, P17; SOLL AH, 1981, GASTROENTEROLOGY, V80, P717; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; TAGLIABUE A, 1982, J EXP MED, V155, P1785, DOI 10.1084/jem.155.6.1785; TERTIAN G, 1981, J IMMUNOL, V127, P788; WATANABE S, 1974, LAB INVEST, V31, P555; ZUCKERFRANKLIN D, 1980, BLOOD, V56, P534	59	170	172	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	6					407	412		10.1016/0091-6749(82)90001-X	http://dx.doi.org/10.1016/0091-6749(82)90001-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PT744	6183305				2022-12-18	WOS:A1982PT74400001
J	Lefaudeux, D; De Meulder, B; Loza, MJ; Peffer, N; Rowe, A; Baribaud, F; Bansal, AT; Lutter, R; Sousa, AR; Corfield, J; Pandis, I; Bakke, PS; Caruso, M; Chanez, P; Dahlen, SE; Fleming, LJ; Fowler, SJ; Horvath, I; Krug, N; Montuschi, P; Sanak, M; Sandstrom, T; Shaw, DE; Singer, F; Sterk, PJ; Roberts, G; Adcock, IM; Djukanovic, R; Auffray, C; Chung, KF				Lefaudeux, Diane; De Meulder, Bertrand; Loza, Matthew J.; Peffer, Nancy; Rowe, Anthony; Baribaud, Frederic; Bansal, Aruna T.; Lutter, Rene; Sousa, Ana R.; Corfield, Julie; Pandis, Ioannis; Bakke, Per S.; Caruso, Massimo; Chanez, Pascal; Dahlen, Sven-Erik; Fleming, Louise J.; Fowler, Stephen J.; Horvath, Ildiko; Krug, Norbert; Montuschi, Paolo; Sanak, Marek; Sandstrom, Thomas; Shaw, Dominic E.; Singer, Florian; Sterk, Peter J.; Roberts, Graham; Adcock, Ian M.; Djukanovic, Ratko; Auffray, Charles; Chung, Kian Fan		U-BIOPRED Study Grp	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; clustering; sputum eosinophilia; partition-around-medoids algorithm	EPITHELIAL-CELLS; PHENOTYPES; EXPRESSION; IDENTIFICATION; DISCOVERY; LYN	Background: Asthma is a heterogeneous disease in which there is a differential response to asthma treatments. This heterogeneity needs to be evaluated so that a personalized management approach can be provided. Objectives: We stratified patients with moderate-to-severe asthma based on clinicophysiologic parameters and performed an omics analysis of sputum. Methods: Partition-around-medoids clustering was applied to a training set of 266 asthmatic participants from the European Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes (U-BIOPRED) adult cohort using 8 prespecified clinic-physiologic variables. This was repeated in a separate validation set of 152 asthmatic patients. The clusters were compared based on sputum proteomics and transcriptomics data. Results: Four reproducible and stable clusters of asthmatic patients were identified. The training set cluster T1 consists of patients with well-controlled moderate-to-severe asthma, whereas cluster T2 is a group of patients with late-onset severe asthma with a history of smoking and chronic airflow obstruction. Cluster T3 is similar to cluster T2 in terms of chronic airflow obstruction but is composed of nonsmokers. Cluster T4 is predominantly composed of obese female patients with uncontrolled severe asthma with increased exacerbations but with normal lung function. The validation set exhibited similar clusters, demonstrating reproducibility of the classification. There were significant differences in sputum proteomics and transcriptomics between the clusters. The severe asthma clusters (T2, T3, and T4) had higher sputum eosinophilia than cluster T1, with no differences in sputum neutrophil counts and exhaled nitric oxide and serum IgE levels. Conclusion: Clustering based on clinicophysiologic parameters yielded 4 stable and reproducible clusters that associate with different pathobiological pathways.	[Lefaudeux, Diane; De Meulder, Bertrand; Auffray, Charles] CNRS ENS UCBL INSERM, CIRI UMR5308, European Inst Syst Biol & Med, Lyon, France; [Loza, Matthew J.; Peffer, Nancy; Baribaud, Frederic] Janssen Res & Dev LLC, Spring House, PA USA; [Rowe, Anthony] Janssen Res & Dev Ltd, High Wycombe, Bucks, England; [Bansal, Aruna T.] St Johns Innovat Ctr, Acclarogen, Cambridge, England; [Lutter, Rene] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Sousa, Ana R.] GlaxoSmithKline, Resp Therapeut Unit, Stockley Pk, Uxbridge, Middx, England; [Corfield, Julie] AstraZeneca R&D, Nottingham, England; [Corfield, Julie] Areteva R&D, Nottingham, England; [Pandis, Ioannis] Imperial Coll London, Data Sci Inst, London, England; [Bakke, Per S.] Univ Bergen, Dept Clin Sci, Bergen, Norway; [Caruso, Massimo] Univ Catania, Dept Clin & Expt Med, Catania, Italy; [Chanez, Pascal] Aix Marseille Univ, Dept Malad Resp, Marseille, France; [Dahlen, Sven-Erik] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Fleming, Louise J.; Adcock, Ian M.; Chung, Kian Fan] Imperial Coll, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England; [Fleming, Louise J.; Adcock, Ian M.; Chung, Kian Fan] Royal Brompton & Harefield NHS Trust, Biomed Res Unit, London, England; [Fowler, Stephen J.] Univ Manchester, Ctr Resp Med & Allergy, Manchester, Lancs, England; [Horvath, Ildiko] Semmelweis Univ, Dept Pulmonol, Budapest, Hungary; [Krug, Norbert] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; [Montuschi, Paolo] Univ Cattolica Sacro Cuore, Fac Med, Rome, Italy; [Sanak, Marek] Jagiellonian Univ, Sch Med, Dept Med, Krakow, Poland; [Sandstrom, Thomas] Umea Univ, Dept Publ Hlth & Clin Med, Med, Umea, Sweden; [Shaw, Dominic E.] Univ Nottingham, Resp Res Unit, Nottingham, England; [Singer, Florian] Univ Childrens Hosp, Bern, Switzerland; [Sterk, Peter J.] NIHR Resp Biomed Res Unit, Clin & Expt Sci, Southampton, Hants, England; [Roberts, Graham; Djukanovic, Ratko] Univ Southampton, Fac Med, Southampton, Hants, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; St Johns Innovation Centre - UK; University of Amsterdam; Academic Medical Center Amsterdam; GlaxoSmithKline; AstraZeneca; Imperial College London; University of Bergen; University of Catania; UDICE-French Research Universities; Aix-Marseille Universite; Karolinska Institutet; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; University of Manchester; Semmelweis University; Fraunhofer Gesellschaft; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Jagiellonian University; Umea University; University of Nottingham; University of Bern; University Hospital of Bern; University of Southampton	Chung, KF (corresponding author), Imperial Coll, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk	Thorsen, Jonathan/AAQ-9269-2021; Gómez Castellà, Cristina/B-2726-2017; Bisgaard, Hans/N-4761-2016; Chung, Kian Fan/B-1872-2012; Singer, Florian/AAO-1460-2021; Sterk, P.J./AAK-8175-2020; Singer, Florian/O-7651-2015; Sanak, Marek/AAV-1628-2021; Szentkereszty, Márton/S-2825-2018; Adcock, Ian/L-3217-2019; Musiał, Jacek/U-5930-2018; Fleming, Louise/ABD-7452-2020; Horvath, Ildiko/M-7874-2019; Horváth, Ildikó/GPP-6088-2022; Caruso, Massimo/P-4161-2016; Braun, Armin/B-8750-2009; shaw, dominick/N-1293-2014	Thorsen, Jonathan/0000-0003-0200-0461; Gómez Castellà, Cristina/0000-0001-8518-0095; Bisgaard, Hans/0000-0003-4131-7592; Chung, Kian Fan/0000-0001-7101-1426; Singer, Florian/0000-0003-3471-5664; Singer, Florian/0000-0003-3471-5664; Sanak, Marek/0000-0001-7635-8103; Szentkereszty, Márton/0000-0001-8891-8657; Musiał, Jacek/0000-0002-8994-0036; Caruso, Massimo/0000-0002-4412-2080; Braun, Armin/0000-0002-1142-1463; Emma, Rosalia/0000-0002-2564-553X; Murray, Clare/0000-0002-8961-8055; Pahus, Laurie/0000-0002-5265-2874; Yang, Xian/0000-0002-1496-8923; von Garnier, Christophe/0000-0003-3585-9176; Schofield, James/0000-0003-4542-6614; Adcock, Ian/0000-0003-2101-8843; Nicholas, Benjamin/0000-0003-1467-9643; Barber, Clair Gillian Mary/0000-0001-5335-5129; Postle, Anthony/0000-0001-7361-0756; Fowler, Stephen/0000-0002-4524-1663; shaw, dominick/0000-0003-4106-8469; Fleming, Louise/0000-0002-7268-7433; Knox, Alan/0000-0002-5906-4143; MONTUSCHI, Paolo/0000-0001-5589-1750; Hashimoto, Simone/0000-0001-8995-3817; Roberts, Graham/0000-0003-2252-1248; Brinkman, Paul/0000-0003-4546-8478; Menzies-Gow, Andrew/0000-0001-9707-4986; Balgoma Hernando, David/0000-0001-6463-4502; Kots, Maxim/0000-0003-3466-4641; Nordlund, Bjorn/0000-0001-9888-1659; Howarth, Peter/0000-0003-0619-7927; Djukanovic, Ratko/0000-0001-6039-5612; Santini, Giuseppe/0000-0002-3785-7089; Kupczyk, Maciej/0000-0003-0800-7867; Reinke, Stacey/0000-0002-0758-0330; Rossios, Christos/0000-0003-3470-3233; chanez, pascal/0000-0003-4059-0917; Frey, Urs/0000-0003-3773-2822; Rowe, Anthony/0000-0003-1829-1179; Loza, Matthew/0000-0002-8609-118X; Wiegman, Coen/0000-0001-9161-0581	Innovative Medicines Initiative Joint Undertaking [115010]; European Union's Seventh Framework Programme (FP7); IMI (EU) [115446]; Medical Research Council [G1000758, G1001367] Funding Source: researchfish; National Institute for Health Research [NF-SI-0514-10085, NF-SI-0515-10016] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre] Funding Source: researchfish; MRC [G1001367] Funding Source: UKRI	Innovative Medicines Initiative Joint Undertaking; European Union's Seventh Framework Programme (FP7); IMI (EU); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	U-BIOPRED is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115010, resources of which are composed of a financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution (www.imi.europa.eu). We would also like to acknowledge help from the IMI-funded eTRIKS project (EU Grant Code no. 115446). This study is registered on ClinicalTrials.gov (identifier: NCT01982162).	Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Bateman ED, 2015, LANCET RESP MED, V3, P719, DOI 10.1016/S2213-2600(15)00254-4; Beavitt SJE, 2005, J IMMUNOL, V175, P1867, DOI 10.4049/jimmunol.175.3.1867; BELLINI A, 1993, J ALLERGY CLIN IMMUN, V92, P412, DOI 10.1016/0091-6749(93)90120-5; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; CALINSKI T, 1968, BIOMETRICS, V24, P207; Charles N, 2009, IMMUNITY, V30, P533, DOI 10.1016/j.immuni.2009.02.008; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; Di Stefano A, 2009, THORAX, V64, P968, DOI 10.1136/thx.2009.113647; Fox J., 2019, R COMPANION APPL REG, V3rd; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karatzoglou A., 2004, J STAT SOFTW, V11, P20; Kaufman L, 1987, REPORTS FACULTY MATH; Kim TB, 2013, EUR RESPIR J, V41, P1308, DOI 10.1183/09031936.00100811; Konno S, 2015, ANN AM THORAC SOC, V12, P1771, DOI 10.1513/AnnalsATS.201507-407OC; Kuhn M., 2022, PACKAGE CARET; Laberge S, 1997, AM J RESP CELL MOL, V17, P193, DOI 10.1165/ajrcmb.17.2.2750; McFadden C, 2007, J IMMUNOL, V179, P6439, DOI 10.4049/jimmunol.179.10.6439; Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Reimand J, 2011, NUCLEIC ACIDS RES, V39, pW307, DOI 10.1093/nar/gkr378; Rohloff JC, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.49; Rovina N, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/413735; Senbabaoglu Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06207; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Vlahos R, 2010, AM J RESP CRIT CARE, V182, P34, DOI 10.1164/rccm.200912-1794OC; Wang W, 2014, CURR MOL MED, V14, P663, DOI 10.2174/1566524014666140603095027; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Wenzel SE, 2013, PULM PHARMACOL THER, V26, P710, DOI 10.1016/j.pupt.2013.07.003; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yan XT, 2015, AM J RESP CRIT CARE, V191, P1116, DOI 10.1164/rccm.201408-1440OC; Yee J, 2009, J CLIN ONCOL, V27, P2787, DOI 10.1200/JCO.2008.19.4233	39	169	171	2	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1797	1807		10.1016/j.jaci.2016.08.048	http://dx.doi.org/10.1016/j.jaci.2016.08.048			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27773852	Bronze, Green Accepted, Green Submitted, Green Published			2022-12-18	WOS:000402724600011
J	Siracusa, MC; Kim, BS; Spergel, JM; Artis, D				Siracusa, Mark C.; Kim, Brian S.; Spergel, Jonathan M.; Artis, David			Basophils and allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophil; allergy; T(H)2 cytokine; thymic stromal lymphopoietin; allergic rhinitis; asthma; atopic dermatitis; urticaria; food allergy; eosinophilic esophagitis; IgE	THYMIC STROMAL LYMPHOPOIETIN; FC-EPSILON-RI; ANTIGEN-PRESENTING CELLS; MAST-CELLS; HISTAMINE-RELEASE; IN-VITRO; NIPPOSTRONGYLUS-BRASILIENSIS; BLOOD BASOPHILS; IL-4 PRODUCTION; BONE-MARROW	Basophils were discovered by Paul Ehrlich in 1879 and represent the least abundant granulocyte population in mammals. The relative rarity of basophils and their phenotypic similarities with mast cells resulted in this cell lineage being historically overlooked, both clinically and experimentally. However, recent studies in human subjects and murine systems have shown that basophils perform nonredundant effector functions and significantly contribute to the development and progression of T(H)2 cytokine-mediated inflammation. Although the potential functions of murine and human basophils have provoked some controversy, recent genetic approaches indicate that basophils can migrate into lymphoid tissues and, in some circumstances, cooperate with other immune cells to promote optimal T(H)2 cytokine responses in vivo. This article provides a brief historical perspective on basophil-related research and discusses recent studies that have identified previously unappreciated molecules and pathways that regulate basophil development, activation, and function in the context of allergic inflammation. Furthermore, we highlight the unique effector functions of basophils and discuss their contributions to the development and pathogenesis of allergic inflammation in human disease. Finally, we discuss the therapeutic potential of targeting basophils in preventing or alleviating the development and progression of allergic inflammation.	[Siracusa, Mark C.; Kim, Brian S.; Artis, David] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; [Siracusa, Mark C.; Kim, Brian S.; Spergel, Jonathan M.; Artis, David] Univ Penn, Inst Immunol, Philadelphia, PA 19104 USA; [Kim, Brian S.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; [Spergel, Jonathan M.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Artis, David] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; [Spergel, Jonathan M.] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Artis, D (corresponding author), Univ Penn, Perelman Sch Med, Inst Immunol, Dept Microbiol, BRB 2-3 Rm 356,421 Curie Blvd, Philadelphia, PA 19104 USA.	dartis@mail.med.upenn.edu	Kim, Brian/GZK-6649-2022	Kim, Brian/0000-0002-8100-7161; Artis, David/0000-0002-1753-4100; Spergel, Jonathan/0000-0002-4658-5353	National Institutes of Health [AI061570, AI087990, AI074878, AI095776, AI102942, AI095466, AI095608, AI097333]; Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award [KL2-RR024132, F32-AI085828]; National Institutes of Health (NIH); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI085828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057217] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Research in the Artis laboratory is supported by the National Institutes of Health (AI061570, AI087990, AI074878, AI095776, AI102942, AI095466, AI095608, and AI097333 to D. A.), Advanced Research Fellowships (KL2-RR024132 to B. S. K. and F32-AI085828 to M. C. S.), and the Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award (to D.A.).; Disclosure of potential conflict of interest: M. C. Siracusa, B. S. Kim, and D. Artis have received grants from the National Institutes of Health (NIH) and have received payment for preparation of this manuscript from the Journal of Allergy and Clinical Immunology. J. M. Spergel has received a grant from the Department of Defense and has received a consulting fee/honorarium from DBV Tech; has consultant arrangements with Danone; has provided expert testimony in a malpractice case on immunotherapy; has received grants from Food Allergy Research Education and the NIH; has received payment for lectures and development of educational presentations from MEI; and has stock/stock options in DBV.	Alvares ML, 2011, CURR ALLERGY ASTHM R, V11, P107, DOI 10.1007/s11882-010-0166-3; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Arinobu Y, 2005, P NATL ACAD SCI USA, V102, P18105, DOI 10.1073/pnas.0509148102; Arock M, 2002, J LEUKOCYTE BIOL, V71, P557; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; Bieneman AP, 2005, J ALLERGY CLIN IMMUN, V115, P295, DOI 10.1016/j.jaci.2004.10.018; Boden SR, 2011, IMMUNOL REV, V242, P247, DOI 10.1111/j.1600-065X.2011.01028.x; Bouvet Jean-Pierre, 2007, Chem Immunol Allergy, V93, P58, DOI 10.1159/000100858; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Brandt Eric B, 2011, J Clin Cell Immunol, V2; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Campo P, 2013, J INVEST ALLERG CLIN, V23, P76; Castro-Rodriguez JA, 2012, PEDIATRICS, V130, pE650, DOI 10.1542/peds.2012-0162; Charles N, 2010, NAT MED, V16, P701, DOI 10.1038/nm.2159; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; Chen YH, 2003, J ALLERGY CLIN IMMUN, V112, P944, DOI 10.1016/j.jaci.2003.08.027; Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051268; Cobanoglu B, 2013, CURR ALLERGY ASTHM R, V13, P203, DOI 10.1007/s11882-013-0341-4; COLVIN RB, 1974, LANCET, V1, P212, DOI 10.1016/S0140-6736(74)92512-4; DENBURG JA, 1992, BLOOD, V79, P846; Dretzke J, 2013, J ALLERGY CLIN IMMUN, V131, P1361, DOI 10.1016/j.jaci.2013.02.013; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; DVORAK AM, 1982, BLOOD, V59, P1279; DVORAK HF, 1972, J EXP MED, V135, P235, DOI 10.1084/jem.135.2.235; DVORAK HF, 1979, J EXP MED, V150, P322, DOI 10.1084/jem.150.2.322; Eckl-Dorna J, 2012, ALLERGY, V67, P601, DOI 10.1111/j.1398-9995.2012.02792.x; Eckman JA, 2008, J INVEST DERMATOL, V128, P1956, DOI 10.1038/jid.2008.55; Eckman JA, 2010, J ALLERGY CLIN IMMUN, V125, P889, DOI 10.1016/j.jaci.2009.09.012; EHRLICH P, 1878, THESIS LEIPZIG U; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Galli SJ, 2000, CURR OPIN HEMATOL, V7, P32, DOI 10.1097/00062752-200001000-00007; GALLI SJ, 1984, PROG ALLERGY, V34, P1; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gelbard Christina M, 2008, Patient Prefer Adherence, V2, P387; Gentinetta T, 2011, J ALLERGY CLIN IMMUN, V128, P1227, DOI 10.1016/j.jaci.2011.07.021; Gessner A, 2005, J IMMUNOL, V174, P1063, DOI 10.4049/jimmunol.174.2.1063; Giacomin PR, 2012, J IMMUNOL, V189, P4371, DOI 10.4049/jimmunol.1200691; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; Golden DBK, 2007, CURR OPIN ALLERGY CL, V7, P331, DOI 10.1097/ACI.0b013e3281f8290c; Griseri T, 2012, IMMUNITY, V37, P1116, DOI 10.1016/j.immuni.2012.08.025; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Heil PM, 2010, J DTSCH DERMATOL GES, V8, P990, DOI 10.1111/j.1610-0387.2010.07497.x; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hill DA, 2012, NAT MED, V18, P538, DOI 10.1038/nm.2657; Huang F, 2012, J ALLERGY CLIN IMMUN, V129, P162, DOI 10.1016/j.jaci.2011.09.018; Iijima H, 2013, ALLERGOL INT, V62, P123, DOI 10.2332/allergolint.12-OA-0488; Ito Y, 2011, ALLERGY, V66, P1107, DOI 10.1111/j.1398-9995.2011.02570.x; Iwasaki H, 2007, IMMUNITY, V26, P726, DOI 10.1016/j.immuni.2007.06.004; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; Jeffery Peter K, 2006, BMC Pulm Med, V6 Suppl 1, pS5, DOI 10.1186/1471-2466-6-S1-S5; Junttila IS, 2013, J ALLERGY CLIN IMMUN, V132, P704, DOI 10.1016/j.jaci.2013.03.033; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053, DOI 10.1164/ajrccm.164.6.2102025; Kim S, 2010, J IMMUNOL, V184, P1143, DOI 10.4049/jimmunol.0902447; KIMURA I, 1975, Clinical Allergy, V5, P95, DOI 10.1111/j.1365-2222.1975.tb01840.x; Kimura S, 2011, ALLERGY ASTHMA IMMUN, V3, P186, DOI 10.4168/aair.2011.3.3.186; Kitzmuller C, 2012, ALLERGY, V67, P593, DOI 10.1111/j.1398-9995.2011.02764.x; Korosec P, 2009, WIEN KLIN WOCHENSCHR, V121, P339, DOI 10.1007/s00508-009-1168-9; Kroeger KM, 2009, J LEUKOCYTE BIOL, V86, P769, DOI 10.1189/jlb.0708452; Kummeling I, 2007, PEDIATRICS, V119, pE225, DOI 10.1542/peds.2006-0896; Lantz CS, 2008, LAB INVEST, V88, P1134, DOI 10.1038/labinvest.2008.88; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lie WJ, 2003, CLIN EXP ALLERGY, V33, P1125, DOI 10.1046/j.1365-2222.2003.01726.x; Lieberman JA, 2013, CURR ALLERGY ASTHM R, V13, P78, DOI 10.1007/s11882-012-0316-x; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MACGLASHAN DW, 1983, FED PROC, V42, P2504; Magerl M, 2010, J ALLERGY CLIN IMMUN, V126, P665, DOI 10.1016/j.jaci.2010.05.047; Marra F, 2009, PEDIATRICS, V123, P1003, DOI 10.1542/peds.2008-1146; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; McGowan EC, 2013, CURR ALLERGY ASTHM R, V13, P101, DOI 10.1007/s11882-012-0324-x; MELLBLOM L, 1980, CELL TISSUE RES, V208, P485; Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590; MITCHELL EB, 1983, CLIN REV ALLERG, V1, P427; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Mukai K, 2012, BLOOD, V120, P76, DOI 10.1182/blood-2011-12-399113; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN; Noga O, 2008, INT ARCH ALLERGY IMM, V146, P66, DOI 10.1159/000112504; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Obata K, 2007, BLOOD, V110, P913, DOI 10.1182/blood-2007-01-068718; OGILVIE BM, 1978, EXP PARASITOL, V46, P20, DOI 10.1016/0014-4894(78)90153-4; OGILVIE BM, 1980, IMMUNOLOGY, V39, P385; Ohmori K, 2009, J IMMUNOL, V182, P2835, DOI 10.4049/jimmunol.0802870; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Ohnmacht C, 2010, J IMMUNOL, V184, P344, DOI 10.4049/jimmunol.0901841; Ohnmacht C, 2009, BLOOD, V113, P2816, DOI 10.1182/blood-2008-05-154773; Oliver JM, 2010, INT ARCH ALLERGY IMM, V151, P275, DOI 10.1159/000250436; Patella V, 2000, J IMMUNOL, V164, P589, DOI 10.4049/jimmunol.164.2.589; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Phillips C, 2003, J LEUKOCYTE BIOL, V73, P165, DOI 10.1189/jlb.0702356; Plager DA, 2006, J ALLERGY CLIN IMMUN, V117, P626, DOI 10.1016/j.jaci.2005.10.023; Poulsen BC, 2012, J IMMUNOL METHODS, V381, P66, DOI 10.1016/j.jim.2012.04.009; Qi YL, 2010, J ALLERGY CLIN IMMUN, V126, P1260, DOI 10.1016/j.jaci.2010.08.040; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Redrup AC, 1998, J IMMUNOL, V160, P1957; Robinson PD, 2013, PEDIATR DRUGS, V15, P291, DOI 10.1007/s40272-013-0020-x; Rocha R, 2011, EUR J PEDIATR, V170, P1471, DOI 10.1007/s00431-011-1540-4; Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047; Rondon C, 2012, J ALLERGY CLIN IMMUN, V129, P1460, DOI 10.1016/j.jaci.2012.02.032; ROSENTHAL S, 1977, BRIT J HAEMATOL, V36, P367, DOI 10.1111/j.1365-2141.1977.tb00660.x; ROTH RL, 1980, EXP PARASITOL, V50, P331, DOI 10.1016/0014-4894(80)90036-3; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; ROTHWELL TL, 1972, IMMUNOLOGY, V22, P733; ROTHWELL TLW, 1975, J PATHOL, V116, P51, DOI 10.1002/path.1711160109; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Saini SS, 2012, J IMMUNOL METHODS, V383, P60, DOI 10.1016/j.jim.2012.05.016; Saini SS, 1999, J IMMUNOL, V162, P5624; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; SCHRADER JW, 1981, P NATL ACAD SCI-BIOL, V78, P323, DOI 10.1073/pnas.78.1.323; Schramm G, 2007, J IMMUNOL, V178, P6023, DOI 10.4049/jimmunol.178.10.6023; Schroeder JT, 2011, IMMUNOL REV, V242, P144, DOI 10.1111/j.1600-065X.2011.01023.x; Schroeder JT, 2009, J IMMUNOL, V182, P2432, DOI 10.4049/jimmunol.0801782; Schroeder JT, 2009, ADV IMMUNOL, V101, P123, DOI 10.1016/S0065-2776(08)01004-3; Schroeder JT, 2002, J ALLERGY CLIN IMMUN, V109, P507, DOI 10.1067/mai.2002.122460; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; Sharma M, 2013, SCI REP-UK, V3, DOI 10.1038/srep01188; Shen T, 2008, INT IMMUNOL, V20, P1201, DOI 10.1093/intimm/dxn077; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Shiraishi Y, 2013, J IMMUNOL, V190, P539, DOI 10.4049/jimmunol.1202049; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Siracusa MC, 2011, ANN NY ACAD SCI, V1217, P166, DOI 10.1111/j.1749-6632.2010.05918.x; SIRAGANIAN RP, 1976, J IMMUNOL, V116, P639; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; SPIERS ASD, 1977, CLIN HAEMATOL, V6, P77; Sullivan BM, 2011, NAT IMMUNOL, V12, P527, DOI 10.1038/ni.2036; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Vashisht P, 2013, EXPERT OPIN BIOL TH, V13, P933, DOI 10.1517/14712598.2013.795943; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Wu JX, 2013, CELL BIOCHEM FUNCT, V31, P496, DOI 10.1002/cbf.2926; Yasnowsky KM, 2006, J ALLERGY CLIN IMMUN, V117, P1430, DOI 10.1016/j.jaci.2006.02.016; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Youssef LA, 2007, J IMMUNOL, V178, P4584, DOI 10.4049/jimmunol.178.7.4584; Zaidi AK, 2010, J ALLERGY CLIN IMMUN, V125, P902, DOI 10.1016/j.jaci.2009.12.996; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015; Zhang Z, 2009, P NATL ACAD SCI USA, V106, P1536, DOI 10.1073/pnas.0812668106	150	169	176	3	47	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					789	801		10.1016/j.jaci.2013.07.046	http://dx.doi.org/10.1016/j.jaci.2013.07.046			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	24075190	Green Accepted			2022-12-18	WOS:000325096500002
J	Collison, A; Mattes, J; Plank, M; Foster, PS				Collison, Adam; Mattes, Joerg; Plank, Maximilian; Foster, Paul S.			Inhibition of house dust mite-induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						miRNA; asthma; allergy; inflammation; dexamethasone; glucocorticoid; HDM; antagomir	EXPERIMENTAL ASTHMA; EOSINOPHIL RECRUITMENT; IMMUNE-SYSTEM; T(H)2 CELLS; IN-VIVO; EXPRESSION; MODULATION; INFLAMMATION; MECHANISMS; MODEL	Background: Glucocorticoids are used as mainstay therapy for asthma, but some patients remain resistant to therapy. MicroRNAs (miRNAs) are important regulators of the immune system by promoting the catabolism of their target transcripts as well as attenuating their translation. The role of miRNA in regulating allergic inflammation remains largely unknown. Blocking miRNA function may provide a new nonsteroidal anti-inflammatory approach to treatment. Objectives: To (1) determine the role of specific miRNAs in the regulation of hallmark features of allergic airways inflammation and (2) compare the efficacy of antagonizing miRNA function with that of steroid treatment. Methods: Mice were sensitized and then aeroallergen-challenged with house dust mite to induce allergic airways disease, and alterations in the expression of miRNAs were characterized. Next mice were treated with antagomirs that inhibited the function of specific miRNAs in the lung or treated with dexamethasone and inflammatory lesions, and airway hyperresponsiveness was measured. Results: miR-145, miR-21, and let-7b have been implicated in airway smooth muscle function, inflammation, and airways epithelial cell function, respectively. Inhibition of miR-145, but not miR-21 or lethal-7b, inhibited eosinophilic inflammation, mucus hypersecretion, T(H)2 cytokine production, and airway hyperresponsiveness. The anti-inflammatory effects of miR-145 antagonism were comparable to steroid treatment. Conclusion: Our study highlights the importance of understanding the contribution of miRNAs to pathogenesis of human allergic disease and their potential as novel anti-inflammatory targets. (J Allergy Clin Immunol 2011; 128: 160-7.)	[Collison, Adam; Plank, Maximilian; Foster, Paul S.] Univ Newcastle, Cooperat Res Ctr Asthma & Airways, Ctr Asthma & Resp Dis, Sch Biomed Sci & Pharm,Fac Hlth, Newcastle, NSW 2300, Australia; [Collison, Adam; Mattes, Joerg] Univ Newcastle, Cooperat Res Ctr Asthma & Airways, Expt & Translat Resp Grp, Sch Biomed Sci & Pharm,Fac Hlth, Newcastle, NSW 2300, Australia	University of Newcastle; University of Newcastle	Foster, PS (corresponding author), Univ Newcastle, Cooperat Res Ctr Asthma & Airways, Ctr Asthma & Resp Dis, Sch Biomed Sci & Pharm,Fac Hlth, 5th Floor David Maddison Clin Sci Bldg, Newcastle, NSW 2300, Australia.	joerg.mattes@newcastle.edu.au; paul.foster@newcastle.edu.au	Foster, Paul/G-5057-2013; MATTES, JOERG/M-5179-2019; Collison, Adam/G-7718-2013	, Paul/0000-0002-0827-8299; Collison, Adam/0000-0002-3074-3046	National Health and Medical Research Council; Cooperative Research Centre for Asthma and Airways	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cooperative Research Centre for Asthma and Airways(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme)	Supported by a National Health and Medical Research Council project grant (to J.M. and P.S.F.), a National Health and Medical Research Council Health Professional Research Fellowship (to J.M.), and the Cooperative Research Centre for Asthma and Airways (to J.M. and P.S.F.).	Aberdam D, 2008, TRENDS BIOCHEM SCI, V33, P583, DOI 10.1016/j.tibs.2008.09.002; Adcock IM, 2008, CURR ALLERGY ASTHM R, V8, P171, DOI 10.1007/s11882-008-0028-4; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Barnes PJ, 2006, EUR RESPIR J, V27, P413, DOI 10.1183/09031936.06.00125404; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Currie GP, 2005, RESP MED, V99, P683, DOI 10.1016/j.rmed.2004.11.008; Fabani MM, 2010, NUCLEIC ACIDS RES, V38, P4466, DOI 10.1093/nar/gkq160; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gotte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; He T, 2009, BIOINFORMATION, V4, P112, DOI 10.6026/97320630004112; Herbert C, 2008, CLIN EXP ALLERGY, V38, P847, DOI 10.1111/j.1365-2222.2008.02950.x; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; La Rocca G, 2011, J CELL PHYSIOL, V226, P602, DOI 10.1002/jcp.22368; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Mattes J, 2008, CURR OPIN MOL THER, V10, P150; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Polikepahad S, 2010, J BIOL CHEM, V285, P30139, DOI 10.1074/jbc.M110.145698; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2009, INT REV IMMUNOL, V28, P535, DOI 10.3109/08830180903208303; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; Ulrich K, 2008, PULM PHARMACOL THER, V21, P637, DOI 10.1016/j.pupt.2008.02.006; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Witwer KW, 2010, J IMMUNOL, V184, P2369, DOI 10.4049/jimmunol.0902712; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Zhang JG, 2010, CLIN CHIM ACTA, V411, P846, DOI 10.1016/j.cca.2010.02.074	45	169	186	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					160	U251		10.1016/j.jaci.2011.04.005	http://dx.doi.org/10.1016/j.jaci.2011.04.005			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21571357				2022-12-18	WOS:000292245600021
J	Nowak-Wegrzyn, A; Sampson, HA				Nowak-Wegrzyn, Anna; Sampson, Hugh A.			Future therapies for food allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Food allergy; oral immunotherapy; sublingual immunotherapy; probiotics; epicutaneous immunotherapy; desensitization; milk allergy; peanut allergy; egg allergy; anti-IgE; anti-IgE therapy; anti-IL-5 therapy	ORAL TOLERANCE INDUCTION; PEANUT-INDUCED ANAPHYLAXIS; HELMINTH INFECTION PROTECTS; PLACEBO-CONTROLLED TRIAL; TRICHURIS-SUIS THERAPY; IGG-BINDING EPITOPES; FC-EPSILON-RI; COWS MILK; SUBLINGUAL IMMUNOTHERAPY; BIRCH-POLLEN	Food allergy is an increasingly prevalent problem in westernized countries, and there is an unmet medical need for an effective form of therapy. A number of therapeutic strategies are under investigation targeting foods that most frequently provoke severe IgE-mediated anaphylactic reactions (peanut, tree nuts, and shellfish) or are most common in children, such as cow's milk and hen's egg. Approaches being pursued are both food allergen specific and nonspecific. Allergen-specific approaches include oral, sublingual, and epicutaneous immunotherapy (desensitization) with native food allergens and mutated recombinant proteins, which have decreased IgE-binding activity, coadministered within heat-killed Escherichia coli to generate maximum immune response. Diets containing extensively heated (baked) milk and egg represent an alternative approach to food oral immunotherapy and are already changing the paradigm of strict dietary avoidance for patients with food allergy. Nonspecific approaches include monoclonal anti-IgE antibodies, which might increase the threshold dose for food allergen in patients with food allergy, and a Chinese herbal formulation, which prevented peanut-induced anaphylaxis in a murine model and is currently being investigated in clinical trials. The variety of strategies for treating food allergy increases the likelihood of success and gives hope that accomplishing an effective therapy for food allergy is within reach. (J Allergy Clin Immunol 2011; 127:558-73.)	[Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sampson, HA (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, 1 Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	hugh.sampson@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854	Food Allergy Initiative; National Institute of Allergy and Infectious Diseases/National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI044236] Funding Source: NIH RePORTER	Food Allergy Initiative; National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	A. Nowak-Wegrzyn has declared that she has no conflict of interest. H. A. Sampson is a consultant for Allertein Therapeutics, LLC; has received research support from and is a consultant and scientific advisor for the Food Allergy Initiative and the National Institute of Allergy and Infectious Diseases/National Institutes of Health; is a medical advisor for the Food Allergy & Anaphylaxis Network; is a scientific advisor for the University of Nebraska FARRP; and is a 45% owner of Herbal Springs, LLC.	Alonso R, 2007, INT ARCH ALLERGY IMM, V143, P185, DOI 10.1159/000099310; Ando H, 2008, J ALLERGY CLIN IMMUN, V122, P583, DOI 10.1016/j.jaci.2008.06.016; Asero R, 1998, CLIN EXP ALLERGY, V28, P1368, DOI 10.1046/j.1365-2222.1998.00399.x; Asero R, 2003, ALLERGY, V58, P435, DOI 10.1034/j.1398-9995.2003.00139.x; Bager P, 2010, J ALLERGY CLIN IMMUN, V125, P123, DOI 10.1016/j.jaci.2009.08.006; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Boyce Joshua A, 2010, J Allergy Clin Immunol, V126, P1105, DOI 10.1016/j.jaci.2010.10.008; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Cooke SK, 1997, J IMMUNOL, V159, P2026; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cortes-Perez NG, 2007, CLIN VACCINE IMMUNOL, V14, P226, DOI 10.1128/CVI.00299-06; Cortes-Perez NG, 2009, INT ARCH ALLERGY IMM, V150, P25, DOI 10.1159/000210377; De Benedetto A, 2010, J ALLERGY CLIN IMMUN; de Boissieu D, 2006, ALLERGY, V61, P1238, DOI 10.1111/j.1398-9995.2006.01196.x; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Enrique E, 2008, ANN ALLERG ASTHMA IM, V100, P283, DOI 10.1016/S1081-1206(10)60456-5; Fernandez-Rivas M, 2009, ALLERGY, V64, P876, DOI 10.1111/j.1398-9995.2008.01921.x; Fisher HR, 2010, ARCH DIS CHILD; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Frossard CP, 2007, J ALLERGY CLIN IMMUN, V119, P952, DOI 10.1016/j.jaci.2006.12.615; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Gruber C, 2010, J ALLERGY CLIN IMMUN, V126, P791, DOI 10.1016/j.jaci.2010.07.022; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Hol J, 2008, J ALLERGY CLIN IMMUN, V121, P1448, DOI 10.1016/j.jaci.2008.03.018; Horner AA, 2000, J ALLERGY CLIN IMMUN, V106, P349, DOI 10.1067/mai.2000.107933; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; Kim Edwin H, 2011, J Allergy Clin Immunol, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li SD, 2001, J ALLERGY CLIN IMMUN, V107, pS233; Li XM, 1999, J IMMUNOL, V162, P3045; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Mangan NE, 2004, J IMMUNOL, V173, P6346, DOI 10.4049/jimmunol.173.10.6346; Medeiros M, 2003, J ALLERGY CLIN IMMUN, V111, P947, DOI 10.1067/mai.2003.1381; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Mempel M, 2003, J ALLERGY CLIN IMMUN, V111, P1406, DOI 10.1067/mai.2003.1497; Morisset M, 2007, Eur Ann Allergy Clin Immunol, V39, P12; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; PATRIARCA C, 1984, ALLERGOL IMMUNOPATH, V12, P275; Patriarca G, 2003, ALIMENT PHARM THER, V17, P459, DOI 10.1046/j.1365-2036.2003.01468.x; Patriarca G, 1998, HEPATO-GASTROENTEROL, V45, P52; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P255, DOI 10.1016/j.jaci.2007.04.027; Prickett SR, 2010, J ALLERGY CLIN IMMUN; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, DOI [10.1016/j.jaci.2011.01.051, DOI 10.1016/J.JACI.2011.01.051]; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Schiavi E, 2010, ALLERGY; Schnoeller C, 2008, J IMMUNOL, V180, P4265, DOI 10.4049/jimmunol.180.6.4265; Schofield AT, 1908, LANCET, V1, P716; Scurlock AM, 2009, CURR ALLERGY ASTHM R, V9, P186, DOI 10.1007/s11882-009-0028-z; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Srivastava K, 2001, J ALLERGY CLIN IMMUN, V107, pS233; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; Srivastava KD, 2002, J ALLERGY CLIN IMMUN, V109, pS287, DOI 10.1016/S0091-6749(02)82012-7; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V127, P576, DOI 10.1016/j.jaci.2010.12.1116; Wang JL, 2010, ANN ALLERG ASTHMA IM, V105, P75, DOI 10.1016/j.anai.2010.05.005; Wang J, 2009, ALLERGY ASTHMA IMMUN, V1, P19, DOI 10.4168/aair.2009.1.1.19; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017; Zhang K, 2004, J ALLERGY CLIN IMMUN, V114, P321, DOI 10.1016/j.jaci.2004.03.058; Zhou YF, 2010, NAT MED, V16, P1128, DOI 10.1038/nm.2201; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zhu FG, 2007, J ALLERGY CLIN IMMUN, V120, P631, DOI 10.1016/j.jaci.2007.05.015	112	169	172	4	80	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					558	575		10.1016/j.jaci.2010.12.1098	http://dx.doi.org/10.1016/j.jaci.2010.12.1098			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21277625	Green Accepted, Bronze			2022-12-18	WOS:000288018400002
J	Asero, R; Tedeschi, A; Riboldi, P; Cugno, M				Asero, R; Tedeschi, A; Riboldi, P; Cugno, M			Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic urticaria; skin tests; histamine release; plasma; histamine releasing factors	CHRONIC IDIOPATHIC URTICARIA; FC-EPSILON-RI; HISTAMINE-RELEASING ACTIVITY; ANTI-IGE AUTOANTIBODIES; RAT MAST-CELLS; SEROLOGICAL MEDIATOR; SKIN REACTIVITY; PROTHROMBIN; ACTIVATION; BASOPHILS	Background: Several aspects of the pathogenesis of chronic urticaria (CU) remain contradictory. Autologous serum skin tests (ASSTs) and in vitro histamine release assays seem to look into distinct aspects of the disease, and the specificity of ASST has been questioned. Objective: We compared the autologous plasma skin test (APST) with ASST to detect autoreactivity in patients with CU. The clotting process was investigated as well by measuring in vivo thrombin generation. Methods: A total of 96 adults with CU underwent ASST; 71 of them underwent APST with Na citrate-anticoagulated plasma. Prothrombin fragment 1+2 plasma levels were measured by a sandwich ELISA in Na citrate-anticoagulated plasmas from 28 patients and 27 controls. Results: Fifty-one of 96 (53%) patients scored positive on ASST, whereas 61 of 71 (86%) patients scored positive on APST (21/30 [70%] ASST-negative and 40/41 [98%] ASST-positive). Plasma prothrombin fragment 1+2 was higher in patients than controls (3.06 [SD 3.36] vs 0.80 [0.34]; P < .001) and in ASST-positive/APST-positive than in ASST-negative/APST-positive patients (3.89 [SD 3.68] vs 1.33 [1.64]; P = 0.058) and was directly related to urticaria severity (r = 0.37; P < .05). Conclusion: Most patients with CU are positive on APST-Na citrate. CU is associated with the generation of thrombin, a serine protease able to activate mast cells and to cause relevant increase in permeability of endothelium. APST and ASST only partially depend on the presence of circulating antibodies to Fc epsilon RI or to IgE. Clinical implications: These findings provide new insights into the pathogenesis of CU and suggest new therapeutic opportunities far treating this disease.	Clin San Carlo, Ambulatorio Allergol, I-20037 Paderno Dugnano, MI, Italy; Osped Maggiore Policlin, Unita Operat Med Interna 2, Fdn IRCSS, Milan, Italy; IRCCS, Ist Auxol, Unita Allergol Immunol Clin & Reumatol, Milan, Italy; Univ Milan, Dipartimento Med Interna, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Istituto Auxologico Italiano; University of Milan	Asero, R (corresponding author), Clin San Carlo, Ambulatorio Allergol, Via Osped 21, I-20037 Paderno Dugnano, MI, Italy.	r.asero@libero.it	Cugno, Massimo/K-8106-2016; meroni, pier luigi/K-8473-2016	Cugno, Massimo/0000-0002-9918-0763; meroni, pier luigi/0000-0002-3394-1451				Asero R, 2001, CLIN EXP ALLERGY, V31, P1105, DOI 10.1046/j.1365-2222.2001.01131.x; Asero R, 2004, CLIN EXP ALLERGY, V34, P1111, DOI 10.1111/j.1365-2222.2004.01997.x; BAUER KA, 2001, HEMOSTASIS THROMBOSI, P1113; BRUHN HD, 1992, THROMB RES, V68, P317, DOI 10.1016/0049-3848(92)90089-S; Chua SL, 2005, BRIT J DERMATOL, V153, P216, DOI 10.1111/j.1365-2133.2005.06694.x; Cirino G, 1996, J EXP MED, V183, P821, DOI 10.1084/jem.183.3.821; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Cugno M, 1997, BLOOD, V89, P3213, DOI 10.1182/blood.V89.9.3213; DEMICHELE MAA, 1990, J APPL PHYSIOL, V69, P1599, DOI 10.1152/jappl.1990.69.5.1599; Fagiolo U, 1999, J ALLERGY CLIN IMMUN, V103, P1143, DOI 10.1016/S0091-6749(99)70190-9; Fagiolo U, 2000, J ALLERGY CLIN IMMUN, V106, P567, DOI 10.1067/mai.2000.108913; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; Goldsack NR, 1998, INT J BIOCHEM CELL B, V30, P641, DOI 10.1016/S1357-2725(98)00011-9; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1988, BRIT J DERMATOL, V119, P179, DOI 10.1111/j.1365-2133.1988.tb03199.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Greaves M, 2000, J ALLERGY CLIN IMMUN, V105, P664, DOI 10.1067/mai.2000.105706; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; HURSTING MJ, 1993, CLIN CHEM, V39, P583; Kaplan AP, 1999, INFLAMMATION BASIC P, P331; KIDO H, 1985, BIOCHEM BIOPH RES CO, V132, P613, DOI 10.1016/0006-291X(85)91177-5; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; NEMETH A, 1987, AGENTS ACTIONS, V20, P149, DOI 10.1007/BF02074654; Parslew R, 2000, CLIN EXP ALLERGY, V30, P1161; PELZER H, 1991, THROMB HAEMOSTASIS, V65, P153; RAZIN E, 1984, J IMMUNOL, V133, P3282; Sabroe RA, 2002, J ALLERGY CLIN IMMUN, V110, P492, DOI 10.1067/mai.2002.126782; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; Sabroe RA, 1998, J ALLERGY CLIN IMMUN, V102, P651, DOI 10.1016/S0091-6749(98)70283-0; SCHAEFFER RC, 1993, AM J PHYSIOL, V264, pH1798, DOI 10.1152/ajpheart.1993.264.6.H1798; Sheldon PJ, 2000, J VASC INTERV RADIOL, V11, P759, DOI 10.1016/S1051-0443(07)61636-4; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Vliagoftis H, 2002, J IMMUNOL, V169, P4551, DOI 10.4049/jimmunol.169.8.4551; WARD PA, 1970, J IMMUNOL, V104, P535; WEST GB, 1982, INT ARCH ALLER A IMM, V68, P399, DOI 10.1159/000233134; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	42	169	174	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1113	1117		10.1016/j.jaci.2005.12.1343	http://dx.doi.org/10.1016/j.jaci.2005.12.1343			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675340				2022-12-18	WOS:000237436300020
J	Venter, C; Pereira, B; Grundy, J; Clayton, CB; Roberts, G; Higgins, B; Dean, T				Venter, Carina; Pereira, Brett; Grundy, Jane; Clayton, C. Bernie; Roberts, Graham; Higgins, Bernie; Dean, Taraneh			Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; infants; double-blind; placebo-controlled food challenge	YOUNG-CHILDREN; ADVERSE-REACTIONS; PREVALENCE; ALLERGY; MILK; INFANTS; EGG	Background: There are very few population-based studies investigating the incidence of food hypersensitivity during the first year of life. Objective: To determine the incidence of parentally reported food hypersensitivity and objectively diagnosed food hypersensitivity during the first year of life. Methods: A birth cohort was recruited (n = 969). At 3, 6, 9, and 12 months, information regarding feeding practices and reported symptoms of atopy were obtained. At I year, infants underwent a medical examination and skin prick testing to a battery of allergens. Symptomatic infants underwent food challenges. Results: Adverse reactions to foods were reported by 132 (14.2%) parents at 3,83 (9.1%) at 6,49 (5.5%) at 9, and 65 (7.2%) at 12 months. Of the subjects, 1.0% (8/763) were sensitized to aeroallergens and 2.2% (17/763) to food allergens. Between 6 and 9 months and 9 and 12 months, 1.4 % (14/969) and 2.8 % (27/969) infants were diagnosed with food hypersensitivity on the basis of open food challenges and 0.9% (9/969) and 2.5% (24/969) on the basis of double-blind, placebo-controlled food challenges. Cumulative incidence of food hypersensitivity by 12 months was 4% (39/969; 95% CI, 2.9% to 5.5%) on the basis of open food challenges and 3.2% (31/969; 95 % CI, 2.2 % to 4.5%) on the basis of double-blind, placebo-controlled food challenges. Conclusion: Between 2.2% and 5.5% of infants have food hypersensitivity in the first year of life. The rate of parental perception of food hypersensitivity is higher than the prevalence of atopic sensitization to main food allergens or objectively assessed food hypersensitivity. Clinical implications: In the first year of life, the rate of parentally perceived food hypersensitivity is considerably higher than objectively assessed food hypersensitivity.	Univ Portsmouth, Sch Hlth Sci & Social Work, Portsmouth PO1 2HY, Hants, England; St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, England	University of Portsmouth	Dean, T (corresponding author), Univ Portsmouth, Sch Hlth Sci & Social Work, St Georges Bldg,141 High St, Portsmouth PO1 2HY, Hants, England.	tara.dean@port.ac.uk		Dean, Taraneh/0000-0002-0123-7646; Roberts, Graham/0000-0003-2252-1248	Department of Health [PDF/01/055] Funding Source: Medline	Department of Health		BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; *DEP HLTH, 1998, CONS PROD ENV PEAN A; Eggesbo M, 1999, PEDIATR ALLERGY IMMU, V10, P122, DOI 10.1034/j.1399-3038.1999.00022.x; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Eggesbo M, 2001, ALLERGY, V56, P393, DOI 10.1034/j.1398-9995.2001.056005393.x; GERRARD JW, 1973, ACTA PAEDIATR SCAND, P1; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P118, DOI 10.1016/j.jaci.2004.03.056; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x	13	169	181	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1118	1124		10.1016/j.jaci.2005.12.1352	http://dx.doi.org/10.1016/j.jaci.2005.12.1352			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675341				2022-12-18	WOS:000237436300023
J	Bowen, T; Cicardi, M; Farkas, H; Bork, K; Kreuz, W; Zingale, L; Varga, L; Martinez-Saguer, I; Aygoren-Pursun, E; Binkley, K; Zuraw, B; Davis, A; Hebert, J; Ritchie, B; Burnham, J; Castaldo, A; Menendez, A; Nagy, I; Harmat, G; Bucher, C; Lacuesta, G; Issekutz, A; Warrington, R; Yang, W; Dean, J; Kanani, A; Stark, D; McCusker, C; Wagner, E; Rivard, GE; Leith, E; Tsai, E; MacSween, M; Lyanga, J; Serushago, B; Leznoff, A; Waserman, S; de Serres, J				Bowen, T; Cicardi, M; Farkas, H; Bork, K; Kreuz, W; Zingale, L; Varga, L; Martinez-Saguer, I; Aygoren-Pursun, E; Binkley, K; Zuraw, B; Davis, A; Hebert, J; Ritchie, B; Burnham, J; Castaldo, A; Menendez, A; Nagy, I; Harmat, G; Bucher, C; Lacuesta, G; Issekutz, A; Warrington, R; Yang, W; Dean, J; Kanani, A; Stark, D; McCusker, C; Wagner, E; Rivard, GE; Leith, E; Tsai, E; MacSween, M; Lyanga, J; Serushago, B; Leznoff, A; Waserman, S; de Serres, J		PREHAEAT	Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; C1 inhibitor deficiency; C1 inhibitor; consensus	HORMONE REPLACEMENT THERAPY; CONVERTING ENZYME-ACTIVITY; C1 INHIBITOR CONCENTRATE; UPPER AIRWAY-OBSTRUCTION; TRANEXAMIC ACID; POSTMENOPAUSAL WOMEN; ANGIONEUROTIC-EDEMA; ESSENTIAL-HYPERTENSION; PLASMA-LEVELS; DANAZOL	Cl inhibitor deficiency (hereditary angioedema [HAE]) is a rare disorder for which there is a lack of consensus concerning diagnosis, therapy, and management, particularly in Canada. European initiatives have driven the approach to managing HAE with 3 C1-INH Deficiency Workshops held every 2 years in Hungary starting in 1999, with the third Workshop having recently been held in May 2003. The European Contact Board has established a European HAE Registry that will hopefully advance our knowledge of this disorder. The Canadian Hereditary Angioedema Society/Societe d'Angioedeme Hereditaire du Canada organized a Canadian International Consensus Conference held in Toronto, Ontario, Canada, on October 24 to 26, 2003, to foster consensus between major European and North American HAE treatment centers. Papers were presented by investigators from Europe and North America, and this consensus algorithm approach was discussed. There is a paucity of double-blind placebo-controlled trials in the treatment of HAE, making levels of evidence to support the algorithm less than optimal. Enclosed is the consensus algorithm approach recommended for the diagnosis, therapy, and management of HAE and agreed to by the authors of this article. This document is only a consensus algorithm approach and requires validation. As such, participants agreed to make this a living 2003 algorithm (ie, a work in progress) and agreed to review its content at future international HAE meetings. The consensus, however, has strength in that it was arrived at by the meeting of patient-care providers along with patient group representatives and individual patients reviewing information available to date and reaching agreement on how to approach the diagnosis, therapy, and management of HAE circa 2003. Hopefully evidence to support approaches to the management of HAE will approach the level of meta-analysis of randomized controlled trials in the near future.	Univ Calgary, Dept Med, Calgary, AB T2N 2T8, Canada; Univ Calgary, Dept Paediat, Calgary, AB T2N 2T8, Canada; Univ Milan, Oseped S Giuseppe, Dept Internal Med, I-20122 Milan, Italy; Semmelweis Univ, Budapest, Hungary; Univ Mainz Hosp, Dept Dermatol, Mainz, Germany; JW Goethe Univ Hosp, Dept Pediat, Frankfurt, Germany; Univ Toronto, Dept Med, Toronto, ON, Canada; Scripps Res Inst, Dept Expt & Mol Med, La Jolla, CA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA USA; Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; Univ Alberta, Dept Med, Claresholm, AB, Canada; Univ Alberta, Dept Med Oncol, Claresholm, AB, Canada; Canadian Hereditary Angioedema Soc Soc Angioedeme, Claresholm, AB, Canada; Grp Pacientes AEH Argentina, Buenos Aires, DF, Argentina; Hungarian HAE Patients Assoc, Budapest, Hungary; Universitatsspital, Dematol Klin, Zurich, Switzerland; Dalhousie Univ, Dept Med, Halifax, NS, Canada; Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; Univ Manitoba, Dept Med, Winnipeg, MB, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1W5, Canada; McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ, Canada; Univ Montreal, Hop Sainte Justine, Dept Pediat, Montreal, PQ, Canada; Univ Toronto, Dept Med, Oakville, ON, Canada	University of Calgary; University of Calgary; University of Milan; Semmelweis University; University Hospital Mainz; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Toronto; Scripps Research Institute; Harvard University; Harvard Medical School; Laval University; University of Alberta; University of Alberta; Dalhousie University; Dalhousie University; University of Manitoba; University of Ottawa; University of British Columbia; University of British Columbia; McGill University; Universite de Montreal; University of Toronto	Bowen, T (corresponding author), Univ Calgary, Dept Med, 705 S Tower,3031 Hosp Dr NW, Calgary, AB T2N 2T8, Canada.	tbowen@pol.net	Bork, Konrad/AAE-4985-2022; cicardi, marco/K-9219-2016; Zingale, Lorenza Chiara/AAB-8598-2020; Varga, Lilian/F-2491-2010	Bork, Konrad/0000-0002-6084-4577; cicardi, marco/0000-0003-1251-225X; Farkas, Henriette/0000-0003-2929-1721; Zuraw, Bruce/0000-0003-0640-6768; Zingale, Lorenza Chiara/0000-0001-8577-7449; Varga, Lilian/0000-0002-5484-364X; Ritchie, Bruce/0000-0003-4754-1050				AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; AGOSTONI A, 1980, J ALLERGY CLIN IMMUN, V65, P75, DOI 10.1016/0091-6749(80)90181-5; AGOSTONI A, 1980, ANN ALLERGY, V44, P299; Agostoni A, 2001, DRUG SAFETY, V24, P599, DOI 10.2165/00002018-200124080-00004; AGOSTONI A, 1991, AM J MED, V90, P278; ANDRIOLE GL, 1986, J UROLOGY, V135, P44, DOI 10.1016/S0022-5347(17)45509-1; Berntorp E, 2001, THROMB HAEMOSTASIS, V86, P714; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Binkley KE, 2003, TRANSFUS APHER SCI, V29, P215, DOI 10.1016/j.transci.2003.08.002; BLOHME G, 1972, ACTA MED SCAND, V192, P293; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; Bork K, 2003, AM J MED, V114, P294, DOI 10.1016/S0002-9343(02)01526-7; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bork K, 2003, TRANSFUS APHER SCI, V29, P235, DOI 10.1016/j.transci.2003.08.007; Bork K, 1999, LANCET, V353, P1066, DOI 10.1016/S0140-6736(99)00110-5; Bork K, 2002, J HEPATOL, V36, P707, DOI 10.1016/S0168-8278(02)00035-1; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Bouillet L, 2003, DERMATOLOGY, V206, P106, DOI 10.1159/000068456; Bowen T, 2003, TRANSFUS APHER SCI, V29, P205, DOI 10.1016/j.transci.2003.08.009; Bowen T, 2003, TRANSFUS APHER SCI, V29, P193, DOI 10.1016/j.transci.2003.08.011; *CAN PAED SOC, 2003, PAEDIAT CHILD HLTH, V8, P135; Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2; Cicardi M, 2003, TRANSFUS APHER SCI, V29, P221, DOI 10.1016/S1473-0502(03)00164-2; CICARDI M, 1991, J ALLERGY CLIN IMMUN, V87, P768, DOI 10.1016/0091-6749(91)90120-D; Crampon D, 1998, J HEPATOL, V29, P1035, DOI 10.1016/S0168-8278(98)80140-2; Dalmau A, 2001, ANESTH ANALG, V93, P516; DAVIES D, 1977, LANCET, V1, P49; Davis AE, 2003, TRANSFUS APHER SCI, V29, P195, DOI 10.1016/j.transci.2003.08.012; De Serres J, 2003, TRANSFUS APHER SCI, V29, P247, DOI 10.1016/j.transci.2003.08.006; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DORE M, 1990, 5 C ASS NAZ MED URG, P1083; ENDO Y, 1988, JAMA-J AM MED ASSOC, V259, P3561, DOI 10.1001/jama.1988.03720240023026; EWALD GA, 1995, CIRCULATION, V91, P28, DOI 10.1161/01.CIR.91.1.28; FALK H, 1979, LANCET, V2, P1120; Farkas H, 2003, TRANSFUS APHER SCI, V29, P229, DOI 10.1016/j.transci.2003.08.003; Farkas H, 1999, J ORAL MAXIL SURG, V57, P404, DOI 10.1016/S0278-2391(99)90280-X; Farkas H, 2001, ACTA DERM-VENEREOL, V81, P376; Farkas H, 2002, PEDIAT ALLERG IMM-UK, V13, P153, DOI 10.1034/j.1399-3038.2002.01014.x; Farkas H, 2001, EUR J GASTROEN HEPAT, V13, P1225, DOI 10.1097/00042737-200110000-00016; FARRELL GC, 1975, LANCET, V1, P430; FRANCIS CW, 1991, BRIT J HAEMATOL, V77, P562; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; Gallagher PE, 1999, HYPERTENSION, V33, P323, DOI 10.1161/01.HYP.33.1.323; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Hellstern P, 2002, THROMB RES, V107, pS53, DOI 10.1016/S0049-3848(02)00153-6; JOHNSON FL, 1972, LANCET, V2, P1273; KEW MC, 1976, S AFR MED J, V50, P1233; KREUZ W, 2003, CAN INT C MAN HER AN; Lansink M, 1999, BLOOD, V94, P1330, DOI 10.1182/blood.V94.4.1330.416k19_1330_1336; LINDOFF C, 1993, THROMB HAEMOSTASIS, V70, P238; LYNCH M, 1993, CLIN EXP IMMUNOL, V94, P279; Mantel-Teeuwisse AK, 2001, DRUG SAFETY, V24, P443, DOI 10.2165/00002018-200124060-00003; NIELSEN EW, 1994, PEDIATR RES, V35, P184, DOI 10.1203/00006450-199402000-00012; Nogawa N, 2001, MENOPAUSE, V8, P210, DOI 10.1097/00042192-200105000-00011; NUIJENS J, 2003, CAN INT C MAN HER AN; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Pappalardo E, 2000, J ALLERGY CLIN IMMUN, V106, P1147, DOI 10.1067/mai.2000.110471; PICKERING RJ, 1969, LANCET, V1, P326; Ritchie BC, 2003, TRANSFUS APHER SCI, V29, P259, DOI 10.1016/j.transci.2003.08.004; Ritchie BC, 2003, TRANSFUS APHER SCI, V29, P269, DOI 10.1016/j.transci.2003.08.010; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; ROSENKRANZ B, 2003, CAN INT C MAN HER AN; RYDIN E, 1976, LANCET, V2, P49; Skidgel R A, 1987, Agents Actions Suppl, V22, P289; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739; Sumino H, 2003, HYPERTENS RES, V26, P53; Sumino H, 1999, AM J HYPERTENS, V12, P1044, DOI 10.1016/S0895-7061(99)00094-1; Taparia M, 2002, EUR J HAEMATOL, V68, P307, DOI 10.1034/j.1600-0609.2002.01607.x; THEIL PL, 1981, ACTA OPHTHALMOL, V59, P237; Trachsel D, 1999, INTENS CARE MED, V25, P1335, DOI 10.1007/s001340051072; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; Williams A, 2003, TRANSFUS APHER SCI, V29, P255, DOI 10.1016/S1473-0502(03)00170-8; WOO KS, 1989, BRIT J CLIN PRACT, V43, P465; Zingale LC, 2002, INT IMMUNOPHARMACOL, V318, P1385; Zuraw BL, 2003, TRANSFUS APHER SCI, V29, P239, DOI 10.1016/j.transci.2003.08.008; ZURAW BL, 1986, J ALLERGY CLIN IMMUN, V78, P1115, DOI 10.1016/0091-6749(86)90259-9	77	169	171	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					629	637		10.1016/j.jaci.2004.06.043	http://dx.doi.org/10.1016/j.jaci.2004.06.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356569	Bronze			2022-12-18	WOS:000223799600025
J	van Strien, RT; Engel, R; Holst, O; Bufe, A; Eder, W; Waser, M; Braun-Fahrlander, C; Riedler, J; Nowak, D; von Mutius, E				van Strien, RT; Engel, R; Holst, O; Bufe, A; Eder, W; Waser, M; Braun-Fahrlander, C; Riedler, J; Nowak, D; von Mutius, E		ALEX Study Team	Microbial exposure of rural school children, as assessed by levels of N-acetyl-muramic acid in mattress dust, and its association with respiratory health	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						farming; allergy; asthma; peptidoglycan; muramic acid; microbial exposure; hygiene hypothesis	TANDEM MASS-SPECTROMETRY; ALLERGIC SENSITIZATION; ENDOTOXIN LEVELS; HAY-FEVER; FARMERS CHILDREN; ASTHMA; ENVIRONMENTS; AGE; DETERMINANTS; COMMUNITY	Background: Endotoxin exposure has been shown to be associated with a decreased prevalence of atopic sensitization and symptoms. Yet endotoxin represents only a part of the indoor microbial exposure. Muramic acid, a constituent of peptidoglycan, is present in gram-negative and gram-positive bacteria in the environment and may therefore serve as an additional marker of microbial exposure. Objective: To study the factors determining the level of indoor exposure to muramic acid/peptidoglycan, as well as its potential association with respiratory health. Methods: In 553 farm and nonfarm school children from Austria, Switzerland, and Germany, mattress dust muramic acid concentrations were determined, and health was assessed by using IgE measurements and questionnaire information. Results: The muramic acid concentration was found to be significantly higher in dust from farm children's mattresses than in dust from nonfarm children's mattresses (157 vs 131 ng/mg). Children with higher mattress dust muramic acid concentrations had a significantly lower prevalence of wheezing (odds ratio of highest vs lowest tertile of muramic acid concentration, 0.3; 95 % CI, 0.1-0.9), regardless of farming status and endotoxin exposure. The association for asthma was similar, and no association was found with atopic sensitization. Conclusion: Next to endotoxin, muramic acid provides us with an independent marker of microbial exposure. Unlike endotoxin, muramic acid was inversely associated with wheezing rather than with atopic sensitization.	Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Res Ctr Borstel, Div Struct Biochem, Leibniz Ctr Med & Biol Sci, Borstel, Germany; Ruhr Univ Bochum, Dept Expt Pneumol, D-4630 Bochum, Germany; Arizona Resp Ctr, Tucson, AZ USA; Inst Social & Prevent Med, Basel, Switzerland; Childrens Hosp, Salzburg, Austria; Inst Occupat & Environm Med, Munich, Germany	University of Munich; Forschungszentrum Borstel; Ruhr University Bochum	von Mutius, E (corresponding author), Von Haunersche Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.	erika.von.mutius@med.uni-muenchen.de	riedler, josef/AAQ-4666-2020	von Mutius, Erika/0000-0002-8893-4515; Bufe, Albrecht/0000-0001-7335-9362				BLACK GE, 1994, ANAL CHEM, V66, P4171, DOI 10.1021/ac00095a010; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Heine H, 2003, INT ARCH ALLERGY IMM, V130, P180, DOI 10.1159/000069517; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; Krahmer M, 1998, AM IND HYG ASSOC J, V59, P524, DOI 10.1080/15428119891010695; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Laitinen S, 2001, ANN AGR ENV MED, V8, P213; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Liu LJS, 2000, J AIR WASTE MANAGE, V50, P1957, DOI 10.1080/10473289.2000.10464225; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; MIELNICZUK Z, 1995, J CHROMATOGR B, V670, P167, DOI 10.1016/0378-4347(95)00152-9; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Saraf A, 1999, INDOOR AIR, V9, P219, DOI 10.1111/j.1600-0668.1999.00002.x; Sebastian A, 2003, APPL ENVIRON MICROB, V69, P3103, DOI 10.1128/AEM.69.6.3103-3109.2003; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; Wang ZP, 1996, AM J RESP CRIT CARE, V154, P1261, DOI 10.1164/ajrccm.154.5.8912733; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; Wickens K, 2003, INDOOR AIR, V13, P128, DOI 10.1034/j.1600-0668.2003.00187.x	30	169	171	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					860	867		10.1016/j.jaci.2004.01.078	http://dx.doi.org/10.1016/j.jaci.2004.01.078			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131567				2022-12-18	WOS:000221269000007
J	Eggesbo, M; Botten, G; Stigum, H; Nafstad, P; Magnus, P				Eggesbo, M; Botten, G; Stigum, H; Nafstad, P; Magnus, P			Is delivery by cesarean section a risk factor for food allergy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; egg allergy; double-blind; placebo-controlled food challenge; risk factors; cesarean section; antibiotics; hygiene	INTESTINAL MICROFLORA; TURNOVER RATE; INFANTS; ASTHMA; COLONIZATION; HYGIENE; FLORA; COMPLICATIONS; PREVALENCE; COMMENSAL	Background: Cesarean delivery might delay the colonization of the newborn intestine. A delayed or aberrant colonization process has been offered as an explanation for the increase in allergic diseases. Objective: The aim of this study was to examine whether cesarean delivery and the use of antibiotics were associated with subsequent food allergy. Methods: In a population-based birth cohort of 2803 children, information regarding mode of delivery, maternal or infant use of antibiotics, and information on potential confounders was obtained prospectively from parental reports and the Norwegian Birth Registry. Parentally perceived reactions to egg, fish, or nuts, as well as objectively confirmed reactions to egg at the age of 21/2 years, were chosen as outcomes. Results: Among children whose mothers were allergic, cesarean section was associated with a 7-fold increased risk of parentally perceived reactions to egg, fish, or nuts (odds ratio, 7.0; CI, 1.8-28; P = .005) and a 4-fold increased risk of confirmed egg allergy (odds ratio, 4.1; CI, 0.9-19; P = .08) in a logistic regression analysis, adjusting for pregnancy complications, birth weight, gestational length, and socioeconomic factors. Among children whose mothers were not allergic, the association was much weaker and not significant. Maternal or infant use of antibiotics was not associated with an increased risk of food allergy. Conclusion: The results indicate that in predisposed children cesarean section might increase the risk of development of food allergy, which supports the theory that factors interfering with the colonization process might play a role in the development of food allergy.	Norwegian Inst Publ Hlth, Div Epidemiol, N-0403 Oslo, Norway; Univ Oslo, Natl Hosp, Ctr Hlth Adm, N-0027 Oslo, Norway	Norwegian Institute of Public Health (NIPH); University of Oslo; National Hospital Norway	Eggesbo, M (corresponding author), Norwegian Inst Publ Hlth, Div Epidemiol, POB 4404, N-0403 Oslo, Norway.			Eggesbo, Merete/0000-0002-0006-5336				Adlerberth I, 1998, EPIDEMIOL INFECT, V121, P587, DOI 10.1017/S0950268898001484; ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Annesi-Maesano I, 2001, ALLERGY, V56, P491, DOI 10.1034/j.1398-9995.2001.056006491.x; BENNET R, 1987, INFECTION, V15, P332, DOI 10.1007/BF01647733; BENNET R, 1991, SCAND J INFECT DIS, V23, P63, DOI 10.3109/00365549109023376; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; DAHLGREN UIH, 1991, IMMUNOLOGY, V73, P394; Eggesbo M, 1999, PEDIATR ALLERGY IMMU, V10, P122, DOI 10.1034/j.1399-3038.1999.00022.x; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Escherich T, 1885, FORTSCHR MED, V3, P515; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Hooper LV, 1999, P NATL ACAD SCI USA, V96, P9833, DOI 10.1073/pnas.96.17.9833; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Irgens LM, 2000, ACTA OBSTET GYN SCAN, V79, P435, DOI 10.1034/j.1600-0412.2000.079006435.x; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kero J, 2002, PEDIATR RES, V52, P6, DOI 10.1023/01.PDR.0000017263.01840.F0; KUHN I, 1986, INFECTION, V14, P7, DOI 10.1007/BF01644802; LONG SS, 1977, J PEDIATR-US, V91, P298, DOI 10.1016/S0022-3476(77)80836-6; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P800, DOI 10.1067/mai.2002.124046; Nafstad P, 1996, EUR RESPIR J, V9, P2623, DOI 10.1183/09031936.96.09122623; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; NEUT C, 1987, ZBL BAKT-INT J MED M, V266, P330; SIMHON A, 1982, ARCH DIS CHILD, V57, P54; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sudo N, 1997, J IMMUNOL, V159, P1739; Tomeo CA, 1999, EPIDEMIOLOGY, V10, P774, DOI 10.1097/00001648-199911000-00022; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; Xu BZ, 2000, J ASTHMA, V37, P589, DOI 10.3109/02770900009090814	35	169	177	1	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					420	426		10.1067/mai.2003.1610	http://dx.doi.org/10.1067/mai.2003.1610			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897751				2022-12-18	WOS:000184650600029
J	KAPLAN, AP; HORAKOVA, Z; KATZ, SI				KAPLAN, AP; HORAKOVA, Z; KATZ, SI			ASSESSMENT OF TISSUE FLUID HISTAMINE LEVELS IN PATIENTS WITH URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NHLBI, PULM BRANCH, BETHESDA, MD 20014 USA; NCI, DERMATOL BRANCH, BETHESDA, MD 20014 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KAPLAN, AP (corresponding author), NIAID, CLIN INVEST LAB, ALLERG DIS SECT, BLDG 10, ROOM 11N246, BETHESDA, MD 20014 USA.							BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BEERENS EGJ, 1975, J INVEST DERMATOL, V65, P513, DOI 10.1111/1523-1747.ep12610200; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; KIISTALA U, 1968, J INVEST DERMATOL, V50, P129, DOI 10.1038/jid.1968.15; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	9	169	171	2	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	6					350	354		10.1016/0091-6749(78)90113-6	http://dx.doi.org/10.1016/0091-6749(78)90113-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC593	659726				2022-12-18	WOS:A1978FC59300002
J	West, CE; Renz, H; Jenmalm, MC; Kozyrskyj, AL; Allen, KJ; Vuillermin, P; Prescott, SL; MacKay, C; Salminen, S; Wong, G; Sinn, J; Stokholm, J; Bisgaard, H; Pawankar, R; Noakes, P; Kesper, D; Tulic, M				West, Christina E.; Renz, Harald; Jenmalm, Maria C.; Kozyrskyj, Anita L.; Allen, Katrina J.; Vuillermin, Peter; Prescott, Susan L.; MacKay, Charles; Salminen, Seppo; Wong, Gary; Sinn, John; Stokholm, Jakob; Bisgaard, Hans; Pawankar, Ruby; Noakes, Paul; Kesper, Doerthe; Tulic, Meri		In-FLAME Microbiome Interest Grp	The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Fecal microbiota transplantation; gut microbiome; inflammation; noncommunicable diseases; prebiotics; probiotics; short-chain fatty acids	CLOSTRIDIUM-DIFFICILE INFECTION; FECAL MICROBIOTA; INTESTINAL MICROBIOTA; ALLERGIC DISEASE; EARLY-LIFE; PROBIOTIC SUPPLEMENTATION; HEALTHY-CHILDREN; CESAREAN-SECTION; FOLLOW-UP; AT-RISK	Rapid environmental transition and modern lifestyles are likely driving changes in the biodiversity of the human gut microbiota. With clear effects on physiologic, immunologic, and metabolic processes in human health, aberrations in the gut microbiome and intestinal homeostasis have the capacity for multisystem effects. Changes in microbial composition are implicated in the increasing propensity for a broad range of inflammatory diseases, such as allergic disease, asthma, inflammatory bowel disease (IBD), obesity, and associated noncommunicable diseases (NCDs). There are also suggestive implications for neurodevelopment and mental health. These diverse multisystem influences have sparked interest in strategies that might favorably modulate the gut microbiota to reduce the risk of many NCDs. For example, specific prebiotics promote favorable intestinal colonization, and their fermented products have anti-inflammatory properties. Specific probiotics also have immunomodulatory and metabolic effects. However, when evaluated in clinical trials, the effects are variable, preliminary, or limited in magnitude. Fecal microbiota transplantation is another emerging therapy that regulates inflammation in experimental models. In human subjects it has been successfully used in cases of Clostridium difficile infection and IBD, although controlled trials are lacking for IBD. Here we discuss relationships between gut colonization and inflammatory NCDs and gut microbiota modulation strategies for their treatment and prevention.	[West, Christina E.] Umea Univ, Dept Clin Sci, SE-90185 Umea, Sweden; [Renz, Harald; Kesper, Doerthe] Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany; [Jenmalm, Maria C.] Linkoping Univ, Dept Clin & Expt Med, S-58183 Linkoping, Sweden; [Kozyrskyj, Anita L.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Allen, Katrina J.] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic 3010, Australia; [Allen, Katrina J.] Univ Melbourne, Dept Pediat, Melbourne, Vic 3010, Australia; [Vuillermin, Peter] Barwon Hlth, Child Hlth Res Unit, Geelong, Vic, Australia; [Prescott, Susan L.; Noakes, Paul] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [MacKay, Charles] Monash Univ, Fac Med, Clayton, Vic, Australia; [Salminen, Seppo] Univ Turku, Funct Foods Forum, SF-20500 Turku, Finland; [Wong, Gary] Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Hong Kong, Peoples R China; [Wong, Gary] Chinese Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China; [Sinn, John] Univ Sydney, Dept Neonatol, Sydney, NSW 2006, Australia; [Stokholm, Jakob; Bisgaard, Hans] Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood Hlth, DK-1168 Copenhagen, Denmark; [Pawankar, Ruby] Nippon Med Sch, Dept Pediat, Div Allergy, Tokyo 113, Japan; [Tulic, Meri] Univ Nice Sophia Antipolis, F-06189 Nice, France	Umea University; Philipps University Marburg; Linkoping University; University of Alberta; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; University of Western Australia; Monash University; University of Turku; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Sydney; University of Copenhagen; Nippon Medical School; UDICE-French Research Universities; Universite Cote d'Azur	West, CE (corresponding author), Umea Univ, Dept Clin Sci, SE-90185 Umea, Sweden.	christina.west@umu.se	Allen, Katrina/I-4361-2018; Tulic, Meri/P-6613-2016; Mackay, Charles R/A-9673-2008; Tulic, Meri K/ABB-5138-2020; Bisgaard, Hans/N-4761-2016; Wong, Gary WK/AAY-9207-2020; Jenmalm, Maria C/C-9679-2009	Allen, Katrina/0000-0002-1921-4493; Tulic, Meri/0000-0002-2661-2369; Mackay, Charles R/0000-0002-6338-7340; Tulic, Meri K/0000-0002-2661-2369; Bisgaard, Hans/0000-0003-4131-7592; Wong, Gary WK/0000-0001-5939-812X; Jenmalm, Maria C/0000-0002-2117-5366; Stokholm, Jakob/0000-0003-4989-9769; West, Christina/0000-0001-9599-2580				Aagaard K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008599; Aagaard K, 2013, FASEB J, V27, P1012, DOI 10.1096/fj.12-220806; Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Abrahamsson TR, 2013, PEDIAT ALLERG IMM-UK, V24, P556, DOI 10.1111/pai.12104; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Azad MB, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6471; Azad MB, 2013, CAN MED ASSOC J, V185, P385, DOI 10.1503/cmaj.121189; Bertelsen RJ, 2014, J ALLERGY CLIN IMMUN, V133, P165, DOI 10.1016/j.jaci.2013.07.032; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Borre YE, 2014, TRENDS MOL MED, V20, P509, DOI 10.1016/j.molmed.2014.05.002; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Cheng J, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-113; Cho I, 2012, NATURE, V488, P621, DOI 10.1038/nature11400; Chorell E, 2013, BRIT J NUTR, V110, P116, DOI 10.1017/S0007114512004618; Cox LM, 2014, CELL, V158, P705, DOI 10.1016/j.cell.2014.05.052; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; de Goffau MC, 2013, DIABETES, V62, P1238, DOI 10.2337/db12-0526; Doll HM, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-259; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Ellwood P, 2013, THORAX, V68, P351, DOI 10.1136/thoraxjnl-2012-202285; Fiocchi A, 2012, WORLD ALLERGY ORGAN, V5, P148, DOI 10.1097/WOX.0b013e3182784ee0; Food and Agriculture Organization of the United Nations World Health Organization, 2002, GUIDELINES EVALUATIO; Fouhy F, 2012, GUT MICROBES, V3, P203, DOI 10.4161/gmic.20169; Fraher MH, 2012, NAT REV GASTRO HEPAT, V9, P312, DOI 10.1038/nrgastro.2012.44; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Garn H, 2013, J ALLERGY CLIN IMMUN, V131, P1465, DOI 10.1016/j.jaci.2013.04.031; Gevers D, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001377; Goodrich JK, 2014, CELL, V158, P250, DOI 10.1016/j.cell.2014.06.037; Gosalbes MJ, 2013, CLIN EXP ALLERGY, V43, P198, DOI 10.1111/cea.12063; Haahtela T, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-3; Hamilton MJ, 2013, GUT MICROBES, V4, P125, DOI 10.4161/gmic.23571; Hanson M, 2011, PROG BIOPHYS MOL BIO, V106, P272, DOI 10.1016/j.pbiomolbio.2010.12.008; Heintze K, 2013, EUR J CLIN PHARMACOL, V69, P1197, DOI 10.1007/s00228-012-1463-7; Huang RC, 2009, DIABETES CARE, V32, P695, DOI 10.2337/dc08-1917; Ismail IH, 2012, PEDIAT ALLERG IMM-UK, V23, P674, DOI 10.1111/j.1399-3038.2012.01328.x; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; Jeffery IB, 2012, NAT REV MICROBIOL, V10, P591, DOI 10.1038/nrmicro2859; Jenny NS, 2007, AM J EPIDEMIOL, V165, P684, DOI 10.1093/aje/kwk057; Jensen MP, 2012, J ALLERGY CLIN IMMUN, V130, P1209, DOI 10.1016/j.jaci.2012.07.018; Jumpstart Consortium Human Microbiome Project Data Generation Working Group, 2012, PLOS ONE, V7; Kadooka Y, 2010, EUR J CLIN NUTR, V64, P636, DOI 10.1038/ejcn.2010.19; Kalliomaki M, 2008, AM J CLIN NUTR, V87, P534, DOI 10.1093/ajcn/87.3.534; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Karlsson CLJ, 2012, OBESITY, V20, P2257, DOI 10.1038/oby.2012.110; Karlstrom A, 2013, BJOG-INT J OBSTET GY, V120, P479, DOI 10.1111/1471-0528.12129; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Ke XY, 2012, AM J HUM GENET, V91, P185, DOI 10.1016/j.ajhg.2012.05.020; Kolokotroni O, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-179; Koren O, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002863; Korpela K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090702; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Kumar M, 2012, EXP DIABETES RES, DOI 10.1155/2012/902917; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Le Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506; Lee CK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044224; Li H, 2014, PEDIATR OBES, V9, P10, DOI 10.1111/j.2047-6310.2013.00151.x; Loo EXL, 2014, INT ARCH ALLERGY IMM, V163, P25, DOI 10.1159/000356338; Lozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550; Luoto R, 2010, BRIT J NUTR, V103, P1792, DOI 10.1017/S0007114509993898; McDade TW, 2012, P NATL ACAD SCI USA, V109, P17281, DOI 10.1073/pnas.1202244109; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Merras-Salmio L, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-8; Morgan XC, 2014, GASTROENTEROLOGY, V146, P1437, DOI 10.1053/j.gastro.2014.01.049; Murri M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-46; Nylund L, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-12; Osborn DA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006474.pub3; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Postigo R, 2012, INFECTION, V40, P643, DOI 10.1007/s15010-012-0307-9; Prescott SL, 2013, J ALLERGY CLIN IMMUN, V131, P23, DOI 10.1016/j.jaci.2012.11.019; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rautava S, 2012, NAT REV GASTRO HEPAT, V9, P565, DOI 10.1038/nrgastro.2012.144; Reiprich M, 2013, ALLERGY, V68, P481, DOI 10.1111/all.12121; Renz H, 2012, NAT REV IMMUNOL, V12, P9, DOI 10.1038/nri3112; Rook GA, 2013, P NATL ACAD SCI USA, V110, P18360, DOI 10.1073/pnas.1313731110; Sjogren YM, 2009, CLIN EXP ALLERGY, V39, P1842, DOI 10.1111/j.1365-2222.2009.03326.x; Smits LP, 2013, GASTROENTEROLOGY, V145, P946, DOI 10.1053/j.gastro.2013.08.058; Sommer F, 2013, NAT REV MICROBIOL, V11, P227, DOI 10.1038/nrmicro2974; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Stene LC, 2013, DIABETOLOGIA, V56, P1888, DOI 10.1007/s00125-013-2929-6; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sudo N, 2004, J PHYSIOL-LONDON, V558, P263, DOI 10.1113/jphysiol.2004.063388; Sudo N, 1997, J IMMUNOL, V159, P1739; Thorburn AN, 2014, IMMUNITY, V40, P833, DOI 10.1016/j.immuni.2014.05.014; Vaarala O, 2012, IMMUNOL CELL BIOL, V90, P271, DOI 10.1038/icb.2011.115; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vulevic J, 2013, J NUTR, V143, P324, DOI 10.3945/jn.112.166132; Wang J, 2014, ISME J; Wang SG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097523; Wang X, 2013, DIABETES CARE, V36, P166, DOI 10.2337/dc12-0702; West CE, 2013, ALLERGY, V68, P1015, DOI 10.1111/all.12191; West CE, 2014, CLIN EXP ALLERGY; West CE, 2014, CURR OPIN CLIN NUTR, V17, P261, DOI 10.1097/MCO.0000000000000044; Wickens K, 2013, CLIN EXP ALLERGY, V43, P1048, DOI 10.1111/cea.12154; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Yousuf O, 2013, J AM COLL CARDIOL, V62, P397, DOI 10.1016/j.jacc.2013.05.016	99	168	178	2	186	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					3	14		10.1016/j.jaci.2014.11.012	http://dx.doi.org/10.1016/j.jaci.2014.11.012			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25567038	Green Submitted			2022-12-18	WOS:000347298200001
J	Pellerin, L; Henry, J; Hsu, CY; Balica, S; Jean-Decoster, C; Mechin, MC; Hansmann, B; Rodriguez, E; Weindinger, S; Schmitt, AM; Serre, G; Paul, C; Simon, M				Pellerin, Laurence; Henry, Julie; Hsu, Chiung-Yueh; Balica, Stefana; Jean-Decoster, Catherine; Mechin, Marie-Claire; Hansmann, Britta; Rodriguez, Elke; Weindinger, Stefan; Schmitt, Anne-Marie; Serre, Guy; Paul, Carle; Simon, Michel			Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; skin; keratinocytes; filaggrin; hornerin; stratum corneum; skin barrier; cytokine	EPIDERMAL DIFFERENTIATION COMPLEX; OF-FUNCTION MUTATIONS; BARRIER FUNCTION; FUNCTION VARIANTS; STRATUM-CORNEUM; UNINVOLVED SKIN; POSSIBLE LINK; DERMATITIS; EXPRESSION; GENE	Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbed epidermal barrier. In a subset of patients, this is explained by nonsense mutations in the gene encoding filaggrin (FLG). Objectives: We sought to evaluate the respective role of FLG mutations and proinflammatory cytokines and to assess the expression of FLG, hornerin (HRNR), and FLG2, 2 FLG-like proteins, which are involved in epidermal barrier functions, in normal skin and both lesional and nonlesional skin of patients with AD. Methods: An FLG-genotyped cohort of 73 adults with AD and 73 aged-matched control subjects was analyzed by using immunohistochemistry and immunoblotting. Normal primary human keratinocytes were differentiated in either the absence or presence of IL-4, IL-13, and IL-25. Results: Compared with control subjects, FLG, HRNR, and FLG2 were detected at significantly lower levels in the skin of patients with AD, irrespective of their FLG genotype. The reduction was greater in lesional compared with nonlesional skin. In addition, the proFLG/FLG ratio was found to be higher in the skin of wild-type patients than in control subjects. Cytokine treatment of keratinocytes induced a dramatic reduction in FLG, FLG2, and HRNR expression both at the mRNA and protein levels. Conclusion: The stratum corneum of lesional but also clinically unaffected skin of adults with AD is abnormal, with reduced expression of FLG and FLG-like proteins. In addition to nonsense mutations, proinflammatory cytokines and some defects in the proFLG processing can contribute to the FLG downregulation. Our study suggests that skin inflammation reduces the expression of FLG-like proteins, contributing to the AD-related epidermal barrier dysfunction. (J Allergy Clin Immunol 2013; 131:1094-102.)	[Pellerin, Laurence; Henry, Julie; Hsu, Chiung-Yueh; Mechin, Marie-Claire; Serre, Guy; Paul, Carle; Simon, Michel] CNRS, UMR5165, Toulouse, France; [Pellerin, Laurence; Henry, Julie; Hsu, Chiung-Yueh; Mechin, Marie-Claire; Serre, Guy; Paul, Carle; Simon, Michel] Fac Med Toulouse, INSERM, U1056, F-31073 Toulouse, France; [Pellerin, Laurence; Henry, Julie; Hsu, Chiung-Yueh; Mechin, Marie-Claire; Serre, Guy; Paul, Carle; Simon, Michel] Univ Toulouse, Toulouse, France; [Balica, Stefana; Paul, Carle] Univ Hosp Toulouse, Dept Dermatol, Toulouse, France; [Jean-Decoster, Catherine; Schmitt, Anne-Marie] Pierre Fabre Dermocosmet, CERPER, Toulouse, France; [Hansmann, Britta; Rodriguez, Elke; Weindinger, Stefan] Univ Hosp Schleswig Holstein, Dept Dermatol, Kiel, Germany	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; CHU de Toulouse; University of Kiel; Schleswig Holstein University Hospital	Simon, M (corresponding author), CHU Purpan, CNRS UPS UMR5165, Pl Dr Baylac TSA40031, F-31059 Toulouse 9, France.	michel.simon@udear.cnrs.fr	Rodríguez, Elke/C-4259-2013; Simon, Michel/B-7308-2011; Pellerin, Laurence/AAH-3424-2020	Rodríguez, Elke/0000-0003-3692-3950; Simon, Michel/0000-0003-3655-6329; Paul, Carle/0000-0003-0165-5263; HSU, Chiung-Yueh/0000-0002-4671-0919	CNRS; Toulouse University; INSERM; Pierre-Fabre DermoCosmetique; Societe de Recherche Dermatologique (SRD); French Society for Dermatology (SFD); European COST program "SKINBAD'' [BM0903]	CNRS(Centre National de la Recherche Scientifique (CNRS)); Toulouse University; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Pierre-Fabre DermoCosmetique; Societe de Recherche Dermatologique (SRD); French Society for Dermatology (SFD); European COST program "SKINBAD''	Supported by grants from CNRS, Toulouse University, INSERM, Pierre-Fabre DermoCosmetique, Societe de Recherche Dermatologique (SRD) and the French Society for Dermatology (SFD), and the European COST program "SKINBAD'' (action BM0903).; Disclosure of potential conflict of interest: J. Henry, C.-Y. Hsu, S. Balica, C. Jean-Decoster, B. Hansmann, E. Rodriguez, and M. Simon have been supported by one or more grants from Pierre Fabre Dermo-Cosmetique, Societe de Recherche Dermatologique, and Societe Francaise de Dermatologie and has received support for travel from European COST program "SKINBAD'' (action BM0903). S. Weindinger is a Board member for Allergy; has consultancy arrangements with Novartis, Astellas, and Danone; and has received one or more grants from or has one or more grants pending with DFG, BMBF. C. Paul has been supported by one or more grants from Pierre Fabre; is a Board member for Pierre Fabre, Astellas, Abbott, and Celgene; has consultancy arrangements with Janssen, Novartis, Pfizer, and Sanofi; has provided expert testimony for Astellas; has received one or more grants from or has one or more grants pending with Abbott; has received one or more payments for lecturing from or is on the speakers' bureau for Abbott, Janssen, and Astellas; and has received one or more payments for the development of educational presentations for Novartis. The rest of the authors declare that they have no relevant conflicts of interest.	Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Brandt Eric B, 2011, J Clin Cell Immunol, V2; Broccardo CJ, 2011, J ALLERGY CLIN IMMUN, V127, P186, DOI 10.1016/j.jaci.2010.10.033; Brown SJ, 2009, J INVEST DERMATOL, V129, P543, DOI 10.1038/jid.2008.413; Cascella R, 2011, J INVEST DERMATOL, V131, P982, DOI 10.1038/jid.2010.398; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; DALE BA, 1985, ANN NY ACAD SCI, V455, P330, DOI 10.1111/j.1749-6632.1985.tb50420.x; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Glasser R, 2009, J ALLERGY CLIN IMMUN, V123, P1117, DOI 10.1016/j.jaci.2009.01.043; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Henry J, 2012, FRONT BIOSCI-LANDMRK, V17, P1517, DOI 10.2741/4001; Henry J, 2011, FASEB J, V25, P1567, DOI 10.1096/fj.10-168658; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Hsu CY, 2011, J BIOL CHEM, V286, P23222, DOI 10.1074/jbc.M110.197400; Hvid M, 2011, EXP DERMATOL, V20, P633, DOI 10.1111/j.1600-0625.2011.01280.x; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Jakasa I, 2006, BRIT J DERMATOL, V155, P104, DOI 10.1111/j.1365-2133.2006.07319.x; Jakasa I, 2007, J INVEST DERMATOL, V127, P129, DOI 10.1038/sj.jid.5700582; Jakasa I, 2011, J INVEST DERMATOL, V131, P540, DOI 10.1038/jid.2010.307; Jungersted JM, 2010, ALLERGY, V65, P911, DOI 10.1111/j.1398-9995.2010.02326.x; Kezic S, 2011, ALLERGY, V66, P934, DOI 10.1111/j.1398-9995.2010.02540.x; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kusunoki T, 2005, J ALLERGY CLIN IMMUN, V115, P636, DOI 10.1016/j.jaci.2004.12.1114; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Marenholz I, 2011, J INVEST DERMATOL, V131, P1644, DOI 10.1038/jid.2011.90; McGrath JA, 2008, AUSTRALAS J DERMATOL, V49, P67, DOI 10.1111/j.1440-0960.2008.00443.x; Mlitz V, 2012, J EUR ACAD DERMATOL, V26, P983, DOI 10.1111/j.1468-3083.2011.04198.x; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Morizane S, 2012, J ALLERGY CLIN IMMUN, V130, P259, DOI 10.1016/j.jaci.2012.03.006; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rawlings A.V., 2004, DERMATOL THER, V17, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; SIMON M, 1995, J INVEST DERMATOL, V105, P432, DOI 10.1111/1523-1747.ep12321148; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Smith G, 2003, J INVEST DERMATOL, V121, P390, DOI 10.1046/j.1523-1747.2003.12354.x; Strong CD, 2010, HUM MOL GENET, V19, P1453, DOI 10.1093/hmg/ddq019; Sutter CH, 2011, TOXICOL SCI, V124, P128, DOI 10.1093/toxsci/kfr205; Tan SP, 2012, BRIT J DERMATOL, V166, P1137, DOI 10.1111/j.1365-2133.2011.10750.x; Vasilopoulos Y, 2011, J DERMATOL SCI, V61, P131, DOI 10.1016/j.jdermsci.2010.11.013; Winge MCG, 2011, BRIT J DERMATOL, V165, P1074, DOI 10.1111/j.1365-2133.2011.10475.x; Winge MCG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028254; Wu ZH, 2009, J INVEST DERMATOL, V129, P1446, DOI 10.1038/jid.2008.370; Wu ZH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005227	49	168	172	0	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1094	1102		10.1016/j.jaci.2012.12.1566	http://dx.doi.org/10.1016/j.jaci.2012.12.1566			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23403047				2022-12-18	WOS:000317187200019
J	Beckett, EL; Stevens, RL; Jarnicki, AG; Kim, RY; Hanish, I; Hansbro, NG; Deane, A; Keely, S; Horvat, JC; Yang, M; Oliver, BG; van Rooijen, N; Inman, MD; Adachi, R; Soberman, RJ; Hamadi, S; Wark, PA; Foster, PS; Hansbro, PM				Beckett, Emma L.; Stevens, Richard L.; Jarnicki, Andrew G.; Kim, Richard Y.; Hanish, Irwan; Hansbro, Nicole G.; Deane, Andrew; Keely, Simon; Horvat, Jay C.; Yang, Ming; Oliver, Brian G.; van Rooijen, Nico; Inman, Mark D.; Adachi, Roberto; Soberman, Roy J.; Hamadi, Sahar; Wark, Peter A.; Foster, Paul S.; Hansbro, Philip M.			A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cigarette smoke; chronic obstructive pulmonary disease; inflammation; emphysema; airway remodeling; lung function; macrophage; mast cell; protease; mouse mast cell protease 6; htryptase-beta	ALLERGIC AIRWAYS DISEASE; RESPIRATORY-INFECTION; TGF-BETA; INFLAMMATION; EMPHYSEMA; POPULATIONS; ACTIVATION; INHIBITION; PHENOTYPES; CESSATION	Background: Cigarette smoke-induced chronic obstructive pulmonary disease (COPD) is a life-threatening inflammatory disorder of the lung. The development of effective therapies for COPD has been hampered by the lack of an animal model that mimics the human disease in a short timeframe. Objectives: We sought to create an early-onset mouse model of cigarette smoke-induced COPD that develops the hallmark features of the human condition in a short time-frame. We also sought to use this model to better understand pathogenesis and the roles of macrophages and mast cells (MCs) in patients with COPD. Methods: Tightly controlled amounts of cigarette smoke were delivered to the airways of mice, and the development of the pathologic features of COPD was assessed. The roles of macrophages and MC tryptase in pathogenesis were evaluated by using depletion and in vitro studies and MC protease 6-deficient mice. Results: After just 8 weeks of smoke exposure, wild-type mice had chronic inflammation, mucus hypersecretion, airway remodeling, emphysema, and reduced lung function. These characteristic features of COPD were glucocorticoid resistant and did not spontaneously resolve. Systemic effects on skeletal muscle and the heart and increased susceptibility to respiratory tract infections also were observed. Macrophages and tryptase-expressing MCs were required for the development of COPD. Recombinant MC tryptase induced proinflammatory responses from cultured macrophages. Conclusion: A short-term mouse model of cigarette smoke-induced COPD was developed in which the characteristic features of the disease were induced more rapidly than in existing models. The model can be used to better understand COPD pathogenesis, and we show a requirement for macrophages and tryptase-expressing MCs. (J Allergy Clin Immunol 2013;131:752-62.)	[Beckett, Emma L.; Jarnicki, Andrew G.; Kim, Richard Y.; Hanish, Irwan; Hansbro, Nicole G.; Deane, Andrew; Keely, Simon; Horvat, Jay C.; Yang, Ming; Wark, Peter A.; Foster, Paul S.; Hansbro, Philip M.] Univ Newcastle, Prior Res Ctr Asthma & Resp Dis, Newcastle, NSW 2308, Australia; [Beckett, Emma L.; Jarnicki, Andrew G.; Kim, Richard Y.; Hanish, Irwan; Hansbro, Nicole G.; Deane, Andrew; Keely, Simon; Horvat, Jay C.; Yang, Ming; Wark, Peter A.; Foster, Paul S.; Hansbro, Philip M.] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW 2308, Australia; [Stevens, Richard L.; Soberman, Roy J.] Harvard Univ, Dept Med, Sch Med, Cambridge, MA 02138 USA; [Stevens, Richard L.; Hamadi, Sahar] Brigham & Womens Hosp, Boston, MA 02115 USA; [Oliver, Brian G.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Oliver, Brian G.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia; [van Rooijen, Nico] Vrije Univ, Dept Mol Cell Biol, Med Ctr, Amsterdam, Netherlands; [Inman, Mark D.] St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada; [Adachi, Roberto] Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA; [Soberman, Roy J.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Wark, Peter A.] John Hunter Hosp, Dept Resp & Sleep Med, Newcastle, NSW, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; Harvard University; Harvard University; Brigham & Women's Hospital; University of Sydney; University of Sydney; Woolcock Institute of Medical Research; Vrije Universiteit Amsterdam; McMaster University; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; John Hunter Hospital	Hansbro, PM (corresponding author), Univ Newcastle, Prior Res Ctr Asthma & Resp Dis, Newcastle, NSW 2308, Australia.	Philip.Hansbro@newcastle.edu.au	Van Rooijen, Nico/Z-1578-2019; Keely, Simon/AAV-9973-2020; Wark, Peter/G-7037-2013; Hanish, Irwan/V-9325-2019; Deane, Andrew/J-1513-2018; Foster, Paul/G-5057-2013; Oliver, Brian/E-7939-2010; Hansbro, Phil/G-7486-2013; Beckett, Emma/AAU-8537-2021	Keely, Simon/0000-0002-1248-9590; Wark, Peter/0000-0001-5676-6126; Hanish, Irwan/0000-0002-0478-7424; Deane, Andrew/0000-0001-7871-9435; Oliver, Brian/0000-0002-7122-9262; Hansbro, Phil/0000-0002-4741-3035; Beckett, Emma/0000-0002-8888-3789; , Paul/0000-0002-0827-8299; Adachi, Roberto/0000-0002-0146-0768; Kim, Richard/0000-0002-8709-5270; Horvat, Jay/0000-0002-8526-0631	National Health and Medical Research Council of Australia [510762, 569219, 1003565, 1003593, 1023131]; US National Institutes of Health [AI065858, AI059746]; Harvard Club of Australia Foundation; National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI065858, R01AI059746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057521] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Club of Australia Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the National Health and Medical Research Council of Australia (510762, 569219, 1003565, 1003593, and 1023131), the US National Institutes of Health (AI065858 and AI059746), and the Harvard Club of Australia Foundation.; Disclosure of potential conflict of interest: R. L. Stevens has been supported by one or more grants from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Andersson CK, 2010, AM J RESP CRIT CARE, V181, P206, DOI 10.1164/rccm.200906-0932OC; Asquith KL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001339; Atkinson JJ, 2011, AM J RESP CRIT CARE, V183, P876, DOI 10.1164/rccm.201005-0718OC; Ballarin A, 2012, AM J RESP CRIT CARE, V186, P233, DOI 10.1164/rccm.201112-2142OC; Barnes PJ, 2009, EUR RESPIR J, V33, P1165, DOI 10.1183/09031936.00128008; Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x; Battaglia S, 2007, J CLIN PATHOL, V60, P907, DOI 10.1136/jcp.2006.037002; Bedoret D, 2009, J CLIN INVEST, V119, P3723, DOI 10.1172/JCI39717; Braber S, 2010, AM J PHYSIOL-LUNG C, V299, pL843, DOI 10.1152/ajplung.00192.2010; Bracke KR, 2006, J IMMUNOL, V177, P4350, DOI 10.4049/jimmunol.177.7.4350; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; Essilfie AT, 2012, THORAX, V67, P588, DOI 10.1136/thoraxjnl-2011-200160; Essilfie AT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002244; Gaschler GJ, 2007, AM J RESP CELL MOL B, V38, P218; Hamilton MJ, 2011, P NATL ACAD SCI USA, V108, P290, DOI 10.1073/pnas.1005758108; Harris R Scott, 2005, Respir Care, V50, P78; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hodge S, 2011, AM J RESP CELL MOL, V44, P673, DOI 10.1165/rcmb.2009-0459OC; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Horvat JC, 2007, AM J RESP CRIT CARE, V176, P556, DOI 10.1164/rccm.200607-1005OC; Horvat JC, 2010, J IMMUNOL, V184, P4159, DOI 10.4049/jimmunol.0902287; Horvat JC, 2010, J ALLERGY CLIN IMMUN, V125, P617, DOI 10.1016/j.jaci.2009.10.018; Houghton AM, 2008, NAT MED, V14, P1023, DOI 10.1038/nm1008-1023; Hsu ACY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032947; Hsu ACY, 2011, AM J RESP CELL MOL, V44, P906, DOI 10.1165/rcmb.2010-0157OC; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; Huvenne W, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-100; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Keely S, 2012, MUCOSAL IMMUNOL, V5, P7, DOI 10.1038/mi.2011.55; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P1796, DOI 10.1111/j.1365-2222.2004.02097.x; Li JJ, 2010, J IMMUNOL, V185, P4401, DOI 10.4049/jimmunol.1001039; McNeil HP, 2008, ARTHRITIS RHEUM-US, V58, P2338, DOI 10.1002/art.23639; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; Miravitlles M, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-58; Morris DG, 2003, NATURE, V422, P169, DOI 10.1038/nature01413; Mortaz E, 2012, BBA-MOL BASIS DIS, V1822, P1154, DOI 10.1016/j.bbadis.2012.03.006; Mortaz E, 2011, PULM PHARMACOL THER, V24, P367, DOI 10.1016/j.pupt.2011.03.007; Motz GT, 2010, J IMMUNOL, V184, P4460, DOI 10.4049/jimmunol.0903654; O'Reilly M, 2009, AM J PHYSIOL-LUNG C, V297, pL992, DOI 10.1152/ajplung.00099.2009; Ofulue AF, 1998, AM J PHYSIOL-LUNG C, V275, pL1134, DOI 10.1152/ajplung.1998.275.6.L1134; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Preston JA, 2011, EUR RESPIR J, V37, P53, DOI 10.1183/09031936.00049510; Preston JA, 2004, EUR RESPIR J, V23, P224, DOI 10.1183/09031936.03.00081403; Preston JA, 2007, VACCINE, V25, P8154, DOI 10.1016/j.vaccine.2007.09.034; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Ruwanpura SM, 2011, AM J RESP CELL MOL, V45, P720, DOI 10.1165/rcmb.2010-0462OC; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; Seguin RM, 2009, EXPERT OPIN INV DRUG, V18, P1505, DOI 10.1517/13543780903179294; Shin K, 2008, J IMMUNOL, V180, P4885, DOI 10.4049/jimmunol.180.7.4885; Shin K, 2009, J IMMUNOL, V182, P647, DOI 10.4049/jimmunol.182.1.647; Singh S, 2009, ARCH INTERN MED, V169, P219, DOI 10.1001/archinternmed.2008.550; Starkey MR, 2012, MUCOSAL IMMUNOL; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Thakurdas SM, 2007, J BIOL CHEM, V282, P20809, DOI 10.1074/jbc.M611842200; Thorburn AN, 2012, J IMMUNOL, V188, P4611, DOI 10.4049/jimmunol.1101299; Thorburn AN, 2010, THORAX, V65, P1053, DOI 10.1136/thx.2009.131508; Vanoirbeek JAJ, 2010, AM J RESP CELL MOL, V42, P96, DOI 10.1165/rcmb.2008-0487OC; Vlahos R, 2006, PULM PHARMACOL THER, V19, P12, DOI 10.1016/j.pupt.2005.02.006; WARREN MK, 1985, J IMMUNOL, V134, P982; Welte T, 2009, SEMIN RESP CRIT CARE, V30, P127, DOI 10.1055/s-0029-1202941; Wilkinson TMA, 2003, AM J RESP CRIT CARE, V167, P1090, DOI 10.1164/rccm.200210-1179OC; World Health Organization, 2008, GLOB BURD DIS 2004 U; Wright JL, 2002, INHAL TOXICOL, V14, P1153, DOI 10.1080/08958370290084836; Yang IA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002991.pub2; Zhang XJ, 2011, TOHOKU J EXP MED, V224, P179, DOI 10.1620/tjem.224.179; Zhu MH, 2006, J BIOL CHEM, V281, P18408, DOI 10.1074/jbc.M601535200	70	168	177	1	58	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					752	+		10.1016/j.jaci.2012.11.053	http://dx.doi.org/10.1016/j.jaci.2012.11.053			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23380220	Green Accepted, Green Submitted			2022-12-18	WOS:000315587800017
J	Bacharier, LB; Cohen, R; Schweiger, T; Yin-DeClue, H; Christie, C; Zheng, J; Schechtman, KB; Strunk, RC; Castro, M				Bacharier, Leonard B.; Cohen, Rebecca; Schweiger, Toni; Yin-DeClue, Huiquing; Christie, Chandrika; Zheng, Jie; Schechtman, Kenneth B.; Strunk, Robert C.; Castro, Mario			Determinants of asthma after severe respiratory syncytial virus bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchiolitis; respiratory syncytial virus; asthma; prospective cohort; CCL5	DAY-CARE ATTENDANCE; EARLY-CHILDHOOD; RSV BRONCHIOLITIS; EARLY-LIFE; ALLERGIC SENSITIZATION; PARENTAL HISTORY; DIAGNOSED ASTHMA; 1ST YEAR; RISK; WHEEZE	Background: The development of asthma after respiratory syncytial virus (RSV) bronchiolitis has been demonstrated in case-control studies, although the determinants of post-RSV asthma remain undefined. Objectives: We sought to evaluate the potential determinants of physician-diagnosed asthma after severe RSV bronchiolitis during infancy. Methods: We enrolled 206 children during an initial episode of severe RSV bronchiolitis at 12 months of age or less in a prospective cohort study and followed these children for up to 6 years. In a subset of 81 children, we analyzed CCL5 (RANTES) mRNA expression in upper airway epithelial cells. Results: Forty-eight percent of children had physician-diagnosed asthma before the seventh birthday. Independent determinants significantly associated with increased risk for physician-diagnosed asthma by the seventh birthday included maternal asthma (odds ratio [OR], 5.2; 95% CI, 1.7-15.9; P = .004), exposure to high levels of dog allergen (OR, 3.2; 95% CI, 1.3-7.7; P = .012), aeroallergen sensitivity at age 3 years (OR, 10.7; 95% CI, 2.1-55.0; P = .005), recurrent wheezing during the first 3 years of life (OR, 7.3; 95% CI, 1.2-43.3; P = .028), and CCL5 expression in nasal epithelia during acute RSV infection (OR, 3.8; 95% CI, 1.2-2.4; P < .001). White children (OR, 0.19; 95% CI, 0.04-0.93; P = .041) and children attending day care (OR, 0.18; 95% CI, 0.04-0.84; P = .029) had a decreased risk of physician-diagnosed asthma. Conclusions: Approximately 50% of children who experience severe RSV bronchiolitis have a subsequent asthma diagnosis. The presence of increased CCL5 levels in nasal epithelia at the time of bronchiolitis or the development of allergic sensitization by age 3 years are associated with increased likelihood of subsequent asthma. (J Allergy Clin Immunol 2012;130:91-100.)	[Cohen, Rebecca; Schweiger, Toni; Yin-DeClue, Huiquing; Christie, Chandrika; Castro, Mario] Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; [Bacharier, Leonard B.; Strunk, Robert C.] Washington Univ, Sch Med, Dept Pediat, Div Pediat Allergy Immunol & Pulm Med, St Louis, MO 63110 USA; [Zheng, Jie; Schechtman, Kenneth B.] Washington Univ, Sch Med, Dept Biostat, St Louis, MO 63110 USA; [Zheng, Jie; Schechtman, Kenneth B.] St Louis Childrens Hosp, St Louis, MO 63178 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Castro, M (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Campus Box 8052,660 S Euclid, St Louis, MO 63110 USA.	castrom@wustl.edu		Bacharier, Leonard/0000-0003-0432-2704; ZHENG, JIE/0000-0003-4958-2091	National Institutes of Health [HL 61895]; Asthmatx; Amgen; Ception/Cephalon; Genentech; MedImmune; Merck; National Institutes of Health; Novartis; GlaxoSmithKline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061895] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Asthmatx; Amgen(Amgen); Ception/Cephalon; Genentech(Roche HoldingGenentech); MedImmune(AstraZenecaMedimmune); Merck(Merck & Company); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant HL 61895.; Disclosure of potential conflict of interest: L. B. Bacharier is on the advisory board for AstraZeneca, has received honoraria from GlaxoSmithKline, and is on the advisory board and has received honoraria from Merck. M. Castro is a consultant and speaker for Asthmatx; is on the advisory board and is a speaker for Genentech; is a speaker for AstraZeneca, Merck, and GlaxoSmithKline; has received research support from Asthmatx, Amgen, Ception/Cephalon, Genentech, MedImmune, Merck, the National Institutes of Health, Novartis, and GlaxoSmithKline; and has received royalties from Elsevier. The rest of the authors declare that they have no relevant conflicts of interest.	Akinbami LJ, 2005, PEDIATRICS, V115, P1254, DOI 10.1542/peds.2004-0897; ALAM R, 1993, J IMMUNOL, V150, P3442; Alford SH, 2004, J ALLERGY CLIN IMMUN, V114, P1046, DOI 10.1016/j.jaci.2004.08.036; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Bjerg A, 2007, PEDIATRICS, V120, P741, DOI 10.1542/peds.2006-3742; Bradley JP, 2005, PEDIATRICS, V115, pE7, DOI 10.1542/peds.2004-0059; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Castro M, 2008, J ALLERGY CLIN IMMUN, V122, P726, DOI 10.1016/j.jaci.2008.07.010; Caudri D, 2009, AM J RESP CRIT CARE, V180, P491, DOI 10.1164/rccm.200903-0327OC; Celedon JC, 2002, ARCH PEDIAT ADOL MED, V156, P241, DOI 10.1001/archpedi.156.3.241; Dik N, 2004, CHEST, V126, P1147, DOI 10.1378/chest.126.4.1147; Finkelstein JA, 2000, PEDIATRICS, V106, P886; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Goetghebuer T, 2004, PEDIATR PULM, V38, P321, DOI 10.1002/ppul.20069; Goetghebuer T, 2004, CLIN EXP ALLERGY, V34, P801, DOI 10.1111/j.1365-2222.2004.1947.x; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Janssen R, 2007, J INFECT DIS, V196, P826, DOI 10.1086/520886; Jedrychowski W, 2008, INT J OCCUP MED ENV, V21, P111, DOI 10.2478/v10001-008-0013-0; Juntti H, 2003, ALLERGY, V58, P878, DOI 10.1034/j.1398-9995.2003.00233.x; Koga S, 1999, TRANSPLANTATION, V67, P854, DOI 10.1097/00007890-199903270-00012; Koponen P, 2012, EUR RESPIR J, V39, P76, DOI 10.1183/09031936.00040211; KORPPI M, 1994, ARCH PEDIAT ADOL MED, V148, P1079, DOI 10.1001/archpedi.1994.02170100077015; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Leader S, 2002, PEDIATR INFECT DIS J, V21, P629, DOI 10.1097/00006454-200207000-00005; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; MCCONNOCHIE KM, 1985, J PEDIATR-US, V107, P54, DOI 10.1016/S0022-3476(85)80614-4; McDaniel M, 2006, PEDIATRICS, V117, pE868, DOI 10.1542/peds.2005-1721; Miller JE, 2001, AM J EPIDEMIOL, V154, P245, DOI 10.1093/aje/154.3.245; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2001, AM J RESP CRIT CARE, V163, pS2, DOI 10.1164/ajrccm.163.supplement_1.2011109; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Simon PA, 2003, J ASTHMA, V40, P535, DOI 10.1081/JAS-120018788; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC; Turner S, 2011, AM J RESP CRIT CARE, V184, P407, DOI 10.1164/rccm.201012-2075OC; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Wegienka G, 2011, CLIN EXP ALLERGY, V41, P979, DOI 10.1111/j.1365-2222.2011.03747.x; Werk LN, 2000, PEDIATRICS, V105, P585, DOI 10.1542/peds.105.3.585; Yoo KH, 2007, J ALLERGY CLIN IMMUN, V120, P1468, DOI 10.1016/j.jaci.2007.09.008	52	168	181	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					91	+		10.1016/j.jaci.2012.02.010	http://dx.doi.org/10.1016/j.jaci.2012.02.010			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22444510	Green Accepted			2022-12-18	WOS:000306644800012
J	Ben-Shoshan, M; Harrington, DW; Soller, L; Fragapane, J; Joseph, L; St Pierre, Y; Godefroy, SB; Elliot, SJ; Clarke, AE				Ben-Shoshan, Moshe; Harrington, Daniel W.; Soller, Lianne; Fragapane, Joseph; Joseph, Lawrence; St Pierre, Yvan; Godefroy, Samuel B.; Elliot, Susan J.; Clarke, Ann E.			A population-based study on peanut, tree nut, fish, shellfish, and sesame allergy prevalence in Canada	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut allergy; tree nut allergy; fish allergy; shellfish allergy; sesame allergy; perceived food allergy.; probable food allergy; confirmed food allergy	DIAL TELEPHONE SURVEY; FOOD ALLERGY; NATURAL-HISTORY; UNITED-STATES; DOUBLE-BLIND; CLINICAL CHARACTERISTICS; ANAPHYLACTIC REACTIONS; ADVERSE-REACTIONS; HAZELNUT ALLERGY; RANDOMIZED-TRIAL	Background: Recent studies suggest an increased prevalence of food-induced allergy and an increased incidence of food-related anaphylaxis. However, prevalence estimates of food allergies vary considerably between studies. Objectives: To determine the prevalence of peanut, tree nut, fish, shellfish, and sesame allergy in Canada. Methods: Using comparable methodology to Sicherer et al in the United States in 2002, we performed a cross-Canada, random telephone survey. Food allergy was defined as perceived (based on self-report), probable (based on convincing history or self-report of physician diagnosis), or confirmed (based on history and evidence of confirmatory tests). Results: Of 10,596 households surveyed in 2008 and 2009, 3666 responded (34.6% participation rate), of which 3613 completed the entire interview, representing 9667 individuals. The prevalence of perceived peanut allergy was 1.00% (95% Cl, 0.80%-1.20%); tree nut, 1.22% (95% CI, 1.00%-1.44%); fish, 0.51% (95% CI, 0.37%-0.65%); shellfish, 1.60% (95% Cl, 1.35%-1.86%); and sesame, 0.10% (95% Cl, 0.04%-0.17%). The prevalence of probable allergy was 0.93% (95% Cl, 0.74%-1.12%); 1.14% (95% Cl, 0.92%-1.35%); 0.48% (95% CI, 0.34%-0.61%); 1.42% (95% Cl. 1.18%-1.66%); and 0.09% (95% CI, 0.03%-0.15%), respectively. Because of the infrequency of confirmatory tests and the difficulty in obtaining results if performed, the prevalence of confirmed allergy was much lower. Conclusion: This is the first nationwide Canadian study to determine the prevalence of severe food allergies. Our results indicate disparities between perceived and confirmed food allergy that might contribute to the wide range of published prevalence estimates. (J Allergy Clin Immunol 2010;125:1327-35.)	[Ben-Shoshan, Moshe] McGill Univ, Dept Pediat, Div Pediat Allergy & Clin Immunol, Ctr Hlth, Montreal, PQ H3A 2T5, Canada; [Soller, Lianne; Fragapane, Joseph; Joseph, Lawrence; St Pierre, Yvan; Clarke, Ann E.] McGill Univ, Dept Med, Div Clin Epidemiol, Ctr Hlth, Montreal, PQ H3A 2T5, Canada; [Clarke, Ann E.] McGill Univ, Dept Med, Div Clin Immunol & Allergy, Ctr Hlth, Montreal, PQ H3A 2T5, Canada; [Joseph, Lawrence] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada; [Joseph, Lawrence] McGill Univ, Dept Biostat, Montreal, PQ, Canada; [Elliot, Susan J.] McMaster Univ, Sch Geog & Earth Sci, Hamilton, ON L8S 4L8, Canada; [Godefroy, Samuel B.] Hlth Canada, Food Directorate, Ottawa, ON K1A 0L2, Canada	McGill University; McGill University; McGill University; McGill University; McGill University; McMaster University; Health Canada	Ben-Shoshan, M (corresponding author), Montreal Childrens Hosp, 2300 Tupper St, Montreal, PQ H3H 1P3, Canada.	daliamoshebs@gmail.com	Soller, Lianne/AGR-7219-2022		Allergy, Genes, and Environment (AllerGen) Network of Centres of Excellence, Health Canada; Research Institute of the Montreal Children's Hospital; Social Sciences and Humanities Research Council	Allergy, Genes, and Environment (AllerGen) Network of Centres of Excellence, Health Canada; Research Institute of the Montreal Children's Hospital; Social Sciences and Humanities Research Council(Social Sciences and Humanities Research Council of Canada (SSHRC))	Supported by the Allergy, Genes, and Environment (AllerGen) Network of Centres of Excellence, Health Canada. M.B.-S. was partially supported by the Ross Fellowship from the Research Institute of the Montreal Children's Hospital, and D.H. is supported by a Social Sciences and Humanities Research Council fellowship. L.J. and A.E.C. are Scholars of the Fonds de la recherche en sante du Quebec.	Aaronov D, 2008, ANN ALLERG ASTHMA IM, V101, P637, DOI 10.1016/S1081-1206(10)60228-1; BARR SI, 1994, J CAN DIET ASSOC, V55, P29; Ben-Shoshan M, 2009, J ALLERGY CLIN IMMUN, V123, P783, DOI 10.1016/j.jaci.2009.02.004; BENSHOSHAN M, 2010, PEDIAT ALLE IN PRESS; BOCK SA, 1987, PEDIATRICS, V79, P683; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Brogger J, 2004, EUR RESPIR J, V23, P281, DOI 10.1183/09031936.03.00041103; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Calvani M, 2008, INT J IMMUNOPATH PH, V21, P977, DOI 10.1177/039463200802100422; Choi Sung-Jin, 2009, Korean Journal of Internal Medicine, V24, P160, DOI 10.3904/kjim.2009.24.2.160; Cochrane WG, 1997, SAMPLING TECHNIQUES, Vthird; Cohen A, 2007, PEDIAT ALLERG IMM-UK, V18, P217, DOI 10.1111/j.1399-3038.2006.00506.x; Couture C, 2003, AM J SURG PATHOL, V27, P1167, DOI 10.1097/00000478-200308000-00017; CRESPO JF, 1995, PEDIAT ALLERG IMM-UK, V6, P39, DOI 10.1111/j.1399-3038.1995.tb00256.x; Csizmadi I, 2007, PUBLIC HEALTH NUTR, V10, P88, DOI 10.1017/S1368980007184287; DAL GE, 2005, AUST NZ J PUBL HEAL, V29, P448; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; Davern M, 2007, MED CARE, V45, P1098, DOI 10.1097/MLR.0b013e3181271450; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Derby CJ, 2005, PEDIAT ALLERG IMM-UK, V16, P171, DOI 10.1111/j.1399-3038.2005.00232.x; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Ewan PW, 1996, BRIT MED J, V312, P1074; Feveile H, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-27; Fitzpatrick KC, 2004, AM J CLIN NUTR, V79, p1217S, DOI 10.1093/ajcn/79.6.1217S; Fleischer DM, 2007, CURR ALLERGY ASTHM R, V7, P175, DOI 10.1007/s11882-007-0018-y; Fleischer DM, 2005, J ALLERGY CLIN IMMUN, V116, P1087, DOI 10.1016/j.jaci.2005.09.002; Flinterman AE, 2008, CURR OPIN ALLERGY CL, V8, P261, DOI 10.1097/ACI.0b013e3282ffb145; Galea S, 2006, ANN EPIDEMIOL, V16, P273, DOI 10.1016/j.annepidem.2005.04.016; Gangur V, 2005, ANN ALLERG ASTHMA IM, V95, P4, DOI 10.1016/S1081-1206(10)61181-7; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Hofer TP, 1996, AM J PUBLIC HEALTH, V86, P1755, DOI 10.2105/AJPH.86.12.1755; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Kagan R, 2003, ANN ALLERG ASTHMA IM, V90, P640, DOI 10.1016/S1081-1206(10)61869-8; Kmetic A, 2002, EPIDEMIOLOGY, V13, P437, DOI 10.1097/00001648-200207000-00012; Lavon O, 2008, ISR MED ASSOC J, V10, P789; Leung TF, 2009, PEDIATR ALLERGY IMMU, V20, P339, DOI 10.1111/j.1399-3038.2008.00801.x; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Lunet N, 2005, PUBLIC HEALTH, V119, P587, DOI 10.1016/j.puhe.2004.07.013; Marklund Birgitta, 2004, Health Qual Life Outcomes, V2, P65, DOI 10.1186/1477-7525-2-65; Moberg C, 2006, BRIT J DERMATOL, V155, P557, DOI 10.1111/j.1365-2133.2006.07372.x; Ngo-Metzger Q, 2004, MED CARE, V42, P893, DOI 10.1097/01.mlr.0000135819.15178.bc; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; Pascual CY, 2008, PEDIATR ALLERGY IMMU, V19, P573, DOI 10.1111/j.1399-3038.2008.00822.x; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Piromrat K, 2008, ASIAN PAC J ALLERGY, V26, P121; Priftis KN, 2008, J ASTHMA, V45, P590, DOI 10.1080/02770900802032941; Pucar F, 2001, CLIN EXP ALLERGY, V31, P40, DOI 10.1046/j.1365-2222.2001.00962.x; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Rangaraj S, 2004, PEDIAT ALLERG IMM-UK, V15, P449, DOI 10.1111/j.1399-3038.2004.00174.x; Roehr CC, 2004, CLIN EXP ALLERGY, V34, P1534, DOI 10.1111/j.1365-2222.2004.02080.x; Rogers A, 2004, AM J EPIDEMIOL, V160, P85, DOI 10.1093/aje/kwh176; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Rubin DB, 2004, MULTIPLE IMPUTATION; Sampson HA, 1996, PEDIAT ALLERG IMM-UK, V7, P42, DOI 10.1111/j.1399-3038.1996.tb00394.x; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sheikh A, 2000, BRIT MED J, V320, P1441, DOI 10.1136/bmj.320.7247.1441; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pAB216, DOI 10.1016/j.jaci.2009.12.845; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Simon MR, 2008, ALLERGY, V63, P1077, DOI 10.1111/j.1398-9995.2008.01737.x; Sloane D, 2001, ALLERGY ASTHMA PROC, V22, P321; SMITH W, 1995, J PUBLIC HEALTH MED, V17, P33; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Stang A, 2005, EUR J EPIDEMIOL, V20, P489, DOI 10.1007/s10654-005-5529-z; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; Venter C, 2006, PEDIAT ALLERG IMM-UK, V17, P356, DOI 10.1111/j.1399-3038.2006.00428.x; Wensing M, 2002, CLIN EXP ALLERGY, V32, P1757, DOI 10.1046/j.1365-2222.2002.01555.x; Woods RK, 2002, ANN ALLERG ASTHMA IM, V88, P183, DOI 10.1016/S1081-1206(10)61994-1; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1; Zuberbier T, 2004, ALLERGY, V59, P338, DOI 10.1046/j.1398-9995.2003.00403.x; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019	80	168	172	3	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1327	1335		10.1016/j.jaci.2010.03.015	http://dx.doi.org/10.1016/j.jaci.2010.03.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	611PH	20451985	hybrid			2022-12-18	WOS:000278831000022
J	Arbes, SJ; Gergen, PJ; Vaughn, B; Zeldin, DC				Arbes, Samuel J., Jr.; Gergen, Peter J.; Vaughn, Ben; Zeldin, Darryl C.			Asthma cases attributable to atopy: Results from the third national health and nutrition examination survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; allergic sensitization; allergy skin test; asthma; atopy; epidemiology; NHANES III; skin prick test; survey	HOUSE-DUST MITE; COMMON ALLERGENS; CAT ALLERGEN; ASSOCIATION; SENSITIZATION; POPULATION; EXPOSURE; REACTIVITY; CHILDHOOD; CHILDREN	Background: The percentage of asthma cases attributable to atopy is the subject of debate. Objectives: The objectives were to estimate the percentage of asthma cases in the US population attributable to atopy and to examine associations between allergen-specific skin tests and asthma. Methods: Data were obtained from the Third National Health and Nutrition Examination Survey, in which subjects age 6 to 59 years were skin tested with 10 allergens. Atopy was defined as at least 1 positive allergen-specific test. Doctor-diagnosed current asthma was assessed by questionnaire. Results: In the United States, 56.3% of the asthma cases were attributable to atopy, and that percentage was greater among males than females, among persons in the highest education category than in lower education categories, and among persons living in highly populated metropolitan areas than in all other areas. Each allergen-specific test was strongly associated with asthma before adjustment (odds ratios varied from 2.1 to 4.5); however, after adjustment by all the allergens, only tests to cat, Alternaria, white oak, and perennial rye were independently associated with asthma. Perennial rye was inversely associated with asthma. Of the 10 allergens, a positive response to cat accounted for the highest percentage of asthma cases (29.3%). Conclusion: About half of the current asthma cases in the US population represented by the Third National Health and Nutrition Examination Survey were attributable to atopy. Some allergen-specific skin tests were not independently associated with asthma. Clinical implications: If atopy could be prevented or reversed, or its effect on asthma blocked, then a large percentage of asthma cases in the US population could be prevented.	NIEHS, Lab Resp Biol, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; Rho Inc, Chapel Hill, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Rho	Zeldin, DC (corresponding author), NIEHS, Lab Resp Biol, Div Intramural Res, NIH, POB 12233,MD D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307	Intramural NIH HHS [Z01 ES025041-10] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025041] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Cohn RD, 2006, ENVIRON HEALTH PERSP, V114, P522, DOI 10.1289/ehp.8561; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Jaakkola MS, 2006, J ALLERGY CLIN IMMUN, V117, P642, DOI 10.1016/j.jaci.2005.11.003; Judkins D. R., 1990, J OFF STAT, V6, P223; Lanphear BP, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e98; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; *NAT CTR HLTH STA, 1986, PUBL US DAT TAP DOC; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; Rothman K, 1986, MODERN EPIDEMIOLOGY; Sood A, 2006, THORAX, V61, P300, DOI 10.1136/thx.2004.031468; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; von Mutius Erika, 2007, Proc Am Thorac Soc, V4, P212, DOI 10.1513/pats.200701-028AW	22	168	169	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1139	1145		10.1016/j.jaci.2007.07.056	http://dx.doi.org/10.1016/j.jaci.2007.07.056			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17889931	Green Accepted			2022-12-18	WOS:000250973400024
J	Majde, JA; Krueger, JM				Majde, JA; Krueger, JM			Links between the innate immune system and sleep	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						sleep; infection; innate immunity; virus; bacteria; toll-like receptors; cytokines; circadian rhythms; stress; asthma	DOUBLE-STRANDED-RNA; INFLUENZA-VIRUS INFECTION; TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTORS; INDUCED SICKNESS BEHAVIOR; ACUTE-PHASE RESPONSE; NOCTURNAL ASTHMA; VIRAL-INFECTIONS; INTERLEUKIN-6-DEFICIENT MICE; PEPTIDOGLYCAN RECOGNITION	Sleep is a fundamental physiologic process with unknown functions. It is divided into 2 distinct states: non-rapid-eye-movement sleep and rapid-eye-movement sleep. After acute infection with nonneurotropic agents, there are stereotypic changes in non-rapid-eye-movement sleep, particularly increased time spent in slow-wave sleep, and often a reduction of time spent in rapid-eye-movement sleep. It is now recognized that both infection-associated sleep and spontaneous sleep are regulated, in part, by immune mediators called cytokines. This review provides brief tutorials on the elements of the innate immune system that detect infection, how sleep is characterized in the laboratory, issues regarding the interpretation of sleep effects on immune function, the interaction of sleep with circadian rhythms and stress, and some of the microbial products, cytokines, and neuropeptides associated with sleep regulation. We also summarize our current understanding of the role of sleep in host defense and asthma exacerbation.	Washington State Univ, Coll Vet Med, Dept VCAPP, Pullman, WA 99164 USA	Washington State University	Krueger, JM (corresponding author), Washington State Univ, Coll Vet Med, Dept VCAPP, POB 646520, Pullman, WA 99164 USA.	Krueger@vetmed.wsu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD036520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031453, R01NS025378] Funding Source: NIH RePORTER; NICHD NIH HHS [HD36520] Funding Source: Medline; NINDS NIH HHS [NS31453, NS25378] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraham E, 1991, Methods Achiev Exp Pathol, V14, P45; AGACE W, 1993, INFECT IMMUN, V61, P602, DOI 10.1128/IAI.61.2.602-609.1993; Alt JA, 2003, J APPL PHYSIOL, V95, P460, DOI 10.1152/japplphysiol.01190.2002; Ancoli-Israel S, 2001, PSYCHOSOM MED, V63, P778, DOI 10.1097/00006842-200109000-00011; ANCOLIISRAEL S, 2005, FATIGUE SLEEP CIRCAD; Andersen ML, 2004, BRAZ J MED BIOL RES, V37, P791, DOI 10.1590/S0100-879X2004000600003; Ballard RD, 1999, CHRONOBIOL INT, V16, P565, DOI 10.3109/07420529908998729; Basset C, 2003, VACCINE, V21, pS12, DOI 10.1016/S0264-410X(03)00195-6; Belardelli F, 2002, TRENDS IMMUNOL, V23, P201, DOI 10.1016/S1471-4906(02)02195-6; Benca RM, 1997, SLEEP, V20, P1027; Bernton E, 1995, ANN NY ACAD SCI, V774, P217; Bohadana AB, 2002, J ASTHMA, V39, P85, DOI 10.1081/JAS-120002190; Bohnet SG, 2004, BRAIN RES, V1027, P117, DOI 10.1016/j.brainres.2004.08.041; Bonekat HW, 2003, CLIN REV ALLERG IMMU, V25, P191, DOI 10.1385/CRIAI:25:2:191; Bowie AG, 2005, MOL IMMUNOL, V42, P859, DOI 10.1016/j.molimm.2004.11.007; BROWN R, 1989, Regional Immunology, V2, P321; Bryant PA, 2004, NAT REV IMMUNOL, V4, P457, DOI 10.1038/nri1369; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Calhoun WJ, 2003, CHEST, V123, p399S, DOI 10.1378/chest.123.3_suppl.399S; CATTERALL JR, 1986, THORAX, V41, P676, DOI 10.1136/thx.41.9.676; Chang FC, 2002, AM J PHYSIOL-REG I, V283, pR400, DOI 10.1152/ajpregu.00758.2001; Ciftci TU, 2005, RESP MED, V99, P529, DOI 10.1016/j.rmed.2004.10.011; CONN CA, 1995, AM J PHYSIOL-REG I, V268, pR78, DOI 10.1152/ajpregu.1995.268.1.R78; Cooke HJ, 2000, ANN NY ACAD SCI, V915, P77; D'Aiuto F, 2005, J DENT RES, V84, P269, DOI 10.1177/154405910508400312; D'Alonzo GE, 1999, CHRONOBIOL INT, V16, P663, DOI 10.3109/07420529908998734; Dantzer R, 2004, EUR J PHARMACOL, V500, P399, DOI 10.1016/j.ejphar.2004.07.040; DARKO DF, 1995, ADV NEUROIMMUNOL, V5, P57, DOI 10.1016/0960-5428(94)00044-O; Dewasmes G, 2004, NEUROSCI LETT, V355, P17, DOI 10.1016/j.neulet.2003.10.031; DHABHAR FS, 1994, BRAIN BEHAV IMMUN, V8, P66, DOI 10.1006/brbi.1994.1006; Dickstein JB, 1999, SLEEP MED REV, V3, P219, DOI 10.1016/S1087-0792(99)90003-5; Dimitrov S, 2004, BRAIN BEHAV IMMUN, V18, P341, DOI 10.1016/j.bbi.2003.08.004; DINGES DF, 1995, ADV NEUROIMMUNOL, V5, P97, DOI 10.1016/0960-5428(95)00002-J; Drake CL, 2000, PHYSIOL BEHAV, V71, P75, DOI 10.1016/S0031-9384(00)00322-X; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Espana RA, 2004, SLEEP, V27, P811; Everson CA, 2000, AM J PHYSIOL-REG I, V278, pR905, DOI 10.1152/ajpregu.2000.278.4.R905; Everson CA, 2002, AM J PHYSIOL-ENDOC M, V283, pE85, DOI 10.1152/ajpendo.00558.2001; Fang JD, 1995, P SOC EXP BIOL MED, V210, P242; Gelfand EW, 2004, J ALLERGY CLIN IMMUN, V114, pS135, DOI 10.1016/j.jaci.2004.08.043; Gentile DA, 1999, J ALLERGY CLIN IMMUN, V103, P1045, DOI 10.1016/S0091-6749(99)70177-6; Germain RN, 2004, NAT MED, V10, P1307, DOI 10.1038/nm1159; Gern JE, 2002, NAT REV IMMUNOL, V2, P132, DOI 10.1038/nri725; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; GOURMELON P, 1991, BRAIN RES, V554, P159, DOI 10.1016/0006-8993(91)90184-W; GUILLEMINAULT C, 1986, ARCH INTERN MED, V146, P1333, DOI 10.1001/archinte.146.7.1333; Guo JS, 2005, LIFE SCI, V77, P220, DOI 10.1016/j.lfs.2004.12.027; Haack M, 2002, PSYCHONEUROENDOCRINO, V27, P921, DOI 10.1016/S0306-4530(02)00006-9; Haus E, 1999, CHRONOBIOL INT, V16, P581, DOI 10.3109/07420529908998730; Hedges JF, 2005, J IMMUNOL, V174, P6045, DOI 10.4049/jimmunol.174.10.6045; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Heller C., 2005, PRINCIPLES PRACTICE, P292, DOI DOI 10.1016/B0-72-160797-7/50031-8; HOHAGEN F, 1993, NEUROPSYCHOBIOLOGY, V28, P9, DOI 10.1159/000118993; Irie M, 2003, INT ARCH ALLERGY IMM, V130, P300, DOI 10.1159/000070217; Irwin M, 1999, J CLIN ENDOCR METAB, V84, P1979, DOI 10.1210/jc.84.6.1979; JARJOUR NN, 1995, AM J RESP CRIT CARE, V152, P1474, DOI 10.1164/ajrccm.152.5.7582279; JOHANNSEN L, 1991, AM J PHYSIOL, V260, pR126, DOI 10.1152/ajpregu.1991.260.1.R126; Kaisho T, 2004, MICROBES INFECT, V6, P1388, DOI 10.1016/j.micinf.2004.08.019; Kawazoe S, 2001, MATER SCI TECH SER, V17, P338, DOI 10.1179/026708301773002563; Kelly EAB, 2004, CLIN EXP ALLERGY, V34, P227, DOI 10.1111/j.1365-2222.2004.01866.x; KIMURATAKEUCHI M, 1992, J INFECT DIS, V166, P1266, DOI 10.1093/infdis/166.6.1266; KIMURATAKEUCHI M, 1992, AM J PHYSIOL, V263, pR1115, DOI 10.1152/ajpregu.1992.263.5.R1115; KLEIN MS, 1992, PHYSIOL BEHAV, V52, P1133, DOI 10.1016/0031-9384(92)90472-E; Kluger MJ, 1996, INFECT DIS CLIN N AM, V10, P1, DOI 10.1016/S0891-5520(05)70282-8; Konsman JP, 2002, TRENDS NEUROSCI, V25, P154, DOI 10.1016/S0166-2236(00)02088-9; Kraft M, 1999, CHRONOBIOL INT, V16, P683, DOI 10.3109/07420529908998735; KRUEGER J M, 1989, Journal of Rheumatology, V16, P52; KRUEGER JM, 1990, TRENDS PHARMACOL SCI, V11, P122, DOI 10.1016/0165-6147(90)90198-H; Krueger JM, 2003, ANN NY ACAD SCI, V992, P9, DOI 10.1111/j.1749-6632.2003.tb03133.x; Krueger JM, 2003, BRAIN BEHAV IMMUN, V17, pS41; KRUEGER JM, 1994, CRIT REV IMMUNOL, V14, P355, DOI 10.1615/CritRevImmunol.v14.i3-4.70; Krueger JM, 2001, ANN NY ACAD SCI, V933, P211; KRUEGER JM, 1987, BRAIN RES, V403, P249, DOI 10.1016/0006-8993(87)90062-X; Krueger JM, 2005, PRINCIPLES PRACTICE, P256; KRUEGER JM, 1993, NEUROBIOLOGY CYTOK B, P111; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; LAMBORE S, 1991, J FAM PRACTICE, V33, P33; Lange T, 2003, PSYCHOSOM MED, V65, P831, DOI 10.1097/01.PSY.0000091382.61178.F1; Lavie P, 2001, ANNU REV PSYCHOL, V52, P277, DOI 10.1146/annurev.psych.52.1.277; Lee BN, 2004, NEUROIMMUNOMODULAT, V11, P279, DOI 10.1159/000079408; LIU L, 2005, SUPPORT CARE CANC; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Majde JA, 2000, J INTERF CYTOK RES, V20, P259, DOI 10.1089/107999000312397; MAJDE JA, 1993, PEPTIDES, V14, P629, DOI 10.1016/0196-9781(93)90155-A; Majde JA, 2002, TXB BIOL PSYCHIAT, P1247; Martin RJ, 1999, CHRONOBIOL INT, V16, P623, DOI 10.3109/07420529908998731; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; Meerlo P, 2002, J NEUROENDOCRINOL, V14, P397, DOI 10.1046/j.0007-1331.2002.00790.x; Mohren DCL, 2002, J OCCUP ENVIRON MED, V44, P1003, DOI 10.1097/00043764-200211000-00005; MOLINA JM, 1990, J VIROL, V64, P2901, DOI 10.1128/JVI.64.6.2901-2906.1990; Morrow JD, 2005, BRAIN BEHAV IMMUN, V19, P28, DOI 10.1016/j.bbi.2004.02.003; Morrow JD, 2005, BRAIN BEHAV IMMUN, V19, P40, DOI 10.1016/j.bbi.2004.04.001; Mullington JM, 2003, J NEUROENDOCRINOL, V15, P851, DOI 10.1046/j.1365-2826.2003.01069.x; NORMAN SE, 1992, SLEEP, V15, P150, DOI 10.1093/sleep/15.2.150; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Obal F, 2003, FRONT BIOSCI-LANDMRK, V8, pD520, DOI 10.2741/1033; Obal F, 2003, AM J PHYSIOL-REG I, V284, pR131, DOI 10.1152/ajpregu.00361.2002; Opp MR, 1997, AM J PHYSIOL-REG I, V272, pR648, DOI 10.1152/ajpregu.1997.272.2.R648; Opp MR, 2004, BRAIN BEHAV IMMUN, V18, P295, DOI 10.1016/j.bbi.2003.12.008; Petrovsky N, 1998, Int Rev Immunol, V16, P635, DOI 10.3109/08830189809043012; PLATASALAMAN CR, 1991, NEUROSCI BIOBEHAV R, V15, P185, DOI 10.1016/S0149-7634(05)80001-6; Pollmacher T, 2002, BRAIN BEHAV IMMUN, V16, P525, DOI 10.1016/S0889-1591(02)00004-1; POLLMACHER T, 1995, ADV NEUROIMMUNOL, V5, P155, DOI 10.1016/0960-5428(95)00006-N; Rechtschaffen A, 2002, SLEEP, V25, p68B, DOI 10.1093/sleep/25.1.68; Redwine L, 2000, J CLIN ENDOCR METAB, V85, P3597, DOI 10.1210/jc.85.10.3597; Rehman A, 2001, CYTOKINE, V13, P8, DOI 10.1006/cyto.2000.0800; Renegar KB, 2000, SLEEP, V23, P859; Rogers N L, 2001, Semin Clin Neuropsychiatry, V6, P295, DOI 10.1053/scnp.2001.27907; Romanovsky AA, 2005, FRONT BIOSCI-LANDMRK, V10, P2193, DOI 10.2741/1690; Samel A, 2004, AVIAT SPACE ENVIR MD, V75, P935; Schmitz N, 2005, J VIROL, V79, P6441, DOI 10.1128/JVI.79.10.6441-6448.2005; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P165, DOI 10.1067/mai.2001.112270; SHERIDAN JF, 1994, CLIN MICROBIOL REV, V7, P200, DOI 10.1128/CMR.7.2.200-212.1994; Sivori S, 2004, P NATL ACAD SCI USA, V101, P10116, DOI 10.1073/pnas.0403744101; SMITH A, 1992, SLEEP, AROUSAL, AND PERFORMANCE, P233; Spiegel K, 2002, JAMA-J AM MED ASSOC, V288, P1471, DOI 10.1001/jama.288.12.1471-a; Sutherland ER, 2005, CURR ALLERGY ASTHM R, V5, P161, DOI 10.1007/s11882-005-0091-z; Syabbalo N, 1997, INT J CLIN PRACT, V51, P455; ten Hacken NHT, 1998, EUR RESPIR J, V11, P312, DOI 10.1183/09031936.98.11020312; Toth LA, 1998, LIFE SCI, V63, P701, DOI 10.1016/S0024-3205(98)00321-X; TOTH LA, 1995, J SLEEP RES, V4, P30, DOI 10.1111/j.1365-2869.1995.tb00148.x; Toth LA, 2004, BRAIN BEHAV IMMUN, V18, P375, DOI 10.1016/j.bbi.2003.12.005; TOTH LA, 1993, P SOC EXP BIOL MED, V203, P179, DOI 10.3181/00379727-203-43590; TOTH LA, 1995, J NEUROIMMUNOL, V58, P89, DOI 10.1016/0165-5728(94)00193-R; Toth LA, 2003, BEHAV GENET, V33, P325, DOI 10.1023/A:1023402709896; Toth LA., 1999, HDB BEHAV STATE CONT, P641; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Traynor TR, 2004, LIFE SCI, V74, P2563, DOI 10.1016/j.lfs.2003.10.010; Vgontzas AN, 2002, ENDOCRIN METAB CLIN, V31, P15, DOI 10.1016/S0889-8529(01)00005-6; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P4409, DOI 10.1210/jc.2003-031929; Viala M, 2004, CR BIOL, V327, P551, DOI 10.1016/j.crvi.2004.02.010; Vir R, 1997, ANN ALLERG ASTHMA IM, V79, P251, DOI 10.1016/S1081-1206(10)63010-4; Wang JP, 1997, NEUROIMMUNOMODULAT, V4, P230, DOI 10.1159/000097341; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wisor JP, 2005, SLEEP, V28, P357; Zepelin H., 2005, PRINC PRACT SLEEP ME, P91	136	168	176	0	53	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1188	1198		10.1016/j.jaci.2005.08.005	http://dx.doi.org/10.1016/j.jaci.2005.08.005			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337444				2022-12-18	WOS:000235687000002
J	Ricciardolo, FLM; Gaston, B; Hunt, J				Ricciardolo, FLM; Gaston, B; Hunt, J			Acid stress in the pathology of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway pH; gastroesophageal reflux; tachykinins; capsaicin; exhaled breath condensate; acid; asthma; chronic obstructive pulmonary disease; cough; bronchoconstriction	EXHALED BREATH CONDENSATE; INDUCED AIRWAY HYPERRESPONSIVENESS; TACHYKININ RECEPTOR ANTAGONISTS; GUINEA-PIGS; CITRIC-ACID; INDUCED BRONCHOCONSTRICTION; NITRIC-OXIDE; GASTROESOPHAGEAL-REFLUX; CYSTIC-FIBROSIS; INDUCED COUGH	Although alteration of airway pH may serve an innate host defense capacity, it also is implicated in the pathophysiology of obstructive airway diseases. Acid-induced asthma appears in association with gastroesophageal reflux after accidental inhalation of acid (fog, pollution, and workplace exposure) and in the presence of altered airway pH homeostasis. Endogenous and exogenous exposures to acids evoke cough, bronchoconstriction, airway hyperreactivity, microvascular leakage, and heightened production of mucous, fluid, and nitric oxide. Abnormal acidity of the airways is reflected in exhaled breath assays. The intimate mechanisms of acid-induced airway obstruction are dependent on activation of capsaicin-sensitive sensory nerves. Protons activate these nerves with the subsequent release of tachykinins (major mediators of this pathway) that, in conjunction with kinins, nitric oxide, oxygen radicals, and proteases, modulate diverse aspects of airway dysfunction and inflammation. The recognition that acid stress might initiate or exacerbate airway obstructive symptomatology has prompted the consideration of new therapies targeting pH homeostasis.	Univ Virginia, Div Pediat Resp Med, Hlth Syst, Charlottesville, VA 22908 USA; G Gaslini Inst Children, Unit Resp Dis, Genoa, Italy	University of Virginia; University of Genoa; IRCCS Istituto Giannina Gaslini	Hunt, J (corresponding author), Univ Virginia, Div Pediat Resp Med, Hlth Syst, Box 800386, Charlottesville, VA 22908 USA.		Ricciardolo, F. L. M./K-5330-2018	Ricciardolo, F. L. M./0000-0003-1826-5018				ADLER K, 1972, AM REV RESPIR DIS, V106, P86, DOI 10.1164/arrd.1972.106.1.86; Antczak A, 2001, AM J RESP CRIT CARE, V163, p725A; BALDWIN SR, 1986, LANCET, V1, P11; BALMES J R, 1989, Environmental Health Perspectives, V79, P163, DOI 10.2307/3430544; BALMES JR, 1988, AM REV RESPIR DIS, V138, P35, DOI 10.1164/ajrccm/138.1.35; Baud L, 1997, B ACAD NAT MED PARIS, V181, P247; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; Blaisdell CJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1248, DOI 10.1152/ajplung.2000.278.6.L1248; BOYLE JT, 1985, AM REV RESPIR DIS, V131, pS16; Burvall K, 2002, LIFE SCI, V71, P299, DOI 10.1016/S0024-3205(02)01644-2; CAIN D, 2002, EUR RESPIR J, V20, pP3280; Canning BJ, 2001, J APPL PHYSIOL, V91, P2642, DOI 10.1152/jappl.2001.91.6.2642; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; Curran DR, 2002, CURR OPIN PHARMACOL, V2, P243, DOI 10.1016/S1471-4892(02)00155-8; Daoui S, 1998, AM J RESP CRIT CARE, V158, P42, DOI 10.1164/ajrccm.158.1.9705052; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Di Franco A, 2001, PULM PHARMACOL THER, V14, P35, DOI 10.1006/pupt.2000.0264; Douidar SM, 1997, PEDIATR EMERG CARE, V13, P406, DOI 10.1097/00006565-199712000-00014; Dudeja PK, 1999, AM J PHYSIOL-LUNG C, V276, pL971, DOI 10.1152/ajplung.1999.276.6.L971; EFFROS RM, 1994, J APPL PHYSIOL, V77, P1460, DOI 10.1152/jappl.1994.77.3.1460; FINE JM, 1987, AM REV RESPIR DIS, V136, P1122, DOI 10.1164/ajrccm/136.5.1122; Fischer H, 2002, AM J PHYSIOL-CELL PH, V282, pC736, DOI 10.1152/ajpcell.00369.2001; FOLINSBEE LJ, 1989, ENVIRON HEALTH PERSP, V79, P195, DOI 10.2307/3430550; Forsberg K, 1988, Pulm Pharmacol, V1, P33, DOI 10.1016/0952-0600(88)90008-7; GATTO LA, 1985, LUNG, V163, P109, DOI 10.1007/BF02713812; GATTO LA, 1981, J APPL PHYSIOL, V50, P1224, DOI 10.1152/jappl.1981.50.6.1224; GEFFNER JR, 1993, CLIN EXP IMMUNOL, V91, P164; Gessner C, 2003, RESP MED, V97, P1188, DOI 10.1016/S0954-6111(03)00225-7; Girard V, 1996, AM J RESP CRIT CARE, V153, P1496, DOI 10.1164/ajrccm.153.5.8630592; GOLDMAN G, 1992, J APPL PHYSIOL, V73, P571, DOI 10.1152/jappl.1992.73.2.571; Hay DWP, 2002, J PHARMACOL EXP THER, V300, P314, DOI 10.1124/jpet.300.1.314; HERVE P, 1986, AM REV RESPIR DIS, V134, P986, DOI 10.1164/arrd.1986.134.5.986; HOLMA B, 1985, SCI TOTAL ENVIRON, V41, P101, DOI 10.1016/0048-9697(85)90181-0; HOLMA B, 1977, ARCH ENVIRON HEALTH, V32, P216; HOLZER P, 1991, PHARMACOL REV, V43, P143; Honma S, 2000, RESP MED, V94, P935, DOI 10.1053/rmed.2000.0816; HUGHES JH, 1974, J IMMUNOL, V112, P919; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101, DOI 10.1164/ajrccm.165.1.2104131; Ishikawa T, 1999, J APPL PHYSIOL, V86, P1226, DOI 10.1152/jappl.1999.86.4.1226; JACK CIA, 1994, RESP MED, V88, P441, DOI 10.1016/S0954-6111(05)80047-2; JACK CIA, 1995, THORAX, V50, P201, DOI 10.1136/thx.50.2.201; JACK CIA, 1991, THORAX, V46, pP751; Jacoby DB, 2001, J ALLERGY CLIN IMMUN, V107, P211, DOI 10.1067/mai.2001.112940; Jankowski W, 1969, Otolaryngol Pol, V23, P493; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; JENSEN PE, 1993, J IMMUNOL, V150, P3347; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747, DOI 10.1016/S0091-6749(99)70283-6; Kanazawa H, 1997, J ALLERGY CLIN IMMUN, V99, P624, DOI 10.1016/S0091-6749(97)70024-1; KARNAD DR, 1990, CRIT CARE MED, V18, P699, DOI 10.1097/00003246-199007000-00003; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; Kohrogi H, 2001, AM J MED, V111, P25, DOI 10.1016/S0002-9343(01)00859-2; KopferschmittKubler MC, 1996, REV MAL RESPIR, V13, P421; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; Kruk-Zagajewska A, 1976, Otolaryngol Pol, V30, P479; Lai YL, 1999, BRIT J PHARMACOL, V126, P778, DOI 10.1038/sj.bjp.0702352; LALLOO UG, 1995, J APPL PHYSIOL, V79, P1082, DOI 10.1152/jappl.1995.79.4.1082; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Leblebicioglu B, 1999, INFECT IMMUN, V67, P2019; Lee KH, 1998, CRIT CARE MED, V26, P2042, DOI 10.1097/00003246-199812000-00038; Lee LY, 2001, J APPL PHYSIOL, V91, P1318, DOI 10.1152/jappl.2001.91.3.1318; Long R, 1999, ANTIMICROB AGENTS CH, V43, P403, DOI 10.1128/AAC.43.2.403; Lopes FDTQS, 2002, J APPL PHYSIOL, V93, P842, DOI 10.1152/japplphysiol.00013.2002; Lopez DH, 1999, IMMUNOLOGY, V98, P450, DOI 10.1046/j.1365-2567.1999.00884.x; LOU YP, 1991, ACTA PHYSIOL SCAND, V142, P191, DOI 10.1111/j.1748-1716.1991.tb09147.x; MAGGI CA, 1995, PHYSIOL REV, V75, P277, DOI 10.1152/physrev.1995.75.2.277; Maggi CA, 1997, TRENDS PHARMACOL SCI, V18, P351, DOI 10.1016/S0165-6147(97)90663-5; MARTLING CR, 1988, ANESTHESIOLOGY, V68, P350, DOI 10.1097/00000542-198803000-00005; McShane D, 2003, EUR RESPIR J, V21, P37, DOI 10.1183/09031936.03.00027603; Metheny NA, 1999, NURS RES, V48, P189, DOI 10.1097/00006199-199907000-00001; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Nader-Djalal N, 1998, ANESTH ANALG, V87, P127, DOI 10.1097/00000539-199807000-00028; NAHAS GG, 1971, P SOC EXP BIOL MED, V138, P350; NEAS LM, 1995, AM J EPIDEMIOL, V141, P111, DOI 10.1093/oxfordjournals.aje.a117399; NGAMTRAKULPANIT L, 2003, AM J RESP CRIT CARE, V167, pA446; NUUTINEN J, 1993, J OTOLARYNGOL, V22, P79; Ohrui T, 1997, CHEST, V111, P454, DOI 10.1378/chest.111.2.454; PALMER LB, 1986, AM REV RESPIR DIS, V133, P784; RABINOVITCH M, 1980, J RETICULOENDOTH SOC, V27, P189; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; RATNER S, 1992, CELL IMMUNOL, V139, P399, DOI 10.1016/0008-8749(92)90081-Y; REGOLI D, 1994, PHARMACOL REV, V46, P551; Ricciardolo FLM, 1999, AM J RESP CRIT CARE, V159, P557, DOI 10.1164/ajrccm.159.2.9804022; Ricciardolo FLM, 2001, AM J MED, V111, P18, DOI 10.1016/S0002-9343(01)00816-6; ROTSTEIN OD, 1988, J SURG RES, V45, P298, DOI 10.1016/0022-4804(88)90079-0; SATOH H, 1993, EUR J PHARMACOL, V236, P367, DOI 10.1016/0014-2999(93)90473-U; Song YL, 2003, J GEN PHYSIOL, V122, P511, DOI 10.1085/jgp.200308866; Tate S, 2002, THORAX, V57, P926, DOI 10.1136/thorax.57.11.926; Teramoto S, 2003, CHEST, V123, P524, DOI 10.1378/chest.123.2.524; Trevani AS, 1999, J IMMUNOL, V162, P4849; Vaughan J, 2003, EUR RESPIR J, V22, P889, DOI 10.1183/09031936.03.00038803; Vincent D, 1997, EUR RESPIR J, V10, P2255, DOI 10.1183/09031936.97.10102255; Wadsworth SJ, 1997, AM J PHYSIOL-LUNG C, V273, pL427, DOI 10.1152/ajplung.1997.273.2.L427; Yasumitsu R, 1996, EUR J PHARMACOL, V300, P215, DOI 10.1016/0014-2999(95)00881-0; ZIGMOND SH, 1981, J IMMUNOL, V126, P478	98	168	172	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					610	619		10.1016/j.jaci.2003.12.034	http://dx.doi.org/10.1016/j.jaci.2003.12.034			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100663				2022-12-18	WOS:000220956600005
J	TOBIN, D; NABARRO, G; DELAFAILLE, HB; VANVLOTEN, WA; VANDERPUTTE, SCJ; SCHUURMAN, HJ				TOBIN, D; NABARRO, G; DELAFAILLE, HB; VANVLOTEN, WA; VANDERPUTTE, SCJ; SCHUURMAN, HJ			INCREASED NUMBER OF IMMUNOREACTIVE NERVE-FIBERS IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; DERMATOSES; INFLAMMATION; INNERVATION; NEUROPEPTIDES; SKIN	CUTANEOUS SENSORY NERVES; GENE-PRODUCT 9.5; SUBSTANCE-P; SKIN-DISEASE; NEUROPEPTIDES; PSORIASIS; INNERVATION; STIMULATION; URTICARIA; HISTAMINE	The presence of immunologic markers for neurofilaments, neuropeptides of sensory nerve fibers (Calcitonin gene-related peptide and substance P), for noradrenergic innervation (neuropeptide Y and Tyrosine hydroxylase), and Neuron-specific protein 9.5 was evaluated in frozen tissue sections from normal skin (n = 34) and from skin biopsies manifesting urticaria (n = 6), leukocytoclastic vasculitis (n = 4), systemic lupus erythematosus (n = 23), and atopic dermatitis (n = 40, of which 16 were from lesions induced by epicutaneous atopic allergen patch tests). In some normal skin specimens immunoreactive nerve fibers expressing Neuron-specific protein 9.5 were observed in the epidermis, dermis, and around blood vessels. For the other markers, immunolabeling was mainly observed in the dermis around blood vessels. Neurofilaments, which are scarce in normal skin epidermis, were present in higher density in the epidermis of affected skin in all disease conditions. Biopsies from urticaria and systemic lupus erythematosus showed a decrease in density of fibers immunolabeled for neuropeptides substance P and Calcitonin gene-related peptide and for Neuropeptide Y. In biopsies from skin with atopic dermatitis, an increased density of fibers was observed for all markers except Neuropeptide Y and Tyrosine hydroxylase. In this group, biopsies from positive atopic allergen patch tests showed an enhanced density of fibers labeled by antibody to Neuron-specific protein 9.5 and a lower density in labeling for Tyrosine hydroxylase. The data indicate a potential role of innervation and neuropeptides in dermatoses like atopic dermatitis.	UNIV HOSP UTRECHT,DEPT PATHOL,DIV HISTOCHEM & ELECTRON MICROSCOPY,POB 85500,3508 GA UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,DEPT INTERNAL MED,3511 GV UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,DEPT DERMATOL,3511 GV UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center			Tobin, Desmond/A-5228-2009	Tobin, Desmond/0000-0003-4566-9392				ANAND P, 1991, BRIT J DERMATOL, V124, P547, DOI 10.1111/j.1365-2133.1991.tb04948.x; BARANIUK JN, 1990, SKIN IMMUNE SYSTEM S, P307; BRUIJNZEELKOOME.CA, 1991, BRIT J DERMATOL, V118, P229; COULSON IH, 1990, BRIT J DERMATOL, V122, P343, DOI 10.1111/j.1365-2133.1990.tb08282.x; DALSGAARD CJ, 1989, HISTOCHEMISTRY, V92, P385, DOI 10.1007/BF00492495; DALSGAARD CJ, 1984, HISTOCHEMISTRY, V81, P111, DOI 10.1007/BF00490102; EEDY DJ, 1991, J INVEST DERMATOL, V96, P434, DOI 10.1111/1523-1747.ep12469898; FINK T, 1988, NEUROSCI LETT, V90, P39, DOI 10.1016/0304-3940(88)90783-5; GIANNETTI A, 1989, BRIT J DERMATOL, V121, P681, DOI 10.1111/j.1365-2133.1989.tb08209.x; KARANTH SS, 1989, J PATHOL, V157, P15, DOI 10.1002/path.1711570104; KARANTH SS, 1991, AM J ANAT, V191, P369, DOI 10.1002/aja.1001910404; KENINS P, 1981, NEUROSCI LETT, V25, P137, DOI 10.1016/0304-3940(81)90321-9; NAUKKARINEN A, 1989, J INVEST DERMATOL, V92, P126, DOI 10.1111/1523-1747.ep13071340; PAYAN DG, 1983, J IMMUNOL, V131, P1613; PINCELLI C, 1990, BRIT J DERMATOL, V122, P745, DOI 10.1111/j.1365-2133.1990.tb06261.x; SARIA A, 1983, N-S ARCH PHARMACOL, V324, P212, DOI 10.1007/BF00503897; TOTHKASA I, 1983, J INVEST DERMATOL, V80, P34, DOI 10.1111/1523-1747.ep12530993; WALLENGREN J, 1987, ARCH DERMATOL RES, V279, P512, DOI 10.1007/BF00413281; WALLENGREN J, 1987, ACTA DERM-VENEREOL, V67, P185; WEIGENT DA, 1987, IMMUNOL REV, V100, P79, DOI 10.1111/j.1600-065X.1987.tb00528.x; WEIHE E, 1988, SEMIN DERMATOL, V7, P284; WINKELMANN RK, 1988, SEMIN DERMATOL, V7, P236; WINKELMANN RK, 1988, SEMIN DERMATOL, V7, P233	23	168	171	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				613	622		10.1016/0091-6749(92)90134-N	http://dx.doi.org/10.1016/0091-6749(92)90134-N			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1383306				2022-12-18	WOS:A1992JT99500007
J	DOYLE, WJ; BOEHM, S; SKONER, DP				DOYLE, WJ; BOEHM, S; SKONER, DP			PHYSIOLOGICAL-RESPONSES TO INTRANASAL DOSE-RESPONSE CHALLENGES WITH HISTAMINE, METHACHOLINE, BRADYKININ, AND PROSTAGLANDIN IN ADULT VOLUNTEERS WITH AND WITHOUT NASAL ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							AIRWAY-RESISTANCE; EUSTACHIAN-TUBE; DOUBLE-BLIND; PROVOCATION; MEDIATOR; RHINITIS; RELEASE; PATENCY	The dose-response (dose, 0.01, 0.05, 0.1, 0.5, 1, and 5 mg) profiles of 10 atopic and 10 nonatopic subjects were determined for nasal patency, secretion weight, pulmonary function, eustachian tube function, middle-ear function, and symptoms after intranasal inhalation challenges with histamine, bradykinin, methacholine, prostaglandin D2, and prostaglandin F2-alpha (PGF2-alpha). Results demonstrated that challenge with PGF2-alpha increased nasal patency, whereas challenge with all other substances decreased patency. The relationship between substances in eliciting a nasal congestive response was prostaglandin D2 > histamine > bradykinin > metacholine. A similar effect ordering was noted for the postchallenge development of eustachian tube dysfunction. Secretion weights were significantly greater after challenge with histamine compared to all other substances. A decrease in pulmonary function was observed only after challenge with PGF2-alpha, although the effect was not statistically significant. No changes in middle-ear pressure were observed for challenges with any of the substances. Only histamine challenge provoked sneezing, whereas challenge with either of the prostaglandins provoked cough. With the exception of metacholine, all substances caused symptoms of rhinorrhea, congestion, and sore throat. Bradykinin was particularly effective in provoking "pain/pressure"-related symptoms. With the exception of secretion weight, the differences between responses of atopic and nonatopic subjects were not statistically significant. These results document mediator specificity in the physiologic and symptomatic responses to intranasal challenge.	UNIV PITTSBURGH,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DOYLE, WJ (corresponding author), UNIV PITTSBURGH,CHILDRENS HOSP,SCH MED,DEPT OTOLARYNGOL,3705 5TH AVE,PITTSBURGH,PA 15213, USA.							BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; BROWN MS, 1987, ARCH OTOLARYNGOL, V113, P179; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DOYLE WJ, 1988, PEDIATR INFECT DIS J, V7, P229, DOI 10.1097/00006454-198803000-00033; GWALTNEY JM, 1966, AM REV RESPIR DIS, V93, P362; JACKSON RT, 1970, CURR THER RES CLIN E, V12, P711; KARIM SMM, 1979, PROSTAG LEUKOTR ESS, V3, P33, DOI 10.1016/0161-4630(79)90013-2; KARIM SMM, 1978, PROSTAGLANDINS, V15, P457, DOI 10.1016/0090-6980(78)90129-6; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW DIMENSIONS OTORH, V2, P341; NACLERIO RM, 1988, PEDIATR INFECT DIS J, V7, P215; PETERS SP, 1987, AM REV RESPIR DIS, V135, pS42; PIPKORN U, 1982, ALLERGY, V37, P359, DOI 10.1111/j.1398-9995.1982.tb01922.x; PIPKORN U, 1987, ALLERGY, V42, P496, DOI 10.1111/j.1398-9995.1987.tb00371.x; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; SKONER DP, 1987, J ALLERGY CLIN IMMUN, V79, P27, DOI 10.1016/S0091-6749(87)80012-X; SKONER DP, 1989, AM J RHINOL, V3, P53; TONNESEN P, 1985, ALLERGY, V40, P350, DOI 10.1111/j.1398-9995.1985.tb00246.x; TRZECIAKOWSKI JP, 1983, ALLERGY PRINCIPLES P, P575; VANWIJK RG, 1987, CLIN ALLERGY, V17, P563; VANWIJK RG, 1987, RHINOLOGY, V225, P41	23	168	172	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				924	935		10.1016/S0091-6749(05)80156-3	http://dx.doi.org/10.1016/S0091-6749(05)80156-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262647	Bronze			2022-12-18	WOS:A1990EQ04500014
J	MANNING, PJ; ROKACH, J; MALO, JL; ETHIER, D; CARTIER, A; GIRARD, Y; CHARLESON, S; OBYRNE, PM				MANNING, PJ; ROKACH, J; MALO, JL; ETHIER, D; CARTIER, A; GIRARD, Y; CHARLESON, S; OBYRNE, PM			URINARY LEUKOTRIENE-E4 LEVELS DURING EARLY AND LATE ASTHMATIC RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV, HLTH SCI CTR, DEPT MED, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; HOP SACRE COEUR, MONTREAL H4J 1C5, QUEBEC, CANADA; MERCK FROSST CTR THERAPEUT RES, KIRKLAND, QUEBEC, CANADA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Universite de Montreal; Merck & Company				Rokach, Joshu/0000-0003-1814-7505; O'Byrne, Paul/0000-0003-0979-281X				ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1984, CLIN ALLERGY, V14, P61, DOI 10.1111/j.1365-2222.1984.tb02191.x; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CURZEN N, 1987, THORAX, V42, P946, DOI 10.1136/thx.42.12.946; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DELORME D, 1988, PROSTAGLANDINS, V36, P291, DOI 10.1016/0090-6980(88)90071-8; DELUCA S, 1988, EUR RESPIR J, V1, P540; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENZLINGER C, 1986, J BIOL CHEM, V261, P5601; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; FOSTER A, 1987, BIOCHEM BIOPH RES CO, V148, P1237, DOI 10.1016/S0006-291X(87)80265-6; FOSTER A, 1987, BIOCHIM BIOPHYS ACTA, V921, P486, DOI 10.1016/0005-2760(87)90076-2; FOSTER A, 1988, J IMMUNOL, V141, P3544; HAYES EC, 1983, J IMMUNOL, V131, P429; HEGARDT B, 1981, ALLERGY, V36, P115, DOI 10.1111/j.1398-9995.1981.tb04105.x; KIRBY JG, 1989, J APPL PHYSIOL, V66, P578, DOI 10.1152/jappl.1989.66.2.578; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OBYRNE PM, 1988, ANN NY ACAD SCI, V524, P282, DOI 10.1111/j.1749-6632.1988.tb38551.x; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; ORNING L, 1988, PROSTAGLANDINS, V35, P493, DOI 10.1016/0090-6980(88)90025-1; ORNING L, 1985, BIOCHEM BIOPH RES CO, V130, P214, DOI 10.1016/0006-291X(85)90404-8; PARKER CW, 1980, BIOCHEM BIOPH RES CO, V97, P1038, DOI 10.1016/0006-291X(80)91480-1; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; STENE DO, 1988, J BIOL CHEM, V263, P2773; TAGARI P, 1989, CLIN CHEM, V35, P388; TAYLOR GW, 1989, LANCET, V1, P584; VERHAGEN J, 1987, BIOCHEM BIOPH RES CO, V148, P864, DOI 10.1016/0006-291X(87)90955-7; YOUNG RN, 1982, PROSTAGLANDINS, V23, P603, DOI 10.1016/0090-6980(82)90120-4	37	168	171	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					211	220		10.1016/S0091-6749(05)80068-5	http://dx.doi.org/10.1016/S0091-6749(05)80068-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2166758				2022-12-18	WOS:A1990DV31600011
J	FREDENS, K; DAHL, R; VENGE, P				FREDENS, K; DAHL, R; VENGE, P			THE GORDON PHENOMENON INDUCED BY THE EOSINOPHIL CATIONIC PROTEIN AND EOSINOPHIL PROTEIN-X	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									AARHUS KOMMUNE HOSP, DEPT LUNG MED, DK-8000 AARHUS, DENMARK; UNIV UPPSALA HOSP, DEPT CLIN CHEM, S-75014 UPPSALA, SWEDEN	Aarhus University; Uppsala University; Uppsala University Hospital	FREDENS, K (corresponding author), AARHUS UNIV, INST ANAT B, DK-8000 AARHUS, DENMARK.		Dahl, Ronahl/F-8170-2013					BENVENISTI DS, 1969, ANN INTERN MED, V71, P731, DOI 10.7326/0003-4819-71-4-731; BLACKWOOD W, 1971, GREENFIELDS NEUROPAT, P257; CHAR DFB, 1967, J PEDIATR-US, V70, P28, DOI 10.1016/S0022-3476(67)80162-8; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; DAHL R, 1979, THROMB RES, V14, P599, DOI 10.1016/0049-3848(79)90115-4; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; FLOR WJ, 1972, THESIS STANFORD U ST; Gordon M.H, 1932, STUDIES AETIOLOGY LY, P7; HALLGREN R, J NEUROSCI; HJORTHSIMONSEN A, 1970, STAIN TECHNOL, V45, P199, DOI 10.3109/10520297009067479; Kelser RA, 1936, AM J PATHOL, V12, P317; King LS, 1939, J EXP MED, V70, P303, DOI 10.1084/jem.70.3.303; LOHMAN AHM, 1976, BRAIN RES, V102, P197, DOI 10.1016/0006-8993(76)90588-6; Mcnaught JB, 1938, J AMER MED ASSOC, V111, P1280, DOI 10.1001/jama.1938.02790400026007; MEYER JS, 1953, J NEUROPATH EXP NEUR, V12, P349, DOI 10.1097/00005072-195312040-00002; OLSSON I, 1974, BLOOD, V44, P235, DOI 10.1182/blood.V44.2.235.235; PETERSEN C, UNPUB ISOLATION CHAR; PUNYAGUPTA S, 1975, AM J TROP MED HYG, V24, P921, DOI 10.4269/ajtmh.1975.24.921; TURNER JC, 1939, AM J MED SCI, V27, P27; VENGE P, 1979, THROMB RES, V14, P641, DOI 10.1016/0049-3848(79)90119-1	20	168	170	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					361	366		10.1016/0091-6749(82)90025-2	http://dx.doi.org/10.1016/0091-6749(82)90025-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	7130551				2022-12-18	WOS:A1982PQ10500007
J	Paller, AS; Kong, HH; Seed, P; Naik, S; Scharschmidt, TC; Gallo, RL; Luger, T; Irvine, AD				Paller, Amy S.; Kong, Heidi H.; Seed, Patrick; Naik, Shruti; Scharschmidt, Tiffany C.; Gallo, Richard L.; Luger, Thomas; Irvine, Alan D.			The microbiome in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; biotherapy; commensal; host-microbiome interaction; immune regulation; microbiome; Staphylococcus aureus	HUMAN SKIN MICROBIOME; REGULATORY T-CELLS; STAPHYLOCOCCUS-AUREUS; BODY HABITATS; COLONIZATION; IMMUNITY; DISEASE; DIVERSITY; INFLAMMATION; COMMUNITIES	As an interface with the environment, the skin is a complex ecosystem colonized by many microorganisms that coexist in an established balance. The cutaneous microbiome inhibits colonization with pathogens, such as Staphylococcus aureus, and is a crucial component for function of the epidermal barrier. Moreover, crosstalk between commensals and the immune system is now recognized because microorganisms can modulate both innate and adaptive immune responses. Host-commensal interactions also have an effect on the developing immune system in infants and, subsequently, the occurrence of diseases, such as asthma and atopic dermatitis (AD). Later in life, the cutaneous microbiome contributes to the development and course of skin disease. Accordingly, in patients with AD, a decrease in microbiome diversity correlates with disease severity and increased colonization with pathogenic bacteria, such as S aureus. Early clinical studies suggest that topical application of commensal organisms (eg, Staphylococcus hominis or Roseomonas mucosa) reduces AD severity, which supports an important role for commensals in decreasing S aureus colonization in patients with AD. Advancing knowledge of the cutaneous microbiome and its function in modulating the course of skin disorders, such as AD, might result in novel therapeutic strategies.	[Paller, Amy S.; Seed, Patrick] Northwestern Univ, Feinberg Sch Med, Dermatol & Infect Dis, Chicago, IL 60611 USA; [Paller, Amy S.; Seed, Patrick] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Kong, Heidi H.] NIAMSD, Dermatol Branch, Bethesda, MD 20892 USA; [Naik, Shruti] NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY 10003 USA; [Scharschmidt, Tiffany C.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Gallo, Richard L.] Univ Calif San Diego, Dermatol, San Diego, CA 92103 USA; [Luger, Thomas] Univ Munster, Dermatol, Munster, Germany; [Irvine, Alan D.] Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Paediat Dermatol, Dublin, Ireland; [Irvine, Alan D.] Trinity Coll Dublin, Dublin, Ireland	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); New York University; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of Munster; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; Trinity College Dublin	Paller, AS (corresponding author), Dept Dermatol, 676 N St Clair,Suite 1600, Chicago, IL 60611 USA.; Irvine, AD (corresponding author), Our Ladys Childrens Hosp, Dermatol, Dublin 12, Ireland.	apaller@northwestern.edu; irvinea@tcd.ie	Gallo, Richard L/A-8931-2009; Irvine, Alan D/A-3982-2008; Kong, Heidi H/L-4856-2018	Gallo, Richard L/0000-0002-1401-7861; Irvine, Alan D/0000-0002-9048-2044; Kong, Heidi H/0000-0003-4424-064X	International Eczema Council (IEC); NATIONAL CANCER INSTITUTE [ZIABC010938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR076082] Funding Source: NIH RePORTER	International Eczema Council (IEC); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors acknowledge the support of the International Eczema Council (IEC) in facilitating and sponsoring a symposium on the Microbiome in Atopic Dermatitis, San Diego, February 2018. This work reflects ideas and collaboration initiated in the IEC symposium.	Anderson MJ, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00064; Belkaid Y, 2014, SCIENCE, V346, P954, DOI 10.1126/science.1260144; Belkaid Y, 2013, NAT IMMUNOL, V14, P646, DOI 10.1038/ni.2604; Berube BJ, 2013, TOXINS, V5, P1140, DOI 10.3390/toxins5061140; Bin LH, 2012, J ALLERGY CLIN IMMUN, V130, P683, DOI 10.1016/j.jaci.2012.06.019; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Byrd AL, 2018, NAT REV MICROBIOL, V16, P143, DOI 10.1038/nrmicro.2017.157; Byrd AL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4651; Capone KA, 2011, J INVEST DERMATOL, V131, P2026, DOI 10.1038/jid.2011.168; Cheuk S, 2014, J IMMUNOL, V192, P3111, DOI 10.4049/jimmunol.1302313; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P269, DOI 10.1067/mai.2001.117455; Chu DM, 2017, NAT MED, V23, P314, DOI 10.1038/nm.4272; Clark RA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010641; Clowry J, 2019, J ALLERGY CLIN IMMUN, V143, P78, DOI 10.1016/j.jaci.2018.08.038; Cogen AL, 2008, BRIT J DERMATOL, V158, P442, DOI 10.1111/j.1365-2133.2008.08437.x; Cordoro KM, 2017, J AM ACAD DERMATOL, V77, P417, DOI 10.1016/j.jaad.2017.05.017; Costello EK, 2013, MBIO, V4, DOI 10.1128/mBio.00782-13; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; de Oliveira M R, 1999, Rev Inst Med Trop Sao Paulo, V41, P87, DOI 10.1590/S0036-46651999000200005; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Feuillie C, 2018, MBIO, V9, DOI 10.1128/mBio.01184-18; Findley K, 2013, NATURE, V498, P367, DOI 10.1038/nature12171; Fleury OM, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00994-16; Flores GE, 2014, J DRUGS DERMATOL, V13, P1365; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Gallo RL, 2017, J INVEST DERMATOL, V137, P1213, DOI 10.1016/j.jid.2016.11.045; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Geoghegan JA, 2018, TRENDS MICROBIOL, V26, P484, DOI 10.1016/j.tim.2017.11.008; Gimblet C, 2017, CELL HOST MICROBE, V22, P13, DOI 10.1016/j.chom.2017.06.006; Gonzalez ME, 2016, J AM ACAD DERMATOL, V75, P481, DOI 10.1016/j.jaad.2016.04.066; Grice EA, 2014, SEMIN CUTAN MED SURG, V33, P98, DOI 10.12788/j.sder.0087; Grice EA, 2010, P NATL ACAD SCI USA, V107, P14799, DOI 10.1073/pnas.1004204107; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Gueniche A, 2014, BENEF MICROBES, V5, P137, DOI [10.3920/BM2013.0001, 10.]; Guzik TJ, 2005, CLIN EXP ALLERGY, V35, P448, DOI 10.1111/j.1365-2222.2005.02210.x; Hata TR, 2010, BRIT J DERMATOL, V163, P659, DOI 10.1111/j.1365-2133.2010.09892.x; Higaki S, 1999, INT J DERMATOL, V38, P265, DOI 10.1046/j.1365-4362.1999.00686.x; Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027; Jo JH, 2016, J INVEST DERMATOL, V136, P2356, DOI 10.1016/j.jid.2016.05.130; Kennedy EA, 2017, J ALLERGY CLIN IMMUN, V139, P166, DOI 10.1016/j.jaci.2016.07.029; Kollmann TR, 2012, IMMUNITY, V37, P771, DOI 10.1016/j.immuni.2012.10.014; Kong HH, 2017, J INVEST DERMATOL, V137, pE119, DOI 10.1016/j.jid.2016.07.045; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Lai YP, 2010, J INVEST DERMATOL, V130, P2211, DOI 10.1038/jid.2010.123; Lai YP, 2009, NAT MED, V15, P1377, DOI 10.1038/nm.2062; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Linehan JL, 2018, CELL, V172, P784, DOI 10.1016/j.cell.2017.12.033; Liu HY, 2017, CELL HOST MICROBE, V22, P653, DOI 10.1016/j.chom.2017.10.006; McGovern N, 2017, NATURE, V546, P662, DOI 10.1038/nature22795; Meylan P, 2017, J INVEST DERMATOL, V137, P2497, DOI 10.1016/j.jid.2017.07.834; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Nguyen MT, 2016, INFECT IMMUN, V84, P205, DOI 10.1128/IAI.00822-15; Myles IA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120608; Naik S, 2015, NATURE, V520, P104, DOI 10.1038/nature14052; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; Nakagawa S, 2017, CELL HOST MICROBE, V22, P667, DOI 10.1016/j.chom.2017.10.008; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Nakatsuji T, 2018, J INVEST DERMATOL, V138, pS72, DOI 10.1016/j.jid.2018.03.433; Nakatsuji T, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao4502; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Nakatsuji T, 2016, J INVEST DERMATOL, V136, P2192, DOI 10.1016/j.jid.2016.05.127; Nakatsuji T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2441; Oh J, 2016, CELL, V165, P854, DOI 10.1016/j.cell.2016.04.008; Oh J, 2014, NATURE, V514, P59, DOI 10.1038/nature13786; Oh J, 2013, GENOME RES, V23, P2103, DOI 10.1101/gr.159467.113; Oh J, 2012, GENOME MED, V4, DOI 10.1186/gm378; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Paharik AE, 2017, CELL HOST MICROBE, V22, P746, DOI 10.1016/j.chom.2017.11.001; Park HY, 2013, ANN DERMATOL, V25, P410, DOI 10.5021/ad.2013.25.4.410; Ridaura VK, 2018, J EXP MED, V215, P785, DOI 10.1084/jem.20171079; Riethmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P1573, DOI 10.1016/j.jaci.2015.04.042; Roberts SJ, 2007, P NATL ACAD SCI USA, V104, P6770, DOI 10.1073/pnas.0604982104; Scharschmidt TC, 2017, CELL HOST MICROBE, V21, P467, DOI 10.1016/j.chom.2017.03.001; Scharschmidt TC, 2015, IMMUNITY, V43, P1011, DOI 10.1016/j.immuni.2015.10.016; Schlapbach C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007828; Sen S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165300; Shen W, 2014, P NATL ACAD SCI USA, V111, pE2977, DOI 10.1073/pnas.1401820111; Shi BC, 2018, J INVEST DERMATOL, V138, P1668, DOI 10.1016/j.jid.2018.01.022; Shi BC, 2016, J ALLERGY CLIN IMMUN, V138, P1233, DOI 10.1016/j.jaci.2016.04.053; Simpson EL, 2018, J INVEST DERMATOL, V138, P2224, DOI 10.1016/j.jid.2018.03.1517; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Spaulding AR, 2013, CLIN MICROBIOL REV, V26, P422, DOI 10.1128/CMR.00104-12; Sun Y, 2012, J BACTERIOL, V194, P5274, DOI 10.1128/JB.00045-12; Tauber M, 2016, J ALLERGY CLIN IMMUN, V137, P1272, DOI 10.1016/j.jaci.2015.07.052; Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008; Totte JEE, 2016, BRIT J DERMATOL, V175, P687, DOI 10.1111/bjd.14566; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Williams MR, 2017, CELL HOST MICROBE, V22, P579, DOI 10.1016/j.chom.2017.10.015; Yang SY, 2015, SCIENCE, V348, P589, DOI 10.1126/science.aaa7017; Zhang LJ, 2016, CURR BIOL, V26, pR14, DOI 10.1016/j.cub.2015.11.017; Zipperer A, 2016, NATURE, V535, P511, DOI 10.1038/nature18634	93	167	179	17	86	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					26	35		10.1016/j.jaci.2018.11.015	http://dx.doi.org/10.1016/j.jaci.2018.11.015			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30476499	hybrid, Green Accepted, Green Published			2022-12-18	WOS:000454918300003
J	Santos, AF; Douiri, A; Becares, N; Wu, SY; Stephens, A; Radulovic, S; Chan, SMH; Fox, AT; Du Toit, G; Turcanu, V; Lack, G				Santos, Alexandra F.; Douiri, Abdel; Becares, Natalia; Wu, Shih-Ying; Stephens, Alick; Radulovic, Suzana; Chan, Susan M. H.; Fox, Adam T.; Du Toit, George; Turcanu, Victor; Lack, Gideon			Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; basophil activation test; CD203c; CD63; diagnosis; flow cytometry; food allergy; peanut allergy; ROC curve	POSITIVE FOOD CHALLENGES; SKIN PRICK; DOUBLE-BLIND; IGE CONCENTRATIONS; COWS MILK; DIAGNOSIS; RISK; UTILITY	Background: Most of the peanut-sensitized children do not have clinical peanut allergy. In equivocal cases, oral food challenges (OFCs) are required. However, OFCs are laborious and not without risk; thus, a test that could accurately diagnose peanut allergy and reduce the need for OFCs is desirable. Objective: To assess the performance of basophil activation test (BAT) as a diagnostic marker for peanut allergy. Methods: Peanut-allergic (n = 43), peanut-sensitized but tolerant (n = 36) and non-peanut-sensitized nonallergic (n = 25) children underwent skin prick test (SPT) and specific IgE (sIgE) to peanut and its components. BAT was performed using flow cytometry, and its diagnostic performance was evaluated in relation to allergy versus tolerance to peanut and validated in an independent population (n = 65). Results: BAT in peanut-allergic children showed a peanut dose-dependent upregulation of CD63 and CD203c while there was no significant response to peanut in peanut-sensitized but tolerant (P < .001) and non-peanut-sensitized nonallergic children (P < .001). BAT optimal diagnostic cutoffs showed 97% accuracy, 95% positive predictive value, and 98% negative predictive value. BAT allowed reducing the number of required OFCs by two-thirds. BAT proved particularly useful in cases in which specialists could not accurately diagnose peanut allergy with SPT and sIgE to peanut and to Arah2. Using a 2-step diagnostic approach in which BAT was performed only after equivocal SPT or Arah2-sIgE, BAT had a major effect (97% reduction) on the number of OFCs required. Conclusions: BAT proved to be superior to other diagnostic tests in discriminating between peanut allergy and tolerance, particularly in difficult cases, and reduced the need for OFCs.	[Santos, Alexandra F.; Becares, Natalia; Wu, Shih-Ying; Stephens, Alick; Radulovic, Suzana; Chan, Susan M. H.; Fox, Adam T.; Du Toit, George; Turcanu, Victor; Lack, Gideon] Kings Coll London, Dept Pediat Allergy, Div Asthma Allergy & Lung Biol, London, England; [Santos, Alexandra F.; Becares, Natalia; Wu, Shih-Ying; Stephens, Alick; Radulovic, Suzana; Chan, Susan M. H.; Fox, Adam T.; Du Toit, George; Turcanu, Victor; Lack, Gideon] MRC, London, England; [Santos, Alexandra F.; Becares, Natalia; Wu, Shih-Ying; Stephens, Alick; Radulovic, Suzana; Chan, Susan M. H.; Fox, Adam T.; Du Toit, George; Turcanu, Victor; Lack, Gideon] Asthma UK Ctr Allerg Mech Asthma, London, England; [Santos, Alexandra F.] Coimbra Univ Hosp, Immunoallergol Dept, Coimbra, Portugal; [Santos, Alexandra F.] Gulbenkian Programme Adv Med Educ, Lisbon, Portugal; [Douiri, Abdel] Kings Coll London, Sch Med, Dept Publ Hlth Sci, London, England; [Douiri, Abdel] Guys & St Thomas Hosp NHS Fdn, Biomed Res Ctr, Natl Inst Hlth Res, London, England	University of London; King's College London; University of London; King's College London; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Lack, G (corresponding author), St Thomas Hosp, Dept Pediat Allergy, 2nd Fl,Stairwell B,S Wing,Westminster Bridge Rd, London SE1 7EH, England.	gideon.lack@kcl.ac.uk	Fox, Adam/O-3547-2015	Fox, Adam/0000-0002-3533-9798; Douiri, Abdel/0000-0002-4354-4433; Wu, Shih-Ying/0000-0002-9772-0877; Santos, Alexandra/0000-0002-7805-1436; Lack, Gideon/0000-0001-7350-4021; Du Toit, George/0000-0002-0321-2928	Medical Research Council [G0902018]; National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London; Goldman Sachs Gives; Medical Research Council [G1000758] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish; MRC [G0902018] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London; Goldman Sachs Gives; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by the Medical Research Council (grant no. G0902018). The authors acknowledge financial support from the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London and from Goldman Sachs Gives. The views expressed in this article are those of the authors and not necessarily those of the BRC, the National Health Service (NHS), the NIHR, or the Department of Health.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P623, DOI 10.1016/j.jaci.2013.02.035; Caffarelli C, 2001, LANCET, V358, P1871, DOI 10.1016/S0140-6736(01)06897-0; Chirumbolo Salvatore, 2008, Clin Mol Allergy, V6, P12, DOI 10.1186/1476-7961-6-12; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Ebo DG, 2008, CYTOM PART B-CLIN CY, V74B, P201, DOI 10.1002/cyto.b.20419; Ebo DG, 2005, CYTOM PART B-CLIN CY, V64B, P28, DOI 10.1002/cyto.b.20042; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Javaloyes G, 2012, J INVEST ALLERG CLIN, V22, P508; Lieberman JA, 2013, J ALLER CL IMM-PRACT, V1, P75, DOI 10.1016/j.jaip.2012.11.002; Ludman S, 2013, PEDIAT ALLERG IMM-UK, V24, P276, DOI 10.1111/pai.12059; Marrs T, 2013, J ALLERGY CLIN IMMUN, V132, P502, DOI 10.1016/j.jaci.2013.04.040; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nolan RC, 2007, PEDIAT ALLERG IMM-UK, V18, P224, DOI 10.1111/j.1399-3038.2007.00519.x; Ocmant A, 2009, CLIN EXP ALLERGY, V39, P1234, DOI 10.1111/j.1365-2222.2009.03292.x; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Roberts G, 2000, CLIN EXP ALLERGY, V30, P1495, DOI 10.1046/j.1365-2222.2000.00960.x; Rubio A, 2011, ALLERGY, V66, P92, DOI 10.1111/j.1398-9995.2010.02432.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Sicherer SH, 2013, J ALLER CL IMM-PRACT, V1, P1, DOI 10.1016/j.jaip.2012.10.004; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; van Nieuwaal NHG, 2010, J ALLERGY CLIN IMMUN, V125, P1391, DOI 10.1016/j.jaci.2010.01.057; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; Viera AJ, 2005, FAM MED, V37, P360; Zhou XH, 2005, STAT MED, V24, P465, DOI 10.1002/sim.1563	34	167	174	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					645	652		10.1016/j.jaci.2014.04.039	http://dx.doi.org/10.1016/j.jaci.2014.04.039			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25065721	Green Submitted, Green Published, hybrid			2022-12-18	WOS:000341372400017
J	Rautava, S; Kainonen, E; Salminen, S; Isolauri, E				Rautava, Samuli; Kainonen, Essi; Salminen, Seppo; Isolauri, Erika			Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eczema; probiotics; breast-feeding; infant	PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; 1ST 6 MONTHS; DOUBLE-BLIND; LACTOBACILLUS GG; PRIMARY PREVENTION; ATOPIC-DERMATITIS; SKIN PRICK; BIFIDOBACTERIUM-LACTIS; INTESTINAL MICROBIOTA	Background: Probiotics have shown promising potential in reducing the risk of eczema in infants. Optimal probiotic intervention regimen remains to be determined. Objective: We investigated whether maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of developing eczema in high-risk infants. Methods: This was a parallel, double-blind placebo-controlled trial of 241 mother-infant pairs. Mothers with allergic disease and atopic sensitization were randomly assigned to receive (1) Lactobacillus rhamnosus LPR and Bifidobacterium longum BL999 (LPR+BL999), (2) L paracasei ST11 and B longum BL999 (ST11+BL999), or (3) placebo, beginning 2 months before delivery and during the first 2 months of breast-feeding. The infants were followed until the age of 24 months. Skin prick tests were performed at the ages of 6, 12, and 24 months. Results: Altogether 205 infants completed the follow-up and were included in the analyses. The risk of developing eczema during the first 24 months of life was significantly reduced in infants of mothers receiving LPR+BL999 (odds ratio [OR], 0.17; 95% CI, 0.08-0.35; P < .001) and ST11+BL999 (OR, 0.16; 95% CI, 0.08-0.35; P < .001). The respective ORs for chronically persistent eczema were 0.30 (95% CI, 0.12-0.80; P = .016) and 0.17 (95% CI, 0.05-0.56; P = .003). Probiotics had no effect on the risk of atopic sensitization in the infants. No adverse effects were related to the use of probiotics. Conclusion: Prevention regimen with specific probiotics administered to the pregnant and breast-feeding mother, that is, prenatally and postnatally, is safe and effective in reducing the risk of eczema in infants with allergic mothers positive for skin prick test. (J Allergy Clin Immunol 2012;130:1355-60.)	[Rautava, Samuli; Kainonen, Essi; Isolauri, Erika] Turku Univ, Cent Hosp, Dept Paediat, Turku 20520, Finland; [Salminen, Seppo] Univ Turku, SF-20500 Turku, Finland	University of Turku; University of Turku	Rautava, S (corresponding author), Turku Univ, Cent Hosp, Dept Paediat, Kiinamyllynkatu 4-8, Turku 20520, Finland.	samrau@utu.fi		Rautava, Samuli/0000-0003-0935-3593	Sigrid Juselius Foundation; Turku University Hospital EVO; Turku University Hospital; Academy of Finland; Finnish Society for Pediatric Research; Finnish Allergy Research Foundation; European Food Safety Authority; Sigrid Juselius Fondation; International Academic Meetings	Sigrid Juselius Foundation(Sigrid Juselius Foundation); Turku University Hospital EVO; Turku University Hospital; Academy of Finland(Academy of Finland); Finnish Society for Pediatric Research; Finnish Allergy Research Foundation; European Food Safety Authority; Sigrid Juselius Fondation(Sigrid Juselius Foundation); International Academic Meetings	Supported by a research grant from the Sigrid Juselius Foundation and Turku University Hospital EVO research funding.; S. Rautava has received research support from the Sigrid Juselius Foundation, EVO research funding of Turku University Hospital, the Academy of Finland, and the Finnish Society for Pediatric Research and received the probiotic strains from Nestle without compensation. E. Kainonen has received research support from the Finnish Allergy Research Foundation and is employed by the Intermunicipal Hospital District of Southwest Finland. S. Salminen has received travel expenses from the European Food Safety Authority. E. Isolauri has received research support from the Sigrid Juselius Fondation and has received lecture fees and travel expenses from International Academic Meetings.	Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Abrahamsson TR, 2009, J PEDIATR GASTR NUTR, V49, P349, DOI 10.1097/MPG.0b013e31818f091b; Boyle RJ, 2011, ALLERGY, V66, P509, DOI 10.1111/j.1398-9995.2010.02507.x; CAFFARELLI C, 1995, J ALLERGY CLIN IMMUN, V95, P1215, DOI 10.1016/S0091-6749(95)70078-1; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Donnet-Hughes A, 2010, P NUTR SOC, V69, P407, DOI 10.1017/S0029665110001898; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; Gueimonde M, 2007, NEONATOLOGY, V92, P64, DOI 10.1159/000100088; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; Harmsen HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kim JY, 2010, PEDIAT ALLERG IMM-UK, V21, pE386, DOI 10.1111/j.1399-3038.2009.00958.x; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Laitinen K, 2005, BRIT J NUTR, V94, P565, DOI 10.1079/BJN20051503; Land MH, 2005, PEDIATRICS, V115, P178, DOI 10.1542/peds.2004-2137; Luoto R, 2010, CLIN INFECT DIS, V50, P1327, DOI 10.1086/651694; Majamaa H, 1999, ALLERGY, V54, P851, DOI 10.1034/j.1398-9995.1999.00081.x; Manzoni P, 2011, EARLY HUM DEV, V87, pS35, DOI 10.1016/j.earlhumdev.2011.01.036; Mold JE, 2008, SCIENCE, V322, P1562, DOI 10.1126/science.1164511; Niers L, 2009, ALLERGY, V64, P1349, DOI 10.1111/j.1398-9995.2009.02021.x; Ohishi A, 2010, J PEDIATR-US, V156, P679, DOI 10.1016/j.jpeds.2009.11.041; Ouwehand AC, 2000, LETT APPL MICROBIOL, V30, P10, DOI [10.1046/j.1472-765x.2000.00590.x, 10.1046/j.1472-765X.2000.00590.x]; Rautava S, 2005, J ALLERGY CLIN IMMUN, V116, P31, DOI 10.1016/j.jaci.2005.02.010; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; Rautava S, 2012, NAT REV GASTROENTERO; Rautava S, 2012, NEONATOLOGY, V102, P178, DOI 10.1159/000339182; Rautava S, 2012, J PEDIATR GASTR NUTR, V54, P630, DOI 10.1097/MPG.0b013e31823e7c29; Rautava S, 2011, NEONATOLOGY, V99, P192, DOI 10.1159/000314109; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Soh SE, 2009, CLIN EXP ALLERGY, V39, P571, DOI 10.1111/j.1365-2222.2008.03133.x; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; von Kobyletzki LB, 2012, BMC DERMATOL, V12, DOI 10.1186/1471-5945-12-11; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011	37	167	187	3	55	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1355	1360		10.1016/j.jaci.2012.09.003	http://dx.doi.org/10.1016/j.jaci.2012.09.003			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23083673	Bronze			2022-12-18	WOS:000311641100016
J	Bousquet, J; Bachert, C; Canonica, GW; Casale, TB; Cruz, AA; Lockey, RJ; Zuberbier, T				Bousquet, Jean; Bachert, Claus; Canonica, Giorgio W.; Casale, Thomas B.; Cruz, Alvaro A.; Lockey, Richard J.; Zuberbier, Torsten		Global Allergy Asthma; World Allergy Org; Allergic Rhinitis Its Impact	Unmet needs in severe chronic upper airway disease (SCUAD)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe chronic upper airway disease; rhinitis; rhinosinusitis	ALLERGIC RHINITIS; IMPACT; RHINOSINUSITIS; ASTHMA; PREVALENCE; QUESTIONS; SINUSITIS; GA(2)LEN	Although the majority of patients with chronic upper airway diseases have controlled symptoms during treatment, many patients have severe chronic upper airway diseases (SCUADs). SCUAD defines those patients whose symptoms are inadequately controlled despite adequate (ie, effective, safe, and acceptable) pharmacologic treatment based on guidelines. These patients have impaired quality of life, social functioning, sleep, and school/work performance. Severe uncontrolled allergic rhinitis, nonallergic rhinitis, chronic rhinosinusitis, aspirin-exacerbated respiratory diseases, or occupational airway diseases are defined as SCUADs. Pediatric SCUADs are still unclear. In developing countries SCUADs exist, but risk factors can differ from those seen in developed countries. Comorbidities are common in patients with SCUADs and might increase their severity. The present document is the position of a group of experts considering that SCUADs should be considered differently from mild chronic upper airway diseases. It reviews the state of the art, highlighting gaps in our knowledge, and proposes several areas for a better understanding, prevention, and management of SCUADs. This document can also serve to optimize the pharmacoeconomic evaluation of SCUADs by means of comparison with mild chronic upper airway diseases. (J Allergy Clin Immunol 2009;124:428-33.)	[Bousquet, Jean] Univ Hosp, Montpellier, France; [Bachert, Claus] Ghent Univ Hosp, UZG, B-9000 Ghent, Belgium; [Canonica, Giorgio W.] Univ Genoa, Allergy & Resp Dis Clin, Genoa, Italy; [Casale, Thomas B.] Creighton Univ, Omaha, NE 68178 USA; [Cruz, Alvaro A.] Univ Fed Bahia, ProAR FMB, Salvador, BA, Brazil; [Lockey, Richard J.] Univ S Florida, Coll Med, Tampa, FL USA; [Zuberbier, Torsten] Charite, Allergy Ctr Charite, D-13353 Berlin, Germany	Universite de Montpellier; CHU de Montpellier; Ghent University; Ghent University Hospital; University of Genoa; Creighton University; Universidade Federal da Bahia; State University System of Florida; University of South Florida; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Bousquet, J (corresponding author), Hop Arnaud Villeneuve, Serv Malad Resp, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France.	jean.bousquet@inserm.fr	Price, David/H-2837-2019; Yusuf, M Osman/AAI-1142-2020; Bousquet, Jean/O-4221-2019; canonica, giorgio walter/ABF-2037-2020; Custovic, Adnan/A-2435-2012; Casale, Thomas B/K-4334-2013; Beldar, Sagar V/C-8542-2011; Delgado, Luis/L-8035-2013; Leynaert, Benedicte/N-5251-2018; Bonini, Sergio/T-6594-2019; Bachert, Claus/J-8825-2012; van Weel, Chris/D-4375-2009; Cruz, Alvaro A/I-1676-2012; Jensen-Jarolim, Erika/C-5120-2018	Price, David/0000-0002-9728-9992; Yusuf, M Osman/0000-0002-8067-1204; canonica, giorgio walter/0000-0001-8467-2557; Custovic, Adnan/0000-0001-5218-7071; Casale, Thomas B/0000-0002-3149-7377; Delgado, Luis/0000-0003-2375-9071; Bonini, Sergio/0000-0003-0079-3031; van Weel, Chris/0000-0003-3653-4701; Cruz, Alvaro A/0000-0002-7403-3871; Ivancevich, Juan Carlos/0000-0001-8713-6258; Popov, Todor/0000-0001-5052-5866; Todo-Bom, Ana/0000-0002-1850-6689; Leynaert, Benedicte/0000-0001-5045-2492; Ryan, Dermot/0000-0002-4115-7376; Bousquet, Philippe Jean/0000-0002-0217-5483; Jensen-Jarolim, Erika/0000-0003-4019-5765	European Union [FOOD-CT-2004-506378]; Pfizer; Stallergenes; Mantecorp; CHIESI; Novartis; GlaxoSmithKline; Wellcome Trust; FAPESB (Brazil); CNPq (National Research Council, Brazil); Medical Research Council [G0800766] Funding Source: researchfish; MRC [G0800766] Funding Source: UKRI	European Union(European Commission); Pfizer(Pfizer); Stallergenes; Mantecorp; CHIESI(Chiesi Pharmaceuticals Inc); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); Wellcome Trust(Wellcome TrustEuropean Commission); FAPESB (Brazil)(Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)); CNPq (National Research Council, Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Members of the Global Allergy and Asthma European Network, supported by the European Union Framework programme for research contract no. FOOD-CT-2004-506378.; J. Bousquet has received fees for lectures or participation on advisory boards from Stallergenes, Schering-Plough, UCB, Merck, Sanofi-Aventis, and Allmiral. T. B. Casale has received research support through his institution from Pfizer and Stallergenes. A. A. Cruz is a consultant for AstraZeneca; has received honoraria, travel grants, or other grants from Mantecorp, CHIESI, and Novartis; and has received research support from GlaxoSmithKline, Wellcome Trust, FAPESB (Brazil), and CNPq (National Research Council, Brazil). T. Zuberbier is a consultant for Schering-Plough, Novartis, Leti, Stallergenes, Bayer Schering, Ansell, Kryolan, UCB, Merck, Sharp&Dohme, and Procter&Gamble. The rest of the authors have declared that they have no conflict of interest.	Ait-Khaled N, 2009, ALLERGY, V64, P123, DOI 10.1111/j.1398-9995.2008.01884.x; Alobid I, 2008, ALLERGY, V63, P1267, DOI 10.1111/j.1398-9995.2008.01828.x; Bachert C, 2006, CURR OPIN ALLERGY CL, V6, P29, DOI 10.1097/01.all.0000200504.54425.0e; Bachert C, 2008, CURR OPIN ALLERGY CL, V8, P34, DOI 10.1097/ACI.0b013e3282f4178f; Borish L, 2005, J ALLERGY CLIN IMMUN, V116, P1269, DOI 10.1016/j.jaci.2005.08.038; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2008, ALLERGY, V63, P143, DOI 10.1111/j.1398-9995.2007.01615.x; Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet PJ, 2008, ALLERGY, V63, P1301, DOI 10.1111/j.1398-9995.2008.01824.x; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; FOKKENS W, 2007, RHINOL S, V20, P1; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; Greiner AN, 2006, J ALLERGY CLIN IMMUN, V118, P985, DOI 10.1016/j.jaci.2006.06.029; Khaltaev N, 2007, GLOBAL SURVEILLANCE; Meltzer EO, 2006, J ALLERGY CLIN IMMUN, V118, pS17, DOI 10.1016/j.jaci.2006.09.005; Moscato RG, 2008, ALLERGY, V63, P969, DOI [10.1111/j.1398-9995.2008.01752.x, 10.1111/j.1398-9995.2008.01801.x]; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Santos CB, 2006, ANN ALLERG ASTHMA IM, V97, P579, DOI 10.1016/S1081-1206(10)61084-8; SANTOS CB, 2006, ANN ALLERG ASTHMA IM, V97, P671, DOI DOI 10.1016/S1081-1206(10)61084-8; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Weinmayr G, 2008, EUR RESPIR J, V32, P1250, DOI 10.1183/09031936.00157807; White P, 1998, CLIN EXP ALLERGY, V28, P266	28	167	178	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					428	433		10.1016/j.jaci.2009.06.027	http://dx.doi.org/10.1016/j.jaci.2009.06.027			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19660803				2022-12-18	WOS:000274315900005
J	Van Bruaene, N; Derycke, L; Perez-Novo, CA; Gevaert, P; Holtappels, G; De Ruyck, N; Cuvelier, C; Van Cauvvenberge, P; Bachert, C				Van Bruaene, Nicholas; Derycke, Lara; Perez-Novo, Claudina Angela; Gevaert, Philippe; Holtappels, Gabriele; De Ruyck, Natalie; Cuvelier, Claude; Van Cauvvenberge, Paul; Bachert, Claus			TGF-beta signaling and collagen deposition in chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; collagen; inflammation; nasal polyposis; phospho-Smad 2; remodeling; TGF-beta	TISSUE INHIBITOR; SEVERE ASTHMA; NASAL; EXPRESSION; MODERATE; MMP-9	Background: Chronic rhinosinusitis is an inflammatory disease with distinct cytokine and remodeling patterns. Objective: The objective was to analyze the presence of TGF-beta isoforms, receptors, intracellular signaling, and collagen deposition in chronic rhinosinusitis. Methods: Sinonasal mucosal samples obtained from chronic rhinosinusitis with nasal polyps (CRSwNP; n = 13), chronic rhinosinusitis without nasal polyps (CRSsNP; n = 13), and controls (n = 10) were analyzed for TGF-beta isoforms 1 and 2 by means of ELISA and IHC, and for TGF-beta R1, 2, and 3 by RT-PCR and IHC. As downstream proteins, phospho-Smad 2 (pSmad 2) and collagen were analyzed by performing immunostaining and picrosirius red staining, respectively. Results: TGF-beta 1 and 2 protein concentrations, TGF-beta receptor (R) I and TGF-beta RIII mRNA expression, the number of pSmad 2-positive cells, and total collagen amount were significantly higher in CRSsNP versus controls. In CRSwNP, TGF-beta 1 protein concentration, TGF-beta RII and TGF-beta RIII mRNA expression, the number of pSmad 2-positive cells, and total collagen amount were significantly lower versus controls. Only TGF-beta 2 protein was found higher in CRSwNP versus controls. Conclusion: A high TGF-beta 1 protein expression, increased TGF-beta RI expression, and a high number of pSmad 2-positive cells all indicate an enhanced TGF-beta signaling in CRSsNP, whereas a low TGF-beta 1 protein concentration, a decreased expression of TGF-beta RII, and a low number of pSmad 2-positive cells in CRSwNP indicate a low level of TGF-beta signaling in CRSwNP. These findings are compatible with the remodeling patterns observed, reflected by a lack of collagen in CRSwNP, and excessive collagen production with thickening of the collagen fibers in the extracellular matrix in CRSsNP. (J Allergy Clin Immunol 2009;124:253-9.)	[Van Bruaene, Nicholas; Derycke, Lara; Perez-Novo, Claudina Angela; Gevaert, Philippe; Holtappels, Gabriele; De Ruyck, Natalie; Van Cauvvenberge, Paul; Bachert, Claus] Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airway Res Lab, B-9000 Ghent, Belgium; [Van Cauvvenberge, Paul] Ghent Univ Hosp, Dept Pathol, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Van Bruaene, N (corresponding author), Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airway Res Lab, B-9000 Ghent, Belgium.	Nicholas.Vanbruaene@Ugent.be	Novo, Claudina A Perez/E-6098-2011; Gevaert, Philippe/ABA-4588-2021; Novo, Claudina Angela Perez/H-9697-2016; Gevaert, Philippe/AAP-1892-2020; Bachert, Claus/J-8825-2012	Novo, Claudina A Perez/0000-0003-4562-4346; Gevaert, Philippe/0000-0002-1629-8468; 	Flemish Scientific Research Board; FWO [A 12/5-HB-KH3, G.0436.04]; Global Allergy and Asthma European Network; Interuniversity Attraction Poles Programme; Belgian State; Belgian Science Policy [IAP P6/35]	Flemish Scientific Research Board(FWO); FWO(FWO); Global Allergy and Asthma European Network; Interuniversity Attraction Poles Programme(Belgian Federal Science Policy Office); Belgian State; Belgian Science Policy(Belgian Federal Science Policy Office)	Supported by grants to C.B. from the Flemish Scientific Research Board, FWO, #A 12/5-HB-KH3 and #G.0436.04, the Global Allergy and Asthma European Network, and the Interuniversity Attraction Poles Programme, Belgian State, Belgian Science Policy, #IAP P6/35, and to P.G. (postdoctoral grant of the Research Foundation, Flanders [FWO]).	Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chen YS, 2007, ALLERGY, V62, P66, DOI 10.1111/j.1398-9995.2006.01255.x; Figueiredo CR, 2007, AM J RHINOL, V21, P231, DOI 10.2500/ajr.2007.21.2968; FOKKENS W, 2007, RHINOL S, V20, P1; Hamilos DL, 1999, J ALLERGY CLIN IMMUN, V103, P79, DOI 10.1016/S0091-6749(99)70529-4; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Kostamo K, 2007, LARYNGOSCOPE, V117, P638, DOI 10.1097/MLG.0b013e318030aca6; Lechapt-Zalcman E, 2001, J PATHOL, V193, P233, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH771>3.0.CO;2-W; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Perez-Novo CA, 2005, BIOTECHNIQUES, V39, P52; Redington A E, 2000, Monaldi Arch Chest Dis, V55, P317; Rostkowska-Nadolska Beata, 2007, Postepy Hig Med Dosw (Online), V61, P702; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Watelet JB, 2004, ALLERGY, V59, P54, DOI 10.1046/j.1398-9995.2003.00364.x; WHITTAKER P, 1994, BASIC RES CARDIOL, V89, P397, DOI 10.1007/BF00788278	26	167	169	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					253	259		10.1016/j.jaci.2009.04.013	http://dx.doi.org/10.1016/j.jaci.2009.04.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19500825				2022-12-18	WOS:000268860400011
J	KELSO, JM; JONES, RT; YUNGINGER, JW				KELSO, JM; JONES, RT; YUNGINGER, JW			ANAPHYLAXIS TO MEASLES, MUMPS, AND RUBELLA VACCINE MEDIATED BY IGE TO GELATIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MMR; ALLERGY; GELATIN; IGE ANTIBODY	ALLERGIC REACTIONS; EGG PROTEIN; CHILDREN; HYPERSENSITIVITY; IMMUNIZATION; HAEMACCEL; SAFETY	Background: Allergic reactions to measles, mumps, and rubella (MMR) vaccine are rare; some have been attributed to allergy to trace quantities of egg proteins. We report a 17-year-old female who had an anaphylactic reaction to MMR vaccine. A primary vaccination with MMR at age 15 months had been uneventful. She is not allergic to eggs; however, ear and throat pruritus and tongue swelling develop after she eats gelatin. MMR vaccine contains gelatin as a stabilizer. Methods and Results: Prick skin tests were positive to 1:10 wt/vol dilutions of MMR vaccine and gelatin but negative to egg. By immunoassay, her serum IgE antibodies were elevated to both MMR vaccine and gelatin, but not to isolated MMR antigens. IgE binding to the gelatin carrier could be inhibited in a dose-dependent fashion by addition of not only MMR vaccine but also gelatin from a variety of animal sources. Immunoblotting confirmed the presence of IgE antibodies to multiple gelatin components as well as to MMR vaccine components. Conclusions: We conclude that the patient has an anaphylactic sensitivity to gelatin, and that her anaphylaxis to MMR vaccine was caused by the gelatin component. This sensitivity may explain other cases of MMR anaphylaxis.	USN HOSP,DEPT INTERNAL MED,DIV ALLERGY,SAN DIEGO,CA 92134; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905	United States Department of Defense; United States Navy; Mayo Clinic	KELSO, JM (corresponding author), USN HOSP,DEPT CLIN INVEST,SAN DIEGO,CA 92134, USA.							Adolphson C. R., 1986, MANUAL CLIN LABORATO, P652; AUKRUST L, 1980, ALLERGY, V35, P581, DOI 10.1111/j.1398-9995.1980.tb01808.x; BECK SA, 1991, PEDIATRICS, V88, P913; BRUNO G, 1990, LANCET, V335, P739, DOI 10.1016/0140-6736(90)90863-Z; FASANO M B, 1991, Journal of Allergy and Clinical Immunology, V87, P175, DOI 10.1016/0091-6749(91)91430-2; FREEMAN MK, 1979, ANAESTHESIA, V34, P341, DOI 10.1111/j.1365-2044.1979.tb04933.x; GREENBERG MA, 1988, J PEDIATR-US, V113, P504, DOI 10.1016/S0022-3476(88)80639-5; HERMAN JJ, 1983, J PEDIATR-US, V102, P196, DOI 10.1016/S0022-3476(83)80519-8; KAMIN PB, 1963, JAMA-J AM MED ASSOC, V185, P647, DOI 10.1001/jama.1963.03060080043012; KAMIN PB, 1965, JAMA-J AM MED ASSOC, V193, P143; KEMP A, 1990, AM J DIS CHILD, V144, P33, DOI 10.1001/archpedi.1990.02150250039027; LAVI S, 1990, JAMA-J AM MED ASSOC, V263, P269, DOI 10.1001/jama.263.2.269; LORENZ W, 1976, BRIT J ANAESTH, V48, P151, DOI 10.1093/bja/48.2.151; LORENZ W, 1980, AGENTS ACTIONS, V10, P114, DOI 10.1007/BF02024192; LUND N, 1973, BRIT J ANAESTH, V45, P929, DOI 10.1093/bja/45.8.929; Lundsgaard-Hansen P, 1980, Dev Biol Stand, V48, P251; MCEWEN J, 1983, MED J AUSTRALIA, V2, P503, DOI 10.5694/j.1326-5377.1983.tb122619.x; MILLER JR, 1983, J ALLERGY CLIN IMMUN, V71, P568; NIEBURG PI, 1980, PEDIATRICS, V65, P365, DOI 10.1542/peds.65.2.365; Rietschel RL, 1981, JAMA-J AM MED ASSOC, V13, P245; RING J, 1977, LANCET, V1, P466; SADDLER JM, 1987, ANAESTHESIA, V42, P998, DOI 10.1111/j.1365-2044.1987.tb05376.x; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; VANASPEREN PP, 1981, MED J AUSTRALIA, V2, P330; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P535, DOI 10.1016/0091-6749(83)90433-5; WAHL R, 1989, CLIN EXP ALLERGY, V19, P77, DOI 10.1111/j.1365-2222.1989.tb02348.x; WISBORG K, 1973, BRIT J ANAESTH, V47, P1116; 1992, PHYSICIANS DESK REFE, P1494	28	167	176	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					867	872		10.1016/0091-6749(93)90344-F	http://dx.doi.org/10.1016/0091-6749(93)90344-F			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473675	Bronze			2022-12-18	WOS:A1993KY25100007
J	FALTHMAGNUSSON, K; KJELLMAN, NIM				FALTHMAGNUSSON, K; KJELLMAN, NIM			ALLERGY PREVENTION BY MATERNAL ELIMINATION DIET DURING LATE PREGNANCY - A 5-YEAR FOLLOW-UP OF A RANDOMIZED STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY PREVENTION; MATERNAL DIET	ATOPIC DISEASE; AVOIDANCE; LACTATION; INFANTS; MILK	The 209 mothers to be, enrolled in a randomized, prospective, allergy-prevention study from allergy-prone families, totally abstained from cow's milk and egg from gestational week 28 to delivery. This article presents the development of allergic disease at 5 years of age in their children, compared with the development of allergic disease in the children of the control mothers who took normal food throughout pregnancy. The prevalence of allergic disease could be evaluated in 198 children (95%). Allergic disease was monitored with questionnaires, skin prick testing, serum-IgE determinations, and physical examination. Eczema, allergic rhinoconjunctivitis, and asthma was equally common in the groups. Persistent food intolerance to egg was significantly more common in children of the mothers receiving the diet. This long-term follow-up confirms our previous findings that maternal elimination diet during late pregnancy does not prevent the development of allergic disease in the genetically predisposed child.			FALTHMAGNUSSON, K (corresponding author), LINKOPING UNIV, FAC HLTH SCI, DEPT PEDIAT, S-58185 LINKOPING, SWEDEN.							CHANDRA RK, 1986, CLIN ALLERGY, V16, P563, DOI 10.1111/j.1365-2222.1986.tb01995.x; FALTHMAGNUSSON K, 1987, ALLERGY, V42, P64, DOI 10.1111/j.1398-9995.1987.tb02189.x; FALTHMAGNUSSON K, 1989, ACTA PAEDIATR SCAND, P53; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P868, DOI 10.1016/S0091-6749(87)80279-8; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; LILJA G, 1988, CLIN ALLERGY, V18, P131, DOI 10.1111/j.1365-2222.1988.tb02852.x; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	10	167	172	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					709	713		10.1016/0091-6749(92)90378-F	http://dx.doi.org/10.1016/0091-6749(92)90378-F			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545092				2022-12-18	WOS:A1992HJ34000010
J	POLLART, SM; SMITH, TF; MORRIS, EC; GELBER, LE; PLATTSMILLS, TAE; CHAPMAN, MD				POLLART, SM; SMITH, TF; MORRIS, EC; GELBER, LE; PLATTSMILLS, TAE; CHAPMAN, MD			ENVIRONMENTAL EXPOSURE TO COCKROACH ALLERGENS - ANALYSIS WITH MONOCLONAL ANTIBODY-BASED ENZYME IMMUNOASSAYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HOUSEHOLD-DUST SAMPLES; MITE-ALLERGEN; RISK FACTOR; ASTHMA; SENSITIZATION; EPIDEMIOLOGY; ASSOCIATION; REACTIVITY; CHILDHOOD; AVOIDANCE	Quantitative two-site monoclonal antibody (MAb)-based enzyme-linked immunoassays for two cockroach (CR) allergens, Bla g I and Bla g II, have been developed and used to measure allergen levels in house-dust samples. Dust collected from the CR-infested homes of two patients with asthma from Charlottesville, Va., demonstrated wide variation in the levels of Bla g I, depending on the location of dust collection. Dust from kitchen floors and cabinets contained 50-fold more allergen (mean, 10,755 U/gm of dust) than dust from bedrooms and upholstered furniture (mean, 204 U/gm). One hundred forty-five dust samples were collected from the bedrooms and living rooms of 22 children with asthma and 16 control subjects without asthma living in Atlanta, Ga. Twenty-seven of the 38 homes (17/22 children with asthma; 10/16 control subjects) had detectable Bla g I (4 to 1340 U/gm of dust). Bla g II levels were assayed in 40 kitchen, bedroom, and living room samples from homes in Wilmington, Del. Highest levels of Bla g II were detected in kitchen-floor dust (300 U/gm of dust). Additionally, approximately 20% of homes with no visual evidence of CR infestation had significant levels of Bla g II in at least one dust sample (> 4 U/gm of dust). Our results demonstrate that CR may be an occult allergen in homes. The kitchen appears to be the primary site of CR-allergen accumulation, but significant CR-allergen levels can also be found at other sites in the home. The MAb-based assays can be used for quantitation of environmental exposure to CR allergens. MAbs should be very useful in epidemiologic studies to establish levels of CR-allergen exposure that should be considered as a risk factor for the development of allergic diseases, particularly asthma.	EMORY UNIV, SCH MED, DEPT PEDIAT, ATLANTA, GA 30322 USA	Emory University	POLLART, SM (corresponding author), UNIV VIRGINIA, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, BOX 225, CHARLOTTESVILLE, VA 22908 USA.			Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024687, R01AI020565, R37AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, AI-24687] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CHAPMAN MD, 1988, CHEST, V94, P185, DOI 10.1378/chest.94.1.185; GELBER L, 1990, Journal of Allergy and Clinical Immunology, V85, P193; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LOMBARDERO M, 1988, J IMMUNOL METHODS, V108, P71, DOI 10.1016/0022-1759(88)90404-8; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MORRIS EC, 1986, J ALLERGY CLIN IMMUN, V77, P206; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P199; WOOLCOCK AJ, 1983, EUR J RESPIR DIS, V64, P571	23	167	167	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					505	510		10.1016/0091-6749(91)90009-D	http://dx.doi.org/10.1016/0091-6749(91)90009-D			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993810				2022-12-18	WOS:A1991EX98700008
J	BROOKS, SM; MCGOWAN, K; BERNSTEIN, IL; ALTENAU, P; PEAGLER, J				BROOKS, SM; MCGOWAN, K; BERNSTEIN, IL; ALTENAU, P; PEAGLER, J			RELATIONSHIP BETWEEN NUMBERS OF BETA-ADRENERGIC RECEPTORS IN LYMPHOCYTES AND DISEASE SEVERITY IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI, COLL MED, KETTERING LAB, CINCINNATI, OH 45267 USA	University of Cincinnati	BROOKS, SM (corresponding author), UNIV CINCINNATI, COLL MED, DEPT ENVIRONM HLTH, DIV CLIN STUDIES, CINCINNATI, OH 45267 USA.							ALEXANDER W, 1975, P NATL ACAD SCI USA, V72, P1564; BERG DK, 1974, SCIENCE, V184, P473, DOI 10.1126/science.184.4135.473; BOSSE WW, 1976, J ALLERGY CLIN IMMUN, V58, P586; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROOKS SM, 1978, STATUS ASTHMATICUS, P115; CONALLY ME, 1976, J CLIN INVEST, V58, P1307; FIREMAN P, 1973, INT ARCH ALLER A IMM, V45, P123, DOI 10.1159/000231014; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GONZALEZMOLINA A, 1977, J CLIN INVEST, V59, P616, DOI 10.1172/JCI108679; HABER E, 1976, PHYSIOL REV, V56, P317, DOI 10.1152/physrev.1976.56.2.317; HOLGATE ST, 1977, LANCET, V2, P375; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; JENNE JW, 1978, J ALLERGY CLIN IMMUN, V60, P346; KAHN CR, 1977, ANN INTERN MED, V86, P205, DOI 10.7326/0003-4819-86-2-205; KAHN CR, 1976, J CELL BIOL, V70, P261, DOI 10.1083/jcb.70.2.261; KARIMAN K, 1977, CLIN RES, V25, pA503; LACKEY SD, 1967, J ALLERGY, V40, P349; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LEFKOWITZ RJ, 1976, NEW ENGL J MED, V295, P323, DOI 10.1056/NEJM197608052950607; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCIA CA, 1977, J ALLERGY CLIN IMMUN, V59, P101, DOI 10.1016/0091-6749(77)90210-X; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MORRIS HG, 1977, CLIN PHARMACOL THER, V22, P352; MORRIS HG, 1977, J CYCLIC NUCL PROT, V3, P439; MUKHERJEE C, 1976, ENDOCRINOLOGY, V99, P347, DOI 10.1210/endo-99-2-347; MUKHERJEE C, 1975, J BIOL CHEM, V250, P4869; MUKHERJEE C, 1975, P NATL ACAD SCI USA, V72, P145; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; NIAUDET P, 1976, EUR J IMMUNOL, V6, P834, DOI 10.1002/eji.1830061117; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; REED CE, 1970, J ALLERGY, V46, P90, DOI 10.1016/0021-8707(70)90076-6; REED CE, 1968, J ALLERGY, V42, P238, DOI 10.1016/S0021-8707(68)90119-6; SAXON A, 1978, J CLIN INVEST, V61, P922, DOI 10.1172/JCI109017; SCHIMKE RT, 1975, METHODS MEMBRANE BIO, V3, P201; SHEPPARD JR, 1977, NATURE, V269, P693, DOI 10.1038/269693a0; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TOWNLEY RG, 1970, J ALLERGY, V45, P71; WILLIAMS LT, 1976, J CLIN INVEST, V57, P149, DOI 10.1172/JCI108254	41	167	167	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	6					401	406		10.1016/0091-6749(79)90213-6	http://dx.doi.org/10.1016/0091-6749(79)90213-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GY514	221557				2022-12-18	WOS:A1979GY51400006
J	AAS, K; JOHANSSON, SG				AAS, K; JOHANSSON, SG			RADIOALLERGOSORBENT TEST IN IN-VITRO DIAGNOSIS OF MULTIPLE REAGINIC ALLERGY - COMPARISON OF DIAGNOSTIC APPROACHES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AAS K, 1970, ARCH DIS CHILD, V45, P221, DOI 10.1136/adc.45.240.221; AAS K, 1967, INT ARCH ALLER A IMM, V32, P1, DOI 10.1159/000229911; AAS K, 1966, INT ARCH ALLER A IMM, V29, P346, DOI 10.1159/000229716; AAS K, 1969, ARCH DIS CHILD, V44, P1, DOI 10.1136/adc.44.233.1; AAS K, 1971, 10 SCAND C ALL STOCK; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BERG T, IN PRESS; COLLDAHL HELGE, 1952, ACTA ALLERGOL, V5, P133, DOI 10.1111/j.1398-9995.1952.tb03444.x; FAGERBERG E, 1970, INT ARCH ALLER A IMM, V39, P301, DOI 10.1159/000230356; FRIEDEWALD VE, 1952, J ALLERGY, V23, P420, DOI 10.1016/0021-8707(52)90005-1; HORESH AJ, 1959, PEDIATR CLIN N AM, V6, P663; Johansson S., IN PRESS; KIM CJ, 1965, J ALLERGY, V36, P353, DOI 10.1016/0021-8707(65)90042-0; MILLER MW, 1965, MED CLIN N AM, V49, P1415, DOI 10.1016/S0025-7125(16)33274-6; PARISH WE, 1970, LANCET, V2, P791; RIPE E, 1967, ACTA ALLERGOL, VS 22, P103; SOBEL G, 1962, J ALLERGY, V33, P432, DOI 10.1016/0021-8707(62)90048-5; STENIUS B, 1969, LANCET, V2, P455; WIDE L, 1967, LANCET, V2, P105; WILKENJENSEN K, 1959, INT TEXTBOOK ALLERGY, P120	20	167	167	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	3					134	+		10.1016/0091-6749(71)90008-X	http://dx.doi.org/10.1016/0091-6749(71)90008-X			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K3234	5284939	Bronze			2022-12-18	WOS:A1971K323400002
J	Trouillet-Assant, S; Viel, S; Gaymard, A; Pons, S; Richard, JC; Perret, M; Villard, M; Brengel-Pesce, K; Lina, B; Mezidi, M; Bitker, L; Belot, A				Trouillet-Assant, Sophie; Viel, Sebastien; Gaymard, Alexandre; Pons, Sylvie; Richard, Jean-Christophe; Perret, Magali; Villard, Marine; Brengel-Pesce, Karen; Lina, Bruno; Mezidi, Mehdi; Bitker, Laurent; Belot, Alexandre		COVID HCL Study Grp	Type I IFN immunoprofiling in COVID-19 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTERFERON		[Trouillet-Assant, Sophie; Pons, Sylvie; Brengel-Pesce, Karen] Lyon Sud Hosp, Hosp Civils Lyon, Hosp Civils Lyon bioMerieux, Joint Res Unit, Pierre Benite, France; [Trouillet-Assant, Sophie; Viel, Sebastien; Gaymard, Alexandre; Perret, Magali; Villard, Marine; Lina, Bruno; Belot, Alexandre] Lyon Univ, Int Ctr Res Infectiol, INSERM U1111, CNRS UMR 5308,ENS,UCBL, Lyon, France; [Viel, Sebastien; Perret, Magali; Villard, Marine] Lyon Sud Hosp, Hosp Civils Lyon, Immunol Lab, Pierre Benite, France; [Viel, Sebastien; Belot, Alexandre] Natl Referee Ctr Rheumat & AutoImmune & Syst Dis, Lyon, France; [Viel, Sebastien; Belot, Alexandre] Hosp Civils Lyon, Lyon Immunopathol Federat LIFE, Lyon, France; [Gaymard, Alexandre; Lina, Bruno] North Hosp Network, Natl Reference Ctr Resp Viruses, Infect Agents Inst, Dept Virol, Lyon, France; [Richard, Jean-Christophe; Mezidi, Mehdi; Bitker, Laurent] Lyon Univ, CREATIS, CNRS UMR5220, Inserm U1044,INSA, Lyon, France; [Richard, Jean-Christophe; Mezidi, Mehdi; Bitker, Laurent] Hosp Civils Lyon, Intens Care Unit, Lyon, France; [Belot, Alexandre] Hosp Civils Lyon, Pediat Nephrol, Rheumatol, Dermatol Unit, Lyon, France	CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; CHU Lyon; CHU Lyon	Trouillet-Assant, S (corresponding author), Lyon Sud Hosp, Hosp Civils Lyon, Hosp Civils Lyon bioMerieux, Joint Res Unit, Pierre Benite, France.; Trouillet-Assant, S; Belot, A (corresponding author), Lyon Univ, Int Ctr Res Infectiol, INSERM U1111, CNRS UMR 5308,ENS,UCBL, Lyon, France.; Belot, A (corresponding author), Natl Referee Ctr Rheumat & AutoImmune & Syst Dis, Lyon, France.; Belot, A (corresponding author), Hosp Civils Lyon, Lyon Immunopathol Federat LIFE, Lyon, France.; Belot, A (corresponding author), Hosp Civils Lyon, Pediat Nephrol, Rheumatol, Dermatol Unit, Lyon, France.	sophie.assant@chu-lyon.fr; alexandre.belot@chu-lyon.fr	Belot, Alexandre/C-7378-2013; Viel, Sebastien/A-7258-2016; Bitker, Laurent/V-9330-2018; RICHARD, Jean-Christophe/A-4097-2009; Gaymard, Alexandre/J-2622-2019; Walzer, Thierry/L-9418-2014	Belot, Alexandre/0000-0003-4902-5332; Viel, Sebastien/0000-0002-5085-443X; Bitker, Laurent/0000-0002-4698-053X; RICHARD, Jean-Christophe/0000-0003-1503-3035; Gaymard, Alexandre/0000-0002-8194-6126; Walzer, Thierry/0000-0002-0857-8179; Valour, Florent/0000-0002-1467-6162; lina, bruno/0000-0002-8959-2123; VILLARD, Marine/0000-0002-3905-8993; PONS, SYLVIE/0000-0002-6286-0546; Bal, Antonin/0000-0002-0261-2495				Alevy YG, 2012, J CLIN INVEST, V122, P4555, DOI 10.1172/JCI64896; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Liu RJ, 2015, NUCLEIC ACIDS RES, V43, pE97, DOI 10.1093/nar/gkv412; Lokugamage K.G., 2020, J VIROL, V2020, DOI [10.1101/2020.03.07.982264, DOI 10.1101/2020.03.07.982264]; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodero MP, 2017, J EXP MED, V214, P1547, DOI 10.1084/jem.20161451; Smedley D, 2015, NUCLEIC ACIDS RES, V43, pW589, DOI 10.1093/nar/gkv350; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Trouillet-Assant S, 2020, CLIN CHEM, V66, P802, DOI 10.1093/clinchem/hvaa089	12	166	169	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					206	+		10.1016/j.jaci.2020.04.029	http://dx.doi.org/10.1016/j.jaci.2020.04.029			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32360285	Green Published, Bronze			2022-12-18	WOS:000579170500030
J	MacGinnitie, AJ; Rachid, R; Gragg, H; Little, SV; Lakin, P; Cianferoni, A; Heimall, J; Makhija, M; Robison, R; Chinthrajah, RS; Lee, J; Lebovidge, J; Dominguez, T; Rooney, C; Lewis, MO; Koss, J; Burke-Roberts, E; Chin, K; Logvinenko, T; Pongracic, JA; Umetsu, DT; Spergel, J; Nadeau, KC; Schneider, LC				MacGinnitie, Andrew J.; Rachid, Rima; Gragg, Hana; Little, Sara V.; Lakin, Paul; Cianferoni, Antonella; Heimall, Jennifer; Makhija, Melanie; Robison, Rachel; Chinthrajah, R. Sharon; Lee, John; Lebovidge, Jennifer; Dominguez, Tina; Rooney, Courtney; Lewis, Megan Ott; Koss, Jennifer; Burke-Roberts, Elizabeth; Chin, Kimberly; Logvinenko, Tanya; Pongracic, Jacqueline A.; Umetsu, Dale T.; Spergel, Jonathan; Nadeau, Kari C.; Schneider, Lynda C.			Omalizumab facilitates rapid oral desensitization for peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; food allergy; desensitization; omalizumab	FOOD ALLERGY; DOUBLE-BLIND; EOSINOPHILIC ESOPHAGITIS; TOLERANCE INDUCTION; IGE LEVELS; ANTI-IGE; IMMUNOTHERAPY; CHILDREN; EGG; CHALLENGE	Background: Peanut oral immunotherapy is a promising approach to peanut allergy, but reactions are frequent, and some patients cannot be desensitized. The anti-IgE medication omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more rapid peanut updosing and decrease reactions. Objective: We sought to evaluate whether omalizumab facilitated rapid peanut desensitization in highly allergic patients. Methods: Thirty-seven subjects were randomized to omalizumab (n = 29) or placebo (n = 8). After 12 weeks of treatment, subjects underwent a rapid 1-day desensitization of up to 250 mg of peanut protein, followed by weekly increases up to 2000 mg. Omalizumab was then discontinued, and subjects continued on 2000 mg of peanut protein. Subjects underwent an open challenge to 4000 mg of peanut protein 12 weeks after stopping study drug. If tolerated, subjects continued on 4000 mg of peanut protein daily. Results: The median peanut dose tolerated on the initial desensitization day was 250 mg for omalizumab-treated subjects versus 22.5 mg for placebo-treated subject. Subsequently, 23 (79%) of 29 subjects randomized to omalizumab tolerated 2000 mg of peanut protein 6 weeks after stopping omalizumab versus 1 (12%) of 8 receiving placebo (P < .01). Twenty-three subjects receiving omalizumab versus 1 subject receiving placebo passed the 4000-mg food challenge. Overall reaction rates were not significantly lower in omalizumab-treated versus placebo-treated subjects (odds ratio, 0.57; P = .15), although omalizumab-treated subjects were exposed to much higher peanut doses. Conclusion: Omalizumab allows subjects with peanut allergy to be rapidly desensitized over as little as 8 weeks of peanut oral immunotherapy. In the majority of subjects, this desensitization is sustained after omalizumab is discontinued. Additional studies will help clarify which patients would benefit most from this approach.	[MacGinnitie, Andrew J.; Rachid, Rima; Little, Sara V.; Lee, John; Lebovidge, Jennifer; Burke-Roberts, Elizabeth; Schneider, Lynda C.] Boston Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA; [Gragg, Hana; Lakin, Paul; Chin, Kimberly; Logvinenko, Tanya] Boston Childrens Hosp, Clin Res Ctr, Boston, MA USA; [Cianferoni, Antonella; Heimall, Jennifer; Rooney, Courtney; Lewis, Megan Ott; Spergel, Jonathan] Childrens Hosp Philadelphia, Div Allergy, Philadelphia, PA 19104 USA; [Makhija, Melanie; Robison, Rachel; Chin, Kimberly; Logvinenko, Tanya] Ann & Robert H Lurie Childrens Hosp Chicago, Div Allergy, Chicago, IL 60611 USA; [Chinthrajah, R. Sharon; Dominguez, Tina; Nadeau, Kari C.] Lucille Packard Childrens Hosp, Div Allergy Immunol & Rheumatol, Palo Alto, CA USA; [Umetsu, Dale T.] Genentech Inc, San Francisco, CA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Ann & Robert H. Lurie Children's Hospital of Chicago; Lucile Packard Children's Hospital (LPCH); Roche Holding; Genentech	Schneider, LC (corresponding author), Boston Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	Lynda.Schneider@childrens.harvard.edu	Schneider, Lynda C/AAY-6545-2021	Schneider, Lynda C/0000-0002-5633-0178; Robison, Rachel/0000-0003-0160-0529; Little, Sara/0000-0003-3908-593X; Chinthrajah, Sharon/0000-0003-2467-4256	Food Allergy Research & Education (FARE); Bunning Food Allergy Project; Genentech; Harvard Catalyst/Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award) [UL1 TR001102]; arvard University and its affiliated academic health care centers; Sean N Parker Center for Allergy and Asthma Research at Stanford University [U19AI1042090]; Myra Reinhard Foundation; Stuart Starr Endowed Chair of Pediatrics; Children's Hospital of Philadelphia Food Allergy Research Fund; National Center for Research Resources [UL1RR024134]; National Center for Advancing Translational Sciences [UL1TR000003]; National Center for Advancing Translational Science (NCATS) [8UL1TR000150]; National Institutes of Health and the Bunning Food Allergy Project; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000003, UL1TR001102, UL1TR000150, UL1TR001422] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104209] Funding Source: NIH RePORTER	Food Allergy Research & Education (FARE); Bunning Food Allergy Project; Genentech(Roche HoldingGenentech); Harvard Catalyst/Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award); arvard University and its affiliated academic health care centers; Sean N Parker Center for Allergy and Asthma Research at Stanford University; Myra Reinhard Foundation; Stuart Starr Endowed Chair of Pediatrics; Children's Hospital of Philadelphia Food Allergy Research Fund; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Advancing Translational Science (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institutes of Health and the Bunning Food Allergy Project(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding for this study was provided by Food Allergy Research & Education (FARE), the Bunning Food Allergy Project, and Genentech. This work was conducted with support from Harvard Catalyst/Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health care centers. Funding was also provided by the Sean N Parker Center for Allergy and Asthma Research at Stanford University (grant U19AI1042090) and the Myra Reinhard Foundation. J. S. is supported by Stuart Starr Endowed Chair of Pediatrics. Work at Children's Hospital of Philadelphia was funded by the Children's Hospital of Philadelphia Food Allergy Research Fund and the project described was supported by the National Center for Research Resources (grant UL1RR024134) and is now at the National Center for Advancing Translational Sciences (grant UL1TR000003). Work at Ann and Robert H. Lurie Children's Hospital of Chicago was supported in part by 8UL1TR000150 from the National Center for Advancing Translational Science (NCATS) and National Institutes of Health and the Bunning Food Allergy Project. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health.	Anagnostou K, 2011, CLIN EXP ALLERGY, V41, P1273, DOI 10.1111/j.1365-2222.2011.03699.x; Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Baptiste A, 2012, GRIDEXTRA FUNCTIONS; Bedoret D, 2012, MUCOSAL IMMUNOL, V5, P267, DOI 10.1038/mi.2012.5; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-1; Bird JA, 2015, J ALLER CL IMM-PRACT, V3, P433, DOI 10.1016/j.jaip.2014.11.020; Bird JA, 2015, J ALLER CL IMM-PRACT, V3, P1, DOI 10.1016/j.jaip.2014.06.008; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Bunyavanich S, 2014, J ALLERGY CLIN IMMUN, V134, P753, DOI 10.1016/j.jaci.2014.05.050; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Cancer Therapy Evaluation Program, 2010, COMM TERM CRIT ADV E; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; Corren J, 2008, J ALLERGY CLIN IMMUN, V121, P506, DOI 10.1016/j.jaci.2007.11.026; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Dyer AA, 2015, ALLERGY ASTHMA PROC, V36, P58, DOI 10.2500/aap.2015.36.3819; Fried AJ, 2010, CURR OPIN PEDIATR, V22, P758, DOI 10.1097/MOP.0b013e3283404201; Hendeles L, 2007, ANN PHARMACOTHER, V41, P1397, DOI 10.1345/aph.1K005; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Kostadinova AI, 2013, PEDIAT ALLERG IMM-UK, V24, P633, DOI 10.1111/pai.12122; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lieberman JA, 2011, CURR OPIN ALLERGY CL, V11, P236, DOI 10.1097/ACI.0b013e3283464cf0; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Lucendo AJ, 2014, ANN ALLERG ASTHMA IM, V113, P624, DOI 10.1016/j.anai.2014.08.004; Meglio P, 2013, PEDIAT ALLERG IMM-UK, V24, P75, DOI 10.1111/j.1399-3038.2012.01341.x; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; R Development Core Team, 2016, R FDN STAT COMP, DOI DOI 10.1007/978-3-540-74686-7; Rinaldi M, 2012, J ALLERGY CLIN IMMUN, V130, P945, DOI 10.1016/j.jaci.2012.07.042; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P625, DOI 10.1016/j.jaci.2009.08.025; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vazquez-Ortiz M, 2014, CLIN EXP ALLERGY, V44, P130, DOI 10.1111/cea.12233; Vazquez-Ortiz M, 2013, CLIN EXP ALLERGY, V43, P92, DOI 10.1111/cea.12012; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P973, DOI 10.1016/j.jaci.2016.01.001; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005; Wood RA, 2014, J ALLER CL IMM-PRACT, V2, P97, DOI 10.1016/j.jaip.2013.11.010	52	166	170	2	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					873	+	0091-6749	10.1016/j.jaci.2016.08.010	http://dx.doi.org/10.1016/j.jaci.2016.08.010			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27609658	Green Accepted, Bronze			2022-12-18	WOS:000397295800020
J	Kanemitsu, Y; Matsumoto, H; Izuhara, K; Tohda, Y; Kita, H; Horiguchi, T; Kuwabara, K; Tomii, K; Otsuka, K; Fujimura, M; Ohkura, N; Tomita, K; Yokoyama, A; Ohnishi, H; Nakano, Y; Oguma, T; Hozawa, S; Nagasaki, T; Ito, I; Oguma, T; Inoue, H; Tajiri, T; Iwata, T; Izuhara, Y; Ono, J; Ohta, S; Tamari, M; Hirota, T; Yokoyama, T; Niimi, A; Mishima, M				Kanemitsu, Yoshihiro; Matsumoto, Hisako; Izuhara, Kenji; Tohda, Yuji; Kita, Hideo; Horiguchi, Takahiko; Kuwabara, Kazunobu; Tomii, Keisuke; Otsuka, Kojiro; Fujimura, Masaki; Ohkura, Noriyuki; Tomita, Katsuyuki; Yokoyama, Akihito; Ohnishi, Hiroshi; Nakano, Yasutaka; Oguma, Tetsuya; Hozawa, Soichiro; Nagasaki, Tadao; Ito, Isao; Oguma, Tsuyoshi; Inoue, Hideki; Tajiri, Tomoko; Iwata, Toshiyuki; Izuhara, Yumi; Ono, Junya; Ohta, Shoichiro; Tamari, Mayumi; Hirota, Tomomitsu; Yokoyama, Tetsuji; Niimi, Akio; Mishima, Michiaki			Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; inhaled corticosteroids; lung function decline; periostin; POSTN gene polymorphism; sinusitis; treatment step	LUNG-FUNCTION DECLINE; SEVERE EXACERBATIONS; ALLERGIC RHINITIS; BRONCHIAL-ASTHMA; FOLLOW-UP; INFLAMMATION; ADULTS; EXPRESSION; SINUSITIS; BIOMARKER	Background: Periostin, an extracellular matrix protein, contributes to subepithelial thickening in asthmatic airways, and its serum levels reflect airway eosinophilic inflammation. However, the relationship between periostin and the development of airflow limitation, a functional consequence of airway remodeling, remains unknown. Objective: We aimed to determine the relationship between serum periostin levels and pulmonary function decline in asthmatic patients on inhaled corticosteroid (ICS) treatment. Methods: Two hundred twenty-four asthmatic patients (average age, 62.3 years) treated with ICS for at least 4 years were enrolled. Annual changes in FEV1, from at least 1 year after the initiation of ICS treatment to the time of enrollment or later (average, 16.2 measurements over 8 years per individual), were assessed. At enrollment, clinical indices, biomarkers that included serum periostin, and periostin gene polymorphisms were examined. Associations between clinical indices or biomarkers and a decline in FEV1 of 30 mL or greater per year were analyzed. Results: High serum periostin levels (>= 95 ng/mL) at enrollment, the highest treatment step, higher ICS daily doses, a history of admission due to asthma exacerbation, comorbid or a history of sinusitis, and ex-smoking were associated with a decline in FEV1 of 30 mL or greater per year. Multivariate analysis showed that high serum periostin, the highest treatment step, and ex-smoking were independent risk factors for the decline. Polymorphisms of periostin gene were related to higher serum periostin levels (rs3829365) and a decline in FEV1 of 30 mL or greater per year (rs9603226). Conclusions: Serum periostin appears to be a useful biomarker for the development of airflow limitation in asthmatic patients on ICS.	[Kanemitsu, Yoshihiro; Matsumoto, Hisako; Otsuka, Kojiro; Nagasaki, Tadao; Ito, Isao; Oguma, Tsuyoshi; Inoue, Hideki; Tajiri, Tomoko; Iwata, Toshiyuki; Izuhara, Yumi; Niimi, Akio; Mishima, Michiaki] Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto 6068507, Japan; [Kanemitsu, Yoshihiro; Matsumoto, Hisako; Tohda, Yuji; Kita, Hideo; Horiguchi, Takahiko; Kuwabara, Kazunobu; Tomii, Keisuke; Otsuka, Kojiro; Fujimura, Masaki; Ohkura, Noriyuki; Tomita, Katsuyuki; Yokoyama, Akihito; Ohnishi, Hiroshi; Nakano, Yasutaka; Oguma, Tetsuya; Hozawa, Soichiro; Niimi, Akio; Mishima, Michiaki] Kinki Hokuriku Airway Dis Conf KiHAC, Osaka, Japan; [Izuhara, Kenji] Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga, Japan; [Tohda, Yuji; Tomita, Katsuyuki] Kinki Univ, Fac Med, Dept Resp Med & Allergol, Osaka, Japan; [Kita, Hideo] Takatsuki Red Cross Hosp, Dept Resp Med, Osaka, Japan; [Horiguchi, Takahiko; Kuwabara, Kazunobu] Fujita Hlth Univ, Educ Hosp 2, Dept Resp Internal Med, Toyoake, Aichi, Japan; [Tomii, Keisuke; Otsuka, Kojiro] Gen Hosp, Kobe City Med Ctr, Dept Resp Med, Kobe, Hyogo, Japan; [Fujimura, Masaki; Ohkura, Noriyuki] Kanazawa Univ, Grad Sch Med, Dept Resp Med, Kanazawa, Ishikawa, Japan; [Yokoyama, Akihito; Ohnishi, Hiroshi] Kochi Univ, Dept Hematol & Resp Med, Kochi 780, Japan; [Nakano, Yasutaka; Oguma, Tetsuya] Shiga Univ Med Sci, Dept Internal Med, Div Resp Med, Otsu, Shiga, Japan; [Hozawa, Soichiro] Hiroshima Allergy & Resp Clin, Hiroshima, Japan; [Ono, Junya] Shinotest Corp, Kanagawa, Japan; [Ohta, Shoichiro] Saga Med Sch, Dept Lab Med, Saga, Japan; [Tamari, Mayumi; Hirota, Tomomitsu] RIKEN, Ctr Genom Med, Lab Resp Dis, Yokohama, Kanagawa, Japan; [Yokoyama, Tetsuji] Natl Inst Publ Hlth, Dept Hlth Promot, Wako, Saitama 3510197, Japan; [Niimi, Akio] Nagoya City Univ, Sch Med Sci, Dept Med Oncol & Immunol, Nagoya, Aichi, Japan	Kyoto University; Saga University; Kindai University (Kinki University); Fujita Health University; Kobe City Medical Center General Hospital; Kanazawa University; Kochi University; Shiga University of Medical Science; Saga University; RIKEN; National Institute of Public Health - Japan; Nagoya City University	Matsumoto, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Resp Med, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	hmatsumo@kuhp.kyoto-u.ac.jp	Tamari, Mayumi/N-5378-2015	Ohkura, Noriyuki/0000-0002-6155-5101; Inoue, Hideki/0000-0002-8624-6524; Ohnishi, Hiroshi/0000-0002-7863-4519; Ito, Isao/0000-0003-3109-898X	Ono Pharm; Novartis; AstraZeneca; Kyorin; GlaxoSmithKline; Teijin Pharm; Merk Sharp Dohme; Boehringer Ingelheim; Astellas; Nippon Boehringer Ingelheim; Sanofi Aventis; Grants-in-Aid for Scientific Research [24591466] Funding Source: KAKEN	Ono Pharm; Novartis(Novartis); AstraZeneca(AstraZeneca); Kyorin; GlaxoSmithKline(GlaxoSmithKline); Teijin Pharm; Merk Sharp Dohme; Boehringer Ingelheim(Boehringer Ingelheim); Astellas(Astellas Pharmaceuticals); Nippon Boehringer Ingelheim(Boehringer Ingelheim); Sanofi Aventis(Sanofi-Aventis); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	K. Izuhara has consultant arrangements with Chugai Pharmaceutical Company and has a patent with F. Hoffmann-LaRoche Ltd. A. Yokoyama has received grants from Ono Pharm, Novartis, AstraZeneca, Kyorin, GlaxoSmithKline, and Teijin Pharm and has received payment for lectures from Ono Pharm, Novartis, AstraZeneca, Kyorin, GlaxoSmithKline, Merk Sharp & Dohme, and Boehringer Ingelheim. H. Ohnishi has received payment for lectures from GlaxoSmithKline, Astellas, and AstraZeneca. Y. Nakano has received payment for lectures from Nippon Boehringer Ingelheim. Tsuyoshi Oguma has received payment for lectures from GlaxoSmithKline and AstraZeneca. M. Tamari has received payment for lectures from GlaxoSmithKline, Boehringer Ingelheim, and Sanofi Aventis. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Broekema M, 2010, RESP MED, V104, P1254, DOI 10.1016/j.rmed.2010.03.030; Chaudhuri R, 2006, AM J RESP CRIT CARE, V174, P127, DOI 10.1164/rccm.200510-1589OC; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; de Marco R, 2007, J ALLERGY CLIN IMMUN, V119, P611, DOI 10.1016/j.jaci.2006.11.696; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Dixon AE, 2006, CHEST, V130, P429, DOI 10.1378/chest.130.2.429; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; GINA, 2010, GLOB STRAT ASTHM MAN; Gordon ED, 2012, CLIN EXP ALLERGY, V42, P144, DOI 10.1111/j.1365-2222.2011.03840.x; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Ishida A, 2012, ALLERGOL INT, V61, P589, DOI 10.2332/allergolint.11-OA-0370; Japanese Society of Allergology, 2012, ASTHM PREV MAN GUID; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Kii I, 2010, J BIOL CHEM, V285, P2028, DOI 10.1074/jbc.M109.051961; Koppelman GH, 2011, J ALLERGY CLIN IMMUN, V128, P479, DOI 10.1016/j.jaci.2011.05.036; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Levine SJ, 2010, ANN INTERN MED, V152, P232, DOI 10.7326/0003-4819-152-4-201002160-00008; Mascia K, 2005, ANN ALLERG ASTHMA IM, V94, P652, DOI 10.1016/S1081-1206(10)61323-3; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; Norris RA, 2007, J CELL BIOCHEM, V101, P695, DOI 10.1002/jcb.21224; O'Byrne PM, 2006, CHEST, V129, P1478, DOI 10.1378/chest.129.6.1478; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Okamoto M, 2011, EUR RESPIR J, V37, P1119, DOI 10.1183/09031936.00059810; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Sehra S, 2011, J IMMUNOL, V186, P4959, DOI 10.4049/jimmunol.1002359; Selroos O, 2004, RESP MED, V98, P254, DOI 10.1016/j.rmed.2003.10.007; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; Ueda T, 2006, J ALLERGY CLIN IMMUN, V118, P1019, DOI 10.1016/j.jaci.2006.07.032; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; van Veen IH, 2008, EUR RESPIR J, V32, P344, DOI 10.1183/09031936.00135907; Wang ML, 2000, AM J RESP CRIT CARE, V162, P2134, DOI 10.1164/ajrccm.162.6.2003171; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	47	166	172	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					305	+		10.1016/j.jaci.2013.04.050	http://dx.doi.org/10.1016/j.jaci.2013.04.050			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23791506	Bronze, Green Submitted, Green Published			2022-12-18	WOS:000322631700006
J	Durrani, SR; Montville, DJ; Pratt, AS; Sahu, S; DeVries, MK; Rajamanickam, V; Gangnon, RE; Gill, MA; Gern, JE; Lemanske, RF; Jackson, DJ				Durrani, Sandy R.; Montville, Daniel J.; Pratt, Allison S.; Sahu, Sanjukta; DeVries, Mark K.; Rajamanickam, Victoria; Gangnon, Ronald E.; Gill, Michelle A.; Gern, James E.; Lemanske, Robert F., Jr.; Jackson, Daniel J.			Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic; rhinovirus; interferon; Fc epsilon RI; IgE receptor; plasmacytoid dendritic cells	FC-EPSILON-RI; HOSPITAL ADMISSIONS; PERSISTENT ASTHMA; VIRAL-INFECTIONS; DENDRITIC CELLS; ATOPY; EXACERBATIONS; SENSITIZATION	Background: Children with allergic asthma have more frequent and severe human rhinovirus (HRV)-induced wheezing and asthma exacerbations through unclear mechanisms. Objective: We sought to determine whether increased high-affinity IgE receptor (Fc epsilon RI) expression and cross-linking impairs innate immune responses to HRV, particularly in allergic asthmatic children. Methods: PBMCs were obtained from 44 children, and surface expression of Fc epsilon RI on plasmacytoid dendritic cells (pDCs), myeloid dendritic cells, monocytes, and basophils was assessed by using flow cytometry. Cells were also incubated with rabbit anti-human IgE to cross-link Fc epsilon RI, followed by stimulation with HRV-16, and IFN-alpha and IFN-lambda 1 production was measured by Luminex. The relationships among Fc epsilon RI expression and cross-linking, HRV-induced IFN-alpha and IFN-lambda 1 production, and childhood allergy and asthma were subsequently analyzed. Results: Fc epsilon RI alpha expression on pDCs was inversely associated with HRV-induced IFN-alpha and IFN-lambda 1 production. Cross-linking Fc epsilon RI before HRV stimulation further reduced PBMC IFN-alpha (47% relative reduction; 95% CI, 32% to 62%; P < .0001) and IFN-lambda 1 ( 81% relative reduction; 95% CI, 69% to 93%; P < .0001) secretion. Allergic asthmatic children had higher surface expression of Fc epsilon RIa on pDCs and myeloid dendritic cells when compared with that seen in nonallergic nonasthmatic children. Furthermore, after Fc epsilon RI cross-linking, allergic asthmatic children had significantly lower HRV-induced IFN responses than allergic nonasthmatic children (IFN-alpha, P = .004; IFN-lambda 1, P = .02) and nonallergic nonasthmatic children ( IFN-alpha, P = .002; IFN-lambda 1, P = .01). Conclusions: Allergic asthmatic children have impaired innate immune responses to HRV that correlate with increased Fc epsilon RI expression on pDCs and are reduced by Fc epsilon RI cross-linking. These effects likely increase susceptibility to HRV-induced wheezing and asthma exacerbations. (J Allergy Clin Immunol 2012; 130:489-95.)	[Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Sect Allergy Immunol & Rheumatol,Clin Sci Ctr K4, Madison, WI 53792 USA; [Durrani, Sandy R.; Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA; [Rajamanickam, Victoria; Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat, Madison, WI 53792 USA; [Gill, Michelle A.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Southwestern Medical Center Dallas	Jackson, DJ (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Sect Allergy Immunol & Rheumatol,Clin Sci Ctr K4, 600 Highland Ave, Madison, WI 53792 USA.	djj@medicine.wisc.edu		Gangnon, Ronald/0000-0003-2587-6714	National Institutes of Health from Clinical and Translational Science Award (CTSA) of National Center for Research Resources (NCRR) [R01 HL61879, P01 HL70831, M01 RR03186, T32 AI007635]; American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline Career Development Award; National Institutes of Health (NIH); GlaxoSmithKline; Biota; Centocor; Boehringer Ingelheim; MedImmune; Gilead; Theraclone; Synairgen; Pulmatrix; Merck; AstraZeneca; National Heart, Lung, and Blood Institute; SA Boney and Associates; Strategic Pharmaceutical Advisors; ICON Clinical Research; Pharmaxis; Colorado Allergy Society; Pennsylvania Allergy Society, Harvard Pilgrim Health Care; California Allergy Society, West Pennsylvania Allegheny Health Systems; American College of Chest Physicians; American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, M01RR003186, KL2RR025012] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061879, P01HL070831] Funding Source: NIH RePORTER	National Institutes of Health from Clinical and Translational Science Award (CTSA) of National Center for Research Resources (NCRR); American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline Career Development Award; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); Biota; Centocor; Boehringer Ingelheim(Boehringer Ingelheim); MedImmune(AstraZenecaMedimmune); Gilead(Gilead Sciences); Theraclone; Synairgen; Pulmatrix; Merck(Merck & Company); AstraZeneca(AstraZeneca); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); SA Boney and Associates; Strategic Pharmaceutical Advisors; ICON Clinical Research; Pharmaxis; Colorado Allergy Society; Pennsylvania Allergy Society, Harvard Pilgrim Health Care; California Allergy Society, West Pennsylvania Allegheny Health Systems; American College of Chest Physicians(General Electric); American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline(GlaxoSmithKline); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grants 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources (NCRR), R01 HL61879, P01 HL70831, M01 RR03186, and T32 AI007635 and an American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline Career Development Award.; S. R. Durrani, D. J. Montville, A. S. Pratt, S. Sahu, M. K. DeVries, V. Rajamanickam, and R. E. Gangnon have received research support from the National Institutes of Health (NIH). M. A. Gill has received research support from the NIH; is employed by the University of Texas Southwestern Medical Center; and has received an honorarium from the Journal of Allergy and Clinical Immunology for preparing a review article. J. E. Gern is on the 3V BioSciences Board; has received consultancy fees from GlaxoSmithKline, Biota, Centocor, Boehringer Ingelheim, MedImmune, Gilead, Theraclone, Synairgen, and Pulmatrix; has received research support from Merck, AstraZeneca, and GlaxoSmithKline; and has stock options in 3V BioSciences. R. F. Lemanske has received research support, travel support, and a research coordinator's salary from the National Heart, Lung, and Blood Institute; has received consultancy fees from SA Boney and Associates, GlaxoSmithKline, Merck, Strategic Pharmaceutical Advisors, and ICON Clinical Research; is employed by the University of Wisconsin School of Medicine and Public Health; has received research support from Pharmaxis, the Colorado Allergy Society, the Pennsylvania Allergy Society, Harvard Pilgrim Health Care, the California Allergy Society, West Pennsylvania Allegheny Health Systems, and the American College of Chest Physicians; and has received royalties from Elsevier and UpToDate. D. J. Jackson has received research support from the NIH, the American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline, and Pharmaxis and has received consultancy fees from Gilead.	Barchet W, 2005, IMMUNOL RES, V32, P75, DOI 10.1385/IR:32:1-3:075; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cao W, 2007, PLOS BIOL, V5, P2190, DOI 10.1371/journal.pbio.0050248; Cao W, 2006, J EXP MED, V203, P1399, DOI 10.1084/jem.20052454; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Gottenberg JE, 2006, P NATL ACAD SCI USA, V103, P2770, DOI 10.1073/pnas.0510837103; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; McDonnell JM, 2001, NAT STRUCT BIOL, V8, P437, DOI 10.1038/87603; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Ronnblom L, 2008, LUPUS, V17, P394, DOI 10.1177/0961203308090020; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x	28	166	174	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					489	495		10.1016/j.jaci.2012.05.023	http://dx.doi.org/10.1016/j.jaci.2012.05.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22766097	Green Accepted, Bronze			2022-12-18	WOS:000307002200032
J	Sampson, HA; Leung, DYM; Burks, AW; Lack, G; Bahna, SL; Jones, SM; Wong, DA				Sampson, Hugh A.; Leung, Donald Y. M.; Burks, A. Wesley; Lack, Gideon; Bahna, Sami L.; Jones, Stacie M.; Wong, Dennis A.			A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Sampson, Hugh A.] Mt Sinai Sch Med, New York, NY 10029 USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Denver, CO USA; [Burks, A. Wesley] Duke Univ, Med Ctr, Durham, NC USA; [Lack, Gideon] St Marys Hosp, London, England; [Bahna, Sami L.] Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA 71105 USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Wong, Dennis A.] Genentech Inc, San Francisco, CA 94080 USA	Icahn School of Medicine at Mount Sinai; National Jewish Health; Duke University; Imperial College London; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Arkansas System; University of Arkansas Medical Sciences; Roche Holding; Genentech	Sampson, HA (corresponding author), Mt Sinai Sch Med, New York, NY 10029 USA.	hugh.sampson@mssm.edu	Wong, Dennis A/AAH-2958-2020					Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Wang JL, 2007, CLIN EXP ALLERGY, V37, P651, DOI 10.1111/j.1365-2222.2007.02682.x	7	166	175	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1309	U338		10.1016/j.jaci.2011.01.051	http://dx.doi.org/10.1016/j.jaci.2011.01.051			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21397314				2022-12-18	WOS:000290018600033
J	Golden, DBK; Moffitt, J; Nicklas, RA; Freeman, T; Graft, DF; Reisman, RE; Tracy, JM; Bernstein, D; Blessing-Moore, J; Cox, L; Khan, DA; Lang, DM; Oppenheimer, J; Portnoy, JM; Randolph, C; Schuller, DE; Spector, SL; Tilles, SA; Wallace, D				Golden, David B. K.; Moffitt, John; Nicklas, Richard A.; Freeman, Theodore; Graft, David F.; Reisman, Robert E.; Tracy, James M.; Bernstein, David; Blessing-Moore, Joann; Cox, Linda; Khan, David A.; Lang, David M.; Oppenheimer, John; Portnoy, Jay M.; Randolph, Christopher; Schuller, Diane E.; Spector, Sheldon L.; Tilles, Steven A.; Wallace, Dana			Stinging insect hypersensitivity: A practice parameter update 2011	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Insect hypersensitivity; anaphylaxis	IMPORTED FIRE ANT; LARGE LOCAL REACTIONS; HYMENOPTERA VENOM ALLERGY; EMERGENCY-DEPARTMENT VISITS; SKIN-TEST REACTIVITY; YELLOW JACKET VENOM; LINE SERUM TRYPTASE; NATURAL-HISTORY; ANAPHYLACTIC REACTIONS; HONEYBEE VENOM	These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing "Stinging insect hypersensitivity: a practice parameter update II.'' Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. These parameters are not designed for use by pharmaceutical companies in drug promotion. The Joint Task Force understands that the cost of diagnostic tests and therapeutic agents is an important concern that may appropriately influence the work-up and treatment chosen for a given patient. The Joint Task Force recognizes that the emphasis of our primary recommendations regarding a medication may vary, for example, depending on third party payer issues and product patent expiration dates. However, since a given test or agent's cost is so widely variable, and there is a paucity of pharmacoeconomic data, the Joint Task Force generally does not consider cost when formulating Practice Parameter recommendations. In extraordinary circumstances, when the cost benefit of an intervention is prohibitive as supported by pharmacoeconomic data, commentary may be provided. (J Allergy Clin Immunol 2011;127:852-4.)	[Golden, David B. K.] Joint Council Allergy Asthma & Immunol, Palatine, IL 60067 USA		Golden, DBK (corresponding author), Joint Council Allergy Asthma & Immunol, 50 N Brockway St,3-3, Palatine, IL 60067 USA.		Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870	Schering-Plough; Meda; AstraZeneca; Novartis; Vanberg Family Foundation; Sellars Family Foundation; Genentech/Novartis; GlaxoSmithKline; Merck; Amgen; Boehringer Ingelheim; Merck/Schering; Sepracor; Alcon; Genentech; Pharmaxis; Amphestar; Astellos; Ception; Icagen; MAP Pharma; Roxane	Schering-Plough(Merck & CompanySchering Plough Corporation); Meda; AstraZeneca(AstraZeneca); Novartis(Novartis); Vanberg Family Foundation; Sellars Family Foundation; Genentech/Novartis(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Amgen(Amgen); Boehringer Ingelheim(Boehringer Ingelheim); Merck/Schering(Merck & Company); Sepracor; Alcon(Novartis); Genentech(Roche HoldingGenentech); Pharmaxis; Amphestar; Astellos; Ception; Icagen; MAP Pharma; Roxane	Disclosure of potential conflict of interest: D. B. K. Golden is on the speakers' bureau for ALK-Abello and Novartis-Genentech. R. A. Nicklas is Committee Chair for the American College of Allergy, Asthma & Immunology (ACAAI). T. Freeman is a member of the Texas Medicare Contracted Managed Care Advisory Board, has reviewed various legal cases for the Texas Medical Board, and is a speaker for the ACAAI and the Texas AAI Society. D. F. Graft is a speaker for Teva and Merck, is an author of Up To Date, and is Chair of the ACAAI Insect Hypersensitivity Committee. J. M. Tracy has received research support from Novartis. J. Blessing-Moore is on the speakers' bureau for Merck, Schering-Plough, Meda, AstraZeneca, and Novartis; has received research support from Meda and Novartis; and is a member of the American Thoracic Society, the American College of Asthma and Allergy, and the American College of Chest Physicians. L. Cox is a consultant for Genentech/Novartis, Hollister-Stier, and Stallergenes; has provided expert testimony on drug-related anaphylaxis treatment; and is on the Board of Directors for the ACAAI, BMCA, and FMA. D. A. Kahn is a speaker for AstraZeneca and Merck, has received research support from the Vanberg Family Foundation and Sellars Family Foundation, is Conjoint Board Review Chair for the ACAAI, and is a TAAIS past-president. D. M. Lang has received honoraria from or served as a consultant for GlaxoSmithKline, Sanofi-Aventis, Merck, AstraZeneca, Genentech/Novartis, and MedImmune; has received research support from Genentech/Novartis and GlaxoSmithKline; and is on the ACAAI Committee. J. Oppenheimer has received research support from AstraZeneca, Merck, and Genentech/Novartis and provided expert witness testimony in malpractice defense. S. L. Spector is a consultant for AstraZeneca, Merck/Schering, and Genentech; is on the Advisory Board for Novartis, Merck/Schering, and Genentech; is a speaker for AstraZeneca, Merck/Schering, and Genentech; has received honoraria from AstraZeneca, Merck/Schering, Sepracor, and Genentech; and has received research support from AstraZeneca, Amgen, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Merck/Schering, Sepracor, Alcon, Genentech, and Pharmaxis. S. A. Tilles is a speaker for Alcon and Ista Pharmaceuticals; is on the Advisory Board for ALK-Abello, Merck, and Stallergenes; has received research support from Alcon, Amgen, Amphestar, Astellos, Boehringer Ingelheim, Ception, Genentech, Icagen, MAP Pharma, Meda, Merck, Novartis, Roxane, and Sepracor; is Associate Editor of Allergy Watch and Annals of Allergy, Asthma and Immunology; and is a task force member for the Joint Task Force for Practice Parameters. D. Wallace is a speaker and advisor for Alcon, is a speaker for Merck and Sanofi-Aventis, and is President-Elect of ACAAI. The rest of the authors have declared that they have no conflict of interest.	Bautista E, 2002, INT ARCH ALLERGY IMM, V128, P151, DOI 10.1159/000059406; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; Bilo BM, 2008, CURR OPIN ALLERGY CL, V8, P330, DOI 10.1097/ACI.0b013e32830638c5; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Bilo MB, 2009, CLIN EXP ALLERGY, V39, P1467, DOI 10.1111/j.1365-2222.2009.03324.x; BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; Birnbaum J, 2003, CLIN EXP ALLERGY, V33, P58, DOI 10.1046/j.1365-2222.2003.01564.x; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; BOUSQUET J, 1984, J ALLERGY CLIN IMMUN, V73, P332, DOI 10.1016/0091-6749(84)90405-6; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P944, DOI 10.1016/0091-6749(89)90393-X; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown SGA, 2003, LANCET, V361, P1001, DOI 10.1016/S0140-6736(03)12827-9; BUTCHER BT, 1988, J ALLERGY CLIN IMMUN, V81, P1096, DOI 10.1016/0091-6749(88)90875-5; CHABANE MH, 1988, ANN ALLERGY, V61, P216; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Clark S, 2006, CURR OPIN ALLERGY CL, V6, P279, DOI 10.1097/01.all.0000235902.02924.e9; de Groot H, 2006, CURR OPIN ALLERGY CL, V6, P294, DOI 10.1097/01.all.0000235905.87676.09; DeBandt M, 1997, J RHEUMATOL, V24, P1195; Demain JG, 2009, ALLERGY ASTHMA PROC, V30, P238, DOI 10.2500/aap.2009.30.3231; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; Ellis AK, 2007, ANN ALLERG ASTHMA IM, V98, P64, DOI 10.1016/S1081-1206(10)60861-7; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Forester JP, 2007, ALLERGY ASTHMA PROC, V28, P485, DOI 10.2500/aap.2007.28.3021; FRANCA FOS, 1994, Q J MED, V87, P269; FRANKEN HH, 1994, J ALLERGY CLIN IMMUN, V93, P431, DOI 10.1016/0091-6749(94)90351-4; Freeman TM, 2008, CURR OPIN ALLERGY CL, V8, P308, DOI 10.1097/ACI.0b013e32830656ec; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Freeman TM, 2004, NEW ENGL J MED, V351, P1978, DOI 10.1056/NEJMcp042013; GADDE J, 1985, ANN ALLERGY, V54, P348; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; Ghaffari G, 2006, J ALLERGY CLIN IMMUN, V117, pS309, DOI 10.1016/j.jaci.2005.12.1221; Goldberg A, 2001, J ALLERGY CLIN IMMUN, V107, P902, DOI 10.1067/mai.2001.114986; Goldberg A, 1997, J ALLERGY CLIN IMMUN, V100, P182, DOI 10.1016/S0091-6749(97)70222-7; Goldberg A, 2007, ANN ALLERG ASTHMA IM, V99, P352, DOI 10.1016/S1081-1206(10)60552-2; Golden DBK, 2009, ANN ALLERG ASTHMA IM, V102, P47, DOI 10.1016/S1081-1206(10)60107-X; Golden DBK, 2009, J ALLERGY CLIN IMMUN, V123, P1371, DOI 10.1016/j.jaci.2009.03.017; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; Golden DBK, 2006, J ALLERGY CLIN IMMUN, V117, P670, DOI 10.1016/j.jaci.2005.12.1313; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI [10.1067/mai.2003.1606, 10.1016/S0091-6749(03)01537-9]; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P925, DOI 10.1067/mai.2001.115095; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; Golden DBK, 2009, MIDDLETONS ALLERGY P, V7th, P1005; Graft DF, 2006, MED CLIN N AM, V90, P211, DOI 10.1016/j.mcna.2005.08.006; Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573, DOI 10.1016/S0091-6749(98)70161-7; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; Graif Y, 2006, ANN ALLERG ASTHMA IM, V96, P24, DOI 10.1016/S1081-1206(10)61035-6; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; Hafner T, 2008, ANN ALLERG ASTHMA IM, V100, P162, DOI 10.1016/S1081-1206(10)60425-5; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V86, P353, DOI 10.1016/S1081-1206(10)62477-5; Hamilton RG, 2004, CURR OPIN ALLERGY CL, V4, P297, DOI 10.1097/01.all.0000136755.13077.b5; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; Hoffman DR, 2003, ALLERGY ASTHMA PROC, V24, P123; HOFFMAN DR, 1979, ANN ALLERGY, V43, P211; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; Kemp SF, 2000, J ALLERGY CLIN IMMUN, V105, P683, DOI 10.1067/mai.2000.105707; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; Korenblat P, 1999, ALLERGY ASTHMA PROC, V20, P383, DOI 10.2500/108854199778251834; LANTNER R, 1989, J ALLERGY CLIN IMMUN, V84, P900, DOI 10.1016/0091-6749(89)90387-4; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; LICHTENSTEIN LM, 1983, HOSP PRACT, V18, P36; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; LIEBERMAN P, 2005, J ALLERGY CLIN IMMUN, V115, pS483, DOI DOI 10.1016/J.JACI.2005.01.010; LIGHT W C, 1975, Clinical Allergy, V5, P389, DOI 10.1111/j.1365-2222.1975.tb01878.x; Light WC, 2001, J ALLERGY CLIN IMMUN, V107, P925, DOI 10.1067/mai.2001.114985; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; MCKENNA WR, 2003, MONOGRAPH INSECT ALL, P27; Moffitt JE, 2003, SOUTH MED J, V96, P1073, DOI 10.1097/01.SMJ.0000097885.28467.21; Moffitt JE, 1997, ANN ALLERG ASTHMA IM, V79, P125, DOI 10.1016/S1081-1206(10)63098-0; Muller UR, 2009, CLIN EXP ALLERGY, V39, P620, DOI 10.1111/j.1365-2222.2009.03251.x; Muller UR, 2008, J ALLERGY CLIN IMMUN, V122, P1001, DOI 10.1016/j.jaci.2008.08.007; Mueller UR, 2007, CURR OPIN ALLERGY CL, V7, P337, DOI 10.1097/ACI.0b013e328259c328; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jaci.2004.11.012, 10.1016/j.jsci.2004.11.012]; Nguyen SA, 2005, ANN ALLERG ASTHMA IM, V94, P387, DOI 10.1016/S1081-1206(10)60992-1; Patridge ME, 2008, ANN ALLERG ASTHMA IM, V100, P54; PATRIZZI R, 1979, ALLERGY, V34, P249, DOI 10.1111/j.1398-9995.1979.tb01705.x; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1991, J ALLERGY CLIN IMMUN, V87, P618, DOI 10.1016/0091-6749(91)90378-2; REISMAN RE, 1984, J ALLERGY CLIN IMMUN, V73, P246, DOI 10.1016/S0091-6749(84)80015-9; Reisman RE, 2001, J ALLERGY CLIN IMMUN, V107, P781, DOI 10.1067/mai.2001.115042; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V84, P331, DOI 10.1016/0091-6749(89)90417-X; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; RHOADES RB, 1993, J ALLERGY CLIN IMMUN, V91, P282; RHOADES RB, 1977, J FLA MED ASSOC, V64, P247; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; SAKHUJA V, 1988, NEPHRON, V49, P319, DOI 10.1159/000185083; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SCHUMACHER MJ, 1994, J ALLERGY CLIN IMMUN, V93, P831, DOI 10.1016/0091-6749(94)90373-5; SCHWARTZ HJ, 1995, CLIN EXP ALLERGY, V25, P866, DOI 10.1111/j.1365-2222.1995.tb00029.x; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; Severino MG, 2008, J ALLERGY CLIN IMMUN, V122, P44, DOI 10.1016/j.jaci.2008.03.031; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Stafford CT, 1996, ANN ALLERG ASTHMA IM, V77, P87, DOI 10.1016/S1081-1206(10)63493-X; STROM GB, 1983, J ALLERGY CLIN IMMUN, V72, P46, DOI 10.1016/0091-6749(83)90051-9; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TRACY JM, 1995, J ALLERGY CLIN IMMUN, V95, P824, DOI 10.1016/S0091-6749(95)70125-7; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VALENTINE MD, 1993, ANN INTERN MED, V118, P225, DOI 10.7326/0003-4819-118-3-199302010-00013; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; Walker R, 1999, J ALLERGY CLIN IMMUN, V103, pS180; Wohrl S, 2007, INT ARCH ALLERGY IMM, V144, P137, DOI 10.1159/000103225; Yocum MW, 1996, J ALLERGY CLIN IMMUN, V97, P1424, DOI 10.1016/S0091-6749(96)70217-8	145	166	172	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					852	U57		10.1016/j.jaci.2011.01.025	http://dx.doi.org/10.1016/j.jaci.2011.01.025			26	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21458655				2022-12-18	WOS:000289055800002
J	Shen, L; Siliciano, RF				Shen, Lin; Siliciano, Robert F.			Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HAART; latency; reservoir; antiretroviral drug; residual viremia; slope; eradication	IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; COMBINATION THERAPY; IN-VIVO; DRUG SUSCEPTIBILITY; LATENT RESERVOIR; REVERSE-TRANSCRIPTASE; INHIBITORY QUOTIENT; PHENOTYPIC ASSAY; REPLICATION	Although highly active antiretroviral therapy (HAART) can reduce HIV-1 viremia to levels that are below the limit of detection of clinical Assays, the virus persists in reservoirs, and trace levels of free virions can be found in the plasma. Whether this residual viremia represents ongoing cycles of replication continuing despite HAART or simply the release of virus from stable reservoirs has been controversial. Here we summarize the evidence that HAART can stop ongoing cycles of replication. The evidence comes from a detailed analysis of the residual viremia, which shows it to be archival and nonevolving in character. In addition, new pharmacodynamic measures incorporating a previously ignored slope parameter have provided the first real indication of how well HAART actually suppresses viral replication in vivo. Together, these results argue that the ultimate theoretical potential of HAART to control viral replication has already been reached. Progress toward eradication of the infection will require novel approaches to target the stable reservoirs that persist even when viral replication is completely halted.	[Shen, Lin; Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 879 Broadway Res Bldg,733 N Broadway, Baltimore, MD 21205 USA.	rsiliciano@jhmi.edu	Abrams, William R/A-5782-2008		Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI043222, R01 AI051178] Funding Source: Medline; PHS HHS [51178] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051178, R01AI043222] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; BARTLETT JG, 2007, GUIDELINES USE ANTIR; Bartlett JA, 2006, AIDS, V20, P2051, DOI 10.1097/01.aids.0000247578.08449.ff; Butler SL, 2002, J VIROL, V76, P3739, DOI 10.1128/JVI.76.8.3739-3747.2002; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHOU TC, 1976, J THEOR BIOL, V59, P253, DOI 10.1016/0022-5193(76)90169-7; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; ELLNER PD, 1981, JAMA-J AM MED ASSOC, V246, P1575, DOI 10.1001/jama.246.14.1575; Ferguson NM, 2001, TRENDS PHARMACOL SCI, V22, P97, DOI 10.1016/S0165-6147(00)01615-1; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Frenkel LM, 2003, J VIROL, V77, P5721, DOI 10.1128/JVI.77.10.5721-5730.2003; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Han YF, 2007, NAT REV MICROBIOL, V5, P95, DOI 10.1038/nrmicro1580; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Hill A., 1910, J PHYSIOL-LONDON, V40, piv; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Keele BF, 2008, J VIROL, V82, P5548, DOI 10.1128/JVI.00124-08; KELLAM P, 1994, ANTIMICROB AGENTS CH, V38, P23, DOI 10.1128/AAC.38.1.23; Kieffer TL, 2004, J INFECT DIS, V189, P1452, DOI 10.1086/382488; Lassen K, 2004, TRENDS MOL MED, V10, P525, DOI 10.1016/j.molmed.2004.09.006; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; Morse GD, 2006, LANCET INFECT DIS, V6, P215, DOI 10.1016/S1473-3099(06)70436-4; Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817; NEU HC, 1983, B NEW YORK ACAD MED, V59, P430; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Persaud D, 2004, J VIROL, V78, P968, DOI 10.1128/JVI.78.2.968-979.2004; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; Pierson TC, 2002, J VIROL, V76, P4138, DOI 10.1128/JVI.76.8.4138-4144.2002; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Sedaghat AR, 2007, PLOS PATHOG, V3, P1165, DOI 10.1371/journal.ppat.0030122; Sharkey M, 2005, J VIROL, V79, P5203, DOI 10.1128/JVI.79.8.5203-5210.2005; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; SHEN L, 2008, NAT MED         0115; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Williams SA, 2007, CYTOKINE, V39, P63, DOI 10.1016/j.cyto.2007.05.017; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang HL, 2004, J VIROL, V78, P1718, DOI 10.1128/JVI.78.4.1718-1729.2004; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zhu TF, 2002, J VIROL, V76, P707, DOI 10.1128/JVI.76.2.707-716.2002	55	166	173	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					22	28		10.1016/j.jaci.2008.05.033	http://dx.doi.org/10.1016/j.jaci.2008.05.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18602567	Bronze, Green Accepted			2022-12-18	WOS:000257605100003
J	Tamachi, T; Maezawa, Y; Ikeda, K; Kagami, SI; Hatano, M; Seto, Y; Suto, A; Suzuki, K; Watanabe, N; Saito, Y; Tokuhisa, T; Iwamoto, I; Nakajima, H				Tamachi, Tomohiro; Maezawa, Yuko; Ikeda, Kei; Kagami, Shin-ichiro; Hatano, Masahiko; Seto, Yohei; Suto, Akira; Suzuki, Kotaro; Watanabe, Norihiko; Saito, Yasushi; Tokuhisa, Takeshi; Iwamoto, Itsuo; Nakajima, Hiroshi			IL-25 enhances allergic airway inflammation by amplifying a T(H)2 cell-dependent pathway in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic inflammation; IL-25; eosinophils; T(H)2 cells	ANTIGEN-INDUCED EOSINOPHIL; EXPRESSION; LUNG; INTERLEUKIN-5; RECEPTOR; HYPERREACTIVITY; LYMPHOCYTES; ASTHMA; IL-13	Background: A novel IL-17 family cytokine, IL-25, has been reported to induce IL-4, IL-5, and IL-13 production from undefined non-T/non-B cells and then induce T(H)2-type immune responses. However, the roles of IL-25 in inducing allergic airway inflammation remain unknown. Objective: We sought to determine whether IL-25 is involved in causing allergic airway inflammation. Methods: We examined the expression of IL-25 mRNA in the lungs of sensitized mice on antigen inhalation. We also examined the effect of IL-25 neutralization by soluble IL-25 receptor on antigen-induced airway inflammation. We then generated IL-25 transgenic mice that express IL-25 specifically in the lung under the control of the Clara cells-10-kd protein promoter and investigated the effect of enforced IL-25 expression on antigen-induced airway inflammation. Results: IL-25 mRNA was expressed in the lungs of sensitized mice on antigen inhalation, and the neutralization of IL-25 by soluble IL-25 receptor decreased antigen-induced eosinophil and CD4(+) T-cell recruitment into the airways. The enforced expression of IL-25 in the lung itself failed to induce allergic airway inflammation, whereas the expression of IL-25 significantly enhanced antigen-induced T(H)2 cytokine production, eosinophil and CD4(+) T cell recruitment, and goblet cell hyperplasia in the airways. Moreover, IL-25-induced enhancement of allergic airway inflammation was inhibited by the depletion of CD4(+) T cells or by the absence of signal transducer and activator of transcription 6. Conclusion: IL-25 enhances antigen-induced allergic airway inflammation by amplifying a T(H)2 cell-dependent pathway. Clinical implications: IL-25 might be involved in the enhancement, prolongation, or both of T(H)2 cell-mediated allergic diseases, such as asthma.	Chiba Univ, Grad Sch Med, Dept Mol Genet, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Allergy & Clin Immunol, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Dev Genet, Chiba 2608670, Japan; Asahi Gen Hosp, Res Ctr Allergy & Clin Immunol, Chiba, Japan	Chiba University; Chiba University; Chiba University	Nakajima, H (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Genet, 1-8-1 Inohana, Chiba 2608670, Japan.	nakajimh@faculty.chiba-u.jp	Tamachi, Tomohiro/I-1468-2017; Ikeda, Kei/H-5886-2018; Nakajima, Hiroshi/AFU-9313-2022	Tamachi, Tomohiro/0000-0001-8295-1472; Ikeda, Kei/0000-0003-0574-9611; Nakajima, Hiroshi/0000-0001-8595-9381; Suto, Akira/0000-0002-2593-565X				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Glimcher LH, 2000, GENE DEV, V14, P1693; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Ikeda K, 2003, BLOOD, V101, P3594, DOI 10.1182/blood-2002-09-2817; Kagami S, 2000, BLOOD, V95, P1370, DOI 10.1182/blood.V95.4.1370.004k29_1370_1377; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006; Kim MR, 2002, BLOOD, V100, P2330, DOI 10.1182/blood-2002-01-0012; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Letuve S, 2006, J ALLERGY CLIN IMMUN, V117, P590, DOI 10.1016/j.jaci.2005.10.025; Leung SY, 2005, J ALLERGY CLIN IMMUN, V115, P989, DOI 10.1016/j.jaci.2005.01.036; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; Maezawa Y, 2006, J IMMUNOL, V176, P1013, DOI 10.4049/jimmunol.176.2.1013; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Pan GH, 2001, J IMMUNOL, V167, P6559, DOI 10.4049/jimmunol.167.11.6559; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Schwarzenberger P, 1998, J IMMUNOL, V161, P6383; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Tian EM, 2000, ONCOGENE, V19, P2098, DOI 10.1038/sj.onc.1203577; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	29	166	191	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					606	614		10.1016/j.jaci.2006.04.051	http://dx.doi.org/10.1016/j.jaci.2006.04.051			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950278	Bronze			2022-12-18	WOS:000240649000012
J	Radauer, C; Breiteneder, H				Radauer, C; Breiteneder, H			Pollen allergens are restricted to few protein families and show distinct patterns of species distribution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pollen allergens; protein families; taxonomy; cross-reactivity	CROSS-REACTIVE ALLERGENS; BIRCH POLLEN; FOOD ALLERGENS; CLONING; IDENTIFICATION; POLLINOSIS; PREVALENCE; DIAGNOSIS; DATABASE; ASTHMA	Background: Inhalative allergies are elicited predominantly by pollen of various plant species. However, a classification of the large number of identified pollen allergens is still missing. Objective: To analyze pollen allergen sequences with respect to protein family membership, taxonomic distribution of protein families, and interspecies variability. Methods: Protein family memberships of all plant allergen sequences from the Allergome database were determined by using the Protein Families Database of Alignments and Hidden Markov Models. The taxonomic distribution of pollen allergens was established from the Integrated Taxonomic Information System. Members of abundant pollen allergen families were compared with allergenic and nonallergenic homologues by database similarity searches and multiple sequence alignments. Results: Pollen allergens were classified into 29 of 7868 protein families. Expansins, profilins, and calcium-binding proteins constitute the major pollen allergen families, whereas most plant food allergens belong to the prolamin, cupin, or profilin families. Pollen allergens were revealed to be ubiquitous (eg, profilins), present in certain plant families (eg, pectate lyases), or limited to a single taxon (eg, thaumatin-like proteins). Allergenic plant profilins constitute a highly conserved family with sequence identities of 70% to 85% among each other but low identities of 30% to 40% with nonallergenic profilins from other eukaryotes, including human beings. Similarly, allergenic polcalcins possess sequence identities of 64% to 92 % but show low identities of 39 % to 42 % to related nonallergenic calmodulins and calmodulin-like proteins from vegetative plant tissues and man. Conclusion: This classification of pollen allergens into protein families will aid in predicting cross-reactivity, designing comprehensive diagnostic devices, and assessing the allergenic potential of novel proteins.	Med Univ Vienna, Dept Pathophysiol, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria	Medical University of Vienna	Breiteneder, H (corresponding author), Med Univ Vienna, Dept Pathophysiol, Ctr Physiol & Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Heimo.Breiteneder@meduniwien.ac.at	Radauer, Christian/AAN-6260-2021	Radauer, Christian/0000-0001-9920-4449				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Asturias JA, 2005, CLIN EXP ALLERGY, V35, P374, DOI 10.1111/j.1365-2222.2005.02179.x; Barderas R, 2002, INT ARCH ALLERGY IMM, V127, P47, DOI 10.1159/000048168; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Boral D, 2004, ANN AGR ENV MED, V11, P45; Breiteneder H, 2004, ALLERGY, V59, P479, DOI 10.1046/j.1398-9995.2003.00421.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Bublin M, 2003, FASEB J, V17, P1697, DOI 10.1096/fj.02-0872fje; Calabozo B, 2003, BIOCHEM J, V372, P889, DOI 10.1042/BJ20021491; Chew FT, 2000, ALLERGY, V55, P340, DOI 10.1034/j.1398-9995.2000.00308.x; Colombo P, 2003, INT ARCH ALLERGY IMM, V130, P173, DOI 10.1159/000069520; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; Di Felice G, 2001, INT ARCH ALLERGY IMM, V125, P280, DOI 10.1159/000053828; Gadermaier G, 2004, CURR ALLERGY ASTHM R, V4, P391, DOI 10.1007/s11882-004-0090-5; Hamilton RG, 2004, J ALLERGY CLIN IMMUN, V114, P213, DOI 10.1016/j.jaci.2004.06.046; Hong SJ, 2004, CLIN EXP ALLERGY, V34, P1556, DOI 10.1111/j.1365-2222.2004.02084.x; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Kaneko Y, 2005, INT ARCH ALLERGY IMM, V136, P365, DOI 10.1159/000084256; Karamloo F, 2001, EUR J BIOCHEM, V268, P5310, DOI 10.1046/j.0014-2956.2001.02463.x; Lombardero M, 2002, ALLERGY, V57, P29, DOI 10.1034/j.1398-9995.2002.057s71029.x; Mari A., 2004, Journal of Allergy and Clinical Immunology, V113, pS301; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Mothes N, 2004, INT ARCH ALLERGY IMM, V135, P357, DOI 10.1159/000082332; Moverare R, 2002, INT ARCH ALLERGY IMM, V128, P325, DOI 10.1159/000063855; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Rodriguez R, 2001, INT ARCH ALLERGY IMM, V125, P185, DOI 10.1159/000053815; Rybnicek O., 2001, ALLERGY CLIN IMMUNOL, V13, P60, DOI DOI 10.1027/0838-1925.13.2.60; Salcedo G, 2004, CLIN EXP ALLERGY, V34, P1336, DOI 10.1111/j.1365-2222.2004.02018.x; Sibanda EN, 2003, INT ARCH ALLERGY IMM, V130, P2, DOI 10.1159/000068377; Stadler MB, 2003, FASEB J, V17, P1141, DOI 10.1096/fj.02-1052fje; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thompson JL, 2003, IMMUNOL ALLERGY CLIN, V23, P371, DOI 10.1016/S0889-8561(03)00006-7; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Weber RW, 2003, J ALLERGY CLIN IMMUN, V112, P229, DOI 10.1067/mai.2003.1683; Wheeler AW, 2004, EXPERT OPIN BIOL TH, V4, P1473, DOI 10.1517/14712598.4.9.1473; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425, DOI 10.1016/S1081-1206(10)61509-8	40	166	171	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					141	147		10.1016/j.jaci.2005.09.010	http://dx.doi.org/10.1016/j.jaci.2005.09.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387597				2022-12-18	WOS:000235687100022
J	Holt, PG; Upham, JW; Sly, PD				Holt, PG; Upham, JW; Sly, PD			Contemporaneous maturation of immunologic and respiratory functions during early childhood: Implications for development of asthma prevention strategies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopy; asthma; immune development; innate immunity; T cells; dendritic cells	BLOOD MONONUCLEAR-CELLS; PLASMACYTOID DENDRITIC CELLS; NECROSIS-FACTOR-ALPHA; IN-VITRO STIMULATION; AGE-RELATED-CHANGES; NEONATAL T-CELL; IFN-GAMMA GENE; CORD-BLOOD; PERIPHERAL-BLOOD; INTERFERON-GAMMA	The term asthma refers to a spectrum of wheezing syndromes resulting from airways inflammation triggered by a range of environmental stimuli, the most important of which are aeroallergens and viruses. We describe below a model for the cause of atopic asthma in which discrete sets of developmental factors governing the postnatal maturation of the immune and respiratory systems play central and complementary roles in disease causality. Within the immune system, the relevant developmental processes involve maturation of T(H)1 and associated innate immune functions that combat infection and concomitantly antagonize the early programming of T(H)2-polarized immunologic memory against inhalant allergens. Within the respiratory system, the relevant developmental processes involve intensive lung growth and airway remodeling during infancy. We hypothesize that delayed maturation of T(H)1-associated functions during early postnatal life increases the risk for sensitization to aeroallergens and for severe respiratory infection, resulting in airway inflammation at a crucial stage in lung development and precipitating changes in lung growth that are the harbingers of susceptibility to persistent asthma. We further hypothesize that protection of the growing lung against the effects of inflammation during infancy and early childhood has unique potential as a generic strategy for asthma prophylaxis.	Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Div Cell Biol, Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia	Holt, PG (corresponding author), Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	patrick@ichr.uwa.edu.au	Sly, Peter D/F-1486-2010; Upham, John/F-4420-2010; Holt, Patrick G/H-1548-2011; Study, Raine/K-4517-2013	Sly, Peter D/0000-0001-6305-2201; Upham, John/0000-0002-0017-3433; Holt, Patrick G/0000-0003-1193-0935; 				ANDERSSON U, 1981, IMMUNOL REV, V57, P5, DOI 10.1111/j.1600-065X.1981.tb00440.x; Arkwright PD, 2000, CLIN EXP IMMUNOL, V122, P16, DOI 10.1046/j.1365-2249.2000.01338.x; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; BERTOTTO A, 1990, CELL IMMUNOL, V127, P247, DOI 10.1016/0008-8749(90)90130-J; Bont L, 2001, J INFECT DIS, V184, P355, DOI 10.1086/322035; Borras FE, 2001, BRIT J HAEMATOL, V113, P925, DOI 10.1046/j.1365-2141.2001.02840.x; Boushey HA, 2000, LANCET, V356, P2114, DOI 10.1016/S0140-6736(00)03486-3; Calado RT, 1999, CYTOMETRY, V38, P133, DOI 10.1002/(SICI)1097-0320(19990615)38:3<133::AID-CYTO8>3.0.CO;2-9; CEDERBLAD B, 1990, PEDIATR RES, V27, P7, DOI 10.1203/00006450-199001000-00002; Chalmers IMH, 1998, BLOOD, V92, P11, DOI 10.1182/blood.V92.1.11.413a39_11_18; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; Chheda S, 1996, PEDIATR RES, V40, P475, DOI 10.1203/00006450-199609000-00018; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; de Vries E, 2000, PEDIATR RES, V47, P528, DOI 10.1203/00006450-200004000-00019; De Wit D, 2004, BLOOD, V103, P1030, DOI 10.1182/blood-2003-04-1216; De Wit D, 2003, J AUTOIMMUN, V21, P277, DOI 10.1016/j.jaut.2003.08.003; DURANDY A, 1995, J IMMUNOL, V154, P1560; Early EM, 1996, EUR J IMMUNOL, V26, P2885, DOI 10.1002/eji.1830261212; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; FULEIHAN R, 1994, EUR J IMMUNOL, V24, P1925, DOI 10.1002/eji.1830240832; Gonzalez J, 1999, CHASQUI, V28, P175, DOI 10.2307/29741560; GRIFFITHSCHU S, 1984, BLOOD, V64, P296; Hagendorens MM, 2003, CLIN EXP ALLERGY, V33, P633, DOI 10.1046/j.1365-2222.2003.01649.x; Hall GL, 2001, AM J RESP CRIT CARE, V164, P1387, DOI 10.1164/ajrccm.164.8.2012148; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Hanrahan JP, 1996, AM J RESP CRIT CARE, V154, P670, DOI 10.1164/ajrccm.154.3.8810604; Hassan J, 1996, IMMUNOLOGY, V87, P604, DOI 10.1046/j.1365-2567.1996.476587.x; Hassan J, 2001, J IMMUNOL, V167, P1970, DOI 10.4049/jimmunol.167.4.1970; HASSAN J, 1995, CLIN EXP IMMUNOL, V102, P192; Hayward A R, 1991, Adv Exp Med Biol, V310, P71; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; HIBBERT ME, 1990, PEDIATR PULM, V8, P172, DOI 10.1002/ppul.1950080308; Holgate ST, 1998, CLIN EXP ALLERGY, V28, P97; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 2004, NAT IMMUNOL, V5, P695, DOI 10.1038/ni0704-695; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; Holt PG, 2002, EUR RESPIR J, V19, P538, DOI 10.1183/09031936.02.00229302; Hoo AF, 2002, J PEDIATR-US, V141, P652, DOI 10.1067/mpd.2002.128114; HUNT DWC, 1994, BLOOD, V84, P4333, DOI 10.1182/blood.V84.12.4333.bloodjournal84124333; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kaditis AG, 2003, PEDIATR PULM, V35, P241, DOI 10.1002/ppul.10243; Katamura K, 1998, MOL IMMUNOL, V35, P39; LANDAU LI, 1999, PEDIAT RESP MED, P935; Larsen GL, 1999, J PEDIATR-US, V135, pS21; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Levy O, 2004, J IMMUNOL, V173, P4627, DOI 10.4049/jimmunol.173.7.4627; Long JA, 2004, AM J RESP CRIT CARE, V170, P485, DOI 10.1164/rccm.200311-1595OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez X, 1997, P NATL ACAD SCI USA, V94, P8726, DOI 10.1073/pnas.94.16.8726; Matsuda H, 2002, AM J RESP CRIT CARE, V166, P1050, DOI 10.1164/rccm.2110066; Matthews NC, 2000, J IMMUNOL, V164, P6206, DOI 10.4049/jimmunol.164.12.6206; Min BK, 2000, CELL IMMUNOL, V200, P45, DOI 10.1006/cimm.2000.1618; Miscia S, 1999, J IMMUNOL, V163, P2416; Miyazaki S, 2003, J LEUKOCYTE BIOL, V74, P514, DOI 10.1189/jlb.1102566; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; NEUSTOCK P, 1993, LYMPHOKINE CYTOK RES, V12, P109; Nilsson C, 2004, CLIN EXP ALLERGY, V34, P373, DOI 10.1111/j.1365-2222.2004.01896.x; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PIRENNE H, 1992, PEDIATR RES, V32, P81, DOI 10.1203/00006450-199207000-00016; Pohunek P, 1997, EUR RESPIR J, V10, P160; Porcu P, 1998, P NATL ACAD SCI USA, V95, P4538, DOI 10.1073/pnas.95.8.4538; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 2003, CLIN EXP ALLERGY, V33, P566, DOI 10.1046/j.1365-2222.2003.01659.x; Prescott SL, 1998, J IMMUNOL, V160, P4730; Qian JX, 1997, BLOOD, V90, P3106, DOI 10.1182/blood.V90.8.3106; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Rowe J, 2001, J INFECT DIS, V184, P80, DOI 10.1086/320996; Serushago B, 1996, J INTERF CYTOK RES, V16, P381, DOI 10.1089/jir.1996.16.381; Sherrill D, 1999, CLIN EXP ALLERGY, V29, P905; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SHU U, 1994, J CLIN INVEST, V94, P1352, DOI 10.1172/JCI117469; Sorg RV, 1999, BLOOD, V93, P2302, DOI 10.1182/blood.V93.7.2302.407a25_2302_2307; SPLAWSKI JB, 1991, J CLIN INVEST, V88, P967, DOI 10.1172/JCI115400; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stern D A, 1992, Dev Immunol, V2, P175, DOI 10.1155/1992/64292; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Szefler S, 2000, NEW ENGL J MED, V343, P1054; TAKAHASHI N, 1995, J IMMUNOL, V155, P5213; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TAYLOR S, 1985, J IMMUNOL, V134, P1493; Teig N, 2002, SCAND J IMMUNOL, V55, P453, DOI 10.1046/j.1365-3083.2002.01068.x; Thornton CA, 2004, J IMMUNOL, V173, P3084, DOI 10.4049/jimmunol.173.5.3084; Trivedi HN, 1997, HUM IMMUNOL, V57, P69, DOI 10.1016/S0198-8859(97)00202-4; Uchida Y, 2001, J ALLERGY CLIN IMMUN, V108, P1005, DOI 10.1067/mai.2001.119741; Ulevitch RJ, 1999, NAT MED, V5, P144, DOI 10.1038/5504; Upham JW, 2004, J ALLERGY CLIN IMMUN, V114, P1202, DOI 10.1016/j.jaci.2004.06.051; Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420, DOI 10.1164/ajrccm.149.6.8004293; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WESTON WL, 1977, AM J DIS CHILD, V131, P1241, DOI 10.1001/archpedi.1977.02120240059011; WHISLER RL, 1995, MECH AGEING DEV, V77, P197, DOI 10.1016/0047-6374(94)01526-R; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383; Yan SR, 2004, INFECT IMMUN, V72, P1223, DOI 10.1128/IAI.72.3.1223-1229.2004; YOUNG HA, 1994, J IMMUNOL, V153, P3603	102	166	171	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					16	24		10.1016/j.jaci.2005.04.017	http://dx.doi.org/10.1016/j.jaci.2005.04.017			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990766				2022-12-18	WOS:000235686300002
J	Schmid-Grendelmeier, P; Fluckiger, S; Disch, R; Trautmann, A; Wuthrich, B; Blaser, K; Scheynius, A; Crameri, R				Schmid-Grendelmeier, P; Fluckiger, S; Disch, R; Trautmann, A; Wuthrich, B; Blaser, K; Scheynius, A; Crameri, R			IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						autoallergy; Aspergillus fumigatus; atopic dermatitis; atopy; fungi; Malassezia sympodialis; intrinsic type; nonatopic eczema; recombinant allergens	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; FUMIGATUS ALLERGENS; PATCH TEST; MALASSEZIA; DISEASE; AUTOANTIBODIES; ITRACONAZOLE; REACTIVITY; RESPONSES; CLONING	Background: Autoreactivity of patients with atopic dermatitis (AD) to human proteins has been postulated as a decisive pathogenetic factor for AD. Objective: In this study, it was investigated whether the stress-inducible enzyme manganese superoxide dismutase (MnSOD) of human and fungal origin might act as an autoallergen in atopic dermatitis. Methods: Patients with AD (n = 69; mean SCORAD [SCORing Atopic Dermatitis], 27) and other inflammatory skin diseases as well as with inhalant allergies were investigated. The presence of specific IgE against recombinant MnSOD of fungal and human origin and the fungal extracts of Aspergillus fumigatus and Malassezia sympodialis was measured by CAP, ELISA, skin prick test, and in subset of patients also by atopy patch tests (APTs) and PBMC proliferation assays. Cross-reactivity between allergens was determined by CAP inhibition. The presence of MnSOD in human skin in various inflammatory skin conditions was investigated by immunohistochemistry. Results: Specific IgE antibodies against human MnSOD correlating with the disease activity were found in 29 out of 67 patients with AD. The human protein was able to induce in vitro T-cell reactivity and eczematous reactions in APT in MnSOD-sensitized patients with AD. MnSOD was upregulated in various inflammatory skin reactions and APT skin specimens. Cosensitization to structurally related and cross-reacting fungal MnSOD and the skin-colonizing yeast M sympodialis was observed in all patients sensitized against human MnSOD. Conclusion: Human MnSOD may play a role as an autoallergen in a subset of patients with AD, including nonatopic eczema. By molecular mimicry leading to cross-reactivity such sensitization might be induced primarily by exposure to environmental fungal MnSOD of M sympodialis.	Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; BioVisioN Schweiz AG, Davos, Switzerland; Alexanderhaus Klin, Davos, Switzerland; Karolinska Hosp & Inst, Dept Med, Unit Clin Allergy Res, Stockholm, Sweden	University of Zurich; University Zurich Hospital; Swiss Institute of Allergy & Asthma Research; Karolinska Institutet; Karolinska University Hospital	Schmid-Grendelmeier, P (corresponding author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.	peter.schmid@usz.ch						Andersson A, 2004, EUR J BIOCHEM, V271, P1885, DOI 10.1111/j.1432-1033.2004.04098.x; Crameri R, 1998, INT IMMUNOL, V10, P1211, DOI 10.1093/intimm/10.8.1211; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; Fluckiger S, 2002, J IMMUNOL, V168, P1267, DOI 10.4049/jimmunol.168.3.1267; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hemmann S, 1998, EUR J IMMUNOL, V28, P1155, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1155::AID-IMMU1155&gt;3.0.CO;2-6; Hemmann S, 1999, J ALLERGY CLIN IMMUN, V104, P601, DOI 10.1016/S0091-6749(99)70330-1; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Hofer MF, 1999, J INVEST DERMATOL, V112, P171, DOI 10.1046/j.1523-1747.1999.00492.x; Ikezawa Z, 2004, EUR J DERMATOL, V14, P400; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kinaciyan T, 2002, J ALLERGY CLIN IMMUN, V109, P717, DOI 10.1067/mai.2002.123303; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Linder MT, 2000, CLIN EXP ALLERGY, V30, P122, DOI 10.1046/j.1365-2222.2000.00702.x; Lintu P, 2001, ALLERGY, V56, P512, DOI 10.1034/j.1398-9995.2001.056006512.x; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; Mayer C, 1999, J EXP MED, V189, P1507, DOI 10.1084/jem.189.9.1507; Mayer C, 1997, INT ARCH ALLERGY IMM, V113, P213, DOI 10.1159/000237550; Nakabayashi A, 2000, MED MYCOL, V38, P337, DOI 10.1080/mmy.38.5.337.341; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Ochs RL, 2000, J ALLERGY CLIN IMMUN, V105, P1211, DOI 10.1067/mai.2000.107039; Omata N, 2001, LIFE SCI, V69, P223, DOI 10.1016/S0024-3205(01)01124-9; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Patterson R, 2000, CHEST, V118, P7, DOI 10.1378/chest.118.1.7; Poswig A, 1999, J INVEST DERMATOL, V112, P13, DOI 10.1046/j.1523-1747.1999.00465.x; Scheynius A, 2002, INT ARCH ALLERGY IMM, V127, P161, DOI 10.1159/000053860; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Schmid-Grendelmeier P, 2001, INT ARCH ALLERGY IMM, V125, P96, DOI 10.1159/000053803; Svejgaard EI, 2004, J EUR ACAD DERMATOL, V18, P445, DOI 10.1111/j.1468-3083.2004.00963.x; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, TRENDS IMMUNOL, V22, P530, DOI 10.1016/S1471-4906(01)02004-X; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Werfel T, 1998, ALLERGY, V53, P731; 1992, ALLERGY, V47, P1; 1993, CONSENSUS REPORT EUR, V186, P23	38	166	180	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1068	1075		10.1016/j.jaci.2005.01.065	http://dx.doi.org/10.1016/j.jaci.2005.01.065			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867868				2022-12-18	WOS:000229055100026
J	Oh, JW; Seroogy, CM; Meyer, EH; Akbari, O; Berry, G; Fathman, CG; DeKruyff, RH; Umetsu, DT				Oh, JW; Seroogy, CM; Meyer, EH; Akbari, O; Berry, G; Fathman, CG; DeKruyff, RH; Umetsu, DT			CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-10; T(H)2 cells; airway hyperreactivity; asthma; regulatory cells	MESSENGER-RNA EXPRESSION; GROWTH-FACTOR-BETA; IMMUNE-RESPONSE; CYTOKINE PRODUCTION; AUTOIMMUNE-DISEASE; DENDRITIC CELLS; INTERLEUKIN-10; ANTIGEN; MICE; TOLERANCE	Background: T(H)2 cells play a critical role in the pathogenesis of asthma, but the precise immunologic mechanisms that inhibit T(H)2 cell function in vivo are not well understood. Objective: The purpose of our studies was to determine whether T cells producing IL-10 regulate the development of asthma. Methods: We used gene therapy to generate ovalbumin-specific CD4 T-helper cells to express IL-10, and we examined their capacity to regulate allergen-induced airway hyperreactivity. Results: We demonstrated that the CD4 T-helper cells engineered to express IL-10 abolished airway hyperreactivity and airway eosinophilia in BALB/c mice sensitized and challenged with ovalbumin and in SCID mice reconstituted with ovalbumin-specific T(H)2 effector cells. The inhibitory effect of the IL-10-secreting T-helper cells was accompanied by the presence of increased quantities of IL-10 in the bronchoalveolar lavage fluid, was antigen-specific, and was reversed by neutralization of IL-10. Moreover, neutralization of IL-10 by administration of anti-IL-10 mAb in mice sensitized and challenged with ovalbumin seriously exacerbated airway hyperreactivity and airway inflammation. Conclusion: Our results demonstrate that T cells, secreting IL-10 in the respiratory mucosa can indeed regulate T(H)2-induced airway hyperreactivity and inflammation, and they strongly suggest that IL-10 plays an important inhibitory role in allergic asthma.	Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Div Immunol, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Umetsu, DT (corresponding author), Stanford Univ, Dept Pediat, Div Immunol & Allergy, Room G309, Stanford, CA 94305 USA.			Berry, Gerald/0000-0002-6176-2629	NHLBI NIH HHS [R01HL62348] Funding Source: Medline; NIAID NIH HHS [K08AI01731-02, R01AI24571, R01AI26322, T32 AI007290] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024571, T32AI007290, R01AI026322, K08AI001731] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Borish L, 1998, J ALLERGY CLIN IMMUN, V101, P293, DOI 10.1016/S0091-6749(98)70238-6; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COFFMAN RL, 1991, IMMUNOL REV, V123, P189, DOI 10.1111/j.1600-065X.1991.tb00611.x; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; CRISI GM, 1995, EUR J IMMUNOL, V25, P3035, DOI 10.1002/eji.1830251108; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; DeKruyff R, 1998, J IMMUNOL, V160, P2231; DING L, 1993, J IMMUNOL, V151, P1224; Fuss IJ, 2002, J IMMUNOL, V168, P900, DOI 10.4049/jimmunol.168.2.900; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gerosa F, 1996, J EXP MED, V183, P2559, DOI 10.1084/jem.183.6.2559; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; HANSEN G, 2000, J CLIN INVEST, V11, P89; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Kim TS, 1997, J IMMUNOL, V158, P4137; Kitani A, 2000, J EXP MED, V192, P41, DOI 10.1084/jem.192.1.41; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Macaulay AE, 1998, J IMMUNOL, V160, P1694; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Randolph DA, 1999, J IMMUNOL, V162, P2375; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113, DOI 10.1165/ajrcmb.14.2.8630259; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Segal BM, 1998, J EXP MED, V187, P537, DOI 10.1084/jem.187.4.537; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P775; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Tsitoura DC, 2000, J ALLERGY CLIN IMMUN, V106, P239; Tsuyuki S, 1997, J EXP MED, V185, P1671, DOI 10.1084/jem.185.9.1671; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Weiner HL, 2001, NAT IMMUNOL, V2, P671, DOI 10.1038/90604; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xiao BG, 1998, J NEUROIMMUNOL, V84, P230, DOI 10.1016/S0165-5728(97)00264-6; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	49	166	184	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					460	468		10.1067/mai.2002.127512	http://dx.doi.org/10.1067/mai.2002.127512			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209095	Bronze			2022-12-18	WOS:000177936900018
J	HAUGAARD, L; DAHL, R; JACOBSEN, L				HAUGAARD, L; DAHL, R; JACOBSEN, L			A CONTROLLED DOSE-RESPONSE STUDY OF IMMUNOTHERAPY WITH STANDARDIZED, PARTIALLY PURIFIED EXTRACT OF HOUSE DUST MITE - CLINICAL EFFICACY AND SIDE-EFFECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DOSE RESPONSE; IMMUNOTHERAPY; BRONCHIAL ASTHMA; HOUST DUST MITE ALLERGY	DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; INHALANT ALLERGEN IMMUNOTHERAPY; SYSTEMIC REACTIONS; CONTROLLED TRIAL; BRONCHIAL-ASTHMA; POLLEN EXTRACTS; HAY-FEVER; HYPOSENSITIZATION; SAFETY; PREDICTION	Background: Seventy-four asthmatic patients allergic to house dust mite were included in a double-blind, controlled study to establish the optimal maintenance dose of a standardized extract of Dermatophagoides pteronyssinus (Der p I) during 24 months of immunotherapy (IT). Methods: The patients were given the following maintenance doses: 19 patients 10,000 standardized quality units (SQ-U) (group 10, 0.7 mug Der p I), 20 patients 100,000 SQ-U (group 100, 7 mug Der p I), 16 patients 300,000 SQ-U (group 300, 21 mug Der p I), and 19 control patients (group 0) had no injections. After 24 months bronchial challenge demonstrated a dose-related increased tolerance to Der p I, group 10 (p = 0.003), group 100 (p = 0.0005), group 300 (p = 0.0007), with no change in group 0 (p = 0.6). Patients given IT had a decrease in medication and peak expiratory flow score. In total, 2104 injections were given, and 3.5% were followed by a systemic reaction, defined as a fall 15% or greater in forced. expiratory volume in 1 second within 30 minutes. A dose-response relation was demonstrated, with rates of systemic reactions in percent of injections; group 10, 0.56%; group 100, 3.30%; and group 300, 7.10% (p < 0.0001). No anaphylactic reactions occurred, and no late systemic reactions were observed. This study demonstrated a dose dependence of efficacy and side effects of IT in asthmatic patients. We suggest a maintenance dose of 100,000 SQ-U (7 mug Der p I) as an appropriate guideline for IT with house dust mite extract.	ALK RES GRP, HORSHOLM, DENMARK		HAUGAARD, L (corresponding author), AARHUS UNIV HOSP, DEPT RESP DIS, ALLERGOL SECT, DK-8000 AARHUS, DENMARK.		Dahl, Ronahl/F-8170-2013					AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; AMARALMARQUES R, 1978, ALLERGOL IMMUNOPATH, V6, P231; [Anonymous], 1986, Br Med J (Clin Res Ed), V293, P948; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DEBOECK C, 1984, ANN ALLERGY, V53, P30; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; FORMGREN H, 1985, ANN ALLERGY, V55, P312; FRANKLINW, 1967, JAMA-J AM MED ASSOC, V201, P95; GADDIE J, 1976, BRIT MED J, V2, P561, DOI 10.1136/bmj.2.6035.561; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; GREENBERG MA, 1988, J ALLERGY CLIN IMMUN, V82, P287, DOI 10.1016/0091-6749(88)91013-5; HALLAS TE, 1983, ALLERGOL IMMUNOPATH, V11, P195; HAUGAARD L, 1992, ALLERGY, V47, P249, DOI 10.1111/j.1398-9995.1992.tb00658.x; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; KAY AB, 1989, CLIN EXP ALLERGY, V19, P591, DOI 10.1111/j.1365-2222.1989.tb02751.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MALLING HJ, 1988, ALLERGY, V43, P5; MAUNSELL K, 1971, LANCET, V1, P967; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; MOSBECH H, 1990, ALLERGY, V45, P142, DOI 10.1111/j.1398-9995.1990.tb00472.x; MOSBECH H, 1989, ALLERGY, V44, P499, DOI 10.1111/j.1398-9995.1989.tb04189.x; MOSBECH H, 1989, ALLERGY, V44, P487, DOI 10.1111/j.1398-9995.1989.tb04188.x; MURRAY AB, 1985, ANN ALLERGY, V54, P541; NELSON BL, 1986, ANN ALLERGY, V56, P331; NEWTON DAG, 1978, BRIT J DIS CHEST, V72, P21, DOI 10.1016/0007-0971(78)90004-9; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1987, J ALLERGY CLIN IMMUN, V79, P572, DOI 10.1016/S0091-6749(87)80150-1; NORUSIS MJ, 1988, SPSS PC PLUS V 30 UP; OHMAN JL, 1989, J ALLERGY CLIN IMMUN, V84, P133, DOI 10.1016/0091-6749(89)90313-8; OSTERBALLE O, 1982, ALLERGY, V37, P553, DOI 10.1111/j.1398-9995.1982.tb02340.x; PAULI G, 1985, EUR J RESPIR DIS, V67, P369; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P205; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR B, 1974, CLIN ALLERGY, V4, P35, DOI 10.1111/j.1365-2222.1974.tb01360.x; THOMPSON RA, 1989, LANCET, V1, P259; TURKELTAUB PC, 1986, J ALLERGY CLIN IMMUN, V77, P211; TURKELTAUB PC, 1990, ALLERGY, V45, P528, DOI 10.1111/j.1398-9995.1990.tb00529.x; VALOVIRTA E, 1984, ANN ALLERGY, V53, P85; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; VANMETRE TE, 1988, ALLERGY PRINCIPLES P, V2, P1327; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x; WAHN U, 1988, J ALLERGY CLIN IMMUN, V82, P360, DOI 10.1016/0091-6749(88)90007-3; WARNER JO, 1978, LANCET, V2, P912; 1979, BR J DIS CHEST, V73, P260; 1987, AM REV RESPIR DIS, V135, P225	59	166	178	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					709	722		10.1016/0091-6749(93)90190-Q	http://dx.doi.org/10.1016/0091-6749(93)90190-Q			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454793				2022-12-18	WOS:A1993KU20300003
J	TURKELTAUB, PC; RASTOGI, SC; BAER, H; ANDERSON, MC; NORMAN, PS				TURKELTAUB, PC; RASTOGI, SC; BAER, H; ANDERSON, MC; NORMAN, PS			A STANDARDIZED QUANTITATIVE SKIN-TEST ASSAY OF ALLERGEN POTENCY AND STABILITY - STUDIES ON THE ALLERGEN DOSE-RESPONSE CURVE AND EFFECT OF WHEAL, ERYTHEMA, AND PATIENT SELECTION ON ASSAY RESULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,DIV CLIN IMMUNOL,BALTIMORE,MD 21239	Johns Hopkins University	TURKELTAUB, PC (corresponding author), US FDA,BUR BIOL,ALLERGEN PROD BRANCH,BLDG 29,RM 124,8800 ROCKVILLE PIKE,BETHESDA,MD 20205, USA.		turkeltaub, paul/U-7729-2019; turkeltaub, paul/AAG-6160-2019	turkeltaub, paul/0000-0002-7350-1469				Aas K, 1975, Dev Biol Stand, V29, P341; ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; ANDERSON MC, 1981, RAST INHIBITION PROC; ARBESMAN CARL E., 1939, JOUR ALLERGY, V10, P521, DOI 10.1016/S0021-8707(39)90247-9; AUGUSTIN R, 1959, IMMUNOLOGY, V2, P230; Axelsen N. H., 1973, SCAND J IMMUNOL S1, V2, P1; BAER H, 1980, J ALLERGY CLIN IMMUN, V66, P281, DOI 10.1016/0091-6749(80)90022-6; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BECKER EL, 1948, J ALLERGY, V19, P108, DOI 10.1016/0021-8707(48)90097-5; BECKER EL, 1948, J ALLERGY, V19, P317, DOI 10.1016/0021-8707(48)90112-9; BELIN L, 1972, INT ARCH ALLER A IMM, V42, P300, DOI 10.1159/000230613; BELIN LGA, 1977, CLIN ALLERGY, V7, P55, DOI 10.1111/j.1365-2222.1977.tb01425.x; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; Brighton W D, 1975, Dev Biol Stand, V29, P362; BROWNLEE KA, 1965, STATISTICAL THEORY M, P352; BURN JH, 1950, BIOL STANDARDIZATION, P24; Cochran W.G, 1957, STAT METHODS, V6th ed; EFRON BG, 1938, J ALLERGY, V9, P464; GERACI D, 1978, IMMUNOCHEMISTRY, V15, P491, DOI 10.1016/0161-5890(78)90079-2; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; Pepys J, 1975, Dev Biol Stand, V29, P284; SIEGEL B B, 1959, Bull World Health Organ, V21, P703; SPIES JR, 1945, J ALLERGY, V16, P267, DOI 10.1016/0021-8707(45)90012-8; SQUIRE JR, 1950, CLIN SCI, V9, P127; VARGA JM, 1972, J ALLERGY CLIN IMMUN, V49, P274, DOI 10.1016/0091-6749(72)90095-4; VOORHORST R, 1975, ANN ALLERGY, V34, P77; 1981, FED REG 39129   0731, V46	30	166	169	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					343	352		10.1016/0091-6749(82)90023-9	http://dx.doi.org/10.1016/0091-6749(82)90023-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	7130550				2022-12-18	WOS:A1982PQ10500005
J	Cao, Y; Wei, J; Zou, L; Jiang, TB; Wang, GX; Chen, LT; Huang, L; Meng, FK; Huang, LF; Wang, N; Zhou, XX; Luo, H; Mao, ZK; Chen, X; Xie, JG; Liu, J; Cheng, H; Zhao, JP; Huang, G; Wang, W; Zhou, JF				Cao, Yang; Wei, Jia; Zou, Liang; Jiang, Tiebin; Wang, Gaoxiang; Chen, Liting; Huang, Liang; Meng, Fankai; Huang, Lifang; Wang, Na; Zhou, Xiaoxi; Luo, Hui; Mao, Zekai; Chen, Xing; Xie, Jungang; Liu, Jing; Cheng, Hui; Zhao, Jianping; Huang, Gang; Wang, Wei; Zhou, Jianfeng			Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ruxolitinib; COVID-19; cytokine storm; efficacy; safety; randomized controlled trial	CHEMOKINES; PNEUMONIA; CYTOKINES; WUHAN	Background: Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation. Objective: This study evaluated the efficacy and safety of ruxolitinib, a JAK1/2 inhibitor, for coronavirus disease 2019. Methods: We conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe coronavirus disease 2019. Results: Forty-three patients were randomly assigned (1:1) to receive ruxolitinib plus standard-of-care treatment (22 patients) or placebo based on standard-of-care treatment (21 patients). After exclusion of 2 patients (1 ineligible, 1 consent withdrawn) from the ruxolitinib group, 20 patients in the intervention group and 21 patients in the control group were included in the study. Treatment with ruxolitinib plus standard-of-care was not associated with significantly accelerated clinical improvement in severe patients with coronavirus disease 2019, although ruxolitinib recipients had a numerically faster clinical improvement. Eighteen (90%) patients from the ruxolitinib group showed computed tomography improvement at day 14 compared with 13 (61.9%) patients from the control group (P = .0495). Three patients in the control group died of respiratory failure, with 14.3% overall mortality at day 28; no patients died in the ruxolitinib group. Ruxolitinib was well tolerated with low toxicities and no new safety signals. Levels of 7 cytokines were significantly decreased in the ruxolitinib group in comparison to the control group. Conclusions: Although no statistical difference was observed, ruxolitinib recipients had a numerically faster clinical improvement. Significant chest computed tomography improvement, a faster recovery from lymphopenia, and favorable side-effect profile in the ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.	[Cao, Yang; Wei, Jia; Wang, Gaoxiang; Chen, Liting; Huang, Liang; Meng, Fankai; Huang, Lifang; Wang, Na; Zhou, Xiaoxi; Luo, Hui; Mao, Zekai; Chen, Xing; Zhou, Jianfeng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Cao, Yang; Wei, Jia; Wang, Gaoxiang; Chen, Liting; Huang, Liang; Meng, Fankai; Huang, Lifang; Wang, Na; Zhou, Xiaoxi; Luo, Hui; Mao, Zekai; Chen, Xing; Zhou, Jianfeng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Clincal Trial & Res Ctr, Wuhan, Peoples R China; [Zou, Liang; Cheng, Hui] Wuhan 1 Hosp, Dept Hematol, Wuhan, Peoples R China; [Jiang, Tiebin; Liu, Jing] Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Peoples R China; [Xie, Jungang; Zhao, Jianping] Huazhong Univ Sci & Technol, Dept Resp & Crit Care Med, Key Site Natl Clin Res Ctr Resp Dis, Tongji Hosp,Tongji Med Coll,Key Lab Pulm Dis,Hlth, Wuhan, Peoples R China; [Huang, Gang] Cincinnati Childrens Hosp Med Ctr, Div Pathol, 3333 Burnet Ave,Rm S7-224, Cincinnati, OH 45229 USA; [Huang, Gang] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, 3333 Burnet Ave,Rm S7-224, Cincinnati, OH 45229 USA; [Wang, Wei] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Central South University; Huazhong University of Science & Technology; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Huazhong University of Science & Technology	Zhou, JF (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.; Huang, G (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Pathol, 3333 Burnet Ave,Rm S7-224, Cincinnati, OH 45229 USA.; Huang, G (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, 3333 Burnet Ave,Rm S7-224, Cincinnati, OH 45229 USA.; Wang, W (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.	Gang.Huang@cchmc.org; wwang@vip.126.com; jfzhou@tjh.tjmu.edu.cn	Wei, Jia/M-5397-2013; Cao, Yang/HGD-6463-2022; Huang, Liang/I-3299-2019	Huang, Liang/0000-0002-8370-3232	Emergency Research Project of Tongji Hospital; Emergency Research Project of Tongji Hospital of Huazhong University of Science and Technology [2020kfyXGYJ045]; Emergency Research Project of Hubei province [2020FCA006]	Emergency Research Project of Tongji Hospital; Emergency Research Project of Tongji Hospital of Huazhong University of Science and Technology; Emergency Research Project of Hubei province	This work was supported by the Emergency Research Project of Tongji Hospital (to J.Z.), Emergency Research Project of Tongji Hospital of Huazhong University of Science and Technology (grant no. 2020kfyXGYJ045 to J.Z.), and Emergency Research Project of Hubei province (grant no. 2020FCA006 to W.W.). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.	Ahmed A, 2019, LANCET HAEMATOL, V6, pE630, DOI 10.1016/S2352-3026(19)30156-5; Ajayi Stefanie, 2018, Recent Results Cancer Res, V212, P119, DOI 10.1007/978-3-319-91439-8_6; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1001/jama.2020.2565, 10.1056/NEJMoa2001316]; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cao YH, 2020, J MED VIROL, V92, P1449, DOI 10.1002/jmv.25822; Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x; Chen HL, 2019, FRONT MED-PRC, V13, P610, DOI 10.1007/s11684-019-0714-8; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chien JY, 2006, RESPIROLOGY, V11, P715, DOI 10.1111/j.1440-1843.2006.00942.x; China National Health Commission, 2020, DIAGN TREATM PNEUM C; Cooper AM, 2007, TRENDS IMMUNOL, V28, P33, DOI 10.1016/j.it.2006.11.002; Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119; Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC; Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jagasia M, 2020, BLOOD, V135, P1739, DOI 10.1182/blood.2020004823; Kiladjian JJ, 2020, LANCET HAEMATOL, V7, pE226, DOI 10.1016/S2352-3026(19)30207-8; Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904; Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012; Li XM, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02324-w; MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1036; Meng GQ, 2020, ANN HEMATOL, V99, P343, DOI 10.1007/s00277-019-03864-y; Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359-6101(02)00045-X; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Schulz O, 2016, ANNU REV IMMUNOL, V34, P203, DOI 10.1146/annurev-immunol-041015-055649; Stebbing Justin, 2020, Lancet Infect Dis, V20, P400, DOI 10.1016/S1473-3099(20)30132-8; Wang CH, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-42; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wang YR, 2020, J INFECT DIS, V221, P1770, DOI 10.1093/infdis/jiaa119; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Xu Zhe, 2020, Lancet Respir Med, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yan XH., 2020, RADIOL P RACTICE, V35, P428; Yao X, 2020, ZHONGHUA BING LI XUE, V49, pE009, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]; Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954; Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	38	165	169	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					137	+		10.1016/j.jaci.2020.05.019	http://dx.doi.org/10.1016/j.jaci.2020.05.019			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB		Green Published, Bronze			2022-12-18	WOS:000579170500023
J	Charbonnier, LM; Janssen, E; Chou, J; Ohsumi, TK; Keles, S; Hsu, JT; Massaad, MJ; Garcia-Lloret, M; Hanna-Wakim, R; Dbaibo, G; Alangari, AA; Alsultan, A; Al-Zahrani, D; Geha, RS; Chatila, TA				Charbonnier, Louis-Marie; Janssen, Erin; Chou, Janet; Ohsumi, Toshiro K.; Keles, Sevgi; Hsu, Joyce T.; Massaad, Michel J.; Garcia-Lloret, Maria; Hanna-Wakim, Rima; Dbaibo, Ghassan; Alangari, Abdullah A.; Alsultan, Abdulrahman; Al-Zahrani, Daifulah; Geha, Raif S.; Chatila, Talal A.			Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoantibodies; autoimmunity; forkhead box P3; immune dysregulation; polyendocrinopathy; enteropathy; X-linked syndrome; LPS-responsive beige-like anchor; mammalian target of rapamycin complex; T follicular helper cells; T follicular regulatory cells; regulatory T cells	SYSTEMIC-LUPUS-ERYTHEMATOSUS; FOXP3; AUTOIMMUNITY; EXPRESSION; DISEASE; PROTEIN; GENE; DIFFERENTIATION; ACCUMULATION; MECHANISMS	Background: A number of heritable immune dysregulatory diseases result from defects affecting regulatory T (Treg) cell development, function, or both. They include immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, which is caused by mutations in forkhead box P3 (FOXP3), and IPEX-like disorders caused by mutations in IL-2 receptor a (IL2RA), signal transducer and activator of transcription 5b (STAT5b), and signal transducer and activator of transcription 1 (STAT1). However, the genetic defects underlying many cases of IPEX-like disorders remain unknown. Objective: We sought to identify the genetic abnormalities in patients with idiopathic IPEX-like disorders. Methods: We performed whole-exome and targeted gene sequencing and phenotypic and functional analyses of Treg cells. Results: A child who presented with an IPEX-like syndrome and severe Treg cell deficiency was found to harbor a nonsense mutation in the gene encoding LPS-responsive beige-like anchor (LRBA), which was previously implicated as a cause of common variable immunodeficiency with autoimmunity. Analysis of subjects with LRBA deficiency revealed marked Treg cell depletion; profoundly decreased expression of canonical Treg cell markers, including FOXP3, CD25, Helios, and cytotoxic T lymphocyte-associated antigen 4; and impaired Treg cellmediated suppression. There was skewing in favor of memory T cells and intense autoantibody production, with marked expansion of T follicular helper and contraction of T follicular regulatory cells. Whereas the frequency of recent thymic emigrants and the differentiation of induced Treg cells were normal, LRBA-deficient T cells exhibited increased apoptosis and reduced activities of the metabolic sensors mammalian target of rapamycin complexes 1 and 2. Conclusion: LRBA deficiency is a novel cause of IPEX-like syndrome and Treg cell deficiency associated with metabolic dysfunction and increased apoptosis of Treg cells.	[Charbonnier, Louis-Marie; Janssen, Erin; Chou, Janet; Keles, Sevgi; Hsu, Joyce T.; Massaad, Michel J.; Geha, Raif S.; Chatila, Talal A.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Charbonnier, Louis-Marie; Janssen, Erin; Chou, Janet; Keles, Sevgi; Hsu, Joyce T.; Massaad, Michel J.; Geha, Raif S.; Chatila, Talal A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Ohsumi, Toshiro K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Garcia-Lloret, Maria] Univ Calif Los Angeles, Dept Pediat, Div Immunol, Los Angeles, CA 90024 USA; [Hanna-Wakim, Rima; Dbaibo, Ghassan] Amer Univ Beirut, Div Pediat Infect Dis, Beirut, Lebanon; [Alangari, Abdullah A.; Alsultan, Abdulrahman] King Saud Univ, Coll Med, Dept Pediat, Riyadh 11461, Saudi Arabia; [Al-Zahrani, Daifulah] King Abdul Aziz Med City, Immunol & Allergy Pediat Dept, Jeddah, Saudi Arabia	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of California System; University of California Los Angeles; American University of Beirut; King Saud University; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Jeddah	Chatila, TA (corresponding author), Boston Childrens Hosp, Div Immunol, One Blackfan Circle, Boston, MA 02115 USA.	talal.chatila@childrens.harvard.edu	Dbaibo, Ghassan S./X-2978-2019	Hsu, Joyce/0000-0002-1825-4733; Janssen, Erin/0000-0002-0687-2550; Chatila, Talal/0000-0001-7439-2762; Alsultan, Abdulrahman/0000-0001-5577-3228; Charbonnier, Louis-Marie/0000-0002-4594-7893	National Institutes of Health (NIH) [R01AI085090, 1R01AI100315]; Children's Health Research Centers Career Development Awards [5K12HD052896, 1K12HD052896-01A1]; Jeffrey Modell Foundation Translational Research Program Grant Award; Dubai-Harvard Foundation for Medical Research; Jeffrey Model Foundation; Scientific and Technological Research Council of Turkey [059B191300622]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI100315, R01AI085090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Health Research Centers Career Development Awards; Jeffrey Modell Foundation Translational Research Program Grant Award; Dubai-Harvard Foundation for Medical Research; Jeffrey Model Foundation; Scientific and Technological Research Council of Turkey(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health (NIH) grants R01AI085090 (to T. A.C.) and 1R01AI100315 (to R.S.G), Children's Health Research Centers Career Development Awards 5K12HD052896 and 1K12HD052896-01A1 (to E.J and J.C., respectively), a Jeffrey Modell Foundation Translational Research Program Grant Award (to J.C.), grants from the Dubai-Harvard Foundation for Medical Research and the Jeffrey Model Foundation (to R. S.G.) and a Scientific and Technological Research Council of Turkey grant 059B191300622 (to S.K.).	Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Barzaghi F, 2012, J AUTOIMMUN, V38, P49, DOI 10.1016/j.jaut.2011.12.009; Barzaghi F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00211; Burns SO, 2012, J ALLERGY CLIN IMMUN, V130, P1428, DOI 10.1016/j.jaci.2012.07.035; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chatila T, 2007, IMMUNITY, V27, P693, DOI 10.1016/j.immuni.2007.11.004; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Cohen AC, 2006, J IMMUNOL, V177, P2770, DOI 10.4049/jimmunol.177.5.2770; Cullinane AR, 2013, TRAFFIC, V14, P749, DOI 10.1111/tra.12069; de Souza N, 2007, DEVELOPMENT, V134, P691, DOI 10.1242/dev.02767; Dunlop E.A., 2014, SEMIN CELL DEV BIOL; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Fritzius T, 2008, EMBO J, V27, P1399, DOI 10.1038/emboj.2008.67; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Haribhai D, 2011, IMMUNITY, V35, P109, DOI 10.1016/j.immuni.2011.03.029; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Hubbard VM, 2010, J IMMUNOL, V185, P7349, DOI 10.4049/jimmunol.1000576; Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084/jem.20110304; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Kang HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023367; Kinnunen T, 2013, BLOOD, V121, P1595, DOI 10.1182/blood-2012-09-457465; Li QZ, 2007, CLIN EXP IMMUNOL, V147, P60, DOI 10.1111/j.1365-2249.2006.03251.x; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Ohsumi TK, 2012, BIOINFORMATICS, V28, P2412, DOI 10.1093/bioinformatics/bts458; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Sage PT, 2013, NAT IMMUNOL, V14, P152, DOI 10.1038/ni.2496; Saito R, 2005, J NEUROIMMUNOL, V170, P172, DOI 10.1016/j.jneuroim.2005.09.001; Sampaio EP, 2012, J CLIN IMMUNOL, V32, P681, DOI 10.1007/s10875-012-9659-2; Sharfe N, 1997, P NATL ACAD SCI USA, V94, P3168, DOI 10.1073/pnas.94.7.3168; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Simpson N, 2010, ARTHRITIS RHEUM-US, V62, P234, DOI 10.1002/art.25032; Torgerson TR, 2007, J ALLERGY CLIN IMMUN, V120, P744, DOI 10.1016/j.jaci.2007.08.044; Van der Auwera GA, 2013, CURR PROTOC BIOINFOR, V43; Verbsky JW, 2013, CURR OPIN PEDIATR, V25, P708, DOI 10.1097/MOP.0000000000000029; Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567; Wang JW, 2001, J IMMUNOL, V166, P4586, DOI 10.4049/jimmunol.166.7.4586; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wollenberg I, 2011, J IMMUNOL, V187, P4553, DOI 10.4049/jimmunol.1101328; Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297	43	165	174	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					217	U336		10.1016/j.jaci.2014.10.019	http://dx.doi.org/10.1016/j.jaci.2014.10.019			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25468195	Green Accepted, Bronze			2022-12-18	WOS:000347298200026
J	Malinovschi, A; Fonseca, JA; Jacinto, T; Alving, K; Janson, C				Malinovschi, Andrei; Fonseca, Joao A.; Jacinto, Tiago; Alving, Kjell; Janson, Christer			Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; wheeze; exhaled nitric oxide; blood eosinophils; National Health and Nutrition Examination Survey; inflammation	OBSTRUCTIVE PULMONARY-DISEASE; GENERAL-POPULATION SAMPLE; CATIONIC PROTEIN; PERSISTENT ASTHMA; INFLAMMATORY MARKERS; AIRWAY INFLAMMATION; BRONCHIAL-ASTHMA; DOUBLE-BLIND; CHILDREN; EXACERBATIONS	Background: Fraction of exhaled nitric oxide (FENO) and blood eosinophil count (B-Eos) values, markers of local and systemic eosinophilic inflammation, respectively, are increased in asthmatic patients. Little is known about the relation of these markers to reportedwheeze and asthma events in a random population sample. Objectives: We sought to determine the individual and independent values of B-Eos and FENO in relation to wheeze, asthma diagnosis, and asthma events in a cross-sectional study. Methods: FENO and B-Eos values were measured in 12,408 subjects aged 6 to 80 years from the National Health and Nutrition Examination Survey 2007-2008 and 2009-2010. Current wheeze and asthma diagnosis, as well as asthma attacks and asthma-related emergency department (ED) visits within the last 12 months, were assessed by means of questionnaires. Results: Intermediate or high FENO values and intermediate or high B-Eos values were independently associated with having asthma, wheeze, and asthma attacks. However, only intermediate and high B-Eos values were independently associated with asthma-related ED visits. High FENO (>= 50 ppb) and B-Eos (>= 500 cells/ mm(3)) values rendered an adjusted odds ratio of 4.5 of having wheeze, 5.1 of having asthma, 5.4 for asthma attacks, and 2.9 for asthma-related ED visits compared with normal FENO (< 25 ppb) and B-Eos (< 300 cells/ mm(3)) values. Conclusions: Exhaled nitric oxide and B-Eos values offered independent information in relation to the prevalence of wheeze, asthma diagnosis, and asthma events in this random population sample. The clinical importance of these findings in asthmatic patients with regard to phenotyping and individualized treatment, considering both local and systemic eosinophilic inflammation, needs to be determined.	[Malinovschi, Andrei] Uppsala Univ, Dept Med Sci Clin Physiol, S-75185 Uppsala, Sweden; [Alving, Kjell] Uppsala Univ, Dept Womens & Childrens Hlth, S-75185 Uppsala, Sweden; [Janson, Christer] Uppsala Univ, Dept Med Sci Resp Med & Allergol, S-75185 Uppsala, Sweden; [Fonseca, Joao A.; Jacinto, Tiago] Univ Porto, Fac Med, CINTESIS, P-4100 Oporto, Portugal; [Fonseca, Joao A.; Jacinto, Tiago] Inst & Hosp CUF Porto, Oporto, Portugal	Uppsala University; Uppsala University; Uppsala University; Universidade do Porto	Malinovschi, A (corresponding author), Uppsala Univ, Dept Med Sci Clin Physiol, Akad Sjukhuset, S-75185 Uppsala, Sweden.	Andrei.Malinovschi@medsci.uu.se	Fonseca, João A./B-7562-2008; Jacinto, Tiago/G-9826-2014; Alving, Kjell/M-4579-2014; , CINTESIS/C-6631-2014	Fonseca, João A./0000-0002-0887-8796; Jacinto, Tiago/0000-0002-7897-1101; Alving, Kjell/0000-0003-0784-0443; , CINTESIS/0000-0001-7248-2086	Uppsala University Hospital; Aerocrine AB; Merck; Novartis	Uppsala University Hospital; Aerocrine AB; Merck(Merck & Company); Novartis(Novartis)	A.M. was supported by Uppsala University Hospital.; Disclosure of potential conflict of interest: J. A. Fonseca has received payment for lectures from Aerocrine AB, Merck, and Novartis. K. Alving is employed by and receives stock/stock options from Aerocrine AB. The rest of the authors declare that they have no relevant conflicts of interest.	Alving K, 2010, EUR RESPIR MONOGR, P1, DOI 10.1183/1025448x.00028509; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P912; Bastain TM, 2011, EUR RESPIR J, V37, P523, DOI 10.1183/09031936.00021210; BJORNSSON E, 1994, ALLERGY, V49, P730, DOI 10.1111/j.1398-9995.1994.tb02095.x; BURROWS B, 1991, J ALLERGY CLIN IMMUN, V88, P870, DOI 10.1016/0091-6749(91)90243-H; BURROWS B, 1980, AM REV RESPIR DIS, V122, P709, DOI 10.1164/arrd.1980.122.5.709; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Currie GP, 2003, ALLERGY, V58, P602, DOI 10.1034/j.1398-9995.2003.00188.x; DeMore JP, 2009, J ALLERGY CLIN IMMUN, V124, P245, DOI 10.1016/j.jaci.2009.05.030; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Gotlib J, 2011, AM J HEMATOL, V86, P678, DOI 10.1002/ajh.22062; Grissell TV, 2005, AM J RESP CRIT CARE, V172, P433, DOI 10.1164/rccm.200412-1621OC; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Hospers JJ, 1999, AM J RESP CRIT CARE, V160, P1869, DOI 10.1164/ajrccm.160.6.9811041; Ishigaki N, 2000, Arerugi, V49, P1093; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Kips JC, 1998, CLIN EXP ALLERGY, V28, P1; Malinovschi A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-92; Mattes J, 1999, EUR RESPIR J, V13, P1391, DOI 10.1183/09031936.99.13613969; Nielsen LP, 2009, ALLERGY, V64, P733, DOI 10.1111/j.1398-9995.2008.01869.x; Nordvall SL, 2005, ALLERGY, V60, P469, DOI 10.1111/j.1398-9995.2005.00735.x; Olin AC, 2010, AM J RESP CRIT CARE, V181, P324, DOI 10.1164/rccm.200907-1079OC; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pijnenburg M W, 2001, Ned Tijdschr Geneeskd, V145, P946; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; See KC, 2013, CHEST, V143, P107, DOI 10.1378/chest.12-0416; SIMMONS A, 1974, J CLIN PATHOL, V27, P55, DOI 10.1136/jcp.27.1.55; Spahn JD, 2006, ANN ALLERG ASTHMA IM, V96, P541, DOI 10.1016/S1081-1206(10)63548-X; Stelmach I, 2002, J ALLERGY CLIN IMMUN, V109, P257, DOI 10.1067/mai.2002.121456; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Syk J, 2012, EUR RESPIR J, V40, p797s; van der Valk RJP, 2012, ALLERGY, V67, P265, DOI 10.1111/j.1398-9995.2011.02734.x; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wos M, 2008, AM J RESP CRIT CARE, V177, P1082, DOI 10.1164/rccm.200607-973OC; Wouters Emiel F M, 2009, Proc Am Thorac Soc, V6, P638, DOI 10.1513/pats.200907-073DP	38	165	174	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					821	+		10.1016/j.jaci.2013.06.007	http://dx.doi.org/10.1016/j.jaci.2013.06.007			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23890753	Green Published			2022-12-18	WOS:000325096500006
J	Fujimura, KE; Johnson, CC; Ownby, DR; Cox, MJ; Brodie, EL; Havstad, SL; Zoratti, EM; Woodcroft, KJ; Bobbitt, KR; Wegienka, G; Boushey, HA; Lynch, SV				Fujimura, Kei E.; Johnson, Christine C.; Ownby, Dennis R.; Cox, Michael J.; Brodie, Eoin L.; Havstad, Suzanne L.; Zoratti, Edward M.; Woodcroft, Kimberley J.; Bobbitt, Kevin R.; Wegienka, Ganesa; Boushey, Homer A.; Lynch, Susan V.			Man's best friend? The effect of pet ownership on house dust microbial communities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXPOSURE; ALLERGY		[Fujimura, Kei E.; Cox, Michael J.; Lynch, Susan V.] Univ Calif San Francisco, Div Gastroenterol, Colitis & Crohns Dis Ctr, San Francisco, CA 94143 USA; [Boushey, Homer A.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, San Francisco, CA USA; [Johnson, Christine C.; Havstad, Suzanne L.; Woodcroft, Kimberley J.; Bobbitt, Kevin R.; Wegienka, Ganesa] Henry Ford Hosp, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; [Zoratti, Edward M.] Henry Ford Hosp, Dept Internal Med, Div Allergy & Immunol, Detroit, MI 48202 USA; [Ownby, Dennis R.] Med Coll Georgia, Dept Pediat, Div Allergy Immunol, Augusta, GA 30912 USA; [Brodie, Eoin L.] Lawrence Berkeley Natl Lab, Ctr Environm Biotechnol, Berkeley, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Fujimura, KE (corresponding author), Univ Calif San Francisco, Div Gastroenterol, Colitis & Crohns Dis Ctr, San Francisco, CA 94143 USA.	susan.lynch@ucsf.edu	Brodie, Eoin L/A-7853-2008; Cox, Michael/A-6959-2010	Brodie, Eoin L/0000-0002-8453-8435; Johnson, Christine Cole/0000-0002-6864-6604; Cox, Michael/0000-0002-4002-1506	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059415, R01AI050681] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI050681, R01 AI059415-05, R01 AI050681-05, R01 AI059415] Funding Source: Medline; PHS HHS [A159415, A150681] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aichbhaumik N, 2008, CLIN EXP ALLERGY, V38, P1787, DOI 10.1111/j.1365-2222.2008.03079.x; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Brodie EL, 2006, APPL ENVIRON MICROB, V72, P6288, DOI 10.1128/AEM.00246-06; Havaux X, 2005, CLIN EXP IMMUNOL, V139, P179, DOI 10.1111/j.1365-2249.2004.02679.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Penders J, 2006, CLIN EXP ALLERGY, V36, P1602, DOI 10.1111/j.1365-2222.2006.02599.x; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010	9	165	167	3	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2								10.1016/j.jaci.2010.05.042	http://dx.doi.org/10.1016/j.jaci.2010.05.042			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20633927	Green Accepted			2022-12-18	WOS:000281203800038
J	Nomura, T; Sandilands, A; Akiyama, M; Liao, HH; Evans, AT; Sakai, K; Ota, M; Sugiura, H; Yamamoto, K; Sato, H; Palmer, CNA; Smith, FJD; McLean, WHI; Shimizu, H				Nomura, Toshifumi; Sandilands, Aileen; Akiyama, Masashi; Liao, Haihui; Evans, Alan T.; Sakai, Kaori; Ota, Mitsuhito; Sugiura, Hisashi; Yamamoto, Kazuo; Sato, Hiroshi; Palmer, Colin N. A.; Smith, Frances J. D.; McLean, W. H. Irwin; Shimizu, Hiroshi			Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						filaggrin; eczema; ichthyosis; keratinization; skin barrier; atopy; skin; genodermatosis; genetics; mutation	OF-FUNCTION MUTATIONS; PREDISPOSE; BARRIER; MODEL	Background: Filaggrin is a key protein involved in skin barrier function. Recently, mutations in the filaggrin gene, FLG, were identified in European families with ichthyosis vulgaris (IV) and shown to be an important predisposing factor for atopic dermatitis (AD). Objective: To study the role of FLG mutations in IV/AD in Japan. Methods: The known filaggrin mutations were studied by genotyping and new mutations identified by DNA sequencing. Results: The European-specific mutations R501X and 2282del4 were absent from 253 Japanese individuals. We therefore sequenced the FLG gene in 4 Japanese families with IV and identified 2 novel mutations, 3321delA and S2554X. Immunohistologic and ultrastructural observations indicated that both truncation mutations lead to a striking reduction of keratohyalin granules in the epidermis. We screened 143 Japanese patients with AD for these FLG null mutations and identified them in 8 patients with AD (5.6%), including S2554X in 6 patients (4.2%) and 3321delA in 2 patients (1.4%). Both null variants were absent from 156 unrelated Japanese nonatopic and nonichthyotic controls, giving a significant statistical association between the FLG mutations and AD (chi(2) P value, .0015). This is the first report of FLG mutations in a non-European population. Conclusion: Our data indicate that FLG mutations in Japan are unique from those found in European-origin populations. Clinical implications: Filaggrin null variants are also significant predisposing factors for AD in Japan and, on the basis of the recent European studies, may predict a more severe and persistent form of atopy.	Hokkaido Univ, Dept Dermatol, Grad Sch Med, Sapporo, Hokkaido, Japan; Univ Dundee, Epithelial Genet Grp, Human Genet Unit, Div Pathol & Neurosci,Ninewells Hosp & Med Sch, Dundee, Scotland; Tayside Univ Hosp, Natl Hlth Serv Trust, Dept Pathol, Dundee, Scotland; Oji Gen Hosp, Dept Dermatol, Tomakomai, Japan; Shiga Univ Med Sci, Dept Biosci, Otsu, Shiga, Japan; Univ Dundee, Ninewells Hosp & Med Sch, Populat Pharmacogenet Grp, Biomed Res Ctr, Dundee DD1 9SY, Scotland	Hokkaido University; University of Dundee; Shiga University of Medical Science; University of Dundee	McLean, WHI (corresponding author), Univ Dundee, Human Genet Unit, Dundee DD1 9SY, Scotland.	w.h.i.mclean@dundee.ac.uk	Akiyama, Masashi/I-1122-2012; Palmer, Colin/C-7053-2008	McLean, William Henry Irwin/0000-0001-5539-5757; Palmer, Colin/0000-0002-6415-6560; Nomura, Toshifumi/0000-0002-9954-6446	Medical Research Council [G0700314] Funding Source: Medline; MRC [G0700314] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARKER JN, 2006, J INVEST DERMAT 0921; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; DALE BA, 1985, ANN NY ACAD SCI, V455, P330, DOI 10.1111/j.1749-6632.1985.tb50420.x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Listwan P, 2004, METHOD CELL BIOL, V78, P817; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; MEVORAH B, 1985, BRIT J DERMATOL, V112, P679, DOI 10.1111/j.1365-2133.1985.tb02336.x; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Rawlings A.V., 2004, DERMATOL THER, V17, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; STEMMLER S, 2006, J INVEST DERMAT 0928; SYBERT VP, 1985, J INVEST DERMATOL, V84, P191, DOI 10.1111/1523-1747.ep12264813; VOLZ A, 1993, GENOMICS, V18, P92, DOI 10.1006/geno.1993.1430; WEIDINGER S, 2006, J INVEST DERMAT 1109; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004	23	165	178	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					434	440		10.1016/j.jaci.2006.12.646	http://dx.doi.org/10.1016/j.jaci.2006.12.646			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291859				2022-12-18	WOS:000244327900023
J	Fitzpatrick, AM; Gaston, BM; Erzurum, SC; Teague, WG				Fitzpatrick, Anne M.; Gaston, Benjamin M.; Erzurum, Serpil C.; Teague, W. Gerald		Natl Inst Hlth; Natl Heart Lung Blood Inst Severe	Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; asthma; atopy; nitric oxide; pulmonary function testing	DIFFICULT ASTHMA; ALLERGEN EXPOSURE; CHILDHOOD ASTHMA; RISK-FACTORS; INFLAMMATION; DISPARITIES; SYMPTOMS; VALUES	Background: Children with severe asthma have persistent symptoms despite treatment with inhaled corticosteroids (ICSs). The differentiating features of severe asthma in children are poorly defined. Objective: To identify features of severe versus mild-to-moderate asthma in school-age children using noninvasive assessments of lung function, atopy, and airway inflammation. Methods: A total of 75 children (median age, 10 years) with asthma underwent baseline characterization including spirometry and lung volume testing, methacholine bronchoprovocation, allergy evaluation, and offline measurement of exhaled nitric oxide (F-ENO). Twenty-eight were followed longitudinally over 6 months. Participants were assigned to the severe asthma subgroup if they required high-dose ICS plus 2 or more minor criteria. Results: Children with severe versus mild-to-moderate asthma had more symptoms, greater airway obstruction, more gas trapping, and increased bronchial responsiveness to methacholine. Subjects with severe asthma also had higher concentrations of F-ENO and significantly greater sensitization to aeroallergens. With long-term study, both the reduction in FEVI and increase in F-ENO persisted in the severe versus mild-to-moderate group. Furthermore, despite adjustments in ICS doses, the frequency of exacerbations was significantly higher in subjects with severe (83%) versus mild-to-moderate asthma (43%). Conclusion: Severe asthma in childhood is characterized by poor symptom control despite high-dose ICS treatment and can be differentiated from mild-to-moderate asthma by measurement of lung function and F-ENO. Clinical implications: Clinicians should suspect severe asthma in children with poor response to ICS, airway obstruction, and high F-ENO.	Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; Univ Virginia, Dept Pediat, Charlottesville, VA 22903 USA	Emory University; University of Virginia	Fitzpatrick, AM (corresponding author), Emory Univ, Sch Med, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu		Fitzpatrick, Anne/0000-0002-2933-5926	NHLBI NIH HHS [R01 HL069170, U10 HL109250, R01 HL069170-06, R01 HL69170] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069170] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; *AM THOR SOC EUR R, 2005, AM H RESP CRIT CARE, V181, P912; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Berkman N, 2005, THORAX, V60, P383, DOI 10.1136/thx.2004.031104; Borish L, 2005, ANN ALLERG ASTHMA IM, V95, P247, DOI 10.1016/S1081-1206(10)61221-5; Brussee JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604; Cieslewicz G, 1999, J CLIN INVEST, V104, P301, DOI 10.1172/JCI7010; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Crater SE, 1999, AM J RESP CRIT CARE, V159, P806, DOI 10.1164/ajrccm.159.3.9805103; de Blic J, 2004, J ALLERGY CLIN IMMUN, V113, P94, DOI 10.1016/j.jaci.2003.10.045; de Kluijver J, 2002, AM J RESP CRIT CARE, V166, P294, DOI 10.1164/rccm.2112097; *EUR RESP SOC TASK, 2002, EUR RESPIR J, V20, P1; Frank TL, 1998, AM J RESP CRIT CARE, V158, P1032, DOI 10.1164/ajrccm.158.4.9707143; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Higgins PS, 2005, CHEST, V128, P3846, DOI 10.1378/chest.128.6.3846; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; McDaniel M, 2006, PEDIATRICS, V117, pE868, DOI 10.1542/peds.2005-1721; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; *NAT ASTHM ED PREV, 2003, 025075 NAT HEART LUN; Nelson BV, 1997, J PEDIATR-US, V130, P423, DOI 10.1016/S0022-3476(97)70204-X; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Payne DNR, 2001, THORAX, V56, P345, DOI 10.1136/thorax.56.5.345; Pearlman DN, 2006, J NATL MED ASSOC, V98, P239; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Roberts G, 2004, THORAX, V59, P752, DOI 10.1136/thx.2003.008722; Robinson DS, 2003, EUR RESPIR J, V22, P478, DOI 10.1183/09031936.03.00017003; Stirling RG, 1998, THORAX, V53, P1030, DOI 10.1136/thx.53.12.1030; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Warke TJ, 2002, THORAX, V57, P383, DOI 10.1136/thorax.57.5.383; Wraight JM, 2002, RESPIROLOGY, V7, P133, DOI 10.1046/j.1440-1843.2002.00374.x	37	165	166	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1218	1225		10.1016/j.jaci.2006.08.019	http://dx.doi.org/10.1016/j.jaci.2006.08.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157650	Green Accepted			2022-12-18	WOS:000242880300003
J	Mastalerz, L; Setkowicz, M; Sanak, M; Szczeklik, A				Mastalerz, L; Setkowicz, M; Sanak, M; Szczeklik, A			Hypersensitivity to aspirin: Common eicosanoid alterations in urticaria and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						urticaria; eicosanoids; aspirin; NSAIDs; asthma	LEUKOTRIENE C-4 SYNTHASE; CHRONIC IDIOPATHIC URTICARIA; PROMOTER POLYMORPHISM; RECEPTOR ANTAGONIST; BRONCHIAL-ASTHMA; AUTOANTIBODIES; MONTELUKAST; INTOLERANCE; HISTAMINE; RELEASE	Background: Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) can precipitate adverse reactions in two apparently different clinical conditions: bronchial asthma and chronic idiopathic urticaria (CIU). Recent evidence indicates that the reactions are triggered by the drugs that inhibit cyclooxygenase-1 but not cyclooxygenase-2. Objective: To assess whether patients with CIU and aspirin sensitivity share common eicosanoid alterations with patients who have aspirin-sensitive asthma. Methods: Seventy-four patients with CIU and a history of sensitivity to aspirin and NSAIDs underwent placebo-controlled oral aspirin challenge tests. Concentrations of urinary leukotriene E4 (uLTE4) were measured by ELISA and plasma stable prostaglandin D2 metabolite, 9alpha,11beta prostaglandin F-2 by GC/MS. All measurements were carried out at baseline and after aspirin dosing. Patients were genotyped for the leukotriene C4 synthase (LTC4S) promoter single nucleotide polymorphism. Results: In 30 of 74 patients, the aspirin challenge was positive, resulting in urticaria/angioedema. In these 30 patients, baseline uLTE4 levels were higher than in nonresponders and the healthy control subjects and increased further (significantly) after the onset of clinical reaction. No such increase occurred in subjects with negative aspirin challenge. Baseline uLTE4 levels correlated with severity of skin reactions. Plasma 9alpha,11beta prostaglandin F2 levels rose significantly in both aspirin responders and nonresponders, although in the latter group the increase occurred later than in the former. In patients who reacted to aspirin, frequency of C-444 allele of LTC4S was significantly higher than in patients who did not react. Conclusions: CIU with aspirin sensitivity is characterized by the eicosanoid alterations, which are similar to those present in aspirin-induced asthma.	Jagiellonian Univ, Sch Med, Dept Med, PL-31066 Krakow, Poland; Jagiellonian Univ, Sch Med, Dept Dermatol, PL-31066 Krakow, Poland	Jagiellonian University; Jagiellonian University	Szczeklik, A (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, Skawinska 8, PL-31066 Krakow, Poland.		Mastalerz, Lucyna/U-5974-2018; Sanak, Marek/AAV-1628-2021; Sanak, Marek/A-2115-2008	Mastalerz, Lucyna/0000-0002-8994-0036; Sanak, Marek/0000-0001-7635-8103; 				Asano K, 2002, PHARMACOGENETICS, V12, P565, DOI 10.1097/00008571-200210000-00009; Asero R, 2002, ANN ALLERG ASTHMA IM, V88, P468, DOI 10.1016/S1081-1206(10)62384-8; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Berges-Gimeno MP, 2001, ALLERGY, V56, P1017, DOI 10.1034/j.1398-9995.2001.00206.x; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Celik G, 2001, CLIN EXP ALLERGY, V31, P1615, DOI 10.1046/j.1365-2222.2001.01074.x; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Di Lorenzo G, 2002, ALLERGY, V57, P1180, DOI 10.1034/j.1398-9995.2002.23767.x; Erbagci Z, 2002, J ALLERGY CLIN IMMUN, V110, P484, DOI 10.1067/mai.2002.126676; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; FOLCO G, 1999, NOVEL INHIBITORS LEU; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Greaves MW, 2002, INT ARCH ALLERGY IMM, V127, P3, DOI 10.1159/000048163; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; JUHLIN L, 1981, BRIT J DERMATOL, V104, P369, DOI 10.1111/j.1365-2133.1981.tb15306.x; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; KUMLIN M, 1995, CLIN EXP ALLERGY, V25, P467, DOI 10.1111/j.1365-2222.1995.tb01079.x; Marone G., 2000, MAST CELLS BASOPHILS; Nasser SMS, 1998, LUNG BIOL HEALTH DIS, V114, P317; NETTIS E, 2002, ANN ALLERGY ASTHMA I; OBATA T, 1994, J CHROMATOGR B, V655, P173, DOI 10.1016/0378-4347(94)00100-6; Pacor ML, 2001, CLIN EXP ALLERGY, V31, P1607, DOI 10.1046/j.1365-2222.2001.01189.x; PACOR ML, 2002, CLIN EXP ALLERGY, V109, pS140; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; SANCHEZBORGES M, 2003, ACI INT, V15, P110; Sayers I, 2003, THORAX, V58, P417, DOI 10.1136/thorax.58.5.417; Setkowicz M., 2003, Journal of Allergy and Clinical Immunology, V111, pS272, DOI 10.1016/S0091-6749(03)80977-6; SETTIPANE GA, 1990, ALLERGY PROC, V11, P251, DOI 10.2500/108854190778879909; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; STEVENSON DD, 1998, ALLERGY PRINCIPLES P, P1225; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1995, LANCET, V345, P1056, DOI 10.1016/S0140-6736(95)90799-8; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; SZCZEKLIK A, 1995, AM J RESP CRIT CARE, V152, P1753, DOI 10.1164/ajrccm.152.6.8520733; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Van Sambeek R, 2000, J ALLERGY CLIN IMMUN, V106, P72, DOI 10.1067/mai.2000.107603; Zembowicz A, 2003, ARCH DERMATOL, V139, P1577, DOI 10.1001/archderm.139.12.1577	43	165	169	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					771	775		10.1016/j.jaci.2003.12.323	http://dx.doi.org/10.1016/j.jaci.2003.12.323			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100686	Green Published			2022-12-18	WOS:000220956600028
J	Kapp, A; Papp, K; Bingham, A; Folster-Holst, R; Ortonne, JP; Potter, PC; Gulliver, W; Paul, C; Molloy, S; Barbier, N; Thurston, M; de Prost, Y				Kapp, A; Papp, K; Bingham, A; Folster-Holst, R; Ortonne, JP; Potter, PC; Gulliver, W; Paul, C; Molloy, S; Barbier, N; Thurston, M; de Prost, Y		Flare Reduct Eczema Elidel	Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pimecrolimus; Elidel; SDZ ASM 981; atopic dermatitis; eczema; long-term management	PERCUTANEOUS-ABSORPTION; SDZ ASM-981; SKIN; CHILDREN; ECZEMA; HYDROCORTISONE; SDZ-ASM-981; SEVERITY; INDEX	Background: Pimecrolimus cream 1% (Elidel, SDZ ASM 981), a nonsteroid selective inhibitor of inflammatory cytokines, is effective in the treatment of atopic dermatitis (AD). In this study we compared early intervention with pimecrolimus cream with treatment with a vehicle control. Objective: The purpose of this investigation was to assess whether early treatment in infants of AD signs/symptoms with pimecrolimus could influence long-term outcome by preventing disease flares. Methods: In this 1-year, double-blind controlled study, 251 infants aged 3 to 23 months with AD were randomized 4:1 to a pimecrolimus-based regimen (n = 204) or a conventional treatment regimen (n = 47). Both groups used emollients for dry skin. Early AD signs and symptoms were treated either with pimecrolimus cream to prevent flares or, in the control group, with vehicle. Vehicle was used to maintain blinding conditions. In the event of flares, moderately potent corticosteroid was permitted in both groups. The primary efficacy end point was the incidence of flares at 6 months. Results: Pimecrolimus significantly reduced the incidence of flares compared with control treatment (P < .001), with 67.6% versus 30.4% of patients completing 6 months with no flare and 56.9% versus 28.3% completing 12 months with no flare. Overall corticosteroid use was substantially lower in the pimecrolimus group: 63.7% versus 34.8% of patients did not use corticosteroids at all during the study. Pimecrolimus was also more effective than control treatment in the long-term control of pruritus and the signs of AD. There were no clinically significant differences in incidence of adverse events between the 2 treatment groups. Conclusions: Treatment with pimecrolimus of early signs and symptoms significantly modified the disease course in infants by reducing the incidence of flares and improving overall control of AD. Pimecrolimus was safe and well tolerated.	Hannover Med Sch, Dept Dermatol & Allergol, D-30449 Hannover, Germany; Grp Hosp Necker Enfants Malad, Paris, France; Novartis Pharma AG, Basel, Switzerland; Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; Hop Archet 2, Nice, France; Univ Kiel, Hautklin, Kiel, Germany; Royal Hosp, Belfast, Antrim, North Ireland; Prob Med Res, Waterloo, ON, Canada	Hannover Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Novartis; University of Cape Town; CHU Nice; University of Kiel	Kapp, A (corresponding author), Hannover Med Sch, Dept Dermatol & Allergol, Ricklingerstr 5, D-30449 Hannover, Germany.			Paul, Carle/0000-0003-0165-5263; Kapp, Alexander/0000-0002-1748-6276; Papp, Kim A./0000-0001-9557-3642				BODE HH, 1980, JAMA-J AM MED ASSOC, V244, P813, DOI 10.1001/jama.244.8.813; Charman CR, 2000, BRIT J DERMATOL, V142, P931, DOI 10.1046/j.1365-2133.2000.03473.x; Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187; FISCHER G, 1996, AUST J DERMATOL S1, V37, P10; Fukaya M, 2000, DERMATOLOGY, V201, P242, DOI 10.1159/000018495; GOULD AL, 1980, BIOMETRICS, V36, P721, DOI 10.2307/2556126; Grassberger M, 1999, BRIT J DERMATOL, V141, P264; Gunther S, 1976, Z Hautkr, V51, P569; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Harper J, 2001, BRIT J DERMATOL, V144, P781, DOI 10.1046/j.1365-2133.2001.04133.x; Hepburn D, 1994, Adv Dermatol, V9, P225; HILL CJH, 1978, CUTIS, V21, P624; Hoare C, 2000, Health Technol Assess, V4, P1; Hultsch T, 1998, ARCH DERMATOL RES, V290, P501, DOI 10.1007/s004030050343; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPP A, 1995, CLIN EXP ALLERGY, V25, P210, DOI 10.1111/j.1365-2222.1995.tb01031.x; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; LARSEN FS, 1993, MONOGR ALLERGY, V31, P9; Lewis-Jones MS, 2001, BRIT J DERMATOL, V144, P104, DOI 10.1046/j.1365-2133.2001.03960.x; MCLEAN CJ, 1995, LANCET, V345, P330, DOI 10.1016/S0140-6736(95)90324-0; Meingassner JG, 1997, BRIT J DERMATOL, V137, P568, DOI 10.1111/j.1365-2133.1997.tb03788.x; MORLEY N, 1988, PRACTITIONER, V232, P949; Queille C, 1984, Pediatr Dermatol, V1, P246, DOI 10.1111/j.1525-1470.1984.tb01124.x; Queille-Roussel C, 2001, BRIT J DERMATOL, V144, P507, DOI 10.1046/j.1365-2133.2001.04076.x; Raimer SS, 2000, CLIN PEDIATR, V39, P1, DOI 10.1177/000992280003900101; RUIZMALDONADO R, 1982, AM J DIS CHILD, V136, P274, DOI 10.1001/archpedi.1982.03970390088024; Sackett DL, 2000, EVIDENCE BASED MED; SAURAT JH, 1982, SEM HOP PARIS, V58, P1643; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; TURPEINEN M, 1986, BRIT J DERMATOL, V115, P475, DOI 10.1111/j.1365-2133.1986.tb06242.x; TURPEINEN M, 1988, BRIT J DERMATOL, V118, P517, DOI 10.1111/j.1365-2133.1988.tb02461.x; Wadonda N, 2000, BR J DERMATOL S57, V143, P33; Werfel T, 2001, ALLERGY, P105	33	165	191	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					277	284	UNSP 1/85/126500	10.1067/mai.2002.126500	http://dx.doi.org/10.1067/mai.2002.126500			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170269				2022-12-18	WOS:000177509800013
J	Helenius, I; Rytila, P; Sarna, S; Lumme, A; Helenius, M; Remes, V; Haahtela, T				Helenius, I; Rytila, P; Sarna, S; Lumme, A; Helenius, M; Remes, V; Haahtela, T			Effect of continuing or finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: A 5-year prospective follow-up study of 42 highly trained swimmers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; athletes; airway inflammation; bronchial hyperresponsiveness; swimming; sports medicine	INDUCED SPUTUM; PREVALENCE; RESPONSIVENESS; EXPOSURE; RISK	Background: Mild eosinophilic airway inflammation and bronchial hyperresponsiveness-ie, mild asthma-have been shown to affect a high proportion of endurance athletes. The persistence of airway inflammation, bronchial hyperresponsiveness, and asthma in this population is not known, however, inasmuch as follow-up studies of athletes' asthma have not been performed. Objective: The purpose of this study was to investigate effect of finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma. Methods: Forty-two elite competitive swimmers, most of them from the Finnish national team (37/42; 88%), were followed for 5 years in a prospective manner. All of the swimmers completed questionnaires and underwent resting spirometry, histamine challenge testing, and skin prick tests at baseline and at follow-up. Twenty-nine swimmers (69%) also gave induced sputum samples on both occasions. Sixteen (38%) of the swimmers had continued their competitive careers during follow-up (active swimmers), but 26 (62%) had stopped competing more than 3 months before the follow-up examination (past swimmers). Results: Bronchial responsiveness was increased in 7 (44%) of the 16 active swimmers at baseline and in 8 (50%) of the 16 active swimmers at follow-up; it was increased in 8 (31%) of the 26 past swimmers at baseline and in 3 (12%) of the 26 past swimmers at follow-up (McNemar test, P = .025). The difference in the change in bronchial hyperresponsiveness between the study groups was significant (likelihood ratio test, P = .023). Current asthma (defined as bronchial hyperresponsiveness and exercise-induced bronchial symptoms monthly) was observed in 5 (31%) of the active swimmers at baseline and in 7 (44%) of the active swimmers at follow-up; of the past swimmers, it occurred in 6 (23%) at baseline and in 1 (4%) at follow-up (McNemar test, P = .025). The difference in the change in current asthma between the study groups was significant (likelihood ratio test, P = .0040). The sputum differential cell counts of eosinophils and lymphocytes increased significantly during the follow-up period in the active swimmers (Wilcoxon signed rank sum test; P = .033 and P = .0029, respectively); in the past swimmers, the sputum differential cell counts of eosinophils tended to decrease during the follow-up period (P = .17), whereas the differential cell counts of lymphocytes did not change significantly. The changes in the sputum differential cell counts of eosinophils between the study groups differed significantly (Mann-Whitney U test, P = .019). Conclusion: In swimmers who had stopped high-level training, bronchial hyperresponsiveness and asthma attenuated or even disappeared. Mild eosinophilic airway inflammation was aggravated among highly trained swimmers who remained active during the 5-year follow-up. Our results suggest that athletes' asthma is partly reversible and that it may develop during and subside after an active sports career.	Univ Helsinki, Cent Hosp, Div Allergy, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Helenius, I (corresponding author), Arhipanpolku 8 B A, FIN-00420 Helsinki, Finland.		Helenius, Ilkka/AAM-5803-2020	Sarna, Seppo/0000-0003-3458-1627				AGGAZZOTTI G, 1993, ARCH ENVIRON HEALTH, V48, P250, DOI 10.1080/00039896.1993.9940368; *AM THOR SOC, 1987, AM REV RESPIR DIS, V121, P1285; Anderson SD, 1997, ALLERGIC RESP DIS SP, P87; Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676, DOI 10.1164/ajrccm.149.6.8004329; Drobnic F, 1996, MED SCI SPORT EXER, V28, P271, DOI 10.1097/00005768-199602000-00018; *FINN MIN ED, 1998, WAT QUAL IND SWIMM P; FITCH KD, 1984, J ALLERGY CLIN IMMUN, V73, P722, DOI 10.1016/0091-6749(84)90314-2; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; Helenius I, 2000, J ALLERGY CLIN IMMUN, V106, P444, DOI 10.1067/mai.2000.107749; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646, DOI 10.1016/S0091-6749(98)70173-3; Helenius IJ, 1997, THORAX, V52, P157, DOI 10.1136/thx.52.2.157; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; Kujala UM, 1996, THORAX, V51, P288, DOI 10.1136/thx.51.3.288; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479, DOI 10.1164/ajrccm.161.5.9909008; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; Metso T, 1996, ALLERGY, V51, P226; Peleman RA, 1999, EUR RESPIR J, V13, P839, DOI 10.1034/j.1399-3003.1999.13d24.x; Potts J, 1996, SPORTS MED, V21, P256, DOI 10.2165/00007256-199621040-00002; SOVIJARVI ARA, 1993, CHEST, V104, P164, DOI 10.1378/chest.104.1.164; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597, DOI 10.1164/ajrccm.158.2.9711012; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; VILJANEN AA, 1982, SCAND J CLIN LAB INV, V42, P5; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; ZWICK H, 1990, LUNG, V168, P111, DOI 10.1007/BF02719681	28	165	170	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					962	968		10.1067/mai.2002.124769	http://dx.doi.org/10.1067/mai.2002.124769			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063525				2022-12-18	WOS:000176442700011
J	Reitamo, S; Rustin, M; Ruzicka, T; Cambazard, F; Kalimo, K; Friedmann, PS; Schoepf, E; Lahfa, M; Diepgen, TL; Judodihardjo, H; Wollenberg, A; Berth-Jones, J; Bieber, T				Reitamo, S; Rustin, M; Ruzicka, T; Cambazard, F; Kalimo, K; Friedmann, PS; Schoepf, E; Lahfa, M; Diepgen, TL; Judodihardjo, H; Wollenberg, A; Berth-Jones, J; Bieber, T		European Tacrolimus Ointment Study	Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tacrolimus; FK506; atopic dermatitis; efficacy; safety; ointment; topical	COLLAGEN-SYNTHESIS; TRIAL; FK506; CHILDREN; CELLS; BETAMETHASONE; FK-506	Background: Vehicle-controlled studies have demonstrated the efficacy and safety of tacrolimus ointment for patients with atopic dermatitis. Objective: This study was undertaken to compare 0.03% and 0.1 % tacrolimus ointment with 0.1% hydrocortisone-17-butyrate ointment, a midpotent to potent topical corticosteroid, in the treatment of adult patients with moderate-to-severe atopic dermatitis. Methods: Patients applied ointment twice daily to all affected areas for 3 weeks in this multicenter, randomized, doubleblind, parallel-group study. The primary endpoint was the modified eczema area and severity index (mEASI) mean area under the curve as a percentage of baseline. Results: Five hundred seventy patients were randomized and received treatment. Discontinuations included 22 of 193 patients from the 0.03% tacrolimus group, 22 of 191 patients from the 0.1 % tacrolimus group, and 17 of 186 patients from the hydrocortisone butyrate group. The median mEASI mean area under the curve as a percentage of baseline was 47.0%, 36.5%, and 36.1% for patients who received 0.03% tacrolimus, 0.1% tacrolimus, and 0.1% hydrocortisone butyrate, respectively. There was no statistically significant difference between 0.1% tacrolimus and 0.1% hydrocortisone butyrate; however, the lower improvement in mEASI for 0.03% tacrolimus was statistically significant when compared with 0.1% tacrolimus (P < .001) or hydrocortisone butyrate (P = .002). Skin burning and pruritus at the application site showed a higher incidence in the tacrolimus treatment groups than in the hydrocortisone butyrate group (P < .05). Laboratory parameters showed no treatment differences and no marked changes over time. Conclusions: The efficacy of 0.1% tacrolimus ointment was similar to that of 0.1% hydrocortisone butyrate ointment and was lower for 0.03% tacrolimus ointment. No serious safety concerns were identified.	Univ Helsinki, Hosp Skin & Allerg Dis, Dept Dermatol, Helsinki 00250, Finland; Royal Free Hosp, Dept Dermatol, London NW3 2QG, England; Univ Dusseldorf, Haut Klin, D-4000 Dusseldorf, Germany; Hop Nord St Etienne, Serv Dermatol, St Etienne, France; Turku Univ Hosp, Dept Dermatol, FIN-20520 Turku, Finland; Southampton Gen Hosp, Southampton SO9 4XY, Hants, England; Univ Freiburg Klinikum, Hautklin, Freiburg, Germany; Hop St Louis, Serv Dermatol, F-75475 Paris, France; Univ Klinikum Heidelberg, Inst Poliklin Arbeits & Sozialmed, Heidelberg, Germany; Cardiff Univ, Coll Med, Dept Dermatol, Cardiff CF1 3NS, S Glam, Wales; Univ Munich, Klin & Poliklin Dermatol & Allergol, Munich, Germany; Walsgrave Gen Hosp, Dept Dermatol, Coventry, W Midlands, England; Klinikum Univ Bonn, Dermatol Klin & Poliklin, Bonn, Germany	University of Helsinki; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Heinrich Heine University Dusseldorf; CHU de St Etienne; University of Turku; University of Southampton; University of Freiburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Ruprecht Karls University Heidelberg; Cardiff University; University of Munich; University of Bonn	Reitamo, S (corresponding author), Univ Helsinki, Hosp Skin & Allerg Dis, Dept Dermatol, Meilahdentie 2, Helsinki 00250, Finland.		Judodihardjo, Harryono/AAL-3157-2020	Judodihardjo, Harryono/0000-0002-8213-9246				Alaiti S, 1998, J AM ACAD DERMATOL, V38, P69, DOI 10.1016/S0190-9622(98)70541-9; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; DYKES PJ, 1988, TOPICAL CORTICOSTERO; *FK506 OINTM STUD, 1997, NISHINIHON J DERMATO, V59, P870; GOERZ G, 1991, HDB ATOPIC ECZEMA, P375; GOTO T, 1987, TRANSPLANT P, V19, P4; HAAPASAARI KM, 1995, ACTA DERM-VENEREOL, V75, P269; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hanifin JM, 2001, J AM ACAD DERMATOL, V44, pS28, DOI 10.1067/mjd.2001.109810; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Kang S, 2001, J AM ACAD DERMATOL, V44, pS58, DOI 10.1067/mjd.2001.109812; KORTING HC, 1992, J AM ACAD DERMATOL, V27, P87, DOI 10.1016/0190-9622(92)70162-9; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 1997, ANN ALLERG ASTHMA IM, V79, P197, DOI 10.1016/S1081-1206(10)63003-7; MUKAI H, 1990, Journal of Dermatology (Tokyo), V17, P477; Paller A, 2001, J AM ACAD DERMATOL, V44, pS47, DOI 10.1067/mjd.2001.109813; Panhans-Gross A, 2001, J ALLERGY CLIN IMMUN, V107, P345, DOI 10.1067/mai.2001.112600; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Reitamo S, 2000, ARCH DERMATOL, V136, P999, DOI 10.1001/archderm.136.8.999; Reitamo S, 1998, J INVEST DERMATOL, V111, P396, DOI 10.1046/j.1523-1747.1998.00323.x; Reitamo S, 2001, J ALLERGY CLIN IMMUN, V107, P445, DOI 10.1067/mai.2001.113521; Remitz A, 2001, J ALLERGY CLIN IMMUN, V107, P196, DOI 10.1067/mai.2001.112131; Reynolds J.E.F., 1993, MARTINDALE THE EXTRA; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Soter NA, 2001, J AM ACAD DERMATOL, V44, pS39, DOI 10.1067/mjd.2001.109817; THORMANN J, 1976, DERMATOLOGICA, V152, P209, DOI 10.1159/000257891; TOCCI MJ, 1989, J IMMUNOL, V143, P718; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942	29	165	178	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					547	555		10.1067/mai.2002.121832	http://dx.doi.org/10.1067/mai.2002.121832			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11898005				2022-12-18	WOS:000174586400025
J	Rhodes, HL; Sporik, R; Thomas, P; Holgate, ST; Cogswell, JJ				Rhodes, HL; Sporik, R; Thomas, P; Holgate, ST; Cogswell, JJ			Early life risk factors for adult asthma: A birth cohort study of subjects at risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; bronchial hyperresponsiveness; food allergen; aeroallergen; risk factors	ALLERGIC AIRWAY DISEASE; DUST MITE ALLERGEN; SERUM IGE; CHILDHOOD ASTHMA; LUNG-FUNCTION; CHILDREN; ATOPY; EXPOSURE; AGE; RESPONSIVENESS	Background: Prediction of adult asthma is important, and early prevention strategies should be targeted at those most at risk. Identifying high-risk children at an early age, however, is currently difficult. Objective: We sought to determine those factors present in early life that predict an increased risk of adult asthma. Methods: A prospective cohort study of subjects at risk of asthma and atopy was undertaken in Poole, England. One hundred babies of atopic parents were recruited at birth. During the first 5 years of life, subjects were recalled annually, all respiratory events were reported, and skin prick tests and total serum IgE measurements were performed. At 11 and 22 years, bronchial hyperresponsiveness was also measured. Seventy-three subjects were followed up at 5 years, 67 at 11 years, and 63 at 22 years. Results: Twenty-three (37%) adult subjects reported wheezing within the previous 12 months. Fifteen (25%) of these subjects showed signs of bronchial hyperresponsiveness and were regarded as asthmatic. Wheezing before the age of 2 years occurred in 28% and was not significantly related to adult asthma (odds ratio, 0.3; 95% CI, 0.03-1.7; P =.19). A positive skin prick test response to hen's egg, cow's milk, or both in the first year was independently predictive of adult asthma (odds ratio, 10.7; 95% CI, 2.1-55.1; P =.001; sensitivity, 57%; specificity, 89%). Conclusion: Prediction of adult asthma remains difficult. In this study of subjects at risk of atopy, skin sensitivity to hen's egg or cow's milk in the first year was predictive of adult asthma.	Poole Hosp, Dept Paediat, Poole, Dorset, England; Bournemouth Univ, Poole Hosp, Dorset Res & Dev Support Unit, Bournemouth, Dorset, England; Dept Univ Med, Southampton, Hants, England	Poole Hospital; Bournemouth University; Poole Hospital	Rhodes, HL (corresponding author), Southampton Gen Hosp, Room EG228,Mail Point 43,Tremona Rd, Southampton SO16 6YD, Hants, England.			Thomas, Peter/0000-0003-2478-4324				Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; BRITTEN N, 1987, BRIT MED J, V294, P1317, DOI 10.1136/bmj.294.6583.1317; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Clough JB, 1999, AM J RESP CRIT CARE, V160, P1473, DOI 10.1164/ajrccm.160.5.9807019; Cook DG, 1999, THORAX, V54, P357, DOI 10.1136/thx.54.4.357; *CYTEL SOFTW CORP, 1999, LOGX 4 WIND LOG REGR; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; HORN MEC, 1979, THORAX, V34, P23, DOI 10.1136/thx.34.1.23; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Leadbitter P, 1999, THORAX, V54, P905, DOI 10.1136/thx.54.10.905; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; NICKEL R, 1999, J ALLERGY CLIN IMMUN, V5, P613; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; Rasanen M, 2000, THORAX, V55, P25, DOI 10.1136/thorax.55.1.25; RONMARK E, 2000, EUR RESP J S31, V16, pS515; RONNA RJ, 1993, THORAX, V48, P21; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050, DOI 10.1136/adc.66.9.1050; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STROPE GL, 1991, AM REV RESPIR DIS, V144, P655, DOI 10.1164/ajrccm/144.3_Pt_1.655; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; Warner JO, 1998, CLIN EXP ALLERGY, V28, P71; WILSON NM, 1992, ARCH DIS CHILD, V22, P325; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	38	165	170	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					720	725		10.1067/mai.2001.119151	http://dx.doi.org/10.1067/mai.2001.119151			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692095				2022-12-18	WOS:000172523800010
J	Chapman, MD; Smith, AM; Vailes, LD; Arruda, LK; Dhanaraj, V; Pomes, A				Chapman, MD; Smith, AM; Vailes, LD; Arruda, LK; Dhanaraj, V; Pomes, A			Recombinant allergens for diagnosis and therapy of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant allergens; mites; animal allergens; allergy diagnostics; allergy therapeutics; asthma; allergy vaccines; allergen immunotherapy	HOUSE-DUST-MITE; DER-P-I; CROSS-REACTIVE ALLERGEN; HIGH-LEVEL EXPRESSION; IGE-BINDING; PICHIA-PASTORIS; MOLECULAR-CLONING; MAJOR ALLERGEN; X-RAY; DERMATOPHAGOIDES-PTERONYSSINUS	Many of the problems associated with using natural allergenic products for allergy diagnosis and treatment can be overcome with use of genetically engineered recombinant allergens. Over the past 10 years, the most important allergens from mites, pollens, animal dander, insects, and foods have been cloned, sequenced, and expressed. In many cases the three-dimensional allergen structure has been determined and B-cell and T-cell epitopes have been mapped. These studies show that allergens have diverse biologic functions (they may be enzymes, enzyme inhibitors, lipocalins, or structural proteins) and that as a rule the allergen function is unrelated to its ability to cause IgE antibody responses, High-level expression systems have been developed to produce recombinant allergens in bacteria, yeast, or insect cells. Recombinant allergens show comparable IgE antibody binding to their natural counterparts (where available) and show excellent reactivity on skin testing and in in vitro diagnostic tests. Cocktails of recombinant allergens can be formulated with predetermined and uniform allergen levels, which could replace natural allergens and result in the development of innovative, patient-based tests for allergy diagnosis. Recombinant allergens also offer the exciting possibility of developing new forms of allergen immunotherapy, including the use of hypoallergens, allergens coupled to IgE suppressive adjuvants, and peptide-based therapies. The production of recombinant allergens as defined molecular entities makes it feasible to consider the possibility of developing prophylactic allergen vaccines. The introduction of recombinant allergens in research and in clinical trials should lead to significant improvements in allergy diagnosis and treatment.	Univ Virginia, Asthma & Allerg Dis Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Microbiol Immunol & Parasitol, Ribeirao Preto, Brazil; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Virginia; Universidade de Sao Paulo; University of Cambridge	Chapman, MD (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, Dept Internal Med, Box 801355, Charlottesville, VA 22908 USA.		Arruda, L. Karla/D-5845-2013; Pomés, Anna/H-7010-2019	Arruda, L. Karla/0000-0002-7505-210X; Pomés, Anna/0000-0002-8729-1829; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, R01AI032557, U19AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32557, AI 34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; [Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; ARRUDA LK, 1999, ALLERGY CLIN IMMUNOL, V11, P167; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Benson DA, 2000, NUCLEIC ACIDS RES, V28, P15, DOI 10.1093/nar/28.1.15; Best EA, 2000, J ALLERGY CLIN IMMUN, V105, pS168, DOI 10.1016/S0091-6749(00)90940-0; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Burks AW, 1999, INT ARCH ALLERGY IMM, V118, P313, DOI 10.1159/000024114; Burks W, 1999, INT ARCH ALLERGY IMM, V119, P165, DOI 10.1159/000024191; CHAPMAN MD, 1991, J ALLERGY CLIN IMMUN, V88, P300, DOI 10.1016/0091-6749(91)90091-2; Chapman MD, 1997, ALLERGY, V52, P374, DOI 10.1111/j.1398-9995.1997.tb01014.x; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; EBNER C, 1997, ACI INT, V9, P69; ESCH RE, 1992, ARB PEI GSH, V85, P171; Ferrari E, 1997, FEBS LETT, V401, P73, DOI 10.1016/S0014-5793(96)01436-6; Flower DR, 1996, BIOCHEM J, V318, P1; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Holt PG, 1998, ALLERGY, V53, P72, DOI 10.1111/j.1398-9995.1998.tb04944.x; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; Ichikawa K, 1999, J ALLERGY CLIN IMMUN, V103, pS184; ICHIKAWA K, 2000, IN PRESS INT ARCH AL; Jacquet A, 2000, CLIN EXP ALLERGY, V30, P677, DOI 10.1046/j.1365-2222.2000.00823.x; Jorge PPO, 2000, J ALLERGY CLIN IMMUN, V105, pS169, DOI 10.1016/S0091-6749(00)90943-6; KEATING KM, 1993, MOL IMMUNOL, V30, P559; King C, 1998, J IMMUNOL, V161, P3645; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; KOSHTE VL, 1992, INT ARCH ALLERGY IMM, V97, P17, DOI 10.1159/000236090; LARCHE M, 2000, IN PRESS INT ARCH AL; Lascombe MB, 2000, J BIOL CHEM, V275, P21572, DOI 10.1074/jbc.M002854200; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; LITWIN A, 1991, CLIN EXP ALLERGY, V21, P457, DOI 10.1111/j.1365-2222.1991.tb01686.x; Maecker HT, 1999, FASEB J, V13, pA319; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Melen E, 1999, J ALLERGY CLIN IMMUN, V103, P859, DOI 10.1016/S0091-6749(99)70430-6; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P441; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2000, J ALLERGY CLIN IMMUN, V105, pS168, DOI 10.1016/S0091-6749(00)90938-2; POMES A, 2001, IN PRESS ALLERGY CLI; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; Rouvinen J, 1999, J BIOL CHEM, V274, P2337, DOI 10.1074/jbc.274.4.2337; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; Schramm G, 1999, J IMMUNOL, V162, P2406; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Shakib F, 2000, CLIN EXP ALLERGY, V30, P751, DOI 10.1046/j.1365-2222.2000.00865.x; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; SHANTI KN, 1993, J IMMUNOL, V151, P5354; Shoji H, 1997, BIOSCI BIOTECH BIOCH, V61, P1668, DOI 10.1271/bbb.61.1668; SLUNT JB, 1995, J ALLERGY CLIN IMMUN, V95, P1221, DOI 10.1016/S0091-6749(95)70079-X; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith AM, 1999, LUNG BIOL HEALTH DIS, V136, P99; SMITH AM, 2000, IN PRESS INT ARCH AL; Smith PM, 1996, J ALLERGY CLIN IMMUN, V98, P331, DOI 10.1016/S0091-6749(96)70158-6; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274, DOI 10.1016/S0091-6749(98)70393-8; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; van Ree R, 1999, ALLERGY CLIN IMMUNOL, V11, P55; Van Uden J, 1999, J ALLERGY CLIN IMMUN, V104, P902, DOI 10.1016/S0091-6749(99)70066-7; vanderVeen MJ, 1996, J ALLERGY CLIN IMMUN, V98, P1028, DOI 10.1016/S0091-6749(96)80187-4; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; vanRee R, 1996, ALLERGY, V51, P387, DOI 10.1111/j.1398-9995.1996.tb00147.x; vantHof W, 1997, J BIOL CHEM, V272, P1837; Vaughan JW, 2000, J ALLERGY CLIN IMMUN, V105, pS363, DOI 10.1016/S0091-6749(00)91493-3; Virtanen T, 1999, IMMUNOL TODAY, V20, P398, DOI 10.1016/S0167-5699(99)01515-7; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; Wills-Karp M, 1998, ALLERGY, V53, P113, DOI 10.1111/j.1398-9995.1998.tb03858.x; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56, DOI 10.1159/000236803; Wu SY, 1999, J BIOL CHEM, V274, P170, DOI 10.1074/jbc.274.1.170	91	165	187	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					409	418		10.1067/mai.2000.109832	http://dx.doi.org/10.1067/mai.2000.109832			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984358				2022-12-18	WOS:000089471900001
J	Kalliomaki, M; Ouwehand, A; Arvilommi, H; Kero, P; Isolauri, E				Kalliomaki, M; Ouwehand, A; Arvilommi, H; Kero, P; Isolauri, E			Transforming growth factor-beta in breast milk: A potential regulator of atopic disease at an early age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						transforming growth factor beta; breast milk; atopic disease; immunoglobulin A; oral tolerance	BOVINE COLOSTRUM SAMPLES; TGF-BETA; CELLS; DERMATITIS; INFANTS; ALLERGY; LACTOGLOBULIN; CHILDREN; MOTHERS; IGA2	Background: According to data from animal and in vitro studies, transforming growth factor-beta (TGF-beta) has a crucial effect on 2 essential parts of the mucosal immune system: IgA production and oral tolerance induction. Objective: We sought to ascertain whether TGF-beta in breast milli is associated with specific IgA production and atopic disease in human subjects. Methods: Forty-seven infants with several atopic family members were followed during their first year of life. The concentrations of TGF-beta 1 and TGF-beta 2 in maternal colostrum, mature milk, and the infants' sera were determined. The enzyme-linked immunospot assay was used to assess the infants' specific IgA production in response to beta-lactoglobulin, casein, gliadin, and ovalbumin, Results: At 12 months, atopic dermatitis was confirmed in 29 of 47 infants; in 11, atopic disease had begun during exclusive breast-feeding (preweaning onset), whereas in 18 the disease manifested itself after weaning (postweaning onset), The concentrations of both TGF-beta 1 and TGF-beta 2 were higher in maternal colostrum, but not in mature milk and infants' serum, in infants with postweaning-onset atopic disease compared with those with preweaning-onset disease (P = .0008 and P = .015, respectively), The concentration of TGF-beta 2 was, and that of TGF-beta 1 tended to be, higher in the colostrum of mothers whose infants had specific IgA-secreting cells at 3 months in response to at least one of the dietary antigens tested compared with those who did not have such cells (P = .048 and P = .076, respectively). Conclusion: TGF-beta in colostrum may prevent the development of atopic disease during exclusive breast-feeding and promote specific IgA production in human subjects.	Turku Univ, Dept Paediat, FIN-20521 Turku, Finland; Turku Univ, Dept Biochem & Food Chem, FIN-20521 Turku, Finland; Natl Publ Hlth Inst, Turku, Finland	University of Turku; University of Turku; Finland National Institute for Health & Welfare	Kalliomaki, M (corresponding author), Turku Univ, Dept Paediat, POB 52, FIN-20521 Turku, Finland.			Ouwehand, Arthur/0000-0001-8348-0633				Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Christ AD, 1997, SPRINGER SEMIN IMMUN, V18, P449, DOI 10.1007/BF00824052; Ginjala V, 1998, J IMMUNOASSAY, V19, P195, DOI 10.1080/01971529808005480; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hacsek G, 1996, J PEDIATR GASTR NUTR, V22, P307, DOI 10.1097/00005176-199604000-00014; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; HOST A, 1990, CLIN EXP ALLERGY, V20, P383, DOI 10.1111/j.1365-2222.1990.tb02798.x; Isolauri E, 1999, J PEDIATR-US, V134, P27, DOI 10.1016/S0022-3476(99)70368-9; ISOLAURI E, 1990, PEDIATR RES, V28, P582, DOI 10.1203/00006450-199012000-00006; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V75, P8, DOI 10.1159/000233582; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; Pakkanen R, 1998, J IMMUNOASSAY, V19, P23, DOI 10.1080/01971529808005469; Pecquet S, 1999, IMMUNOLOGY, V96, P278, DOI 10.1046/j.1365-2567.1999.00678.x; Penttila IA, 1998, PEDIATR RES, V44, P524, DOI 10.1203/00006450-199810000-00010; PERKKIO M, 1980, PEDIATR RES, V14, P953, DOI 10.1203/00006450-198008000-00012; Petitprez K, 1999, SCAND J IMMUNOL, V49, P14; SAITO S, 1993, CLIN EXP IMMUNOL, V94, P220, DOI 10.1111/j.1365-2249.1993.tb06004.x; Seder RA, 1998, J IMMUNOL, V160, P5719; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SORVA R, 1994, J ALLERGY CLIN IMMUN, V93, P787, DOI 10.1016/0091-6749(94)90259-3; Srivastava MD, 1996, RES COMMUN MOL PATH, V93, P263; STAVNEZER J, 1995, J IMMUNOL, V155, P1647; Strober W, 1998, J CLIN IMMUNOL, V18, P1, DOI 10.1023/A:1023222003039; Von Mutius E, 1998, CLIN EXP ALLERGY, V28, P45; Zan H, 1998, J IMMUNOL, V161, P5217	29	165	174	2	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1251	1257		10.1016/S0091-6749(99)70021-7	http://dx.doi.org/10.1016/S0091-6749(99)70021-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589009				2022-12-18	WOS:000084289200021
J	Solomon, A; Aloe, L; Pe'er, J; Frucht-Pery, J; Bonini, S; Bonini, S; Levi-Schaffer, F				Solomon, A; Aloe, L; Pe'er, J; Frucht-Pery, J; Bonini, S; Bonini, S; Levi-Schaffer, F			Nerve growth factor is preformed in and activates human peripheral blood eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil peroxidase; IL-6; nerve growth factor; allergic diseases	HUMAN MAST-CELLS; FUNCTIONAL TRKA; GM-CSF; SURVIVAL; RECEPTOR; RELEASE; INTERLEUKIN-6; EXPRESSION; DISEASES; INVITRO	Background: Recent studies have shown that nerve growth factor (NGF) is produced by and can act on several immune-inflammatory cells. Objectives: The objective of this study was to study the effects of NGF on human peripheral blood eosinophils and assess whether these cells produce and store NGF. Methods: Eosinophils were purified by negative immunoselection (magnetic cell sorting systems, purity 98% to 100%) from 13 subjects (9 to 26 years old) with mild blood eosinophilia, mainly of allergic origin. Eosinophils were incubated with NGF (50 to 1000 ng/mL), and supernatants were collected for measurement of eosinophil peroxidase (EPO, 20 minutes, colorimetric enzymatic assay) and IL-6 (12 hours, ELISA), Eosinophil viability was evaluated by Trypan blue test (days 2, 3, and 4), NGF content in freshly isolated eosinophils, after ultrasound disruption, was determined with a 2-site immunoenzymatic assay. The presence of mRNA for NGF was evaluated by reverse transcription PCR. Results: NGF caused EPO release (highly significant at 1000 ng/mL NGF), IL-6 release from eosinophils was not higher than IL-6 spontaneously released into culture medium alone, NGF did not significantly affect the number of viable eosinophils. NGF was found in the eosinophil sonicates (1.5 to 17.8 pg/mL per 10(6) cells). Similarly, mRNA for NGF,vas detected by reverse transcription PCR in the freshly isolated eosinophils. Conclusions: NGF activates human peripheral blood eosinophils from subjects with mild eosinophilia to selectively release inflammatory mediators. Eosinophils store and produce NGF. Therefore the capability of NGF to induce a secretory response and its production and storage by circulating human eosinophils suggest a possible role for NGF in conditions associated with eosinophilia, including allergic disease.	Hebrew Univ Jerusalem, Hadassah Med Sch, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Ophthalmol, IL-91120 Jerusalem, Israel; CNR, Inst Neurobiol, Rome, Italy; Univ Roma Tor Vergata, GB Bietti Eye Fdn, Dept Ophthalmol, Rome, Italy; CNR, Inst Expt Med, Rome, Italy; Univ Naples 2, Naples, Italy	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Consiglio Nazionale delle Ricerche (CNR); IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in Oftalmologia; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Universita della Campania Vanvitelli	Levi-Schaffer, F (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Sch Pharm, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.		Bonini, Sergio/T-6594-2019; Bonini, Stefano/A-2250-2012	Bonini, Sergio/0000-0003-0079-3031; Bonini, Stefano/0000-0002-7787-2144; Solomon, Abraham/0000-0003-3222-9507; Levi-Schaffer, Francesca/0000-0003-0620-2810				Aloe L, 1997, ALLERGY, V52, P883, DOI 10.1111/j.1398-9995.1997.tb01247.x; ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; BRACCI-LAUDIERO L, 1992, NEUROSCI LETT, V147, P9; CALLISSANO P, 1984, HORMONAL PROTEINS PE, V12, P1; CARACCIOLO D, 1989, BLOOD, V73, P666; CARTWRIGHT M, 1994, INT J DEV NEUROSCI, V12, P685, DOI 10.1016/0736-5748(94)90048-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Hamada A, 1996, BRIT J HAEMATOL, V93, P299, DOI 10.1046/j.1365-2141.1996.5151055.x; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; KANNAN Y, 1992, BIOCHEM BIOPH RES CO, V186, P4638; KAWAMOTO K, 1995, BLOOD, V86, P4638, DOI 10.1182/blood.V86.12.4638.bloodjournal86124638; Lacy P, 1998, BLOOD, V91, P2508, DOI 10.1182/blood.V91.7.2508.2508_2508_2516; Lambiase A, 1997, J ALLERGY CLIN IMMUN, V100, P408, DOI 10.1016/S0091-6749(97)70256-2; Lambiase A, 1998, INVEST OPHTH VIS SCI, V39, P1272; LAMBIASE A, 1995, INVEST OPHTH VIS SCI, V36, P2127; LEARY AG, 1988, BLOOD, V71, P1759; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVISCHAFFER F, 1995, BLOOD, V85, P2579, DOI 10.1182/blood.V85.9.2579.bloodjournal8592579; MARSHALL JS, 1990, J IMMUNOL, V144, P1886; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; Nilsson G, 1997, EUR J IMMUNOL, V27, P2295, DOI 10.1002/eji.1830270925; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; TAKAFUJI S, 1992, EUR J IMMUNOL, V22, P969, DOI 10.1002/eji.1830220414; Tam SY, 1997, BLOOD, V90, P1807, DOI 10.1182/blood.V90.5.1807; THOENEN H, 1985, SCIENCE, V229, P238, DOI 10.1126/science.2409599; TOMASSINI M, 1991, J ALLERGY CLIN IMMUN, V88, P365, DOI 10.1016/0091-6749(91)90099-A; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; VERCELLI D, 1989, EUR J IMMUNOL, V18, P929; WHITE SR, 1991, J IMMUNOL METHODS, V144, P257, DOI 10.1016/0022-1759(91)90094-V; YANAGIDA M, 1995, BLOOD, V86, P3705, DOI 10.1182/blood.V86.10.3705.bloodjournal86103705	35	165	168	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					454	460		10.1016/S0091-6749(98)70135-6	http://dx.doi.org/10.1016/S0091-6749(98)70135-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768588				2022-12-18	WOS:000076212800021
J	SCHLEIMER, RP; BOCHNER, BS				SCHLEIMER, RP; BOCHNER, BS			THE EFFECTS OF GLUCOCORTICOIDS ON HUMAN EOSINOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							COLONY-STIMULATING FACTOR; LEUKOCYTE ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; PROTEIN-PROTEIN-INTERACTION; PLATELET-ACTIVATING-FACTOR; AIRWAY INFLAMMATION; GENE-EXPRESSION; GM-CSF; INTERLEUKIN-1 PRODUCTION				SCHLEIMER, RP (corresponding author), JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS ASTHMA & ALLERGY CTR, ROOM 3A62, BALTIMORE, MD 21224 USA.							ABRAHAM WM, 1994, J CLIN INVEST, V93, P776, DOI 10.1172/JCI117032; ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALLISON F, 1955, J EXP MED, V102, P655, DOI 10.1084/jem.102.6.655; ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; ANDERSSON P, 1985, GLUCOCORTICOSTEROIDS, P132; BARCLAY WR, 1953, ANN NY ACAD SCI, V56, P634, DOI 10.1111/j.1749-6632.1953.tb27384.x; BARINAGA M, 1994, SCIENCE, V263, P754, DOI 10.1126/science.8303290; BATES ME, 1994, J ALLERGY CLIN IMMUN, V93, P268; BECK LA, 1994, J ALLERGY CLIN IMMUN, V93, P234; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BJORNSON BH, 1985, J CLIN INVEST, V76, P924, DOI 10.1172/JCI112091; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOCHNER BS, 1987, J IMMUNOL, V139, P2303; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOCHNER BS, 1991, J ALLERGY CLIN IMMUN, V88, P629, DOI 10.1016/0091-6749(91)90157-J; BOCHNER BS, 1988, J CLIN INVEST, V81, P1355, DOI 10.1172/JCI113463; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORISH L, 1992, J IMMUNOL, V149, P3078; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; BUTTERFIELD JH, 1992, BLOOD, V79, P688; BUTTERFIELD JH, 1986, J ALLERGY CLIN IMMUN, V78, P450, DOI 10.1016/0091-6749(86)90032-1; CELADA A, 1993, J EXP MED, V177, P691, DOI 10.1084/jem.177.3.691; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHARLESWORTH EN, 1991, J IMMUNOL, V146, P671; CHATTERJEE VKK, 1991, MOL ENDOCRINOL, V5, P100, DOI 10.1210/mend-5-1-100; CHURCHILL L, 1992, IMMUNOLOGY, V75, P189; CLARK RAF, 1979, BLOOD, V53, P633; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991; CULPEPPER JA, 1985, J IMMUNOL, V135, P3191; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; EBERT RH, 1952, ANN INTERN MED, V37, P506, DOI 10.7326/0003-4819-37-3-506; EBISAWA M, 1994, J IMMUNOL, V152, P4590; EBISAWA M, 1994, IN PRESS LEUKOCYTE T, V5; EVANS PM, 1993, J ALLERGY CLIN IMMUN, V91, P643, DOI 10.1016/0091-6749(93)90270-P; FADOK VA, 1992, J IMMUNOL, V149, P4029; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; FLOWER RJ, 1989, ANTIINFLAMMATORY STE, P48; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HALLAM C, 1982, CLIN EXP IMMUNOL, V48, P641; HALLSWORTH MP, 1992, IMMUNOLOGY, V75, P382; HARLAN J, 1992, ADHESION ITS ROLE IN, V1, P202; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HOWE RS, 1990, ENDOCRINOLOGY, V126, P3193, DOI 10.1210/endo-126-6-3193; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAISER J, 1993, J PHARMACOL EXP THER, V267, P245; KATO M, 1994, LUNG, V172, P113; KAWABORI S, 1991, LAB INVEST, V64, P224; KITA H, 1991, J ALLERGY CLIN IMMUN, V87, P70, DOI 10.1016/0091-6749(91)90214-9; KURIHARA K, 1989, J ALLERGY CLIN IMMUN, V83, P83, DOI 10.1016/0091-6749(89)90480-6; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAMAS AM, 1991, J IMMUNOL, V147, P254; LAMAS AM, 1989, J IMMUNOL, V142, P3978; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V93, P183; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; LIU MC, 1993, AM REV RESPIR DIS, V147, pA521; LIU MC, 1994, AM REV RESPIR DIS, V149, pA944; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MASSEY W, 1993, J ALLERGY CLIN IMMUN, V91, P317; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MATSUMOTO K, 1994, J ALLERGY CLIN IMMUN, V93, P268; METZGER WJ, 1994, J ALLERGY CLIN IMMUN, V93, P183; MICHAEL M, 1951, P SOC EXP BIOL MED, V76, P754; MIER JW, 1990, BLOOD, V76, P1933; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; MOON VH, 1952, P SOC EXP BIOL MED, V79, P63; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PALIOGIANNI F, 1993, J CLIN INVEST, V91, P1481, DOI 10.1172/JCI116353; PAZDRAK K, 1994, J ALLERGY CLIN IMMUN, V93, P267; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PRIN L, 1989, CLIN EXP IMMUNOL, V78, P383; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROLFE FG, 1992, IMMUNOLOGY, V77, P494; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SABAG N, 1978, EXPERIENTIA, V34, P666, DOI 10.1007/BF01937022; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SAUNDERS RH, 1950, BLOOD, V5, P732, DOI 10.1182/blood.V5.8.732.732; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SCHLEIMER RP, 1989, J PHARMACOL EXP THER, V250, P598; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHLEIMER RP, 1993, ASTHMA, P375; SCHLEIMER RP, 1993, ALLERGY PRINCIPLES P, P893; SCHLEIMER RP, 1992, ANTIINFLAMMATORY STE, P483; SCHLEIMER RP, 1989, ANTIINFLAMMATORY STE, P226; SCHLEIMER RP, 1992, MAST CELL HLTH DIS, P483; SCHREIBER D, 1994, J ALLERGY CLIN IMMUN, V93, P267; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHALIT M, 1994, J ALLERGY CLIN IMMUN, V93, P268; SHER A, 1990, J IMMUNOL, V145, P3911; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; SLOVICK FT, 1985, BLOOD, V66, P1072; SMITH KA, 1980, IMMUNOL REV, V51, P337, DOI 10.1111/j.1600-065X.1980.tb00327.x; SNYDER DS, 1982, J IMMUNOL, V129, P1803; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STELLATO C, 1994, FASEB J, V8, pA225; STERN M, 1992, J IMMUNOL, V148, P3543; SUR S, 1993, ALLERGY PRINCIPLES P, P169; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; TOBLER A, 1992, BLOOD, V79, P45; TOMIOKA K, 1993, J IMMUNOL, V151, P4989; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; VANOTTEREN GM, 1994, AM J RESP CELL MOL, V10, P8, DOI 10.1165/ajrcmb.10.1.8292385; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WAAGE A, 1988, IMMUNOLOGY, V63, P299; WALLEN N, 1991, J IMMUNOL, V147, P3490; WALSH GM, 1991, J IMMUNOL, V146, P3419; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; WERTHEIM WA, 1993, J IMMUNOL, V151, P2166; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZORA JA, 1984, ANN ALLERGY, V53, P45	152	165	171	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1202	1213		10.1016/0091-6749(94)90333-6	http://dx.doi.org/10.1016/0091-6749(94)90333-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798561	hybrid			2022-12-18	WOS:A1994QA02000013
J	PASTORELLO, EA; ORTOLANI, C; FARIOLI, L; PRAVETTONI, V; ISPANO, M; BORGA, A; BENGTSSON, A; INCORVAIA, C; BERTI, C; ZANUSSI, C				PASTORELLO, EA; ORTOLANI, C; FARIOLI, L; PRAVETTONI, V; ISPANO, M; BORGA, A; BENGTSSON, A; INCORVAIA, C; BERTI, C; ZANUSSI, C			ALLERGENIC CROSS-REACTIVITY AMONG PEACH, APRICOT, PLUM, AND CHERRY IN PATIENTS WITH ORAL ALLERGY SYNDROME - AN IN-VIVO AND IN-VITRO STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ORAL ALLERGY SYNDROME; CROSS-ALLERGENICITY; PRUNOIDEAE; IMMUNOBLOTTING	BIRCH POLLEN-ALLERGY; FOOD HYPERSENSITIVITY; IGE ANTIBODIES; SENSITIVITY; IDENTIFICATION; PROFILIN; FRUITS; APPLE	Background: Oral allergy syndrome In response to fruits and vegetables frequently occurs as clusters of hypersensitivity to members of the same botanical family, for which the immunologic basis lies in a number of common allergens, most of them still unidentified. Objective: This study was designed to assess the in vivo and in vitro cross-reactivity between fruits of the Prunoideae subfamily (i.e., peach, cherry, apricot, and plum) and to identify their major allergens and the cross-reactivity of the peach extract with grass and birch pollen. Methods: The in vivo study was conducted by skin prick tests and open food challenges with fresh fruits in 23 patients with oral allergy syndrome for peach and positive skin prick test and RAST results for the other Prunoideae. In vitro sodium dodecylsulfate-polyacrylamide gel electrophoresis was followed by immunoblotting and immunoblotting inhibition. Results: A 13 kd component was identified as the only major allergen common to all the Prunoideae, the other major allergens were found at 14 kd in peach and at 30 kd in cherry. Immunoblotting inhibition showed wide cross-reactivity within the Prunoideae, whereas grass and birch pollen partially inhibited the peach blotting. Conclusions: Clinical cross-reactivity to Prunoideae is essentially due to a common 13 kd IgE-binding component, which seems to be the most important major allergen of this subfamily not shared with grass and birch pollen.	OSPED NIGUARDA CA GRANDA,DIV BIZZOZERO,MILAN,ITALY; KABI PHARM DIAGNOST AB,UPPSALA,SWEDEN	IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda	PASTORELLO, EA (corresponding author), UNIV MILAN,PADIGLIONE GRANELLI,DEPT INTERNAL MED 1,VIA FRANCESCO SFORZA 35,I-20122 MILAN,ITALY.		PASTORELLO, ELIDE ANNA/E-3897-2017	PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BROADBENT JB, 1989, J ALLERGY CLIN IMMUN, V83, P435; BROADBENT JB, 1992, J ALLERGY CLIN IMMUN, V89, P730; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; DREBORG S, 1989, ALLERGY S10, V44; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EKRAMODDOULLAH AKM, 1982, MOL IMMUNOL, V19, P1527, DOI 10.1016/0161-5890(82)90263-2; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; ERIKSSON NE, 1984, ALLERGOL IMMUNOPATH, V12, P28; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; JOHANSON P, 1965, EUR POLYN J, V1, P63; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LLEONART R, 1992, ANN ALLERGY, V69, P128; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; Tuft Louis, 1942, JOUR ALLERGY, V13, P574, DOI 10.1016/S0021-8707(42)90070-4; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P744; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; WADEE AA, 1990, J ALLERGY CLIN IMMUN, V85, P801, DOI 10.1016/0091-6749(90)90202-F	28	165	170	0	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					699	707		10.1016/0091-6749(94)90177-5	http://dx.doi.org/10.1016/0091-6749(94)90177-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930303				2022-12-18	WOS:A1994PM27300008
J	MRAIHI, L; CHARPIN, D; PONS, A; BONGRAND, P; VERVLOET, D				MRAIHI, L; CHARPIN, D; PONS, A; BONGRAND, P; VERVLOET, D			CROSS-REACTIVITY BETWEEN LATEX AND BANANA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							RUBBER		HOP ST MARGUERITE,DEPT MALAD RESP,BP 29,F-13277 MARSEILLE 9,FRANCE; HOP ST MARGUERITE,IMMUNOL LAB,F-13277 MARSEILLE 9,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Bongrand, Pierre/C-4456-2013	Bongrand, Pierre/0000-0001-6185-6572				AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; LEYNADIER F, 1988, PRESSE MED, V17, P390; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029	5	165	167	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				129	130		10.1016/0091-6749(91)90224-C	http://dx.doi.org/10.1016/0091-6749(91)90224-C			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991916				2022-12-18	WOS:A1991EX98500019
J	ANDERTON, RC; CUFF, MT; FRITH, PA; COCKCROFT, DW; MORSE, JLC; JONES, NL; HARGREAVE, FE				ANDERTON, RC; CUFF, MT; FRITH, PA; COCKCROFT, DW; MORSE, JLC; JONES, NL; HARGREAVE, FE			BRONCHIAL RESPONSIVENESS TO INHALED HISTAMINE AND EXERCISE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,REG CHEST & ALLERGY UNIT,HAMILTON L8N 1Y4,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McMaster University				Frith, Peter Anthony/0000-0003-3265-0131				ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; EGGLESTON PA, 1976, J ALLERGY CLIN IMMUN, V58, P414, DOI 10.1016/0091-6749(76)90122-6; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P199, DOI 10.1016/0091-6749(73)90058-4; GODFREY S, 1975, J ALLERGY CLIN IMMUN, V56, P1, DOI 10.1016/0091-6749(75)90029-9; Jones NL., 1975, CLIN EXERCISE TESTIN; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KIVILOOG J, 1973, SCAND J RESPIR DIS, V54, P347; Lange-Anderson K, 1971, FUNDAMENTALS EXERCIS; MELLIS CM, 1978, AM REV RESPIR DIS, V117, P911; MILLER GJ, 1975, THORAX, V30, P306, DOI 10.1136/thx.30.3.306; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; WENG TR, 1969, AM REV RESPIR DIS, V99, P870	18	165	165	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	5					315	320		10.1016/0091-6749(79)90125-8	http://dx.doi.org/10.1016/0091-6749(79)90125-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GU943	429710				2022-12-18	WOS:A1979GU94300004
J	TOWNLEY, RG; BEWTRA, AK; NAIR, NM; BRODKEY, FD; WATT, GD; BURKE, KM				TOWNLEY, RG; BEWTRA, AK; NAIR, NM; BRODKEY, FD; WATT, GD; BURKE, KM			METHACHOLINE INHALATION CHALLENGE STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											TOWNLEY, RG (corresponding author), CREIGHTON UNIV, CTR ALLERG DIS, SCH MED, DEPT MED, OMAHA, NE 68179 USA.							CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; CURRY JJ, 1948, J ALLERGY, V19, P9, DOI 10.1016/0021-8707(48)90072-0; HAJOS MK, 1962, ACTA ALLERGOL, V17, P358; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P27, DOI 10.1159/000227898; KANG B, 1976, BMJ-BRIT MED J, V1, P867, DOI 10.1136/bmj.1.6014.867; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; REED CE, 1978, ALLERGY PRINCIPLES P, P659; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; STORMS WW, 1975, AM REV RESPIR DIS, V111, P419; TIFFENEAU R, 1955, ANN MED, V56, P582; TIFFENEAU R, 1950, ACTA ALLERGOL S, V5, P137; TOWNLEY R, 1975, J ALLERGY CLIN IMMUN, V55, P92; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P358, DOI 10.1016/0091-6749(76)90093-2; TOWNLEY RG, 1977, AM ACADEMY ALLERGY N; TOWNLEY RG, 1972, TICES PRACTICE MEDIC, V1, pCH40; WATT G, J ALLERGY CLIN IMMUN; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823	21	165	166	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					569	574		10.1016/0091-6749(79)90014-9	http://dx.doi.org/10.1016/0091-6749(79)90014-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512247	Bronze			2022-12-18	WOS:A1979HX84300002
J	Valovirta, E; Petersen, TH; Piotrowska, T; Laursen, MK; Andersen, JS; Sorensen, HF; Klink, R				Valovirta, Erkka; Petersen, Thomas H.; Piotrowska, Teresa; Laursen, Mette K.; Andersen, Jens S.; Sorensen, Helle F.; Klink, Rabih		GAP Investigators	Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy immunotherapy; asthma symptoms; children; disease-modifying treatment; long-term trial	FOLLOW-UP; RHINITIS; CHILDHOOD; RHINOCONJUNCTIVITIS; PAT; IMPACT; RISK	Background: Allergy immunotherapy targets the immunological cause of allergic rhinoconjunctivitis and allergic asthma and has the potential to alter the natural course of allergic disease. Objective: The primary objective was to investigate the effect of the SQ grass sublingual immunotherapy tablet compared with placebo on the risk of developing asthma. Methods: A total of 812 children (5-12 years), with a clinically relevant history of grass pollen allergic rhinoconjunctivitis and no medical history or signs of asthma, were included in the randomized, double-blind, placebo-controlled trial, comprising 3 years of treatment and 2 years of follow-up. Results: There was no difference in time to onset of asthma, defined by prespecified asthma criteria relying on documented reversible impairment of lung function (primary endpoint). Treatment with the SQ grass sublingual immunotherapy tablet significantly reduced the risk of experiencing asthma symptoms or using asthma medication at the end of trial (odds ratio = 0.66, P < .036), during the 2-year posttreatment follow-up, and during the entire 5-year trial period. Also, grass allergic rhinoconjunctivitis symptoms were 22% to 30% reduced (P < .005 for all 5 years). At the end of the trial, the use of allergic rhinoconjunctivitis pharmacotherapy was significantly less (27% relative difference to placebo, P < .001). Total IgE, grass pollen-specific IgE, and skin prick test reactivity to grass pollen were all reduced compared to placebo. Conclusions: Treatment with the SQ grass sublingual immunotherapy tablet reduced the risk of experiencing asthma symptoms and using asthma medication, and had a positive, long-term clinical effect on rhinoconjunctivitis symptoms and medication use but did not show an effect on the time to onset of asthma.	[Valovirta, Erkka] Univ Turku, Dept Lung Dis & Clin Allergol, Turku, Finland; [Valovirta, Erkka] Terveystalo Allergy Clin, Turku, Finland; [Petersen, Thomas H.] Kolding Cty Hosp, Dept Paediat, Kolding, Finland; [Piotrowska, Teresa] NZOZ Promed, Bialystok, Poland; [Laursen, Mette K.; Andersen, Jens S.; Sorensen, Helle F.] ALK, Global Clin Dev, Horsholm, Denmark; [Klink, Rabih] Off Paediat & Allergol Pneumo Pediat, Laon, France	University of Turku	Valovirta, E (corresponding author), Univ Turku, Terveystalo Turku, Allergy Clin, Aninkaistenkatu 13, Turku 20100, Finland.	erkka.valovirta@terveystalo.com	Infante, Sonsoles/P-6259-2019; Custovic, Adnan/A-2435-2012; Csonka, Peter/AAB-3172-2022; Csonka, Peter/AAC-6190-2022	Infante, Sonsoles/0000-0001-9061-7204; Custovic, Adnan/0000-0001-5218-7071; Csonka, Peter/0000-0003-0819-7875; Agertoft, Lone/0000-0001-6840-7921; Jorgensen, Inger Merete/0000-0001-5229-2381	ALK-Abello; Meda; Stallergenes-Greer; ALK-Abello A/S	ALK-Abello; Meda; Stallergenes-Greer; ALK-Abello A/S	E. Valovirta has received grants from ALK-Abello, Meda, and Stallergenes-Greer. T. H. Petersen and T. Piotrowska have received grants from ALK-Abello A/S. M. K. Laursen, J. S. Andersen, and H. F. Sorensen are employed by ALK. R. Klink declares that he has no relevant conflicts of interest.	[Anonymous], 2009, A S INTERNAL REPORT; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2016, BP STAT REV WORLD EN, P1; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; Demoly P, 2008, ALLERGY, V63, P251, DOI 10.1111/j.1398-9995.2008.01628.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; European Medicine Agency, 2008, CHMPEWP1850420 EUR M; GINA Executive Committee, 2012, GLOB IN ASTHM GLOB S; International Conference on Harmonization, 2001, CPMPICH36496; International Conference on Harmonization, 1996, ICH HARM TRIP GUID T; International Conference on Harmonization, 1995, ICH HARM TRIP GUID I; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Jacobsen L, 2001, ANN ALLERG ASTHMA IM, V87, P43, DOI 10.1016/S1081-1206(10)62194-1; Masoli M, 2004, GLOBAL BURDEN ASTHMA, P1; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Schmitt J, 2015, J ALLERGY CLIN IMMUN, V136, P1511, DOI 10.1016/j.jaci.2015.07.038; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Valovirta E, 2011, CLIN THER, V33, P1537, DOI 10.1016/j.clinthera.2011.09.013; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Zolkipli Z, 2015, J ALLERGY CLIN IMMUN, V136, P1541, DOI 10.1016/j.jaci.2015.04.045	25	164	170	0	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					529	+		10.1016/j.jaci.2017.06.014	http://dx.doi.org/10.1016/j.jaci.2017.06.014			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28689794	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000424410800010
J	Zhao, ZT; Ji, CM; Yu, WJ; Meng, L; Hawro, T; Wei, JF; Maurer, M				Zhao, Zuo-Tao; Ji, Chun-Mei; Yu, Wen-Jun; Meng, Ling; Hawro, Tomasz; Wei, Ji-Fu; Maurer, Marcus			Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Omalizumab; meta-analysis; CSU; weekly itch score; weekly wheal score; adverse event	CHRONIC IDIOPATHIC URTICARIA; GRAPHICAL TEST; MANAGEMENT; EFFICACY; HETEROGENEITY; THERAPY; DISEASE; BIAS; IGE	Background: Chronic spontaneous urticaria (CSU) is defined by itchy hives, angioedema, or both for at least 6 weeks. Omalizumab, an anti-IgE antibody that affects mast cell and basophil function, is a promising new treatment option. As of now, however, the efficacy and safety of different doses of omalizumab used in clinical trials for CSU have not been systematically analyzed and summarized. Objective: We sought to assess the efficacy and safety of different doses of omalizumab for the treatment of CSU in a meta-analysis of clinical trial results. Methods: Suitable trials were identified by searching PubMed, Medline, Embase, and Web of Science databases and with the help of omalizumab's manufacturers. Only double-blind, randomized, placebo-controlled studies with omalizumab-treated versus placebo-treated patients with CSU were included in this analysis. Results: We identified 7 randomized, placebo-controlled studies with 1312 patients with CSU. Patients treated with omalizumab (75-600 mg every 4 weeks) had significantly reduced weekly itch and weekly wheal scores compared with the placebo group. Omalizumab's effects were dose dependent, with the strongest reduction in weekly itch and weekly wheal scores observed with 300 mg. Rates of complete response were significantly higher in the omalizumab group (relative risk, 4.55; P < .00001) and dose dependent, with the highest rates in the 300-mg group. Rates of patients with adverse events were similar in the omalizumab and placebo groups. Conclusion: This meta-analysis provides high-quality evidence for the efficacy and safety of omalizumab in patients with CSU and for treating these patients with 300 mg of omalizumab every 4 weeks.	[Zhao, Zuo-Tao; Maurer, Marcus] Peking Univ, Hosp 1, Dept Dermatol & Venereol, Beijing 100871, Peoples R China; [Ji, Chun-Mei; Meng, Ling; Wei, Ji-Fu] Nanjing Med Univ, Affiliated Hosp 1, Res Div Clin Pharmacol, Nanjing 210029, Jiangsu, Peoples R China; [Yu, Wen-Jun] Jiangsu Prov Official Hosp, Jiangsu Prov Geriatr Inst, Dept Cadre Hlth Care, Nanjing, Jiangsu, Peoples R China; [Zhao, Zuo-Tao; Hawro, Tomasz; Maurer, Marcus] Charite, Dept Dermatol & Allergy, Allergie Ctr Charite, D-10117 Berlin, Germany	Peking University; Nanjing Medical University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wei, JF (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Res Div Clin Pharmacol, Nanjing 210029, Jiangsu, Peoples R China.; Maurer, M (corresponding author), Charite, Dept Dermatol & Allergy, Allergie Ctr Charite, D-10117 Berlin, Germany.	weijifu@hotmail.com; marcus.maurer@charite.de	Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X; Hawro, Tomasz/0000-0001-9990-1332	National Natural Science Foundation of China [GZ901, 81571568]; Deutsche Forschungsgemeinschaft [GZ901]; National Major Scientific and Technological Special Project [2011ZX09302-003-02]; Jiangsu Province Major Scientific and Technological Special Project [BM2011017]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); National Major Scientific and Technological Special Project; Jiangsu Province Major Scientific and Technological Special Project; Priority Academic Program Development of Jiangsu Higher Education Institutions	Supported by a joint Sino-Germany Research Project funded by the National Natural Science Foundation of China and the Deutsche Forschungsgemeinschaft (GZ901), the National Natural Science Foundation of China (no. 81571568); a National Major Scientific and Technological Special Project for "Significant New Drugs Development'' (2011ZX09302-003-02), Jiangsu Province Major Scientific and Technological Special Project (BM2011017); and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Armengot-Carbo M, 2013, DERMATOL THER, V26, P257, DOI 10.1111/j.1529-8019.2013.01549.x; Asero R, 2015, EXPERT REV CLIN IMMU, V11, P1073, DOI 10.1586/1744666X.2015.1069708; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Irwig L, 1998, BRIT MED J, V316, P470; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Koti I, 2013, DERMATOLOGY, V226, P371, DOI 10.1159/000351711; Magerl M, 2010, J ALLERGY CLIN IMMUN, V126, P665, DOI 10.1016/j.jaci.2010.05.047; Maurer M, 2015, J EUR ACAD DERMATOL, V29, P16, DOI 10.1111/jdv.13198; Maurer M, 2011, ALLERGY, V66, P317, DOI 10.1111/j.1398-9995.2010.02496.x; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Maurer M, 2011, J ALLERGY CLIN IMMUN, V128, P202, DOI 10.1016/j.jaci.2011.04.038; Metz M, 2014, J INVEST DERMATOL, V134, pS30; Ruggeri RM, 2013, J ENDOCRINOL INVEST, V36, P531, DOI 10.3275/8940; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Saini SS, 2015, J INVEST DERMATOL, V135, P925, DOI [10.1038/jid.2014.512, 10.1038/jid.2014.306]; Silva PM, 2015, ALLERGOL IMMUNOPATH, V43, P168, DOI 10.1016/j.aller.2013.11.007; Spector SL, 2007, ANN ALLERG ASTHMA IM, V99, P190, DOI 10.1016/S1081-1206(10)60644-8; Staubach P, 2016, ALLERGY; Stuck AE, 1998, BRIT MED J, V316, P469, DOI 10.1136/bmj.316.7129.469; Toubi E, 2004, ALLERGY, V59, P869, DOI 10.1111/j.1398-9995.2004.00473.x; Urgert MC, 2015, BRIT J DERMATOL, V173, P404, DOI 10.1111/bjd.13845; Vestergaard C, 2010, ACTA DERM-VENEREOL, V90, P443, DOI 10.2340/00015555-0884; Viswanathan RK, 2013, ALLERGY ASTHMA PROC, V34, P446, DOI 10.2500/aap.2013.34.3694; Wright JD, 2015, SCI REP-UK, V5, DOI 10.1038/srep11581; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	28	164	175	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1742	+		10.1016/j.jaci.2015.12.1342	http://dx.doi.org/10.1016/j.jaci.2015.12.1342			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27040372	Bronze			2022-12-18	WOS:000377527200014
J	Brown, SGA; Stone, SF; Fatovich, DM; Burrows, SA; Holdgate, A; Celenza, A; Coulson, A; Hartnett, L; Nagree, Y; Cotterell, C; Isbister, GK				Brown, Simon G. A.; Stone, Shelley F.; Fatovich, Daniel M.; Burrows, Sally A.; Holdgate, Anna; Celenza, Antonio; Coulson, Adam; Hartnett, Leanne; Nagree, Yusuf; Cotterell, Claire; Isbister, Geoffrey K.			Anaphylaxis: Clinical patterns, mediator release, and severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; emergency department; mast cell tryptase; histamine; interleukin; soluble tumor necrosis factor receptor I; platelet activating factor; platelet activating factor acetyl hydrolase; biphasic anaphylaxis	PLATELET-ACTIVATING-FACTOR; GENERATION; MANAGEMENT; HISTAMINE; DIAGNOSIS; TRYPTASE; C3A	Background: Prospective human studies of anaphylaxis and its mechanisms have been limited, with few severe cases or examining only 1 or 2 mediators. Objectives: We wanted to define the clinical patterns of anaphylaxis and relationships between mediators and severity. Methods: Data were collected during treatment and before discharge. Serial blood samples were taken for assays of mast cell tryptase, histamine, anaphylatoxins (C3a, C4a, C5a), cytokines (IL-2, IL-6, IL-10), soluble tumor necrosis factor receptor I, and platelet activating factor acetyl hydrolase. Principal component analysis defined mediator patterns, and logistic regression identified risk factors and mediator patterns associated with reaction severity and delayed reactions. Results: Of 412 reactions in 402 people, 315 met the definition for anaphylaxis by the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network. Of 97 severe reactions 45 (46%) were hypotensive, 23 (24%) were hypoxemic, and 29 (30%) were mixed. One patient died. Severe reactions were associated with older age, pre-existing lung disease, and drug causation. Delayed deteriorations treated with epinephrine occurred in 29 of 315 anaphylaxis cases (9.2%) and were more common after hypotensive reactions and with preexisting lung disease. Twenty-two of the 29 delayed deteriorations (76%) occurred within 4 hours of initial epinephrine treatment. Of the remaining 7 cases, 2 were severe and occurred after initially severe reactions, within 10 hours. All mediators were associated with severity, and 1 group (mast cell tryptase, histamine, IL-6, IL-10, and tumor necrosis factor receptor I) was also associated with delayed deteriorations. Low platelet activating factor acetyl hydrolase activity was associated with severe reactions. Conclusion: The results suggest that multiple inflammatory pathways drive reaction severity and support recommendations for safe observation periods after initial treatment.	[Brown, Simon G. A.; Stone, Shelley F.; Fatovich, Daniel M.; Cotterell, Claire] Western Australian Inst Med Res, Ctr Clin Res Emergency Med, Perth, WA, Australia; [Brown, Simon G. A.; Stone, Shelley F.; Fatovich, Daniel M.; Burrows, Sally A.; Celenza, Antonio] Univ Western Australia, Crawley, Australia; [Brown, Simon G. A.; Fatovich, Daniel M.] Royal Perth Hosp, Perth, WA 6847, Australia; [Brown, Simon G. A.; Hartnett, Leanne; Nagree, Yusuf] Fremantle Hosp, Fremantle, WA, Australia; [Holdgate, Anna] Liverpool Hosp, Sydney, NSW, Australia; [Holdgate, Anna] Univ New S Wales, Sydney, NSW, Australia; [Celenza, Antonio] Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia; [Coulson, Adam] Bunbury Reg Hosp, Bunbury, Australia; [Hartnett, Leanne] Rockingham Gen Hosp, Rockingham, Australia; [Nagree, Yusuf] Armadale Kelmscott Mem Hosp, Armadale, Australia; [Isbister, Geoffrey K.] Calvary Mater Hosp, Newcastle, NSW, Australia; [Isbister, Geoffrey K.] Univ Newcastle, Newcastle, NSW 2300, Australia	University of Western Australia; University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Western Australia; Liverpool Hospital; University of New South Wales Sydney; University of Western Australia; Calvary Mater Newcastle Hospital; University of Newcastle	Brown, SGA (corresponding author), Royal Perth Hosp, Dept Emergency Med, GPO Box X2213, Perth, WA 6847, Australia.	simon.brown@uwa.edu.au	Burrows, Sally/H-8914-2014; Isbister, Geoffrey K/G-8052-2015; Fatovich, Daniel/J-5510-2013	Burrows, Sally/0000-0002-8499-4537; Isbister, Geoffrey K/0000-0003-1519-7419; Fatovich, Daniel/0000-0001-9414-6905	Food Allergy and Anaphylaxis Network (FAAN); Fremantle Hospital Medical Research Foundation; Royal Perth Hospital Medical Research Foundation; National Health and Medical Research Council (NHMRC) [ID1023265]; NHMRC [ID605817]	Food Allergy and Anaphylaxis Network (FAAN); Fremantle Hospital Medical Research Foundation; Royal Perth Hospital Medical Research Foundation; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	Supported by grants from the Food Allergy and Anaphylaxis Network (FAAN), the Fremantle Hospital Medical Research Foundation, and the Royal Perth Hospital Medical Research Foundation. S.G.A.B. is supported by National Health and Medical Research Council (NHMRC) Career Development Fellowship Award ID1023265. G.K.I. is supported by an NHMRC Clinical Career Development Award ID605817. The funders had no role in study design, conduct, interpretation, or write-up.	Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Braganza SC, 2006, ARCH DIS CHILD, V91, P159, DOI 10.1136/adc.2004.069914; Brown SGA, 2011, CLIN EXP ALLERGY, V41, P1660, DOI 10.1111/j.1365-2222.2011.03893.x; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown SGA, 2006, MED J AUSTRALIA, V185, P283, DOI 10.5694/j.1326-5377.2006.tb00563.x; Brown Simon G A, 2004, Emerg Med Australas, V16, P120, DOI 10.1111/j.1742-6723.2004.00562.x; DELBALZO U, 1988, J PHARMACOL EXP THER, V246, P911; Fukuoka Y, 2008, J IMMUNOL, V180, P6307, DOI 10.4049/jimmunol.180.9.6307; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Huang F, 2012, J ALLERGY CLIN IMMUN, V129, P162, DOI 10.1016/j.jaci.2011.09.018; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Jollife I.T., 2002, PRINCIPAL COMPONENT; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Marc MM, 2004, AM J RESP CELL MOL, V31, P216, DOI 10.1165/rcmb.2003-0394OC; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Ogawa Y, 2007, IMMUNOL ALLERGY CLIN, V27, P249, DOI 10.1016/j.iac.2007.03.013; Ono E, 2009, CLIN EXP ALLERGY, V39, P72, DOI 10.1111/j.1365-2222.2008.03104.x; Pidde-Queiroz G, 2010, MOL IMMUNOL, V47, P2537, DOI 10.1016/j.molimm.2010.07.003; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Rogers W, 1994, STATA TECHNICAL B, V3, P1; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Simons FER, 2011, WORLD ALLERGY ORGAN, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Stone SF, 2009, J ALLERGY CLIN IMMUN, V124, P786, DOI 10.1016/j.jaci.2009.07.055; Tole JW, 2007, IMMUNOL ALLERGY CLIN, V27, P309, DOI 10.1016/j.iac.2007.03.011; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Yao FZ, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-24	31	164	170	1	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1141	+		10.1016/j.jaci.2013.06.015	http://dx.doi.org/10.1016/j.jaci.2013.06.015			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23915715	Bronze			2022-12-18	WOS:000326235600015
J	Kezic, S; O'Regan, GM; Lutter, R; Jakasa, I; Koster, ES; Saunders, S; Caspers, P; Kemperman, PMJH; Puppels, GJ; Sandilands, A; Chen, HJ; Campbell, LE; Kroboth, K; Watson, R; Fallon, PG; McLean, WHI; Irvine, AD				Kezic, Sanja; O'Regan, Grainne M.; Lutter, Rene; Jakasa, Ivone; Koster, Ellen S.; Saunders, Sean; Caspers, Peter; Kemperman, Patrick M. J. H.; Puppels, Gerwin J.; Sandilands, Aileen; Chen, Huijia; Campbell, Linda E.; Kroboth, Karin; Watson, Rosemarie; Fallon, Padraic G.; McLean, W. H. Irwin; Irvine, Alan D.			Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; confocal Raman spectroscopy; eczema; filaggrin; natural moisturizing factor; pH; transepidermal water loss; IL-1; IL-18; skin barrier; FLG gene mutations; Flg(ft)/Flg(ft)(Flg(delAPfal)) mice	PERMEABILITY BARRIER HOMEOSTASIS; INTERLEUKIN-1 RECEPTOR ANTAGONIST; UNCONVENTIONAL PROTEIN SECRETION; NATURAL MOISTURIZING FACTOR; SKIN BARRIER; HUMAN KERATINOCYTES; TERM CULTURE; IN-VITRO; EPIDERMIS; IL-1-BETA	Background: Filaggrin (FLG) mutations result in reduced stratum corneum (SC) natural moisturizing factor (NMF) components and consequent increased SC pH. Because higher pH activates SC protease activity, we hypothesized an enhanced release of proinflammatory IL-1 cytokines from corneocytes in patients with atopic dermatitis (AD) with FLG mutations (AD(FLG)) compared with that seen in patients with AD without these mutations (AD(NON-FLG)). Objectives: We sought to investigate SC IL-1 cytokine profiles in the uninvolved skin of controls and patients with AD(FLG) versus patients with AD(NON-FLG). We also sought to examine the same profiles in a murine model of filaggrin deficiency (Flg(ft)/Flg(ft) [Flg(delAPfal)] mice). Methods: One hundred thirty-seven patients were studied. NMF levels were ascertained using confocal Raman spectroscopy; transepidermal water loss and skin surface pH were measured. IL-1 alpha, IL-1 beta, IL-18, IL-1 receptor antagonist (IL-1RA), and IL-8 levels were determined in SC tape strips from 93 patients. All subjects were screened for 9 FLG mutations. Flg(ft)/Flg(ft) (Flg(delAPfal)) mice, separated from maFlg(ft)/maFlg(ft) (flaky tail) mice, were used for the preparation and culture of primary murine keratinocytes and as a source of murine skin. RT-PCR was performed using primers specific for murine IL-1 alpha, IL-1 beta, and IL-1RA. Results: SC IL-1 levels were increased in patients with AD(FLG); these levels were inversely correlated with NMF levels. NMF values were also inversely correlated with skin surface pH. Skin and keratinocytes from Flg(ft)/Flg(ft) mice had upregulated expression of IL-1 beta and IL-1RA mRNA. Conclusions: AD(FLG) is associated with an increased SC IL-1 cytokine profile; this profile is also seen in a murine homologue of filaggrin deficiency. These findings might have importance in understanding the influence of FLG mutations on the inflammasome in the pathogenesis of AD and help individualize therapeutic approaches. (J Allergy Clin Immunol 2012;129:1031-9.)	[O'Regan, Grainne M.; Saunders, Sean; Fallon, Padraic G.; Irvine, Alan D.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin 12, Ireland; [O'Regan, Grainne M.; Watson, Rosemarie; Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Paediat Dermatol, Dublin 12, Ireland; [Kezic, Sanja; Jakasa, Ivone; Koster, Ellen S.] Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat Hlth, NL-1105 AZ Amsterdam, Netherlands; [Lutter, Rene] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands; [Lutter, Rene] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, NL-1105 AZ Amsterdam, Netherlands; [Jakasa, Ivone] Univ Zagreb, Analyt Chem Lab, Dept Chem & Biochem, Fac Food Technol & Biotechnol, Zagreb 41000, Croatia; [Caspers, Peter; Puppels, Gerwin J.] Erasmus MC, Ctr Opt Diagnost & Therapy, Dept Dermatol, Rotterdam, Netherlands; [Caspers, Peter; Puppels, Gerwin J.] River Diagnost BV, Rotterdam, Netherlands; [Sandilands, Aileen; Chen, Huijia; Campbell, Linda E.; Kroboth, Karin; McLean, W. H. Irwin] Univ Dundee, Epithelial Genet Grp, Inst Med Sci, Dundee DD1 4HN, Scotland; [Saunders, Sean; Fallon, Padraic G.; Irvine, Alan D.] Univ Dublin Trinity Coll, Dept Med, Dublin 2, Ireland	National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Zagreb; Erasmus University Rotterdam; Erasmus MC; University of Dundee; Trinity College Dublin	Irvine, AD (corresponding author), Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin 12, Ireland.	irvinea@tcd.ie	Irvine, Alan D/A-3982-2008; Fallon, Padraic/Y-2711-2019	Irvine, Alan D/0000-0002-9048-2044; Fallon, Padraic/0000-0002-8401-7293; Caspers, Peter/0000-0002-6122-5049; McLean, William Henry Irwin/0000-0001-5539-5757; Saunders, Sean/0000-0003-1689-3598	COST Action [BM0903]; National Children's Research Centre, Dublin; British Skin Foundation; National Eczema Society; Medical Research Council [G0700314]; Tayside Region of Scotland; Wellcome Trust [090066/B/09/Z, 092530/Z/10/Z]; National Children's Research Centre; Science Foundation, Ireland; MRC [G0700314] Funding Source: UKRI	COST Action(European Cooperation in Science and Technology (COST)); National Children's Research Centre, Dublin; British Skin Foundation; National Eczema Society; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Tayside Region of Scotland; Wellcome Trust(Wellcome Trust); National Children's Research Centre; Science Foundation, Ireland(Science Foundation IrelandEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by COST Action BM0903 (SKINBAD). P.C. and G.J.P. are employees of River Diagnostics BV, Rotterdam, The Netherlands. A.D.I. and G.M.O. are supported by the National Children's Research Centre, Dublin. Filaggrin research in the McLean laboratory is supported by grants from the British Skin Foundation, the National Eczema Society, the Medical Research Council (G0700314), and donations from anonymous families affected by eczema in the Tayside Region of Scotland. A.D.I. and W.H.I.M. are supported by the Wellcome Trust (090066/B/09/Z and 092530/Z/10/Z). P.G.F. is supported by a research grant from the Wellcome Trust (092530/Z/10/Z).; G. M. O'Regan has received research support and is employed by the National Children's Research Centre. P. G. Fallon has received research support from the Science Foundation, Ireland; the National Children's Research Centre; and the Wellcome Trust. A. D. Irvine has received research support from the Wellcome Trust and National Children's Research Centre. The rest of the authors declare that they have no relevant conflicts of interest.	ANSEL JC, 1988, J IMMUNOL, V140, P2274; Barland CO, 2004, J INVEST DERMATOL, V122, P330, DOI 10.1046/j.0022-202X.2004.22203.x; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; de Jongh CM, 2007, SKIN RES TECHNOL, V13, P390, DOI 10.1111/j.1600-0846.2007.00242.x; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2007, SEMIN IMMUNOPATHOL, V29, P3, DOI 10.1007/s00281-007-0060-9; Elias PM, 2009, CURR OPIN ALLERGY CL, V9, P437, DOI 10.1097/ACI.0b013e32832e7d36; Elias PM, 2001, ARCH DERMATOL, V137, P1079; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; FAIRLEY JA, 1991, SEMIN DERMATOL, V10, P225; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Feldmeyer L, 2010, EUR J CELL BIOL, V89, P638, DOI 10.1016/j.ejcb.2010.04.008; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Hachem JP, 2006, J INVEST DERMATOL, V126, P2074, DOI 10.1038/sj.jid.5700351; Hachem JP, 2003, J INVEST DERMATOL, V121, P345, DOI 10.1046/j.1523-1747.2003.12365.x; Hager B, 1999, J INVEST DERMATOL, V112, P971, DOI 10.1046/j.1523-1747.1999.00605.x; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hirasawa Y, 2010, J INVEST DERMATOL, V130, P614, DOI 10.1038/jid.2009.257; Hosomi N, 2008, BRIT J DERMATOL, V159, P744, DOI [10.1111/j.1365-2133.2008.08706.x, 10.1111/j.1365-2133.2008.08706]; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Inoue Y, 2011, BRIT J DERMATOL, V164, P560, DOI 10.1111/j.1365-2133.2010.10145.x; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Ishisaka R, 1999, CELL STRUCT FUNCT, V24, P465, DOI 10.1247/csf.24.465; Jakasa I, 2011, J INVEST DERMATOL, V131, P540, DOI 10.1038/jid.2010.307; Jeon SK, 2008, J INVEST DERMATOL, V128, P1930, DOI 10.1038/jid.2008.13; Jeong CW, 2003, CLIN EXP ALLERGY, V33, P1717, DOI 10.1111/j.1365-2222.2003.01782.x; Jungersted JM, 2010, ALLERGY, V65, P911, DOI 10.1111/j.1398-9995.2010.02326.x; Junghans V, 1998, J INVEST DERMATOL, V111, P1184, DOI 10.1046/j.1523-1747.1998.00409.x; Kato T, 2009, ALLERGY, V64, P1366, DOI 10.1111/j.1398-9995.2009.02023.x; Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040; Kezic S, 2011, ALLERGY, V66, P934, DOI 10.1111/j.1398-9995.2010.02540.x; Kezic S, 2009, BRIT J DERMATOL, V161, P1098, DOI 10.1111/j.1365-2133.2009.09342.x; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Kikuchi Y, 2006, J IMMUNOL, V177, P1609, DOI 10.4049/jimmunol.177.3.1609; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KONDO S, 1995, J INVEST DERMATOL, V105, P334, DOI 10.1111/1523-1747.ep12320329; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Murphy JE, 2000, J INVEST DERMATOL, V114, P602, DOI 10.1046/j.1523-1747.2000.00917.x; Nickel W, 2009, NAT REV MOL CELL BIO, V10, P148, DOI 10.1038/nrm2617; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; NylanderLundqvist E, 1996, J IMMUNOL, V157, P1699; NylanderLundqvist E, 1997, ACTA DERM-VENEREOL, V77, P203; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V126, P574, DOI 10.1016/j.jaci.2010.04.038; Ong PY, 2002, CL ALLER IM, V16, P355; Ovaere P, 2009, TRENDS BIOCHEM SCI, V34, P453, DOI 10.1016/j.tibs.2009.08.001; Roelandt T, 2008, J INVEST DERMATOL, V128, P1878, DOI 10.1038/jid.2008.168; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Terui T, 1998, EXP DERMATOL, V7, P327, DOI 10.1111/j.1600-0625.1998.tb00332.x; Wiedow O, 2005, J INTERN MED, V257, P319, DOI 10.1111/j.1365-2796.2005.01476.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; Wood LC, 1996, J INVEST DERMATOL, V106, P397, DOI 10.1111/1523-1747.ep12343392; Ye J, 2002, EXP DERMATOL, V11, P209, DOI 10.1034/j.1600-0625.2002.110303.x; Zepter K, 1997, J IMMUNOL, V159, P6203	61	164	167	1	44	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1031	U542		10.1016/j.jaci.2011.12.989	http://dx.doi.org/10.1016/j.jaci.2011.12.989			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22322004	Green Published, hybrid			2022-12-18	WOS:000302144600019
J	Ballow, M				Ballow, Mark			The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intravenous immune globulin; immune response modifier; complement; Fc gamma receptors; apoptosis	GUILLAIN-BARRE-SYNDROME; REGULATORY T-CELLS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN-G; GAMMA-GLOBULIN; ANTIINFLAMMATORY ACTIVITY; IN-VITRO; ANTIHEMOPHILIC-FACTOR; MYASTHENIA-GRAVIS; KAWASAKI SYNDROME	Intravenous immune globulin (IVIG) is an important treatment modality in patients with humoral or B-cell immune deficiency as replacement therapy. Soon after its introduction in the early 1980s for the treatment of patients with immune deficiency, IVIG was used in the treatment of children with idiopathic thrombocytopenia purpura. Presently, more commercial IVIG is used for the treatment of autoimmune and inflammatory disorders than as replacement therapy in patients with immune deficiency. Understanding the mechanisms of action of IVIG in these autoimmune and inflammatory disorders has occupied investigators over the past 3 decades. A number of mechanisms for the immune modulation and anti-inflammatory actions of IVIG have been described, including Fc receptor blockade, inhibition of complement deposition, enhancement of regulatory T cells, inhibition or neutralization of cytokines and growth factors, accelerated clearance of autoantibodies, modulation of adhesion molecules and cell receptors, and activation of regulatory macrophages through the Fc gamma RIIb receptor. It can now be appreciated that IVIG affects many different pathways to modulate the immune and inflammatory response. Further delineation of these pathways might lead to new treatment strategies. (J Allergy Clin Immunol 2011;127:315-23.)	[Ballow, Mark] SUNY Buffalo, Womens & Childrens Hosp, Allergy Clin Immunol Div, Dept Pediat, Buffalo, NY 14222 USA; [Ballow, Mark] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Women & Children's Hospital of Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ballow, M (corresponding author), SUNY Buffalo, Womens & Childrens Hosp, Allergy Clin Immunol Div, Dept Pediat, 219 Bryant St, Buffalo, NY 14222 USA.	ballow@buffalo.edu			Grifols	Grifols	M. Ballow is on advisory boards for Talecris Biotherapeutics, CSL-Behring, and Baxter; has received research support from Grifols; and has provided legal consultation or expert witness testimony related to a patient with immune deficiency.	ABE Y, 1994, IMMUNOL REV, V139, P5, DOI 10.1111/j.1600-065X.1994.tb00854.x; Altznauer F, 2003, J ALLERGY CLIN IMMUN, V112, P1185, DOI 10.1016/j.jaci.2003.09.045; Amemiya K, 2000, CLIN IMMUNOL, V94, P99, DOI 10.1006/clim.1999.4823; AMRAN D, 1994, CLIN IMMUNOL IMMUNOP, V73, P180, DOI 10.1006/clin.1994.1186; Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Arumugam TV, 2007, P NATL ACAD SCI USA, V104, P14104, DOI 10.1073/pnas.0700506104; Aukrust P, 1997, CLIN EXP IMMUNOL, V107, P50, DOI 10.1046/j.1365-2249.1997.d01-904.x; Aukrust P, 1999, CLIN EXP IMMUNOL, V115, P136; Ballow M, 1997, J ALLERGY CLIN IMMUN, V100, P151, DOI 10.1016/S0091-6749(97)70217-3; Basta M, 1996, J NEUROIMMUNOL, V71, P227, DOI 10.1016/S0165-5728(96)00133-6; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; Bayry J, 2004, P NATL ACAD SCI USA, V101, P14210, DOI 10.1073/pnas.0402183101; Bayry J, 2003, BLOOD, V101, P758, DOI 10.1182/blood-2002-05-1447; BERCHTOLD P, 1989, BLOOD, V74, P2414; BERGER M, 1985, CLIN IMMUNOL IMMUNOP, V34, P227, DOI 10.1016/0090-1229(85)90027-3; BLANCHETTE VS, 1993, J PEDIATR-US, V123, P989, DOI 10.1016/S0022-3476(05)80400-7; Bouhlal H, 2001, J IMMUNOL, V166, P7606, DOI 10.4049/jimmunol.166.12.7606; BUSSEL J, 1986, J CLIN IMMUNOL, V6, P50, DOI 10.1007/BF00915364; BUSSEL JB, 1989, J ALLERGY CLIN IMMUN, V84, P566, DOI 10.1016/0091-6749(89)90193-0; Chang JS, 2008, BLOOD, V111, P915, DOI 10.1182/blood-2007-04-084061; CLARKSON SB, 1986, NEW ENGL J MED, V314, P1236, DOI 10.1056/NEJM198605083141907; Crow AR, 2003, J PEDIAT HEMATOL ONC, V25, pS14, DOI 10.1097/00043426-200312001-00004; Crow AR, 2001, BRIT J HAEMATOL, V115, P679, DOI 10.1046/j.1365-2141.2001.03136.x; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dalakas MC, 1998, ARCH NEUROL-CHICAGO, V55, P1509, DOI 10.1001/archneur.55.12.1509; Dalakas MC, 1999, MUSCLE NERVE, V22, P1479, DOI 10.1002/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; Dalakas MC, 1998, NEUROLOGY, V51, pS37, DOI 10.1212/WNL.51.6_Suppl_5.S37; de Grandmont MJ, 2003, BLOOD, V101, P3065, DOI 10.1182/blood-2002-06-1684; De Groot AS, 2008, BLOOD, V112, P3303, DOI 10.1182/blood-2008-02-138073; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; DIETRICH G, 1990, J CLIN INVEST, V85, P620, DOI 10.1172/JCI114483; Ephrem A, 2008, BLOOD, V111, P715, DOI 10.1182/blood-2007-03-079947; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; Furuno K, 2004, J PEDIATR-US, V145, P385, DOI 10.1016/j.jpeds.2004.05.048; GEHA RS, 1981, NEW ENGL J MED, V305, P25, DOI 10.1056/NEJM198107023050105; Gergely J, 1996, SCAND J IMMUNOL, V44, P1; Gupta M, 2001, J CLIN IMMUNOL, V21, P193, DOI 10.1023/A:1011039216251; Hansen RJ, 2002, THROMB HAEMOSTASIS, V88, P898, DOI 10.1055/s-0037-1613331; Hansen RJ, 2002, BLOOD, V100, P2087, DOI 10.1182/blood.V100.6.2087.h81802002087_2087_2093; Hirono K, 2009, PEDIATR RES, V65, P696, DOI 10.1203/01.pdr.0000352115.41382.65; IMBACH P, 1981, LANCET, V1, P1228; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kaveri S, 1996, J CLIN INVEST, V97, P865, DOI 10.1172/JCI118488; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Kessel A, 2007, J IMMUNOL, V179, P5571, DOI 10.4049/jimmunol.179.8.5571; KIMBERLY RP, 1995, ARTHRITIS RHEUM, V38, P306, DOI 10.1002/art.1780380303; KIMBERLY RP, 1984, J IMMUNOL, V132, P745; Le Pottier L, 2007, J CLIN IMMUNOL, V27, P257, DOI 10.1007/s10875-007-9082-2; Leung D Y, 1989, Immunodefic Rev, V1, P261; Leung DYM, 1996, CLIN EXP IMMUNOL, V104, P49, DOI 10.1111/cei.1996.104.s1.49; Leung DYM, 1998, ARTHRITIS RHEUM-US, V41, P1538, DOI 10.1002/1529-0131(199809)41:9<1538::AID-ART3>3.0.CO;2-M; Li N, 2005, J CLIN INVEST, V115, P3440, DOI 10.1172/JCI24394; LIBLAU R, 1991, J CLIN IMMUNOL, V11, P128, DOI 10.1007/BF00918680; MacMillan HF, 2009, CLIN IMMUNOL, V132, P222, DOI 10.1016/j.clim.2009.04.002; Malik U, 1996, ANN NEUROL, V39, P136, DOI 10.1002/ana.410390121; MARCHALONIS JJ, 1992, P NATL ACAD SCI USA, V89, P3325, DOI 10.1073/pnas.89.8.3325; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Pachner AR, 1997, NEUROLOGY, V49, P147, DOI 10.1212/WNL.49.1.147; Prasad NKA, 1998, J IMMUNOL, V161, P3781; Proulx DP, 2010, CLIN IMMUNOL, V135, P422, DOI 10.1016/j.clim.2010.01.001; ROSSI F, 1989, J IMMUNOL, V143, P4104; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; SHOENFELD Y, 1994, FASEB J, V8, P1296, DOI 10.1096/fasebj.8.15.8001742; Sigman K, 1998, J ALLERGY CLIN IMMUN, V102, P421, DOI 10.1016/S0091-6749(98)70130-7; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; SULTAN Y, 1987, P NATL ACAD SCI USA, V84, P828, DOI 10.1073/pnas.84.3.828; SULTAN Y, 1984, LANCET, V2, P765; SVENSON M, 1993, J CLIN INVEST, V92, P2533, DOI 10.1172/JCI116862; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; Tha-In T, 2008, TRENDS IMMUNOL, V29, P608, DOI 10.1016/j.it.2008.08.004; Turhan A, 2004, BLOOD, V103, P2397, DOI 10.1182/blood-2003-07-2209; Vaccaro C, 2005, NAT BIOTECHNOL, V23, P1283, DOI 10.1038/nbt1143; vanderMeche FGA, 1996, REV NEUROL, V152, P355; vanderMeche FGA, 1997, J INFECT DIS, V176, pS99, DOI 10.1086/513779; VASSILEV T, 1993, CLIN EXP IMMUNOL, V92, P369; Vassilev TL, 1999, BLOOD, V93, P3624, DOI 10.1182/blood.V93.11.3624.411a28_3624_3631; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; von Gunten S, 2007, J ALLERGY CLIN IMMUN, V119, P1005, DOI 10.1016/j.jaci.2007.01.023; von Gunten S, 2006, BLOOD, V108, P4255, DOI 10.1182/blood-2006-05-021568; Wasserbauer N, 2009, J ALLERGY CLIN IMMUN, V123, pS162, DOI 10.1016/j.jaci.2008.12.610; Xu C, 1998, AM J PATHOL, V153, P1257, DOI 10.1016/S0002-9440(10)65670-2; Yu ZY, 1999, NEW ENGL J MED, V340, P227, DOI 10.1056/NEJM199901213400311; Yuki N, 1996, J NEUROL SCI, V139, P160, DOI 10.1016/0022-510X(96)00053-6; Zhuang QL, 2001, J ALLERGY CLIN IMMUN, V108, P229, DOI 10.1067/mai.2001.116291	90	164	168	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					315	323		10.1016/j.jaci.2010.10.030	http://dx.doi.org/10.1016/j.jaci.2010.10.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21185071				2022-12-18	WOS:000286808000002
J	Esser, J; Gehrmann, U; D'Alexandri, FL; Hidalgo-Estevez, AM; Wheelock, CE; Scheynius, A; Gabrielsson, S; Radmark, O				Esser, Julia; Gehrmann, Ulf; D'Alexandri, Fabio Luiz; Hidalgo-Estevez, Alicia M.; Wheelock, Craig E.; Scheynius, Annika; Gabrielsson, Susanne; Radmark, Olof			Exosomes from human macrophages and dendritic cells contain enzymes for leukotriene biosynthesis and promote granulocyte migration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antigen-presenting cells; eicosanoids; exosomes; inflammation; leukotrienes; TGF-beta 1	GROWTH-FACTOR-BETA; IMMUNE-RESPONSES; LANGERHANS CELLS; CYSTEINYL LEUKOTRIENES; UP-REGULATION; IN-VIVO; VESICLES; EXPRESSION; ANTIGEN; 5-LIPOXYGENASE	Background: Leukotrienes (LTs) are potent proinflammatory lipid mediators with key roles in the pathogenesis of asthma and inflammation. Recently, nanovesicles (exosomes), released from macrophages and dendritic cells (DCs), have become increasingly appreciated as messengers in immunity. Objective: We investigated whether exosomes from human macrophages, DCs, and plasma contain enzymes for LT biosynthesis and studied potential roles for exosomes in transcellular LT metabolism and granulocyte chemotaxis. Methods: The presence of LT pathway enzymes and LT biosynthesis in exosomes and cells was analyzed by Western blot, immunoelectron microscopy, and enzyme activity assays. Surface marker expression was evaluated by flow cytometry, and granulocyte migration was assessed in a multiwell chemotaxis system. Results: Exosomes from macrophages and DCs contain functional enzymes for LT biosynthesis. After incubation of intact cells with the LT biosynthesis intermediate LTA(4), LTB(4) was the major product of macrophages, whereas DCs primarily formed LTC(4). However, in exosomes from both cell types, LTC(4) was the predominant LTA(4) metabolite. Exosomal LTC(4) formation (per milligram protein) exceeded that of cells. In macrophages and DCs, TGF-beta 1 upregulated LTA(4) hydrolase along with increased LTB(4) formation also in the exosomes. Moreover, TGF-beta 1 modified the expression of surface marker proteins on cells and exosomes and reduced the exosome yield from macrophages. On Ca(2+)-ionophore and arachidonic acid stimulation, exosomes produced chemotactic eicosanoids and induced granulocyte migration. Interestingly, active LTA(4) hydrolase and LTC(4) synthase were present also in exosomes from human plasma. Conclusion: Our findings indicate that exosomes can contribute to inflammation by participation in LT biosynthesis and granulocyte recruitment. (J Allergy Clin Immunol 2010;126:1032-40.)	[Esser, Julia; D'Alexandri, Fabio Luiz; Hidalgo-Estevez, Alicia M.; Wheelock, Craig E.; Radmark, Olof] Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; [Gehrmann, Ulf; Scheynius, Annika; Gabrielsson, Susanne] Karolinska Inst, Dept Med Solna, Clin Allergy Res Unit, Solna, Sweden; [Gehrmann, Ulf; Scheynius, Annika; Gabrielsson, Susanne] Univ Hosp, Solna, Sweden	Karolinska Institutet; Karolinska Institutet	Gabrielsson, S (corresponding author), Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	susanne.gabrielsson@ki.se; olof.radmark@ki.se	Gabrielsson, S./E-4145-2014; Hidalgo, Alicia/F-2361-2016	Gabrielsson, S./0000-0003-1771-1346; Hidalgo, Alicia/0000-0001-8849-7573; Esser-von Bieren, Julia/0000-0003-1898-9382	Swedish Research Council [03X-217, 57X-15242-05-2]; EU [LSHM-CT-2004-00533, FP7-Health-201668]; Vardal Foundation; Center for Allergy Research, Karolinska Institutet; Swedish Asthma and Allergy Association's Research Foundation; Hesselman's Foundation; Cancer and Allergy Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); EU(European Commission); Vardal Foundation; Center for Allergy Research, Karolinska Institutet(Karolinska Institutet); Swedish Asthma and Allergy Association's Research Foundation; Hesselman's Foundation; Cancer and Allergy Foundation	Supported by grants from the Swedish Research Council (03X-217, 57X-15242-05-2), EU (LSHM-CT-2004-00533, FP7-Health-201668), the Vardal Foundation, the Center for Allergy Research, Karolinska Institutet, the Swedish Asthma and Allergy Association's Research Foundation, the Hesselman's Foundation, and the Cancer and Allergy Foundation.	Admyre C, 2008, ALLERGY, V63, P404, DOI 10.1111/j.1398-9995.2007.01600.x; Admyre C, 2006, EUR J IMMUNOL, V36, P1772, DOI 10.1002/eji.200535615; Altraja S, 2010, J PROTEOMICS, V73, P1230, DOI 10.1016/j.jprot.2010.02.017; Barocchi MA, 2006, P NATL ACAD SCI USA, V103, P2857, DOI 10.1073/pnas.0511017103; Beauvillain C, 2007, MICROBES INFECT, V9, P1614, DOI 10.1016/j.micinf.2007.07.002; Bhatnagar S, 2007, BLOOD, V110, P3234, DOI 10.1182/blood-2007-03-079152; Borkowski TA, 1996, J EXP MED, V184, P2417, DOI 10.1084/jem.184.6.2417; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871; Del Prete A, 2007, BLOOD, V109, P626, DOI 10.1182/blood-2006-02-003665; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Geissmann F, 1999, J IMMUNOL, V162, P4567; Gupta N, 1999, FEBS LETT, V449, P66, DOI 10.1016/S0014-5793(99)00397-X; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; Harizi H, 2002, PROSTAG LEUKOTR ESS, V66, P459, DOI 10.1054/plef.2002.0383; Jakobsson PJ, 2000, AM J RESP CRIT CARE, V161, pS20, DOI 10.1164/ajrccm.161.supplement_1.ltta-5; Kardassis D, 2009, FEBS J, V276, P2947, DOI 10.1111/j.1742-4658.2009.07031.x; LAUENER RP, 1990, EUR J IMMUNOL, V20, P2375, DOI 10.1002/eji.1830201103; Mandal AK, 2004, P NATL ACAD SCI USA, V101, P6587, DOI 10.1073/pnas.0308523101; Mor-Vaknin N, 2006, MOL CELL BIOL, V26, P9484, DOI 10.1128/MCB.01030-06; Neves JS, 2010, J ALLERGY CLIN IMMUN, V125, P477, DOI 10.1016/j.jaci.2009.11.029; Okunishi K, 2004, J IMMUNOL, V173, P6393, DOI 10.4049/jimmunol.173.10.6393; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Peters-Golden M, 2005, J IMMUNOL, V174, P589, DOI 10.4049/jimmunol.174.2.589; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; RADMARK O, 1984, J BIOL CHEM, V259, P2339; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Salib RJ, 2009, CLIN EXP ALLERGY, V39, P1128, DOI 10.1111/j.1365-2222.2009.03239.x; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Shearer GC, 2009, J LIPID RES; Shearer GC, 2010, J LIPID RES, V51, P2074, DOI 10.1194/M900193-JLR200; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; STEINHILBER D, 1989, J CHROMATOGR-BIOMED, V493, P361, DOI 10.1016/S0378-4347(00)82742-5; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; You HJ, 2007, MOL CELLS, V23, P57; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	44	164	173	2	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1032	U213		10.1016/j.jaci.2010.06.039	http://dx.doi.org/10.1016/j.jaci.2010.06.039			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20728205				2022-12-18	WOS:000283727100021
J	Ponikau, JU; Sherris, DA; Weaver, A; Kita, H				Ponikau, JU; Sherris, DA; Weaver, A; Kita, H			Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; antifungal; chronic sinusitis; nasal polyps; chronic rhinosinusitis; amphotericin B	CHRONIC HYPERPLASTIC SINUSITIS; MESSENGER-RNA EXPRESSION; ANTIFUNGAL TREATMENT; MECHANISM; DIAGNOSIS; IL-5	Background: Chronic rhinosinusitis (CRS) is one of the most common chronic diseases. Its etiology is unknown, and there is a paucity of effective medical treatments. Objective: We tested the hypothesis that intranasal antifungal treatment improves the objective computed tomography (CT) findings (inflammatory mucosal thickening), nasal endoscopy stages, and symptoms of CRS. Methods: A randomized, placebo-controlled, double-blind, single-center trial used amphotericin B to treat 30 randomly selected patients with CRS. Patients were instructed to instill 20 mL amphotericin B (250 mug/mL) or placebo to each nostril twice daily for 6 months. The primary outcome was a quantitative reduction in inflammatory mucosal thickening on CT scans of a standardized coronal cut. Secondary outcome measures were endoscopic scores, patient symptom scores, and levels of intranasal inflammatory mediators. Results: Twenty-four patients completed the 6 months of treatment. Patients receiving amphotericin B achieved a relative reduction in the percentage of mucosal thickening on CT scans (n = 10; -8.8%) compared with placebo (n = 14; +2.5%; P=.030). Likewise, the changes in the endoscopic scores improved in the amphotericin B group compared with placebo (P =.038). Between-group comparisons of the changes in the intranasal mucus levels of eosinophil-derived neurotoxin showed a reduction in the amphotericin B group and an increase in the placebo group (P =.046); levels of IL-5 showed similar tendencies (P =.082). Conclusion: Intranasal amphotericin B reduced inflammatory mucosal thickening on both CT scan and nasal endoscopy and decreased. the levels of intranasal markers for eosinophilic inflammation in patients with CRS.	Mayo Clin, Dept Otorhinolaryngol Head & Neck Surg, Rochester, MN 55905 USA; SUNY Buffalo, Dept Otorhinolaryngol, Buffalo, NY 14260 USA; Mayo Clin, Dept Hlth Sci Res, Div Biostat, Rochester, MN 55905 USA; Mayo Clin, Dept Internal Med, Div Allerg Dis, Rochester, MN 55905 USA	Mayo Clinic; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Mayo Clinic; Mayo Clinic	Ponikau, JU (corresponding author), Mayo Clin, Dept Otorhinolaryngol Head & Neck Surg, 200 1st St SW, Rochester, MN 55905 USA.	ponikau.jens@mayo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049235] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; BENNETT JE, 1996, ANTIMICROBIAL AGENTS, P1175; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; Braun H, 2003, LARYNGOSCOPE, V113, P264, DOI 10.1097/00005537-200302000-00013; CHEUNG SC, 1975, ANTIMICROB AGENTS CH, V8, P426, DOI 10.1128/AAC.8.4.426; GALLELLI JF, 1967, DRUG INTELL, V1, P102; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; Hamilos DL, 2000, J ALLERGY CLIN IMMUN, V106, P213, DOI 10.1067/mai.2000.109269; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Kaliner MA, 1997, OTOLARYNG HEAD NECK, V116, pS1; Kenny TJ, 2001, OTOLARYNG HEAD NECK, V125, P40, DOI 10.1067/mhn.2001.116779; Kita H, 2000, J ALLERGY CLIN IMMUN, V106, P521, DOI 10.1067/mai.2000.108430; KITA H, 2003, MIDDLETONS ALLERGY P, P305; LETHBRIGE CM, 2004, VITAL HLTH STAT, V10, P23; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Lowery MM, 2003, ANN ALLERG ASTHMA IM, V91, P460, DOI 10.1016/S1081-1206(10)61514-1; Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022; Ponikau JU, 2003, J ALLERGY CLIN IMMUN, V112, P877, DOI 10.1016/j.jaci.2003.08.009; Ponikau JU, 2002, J ALLERGY CLIN IMMUN, V110, P862, DOI 10.1067/mai.2002.130051; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; PRINCETON NJ, 1994, PRODUCT INFORMATION, P1; Ricchetti A, 2002, J LARYNGOL OTOL, V116, P261, DOI 10.1258/0022215021910708; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Simon HU, 1997, J IMMUNOL, V158, P3902; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; Taylor MJ, 2002, OTOLARYNG HEAD NECK, V127, P377, DOI 10.1067/mhn.2002.128896; *US FOOD DRUG ADM, 2003, CTR DRUG EVAL RES; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Weschta M, 2004, J ALLERGY CLIN IMMUN, V113, P1122, DOI 10.1016/j.jaci.2004.03.038; 2003, DRUG IND DAILY, V2, P5	33	164	179	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					125	131		10.1016/j.jaci.2004.09.037	http://dx.doi.org/10.1016/j.jaci.2004.09.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637558	Bronze			2022-12-18	WOS:000226267000018
J	Peat, JK; Mihrshahi, S; Kemp, AS; Marks, GB; Tovey, ER; Webb, K; Mellis, CM; Leeder, SR				Peat, JK; Mihrshahi, S; Kemp, AS; Marks, GB; Tovey, ER; Webb, K; Mellis, CM; Leeder, SR		Childhood Asthma Study Team	Three-year outcomes of dietary fatty acid modification and house dust mite reduction in the Childhood Asthma Prevention Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen avoidance; allergy; asthma; atopy; omega-3 fatty acids; house dust mite; primary prevention	RESPIRATORY SYMPTOMS; HIGH-RISK; FISH-OIL; COUGH; ATOPY; INTERVENTION; AVOIDANCE; PREGNANCY; BLOOD; TRIAL	Background: Two factors thought to influence the risk of asthma are the promoting effect of sensitization to house dust mites and the preventive effect of increased omega-3 fatty acids. Although house dust mite allergen avoidance has been used as a preventive strategy in several trials, the effect of omega-3 fatty acid supplementation in the primary prevention of asthma and allergic disease is not known. Objective: To measure the effects of dietary supplementation with omega-3 fatty acids and house dust mite allergen avoidance in children with a family history of asthma. Methods: A total of 616 children at high risk of asthma were enrolled antenatally in a randomized controlled trial, and 526 children remained in the trial at age 3 years. The outcomes were symptoms of allergic disease and allergen sensitization. Results: There was a significant 10.0% (95% CI, 3.7-16.4) reduction in the prevalence of cough in atopic children in the active diet group (P = .003; number needed to treat, 10) but a negligible 1.1 % (95 % CI, -7.1 to 9.5) reduction cough among nonatopic children. There was a 7.2% (95% CI, 10.11-14.3) reduction in sensitization to house dust mite in the active allergen avoidance group (P = .05; number needed to treat, 14). No significant differences in wheeze were found with either intervention. Conclusion: These results suggest that our interventions, designed to be used in simple public health campaigns, may have a role in preventing the development of allergic sensitization and airways disease in early childhood. This offers the prospect of reducing allergic disease in later life.	Univ Sydney, Discipline Paediat & Child Hlth, Childrens Hosp, Westmead Clin Sch, Sydney, NSW 2006, Australia; Childrens Hosp, Clin Epidemiol Unit, Westmead, NSW 2145, Australia; Woolcock Inst Med Res, Camperdown, NSW, Australia; Cooperat Res Ctr Asthma, Camperdown, NSW, Australia; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney; Woolcock Institute of Medical Research; University of Sydney; University of Sydney; University of Sydney	Mihrshahi, S (corresponding author), Childrens Hosp, Clin Epidemiol Unit, Locked Bag 4001, Westmead, NSW 2145, Australia.	seemann@chw.edu.au	Tovey, Euan R/G-8604-2017; Mihrshahi, Seema/A-9877-2009; Marks, Guy B./F-5058-2013; Mihrshahi, Seema/AAW-1854-2020	Tovey, Euan R/0000-0002-1802-7266; Mihrshahi, Seema/0000-0001-6567-9884; Marks, Guy B./0000-0002-8976-8053; Mihrshahi, Seema/0000-0002-2394-5432				[Anonymous], 2002, ASTHM MAN HDB; Arntzen KJ, 1998, PROSTAG OTH LIPID M, V56, P183, DOI 10.1016/S0090-6980(98)00048-3; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Calder PC, 2003, CLIN EXP ALLERGY, V33, P412, DOI 10.1046/j.1365-2222.2003.01633.x; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; Chang AB, 1999, ARCH DIS CHILD, V80, P211, DOI 10.1136/adc.80.3.211; COLERIDGE HM, 1976, NATURE, V264, P451, DOI 10.1038/264451a0; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Ewart HS, 2002, J NUTR, V132, P1149, DOI 10.1093/jn/132.6.1149; Faniran AO, 1998, ARCH DIS CHILD, V79, P411, DOI 10.1136/adc.79.5.411; Gore Claudia, 2003, Paediatr Respir Rev, V4, P213, DOI 10.1016/S1526-0542(03)00055-1; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Halmerbauer G, 2002, PEDIAT ALLERG IMM-UK, V13, P47, DOI 10.1034/j.1399-3038.13.s.15.11.x; Hodge L, 1996, MED J AUSTRALIA, V164, P137, DOI 10.5694/j.1326-5377.1996.tb122010.x; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Mantzioris E, 2000, AM J CLIN NUTR, V72, P42; Martinez FD, 1999, ALLERGY, V54, P24, DOI 10.1111/j.1398-9995.1999.tb04384.x; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Mihrshahi S, 2003, ALLERGY, V58, P784, DOI 10.1034/j.1398-9995.2003.00194.x; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; Oddy WH, 2004, J ASTHMA, V41, P319, DOI 10.1081/JAS-120026089; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Ponsonby AL, 2002, J CLIN EPIDEMIOL, V55, P556, DOI 10.1016/S0895-4356(01)00519-4; Raatz SK, 2001, J NUTR, V131, P231; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67, DOI 10.1093/oxfordjournals.aje.a115644; Schwartz J, 2000, AM J CLIN NUTR, V71, p393S, DOI 10.1093/ajcn/71.1.393s; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SHAHAR E, 1994, NEW ENGL J MED, V331, P228, DOI 10.1056/NEJM199407283310403; STONE R, 1992, J APPL PHYSIOL, V73, P649, DOI 10.1152/jappl.1992.73.2.649; Warner JO, 1998, PEDIATR PULM, V25, P1	31	164	173	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					807	813		10.1016/j.jaci.2004.06.057	http://dx.doi.org/10.1016/j.jaci.2004.06.057			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480319				2022-12-18	WOS:000224439100013
J	Bottcher, MF; Hmani-Aifa, M; Lindstrom, A; Jenmalm, MC; Mai, XM; Nilsson, L; Zdolsek, HA; Bjorksten, B; Soderkvist, P; Vaarala, O				Bottcher, MF; Hmani-Aifa, M; Lindstrom, A; Jenmalm, MC; Mai, XM; Nilsson, L; Zdolsek, HA; Bjorksten, B; Soderkvist, P; Vaarala, O			A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; TLR4; lipopolysaccharide; IL-12; IL-10	TOLL-LIKE RECEPTOR-4; T-CELL; ENDOTOXIN EXPOSURE; INTERFERON-GAMMA; ALLERGIC DISEASE; IGE PRODUCTION; HOUSE-DUST; CD14 GENE; ATOPY; CHALLENGE	Background: Bacterial signals play an important role in the maturation of the immune system. Polymorphisms in genes coding for receptors to bacterial components can alter the immune responsiveness of the host to microbial agents and may indicate the development of aberrant immune responses that are associated with immune-mediated diseases such as atopic diseases. Objective: The study's objective was to investigate the relationship between TLR4 and CD14 gene polymorphisms, the LPS responsiveness of PBMCs, and the presence of asthma and allergic rhinoconjunctivitis in children. Methods: The TLR4 (Asp299Gly) and CD14/-159 polymorphisms were determined in 115 Swedish children aged 8 and 14 years. LPS-induced IL-12(p70), IL-10, and IFN-gamma responses of PBMCs from 69 of the children were analyzed by means of ELISA. The levels of soluble CD14 in serum samples were analyzed by means of ELISA, and the total IgE levels were analyzed by means of UniCAP Total IgE (Pharmacia Diagnostics, Uppsala, Sweden). Results: Decreased LPS-induced IL-12(p70) and IL-10 responses were associated with the TLR4 (Asp299Gly) polymorphism and independently with asthma, especially atopic asthma. The TLR4 (Asp299Gly) polymorphism was associated with a 4-fold higher prevalence of asthma in school-aged children (adjusted odds ratio 4.5, 95% CI 1.1-17.4) but not to allergic rhinoconjunctivitis. Conclusion: A TLR4 polymorphism modifies innate immune responses in children and may be an important determinant for the development of asthma. This may influence the outcome of intervention studies that use microbial stimuli as immune modulators.	Linkoping Univ, Dept Mol & Clin Med, Div Pediat, Linkoping, Sweden; Linkoping Univ, Fac Hlth Sci, Clin Res Ctr, Linkoping, Sweden; Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, Linkoping, Sweden; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Stockholm, Sweden; Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland	Linkoping University; Linkoping University; Linkoping University; Karolinska Institutet; Karolinska Institutet; Finland National Institute for Health & Welfare	Bottcher, MF (corresponding author), Linkoping Univ Hosp, Div Paediat, KFC, S-58185 Linkoping, Sweden.	MalFa@imk.liu.se	Jenmalm, Maria C/C-9679-2009	Jenmalm, Maria C/0000-0002-2117-5366; Nilsson, Lennart/0000-0002-5680-6367				Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P1690, DOI 10.1046/j.1365-2222.2002.01463.x; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Cleveland MG, 1996, INFECT IMMUN, V64, P1906, DOI 10.1128/IAI.64.6.1906-1912.1996; Corinti S, 2001, J IMMUNOL, V166, P4312, DOI 10.4049/jimmunol.166.7.4312; Egan RW, 1996, ALLERGY, V51, P71, DOI 10.1111/j.1398-9995.1996.tb00038.x; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gross E, 1999, HUM GENET, V105, P72, DOI 10.1007/s004390051066; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Lorenz E, 2001, AM J PHYSIOL-LUNG C, V281, pL1106, DOI 10.1152/ajplung.2001.281.5.L1106; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Mai XM, 2002, PEDIATR ALLERGY IMMU, V13, P361, DOI 10.1034/j.1399-3038.2002.01011.x; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rccm.200207-634OC; Sudo N, 1997, J IMMUNOL, V159, P1739; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5	32	164	172	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					561	567		10.1016/j.jaci.2004.04.050	http://dx.doi.org/10.1016/j.jaci.2004.04.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356557				2022-12-18	WOS:000223799600014
J	Juniper, EF				Juniper, EF			Measuring health-related quality of life in rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						quality of life; health-related quality of life; rhinitis; disease-specific instruments	SEASONAL ALLERGIC RHINITIS; OF-LIFE; CLINICAL-TRIALS; NASAL SPRAY; QUESTIONNAIRE; RHINOCONJUNCTIVITIS; INSTRUMENTS; ARTHRITIS; VALIDITY; PROFILE	Patients with rhinitis are bothered both by the nasal symptoms themselves and by associated symptoms such as headache and fatigue. The combination can produce quite severe impairment of day-to-day physical, emotional, occupational, and social functioning and can cause emotional distress. This breadth of impairment of health-related quality of life in patients with rhinitis is often not recognized and is sometimes trivialized by some health care professionals. One of the aims of treating patients with rhinitis must be to ensure that all individual patient problems are recognized and treated appropriately. Several studies now show that correlations between conventional nasal symptom-severity diaries and health-related quality of life are only weak to moderate. Therefore, to get an overall picture of a patient's health status, it is essential to measure quality of life. Generic health-status questionnaires are able to compare burden of illness across different medical conditions, but they are often now responsive enough to small but clinically important changes in patients' quality of life. As a result, we have seen the emergence of disease-specific instruments for rhinitis that have strong measurement properties and that are much more sensitive to these changes. Most clinical trials in rhinitis now include a measure of health-related quality of life as a primary outcome, and many clinicians are incorporating quality of life into routine clinical assessments.			Juniper, EF (corresponding author), MCMASTER UNIV, MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, 1200 MAIN ST W, HAMILTON, ON L8N 3Z5, CANADA.							BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; deGraafintVeld T, 1996, J ALLERGY CLIN IMMUN, V98, P508, DOI 10.1016/S0091-6749(96)70083-0; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; Feinstein AR, 1987, CLINIMETRICS, P141, DOI DOI 10.2307/J.CTT1XP3VBC.13; GAUCI M, 1993, PSYCHOSOM MED, V55, P533, DOI 10.1097/00006842-199311000-00009; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; GUYATT GH, 1992, J CLIN EPIDEMIOL, V45, P1341, DOI 10.1016/0895-4356(92)90194-R; GUYATT GH, IN PRESS JAMA; GUYATT GH, IN PRESS PEDIATRICS; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; JONES PW, 1994, AM J RESP CRIT CARE, V149, pA211; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V86, P380, DOI 10.1016/S0091-6749(05)80101-0; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; JUNIPER EF, 1995, MANUAL ASTHMA CONTRO; JUNIPER EF, IN PRESS EUR RESPIR; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; LYDICK E, 1993, QUAL LIFE RES, V2, P221, DOI 10.1007/BF00435226; MARSHALL PS, 1993, ANN ALLERGY, V71, P251; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; RUTTENVANMOLKEN MPMH, 1995, EUR RESPIR J, V8, P888; SACKETT DL, 1977, AM J PUBLIC HEALTH, V67, P423, DOI 10.2105/AJPH.67.5.423; Schipper H, 1990, QUALITY LIFE ASSESSM, P11; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; WELLS GA, 1993, J RHEUMATOL, V20, P557; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	31	164	181	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					S742	S749		10.1016/S0091-6749(97)90000-2	http://dx.doi.org/10.1016/S0091-6749(97)90000-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	WH831	9042066				2022-12-18	WOS:A1997WH83100034
J	AUDICANA, MT; DECORRES, LF; MUNOZ, D; FERNANDEZ, E; NAVARRO, JA; DELPOZO, MD				AUDICANA, MT; DECORRES, LF; MUNOZ, D; FERNANDEZ, E; NAVARRO, JA; DELPOZO, MD			RECURRENT ANAPHYLAXIS CAUSED BY ANISAKIS SIMPLEX PARASITIZING FISH	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							TOXOCARA-CANIS; ASCARIS-SUUM		HOSP SANTIAGO APOSTOL,SERV ALERGOL,E-01004 VITORIA,SPAIN				Fernandez, Eduardo/S-8206-2016	Fernandez, Eduardo/0000-0002-7052-6011				CHRISTIE JF, 1993, CLIN EXP IMMUNOL, V92, P125, DOI 10.1111/j.1365-2249.1993.tb05958.x; DESOWITZ RS, 1985, T ROY SOC TROP MED H, V79, P256, DOI 10.1016/0035-9203(85)90351-7; IKEDA K, 1989, GASTROINTEST ENDOSC, V35, P304, DOI 10.1016/S0016-5107(89)72797-8; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; KENNEDY MW, 1988, MOL BIOCHEM PARASIT, V31, P35, DOI 10.1016/0166-6851(88)90143-0; KIM H, 1991, NEUROPSYCHOLOGIA, V29, P93, DOI 10.1016/0028-3932(91)90095-P; PETITHORY JC, 1991, B ACAD NAT MED PARIS, V175, P273; Van Thiel P. H., 1960, Tropical and Geographical Medicine, V2, P97; WASSERMAN SI, 1988, ALLERGY PRINCIPLES P	9	164	171	0	25	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					558	560		10.1016/S0091-6749(95)70301-2	http://dx.doi.org/10.1016/S0091-6749(95)70301-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560669				2022-12-18	WOS:A1995TA09500018
J	SLY, RM				SLY, RM			MORTALITY FROM ASTHMA, 1979-1984	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									CHILDRENS HOSP,NATL MED CTR,DEPT ALLERGY & IMMUNOL,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT CHILD HLTH & DEV,WASHINGTON,DC 20052	Children's National Health System; George Washington University								[Anonymous], 1984, Thorax, V39, P505; [Anonymous], [No title captured]; BARGER LW, 1988, ANN ALLERGY, V60, P31; BATEMAN JRM, 1979, THORAX, V34, P40, DOI 10.1136/thx.34.1.40; BETHEL RA, 1984, J APPL PHYSIOL, V57, P419, DOI 10.1152/jappl.1984.57.2.419; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BURANAKUL B, 1974, AM J DIS CHILD, V128, P343, DOI 10.1001/archpedi.1974.02110280073009; CARSWELL F, 1985, ARCH DIS CHILD, V60, P25, DOI 10.1136/adc.60.1.25; GERGEN PJ, 1988, PEDIATRICS, V81, P1; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; IMAI M, 1986, ARCH ENVIRON HEALTH, V41, P29, DOI 10.1080/00039896.1986.9935762; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; KLEBBA AJ, 1980, DHEW PHS801120 PUB S, V28; KRAVIS LP, 1986, NEW ENGL REG ALLERGY, V7, P442; KRAVIS LP, 1985, AM J DIS CHILD, V139, P558, DOI 10.1001/archpedi.1985.02140080028026; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MITCHELL EA, 1981, NEW ZEAL MED J, V94, P331; NGUYEN MT, 1985, ANN ALLERGY, V55, P448; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; PAULOZZI LJ, 1986, ANN ALLERGY, V56, P392; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; REA HH, 1987, NEW ZEAL MED J, V100, P10; SCHRENK HH, 1949, PUBLIC HLTH B, P306; SEARS MR, 1986, EUR J RESPIR DIS, V69, P175; SEARS MR, 1985, NEW ZEAL MED J, V98, P271; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; SEARS MR, 1986, ARCH DIS CHILD, V61, P6, DOI 10.1136/adc.61.1.6; SLY RM, 1988, ANN ALLERGY, V60, P433; SLY RM, 1984, ANN ALLERGY, V53, P20; SLY RM, 1985, J ALLERGY CLIN IMMUN, V75, P443; SLY RM, 1986, ANN ALLERGY, V56, P207; SPOTNITZ M, 1965, AM REV RESPIR DIS, V92, P371; STARSINIC DE, 1984, PC80S118 REP S, P7; STEWART CJ, 1985, BRIT J DIS CHEST, V79, P229, DOI 10.1016/S0007-0971(85)80023-1; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; 1950, VITAL STATISTICS U A, V2; 1982, BR MED J, V285, P1251; 1980, STATISTICAL REPORTER, V80, P335; 1979, STATISTICAL REPORTER, V80, P33	40	164	164	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				705	717		10.1016/0091-6749(88)90069-3	http://dx.doi.org/10.1016/0091-6749(88)90069-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3192859	Bronze			2022-12-18	WOS:A1988R170800001
J	Santos, AF; James, LK; Bahnson, HT; Shamji, MH; Couto-Francisco, NC; Islam, S; Houghton, S; Clark, AT; Stephens, A; Turcanu, V; Durham, SR; Gould, HJ; Lack, G				Santos, Alexandra F.; James, Louisa K.; Bahnson, Henry T.; Shamji, Mohammed H.; Couto-Francisco, Natalia C.; Islam, Sabita; Houghton, Sally; Clark, Andrew T.; Stephens, Alick; Turcanu, Victor; Durham, Stephen R.; Gould, Hannah J.; Lack, Gideon			IgG(4) inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ara h 2; basophil; basophil activation test; blocking antibodies; IgE inhibition; IgG(4); mast cells; peanut; peanut allergy; tolerance	ARA H 2; HISTAMINE-RELEASE; IGE; IMMUNOTHERAPY; DEGRANULATION; ANTIBODIES; INDUCTION; DIAGNOSIS; RESPONSES; RISK	Background: Most children with detectable peanut-specific IgE (P-sIgE) are not allergic to peanut. We addressed 2 non-mutually exclusive hypotheses for the discrepancy between allergy and sensitization: (1) differences in P-sIgE levels between children with peanut allergy (PA) and peanut-sensitized but tolerant (PS) children and (2) the presence of an IgE inhibitor, such as peanut-specific IgG(4) (P-sIgG(4)), in PS patients. Methods: Two hundred twenty-eight children (108 patients with PA, 77 PS patients, and 43 nonsensitized nonallergic subjects) were studied. Levels of specific IgE and IgG(4) to peanut and its components were determined. IgE-stripped basophils or a mast cell line were used in passive sensitization activation and inhibition assays. Plasma of PS subjects and patients submitted to peanut oral immunotherapy (POIT) were depleted of IgG(4) and retested in inhibition assays. Results: Basophils and mast cells sensitized with plasma from patients with PA but not PS patients showed dose-dependent activation in response to peanut. Levels of sIgE to peanut and its components could only partially explain differences in clinical reactivity between patients with PA and PS patients. P-sIgG(4) levels (P = .023) and P-sIgG(4)/P-sIgE (P < .001), Ara h 1-sIgG(4)/Ara h 1-sIgE (P = .050), Ara h 2-sIgG(4)/Ara h 2-sIgE (P = .004), and Ara h 3-sIgG(4)/Ara h 3-sIgE (P = .016) ratios were greater in PS children compared with those in children with PA. Peanut-induced activation was inhibited in the presence of plasma from PS children with detectable P-sIgG(4) levels and POIT but not from nonsensitized nonallergic children. Depletion of IgG(4) from plasma of children with PS (and POIT) sensitized to Ara h 1 to Ara h 3 partially restored peanutinduced mast cell activation (P = .007). Conclusions: Differences in sIgE levels and allergen specificity could not justify the clinical phenotype in all children with PA and PS children. Blocking IgG(4) antibodies provide an additional explanation for the absence of clinical reactivity in PS patients sensitized to major peanut allergens.	[Santos, Alexandra F.; Couto-Francisco, Natalia C.; Stephens, Alick; Turcanu, Victor; Lack, Gideon] Kings Coll London, Dept Pediat Allergy, Div Asthma Allergy & Lung Biol, London WC2R 2LS, England; [Santos, Alexandra F.; James, Louisa K.; Shamji, Mohammed H.; Couto-Francisco, Natalia C.; Stephens, Alick; Turcanu, Victor; Durham, Stephen R.; Gould, Hannah J.; Lack, Gideon] MRC, London, England; [Santos, Alexandra F.; James, Louisa K.; Shamji, Mohammed H.; Couto-Francisco, Natalia C.; Stephens, Alick; Turcanu, Victor; Durham, Stephen R.; Gould, Hannah J.; Lack, Gideon] Asthma UK Ctr Allerg Mech Asthma, London, England; [Santos, Alexandra F.] Coimbra Univ Hosp, Immunoallergol Dept, Coimbra, Portugal; [Santos, Alexandra F.] Gulbenkian Programme Adv Med Educ, Lisbon, Portugal; [James, Louisa K.; Gould, Hannah J.] Kings Coll London, Randall Div Cell & Mol Biophys, London WC2R 2LS, England; [Shamji, Mohammed H.; Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, MRC, Allergy & Clin Immunol, London SW7 2AZ, England; [Shamji, Mohammed H.; Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Fac Med, Asthma UK Ctr Allerg Mech Asthma, London SW7 2AZ, England; [Islam, Sabita] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; [Houghton, Sally] Pathol Partnership Cambridge Univ Hosp, Cambridge, England; [Clark, Andrew T.] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Allergy, Cambridge, England	University of London; King's College London; University of London; King's College London; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); University of London; King's College London; Imperial College London; Imperial College London; University of London; King's College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Lack, G (corresponding author), St Thomas Hosp, Dept Pediat Allergy, 2nd Floor,Stairwell B,South Wing, London SE1 7EH, England.	gideon.lack@kcl.ac.uk	Shamji, Mohamed/AAD-1788-2019; James, Louisa/C-9831-2010	James, Louisa/0000-0002-2252-4636; Gould, Hannah/0000-0003-0411-688X; Santos, Alexandra/0000-0002-7805-1436; Lack, Gideon/0000-0001-7350-4021; Shamji, Mohamed/0000-0003-3425-3463	Medical Research Council (MRC) [CRTF G0902018]; Department of Health through the National Institute for Health Research (NIHR); King's College London; King's College Hospital NHS Foundation Trust; Medical Research Council [G1000758B, G0902018, G1100090, G1000758] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre] Funding Source: researchfish; MRC [G0902018, G1100090] Funding Source: UKRI	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health through the National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); King's College London; King's College Hospital NHS Foundation Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Medical Research Council (MRC CRTF G0902018 and MRC Centenary Early Career Award awarded to A.F.S.) and the Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Blanc F, 2009, CLIN EXP ALLERGY, V39, P1277, DOI 10.1111/j.1365-2222.2009.03294.x; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Caubet JC, 2012, J ALLERGY CLIN IMMUN, V129, P739, DOI 10.1016/j.jaci.2011.11.053; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Codreanu F, 2011, INT ARCH ALLERGY IMM, V154, P216, DOI 10.1159/000321108; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Ito Komei, 2012, Clin Mol Allergy, V10, P1, DOI 10.1186/1476-7961-10-1; James LK, 2012, J ALLERGY CLIN IMMUN, V130, P663, DOI 10.1016/j.jaci.2012.04.006; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jensen BM, 2006, ALLERGY, V61, P303, DOI 10.1111/j.1398-9995.2006.00991.x; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; Lin J, 2012, J ALLERGY CLIN IMMUN, V129, P1321, DOI 10.1016/j.jaci.2012.02.012; de Oliveira LCL, 2013, J ALLER CL IMM-PRACT, V1, P394, DOI 10.1016/j.jaip.2013.05.010; McGowan EC, 2014, J ALLERGY CLIN IMMUN, V134, P746, DOI 10.1016/j.jaci.2014.04.040; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Nozawa A, 2014, PEDIAT ALLERG IMM-UK, V25, P323, DOI 10.1111/pai.12243; Okamoto S, 2012, ALLERGY ASTHMA CL IM, V8, DOI 10.1186/1710-1492-8-9; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Ruiter B, 2007, CLIN EXP ALLERGY, V37, P1103, DOI 10.1111/j.1365-2222.2007.02749.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Savilahti EM, 2010, J ALLERGY CLIN IMMUN, V125, P1315, DOI 10.1016/j.jaci.2010.03.025; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048	37	163	166	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1249	1256		10.1016/j.jaci.2015.01.012	http://dx.doi.org/10.1016/j.jaci.2015.01.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25670011	Green Published, hybrid			2022-12-18	WOS:000353980700018
J	Luoto, R; Ruuskanen, O; Waris, M; Kalliomaki, M; Salminen, S; Isolauri, E				Luoto, Raakel; Ruuskanen, Olli; Waris, Matti; Kalliomaki, Marko; Salminen, Seppo; Isolauri, Erika			Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: A randomized, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Galacto-oligosaccharide; gut microbiota; Lactobacillus rhamnosus GG; polydextrose; prebiotic; preterm infant; probiotic; respiratory tract infections; rhinovirus	DOUBLE-BLIND; GUT MICROBIOTA; IMMUNE-SYSTEM; RISK; CHILDREN; FORMULA; IMPACT; VIRUS; LIFE	Background: Simple and safe strategies for the prevention of viral respiratory tract infections (RTIs) are needed. Objective: We hypothesized that early prebiotic or probiotic supplementation would reduce the risk of virus-associated RTIs during the first year of life in a cohort of preterm infants. Methods: In this randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov no. NCT00167700), 94 preterm infants (gestational age, >= 32 + 0 and <= 36 + 6 weeks; birth weight, >1500 g) treated at Turku University Hospital, Turku, Finland, were allocated to receive oral prebiotics (galacto-oligosaccharide and polydextrose mixture, 1:1), a probiotic (Lactobacillus rhamnosus GG, ATCC 53103), or placebo (microcrystalline cellulose) between days 3 and 60 of life. The primary outcome was the incidence of clinically defined virus-associated RTI episodes confirmed from nasal swabs by using nucleic acid testing. Secondary outcomes were the severity and duration of RTIs. Results: A significantly lower incidence of RTIs was detected in infants receiving prebiotics (rate ratio [RR], 0.24; 95% CI, 0.12-0.49; P<.001) or probiotics (RR, 0.50; 95% CI, 0.28-0.90; P=.022) compared with those receiving placebo. Also, the incidence of rhinovirus-induced episodes, which comprised 80% of all RTI episodes, was found to be significantly lower in the prebiotic (RR, 0.31; 95% CI, 0.14-0.66; P=.003) and probiotic (RR, 0.49; 95% CI, 0.24-1.00; P=.051) groups compared with the placebo group. No differences emerged among the study groups in rhinovirus RNA load during infections, duration of rhinovirus RNA shedding, duration or severity of rhinovirus infections, or occurrence of rhinovirus RNA in asymptomatic infants. Conclusions: Gut microbiota modification with specific prebiotics and probiotics might offer a novel and cost-effective means to reduce the risk of rhinovirus infections.	[Luoto, Raakel; Ruuskanen, Olli; Kalliomaki, Marko; Isolauri, Erika] Turku Univ Hosp, Dept Paediat & Adolescent Med, FIN-20520 Turku, Finland; [Waris, Matti] Univ Turku, Dept Virol, Turku, Finland; [Salminen, Seppo] Univ Turku, Funct Foods Forum, Turku, Finland	University of Turku; University of Turku; University of Turku	Luoto, R (corresponding author), Turku Univ Hosp, Dept Paediat & Adolescent Med, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.	raakel.luoto@utu.fi	Waris, Matti E/A-6418-2008	Waris, Matti/0000-0002-6747-0889; Kalliomaki, Marko/0000-0002-9438-7052	Mead Johnson Nutrition Company USA; Juho Vainio Foundation; Paivikki and Sakari Sohlberg Foundation; Jenny and Antti Wihuri Foundation; EVO of Turku University Hospital; Satakunta Central Hospital	Mead Johnson Nutrition Company USA; Juho Vainio Foundation; Paivikki and Sakari Sohlberg Foundation; Jenny and Antti Wihuri Foundation; EVO of Turku University Hospital; Satakunta Central Hospital	The Mead Johnson Nutrition Company USA covered the costs of the prebiotic and probiotic products (prepared by Turku University Hospital Pharmacy) and part of the salary for the first author. Financial support for the study was provided by the Juho Vainio Foundation, the Paivikki and Sakari Sohlberg Foundation, the Jenny and Antti Wihuri Foundation, and EVO Funding of Turku University Hospital and Satakunta Central Hospital.	Archambaud C, 2012, P NATL ACAD SCI USA, V109, P16684, DOI 10.1073/pnas.1212809109; Arslanoglu S, 2008, J NUTR, V138, P1091, DOI 10.1093/jn/138.6.1091; Arslanoglu S, 2007, J NUTR, V137, P2420, DOI 10.1093/jn/137.11.2420; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Brandtzaeg P, 2010, J PEDIATR-US, V156, pS8, DOI 10.1016/j.jpeds.2009.11.014; Faith JJ, 2013, SCIENCE, V341, P44, DOI 10.1126/science.1237439; Food and Agriculture Organization of the United Nations World Health Organization, REP JOINT FAO WHO EX; Ganguli K, 2013, AM J PHYSIOL-GASTR L, V304, pG132, DOI 10.1152/ajpgi.00142.2012; Gareau MG, 2010, NAT REV GASTRO HEPAT, V7, P503, DOI 10.1038/nrgastro.2010.117; Gil-Campos M, 2012, PHARMACOL RES, V65, P231, DOI 10.1016/j.phrs.2011.11.016; Gluck U, 2003, AM J CLIN NUTR, V77, P517; Hao QK, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006895.pub2, 10.1002/14651858.CD006895.pub3]; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Jacobs SE, 2013, CLIN MICROBIOL REV, V26, P135, DOI 10.1128/CMR.00077-12; Jansen RR, 2011, J CLIN MICROBIOL, V49, P2631, DOI 10.1128/JCM.02094-10; Jartti T, 2011, PEDIAT ALLERG IMM-UK, V22, P350, DOI 10.1111/j.1399-3038.2011.01170.x; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Koskenvuo M, 2008, EUR J PEDIATR, V167, P1011, DOI 10.1007/s00431-007-0631-8; Krilov LR, 2009, PEDIATRICS, V124, P1682, DOI 10.1542/peds.2009-2681; Kukkonen K, 2008, PEDIATRICS, V122, P8, DOI 10.1542/peds.2007-1192; Maldonado J, 2012, J PEDIATR GASTR NUTR, V54, P55, DOI 10.1097/MPG.0b013e3182333f18; McLeish NJ, 2012, J CLIN MICROBIOL, V50, P2910, DOI 10.1128/JCM.01172-12; Miller EK, 2012, PEDIATRICS, V129, pE60, DOI 10.1542/peds.2011-0583; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Partty A, 2013, J PEDIATR-US, V163, P1272, DOI 10.1016/j.jpeds.2013.05.035; Peltola V, 2008, J INFECT DIS, V197, P382, DOI 10.1086/525542; Pineiro M, 2008, J CLIN GASTROENTEROL, V42, pS156, DOI 10.1097/MCG.0b013e31817f184e; Rautava S, 2009, BRIT J NUTR, V101, P1722, DOI 10.1017/S0007114508116282; Ruuskanen O, 2013, PEDIATR INFECT DIS J, V32, P553, DOI 10.1097/INF.0b013e3182833c90; Sharma AA, 2012, CLIN IMMUNOL, V145, P61, DOI 10.1016/j.clim.2012.08.006; Taipale T, 2011, BRIT J NUTR, V105, P409, DOI 10.1017/S0007114510003685; van Piggelen RO, 2010, PEDIATR INFECT DIS J, V29, P364, DOI 10.1097/INF.0b013e3181c6e60f; Villena J, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-53; Vouloumanou EK, 2009, INT J ANTIMICROB AG, V34, DOI 10.1016/j.ijantimicag.2008.11.005; Weichert S, 2012, PEDIATR INFECT DIS J, V31, P859, DOI 10.1097/INF.0b013e3182620e52; Weizman Z, 2005, PEDIATRICS, V115, P5, DOI 10.1542/peds.2004-1815	37	163	174	1	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					405	413		10.1016/j.jaci.2013.08.020	http://dx.doi.org/10.1016/j.jaci.2013.08.020			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24131826	Bronze, Green Published			2022-12-18	WOS:000332397100015
J	Carr, W; Bernstein, J; Lieberman, P; Meltzer, E; Bachert, C; Price, D; Munzel, U; Bousquet, J				Carr, Warner; Bernstein, Jonathan; Lieberman, Phil; Meltzer, Eli; Bachert, Claus; Price, David; Munzel, Ullrich; Bousquet, Jean			A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; azelastine; fluticasone propionate; MP29-02; moderate-to-severe	DOUBLE-BLIND; NASAL SPRAY; BURDEN; IMPACT; MANAGEMENT; SYMPTOMS; PROPIONATE; GUIDELINES; GA(2)LEN; EUROPE	Background: Moderate-to-severe allergic rhinitis (AR) is a challenge to treat, with many patients using multiple therapies and achieving limited symptom control. More effective therapies must be developed and tested in well-controlled, randomized, prospective studies with a direct comparison to current standards. Objectives: The aim of these studies was to investigate the efficacy of MP29-02 (a novel formulation of azelastine and fluticasone propionate [FP]) in patients with moderate-to-severe seasonal allergic rhinitis (SAR) and to compare its efficacy with 2 first-line therapies (ie, intranasal azelastine and intranasal FP) in this population. Methods: Three thousand three hundred ninety-eight patients (>= 12 years old) with moderate-to-severe SAR were enrolled into 3 multicenter, randomized, double-blind, placebo-and active-controlled, parallel-group trials (MP4002 [NCT00651118], MP4004 [NCT00740792], and MP4006 [NCT00883168]). Each trial was conducted for 14 days during different allergy seasons. The primary efficacy variable was the sum of the morning and evening change from baseline in reflective total nasal symptom score (range, 0-24) over the treatment period. Outcomes for the meta-analysis included efficacy according to disease severity and time to response in relevant responder criteria. Results: In the meta-analysis MP29-02 reduced the mean reflective total nasal symptom score from baseline (-5.7 [SD, 5.3]) more than FP (-5.1 [SD, 4.9], P < .001), azelastine (-4.4 [SD, 4.8], P < .001), or placebo (-3.0 [SD, 4.2], P < .001). This benefit was observed from the first day of assessment, with improvement in each individual nasal symptom, even in the patients with the most severe disease. MP29-02 achieved response consistently days earlier and showed greater efficacy in patients with moderate-to-severe rhinitis than FP and azelastine. Conclusions: MP29-02 represents a novel therapy that demonstrated superiority to 2 first-line therapies for AR. Patients with moderate-to-severe SAR achieved better control, and their symptoms were controlled earlier with MP29-02 than with recommended medications according to guidelines. (J Allergy Clin Immunol 2012;129:1282-9.)	[Carr, Warner] Allergy & Asthma Associates So Calif, Mission Viejo, CA 92691 USA; [Bernstein, Jonathan] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA; [Lieberman, Phil] Univ Tennessee, Coll Med, Dept Internal Med & Pediat, Memphis, TN USA; [Meltzer, Eli] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; [Bachert, Claus] Ghent Univ Hosp, Dept Otorhinolaryngol, Ghent, Belgium; [Price, David] Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB9 1FX, Scotland; [Munzel, Ullrich] MEDA Pharma GmbH & Co KG, Biostat & Informat, Bad Homburg, Germany; [Bousquet, Jean] Hop Arnaud de Villeneuve Univ Hosp, Dept Resp Dis, Montpellier, France	University System of Ohio; University of Cincinnati; University of Tennessee System; University of Tennessee Health Science Center; Ghent University; Ghent University Hospital; University of Aberdeen; Universite de Montpellier; CHU de Montpellier	Carr, W (corresponding author), Allergy & Asthma Associates So Calif, 27800 Med Ctr Rd,Suite 244, Mission Viejo, CA 92691 USA.	wcarr@allergee.com	Bousquet, Jean/O-4221-2019; Price, David/H-2837-2019; Bachert, Claus/J-8825-2012	Price, David/0000-0002-9728-9992; Bernstein, Jonathan/0000-0002-3476-1196	Meda Pharmaceuticals, Inc; MEDA; Alcon; Ista; Dynova; Amgen; Apotex; HRA; MedImmune; Schering-Plough; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Novartis; Proctor Gamble; Sunovion (Sepracor); Teva; Merck; Mundipharma; Medapharma; Kyorin; Almirall; Chiesi; Pfizer; Aerocrine; UK National Health Service; Nycomed	Meda Pharmaceuticals, Inc; MEDA; Alcon(Novartis); Ista; Dynova; Amgen(Amgen); Apotex; HRA; MedImmune(AstraZenecaMedimmune); Schering-Plough(Merck & CompanySchering Plough Corporation); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Proctor Gamble(Procter & Gamble); Sunovion (Sepracor); Teva(Teva Pharmaceutical Industries); Merck(Merck & Company); Mundipharma; Medapharma; Kyorin; Almirall(Almirall); Chiesi(Chiesi Pharmaceuticals Inc); Pfizer(Pfizer); Aerocrine; UK National Health Service; Nycomed	These studies were funded by Meda Pharmaceuticals, Inc, and were designed to be consistent with recommendations provided in the US Food and Drug Administration guidance document for clinical development of drug products for allergic rhinitis (Guidance for Industry, US Department of Health and Human Services, US Food and Drug Administration Center for Drug Evaluation and Research; April 2000).; Disclosure of potential conflict of interest: W. Carr has consulted for and received research support from MEDA, Alcon, and Ista. J. Bernstein has received research support from Meda and Dynova; is on the Board of Directors and a Fellow of the American Association of Allergy, Asthma & Immunology (AAAAI); is a Fellow at the American College of Allergy, Asthma & Immunology (ACAAI); and is Chairman of the Allergists for Israel (AFI). P. Lieberman is an advisor for the Allergy Foundation of America and Baxter and has given lectures for MEDA, Genentech, Ista, and TEVA. E. Meltzer has received research support from Amgen, Apotex, HRA, MedImmune, Schering-Plough, Alcon, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Proctor & Gamble, Sunovion (Sepracor), and Teva; is a consultant and/or is on the advisory board for Alcon, AstraZeneca, Bausch & Lomb, Dey, Forest, Ista, Johnson & Johnson, Meda, Merck, ONO Pharma, OptiNose, Proctor & Gamble, Rady Children's Hospital, Rigel, Sanofi-Aventis, Sepracor, Stallergenes, Teva, Alexa, Boehringer Ingelheim, Kalypsys, and Sunovion; is a speaker for the AAAAI, Alcon, Allergists for Israel, Dey, Florida Allergy Asthma Immunology Society, Ista, Sepracor, Teva, Merck, and Sunovion; and has provided expert designation in legal matters for Aventis Pharmaceuticals and Sanofi Aventis v. Barr Laboratories, Fexofenadine. D. Price has received consultancy and speaker fees from Merck, Mundipharma, Novartis, Medapharma, Kyorin, and TEVA; has received consultancy fees from GlaxoSmithKline, Almirall, and Chiesi; has received consultancy fees and grants from Pfizer, and AstraZeneca; has received consultancy and speakers' fees and grants from Boehringer Ingelheim; has received speakers' fees and grants from Aerocrine; has received grants from the UK National Health Service, Nycomed, and Medapharma; is director of Research in Real Life Ltd; is a guideline group member for Allergic Rhinitis and its Impact on Asthma and EPOS; is a research committee member for International Primary Care Respiratory Group; and has shares in AKL Ltd. J. Bousquet has received honoraria from Stallergenes, Actelion, Almirall, AstraZeneca, Chiese, GlaxoSmithKline, Merck, Novartis, OM Pharma, Sanofi, TEVA, and Uriach. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2004, CHMPEWP245502; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2005, ALLERGY, V60, P788, DOI 10.1111/j.1398-9995.2005.00820.x; Bousquet J, 2011, EUR AC ALL CLIN IMM; Bousquet J, 2010, INT ARCH ALLERGY IMM, V153, P395, DOI 10.1159/000316351; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Costa DJ, 2011, J ALLERGY CLIN IMMUN, V127, P920, DOI 10.1016/j.jaci.2010.10.058; Dalal AA, 2008, ANN ALLERG ASTHMA IM, V101, P23, DOI 10.1016/S1081-1206(10)60830-7; Demoly P, 2002, ALLERGY, V57, P546, DOI 10.1034/j.1398-9995.2002.t01-1-13370.x; FDA Guideline, 2000, FDA GUID GUID IND AL, P1; Hampel FC, 2010, ANN ALLERG ASTHMA IM, V105, P168, DOI 10.1016/j.anai.2010.06.008; International Committee on Harmonization Harmonized Tripartite Guidelines on Good Clinical Practice, 1996, INT COMM HARM HARM T; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Keith PK, 2009, CURR MED RES OPIN, V25, P2021, DOI 10.1185/03007990903094106; Loh CY, 2004, ALLERGY, V59, P1168, DOI 10.1111/j.1398-9995.2004.00554.x; Marple BF, 2007, OTOLARYNG HEAD NECK, V136, pS107, DOI 10.1016/j.otohns.2007.02.031; Maurer M, 2007, ALLERGY, V62, P1057, DOI 10.1111/j.1398-9995.2007.01367.x; Meltzer EO, 2011, ANN ALLERG ASTHMA IM, V106, pS12, DOI 10.1016/j.anai.2010.10.014; Meltzer EO, 2010, ANN ALLERG ASTHMA IM, V104, P331, DOI 10.1016/j.anai.2010.02.010; Nathan RA, 2008, ALLERGY ASTHMA PROC, V29, P600, DOI 10.2500/aap.2008.29.3179; Plaut M, 2005, NEW ENGL J MED, V353, P1934, DOI 10.1056/NEJMcp044141; Ratner PH, 2008, ANN ALLERG ASTHMA IM, V100, P74, DOI 10.1016/S1081-1206(10)60408-5; Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x; Valovirta E, 2008, CURR OPIN ALLERGY CL, V8, P1, DOI 10.1097/ACI.0b013e3282f3f42f; Vandenplas O, 2008, CURR OPIN ALLERGY CL, V8, P145, DOI 10.1097/ACI.0b013e3282f63d92; Walker S, 2007, J ALLERGY CLIN IMMUN, V120, P381, DOI 10.1016/j.jaci.2007.03.034; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003	28	163	177	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1282	U155		10.1016/j.jaci.2012.01.077	http://dx.doi.org/10.1016/j.jaci.2012.01.077			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22418065				2022-12-18	WOS:000303418000016
J	Ramasamy, A; Curjuric, I; Coin, LJ; Kumar, A; McArdle, WL; Imboden, M; Leynaert, B; Kogevinas, M; Schmid-Grendelmeier, P; Pekkanen, J; Wjst, M; Bircher, AJ; Sovio, U; Rochat, T; Hartikainen, AL; Balding, DJ; Jarvelin, MR; Probst-Hensch, N; Strachan, DP; Jarvis, DL				Ramasamy, Adaikalavan; Curjuric, Ivan; Coin, Lachlan J.; Kumar, Ashish; McArdle, Wendy L.; Imboden, Medea; Leynaert, Benedicte; Kogevinas, Manolis; Schmid-Grendelmeier, Peter; Pekkanen, Juha; Wjst, Matthias; Bircher, Andreas J.; Sovio, Ulla; Rochat, Thierry; Hartikainen, Anna-Liisa; Balding, David J.; Jarvelin, Marjo-Riitta; Probst-Hensch, Nicole; Strachan, David P.; Jarvis, Deborah L.			A genome-wide meta-analysis of genetic variants associated with allergic rhinitis and grass sensitization and their interaction with birth order	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hay fever; IgE sensitization to grass; hygiene hypothesis; older siblings; gene-environment interaction; genome-wide association study; European Community Respiratory Health Survey; British 1958 Birth Cohort; Northern Finland Birth Cohort of 1966; Swiss Study on Air Pollution and Lung Disease in Adults	ENVIRONMENT INTERACTION; CHILDHOOD ECZEMA; CHROMOSOME 11Q13; HAY-FEVER; ASTHMA; COHORT; EXPOSURE; DISEASES; HEALTH; ADULTS	Background: Hay fever or seasonal allergic rhinitis (AR) is a chronic disorder associated with IgE sensitization to grass. The underlying genetic variants have not been studied comprehensively. There is overwhelming evidence that those who have older siblings have less AR, although the mechanism for this remains unclear. Objective: We sought to identify common genetic variant associations with prevalent AR and grass sensitization using existing genome-wide association study (GWAS) data and to determine whether genetic variants modify the protective effect of older siblings. Method: Approximately 2.2 million genotyped or imputed single nucleotide polymorphisms were investigated in 4 large European adult cohorts for AR (3,933 self-reported cases vs 8,965 control subjects) and grass sensitization (2,315 cases vs 10,032 control subjects). Results: Three loci reached genome-wide significance for either phenotype. The HLAvariant rs7775228, which cis-regulates HLA-DRB4, was strongly associated with grass sensitization and weakly with AR (P-grass = 1.6 x 10(-9); P-AR = 8.0 x 10(-3)). Variants in a locus near chromosome 11 open reading frame 30 (C11orf30) and leucine-rich repeat containing 32 (LRRC32), which was previously associated with atopic dermatitis and eczema, were also strongly associated with both phenotypes (rs2155219; P-grass = 9.4 x 10(-9); P-AR = 3.8 x 10(-8))(.) The third genome-wide significant variant was rs17513503 (P-grass = 1.2 x 10(-8); PAR = 7.4 x 10(-7)) which was located near transmembrane protein 232 (TMEM232) and solute carrier family 25, member 46 (SLC25A46). Twelve further loci with suggestive associations were also identified. Using a candidate gene approach, where we considered variants within 164 genes previously thought to be important, we found variants in 3 further genes that may be of interest: thymic stromal lymphopoietin (TSLP), Toll-like receptor 6 (TLR6) and nucleotide-binding oligomerization domain containing 1 (NOD1/CARD4). We found no evidence for variants that modified the effect of birth order on either phenotype. Conclusions: This relatively large meta-analysis of GWASs identified few loci associated with AR and grass sensitization. No birth order interaction was identified in the current analyses. (J Allergy Clin Immunol 2011;128:996-1005.)	[Ramasamy, Adaikalavan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LR, England; [Curjuric, Ivan; Kumar, Ashish; Imboden, Medea; Probst-Hensch, Nicole] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Curjuric, Ivan; Imboden, Medea; Bircher, Andreas J.; Probst-Hensch, Nicole] Univ Basel, CH-4003 Basel, Switzerland; [Coin, Lachlan J.; Sovio, Ulla; Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London SW3 6LR, England; [Kumar, Ashish] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England; [Kumar, Ashish] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX1 2JD, England; [McArdle, Wendy L.] Univ Bristol, Dept Social & Community Med, Avon Longitudinal Study Parents & Children ALSPAC, Bristol BS8 1TH, Avon, England; [Leynaert, Benedicte] INSERM, U700, Paris, France; [Kogevinas, Manolis] Ctr Res Environm Epidemiol, Barcelona, Spain; [Kogevinas, Manolis] IMIM Hosp del Mar, Municipal Inst Med Res, Barcelona, Spain; [Kogevinas, Manolis] CIBER Epidemiol & Salud Publ, Barcelona, Spain; [Kogevinas, Manolis] Univ Crete, Sch Med, Dept Social Med, Iraklion, Greece; [Schmid-Grendelmeier, Peter] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland; [Pekkanen, Juha] Natl Inst Hlth & Welf THL, Dept Environm Hlth, Helsinki, Finland; [Pekkanen, Juha] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland; [Wjst, Matthias] Helmholtz Zentrum Munchen German Res Ctr Environm, Munich, Germany; [Bircher, Andreas J.] Univ Basel Hosp, Dept Dermatol, Allergy Unit, Basel, Switzerland; [Sovio, Ulla] London Sch Hyg & Trop Med, Dept Med Stat, London, England; [Rochat, Thierry] Univ Hosp Geneva, Div Pulm Med, Geneva, Switzerland; [Hartikainen, Anna-Liisa] Univ Oulu, Inst Clin Med, Dept Clin Sci Obstet & Gynecol, Oulu, Finland; [Balding, David J.] UCL, Inst Genet, London WC1E 6BT, England; [Jarvelin, Marjo-Riitta; Jarvis, Deborah L.] Univ London Imperial Coll Sci Technol & Med, MRC HPA Ctr Environm & Hlth, London SW3 6LR, England; [Strachan, David P.] Univ London, Div Community Hlth Sci, London WC1E 7HU, England	Imperial College London; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Imperial College London; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Bristol; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Crete; University of Zurich; University Zurich Hospital; Finland National Institute for Health & Welfare; University of Eastern Finland; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Basel; University of London; London School of Hygiene & Tropical Medicine; University of Geneva; University of Oulu; University of London; University College London; Imperial College London; University of London	Jarvis, DL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Emmanuel Kaye Bldg,Manressa Rd, London SW3 6LR, England.	d.jarvis@imperial.ac.uk	Sovio, Ulla/H-8532-2019; Ramasamy, Adaikalavan/G-2632-2010; Balding, David/G-9898-2011; Kogevinas, Manolis/C-3918-2017; Coin, Lachlan JM/A-9001-2014; Coin, Lachlan/O-4976-2019; Leynaert, Benedicte/N-5251-2018	Sovio, Ulla/0000-0002-0799-1105; Ramasamy, Adaikalavan/0000-0002-7598-2892; Balding, David/0000-0002-1480-6115; Kogevinas, Manolis/0000-0002-9605-0461; Coin, Lachlan JM/0000-0002-4300-455X; Coin, Lachlan/0000-0002-4300-455X; Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Jarvis, Deborah/0000-0002-1753-3896; Kumar, Ashish/0000-0002-7075-5930; Leynaert, Benedicte/0000-0001-5045-2492	European Commission [018996]; Department of Health, United Kingdom; Medical Research Council [G0500539]; Helmholtz Center; EU Project European; Swiss National Foundation for Scientific Research; MRC [G1001799, G0000934] Funding Source: UKRI; Medical Research Council [G0801056B, G0000934, G1001799] Funding Source: researchfish	European Commission(European CommissionEuropean Commission Joint Research Centre); Department of Health, United Kingdom; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Helmholtz Center; EU Project European; Swiss National Foundation for Scientific Research(Swiss National Science Foundation (SNSF)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Details of the many charities, governmental bodies, and scientific funding organizations that supported the epidemiologic study, including phenotyping, DNA collection, and genotyping for the British 1958 Birth Cohort (B58C), the European Community Respiratory Health Survey (ECRHS2), the Northern Finland Birth Cohort of 1966 (NFBC1966), and the Swiss Study on Air Pollution and Lung Disease in Adults (SAPALDIA), can be found in this article's Online Repository at www.jacionline.org. A. R. has received research support from the European Commission (through project GABRIEL, contract no. 018996 under the Integrated Program LSH-2004-1.2.5-1) and the Department of Health, United Kingdom. U.S. was supported by Medical Research Council studentship grant G0500539.; Disclosure of potential conflict of interest: M. Wjst receives research support from the Helmholtz Center and EU Project European. T. Rochat receives research support from the Swiss National Foundation for Scientific Research. The rest of the authors have declared that they have no conflict of interest.	Ackermann-Liebrich U, 2005, SOZ PRAVENTIV MED, V50, P245, DOI 10.1007/s00038-005-4075-5; [Anonymous], GENOME WIDE EVALUATI; [Anonymous], HUGE LIT FINDER HUGE; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; Cramer C, 2010, J ALLERGY CLIN IMMUN, V125, P1254, DOI 10.1016/j.jaci.2010.03.036; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Duetsch G, 2002, HUM MOL GENET, V11, P613, DOI 10.1093/hmg/11.6.613; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fang CL, 2010, ARCH IMMUNOL THER EX, V58, P81, DOI 10.1007/s00005-010-0064-3; Haider S, 2009, NUCLEIC ACIDS RES, V37, pW23, DOI 10.1093/nar/gkp265; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; KOIVIKKO A, 1986, ALLERGY, V41, P233, DOI 10.1111/j.1398-9995.1986.tb02023.x; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; Marenholz I, 2011, HUM MOL GENET, V20, P2443, DOI 10.1093/hmg/ddr117; Michel S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013894; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Murcray CE, 2009, AM J EPIDEMIOL, V169, P219, DOI 10.1093/aje/kwn353; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V125, P170, DOI 10.1016/j.jaci.2009.10.046; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Rantakallio P, 1969, ACTA PAEDIAT SC S193, V193, P11; RCore Team, 2022, R LANG ENV STAT COMP; Strachan DP, 2007, INT J EPIDEMIOL, V36, P522, DOI 10.1093/ije/dyl309; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wan YI, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Wan YZI, 2011, J ALLERGY CLIN IMMUN, V127, P223, DOI 10.1016/j.jaci.2010.10.006; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Weinmayr G, 2010, ALLERGY, V65, P766, DOI 10.1111/j.1398-9995.2009.02283.x; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190	37	163	167	2	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					996	1005		10.1016/j.jaci.2011.08.030	http://dx.doi.org/10.1016/j.jaci.2011.08.030			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	22036096	Bronze			2022-12-18	WOS:000296578200012
J	Schram, ME; Roekevisch, E; Leeflang, MMG; Bos, JD; Schmitt, J; Spuls, PI				Schram, Mandy Elvira; Roekevisch, Evelien; Leeflang, Mariska Maria Geertruida; Bos, Jan Dositheus; Schmitt, Jochen; Spuls, Phyllis Ira			A randomized trial of methotrexate versus azathioprine for severe atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic eczema; atopic dermatitis; azathioprine; methotrexate; off-label; trial	ACTIVATION-REGULATED CHEMOKINE; LOW-DOSE METHOTREXATE; DOUBLE-BLIND; SERUM THYMUS; DERMATITIS; CYCLOSPORINE; LABEL	Background: Patients with severe atopic eczema frequently require systemic treatment to control their disease. Methotrexate and azathioprine are proposed as off-label treatment options, but direct comparisons are lacking. Objectives: We sought to compare the efficacy and safety of methotrexate versus azathioprine in adults with severe atopic eczema. Methods: Patients with severe atopic eczema were randomly assigned in a 1: 1 ratio to receive either methotrexate (dosage, 10-22.5 mg/wk) or azathioprine (dosage, 1.5-2.5 mg/kg/d) for 12 weeks, followed by a 12-week follow-up period. Primary outcome was the mean change in the severity scoring of atopic dermatitis index after 12 weeks. Efficacy assessors blinded for allocation of treatment were used to perform clinical outcome assessment. Analyses were done on an intention-to-treat basis. Results: Of the 45 patients screened, 42 were included. At week 12, patients in the methotrexate group had a mean relative reduction in the severity scoring of atopic dermatitis index of 42% (SD, 18%) compared with 39% (SD, 25%) in the azathioprine group (P = .52). Proportions of patients achieving at least mild disease and reductions on impact of quality of life, symptoms, and levels of thymus and activation-regulated chemokine were similar in both groups at weeks 12 and 24. No statistically significant differences were found in the number and severity of adverse events. Abnormalities in blood count were more common in the azathioprine group. No serious adverse events occurred. Conclusion: Both treatments achieved clinically relevant improvement and were safe in the short term. Methotrexate and azathioprine are appropriate options for the treatment of severe atopic eczema. (J Allergy Clin Immunol 2011;128:353-9.)	[Schram, Mandy Elvira; Roekevisch, Evelien; Bos, Jan Dositheus; Spuls, Phyllis Ira] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1100 DD Amsterdam, Netherlands; [Leeflang, Mariska Maria Geertruida] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, NL-1100 DD Amsterdam, Netherlands; [Schmitt, Jochen] Univ Hosp Carl Gustav Carus, UAC, Dresden, Germany	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Schram, ME (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Dermatol, A0-229,POB 22700, NL-1100 DD Amsterdam, Netherlands.	M.E.Schram@amc.uva.nl	Leeflang, Mariska/AAF-8199-2019	Leeflang, Mariska/0000-0001-5960-0471; Spuls, Phyllis/0000-0002-6035-2863	Department of Dermatology of the Academic Medical Center in Amsterdam; Novartis	Department of Dermatology of the Academic Medical Center in Amsterdam; Novartis(Novartis)	The Department of Dermatology of the Academic Medical Center in Amsterdam paid the salaries of the trial doctors and nurses.; J. Schmitt has received research support from Novartis. The rest of the authors have declared that they have no conflict of interest.	Behnam Shahrad M, 2005, J Drugs Dermatol, V4, P189; Berth-Jones J, 2002, BRIT J DERMATOL, V147, P324, DOI 10.1046/j.1365-2133.2002.04989.x; Brenninkmeijer EEA, 2008, BRIT J DERMATOL, V158, P754, DOI 10.1111/j.1365-2133.2007.08412.x; Charman CR, 2004, ARCH DERMATOL, V140, P1513, DOI 10.1001/archderm.140.12.1513; Goujon C, 2006, EUR J DERMATOL, V16, P155; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Hoekstra M, 2003, ANN RHEUM DIS, V62, P423, DOI 10.1136/ard.62.5.423; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Meggitt SJ, 2006, LANCET, V367, P839, DOI 10.1016/S0140-6736(06)68340-2; Nijsten TEC, 2006, J INVEST DERMATOL, V126, P1244, DOI 10.1038/sj.jid.5700212; Oranje AP, 2007, BRIT J DERMATOL, V157, P645, DOI 10.1111/j.1365-2133.2007.08112.x; Paul C, 2002, BRIT J DERMATOL, V147, P518, DOI 10.1046/j.1365-2133.2002.04833.x; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Schmitt J, 2007, J EUR ACAD DERMATOL, V21, P606, DOI 10.1111/j.1468-3083.2006.02023.x; Schmitt J, 2010, BRIT J DERMATOL, V162, P661, DOI 10.1111/j.1365-2133.2009.09561.x; Schmitt J, 2009, BRIT J DERMATOL, V161, P878, DOI 10.1111/j.1365-2133.2009.09309.x; Schmitt J, 2008, DERMATOLOGY, V217, P299, DOI 10.1159/000151355; Schmitt J, 2007, J ALLERGY CLIN IMMUN, V120, P1389, DOI 10.1016/j.jaci.2007.08.011; Schmitt J, 2007, ACTA DERM-VENEREOL, V87, P100, DOI 10.2340/00015555-0207; Schram ME, 2011, ARCH DERMATOL, V147, P474, DOI 10.1001/archdermatol.2011.79; Shaffrali FCG, 2003, J AM ACAD DERMATOL, V48, P417, DOI 10.1067/mjd.2003.137; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Tofte S., 1998, J EUR ACAD DERMAT S2, V11, pS197; Weatherhead SC, 2007, BRIT J DERMATOL, V156, P346, DOI 10.1111/j.1365-2133.2006.07686.x; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Zoller L, 2008, ISR MED ASSOC J, V10, P413	27	163	165	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					353	359		10.1016/j.jaci.2011.03.024	http://dx.doi.org/10.1016/j.jaci.2011.03.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21514637				2022-12-18	WOS:000293280800016
J	Ho, SM				Ho, Shuk-Mei			Environmental epigenetics of asthma: An update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pulmonary disorder; traffic-related pollutants; polycyclic aromatic hydrocarbons; microbial and viral infection; lipopoly-saccharide; endotoxin; oxidant early-life programming; nutrition; maternal exposure; T-H cells; dendritic cells; macrophages; lung epithelial cells; phenotype plasticity; developmental basis of disease; gene-environment interaction; DNA methylation; histone modification; microRNA; chromatin remodeling; allergen; inflammatory response	ADULT LUNG-FUNCTION; REGULATORY T-CELLS; DIESEL EXHAUST PARTICLES; RETRACTED ARTICLE. SEE; TOBACCO-SMOKE EXPOSURE; DNA METHYLATION; EARLY-CHILDHOOD; AIR-POLLUTION; DENDRITIC CELLS; OXIDATIVE STRESS	Asthma, a chronic inflammatory disorder of the airway, is influenced by interplay between genetic and environmental factors now known to be mediated by epigenetics. Aberrant DNA methylation, altered histone modifications, specific microRNA expression, and other chromatin alterations orchestrate a complex early-life reprogramming of immune T-cell response, dendritic cell function, macrophage activation, and a breach of airway epithelial barrier that dictates asthma risk and severity in later life. Adult-onset asthma is under analogous regulation. The sharp increase in asthma prevalence over the past 2 or 3 decades and the large variations among populations of similar racial/ethnic background but different environmental exposures favors a strong contribution of environmental factors. This review addresses the fundamental question of whether environmental influences on asthma risk, severity, and steroid resistance are partly due to differential epigenetic modulations. Current knowledge on the epigenetic effects of tobacco smoke, microbial allergens, oxidants, airborne particulate matter, diesel exhaust particles, polycyclic aromatic hydrocarbons, dietary methyl donors and other nutritional factors, and dust mites is discussed. Exciting findings have been generated by rapid technological advances and well-designed experimental and population studies. The discovery and validation of epigenetic biomarkers linked to exposure, asthma, or both might lead to better epigenotyping of risk, prognosis, treatment prediction, and development of novel therapies. (J Allergy Clin Immunol 2010;126:453-65.)	[Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Dept Environm Hlth, Ctr Environm Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Ho, SM (corresponding author), 3223 Eden Ave,Kettering Complex,Suite 130, Cincinnati, OH 45267 USA.	shuk-mei.ho@uc.edu	li, ran/K-1896-2012		National Institutes of Health [P30ES006096, R01ES015584, RC2ES018758, RC2ES018789, P50ES015905]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES015905, RC2ES018758, P30ES006096, R01ES015584, RC2ES018789] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health grants P30ES006096, R01ES015584, RC2ES018758, RC2ES018789, and P50ES015905.	Adcock IM, 2007, CURR OPIN IMMUNOL, V19, P694, DOI 10.1016/j.coi.2007.07.016; Androulidaki A, 2009, IMMUNITY, V31, P220, DOI 10.1016/j.immuni.2009.06.024; Anttila S, 2003, CANCER RES, V63, P8623; Asher MI, 1998, EUR RESPIR J, V12, P315; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Backdahl L, 2009, INT J BIOCHEM CELL B, V41, P176, DOI 10.1016/j.biocel.2008.08.023; Bakirtas Arzu, 2009, Inflammation & Allergy Drug Targets, V8, P353; Barker D J, 2001, Med Health Care Philos, V4, P31, DOI 10.1023/A:1009934412988; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1055, DOI 10.1016/j.jaci.2007.01.015; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Beach J, 2007, CHEST, V131, P569, DOI 10.1378/chest.06-0492; Belderbos M, 2009, CURR OPIN PEDIATR, V21, P762, DOI 10.1097/MOP.0b013e3283325e3a; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Biswas S, 2008, MOL NUTR FOOD RES, V52, P987, DOI 10.1002/mnfr.200700259; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; Boezen H Marike, 2009, Proc Am Thorac Soc, V6, P701, DOI 10.1513/pats.200907-058DP; Bogdanovic O, 2009, CHROMOSOMA, V118, P549, DOI 10.1007/s00412-009-0221-9; Bouzigon E, 2007, EUR RESPIR J, V30, P253, DOI 10.1183/09031936.00162206; Braun-Fahrlander C, 2003, CURR OPIN ALLERGY CL, V3, P325, DOI 10.1097/01.all.0000092600.10871.e0; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Busse WW, 2007, J ALLERGY CLIN IMMUN, V119, P43, DOI 10.1016/j.jaci.2006.10.021; Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224; Carlsen Kai-Hakon, 2005, Treat Respir Med, V4, P337, DOI 10.2165/00151829-200504050-00005; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Chan C, 2005, J IMMUNOL, V175, P461, DOI 10.4049/jimmunol.175.1.461; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223; Cook JD, 2005, P NATL ACAD SCI USA, V102, P8644, DOI 10.1073/pnas.0503218102; Cooney Craig A, 2002, J Nutr, V132, p2393S, DOI 10.1093/jn/132.8.2393S; D'Amato G, 2010, J INVEST ALLERG CLIN, V20, P95; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573, DOI 10.1289/ehp.02110s4573; Dietert RR, 2008, BIRTH DEFECTS RES B, V83, P547, DOI 10.1002/bdrb.20170; Digel W, 2005, CRIT REV ONCOL HEMAT, V55, P1, DOI 10.1016/j.critrevonc.2005.02.002; Dimeloe S, 2010, J STEROID BIOCHEM, V120, P86, DOI 10.1016/j.jsbmb.2010.02.029; Doherty SP, 2009, BIOMARKERS, V14, P97, DOI 10.1080/13547500902965898; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Dykewicz MS, 2009, J ALLERGY CLIN IMMUN, V123, P519, DOI 10.1016/j.jaci.2009.01.061; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Edwards CA, 2003, THORAX, V58, P1061, DOI 10.1136/thorax.58.12.1061; Elliott L, 2008, J ALLERGY CLIN IMMUN, V122, P49, DOI 10.1016/j.jaci.2008.04.001; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Finch CE, 2004, SCIENCE, V305, P1736, DOI 10.1126/science.1092556; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; Gilliland FD, 2001, EPIDEMIOLOGY, V12, P43, DOI 10.1097/00001648-200101000-00009; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Gilmour PS, 2003, AM J PHYSIOL-LUNG C, V284, pL533, DOI 10.1152/ajplung.00277.2002; Giri DK, 1998, J IMMUNOL, V161, P4834; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Gorman S, 2010, PHOTOCH PHOTOBIO SCI, V9, P571, DOI 10.1039/b9pp00136k; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Hunt JS, 2005, FASEB J, V19, P681, DOI 10.1096/fj.04-2078rev; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Ito K., 2001, FASEB Journal, V15, P1110; Ito T, 2006, TOXICOL LETT, V165, P66, DOI 10.1016/j.toxlet.2006.01.015; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Jose RS, 2008, ANAL BIOANAL CHEM, V391, P1397, DOI 10.1007/s00216-007-1771-4; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kim DH, 2001, CANCER RES, V61, P3419; Kim DH, 2003, CANCER RES, V63, P3743; Kim JS, 2004, CARCINOGENESIS, V25, P2165, DOI 10.1093/carcin/bgh217; Kim JH, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-49; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Kondo Y, 2009, YONSEI MED J, V50, P455, DOI 10.3349/ymj.2009.50.4.455; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kuehni CE, 2009, AM J RESP CRIT CARE, V179, P1079, DOI 10.1164/rccm.200904-0567ED; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kumar RK, 2009, DIS MODEL MECH, V2, P549, DOI 10.1242/dmm.001719; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P731, DOI 10.1289/ehp.6702; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Launay JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007959; Lawlor DA, 2005, THORAX, V60, P851, DOI 10.1136/thx.2005.042408; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Lillienberg L, 2008, ANN OCCUP HYG, V52, P107, DOI 10.1093/annhyg/mem063; Ling C, 2009, DIABETES, V58, P2718, DOI 10.2337/db09-1003; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Liu XD, 2009, BIOCHEM BIOPH RES CO, V380, P177, DOI 10.1016/j.bbrc.2009.01.066; Locksley RM, 2009, J EXP MED, V206, P1643, DOI 10.1084/jem.20091442; London SJ, 2009, ANNU REV PUBL HEALTH, V30, P55, DOI 10.1146/annurev.publhealth.031308.100151; Los H, 2001, Twin Res, V4, P81, DOI 10.1375/twin.4.2.81; Macaubas Claudia, 2003, Current Drug Targets - Inflammation and Allergy, V2, P175, DOI 10.2174/1568010033484304; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; Mashek DG, 2004, J LIPID RES, V45, P1958, DOI 10.1194/jlr.E400002-JLR200; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Maziak Wasim, 2005, BMC Pulm Med, V5, P5, DOI 10.1186/1471-2466-5-5; Mcleish AC, 2010, J ASTHMA, V47, P345, DOI 10.3109/02770900903556413; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Millman A, 2008, PEDIATRICS, V122, P620, DOI 10.1542/peds.2007-3143; Minekura H, 2001, GENE, V278, P185, DOI 10.1016/S0378-1119(01)00714-4; Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Nahid MA, 2009, J BIOL CHEM, V284, P34590, DOI 10.1074/jbc.M109.056317; Nouri-Aria KT, 2009, ADV EXP MED BIOL, V665, P180; Nuttall SL, 2000, LANCET, V355, P1648, DOI 10.1016/S0140-6736(05)72556-3; Orfei L, 2008, ARCH DIS CHILD, V93, P570, DOI 10.1136/adc.2006.112201; OU TX, 2009, J IMMUNOL, V182, P4994; Patel MM, 2009, CURR OPIN PEDIATR, V21, P235, DOI 10.1097/MOP.0b013e3283267726; Patra SK, 2009, BIOCHEMISTRY-MOSCOW+, V74, P613, DOI 10.1134/S0006297909060042; Pauley KM, 2008, ANN NY ACAD SCI, V1143, P226, DOI 10.1196/annals.1443.009; Peden D, 2010, J ALLERGY CLIN IMMUN, V125, pS150, DOI 10.1016/j.jaci.2009.10.073; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Peters-Golden M, 2004, AM J RESP CELL MOL, V31, P3, DOI 10.1165/rcmb.f279; Ponsonby AL, 2001, CLIN EXP ALLERGY, V31, P1544, DOI 10.1046/j.1365-2222.2001.01163.x; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; Ray A, 2010, MUCOSAL IMMUNOL, V3, P216, DOI 10.1038/mi.2010.4; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Ribeiro M, 2009, AM J IND MED, V52, P261, DOI 10.1002/ajim.20669; Robays LJ, 2009, MUCOSAL IMMUNOL, V2, P206, DOI 10.1038/mi.2009.7; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Sadikovic B, 2008, J BIOL CHEM, V283, P4051, DOI 10.1074/jbc.M707506200; Sadikovic B, 2007, TOXICOL APPL PHARM, V225, P300, DOI 10.1016/j.taap.2007.08.013; Sadikovic B, 2006, TOXICOL APPL PHARM, V216, P458, DOI 10.1016/j.taap.2006.06.012; Schaub B, 2008, ALLERGY, V63, P1438, DOI 10.1111/j.1398-9995.2008.01685.x; Schweizer M, 1999, J GEN VIROL, V80, P1147, DOI 10.1099/0022-1317-80-5-1147; SHAHEEN SO, 1994, AM J RESP CRIT CARE, V149, P616, DOI 10.1164/ajrccm.149.3.8118627; Shankar SL, 2003, J NEUROSCI, V23, P4208; Siedlecki P, 2006, ACTA BIOCHIM POL, V53, P245; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stepanek L, 2005, J NEUROSCI, V25, P3813, DOI 10.1523/JNEUROSCI.4531-04.2005; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Su RC, 2008, J ALLERGY CLIN IMMUN, V121, P57, DOI 10.1016/j.jaci.2007.09.004; Sun LY, 2006, ENDOCRINOLOGY, V147, P5480, DOI 10.1210/en.2006-0586; Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102; TAKIZAWA H, 1990, AM J RESP CELL MOL, V2, P245, DOI 10.1165/ajrcmb/2.3.245; Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; Tiwari VK, 2008, PLOS BIOL, V6, P2911, DOI 10.1371/journal.pbio.0060306; Tykocinski LO, 2005, J BIOL CHEM, V280, P28177, DOI 10.1074/jbc.M502038200; Vaag A, 2007, CURR OPIN CLIN NUTR, V10, P591, DOI 10.1097/MCO.0b013e3282ab9ea6; Valinluck V, 2007, CANCER RES, V67, P946, DOI 10.1158/0008-5472.CAN-06-3123; van Panhuys N, 2008, TISSUE ANTIGENS, V72, P91, DOI 10.1111/j.1399-0039.2008.01068.x; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vercelli D, 2008, J ALLERGY CLIN IMMUN, V122, P267, DOI 10.1016/j.jaci.2008.06.008; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; Wang LQ, 2009, IMMUNOL CELL BIOL, V87, P195, DOI 10.1038/icb.2008.106; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; Weisenberger DJ, 1999, J BIOL CHEM, V274, P23948, DOI 10.1074/jbc.274.34.23948; Weiss ST, 2009, CURR OPIN GENET DEV, V19, P279, DOI 10.1016/j.gde.2009.05.001; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; *WHO, 2000, 206 WHO; WILSON VL, 1983, CELL, V32, P239, DOI 10.1016/0092-8674(83)90514-7; WILSON VL, 1984, CARCINOGENESIS, V5, P1027, DOI 10.1093/carcin/5.8.1027; Windham GC, 2000, EPIDEMIOLOGY, V11, P427, DOI 10.1097/00001648-200007000-00011; Wong GWK, 2008, PEDIATR PULM, V43, P107, DOI 10.1002/ppul.20755; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yanagawa N, 2002, JPN J CANCER RES, V93, P1107, DOI 10.1111/j.1349-7006.2002.tb01212.x; YOUNG HA, 1994, J IMMUNOL, V153, P3603; Zhang N, 2005, J MOL BIOL, V346, P951, DOI 10.1016/j.jmb.2004.12.027; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154	176	163	172	0	59	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					453	465		10.1016/j.jaci.2010.07.030	http://dx.doi.org/10.1016/j.jaci.2010.07.030			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816181	Bronze, Green Accepted			2022-12-18	WOS:000281512500007
J	Perkin, MR; Strachan, DP				Perkin, MR; Strachan, DP			Which aspects of the farming lifestyle explain the inverse association with childhood allergy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; farm; unpasteurized milk; skin prick tests; children	FARMERS CHILDREN; HAY-FEVER; ASTHMA; PREVALENCE; ENDOTOXIN; LIMULUS; MILK; SENSITIZATION; EXPOSURE; DISEASES	Background: Farmers' children have a reduced prevalence of allergic disorders. The specific protective environmental factors responsible are not yet identified. Objective: We sought to determine whether farmers' children in the rural county of Shropshire, England, have a reduced risk of atopy and, if so, to identify the factors responsible. Methods: The Study of Asthma and Allergy in Shropshire was a 2-stage cross-sectional study. In stage 1 a questionnaire to elicit allergic status, diet, and farming exposure was completed by the parents of 4767 children. In stage 2 a stratified subsample of 879 children underwent skin prick testing and measurement of domestic endotoxin. Results: Compared with rural nonfarming children, farmers' children had significantly less current asthma symptoms. (adjusted odds ratio (OR), 0.67; 95% CI, 0.49-0.91; P =.01) and current seasonal allergic rhinitis (adjusted OR, 0.50; 95% CI, 0.33-0.77; P =.002) but not current eczema symptoms (adjusted OR, 0.91; 95% CI, 0.68-1.21; P =.53) or atopy (adjusted OR, 0.68; 95% CI, 0.40-1.16; P =.15). In contrast, current unpasteurized milk consumption was associated with significantly less current eczema symptoms (adjusted OR, 0.59; 95% CI, 0.40-0.87; P =.008) and a greater reduction in atopy (adjusted OR, 0.24; 95% CI, 0.10-0.53; P =.001). The effect was seen in all children, independent of farming status. Unpasteurized milk consumption was associated with a 59% reduction in total IgE levels (P <.001) and higher production of whole blood stimulated IFN-gamma (P = .02). Conclusion: Unpasteurized milk consumption was the exposure mediating the protective effect on skin prick test positivity. The effect was independent of farming status and present with consumption of infrequent amounts of unpasteurized milk. Clinical implications: Unpasteurized milk might be a modifiable influence on allergic sensitization in children.	Univ London, St Georges, Div Clin Dev Sci, London SW17 0RE, England; Univ London, St Georges, Div Community Hlth Sci, London SW17 0RE, England	St Georges University London; University of London; St Georges University London; University of London	Perkin, MR (corresponding author), Univ London, St Georges, Div Clin Dev Sci, Cranmer Terrace, London SW17 0RE, England.	m.perkin@sgul.ac.uk	Perkin, Michael/AID-7491-2022	Perkin, Michael/0000-0001-9272-2585	Wellcome Trust [056906/Z/99/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allerberger F, 2001, Euro Surveill, V6, P147; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C.H., 1996, EPIDEMIOLOGY, V7, pS47, DOI [10.1097/00001648-199607001-00115, DOI 10.1097/00001648-199607001-00115]; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; Cooper JF, 1997, PDA J PHARM SCI TECH, V51, P2; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Harper Catherine M, 2002, Commun Dis Intell Q Rep, V26, P449; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; KLEINETEBBE J, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb02174.x; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; MORGAN D, 1994, EUR J EPIDEMIOL, V10, P581, DOI 10.1007/BF01719576; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Remes ST, 2002, ACTA PAEDIATR, V91, P1163, DOI 10.1111/j.1651-2227.2002.tb00122.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; *STAT, 2003, STAT STAT SOFTW REL; SUHREN G, 1986, MILCHWISSENSCHAFT, V41, P156; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x	24	163	167	0	20	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1374	1381		10.1016/j.jaci.2006.03.008	http://dx.doi.org/10.1016/j.jaci.2006.03.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751000				2022-12-18	WOS:000238332300026
J	Ryan, PH; LeMasters, G; Biagini, J; Bernstein, D; Grinshpun, SA; Shukla, R; Wilson, K; Villareal, M; Burkle, J; Lockey, J				Ryan, PH; LeMasters, G; Biagini, J; Bernstein, D; Grinshpun, SA; Shukla, R; Wilson, K; Villareal, M; Burkle, J; Lockey, J			Is it traffic type, volume, or distance? Wheezing in infants living near truck and bus traffic	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						diesel; traffic; truck; bus; wheezing; geographic information system; infants	DIESEL EXHAUST PARTICLES; AIR-POLLUTION; RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; PARTICULATE MATTER; CYTOKINE PRODUCTION; VEHICLE EMISSIONS; CHILDHOOD ASTHMA; URBAN AIR; CHILDREN	Background: Previous studies of air pollution have not examined the association between exposure to varying types, distance, and amounts of traffic and wheezing in very young infants. Objective: We sought to determine the relationship between types of traffic, traffic volume, and distance and wheezing among infants less than 1 year of age. Methods: A geographic information system and a classification scheme were developed to categorize infants enrolled in the study as living near moving truck and bus traffic (highway > 50 miles per hour, > 1000 trucks daily, < 400 m), stop-and-go truck and bus traffic (< 50 miles per hour, < 100 m), or unexposed and not residing near either. Symptom data were based on health questionnaires administered to parents when the infants were 6 months of age and monthly health diaries. Results: Infants living very near (< 100 m) stop-and-go bus and truck traffic had a significantly increased prevalence of wheezing (adjusted odds ratio, 2.50; 95% CI, 1.15-5.42) when compared with unexposed infants. The prevalence of wheezing among nonwhite infants was at least twice that of white infants, regardless of exposure. Infants living less than 400 m from a high volume of moving traffic, however, did not have an increased prevalence of wheezing. Conclusion: These results suggest that the distance from and type of traffic exposures are more significant risk factors than traffic volume for wheezing in early infancy.	Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Div Immunol, Dept Internal Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Ryan, PH (corresponding author), Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA.	ryanph@email.uc.edu	Ryan, Patrick H/L-7062-2015; Ryan, Patrick/HDO-1133-2022	Wilson, Kimberly/0000-0003-2029-2533; Grinshpun, Sergey/0000-0003-4339-927X; Biagini, Jocelyn/0000-0002-4378-6133; Burkle, Jeff/0000-0002-4670-2193	NIEHS NIH HHS [ES11170, ES10957] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011170, T32ES010957] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Brauer M, 2001, ENVIRON HEALTH PERSP, V109, P1039, DOI 10.2307/3454959; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771, DOI 10.1136/oem.55.11.771; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; El-Sharif N, 2003, CLIN EXP ALLERGY, V33, P176, DOI 10.1046/j.1365-2222.2003.01598.x; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507, DOI 10.1165/ajrcmb.19.3.3143; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Jalaludin BB, 2004, ENVIRON RES, V95, P32, DOI 10.1016/S0013-9351(03)00038-0; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; LEMASTERS GK, 2003, AM THOR SOC INT C MA; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Ormstad H, 2000, TOXICOLOGY, V152, P53, DOI 10.1016/S0300-483X(00)00292-4; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103, DOI 10.1289/ehp.02110s1103; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Pino P, 2004, EPIDEMIOLOGY, V15, P702, DOI 10.1097/01.ede.0000142153.28496.d0; Reponen T, 2003, J ENVIRON MONITOR, V5, P557, DOI 10.1039/b303557c; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Shah SD, 2004, ENVIRON SCI TECHNOL, V38, P2544, DOI 10.1021/es0350583; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; Shima M, 2003, J EPIDEMIOL, V13, P108, DOI 10.2188/jea.13.108; Shima M, 2002, ARCH ENVIRON HEALTH, V57, P529, DOI 10.1080/00039890209602084; Simon PA, 2003, J ASTHMA, V40, P535, DOI 10.1081/JAS-120018788; SOLOMON G, 2001, COALITION CLEAN AIR; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Tong HY, 2000, J AIR WASTE MANAGE, V50, P543, DOI 10.1080/10473289.2000.10464041; Unal A, 2004, J AIR WASTE MANAGE, V54, P130, DOI 10.1080/10473289.2004.10470888; United States Environmental Protection Agency (U.S. EPA), HLTH ASS DOC DIES EN; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802, DOI 10.1136/oem.56.12.802; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/ajrccm.164.12.2106126; Wilkinson P, 1999, THORAX, V54, P1070, DOI 10.1136/thx.54.12.1070	45	163	165	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					279	284		10.1016/j.jaci.2005.05.014	http://dx.doi.org/10.1016/j.jaci.2005.05.014			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083780				2022-12-18	WOS:000235686400006
J	Hart, TK; Cook, RM; Zia-Amirhosseini, P; Minthorn, E; Sellers, TS; Maleeff, BE; Eustis, S; Schwartz, LW; Tsui, P; Appelbaum, ER; Martin, EC; Bugelski, PJ; Herzyk, DJ				Hart, TK; Cook, RM; Zia-Amirhosseini, P; Minthorn, E; Sellers, TS; Maleeff, BE; Eustis, S; Schwartz, LW; Tsui, P; Appelbaum, ER; Martin, EC; Bugelski, PJ; Herzyk, DJ			Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-5; monoclonal antibody; asthma; eosinophilia; monkey; preclinical safety; toxicology	RECOMBINANT HUMAN INTERLEUKIN-5; AIRWAY INFLAMMATION; BRONCHIAL HYPERREACTIVITY; EOSINOPHIL INFILTRATION; MURINE MODEL; GUINEA-PIG; EXPRESSION; ANTIGEN; PHARMACOKINETICS; TRAFFICKING	Background: Allergic respiratory diseases are characterized by large numbers of eosinophils and their reactive products in airways and blood; these are believed to be involved in progressive airway damage and remodeling. IL-5 is the principal cytokine for eosinophil maturation, differentiation, and survival. Mepolizumab (SB-240563), a humanized monoclonal antibody (mAb) specific for human IL-5, is currently in clinical trials fbr treatment of asthma. Objective: The purpose of this study was to characterize the pharmacologic activity and long-term. safety profile of an anti-human IL-5 mAb to support clinical trials in asthmatic patients. Methods. Naive and Ascaris suum-sensitive cynomolgus monkeys received various dose levels of mepolizumab and were monitored for acute and chronic pharmacologic and toxic responses. Results. To support preclinical safety assessment, cynomolgus monkey IL-5 was cloned, expressed, and characterized. Although monkey IL-5 differs from human IL-5 by 2 amino acids (Ala27Gly and Asn40His), mepolizumab has comparable inhibitory activity against both monkey IL-5 and human IL-5. In A suum-sensitive monkeys, single doses of mepolizumab significantly reduced blood eosinophilia, eosinophil migration into lung airways, and levels of RANTES and IL-6 in lungs for 6 weeks. However, mepolizumab did not affect acute bronchoconstrictive responses to inhaled A suum. In an IL-2-induced eosinophilia model (up to 50% blood eosinophilia), 0.5 mg/kg mepolizumab blocked eosinophilia by >80%. Single dose and chronic (6 monthly doses) intravenous and subcutaneous toxicity studies in naive monkeys found no target organ toxicity or immunotoxicity up to 300 mg/kg. Monkeys did not generate anti-human IgG antibodies. Monthly mepolizumab doses greater than 5 mg/kg caused an 80% to 100% decrease in blood and bronchoalveolar lavage eosinophils lasting 2 months after dosing, and there was no effect on eosinophil precursors in bone marrow after 6 months of treatment. Eosinophil decreases correlated with mepolizumab plasma concentrations (half-life = 13 days). Conclusion. These studies demonstrate that chronic antagonism of IL-5 by mepolizumab in monkeys is safe and has the potential, through long-term reductions in circulating and tissue-resident eosinophils, to be beneficial therapy for chronic inflammatory respiratory diseases.	GlaxoSmithKline, Dept Safety Assessment, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Drug Metab & Pharmacokinet, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Biopharmaceut Discovery, King Of Prussia, PA 19406 USA; Primedica Corp, Worcester, MA USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Hart, TK (corresponding author), GlaxoSmithKline, Dept Safety Assessment, Mail Stop UE0360,709 Swedeland Rd, King Of Prussia, PA 19406 USA.							AKUTSU I, 1995, IMMUNOL LETT, V45, P109, DOI 10.1016/0165-2478(94)00241-I; AMES RS, 1995, J IMMUNOL, V154, P6355; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150, DOI 10.1164/ajrccm.160.4.9806034; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; BUGELSKI PJ, 1991, TOXICOL PATHOL, V19, P580, DOI 10.1177/019262339101900403; BUSSE WW, 1993, AM REV RESPIR DIS, V147, pS20, DOI 10.1164/ajrccm/147.6_Pt_2.S20; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Egan RW, 1999, ARZNEIMITTEL-FORSCH, V49, P779; Garlisi CG, 1999, AM J RESP CELL MOL, V20, P248, DOI 10.1165/ajrcmb.20.2.3327; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; HAKIMI J, 1991, J IMMUNOL, V147, P1352; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V120, P8, DOI 10.1159/000024215; Hogan SP, 1997, IMMUNOL CELL BIOL, V75, P284, DOI 10.1038/icb.1997.43; Holgate ST, 1999, CLIN EXP ALLERGY, V29, P90, DOI 10.1046/j.1365-2222.1999.00016.x; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Konno S, 1996, INT ARCH ALLERGY IMM, V109, P73, DOI 10.1159/000237234; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Lalani T, 1999, ANN ALLERG ASTHMA IM, V82, P317, DOI 10.1016/S1081-1206(10)63281-4; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MACDONALD D, 1990, BRIT J HAEMATOL, V76, P168, DOI 10.1111/j.1365-2141.1990.tb07867.x; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; MORELAND LW, 1994, ARTHRITIS RHEUM, V37, P834, DOI 10.1002/art.1780370610; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; Mould AW, 2000, J IMMUNOL, V164, P2142, DOI 10.4049/jimmunol.164.4.2142; NEWMAN R, 1992, BIO-TECHNOL, V10, P1455, DOI 10.1038/nbt1192-1455; OUT TA, 1991, SCAND J IMMUNOL, V33, P719, DOI 10.1111/j.1365-3083.1991.tb02546.x; PISANI CV, 1991, BLOOD, V78, P1538, DOI 10.1182/blood.V78.6.1538.1538; PROPHET EB, 1994, LAB METHODS HISTOTEC, P146; REED CE, 1994, ANN ALLERGY, V72, P376; RODGERS S, 1994, BRIT J HAEMATOL, V86, P746, DOI 10.1111/j.1365-2141.1994.tb04824.x; Sanderson C J, 1988, Dev Biol Stand, V69, P23; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; Thurau AM, 1996, CYTOMETRY, V23, P150, DOI 10.1002/(SICI)1097-0320(19960201)23:2<150::AID-CYTO8>3.0.CO;2-O; TRAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574; VANOOSTERHOUT AJM, 1995, J ALLERGY CLIN IMMUN, V96, P104, DOI 10.1016/S0091-6749(95)70039-0; Vaswani SK, 1998, ANN ALLERG ASTHMA IM, V81, P105, DOI 10.1016/S1081-1206(10)62794-9; VILLINGER F, 1995, J IMMUNOL, V155, P3946; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; YAMAGUCHI Y, 1990, J IMMUNOL, V145, P873; Zia-Amirhosseini P, 1999, J PHARMACOL EXP THER, V291, P1060	47	163	208	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					250	257		10.1067/mai.2001.116576	http://dx.doi.org/10.1067/mai.2001.116576			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496242	Bronze			2022-12-18	WOS:000170584600014
J	Apelberg, BJ; Aoki, Y; Jaakkola, JJK				Apelberg, BJ; Aoki, Y; Jaakkola, JJK			Systematic review: Exposure to pets and risk of asthma and asthma-like symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						pets; asthma; wheeze; domestic animal; meta-analysis; selection bias	RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; HOME-ENVIRONMENT; ATOPIC SENSITIZATION; CHILDREN; PREVALENCE; ALLERGY; CAT; ASSOCIATION; MORBIDITY	Background: Studies of exposure to pets and risk of asthma have yielded conflicting results. Objectives: We performed a systematic review to synthesize the evidence of the effect of exposure to pets in the home on the risk of asthma and asthma-related symptoms. We also assessed differences between the studies as sources of heterogeneity of the results. Methods: We conducted a MEDLINE search (until the end of 1999) using the following boolean search command: (asthma[all] OR wheez*[all]) AND (domestic animal*[all] OR pets[all]). The outcome was limited to either diagnosis of asthma or the symptom of wheezing, The exposure of interest was domestic animals in the home, Appropriate temporal relationship was defined as present in studies with either pet keeping within the first 2 years of life, in the past, or exposure to pets preceding the outcome. Results: Thirty-two of the 217 retrieved articles fulfilled the eligibility criteria. Inappropriate time sequence of the exposure and outcome information was an important source of heterogeneity and an indication of potential selection bias. Therefore we analyzed studies focusing on early exposure or ensuring appropriate temporal sequence. The pooled risk estimates for both asthma (fixed-effects odds ratio, 1.11; 95% CI, 0.98-1.25; heterogeneity, P = .04; random-effects odds ratio, 1.09; 95% CI, 0.89-1.34) and wheezing (fixed-effects odds ratio, 1.19; 95% CI, 1.05-1.35; heterogeneity, P = .03; random-effects odds ratio, 1.17; 95% CI, 0.95-1.44) indicated a small effect, which was limited to studies with a median study population age of over 6 years (fixed-effects odds ratio, 1.19; 95% CI, 1.02-1.40; heterogeneity, P = .04; random-effects odds ratio, 1.15; 95% CI, 0.86-1.56; fixed-effects odds ratio, 1.29; 95% CI, 1.12-1.48; heterogeneity, P = .31). In younger children the harmful effect disappeared for wheezing (odds ratio, 0.80; 95% CI, 0.59-1.08; P = .38). Conclusion: Exposure to pets appears to increase the risk of asthma and wheezing in older children. The observed lower risk among exposed than among unexposed young children is consistent with a protective effect in this age, group but could also be explained by selection bias.	Johns Hopkins Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Jaakkola, JJK (corresponding author), Nord Sch Publ Hlth, Environm Hlth Program, POB 12133, SE-40242 Gothenburg, Sweden.		Jaakkola, Jouni J.K./G-4314-2012	Jaakkola, Jouni/0000-0003-4168-4683				ABDULRAZZAQ YM, 1995, J ASTHMA, V32, P117, DOI 10.3109/02770909509083232; Abuekteish F, 1996, ANN TROP PAEDIATR, V16, P227, DOI 10.1080/02724936.1996.11747831; Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; al Frayh A R, 1989, Allerg Immunol (Paris), V21, P389; ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; Austin JB, 1997, ARCH DIS CHILD, V76, P22, DOI 10.1136/adc.76.1.22; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bener A., 1993, Indian Journal of Pediatrics, V60, P791, DOI 10.1007/BF02751050; Bener A, 1995, Allerg Immunol (Paris), V27, P190; Bener A, 1996, HUM BIOL, V68, P405; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; Burr ML, 1999, THORAX, V54, P27, DOI 10.1136/thx.54.1.27; DAIGLER GE, 1991, LARYNGOSCOPE, V101, P293; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FAGBULE D, 1994, ANN TROP PAEDIATR, V14, P15, DOI 10.1080/02724936.1994.11747686; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HALKEN S, 1991, ALLERGY, V46, P507, DOI 10.1111/j.1398-9995.1991.tb00613.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; HOSEIN HR, 1989, INT J EPIDEMIOL, V18, P390, DOI 10.1093/ije/18.2.390; KALYONCU AF, 1994, ALLERGY, V49, P485, DOI 10.1111/j.1398-9995.1994.tb00846.x; Kane MP, 1999, J ASTHMA, V36, P371, DOI 10.3109/02770909909068230; LEEN MG, 1994, IRISH MED J, V87, P142; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408, DOI 10.1136/adc.73.5.408; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Nilsson L, 1999, ALLERGY, V54, P716, DOI 10.1034/j.1398-9995.1999.00896.x; Noertjojo K, 1999, J ALLERGY CLIN IMMUN, V103, P60, DOI 10.1016/S0091-6749(99)70526-9; Nriagu J, 1999, EUR J EPIDEMIOL, V15, P747, DOI 10.1023/A:1007653709188; ONTEFORT S, 1998, CLIN EXP ALLERGY, V38, P1089; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760, DOI 10.1164/ajrccm.159.3.9804143; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Platts-Mills T A, 1996, Curr Opin Pulm Med, V2, P29; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; Poole C, 1999, AM J EPIDEMIOL, V150, P469, DOI 10.1093/oxfordjournals.aje.a010035; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sears MR, 1998, CLIN EXP ALLERGY, V28, P82; SHARP S, 1998, STAT TECHNICAL B REP, V7, P106; SHARP S, 1998, STATA TECH B, V7, P148; SHAW R, 1994, NEW ZEAL MED J, V107, P387; Siracusa A, 1997, Monaldi Arch Chest Dis, V52, P434; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; *STAT, 1999, STAT STAT SOFTW REL; Steichen TJ, 1998, STAT TECHNICAL B REP, V8, P84; STRACHAN DP, 1995, BRIT MED J, V311, P1053, DOI 10.1136/bmj.311.7012.1053; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352, DOI 10.1164/ajrccm.158.2.9705079; Zacharasiewicz A, 1999, WIEN KLIN WOCHENSCHR, V111, P882	48	163	168	1	19	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					455	460		10.1067/mai.2001.113240	http://dx.doi.org/10.1067/mai.2001.113240			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240945				2022-12-18	WOS:000167793300006
J	BISHOPRIC, NH; COHEN, HJ; LEFKOWITZ, RJ				BISHOPRIC, NH; COHEN, HJ; LEFKOWITZ, RJ			BETA-ADRENERGIC RECEPTORS IN LYMPHOCYTE SUB-POPULATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DUKE UNIV,MED CTR,DEPT MED,HOWARD HUGHES MED INST LAB,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710	Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021					ARCHER JA, 1975, J CLIN INVEST, V55, P166, DOI 10.1172/JCI107907; ATKINSON JP, 1975, J IMMUNOL, V115, P1023; BACH MA, 1975, J CLIN INVEST, V55, P1074, DOI 10.1172/JCI108008; BOURNE HR, 1972, J IMMUNOL, V108, P695; COHEN HJ, 1975, J CLIN INVEST, V55, P84, DOI 10.1172/JCI107921; GALANT SP, 1978, J ALLERGY CLIN IMMUN, V62, P349, DOI 10.1016/0091-6749(78)90135-5; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HENNEY CS, 1972, J IMMUNOL, V108, P1526; ISHIZAKA T, 1971, J IMMUNOL, V106, P1267; JARVIS SC, 1976, BLOOD, V48, P717; JONDAL M, 1973, TRANSPLANT REV, V16, P163; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; LANG P, 1978, J ALLERGY CLIN IMMUN, V61, P248, DOI 10.1016/0091-6749(78)90199-9; MALBON CC, 1978, J BIOL CHEM, V253, P671; MELMON KL, 1974, J CLIN INVEST, V53, P13, DOI 10.1172/JCI107530; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MUKHERJEE C, 1975, J BIOL CHEM, V250, P4869; NIAUDET P, 1976, EUR J IMMUNOL, V6, P834, DOI 10.1002/eji.1830061117; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; SCHWARTZ HJ, 1973, J ALLERGY CLIN IMMUN, V51, P88, DOI 10.1016/S0091-6749(73)80024-7; SHEPPARD JR, 1977, NATURE, V269, P693, DOI 10.1038/269693a0; SMITH U, 1977, EUR J CLIN INVEST, V7, P355, DOI 10.1111/j.1365-2362.1977.tb01620.x; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; WILLIAMS LT, 1976, J CLIN INVEST, V57, P149, DOI 10.1172/JCI108254; WILLIAMS LT, 1977, J BIOL CHEM, V252, P2787	25	163	164	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					29	33		10.1016/0091-6749(80)90173-6	http://dx.doi.org/10.1016/0091-6749(80)90173-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	6243144				2022-12-18	WOS:A1980JB45900005
J	Huang, YJ; Boushey, HA				Huang, Yvonne J.; Boushey, Homer A.			The microbiome in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiome; microbiota; bacterial community composition; immune function; allergy; asthma	MUCOSAL IMMUNE-SYSTEM; EARLY-LIFE; VIRUS-INFECTION; CHLAMYDIA-PNEUMONIAE; CHILDHOOD ASTHMA; MYCOPLASMA-PNEUMONIAE; INTESTINAL MICROFLORA; RESEARCH-PROGRAM; GUT MICROBIOME; AIRWAY DISEASE	The application of recently developed sensitive, specific, culture-independent tools for identification of microbes is transforming concepts of microbial ecology, including concepts of the relationships between the vast complex populations of microbes associated with ourselves and with states of health and disease. Although most work initially focused on the community of microbes (microbiome) in the gastrointestinal tract and its relationship to gastrointestinal disease, interest has expanded to include study of the relationships of the airway microbiome to asthma and its phenotypes and to the relationships between the gastrointestinal microbiome, development of immune function, and predisposition to allergic sensitization and asthma. Here we provide our perspective on the findings of studies of differences in the airway microbiome between asthmatic patients and healthy subjects and of studies of relationships between environmental microbiota, gut microbiota, immune function, and asthma development. In addition, we provide our perspective on how these findings suggest the broad outline of a rationale for approaches involving directed manipulation of the gut and airway microbiome for the treatment and prevention of allergic asthma.	[Huang, Yvonne J.] Univ Michigan, Dept Internal Med, Div Pulm & Crit Med, Ann Arbor, MI 48109 USA; [Boushey, Homer A.] Univ Calif San Francisco, Dept Med, Div Pulm Crit Care Allergy & Sleep Med, San Francisco, CA 94143 USA	University of Michigan System; University of Michigan; University of California System; University of California San Francisco	Boushey, HA (corresponding author), Univ Calif San Francisco, Dept Med, Med Allergy & Immunol Div, 505 Parnassus Ave,Rm M-1292,Box 0130, San Francisco, CA 94143 USA.	homer.boushey@ucsf.edu		Huang, Yvonne/0000-0002-7497-6597	National Institutes of Health; National Heart, Lung, and Blood Institute [NHLBI] [105572]; NHLBI [U10 HL098115]; National Institute of Allergy and Infectious Disease [1 UM1 AI114271-01, P01 AI089473]; Janssen; grant from Genentech for study of "The Airway Microbiome of Severe Asthma'' [A118451]; Allergy; Asthma; Immunology Foundation of Northern California; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL105572] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute [NHLBI](United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); grant from Genentech for study of "The Airway Microbiome of Severe Asthma''; Allergy; Asthma; Immunology Foundation of Northern California; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Y. J. Huang's and H. A. Boushey's institutions have received funding for studies of the microbiome in asthma from the National Institutes of Health (Y. J. Huang from the National Heart, Lung, and Blood Institute [NHLBI; 105572] and H. A. Boushey from NHLBI U10 HL098115 and the National Institute of Allergy and Infectious Disease [1 UM1 AI114271-01 and P01 AI089473]). Within the past 3 years, H. A. Boushey has received a consultancy fee from Janssen; a grant from Genentech for study of "The Airway Microbiome of Severe Asthma'' (A118451); payment for delivering lectures from the Allergy, Asthma, and Immunology Foundation of Northern California; and royalties from McGraw-Hill.	Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Black PN, 2001, AM J RESP CRIT CARE, V164, P536, DOI 10.1164/ajrccm.164.4.2011040; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; CZERKINSKY C, 1987, P NATL ACAD SCI USA, V84, P2449, DOI 10.1073/pnas.84.8.2449; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384; Erturk-Hasdemir D, 2013, CURR OPIN IMMUNOL, V25, P450, DOI 10.1016/j.coi.2013.06.001; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Gern JE, 2010, J ALLERGY CLIN IMMUN, V125, P545, DOI 10.1016/j.jaci.2010.01.037; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Good JT, 2012, CHEST, V141, P599, DOI 10.1378/chest.11-0741; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; Heederik D, 2012, J ALLERGY CLIN IMMUN, V130, P44, DOI 10.1016/j.jaci.2012.01.067; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Holtzman MJ, 2009, ADV IMMUNOL, V102, P245, DOI 10.1016/S0065-2776(09)01205-X; Huang Yvonne J, 2014, Ann Am Thorac Soc, V11 Suppl 1, pS48, DOI 10.1513/AnnalsATS.201306-187MG; Huang YJ, 2013, AM J RESP CRIT CARE, V187, P1382, DOI 10.1164/rccm.201303-0488WS; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; KAPLAN M A, 1958, Antibiot Annu, V6, P273; Karimi K, 2009, AM J RESP CRIT CARE, V179, P186, DOI 10.1164/rccm.200806-951OC; Kitazawa H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00201; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Leyer GJ, 2009, PEDIATRICS, V124, pE172, DOI 10.1542/peds.2008-2666; Luoto R, 2014, J ALLERGY CLIN IMMUN, V133, P405, DOI 10.1016/j.jaci.2013.08.020; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; MESTECKY J, 1987, J CLIN IMMUNOL, V7, P265, DOI 10.1007/BF00915547; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morris A, 2013, AM J RESP CRIT CARE, V187, P1067, DOI 10.1164/rccm.201210-1913OC; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Oddy WH, 2009, ADV EXP MED BIOL, V639, P237, DOI 10.1007/978-1-4020-8749-3_17; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Platts-Mills TAE, 2005, ALLERGY, V60, P25, DOI 10.1111/j.1398-9995.2005.00854.x; Rautava S, 2012, NAT REV GASTRO HEPAT, V9, P565, DOI 10.1038/nrgastro.2012.144; Razi CH, 2010, J ALLERGY CLIN IMMUN, V126, P763, DOI 10.1016/j.jaci.2010.07.038; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Sharma S, 2014, THORAX, V69, P481, DOI 10.1136/thoraxjnl-2014-205166; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; Tomosada Y, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-40; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; von Hertzen L, 2007, ALLERGY, V62, P288, DOI 10.1111/j.1398-9995.2006.01281.x; von Mutius E, 2007, NEW ENGL J MED, V357, P1545, DOI 10.1056/NEJMe078119; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wong EHC, 2014, LANCET RESP MED, V2, P657, DOI 10.1016/S2213-2600(14)70107-9; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; Yasui H, 2004, CLIN DIAGN LAB IMMUN, V11, P675, DOI 10.1128/CDLI.11.4.675-679.2004; Yoo Jennifer, 2007, Proc Am Thorac Soc, V4, P277, DOI 10.1513/pats.200702-033AW	74	162	168	3	116	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					25	30		10.1016/j.jaci.2014.11.011	http://dx.doi.org/10.1016/j.jaci.2014.11.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25567040	Green Accepted			2022-12-18	WOS:000347298200003
J	Burks, AW; Laubach, S; Jones, SM				Burks, A. Wesley; Laubach, Susan; Jones, Stacie M.			Oral tolerance, food allergy, and immunotherapy: Implications for future treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immune tolerance; immunotherapy; food allergy; food hypersensitivity; T cells; TGF-beta; clonal anergy; forkhead box P3 protein; sublingual immunotherapy; oral immunotherapy	REGULATORY T-CELLS; COWS MILK ALLERGY; GROWTH-FACTOR-BETA; QUALITY-OF-LIFE; PEANUT ALLERGY; TGF-BETA; ACTIVE SUPPRESSION; IMMUNE-RESPONSES; SMALL-INTESTINE; MURINE MODEL	The lumen of the gastrointestinal tract is exposed daily to an array of dietary proteins. The vast majority of proteins are tolerated through suppression of cellular or Immoral responses, a process known as oral tolerance. However, in approximately 6% of children and 4% of adults in the United States, tolerance to a given dietary antigen either is not established or breaks down, resulting in food hypersensitivity. Although food allergies can result in sudden and life-threatening symptoms, their prevalence is remarkably low considering the complexities of the gut-associated mucosal system. Suppression involves signaling by an array of nonprofessional antigen-presenting cells, dendritic cells, and regulatory T cells, as well as lymphocyte anergy or deletion. Several factors, including antigen properties, route of exposure, and genetics and age of the host, contribute to the development of oral tolerance. Although the current standard of care for patients with food allergies is based on avoidance of the trigger, increased understanding of the mechanisms involved in tolerance has shifted focus of treatment and prevention toward inducing tolerance. Data from early-phase clinical trials suggest both sublingual and oral immunotherapy are effective in reducing sensitivity to allergens. In this article we review the mechanisms of tolerance, discuss aberrations in oral tolerance, and provide information on novel prevention and treatment paradigms for food allergy.	[Burks, A. Wesley; Laubach, Susan] Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Durham, NC 27710 USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Div Allergy & Immunol, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.] Arkansas Childrens Hosp, Little Rock, AR USA	Duke University; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital	Burks, AW (corresponding author), Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Durham, NC 27710 USA.	wesley.burks@duke.edu						Appleman LJ, 2003, IMMUNOL REV, V192, P161, DOI 10.1034/j.1600-065X.2003.00009.x; Barone KS, 2000, CELL IMMUNOL, V199, P65, DOI 10.1006/cimm.1999.1603; BARONE KS, 1995, CELL IMMUNOL, V163, P19, DOI 10.1006/cimm.1995.1094; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Beyer K, 2005, J ALLERGY CLIN IMMUN, V116, P704, DOI 10.1016/j.jaci.2005.05.007; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; BLAND PW, 1986, IMMUNOLOGY, V58, P9; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; CHEN YH, 1995, J IMMUNOL, V155, P910; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; Dakin R, 1829, AM J MED SCI, V4, P98; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; GARSIDE P, 1995, INT IMMUNOL, V7, P501, DOI 10.1093/intimm/7.3.501; *IMM TOL NETW, LEAP STUD; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kopper RA, 2005, INT ARCH ALLERGY IMM, V136, P16, DOI 10.1159/000082580; Kraehenbuhl J P, 1992, Trends Cell Biol, V2, P170, DOI 10.1016/0962-8924(92)90036-M; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Levy Y, 2003, ALLERGY, V58, P1206, DOI 10.1046/j.1398-9995.2003.00307.x; Li XM, 1999, J IMMUNOL, V162, P3045; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Marth T, 1998, ANN NY ACAD SCI, V859, P290, DOI 10.1111/j.1749-6632.1998.tb11148.x; MASON DW, 1981, NATURE, V293, P150, DOI 10.1038/293150a0; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Menezes JD, 2003, INT IMMUNOL, V15, P447, DOI 10.1093/intimm/dxg043; MICHAEL JG, 1989, IMMUNOL INVEST, V18, P1049, DOI 10.3109/08820138909030606; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Patriarca G, 2003, ALIMENT PHARM THER, V17, P459, DOI 10.1046/j.1365-2036.2003.01468.x; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; SCOTT H, 1980, SCAND J IMMUNOL, V12, P77, DOI 10.1111/j.1365-3083.1980.tb00043.x; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Wells HG, 1911, J INFECT DIS, V9, P147, DOI 10.1093/infdis/9.2.147; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	61	162	175	1	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1344	1350		10.1016/j.jaci.2008.02.037	http://dx.doi.org/10.1016/j.jaci.2008.02.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18410959				2022-12-18	WOS:000256771700007
J	Hourihane, JO; Aiken, R; Briggs, R; Gudgeon, LA; Grimshaw, KEC; DunnGalvin, A; Roberts, SR				Hourihane, Jonathan O'Brien; Aiken, Rachel; Briggs, Rita; Gudgeon, Lesley A.; Grimshaw, Kate E. C.; DunnGalvin, Audrey; Roberts, Stephen R.			The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; children; double-blind placebo-controlled food challenge; peanut allergy; prevalence	FOOD ALLERGY; SENSITIZATION	Background: In June 1998, the United Kingdom government suggested that atopic pregnant and breast-feeding mothers and their infants should avoid peanuts. Objective: We report the prevalence of peanut sensitization in the first school cohort (2003-2005) to have been conceived after the advice was issued. Method: A total of 1072 mother-child pairs were studied in school. Children with positive peanut skin prick test results to peanut had peanut challenges. Results: Overall, 61% of 957 mothers recalled hearing the advice about peanuts in 1998. This figure was unaffected by maternal atopic status. Only 36 mothers (3.8%) followed the Government's advice by stopping the consumption of peanuts while pregnant. Maternal atopy had no effect on peanut consumption while breast-feeding. Mothers were less likely to change their diet if having a second or subsequent child compared with mothers having their first child (odds ratio 0.635, 95% Cis, 0.543-0.743; P < .01). Thirty children (2.8%; 95% Cls, 1.8% to 3.8%) had a positive peanut skin prick test result. Twenty children (1.8%; 95% CIs, 1.1% to 2.7%) were shown to have peanut allergy. This is the highest prevalence for peanut allergy recorded to date. Conclusions: The prevalence of peanut sensitization in this cohort is 2.8%, and peanut allergy now affects 1.8% of British children at school entry. It is difficult to ascertain any impact (either positive or negative) of the United Kingdom government advice on the prevalence of peanut allergy in British children aged 4-5 years from 2003 to 2005. Clinical implications: It remains uncertain if peanut avoidance during pregnancy and breast-feeding has any effect on the prevalence of peanut allergy in children.	Natl Univ Ireland Univ Coll Cork, Cork, Ireland; Univ Southampton, Southampton SO9 5NH, Hants, England; S Manchester Univ Hosp NHS Trust, Manchester, Lancs, England	University College Cork; University of Southampton; Wythenshawe Hospital NHS Foundation Trust	Hourihane, JO (corresponding author), Natl Univ Ireland Univ Coll Cork, Cork Univ Hosp, Dept Paediat & Child Hlth, Cork, Ireland.	j.hourihane@ucc.ie	DunnGalvin, Audrey/G-1741-2012	Grimshaw, Kate/0000-0003-3649-7963				Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Baral VR, 2005, POSTGRAD MED J, V81, P693, DOI 10.1136/pgmj.2004.030288; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; *COMM TOX CHEM FOO, 1998, ADV REACT FOOD FOOD, V11, P91; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Sampson HA, 2005, ALLERGY, V60, P19, DOI 10.1111/j.1398-9995.2005.00853.x; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514	10	162	165	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1197	1202		10.1016/j.jaci.2006.12.670	http://dx.doi.org/10.1016/j.jaci.2006.12.670			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17353036				2022-12-18	WOS:000246427200021
J	Hissaria, P; Smith, W; Wormald, PJ; Taylor, J; Vadas, M; Gillis, D; Kette, F				Hissaria, Pravin; Smith, William; Wormald, Peter J.; Taylor, James; Vadas, Mathew; Gillis, David; Kette, Frank			Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyps; corticosteroids; medical treatment; 31-item rhinosinusitis outcome measure; endoscopy; magnetic resonance imaging; outcome; randomized; double blind; placebo controlled	QUALITY-OF-LIFE; NASAL POLYPOSIS; PHARMACOLOGICAL MANAGEMENT; CLINIMETRIC VALIDITY; RHINOSINUSITIS; TOLERABILITY; SINUSITIS; EFFICACY; SERIES	Background: Topical and systemic corticosteroids are the first choice in medical treatments for sinonasal polyposis, but surprisingly, there is no high-level evidence for the efficacy of oral corticosteroids. Objective: The aim of this study was to establish the efficacy of a short course of oral prednisolone in ameliorating the symptoms of sinonasal polyposis, as well as reducing mucosal inflammation assessed by means of nasendoscopy and magnetic resonance imaging (MRI). A secondary aim was to evaluate the relationship between outcome measures. Methods: Subjects with symptomatic endoscopically diagnosed sinonasal polyposis received 50 mg of prednisolone daily for 14 days or placebo. Outcome was quantified by using the modified 31-item Rhinosinusitis Outcome Measure questionnaire, physician's assessment, nasendoscopy with photography, and MRI. Results: There were 20 subjects in each treatment group. Only the prednisolone-treated group showed significant improvement in nasal symptoms (P < .001). The Rhinosinusitis Outcome Measure score improved in both groups, but the prednisolone-treated group had significantly greater improvement than the placebo group (P < .001). Objectively, there was significant reduction in polyp size, as noted with nasendoscopy (P < .001) and MRI (P < .001), only in the prednisolone-treated group. The outcome measures correlated with each other; the highest level of correlation was between the objective measures of nasendoscopy and MRI (R-2 = 0.76, P < .001). There were no significant adverse events. Conclusion: This trial clearly establishes clinically significant improvement in the symptoms and pathology of sinonasal polyposis with a short course of systemic corticosteroids. MRI scanning and quantitative nasendoscopic photography are objective and valid tools for assessing the outcome of treatment in this condition. Clinical implications: A 14-day course of 50 mg of prednisolone is safe and effective therapy for symptomatic nasal polyposis.	Royal Adelaide Hosp, Dept Human Immunol, Inst Med & Vet Sci, Adelaide, SA 5000, Australia; Royal Adelaide Hosp, Dept Immunol & Allergy, Adelaide, SA 5000, Australia; Royal Adelaide Hosp, Dept Radiol, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Surg Otorhinolaryngol Head & Neck Surg, Adelaide, SA 5005, Australia; Flinders Univ S Australia, Dept Surg Otorhinolaryngol Head & Neck Surg, Adelaide, SA 5001, Australia	Institute Medical & Veterinary Science Australia; Royal Adelaide Hospital; Royal Adelaide Hospital; Royal Adelaide Hospital; University of Adelaide; Flinders University South Australia	Smith, W (corresponding author), Royal Adelaide Hosp, Dept Human Immunol, Inst Med & Vet Sci, Ward R8,N Terrace, Adelaide, SA 5000, Australia.	wsmith@mail.rah.sa.gov.au		Smith, William/0000-0002-4610-998X; Smith, William/0000-0001-9640-1172				Alobid I, 2005, ALLERGY, V60, P452, DOI 10.1111/j.1398-9995.2005.00725.x; Ashraf N, 2001, OTOLARYNG HEAD NECK, V125, P483, DOI 10.1016/S0194-5998(01)43777-6; Bachert C, 2005, DRUGS, V65, P1537, DOI 10.2165/00003495-200565110-00006; Bhattacharyya T, 1997, ARCH OTOLARYNGOL, V123, P1189; Blomqvist EH, 2001, J ALLERGY CLIN IMMUN, V107, P224, DOI 10.1067/mai.2001.112124; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; Gillespie MB, 2004, CURR ALLERGY ASTHM R, V4, P478, DOI 10.1007/s11882-004-0015-3; Jankowski R, 2001, ARCH OTOLARYNGOL, V127, P447, DOI 10.1001/archotol.127.4.447; Johansson L, 2000, ACTA OTO-LARYNGOL, V120, P72; Lildholdt T, 1989, Rhinol Suppl, V8, P31; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Nores JM, 2003, RHINOLOGY, V41, P97; Nores JM, 2002, B ACAD NAT MED PARIS, V186, P1643, DOI 10.1016/S0001-4079(19)34109-3; ODRISCOLL BR, 1993, LANCET, V341, P324, DOI 10.1016/0140-6736(93)90134-3; Penttila M, 2000, CLIN EXP ALLERGY, V30, P94; Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022; Piccirillo JF, 1995, AM J RHINOL, V9, P297, DOI 10.2500/105065895781808711; Slavin RG, 1997, JAMA-J AM MED ASSOC, V278, P1849, DOI 10.1001/jama.278.22.1849; Stewart MG, 1999, AM J RHINOL, V13, P161, DOI 10.2500/105065899781389704; Van Camp C., 1994, Rhinology (Utrecht), V32, P5; Vento SI, 2000, ANN ALLERG ASTHMA IM, V85, P209, DOI 10.1016/S1081-1206(10)62468-4; Wabnitz DAM, 2005, AM J RHINOL, V19, P91, DOI 10.1177/194589240501900116	23	162	169	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					128	133		10.1016/j.jaci.2006.03.012	http://dx.doi.org/10.1016/j.jaci.2006.03.012			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815148				2022-12-18	WOS:000239184800016
J	Shore, SA; Fredberg, JJ				Shore, SA; Fredberg, JJ			Obesity, smooth muscle, and airway hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						leptin; adiponectin; plasminogen activator inhibitor; inflammation; TNF	BODY-MASS INDEX; ASTHMA SYMPTOMS; DISEASE; INFLAMMATION; ASSOCIATION; RESPONSES; LEPTIN; ADULTS; ONSET; WOMEN	Both asthma and obesity are large and growing public health issues. Mounting evidence now implicates obesity as a major risk factor for asthma, thus linking these 2 major epidemics. Moreover, both in human subjects and in mice, obesity appears to predispose toward airway hyperresponsiveness. This review describes potential mechanisms whereby obesity might modify airway smooth muscle function to explain these observations. These mechanisms include both static and dynamic mechanical factors attributable to decreases in functional residual capacity and decreases in tidal volume that are observed in the obese. They include also obesity-related changes in lung development, chronic systemic inflammation (including increased serum levels of inflammatory cytokines and chemokines), and adipocyte-derived factors, including leptin, adiponectin, and plasminogen activator inhibitor.	Harvard Univ, Sch Publ Hlth, Physiol Program, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Fredberg, JJ (corresponding author), Harvard Univ, Sch Publ Hlth, Physiol Program, 665 Huntington Ave, Boston, MA 02115 USA.	jfredber@hsph.harvard.edu	Fredberg, Jeffrey/M-9877-2019; fredberg, jeffrey j/A-7083-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059682, P01HL033009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33009, HL59682] Funding Source: Medline; NIEHS NIH HHS [ES00002] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835, DOI 10.1164/ajrccm.164.10.2105033; Chen H, 2003, J APPL PHYSIOL, V95, P864, DOI 10.1152/japplphysiol.00140.2003; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; DING DJ, 1987, J APPL PHYSIOL, V62, P1324, DOI 10.1152/jappl.1987.62.3.1324; Fredberg JJ, 2000, J ALLERGY CLIN IMMUN, V106, P615, DOI 10.1067/mai.2000.109429; Guerra S, 2004, AM J RESP CRIT CARE, V170, P78, DOI 10.1164/rccm.200309-1224OC; Guler N, 2004, J ALLERGY CLIN IMMUN, V114, P254, DOI 10.1016/j.jaci.2004.03.053; Gump A, 2001, J APPL PHYSIOL, V90, P2306, DOI 10.1152/jappl.2001.90.6.2306; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; Huang L, 2000, Cell Res, V10, P81, DOI 10.1038/sj.cr.7290038; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; Nawrocki AR, 2004, CURR OPIN PHARMACOL, V4, P281, DOI 10.1016/j.coph.2004.03.003; Oh CK, 2002, BIOCHEM BIOPH RES CO, V294, P1155, DOI 10.1016/S0006-291X(02)00577-6; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; SAMPSON MG, 1983, J APPL PHYSIOL, V55, P1269, DOI 10.1152/jappl.1983.55.4.1269; Savov JD, 2003, AM J PHYSIOL-LUNG C, V285, pL940, DOI 10.1152/ajplung.00102.2003; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Thomson CC, 2003, CHEST, V124, P795, DOI 10.1378/chest.124.3.795; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS; YAP JCH, 1995, J APPL PHYSIOL, V79, P1199, DOI 10.1152/jappl.1995.79.4.1199	25	162	172	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					925	927		10.1016/j.jaci.2005.01.064	http://dx.doi.org/10.1016/j.jaci.2005.01.064			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867846				2022-12-18	WOS:000229055100004
J	Johnson, PRA; Burgess, JK; Underwood, PA; Au, W; Poniris, MH; Tamm, M; Ge, Q; Black, JL				Johnson, PRA; Burgess, JK; Underwood, PA; Au, W; Poniris, MH; Tamm, M; Ge, Q; Black, JL			Extracellular matrix proteins modulate asthmatic airway smooth muscle cell proliferation via an autocrine mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						remodeling; airway smooth muscle proliferation; extracellular matrix; asthma	INHIBITION; ADHESION; HEPARIN; DISEASE	Background: Airway remodeling is a key feature of persistent asthma and includes alterations in the extracellular matrix protein profile around the airway smooth muscle (ASM) and hyperplasia of the ASM. We have previously shown that nonasthmatic ASM cells in culture produce a range of extracellular matrix protein proteins and that asthmatic ASM cells proliferate faster than cells from nonasthmatic patients. Objective: In this study, we compared the profile of extracellular matrix proteins produced by nonasthmatic and asthmatic ASM cells. We also examined the influence of these extracellular matrix protein proteins and conditioned medium derived from nonasthmatic or asthmatic ASM cells on the proliferation of nonasthmatic and asthmatic ASM cells. Methods: Extracellular matrix proteins were measured by ELISA; proliferation of ASM cells was measured by tritiated thymidine incorporation. Results: Production of perlecan and collagen I by the cells from asthmatic patients were significantly increased. In contrast, laminin alpha1 and collagen IV were decreased. Chondroitin sulfate was detectable only in the cells from nonasthmatic patients. Compared with nonasthmatic extracellular matrix proteins, proteins from asthmatic cells enhanced ASM cell proliferation. Conditioned medium from asthmatic ASM cells did not induce greater proliferation compared with conditioned medium from nonasthmatic cells. Conclusions: The data show that the profile of extracellular matrix protein components is altered in asthmatic cells and that this altered profile and not soluble mediators secreted from the ASM cells has the potential to influence the proliferation of these cells. These changes are likely to contribute to the airway wall remodeling that occurs in asthma.	Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; CSIRO, Sydney, NSW 2070, Australia; Royal Prince Alfred Hosp, Woolcock Inst Med Res, Sydney, NSW, Australia; Univ Basel, Dept Internal Med, Basel, Switzerland	University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney; Woolcock Institute of Medical Research; University of Basel	Johnson, PRA (corresponding author), Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia.		Burgess, Janette K/A-3597-2010; Burgess, Janette/M-7117-2019; Ge, Qi/D-3988-2013; Black, Judith L/C-6559-2008; Roth, Michael/H-8657-2019	Roth, Michael/0000-0002-8139-2821; Burgess, Janette/0000-0001-9868-9966				Ammit AJ, 2001, J APPL PHYSIOL, V91, P1431, DOI 10.1152/jappl.2001.91.3.1431; Bai TR, 2000, AM J RESP CRIT CARE, V162, P663, DOI 10.1164/ajrccm.162.2.9907151; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; Garg HG, 1999, ARCH BIOCHEM BIOPHYS, V371, P228, DOI 10.1006/abbi.1999.1456; Halayko AJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1040, DOI 10.1152/ajplung.1996.270.6.L1040; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JOHNSON P, 2000, AM J RESP CRIT CARE, V161, pA442; Johnson PRA, 2000, AM J RESP CRIT CARE, V162, P2145, DOI 10.1164/ajrccm.162.6.9909111; JOHNSON PRA, 1995, AM J PHYSIOL-LUNG C, V269, pL514, DOI 10.1152/ajplung.1995.269.4.L514; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V98, pS3, DOI 10.1016/S0091-6749(96)80122-9; MACKLEM PT, 1995, CHEST, V107, pS87, DOI 10.1378/chest.107.3_Supplement.87S; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; Pare P D, 1997, Monaldi Arch Chest Dis, V52, P589; Roberts C R, 1998, Can Respir J, V5, P48; ROBERTS CR, 1995, CHEST, V107, pS111, DOI 10.1378/chest.107.3_Supplement.111S; ROCHE WR, 1989, LANCET, V1, P520; Shichiri M, 2003, REGUL PEPTIDES, V112, P167, DOI 10.1016/S0167-0115(03)00036-3; Thomson R J, 1998, Can Respir J, V5, P61; Underwood PA, 1998, ATHEROSCLEROSIS, V141, P141, DOI 10.1016/S0021-9150(98)00164-6; UNDERWOOD PA, 1992, J CELL SCI, V102, P833; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WILSON JW, 1993, AM REV RESPIR DIS, V148, P806, DOI 10.1164/ajrccm/148.3.806	27	162	171	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					690	696		10.1016/j.jaci.2003.12.312	http://dx.doi.org/10.1016/j.jaci.2003.12.312			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100675	Bronze			2022-12-18	WOS:000220956600017
J	Umetsu, DT; Akbari, O; DeKruyff, RH				Umetsu, DT; Akbari, O; DeKruyff, RH			Regulatory T cells control the development of allergic disease and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T regulatory cells; T(H)2; asthma; allergy	INDUCED AIRWAY HYPERREACTIVITY; IMMUNOLOGICAL SELF-TOLERANCE; TOLEROGENIC DENDRITIC CELLS; IMMUNOGLOBULIN-E PRODUCTION; IMMUNE-RESPONSE; ORAL TOLERANCE; IN-VIVO; HAY-FEVER; AUTOIMMUNE ENCEPHALOMYELITIS; INHALED ANTIGEN	The role of T(H)2 cells in the pathogenesis of allergy and asthma has been well described. However, the immunologic mechanisms that downmodulate and protect against the development of these disorders are poorly characterized. A spectrum of CD4(+) T cells, including T(H)1 cells, T(H)3 cells, regulatory T cells, CD25(+) T cells, and natural killer T cells might play a critical role in regulating these diseases and are discussed in this review.	Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA	Stanford University	Umetsu, DT (corresponding author), Stanford Univ, Dept Pediat, Div Immunol & Allergy, Rm G309, Stanford, CA 94305 USA.				NHLBI NIH HHS [R01 HL 69507, R01 HL 62348] Funding Source: Medline; NIAID NIH HHS [R01 AI 26322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062348, R01HL069507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; BUSSE WW, 1995, AM J RESP CRIT CARE, V152, P388, DOI 10.1164/ajrccm.152.1.7599853; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Feigelstock D, 1998, J VIROL, V72, P6621, DOI 10.1128/JVI.72.8.6621-6628.1998; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hadeiba H, 2003, J IMMUNOL, V170, P5502, DOI 10.4049/jimmunol.170.11.5502; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; HANSEN G, 2000, J CLIN INVEST, V11, P89; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Hoyne GF, 1996, INT IMMUNOL, V8, P335, DOI 10.1093/intimm/8.3.335; Hoyne GF, 2000, AM J RESP CRIT CARE, V162, pS169, DOI 10.1164/ajrccm.162.supplement_3.15tac6; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kim TS, 1997, J IMMUNOL, V158, P4137; Lahn M, 1999, NAT MED, V5, P1150, DOI 10.1038/13476; Maecker HT, 2001, J IMMUNOL, V166, P959, DOI 10.4049/jimmunol.166.2.959; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; McHugh RS, 2002, J IMMUNOL, V168, P5979, DOI 10.4049/jimmunol.168.12.5979; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; Miyamoto K, 2001, NATURE, V413, P531, DOI 10.1038/35097097; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nakao A, 2000, J EXP MED, V192, P151, DOI 10.1084/jem.192.2.151; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; POWRIE F, 1994, J EXP MED, V179, P589, DOI 10.1084/jem.179.2.589; Randolph DA, 1999, J IMMUNOL, V162, P2375; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Schwarze J, 1999, J IMMUNOL, V162, P4207; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Sudo N, 1997, J IMMUNOL, V159, P1739; Suto A, 2001, AM J RESP CRIT CARE, V164, P680, DOI 10.1164/ajrccm.164.4.2010170; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Tsitoura DC, 2000, J ALLERGY CLIN IMMUN, V106, P239; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; UMETSU DT, 1988, J IMMUNOL, V140, P4211; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Walter DM, 2001, J IMMUNOL, V166, P6392, DOI 10.4049/jimmunol.166.10.6392; WANNEMUEHLER MJ, 1982, J IMMUNOL, V129, P959; Weiner HL, 1997, ANNU REV MED, V48, P341; Weiner HL, 2001, NAT IMMUNOL, V2, P671, DOI 10.1038/90604; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; Yeung VP, 1998, J IMMUNOL, V161, P4146; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	83	162	187	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					480	487		10.1067/mai.2003.1717	http://dx.doi.org/10.1067/mai.2003.1717			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679803				2022-12-18	WOS:000185231200003
J	Li, XM; Srivastava, K; Grishin, A; Huang, CK; Schofield, B; Burks, W; Sampson, HA				Li, XM; Srivastava, K; Grishin, A; Huang, CK; Schofield, B; Burks, W; Sampson, HA			Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; murine model; novel immunotherapy; persistent effect	GROWTH-FACTOR-BETA; COWS MILK ALLERGY; ANAPHYLACTIC REACTIONS; LISTERIA-MONOCYTOGENES; INTERFERON-GAMMA; IMMUNE-RESPONSES; CELL RESPONSES; FOOD ALLERGY; IGE BINDING; IFN-GAMMA	Background: Peanut allergy (PNA) is a life-threatening food allergy for which there is no definitive treatment. Objective: We investigated the long-term immunomodulatory effect of heat-killed Escherichia coli producing engineered (mutated) Ara h1, 2, and 3 (HKE-MP123) administered rectally (pr) in a murine model of PNA. Methods: Peanut-allergic C3H/HeJ mice received 0.9 (low dose), 9 (medium dose), or 90 (high dose) mug HKE-MP123 pr, HKE-containing vector (HKE-V) alone, or vehicle alone (sham) weekly for 3 weeks. Mice were challenged 2 weeks later. A second and third challenge were performed at 4-week intervals. Results: After the first challenge, all 3 HKE-MP123 and HKE-V-treated groups exhibited reduced symptom scores (P < .01, .01, .05,.05, respectively) compared with the sham-treated group. Interestingly, only the medium- and high-dose HKE-MP123-treated mice remained protected for up to 10 weeks after treatment accompanied by a significant reduction of plasma histamine levels compared with sham-treated mice (P < .05 and .01, respectively). IgE levels were significantly lower in all HKE-MP123-treated groups (P < .001), being most reduced in the high-dose HKE-MP123-treated group at the time of each challenge. IL-4, IL-13, IL-5, and IL-10 production by splenocytes of high-dose HKE-MP123-treated mice were significantly decreased (P < .01; .001, .001, and .001, respectively), and IFN-gamma and TGF-beta production were significantly increased (P < .001 and .01, respectively) compared with sham-treated mice at the time of the last challenge. Conclusions: Treatment with pr HKE-MP123 can induce long-term "downregulation" of peanut hypersensitivity, which might be secondary to decreased antigen-specific T(H)2 and increased T(H)1 and T regulatory cytokine production.	CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Univ Arkansas, Arkansas Childrens Hosp, Res Inst, Dept Pediat, Little Rock, AR 72204 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	Sampson, HA (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NIAID NIH HHS [AI43668, AI01666] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001666, R01AI043668] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barnes PJ, 2001, CLIN EXP ALLERGY, V31, P667, DOI 10.1046/j.1365-2222.2001.01118.x; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; BECK L, 1989, CELL IMMUNOL, V123, P1, DOI 10.1016/0008-8749(89)90263-3; BISSONNETTE EY, 1990, J IMMUNOL, V145, P3385; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Burks AW, 1999, INT ARCH ALLERGY IMM, V118, P313, DOI 10.1159/000024114; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743, DOI 10.1046/j.1365-2222.1998.00301.x; Donnet-Hughes A, 2000, IMMUNOL CELL BIOL, V78, P74, DOI 10.1046/j.1440-1711.2000.00882.x; DORION BJ, 1994, J ALLERGY CLIN IMMUN, V93, P93, DOI 10.1016/0091-6749(94)90237-2; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; HOWARD M, 1983, ANNU REV IMMUNOL, V1, P307, DOI 10.1146/annurev.iy.01.040183.001515; Husby S, 2001, CURR OPIN ALLERGY CL, V1, P237, DOI 10.1097/01.all.0000011020.20431.84; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; Kowalski ML, 1998, ALLERGY, V53, P485, DOI 10.1111/j.1398-9995.1998.tb04085.x; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2002, CURR OPIN ALLERGY CL, V2, P273, DOI 10.1097/00130832-200206000-00019; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 1999, J IMMUNOL, V162, P3045; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Lorentz A, 1999, EUR J IMMUNOL, V29, P1496, DOI 10.1002/(SICI)1521-4141(199905)29:05<1496::AID-IMMU1496>3.0.CO;2-5; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P1093, DOI 10.1016/S0091-6749(99)70094-1; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Strobel S, 2002, ANN NY ACAD SCI, V958, P47; Yeung VP, 1998, J IMMUNOL, V161, P4146; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	40	162	169	1	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					159	167		10.1067/mai.2003.1622	http://dx.doi.org/10.1067/mai.2003.1622			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847493				2022-12-18	WOS:000184010600024
J	Rothenberg, MA; Mishra, A; Collins, MH; Putnam, PE				Rothenberg, MA; Mishra, A; Collins, MH; Putnam, PE			Pathogenesis and clinical features of eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						allergy; eosinophils; eotaxin; esophagitis; gastroesophageal reflux; IL-5	GASTROESOPHAGEAL REFLUX; CHILDREN; CORTICOSTEROIDS; CHEMOKINES; ALLERGY; DISEASE; ASTHMA; ACID		Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Dept Pediat, Div Pathol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Dept Pediat, Div Gastroenterol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Rothenberg, MA (corresponding author), Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, Cincinnati, OH 45229 USA.		MISHRA, ANIL/S-7983-2017	MISHRA, ANIL/0000-0003-4266-4684	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042242, R01AI045898] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI45898-02, R01 AI42242-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATES B, 2000, PEDIAT NEWS, V34, P4; BROWN LF, 1984, AM J SURG PATHOL, V8, P899, DOI 10.1097/00000478-198412000-00002; Faubion WA, 1998, J PEDIATR GASTR NUTR, V27, P90, DOI 10.1097/00005176-199807000-00016; Furuta GT, 1998, J PEDIATR GASTR NUTR, V26, P468, DOI 10.1097/00005176-199804000-00021; FURUTA GT, 1995, CURR OPIN GASTROEN, V11, P541, DOI 10.1097/00001574-199511000-00013; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Kelly KJ, 2000, J PEDIATR GASTR NUTR, V30, pS28, DOI 10.1097/00005176-200001001-00005; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Liacouras CA, 1998, J PEDIATR GASTR NUTR, V26, P380, DOI 10.1097/00005176-199804000-00004; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Nicholson AG, 1997, J PATHOL, V183, P233, DOI 10.1002/(SICI)1096-9896(199710)183:2<233::AID-PATH936>3.0.CO;2-Z; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Rothenberg ME, 2001, IMMUNOL REV, V179, P139, DOI 10.1034/j.1600-065X.2001.790114.x; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Rothenberg ME, 2001, ADV IMMUNOL, V78, P291, DOI 10.1016/S0065-2776(01)78007-8; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003; WINTER HS, 1982, GASTROENTEROLOGY, V83, P818	24	162	178	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					891	894		10.1067/mai.2001.120095	http://dx.doi.org/10.1067/mai.2001.120095			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742263				2022-12-18	WOS:000172938400002
J	Barnes, PJ				Barnes, PJ			Efficacy of inhaled corticosteroids in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; corticosteroids; airway hyperresponsiveness; inflammation	LONG-TERM TREATMENT; FLUTICASONE PROPIONATE; AIRWAY RESPONSIVENESS; RESISTANT ASTHMA; CLINICAL ASTHMA; BUDESONIDE; GLUCOCORTICOIDS; MANAGEMENT; MODERATE; SYMPTOMS	Inhaled corticosteroids have now become established as first-line therapy for patients with persistent asthma, Corticosteroids are the only currently available asthma therapy that suppress inflammation in asthmatic airways, and they inhibit almost every aspect of the inflammatory process in asthma, Inhaled corticosteroids are effective in most patients with asthma, irrespective of age or asthma severity. They not only control asthma symptoms and improve lung function but also prevent exacerbations and may reduce asthma mortality and the irreversible changes in airway function that occur in some patients. The dose-response curve to inhaled corticosteroids Is relatively flat, and there is increasing evidence that addition of another class of therapy (long-acting inhaled beta(2)-agonists, low-dose theophylline, or antileukotrienes) may be preferable to increasing the dose of inhaled corticosteroids in patients with moderate-to-severe asthma, Inhaled corticosteroids are convenient to use and are the most cost-effective treatment currently available for long-term asthma control, A small proportion of patients are resistant to the antiinflammatory effects of corticosteroids. Future developments may include inhaled corticosteroids with even fewer systemic effects or more specific antiinflammatory drugs.	Univ London Imperial Coll Sci Technol & Med, Dept Thorac Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Thorac Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.			Barnes, Peter/0000-0002-5122-4018				ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; ADCOCK IM, 1998, IN PRESS BR J PHARM; Agertoft L, 1994, RESPIR MED, V5, P369; Barnes PJ, 1996, CLIN EXP ALLERGY, V26, P738; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Barnes PJ, 1996, THORAX, V51, P218, DOI 10.1136/thx.51.2.218; Barnes PJ, 1996, RESP MED, V90, P379, DOI 10.1016/S0954-6111(96)90108-0; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, pS125, DOI 10.1164/ajrccm/152.6_Pt_2.S125; BARNES PJ, 1990, AM REV RESPIR DIS S, V141, P70; DOMPELING E, 1992, EUR RESPIR J, V5, P945; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HILL JM, 1995, THORAX, V50, P577, DOI 10.1136/thx.50.5.577; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356, DOI 10.1136/adc.68.3.356; JONES AH, 1994, RESP MED, V88, P293, DOI 10.1016/0954-6111(94)90059-0; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Levy ML, 1996, THORAX, V51, P1087, DOI 10.1136/thx.51.11.1087; MALO JL, 1989, AM REV RESPIR DIS, V140, P624, DOI 10.1164/ajrccm/140.3.624; *NAT HEART LUNG BL, 1995, PUBL NAT HEART LUNG; *NAT I HLTH, 1997, NIH PUBL; NELSON HS, 1993, AM REV RESPIR DIS, V147, P398, DOI 10.1164/ajrccm/147.2.398; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; OTULANA BA, 1992, RESP MED, V86, P105, DOI 10.1016/S0954-6111(06)80224-6; Pauwels RA, 1997, NEW ENGL J MED, V337, P1412; Schwiebert LM, 1996, AM J RESP CRIT CARE, V154, pS16, DOI 10.1164/ajrccm/154.2_Pt_2.S16; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Szefler SJ, 1997, EUR RESPIR J, V10, P1640, DOI 10.1183/09031936.97.10071640; UKENA D, 1997, EUR RESPIR J, V10, P2745; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VANSCHAYCK CP, 1995, CHEST, V107, P1199, DOI 10.1378/chest.107.5.1199; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Virchow J. C., 1997, European Respiratory Journal Supplement, V10, p420S; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; Woolcock AJ, 1996, AM J RESP CRIT CARE, V153, pS1, DOI 10.1164/ajrccm/153.6_Pt_2.S1; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	45	162	182	1	17	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				531	538		10.1016/S0091-6749(98)70268-4	http://dx.doi.org/10.1016/S0091-6749(98)70268-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802359				2022-12-18	WOS:000076600400001
J	CASTELLS, M; SCHWARTZ, LB				CASTELLS, M; SCHWARTZ, LB			TRYPTASE LEVELS IN NASAL-LAVAGE FLUID AS AN INDICATOR OF THE IMMEDIATE ALLERGIC RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,MCV STN,BOX 263,RICHMOND,VA 23298	Virginia Commonwealth University					NIAID NIH HHS [AI20487] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020487, R01AI020487, R21AI020487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CRAIG SA, 1986, AM J PATHOL, V124, P4270; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CRETICOS PS, 1985, J CLIN INVEST, V76, P2267; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; HOLGATE ST, 1984, J IMMUNOL, V133, P2138; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AA, 1986, CLIN RES, V34, pA277; LEWIS RA, 1979, J IMMUNOL, V123, P1663; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MACDERMOT J, 1984, PROSTAGLANDINS, V27, P163, DOI 10.1016/0090-6980(84)90071-6; MARQUARDT DL, 1984, P NATL ACAD SCI-BIOL, V81, P6192, DOI 10.1073/pnas.81.19.6192; MCGLASHAN DW, 1980, J IMMUNOL, V124, P2519; NACLERIO RM, 1985, CLIN RES, V33, pA613; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NEWBALL HH, 1979, J CLIN INVEST, V64, P466, DOI 10.1172/JCI109484; NORMAN PS, 1985, J ALLERGY CLIN IMMUN, V75, P531, DOI 10.1016/0091-6749(85)90024-7; OELZ O, 1977, PROSTAGLANDIN, V13, P255; OHTSUKA H, 1981, ARCH OTO-RHINO-LARYN, V233, P227, DOI 10.1007/BF00454387; OKUDA M, 1978, ARCH OHREN NASEN KEH, V221, P215, DOI 10.1007/BF01886298; OKUDA M, 1985, ANN ALLERGY, V54, P152; RAULS DO, 1986, J ALLERGY CLIN IMMUN, V77, P673, DOI 10.1016/0091-6749(86)90407-0; ROTHENBERG ME, 1987, J IMMUNOL, V138, P2616; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1985, J IMMUNOL, V134, P526; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1981; WARREN DJ, 1982, J ALLERGY CLIN IMMUN, V70, P82; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; WOLFE D, 1973, NONPARAMETRIC STATIS; ZEIGER RS, 1977, J IMMUNOL, V118, P540	37	162	171	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				348	355		10.1016/0091-6749(88)90005-X	http://dx.doi.org/10.1016/0091-6749(88)90005-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3049743				2022-12-18	WOS:A1988Q322900005
J	HARGREAVE, FE; DOLOVICH, J; OBYRNE, PM; RAMSDALE, EH; DANIEL, EE				HARGREAVE, FE; DOLOVICH, J; OBYRNE, PM; RAMSDALE, EH; DANIEL, EE			THE ORIGIN OF AIRWAY HYPERRESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT PAEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT NEUROSCI,HAMILTON L8S 4L8,ONTARIO,CANADA; ST JOSEPH HOSP & HLTH SCI CTR,DEPT MED,HAMILTON,ONTARIO,CANADA; ST JOSEPH HOSP & HLTH SCI CTR,DEPT PAEDIAT,HAMILTON,ONTARIO,CANADA	McMaster University; McMaster University; McMaster University; McMaster University				O'Byrne, Paul/0000-0003-0979-281X				ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P839; AGRAWAL R, 1986, AM J PHYSIOL, V250, pC495, DOI 10.1152/ajpcell.1986.250.3.C495; BARNES PJ, 1986, LANCET, V1, P242; BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BLACK JL, 1985, THORAX, V40, P427, DOI 10.1136/thx.40.6.427; BLYTHE S, 1984, American Review of Respiratory Disease, V129, pA4; BOSCHETTO P, 1986, J ALLERGY CLIN IMMUN, V77, P244; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOULET LP, 1984, AM REV RESPIR DIS, V130, P368; BYLIN G, 1985, EUR J RESPIR DIS, V66, P205; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CASTERLINE CL, 1976, J ALLERGY CLIN IMMUN, V58, P608; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1985, J ALLERGY CLIN IMMUN, V75, P142, DOI 10.1016/0091-6749(85)90286-6; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; CUSS FM, 1986, AM REV RESPIR DIS, V133, pA212; DANIEL EE, 1980, AIRWAY REACTIVITY, P80; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENJEAN A, 1985, CHEST, V87, pS201, DOI 10.1378/chest.87.5_Supplement.201S; ELWOOD RK, 1983, AM REV RESPIR DIS, V128, P523, DOI 10.1164/arrd.1983.128.3.523; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FAIRFAX AJ, 1983, CLIN EXP IMMUNOL, V52, P393; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HARGREAVE FE, 1984, AM REV RESPIR DIS, V130, P513; HARIPARSAD D, 1984, CLIN ALLERGY, V14, P81, DOI 10.1111/j.1365-2222.1984.tb02194.x; HOGG JC, 1981, J ALLERGY CLIN IMMUN, V67, P421, DOI 10.1016/0091-6749(81)90094-4; HOLGATE ST, 1984, ASTHMA PHYSL IMMUNOP, P391; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KAY AB, 1984, ASTHMA PHYSL IMMUNOP, P211; KENNEDY SM, 1984, AM REV RESPIR DIS, V129, P143; KONIG P, 1974, J ALLERGY CLIN IMMUN, V54, P280, DOI 10.1016/0091-6749(74)90014-1; LARSEN GL, 1984, ASTHMA PHYSL IMMUNOP, P245; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARTIN JG, 1986, AM REV RESPIR DIS, V133, pA15; MORLEY J, 1985, INT ARCH ALLER A IMM, V77, P73, DOI 10.1159/000233756; NADEL J A, 1973, P29; OBYRNE PM, 1983, AM REV RESPIR DIS, V128, P611; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P220; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; OUELLETTE JJ, 1965, J ALLERGY, V36, P558, DOI 10.1016/0021-8707(65)90193-0; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; RAMSDALE EH, 1985, THORAX, V40, P422, DOI 10.1136/thx.40.6.422; RAMSDELL JW, 1982, AM REV RESPIR DIS, V125, P289; ROBERTS JA, 1985, THORAX, V40, P261, DOI 10.1136/thx.40.4.261; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SCHELLENBERG RR, 1985, CLIN INVEST MED, V8, pA202; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SHEPHARD EG, 1985, BRIT J CLIN PHARMACO, V19, P459, DOI 10.1111/j.1365-2125.1985.tb02671.x; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; STERK PJ, 1985, AM REV RESPIR DIS, V132, P865; STERK PJ, 1985, AM REV RESPIR DIS, V132, P272; SUZUKI S, 1985, ANN ALLERGY, V54, P136; TAYLOR SM, 1985, AM REV RESPIR DIS, V132, P30; THOMPSON P J, 1984, American Review of Respiratory Disease, V129, pA3; THOMSON NC, 1981, J ALLERGY CLIN IMMUN, V68, P392, DOI 10.1016/0091-6749(81)90138-X; THOMSON NC, 1983, EUR J RESPIR DIS, V64, P206; THOMSON NC, 1982, AM REV RESPIR DIS, V126, P521; TINKELMAN DG, 1976, AM REV RESPIR DIS, V114, P87; TURNER KJ, 1986, J ALLERGY CLIN IMMUN, V77, P558, DOI 10.1016/0091-6749(86)90345-3; VINCENC KS, 1983, AM REV RESPIR DIS, V128, P875; WILSON N, 1984, BR MED J, V284, P1226; WILSON NM, 1985, EUR J RESPIR DIS, V66, P25; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71	69	162	164	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				825	832		10.1016/0091-6749(86)90226-5	http://dx.doi.org/10.1016/0091-6749(86)90226-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	3537079				2022-12-18	WOS:A1986E971300001
J	RAMSDALE, EH; MORRIS, MM; ROBERTS, RS; HARGREAVE, FE				RAMSDALE, EH; MORRIS, MM; ROBERTS, RS; HARGREAVE, FE			ASYMPTOMATIC BRONCHIAL HYPERRESPONSIVENESS IN RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,FIRESTONE REG CHEST & ALLERGY UNIT,50 CHARLTON AVE E,HAMILTON L8N 4A6,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McMaster University								AQUILINA AT, 1983, THORAX, V38, P766, DOI 10.1136/thx.38.10.766; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; FERRIS BG, 1978, AM REV RESPIR DIS S, V118, P10; FERRUS L, 1980, RESP PHYSIOL, V39, P367, DOI 10.1016/0034-5687(80)90067-5; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SCADDING GA, 1976, BRONCHIAL ASTHMA MEC, P19; STRAUSS RH, 1978, J CLIN INVEST, V61, P133; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; WEISS JW, 1983, J ALLERGY CLIN IMMUN, V72, P140, DOI 10.1016/0091-6749(83)90521-3; WEST RC, 1977, HDB CHEM PHYSICS, pE35	23	162	165	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					573	577						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	4039344				2022-12-18	WOS:A1985AHV0700006
J	DIAZ, P; GALLEGUILLOS, FR; GONZALEZ, MC; PANTIN, CFA; KAY, AB				DIAZ, P; GALLEGUILLOS, FR; GONZALEZ, MC; PANTIN, CFA; KAY, AB			BRONCHOALVEOLAR LAVAGE IN ASTHMA - THE EFFECT OF DISODIUM-CROMOGLYCATE (CROMOLYN) ON LEUKOCYTE COUNTS, IMMUNOGLOBULINS, AND COMPLEMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,INST CARDIOTHORAC,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6HP,ENGLAND; BROMPTON HOSP,DEPT MED,LONDON SW3 6HP,ENGLAND; UNIV CHILE,CLIN ENFERMEDADES RESP MIGUEL DE SERVET,SANTIAGO,CHILE; UNIV CHILE,DEPT MED EXPTL,DIV SUR,SANTIAGO,CHILE	Royal Brompton Hospital; Royal Brompton Hospital; Universidad de Chile; Universidad de Chile								BRYANT DH, 1977, CLIN ALLERGY, V7, P211, DOI 10.1111/j.1365-2222.1977.tb01445.x; CHURCH MK, 1982, CLIN ALLERGY, V12, P223, DOI 10.1111/j.1365-2222.1982.tb02522.x; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; Dunnill M S, 1971, Ciba Found Study Group, V38, P35; Engwall E, 1972, J IMMUNOL, V109, P129; FILLEY WV, 1982, LANCET, V2, P11; GODARD P, 1981, NOUV PRESSE MED, V10, P3141; HARRIES MG, 1981, LANCET, V1, P5; HELM WH, 1972, ANN ALLERGY, V30, P518; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P163; KAY AB, 1971, J IMMUNOL, V107, P899; KAY AB, 1970, CLIN EXP IMMUNOL, V6, P75; NAKHOSTEEN JA, 1978, RESPIRATION, V36, P112, DOI 10.1159/000193934; PAPAGEORGIOU N, 1983, LANCET, V2, P1220; SHEARD P, 1970, INT ARCH ALLER A IMM, V38, P217, DOI 10.1159/000230274; SPENCER K, 1977, ANN CLIN BIOCHEM, V14, P105, DOI 10.1177/000456327701400119; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P3418; 1976, WHO CHRON, V30, P360	18	162	169	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					41	48		10.1016/0091-6749(84)90085-X	http://dx.doi.org/10.1016/0091-6749(84)90085-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6429229	Bronze			2022-12-18	WOS:A1984SZ64800006
J	KALINER, M; SHELHAMER, JH; OTTESEN, EA				KALINER, M; SHELHAMER, JH; OTTESEN, EA			EFFECTS OF INFUSED HISTAMINE - CORRELATION OF PLASMA HISTAMINE LEVELS AND SYMPTOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIA,CLIN INVEST LAB,BETHESDA,MD 20205; NIA,PARASIT DIS LAB,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								ADAM HM, 1950, Q J EXP PHYSIOL CMS, V35, P281, DOI 10.1113/expphysiol.1950.sp000954; ALBINUS M, 1974, AGENTS ACTIONS, V4, P222, DOI 10.1007/BF01965223; ANSELL G, 1970, INVEST RADIOL, V5, P374, DOI 10.1097/00004424-197011000-00002; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; CARROLL PR, 1974, AUST J EXP BIOL MED, V52, P577, DOI 10.1038/icb.1974.55; GANELLIN CR, 1977, AGENTS ACTIONS, V7, P93, DOI 10.1007/BF01964887; GILMAN AG, 1980, PHARM BASIS THERAPEU, P623; GOETZL EJ, 1980, NEW ENGL J MED, V303, P822, DOI 10.1056/NEJM198010023031421; HIRSCHOWITZ BI, 1979, ANNU REV PHARMACOL, V19, P203, DOI 10.1146/annurev.pa.19.040179.001223; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; KALINER MA, 1980, J ALLERGY CLIN IMMUN, V66, P1, DOI 10.1016/0091-6749(80)90131-1; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; LORENZ W, 1980, AGENTS ACTIONS, V10, P114, DOI 10.1007/BF02024192; MITCHELL RG, 1956, BRIT J PHARM CHEMOTH, V11, P462, DOI 10.1111/j.1476-5381.1956.tb00018.x; MYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305, DOI 10.1016/0091-6749(81)90026-9; Orange RP, 1978, ALLERGY PRINCIPLES P, P563; PLOYSONGSANG Y, 1978, J APPL PHYSIOL, V44, P690, DOI 10.1152/jappl.1978.44.5.690; ROBERTS LJ, 1979, NEW ENGL J MED, V300, P236, DOI 10.1056/NEJM197902013000506; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; Weiss S, 1932, ARCH INTERN MED, V49, P360, DOI 10.1001/archinte.1932.00150100017002; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; WYLLIE JH, 1972, LANCET, V2, P1117	29	162	163	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	3					283	289		10.1016/S0091-6749(82)80005-5	http://dx.doi.org/10.1016/S0091-6749(82)80005-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NF697	6120967				2022-12-18	WOS:A1982NF69700005
J	Johnston, A; Xing, XY; Wolterink, L; Barnes, DH; Yin, ZQ; Reingold, L; Kahlenberg, JM; Harms, PW; Gudjonsson, JE				Johnston, Andrew; Xing, Xianying; Wolterink, Liza; Barnes, Drew H.; Yin, ZhiQiang; Reingold, Laura; Kahlenberg, J. Michelle; Harms, Paul W.; Gudjonsson, Johann E.			IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Generalized pustular psoriasis; inflammation; interleukin; psoriasis	INTERLEUKIN-36-RECEPTOR ANTAGONIST DEFICIENCY; RECEPTOR ANTAGONIST; NEUTROPHIL ELASTASE; IL36RN MUTATIONS; EXPRESSION; ACTIVATION; ANAKINRA; AGONIST; SKIN; INFLIXIMAB	Background: Generalized pustular psoriasis (GPP) is a rare, debilitating, and often life-threatening inflammatory disease characterized by episodic infiltration of neutrophils into the skin, pustule development, and systemic inflammation, which can manifest in the presence or absence of chronic plaque psoriasis (PV). Current treatments are unsatisfactory and warrant a better understanding of GPP pathogenesis. Objective: We sought to understand better the disease mechanism of GPP to allow improved targeted therapies. Methods: We performed a gene expression study on formalin-fixed paraffin-embedded GPP (n = 28) and PV (n = 12) lesional biopsies and healthy control (n = 20) skin. Differential gene expression was analyzed using gene ontology and enrichment analysis. Gene expression was validated with quantitative RT-PCR and immunohistochemistry, and a potential disease mechanism was investigated using primary human cell culture. Results: Compared with healthy skin, GPP lesions yielded 479 and PV 854 differentially expressed genes, respectively, with 184 upregulated in both diseases. We detected significant contributions of IL-17A, TNF, IL-1, IL-36, and interferons in both diseases; although GPP lesions furnished higher IL-1 and IL-36 and lower IL-17A and IFN-gamma mRNA expression than PV lesions did. We detected prominent IL-36 expression by keratinocytes proximal to neutrophilic pustules, and we show that both neutrophils and neutrophil proteases activate IL-36. Suggesting another mechanism regulating IL-36 activity, the protease inhibitors serpin A1 and A3, which inhibit elastase and cathepsin G, respectively, were upregulated in both diseases and inhibited activation of IL-36. Conclusions: Our data indicate sustained activation of IL-1 and IL-36 in GPP, inducing neutrophil chemokine expression, infiltration, and pustule formation, suggesting that the IL-1/IL-36 inflammatory axis is a potent driver of disease pathology in GPP.	[Johnston, Andrew; Xing, Xianying; Wolterink, Liza; Barnes, Drew H.; Yin, ZhiQiang; Reingold, Laura; Harms, Paul W.; Gudjonsson, Johann E.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Kahlenberg, J. Michelle] Univ Michigan, Dept Rheumatol, Ann Arbor, MI 48109 USA; [Harms, Paul W.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Yin, ZhiQiang] Nanjing Med Univ, Dept Dermatol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Nanjing Medical University	Johnston, A (corresponding author), Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA.	andjoh@med.umich.edu	Johnston, Andrew/I-7904-2014	Johnston, Andrew/0000-0002-1313-9402; Kahlenberg, J. Michelle/0000-0002-4006-8945; Harms, Paul/0000-0002-0802-2883	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [K01 AR064765]; National Psoriasis Foundation USA; Babcock Memorial Trust; NIH NIAMS [K08 AR063668, K08 AR060802, R01 AR069071]; A. Alfred Taubman Medical Research Institute; Doris Duke Charitable Foundation [2013106]; Jiangsu Government Scholarship for Overseas Studies; Novartis; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR064765, K08AR060802, K08AR063668, R01AR069071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [UM1DK100845] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Psoriasis Foundation USA; Babcock Memorial Trust; NIH NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); A. Alfred Taubman Medical Research Institute; Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Jiangsu Government Scholarship for Overseas Studies; Novartis(Novartis); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	A.J. is supported by National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) K01 AR064765, the National Psoriasis Foundation USA and the Babcock Memorial Trust. J.M.K. is supported by the NIH NIAMS K08 AR063668. J.E.G. is supported by NIH NIAMS K08 AR060802, R01 AR069071, The A. Alfred Taubman Medical Research Institute as the Kenneth and Frances Eisenberg Emerging Scholar, and a Doris Duke Charitable Foundation Grant (#2013106). Z.Q.Y. is supported by the Jiangsu Government Scholarship for Overseas Studies. This work was supported in part by a grant from Novartis to J.E.G. The funding institutions had no role in the study.	Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Blumberg H, 2007, J EXP MED, V204, P2603, DOI 10.1084/jem.20070157; Boehner A, 2016, JAMA DERMATOL, V152, P482, DOI 10.1001/jamadermatol.2015.4686; Carrier Y, 2011, J INVEST DERMATOL, V131, P2428, DOI 10.1038/jid.2011.234; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Clark R A, 2001, Curr Protoc Immunol, VChapter 7, DOI 10.1002/0471142735.im0723s19; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Debets R, 2001, J IMMUNOL, V167, P1440, DOI 10.4049/jimmunol.167.3.1440; Elewski BE, 2002, J AM ACAD DERMATOL, V47, P796, DOI 10.1067/mjd.2002.128382; Foster AM, 2014, J IMMUNOL, V192, P6053, DOI 10.4049/jimmunol.1301481; Gudjonsson JE, 2012, FITZPATRICKS DERMATO; Gunther S, 2014, J IMMUNOL, V193, P921, DOI 10.4049/jimmunol.1400538; Henry CM, 2016, CELL REP, V14, P708, DOI 10.1016/j.celrep.2015.12.072; Hodgin JB, 2010, AM J PATHOL, V177, P1674, DOI 10.2353/ajpath.2010.090746; Huffmeier U, 2014, BRIT J DERMATOL, V170, P202, DOI 10.1111/bjd.12548; Hussain S, 2015, J ALLERGY CLIN IMMUN, V135, P1067, DOI 10.1016/j.jaci.2014.09.043; Imafuku S, 2016, J DERMATOL, V43, P1011, DOI 10.1111/1346-8138.13306; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Johnston A, 2014, BRIT J DERMATOL, V171, P97, DOI 10.1111/bjd.12937; Johnston A, 2011, J IMMUNOL, V186, P2613, DOI 10.4049/jimmunol.1003162; Jordan CT, 2012, AM J HUM GENET, V90, P784, DOI 10.1016/j.ajhg.2012.03.012; Korber A, 2013, J INVEST DERMATOL, V133, P2634, DOI 10.1038/jid.2013.214; Law RHP, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-216; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Leonardi CL, 2015, DERMATOL CLIN, V33, P111, DOI 10.1016/j.det.2014.09.009; Macleod T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24880; Marrakchi S, 2011, NEW ENGL J MED, V365, P620, DOI 10.1056/NEJMoa1013068; Mutamba S, 2012, EUR J IMMUNOL, V42, P607, DOI 10.1002/eji.201142035; Newland MR, 2002, INT J DERMATOL, V41, P449, DOI 10.1046/j.1365-4362.2002.01543.x; Onoufriadis A, 2011, AM J HUM GENET, V89, P432, DOI 10.1016/j.ajhg.2011.07.022; Robinson A, 2012, J AM ACAD DERMATOL, V67, P279, DOI 10.1016/j.jaad.2011.01.032; Rossi-Semerano L, 2013, PEDIATRICS, V132, pE1043, DOI 10.1542/peds.2012-3935; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Schmitt J, 2014, BRIT J DERMATOL, V170, P274, DOI 10.1111/bjd.12663; Setta-Kaffetzi N, 2014, AM J HUM GENET, V94, P790, DOI 10.1016/j.ajhg.2014.04.005; Setta-Kaffetzi N, 2013, J INVEST DERMATOL, V133, P1366, DOI 10.1038/jid.2012.490; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sugiura K, 2013, J INVEST DERMATOL, V133, P2514, DOI 10.1038/jid.2013.230; Swindell WR, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-27; Swindell WR, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-527; Tauber M, 2014, BRIT J DERMATOL, V170, P1198, DOI 10.1111/bjd.12805; Tortola L, 2012, J CLIN INVEST, V122, P3965, DOI 10.1172/JCI63451; Towne JE, 2011, J BIOL CHEM, V286, P42594, DOI 10.1074/jbc.M111.267922; Viguier M, 2010, ANN INTERN MED, V153, P66, DOI 10.7326/0003-4819-153-1-201007060-00030; Wolf J, 2014, EXPERT OPIN THER PAT, V24, P477, DOI 10.1517/13543776.2014.881473; Yamasaki K, 2016, BR J DERMATOL	49	161	169	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					109	120		10.1016/j.jaci.2016.08.056	http://dx.doi.org/10.1016/j.jaci.2016.08.056			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28043870	Green Accepted, Bronze			2022-12-18	WOS:000404542000011
J	Wen, T; Dellon, ES; Moawad, FJ; Furuta, GT; Aceves, SS; Rothenberg, ME				Wen, Ting; Dellon, Evan S.; Moawad, Fouad J.; Furuta, Glenn T.; Aceves, Seema S.; Rothenberg, Marc E.			Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; glucocorticosteroid; molecular signature; eotaxin; reflux	KIR2.1 K+ CHANNELS; CONSENSUS RECOMMENDATIONS; SECRETORY MEMBRANE; PARIETAL-CELL; EXPRESSION; DIAGNOSIS; MANAGEMENT; EOTAXIN-3; CHILDREN; ADULTS	Background: Esophageal eosinophilia can be proton pump inhibitor (PPI) resistant or responsive, representing 2 entities known as eosinophilic esophagitis (EoE) and PPI-responsive esophageal eosinophilia (PPI-REE), respectively. Although they present with similar clinical features, EoE is accepted to be an antigen-driven, TH2-associated allergic disorder, whereas the cause of PPI-REE remains a mystery. Objective: In this study, our aim was to investigate the pathogenesis of PPI-REE by using a recently described EoE diagnostic panel (EDP) composed of a set of 94 esophageal transcripts and to determine whether PPI therapy reverses any esophageal transcriptional abnormalities. Methods: We evaluated the EDP signature in biopsy samples obtained from adult and pediatric patients with PPI-REE from 4 institutions and compared the pre-and post-PPI therapy expression profiles of these subjects with those of patients with active EoE. Results: The EDP differentiated patients with EoE from control subjects with 100% accuracy among the 4 clinical sites. Bioinformatics analysis revealed largely overlapping transcriptomes between patients with PPI-REE and those with EoE, including the genes for eosinophil chemotaxis (eotaxin 3, CCL26), barrier molecules (desmoglein 1, DSG1), tissue remodeling (periostin, POSTN), and mast cells (carboxypeptidase A, CPA3). PPI monotherapy alone almost completely reversed the allergic inflammatory transcriptome of patients with PPIREE. Furthermore, we identified a set of candidate genes to differentiate patients with EoE from those with PPI-REE before treatment. Conclusion: These findings provide definitive evidence that PPI-REE is a disease entity with significant molecular overlap with EoE, suggesting that many patients with PPI-REE represent a continuum of the same pathogenic allergic mechanisms that underlie EoE and thus might constitute a subphenotype of patients with EoE. The ability of PPI therapy to nearly entirely reverse gene expression associated with PPI-REE, particularly that associated with classic features of allergic inflammation, provides new insight into potential disease etiology and management strategies for patients with significant esophageal eosinophilia.	[Wen, Ting; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45221 USA; [Dellon, Evan S.] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Ctr Esophageal Dis & Swallowing, Chapel Hill, NC USA; [Moawad, Fouad J.] Walter Reed Natl Mil Med Ctr, Dept Med, Gastroenterol Serv, Bethesda, MD USA; [Furuta, Glenn T.] Univ Colorado, Sch Med, Gastrointestinal Eosinophil Dis Program, Dept Pediat,Childrens Hosp Colorado,Digest Hlth I, Aurora, CO USA; [Aceves, Seema S.] Univ Calif San Diego, Rady Childrens Hosp, Dept Pediat & Med, Div Allergy & Immunol, La Jolla, CA 92093 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Walter Reed National Military Medical Center; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Rady Childrens Hospital San Diego; University of California System; University of California San Diego	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org			NIH [P30 DK078392]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235, R01AI092135, R01AI083450, R37AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK100303, K23DK090073, P30DK078392, R01DK076893] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by NIH P30 DK078392; NIH grants R37 A1045898, R01 AI083450, R01 DK076893, U19 AI070235, R01 AI092135 (to S. S. A.), K23 DK090073 (to E. S. D.), and K24 DK100303 (to G. T. F.); DOD FA100044 (to S. A.); the University of Cincinnati Institutional CTSA (UL1 TR000077); Campaign Urging Research for Eosinophilic Diseases (CURED) Foundation; the Food Allergy Research and Education (FARE); and the Buckeye Foundation.	Aceves SS, 2014, CLIN GASTROENTEROL H, V12, P1216, DOI 10.1016/j.cgh.2013.09.007; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Cheng E, 2013, GUT, V62, P824, DOI 10.1136/gutjnl-2012-302250; Cheng E, 2012, AM J PHYSIOL-GASTR L, V303, pG1175, DOI 10.1152/ajpgi.00313.2012; Dellon ES, 2014, GASTROINTEST ENDOSC, V79, P577, DOI 10.1016/j.gie.2013.10.027; Dellon ES, 2013, AM J GASTROENTEROL, V108, P1854, DOI 10.1038/ajg.2013.363; Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71; Dohil R, 2012, DIGEST DIS SCI, V57, P1413, DOI 10.1007/s10620-011-1991-5; Forte JG, 2004, AM J PHYSIOL-CELL PH, V286, pC478, DOI 10.1152/ajpcell.00531.2003; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Ji JZ, 2000, AM J PHYSIOL-GASTR L, V279, pG951, DOI 10.1152/ajpgi.2000.279.5.G951; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Malinowska DH, 2004, AM J PHYSIOL-CELL PH, V286, pC495, DOI 10.1152/ajpcell.00386.2003; Moawad FJ, 2014, ALIMENT PHARM THER, V39, P603, DOI 10.1111/apt.12636; Papadopoulou A, 2014, J PEDIATR GASTR NUTR, V58, P107, DOI 10.1097/MPG.0b013e3182a80be1; Park JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101391; Pauwels A, 2013, J CYST FIBROS, V12, P700, DOI 10.1016/j.jcf.2013.03.006; Sayej WN, 2009, J PEDIATR GASTR NUTR, V49, P393, DOI 10.1097/MPG.0b013e31819c4b3e; Straumann A, 2012, NAT REV GASTRO HEPAT, V9, P697, DOI 10.1038/nrgastro.2012.182; van Rhijn BD, 2014, CLIN GASTROENTEROL H; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Wenzl TG, 2012, J PEDIATR GASTR NUTR, V55, P230, DOI 10.1097/MPG.0b013e3182592b65; Yoshida N, 2000, ALIMENT PHARM THERAP, V14, P74, DOI 10.1046/j.1365-2036.2000.014s1074.x; Zhang X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050037	25	161	167	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					187	U284		10.1016/j.jaci.2014.08.043	http://dx.doi.org/10.1016/j.jaci.2014.08.043			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25441638	Green Published, Green Accepted			2022-12-18	WOS:000347298200023
J	Malmhall, C; Alawieh, S; Sjostrand, M; Bossios, A; Eldh, M; Radinger, M				Malmhall, Carina; Alawieh, Sahar; Sjostrand, Margareta; Bossios, Apostolos; Eldh, Maria; Radinger, Madeleine			MicroRNA-155 is essential for TH2-mediated allergen-induced eosinophilic inflammation in the lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							REGULATORY T-CELLS; AIRWAY INFLAMMATION; T(H)2 CELLS; BONE-MARROW; TH2 CELLS; ASTHMA; EXPRESSION; INTERLEUKIN-13; PERIOSTIN; EOTAXIN-2	Background: Allergic asthma is a chronic disease of the conducting airways characterized by TH2 inflammation and tissue remodeling after exposure to inhaled allergens. Although the TH2 profile is undisputed, the underlying molecular mechanisms leading to this abnormal TH2 profile remain largely unclear. MicroRNAs (miRNAs) are short noncoding RNAs that are important regulators of gene expression in the immune system. However, the role of miRNAs, specifically miR-155, in the regulation of allergic airway inflammation is unexplored. Objectives: We sought to assess the contribution of miR-155 in a mouse model of allergic airway inflammation. Methods: To investigate a role for miR-155 in the regulation of allergic inflammation in vivo, we used miR-155 knockout (KO) and wild-type (WT) mice sensitized and exposed to ovalbumin. Results: miR-155 deficiency resulted in diminished eosinophilic inflammation and mucus hypersecretion in the lungs of allergen-sensitized and allergen-challenged mice compared with WT control animals. This was supported by a reduction in TH2 cell numbers and airway TH2 cytokine levels and complete abrogation of allergen-induced airway eotaxin-2/CCL24 and periostin levels in miR-155 KO mice. Intranasal instillation of eotaxin-2/CCL24 before allergen challenge partially restored airway eosinophilia in miR-155 KO mice, and adoptive transfer of CD4(+) T cells resulted in a similar degree of airway eosinophilia in miR-155 KO and WT mice. Furthermore, the transcription factor PU.1, a negative regulator of TH2 cytokine production, was upregulated in the airways of allergen challenged miR-155 KO mice compared with WT mice. Conclusions: Our data provides evidence that miR-155 contributes to the regulation of allergic airway inflammation by modulating TH2 responses through the transcription factor PU.1.	[Malmhall, Carina; Alawieh, Sahar; Sjostrand, Margareta; Bossios, Apostolos; Eldh, Maria; Radinger, Madeleine] Univ Gothenburg, Krefting Res Ctr, Inst Med, Dept Internal Med & Clin Nutr, SE-40530 Gothenburg, Sweden	University of Gothenburg	Radinger, M (corresponding author), Univ Gothenburg, Krefting Res Ctr, Dept Internal Med & Clin Nutr, Box 424, SE-40530 Gothenburg, Sweden.	madeleine.radinger@gu.se	Eldh, Maria/AFO-1744-2022; Bossios, Apostolos/ABH-8262-2020	Bossios, Apostolos/0000-0002-0494-2690; Eldh, Maria/0000-0003-2173-1796; Radinger, Madeleine/0000-0002-0652-7378	Swedish Heart and Lung Foundation; Sahlgrenska Academy; Magnus Bergwalls Stiftelse; Konsul Th C Stiftelse	Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Sahlgrenska Academy; Magnus Bergwalls Stiftelse; Konsul Th C Stiftelse	C. Malmhall has received support for travel from the Swedish Heart and Lung Foundation and Sahlgrenska Academy (travel grants for PhD students). M. Radinger has been supported by one or more grants from Magnus Bergwalls Stiftelse, the Swedish Heart and Lung Foundation, and Konsul Th C Stiftelse and has received support for travel from the Swedish Heart and Lung Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Asquith KL, 2008, J IMMUNOL, V180, P1199, DOI 10.4049/jimmunol.180.2.1199; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Bluml S, 2011, ARTHRITIS RHEUM-US, V63, P1281, DOI 10.1002/art.30281; Blumenthal MN, 2006, J ALLERGY CLIN IMMUN, V117, P79, DOI 10.1016/j.jaci.2005.09.038; Bowen H, 2008, CLIN EXP ALLERGY, V38, P1422, DOI 10.1111/j.1365-2222.2008.03067.x; Chang HC, 2005, IMMUNITY, V22, P693, DOI 10.1016/j.immuni.2005.03.016; Collison A, 2011, J ALLERGY CLIN IMMUN, V128, P160, DOI 10.1016/j.jaci.2011.04.005; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Faraoni I, 2009, BBA-MOL BASIS DIS, V1792, P497, DOI 10.1016/j.bbadis.2009.02.013; Haasch D, 2002, CELL IMMUNOL, V217, P78, DOI 10.1016/S0008-8749(02)00506-3; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Kohlhaas S, 2009, J IMMUNOL, V182, P2578, DOI 10.4049/jimmunol.0803162; Kumar RK, 2002, CLIN EXP ALLERGY, V32, P1104, DOI 10.1046/j.1365-2222.2002.01420.x; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Lu LF, 2009, IMMUNITY, V30, P80, DOI 10.1016/j.immuni.2008.11.010; Lu TX, 2013, J ALLERGY CLIN IMMUN, V132, P3, DOI 10.1016/j.jaci.2013.04.039; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Lu Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019889; Malmhall C, 2007, ALLERGY, V62, P1007, DOI 10.1111/j.1398-9995.2007.01420.x; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Mattes J, 2008, CURR OPIN MOL THER, V10, P150; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009; Oertli M, 2011, J IMMUNOL, V187, P3578, DOI 10.4049/jimmunol.1101772; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Pope SM, 2005, J IMMUNOL, V175, P5341, DOI 10.4049/jimmunol.175.8.5341; Pope SM, 2005, J BIOL CHEM, V280, P13952, DOI 10.1074/jbc.M406037200; Radinger M, 2007, ALLERGY, V62, P1410, DOI 10.1111/j.1398-9995.2007.01509.x; Radinger M, 2004, J ALLERGY CLIN IMMUN, V113, P1109, DOI 10.1016/j.jaci.2004.03.022; Rebane A, 2013, J ALLERGY CLIN IMMUN, V132, P15, DOI 10.1016/j.jaci.2013.04.011; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Suojalehto H, 2013, INT FORUM ALLERGY RH, V3, P612, DOI 10.1002/alr.21179; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027; Yang M, 2003, J ALLERGY CLIN IMMUN, V112, P935, DOI 10.1016/j.jaci.2003.08.010; Yang M, 2012, J LEUKOCYTE BIOL, V91, P557, DOI 10.1189/jlb.0711357; Yao R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046082; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	45	161	178	1	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1429	U333		10.1016/j.jaci.2013.11.008	http://dx.doi.org/10.1016/j.jaci.2013.11.008			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24373357				2022-12-18	WOS:000335450700026
J	Nagarkar, DR; Poposki, JA; Tan, BK; Comeau, MR; Peters, AT; Hulse, KE; Suh, LA; Norton, J; Harris, KE; Grammer, LC; Chandra, RK; Conley, DB; Kern, RC; Schleimer, RP; Kato, A				Nagarkar, Deepti R.; Poposki, Julie A.; Tan, Bruce K.; Comeau, Michael R.; Peters, Anju T.; Hulse, Kathryn E.; Suh, Lydia A.; Norton, James; Harris, Kathleen E.; Grammer, Leslie C.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.; Schleimer, Robert P.; Kato, Atsushi			Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; thymic stromal lymphopoietin; epithelial cells; mast cells; T(H)2 cells; IL-5; proteases	AIRWAY EPITHELIAL-CELLS; INCREASED EXPRESSION; ACTIVATING FACTOR; CUTTING EDGE; TNF FAMILY; MAST-CELLS; INFLAMMATION; CHEMOKINES; INNATE; TSLP	Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with T(H)2-dominant inflammation. Thymic stromal lymphopoietin (TSLP) is a cytokine that triggers dendritic cell-mediated T(H)2 inflammatory responses and that enhances IL-1-dependent T(H)2 cytokine production in mast cells. Although increased TSLP mRNA levels have been found in nasal polyps (NPs), expression of TSLP protein and its function in patients with chronic rhinosinusitis (CRS) have not been fully explored. Objectives: The objective of this study was to investigate the role of TSLP in patients with CRS. Methods: We investigated the presence and stability of TSLP protein in NPs using ELISA and Western blotting and investigated the function of TSLP in nasal tissue extracts with a bioassay based on activation of human mast cells. Results: Although TSLP mRNA levels were significantly increased in NP tissue from patients with CRSwNP compared with uncinate tissue from patients with CRS or control subjects, TSLP protein was significantly decreased in NP tissue, as detected by using the commercial ELISA kit. We found that recombinant TSLP was time-dependently degraded by NP extracts, and this degradation was completely inhibited by a protease inhibitor cocktail, suggesting that TSLP is sensitive to tissue proteases. Interestingly, NP extract-treated TSLP had higher activity in mast cells, although the amount of full-length TSLP was reduced up to 85%. NP extracts significantly enhanced IL-1 beta-dependent IL-5 production in mast cells compared with uncinate tissue homogenates, and responses were significantly inhibited by anti-TSLP, suggesting that NPs contain biologically relevant levels of TSLP activity. Conclusion: TSLP and its metabolic products might play an important role in the inflammation seen in patients with CRSwNP.	[Nagarkar, Deepti R.; Poposki, Julie A.; Peters, Anju T.; Hulse, Kathryn E.; Suh, Lydia A.; Norton, James; Harris, Kathleen E.; Grammer, Leslie C.; Schleimer, Robert P.; Kato, Atsushi] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Tan, Bruce K.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA; [Comeau, Michael R.] Dept Inflammat Res, Seattle, WA USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Kato, A (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, 240 E Huron,Rm M305, Chicago, IL 60611 USA.	a-kato@northwestern.edu		Kato, Atsushi/0000-0001-9144-3138; Hulse, Kathryn/0000-0003-0969-999X; Grammer, Leslie/0000-0001-6860-2014; Chandra, Rakesh/0000-0002-3612-0026	National Institutes of Health [R01 HL078860, R01 AI072570, R37 HL068546]; Ernest S. Bazley Trust; National Institutes of Health (NIH); Baxter; NIH; Food Allergy Network; SC Electric; Bazley Foundation; Astellas Pharmaceuticals; American Academy of Allergy, Asthma Immunology; Intersect ENT; GlaxoSmithKline; Allakos; Aurasense; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055884] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068546, R37HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI083216, P01AI106683, R01AI072570] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Baxter; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Network; SC Electric; Bazley Foundation; Astellas Pharmaceuticals(Astellas Pharmaceuticals); American Academy of Allergy, Asthma Immunology; Intersect ENT; GlaxoSmithKline(GlaxoSmithKline); Allakos; Aurasense; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by National Institutes of Health grants R01 HL078860, R01 AI072570, and R37 HL068546 and by a grant from the Ernest S. Bazley Trust.; J. A. Poposki and B. K. Tan have received research support from the National Institutes of Health (NIH). M. R. Comeau is employed by and has stock/stock options in Amgen and has patents related to TSLP. A. T. Peters has provided expert testimony on SJS/TEN and has received lecture fees from Baxter. L. C. Grammer has received research and travel support from the NIH; has received research support from the Food Allergy Network and S&C Electric and a Bazley Foundation grant; has received consultancy fees from Astellas Pharmaceuticals; is employed by Northwestern University and Northwestern Medical Faculty Foundation; has received lecture fees from the American Academy of Allergy, Asthma & Immunology; and receives royalties from Lippincott, UpToDate, BMU, and Elsevier. R. P. Schleimer has received research support from the NIH; has received consultancy fees from Intersect ENT, GlaxoSmithKline, Allakos, and Aurasense; and has stock/stock options in Allakos. A. Kato has received research support from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Bachert C, 2009, ALLERGY, V64, P520, DOI 10.1111/j.1398-9995.2009.01964.x; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Bhattacharyya N, 2011, ANN OTO RHINOL LARYN, V120, P423, DOI 10.1177/000348941112000701; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Comeau MR, 2010, MUCOSAL IMMUNOL, V3, P138, DOI 10.1038/mi.2009.134; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kato A, 2006, J IMMUNOL, V177, P7164, DOI 10.4049/jimmunol.177.10.7164; Kato A, 2009, J IMMUNOL, V182, P7233, DOI 10.4049/jimmunol.0801375; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Kimura S, 2011, ALLERGY ASTHMA IMMUN, V3, P186, DOI 10.4168/aair.2011.3.3.186; Liu T, 2011, AM J MED SCI, V341, P40, DOI 10.1097/MAJ.0b013e3181f20489; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Nagarkar DR, 2012, J ALLERGY CLIN IMMUN, V130, P225, DOI 10.1016/j.jaci.2012.04.019; Okayama Y, 2009, EUR RESPIR J, V34, P425, DOI 10.1183/09031936.00121008; Peterson S, 2012, J ALLERGY CLIN IMMUN, V129, P119, DOI 10.1016/j.jaci.2011.08.021; Quentmeier H, 2001, LEUKEMIA, V15, P1286, DOI 10.1038/sj.leu.2402175; Reche PA, 2001, J IMMUNOL, V167, P336, DOI 10.4049/jimmunol.167.1.336; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Schleimer Robert P, 2009, Proc Am Thorac Soc, V6, P288, DOI 10.1513/pats.200808-088RM; Seidah NG, 2012, NAT REV DRUG DISCOV, V11, P367, DOI 10.1038/nrd3699; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Van Bruaene N, 2011, CURR OPIN ALLERGY CL, V11, P8, DOI 10.1097/ACI.0b013e32834233ef; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790	36	161	167	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					593	+		10.1016/j.jaci.2013.04.005	http://dx.doi.org/10.1016/j.jaci.2013.04.005			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23688414	Bronze, Green Accepted			2022-12-18	WOS:000323612000010
J	Simons, FER				Simons, F. Estelle R.			Anaphylaxis: Recent advances in assessment and treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Anaphylaxis; systemic allergic reaction; food allergy; medication allergy; insect venom allergy; epinephrine; adrenaline	EPINEPHRINE AUTO-INJECTORS; ORAL TOLERANCE INDUCTION; FOOD ALLERGY; HYPERSENSITIVITY REACTIONS; VENOM IMMUNOTHERAPY; EMERGENCY TREATMENT; 1ST-AID TREATMENT; CROSS-REACTIVITY; NEEDLE LENGTH; RISK	The incidence rate of anaphylaxis is increasing, particularly during the first 2 decades of life. Common triggers include foods, medications, and insect stings. Clinical diagnosis is based on a meticulous history of an exposure or event preceding characteristic symptoms and signs, sometimes but not always supported by a laboratory test such as an elevated serum total tryptase level. Physician-initiated investigation of patients with anaphylaxis whose symptoms and signs are atypical sometimes leads to important insights into previously unrecognized triggers and mechanisms. In idiopathic anaphylaxis, in which no trigger can be confirmed by means of skin testing or measurement of specific IgE, the possibility of mastocytosis or a clonal mast cell disorder must be considered in addition to the possibility of a previously unrecognized trigger. Long-term risk reduction in patients with anaphylaxis focuses on optimal management of relevant comorbidities such as asthma and other respiratory diseases, cardiovascular disease, and mastocytosis or a clonal mast cell disorder; avoidance of the relevant confirmed allergen trigger; and relevant immunomodulation such as medication desensitization, venom immunotherapy, and possibly in the future, immunotherapy with food. Emergency preparedness for recurrence of anaphylaxis in community settings includes having epinephrine (adrenaline) autoinjectors available, knowing when and how to use them, and having a written, personalized anaphylaxis emergency action plan and up-to-date medical identification. Randomized controlled trials of the pharmacologic interventions used in an acute anaphylaxis episode are needed. (J Allergy Clin Immunol 2009;124:625-36.)	[Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; University of Manitoba	Simons, FER (corresponding author), FAAAAI,Room FE125,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca			Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Dr. Simons has received research support from the Canadian Institutes of Health Research, and is a member of advisory boards for the Food Allergy and Anaphylaxis Network, Dey, Intelliject, ALK-Abello, and Sciele.	Alrasbi M, 2007, ALLERGY, V62, P838, DOI 10.1111/j.1398-9995.2007.01434.x; Astier C, 2009, ALLERGY, V64, P819, DOI 10.1111/j.1398-9995.2009.01980.x; Basagana M, 2008, J ALLERGY CLIN IMMUN, V121, P233, DOI 10.1016/j.jaci.2007.10.008; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Boyano-Martinez T, 2009, J ALLERGY CLIN IMMUN, V123, P883, DOI 10.1016/j.jaci.2008.12.1125; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brotherton JML, 2008, CAN MED ASSOC J, V179, P525, DOI 10.1503/cmaj.080916; Burks AW, 2008, J ALLERGY CLIN IMMUN, V121, P1344, DOI 10.1016/j.jaci.2008.02.037; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; CELIK W, 2009, MIDDLETONS ALLERGY P, P1205; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Chaudhuri K, 2008, INT J OBSTET ANESTH, V17, P350, DOI 10.1016/j.ijoa.2008.05.002; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Clark S, 2007, IMMUNOL ALLERGY CLIN, V27, P145, DOI 10.1016/j.iac.2007.03.002; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; de Graaf DC, 2009, J PROTEOMICS, V72, P145, DOI 10.1016/j.jprot.2009.01.017; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; De Olano DG, 2008, J ALLERGY CLIN IMMUN, V121, P519, DOI 10.1016/j.jaci.2007.11.010; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Du Toit G, 2007, PEDIATR ALLERGY IMMU, V18, P455, DOI 10.1111/j.1399-3038.2007.00599.x; Estelle F, 2008, J ALLERGY CLIN IMMUN, V121, pS402, DOI 10.1016/j.jaci.2007.08.061; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Femando SL, 2009, J PEDIATR, V154, P148, DOI 10.1016/j.jpeds.2008.06.033; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Freeman TM, 2004, NEW ENGL J MED, V351, P1978, DOI 10.1056/NEJMcp042013; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Greenberger PA, 2007, IMMUNOL ALLERGY CLIN, V27, P273, DOI 10.1016/j.iac.2007.03.009; Greenberger PA, 2007, ANN ALLERG ASTHMA IM, V98, P252, DOI 10.1016/S1081-1206(10)60714-4; Greenhawt MJ, 2009, J ALLERGY CLIN IMMUN, V124, P323, DOI 10.1016/j.jaci.2009.05.028; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Kontou-Fili K, 2008, ALLERGY, V63, P376, DOI 10.1111/j.1398-9995.2007.01604.x; Korhonen H, 2009, J EXP MED, V206, P411, DOI 10.1084/jem.20082150; Kuehn A, 2009, J ALLERGY CLIN IMMUN, V123, P708, DOI 10.1016/j.jaci.2008.12.012; Lang DM, 2008, CURR ALLERGY ASTHM R, V8, P37, DOI 10.1007/s11882-008-0008-8; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; Lieberman P, 2007, ANN ALLERG ASTHMA IM, V98, P519, DOI 10.1016/S1081-1206(10)60729-6; LIEBERMAN PL, 2009, MIDDLETONS ALLERGY P, P1027; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Mehr S, 2007, PEDIAT ALLERG IMM-UK, V18, P448, DOI 10.1111/j.1399-3038.2007.00529.x; Moore LM, 2007, ANN ALLERG ASTHMA IM, V98, P92, DOI 10.1016/S1081-1206(10)60866-6; Muller UR, 2009, CLIN EXP ALLERGY, V39, P620, DOI 10.1111/j.1365-2222.2009.03251.x; Mueller UR, 2007, CURR OPIN ALLERGY CL, V7, P337, DOI 10.1097/ACI.0b013e328259c328; Nishitani N, 2009, INT J DERMATOL, V48, P522, DOI 10.1111/j.1365-4632.2009.03926.x; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Nurmatov U, 2008, J ALLERGY CLIN IMMUN, V122, P353, DOI 10.1016/j.jaci.2008.05.028; Ono E, 2009, CLIN EXP ALLERGY, V39, P72, DOI 10.1111/j.1365-2222.2008.03104.x; Elberink JNG, 2006, CURR OPIN ALLERGY CL, V6, P298, DOI 10.1097/01.all.0000235906.95300.3e; Peavy RD, 2008, CURR OPIN ALLERGY CL, V8, P310, DOI 10.1097/ACI.0b013e3283036a90; Peng ZK, 2004, J ALLERGY CLIN IMMUN, V114, P1189, DOI 10.1016/j.jaci.2004.08.014; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; Rawas-Qalaji MM, 2006, J ALLERGY CLIN IMMUN, V117, P398, DOI 10.1016/j.jaci.2005.12.1310; Rezvani M, 2007, IMMUNOL ALLERGY CLIN, V27, P295, DOI 10.1016/j.iac.2007.03.010; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Schwartz LB, 2008, NEW ENGL J MED, V358, P2505, DOI 10.1056/NEJMe0803599; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Sheikh A, 2007, ALLERGY, V62, P830, DOI 10.1111/j.1398-9995.2007.01435.x; Sheikh A, 2009, ALLERGY, V64, P204, DOI 10.1111/j.1398-9995.2008.01926.x; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Simons FER, 2008, BMJ-BRIT MED J, V336, P1141, DOI 10.1136/bmj.39547.452153.80; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025; Simons FER, 2007, IMMUNOL ALLERGY CLIN, V27, P231, DOI 10.1016/j.iac.2007.03.007; Simons FER, 2009, ANN ALLERG ASTHMA IM, V102, P403, DOI 10.1016/S1081-1206(10)60512-1; Simons FER, 2009, ANN ALLERG ASTHMA IM, V102, P282, DOI 10.1016/S1081-1206(10)60332-8; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P301, DOI 10.1016/j.jaci.2009.03.050; Simons FER, 2008, J ALLERGY CLIN IMMUN, V122, P1166, DOI 10.1016/j.jaci.2008.10.019; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Soar J, 2008, RESUSCITATION, V77, P157, DOI 10.1016/j.resuscitation.2008.02.001; Song TT, 2005, ANN ALLERG ASTHMA IM, V94, P539, DOI 10.1016/S1081-1206(10)61130-1; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Stecher D, 2009, PEDIATRICS, V124, P65, DOI 10.1542/peds.2008-3388; Stoevesandt J, 2020, ALLERGY, V75, P535, DOI 10.1111/all.13945; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Wang J, 2008, J ALLERGY CLIN IMMUN, V121, P1219, DOI 10.1016/j.jaci.2007.12.1150; Yamashita Y, 2007, J IMMUNOL, V179, P740, DOI 10.4049/jimmunol.179.2.740; Zanoni G, 2008, J ALLERGY CLIN IMMUN, V122, P1233, DOI 10.1016/j.jaci.2008.09.015	99	161	177	1	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					625	636		10.1016/j.jaci.2009.08.025	http://dx.doi.org/10.1016/j.jaci.2009.08.025			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19815109				2022-12-18	WOS:000270802800001
J	Patou, J; Gevaert, P; Van Zele, T; Holtappels, G; van Cauwenberge, P; Bachert, C				Patou, Joke; Gevaert, Philippe; Van Zele, Thibaut; Holtappels, Gabriele; van Cauwenberge, Paul; Bachert, Claus			Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyps; chronic rhinosinusitis; Staphylococcus aureus; protein A; lipoteichoic acid; tissue stimulations	MAST-CELLS; BACTERIAL SUPERANTIGENS; ATOPIC-DERMATITIS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; IGE; ACTIVATION; EXOTOXINS; COLONIZATION; RESPONSES	Background: Increasing evidence points toward a modifying role of Staphylococcus aureus and its products in the pathogenesis of nasal polyposis. Objective: The aim of this study was to investigate cytokine and mediator production after stimulation with S aureus-derived proteins enterotoxin B, protein A, and lipoteichoic acid in nasal polyp and control inferior turbinate tissue. Methods: Tissue fragments were stimulated with RPMI (negative control), enterotoxin B, protein A, and lipoteichoic acid for 30 minutes and 24 hours. Supernatants were measured by multiplex for proinflammatory cytokines (IL-1 beta, TNF-alpha) and T-cell and subset-related cytokines (IFN-gamma, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13). Histamine, TGF-beta 1, cysteinyl leukotrienes, and prostaglandin D-2 were analyzed by ELISA. Results: Thirty minutes of protein A stimulation resulted in a significant increase of histamine, leukotrienes, and prostaglandin D-2. Enterotoxin B stimulation over a period of 24 hours induced a significant increase of IL-10, TNF-alpha, IFN-gamma, IL-2, IL-4, IL-5, IL-10, and IL-13 in both groups, with this increase significantly higher in nasal polyps compared with controls. Conclusion: We here show that S aureus products have various effects on mucosal tissues: surface protein A induces mast cell degranulation, whereas enterotoxins induce the release of cytokines, with a T(H)2-skewed pattern in nasal polyps, supporting the stimulatory role of superantigens in the development of this inflammatory disease.	[Patou, Joke; Gevaert, Philippe; Van Zele, Thibaut; Holtappels, Gabriele; van Cauwenberge, Paul; Bachert, Claus] State Univ Ghent Hosp, Dept Otorhinolaryngol, Upper Airways Res Lab, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	Patou, J (corresponding author), State Univ Ghent Hosp, Dept Otorhinolaryngol, Upper Airways Res Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	Joke.Patou@Ugent.be	Bachert, Claus/J-8825-2012; Gevaert, Philippe/ABA-4588-2021; Gevaert, Philippe/AAP-1892-2020	Gevaert, Philippe/0000-0002-1629-8468; Van Zele, Thibaut/0000-0002-6031-4293				Ackermann L, 1998, IMMUNOLOGY, V94, P247, DOI 10.1046/j.1365-2567.1998.00508.x; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Cardona ID, 2006, AM J CLIN DERMATOL, V7, P273, DOI 10.2165/00128071-200607050-00001; Du CG, 2000, CELL IMMUNOL, V199, P50, DOI 10.1006/cimm.1999.1595; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; FORSGREN A, 1966, J IMMUNOL, V97, P822; Genovese A, 2000, INFECT IMMUN, V68, P5517, DOI 10.1128/IAI.68.10.5517-5524.2000; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Graille M, 2000, P NATL ACAD SCI USA, V97, P5399, DOI 10.1073/pnas.97.10.5399; Heaton T, 2003, ALLERGY, V58, P252, DOI 10.1034/j.1398-9995.2003.00088.x; INGANAS M, 1981, SCAND J IMMUNOL, V13, P343, DOI 10.1111/j.1365-3083.1981.tb00143.x; KAWABORI S, 1992, AM J RESP CELL MOL, V6, P37, DOI 10.1165/ajrcmb/6.1.37; Kirsch J P, 1990, J La State Med Soc, V142, P11; KOMISAR J, 1992, INFECT IMMUN, V60, P2969, DOI 10.1128/IAI.60.7.2969-2975.1992; Lehmann HS, 2004, INT ARCH ALLERGY IMM, V135, P306, DOI 10.1159/000082324; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; MARONE G, 1982, CLIN EXP IMMUNOL, V50, P661; Palmqvist N, 2005, MICROBES INFECT, V7, P1501, DOI 10.1016/j.micinf.2005.05.008; Proft T, 2003, CLIN EXP IMMUNOL, V133, P299, DOI 10.1046/j.1365-2249.2003.02203.x; SASAKI Y, 1986, ACTA OTO-LARYNGOL, P34; Thakur A, 1997, AUST NZ J OPHTHALMOL, V25, pS43; Tripathi A, 2005, AM J RHINOL, V19, P327, DOI 10.1177/194589240501900401; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Wedi B, 2002, J ALLERGY CLIN IMMUN, V109, P477, DOI 10.1067/mai.2002.121702; Wehner J, 2001, BRIT J DERMATOL, V145, P302, DOI 10.1046/j.1365-2133.2001.04352.x; Weidenmaier C, 2004, NAT MED, V10, P243, DOI 10.1038/nm991	29	161	164	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					110	115		10.1016/j.jaci.2007.08.059	http://dx.doi.org/10.1016/j.jaci.2007.08.059			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17980412				2022-12-18	WOS:000252372000016
J	Akdis, CA; Blaser, K				Akdis, CA; Blaser, K			Histamine in the immune regulation of allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine; histamine receptors; T cells; B cells; dendritic cells; antihistamines; G protein-coupled receptors; allergy; asthma; chemotaxis; antibodies; IgE	BRONCHIAL EPITHELIAL-CELLS; AIRWAY SMOOTH-MUSCLE; HUMAN NASAL-MUCOSA; NF-KAPPA-B; DENDRITIC CELLS; HISTIDINE-DECARBOXYLASE; ENDOTHELIAL-CELLS; MAST-CELLS; T-CELL; EOSINOPHIL MIGRATION	Histamine was the first mediator implicated in mechanisms of allergy, asthma, and anaphylactic shock because it has been discovered to mimic several features of these diseases. In addition to its well-characterized effects in the acute inflammatory and allergic responses, it was recently demonstrated that histamine regulates several essential events in the immune response. Histamine affects the maturation of immune system cells and alters their activation, polarization, chemotaxis, and effector functions. Histamine also regulates antigen-specific T(H)1 and T(H)2 cells, as well as related antibody isotype responses. Histamine binds to 4 different G protein-coupled receptors that transduce signals to cells through distinct pathways. The expression of these receptors on different cells and cell subsets is regulated, and apparently, the diverse effects of histamine on immune regulation are due to differential expression of 4 histamine receptors and their distinct intracellular signals. This article highlights novel discoveries in histamine immunobiology and discusses clinical findings or disease models that indicate immune regulation by histamine.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.							ABE Y, 1993, CLIN EXP ALLERGY, V23, P132, DOI 10.1111/j.1365-2222.1993.tb00308.x; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Aoki Y, 1998, AM J PHYSIOL-LUNG C, V274, pL1030, DOI 10.1152/ajplung.1998.274.6.L1030; Bakker RA, 2001, MOL PHARMACOL, V60, P1133, DOI 10.1124/mol.60.5.1133; Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; Bayram H, 1999, J ALLERGY CLIN IMMUN, V104, P93, DOI 10.1016/S0091-6749(99)70119-3; Benovic Jeffrey L., 2002, Journal of Allergy and Clinical Immunology, V110, pS229, DOI 10.1067/mai.2002.129370; BURY TB, 1992, ALLERGY, V47, P624, DOI 10.1111/j.1398-9995.1992.tb02385.x; Caron G, 2001, J IMMUNOL, V167, P3682, DOI 10.4049/jimmunol.167.7.3682; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; CHAND N, 1975, AGENTS ACTIONS, V5, P277, DOI 10.1007/BF02205232; CLARK RAF, 1977, J IMMUNOL, V118, P137; COLOMBO M, 1984, LIVER, V4, P201; Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; DelValle J, 1997, AM J PHYSIOL-GASTR L, V273, pG987, DOI 10.1152/ajpgi.1997.273.5.G987; DIMITRIADOU V, 1994, CLIN SCI, V87, P151, DOI 10.1042/cs0870151; DY M, 1981, J EXP MED, V153, P293, DOI 10.1084/jem.153.2.293; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; ENDO Y, 1982, BIOCHEM PHARMACOL, V31, P1643, DOI 10.1016/0006-2952(82)90394-X; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; Field SK, 1998, CHEST, V114, P275, DOI 10.1378/chest.114.1.275; Fujikura T, 2001, J ALLERGY CLIN IMMUN, V107, P123, DOI 10.1067/mai.2001.111236; Gantner F, 2002, J PHARMACOL EXP THER, V303, P300, DOI 10.1124/jpet.102.036939; Ghosh AK, 2002, J EXP MED, V195, P973, DOI 10.1084/jem.20011782; GIFFORD RRM, 1979, SURG FORUM, V30, P113; GONZALEZ H, 1986, CHEST, V89, P491, DOI 10.1378/chest.89.4.491; GRANDORDY BM, 1987, AM REV RESPIR DIS, V136, pS17, DOI 10.1164/ajrccm/136.4_Pt_2.S17; Gutzmer R, 2002, J ALLERGY CLIN IMMUN, V109, P524, DOI 10.1067/mai.2002.121944; Hardy E, 1996, BRIT J PHARMACOL, V118, P1079, DOI 10.1111/j.1476-5381.1996.tb15509.x; Hill SJ, 1997, PHARMACOL REV, V49, P253; Idzko M, 2002, J ALLERGY CLIN IMMUN, V109, P839, DOI 10.1067/mai.2002.124044; JEANNIN P, 1994, BLOOD, V84, P2229; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; JUTEL M, 1997, ALLERGY S37, V52, P88; KUBES P, 1994, J IMMUNOL, V152, P3570; Kubo Y, 1999, INFLAMM RES, V48, P149, DOI 10.1007/s000110050438; KUNZMANN S, 2003, IN PRESS FASEB J; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; LO WWY, 1987, BIOCHEM BIOPH RES CO, V148, P47, DOI 10.1016/0006-291X(87)91074-6; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; Ma RLZ, 2002, SCIENCE, V297, P620, DOI 10.1126/science.1072810; Mavligit GM, 1987, PHARMACOTHERAPY, V7, P120, DOI 10.1002/j.1875-9114.1987.tb03536.x; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; MERETEY K, 1991, AGENTS ACTIONS, V33, P189, DOI 10.1007/BF01993163; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; Nakamura T, 2000, BIOCHEM BIOPH RES CO, V279, P615, DOI 10.1006/bbrc.2000.4008; NIELSEN HJ, 1992, MED HYPOTHESES, V39, P349, DOI 10.1016/0306-9877(92)90060-P; O'Reilly M, 2002, J RECEPT SIGNAL TR R, V22, P431, DOI 10.1081/RRS-120014612; Ohtsu H, 2001, FEBS LETT, V502, P53, DOI 10.1016/S0014-5793(01)02663-1; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; Paesen GC, 1999, MOL CELL, V3, P661, DOI 10.1016/S1097-2765(00)80359-7; PANETTIERI RA, 1990, AM J PHYSIOL, V259, pL365, DOI 10.1152/ajplung.1990.259.6.L365; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; Schaefer U, 1999, SHOCK, V12, P309, DOI 10.1097/00024382-199910000-00010; SCHNEIDER E, 1987, J IMMUNOL, V139, P3710; SELIGMANN BE, 1983, J IMMUNOL, V130, P1902; Simons FER, 2002, AM J MED, V113, p38S; Sirois J, 2000, J IMMUNOL, V164, P2964, DOI 10.4049/jimmunol.164.6.2964; Szeberenyi JB, 2001, IMMUNOL LETT, V76, P175, DOI 10.1016/S0165-2478(01)00184-5; Szincsak N, 2002, MELANOMA RES, V12, P231, DOI 10.1097/00008390-200206000-00006; Tanaka S, 2002, J EXP MED, V196, P229, DOI 10.1084/jem.20012037; THOMSON NC, 1980, THORAX, V35, P428, DOI 10.1136/thx.35.6.428; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; VANNIER E, 1993, J CLIN INVEST, V92, P281, DOI 10.1172/JCI116562; WHITE JP, 1987, BRIT J DIS CHEST, V81, P155, DOI 10.1016/0007-0971(87)90134-3; Wilson S, 2000, Drug Des Discov, V17, P105; Yamaki K, 1998, BRIT J PHARMACOL, V123, P390, DOI 10.1038/sj.bjp.0701614; Yoneda K, 1997, JPN J PHARMACOL, V73, P145, DOI 10.1254/jjp.73.145; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Zhu Y, 2001, MOL PHARMACOL, V59, P434, DOI 10.1124/mol.59.3.434	73	161	182	2	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					15	22		10.1067/mai.2003.1585	http://dx.doi.org/10.1067/mai.2003.1585			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847474				2022-12-18	WOS:000184010600004
J	Maleki, SJ; Viquez, O; Jacks, T; Dodo, H; Champagne, ET; Chung, SY; Landry, SJ				Maleki, SJ; Viquez, O; Jacks, T; Dodo, H; Champagne, ET; Chung, SY; Landry, SJ			The major peanut allergen, Ara h 2, functions as a trypsin inhibitor, and roasting enhances this function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; peanut allergy; IgE; Maillard reaction; roasting; AGE	PROTEIN SECONDARY STRUCTURE; GLYCATION END-PRODUCTS; PHASEOLUS-VULGARIS L; MAILLARD REACTION; PREDICTION; EPITOPES; PROFILE	Background: The widespread use of peanut products, the severity of the symptoms, and its persistence in afflicted individuals has made peanut allergy a major health concern in western countries such as the United States, United Kingdom, and Canada. In a previous study, the authors showed that the allergenic properties of peanut proteins are enhanced as a result of thermal processing. Objective: The purpose of this investigation was to determine whether any specific functions are associated with the major peanut allergen, Ara h 2, and whether the functionality of this protein is influenced by processing. An assay was developed and used to assess structure/function changes in Ara h 2 induced by roasting and the effect of these alterations on the allergenic properties of this major peanut allergen. Methods: A protein domain homology search was used to determine possible functions for Ara h 2. One of the putative functions (protease inhibition) was tested by means of appropriate enzyme assays and protein gel electrophoresis. Circular dichroism was used to compare the structural properties of Ara h 2 purified from raw and roasted peanuts. Results: Ara h 2 purified from peanuts is homologous to and functions as a trypsin inhibitor. Roasting caused a 3.6-fold increase in trypsin inhibitory activity. Functional and structural comparison of the Ara h 2 purified from roasted peanuts to native and reduced Ara h 2 from raw peanuts revealed that the roasted Ara h 2 mimics the behavior of native Ara h 2 in a partially reduced form. Conclusions: The data indicate that thermal processing might play an important role in enhancing the allergenic properties of peanuts. Not only has it previously been shown to affect the structural and allergic properties of peanut proteins but also, for the first time, the functional characteristics of an allergen. These structural and functional alterations are likely to influence the allergenicity of peanuts.	ARS, USDA, SRRC, New Orleans, LA 70124 USA; Alabama A&M Univ, Dept Food & Anim Sci, Normal, AL 35762 USA; Tulane Univ, Sch Med, Dept Biochem, New Orleans, LA 70112 USA	United States Department of Agriculture (USDA); Alabama A&M University; Tulane University	Maleki, SJ (corresponding author), ARS, USDA, SRRC, 1100 Robert E Lee Blvd, New Orleans, LA 70124 USA.		Landry, Samuel/AAK-5778-2020	Landry, Samuel/0000-0002-4082-0543				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; BOCK AS, 2001, J ALLERGY CLIN IMMUN, V107, P91; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P889, DOI 10.1016/0091-6749(92)90461-A; DESHPANDE SS, 1987, J FOOD SCI, V52, P1330, DOI 10.1111/j.1365-2621.1987.tb14075.x; DESHPANDE SS, 1987, J FOOD SCI, V52, P1326, DOI 10.1111/j.1365-2621.1987.tb14074.x; Duchateau J, 1998, CLIN EXP ALLERGY, V28, P824, DOI 10.1046/j.1365-2222.1998.00314.x; Ewan PW, 1996, BRIT MED J, V312, P1074; Hefle S L, 1999, Adv Exp Med Biol, V459, P107; HEFLE SL, 1996, CRIT REV FOOD SCI NU, V14, P1269; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; KAKADE ML, 1974, CEREAL CHEM, V51, P376; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; Koppelman SJ, 1999, J BIOL CHEM, V274, P4770, DOI 10.1074/jbc.274.8.4770; Maillard LC, 1912, CR HEBD ACAD SCI, V155, P1554; Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66; Maleki S. J., 2001, FOOD ALLERGY TOLER, V2, P211; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Raghava GP., 2000, CASP, V4, P75; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; SHAHIDI F, 1998, PROCESS INDUCED CHEM; STROBL S, 1995, BIOCHEMISTRY-US, V34, P8281, DOI 10.1021/bi00026a009; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001; Traverso N, 1997, BBA-GEN SUBJECTS, V1336, P409, DOI 10.1016/S0304-4165(97)00052-4; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727	29	161	172	2	43	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					190	195		10.1067/mai.2003.1551	http://dx.doi.org/10.1067/mai.2003.1551			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847498				2022-12-18	WOS:000184010600029
J	von Mutius, E				von Mutius, E			Environmental factors influencing the development and progression of pediatric asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; environmental factors; risk factors; sensitization	ALLERGIC SENSITIZATION; HAY-FEVER; EARLY-CHILDHOOD; CHILDREN; EXPOSURE; COHORT; RISK; AGE; PREVALENCE; COMMUNITY	Recent data underscore the importance of environmental factors in the sensitization of children to certain allergens and the development of asthma. Maternal smoking and family (especially maternal) history of atopy appear to be risk factors for persistent sensitization and development of asthma. Indeed, exposure to tobacco smoke in utero significantly increases asthma risk and influences the timing of sensitization. It must be stated that any smoking at home has consequences for the development of asthma and other respiratory conditions. In addition, reports of possible protective effects of specific environmental conditions suggest that exposure to certain stimuli may reduce or block the development and progression of asthma. Attendance at a day care center early in life appears to offer protective effects against wheezing, as do early episodes of rhinitis, herpes, and measles. Children raised on a farm also have a decreased prevalence of atopic diseases. The protective effect of contact with livestock and poultry is consistent among several studies. Although the pathophysiologic mechanisms involved remain undefined, studies suggest that exposure to endotoxin and other components of bacteria may play an important role in protecting against childhood atopic diseases. Whether in utero exposure is beneficial remains to be determined.	Univ Munich, Childrens Hosp, D-80337 Munich, Germany	University of Munich	von Mutius, E (corresponding author), Univ Munich, Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.			von Mutius, Erika/0000-0002-8893-4515				Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; Cook DG, 1999, THORAX, V54, P357, DOI 10.1136/thx.54.4.357; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; Strachan DP, 1996, BRIT MED J, V312, P1195; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	19	161	167	1	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6		S			S525	S532		10.1067/mai.2002.124565	http://dx.doi.org/10.1067/mai.2002.124565			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	568JU	12063508				2022-12-18	WOS:000176539300003
J	Kikuchi, Y; Kaplan, AP				Kikuchi, Y; Kaplan, AP			Mechanisms of autoimmune activation of basophils in chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic urticaria; basophils; histamine release; complement; IgE receptor; alpha subunit; immunoblot	FC-EPSILON-RI; AFFINITY IGE RECEPTOR; ALPHA AUTOANTIBODIES; THYROID AUTOIMMUNITY; HISTAMINE-RELEASE; ANGIOEDEMA	Background: Approximately 35% to 40% of patients with chronic urticaria possess a circulating antibody directed to the alpha subunit of the high-affinity type I IgE receptor (Fc epsilon RI), which is detectable by using histamine release assays or immunoblotting. Prior reports suggest that purified IgG may not directly activate basophils but rather does so through complement activation, Objective: We sought to further elucidate the mechanism by which this antibody causes basophil histamine release, including the role of complement, and to reassess the relationship of functional versus binding assays. Methods: We incubated human basophils with patient serum, patient IgG, or patient IgG plus normal serum as a complement source and measured histamine release for each condition. IgG fractions were neutralized with cloned a subunit to determine whether histamine release decreased proportionately. We also screened sera from 260 patients to compare histamine release with immunoblotting results, Results: We initially tested 35 sera from patients with chronic urticaria by using basophils from 2 atopic donors and one nonreleaser with rabbit anti-IgE, No histamine was released from the nonreleaser, yet all donors responded identically to monocyte chemotactic protein 1, indicating a requirement for IgE or the IgE receptor. Basophil histamine release was markedly augmented by complement if release by IgG alone was low, Incubation of purified Ige with an increasing concentration of cloned alpha subunit gradually reduced the histamine-releasing capability in patients with positive or negative immunoblot results, Of 260 patients tested, 43% had positive histamine release results, and 47% had positive immunoblot results, yet there was no correlation when individual patients were assessed. Conclusion: A subpopulation of patients with chronic urticaria possess Ige antibody directed to the alpha subunit of Fc epsilon RI. This Ige activates basophils, which is dependent on or augmented by complement. Binding assays for the FceRI a subunit, such as immunoblotting, are not currently feasible as a screening method. A functional assay is required.	Med Univ S Carolina, Dept Med, Div Pulm & Crit Care Allergy & Clin Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Konishi MUSC Inst Inflammat Res, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Kaplan, AP (corresponding author), Med Univ S Carolina, Dept Med, Div Pulm Allergy, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA.							Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Horn MP, 1999, EUR J IMMUNOL, V29, P1139, DOI 10.1002/(SICI)1521-4141(199904)29:04<1139::AID-IMMU1139>3.0.CO;2-J; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; Kaplan AP, 1999, CAN J ALLERGY CLIN I, V4, P286; Kaplan AP, 1999, INFLAMMATION BASIC P, P331; KAPLAN AP, 1999, INFLAMMATION BASIC P, P915; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; SARBJIT SS, 2000, J ALLERGY CLIN IMMUN, V106, P514; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; WARD PA, 1970, J IMMUNOL, V104, P535; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	21	161	168	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1056	1062		10.1067/mai.2001.115484	http://dx.doi.org/10.1067/mai.2001.115484			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398085				2022-12-18	WOS:000169454800019
J	Niederberger, V; Pauli, G; Gronlund, H; Froschl, R; Rumpold, H; Kraft, D; Valenta, R; Spitzauer, S				Niederberger, V; Pauli, G; Gronlund, H; Froschl, R; Rumpold, H; Kraft, D; Valenta, R; Spitzauer, S			Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: A quantitative IgE inhibition study with sera from different populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant birch pollen allergens; Bet v 1; profilin (Ber v 2); cross-reactivity; immunoabsorption; skin prick testing; tree pollen allergy	HIGH-LEVEL EXPRESSION; 3-YEAR DOUBLE-BLIND; TREE-POLLEN; ESCHERICHIA-COLI; MAJOR ALLERGEN; BETULA-VERRUCOSA; CROSS-REACTIVITY; RHESUS-MONKEYS; CDNA CLONING; ANTIBODIES	Background: Pollen from trees of the order Fagales are important allergen sources in most parts of the world. Clinical, immunochemical, and molecular biology studies indicate that they contain cross-reactive allergens. The major birch pollen allergen, Bet v 1, and birch profilin, Bet v 2, a highly crossreactive allergen, have been cloned and expressed in Escherichia coli. Objective: The purpose of this study was to demonstrate the presence of allergens in Fagales pollens that share IgE epitopes with recombinant Bet v 1 and Bet v 2 and to determine the percentage of birch, alder, hornbeam, hazel, and oak pollen-specific IgE that can be preabsorbed with rBet v 1 and rBet v 2 from 102 sera of different populations of subjects allergic to Fagales tree pollen. Methods: The presence of rBet v 1- and rBet v 2-homologous allergens in tree pollen extracts was investigated by IgE immunoblot inhibition experiments, and the percentage of tree (birch, alder, hornbeam, hazel, and oak) pollen-specific IgE that was bound by a mixture of rBet v 1 and rBet v :! was determined by RAST-based quantitative IgE inhibition experiments. The clinical significance of IgE antibody cross-reactivity was studied by skin prick testing with rBet v 1, rBet v 2, and Fagales pollen extracts. Results: Natural birch, alder, hornbeam, hazel, and oak pollen contain allergens that share IgE epitopes with rBet v 1 and rBet v 2. A combination of rBet v 1 and rBet v 2 accounted for82% of tree pollen-specific IgE on average. Most of the tree pollen-specific IgE was directed against rBet v 1. Conclusion: rBet v 1 and rBet v 2 contain most of the Fagales pollen-specific IgE epitopes and may therefore substitute natural tree pollen extracts not only for diagnosis but also for patient-tailored immunotherapy of tree pollen allergy.	Univ Vienna, Inst Gen & Expt Pathol, AKH, A-1090 Vienna, Austria; Univ Vienna, Inst Med & Chem Lab Diagnost, AKH, A-1090 Vienna, Austria; Univ Strasbourg, Hosp Civil, Strasbourg, France; Pharmacia & Upjohn Inc, Uppsala, Sweden	University of Vienna; University of Vienna; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Pfizer; Pharmacia Corporation	Valenta, R (corresponding author), Univ Vienna, Inst Gen & Expt Pathol, AKH, Waehringer Guertel 18-20, A-1090 Vienna, Austria.			Valenta, Rudolf/0000-0001-5944-3365; Gronlund, Hans/0000-0003-4882-7624				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; EMBERLIN JC, 1994, ALLERGY ALLERGIC DIS, P835; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; ERIKSSON NE, 1984, ALLERGY, V39, P610, DOI 10.1111/j.1398-9995.1984.tb01981.x; ERIKSSON NE, 1978, ALLERGY, V33, P299, DOI 10.1111/j.1398-9995.1978.tb01555.x; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Ferreira FD, 1996, J ALLERGY CLIN IMMUN, V97, P95, DOI 10.1016/S0091-6749(96)70287-7; FISCHER S, 1997, ALLERGY CLIN IMMUN S, V4, P146; Gassner M, 1996, ALLERGOLOGIE, V19, P403; GODNICCVAR J, 1997, J ALLERGY CLIN IMMUN, V99, P100; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; IPSEN H, 1988, ALLERGY, V43, P370, DOI 10.1111/j.1398-9995.1988.tb00431.x; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; IPSEN H, 1990, EPITOPES ATOPIC ALLE, P3; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; PETERSEN BN, 1988, ALLERGY, V43, P353, DOI 10.1111/j.1398-9995.1988.tb00429.x; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Twardosz A, 1997, BIOCHEM BIOPH RES CO, V239, P197, DOI 10.1006/bbrc.1997.6860; VALENTA B, 1990, EPITOPES ATOPIC ALLE, P73; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VALENTA R, 1998, IN PRESS ALLERGEN IM; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VIANDER M, 1979, ALLERGY, V34, P289; VIK H, 1986, INT ARCH ALLER A IMM, V80, P17, DOI 10.1159/000234020; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V98, P913, DOI 10.1016/S0091-6749(96)80007-8; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Vrtala S, 1996, BIOCHEM BIOPH RES CO, V226, P42, DOI 10.1006/bbrc.1996.1309; WIHL JA, 1988, ALLERGY, V43, P363, DOI 10.1111/j.1398-9995.1988.tb00430.x; 1985, ALLERGY ALLERGENS	54	161	164	1	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				579	591		10.1016/S0091-6749(98)70273-8	http://dx.doi.org/10.1016/S0091-6749(98)70273-8			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802365				2022-12-18	WOS:000076600400007
J	Derendorf, H; Hochhaus, G; Meibohm, B; Mollmann, H; Barth, J				Derendorf, H; Hochhaus, G; Meibohm, B; Mollmann, H; Barth, J			Pharmacokinetics and pharmacodynamics of inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inhaled corticosteroids; pharmacokinetics; pharmacodynamics; safety; mathematical modeling	TRIAMCINOLONE ACETONIDE; METABOLISM; BUDESONIDE	There are significant differences in the pharmacokinetic properties of inhaled corticosteroids currently used in medical practice. All are rapidly cleared from the body but they show varying levels of oral bioavailability and more importantly variation in the rate of absorption after inhalation. Oral bioavailability is lowest for fluticasone propionate, indicating a low potential for unwanted systemic corticosteroid effects. Mathematical modeling has shown pulmonary residence times to be longest for fluticasone propionate and triamcinolone acetonide but shortest for budesonide and flunisolide. These properties appear to relate to pulmonary solubility, which appears to be the rate-limiting step in the absorption process.	Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA; Ruhr Univ Bochum, D-4630 Bochum, Germany	State University System of Florida; University of Florida; Ruhr University Bochum	Derendorf, H (corresponding author), Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA.		Derendorf, Hartmut/B-4628-2012	Derendorf, Hartmut/0000-0003-4016-1370; Hochhaus, Guenther/0000-0002-7406-5558; Meibohm, Bernd/0000-0003-3923-3648				BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402, DOI 10.1038/clpt.1980.54; CHAPLIN MD, 1980, J ALLERGY CLIN IMMUN, V65, P445, DOI 10.1016/0091-6749(80)90238-9; DERENDORF H, 1995, J CLIN PHARMACOL, V35, P302, DOI 10.1002/j.1552-4604.1995.tb04064.x; Faicoz C, 1995, J CLIN PHARMACOL, V35, P927; Falcoz C., 1996, European Respiratory Journal Supplement, V9, p162S; Falcoz C., 1996, British Journal of Clinical Pharmacology, V41, p459P; Hochhaus G, 1997, J CLIN PHARMACOL, V37, P881, DOI 10.1002/j.1552-4604.1997.tb04262.x; Jenner WN, 1988, BIOANALYSIS DRUGS ME, P77; Mackie AE, 1996, BRIT J CLIN PHARMACO, V41, P539, DOI 10.1046/j.1365-2125.1996.36110.x; MARTIN LE, 1975, POSTGRAD MED J, V51, P11; Meibohm B, 1997, J CLIN PHARMACOL, V37, P704, DOI 10.1002/j.1552-4604.1997.tb04357.x; MEIBOHM B, IN PRESS J BOPHARM C; Meibohm Bernd, 1997, Pharmaceutical Research (New York), V14, pS141; Mollmann H, 1997, J CLIN PHARMACOL, V37, P893; MOLLMANN H, 1998, IN PRESS EUR J CLIN; Rohatagi S, 1996, EUR J PHARM SCI, V4, P341, DOI 10.1016/S0928-0987(96)00174-1; Rohatagi S, 1996, J CLIN PHARMACOL, V36, P938, DOI 10.1002/j.1552-4604.1996.tb04761.x; Rohatagi S, 1995, J CLIN PHARMACOL, V35, P1187, DOI 10.1002/j.1552-4604.1995.tb04045.x; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; TOMLINSON RV, 1982, J STEROID BIOCHEM, V16, P75, DOI 10.1016/0022-4731(82)90146-7; WURTHWEIN G, 1992, PHARM ZELT WISSENSCH, V137, P161	23	161	166	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	2	S			S440	S446		10.1016/S0091-6749(98)70156-3	http://dx.doi.org/10.1016/S0091-6749(98)70156-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZK101	9563369				2022-12-18	WOS:000073285000003
J	Holgate, ST; Bradding, P; Sampson, AP				Holgate, ST; Bradding, P; Sampson, AP			Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; leukotrienes; leukotriene D-4 antagonists; 5-lipoxygenase inhibitors; 5-lipoxygenase-activating protein inhibitors; leukotriene B-4 antagonists	EXERCISE-INDUCED BRONCHOCONSTRICTION; LTD4 RECEPTOR ANTAGONIST; ALLERGEN-INDUCED BRONCHOCONSTRICTION; ANTIGEN-INDUCED BRONCHOCONSTRICTION; INDUCED AIRWAY RESPONSES; BRONCHIAL-ASTHMA; ICI 204,219; 5-LIPOXYGENASE INHIBITOR; INHALED CORTICOSTEROIDS; CHEMOTACTIC RESPONSE	This article briefly reviews the advances in our understanding of asthma with a particular focus on the role of inflammation, before providing a concise overview of current knowledge of leukotrienes in the pathophysiology of the disease. The development of leukotriene receptor antagonists and synthesis inhibitors is briefly described; and acute exercise, allergen, and aspirin challenge studies with these agents are reviewed. Clinical studies with leukotriene antagonists and inhibitors have confirmed the central role of leukotrienes in asthma pathophysiology. In conclusion, we suggest that the new generation of leukotriene receptor antagonists may be suitable as first-line therapy in patients with mild to moderate asthma. Further studies are required to determine whether the leukotriene synthesis inhibitors will be equally effective or provide any additional antiinflammatory benefit.			Holgate, ST (corresponding author), UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP,FAC MED,CTR BLOCK,LEVEL D, TREMONA RD, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND.		Sampson, Anthony/C-1112-2011	Bradding, Peter/0000-0001-8403-0319				ARM JP, 1993, CLIN SCI, V84, P501, DOI 10.1042/cs0840501; BARNES NC, 1995, AM J RESP CRIT CARE, V151, pA378; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BARNES PJ, 1992, J INTERN MED, V231, P453, DOI 10.1111/j.1365-2796.1992.tb00960.x; BEASLEY R, 1993, J ALLERGY CLIN IMMUN, V92, P148, DOI 10.1016/0091-6749(93)90097-Y; BJORCK T, 1993, PULM PHARMACOL, V6, P87, DOI 10.1006/pulp.1993.1012; BURNEY PGJ, 1992, BRIT MED BULL, V48, P10, DOI 10.1093/oxfordjournals.bmb.a072527; CALHOUN WJ, 1995, AM J RESP CRIT CARE, V151, pA42; CHANARIN N, 1994, DRUGS, V47, P12, DOI 10.2165/00003495-199447010-00002; CHENG JB, 1992, PULM PHARMACOL THER, V5, P77, DOI 10.1016/0952-0600(92)90023-A; CHUNG KF, 1992, BRIT MED BULL, V48, P135, DOI 10.1093/oxfordjournals.bmb.a072530; CLOUD ML, 1989, AM REV RESPIR DIS, V140, P1336, DOI 10.1164/ajrccm/140.5.1336; COCKCROFT DW, 1993, ANN ALLERGY, V71, P83; Cohn Judith, 1994, P367; DAHLEN B, 1993, THORAX, V48, P1205, DOI 10.1136/thx.48.12.1205; DAHLEN SE, 1993, AIRWAY HYPERRESPONSI, P188; DAMON M, 1989, EUR RESPIR J, V2, P202; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DRAZEN JM, 1995, ASTHMA RHINITIS, P838; FINDLAY SR, 1992, J ALLERGY CLIN IMMUN, V89, P1040, DOI 10.1016/0091-6749(92)90227-S; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; FUJIMURA M, 1993, RESP MED, V87, P133, DOI 10.1016/0954-6111(93)90141-L; FUJIMURA M, 1986, THORAX, V41, P955, DOI 10.1136/thx.41.12.955; FULLER RW, 1987, BRIT J CLIN PHARMACO, V23, P677, DOI 10.1111/j.1365-2125.1987.tb03101.x; GADDY J, 1990, Journal of Allergy and Clinical Immunology, V85, P197; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; GEDDES DM, 1992, THORAX, V47, P404, DOI 10.1136/thx.47.6.404; GLASS M, 1994, J ALLERGY CLIN IMMUN, V93, P295; HUI KP, 1991, THORAX, V46, P184, DOI 10.1136/thx.46.3.184; HUI KP, 1991, LANCET, V337, P1062, DOI 10.1016/0140-6736(91)91709-4; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; ISRAEL E, 1995, AM J RESP CRIT CARE, V151, pA678; JOOS GF, 1991, PULM PHARMACOL THER, V4, P37, DOI 10.1016/0952-0600(91)90037-4; KIDNEY JC, 1993, AM REV RESPIR DIS, V147, P215, DOI 10.1164/ajrccm/147.1.215; KIPS JC, 1993, AM REV RESPIR DIS, V147, pA297; KOH YY, 1993, AM J RESP CELL MOL, V8, P493, DOI 10.1165/ajrcmb/8.5.493; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; Liu M., 1994, European Respiratory Journal, V7, p282S; MAKKER HK, 1993, AM REV RESPIR DIS, V147, P1413, DOI 10.1164/ajrccm/147.6_Pt_1.1413; MANN JS, 1986, THORAX, V41, P746, DOI 10.1136/thx.41.10.746; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MARGOLSKEE D, 1991, Journal of Allergy and Clinical Immunology, V87, P309, DOI 10.1016/0091-6749(91)91959-W; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MILNE AAY, 1995, BRIT J PHARMACOL, V114, pP50; MIYAMOTO T, 1992, 15 EUR C ALL CLIN IM; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; NATHAN RA, 1994, CHEST, V105, P483, DOI 10.1378/chest.105.2.483; OBYRNE PM, 1985, J APPL PHYSIOL, V59, P1941, DOI 10.1152/jappl.1985.59.6.1941; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1431, DOI 10.1164/ajrccm/147.6_Pt_1.1431; PIACENTINI GL, 1991, AM REV RESPIR DIS, V143, pS96; RASMUSSEN JB, 1991, ANN NY ACAD SCI, V629, P436; Reiss T., 1994, European Respiratory Journal, V7, p282S; REISS TF, 1995, AM J RESP CRIT CARE, V151, pA377; RESTRICK LJ, 1995, THORAX, V50, P67, DOI 10.1136/thx.50.1.67; RICHARDS IM, 1991, ANN NY ACAD SCI, V629, P274; ROBUSCHI M, 1992, AM REV RESPIR DIS, V145, P1285, DOI 10.1164/ajrccm/145.6.1285; ROSENBERG MA, 1995, AM AC ALL IMM ANN C; SAMPSON AP, 1992, BRIT J CLIN PHARMACO, V33, P423, DOI 10.1111/j.1365-2125.1992.tb04062.x; SAMPSON AP, 1994, AM J RESP CRIT CARE, V149, pA964; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCHWARTZ HJ, 1995, AM J RESP CRIT CARE, V151, pA376; SEHMI R, 1992, BLOOD, V79, P2952; SHOWELL HJ, 1995, J PHARMACOL EXP THER, V273, P176; SILBAUGH SA, 1987, AM REV RESPIR DIS, V136, P930, DOI 10.1164/ajrccm/136.4.930; SMITH LJ, 1990, AM REV RESPIR DIS, V141, P988, DOI 10.1164/ajrccm/141.4_Pt_1.988; SMITH LJ, 1993, CLIN PHARMACOL THER, V54, P430, DOI 10.1038/clpt.1993.170; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; SPECTOR S, 1995, AM J RESP CRIT CARE, V151, pA379; SPECTOR S L, 1992, American Review of Respiratory Disease, V145, pA16; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; Storms W, 1995, AM J RESP CRIT CARE, V151, pA377; STREK ME, 1995, AM J RESP CRIT CARE, V151, pA377; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; TANIGUCHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P507, DOI 10.1016/0091-6749(93)90074-P; TAYLOR GW, 1989, LANCET, V1, P584; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, pA377; WAHEDNA I, 1991, BRIT J CLIN PHARMACO, V32, P512, DOI 10.1111/j.1365-2125.1991.tb03941.x; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; YAMAOKA KA, 1993, EUR J IMMUNOL, V23, P2392, DOI 10.1002/eji.1830231003; YAMAOKA KA, 1994, CELL IMMUNOL, V156, P124, DOI 10.1006/cimm.1994.1158	88	161	171	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					1	13		10.1016/S0091-6749(96)70220-8	http://dx.doi.org/10.1016/S0091-6749(96)70220-8			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765812				2022-12-18	WOS:A1996VA69200001
J	DAMATO, G; LOBEFALO, G				DAMATO, G; LOBEFALO, G			ALLERGENIC POLLENS IN THE SOUTHERN MEDITERRANEAN AREA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DAMATO, G (corresponding author), HOSP A CARDARELLI,DEPT RESP DIS,SERV OCCUPAT PULM DIS,VIA E NICOLARDI PARCO AVOLIO 32,I-80131 NAPOLI,ITALY.							AAS K, 1972, ACTA ALLERGOL, V27, P439; AROBBA D, 1986, GRANA, V25, P205, DOI 10.1080/00173138609427721; BLANCA M, 1983, CLIN ALLERGY, V13, P473, DOI 10.1111/j.1365-2222.1983.tb02624.x; BOUSQUET J, 1986, CLIN ALLERGY, V16, P57, DOI 10.1111/j.1365-2222.1986.tb01954.x; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; Charpin J., 1974, ATLAS EUROPEAN ALLER; CORBI AL, 1985, ANN ALLERGY, V54, P142; CORBI AL, 1984, INT ARCH ALLER A IMM, V74, P318, DOI 10.1159/000233567; CORBI AL, 1985, INT ARCH ALLER A IMM, V77, P377, DOI 10.1159/000233812; CRIFO S, 1969, ACTA ALLERGOL, V25, P294; DAMATO G, 1983, CLIN ALLERGY, V13, P537, DOI 10.1111/j.1365-2222.1983.tb02635.x; DAMATO G, 1988, ALLERGY, V43, P258, DOI 10.1111/j.1398-9995.1988.tb00898.x; DAMATO G, 1979, ALLERGOL IMMUNOPATH, V7, P263; DAMATO G, IN PRESS CLIN ALLERG; FORD SA, 1986, INT ARCH ALLER A IMM, V79, P120, DOI 10.1159/000233957; GIULIANI A, 1987, ALLERGY, V42, P434, DOI 10.1111/j.1398-9995.1987.tb00359.x; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; Macchia L, 1987, Experientia Suppl, V51, P95; RUFFILLI A, 1987, MOL IMMUNOL, V24, P305, DOI 10.1016/0161-5890(87)90149-0; SERAFINI UMBERTO, 1957, ACTA ALLERGOL, V11, P3, DOI 10.1111/j.1398-9995.1957.tb03005.x; Solomon W. R., 1983, ALLERGY PRINCIPLES P, P1143; SPIEKSMA FTM, 1986, GRANA, V25, P47, DOI 10.1080/00173138609429932	22	161	165	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					116	122		10.1016/0091-6749(89)90485-5	http://dx.doi.org/10.1016/0091-6749(89)90485-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2913131				2022-12-18	WOS:A1989T041900016
J	ARM, JP; SPUR, BW; LEE, TH				ARM, JP; SPUR, BW; LEE, TH			THE EFFECTS OF INHALED LEUKOTRIENE E4 ON THE AIRWAY RESPONSIVENESS TO HISTAMINE IN SUBJECTS WITH ASTHMA AND NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GUYS HOSP,UNITED MED & DENT SCH,DEPT ALLERGY & ALLIED RESP DISORDERS,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London				Lee, Tak/0000-0002-7554-4059; Spur, Bernd/0000-0002-7581-4741				ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; BARNES N, 1984, THORAX, V39, P697; BARNES N C, 1984, American Review of Respiratory Disease, V129, pA1; BARNES PJ, 1984, THORAX, V39, P561, DOI 10.1136/thx.39.8.561; BIANCO S, 1985, PROG RESPIR RES, V19, P82; BISGAARD H, 1987, CLIN SCI, V72, P585, DOI 10.1042/cs0720585; BROCKLEHURST WE, 1962, PROG ALLERGY, V6, P539, DOI 10.1159/000313810; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHOWIENCZYK PJ, 1981, J APPL PHYSIOL, V50, P672, DOI 10.1152/jappl.1981.50.3.672; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; CUSS FM, 1986, LANCET, V2, P189; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; EISER NM, 1980, CLIN SCI, V58, P537, DOI 10.1042/cs0580537; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KERN R, 1986, AM REV RESPIR DIS, V133, P1127; KRILIS S, 1983, J CLIN INVEST, V71, P909, DOI 10.1172/JCI110845; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LEE CW, 1983, J BIOL CHEM, V258, P5004; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P4922, DOI 10.1073/pnas.81.15.4922; LEWIS RA, 1982, INT J IMMUNOPHARMACO, V4, P85, DOI 10.1016/0192-0561(82)90055-8; LEWIS RA, 1980, BIOCHEM BIOPH RES CO, V96, P271, DOI 10.1016/0006-291X(80)91210-3; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; RUBIN AHE, 1987, AM REV RESPIR DIS, V136, P1145, DOI 10.1164/ajrccm/136.5.1145; SAUTEBIN L, 1985, J PHARMACOL EXP THER, V234, P217; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; STEWART AG, 1984, AGENTS ACTIONS, V15, P500, DOI 10.1007/BF01966763; THOMSON NC, 1981, J ALLERGY CLIN IMMUN, V68, P392, DOI 10.1016/0091-6749(81)90138-X; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; WALTERS EH, 1981, THORAX, V36, P571, DOI 10.1136/thx.36.8.571; 1986, NAG GLIM SYSTEM RELE	41	161	161	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					654	660		10.1016/0091-6749(88)90979-7	http://dx.doi.org/10.1016/0091-6749(88)90979-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	2844876				2022-12-18	WOS:A1988Q639900019
J	TOOGOOD, JH; JENNINGS, B; GREENWAY, RW; CHUANG, L				TOOGOOD, JH; JENNINGS, B; GREENWAY, RW; CHUANG, L			CANDIDIASIS AND DYSPHONIA COMPLICATING BECLOMETHASONE TREATMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN ONTARIO, SCH MED, DEPT MED, HAMILTON, ONTARIO, CANADA; UNIV WESTERN ONTARIO, SCH MED, DEPT OTOLARYNGOL, HAMILTON, ONTARIO, CANADA	McMaster University; Western University (University of Western Ontario); Western University (University of Western Ontario)	TOOGOOD, JH (corresponding author), VICTORIA HOSP, ALLERGY CLIN, LONDON N6A 4G5, ONTARIO, CANADA.							BERGNER RK, 1977, AM FAM PHYSICIAN, V15, P141; CAYTON RM, 1974, LANCET, V2, P303; CHATTERJEE SS, 1977, BRIT J CLIN PHARMACO, V4, P2555; COOPER EJ, 1977, Q J MED, V46, P295; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; FINLAND M, 1973, J INFECT DIS, V128, pS792, DOI 10.1093/infdis/128.Supplement_3.S792; GODFREY S, 1974, BMJ-BRIT MED J, V2, P387, DOI 10.1136/bmj.2.5915.387-b; GRANT IWB, 1974, LANCET, V2, P838; HALLWORTH GW, 1976, J PHARM PHARMACOL, V28, P898, DOI 10.1111/j.2042-7158.1976.tb04088.x; HILLER C, 1978, CLIN RES, V26, pA37; HUSKISSON EC, 1974, BMJ-BRIT MED J, V2, P698, DOI 10.1136/bmj.2.5921.698; KASS I, 1977, CHEST, V71, P703, DOI 10.1378/chest.71.6.703; KERIGAN AT, 1977, CAN MED ASSOC J, V116, P867; KERSHNAR H, 1978, PEDIATRICS, V62, P189; KLEIN R, 1977, PEDIATRICS, V60, P7; KNIGHT L, 1971, J INFECT DIS, V123, P371, DOI 10.1093/infdis/123.4.371; KRIZ RJ, 1976, CHEST, V69, P455, DOI 10.1378/chest.69.4.455; KRIZ RJ, 1977, CHEST, V72, P36, DOI 10.1378/chest.72.1.36; LEEHONG E, 1977, ANN ALLERGY, V38, P242; LEHNER T, 1970, BRIT J DERMATOL, V83, P161, DOI 10.1111/j.1365-2133.1970.tb12878.x; LINDGREN S, 1977, Scandinavian Journal of Respiratory Diseases Supplementum, V101, P163; MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171; MILNE LJR, 1974, BRIT MED J, V3, P797, DOI 10.1136/bmj.3.5934.797; MORROWBROWN H, 1977, BR J CLIN PHARM, V4, pS259; MUNT PW, 1979, CAN MED ASSOC J, V120, P781; NEWHOUSE MT, 1978, CHEST, V735, pS936; OREHEK J, 1976, BRIT MED J, V1, P76, DOI 10.1136/bmj.1.6001.76; PATERSON IC, 1976, BRIT MED J, V1, P76, DOI 10.1136/bmj.1.6001.76-a; PINGLETON WW, 1977, J ALLERGY CLIN IMMUN, V60, P254, DOI 10.1016/0091-6749(77)90140-3; RUFFIN RE, 1978, CLIN PHARMACOL THER, V23, P338; SLY RM, 1978, J ALLERGY CLIN IMMUN, V62, P76, DOI 10.1016/0091-6749(78)90082-9; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TOOGOOD JH, 1978, J ALLERGY CLIN IMMUN, V61, P355, DOI 10.1016/0091-6749(78)90114-8; WALDMAN D, 1976, J ALLERGY CLIN IMMUN, V3, P256; WEBB DR, 1977, JAMA-J AM MED ASSOC, V238, P1508, DOI 10.1001/jama.238.14.1508; WILLEY RF, 1976, BRIT J DIS CHEST, V70, P32, DOI 10.1016/0007-0971(76)90004-8; WILLIAMS MH, 1974, AM REV RESPIR DIS, V109, P538; 1976, BRIT J DIS CHEST, V70, P95; 1969, COMMITTEE STANDARDS; 1977, LANCET, V2, P695	40	161	166	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					145	153		10.1016/0091-6749(80)90200-6	http://dx.doi.org/10.1016/0091-6749(80)90200-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199	7351447	Bronze			2022-12-18	WOS:A1980JF19900011
J	WEBER, RW; HOFFMAN, M; RAINE, DA; NELSON, HS				WEBER, RW; HOFFMAN, M; RAINE, DA; NELSON, HS			INCIDENCE OF BRONCHOCONSTRICTION DUE TO ASPIRIN, AZO DYES, NON-AZO DYES, AND PRESERVATIVES IN A POPULATION OF PERENNIAL ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SECT,DENVER,CO 80240									BASOMBA A, 1976, CLIN ALLERGY, V6, P269, DOI 10.1111/j.1365-2222.1976.tb01907.x; CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; DELANEY JC, 1976, CLIN ALLERGY, V6, P365, DOI 10.1111/j.1365-2222.1976.tb01917.x; DELANEY JC, 1976, PRACTITIONER, V217, P285; Dysart BR, 1933, J AMER MED ASSOC, V101, P446, DOI 10.1001/jama.1933.27430310002009a; FALLIERS CJ, 1973, J ALLERGY CLIN IMMUN, V52, P141, DOI 10.1016/0091-6749(73)90030-4; FISHERMAN EW, 1973, ANN ALLERGY, V31, P126; FRIEDLAENDER S, 1947, ANN INTERN MED, V26, P734, DOI 10.7326/0003-4819-26-5-734; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; Lamson RW, 1932, J AMER MED ASSOC, V99, P107, DOI 10.1001/jama.1932.02740540015005; MacDonald IG, 1932, ANN INTERN MED, V6, P253, DOI 10.7326/0003-4819-6-2-253; MCCARTHY DS, 1975, AM REV RESPIR DIS, V112, P407; RACHELEFSKY GS, 1975, PEDIATRICS, V56, P443; Rosenhall L, 1973, Lakartidningen, V70, P1417; ROSENTHAL L, 1977, ACTA U UPSALIENSIS, P269; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; STENIUS BSM, 1976, CLIN ALLERGY, V6, P119, DOI 10.1111/j.1365-2222.1976.tb01889.x; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; VANLEEUWEN WS, 1928, MUCH MED WOECHENSCHR, V75, P1588; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2	24	161	161	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	1					32	37		10.1016/0091-6749(79)90080-0	http://dx.doi.org/10.1016/0091-6749(79)90080-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HC424	447949				2022-12-18	WOS:A1979HC42400008
J	Cervia, C; Nilsson, J; Zurbuchen, Y; Valaperti, A; Schreiner, J; Wolfensberger, A; Raeber, ME; Adamo, S; Weigang, S; Emmenegger, M; Hasler, S; Bosshard, PP; De Cecco, E; Bachli, E; Rudiger, A; Stussi-Helbling, M; Huber, LC; Zinkernagel, AS; Schaer, DJ; Aguzzi, A; Kochs, G; Held, U; Probst-Muller, E; Rampini, SK; Boyman, O				Cervia, Carlo; Nilsson, Jakob; Zurbuchen, Yves; Valaperti, Alan; Schreiner, Jens; Wolfensberger, Aline; Raeber, Miro E.; Adamo, Sarah; Weigang, Sebastian; Emmenegger, Marc; Hasler, Sara; Bosshard, Philipp P.; De Cecco, Elena; Baechli, Esther; Rudiger, Alain; Stuessi-Helbling, Melina; Huber, Lars C.; Zinkernagel, Annelies S.; Schaer, Dominik J.; Aguzzi, Adriano; Kochs, Georg; Held, Ulrike; Probst-Mueller, Elsbeth; Rampini, Silvana K.; Boyman, Onur			Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; SARS-CoV-2-specific antibodies; SARS-CoV-2-specific IgA; SARS-CoV-2-specific IgG; humoral immune response; mucosal immune response; COVID-19 severity; COVID-19 seroprevalence		Background: Whereas severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody tests are increasingly being used to estimate the prevalence of SARS-CoV-2 infection, the determinants of these antibody responses remain unclear. Objectives: Our aim was to evaluate systemic and mucosal antibody responses toward SARS-CoV-2 in mild versus severe coronavirus disease 2019 (COVID-19) cases. Methods: Using immunoassays specific for SARS-CoV-2 spike proteins, we determined SARS-CoV-2-specific IgA and IgG in sera and mucosal fluids of 2 cohorts, including SARS-CoV-2 PCR-positive patients (n 5 64) and PCR-positive and PCRnegtive health care workers (n 5 109). Results: SARS-CoV-2-specific serum IgA titers in patients with mild COVID-19 were often transiently positive, whereas serum IgG titers remained negative or became positive 12 to 14 days after symptom onset. Conversely, patients with severe COVID19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers after symptom onset. Very high titers of SARS-CoV-2-specific serum IgA were correlated with severe acute respiratory distress syndrome. Interestingly, some health care workers with negative SARS-CoV-2-specific serum antibody titers showed SARS-CoV-2-specific IgA in mucosal fluids with virus-neutralizing capacity in some cases. SARSCoV-2-specific IgA titers in nasal fluids were inversely correlated with age. Conclusions: Systemic antibody production against SARS-CoV2 develops mainly in patients with severe COVID-19, with very high IgA titers seen in patients with severe acute respiratory distress syndrome, whereas mild disease may be associated with transient production of SARS-CoV-2-specific antibodies but may stimulate mucosal SARS-CoV-2-specific IgA secretion. (J Allergy	[Cervia, Carlo; Nilsson, Jakob; Zurbuchen, Yves; Valaperti, Alan; Schreiner, Jens; Raeber, Miro E.; Adamo, Sarah; Hasler, Sara; Probst-Mueller, Elsbeth; Boyman, Onur] Univ Hosp Zurich, Dept Immunol, Gloriastr 23, CH-8091 Zurich, Switzerland; [Wolfensberger, Aline; Zinkernagel, Annelies S.] Univ Hosp Zurich, Dept Infect Dis & Hosp Epidemiol, Zurich, Switzerland; [Emmenegger, Marc; De Cecco, Elena; Aguzzi, Adriano] Univ Hosp Zurich, Inst Neuropathol, Zurich, Switzerland; [Bosshard, Philipp P.] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland; [Schaer, Dominik J.; Rampini, Silvana K.] Univ Hosp Zurich, Dept Internal Med, Zurich, Switzerland; [Weigang, Sebastian; Kochs, Georg] Univ Freiburg, Inst Virol, Med Ctr, Freiburg, Germany; [Kochs, Georg] Univ Freiburg, Fac Med, Freiburg, Germany; [Baechli, Esther] Uster Hosp, Clin Internal Med, Uster, Switzerland; [Rudiger, Alain] Limmattal Hosp, Dept Med, Schlieren, Switzerland; [Stuessi-Helbling, Melina; Huber, Lars C.] City Hosp Triemli Zurich, Clin Internal Med, Zurich, Switzerland; [Held, Ulrike] Univ Zurich, Epidemiol Biostat & Prevent Inst, Dept Biostat, Zurich, Switzerland; [Boyman, Onur] Univ Zurich, Fac Med, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Freiburg; University of Freiburg; Triemli Hospital; University of Zurich; University of Geneva; University of Zurich	Boyman, O (corresponding author), Univ Hosp Zurich, Dept Immunol, Gloriastr 23, CH-8091 Zurich, Switzerland.	onur.boyman@uzh.ch	Cervia, Carlo/GRR-2202-2022; Wolfensberger, Aline/T-1740-2017; Bosshard, Philipp Peter/AFU-8646-2022; Raeber, Miro E/J-7626-2012; Zinkernagel, Annelies/F-1780-2017	Wolfensberger, Aline/0000-0001-9028-0007; Bosshard, Philipp Peter/0000-0002-1154-2281; Raeber, Miro E/0000-0003-2609-0246; Hasler, Sara/0000-0001-7357-9090; Valaperti, Alan/0000-0002-4097-0912; Weigang, Sebastian/0000-0002-8415-6920; Aguzzi, Adriano/0000-0002-0344-6708; Zinkernagel, Annelies/0000-0003-4700-1118; Zurbuchen, Yves/0000-0001-5387-9950; Cervia, Carlo/0000-0001-7120-8739; Boyman, Onur/0000-0001-8279-5545	Swiss National Science Foundation [4078P0-198431, 310030-172978]; Swiss Academy of Medical Sciences [323530-191220, 323530-191230, 323530-177975, YTCR 32/18]; Bangerter Foundation [YTCR 32/18]; Bundesministerium fur Bildung und Forschung through Deutsches Zentrum fur Luft- und Raumfahrt [01KI2077]; University of Zurich; University Hospital Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Academy of Medical Sciences; Bangerter Foundation; Bundesministerium fur Bildung und Forschung through Deutsches Zentrum fur Luft- und Raumfahrt; University of Zurich; University Hospital Zurich	This work was funded by the Swiss National Science Foundation (grant 4078P0-198431 [to O.B. and J.N.] and grant 310030-172978 [to O.B.]), Swiss Academy of Medical Sciences fellowships (No. 323530-191220 [to C.C.], No. 323530-191230 [to Y.Z.], and No. 323530-177975 [to S.A.]), a Young Talents in Clinical Research Fellowship by the Swiss Academy of Medical Sciences and Bangerter Foundation (No. YTCR 32/18 [to M.R.]), the Bundesministerium fur Bildung und Forschung through Deutsches Zentrum fur Luft- und Raumfahrt (No. 01KI2077 [to G.K.]), the Clinical Research Priority Program of University of Zurich for CRPP CYTIMM-Z (to O.B.), the Pandemic Fund of University of Zurich (to O.B.), and an Innovation Grant of University Hospital Zurich (to O.B.).	Adamo S., 2020, LYMPHOPENIA INDUCED, DOI [10.1101/2020.08.04.236521, DOI 10.1101/2020.08.04.236521]; Amanna IJ, 2010, IMMUNOL REV, V236, P125, DOI 10.1111/j.1600-065X.2010.00912.x; [Anonymous], 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457; Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Brodin P, 2017, NAT REV IMMUNOL, V17, P21, DOI 10.1038/nri.2016.125; Bryant JE, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc6347; CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019; Chan CM, 2009, J CLIN VIROL, V45, P54, DOI 10.1016/j.jcv.2009.02.011; Chevrier S, DISTINCT INNATE IMMU, DOI [10.1101/2020.08.04.236315., DOI 10.1101/2020.08.04.236315]; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Emmenegger M, EARLY PEAK RAPID DE, DOI [10.1101/2020.05.31.20118554v4, DOI 10.1101/2020.05.31.20118554V4]; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Goronzy JJ, 2017, IMMUNITY, V46, P364, DOI 10.1016/j.immuni.2017.03.010; Hollander M., 2014, NONPARAMETRIC STAT M; HoLmann M, 2020, CELL, V181, DOI [10.1016/ j.cell.2020.02.052, 10.1016/j.cell.2020.02.052, DOI 10.1016/J.CELL.2020.02.052]; Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16; Kaegi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01990; Kelly, 2020, BIORXIV PREPRINT, DOI [10.1101/2020.04.27.062315, DOI 10.1101/2020.04.27.062315]; Li RY, 2020, SCIENCE, V368, P489, DOI [10.1126/science.abb3221, 10.1101/2020.02.14.20023127]; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2; Meyer B, 2020, Clin Microbiol Infect, V26, P1386, DOI 10.1016/j.cmi.2020.06.024; Ng Kevin W, 2020, Science, V370, P1339, DOI 10.1126/science.abe1107; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Schulz KS, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00498; Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783; Swissnoso, REC HEALTHC WORK HAV; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Thissen D, 2002, J EDUC BEHAV STAT, V27, P77, DOI 10.3102/10769986027001077; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Tong ZD, 2020, EMERG INFECT DIS, V26, P1052, DOI 10.3201/eid2605.200198; van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193; WHO, CLIN MAN SEV RESP IN; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yu HQ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01526-2020; Yu Y., 2020, LANCET RESP MED, V8, P481; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	45	160	161	17	63	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					545	+		10.1016/j.jaci.2020.10.040	http://dx.doi.org/10.1016/j.jaci.2020.10.040		FEB 2021	22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	33221383	Green Published, hybrid, Green Accepted, Green Submitted			2022-12-18	WOS:000616665800015
J	Peters, RL; Koplin, JJ; Gurrin, LC; Dharmage, SC; Wake, M; Ponsonby, AL; Tang, MLK; Lowe, AJ; Matheson, M; Dwyer, T; Allen, KJ				Peters, Rachel L.; Koplin, Jennifer J.; Gurrin, Lyle C.; Dharmage, Shyamali C.; Wake, Melissa; Ponsonby, Anne-Louise; Tang, Mimi L. K.; Lowe, Adrian J.; Matheson, Melanie; Dwyer, Terence; Allen, Katrina J.		HealthNuts Study	The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; eczema; egg allergy; food allergy; allergic rhinitis; HealthNuts; longitudinal study; peanut allergy; prevalence; population-based study; sesame allergy	NATURAL-HISTORY; ASTHMA; PREDICTORS; CHILDREN; EGG; SYMPTOMS; VALIDITY; CRITERIA; PHASE-3; TRENDS	Background: The HealthNuts study previously reported interim prevalence data showing the highest prevalence of challenge-confirmed food allergy in infants internationally. However, population-derived prevalence data on challenge-confirmed food allergy and other allergic diseases in preschool-aged children remain sparse. Objective: This study aimed to report the updated prevalence of food allergy at age 1 year from the whole cohort, and to report the prevalence of food allergy, asthma, eczema, and allergic rhinitis at age 4 years. Methods: HealthNuts is a population-based cohort study with baseline recruitment of 5276 one-year-old children who underwent skin prick test (SPT) to 4 food allergens and those with detectable SPT results had formal food challenges. At age 4 years, parents completed a questionnaire (81.3% completed) and those who previously attended the HealthNuts clinic at age 1 year or reported symptoms of a new food allergy were invited for an assessment that included SPT and oral food challenges. Data on asthma, eczema, and allergic rhinitis were captured by validated International Study of Asthma and Allergies in Childhood questionnaires. Results: The prevalence of challenge-confirmed food allergy at age 1 and 4 years was 11.0% and 3.8%, respectively. At age 4 years, peanut allergy prevalence was 1.9% (95% CI, 1.6% to 2.3%), egg allergy was 1.2% (95% CI, 0.9% to 1.6%), and sesame allergy was 0.4% (95% CI, 0.3% to 0.6%). Late-onset peanut allergy at age 4 years was rare (0.2%). The prevalence of current asthma was 10.8% (95% CI, 9.7% to 12.1%), current eczema was 16.0% (95% CI, 14.7% to 17.4%), and current allergic rhinitis was 8.3% (95% CI, 7.2% to 9.4%). Forty percent to 50% of this population-based cohort experienced symptoms of an allergic disease in the first 4 years of their life. Conclusions: Although the prevalence of food allergy decreased between age 1 year and age 4 years in this population-based cohort, the prevalence of any allergic disease among 4-year-old children in Melbourne, Australia, is remarkably high.	[Peters, Rachel L.; Koplin, Jennifer J.; Wake, Melissa; Ponsonby, Anne-Louise; Tang, Mimi L. K.; Dwyer, Terence; Allen, Katrina J.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Koplin, Jennifer J.; Gurrin, Lyle C.; Dharmage, Shyamali C.; Ponsonby, Anne-Louise; Lowe, Adrian J.; Matheson, Melanie] Univ Melbourne, Sch Populat & Global Hlth, Carlton, Vic, Australia; [Wake, Melissa; Tang, Mimi L. K.; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Wake, Melissa] Univ Auckland, Dept Paediat, Auckland, New Zealand; [Wake, Melissa] Univ Auckland, Liggins Inst, Auckland, New Zealand; [Tang, Mimi L. K.; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic, Australia; [Dwyer, Terence] Univ Oxford, George Inst Global Hlth, Oxford, England; [Allen, Katrina J.] Univ Manchester, Inst Inflammat & Repair, Manchester, Lancs, England	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; University of Auckland; University of Auckland; Royal Children's Hospital Melbourne; University of Oxford; University of Manchester	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Wake, Melissa/J-1396-2012; Allen, Katrina/I-4361-2018; Tang, Mimi/ABD-8350-2020; Ponsonby, Anne-Louise/AAE-4351-2019	Wake, Melissa/0000-0001-7501-9257; Allen, Katrina/0000-0002-1921-4493; Tang, Mimi/0000-0002-3839-5293; Ponsonby, Anne-Louise/0000-0002-6581-3657; Gurrin, Lyle/0000-0001-7052-1969; Peters, Rachel/0000-0002-2411-6628; Koplin, Jennifer/0000-0002-7576-5142	National Health & Medical Research Council (NHMRC) of Australia; Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program; NHMRC Centre for Food and Allergy Research	National Health & Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program; NHMRC Centre for Food and Allergy Research(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by funding from the National Health & Medical Research Council (NHMRC) of Australia, Ilhan Food Allergy Foundation, AnaphylaxiStop, the Charles and Sylvia Viertel Medical Research Foundation, the Victorian Government's Operational Infrastructure Support Program, and the NHMRC Centre for Food and Allergy Research. K.J.A., L.C.G., A.J.L., M.W., J.J.K., and S.C.D. hold NHMRC awards.	Ait-Khaled N, 2009, ALLERGY, V64, P123, DOI 10.1111/j.1398-9995.2008.01884.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Basera W, 2015, ANN ALLERG ASTHMA IM, V115, P113, DOI 10.1016/j.anai.2015.06.003; Ben-Shoshan M, 2012, CURR ALLERGY ASTHM R, V12, P346, DOI 10.1007/s11882-012-0274-3; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Chen J, 2011, PEDIAT ALLERG IMM-UK, V22, P356, DOI 10.1111/j.1399-3038.2011.01139.x; Goksor E, 2016, ACTA PAEDIATR, V105, P1472, DOI 10.1111/apa.13515; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Koplin JJ, 2015, INT J EPIDEMIOL, V44, P1161, DOI 10.1093/ije/dyu261; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; Lai CKW, 2009, THORAX, V64, P476, DOI 10.1136/thx.2008.106609; Lodge CJ, 2014, J PEDIATR-US, V164, P289, DOI 10.1016/j.jpeds.2013.09.056; Lundback B, 2016, EXPERT REV RESP MED, V10, P39, DOI 10.1586/17476348.2016.1114417; Mallol J, 2013, ALLERGOL IMMUNOPATH, V41, P73, DOI 10.1016/j.aller.2012.03.001; Mullins RJ, 2015, J ALLERGY CLIN IMMUN, V136, P367, DOI 10.1016/j.jaci.2015.05.009; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Peters RL, 2013, J ALLERGY CLIN IMMUN, V132, P874, DOI 10.1016/j.jaci.2013.05.038; Prescott S, 2011, PEDIAT ALLERG IMM-UK, V22, P155, DOI 10.1111/j.1399-3038.2011.01145.x; Schoemaker AA, 2015, ALLERGY, V70, P963, DOI 10.1111/all.12630; Tey D, 2014, J ALLERGY CLIN IMMUN, V133, P476, DOI 10.1016/j.jaci.2013.11.019; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Williamson EJ, 2014, RESPIROLOGY, V19, P625, DOI 10.1111/resp.12312; Xepapadaki P, 2016, ALLERGY, V71, P350, DOI 10.1111/all.12801	28	160	168	2	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					145	+		10.1016/j.jaci.2017.02.019	http://dx.doi.org/10.1016/j.jaci.2017.02.019			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28514997	Bronze, Green Submitted			2022-12-18	WOS:000404542000014
J	Ganson, NJ; Povsic, TJ; Sullenger, BA; Alexander, JH; Zelenkofske, SL; Sailstad, JM; Rusconi, CP; Hershfield, MS				Ganson, Nancy J.; Povsic, Thomas J.; Sullenger, Bruce A.; Alexander, John H.; Zelenkofske, Steven L.; Sailstad, Jeffrey M.; Rusconi, Christopher P.; Hershfield, Michael S.			Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							REGULATORY T-CELLS; HUMAN IMMUNE-SYSTEM; TRANSCRIPTION FACTOR FOXP3; HEALTHY-YOUNG MEN; INFLAMMATORY RESPONSE; REG-CELLS; EXERCISE; TOLERANCE; DISEASE; TRIAL		[Ganson, Nancy J.; Hershfield, Michael S.] Duke Univ, Med Ctr, Dept Med, Div Rheumatol, Durham, NC 27710 USA; [Povsic, Thomas J.; Alexander, John H.] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA; [Povsic, Thomas J.; Alexander, John H.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Sullenger, Bruce A.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Zelenkofske, Steven L.] Regado Biosci, Basking Ridge, NJ USA; [Sailstad, Jeffrey M.] Sailstad & Associates, Durham, NC USA; [Rusconi, Christopher P.] Regado Biosci, Durham, NC USA; [Hershfield, Michael S.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Hershfield, MS (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Rheumatol, Durham, NC 27710 USA.; Hershfield, MS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	michael.hershfield@dm.duke.edu	Alexander, John/GVS-7271-2022	Alexander, John/0000-0002-1444-2462	NHLBI NIH HHS [R01 HL065222, U54 HL112307] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL112307] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arvey A, 2014, NAT IMMUNOL, V15, P580, DOI 10.1038/ni.2868; Bommireddy R, 2007, TRENDS MOL MED, V13, P492, DOI 10.1016/j.molmed.2007.08.005; Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; Carbone F, 2014, NAT MED, V20, P69, DOI 10.1038/nm.3411; Chaudhry A, 2013, J CLIN INVEST, V123, P939, DOI 10.1172/JCI57175; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; D'Errico MN, 2012, INT J IMMUNOPATH PH, V25, P1041, DOI 10.1177/039463201202500421; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Fernandes JL, 2011, CLIN RES CARDIOL, V100, P77, DOI 10.1007/s00392-010-0215-x; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Hackney AC, 2012, ACTA CLIN CROAT, V51, P633; Handzlik MK, 2013, EUR J APPL PHYSIOL, V113, P1839, DOI 10.1007/s00421-013-2614-y; Harris MD, 2011, CURR SPORT MED REP, V10, P84, DOI 10.1249/JSR.0b013e3182142381; Hershfield MS, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4500; Kolte L, 2011, BLOOD, V117, P1861, DOI 10.1182/blood-2010-07-298992; Kwoh TJ, 2007, ANTISENSE DRUG TECHN, P365; Lambert CP, 2000, EUR J APPL PHYSIOL, V82, P151, DOI 10.1007/s004210050665; Lipsky PE, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4497; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Longo N, 2014, LANCET, V384, P37, DOI 10.1016/S0140-6736(13)61841-3; Mackinnon LT, 2000, IMMUNOL CELL BIOL, V78, P502, DOI 10.1046/j.1440-1711.2000.00955.x; Marabelle A, 2013, J CLIN INVEST, V123, P2447, DOI 10.1172/JCI64859; Matarese G, 2010, TRENDS MOL MED, V16, P247, DOI 10.1016/j.molmed.2010.04.002; Moreira A, 2009, BRIT MED BULL, V90, P111, DOI 10.1093/bmb/ldp010; Nguyen KD, 2009, J ALLERGY CLIN IMMUN, V123, P933, DOI 10.1016/j.jaci.2008.11.037; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Perandini LA, 2012, AUTOIMMUN REV, V12, P218, DOI 10.1016/j.autrev.2012.06.007; Povsic TJ, 2013, EUR HEART J, V34, P2481, DOI 10.1093/eurheartj/ehs232; Purvis D, 2010, PM&R, V2, P442, DOI 10.1016/j.pmrj.2010.03.025; Roederer M, 2015, CELL, V161, P387, DOI 10.1016/j.cell.2015.02.046; Rudensky AY, 2011, IMMUNOL REV, V241, P260, DOI 10.1111/j.1600-065X.2011.01018.x; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Sjaheim TB, 2013, SCAND J IMMUNOL, V77, P398, DOI 10.1111/sji.12035; Sundstrom J, 2015, ANN INTERN MED, V162, P184, DOI 10.7326/M14-0773; Suzuki K, 2002, EXERC IMMUNOL REV, V8, P6; Ulven SM, 2015, ARCH PHYSIOL BIOCHEM, V121, P41, DOI 10.3109/13813455.2014.1003566; Walsh NP, 2011, EXERC IMMUNOL REV, V17, P6; Woodruff RS, 2015, ARTERIOSCL THROM VAS, V35, P2083, DOI 10.1161/ATVBAHA.115.300131; Yang Q, 2015, WIRES NANOMED NANOBI, V7, P655, DOI 10.1002/wnan.1339; Yin LS, 2015, CELL IMMUNOL, V295, P118, DOI 10.1016/j.cellimm.2015.03.002; Zandman-Goddard G, 2007, AUTOIMMUN REV, V6, P366, DOI 10.1016/j.autrev.2006.10.001; Zhou G, 2007, J IMMUNOL, V178, P2155, DOI 10.4049/jimmunol.178.4.2155	45	160	162	4	54	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1610	1613		10.1016/j.jaci.2015.10.034	http://dx.doi.org/10.1016/j.jaci.2015.10.034			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26688515	hybrid, Green Accepted			2022-12-18	WOS:000376180200044
J	Chinthrajah, RS; Hernandez, JD; Boyd, SD; Galli, SJ; Nadeau, KC				Chinthrajah, R. Sharon; Hernandez, Joseph D.; Boyd, Scott D.; Galli, Stephen J.; Nadeau, Kari C.			Molecular and cellular mechanisms of food allergy and food tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; microbiome; sensitization; desensitization; immunotherapy; tolerance; regulatory T cells; basophils; mast cells; dendritic cells	REGULATORY T-CELLS; INNATE LYMPHOID-CELLS; TRANSEPITHELIAL ANTIGEN TRANSPORT; PEANUT ORAL IMMUNOTHERAPY; OF-FUNCTION MUTATIONS; DUST MITE ALLERGEN; COWS MILK ALLERGY; FC-GAMMA-RIIB; DENDRITIC CELLS; IMMUNE-RESPONSES	Ingestion of innocuous antigens, including food proteins, normally results in local and systemic immune nonresponsiveness in a process termed oral tolerance. Oral tolerance to food proteins is likely to be intimately linked to mechanisms that are responsible for gastrointestinal tolerance to large numbers of commensal microbes. Here we review our current understanding of the immune mechanisms responsible for oral tolerance and how perturbations in these mechanisms might promote the loss of oral tolerance and development of food allergies. Roles for the commensal microbiome in promoting oral tolerance and the association of intestinal dysbiosis with food allergy are discussed. Growing evidence supports cutaneous sensitization to food antigens as one possible mechanism leading to the failure to develop or loss of oral tolerance. A goal of immunotherapy for food allergies is to induce sustained desensitization or even true long-term oral tolerance to food allergens through mechanisms that might in part overlap with those associated with the development of natural oral tolerance.	[Chinthrajah, R. Sharon; Nadeau, Kari C.] Stanford Univ, Dept Med, Sch Med, 269 Campus Dr,CCSR 3215,MC 5366, Stanford, CA 94305 USA; [Chinthrajah, R. Sharon; Hernandez, Joseph D.; Nadeau, Kari C.] Stanford Univ, Dept Pediat, Sch Med, 269 Campus Dr,CCSR 3215,MC 5366, Stanford, CA 94305 USA; [Hernandez, Joseph D.; Boyd, Scott D.; Galli, Stephen J.] Stanford Univ, Dept Pathol, Sch Med, 269 Campus Dr,CCSR 3215,MC 5366, Stanford, CA 94305 USA; [Galli, Stephen J.] Stanford Univ, Dept Microbiol & Immunol, Sch Med, 269 Campus Dr,CCSR 3215,MC 5366, Stanford, CA 94305 USA; [Chinthrajah, R. Sharon; Hernandez, Joseph D.; Boyd, Scott D.; Galli, Stephen J.; Nadeau, Kari C.] Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Sch Med, 269 Campus Dr,CCSR 3215,MC 5366, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Nadeau, KC (corresponding author), Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Sch Med, Div Pulm & Crit Care Med,Dept Med, 269 Campus Dr,CCSR 3215,MC 5366, Stanford, CA 94305 USA.	knadeau@stanford.edu		Chinthrajah, Sharon/0000-0003-2467-4256	Sean N. Parker Center for Allergy and Asthma Research; National Institutes of Health [R01 AR067145, U19AI10420901]; American Academy of Allergy, Asthma & Immunology Mylan Anaphylaxis Award; Child Health Research Institute/Lucile Packard Foundation for Children's Health awards; Stanford CTSA [UL1 TR001085]; Department of Pathology, Stanford University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067145] Funding Source: NIH RePORTER	Sean N. Parker Center for Allergy and Asthma Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma & Immunology Mylan Anaphylaxis Award; Child Health Research Institute/Lucile Packard Foundation for Children's Health awards; Stanford CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Department of Pathology, Stanford University(Stanford University); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Sean N. Parker Center for Allergy and Asthma Research; National Institutes of Health grants R01 AR067145 (to S.J.G.) and U19AI10420901 (to S.J.G., K.C.N., S.D.B., and R.S.C.); the American Academy of Allergy, Asthma & Immunology Mylan Anaphylaxis Award and Child Health Research Institute/Lucile Packard Foundation for Children's Health awards (to J.D.H.); Stanford CTSA (UL1 TR001085); and the Department of Pathology, Stanford University.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Allam JP, 2010, J ALLERGY CLIN IMMUN, V126, P638, DOI 10.1016/j.jaci.2010.04.039; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Aslam A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011028; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Bain CC, 2011, EUR J IMMUNOL, V41, P2494, DOI 10.1002/eji.201141714; Barone KS, 2000, CELL IMMUNOL, V199, P65, DOI 10.1006/cimm.1999.1603; Battaglia M, 2004, ANN NY ACAD SCI, V1029, P142, DOI 10.1196/annals.1309.031; Begin P, 2014, HUM VACC IMMUNOTHER, V10, P2295, DOI 10.4161/hv.29233; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-1; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-7; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Bogunovic M, 2009, IMMUNITY, V31, P513, DOI 10.1016/j.immuni.2009.08.010; Brandtzaeg P, 1998, NUTR REV, V56, pS5; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Bussmann C, 2010, ALLERGY, V65, P1558, DOI 10.1111/j.1398-9995.2010.02430.x; CALLERY MP, 1989, J SURG RES, V46, P391, DOI 10.1016/0022-4804(89)90208-4; Canani RB, 2016, ISME J, V10, P742, DOI 10.1038/ismej.2015.151; Canani RB, 2015, CURR OPIN ALLERGY CL, V15, P243, DOI 10.1097/ACI.0000000000000157; Canani RB, 2013, J PEDIATR-US, V163, P771, DOI 10.1016/j.jpeds.2013.03.008; Canani RB, 2012, J ALLERGY CLIN IMMUN, V129, P580, DOI 10.1016/j.jaci.2011.10.004; Cao S, 2014, FEBS LETT, V588, P4258, DOI 10.1016/j.febslet.2014.04.026; Cassani B, 2011, GASTROENTEROLOGY, V141, P2109, DOI 10.1053/j.gastro.2011.09.015; Chambers SJ, 2004, IMMUNOLOGY, V112, P72, DOI 10.1111/j.1365-2567.2004.01846.x; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Clayburgh DR, 2006, J CLIN INVEST, V116, P2682, DOI 10.1172/JCI29218; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Cox LM, 2014, CELL, V158, P705, DOI 10.1016/j.cell.2014.05.052; David LA, 2015, MBIO, V6, DOI 10.1128/mBio.00381-15; de Boissieu D, 2006, ALLERGY, V61, P1238, DOI 10.1111/j.1398-9995.2006.01196.x; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Di Meglio P, 2011, IMMUNITY, V35, P857, DOI 10.1016/j.immuni.2011.12.003; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Doherty TA, 2014, J ALLERGY CLIN IMMUN, V133, P1203, DOI 10.1016/j.jaci.2013.12.1086; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; Dupont C, 2014, 2014 AM AC ALL ASTHM; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; EBERLEINKONIG B, 1995, CLIN EXP ALLERGY, V25, P704, DOI 10.1111/j.1365-2222.1995.tb00007.x; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Elazab N, 2013, PEDIATRICS, V132, pE666, DOI 10.1542/peds.2013-0246; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Forbes-Blom E, 2012, CLIN EXP ALLERGY, V42, P305, DOI 10.1111/j.1365-2222.2011.03861.x; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Goubier A, 2008, IMMUNITY, V29, P464, DOI 10.1016/j.immuni.2008.06.017; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hammerschmidt SI, 2008, J EXP MED, V205, P2483, DOI 10.1084/jem.20080039; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; Hershberg RM, 1998, J CLIN INVEST, V102, P792, DOI 10.1172/JCI3201; Hoh RA, 2016, J ALLERGY CLIN IMMUN, V137, P157, DOI 10.1016/j.jaci.2015.05.029; Hol J, 2008, J ALLERGY CLIN IMMUN, V121, P1448, DOI 10.1016/j.jaci.2008.03.018; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Huby RDJ, 2000, TOXICOL SCI, V55, P235, DOI 10.1093/toxsci/55.2.235; HUSBY S, 1985, SCAND J IMMUNOL, V22, P83, DOI 10.1111/j.1365-3083.1985.tb01862.x; Jaensson E, 2008, J EXP MED, V205, P2139, DOI 10.1084/jem.20080414; Jakobsson HE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009836; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112, DOI 10.1111/j.1365-2222.1996.tb00496.x; Jyonouchi S, 2011, J ALLERGY CLIN IMMUN, V128, P102, DOI 10.1016/j.jaci.2011.02.026; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V132, P1375, DOI 10.1016/j.jaci.2013.09.008; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Kim KS, 2016, SCIENCE, V351, P858, DOI 10.1126/science.aac5560; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Konstantinou GN, 2014, PEDIAT ALLERG IMM-UK, V25, P64, DOI 10.1111/pai.12143; Kraus TA, 2005, J CLIN INVEST, V115, P2234, DOI 10.1172/JCI19102; Kusunoki T, 2005, J ALLERGY CLIN IMMUN, V115, P636, DOI 10.1016/j.jaci.2004.12.1114; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V130, P473, DOI 10.1016/j.jaci.2012.06.006; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V129, P1579, DOI 10.1016/j.jaci.2012.04.009; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Ling ZX, 2014, APPL ENVIRON MICROB, V80, P2546, DOI 10.1128/AEM.00003-14; Lozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550; Mabbott NA, 2013, MUCOSAL IMMUNOL, V6, P666, DOI 10.1038/mi.2013.30; Macia L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7734; Mackie RI, 1999, AM J CLIN NUTR, V69, p1035S, DOI 10.1093/ajcn/69.5.1035s; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Macpherson AJ, 2015, TRENDS IMMUNOL, V36, P460, DOI 10.1016/j.it.2015.06.006; Makinen-Kiljunen S, 2002, ALLERGY, V57, P1084, DOI 10.1034/j.1398-9995.2002.23836_6.x; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Matteoli G, 2010, GUT, V59, P595, DOI 10.1136/gut.2009.185108; Maynard CL, 2007, NAT IMMUNOL, V8, P931, DOI 10.1038/ni1504; Mazzini E, 2014, IMMUNITY, V40, P248, DOI 10.1016/j.immuni.2013.12.012; Menard S, 2010, MUCOSAL IMMUNOL, V3, P247, DOI 10.1038/mi.2010.5; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; Metsala J, 2013, EPIDEMIOLOGY, V24, P303, DOI 10.1097/EDE.0b013e31827f520f; Milling S, 2010, IMMUNOL REV, V234, P259, DOI 10.1111/j.0105-2896.2009.00866.x; Moghaddam AE, 2014, J ALLERGY CLIN IMMUN, V134, P1453, DOI 10.1016/j.jaci.2014.07.032; Molenaar R, 2009, J IMMUNOL, V183, P6395, DOI 10.4049/jimmunol.0900311; Mondoulet Lucie, 2012, Clin Transl Allergy, V2, P22, DOI 10.1186/2045-7022-2-22; MOOG F, 1981, SCI AM, V245, P154, DOI 10.1038/scientificamerican1181-154; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P234, DOI 10.1097/ACI.0b013e32832b88e7; Oka T, 2013, J ALLERGY CLIN IMMUN, V132, P922, DOI 10.1016/j.jaci.2013.05.004; Olsson S, 1998, MOL IMMUNOL, V35, P1017, DOI 10.1016/S0161-5890(98)00101-1; Pabst O, 2012, MUCOSAL IMMUNOL, V5, P232, DOI 10.1038/mi.2012.4; Paidassi H, 2011, GASTROENTEROLOGY, V141, P1813, DOI 10.1053/j.gastro.2011.06.076; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; PENG HJ, 1990, CLIN EXP IMMUNOL, V81, P510; Perrier C, 2011, CLIN EXP ALLERGY, V41, P20, DOI 10.1111/j.1365-2222.2010.03639.x; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Ryan JF, 2016, P NATL ACAD SCI US; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sakaguchi S, 2013, NAT REV IMMUNOL, V13, P461, DOI 10.1038/nri3464; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P453, DOI 10.1016/j.jaci.2012.05.006; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Schnorr SL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4654; Schofield AT, 1908, LANCET, V1, P716; Schulz O, 2009, J EXP MED, V206, P3101, DOI 10.1084/jem.20091925; Scott CL, 2011, TRENDS IMMUNOL, V32, P412, DOI 10.1016/j.it.2011.06.003; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; SICINSKI P, 1990, GASTROENTEROLOGY, V98, P56, DOI 10.1016/0016-5085(90)91290-M; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007; Smaldini PL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141116; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Spahn TW, 2002, EUR J IMMUNOL, V32, P1109, DOI 10.1002/1521-4141(200204)32:4<1109::AID-IMMU1109>3.3.CO;2-B; Spahn TW, 2001, EUR J IMMUNOL, V31, P1278, DOI 10.1002/1521-4141(200104)31:4<1278::AID-IMMU1278>3.0.CO;2-A; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Suzuki H, 2008, GASTROENTEROLOGY, V135, P917, DOI 10.1053/j.gastro.2008.05.037; Suzuki K, 2004, P NATL ACAD SCI USA, V101, P1981, DOI 10.1073/pnas.0307317101; Swiatczak B, 2012, SEMIN IMMUNOL, V24, P43, DOI 10.1016/j.smim.2011.11.004; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Thomson AW, 2010, NAT REV IMMUNOL, V10, P753, DOI 10.1038/nri2858; Thorburn AN, 2014, IMMUNITY, V40, P833, DOI 10.1016/j.immuni.2014.05.014; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Tsuji M, 2009, SCIENCE, V323, P1488, DOI 10.1126/science.1169152; Untersmayr E, 2005, FASEB J, V19, P656, DOI 10.1096/fj.04-3170fje; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; Untersmayr E, 2008, J ALLERGY CLIN IMMUN, V121, P1301, DOI 10.1016/j.jaci.2008.04.025; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; VANDERHEIJDEN PJ, 1987, IMMUNOLOGY, V62, P551; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Ventura MT, 2006, DIGEST LIVER DIS, V38, P732, DOI 10.1016/j.dld.2006.06.012; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131; Vital M, 2014, MBIO, V5, DOI 10.1128/mBio.00889-14; WALKER WA, 1974, GASTROENTEROLOGY, V67, P531; Wang FJ, 2005, AM J PATHOL, V166, P409, DOI 10.1016/S0002-9440(10)62264-X; WARSHAW AL, 1974, GASTROENTEROLOGY, V66, P987; Webber CM, 2010, ANN ALLERG ASTHMA IM, V104, P101, DOI 10.1016/j.anai.2009.11.007; Williams MR, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0567-4; Woo HY, 2006, ALLERGY, V61, P954, DOI 10.1111/j.1398-9995.2006.01147.x; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Worthington JJ, 2011, GASTROENTEROLOGY, V141, P1802, DOI 10.1053/j.gastro.2011.06.057; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Yang PC, 2000, J CLIN INVEST, V106, P879, DOI 10.1172/JCI9258; YANG R, 1994, J PEDIATR SURG, V29, P1145, DOI 10.1016/0022-3468(94)90297-6; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Yu LCH, 2001, GASTROENTEROLOGY, V121, P370, DOI 10.1053/gast.2001.26470; Yu S, 2014, J ALLERGY CLIN IMMUN, V133, P943, DOI 10.1016/j.jaci.2014.02.015	179	160	179	18	113	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					984	997		10.1016/j.jaci.2016.02.004	http://dx.doi.org/10.1016/j.jaci.2016.02.004			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	27059726	Green Accepted, Bronze			2022-12-18	WOS:000373351200003
J	van Montfrans, JM; Hoepelman, AIM; Otto, S; van Gijn, M; van de Corput, L; de Weger, RA; Monaco-Shawver, L; Banerjee, PP; Sanders, EAM; Jol-van der Zijde, CM; Betts, MR; Orange, JS; Bloem, AC; Tesselaar, K				van Montfrans, Joris M.; Hoepelman, Andy I. M.; Otto, Sigrid; van Gijn, Marielle; van de Corput, Lisette; de Weger, Roel A.; Monaco-Shawver, Linda; Banerjee, Pinaki P.; Sanders, Elisabeth A. M.; Jol-van der Zijde, Cornelia M.; Betts, Michael R.; Orange, Jordan S.; Bloem, Andries C.; Tesselaar, Kiki			CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EBV; viremia; hypogammaglobulinemia; CD27; immunodeficiency; T cell; B cell; natural killer cell; phenotype	EPSTEIN-BARR-VIRUS; T-CELL; B-CELLS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; XIAP DEFICIENCY; MEMORY; CD70; DIFFERENTIATION; GENERATION; EXPRESSION	Background: CD27 is a lymphocyte costimulatory molecule that regulates T-cell, natural killer (NK) cell, B-cell, and plasma cell function, survival, and differentiation. On the basis of its function and expression pattern, we considered CD27 a candidate gene in patients with hypogammaglobulinemia. Objective: We sought to describe the clinical and immunologic phenotypes of patients with genetic CD27 deficiency. Methods: A molecular and extended immunologic analysis was performed on 2 patients lacking CD27 expression. Results: We identified 2 brothers with a homozygous mutation in CD27 leading to absence of CD27 expression. Both patients had persistent symptomatic EBV viremia. The index patient was hypogammaglobulinemic, and immunoglobulin replacement therapy was initiated. His brother had aplastic anemia in the course of his EBV infection and died from fulminant gram-positive bacterial sepsis. Immunologically, lack of CD27 expression was associated with impaired T cell-dependent B-cell responses and T-cell dysfunction. Conclusion: Our findings identify a role for CD27 in human subjects and suggest that this deficiency can explain particular cases of persistent symptomatic EBV viremia with hypogammaglobulinemia and impaired T cell-dependent antibody generation. (J Allergy Clin Immunol 2012;129:787-93.)	[van Montfrans, Joris M.; Sanders, Elisabeth A. M.] Univ Med Ctr Utrecht, Dept Pediat Immunol, Wilhelmina Childrens Hosp, Utrecht, Netherlands; [van Montfrans, Joris M.; Sanders, Elisabeth A. M.] Univ Med Ctr Utrecht, Dept Infect Dis, Wilhelmina Childrens Hosp, Utrecht, Netherlands; [Hoepelman, Andy I. M.] Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Utrecht, Netherlands; [Otto, Sigrid; van Gijn, Marielle] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands; [van de Corput, Lisette; Bloem, Andries C.; Tesselaar, Kiki] Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands; [de Weger, Roel A.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Monaco-Shawver, Linda; Banerjee, Pinaki P.; Orange, Jordan S.] Childrens Hosp Philadelphia, Res Inst, Philadelphia, PA USA; [Jol-van der Zijde, Cornelia M.] Leiden Univ, Dept Pediat, Med Ctr, NL-2300 RA Leiden, Netherlands; [Betts, Michael R.] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Pennsylvania	van Montfrans, JM (corresponding author), POB 85090,KC 03-063-0, NL-3508 AB Utrecht, Netherlands.	j.vanmontfrans@umcutrecht.nl		orange, jordan/0000-0001-7117-7725; Tesselaar, Kiki/0000-0002-9847-0814	National Institutes of Health [NIH AI-067946, NIH RO1 AI076066]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI067946, R01AI076066, R01AI067946] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants NIH AI-067946 (J.S.O.) and NIH RO1 AI076066 (M.R.B.).	Agematsu K, 1999, LEUKEMIA LYMPHOMA, V35, P219, DOI 10.3109/10428199909145724; Borst J, 2005, CURR OPIN IMMUNOL, V17, P275, DOI 10.1016/j.coi.2005.04.004; Brinkman DMC, 2003, J CLIN IMMUNOL, V23, P528, DOI 10.1023/B:JOCI.0000010429.36461.6b; Calattini S, 2010, BLOOD, V116, P4546, DOI 10.1182/blood-2010-05-285452; Chattopadhyay PK, 2006, NAT MED, V12, P972, DOI 10.1038/nm1371; Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179; De Colvenaer V, 2011, IMMUNOL CELL BIOL, V89, P803, DOI 10.1038/icb.2010.171; Dupre L, 2005, BLOOD, V105, P4383, DOI 10.1182/blood-2004-08-3269; Eurelings M, 2006, J NEUROIMMUNOL, V175, P152, DOI 10.1016/j.jneuroim.2006.02.008; Filipovich AH, 2008, IMMUNOL ALLERGY CLIN, V28, P293, DOI 10.1016/j.iac.2008.01.010; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Huck K, 2009, J CLIN INVEST, V119, P1350, DOI 10.1172/JCI37901; JONCAS J, 1989, J MED VIROL, V28, P110, DOI 10.1002/jmv.1890280211; Jung J, 2000, EUR J IMMUNOL, V30, P2437, DOI 10.1002/1521-4141(2000)30:8<2437::AID-IMMU2437>3.0.CO;2-M; Klein U, 1997, BLOOD, V89, P1288, DOI 10.1182/blood.V89.4.1288; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; KOBATA T, 1995, P NATL ACAD SCI USA, V92, P11249, DOI 10.1073/pnas.92.24.11249; Koch S, 2008, IMMUN AGEING, V5, DOI [10.1186/1742-4933-5-6, 10.1186/1742-4933-5-11]; Lens SMA, 1996, EUR J IMMUNOL, V26, P2964, DOI 10.1002/eji.1830261223; Makedonas G, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000798; Marsh RA, 2010, BLOOD, V116, P1079, DOI 10.1182/blood-2010-01-256099; Matter MS, 2008, EUR J IMMUNOL, V38, P1847, DOI 10.1002/eji.200737824; OKANO M, 1991, CLIN MICROBIOL REV, V4, P129, DOI 10.1128/CMR.4.1.129-135.1991; Orange JS, 2011, J CLIN INVEST, V121, P1535, DOI 10.1172/JCI44862; Orange JS, 2002, MICROBES INFECT, V4, P1545, DOI 10.1016/S1286-4579(02)00038-2; Peperzak V, 2010, J CLIN INVEST, V120, P168, DOI 10.1172/JCI40178; Quan TE, 2010, ARTHRITIS RHEUM-US, V62, P1693, DOI 10.1002/art.27408; Rezaei N, 2011, BRIT J HAEMATOL, V152, P13, DOI 10.1111/j.1365-2141.2010.08442.x; Rigaud S, 2006, NATURE, V444, P110, DOI 10.1038/nature05257; Sallusto F, 2000, CURR TOP MICROBIOL, V251, P167; Savoldo B, 2002, BLOOD, V100, P4059, DOI 10.1182/blood-2002-01-0039; Taraban VY, 2008, J IMMUNOL, V180, P4615, DOI 10.4049/jimmunol.180.7.4615; Tesselaar K, 1997, J IMMUNOL, V159, P4959; Tesselaar K, 2003, NAT IMMUNOL, V4, P49, DOI 10.1038/ni869; van Esser JWJ, 2001, BRIT J HAEMATOL, V113, P814, DOI 10.1046/j.1365-2141.2001.02789.x; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; van Lochem EG, 2004, CYTOM PART B-CLIN CY, V60B, P1, DOI 10.1002/cyto.b.20008; Vossen MTM, 2008, J IMMUNOL, V180, P3739, DOI 10.4049/jimmunol.180.6.3739; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Williams H, 2006, BLOOD, V107, P862, DOI 10.1182/blood-2005-07-2702; Wyzgol A, 2009, J IMMUNOL, V183, P1851, DOI 10.4049/jimmunol.0802597; Xiao YL, 2008, J IMMUNOL, V181, P1071, DOI 10.4049/jimmunol.181.2.1071; Xiao YL, 2004, J IMMUNOL, V172, P7432, DOI 10.4049/jimmunol.172.12.7432	44	160	166	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					787	U274		10.1016/j.jaci.2011.11.013	http://dx.doi.org/10.1016/j.jaci.2011.11.013			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22197273	Green Accepted			2022-12-18	WOS:000301189300026
J	Geroldinger-Simic, M; Zelniker, T; Aberer, W; Ebner, C; Egger, C; Greiderer, A; Prem, N; Lidholm, J; Ballmer-Weber, BK; Vieths, S; Bohle, B				Geroldinger-Simic, Marija; Zelniker, Thomas; Aberer, Werner; Ebner, Christof; Egger, Cornelia; Greiderer, Antonia; Prem, Nicole; Lidholm, Jonas; Ballmer-Weber, Barbara K.; Vieths, Stefan; Bohle, Barbara			Birch pollen-related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG(4) antibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Birch pollen allergy; food allergy; oral allergy syndrome; Bet v 1; IgE; blocking antibodies	CROSS-REACTIVITY; DOUBLE-BLIND; SUBLINGUAL IMMUNOTHERAPY; ORAL IMMUNOTHERAPY; COWS MILK; PROFILIN; FRUITS; IDENTIFICATION; SENSITIZATION; BINDING	Background: Patients with birch pollen allergy often develop allergic reactions to plant foods. Objective: To evaluate the prevalence, main symptoms, and triggers of birch pollen-related food allergy and the role of food-specific IgG(4) antibodies in food tolerance. Methods: Food-induced symptoms were evaluated in 225 individuals with birch pollen allergy by using a standardized questionnaire. IgE and IgG(4) levels specific for the major birch pollen allergen Bet v 1 and birch profilin Bet v 2 and the Bet v 1 homologs in apple (Mal d 1) and hazelnut (Cor a 1) were quantified by ImmunoCAP. Mock-treated and IgG-depleted sera from patients tolerating hazelnuts in food challenges were compared for their inhibitory activity for binding of Cor a 1-IgE complexes to B cells. Results: In total, 73% of the study population experienced food allergy, which was perennial in 86% of the affected individuals. The oral allergy syndrome was the main clinical manifestation. However, more than 58% of the patients also experienced food-induced rhinoconjunctivitis. Apples and hazelnuts were identified as the most frequent triggers. Food allergy correlated with IgE reactivity to Bet v 1 but not to Bet v 2. Mal d 1-specific and Cor a 1-specific IgG(4)/IgE ratios were significantly higher in food-tolerant individuals than individuals with food allergy. Sera from IgG(4)-positive food-tolerant patients possessed IgG-dependent IgE-inhibitory activity. Conclusion: Birch pollen-related food allergy is highly prevalent and often perennial. High food allergen-specific IgG(4)/IgE ratios seem associated with food tolerance, potentially because specific IgG(4) blocks IgE binding to food allergens. Thus, the presence of food allergen-specific IgG(4) antibodies is no diagnostic marker for birch pollen-related food allergy. (J Allergy Clin Immunol 2011;127:616-22.)	[Geroldinger-Simic, Marija; Zelniker, Thomas; Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria; [Bohle, Barbara] Med Univ Vienna, Christian Doppler Lab Immunomodulat, A-1090 Vienna, Austria; [Aberer, Werner; Prem, Nicole] Med Univ Graz, Univ Clin Dermatol, Graz, Austria; [Ebner, Christof] Allergy Clin Reumannpl, Vienna, Austria; [Egger, Cornelia; Greiderer, Antonia] Univ Clin Innsbruck, Dept Dermatol, Innsbruck, Austria; [Lidholm, Jonas] Phadia AB, Dept Res & Dev, Uppsala, Sweden; [Ballmer-Weber, Barbara K.] Univ Zurich Hosp, Allergy Unit, Dept Dermatol, Zurich, Switzerland; [Vieths, Stefan] Paul Ehrlich Inst, Div Allergol, D-6070 Langen, Germany	Medical University of Vienna; Medical University of Vienna; Medical University of Graz; Medical University of Innsbruck; Thermo Fisher Scientific; Phadia; University of Zurich; University Zurich Hospital; Paul Ehrlich Institute	Bohle, B (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Waehringer Guertel 18-20,AKH-3Q, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at		Bohle, Barbara/0000-0002-5105-7985; Lidholm, Jonas/0000-0002-7779-3411; Zelniker, Thomas/0000-0002-6444-8598	Austrian Science Fund [SFB-F1807-B13]; Christian Doppler Research Association; Biomay AG, Vienna, Austria; Christian Doppler Laboratory; European Union; German Research Foundation; German Federal Ministry of Education and Research; Research Fund for the German Food Industry, Monsanto Co; Pioneer Hi-Bred International, Inc; Food Allergy Resource and Research Program; European Directorate for the Quality of Medicines and Health Care	Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association; Biomay AG, Vienna, Austria; Christian Doppler Laboratory; European Union(European Commission); German Research Foundation(German Research Foundation (DFG)); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Research Fund for the German Food Industry, Monsanto Co; Pioneer Hi-Bred International, Inc; Food Allergy Resource and Research Program; European Directorate for the Quality of Medicines and Health Care	Supported by the Austrian Science Fund, project SFB-F1807-B13, the Christian Doppler Research Association, and Biomay AG, Vienna, Austria.; B. Bohle receives research support from the Austrian Science Fund and the Christian Doppler Laboratory. S. Vieths is an associate for the Institute for Product Quality; has received honoraria for scientific presentations from Phadia; has received honoraria as an expert reviewer from the Food Allergy Resource and Research Program; has received research support from the European Union, the German Research Foundation, the German Federal Ministry of Education and Research, the Research Fund for the German Food Industry, Monsanto Co, Pioneer Hi-Bred International, Inc, the Food Allergy Resource and Research Program, and the European Directorate for the Quality of Medicines and Health Care; is chairman of the Food Allergy Interest Group and a member of the Executive Committee for EAACI; is chairman of the Allergen Standardization Subcommittee and secretary of the Allergen Nomenclature Subcommittee for the International Union of Immunological Studies; is a Registered Expert for the European Agency for the Evaluation of Medicinal Products and European Pharmacopoeia Commission; is chairman of Technical Committee 275 Working Group 12 "Food Allergens" for the European Committee for Standardization; and is a member of the Food Allergy Working Group for the German Society for Allergy and Clinical Immunology. The rest of the authors have declared that they have no conflict of interest.	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Asero R, 1996, J ALLERGY CLIN IMMUN, V97, P611, DOI 10.1016/S0091-6749(96)70306-8; Asero R, 2008, CLIN EXP ALLERGY, V38, P1033, DOI 10.1111/j.1365-2222.2008.02980.x; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bohle B, 2006, CLIN REV ALLERG IMMU, V30, P97, DOI 10.1385/CRIAI:30:2:97; Bohle B, 2006, J ALLERGY CLIN IMMUN, V118, P242, DOI 10.1016/j.jaci.2006.03.011; Bolhaar STHP, 2005, J ALLERGY CLIN IMMUN, V116, P1080, DOI 10.1016/j.jaci.2005.07.004; Bolhaar STHP, 2004, ALLERGY, V59, P1187, DOI 10.1111/j.1398-9995.2004.00544.x; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Fernandez-Rivas M, 2009, ALLERGY, V64, P876, DOI 10.1111/j.1398-9995.2008.01921.x; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Ghunaim N, 2005, ALLERGY, V60, P185, DOI 10.1111/j.1398-9995.2005.00662.x; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; Hansen KS, 2009, J ALLERGY CLIN IMMUN, V123, P1134, DOI 10.1016/j.jaci.2009.02.005; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P212; Karamloo F, 2001, EUR J BIOCHEM, V268, P5310, DOI 10.1046/j.0014-2956.2001.02463.x; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; Lin RY, 2002, ALLERGY ASTHMA PROC, V23, P253; Mari A, 2005, CURR OPIN ALLERGY CL, V5, P267, DOI 10.1097/01.all.0000168793.27948.b0; Oberhuber C, 2008, MOL NUTR FOOD RES, V52, pS230, DOI 10.1002/mnfr.200800146; Osterballe M, 2005, ALLERGY, V60, P218, DOI 10.1111/j.1398-9995.2005.00674.x; Radauer C, 2006, CLIN EXP ALLERGY, V36, P920, DOI 10.1111/j.1365-2222.2006.02521.x; Reindl J, 2002, INT ARCH ALLERGY IMM, V128, P105, DOI 10.1159/000059400; Ruiter B, 2007, CLIN EXP ALLERGY, V37, P1103, DOI 10.1111/j.1365-2222.2007.02749.x; Savilahti EM, 2010, J ALLERGY CLIN IMMUN, V125, P1315, DOI 10.1016/j.jaci.2010.03.025; Scheurer S, 2000, CLIN EXP ALLERGY, V30, P962, DOI 10.1046/j.1365-2222.2000.00821.x; Scheurer S, 2001, J CHROMATOGR B, V756, P315, DOI 10.1016/S0378-4347(01)00090-1; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Stapel SO, 2008, ALLERGY, V63, P793, DOI 10.1111/j.1398-9995.2008.01705.x; Stevens WJ, 2003, ACTA CLIN BELG, V58, P178, DOI 10.1179/acb.2003.58.3.005; Tomicic S, 2009, PEDIAT ALLERG IMM-UK, V20, P35, DOI 10.1111/j.1399-3038.2008.00738.x; Tuft Louis, 1942, JOUR ALLERGY, V13, P574, DOI 10.1016/S0021-8707(42)90070-4; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wellhausen A, 1996, Z ERNAHRUNGSWISS, V35, P348, DOI 10.1007/BF01610553; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; Westphal S, 2004, ALLERGY, V59, P526, DOI 10.1046/j.1398-9995.2003.00413.x	46	160	162	3	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					616	U124		10.1016/j.jaci.2010.10.027	http://dx.doi.org/10.1016/j.jaci.2010.10.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21251701	Bronze			2022-12-18	WOS:000288018400009
J	Ayuso, R; Grishina, G; Bardina, L; Carrillo, T; Blanco, C; Ibanez, MD; Sampson, HA; Beyer, K				Ayuso, Rosalia; Grishina, Galina; Bardina, Ludmilla; Carrillo, Teresa; Blanco, Carlos; Ibanez, Maria Dolores; Sampson, Hugh A.; Beyer, Kirsten			Myosin light chain is a novel shrimp allergen, Lit v 3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						myosin light chain; allergen; crustacean; shrimp; recombinant; Lit v 3	CROSS-REACTIVITY; FOOD ALLERGY; IDENTIFICATION; TROPOMYOSIN; PROTEOMICS; CRUSTACEA; PROTEINS; EPITOPES	Background: Shellfish allergy is a prevalent, long-lasting disorder usually persisting throughout life. Few options are available for treatment, and avoidance is the only therapy recommended. Objective: We sought to identify relevant crustacean allergens for use as diagnostic and safe immunotherapeutic agents for subjects with shellfish allergy. Methods: Thirty-eight patients were selected with immediate allergic reactions to shrimp and increased shrimp-specific serum IgE levels. One-dimensional and 2-dimensional electrophoresis of shrimp extracts were followed by IgE immunoblotting. Protein identification was done with matrix-assisted laser desorption/ionization-mass spectrometry and Edman sequencing. A cDNA library was generated from white pacific shrimp (Litopenaeus vannamei) and screened with primers designed on the basis of internal sequences obtained from 2-dimensional tryptic digests. Full-length cDNA clones were isolated from the library and sequenced. Recombinant protein was expressed and tested with sera from patients with shrimp allergy. Results: Immunoblotting demonstrated IgE binding to a 20-kDa shrimp protein by 21 (55%) of 38 sera. Tryptic digestion of the protein followed by matrix-assisted laser desorption/ionization-mass spectrometric analysis and Edman sequencing identified it as a myosin light chain (MLC). Screening of the shrimp cDNA library resulted in isolation of a novel protein cDNA. Open reading frame translation provided the amino acid sequence of a new allergenic shrimp protein with high similarity to BIa g 8 (cockroach MLC). Recombinant protein was recognized by 17 patients, confirming the allergenicity of shrimp MLC. Conclusions: We have identified and cloned a new major shrimp allergen, Lit v 3.0101, an MLC protein.	[Ayuso, Rosalia; Grishina, Galina; Bardina, Ludmilla; Sampson, Hugh A.] Mt Sinai Sch Med, Div Allergy & Immunol, New York, NY 10029 USA; [Ayuso, Rosalia; Grishina, Galina; Bardina, Ludmilla; Sampson, Hugh A.] Mt Sinai Sch Med, Jaffe Food Allergy Res Inst, New York, NY 10029 USA; [Carrillo, Teresa] Hosp Univ Dr Negrin, Sect Allergy & Resp Dis, Las Palmas Gran Canaria, Spain; [Blanco, Carlos] Hosp Univ Princesa, Sect Allergy, Madrid, Spain; [Ibanez, Maria Dolores] Hosp Nino Jesus, Madrid, Spain; [Beyer, Kirsten] Univ Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Hospital de La Princesa; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ayuso, R (corresponding author), Mt Sinai Sch Med, Div Allergy & Immunol, 1 Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	rosalia.ayuso@mssm.edu	Blanco, Carlos/B-3895-2012	Blanco, Carlos/0000-0002-2893-6594				Ayuso R, 2002, INT ARCH ALLERGY IMM, V127, P27, DOI 10.1159/000048166; Ayuso R, 2002, INT ARCH ALLERGY IMM, V129, P38, DOI 10.1159/000065172; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P517, DOI 10.1067/mai.2002.127434; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; Carnes J, 2007, ANN ALLERG ASTHMA IM, V98, P349, DOI 10.1016/S1081-1206(10)60881-2; Castillo R, 1996, Allergol Immunopathol (Madr), V24, P93; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; CRESPO JF, 1995, PEDIAT ALLERG IMM-UK, V6, P39, DOI 10.1111/j.1399-3038.1995.tb00256.x; CRESPO JF, 1995, ALLERGY, V50, P918, DOI 10.1111/j.1398-9995.1995.tb02499.x; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; Garcia-Orozco KD, 2007, INT ARCH ALLERGY IMM, V144, P23, DOI 10.1159/000102610; Goetz DW, 2000, ANN ALLERG ASTHMA IM, V85, P461, DOI 10.1016/S1081-1206(10)62572-0; JORAL A, 1995, J INVEST ALLERG CLIN, V5, P47; Leung P.S.C., 1998, FRONT BIOSCI, P306, DOI DOI 10.2741/A243; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; LUZAN SA, 2005, FACTORES EPIDEMIOLOG, P133; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; MUSMAND JJ, 1993, CLIN EXP ALLERGY, V23, P722, DOI 10.1111/j.1365-2222.1993.tb00359.x; Reese G, 2005, J IMMUNOL, V175, P8354, DOI 10.4049/jimmunol.175.12.8354; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; SHANTI KN, 1993, J IMMUNOL, V151, P5354; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Shiomi K, 2008, INT ARCH ALLERGY IMM, V146, P91, DOI 10.1159/000113512; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Steckelbroeck S, 2008, J ALLERGY CLIN IMMUN, V121, P1323, DOI 10.1016/j.jaci.2008.04.008; Steensma DP, 2003, MAYO CLIN PROC, V78, P221, DOI 10.4065/78.2.221; Swoboda I, 2007, J IMMUNOL, V178, P6290, DOI 10.4049/jimmunol.178.10.6290; TAYLOR SL, 1987, ANN ALLERGY, V59, P93; Yu CJ, 2003, J IMMUNOL, V170, P445, DOI 10.4049/jimmunol.170.1.445	32	160	182	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					795	802		10.1016/j.jaci.2008.07.023	http://dx.doi.org/10.1016/j.jaci.2008.07.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	18760458				2022-12-18	WOS:000259989000027
J	Radauer, C; Breiteneder, H				Radauer, Christian; Breiteneder, Heimo			Evolutionary biology of plant food allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; evolution; protein superfamilies; prolamins; cupins; profilins; Bet v 1	SEED STORAGE PROTEINS; LIPID-TRANSFER PROTEINS; BIRCH POLLEN ALLERGEN; PATHOGENESIS-RELATED PROTEINS; CRYSTAL-STRUCTURE; GENE FAMILY; MOLECULAR-CLONING; CROSS-REACTIVITY; WHEAT; PROFILIN	The majority of plant food allergens can be grouped into just 4 protein families. This review summarizes the evolutionary relationships of allergenic and nonallergenic members of these families. Proteins from the prolamin superfamily have been described in vascular plants. This superfamily contains several allergenic (2S albumins, nonspecific lipid transfer proteins, and cereal amylase and protease inhibitors) and nonallergenic (hybrid proline-rich proteins, cereal indolines, and alpha-globulins) member families. The cupin superfamily comprises numerous functionally highly diverse protein families from all groups of organisms. However, allergenicity within the cupins is confined to the vicilin and legumin seed storage proteins. Profilins are ubiquitous eukaryotic proteins that are nonallergenic, with the exception of profilins from flowering plants. Finally, the Bet v 1 superfamily contains the pathogenesis-related proteins 10 family, the family of major latex proteins and ripening-related proteins, the norcoclaurine synthases, and the cytokinin-binding proteins, with pathogenesis-related proteins 10 family members from certain taxa being the only allergenic members. The study of the distribution of allergenic and nonallergenic members of protein families will provide new insights into the evolution of allergenicity and the factors that make proteins allergenic.	Med Univ Vienna, Dept Pathophysiol, AKH EBO 3Q, A-1090 Vienna, Austria	Medical University of Vienna	Breiteneder, H (corresponding author), Med Univ Vienna, Dept Pathophysiol, AKH EBO 3Q, Waehringer Guertal 18 20, A-1090 Vienna, Austria.	heimo.breiteneder@meduniwien.ac.at	Radauer, Christian/AAN-6260-2021	Radauer, Christian/0000-0001-9920-4449				Aalberse RC, 2006, CHEM IMMUNOL ALLERGY, V91, P134; Adachi M, 2003, P NATL ACAD SCI USA, V100, P7395, DOI 10.1073/pnas.0832158100; Arasada R, 2007, BBA-MOL CELL RES, V1773, P631, DOI 10.1016/j.bbamcr.2007.03.009; Bais HP, 2003, J BIOL CHEM, V278, P32413, DOI 10.1074/jbc.M301681200; BAUD F, 1993, J MOL BIOL, V231, P877, DOI 10.1006/jmbi.1993.1334; Baumlein H, 1995, J MOL EVOL, V41, P1070, DOI 10.1007/BF00173188; Breiteneder H, 2005, CURR OPIN ALLERGY CL, V5, P275, DOI 10.1097/01.all.0000168794.35571.a5; Breiteneder H, 2005, J ALLERGY CLIN IMMUN, V115, P14, DOI 10.1016/j.jaci.2004.10.022; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Douliez JP, 2000, J CEREAL SCI, V32, P1, DOI 10.1006/jcrs.2000.0315; Dunwell JM, 2004, PHYTOCHEMISTRY, V65, P7, DOI 10.1016/j.phytochem.2003.08.016; Dunwell JM, 1998, BIOTECHNOL GENET ENG, V15, P1; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Gonneau M, 2001, PLANT MOL BIOL, V46, P539, DOI 10.1023/A:1010693213437; Huang SR, 1996, PLANT PHYSIOL, V111, P115, DOI 10.1104/pp.111.1.115; Jain S, 2006, PLANT PHYSIOL BIOCH, V44, P253, DOI 10.1016/j.plaphy.2006.04.006; Jose-Estanyol M, 2000, PLANT PHYSIOL BIOCH, V38, P97, DOI 10.1016/S0981-9428(00)00165-0; Kandasamy MK, 2002, CELL MOTIL CYTOSKEL, V52, P22, DOI 10.1002/cm.10029; Koistinen KM, 2005, PHYTOCHEMISTRY, V66, P2524, DOI 10.1016/j.phytochem.2005.09.007; KREIS M, 1985, J MOL BIOL, V183, P499, DOI 10.1016/0022-2836(85)90017-8; LANE BG, 1991, J BIOL CHEM, V266, P10461; Liscombe DK, 2005, PHYTOCHEMISTRY, V66, P2500, DOI 10.1016/j.phytochem.2005.04.044; Liu JJ, 2005, PLANTA, V221, P159, DOI 10.1007/s00425-004-1428-x; MACHESKY LM, 1994, BIOCHEMISTRY-US, V33, P10815, DOI 10.1021/bi00201a032; Markovic-Housley Z, 2003, J MOL BIOL, V325, P123, DOI 10.1016/S0022-2836(02)01197-X; Maruyama N, 1998, EUR J BIOCHEM, V255, P739, DOI 10.1046/j.1432-1327.1998.2550739.x; Maruyama N, 2001, EUR J BIOCHEM, V268, P3595, DOI 10.1046/j.1432-1327.2001.02268.x; Mills ENC, 2004, CRIT REV FOOD SCI, V44, P379, DOI 10.1080/10408690490489224; Nakase M, 1996, GENE, V170, P223, DOI 10.1016/0378-1119(95)00887-X; Nam YW, 1999, PLANT MOL BIOL, V39, P629, DOI 10.1023/A:1006179928312; NESSLER CL, 1985, PLANT PHYSIOL, V79, P499, DOI 10.1104/pp.79.2.499; Neudecker P, 2001, J BIOL CHEM, V276, P22756, DOI 10.1074/jbc.M101657200; Osmark P, 1998, PLANT MOL BIOL, V38, P1243, DOI 10.1023/A:1006060224012; Park CJ, 2004, PLANT J, V37, P186, DOI 10.1046/j.1365-313X.2003.01951.x; Pasternak O, 2006, PLANT CELL, V18, P2622, DOI 10.1105/tpc.105.037119; Pastorello EA, 2001, ALLERGY, V56, P45, DOI 10.1034/j.1398-9995.2001.00914.x; Pastorello EA, 2007, INT ARCH ALLERGY IMM, V144, P10, DOI 10.1159/000102609; Poltl G, 2007, GLYCOBIOLOGY, V17, P220, DOI [10.1093/glycob/cw1068, 10.1093/glycob/cwl068]; Polet D, 2006, CELL MOTIL CYTOSKEL, V63, P14, DOI 10.1002/cm.20102; Polet D, 2007, FEBS LETT, V581, P211, DOI 10.1016/j.febslet.2006.12.013; Radauer C, 2007, ALLERGY, V62, P154; Radauer C, 2006, CLIN EXP ALLERGY, V36, P920, DOI 10.1111/j.1365-2222.2006.02521.x; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; RODIN J, 1990, EUR J BIOCHEM, V192, P101, DOI 10.1111/j.1432-1033.1990.tb19201.x; Samanani N, 2004, PLANT J, V40, P302, DOI 10.1111/j.1365-313X.2004.02210.x; Schenk MF, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-168; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; Stromvik MV, 1999, PLANT MOL BIOL, V41, P217, DOI 10.1023/A:1006312228617; SWOBODA I, 1995, PLANT CELL ENVIRON, V18, P865, DOI 10.1111/j.1365-3040.1995.tb00595.x; Thomas Robert A., 1997, Herpetological Natural History, V5, P19; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; Thornburg RW, 2003, PLANT SYST EVOL, V238, P211, DOI 10.1007/s00606-003-0282-9; van Loon LC, 2006, ANNU REV PHYTOPATHOL, V44, P135, DOI 10.1146/annurev.phyto.44.070505.143425; Verhees CH, 2001, J BIOL CHEM, V276, P40926, DOI 10.1074/jbc.M104603200; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wang CS, 1999, PLANT MOL BIOL, V40, P807, DOI 10.1023/A:1006285028495; Wen J, 1997, MOL PHYLOGENET EVOL, V8, P317, DOI 10.1006/mpev.1997.0447; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Woo EJ, 2000, NAT STRUCT BIOL, V7, P1036; Woo EJ, 2002, EMBO J, V21, P2877, DOI 10.1093/emboj/cdf291; Woo YM, 2001, PLANT CELL, V13, P2297, DOI 10.1105/tpc.13.10.2297; Yu XS, 2000, TREE PHYSIOL, V20, P663	64	160	169	0	47	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					518	525		10.1016/j.jaci.2007.07.024	http://dx.doi.org/10.1016/j.jaci.2007.07.024			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17689599				2022-12-18	WOS:000249505400004
J	Boyce, JA				Boyce, Joshua A.			Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						urticaria; anaphylaxis; most cells; IgE	EPSILON-RI EXPRESSION; URTICARIA; RELEASE; IDENTIFICATION	A case of a girl who presented at age 12 years with idiopathic cold urticaria is described. Her reactions to the cold became progressively more severe over a period of approximately 2 years, despite therapy with H1 antagonists and a type I receptor for cysteinyl leukotrienes receptor antagonist. She began to experience systemic symptoms on immersion in ocean water. She was atopic and had moderate persistent asthma. A trial of anti-IgE resulted in complete resolution of her urticaria and its associated manifestations. These findings should prompt a reexamination of the potential pathogenetic role played by IgE and its high-affinity receptor on mast cells in idiopathic cold urticaria.	Brigham & Womens Hosp, Div Rhematol Immunol & Allergy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Boyce, JA (corresponding author), Brigham & Womens Hosp, Div Rhematol Immunol & Allergy, Smith Bldg,Room 626B,1 Jimmy Fund Way, Boston, MA 02115 USA.	jboyce@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, U19AI031599, R01AI048802, R56AI052353, R01AI052353] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-31599, AI-48802, AI-52353] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alangari AA, 2004, PEDIATRICS, V113, pE313, DOI 10.1542/peds.113.4.e313; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bez C, 2004, CLIN EXP ALLERGY, V34, P1079, DOI 10.1111/j.1365-2222.2004.01998.x; Bonadonna P, 2003, J AM ACAD DERMATOL, V49, P714, DOI 10.1067/S0190-9622(03)01590-1; Brandes K, 1970, Z Allgemeinmed, V46, P1219; Buss YL, 2005, BRIT J DERMATOL, V153, P440, DOI 10.1111/j.1365-2133.2005.06757.x; Costanzi J J, 1967, Clin Exp Immunol, V2, P167; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; Hoffman HM, 2000, AM J HUM GENET, V66, P1693, DOI 10.1086/302874; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; Ito A, 2003, J DERMATOL, V30, P321, DOI 10.1111/j.1346-8138.2003.tb00394.x; Johnstone RF, 2003, ANN ALLERG ASTHMA IM, V90, P233, DOI 10.1016/S1081-1206(10)62147-3; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P438; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; Kranke B, 2001, CONTACT DERMATITIS, V44, P57, DOI 10.1034/j.1600-0536.2001.440107-24.x; LIN RY, 1993, BRIT J DERMATOL, V129, P465, DOI 10.1111/j.1365-2133.1993.tb03179.x; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MALTBY NH, 1989, CLIN EXP ALLERGY, V19, P33, DOI 10.1111/j.1365-2222.1989.tb02340.x; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Miralles Lopez J C, 2005, Allergol Immunopathol (Madr), V33, P172, DOI 10.1157/13075702; Morais-Almeida M, 2004, Allergol Immunopathol (Madr), V32, P368; NEITTAANMAKI H, 1985, J AM ACAD DERMATOL, V13, P636, DOI 10.1016/S0190-9622(85)70208-3; ORMEROD AD, 1988, J ALLERGY CLIN IMMUN, V82, P586, DOI 10.1016/0091-6749(88)90968-2; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; WANDERER AA, 1986, J ALLERGY CLIN IMMUN, V78, P417, DOI 10.1016/0091-6749(86)90027-8	26	160	163	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1415	1418		10.1016/j.jaci.2006.04.003	http://dx.doi.org/10.1016/j.jaci.2006.04.003			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751006				2022-12-18	WOS:000238332300032
J	Van Do, T; Elsayed, S; Florvaag, E; Hordvik, I; Endresen, C				Van Do, T; Elsayed, S; Florvaag, E; Hordvik, I; Endresen, C			Allergy to fish parvalbumins: Studies on the cross-reactivity of allergens from 9 commonly consumed fish	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fish allergy; cross-reactivity; parvalbumin; recombinant allergen; cod; pollack; salmon	MAJOR ALLERGEN; IMMUNOCHEMICAL REACTIVITY; CDNA CLONING; IGE-BINDING; COD; IDENTIFICATION; CHALLENGE; HYPERSENSITIVITY; PURIFICATION; EPITOPES	Background: Fish-hypersensitive patients can probably tolerate some fish species while being allergic to others. Objective: To determine the allergenic cross-reactivity between 9 commonly edible fish: cod, salmon, pollack, mackerel, tuna, herring, wolffish, halibut, and flounder. Methods: Sera from 10 patients allergic to fish and rabbit antisera against 3 parvalbumins (Gad c 1, Sal s 1, and The c 1) were used. Cross-reactivity was investigated by SDS/PAGE and IgE immunoblotting, IgG ELISA, IgE ELISA inhibition, and skin prick test (SPT). Results: Cod (Gad c 1), salmon (Sal s 1), pollack (The c 1), herring, and wolffish share antigenic and allergenic determinants as shown by immunoblots and IgE ELISA, whereas halibut, flounder, tuna, and mackerel displayed lowest cross-reactivities. The highest mean IgE ELISA inhibition percent of 10 sera was obtained by Gad c 1, followed by The c 1, herring, Sal s 1, wolffish, halibut, flounder, tuna, and mackerel with the least inhibition. Nine of the 10 patients showed positive SPT to cod, salmon, and pollack; 8 patients reacted to recombinant (r) Sal s 1. Positive SPTs to rGad c 1 and rThe c 1 were demonstrated in 1 patient. Conclusion: Gad c 1, Sal s 1, The c 1, herring, and wolffish contained the most potent cross-reacting allergens, whereas halibut, flounder, tuna, and mackerel were the least allergenic in the current study. The latter could probably be tolerated by some of the tested patients.	Haukeland Hosp, LKB, Allergy Res Grp, Lab Clin Biochem, N-5021 Bergen, Norway; Univ Bergen, Ctr High Technol, Dept Biol, Bergen, Norway	University of Bergen; Haukeland University Hospital; University of Bergen	Elsayed, S (corresponding author), Haukeland Hosp, LKB, Allergy Res Grp, Lab Clin Biochem, N-5021 Bergen, Norway.	said.elsayed@med.uib.no	Hordvik, Ivar/P-7940-2018; Fennell, Hannah/AAI-1408-2019					AAS K, 1967, INT ARCH ALLER A IMM, V32, P1, DOI 10.1159/000229911; AAS K, 1969, J ALLERGY, V44, P333, DOI 10.1016/0021-8707(69)90025-2; Aas K, 1996, INT ARCH ALLERGY, V30, P257; Aas K., 1987, FOOD ALLERGY INTOLER, P356; ALONSO MD, 1993, ALLERGY, V48, P349, DOI 10.1111/j.1398-9995.1993.tb02404.x; APOLD J, 1979, MOL IMMUNOL, V16, P559, DOI 10.1016/0161-5890(79)90118-4; APOLD J, 1980, MOL IMMUNOL, V17, P291, DOI 10.1016/0161-5890(80)90048-6; APOLD J, 1979, MOL IMMUNOL, V16, P205, DOI 10.1016/0161-5890(79)90147-0; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; Das Dores S, 2002, ALLERGY, V57, P84, DOI 10.1034/j.1398-9995.57.s72.6.x; DEMARTINO M, 1990, J ALLERGY CLIN IMMUN, V86, P909, DOI 10.1016/S0091-6749(05)80154-X; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; ELSAYED S, 1972, IMMUNOCHEMISTRY, V9, P647, DOI 10.1016/0019-2791(72)90250-9; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; ELSAYED S, 1971, INT ARCH ALLER A IMM, V40, P428, DOI 10.1159/000230425; ELSAYED S, 1971, J ALLERGY, V47, P283, DOI 10.1016/S0091-6749(71)80006-4; ELSAYED S, 1983, ALLERGY, V38, P449, DOI 10.1111/j.1398-9995.1983.tb02353.x; Elsayed S., 2002, FOOD ALLERGY INTOLER, P425; Hamada Y, 2003, FOOD CHEM TOXICOL, V41, P1149, DOI 10.1016/S0278-6915(03)00074-7; HAYDEL R, 1993, J ALLERGY CLIN IMMUN, V91, P344; Helbling A, 1999, ANN ALLERG ASTHMA IM, V83, P517, DOI 10.1016/S1081-1206(10)62862-1; Holen E, 2001, CLIN EXP ALLERGY, V31, P952, DOI 10.1046/j.1365-2222.2001.01102.x; LEHKY P, 1974, J BIOL CHEM, V249, P4332; Lehrer SB, 2005, ALLERGY, V60, P559, DOI 10.1111/j.1398-9995.2005.00704.x; Lehrer SB, 2003, MAR BIOTECHNOL, V5, P339, DOI 10.1007/s10126-002-0082-1; LIEN K, 2004, NORWEGIAN CONSUMPTIO; Lindstrom CDV, 1996, SCAND J IMMUNOL, V44, P335, DOI 10.1046/j.1365-3083.1996.d01-314.x; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; Pechere JF, 1997, CALCIUM BINDING PROT, P213; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Santiago ML, 1998, INT ARCH ALLERGY IMM, V117, P94, DOI 10.1159/000023995; Van Do T, 2005, MOL IMMUNOL, V42, P345, DOI 10.1016/j.molimm.2004.09.001; Van Do T, 2003, MOL IMMUNOL, V39, P595, DOI 10.1016/S0161-5890(02)00200-6; Yamada S, 1999, ANN ALLERG ASTHMA IM, V82, P395, DOI 10.1016/S1081-1206(10)63290-5	35	160	194	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1314	1320		10.1016/j.jaci.2005.07.033	http://dx.doi.org/10.1016/j.jaci.2005.07.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337465				2022-12-18	WOS:000235687000024
J	Simons, FER; Shikishima, Y; Van Nest, G; Eiden, JJ; Hayglass, KT				Simons, FER; Shikishima, Y; Van Nest, G; Eiden, JJ; Hayglass, KT			Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen-specific immunotherapy; allergen vaccines; Amb a 1; chemokines; cytokines; DNA vaccines; humans; immunostimulatory DNA sequences; ragweed allergy	CPG MOTIFS; IFN-GAMMA; AIRWAY HYPERRESPONSIVENESS; GENETIC IMMUNIZATION; MURINE MODEL; T-CELLS; B-CELL; OLIGODEOXYNUCLEOTIDES; IMMUNOTHERAPY; ASTHMA	Background: In animal models administration of immunostimulatory DNA sequences preferentially elicits T(H)1-dominated (type 1-dominated) immunity and can inhibit developing or ongoing T(H)2 (type 2) responses. Objective: Our objective was to investigate this phenomenon in humans. Methods: In a randomized, third party-blinded, placebo-controlled, proof-of-concept study conducted entirely in the winter in 19 adults with ragweed allergy, we administered 6 subcutaneous injections of purified Amb a 1 linked to the 22-base-long immunostimulatory phosphorothioate oligodeoxyribonucleotide 1018 (Amb a 1-immunostimulatory DNA sequence conjugate [AIC]). Before the course of AIC or placebo injections and 2 and 16 weeks afterward, we measured recall responses to ragweed, streptokinase, and PHA in short-term primary culture of fresh PBMCs after restimulation with antigen. We quantified regulatory cytokine and chemokine responses characteristic of T(H)2 immunity (IL-5, IL-13, CCL17 [TARC], and CCL22 [MDC]), and T(H)1 immunity (IFN-gamma, CXCL9 [Mig], and CXCL10 [IP-10]), as well as IL-10, a cytokine sometimes linked to regulatory T-cell populations. Results: We demonstrated for the first time that human systemic in vivo ragweed-specific T(H)2 responses were selectively redirected toward T(H)1 responses, with significant increases in IFN-gamma, CXCL9, and CXCL10 and significant decreases in IL-5, CCL17, and CCL22 found at 2 and 16 weeks after the sixth injection. Cytokine and chemokine responses to the unrelated bacterial antigen streptokinase and the global capacity to mount immune responses on polyclonal activation with PHA did not change. No clinically significant systemic or local allergic reactions were associated with AIC or placebo injections. Conclusions: AIC, injected in concentrations that were approximately 40-fold lower than those used in most murine studies published to date, led to a prolonged shift from T(H)2 immunity toward T(H)1 immunity and appeared to be safe. This novel approach has the potential for immune redirection in human immediate hypersensitivity diseases.	Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Immunol, Winnipeg, MB R3T 2N2, Canada; Canadian Inst Hlth Res, Natl Training Program Asthma & Allergy, Winnipeg, MB, Canada; Dynavax Technol Corp, Berkeley, CA USA	University of Manitoba; University of Manitoba; Institute for Work & Health	Simons, FER (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.			HayGlass, Kent/0000-0002-4621-7737				Bohle B, 2002, INT ARCH ALLERGY IMM, V129, P198, DOI 10.1159/000066771; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Cho HJ, 2000, NAT BIOTECHNOL, V18, P509, DOI 10.1038/75365; Cohen AD, 1998, FASEB J, V12, P1611, DOI 10.1096/fasebj.12.15.1611; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Gangur V, 1998, FASEB J, V12, P705, DOI 10.1096/fasebj.12.9.705; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Hartmann G, 1999, GENE THER, V6, P893, DOI 10.1038/sj.gt.3300880; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Horner AA, 2001, IMMUNOL REV, V179, P102, DOI 10.1034/j.1600-065X.2001.790111.x; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kline JN, 2000, CURR TOP MICROBIOL, V247, P211; Klinman DM, 1999, VACCINE, V17, P19, DOI 10.1016/S0264-410X(98)00151-0; Kovarik J, 1999, J IMMUNOL, V162, P1611; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2000, CURR OPIN IMMUNOL, V12, P35, DOI 10.1016/S0952-7915(99)00048-5; Lewkowich IP, 2001, J IMMUNOL METHODS, V247, P111, DOI 10.1016/S0022-1759(00)00306-9; Li Y, 1998, J IMMUNOL, V161, P7007; Magone MT, 2000, EUR J IMMUNOL, V30, P1841, DOI 10.1002/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E; Marshall JD, 2003, J LEUKOCYTE BIOL, V73, P781, DOI 10.1189/jlb.1202630; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; NELSON HS, 2003, MIDDLETONS ALLERGY P, P1455; Peng ZK, 2001, INT IMMUNOL, V13, P3, DOI 10.1093/intimm/13.1.3; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Santeliz JV, 2002, J ALLERGY CLIN IMMUN, V109, P455, DOI 10.1067/mai.2002.122156; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Shirota H, 2000, AM J RESP CELL MOL, V22, P176, DOI 10.1165/ajrcmb.22.2.3772; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717	34	160	181	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1144	1151		10.1016/j.jaci.2004.03.003	http://dx.doi.org/10.1016/j.jaci.2004.03.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208597				2022-12-18	WOS:000222091000021
J	Gern, JE; Reardon, CL; Hoffjan, S; Nicolae, D; Li, ZH; Roberg, KA; Neaville, WA; Carlson-Dakes, K; Adler, K; Hamilton, R; Anderson, E; Gilbertson-White, S; Tisler, C; DaSilva, D; Anklam, K; Mikus, LD; Rosenthal, LA; Ober, C; Gangnon, R; Lemanske, RF				Gern, JE; Reardon, CL; Hoffjan, S; Nicolae, D; Li, ZH; Roberg, KA; Neaville, WA; Carlson-Dakes, K; Adler, K; Hamilton, R; Anderson, E; Gilbertson-White, S; Tisler, C; DaSilva, D; Anklam, K; Mikus, LD; Rosenthal, LA; Ober, C; Gangnon, R; Lemanske, RF			Effects of dog ownership and genotype on immune development and atopy in infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Interleukin-10; hypersensitivity; dogs; cats; children; Interleukin-13; allergy; cytokines; CD14; atopic dermatitis	MODIFIED TH2 RESPONSE; ALLERGIC SENSITIZATION; DENDRITIC CELLS; EARLY EXPOSURE; CAT ALLERGEN; RISK-FACTORS; SCHOOL-AGE; EARLY-LIFE; 1ST YEAR; ASTHMA	Background: Exposure to furred pets might confer protection against the development of allergic sensitization through a mechanism that is incompletely understood. Objective: The objective of this study was to determine the effects of pet exposure and genotype on immunologic development and the incidence of atopic markers and diseases in the first year of life. Methods: Pet exposure in the home was compared with cytokine secretion patterns (mitogen-stimulated mononuclear cells at birth and age 1 year) and indicators of atopy (allergen-specific and total IgE, eosinophilia, food allergy, atopic dermatitis) in 285 infants. Interactions with genotype at the CD14 locus were also evaluated in the data analyses. Results: Exposure to dogs was associated with reduced allergen sensitization (19% vs 33%, P =.020) and atopic dermatitis (30% vs 51%, P < .001). The risk for atopic dermatitis was further influenced by genotype at the CD14 locus (P =.006), even after adjusting for exposure to dogs (P =.003). Furthermore, infants with the genotype -159TT were less likely to develop atopic dermatitis if they were exposed to a dog (5% vs 43%, P =.04). Last, dog exposure was associated with increased IL-10 (117 vs 79 pg/mL, P =.002) and IL-13 (280 vs 226 pg/mL, P =.013) responses at age 1 year. Conclusions: Having a dog in infancy is associated with higher IL-10 and IL-13 cytokine secretion profiles and reduced allergic sensitization and atopic dermatitis. These findings suggest that postnatal exposure to dogs can influence immune development in a genotype-specific fashion and thereby attenuate the development of atopy in at-risk children.	Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Chicago; University of Chicago	Gern, JE (corresponding author), K4-918 CSC,600 Highland Ave, Madison, WI 53792 USA.		Rosenthal, Louis/A-8868-2008	Nicolae, Dan/0000-0002-0918-4630; Gilbertson-White, Stephanie/0000-0002-9718-3717	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061879, P01HL070831] Funding Source: NIH RePORTER; NCRR NIH HHS [2 M01 RR03186-16] Funding Source: Medline; NHLBI NIH HHS [1R01HL61879-01, P01 HL70831-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P938, DOI 10.1067/mai.2003.1417; ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; Blahnik MJ, 2001, PEDIATR RES, V50, P726, DOI 10.1203/00006450-200112000-00016; Braback L, 2001, PEDIAT ALLERG IMM-UK, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; DESJARDINS A, 1993, J ALLERGY CLIN IMMUN, V91, P979, DOI 10.1016/0091-6749(93)90210-7; ENK AH, 1994, J EXP MED, V179, P1397, DOI 10.1084/jem.179.4.1397; FREUND RJ, 1997, STAT METHODS; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Jeannin P, 1998, J IMMUNOL, V160, P3555; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; Langrish CL, 2002, CLIN EXP IMMUNOL, V128, P118, DOI 10.1046/j.1365-2249.2002.01817.x; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408, DOI 10.1136/adc.73.5.408; Mirel DB, 2002, DIABETES, V51, P3336, DOI 10.2337/diabetes.51.11.3336; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pagano M., 2018, PRINCIPLES BIOSTATIS; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7	37	160	161	0	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					307	314		10.1016/j.jaci.2003.11.017	http://dx.doi.org/10.1016/j.jaci.2003.11.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767447				2022-12-18	WOS:000188885700020
J	Wensing, M; Akkerdaas, JH; van Leeuwen, A; Stapel, SO; Bruijnzeel-Koomen, CAFM; Aalberse, RC; Bast, BJEG; Knulst, AC; van Ree, R				Wensing, M; Akkerdaas, JH; van Leeuwen, A; Stapel, SO; Bruijnzeel-Koomen, CAFM; Aalberse, RC; Bast, BJEG; Knulst, AC; van Ree, R			IgE to Bet v 1 and profilin: Cross-reactivity patterns and clinical relevance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bet v 1; profilin; cross-reactivity; diagnostic accuracy	BIRCH POLLEN-ALLERGY; RBET V 1; SKIN-TEST; MOLECULAR CHARACTERIZATION; MAJOR ALLERGEN; APPLE; IDENTIFICATION; SENSITIVITY; CARROT; CELERY	Background: Individuals with pollen allergy often have IgE against plant-derived foods. This can be due to cross-reactive IgE against Bet v 1 and homologues, profilins, and/or cross-reactive carbohydrate determinants. Objective: The aim of this study was to correlate sensitization to Bet v 1 and profilin with individual recognition patterns to plant foods and clinical relevance. Methods: Fifty-two patients with pollen allergy and IgE against at least one plant-derived food were included in the study. Adverse reactions to plant-derived foods were documented by using standardized interviews. Skin prick tests were performed for pollen (grass, birch, and mugwort) and 14 plant-derived foods. In addition, recombinant (r) Bet v 1 and rBet v 2 (profilin) were tested intracutaneously. Specific IgE against the abovementioned allergens were determined by means of RAST. Cross-reactivity was studied by means of RAST inhibition. Results: Eighty-five percent of patients were sensitized to Bet v 1, and 71% were sensitized to profilin. Profilin was associated with a higher number of positive RAST results to plant-derived foods than Bet v 1. In contrast, Bet v 1 was associated with more positive skin prick test responses and more food-related symptoms. Sensitization to Bet v 1 was associated with IgE against apple, hazelnut, and peach, whereas sensitization to profilin was associated with positive RAST results to all investigated plant-derived foods except apple, peach, and melon. Conclusions: IgE antibodies against Bet v 1 have a more limited spectrum of cross-reactivity than those against profilin, but they frequently give rise to clinically relevant cross-reactivities to food. In analogy to anticarbohydrate IgE, cross-reactive IgE against food profilins have no or very limited clinical relevance.	CLB, Sanquin Res, Dept Immunopathol, NL-1066 CX Amsterdam, Netherlands; Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	van Ree, R (corresponding author), CLB, Sanquin Res, Dept Immunopathol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Elfman L, 1997, INT ARCH ALLERGY IMM, V113, P249, DOI 10.1159/000237561; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; FAH J, 1995, CLIN EXP ALLERGY, V25, P1018, DOI 10.1111/j.1365-2222.1995.tb00405.x; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; HOFFMAN B, 1997, TERRORISM POLITICAL, V9, P1; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; Karamloo F, 2001, J CHROMATOGR B, V756, P281, DOI 10.1016/S0378-4347(01)00087-1; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; Mari A, 2001, INT ARCH ALLERGY IMM, V125, P57, DOI 10.1159/000053797; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Neudecker P, 2001, J BIOL CHEM, V276, P22756, DOI 10.1074/jbc.M101657200; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; Pierson-Mullany LK, 2002, CLIN EXP ALLERGY, V32, P107, DOI 10.1046/j.0022-0477.2001.01244.x; RUDESCHKO O, 1995, ALLERGY, V50, P575, DOI 10.1111/j.1398-9995.1995.tb01202.x; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; van Ree R, 1999, CLIN EXP ALLERGY, V29, P848, DOI 10.1046/j.1365-2222.1999.00521.x; van Ree R, 1999, LUNG BIOL HEALTH DIS, V136, P399; Van Ree R, 2000, ALLERGY CLIN IMMUNOL, V12, P7; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; WUTHRICH B, 1985, SCHWEIZ MED WSCHR, V115, P358	40	160	167	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					435	442		10.1067/mai.2002.126380	http://dx.doi.org/10.1067/mai.2002.126380			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209091				2022-12-18	WOS:000177936900014
J	Woodruff, PG; Khashayar, R; Lazarus, SC; Janson, S; Avila, P; Boushey, HA; Segal, M; Fahy, JV				Woodruff, PG; Khashayar, R; Lazarus, SC; Janson, S; Avila, P; Boushey, HA; Segal, M; Fahy, JV			Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway obstruction; eosinophils; neutrophils	INDUCED SPUTUM; NEUTROPHILIC INFLAMMATION; CELL; ELASTASE; EOSINOPHILS; CHALLENGE	Background: Although the role of eosinophils in airway inflammation in chronic asthma has been extensively studied, a role for neutrophils has not been well characterized. Furthermore, prior studies have not systematically sought or controlled for factors that might confound the relationship between cellular markers of inflammation and physiologic measures of airway function. Objective: The purpose of this study was to determine whether eosinophilic and neutrophilic inflammation independently contribute to abnormalities of airway function in asthma. Methods: Multivariate analysis of data collected during screening and enrollment of 205 asthmatic adults for clinical trials was conducted to examine the relationships between cellular inflammation in induced sputum and FEV1 and methacholine responsiveness (PC20) while confounding factors were controlled for. Results: We found that age, sex, ethnicity, and use of inhaled corticosteroids were important confounding factors of the relationship between cellular inflammation and airway function. When these factors were controlled for, multivariate analysis showed that eosinophil percentage in induced sputum is independently associated with lower FEV1 and lower PC20 (P =.005 and P =.005, respectively). In the same models, increased sputum neutrophil percentage is independently associated with lower FEV1 (P =.038) but not with PC20 (P =.49). Conclusions: These results suggest that both eosinophilic inflammation and neutrophilic inflammation independently contribute to abnormalities of FEV1 in asthma. Therapies directed specifically at control of neutrophilic inflammation might be useful in improving airway caliber in patients with chronic asthma.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Fahy, JV (corresponding author), Univ Calif San Francisco, Dept Med, Box 0130,505 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056385, U10HL051823, R01HL061662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR003995] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07185, R01 HL-61662, P01 HL-56385, U10 HL-51823] Funding Source: Medline; NINR NIH HHS [NR-03995] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		AMITANI R, 1991, AM J RESP CELL MOL, V4, P26, DOI 10.1165/ajrcmb/4.1.26; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUSSE WW, 1992, ANN ALLERGY, V68, P286; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Gershman NH, 1996, EUR RESPIR J, V9, P2448, DOI 10.1183/09031936.96.09122448; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Liu XH, 1999, NEUROSCI LETT, V276, P1, DOI 10.1016/S0304-3940(99)00794-6; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; Nadel JA, 1999, EUR RESPIR J, V13, P190, DOI 10.1034/j.1399-3003.1999.13a35.x; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; SOMMERHOFF CP, 1990, J CLIN INVEST, V85, P682, DOI 10.1172/JCI114492; Spanevello A, 1997, CLIN EXP ALLERGY, V27, P1138; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Takeyama K, 1998, AM J PHYSIOL-LUNG C, V275, pL294, DOI 10.1152/ajplung.1998.275.2.L294; Veen JCCMI, 1996, EUR RESPIR J, V9, P2441, DOI 10.1183/09031936.96.09122441; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046	28	160	166	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					753	758		10.1067/mai.2001.119411	http://dx.doi.org/10.1067/mai.2001.119411			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692100				2022-12-18	WOS:000172523800015
J	Nelson, HS; Busse, WW; Kerwin, E; Church, N; Emmett, A; Rickard, K; Knobil, K				Nelson, HS; Busse, WW; Kerwin, E; Church, N; Emmett, A; Rickard, K; Knobil, K			Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; Advair; salmeterol; fluticasone propionate; leukotriene modifiers; montelukast; combination therapy; Seretide	LEUKOTRIENE RECEPTOR ANTAGONIST; PERSISTENT ASTHMA; CONTROLLED TRIAL; POWDER INHALERS; SALMETEROL; PROPIONATE; BECLOMETHASONE; EXACERBATIONS; MEDICATIONS; PERCEPTION	Background: Asthma is a disease of chronic inflammation and bronchoconstriction. Inhaled corticosteroids (ICSs) provide important anti-inflammatory treatment but may not provide optimal control of asthma when taken alone. Two therapeutic alternatives for enhanced asthma control are to substitute the combination of fluticasone propionate (FP) and salmeterol (FP/Salm Combo) through the Diskus inhaler or to add montelukast to existing ICS therapy Objective: We compared the efficacy and safety of FP/Salm Combo through the Diskus inhaler versus montelukast added to FP (FP + montelukust) in patients whose symptoms were suboptimally controlled with ICS therapy. Methods: We performed a multicenter, double-blind, double-dummy, parallel-group, 12-week study in 447 patients dth asthma who were symptomatic at baseline while receiving low-dose FP, Patients were treated for 12 weeks,vith one of the following: (1) combination of FP 100 mug plus salmeterol 50 mug twice daily through the Diskus inhaler, or (2) EP 100 mug twice daily through the Diskus inhaler plus oral montelukast 10 mg once daily, Results: FP/Salm Combo treatment provided better overall asthma control than FP + montelukast with significantly greater improvements in morning peak expiratory flow (+24.9 L/min vs +13.0 L/min, P < .001), evening peak expiratory flew (+18.9 L/min vs +9.6 L/min, P < .001), and forced expiratory volume in 1 second (+0.34 L vs +0.20 L, P < .001), as well as a change in the percentage of days with no albuterol use (+26.3 % vs +19.1%, P = .032) and the shortness of breath symptom score (-0.56 vs -0.40, P = .017). The groups had comparable improvements in chest tightness, wheeze, and overall symptom scores. Asthma exacerbation rates were significantly lower (P = .031) in the FP/Salm Combo group (4 patients, 2%) than in the FP + montelukast group (13 patients, 6%). Adverse event profiles were comparable. Conclusion: Symptomatic patients on low-dose ICS therapy had significantly greater improvement in asthma control when switched to the FP/Salm Combo than when montelukast was added to ICS therapy.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Wisconsin, Madison, WI USA; Clin Res Inst So Oregon, Medford, OR USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	National Jewish Health; University of Wisconsin System; University of Wisconsin Madison; GlaxoSmithKline	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							Aubier M, 1999, RESP MED, V93, P876, DOI 10.1016/S0954-6111(99)90053-7; Balsbaugh TA, 1999, J ASTHMA, V36, P591, DOI 10.3109/02770909909087296; Baraniuk J, 1999, CHEST, V116, P625, DOI 10.1378/chest.116.3.625; Barnes NC, 2000, AM J RESP CRIT CARE, V161, pS73, DOI 10.1164/ajrccm.161.supplement_1.ltta-15; Bijl-Hofland ID, 1999, THORAX, V54, P15, DOI 10.1136/thx.54.1.15; Busse W, 1999, J ALLERGY CLIN IMMUN, V103, P1075, DOI 10.1016/S0091-6749(99)70182-X; Busse WW, 1999, CLIN EXP ALLERGY, V29, P110; Chapman K R, 1999, Can Respir J, V6, P45; Condemi JJ, 1999, ANN ALLERG ASTHMA IM, V82, P383, DOI 10.1016/S1081-1206(10)63288-7; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Galant SP, 1999, ANN ALLERG ASTHMA IM, V82, P273, DOI 10.1016/S1081-1206(10)62608-7; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; KELLOWAY JS, 1994, ARCH INTERN MED, V154, P1349, DOI 10.1001/archinte.154.12.1349; Kelloway JS, 2000, ANN ALLERG ASTHMA IM, V84, P324, DOI 10.1016/S1081-1206(10)62781-0; Kelsen SG, 1999, J ASTHMA, V36, P703, DOI 10.3109/02770909909055422; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Matz J, 2000, J ALLERGY CLIN IMMUN, V105, pS162, DOI 10.1016/S0091-6749(00)90923-0; Murray JJ, 1999, ALLERGY ASTHMA PROC, V20, P173, DOI 10.2500/108854199778553028; *NAT ASTHM ED PREV, 1997, NIH PUBL; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V103, P267, DOI 10.1016/S0091-6749(99)70501-4; Noonan MJ, 1998, EUR RESPIR J, V11, P1232, DOI 10.1183/09031936.98.11061232; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pearlman DS, 1999, ANN ALLERG ASTHMA IM, V82, P257, DOI 10.1016/S1081-1206(10)62606-3; Peden DB, 1998, J ALLERGY CLIN IMMUN, V102, P32, DOI 10.1016/S0091-6749(98)70052-1; Pieters WR, 1998, J ASTHMA, V35, P337, DOI 10.3109/02770909809075666; Polgar G, 1971, PULMONARY FUNCTION T; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Rietveld S, 1998, J ASTHMA, V35, P137, DOI 10.3109/02770909809068201; Santanello NC, 1999, EUR RESPIR J, V14, P23, DOI 10.1034/j.1399-3003.1999.14a06.x; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527, DOI 10.1164/ajrccm.161.2.9905091; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Szefler SJ, 1998, J ALLERGY CLIN IMMUN, V102, pS23, DOI 10.1016/S0091-6749(98)70003-X; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; van Noord JA, 1999, THORAX, V54, P207, DOI 10.1136/thx.54.3.207; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	40	160	169	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1088	1095		10.1067/mai.2000.110920	http://dx.doi.org/10.1067/mai.2000.110920			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112891	Bronze			2022-12-18	WOS:000165930300010
J	Kotani, M; Matsumoto, M; Fujita, A; Higa, S; Wang, W; Suemura, M; Kishimoto, T; Tanaka, T				Kotani, M; Matsumoto, M; Fujita, A; Higa, S; Wang, W; Suemura, M; Kishimoto, T; Tanaka, T			Persimmon leaf extract and astragalin inhibit development of dermatitis and IgE elevation in NC/Nga mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						persimmon leaf extract; astragalin; histamine; passive cutaneous reaction; NC/Nga mouse; atopic dermatitis; skin; hypersensitivity; IgE	ATOPIC-DERMATITIS; MAST-CELLS; T-CELLS; FLAVONOIDS; INTERLEUKIN-4; HYPERPRODUCTION; IMMUNE; MODEL	Background: We previously found that persimmon leaf extract contains antiallergic substances that inhibit histamine release by human basophilic cell line KU812 in response to cross-linkage of Fc epsilon RI, Objectives: The purpose of this study was to identify substances in the persimmon leaf extract that are responsible for the effect and to examine their in vivo effects on the allergic mouse model, Methods: HPLC analysis of persimmon Leaf extract was done to measure its content. Inhibitory activity of persimmon leaf extract or its major constituent of flavonoids (astragalin) on the histamine release by KU812 cells was examined. To investigate the effects of these substances in vivo, models of passive cutaneous anaphylaxis and atopic dermatitis mice (NC/Nga) were used. Results: Persimmon leaf extract or astragalin inhibited histamine release from KU812 in response to cross-linkage of FceRI, Oral intake of both substances dose dependently inhibited passive cutaneous reactions, Moreover, oral administration of these substances to NC/Nga atopic dermatitis-model mice led to a striking suppression of the development of dermatitis, scratching behavior, and serum IgE elevation. Histologic analyses revealed that infiltration of inflammatory cells, especially degranulated mast cells, thickening of the epidermis, and prominent hyperkeratosis, were significantly reduced. Immunologic studies showed that the capacity of spleen T cells to produce both IL-4 and IL-13, but not IFN-gamma, was downregulated by means of oral intake of these substances. Conclusion: This study demonstrates a novel activity of astragalin and the dramatic effect of persimmon leaf extract and astragalin on atopic dermatitis-model mice.	Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 5650871, Japan; Sunstar Inc, Ctr Res & Dev, Osaka, Japan	Osaka University	Tanaka, T (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kishimoto, Tadamitsu/C-8470-2009					AMELLAL M, 1985, PLANTA MED, V51, P16, DOI 10.1055/s-2007-969381; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; CHAKRAVARTY N, 1980, ACTA PHARMACOL TOX, V47, P223; Cheong H, 1998, ARCH PHARM RES, V21, P478, DOI 10.1007/BF02974647; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; FEWTRELL CMS, 1977, NATURE, V265, P635, DOI 10.1038/265635a0; FOREMAN JC, 1984, J ALLERGY CLIN IMMUN, V73, P769, DOI 10.1016/0091-6749(84)90446-9; FUNAYAMA S, 1979, CHEM PHARM BULL, V27, P2865; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Graham-Brown R A, 1997, Adv Dermatol, V13, P3; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; HORSMANHEIMO L, 1994, BRIT J DERMATOL, V131, P348, DOI 10.1111/j.1365-2133.1994.tb08522.x; INAGAKI N, 1984, INT ARCH ALLER A IMM, V74, P91, DOI 10.1159/000233523; Ishiguro K, 1997, PHYTOTHER RES, V11, P343, DOI 10.1002/(SICI)1099-1573(199708)11:5<343::AID-PTR103>3.0.CO;2-4; KAKEGAWA H, 1985, CHEM PHARM BULL, V33, P5079; KAMEDA K, 1987, J NAT PROD, V50, P680, DOI 10.1021/np50052a017; KAR K, 1981, PLANTA MED, V42, P75, DOI 10.1055/s-2007-971549; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; Kotani M., 1999, J JPN SOC NUTR FOOD, V52, P147; Leung DYM, 1997, CLIN EXP IMMUNOL, V107, P25; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Matsumoto M, 1999, J IMMUNOL, V162, P1056; Matsuo N, 1997, ALLERGY, V52, P58, DOI 10.1111/j.1398-9995.1997.tb02546.x; MIDDLETON E, 1992, BIOCHEM PHARMACOL, V43, P1167, DOI 10.1016/0006-2952(92)90489-6; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Ochi H, 1996, INT ARCH ALLERGY IMM, V111, P253, DOI 10.1159/000237375; OHMORI Y, 1995, BIOL PHARM BULL, V18, P683, DOI 10.1248/bpb.18.683; PAGONIS C, 1986, BIOCHEM PHARMACOL, V35, P237, DOI 10.1016/0006-2952(86)90520-4; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	33	160	169	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				159	166		10.1067/mai.2000.107194	http://dx.doi.org/10.1067/mai.2000.107194			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887319	Bronze			2022-12-18	WOS:000088393300021
J	Reekers, R; Busche, M; Wittmann, M; Kapp, A; Werfel, T				Reekers, R; Busche, M; Wittmann, M; Kapp, A; Werfel, T			Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; birch pollen-related foods; cross-reactivities; specific T cells	LYMPHOCYTE-RESPONSE; TREE POLLEN; COWS MILK; ALLERGEN; ECZEMA; SKIN; IDENTIFICATION; PROVOCATION; REACTIVITY; CHILDREN	Background: Patients with inhalant allergy caused by birch pollen frequently demonstrate immediate symptoms to crossreactive fruits, vegetables, or both. The nature of late eczematous reactions to pollen related food antigens has not been investigated in detail. Objective: The purpose of this study was to find out whether isolated late eczematous reactions to birch pollen-related food antigens can be observed in patients with atopic dermatitis (AD) who are highly sensitized to birch pollen antigens. A possible linkage of such reactions with specific T-cell responses to birch pollen antigen in the blood and lesional skin was examined as well. Methods: We examined 37 adult patients with AD and hypersensitivity to birch pollen but without any history of immediate responses to food challenges. These patients underwent an elimination diet, including all birch pollen-related food antigens, followed by a double-blind, placebo-controlled, oral provocation, Blood and skin biopsy specimens were taken to examine a birch pollen-specific lymphocyte response. Results: Seventeen patients reacted with a deterioration of AD symptoms. Food- or birch pollen-specific IgE did not differentiate these patients from nonreactive patients. A significantly higher increase in the proportion of blood lymphocytes expressing the cutaneous lymphocyte antigen on incubation with birch pollen antigens was found in cells from reactive compared with nonreactive patients. The proliferative response of skin-derived T-cell lines from reactive patients to birch pollen extract or Bet v 1 was significantly higher than that of nonreactive patients. An enrichment of more than 25% of T-lymphocyte subpopulations defined by T-cell receptor-V beta elements was detected in the majority of such antigen-stimulated T-fell lines from responsive patients. A higher frequency of birch pollen-reactive T cells was calculated from limiting-dilution assays, and a higher rate of birch pollen-specific T-cell clones was generated from cultures with skin-derived T cells from reactive patients. Conclusion: Our results show, for the first time, that a subpopulation of patients with hypersensitivity to birch pollen and AD reacts with worsening of eczema after oral challenge with birch pollen-related foods and that a birch pollen-specific T-cell response can he found in the lesional skin of these patients.	Hannover Med Sch, Dept Dermatol & Allergol, D-30449 Hannover, Germany	Hannover Medical School	Werfel, T (corresponding author), Hannover Med Sch, Dept Dermatol & Allergol, Ricklinger Str 5, D-30449 Hannover, Germany.		Wittmann, Miriam/F-9006-2010; Werfel, Thomas/B-6921-2012; Busche, Marc/AAS-3845-2021	Wittmann, Miriam/0000-0003-2328-4926; Kapp, Alexander/0000-0002-1748-6276				ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; ATHERTON DJ, 1978, LANCET, V1, P401; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FRITSCH R, IN PRESS J ALLERGY C; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; HAMMAR H, 1977, ACTA DERM-VENEREOL, V57, P159; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; KAGI MK, 1994, INT ARCH ALLERGY IMM, V103, P332, DOI 10.1159/000236651; KAPP A, 1995, CLIN EXP ALLERGY, V25, P210, DOI 10.1111/j.1365-2222.1995.tb01031.x; KARPLUS TE, 1987, J IMMUNOL METHODS, V105, P211, DOI 10.1016/0022-1759(87)90268-7; MARTINEZ A, 1995, ACI NEWS, V7, P85; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; Reekers R, 1996, BRIT J DERMATOL, V135, P935, DOI 10.1046/j.1365-2133.1996.d01-1098.x; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SLOPER KS, 1991, Q J MED, V80, P677; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; STRIJBOSCH LWG, 1988, INT J BIOMED COMPUT, V23, P279, DOI 10.1016/0020-7101(88)90020-7; TASWELL C, 1981, J IMMUNOL, V126, P1614; Tuft Louis, 1942, JOUR ALLERGY, V13, P574, DOI 10.1016/S0021-8707(42)90070-4; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; Walzer M, 1927, J IMMUNOL, V14, P143; Werfel T, 1998, ALLERGY, V53, P731; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; Werfel T, 1997, J ALLERGY CLIN IMMUN, V99, P124, DOI 10.1016/S0091-6749(97)81053-6; Werfel T, 1996, CLIN EXP ALLERGY, V26, P1380, DOI 10.1111/j.1365-2222.1996.tb00539.x; WUTHRICH B, 1978, CLIN ALLERGY, V8, P241, DOI 10.1111/j.1365-2222.1978.tb03220.x; Wuthrich B, 1997, ALLERGY, V52, P1187, DOI 10.1111/j.1398-9995.1997.tb02522.x; WUTHRICH B, 1989, DERMATOLOGICA, V178, P51; ZACHARY CB, 1985, BRIT J DERMATOL, V112, P149, DOI 10.1111/j.1365-2133.1985.tb00078.x	37	160	163	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				466	472		10.1016/S0091-6749(99)70395-7	http://dx.doi.org/10.1016/S0091-6749(99)70395-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452773				2022-12-18	WOS:000082364800044
J	Shadick, NA; Liang, MH; Partridge, AJ; Bingham, C; Wright, E; Fossel, AH; Sheffer, AL				Shadick, NA; Liang, MH; Partridge, AJ; Bingham, C; Wright, E; Fossel, AH; Sheffer, AL			The natural history of exercise-induced anaphylaxis: Survey results from a 10-year follow-up study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; urticaria; physical allergy; exercise; exercise-induced anaphylaxis; food allergy	PHYSICAL ALLERGY; FORM	Background: Exercise-induced anaphylaxis (EIA) is a unique physical allergy that is triggered by exertion, the clinical spectrum and modifying factors of which have been previously studied. At the time of initial description, it was postulated that other factors contributed to this disorder. Objective: We sought to determine the clinical course and potential modifying factors in EIA, Methods: In 1993, we conducted a cross-sectional analysis of 671 individuals with exercise-associated symptoms for more than a decade using a validated 75-item questionnaire. Subjects met criteria for EIA if they had anaphylactic symptoms, including hypotension or upper airway obstruction, urticaria, or angioedema with physical exertion but without a passive increase in core body temperature. Results: Of 365 (54%) questionnaire respondents, 279 (87%) met criteria for EIA (199 females and 80 males). At the time of study entry, subjects with EIA (mean age, 37.5 years; range, 13 to 77 years) had an average of 10.6 years of symptoms, which were most frequently triggered by aerobic activities such as jogging or brisk walking (78% and 42%, respectively). On average, subjects reported that the frequency of attacks had decreased (47% of subjects) or stabilized (46% of subjects) since onset. One hundred (41%) subjects reported being completely free of attacks in the past year. Subjects reduced their attacks by avoiding exercise during extremely hot or cold weather (44%), avoiding ingestion of certain foods before exercise (37%), and restricting exercise during their allergy season (36%) or humid weather (33%). The most common pharmacologic agents used to manage symptoms were H1 antagonists (56%) and/or epinephrine (31%), However, 28% used no treatment at all. Conclusion: EIA is an episodic condition in which the frequency of attacks tends to stabilize or decrease over time. Improvement appears to result from individual modification of exercise and avoidance of known environmental and ingestible precipitants.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Multipurpose Arthrit & Musculoskeletal Dis Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Shadick, NA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.				NIAMS NIH HHS [AR36308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARMENTIA A, 1990, ANN ALLERGY, V65, P149; Caffarelli C, 1996, J ALLERGY CLIN IMMUN, V98, P762, DOI 10.1016/S0091-6749(96)70125-2; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; Guinnepain MT, 1996, ANN ALLERG ASTHMA IM, V77, P491, DOI 10.1016/S1081-1206(10)63357-1; JUJI F, 1994, ANN ALLERGY, V72, P452; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P311; KUSHIMOTO H, 1985, ARCH DERMATOL, V121, P355, DOI 10.1001/archderm.121.3.355; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MCNEIL D, 1988, ANN ALLERGY, V61, P440; MOOREROBINSON M, 1968, BRIT J DERMATOL, V80, P794, DOI 10.1111/j.1365-2133.1968.tb11948.x; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V71, P498, DOI 10.1016/0091-6749(83)90468-2; ROSNER B, FUNDAMENTALS STAT, P55; *SAS I INC, 1985, SAS US GUID STAT VER, P569; SCHWARTZ HJ, 1995, J ALLERGY CLIN IMMUN, V95, P917, DOI 10.1016/S0091-6749(95)70139-7; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P479, DOI 10.1016/S0091-6749(85)80021-X; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SILVERSTEIN S R, 1986, Journal of Emergency Medicine, V4, P195, DOI 10.1016/0736-4679(86)90040-5; SMITH HS, 1985, BRIT J OBSTET GYNAEC, V92, P1196, DOI 10.1111/j.1471-0528.1985.tb03038.x; Wade J P, 1989, Prog Clin Biol Res, V297, P175	20	160	164	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					123	127		10.1016/S0091-6749(99)70123-5	http://dx.doi.org/10.1016/S0091-6749(99)70123-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400849				2022-12-18	WOS:000081738900018
J	CHERVINSKY, P; VANAS, A; BRONSKY, EA; DOCKHORN, R; NOONAN, M; LAFORCE, C; PLESKOW, W				CHERVINSKY, P; VANAS, A; BRONSKY, EA; DOCKHORN, R; NOONAN, M; LAFORCE, C; PLESKOW, W			FLUTICASONE PROPIONATE AEROSOL FOR THE TREATMENT OF ADULTS WITH MILD-TO-MODERATE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; FLUTICASONE PROPIONATE; INHALED CORTICOSTEROID	BECLOMETHASONE DIPROPIONATE; STEROIDS; EFFICACY	Background: Recent emphasis on the control of airway inflammation in asthma highlights the need for safe and effective antiinflammatory agents. Fluticasone propionate is one of the most potent antiinflammatory corticosteroids developed to date. Objective: This study assessed the safety and efficacy of fluticasone propionate aerosol in the treatment of mild to moderate asthma. Methods: Fluticasone propionate aerosol (25, 100, or 500 mu g twice daily) or placebo was given for as long as 8 week to adults with mild to moderate asthma in a randomized, double-blind, parallel-group study. Patients were removed from the study if they showed predefined signs of worsening asthma. Results: Sixty-three percent of placebo-treated patients and 23%, 13%, and 4% of patients treated with fluticasone propionate 25, 100, and 500 mu g twice daily, respectively, were removed from the study. Mean forced expiratory volume in 1 second, forced vital capacity, and forced expiratory flow at midexpiratory phase at weekly visits throughout the study demonstrated that fluticasone propionate was more efficacious than placebo in maintaining asthma control. Measurements of peak expiratory flow and symptom scores significantly improved and nighttime awakenings and albuterol use to treat symptoms significantly declined in fluticasone propionate-treated groups relative to the placebo-treated group. Differences among fluticasone propionate groups for these variables were not statistically significant. Incidence and severity of adverse events were similar across groups. Fluticasone propionate did not affect morning or stimulated plasma cortisol concentrations, although slight, transient reductions in urinary free cortisol and urinary 17-hydroxy steroids occurred in the group receiving 500 mu g fluticasone propionate twice daily. Conclusion: These data indicate char fluticasone propionate provides safe and effective treatment for mild to moderate asthma.	ASTHMA & ALLERGY RES CTR, ALBUQUERQUE, NM USA; AAAA MED RES GRP, SALT LAKE CITY, UT USA; IMMUNO ALLERGY TECH CONSULTANTS INC, LENEXA, KS USA; CAROLINA ALLERGY & ASTHMA CONSULTANTS, RALEIGH, NC USA		CHERVINSKY, P (corresponding author), ALLERGY & ASTHMA CTR, N DARTMOUTH, MA 02747 USA.							BARNES NC, 1993, EUR RESPIR J, V6, P877; CHESNUTT MS, 1992, HOSP FORMUL, V27, P466; COSTELLO JF, 1974, THORAX, V29, P571, DOI 10.1136/thx.29.5.571; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; GADDIE J, 1973, LANCET, V2, P280; GEDDES DM, 1992, THORAX, V47, P404, DOI 10.1136/thx.47.6.404; GUSTAFSSON P, 1993, ARCH DIS CHILD, V69, P206, DOI 10.1136/adc.69.2.206; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; HUMMEL S, 1992, LANCET, V340, P1483, DOI 10.1016/0140-6736(92)92750-A; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; SHEFFER AL, 1991, J ALLERGY CLIN IMMUN, V87, P468, DOI 10.1016/0091-6749(91)90002-6; TARLO SM, 1988, CHEST, V93, P998, DOI 10.1378/chest.93.5.998; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; WILLIAMS AJ, 1983, THORAX, V38, P813, DOI 10.1136/thx.38.11.813	15	160	159	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					676	683		10.1016/0091-6749(94)90174-0	http://dx.doi.org/10.1016/0091-6749(94)90174-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930300				2022-12-18	WOS:A1994PM27300005
J	ARLIAN, LG; BERNSTEIN, D; BERNSTEIN, IL; FRIEDMAN, S; GRANT, A; LIEBERMAN, P; LOPEZ, M; METZGER, J; PLATTSMILLS, T; SCHATZ, M; SPECTOR, S; WASSERMAN, SI; ZEIGER, RS				ARLIAN, LG; BERNSTEIN, D; BERNSTEIN, IL; FRIEDMAN, S; GRANT, A; LIEBERMAN, P; LOPEZ, M; METZGER, J; PLATTSMILLS, T; SCHATZ, M; SPECTOR, S; WASSERMAN, SI; ZEIGER, RS			PREVALENCE OF DUST MITES IN THE HOMES OF PEOPLE WITH ASTHMA LIVING IN 8 DIFFERENT GEOGRAPHIC AREAS OF THE UNITED-STATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DERMATOPHAGOIDES-FARINAE; DERMATOPHAGOIDES-PTERONYSSINUS; EUROGLYPHUS-MAYNEI; BLOMIA-TROPICALIS; HOUSE DUST MITES; ALLERGENICITY; ASTHMA; ALLERGIC DISEASE		The density and species prevalence of dust mites were determined at various times over a 5-year-period in 252 homes of dust mite sensitive people with asthma who lived in eight geographic areas of the United States (Cincinnati, Ohio; New Orleans, La.; Memphis, Tenn.; Galveston, Texas; Greenville, N.C.; Delray Beach, Fla.; San Diego and Los Angeles, Calif.). The most common dust mites found in the homes were Dermatophagoides farinae (DF), D. pteronyssinus (DP), Euroglyphus maynei (EM), and Blomia tropicalis. All homes in all locations contained Dermatophagoides spp. mites, but few homes were populated exclusively by either DF or DP alone. Most homes (81.7%) were coinhabitated by both DF and DP. In coinhabited homes one species was predominant and usually made up at least 75% of the total mite population. Prevalence of the dominant or only species present varied between homes within a geographic area. EM occurred in significant numbers in 35.7% of homes in New Orleans, Memphis, Galveston, Delray Beach, and San Diego. Blomia tropicalis occurred in these same cities but in low densities. For all dust samples, only 13 homes of the 252 sampled had 100 or fewer mites/gm dust, which is considered to be the threshold for sensitivity. Most homes had average mite densities of 500 or more mites/gm dust. The results of the present study suggest a significant and widespread occurrence of both DF and DP. Therefore extracts of both mite species should be considered for diagnostic tests and immunotherapy. Significant levels of EM were present in some areas. Thus sensitivity to EM should be considered in these areas.	UNIV CINCINNATI, MED CTR, CINCINNATI, OH 45267 USA; MED CTR DELRAY, DELRAY BEACH, FL USA; UNIV TEXAS, MED BRANCH, GALVESTON, TX 77550 USA; UNIV TENNESSEE CTR HLTH SCI, SCH MED, MEMPHIS, TN 38163 USA; TULANE UNIV, SCH MED, NEW ORLEANS, LA 70112 USA; E CAROLINA UNIV, GREENVILLE, NC 27834 USA; UNIV VIRGINIA, MED CTR, CHARLOTTESVILLE, VA 22903 USA; SO CALIF PERMANENTE MED GRP, SAN DIEGO, CA USA; UNIV CALIF LOS ANGELES, MED CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF SAN DIEGO, MED CTR, LA JOLLA, CA 92093 USA	University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Medical Branch Galveston; University of Tennessee System; University of Tennessee Health Science Center; Tulane University; University of North Carolina; East Carolina University; University of Virginia; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California San Diego	ARLIAN, LG (corresponding author), WRIGHT STATE UNIV, DEPT BIOL SCI, DAYTON, OH 45435 USA.			Zeiger, Robert/0000-0001-5788-5063	NIAID NIH HHS [AI-21984, AI-21987, AI-20565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI021984, R37AI020565, R01AI020565, U01AI021987] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN LG, 1991, EXP APPL ACAROL, V10, P167, DOI 10.1007/BF01198649; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1975, J INSECT PHYSIOL, V21, P1439, DOI 10.1016/0022-1910(75)90204-8; ARLIAN LG, 1982, PHYSIOL ZOOL, V55, P344, DOI 10.1086/physzool.55.4.30155862; ARLIAN LG, 1981, J MED ENTOMOL, V18, P351, DOI 10.1093/jmedent/18.4.351; ARLIAN LG, 1990, J MED ENTOMOL, V27, P1035, DOI 10.1093/jmedent/27.6.1035; ARLIAN LG, 1989, IMMUNOL ALLERGY CLIN, V9, P339; ARLIAN LG, 1981, PHYSIOL ZOOL, V54, P393, DOI 10.1086/physzool.54.4.30155831; ARLIAN LG, 1975, J MED ENTOMOL, V12, P437, DOI 10.1093/jmedent/12.4.437; ARLIAN LG, 1974, J INSECT PHYSIOL, V20, P1063, DOI 10.1016/0022-1910(74)90148-6; ARLIAN LG, 1978, J MED ENTOMOL, V14, P484; ARLIAN LG, 1987, J MED ENTOMOL, V24, P252, DOI 10.1093/jmedent/24.2.252; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P467, DOI 10.1016/0091-6749(87)90364-2; ARLIAN LG, 1992, IN PRESS EXP APPL AC; BRANDT RL, 1976, J MED ENTOMOL, V13, P327, DOI 10.1093/jmedent/13.3.327; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1985, INT ARCH ALLER A IMM, V77, P166, DOI 10.1159/000233774; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; COLLOFF MJ, 1991, EXP APPL ACAROL, V11, P177, DOI 10.1007/BF01246090; FAIN A, 1967, Acarologia (Paris), V9, P179; Fain A., 1965, Revue de Zoologie et de Botanique Africaines, V72, P257; Fain A., 1966, Acarologia, V8, P302; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; GRIFFITHS DA, 1971, J STORED PROD RES, V7, P1, DOI 10.1016/0022-474X(71)90032-4; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HUGHES AM, 1976, MINISTRY AGR FISHERI, V9, P400; KLEIN BS, 1986, AM J EPIDEMIOL, V124, P306, DOI 10.1093/oxfordjournals.aje.a114389; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P132, DOI 10.1016/0091-6749(84)90275-6; LANG JD, 1978, ENVIRON ENTOMOL, V7, P121, DOI 10.1093/ee/7.1.121; LANG JD, 1977, ENVIRON ENTOMOL, V6, P213, DOI 10.1093/ee/6.2.213; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LIND P, 1986, INT ARCH ALLER A IMM, V79, P60, DOI 10.1159/000233943; MULLA MS, 1975, J MED ENTOMOL, V12, P5, DOI 10.1093/jmedent/12.1.5; PLATTSMILLS TAE, 1985, INT ARCH ALLER A IMM, V77, P163; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P398, DOI 10.1016/0091-6749(86)90024-2; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; YOSHIKAWA M, 1979, OHIO J SCI, V79, P280	44	160	171	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				292	300		10.1016/S0091-6749(05)80006-5	http://dx.doi.org/10.1016/S0091-6749(05)80006-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527314	Bronze			2022-12-18	WOS:A1992JP52000004
J	BERNHISELBROADBENT, J; TAYLOR, S; SAMPSON, HA				BERNHISELBROADBENT, J; TAYLOR, S; SAMPSON, HA			CROSS-ALLERGENICITY IN THE LEGUME BOTANICAL FAMILY IN CHILDREN WITH FOOD HYPERSENSITIVITY .2. LABORATORY CORRELATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV HOSP,SCH MED,CMSC-1103,600 N WOLFE ST,BALTIMORE,MD 21205; UNIV NEBRASKA,DEPT FOOD SCI & TECHNOL,OMAHA,NE 68182	Johns Hopkins University; Johns Hopkins Medicine; University of Nebraska System					NCRR NIH HHS [RR-30] Funding Source: Medline; NIAID NIH HHS [AI24439, AI00830] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BARNETT D, 1983, J ALLERGY CLIN IMMUN, V72, P61, DOI 10.1016/0091-6749(83)90053-2; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; BARNETT D, 1988, J ALLERGY CLIN IMMUN, V82, P311, DOI 10.1016/0091-6749(88)91022-6; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BIERMAN CW, 1978, J ALLERGY CLIN IMMUN, V61, P119; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOCK SA, 1986, J ALLERGY CLIN IMMUN, V78, P165, DOI 10.1016/0091-6749(86)90009-6; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BUSH RK, 1988, J ALLERGY CLIN IMMUN, V82, P251, DOI 10.1016/0091-6749(88)91007-X; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; FRIES JH, 1982, ANN ALLERGY, V48, P220; FRIES JH, 1971, ANN ALLERGY, V29, P1; GALANT SP, 1980, ALLERGIC DISEASES IN, P211; LEMANSKE RF, 1987, CLIN REV ALLERG, V5, P26; LOWRY OH, 1951, J BIOL CHEM, V193, P265; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P441, DOI 10.1159/000232472; SPEER F, 1975, ANN ALLERGY, V34, P71; SUTTON R, 1982, CLIN ALLERGY, V12, P67; VOLLER A, 1986, MANUAL CLIN IMMUNOLO, P106; WARNER JO, 1984, ARCH DIS CHILD, V59, P151, DOI 10.1136/adc.59.2.151; 1984, NIH842442 NIAID TASK, P7; 1988, CONSUM REP, V53, P96	27	160	166	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				701	709		10.1016/0091-6749(89)90298-4	http://dx.doi.org/10.1016/0091-6749(89)90298-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2809025				2022-12-18	WOS:A1989CA31400007
J	DOWSE, GK; TURNER, KJ; STEWART, GA; ALPERS, MP; WOOLCOCK, AJ				DOWSE, GK; TURNER, KJ; STEWART, GA; ALPERS, MP; WOOLCOCK, AJ			THE ASSOCIATION BETWEEN DERMATOPHAGOIDES MITES AND THE INCREASING PREVALENCE OF ASTHMA IN VILLAGE COMMUNITIES WITHIN THE PAPUA-NEW-GUINEA HIGHLANDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PRINCESS MARGARET HOSP, CLIN IMMUNOL RES UNIT, SUBIACO, WA, AUSTRALIA; UNIV WESTERN AUSTRALIA, DEPT MICROBIOL, NEDLANDS, WA 6009, AUSTRALIA; PAPUA NEW GUINEA INST MED RES, GOROKA, PAPUA N GUINEA; UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA	University of Western Australia; PNG Institute Of Medical Research; University of Sydney								ANDERSON HR, 1974, CLIN ALLERGY, V4, P171, DOI 10.1111/j.1365-2222.1974.tb01374.x; BLAIR H, 1979, J ROY SOC MED, V72, P42, DOI 10.1177/014107687907200113; BROWN P, 1978, AM J EPIDEMIOL, V108, P266, DOI 10.1093/oxfordjournals.aje.a112619; COOKSON J B, 1975, Clinical Allergy, V5, P375, DOI 10.1111/j.1365-2222.1975.tb01876.x; COOKSON J B, 1977, Central African Journal of Medicine, V23, P96; DOWSE GK, 1983, PAPUA NEW GUINEA MED, V26, P33; GABRIEL M, 1982, CLIN ALLERGY, V12, P157, DOI 10.1111/j.1365-2222.1982.tb01635.x; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; GREEN W, 1982, PAPUA NEW GUINEA MED, V25, P219; HADDOCK DRW, 1977, T ROY SOC TROP MED H, V71, P32, DOI 10.1016/0035-9203(77)90203-6; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; KABASAWA Y, 1976, ACTA ALLERGOL, V31, P442, DOI 10.1111/j.1398-9995.1976.tb01494.x; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; MANTLE J, 1974, CLIN ALLERGY, V4, P161, DOI 10.1111/j.1365-2222.1974.tb01373.x; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; PEAT JK, 1980, AM J EPIDEMIOL, V111, P721, DOI 10.1093/oxfordjournals.aje.a112950; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; PICKERING CA, 1973, B HONG KONG MEDICAL, V25, P95; SINNETT PF, 1975, PAPUA NEW GUINEA I M, V4; SOFOWORA E O, 1970, East African Medical Journal, V47, P434; STANHOPE JM, 1976, INT J EPIDEMIOL, V5, P259, DOI 10.1093/ije/5.3.259; TOVEY ER, 1975, MED J AUSTRALIA, V2, P770, DOI 10.5694/j.1326-5377.1975.tb106278.x; TURNER KJ, 1975, INT ARCH ALLER A IMM, V48, P784, DOI 10.1159/000231367; TURNER KJ, 1982, AUST J EXP BIOL MED, V60, P147, DOI 10.1038/icb.1982.15; TURNER KJ, 1978, PAPUA NEW GUINEA MED, V21, P86; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; WARRELL DA, 1975, Q J MED, V44, P325; WHITLOCK H. V., 1950, JOUR HELMINTHOL, V24, P47, DOI 10.1017/S0022149X00019106; WOOLCOCK AJ, 1972, AUST NZ J MED, V2, P310; WOOLCOCK AJ, 1981, AM REV RESPIR DIS, V123, P564; WOOLCOCK AJ, 1983, EUR J RESPIR DIS, V64, P571	32	160	162	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					75	83		10.1016/0091-6749(85)90016-8	http://dx.doi.org/10.1016/0091-6749(85)90016-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABF26	2578494	Bronze			2022-12-18	WOS:A1985ABF2600012
J	IPSEN, H; LOWENSTEIN, H				IPSEN, H; LOWENSTEIN, H			ISOLATION AND IMMUNOCHEMICAL CHARACTERIZATION OF THE MAJOR ALLERGEN OF BIRCH POLLEN (BETULA-VERRUCOSA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGOL LAB,ALLERGEN RES GRP,KOBENHAVN,DENMARK		IPSEN, H (corresponding author), UNIV COPENHAGEN,PROT LAB,DK-2200 COPENHAGEN,DENMARK.							APOLD J, 1981, INT ARCH ALLER A IMM, V64, P439, DOI 10.1159/000232724; BELIN L, 1972, INT ARCH ALLER A IMM, V42, P329, DOI 10.1159/000230616; BELIN L, 1972, INT ARCH ALLER A IMM, V42, P300, DOI 10.1159/000230613; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; HEARON JZ, 1948, J NATL CANCER I, V9, P1; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; SCHAFERNIELSEN C, 1982, BIOCHIM BIOPHYS ACTA, V696, P323, DOI 10.1016/0167-4781(82)90064-1; SVENDSEN PJ, 1970, PROTIDES BIOL FLUIDS, V17, P413; VIANDER M, 1979, ALLERGY, V34, P289; VIK H, 1982, INT ARCH ALLER A IMM, V68, P70, DOI 10.1159/000233069	11	160	163	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					150	159		10.1016/0091-6749(83)90523-7	http://dx.doi.org/10.1016/0091-6749(83)90523-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD959	6886253				2022-12-18	WOS:A1983RD95900008
J	Bafunno, V; Firinu, D; D'Apolito, M; Cordisco, G; Loffredo, S; Leccese, A; Bova, M; Barca, MP; Santacroce, R; Cicardi, M; Del Giacco, S; Margaglione, M				Bafunno, Valeria; Firinu, Davide; D'Apolito, Maria; Cordisco, Giorgia; Loffredo, Stefania; Leccese, Angelica; Bova, Maria; Barca, Maria Pina; Santacroce, Rosa; Cicardi, Marco; Del Giacco, Stefano; Margaglione, Maurizio			Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hereditary angioedema; angiopoietin-1; gene; mutation; multimers; tunica interna endothelial cell kinase 2 receptor	ENDOTHELIAL PERMEABILITY; VASCULAR LEAKAGE; NORMAL C1-INH; RECEPTOR; PLASMA; DIAGNOSIS	Background: Hereditary angioedema (HAE) is a rare genetic disease usually caused by mutation in the C1 inhibitor or the coagulation Factor XII gene. However, in a series of patients with HAE, no causative variants have been described, and the pathophysiology of the disease remains unknown (hereditary angioedema with yet unknown genetic defect [U-HAE]). Identification of causative genes in patients with U-HAE is valuable for understanding the cause of the disease. Objective: We conducted genetic studies in Italian patients with U-HAE to identify novel causative genes. Methods: Among patients belonging to 10 independent families and unrelated index patients with U-HAE recruited from the Italian Network for C1-INH-HAE (ITACA), we selected a large multiplex family with U-HAE and performed whole-exome sequencing. The angiopoietin-1 gene (ANGPT1) was investigated in all patients with familial or sporadic U-HAE. The effect of ANGPT1 variants was investigated by using in silico prediction and plasma and transfected cells from both patients and control subjects. Results: We identified a missense mutation (ANGPT1, c. 807G> T, p. A119S) in a family with U-HAE. The ANGPT1 p. A119S variant was detected in all members of the index family with U-HAE but not in asymptomatic family members or an additional 20 patients with familial U-HAE, 22 patients with sporadic U-HAE, and 200 control subjects. Protein analysis of the plasma of patients revealed a reduction of multimeric forms and a reduced ability to bind the natural receptor tunica interna endothelial cell kinase 2 of the ANGPT1 p. A119S variant. The recombinant mutated ANGPT1 p. A119S formed a reduced amount of multimers and showed reduced binding capability to its receptor. Conclusion: ANGPT1 impairment is associated with angioedema, and ANGPT1 variants can be the basis of HAE.	[Bafunno, Valeria; D'Apolito, Maria; Cordisco, Giorgia; Leccese, Angelica; Santacroce, Rosa; Margaglione, Maurizio] Univ Foggia, Dept Clin & Expt Med, Med Genet, Viale Pinto, I-71122 Foggia, Italy; [Firinu, Davide; Barca, Maria Pina; Del Giacco, Stefano] Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy; [Loffredo, Stefania; Bova, Maria] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Cicardi, Marco] Univ Milan, Luigi Sacco Hosp Milan, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy	University of Foggia; University of Cagliari; University of Naples Federico II; University of Milan; Luigi Sacco Hospital	Margaglione, M (corresponding author), Univ Foggia, Dept Clin & Expt Med, Med Genet, Viale Pinto, I-71122 Foggia, Italy.	m.margaglione@unifg.it	d'Apolito, Maria/AAQ-9290-2021; firinu, davide/AAF-4366-2020; Del Giacco, S. R./AAG-6186-2019; cicardi, marco/K-9219-2016	Del Giacco, S. R./0000-0002-4517-1749; MARGAGLIONE, MAURIZIO/0000-0001-5627-9221; cicardi, marco/0000-0003-1251-225X; Firinu, Davide/0000-0002-5768-391X				Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH107, DOI 10.1152/ajpheart.00542.2005; Bafunno V, 2014, ANN HUM GENET, V78, P73, DOI 10.1111/ahg.12052; Bjorkqvist J, 2015, J CLIN INVEST, V125, P3132, DOI 10.1172/JCI77139; Bork K, 2017, ALLERGY, V72, P320, DOI 10.1111/all.13076; Bork K, 2015, ALLERGY, V70, P1004, DOI 10.1111/all.12648; Bork K, 2009, J ALLERGY CLIN IMMUN, V124, P129, DOI 10.1016/j.jaci.2009.03.038; Cicardi M, 2016, J INVEST ALLERG CLIN, V26, P212, DOI 10.18176/jiaci.0087; Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380; Cicardi M, 2010, NEW ENGL J MED, V363, P532, DOI 10.1056/NEJMoa0906393; D'Andrea G, 2008, BLOOD COAGUL FIBRIN, V19, P657, DOI 10.1097/MBC.0b013e3283048e42; D'Apolito M, 2007, HAEMATOL-HEMATOL J, V92, P133, DOI 10.3324/haematol.10585; Davis S, 2003, NAT STRUCT BIOL, V10, P38, DOI 10.1038/nsb880; de Maat S, 2016, J ALLERGY CLIN IMMUN, V138, P1414, DOI 10.1016/j.jaci.2016.02.021; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; Firinu D, 2015, CLIN IMMUNOL, V157, P239, DOI 10.1016/j.clim.2015.02.013; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019; Ghosh CC, 2012, P NATL ACAD SCI USA, V109, P10024, DOI 10.1073/pnas.1120755109; Jeansson M, 2011, J CLIN INVEST, V121, P2278, DOI 10.1172/JCI46322; Jho D, 2005, CIRC RES, V96, P1282, DOI 10.1161/01.RES.0000171894.03801.03; Jiang H, 2014, EXP NEUROL, V261, P245, DOI 10.1016/j.expneurol.2014.05.013; Kim KT, 2005, J BIOL CHEM, V280, P20126, DOI 10.1074/jbc.M500292200; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321, DOI 10.1016/S0091-6749(99)70030-8; Sala-Cunill A, 2015, J ALLERGY CLIN IMMUN, V135, P1031, DOI 10.1016/j.jaci.2014.07.057; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Trunzo R, 2013, CLIN BIOCHEM, V46, P1896, DOI 10.1016/j.clinbiochem.2013.06.009; Witzenbichler B, 2005, CIRCULATION, V111, P97, DOI 10.1161/01.CIR.0000151287.08202.8E; Yao JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089148; Zanichelli A, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0233-x	32	159	164	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1009	1017		10.1016/j.jaci.2017.05.020	http://dx.doi.org/10.1016/j.jaci.2017.05.020			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28601681	Bronze			2022-12-18	WOS:000426974800021
J	van de Veen, W; Stanic, B; Wirz, OF; Jansen, K; Globinska, A; Akdis, M				van de Veen, Willem; Stanic, Barbara; Wirz, Oliver F.; Jansen, Kirstin; Globinska, Anna; Akdis, Muebeccel			Role of regulatory B cells in immune tolerance to allergens and beyond	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory B cells; IL-10; IL-35; TGF-beta; IgG(4); tolerance; allergen; autoimmunity; suppression; B(R)1; B10	MODIFIED TH2 RESPONSE; B10 CELLS; T-CELLS; AUTOIMMUNE INFLAMMATION; DELAYED-HYPERSENSITIVITY; INTERNATIONAL CONSENSUS; AIRWAY INFLAMMATION; HELMINTH INFECTION; PROTECTS MICE; MURINE MODEL	Immune tolerance to both self-antigens and innocuous non-self-antigens is essential to protect the host against chronic inflammatory diseases and tissue damage. A wide range of cell types and suppressive molecules are involved in induction and maintenance of tolerance. In addition to their key function in the production of immunoglobulins, B cells can regulate immune responses through their surface molecules and secretion of cytokines. Regulatory B (Breg) cells are characterized by their immunosuppressive capacity, which is often mediated through IL-10 secretion. However, IL-35 and TGF-beta have also been associated with B cell-mediated immunosuppression. Several types of murine and human Breg cells have been described, such as mouse CD5(+)CD1d(hi)B10 cells, CD21(hi)CD23(hi)CD24 hi transitional stage 2-like B cells, and CD138(+) plasma cells and plasmablasts. Human Breg cell types include CD27(+) CD24(high) B10 cells, CD24(hi)CD38(hi) immature transitional B cells, and CD73(-)CD25(+)CD71(+) B(R)1 cells and a subset of plasma cells. Support for the in vivo existence of allergen-specific human Breg cells comes from direct detection of their increase during the course of allergen-specific immunotherapy, as well as their increased expression in nonallergic but high-dose allergen-exposed beekeepers. Human B(R)1 cells selectively upregulate IgG(4) antibodies on differentiation to plasma cells. This suggests an additional immune regulatory role because of the noninflammatory and blocking antibody function of IgG(4). Taken together, Breg cells appear to be involved in mediating allergen tolerance, but many open questions remain to be answered.	[van de Veen, Willem; Stanic, Barbara; Wirz, Oliver F.; Jansen, Kirstin; Globinska, Anna; Akdis, Muebeccel] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [van de Veen, Willem] CK CARE, Davos, Switzerland; [Stanic, Barbara] AO Res Inst Davos, Davos, Switzerland; [Globinska, Anna] Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Medical University Lodz	Akdis, M (corresponding author), Swiss Inst Allergy & Asthma Res SIAF, Oberestr 22, CH-7270 Davos, Switzerland.	akdism@siaf.uzh.ch	Jansen, Kirstin/AAS-3402-2020; Akdis, Cezmi/AAV-4844-2020; Wirz, Oliver/U-7914-2019	Akdis, Cezmi/0000-0001-8020-019X; Wirz, Oliver/0000-0003-0377-6464; van de Veen, Willem/0000-0001-9951-6688; Jansen, Kirstin/0000-0002-9176-8562	Swiss National Science Foundation [320030-159870]; European Commission [261357, 260895]; Christine Kuhne-Center for Allergy Research and Education (CK-CARE)	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Commission(European CommissionEuropean Commission Joint Research Centre); Christine Kuhne-Center for Allergy Research and Education (CK-CARE)	The authors' laboratories are supported by the Swiss National Science Foundation no. 320030-159870, the European Commission's Seventh Framework Programme under grant agreement no. 261357 (MeDALL), the European Commission's Seventh Framework Programme under grant agreement no. 260895 (PREDICTA), and the Christine Kuhne-Center for Allergy Research and Education (CK-CARE).	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7390; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Bankoti R, 2012, J IMMUNOL, V188, P3961, DOI 10.4049/jimmunol.1102880; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Blair PA, 2009, J IMMUNOL, V182, P3492, DOI 10.4049/jimmunol.0803052; Boonpiyathad T, 2016, ALLERGY; Braza F, 2015, ALLERGY, V70, P1421, DOI 10.1111/all.12697; Brisslert M, 2006, IMMUNOLOGY, V117, P548, DOI 10.1111/j.1365-2567.2006.02331.x; Cerutti A, 2013, NAT REV IMMUNOL, V13, P118, DOI 10.1038/nri3383; Das A, 2012, J IMMUNOL, V189, P3925, DOI 10.4049/jimmunol.1103139; Dass S, 2007, ARTHRITIS RHEUM, V56, P2715, DOI 10.1002/art.22811; Ding Q, 2011, J CLIN INVEST, V121, P3645, DOI 10.1172/JCI46274; Evans JG, 2007, J IMMUNOL, V178, P7868, DOI 10.4049/jimmunol.178.12.7868; Fallon PG, 2007, NAT REV IMMUNOL, V7, P220, DOI 10.1038/nri2039; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Flores-Borja F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005407; Fox EM, 2015, J ALLERGY CLIN IMMUN, V135, P1341, DOI 10.1016/j.jaci.2014.07.052; Goetz M, 2007, INFLAMM BOWEL DIS, V13, P1365, DOI 10.1002/ibd.20215; Gray M, 2007, P NATL ACAD SCI USA, V104, P14080, DOI 10.1073/pnas.0700326104; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Kalampokis I, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar3907; KATZ SI, 1974, NATURE, V251, P550, DOI 10.1038/251550a0; Khan AR, 2015, EUR J IMMUNOL, V45, P1842, DOI 10.1002/eji.201445211; Khan AR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6997; Klinker MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070131; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Lal G, 2016, IMMUNOL LETT, V170, P52, DOI 10.1016/j.imlet.2016.01.002; Lampropoulou V, 2008, J IMMUNOL, V180, P4763, DOI 10.4049/jimmunol.180.7.4763; Lee KM, 2012, AM J TRANSPLANT, V12, P2072, DOI 10.1111/j.1600-6143.2012.04055.x; Liu ZQ, 2013, ALLERGY, V68, P1241, DOI 10.1111/all.12218; Lundy SK, 2002, INFECT IMMUN, V70, P812, DOI 10.1128/IAI.70.2.812-819.2002; Mangan NE, 2006, J IMMUNOL, V176, P138, DOI 10.4049/jimmunol.176.1.138; Mangan NE, 2004, J IMMUNOL, V173, P6346, DOI 10.4049/jimmunol.173.10.6346; Matsumoto M, 2014, IMMUNITY, V41, P1040, DOI 10.1016/j.immuni.2014.10.016; Matsushita T, 2016, J ALLERGY CLIN IMMUN; Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Menon M, 2016, IMMUNITY, V44, P683, DOI 10.1016/j.immuni.2016.02.012; Mizoguchi A, 2002, IMMUNITY, V16, P219, DOI 10.1016/S1074-7613(02)00274-1; Moreau A, 2015, EUR J IMMUNOL, V45, P843, DOI 10.1002/eji.201445082; Natarajan P, 2012, MUCOSAL IMMUNOL, V5, P691, DOI 10.1038/mi.2012.42; NETA R, 1974, J IMMUNOL, V113, P1716; Neves P, 2010, IMMUNITY, V33, P777, DOI 10.1016/j.immuni.2010.10.016; OGARRA A, 1992, EUR J IMMUNOL, V22, P711, DOI 10.1002/eji.1830220314; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Parekh VV, 2003, J IMMUNOL, V170, P5897, DOI 10.4049/jimmunol.170.12.5897; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Rafei M, 2009, NAT MED, V15, P1038, DOI 10.1038/nm.2003; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005; Rosser EC, 2014, NAT MED, V20, P1334, DOI 10.1038/nm.3680; Sattler S, 2014, J AUTOIMMUN, V50, P107, DOI 10.1016/j.jaut.2014.01.032; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Shen P, 2014, NATURE, V507, P366, DOI 10.1038/nature12979; Sheng JR, 2014, J IMMUNOL, V193, P2669, DOI 10.4049/jimmunol.1303397; Shi YH, 2015, SCI REP-UK, V5, DOI 10.1038/srep17651; Shimomura Y, 2008, INT IMMUNOL, V20, P729, DOI 10.1093/intimm/dxn031; Simon Q, 2016, J ALLERGY CLIN IMMUN, V137, P1577, DOI 10.1016/j.jaci.2015.09.014; Singh A, 2008, J IMMUNOL, V180, P7318, DOI 10.4049/jimmunol.180.11.7318; Smits HH, 2007, J ALLERGY CLIN IMMUN, V120, P932, DOI 10.1016/j.jaci.2007.06.009; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Tian J, 2001, J IMMUNOL, V167, P1081, DOI 10.4049/jimmunol.167.2.1081; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; van der Vlugt LEPM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030883; Wang RX, 2014, NAT MED, V20, P633, DOI 10.1038/nm.3554; Watanabe R, 2010, J IMMUNOL, V184, P4801, DOI 10.4049/jimmunol.0902385; Wilson MS, 2010, EUR J IMMUNOL, V40, P1682, DOI 10.1002/eji.200939721; Wolf SD, 1996, J EXP MED, V184, P2271, DOI 10.1084/jem.184.6.2271; Wysocki CA, 2005, BLOOD, V106, P3300, DOI 10.1182/blood-2005-04-1632; Xiao S, 2015, J IMMUNOL, V194, P1602, DOI 10.4049/jimmunol.1402632; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yanaba K, 2011, AM J PATHOL, V178, P735, DOI 10.1016/j.ajpath.2010.10.022; Yanaba K, 2009, J IMMUNOL, V182, P7459, DOI 10.4049/jimmunol.0900270; Yang M, 2012, AM J PATHOL, V180, P2375, DOI 10.1016/j.ajpath.2012.03.010; Yoshizaki A, 2012, NATURE, V491, P264, DOI 10.1038/nature11501; Zhang HP, 2013, SCI REP-UK, V3, DOI 10.1038/srep03345; Zhang XM, 2007, J EXP MED, V204, P1107, DOI 10.1084/jem.20062013; Zhang Y, 2015, INT IMMUNOL, V27, P521, DOI 10.1093/intimm/dxv034	85	159	162	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					654	665		10.1016/j.jaci.2016.07.006	http://dx.doi.org/10.1016/j.jaci.2016.07.006			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27596706				2022-12-18	WOS:000385496000002
J	Yang, IV; Pedersen, BS; Liu, A; O'Connor, GT; Teach, SJ; Kattan, M; Misiak, RT; Gruchalla, R; Steinbach, SF; Szefler, SJ; Gill, MA; Calatroni, A; David, G; Hennessy, CE; Davidson, EJ; Zhang, WM; Gergen, P; Togias, A; Busse, WW; Schwartz, DA				Yang, Ivana V.; Pedersen, Brent S.; Liu, Andrew; O'Connor, George T.; Teach, Stephen J.; Kattan, Meyer; Misiak, Rana Tawil; Gruchalla, Rebecca; Steinbach, Suzanne F.; Szefler, Stanley J.; Gill, Michelle A.; Calatroni, Agustin; David, Gloria; Hennessy, Corinne E.; Davidson, Elizabeth J.; Zhang, Weiming; Gergen, Peter; Togias, Alkis; Busse, William W.; Schwartz, David A.			DNA methylation and childhood asthma in the inner city	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DNA methylation; atopic asthma; epigenetics; T(H)2 immunity; inner city	GENOME-WIDE ASSOCIATION; GENE-EXPRESSION; NITRIC-OXIDE; T-CELLS; DISEASE; PATTERNS; CANCER; DIFFERENTIATION; HYPOMETHYLATION; WIDESPREAD	Background: Epigenetic marks are heritable, influenced by the environment, direct the maturation of T lymphocytes, and in mice enhance the development of allergic airway disease. Thus it is important to define epigenetic alterations in asthmatic populations. Objective: We hypothesize that epigenetic alterations in circulating PBMCs are associated with allergic asthma. Methods: We compared DNA methylation patterns and gene expression in inner-city children with persistent atopic asthma versus healthy control subjects by using DNA and RNA from PBMCs. Results were validated in an independent population of asthmatic patients. Results: Comparing asthmatic patients (n = 97) with control subjects (n = 97), we identified 81 regions that were differentially methylated. Several immune genes were hypomethylated in asthma, including IL13, RUNX3, and specific genes relevant to T lymphocytes (TIGIT). Among asthmatic patients, 11 differentially methylated regions were associated with higher serum IgE concentrations, and 16 were associated with percent predicted FEV1. Hypomethylated and hypermethylated regions were associated with increased and decreased gene expression, respectively (P < 6 x 10(-12) for asthma and P < .01 for IgE). We further explored the relationship between DNA methylation and gene expression using an integrative analysis and identified additional candidates relevant to asthma (IL4 and ST2). Methylation marks involved in T-cell maturation (RUNX3), T(H)2 immunity (IL4), and oxidative stress (catalase) were validated in an independent asthmatic cohort of children living in the inner city. Conclusions: Our results demonstrate that DNA methylation marks in specific gene loci are associated with asthma and suggest that epigenetic changes might play a role in establishing the immune phenotype associated with asthma.	[Yang, Ivana V.; Pedersen, Brent S.; Hennessy, Corinne E.; Davidson, Elizabeth J.; Schwartz, David A.] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA; [Yang, Ivana V.; Liu, Andrew; Schwartz, David A.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Yang, Ivana V.; Liu, Andrew; Schwartz, David A.] Natl Jewish Hlth, Dept Med, Denver, CO USA; [O'Connor, George T.; Steinbach, Suzanne F.] Boston Univ, Sch Med, Dept Med, Boston, MA 02215 USA; [Teach, Stephen J.] Childrens Natl Hlth Syst, Washington, DC USA; [Kattan, Meyer] Columbia Univ, Med Ctr, New York, NY USA; [Misiak, Rana Tawil] Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA; [Gruchalla, Rebecca; Gill, Michelle A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Dept Pediat, Colorado Springs, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Aurora, CO 80045 USA; [Calatroni, Agustin; David, Gloria] Rho Fed Syst Div, Chapel Hill, NC USA; [Zhang, Weiming] Univ Colorado, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO 80045 USA; [Schwartz, David A.] Univ Colorado, Dept Immunol, Aurora, CO 80045 USA; [Gergen, Peter; Togias, Alkis] NIAID, Bethesda, MD 20892 USA; [Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA	University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health; National Jewish Health; Boston University; Children's National Health System; Columbia University; Henry Ford Health System; Henry Ford Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Wisconsin System; University of Wisconsin Madison	Schwartz, DA (corresponding author), Univ Colorado, 12631 East 17th Ave,B178, Aurora, CO 80045 USA.	david.schwartz@ucdenver.edu	Yang, Ivana V/P-3059-2018	Yang, Ivana V/0000-0002-1018-489X; Szefler, Stanley/0000-0002-6911-3199	National Institute of Allergy and Infectious Diseases [N01-AI90052]; National Heart, Lung, and Blood Institute [R01-HL101251]; National Institute of Environmental Health Sciences [P01-ES18181]; National Center for Advancing Translational Sciences [UL1TR000075]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL101251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES018181] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001534] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Veterans Affairs(US Department of Veterans Affairs)	Supported by the National Institute of Allergy and Infectious Diseases (N01-AI90052); the National Heart, Lung, and Blood Institute (R01-HL101251); the National Institute of Environmental Health Sciences (P01-ES18181); and the National Center for Advancing Translational Sciences (UL1TR000075).	Akhabir L, 2010, CURR GENOMICS, V11, P591, DOI 10.2174/138920210793360907; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674; Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Baccarelli A, 2012, EPIGENOMICS-UK, V4, P91, DOI [10.2217/EPI.11.106, 10.2217/epi.11.106]; Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533; Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Biernacki C, 2000, IEEE T PATTERN ANAL, V22, P719, DOI 10.1109/34.865189; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Breton CV, 2011, AM J RESP CRIT CARE, V184, P191, DOI 10.1164/rccm.201012-2029OC; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Busse WW, 2007, J ALLERGY CLIN IMMUN, V119, P43, DOI 10.1016/j.jaci.2006.10.021; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416; Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635; Digel W, 2005, CRIT REV ONCOL HEMAT, V55, P1, DOI 10.1016/j.critrevonc.2005.02.002; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Dolzhenko E, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-215; Dvorkin D, 2013, STAT APPL GENET MOL, V12, P469, DOI 10.1515/sagmb-2012-0051; Fainaru O, 2005, P NATL ACAD SCI USA, V102, P10598, DOI 10.1073/pnas.0504787102; Fedulov AV, 2011, AM J RESP CELL MOL, V44, P285, DOI 10.1165/rcmb.2009-0400OC; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fraser HB, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r8; Hansen KD, 2012, ANAL ILLUMINAS 450K; Ho IC, 2009, NAT REV IMMUNOL, V9, P125, DOI 10.1038/nri2476; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jaffe AE, 2012, INT J EPIDEMIOL, V41, P200, DOI 10.1093/ije/dyr238; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kechris KJ, 2010, STAT APPL GENET MOL, V9, DOI 10.2202/1544-6115.1434; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Lockett GA, 2013, CURR OPIN ALLERGY CL, V13, P463, DOI 10.1097/ACI.0b013e328364ea5f; Maccani JZJ, 2013, EPIGENOMICS-UK, V5, P619, DOI 10.2217/epi.13.63; Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44; Marcucci G, 2014, J CLIN ONCOL, V32, P548, DOI 10.1200/JCO.2013.50.6337; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; Marzese DM, 2014, HUM MOL GENET, V23, P226, DOI 10.1093/hmg/ddt420; Mgbemena V, 2012, J IMMUNOL, V189, P606, DOI 10.4049/jimmunol.1102742; Mgbemena V, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-409; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Morales E, 2012, AM J RESP CRIT CARE, V185, P937, DOI 10.1164/rccm.201105-0870OC; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Pascual M, 2011, EPIGENETICS-US, V6, P1131, DOI 10.4161/epi.6.9.16061; Pedersen BS, 2013, BIOINFORMATICS, V29, P3003, DOI 10.1093/bioinformatics/btt534; Pedersen BS, 2012, BIOINFORMATICS, V28, P2986, DOI 10.1093/bioinformatics/bts545; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Qiu WL, 2012, AM J RESP CRIT CARE, V185, P373, DOI 10.1164/rccm.201108-1382OC; Rastogi D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02164; Roessler Jessica, 2012, BMC Res Notes, V5, P210, DOI 10.1186/1756-0500-5-210; Santangelo S, 2002, J IMMUNOL, V169, P1893, DOI 10.4049/jimmunol.169.4.1893; Sharma S, 2014, J ALLERGY CLIN IMMUN, V133, P1246, DOI 10.1016/j.jaci.2013.10.039; SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Stegle O, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000770; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P3, DOI 10.1016/j.jaci.2013.10.018; Touleimat N, 2012, EPIGENOMICS-UK, V4, P325, DOI [10.2217/epi.12.21, 10.2217/EPI.12.21]; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Webster RB, 2007, J BIOL CHEM, V282, P700, DOI 10.1074/jbc.M609501200; Weiss ST, 2011, AM J RESP CRIT CARE, V184, P631, DOI 10.1164/rccm.201103-0485ED; White GP, 2006, PEDIAT ALLERG IMM-UK, V17, P557, DOI 10.1111/j.1399-3038.2006.00465.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wjst M, 2013, CURR OPIN ALLERGY CL, V13, P112, DOI 10.1097/ACI.0b013e32835c1674; Yang IV, 2014, AM J RESP CRIT CARE, V190, P1263, DOI 10.1164/rccm.201408-1452OC; Yang IV, 2012, J ALLERGY CLIN IMMUN, V130, P1243, DOI 10.1016/j.jaci.2012.07.052; Yang Y, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00314	76	159	164	1	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					69	80		10.1016/j.jaci.2015.01.025	http://dx.doi.org/10.1016/j.jaci.2015.01.025			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25769910	Green Accepted			2022-12-18	WOS:000357542200008
J	Cloutier, MM; Schatz, M; Castro, M; Clark, N; Kelly, HW; Mangione-Smith, R; Sheller, J; Sorkness, C; Stoloff, S; Gergen, P				Cloutier, Michelle M.; Schatz, Michael; Castro, Mario; Clark, Noreen; Kelly, H. William; Mangione-Smith, Rita; Sheller, James; Sorkness, Christine; Stoloff, Stuart; Gergen, Peter			Asthma outcomes: Composite scores of asthma control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma Control Questionnaire; Asthma Control Test; Asthma Therapy Assessment Questionnaire; Childhood Asthma Control Test	QUALITY-OF-LIFE; HEALTH-CARE UTILIZATION; PATIENT-REPORTED OUTCOMES; EXHALED NITRIC-OXIDE; CONTROL QUESTIONNAIRE; SPANISH VERSION; REAL-LIFE; UNCONTROLLED DISEASE; ADULT ASTHMATICS; CLINICAL SCORES	Background: Current asthma guidelines recommend assessing the level of a patient's asthma control. Consequently, there is increasing use of asthma control as an outcome measure in clinical research studies. Several composite assessment instruments have been developed to measure asthma control. Objective: National Institutes of Health institutes and federal agencies convened an expert group to propose the most appropriate standardized composite score of asthma control instruments to be used in future asthma studies. Methods: We conducted a comprehensive search of PubMed using both the National Library of Medicine's Medical Subject Headings and key terms to identify studies that attempted to develop and/or test composite score instruments for asthma control. We classified instruments as core (required in future studies), supplemental (used according to study aims and standardized), or emerging (requiring validation and standardization). This work was discussed at a National Institutes of Health-organized workshop convened in March 2010 and finalized in September 2011. Results: We identified 17 composite score instruments with published validation information; all had comparable content. Eight instruments demonstrated responsiveness over time; 3 demonstrated responsiveness to treatment. A minimal clinically important difference has been established for 3 instruments. The instruments have demographic limitations; some are proprietary, and their use could be limited by cost. Conclusion: Two asthma composite score instruments are sufficiently validated for use in adult populations, but additional research is necessary to validate their use in nonwhite populations. Gaps also exist in validating instruments for pediatric populations. (J Allergy Clin Immunol 2012; 129: S24-33.)	[Gergen, Peter] NIAID, DAIT, NIH, Bethesda, MD 20892 USA; [Cloutier, Michelle M.] Univ Connecticut, Farmington, CT USA; [Castro, Mario] Washington Univ, St Louis, MO 63130 USA; [Schatz, Michael] Kaiser Permanente, San Diego, CA USA; [Clark, Noreen] Univ Michigan, Ann Arbor, MI 48109 USA; [Kelly, H. William] Univ New Mexico, Albuquerque, NM 87131 USA; [Mangione-Smith, Rita] Univ Washington, Seattle, WA 98195 USA; [Sheller, James] Vanderbilt Univ, Nashville, TN USA; [Sorkness, Christine] Univ Wisconsin, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Connecticut; Washington University (WUSTL); Kaiser Permanente; University of Michigan System; University of Michigan; University of New Mexico; University of Washington; University of Washington Seattle; Vanderbilt University; University of Wisconsin System; University of Wisconsin Madison	Gergen, P (corresponding author), NIAID, DAIT, NIH, 6610 Rockledge Dr, Bethesda, MD 20892 USA.	pgergen@niaid.nih.gov			National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Environmental Health Sciences; Agency for Healthcare Research and Quality; Merck Childhood Asthma Network; Robert Wood Johnson Foundation; US Environmental Protection Agency; Aerocrine; GlaxoSmithKline; Merck; Genentech; Asthmatx; Elsevier; Amgen; Ception/Cephalon; MedImmune; Novartis; NIH; Actelion Pharmaceuticals	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Merck Childhood Asthma Network; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); US Environmental Protection Agency(United States Environmental Protection Agency); Aerocrine; GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Genentech(Roche HoldingGenentech); Asthmatx; Elsevier; Amgen(Amgen); Ception/Cephalon; MedImmune(AstraZenecaMedimmune); Novartis(Novartis); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Actelion Pharmaceuticals	The Asthma Outcomes workshop was funded by contributions from the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; the Agency for Healthcare Research and Quality; and the Merck Childhood Asthma Network, as well as by a grant from the Robert Wood Johnson Foundation. Contributions from the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences, and the US Environmental Protection Agency funded the publication of this article and all other articles in this supplement.; Disclosure of potential conflict of interest: M. Schatz has consulted for Amgen and has received research support from Aerocrine, GlaxoSmithKline, Merck, and Genentech. M. Castro has received consulting and speaker fees from Asthmatx; is a speaker and is on the advisory board for Genentech; is a speaker for AstraZeneca, Merck, and GlaxoSmithKline; has received royalties from Elsevier; and has received research support from Asthmatx, Amgen, Ception/Cephalon, Genentech, MedImmune, Merck, Novartis, the NIH, and GlaxoSmithKline. J. R. Sheller has received research support from Actelion Pharmaceuticals. S. W. Stoloff is Chairman of the Allergy and Asthma Network Mothers of Asthmatics Board. The rest of the authors declare that they have no relevant conflicts of interest.	Ahmed S, 2007, CAN RESPIR J, V14, P105, DOI 10.1155/2007/340596; Boulet LP, 2002, CHEST, V122, P2217, DOI 10.1378/chest.122.6.2217; Braido F, 2009, ASIAN PAC J ALLERGY, V27, P27; Braido F, 2009, ALLERGY, V64, P937, DOI 10.1111/j.1398-9995.2008.01932.x; Braido F, 2008, ANN ALLERG ASTHMA IM, V101, P370, DOI 10.1016/S1081-1206(10)60312-2; Chen HH, 2008, QUAL LIFE RES, V17, P585, DOI 10.1007/s11136-008-9335-4; Chen H, 2007, J ALLERGY CLIN IMMUN, V120, P396, DOI 10.1016/j.jaci.2007.04.040; Di Marco F, 2010, RESP MED, V104, P22, DOI 10.1016/j.rmed.2009.08.005; Ducharme Francine M, 2004, Can Respir J, V11, P541; Ehrs PO, 2006, CHEST, V129, P925, DOI 10.1378/chest.129.4.925; Fuhlbrigge A, 2009, ALLERGY ASTHMA PROC, V30, P529, DOI 10.2500/aap.2009.30.3276; Hallstrand TS, 2009, ANN ALLERG ASTHMA IM, V103, P225, DOI 10.1016/S1081-1206(10)60186-X; Jones CA, 2009, ANN ALLERG ASTHMA IM, V102, P385, DOI 10.1016/S1081-1206(10)60509-1; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 2001, RESP MED, V95, P319, DOI 10.1053/rmed.2001.1034; Kachru R, 2006, ANN ALLERG ASTHMA IM, V97, P775, DOI 10.1016/S1081-1206(10)60969-6; Khalili B, 2008, ANN ALLERG ASTHMA IM, V101, P124, DOI 10.1016/S1081-1206(10)60199-8; Ko FWS, 2009, RESPIROLOGY, V14, P559, DOI 10.1111/j.1440-1843.2009.01514.x; Kosinski M, 2009, CURR MED RES OPIN, V25, P717, DOI 10.1185/03007990802711602 ; Kwon HS, 2008, J KOREAN MED SCI, V23, P621, DOI 10.3346/jkms.2008.23.4.621; Lababidi H, 2008, ANN THORAC MED, V3, P44, DOI 10.4103/1817-1737.39635; Laforest L, 2006, EUR RESPIR J, V27, P42, DOI 10.1183/09031936.06.00035805; Laforest L, 2006, J ALLERGY CLIN IMMUN, V117, P1404, DOI 10.1016/j.jaci.2006.03.007; Laforest L, 2009, ANN ALLERG ASTHMA IM, V102, P378, DOI 10.1016/S1081-1206(10)60508-X; Lara M, 2000, MED CARE, V38, P342, DOI 10.1097/00005650-200003000-00011; LeBlanc A, 2007, ALLERGY, V62, P120, DOI 10.1111/j.1398-9995.2006.01194.x; Lee EH, 2009, J ASTHMA, V46, P716, DOI 10.1080/02770900903067887; Lee JH, 2006, J ASTHMA, V43, P179, DOI 10.1080/02770900600566405; Leite Mylene, 2008, J. bras. pneumol., V34, P756, DOI 10.1590/S1806-37132008001000002; LeNoir M, 2006, CURR MED RES OPIN, V22, P17, DOI 10.1185/030079905X74925; Leung TF, 2009, J ASTHMA, V46, P130, DOI 10.1080/02770900802468533; Leung TF, 2009, PEDIATR PULM, V44, P442, DOI 10.1002/ppul.20977; Leuppi JD, 2006, CURR MED RES OPIN, V22, P2159, DOI 10.1185/030079906X148454; Lewandowska Katarzyna, 2009, Pneumonol Alergol Pol, V77, P31; Lim KG, 2008, AM J MANAG CARE, V14, P487; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Mattke S, 2009, PEDIATRICS, V123, pS199, DOI 10.1542/peds.2008-2233K; Mihaicuta Stefan, 2009, Pneumologia, V58, P186; Miller D, 2009, J ASTHMA, V46, P179, DOI 10.1080/02770900802604103; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; Murphy KR, 2009, J ALLERGY CLIN IMMUN, V123, P833, DOI 10.1016/j.jaci.2009.01.058; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Asthma Education and Prevention Program NH Lung and Blood Institute National Institutes of Health US Department of Health and Human Services., 2007, 3 US DEP HLTH HUM SE; O'Byrne PM, 2010, EUR RESPIR J, V36, P269, DOI 10.1183/09031936.00124009; Okelo SO, 2004, J PEDIATR-US, V145, P523, DOI 10.1016/j.jpeds.2004.06.043; Patino CM, 2008, J ALLERGY CLIN IMMUN, V122, P936, DOI 10.1016/j.jaci.2008.08.027; Perez-Yarza EG, 2009, PEDIATR PULM, V44, P54, DOI 10.1002/ppul.20929; Peters D, 2006, CHEST, V129, P918, DOI 10.1378/chest.129.4.918; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; Picado C, 2008, CLIN THER, V30, P1918, DOI 10.1016/j.clinthera.2008.10.005; Pinnock H, 2005, J CLIN EPIDEMIOL, V58, P809, DOI 10.1016/j.jclinepi.2005.01.010; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rodrigo GJ, 2008, ANN ALLERG ASTHMA IM, V100, P17, DOI 10.1016/S1081-1206(10)60399-7; ROSIER MJ, 1994, AM J RESP CRIT CARE, V149, P1434, DOI 10.1164/ajrccm.149.6.8004295; Rosner B, 2011, FUNDAMENTALS BIOSTAT; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, pe1; Schatz M, 2007, AM J MANAG CARE, V13, P661; Schatz M, 2007, J ASTHMA, V44, P391, DOI 10.1080/02770900701364296; Schatz M, 2007, J ASTHMA, V44, P341, DOI 10.1080/02770900701344421; Schatz M, 2007, J ALLERGY CLIN IMMUN, V119, P336, DOI 10.1016/j.jaci.2006.08.042; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Schmier JK, 2007, ANN ALLERG ASTHMA IM, V98, P245, DOI 10.1016/S1081-1206(10)60713-2; Senna G, 2007, ALLERGY, V62, P207, DOI 10.1111/j.1398-9995.2006.01250.x; Shirai T, 2008, ANN ALLERG ASTHMA IM, V101, P608, DOI 10.1016/S1081-1206(10)60223-2; Skinner Elizabeth A, 2004, Dis Manag, V7, P305, DOI 10.1089/dis.2004.7.305; Starobin D, 2007, ISRAEL MED ASSOC J, V9, P358; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; Sullivan SD, 2007, ALLERGY, V62, P126, DOI 10.1111/j.1398-9995.2006.01254.x; Tamasi L, 2009, J ASTHMA, V46, P786, DOI 10.3109/02770900903090004; Tan H, 2009, MAYO CLIN PROC, V84, P675, DOI 10.1016/S0025-6196(11)60517-X; Thomas Mike, 2009, Prim Care Respir J, V18, P83, DOI 10.3132/pcrj.2008.00045; van den Nieuwenhof L, 2006, FAM PRACT, V23, P674, DOI 10.1093/fampra/cml041; Vega JM, 2007, J ASTHMA, V44, P867, DOI 10.1080/02770900701752615; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Wallenstein GV, 2007, CURR MED RES OPIN, V23, P369, DOI 10.1185/030079906X167426; Welch MJ, 2007, ANN ALLERG ASTHMA IM, V99, P496, DOI 10.1016/S1081-1206(10)60377-8; Williams SA, 2009, J OCCUP ENVIRON MED, V51, P780, DOI 10.1097/JOM.0b013e3181abb019; Wood PR, 2007, J ALLERGY CLIN IMMUN, V120, P1368, DOI 10.1016/j.jaci.2007.09.025; Zhou X, 2007, CHIN MED J, V120, P5; Zhou XD, 2009, INT J ORAL SCI, V1, P1; Zorc JJ, 2006, J ASTHMA, V43, P753, DOI 10.1080/02770900601031615	87	159	161	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3		S			S24	S33		10.1016/j.jaci.2011.12.980	http://dx.doi.org/10.1016/j.jaci.2011.12.980			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	901OL	22386507	hybrid, Green Accepted			2022-12-18	WOS:000300976600003
J	Simoes, EAF; Carbonell-Estrany, X; Rieger, CHL; Mitchell, I; Fredrick, L; Groothuis, JR				Simoes, Eric A. F.; Carbonell-Estrany, Xavier; Rieger, Christian H. L.; Mitchell, Ian; Fredrick, Linda; Groothuis, Jessie R.		Palivizumab Long-Term Resp	The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory syncytial virus; lower respiratory tract infection; asthma; recurrent wheezing; palivizumab	IMPORTANT RISK-FACTOR; EARLY-LIFE; RHINOVIRUS ILLNESSES; EARLY-CHILDHOOD; ASTHMA; BRONCHIOLITIS; INFANCY; SENSITIZATION; PROPHYLAXIS; INFECTION	Background: Although respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in early life are followed by later airway hyperreactivity, it is unclear whether there is a causal relationship between this and an atopic diathesis. Objectives: To separate the effects of RSV LRTI and an atopic diathesis on subsequent recurrent wheezing, we examined the protective effect of previous palivizumab administration against subsequent recurrent wheeze in infants with and without a family history of atopy. Methods: A prospective multicenter, matched, double cohort study was conducted in 27 centers in Europe and Canada. The rates of physician-diagnosed recurrent wheezing in premature infants <36 weeks gestation who had received palivizumab in the first year of life were compared to those of gestational age-matched controls. Results: The relative protective effect of palivizumab on physician-diagnosed recurrent wheezing through the ages of 2 to 5 years was 68% in those with no family history of asthma (odds ratio, 0.32; (95% CI, 0.14-0.75; N = 146 palivizumab-treated, 171 untreated) and 80% in those with no family history of atopy or food allergies (odds ratio, 0.20; 95% CI, 0.07-0.59; N = 101 palivizumab-treated, 100 untreated). In contrast, there was no effect of palivizumab on subsequent recurrent wheezing in the 90 children with a family history of atopy or food allergies compared to 130 untreated infants with atopic families. Conclusion: Respiratory syncytial virus prophylaxis in nonatopic children decreases by 80% the relative risk of recurrent wheezing but does not have any effect in infants with an atopic family history. This suggests that RSV predisposes to recurrent wheezing in an atopy-independent mechanism. (J Allergy Clin Immunol 2010;126:256-62.)	[Simoes, Eric A. F.] Childrens Hosp, Aurora, CO 80045 USA; [Simoes, Eric A. F.] Univ Colorado, Sch Med, Dept Pediat Infect Dis, Boulder, CO 80309 USA; [Carbonell-Estrany, Xavier] Hosp Clin Barcelona, Serv Neonatol, Barcelona, Spain; [Rieger, Christian H. L.] Ruhr Univ Bochum, Dept Pediat, St Josef Hosp, Bochum, Germany; [Mitchell, Ian] Univ Calgary, Child Hlth Res Unit, Calgary, AB T2N 1N4, Canada; [Fredrick, Linda] Abbott, Abbott Pk, IL USA; [Groothuis, Jessie R.] Medimmune LLC, Gaithersburg, MD USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Barcelona; Hospital Clinic de Barcelona; Ruhr University Bochum; University of Calgary; Abbott Laboratories; Abbott Vascular; AstraZeneca; Medimmune	Simoes, EAF (corresponding author), Childrens Hosp, 13123 E 16th Ave B055, Aurora, CO 80045 USA.	eric.simoes@ucdenver.edu	Berner, Reinhard/P-7351-2017; COLOMER, BELEN FERNANDEZ/L-5716-2019	Berner, Reinhard/0000-0002-6216-9173; blasco-alonso, javier/0000-0003-4008-3747; Gadzinowski, Janusz/0000-0001-8397-6989	Abbott; Abbott International; MedImmune, Inc.; Abbott Canada; Alberta Law Foundation	Abbott(Abbott Laboratories); Abbott International(Abbott Laboratories); MedImmune, Inc.(AstraZenecaMedimmune); Abbott Canada(Abbott Laboratories); Alberta Law Foundation	Supported by Abbott.; E. A. F. Simoes has received grants, honoraria, and research support from Abbott International and MedImmune, Inc. X. Carbonell-Estrany has given lectures sponsored by Abbott. I. Mitchell is a lecturer for Abbott Canada and has received research support from Abbott Canada and the Alberta Law Foundation. J. R. Groothuis is employed by MedImmune and has received research support from Abbott. The rest of the authors have declared that they have no conflict of interest.	Bont L, 2004, THORAX, V59, P512, DOI 10.1136/thx.2003.013391; Bosken CH, 2000, AM J RESP CRIT CARE, V161, P1810, DOI 10.1164/ajrccm.161.6.9903030; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Garcia-Garcia ML, 2007, PEDIATR PULM, V42, P458, DOI 10.1002/ppul.20597; Goetghebuer T, 2004, PEDIATR PULM, V38, P321, DOI 10.1002/ppul.20069; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lee KK, 2007, PEDIATR PULM, V42, P290, DOI 10.1002/ppul.20578; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; O'Donnell DR, 1998, CLIN EXP ALLERGY, V28, P1501; Ostler T, 2001, EUR J IMMUNOL, V31, P2574, DOI 10.1002/1521-4141(200109)31:9<2574::AID-IMMU2574>3.0.CO;2-V; PAPPAS TE, 2007, J ALLERGY CLIN IMM S, V146, P577; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stensballe LG, 2006, PEDIATRICS, V118, pE1360, DOI 10.1542/peds.2006-0907; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Trefny P, 2000, PEDIATR PULM, V30, P302, DOI 10.1002/1099-0496(200010)30:4<302::AID-PPUL5>3.0.CO;2-R; Wenzel SE, 2002, AM J MED, V112, P627, DOI 10.1016/S0002-9343(02)01095-1	22	159	167	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					256	262		10.1016/j.jaci.2010.05.026	http://dx.doi.org/10.1016/j.jaci.2010.05.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624638	Green Published, Bronze			2022-12-18	WOS:000281203800009
J	Flinterman, AE; Knol, EF; Lencer, DA; Bardina, L; Jager, CFDH; Lin, J; Pasmans, SGMA; Bruiinzeel-Koomen, CAFM; Sampson, HA; van Hoffen, E; Shreffler, WG				Flinterman, Annebeth E.; Knol, Edward F.; Lencer, Doerthe A.; Bardina, Ludmilla; Jager, Constance F. den Hartog; Lin, Jing; Pasmans, Suzanne G. M. A.; Bruiinzeel-Koomen, Carla A. F. M.; Sampson, Hugh A.; van Hoffen, Els; Shreffler, Wayne G.			Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; children; peptides; IgE; IgG4; severity of allergic reactions; diversity	BINDING EPITOPES; MICROARRAY IMMUNOASSAY; MUTATIONAL ANALYSIS; FOOD ALLERGY; ARA H1; ANTIBODY; REACTIVITY; TOLERANCE; RELEVANCE; PROTEIN	Background: Better understanding of the relationship between antibody response to peanut and clinical sensitivity might lead to more accurate prognostication. Objective: We sought to investigate peanut-specific IgE and IgG4 epitope diversity in relation to challenge-defined clinical sensitivity to peanut in a group of peanut-sensitized children. Methods: Clinical sensitivity was determined by means of double-blind, placebo-controlled peanut challenges in 24 sensitized children. Six atopic control subjects were included. Specific IgE and IgG4 binding to 419 overlapping 15-amino-acid peptides representing the sequence of recombinant Ara h 1, Ara h 2, and Ara h3 was analyzed by means of microarray immunoassay. Results: Peanut-sensitized patient sera bound significantly more IgE and IgG4 epitopes than control sera. This patient group reacted to the same Ara h 1, Ara h 2, and Ara h 3 epitopes as reported previously. There was a positive correlation between IgE epitope diversity (ie, number of epitopes recognized) and clinical sensitivity (r = 0.6), such that patients with the greatest epitope diversity were significantly more sensitive than those with the lowest diversity (P = .021). No specific epitopes were associated with severe reactions to peanut. IgG4 binding was observed to largely similar epitopes but was less pronounced than IgE binding and did not relate to the clinical sensitivity to peanut. IgE and IgG4 epitope-recognition patterns were largely stable over a 20-month period. Conclusion: Clinical sensitivity, as determined by means of double-blind, placebo-controlled peanut challenge, is positively related to a more polyclonal IgE response, which remains stable over time.	[Flinterman, Annebeth E.; Knol, Edward F.; Jager, Constance F. den Hartog; Pasmans, Suzanne G. M. A.; Bruiinzeel-Koomen, Carla A. F. M.; van Hoffen, Els] Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; [Lencer, Doerthe A.; Bardina, Ludmilla; Lin, Jing; Sampson, Hugh A.; Shreffler, Wayne G.] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY USA; [Lencer, Doerthe A.; Bardina, Ludmilla; Lin, Jing; Sampson, Hugh A.; Shreffler, Wayne G.] Mt Sinai Sch Med, Inst Immunol, New York, NY USA	Utrecht University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Knol, EF (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol, G02-124,POB 85500, NL-3508 GA Utrecht, Netherlands.	e.f.knol@umcutrecht.nl	Pasmans, Suzanne/AAI-6016-2021; Lin, Jing/C-8877-2010	Pasmans, Suzanne/0000-0003-1018-4475; Knol, Edward/0000-0001-7368-9820	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD052890] Funding Source: NIH RePORTER; NICHD NIH HHS [K12HD052890] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernard H, 2003, ALLERGY, V58, P1285, DOI 10.1046/j.1398-9995.2003.00300.x; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; FINTERMAN AE, 2006, J ALLERGY CLIN IMMUN, V117, P448; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; Knol EF, 2006, MOL NUTR FOOD RES, V50, P620, DOI 10.1002/mnfr.200500272; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Michils A, 2000, ALLERGY, V55, P455, DOI 10.1034/j.1398-9995.2000.00412.x; Mitchell AJ, 2002, SCAND J IMMUNOL, V55, P33, DOI 10.1046/j.1365-3083.2002.01012.x; MUDDE GC, 1995, IMMUNOL TODAY, V16, P380, DOI 10.1016/0167-5699(95)80005-0; Mueller H L, 1966, J Asthma Res, V3, P331; Neuberger MS, 2000, PHILOS T ROY SOC B, V355, P357, DOI 10.1098/rstb.2000.0573; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; R Development Core Team, 2007, R LANG ENV STAT COMP; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Ruiter B, 2007, CLIN EXP ALLERGY, V37, P1103, DOI 10.1111/j.1365-2222.2007.02749.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; *SDAP, STRUCT DAT ALL PROT; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; van Neerven RJ, 2006, INT ARCH ALLERGY IMM, V141, P119, DOI 10.1159/000094714; van Wijk F, 2004, CLIN EXP ALLERGY, V34, P1422, DOI 10.1111/j.1365-2222.2004.02062.x; Vanderlugt CL, 1998, IMMUNOL REV, V164, P63, DOI 10.1111/j.1600-065X.1998.tb01208.x	33	159	164	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					737	743		10.1016/j.jaci.2007.11.039	http://dx.doi.org/10.1016/j.jaci.2007.11.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18234310				2022-12-18	WOS:000253918900031
J	Chen, H; Gould, MK; Blanc, PD; Miller, DP; Kamath, TV; Lee, JH; Sullivan, SD				Chen, Hubert; Gould, Michael K.; Blanc, Paul D.; Miller, Dave P.; Kamath, Tripthi V.; Lee, June H.; Sullivan, Sean D.		TENOR Study Grp	Asthma control, severity, and quality of life: Quantifying the effect of uncontrolled disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma control; disease severity; quality of life; health status; questionnaire	HEALTH-CARE UTILIZATION; COST-EFFECTIVENESS; VALIDATION; OUTCOMES; ASSOCIATION; VALUATIONS; STATES	Background: Current practice guidelines emphasize the importance of attaining asthma control. We sought to quantify the degree of quality-of-life impairment associated with different levels of asthma control. Methods: We analyzed prospective data for 987 adults in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. Asthma control was assessed by using the Asthma Therapy Assessment Questionnaire, a validated index of control problems ranging from 0 to 4. Disease-specific quality of life and preference-based health utilities were assessed after 12 months of follow-up by using the Mini-Asthma Quality of Life Questionnaire (AQLQ) and EuroQoL 5-D (EQ-5D). We used multiple linear regression to model the relationship between asthma control and the AQLQ and EQ-5D while controlling for severity classification and lung function. Results: Asthma control varied widely, even within a population with predominantly moderate-to-severe disease. An inverse relationship was observed between the number of asthma control problems and quality of life. Specifically, poorer control at baseline predicted worse AQLQ and EQ-5D scores at follow-up. Asthma control remained an independent predictor of disease-specific quality of life and general health in multivariate models and was a better longitudinal predictor of health status than asthma severity at baseline. Conclusion: Poor asthma control is associated with a substantial degree of impairment and predicts quality of life at 12 months, even after taking baseline asthma severity into account. Clinical implications: Self-assessed measures of asthma control might help to identify and manage those patients at greatest risk for future health impairment.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Genentech Inc, San Francisco, CA 94080 USA; Stanford Univ, Sch Med, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; Oviat Res Grp, San Francisco, CA USA; Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA	University of California System; University of California San Francisco; Roche Holding; Genentech; Stanford University; University of Washington; University of Washington Seattle	Chen, H (corresponding author), 350 Parnassus Ave,Suite 609, San Francisco, CA 94117 USA.	hubert.chen@ucsf.edu		Miller, Dave/0000-0003-2947-152X; Chen, Hubert/0000-0002-6630-239X				Al MJ, 1998, CHEST, V113, P124, DOI 10.1378/chest.113.1.124; Barr JT, 2000, CLIN THER, V22, P1121, DOI 10.1016/S0149-2918(00)80089-2; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; Cohen DJ, 2001, CIRCULATION, V104, P3039, DOI 10.1161/hc5001.100794; de Wit GA, 1998, HEALTH POLICY, V44, P215, DOI 10.1016/S0168-8510(98)00017-7; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Ehrs PO, 2006, CHEST, V129, P925, DOI 10.1378/chest.129.4.925; Graham DM, 2000, ALLERGY ASTHMA PROC, V21, P151, DOI 10.2500/108854100778148990; Graham LM, 2006, CHEST, V130, p13S, DOI 10.1378/chest.130.1_suppl.13S; Hazel M, 2003, RESP MED, V97, P1211, DOI 10.1016/S0954-6111(03)00249-X; Johnson JA, 2005, MED CARE, V43, P221, DOI 10.1097/00005650-200503000-00004; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Li JT, 2005, J ALLERGY CLIN IMMUN, V116, pS3, DOI 10.1016/j.jaci.2005.08.017; Liard R, 2000, EUR RESPIR J, V16, P615, DOI 10.1034/j.1399-3003.2000.16d08.x; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; Moy ML, 2001, AM J RESP CRIT CARE, V163, P924, DOI 10.1164/ajrccm.163.4.2008014; *NIH, 2005, 953659 NIH; Oostenbrink JB, 2001, J VASC SURG, V34, P254, DOI 10.1067/mva.2001.115961; Oppenheimer JJ, 2006, CURR OPIN ALLERGY CL, V6, P119, DOI 10.1097/01.all.0000216855.02947.33; Rasanen P, 2006, INT J TECHNOL ASSESS, V22, P235, DOI 10.1017/S0266462306051051; Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003; Sollano JA, 1998, ANN SURG, V228, P297, DOI 10.1097/00000658-199809000-00003; Stahl Elisabeth, 2005, Health Qual Life Outcomes, V3, P56, DOI 10.1186/1477-7525-3-56; Stoloff SW, 2006, J ALLERGY CLIN IMMUN, V117, P544, DOI 10.1016/j.jaci.2006.01.005; Szende A, 2004, PHARMACOECONOMICS, V22, P537; Sznajder M, 2001, INTENS CARE MED, V27, P146, DOI 10.1007/s001340000760; Teeter JG, 1998, CHEST, V113, P272, DOI 10.1378/chest.113.2.272; Tennvall GR, 2001, DIABETOLOGIA, V44, P2077; UK Prospective Diabetes Study Grp, 1999, DIABETES CARE, V22, P1125; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	35	159	165	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					396	402		10.1016/j.jaci.2007.04.040	http://dx.doi.org/10.1016/j.jaci.2007.04.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17561244				2022-12-18	WOS:000248654900027
J	Chi, W; Yang, PZ; Li, B; Wu, CY; Jin, HL; Zhu, XF; Chen, LN; Zhou, HY; Huang, XK; Kijlstra, A				Chi, Wei; Yang, Peizeng; Li, Bing; Wu, Changyou; Jin, Haoli; Zhu, Xuefei; Chen, Lina; Zhou, Hongyan; Huang, Xiangkun; Kijlstra, Aize			IL-23 promotes CD4(+) T cells to produce IL-17 in Vogt-Koyanagi-Harada disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vogt-Koyanagi-Harada disease; autoimmune disease; IL-23; IL-17	PROINFLAMMATORY CYTOKINE PRODUCTION; AUTOIMMUNE INFLAMMATION; SYMPATHETIC OPHTHALMIA; RHEUMATOID-ARTHRITIS; HUMAN KERATINOCYTES; INTERFERON-GAMMA; INTERLEUKIN-17; EXPRESSION; LYMPHOCYTES; DISTINCT	Background: Vogt-Koyanagi-Harada (VKH) disease is a systemic refractory autoimmune disease. IL-23 has been thought to play a critical role in autoimmune disease through inducing the development of IL-17-producing CD4(+) T cells. Objective: To investigate the expression of IL-23 and IL-17 and the influence of IL-23 on IL-17 production in patients with VKH disease. Methods: Blood samples were taken from 25 patients with VKH disease and 16 healthy controls. Peripheral blood mononuclear cells (PBMCs) were subjected to analysis of IL-23p19 mRNA and IL-23 protein expression using RT-PCR and ELISA, respectively. The IL-17 levels in the supernatants of PBMCs and CD4(+) T cells cultured in the absence or presence of recombinant (r)IL-23, rIL-12, or anti-IFN-gamma were determined by ELISA. Results: The patients with VKH disease with active uveitis showed an elevated level of IL-23p19 mRNA in PBMCs, higher IL-23 in the serum and supernatants of PBMCs, and increased production of IL-17 by polyclonally stimulated PBMCs and CD4+ T cells. Recombinant IL-23 significantly enhanced IL-17 production, whereas rIL-12 and IFN-gamma inhibited IL-17 production. More importantly, IL-17 production was significantly increased in patients with active uveitis in the presence of rIL-23. Both rIL-23 and rIL-12 enhanced IFN-gamma production. Conclusion: The results suggest that IL-23-stimulated production of IL-17 by CD4+ T cells may be responsible for the development of uveitis seen in patients with VKH disease. Clinical implications: This study provides a new insight into the mechanism involved in the development of VKH disease.	Sun Yat Sen Univ, Zhongshan Opthalm Ctr, State Key Lab Ophthalmol, Uveitis Study Ctr, Guangzhou 510060, Peoples R China; Sun Yat Sen Univ, Dept Immunol, Guangzhou 510060, Peoples R China; Harvard Univ, Childrens Hosp, Sch Med, Dept Immunol, Boston, MA 02115 USA; Univ Wageningen & Res Ctr, Div Anim Prod, Anim Sci Grp, Maastricht, Netherlands; Univ Maastricht, Dept Ophthalmol, Maastricht, Netherlands	Sun Yat Sen University; Sun Yat Sen University; Harvard University; Boston Children's Hospital; Harvard Medical School; Wageningen University & Research; Maastricht University	Yang, PZ (corresponding author), Sun Yat Sen Univ, Zhongshan Opthalm Ctr, State Key Lab Ophthalmol, Uveitis Study Ctr, 54 Xianlie Rd, Guangzhou 510060, Peoples R China.	peizengy@126.com	Yang, Peizeng/C-6336-2013					Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Chabaud M, 1999, ARTHRITIS RHEUM-US, V42, P963, DOI 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; GOTO H, 1990, INT OPHTHALMOL CLIN, V30, P279, DOI 10.1097/00004397-199030040-00014; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; He DG, 2006, J IMMUNOL, V177, P6852, DOI 10.4049/jimmunol.177.10.6852; Hoeve MA, 2006, EUR J IMMUNOL, V36, P661, DOI 10.1002/eji.200535239; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Kurasawa K, 2000, ARTHRITIS RHEUM-US, V43, P2455, DOI 10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lee E, 2004, J EXP MED, V199, P125, DOI 10.1084/jem.20030451; Li S, 1994, Ocul Immunol Inflamm, V2, P247, DOI 10.3109/09273949409057083; Ma XT, 2004, CELL BIOL INT, V28, P689, DOI 10.1016/j.cellbi.2004.07.002; Miossec P, 2003, ARTHRITIS RHEUM-US, V48, P594, DOI 10.1002/art.10816; MOORTHY RS, 1995, SURV OPHTHALMOL, V39, P265, DOI 10.1016/S0039-6257(05)80105-5; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Rao NA, 1997, EYE, V11, P213, DOI 10.1038/eye.1997.54; Read RW, 2001, AM J OPHTHALMOL, V131, P647, DOI 10.1016/S0002-9394(01)00925-4; Shin HCK, 1999, CYTOKINE, V11, P257, DOI 10.1006/cyto.1998.0433; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101; Yang PZ, 2005, CURR EYE RES, V30, P943, DOI 10.1080/02713680500263606; Yoshimura T, 2006, J IMMUNOL, V177, P5377, DOI 10.4049/jimmunol.177.8.5377	33	159	210	3	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1218	1224		10.1016/j.jaci.2007.01.010	http://dx.doi.org/10.1016/j.jaci.2007.01.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17335887	Bronze			2022-12-18	WOS:000246427200025
J	Valenta, R; Niederberger, V				Valenta, Rudolf; Niederberger, Verena			Recombinant allergens for immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						recombinant allergens; immunotherapy	BIRCH POLLEN ALLERGEN; RBET V 1; SKIN PRICK; WILD-TYPE; DERIVATIVES; VACCINE; IGE; SENSITIVITY; POPULATION; ANTIBODIES	Recombinant allergens can be produced as defined molecules in consistent quality and unlimited amounts according to the corresponding DNA template. Furthermore, they can be modified to reduce their allergenic activity and to foster certain advantageous immunologic properties. Recombinant allergens equaling the natural allergens are available for diagnostic and therapeutic purposes, and modified versions have been developed with the aim to to reduce IgE-mediated side effects during immunotherapy. First injection immunotherapy trials conducted with recombinant vaccines for birch pollen and grass pollen allergy show that recombinant allergen-based immunotherapy has vaccination characteristics and is clinically effective. The obtained results hold promise that recombinant allergen-based immunotherapy will improve current immunotherapy practice and may open possibilities for new treatment strategies and possibly even for prophylactic vaccination.	Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol,Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Otolaryngol, Vienna, Austria; Guys Hosp, Dept Otolaryngol, London SE1 9RT, England	Medical University of Vienna; Medical University of Vienna; Guy's & St Thomas' NHS Foundation Trust	Valenta, R (corresponding author), Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol,Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria.	Rudolf.valenta@meduniwien.ac.at		Valenta, Rudolf/0000-0001-5944-3365				Batard T, 2005, INT ARCH ALLERGY IMM, V136, P239, DOI 10.1159/000083950; Esch RE, 2006, CURR ALLERGY ASTHM R, V6, P402, DOI 10.1007/s11882-996-0013-8; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; KLIMEK L, 2005, ALLERGY CLIN IMMUN S, V1, P15; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Linhart B, 2005, CURR OPIN IMMUNOL, V17, P646, DOI 10.1016/j.coi.2005.09.010; Linhart B, 2004, INT ARCH ALLERGY IMM, V134, P324, DOI 10.1159/000079535; Mari A, 2005, INT ARCH ALLERGY IMM, V138, P88, DOI 10.1159/000087848; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; NIEDERBERGER V, 2007, J ALLERGY CLIN  0208; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Pauli G, 2006, 25 C EUR AC ALL CLIN, P28; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Schmid-Grendelmeier P, 2001, INT ARCH ALLERGY IMM, V125, P96, DOI 10.1159/000053803; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; vanderVeen MJ, 1996, J ALLERGY CLIN IMMUN, V98, P1028, DOI 10.1016/S0091-6749(96)80187-4; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje	27	159	181	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					826	830		10.1016/j.jaci.2007.01.025	http://dx.doi.org/10.1016/j.jaci.2007.01.025			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17335886				2022-12-18	WOS:000245729500009
J	Lemiere, C; Ernst, P; Olivenstein, R; Yamauchi, Y; Govindaraju, K; Ludwig, MS; Martin, JG; Hamid, G				Lemiere, Catherine; Ernst, Pierre; Olivenstein, Ron; Yamauchi, Yasuhiro; Govindaraju, Karuthapillai; Ludwig, Mara S.; Martin, James G.; Hamid, Gutayba			Airway inflammation assessed by invasive and noninvasive means in severe asthma: Eosinophilic and noneosinophilic phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						severe asthma; bronchial biopsies; exhaled nitric oxide; induced sputum	EXHALED NITRIC-OXIDE; SPUTUM CELL COUNTS; BECLOMETHASONE; EXACERBATIONS; INDEXES	Background: Airway inflammation assessed by bronchial biopsies demonstrates distinct eosinophilic and noneosinophilic phenotypes in severe asthma, but their relationship to other biomarkers of disease (induced sputum and nitric oxide [NO]) is not clear. Objectives: We sought to compare airway inflammation using noninvasive (induced sputum, exhaled NO), and invasive (bronchial biopsies) methods in moderate and severe asthma and to assess whether induced sputum and exhaled NO would allow the identification of eosinophilic and noneosinophilic phenotypes in severe asthma. Methods: We performed a cross-sectional study of 32 subjects with severe asthma and 35 subjects with moderate asthma, from whom we obtained bronchial biopsies, induced sputum, and exhaled NO measurements. Results: Among subjects with severe asthma, we identified eosinophilic and noneosinophilic phenotypes using both bronchial biopsies and sputum cell counts. However, the vast majority of subjects with high sputum eosinophil counts did not have high mucosal eosinophil counts. Exhaled NO was increased in the eosinophilic phenotype as judged from bronchial biopsy findings, but not on the basis of induced sputum. Subjects with high sputum eosinophil counts experienced more asthma exacerbations than the subjects with low sputum eosinophil counts. In contrast, we did not find any differences in the clinical characteristics between eosinophilic and noncosinophilic phenotypes that were identified by bronchial biopsies. Conclusion: The use of sputum cell counts allowed the identification of a subgroup of subjects with severe asthma who were at risk of more frequent asthma exacerbations. Clinical implications: Monitoring sputum eosinophil counts in subjects with severe asthma may allow identifying the subjects with the greatest disease activity.	Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ H3A 2T5, Canada; McGill Univ, Montreal Chest Inst, Montreal, PQ H3A 2T5, Canada	Universite de Montreal; McGill University; McGill University	Lemiere, C (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 W Gouin, Montreal, PQ H4J 1C5, Canada.	catherine.lemiere@umontreal.ca		Martin, James/0000-0001-7574-5363				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1999, Am J Respir Crit Care Med, V160, P2104; Bartoli ML, 2004, RESP MED, V98, P184, DOI 10.1016/j.rmed.2003.09.012; Bergeron C, 2006, J ALLERGY CLIN IMMUN, V117, P703, DOI 10.1016/j.jaci.2005.12.1344; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Chakir J, 2002, CLIN EXP ALLERGY, V32, P578, DOI 10.1046/j.0954-7894.2002.01323.x; Crater SE, 1999, AM J RESP CRIT CARE, V159, P806, DOI 10.1164/ajrccm.159.3.9805103; FAHY JV, 1994, J ALLERGY CLIN IMMUN, V93, P1031, DOI 10.1016/S0091-6749(94)70052-4; Gershman NH, 1999, J ALLERGY CLIN IMMUN, V104, P322, DOI 10.1016/S0091-6749(99)70374-X; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Grootendorst DC, 1997, CLIN EXP ALLERGY, V27, P769, DOI 10.1111/j.1365-2222.1997.tb01211.x; Hargreave FE, 1998, J ALLERGY CLIN IMMUN, V102, pS102, DOI 10.1016/S0091-6749(98)70040-5; Jang AS, 2000, RESPIRATION, V67, P183, DOI 10.1159/000029484; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Jayaram L, 2000, EUR RESPIR J, V16, P150, DOI 10.1034/j.1399-3003.2000.16a27.x; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Kharitonov SA, 2000, EUR RESPIR J, V16, P781, DOI 10.1183/09031936.00.16478100; Langley SJ, 2003, ANN ALLERG ASTHMA IM, V91, P398, DOI 10.1016/S1081-1206(10)61688-2; Leuppi JD, 2002, THORAX, V57, P518, DOI 10.1136/thorax.57.6.518; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800, DOI 10.1164/ajrccm.152.2.7633745; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Pizzichini MMM, 1996, EUR RESPIR J, V9, P449, DOI 10.1183/09031936.96.09030449; Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501, DOI 10.1164/ajrccm.155.5.9154849; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Romagnoli M, 2002, EUR RESPIR J, V20, P1370, DOI 10.1183/09031936.02.00029202; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WONG BJ, 1992, AM REV RESPIR DIS, V146, P1156, DOI 10.1164/ajrccm/146.5_Pt_1.1156; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	38	159	164	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1033	1039		10.1016/j.jaci.2006.08.003	http://dx.doi.org/10.1016/j.jaci.2006.08.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088126				2022-12-18	WOS:000244282300006
J	Kundig, TM; Senti, G; Schnetzler, G; Wolf, C; Vavricka, BMP; Fulurija, A; Hennecke, F; Sladko, K; Jennings, GT; Bachmann, MF				Kuendig, Thomas M.; Senti, Gabriela; Schnetzler, Gabriel; Wolf, Charles; Vavricka, Bettina M. Prinz; Fulurija, Alma; Hennecke, Frank; Sladko, Katia; Jennings, Gary T.; Bachmann, Martin F.			Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Der p 1; virus-like particle; immunotherapy; clinical trial	ALLERGEN-SPECIFIC IGG4; ANTIBODY-RESPONSES; EPITOPE DENSITY; INDUCTION; VACCINE; POLIOMYELITIS; ANTIGENS; IMMUNOTHERAPY; DETERMINANTS; OUTBREAK	Background: In mice, highly repetitive antigens, such as those present on bacterial or viral surfaces, efficiently cross-link B-cell receptors and therefore induce strong IgG responses. In this study we covalently coupled a synthetic 16-amino-acid sequence of the allergen Der p 1 to a virus-like particle derived from the bacteriophage Q beta (Q beta-Der p 1). Objective: We evaluated the safety and immunogenicity of Q beta-Der p 1 in human subjects and compared different doses and routes of immunization. Methods: In a phase I trial 24 healthy volunteers were randomly assigned to one of 4 treatment groups. Group I received 50 mu g of Q beta-Der p 1 intramuscularly, group 2 received 50 mu g of Q beta-Der p 1 subcutaneously, group 3 received 10 mu g of Q beta-Der p 1 intramuscularly, and group 4 received 10 mu g of Q beta-Der p 1 subcutaneously. Boosting immunizations with 10 jig were given after 1 and 3 months. Antibody titers were measured after 1, 3, 4, 6, 12, and 18 months. Results: The vaccine Q beta-Der p 1 was well tolerated. Significant IgG responses were observed 4 weeks after a single injection. Individuals receiving 50 mu g of the vaccine had significantly higher IgG titers than those vaccinated with 10 mu g. However, the route of immunization (subcutaneous vs intramuscular) had no effect. In the 50-mu g dose group, strong antibody responses against Der p 1 with average titers of 1:2000 were obtained. Conclusion: Vaccination with a peptide antigen covalently coupled to highly repetitive virus-like particles represents an adjuvant-free means of rapidly inducing high antibody titers in human subjects. Clinical implications: Allergens coupled to virus-like particles can be used to enhance the efficiency of allergen-specific immunotherapy.	Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland; Cytos Biotechnol AG, Zurich, Switzerland	University of Zurich; University Zurich Hospital	Kundig, TM (corresponding author), Dermatol Klin, Gloriastr 31, CH-8091 Zurich, Switzerland.	thomas.kuendig@usz.ch	Senti, Gabriela/Y-1019-2019	Senti, Gabriela/0000-0002-9066-8383; Fulurija, Alma/0000-0003-1776-785X				AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; AALBERSE RC, 1983, J IMMUNOL, V130, P722; Bachmann MF, 1998, J IMMUNOL, V161, P5791; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235; Bachmann MF, 1996, IMMUNOL TODAY, V17, P553, DOI 10.1016/S0167-5699(96)10066-9; Casale TB, 2004, J ALLERGY CLIN IMMUN, V113, P1036, DOI 10.1016/j.jaci.2004.04.017; Chackerian B, 2002, J IMMUNOL, V169, P6120, DOI 10.4049/jimmunol.169.11.6120; Chackerian B, 2001, J CLIN INVEST, V108, P415, DOI 10.1172/JCI200111849; DESAYMARD C, 1975, EUR J IMMUNOL, V5, P537, DOI 10.1002/eji.1830050806; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; Evans TG, 2001, J INFECT DIS, V183, P1485, DOI 10.1086/320190; FELDMANN M, 1971, J EXP MED, V134, P103, DOI 10.1084/jem.134.1.103; Greensfelder L, 2000, SCIENCE, V290, P1867; Harro CD, 2001, JNCI-J NATL CANCER I, V93, P284, DOI 10.1093/jnci/93.4.284; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JEANNIN P, 1993, MOL IMMUNOL, V30, P1511, DOI 10.1016/0161-5890(93)90459-O; Jegerlehner A, 2002, EUR J IMMUNOL, V32, P3305, DOI 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J; Jegerlehner A, 2002, VACCINE, V20, P3104, DOI 10.1016/S0264-410X(02)00266-9; Johnson JE, 2000, CURR OPIN STRUC BIOL, V10, P229, DOI 10.1016/S0959-440X(00)00073-7; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; Kew O, 2002, SCIENCE, V296, P356, DOI 10.1126/science.1068284; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Lu FM, 1998, ANN ALLERG ASTHMA IM, V80, P419, DOI 10.1016/S1081-1206(10)62995-X; Nelson HS, 2005, J ALLERGY CLIN IMMUN, V115, P676, DOI 10.1016/j.jaci.2005.01.037; Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7; Norman PS, 2004, J ALLERGY CLIN IMMUN, V113, P1013, DOI 10.1016/j.jaci.2004.03.020; PASTORELLO EA, 1990, ALLERGY, V45, P505, DOI 10.1111/j.1398-9995.1990.tb00526.x; Pumpens P, 2001, INTERVIROLOGY, V44, P98, DOI 10.1159/000050037; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; SABIN AB, 1985, J INFECT DIS, V151, P420, DOI 10.1093/infdis/151.3.420; SALK D, 1984, LANCET, V2, P1317; Schiller JT, 2001, EXPERT OPIN BIOL TH, V1, P571; Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058; Yasue M, 1998, INT ARCH ALLERGY IMM, V115, P303, DOI 10.1159/000069461; Zhang LF, 2000, VACCINE, V18, P1051, DOI 10.1016/S0264-410X(99)00351-5	37	159	164	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1470	1476		10.1016/j.jaci.2006.01.040	http://dx.doi.org/10.1016/j.jaci.2006.01.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751015				2022-12-18	WOS:000238332300041
J	Lucas, SR; Platts-Mills, TAE				Lucas, SR; Platts-Mills, TAE			Physical activity and exercise in asthma: Relevance to etiology and treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma exercise; conditioning; etiology; pathophysiology; sedentary lifestyle; activity; therapy; incidence; severity	DEEP INSPIRATION; SMOOTH-MUSCLE; CHILDREN; PROGRAM; OBESITY; OVERWEIGHT; INTENSITY; RISK	There is little doubt that the cause of the increased prevalence and severity of asthma is multifactorial. Although the factors of allergen exposure and hygiene are almost certainly necessary for its development, there is a growing body of literature that implicates lifestyle change, specifically decreased physical activity, as a contributor to the increase in asthma prevalence and severity. Several literature reviews of exercise conditioning in patients with asthma have been published. These reviews and recent controlled trials emphasize that although many of the studies of exercise conditioning in asthmatic patients involved different methods and outcome measures, the overwhelming majority of studies demonstrated the capacity for asthmatic subjects to exercise safely and significantly improve their cardiovascular fitness and quality of life. There are several proposed pathophysiologic mechanisms responsible for the effects of decreased activity on the lung function of patients with asthma. A prescription for exercise has been endorsed for all asthmatic subjects by the American College of Sports Medicine and the American Thoracic Society. The allergy community has placed emphasis on medical therapy and allergen avoidance; in addition, exercise avoidance has not been formally incorporated into the National Asthma Education and Prevention Program guidelines. It is our belief that an exercise prescription should be part of the treatment for all cases of asthma. The real question is whether prolonged physical activity and, in particular, outdoor play of children plays a role in prophylaxis against persistent wheezing. If so, the decrease in physical activity might have played a major role in recent increases in asthma prevalence and severity.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI-20565, P01-AI-50989] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, P01AI050989, R37AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		American College of Sports Medicine, 2000, ACSMS GUID EX TEST P; American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; Biring MS, 1999, AM J MED SCI, V318, P293, DOI 10.1097/00000441-199911000-00002; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; BUTTON B, 2004, PEDIATR PULM, V27, P213; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Cambach W, 1997, EUR RESPIR J, V10, P104, DOI 10.1183/09031936.97.10010104; CLARK CJ, 1993, PRINCIPLES PRACTICE, P424; COCHRANE LM, 1990, THORAX, V45, P345, DOI 10.1136/thx.45.5.345; Crater Scott E., 1998, Current Opinion in Pediatrics, V10, P594; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; Figueroa-Munoz JI, 2001, THORAX, V56, P133, DOI 10.1136/thorax.56.2.133; FIRRINCIELI V, 2004, IN PRESS PEDIAT PULM; FISH JE, 1981, J APPL PHYSIOL, V50, P1079, DOI 10.1152/jappl.1981.50.5.1079; Fredberg JJ, 1999, AM J RESP CRIT CARE, V159, P959, DOI 10.1164/ajrccm.159.3.9804060; Hallstrand TS, 2000, CHEST, V118, P1460, DOI 10.1378/chest.118.5.1460; Hark WT, 2005, ANN ALLERG ASTHMA IM, V94, P247, DOI 10.1016/S1081-1206(10)61303-8; Huovinen E, 2001, THORAX, V56, P234, DOI 10.1136/thorax.56.3.234; Kapsali T, 2000, J APPL PHYSIOL, V89, P711, DOI 10.1152/jappl.2000.89.2.711; MALMBERG P, 1993, EUR RESPIR J, V6, P680; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; NADEL JA, 1961, J APPL PHYSIOL, V16, P717, DOI 10.1152/jappl.1961.16.4.717; National Center for Health Statistics, 2000, AD HLTH CHARTB; Nystad W, 2001, EUR J EPIDEMIOL, V17, P209, DOI 10.1023/A:1017926403763; Orenstein DM, 2002, PEDIATR CLIN N AM, V49, P709, DOI 10.1016/S0031-3955(02)00023-8; ORENSTEIN DM, 1996, CHILD ADOLESCENT ATH, V5, P433; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; Rasmussen F, 2000, EUR RESPIR J, V16, P866, DOI 10.1183/09031936.00.16586600; Ricciardolo FLM, 2001, AM J MED, V111, P18, DOI 10.1016/S0002-9343(01)00816-6; ROBINSON DM, 1992, NEW ZEAL MED J, V105, P253; SALTER HH, 1882, ASTHMA ITS PATHOLOGY; SASAKI H, 1979, J APPL PHYSIOL, V47, P1251, DOI 10.1152/jappl.1979.47.6.1251; Satta A, 2000, J SPORT MED PHYS FIT, V40, P277; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; SKLOOT G, 1995, J CLIN INVEST, V96, P2393, DOI 10.1172/JCI118296; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Tantisira KG, 2001, THORAX, V56, P64; Thomson RJ, 1996, AM J RESP CRIT CARE, V154, P749, DOI 10.1164/ajrccm.154.3.8810615; VARRAY AL, 1991, CHEST, V99, P579, DOI 10.1378/chest.99.3.579; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Visser M, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.1.e13; Westerterp KR, 2001, NATURE, V410, P539, DOI 10.1038/35069142	44	159	168	3	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					928	934		10.1016/j.jaci.2005.01.033	http://dx.doi.org/10.1016/j.jaci.2005.01.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867847				2022-12-18	WOS:000229055100005
J	Naisbitt, DJ; Farrell, J; Wong, G; Depta, JPH; Dodd, CC; Hopkins, JE; Gibney, CA; Chadwick, DW; Pickler, WJ; Pirmohamed, M; Park, BK				Naisbitt, DJ; Farrell, J; Wong, G; Depta, JPH; Dodd, CC; Hopkins, JE; Gibney, CA; Chadwick, DW; Pickler, WJ; Pirmohamed, M; Park, BK			Characterization of drug-specific T cells in lamotrigine hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lamotrigine; anticonvulsant hypersensitivity; T cells; antigen processing; cytokines; chemokines; T-cell receptors	LYMPHOCYTE-TRANSFORMATION TEST; TOXIC EPIDERMAL NECROLYSIS; IN-VITRO; REACTIVE METABOLITES; COVALENT BINDING; CARBAMAZEPINE; RECOGNITION; SULFAMETHOXAZOLE; ACTIVATION; MECHANISMS	Background: Lamotrigine is associated with hypersensitivity reactions, which are most commonly characterized by skin rash. An immune etiology has been postulated, though the nature of this is unclear. Objectives: The aim of this study was to characterize the role of T cells in lamotrigine hypersensitivity. Methods: A lymphocyte transformation test was performed on 4 hypersensitive patients. Lymphocytes from 3 of 4 lamotrigine-hypersensitive patients proliferated when stimulated with lamotrigine. T-cell clones were generated from one patient to further characterize the nature of the T-cell involvement. Cells were characterized in terms of their phenotype, functionality, and mechanisms of antigen presentation and cytotoxicity. Results: Of the 44 drug-specific T-cell clones generated, most were CD4(+) with occasional CD8(+) cells. All clones expressed the up T-cell receptor; several Vbeta 5.1(+) or 9(+) T-cell clones were generated. All clones also expressed the skin-homing receptor cutaneous lymphocyte antigen. Lamotrigine-stimulated T cells were cytotoxic and secreted perforin, IFN-gamma, IL-5, and macrophage inflammatory protein la, macrophage inflammatory protein 1beta, RANTES, and I-309. Lamotrigine was present on HLA-DR and HLA-DQ by antigen-presenting cells in the absence of drug metabolism and processing. The T-cell receptor of certain clones could accommodate analogs of lamotrigine, but no cross-reactivity was seen with other anticonvulsants. Conclusions: Our data provide evidence that T cells are involved in the pathogenesis of some lamotrigine-hypersensitivity reactions. The identification of drug-specific cells that express cutaneous lymphocyte antigen and type 1 cytokines after T-cell receptor activation is consistent with the clinical symptoms. Furthermore, identification of large numbers of Vbeta 5.1(+) T cells suggests that polymorphisms within T-cell receptor genes might act as determinants of susceptibility. (J Allergy Clin Immunol 2003;111:1393-1403.).	Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Dept Dermatol, Liverpool L69 3GE, Merseyside, England; Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, Bern, Switzerland; Univ Liverpool, Dept Neurol Sci, Liverpool L69 3BX, Merseyside, England	University of Liverpool; University of Liverpool; University of Bern; University Hospital of Bern; University of Liverpool	Naisbitt, DJ (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Sherrington Bldg,Ashton St,POB 147, Liverpool L69 3GE, Merseyside, England.		Pirmohamed, Munir/H-6004-2011	Pirmohamed, Munir/0000-0002-7534-7266; Farrell, John/0000-0002-8726-5997; Pichler, Werner J./0000-0002-8117-359X; Naisbitt, Dean/0000-0003-4107-7832				Blanca M, 2000, ALLERGY, V55, P998, DOI 10.1034/j.1398-9995.2000.00628.x; Bocquet H, 1996, SEMIN CUTAN MED SURG, V15, P250, DOI 10.1016/S1085-5629(96)80038-1; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Brown KL, 1999, DEV MED CHILD NEUROL, V41, P267, DOI 10.1017/S0012162299000560; BRUNNER KT, 1968, IMMUNOLOGY, V14, P181; Dorner BG, 2002, P NATL ACAD SCI USA, V99, P6181, DOI 10.1073/pnas.092141999; FRIEDMANN PS, 1994, ARCH DERMATOL, V130, P598, DOI 10.1001/archderm.130.5.598; Gonzalez FJ, 1997, INT ARCH ALLERGY IMM, V113, P345, DOI 10.1159/000237597; Hari Y, 2001, CLIN EXP ALLERGY, V31, P1398, DOI 10.1046/j.1365-2222.2001.01164.x; Hashizume H, 2002, J IMMUNOL, V168, P5359, DOI 10.4049/jimmunol.168.10.5359; KAHN HD, 1984, ARCH INTERN MED, V144, P1677, DOI 10.1001/archinte.144.8.1677; Kalish RS, 1999, J ALLERGY CLIN IMMUN, V103, P192, DOI 10.1016/S0091-6749(99)70489-6; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; Leeder JS, 1998, EPILEPSIA, V39, pS8, DOI 10.1111/j.1528-1157.1998.tb01679.x; Leyva L, 2000, J ALLERGY CLIN IMMUN, V105, P157, DOI 10.1016/S0091-6749(00)90191-X; Maggs JL, 2000, CHEM RES TOXICOL, V13, P1075, DOI 10.1021/tx0000825; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Naisbitt DJ, 2003, MOL PHARMACOL, V63, P732, DOI 10.1124/mol.63.3.732; Naisbitt DJ, 2002, MOL PHARMACOL, V62, P628, DOI 10.1124/mol.62.3.628; Naisbitt DJ, 2000, DRUG SAFETY, V23, P483, DOI 10.2165/00002018-200023060-00002; Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175, DOI 10.1111/j.1365-2222.1997.tb00690.x; Park BK, 2001, TOXICOLOGY, V158, P11, DOI 10.1016/S0300-483X(00)00397-8; Pichler Werner J, 2002, Am J Clin Dermatol, V3, P229, DOI 10.2165/00128071-200203040-00001; Pichler WJ, 1997, INT ARCH ALLERGY IMM, V113, P177, DOI 10.1159/000237539; PICKER LJ, 1990, AM J PATHOL, V136, P1053; Pirmohamed M, 2001, NEUROLOGY, V56, P890, DOI 10.1212/WNL.56.7.890; ROUJEAU JC, 1985, INT ARCH ALLER A IMM, V78, P22, DOI 10.1159/000233856; Sachs B, 1997, DERMATOLOGY, V195, P60, DOI 10.1159/000245690; Schaub N, 2000, ALLERGY, V55, P191, DOI 10.1034/j.1398-9995.2000.00467.x; Schnyder B, 1998, CLIN EXP ALLERGY, V28, P1412, DOI 10.1046/j.1365-2222.1998.00419.x; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; Torres MJ, 1998, CLIN EXP ALLERGY, V28, P1264; Troger U, 2000, INT J CLIN PHARM TH, V38, P452; VanSnick J, 1996, J IMMUNOL, V157, P2570; von Greyerz S, 1999, J IMMUNOL, V162, P595; von Greyerz S, 2001, INT IMMUNOL, V13, P877, DOI 10.1093/intimm/13.7.877; Wolkenstein P, 1998, CHEM-BIOL INTERACT, V113, P39, DOI 10.1016/S0009-2797(98)00021-0; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Yawalkar N, 2000, J ALLERGY CLIN IMMUN, V106, P1171, DOI 10.1067/mai.2000.110922; ZAKRZEWSKA JM, 1988, J ALLERGY CLIN IMMUN, V82, P110, DOI 10.1016/0091-6749(88)90059-0; Zanni MP, 1998, J CLIN INVEST, V102, P1591, DOI 10.1172/JCI3544; Zanni MP, 1999, J INVEST DERMATOL, V112, P197, DOI 10.1046/j.1523-1747.1999.00484.x	44	159	177	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1393	1403		10.1067/mai.2003.1507	http://dx.doi.org/10.1067/mai.2003.1507			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789244				2022-12-18	WOS:000183424700032
J	Vignola, AM; Chanez, P; Chiappara, G; Siena, L; Merendino, A; Reina, C; Gagliardo, R; Profita, M; Bousquet, J; Bonsignore, G				Vignola, AM; Chanez, P; Chiappara, G; Siena, L; Merendino, A; Reina, C; Gagliardo, R; Profita, M; Bousquet, J; Bonsignore, G			Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; asthma; chronic bronchitis; eosinophils	BCL-2 GENE FAMILY; CELLULAR INFILTRATION; AIRWAY INFLAMMATION; IN-VITRO; GM-CSF; CELLS; EXPRESSION; SURVIVAL; PROTEIN; RESOLUTION	Background: Apoptosis regulates inflammatory cell survival, and its reduction contributes to the chronicity of an inflammatory process. Apoptosis is controlled by suppressing or inducing genes, such as beta and p53, respectively. Objective: We sought to assess apoptosis of eosinophils, macrophages, and T lymphocytes in bronchial biopsy specimens from asthmatic subjects and to examine its regulation by evaluating the expression of B-cell lymphoma leukemia-2 (Bcl-2) and P53 proteins. We also sought to explore the relationships between cell apoptosis and GM-CSF, a cytokine able to increase eosinophil and macrophage survival. Methods: Apoptosis in eosinophils, macrophages, and T lymphocytes was evaluated in bronchial biopsy specimens obtained from 30 asthmatic subjects, 26 subjects with chronic bronchitis, and 15 control subjects by combining the terminal deoxynucleotidyl transferase-mediated dNTP nick end-labeling technique and immunohistochemistry. The expression of P53, Bcl-2, and GM-CSF was studied through immunohistochemistry by using specific mAbs. Results: The number of apoptotic eosinophils and macrophages was lower in subjects with asthma than in those with chronic bronchitis (P < .007 and P < .001, respectively) and inversely correlated with the clinical severity of asthma (P < .001 and P < .002, respectively). Few T lymphocytes were apoptotic in all groups studied. In asthma GM-CSF+ cells correlated with the number of nonapoptotic eosinophils acid macrophages (P = .0001) and with the severity of the disease (P < .003). In asthma Bcl-2+ cells were higher than in control subjects and subjects with chronic bronchitis (P < .002 and P < .015, respectively), they outnumbered P53+ cells, and they correlated with the number of T lymphocytes (P < .001) and with the severity of the disease (P < .003). Conclusion: Airway inflammation in asthma is associated with an enhanced survival of different cell types caused by reduced apoptosis.	CNR, Ist Fisiopatol Resp, I-90146 Palermo, Italy; Hop Arnaud de Villeneuve, Clin Malad Resp, Montpellier, France; Hop Arnaud de Villeneuve, INSERM, U454, Montpellier, France; Univ Palermo, Clin Malatie Resp, Palermo, Italy	Consiglio Nazionale delle Ricerche (CNR); Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; University of Palermo	Vignola, AM (corresponding author), CNR, Ist Fisiopatol Resp, Via Trabucco 180, I-90146 Palermo, Italy.		Profita, Mirella/AAY-3165-2020; Bousquet, Jean/O-4221-2019; Profita, Mirella/D-8957-2018; Gagliardo, Rosalia/AAX-7244-2020; Profita, Mirella/AFU-7423-2022	Profita, Mirella/0000-0002-7821-8283; SIENA, LIBORIA/0000-0002-3182-9503; CHIAPPARA, GIUSEPPINA/0000-0002-7226-5660; chanez, pascal/0000-0003-4059-0917				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; Anderson GP, 1996, TRENDS PHARMACOL SCI, V17, P438, DOI 10.1016/S0165-6147(96)01004-8; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; CHANEZ P, 1991, AM REV RESPIR DIS, V144, P923, DOI 10.1164/ajrccm/144.4.923; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; HAWKINS CJ, 1994, IMMUNOL REV, V142, P127, DOI 10.1111/j.1600-065X.1994.tb00886.x; HOLGATE ST, 1993, EUR RESPIR J, V6, P1507; Iversen PO, 1997, AM J RESP CRIT CARE, V156, P1628, DOI 10.1164/ajrccm.156.5.9612097; JAATTELA M, 1995, ONCOGENE, V10, P2297; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; LAITINEN LA, 1991, AM REV RESPIR DIS, V143, P423, DOI 10.1164/ajrccm/143.2.423; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; NOGUCHI K, 1995, JPN J CANCER RES, V86, P217, DOI 10.1111/j.1349-7006.1995.tb03042.x; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; Salmon M, 1997, J CLIN INVEST, V99, P439, DOI 10.1172/JCI119178; SALMON M, 1997, IMMUNOLOGIST, V5, P87; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; SHORROCK K, 1991, J PATHOL, V165, P105, DOI 10.1002/path.1711650204; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; Simon HU, 1997, J IMMUNOL, V158, P3902; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; Stern M, 1996, AM J PATHOL, V149, P911; Synek M, 1996, AM J RESP CRIT CARE, V154, P224, DOI 10.1164/ajrccm.154.1.8680684; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; Walsh GM, 1997, J ALLERGY CLIN IMMUN, V100, P208, DOI 10.1016/S0091-6749(97)70226-4; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; Ying S, 1997, P ASSOC AM PHYSICIAN, V109, P42; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Zhang S, 1996, EUR RESPIR J, V9, P1839, DOI 10.1183/09031936.96.09091839	49	159	176	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					563	573		10.1016/S0091-6749(99)70225-3	http://dx.doi.org/10.1016/S0091-6749(99)70225-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200002				2022-12-18	WOS:000079723900005
J	STEWART, GE; LOCKEY, RF				STEWART, GE; LOCKEY, RF			SYSTEMIC REACTIONS FROM ALLERGEN IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; PLACEBO-CONTROLLED IMMUNOTHERAPY; GRASS-POLLEN ALLERGOIDS; SKIN TESTING ST; DOUBLE-BLIND; RUSH IMMUNOTHERAPY; VENOM IMMUNOTHERAPY; SAFETY; RAGWEED; ASTHMA				STEWART, GE (corresponding author), JAMES A HALEY VET ADM MED CTR,UNIV S FLORIDA,COLL MED,DIV ALLERGY & IMMUNOL,TAMPA,FL 33612, USA.							BIRNBAUM J, 1990, Journal of Allergy and Clinical Immunology, V85, P212; BIRNBAUM J, 1990, Journal of Allergy and Clinical Immunology, V85, P210; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; GRAMMER LC, 1986, J ALLERGY CLIN IMMUN, V78, P1180, DOI 10.1016/0091-6749(86)90269-1; GRAMMER LC, 1989, J ALLERGY CLIN IMMUN, V83, P750, DOI 10.1016/0091-6749(89)90010-9; GRAMMER LC, 1986, J ALLERGY CLIN IMMUN, V77, P53, DOI 10.1016/0091-6749(86)90322-2; GRANT IWB, 1986, CLIN ALLERGY, V16, P7, DOI 10.1111/j.1365-2222.1986.tb01947.x; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; GREENBERG MA, 1988, J ALLERGY CLIN IMMUN, V82, P287, DOI 10.1016/0091-6749(88)91013-5; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; HEJJAOUI A, 1992, J ALLERGY CLIN IMMUN, V89, P925, DOI 10.1016/0091-6749(92)90214-M; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; HEPNER M, 1987, J ALLERGY CLIN IMMUN, V79, P133; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; KANAREK H, 1992, ANN ALLERGY, V68, P71; Lamson R.W., 1924, JAMA-J AM MED ASSOC, V82, P1091; LEVINE MI, 1979, J ALLERGY CLIN IMMUN, V63, P209; LIN M S, 1990, Journal of Allergy and Clinical Immunology, V85, P180; LOCKEY R, 1985, J ALLERGY CLIN IMMUN, V75, P166, DOI 10.1016/0091-6749(85)90381-1; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; MATLOFF SM, 1992, J ALLERGY CLIN IMMUN, V89, P273; MCCOMICK D S, 1991, Journal of Allergy and Clinical Immunology, V87, P237, DOI 10.1016/0091-6749(91)91673-H; NELSON BL, 1986, ANN ALLERGY, V56, P331; NORMAN PS, 1990, J ALLERGY CLIN IMMUN, V85, P88, DOI 10.1016/0091-6749(90)90227-U; NORMAN PS, 1990, J ALLERGY CLIN IMMUN, V85, P522, DOI 10.1016/0091-6749(90)90165-Z; OHMAN JL, 1991, ALLERGEN IMMUNOTHERA, P209; PARKER JW, 1990, J ALLERGY CLIN IMMUN, V86, P214; REID M J, 1990, Journal of Allergy and Clinical Immunology, V85, P180; REID MJ, 1992, J ALLERGY CLIN IMMUN, V89, P350; RIECKENBERG MR, 1990, ANN ALLERGY, V64, P364; SCHWARTZ HJ, 1990, J ALLERGY CLIN IMMUN, V85, P709, DOI 10.1016/0091-6749(90)90188-A; SQUILLACE D L, 1991, Journal of Allergy and Clinical Immunology, V87, P193, DOI 10.1016/0091-6749(91)91500-S; VANARSDEL PP, 1957, J ALLERGY, V28, P251, DOI 10.1016/0021-8707(57)90130-2; VANBEVER HP, 1990, J ALLERGY CLIN IMMUN, V86, P141, DOI 10.1016/S0091-6749(05)80058-2; Vance BM, 1942, ARCH PATHOL, V34, P849; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x; 1990, J ALLERGY CLIN IMMUN, V85, P526; 1986, BMJ, V293, P948	47	159	164	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				567	578		10.1016/0091-6749(92)90129-P	http://dx.doi.org/10.1016/0091-6749(92)90129-P			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1401640	Bronze			2022-12-18	WOS:A1992JT99500002
J	LOCKEY, RF; TURKELTAUB, PC; OLIVE, ES; HUBBARD, JM; BAIRDWARREN, IA; BUKANTZ, SC				LOCKEY, RF; TURKELTAUB, PC; OLIVE, ES; HUBBARD, JM; BAIRDWARREN, IA; BUKANTZ, SC			THE HYMENOPTERA VENOM STUDY .3. SAFETY OF VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV S FLORIDA,CTR COMP,TAMPA,FL 33620; US FDA,ALLERGEN PROD LAB,OFF BIOL RES,BETHESDA,MD 20014	State University System of Florida; University of South Florida; US Food & Drug Administration (FDA)	LOCKEY, RF (corresponding author), UNIV S FLORIDA,COLL MED,JAMES A HALEY VET ADM HOSP,DEPT MED,DIV ALLERGY & IMMUNOL,TAMPA,FL 33612, USA.		turkeltaub, paul/U-7729-2019; turkeltaub, paul/AAG-6160-2019	turkeltaub, paul/0000-0002-7350-1469				[Anonymous], 1986, BMJ-BRIT MED J, V293, P948; BOUSQUET J, 1987, ALLERGY, V42, P401, DOI 10.1111/j.1398-9995.1987.tb00355.x; Golden D. B. K., 1986, Monograph on insect allergy, P57; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; LOCKEY RF, 1989, J ALLERGY CLIN IMMUN, V84, P967, DOI 10.1016/0091-6749(89)90396-5; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; REISMAN RE, 1988, ANN ALLERGY, V671, P383; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; PACKAGE INSERT ALBAN; PACKAGE INSERT PHARM	11	159	161	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					775	780		10.1016/S0091-6749(05)80182-4	http://dx.doi.org/10.1016/S0091-6749(05)80182-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2229842				2022-12-18	WOS:A1990EJ63100010
J	BOWYER, SL; LAMOTHE, MP; HOLLISTER, JR				BOWYER, SL; LAMOTHE, MP; HOLLISTER, JR			STEROID MYOPATHY - INCIDENCE AND DETECTION IN A POPULATION WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BOWYER, SL (corresponding author), UNIV COLORADO,NATL JEWISH HOSP & RES CTR,NATL ASTHMA CTR,CTR HLTH SCI,DEPT PEDIAT,3800 E COLFAX,DENVER,CO 80206, USA.							AFIFI AK, 1969, JOHNS HOPKINS MED J, V124, P66; AFIFI AK, 1968, JOHNS HOPKINS MED J, V123, P158; ANIANSSON A, 1980, AGE AGEING, V9, P186, DOI 10.1093/ageing/9.3.186; ASKARI A, 1976, AM J MED, V61, P485, DOI 10.1016/0002-9343(76)90327-2; BYERS RK, 1962, PEDIATRICS, V29, P26; COOMES EN, 1965, NEUROLOGY, V15, P523, DOI 10.1212/WNL.15.6.523; Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137; Daniels L, 1972, MUSCLE TESTING TECHN; DUBOIS DC, 1980, ENDOCRINOLOGY, V107, P1649, DOI 10.1210/endo-107-5-1649; DUBOIS EL, 1968, JAMA, V167, P1590; ELLIS JT, 1956, AM J PATHOL, V32, P993; FALUDI G, 1964, ACTA ENDOCRINOL-COP, V45, P68, DOI 10.1530/acta.0.0450068; Folin O, 1919, J BIOL CHEM, V38, P81; FREYBERG RH, 1958, ARTHRITIS RHEUM, V1, P215, DOI 10.1002/art.1780010304; IDDINGS D M, 1961, Phys Ther Rev, V41, P249; KANAYAMA Y, 1981, ARCH INTERN MED, V141, P1176, DOI 10.1001/archinte.141.9.1176; Kendall HO., 1971, MUSCLES TESTING FUNC; LARSSON L, 1978, ACTA PHYSIOL SCAND, V103, P31, DOI 10.1111/j.1748-1716.1978.tb06187.x; Larsson L, 1978, Acta Physiol Scand Suppl, V457, P1; MANDEL S, 1982, POSTGRAD MED, V72, P207, DOI 10.1080/00325481.1982.11716260; PERKOFF GT, 1959, AM J MED, V26, P891, DOI 10.1016/0002-9343(59)90211-6; ROTHSTEIN JM, 1983, MUSCLE NERVE, V6, P128, DOI 10.1002/mus.880060208; SHEAHAN MG, 1969, ARTHRITIS RHEUM, V12, P491, DOI 10.1002/art.1780120505; STERN LZ, 1973, JAMA-J AM MED ASSOC, V223, P1287, DOI 10.1001/jama.223.11.1287; THORSTENSSON A, 1976, ACTA PHYSL SCAND   S, V443, P1; Yates D A, 1971, Rheumatol Phys Med, V11, P28, DOI 10.1093/rheumatology/11.1.28	26	159	162	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					234	242		10.1016/0091-6749(85)90708-0	http://dx.doi.org/10.1016/0091-6749(85)90708-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	4019954	Bronze			2022-12-18	WOS:A1985APE8800020
J	KODA, A; NAGAI, H; WATANABE, S; YANAGIHARA, Y; SAKAMOTO, K				KODA, A; NAGAI, H; WATANABE, S; YANAGIHARA, Y; SAKAMOTO, K			INHIBITION OF HYPERSENSITIVITY REACTIONS BY A NEW DRUG, N(3',4'-DIMETHOXYCINNAMOYL) ANTHRANILIC ACID (N-5')	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GIFU COLL PHARM,DEPT PHARMACOL & IMMUNOL,GIFU 502,JAPAN	Gifu Pharmaceutical University								ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; ASSEM ESK, 1974, BMJ-BRIT MED J, V2, P93, DOI 10.1136/bmj.2.5910.93; AZUMA H, COMMUNICATION; Coombs RRA., 1968, CLIN ASPECTS IMMUNOL, V2, P575; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; GLOVSKY MM, 1969, J IMMUNOL, V102, P1; HARADA M, 1971, J PHARM PHARMACOL, V23, P218, DOI 10.1111/j.2042-7158.1971.tb08647.x; KODA A, 1970, FOLIA PHARMACOL JAP, V66, P471; KODA A, 1972, Japanese Journal of Pharmacology, V22, P111; KODA A, 1973, METABOLISM DISEASE, V10, P730; KODA A, 1973, 22ND JAP C ALL, P155; KODA A, 1970, JAPAN J ALLERGOLOGY, V19, P597; KOOPMAN WJ, 1970, J IMMUNOL, V105, P1096; LEVINE BB, 1971, J IMMUNOL, V106, P29; LICHTENSTEIN LM, 1969, J IMMUNOL, V103, P866; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; NAGAI H, 1975, JPN J PHARMACOL, V25, P763, DOI 10.1254/jjp.25.763; NISHIOKA K, 1966, NUCLEIC ACID ENZYME, V11, P1509; SHIOTA H, COMMUNICATION; TADA T, 1971, J IMMUNOL, V106, P1002; UNGAR G, 1959, ARCH INT PHARMACOD T, V123, P71	21	159	164	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	5					396	407		10.1016/0091-6749(76)90054-3	http://dx.doi.org/10.1016/0091-6749(76)90054-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BR201	131140	Bronze			2022-12-18	WOS:A1976BR20100002
J	Taylor, SL; Leong, LEX; Choo, JM; Wesselingh, S; Yang, IA; Upham, JW; Reynolds, PN; Hodge, S; James, AL; Jenkins, C; Peters, MJ; Baraket, M; Marks, GB; Gibson, PG; Simpson, JL; Rogers, GB				Taylor, Steven L.; Leong, Lex E. X.; Choo, Jocelyn M.; Wesselingh, Steve; Yang, Ian A.; Upham, John W.; Reynolds, Paul N.; Hodge, Sandra; James, Alan L.; Jenkins, Christine; Peters, Matthew J.; Baraket, Melissa; Marks, Guy B.; Gibson, Peter G.; Simpson, Jodie L.; Rogers, Geraint B.			Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; microbiome; neutrophil; eosinophil	INDUCED SPUTUM; HAEMOPHILUS-INFLUENZAE; EXACERBATIONS; DYNAMICS; FEATURES; SAMPLES	Background: Asthma pathophysiology and treatment responsiveness are predicted by inflammatory phenotype. However, the relationship between airway microbiology and asthma phenotype is poorly understood. Objective: We aimed to characterize the airway microbiota in patients with symptomatic stable asthma and relate composition to airway inflammatory phenotype and other phenotypic characteristics. Methods: The microbial composition of induced sputum specimens collected from adult patients screened for a multicenter randomized controlled trial was determined by using 16SrRNA gene sequencing. Inflammatory phenotypes were defined by sputum neutrophil and eosinophil cell proportions. Microbiota were defined by using alpha- and beta-diversity measures, and interphenotype differences were identified by using similarity of percentages, network analysis, and taxon fold change. Phenotypic predictors of airway microbiology were identified by using multivariate linear regression. Results: Microbiota composition was determined in 167 participants and classified as eosinophilic (n = 84), neutrophilic (n = 14), paucigranulocytic (n = 60), or mixed neutrophilic-eosinophilic (n = 9) asthma phenotypes. Airway microbiology was significantly less diverse (P = .022) and more dissimilar (P = .005) in neutrophilic compared with eosinophilic participants. Sputum neutrophil proportions, but not eosinophil proportions, correlated significantly with these diversity measures (a-diversity: Spearman r = -20.374, P < .001; beta-diversity: r = 0.238, P = .002). Interphenotype differences were characterized by a greater frequency of pathogenic taxa at high relative abundance and reduced Streptococcus, Gemella, and Porphyromonas taxa relative abundance in patients with neutrophilic asthma. Multivariate regression confirmed that sputum neutrophil proportion was the strongest predictor of microbiota composition. Conclusions: Neutrophilic asthma is associated with airway microbiology that is significantly different from that seen in patients with other inflammatory phenotypes, particularly eosinophilic asthma. Differences in microbiota composition might influence the response to antimicrobial and steroid therapies and the risk of lung infection.	[Taylor, Steven L.; Leong, Lex E. X.; Choo, Jocelyn M.; Wesselingh, Steve; Rogers, Geraint B.] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia; [Taylor, Steven L.; Leong, Lex E. X.; Choo, Jocelyn M.; Wesselingh, Steve; Rogers, Geraint B.] Flinders Univ S Australia, Sch Med, SAHMRI Microbiome Res Lab, Adelaide, SA, Australia; [Yang, Ian A.; Upham, John W.] Univ Queensland, Sch Med, St Lucia, Qld, Australia; [Yang, Ian A.] Prince Charles Hosp, Dept Thorac Med, Chermside, Australia; [Upham, John W.] Princess Alexandra Hosp, Translat Res Inst, Woolloongabba, Qld, Australia; [Reynolds, Paul N.; Hodge, Sandra] Royal Adelaide Hosp, Dept Thorac Med, Adelaide, SA, Australia; [Reynolds, Paul N.; Hodge, Sandra] Hanson Inst, Lung Res Lab, Adelaide, SA, Australia; [Reynolds, Paul N.; Hodge, Sandra] Univ Adelaide, Sch Med, Adelaide, SA, Australia; [James, Alan L.] Sir Charles Gairdner Hosp, Dept Pulm Physiol & Sleep Med, Nedlands, WA, Australia; [James, Alan L.] Univ Western Australia, Sch Med & Pharmacol, Crawley, Australia; [Jenkins, Christine] George Inst Global Hlth, Resp Trials, Newtown, Tas, Australia; [Jenkins, Christine; Peters, Matthew J.] Macquarie Univ, Australian Sch Adv Med, N Ryde, NSW, Australia; [Peters, Matthew J.] Concord Gen Hosp, Dept Thorac Med, Concord West, NSW, Australia; [Baraket, Melissa; Marks, Guy B.] Liverpool Hosp, Resp Med Dept, Liverpool, NSW, Australia; [Baraket, Melissa; Marks, Guy B.] Liverpool Hosp, Ingham Inst, Liverpool, NSW, Australia; [Marks, Guy B.; Gibson, Peter G.] Woolcock Inst Med Res, Glebe, NSW, Australia; [Gibson, Peter G.; Simpson, Jodie L.] Univ Newcastle, Prior Res Ctr Healthy Lungs, Resp & Sleep Med, Callaghan, NSW, Australia; [Marks, Guy B.] Univ New South Wales, South Western Sydney Clin Sch, Sydney, NSW, Australia	South Australian Health & Medical Research Institute (SAHMRI); Flinders University South Australia; South Australian Health & Medical Research Institute (SAHMRI); University of Queensland; Prince Charles Hospital; Royal Adelaide Hospital; Hanson Institute; University of Adelaide; University of Western Australia; University of Western Australia; George Institute for Global Health; University of Sydney; Macquarie University; Concord Repatriation General Hospital; Liverpool Hospital; Ingham Institute for Applied Medical Research; Liverpool Hospital; University of Sydney; Woolcock Institute of Medical Research; University of Newcastle; University of New South Wales Sydney	Rogers, GB (corresponding author), Flinders Univ S Australia, Sch Med, Univ Dr, Adelaide, SA 5042, Australia.	geraint.rogers@sahmri.com	SIMPSON, JODIE LOUISE/G-7639-2013; Upham, John/F-4420-2010; Leong, Lex/AAH-4211-2021; Taylor, Steven/AAD-7827-2019; Rogers, Geraint/AAD-1011-2020; Marks, Guy B./F-5058-2013; Yang, Ian A/B-9609-2008; gibson, peter/G-6194-2014; Rogers, Geraint/N-1957-2013	SIMPSON, JODIE LOUISE/0000-0002-3626-680X; Upham, John/0000-0002-0017-3433; Taylor, Steven/0000-0003-4357-8243; Marks, Guy B./0000-0002-8976-8053; Yang, Ian A/0000-0001-8338-1993; Leong, Lex Ee Xiang/0000-0002-5073-2272; Peters, Matthew/0000-0002-9649-8741; gibson, peter/0000-0001-5865-489X; Rogers, Geraint/0000-0003-4054-1947	Australian National Health and Medical Research Council (NHMRC) [569246]; John Hunter Hospital Charitable Trust	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); John Hunter Hospital Charitable Trust	Supported by the Australian National Health and Medical Research Council (NHMRC); grant no. 569246) and a grant from the John Hunter Hospital Charitable Trust.	Anderson MJ, 2006, ECOL LETT, V9, P683, DOI 10.1111/j.1461-0248.2006.00926.x; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bacci E, 2002, MEDIAT INFLAMM, V11, P293, DOI 10.1080/09629350210000015692; Brooks CR, 2013, RESPIROLOGY, V18, P857, DOI 10.1111/resp.12079; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cuthbertson L, 2016, ISME J, V10, P1081, DOI 10.1038/ismej.2015.198; Daniels TWV, 2013, J CYST FIBROS, V12, P22, DOI 10.1016/j.jcf.2012.05.008; Denner DR, 2016, J ALLERGY CLIN IMMUN, V137, P1398, DOI 10.1016/j.jaci.2015.10.017; Durack J, 2017, J ALLERGY CLIN IMMUN, V140, P63, DOI 10.1016/j.jaci.2016.08.055; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Essilfie AT, 2012, THORAX, V67, P588, DOI 10.1136/thoraxjnl-2011-200160; Friedman J, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002687; Gibson PG, 1998, AM J RESP CRIT CARE, V158, P36, DOI 10.1164/ajrccm.158.1.9705031; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Hancox RJ, 2012, RESPIROLOGY, V17, P461, DOI 10.1111/j.1440-1843.2011.02113.x; Hofstra JJ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1081-y; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Huang YJ, 2014, J CLIN MICROBIOL, V52, P2813, DOI 10.1128/JCM.00035-14; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Jervis-Bardy J, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0083-8; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; McKeever T, 2013, CHEST, V144, P1788, DOI 10.1378/chest.13-0871; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257, DOI 10.1099/00221287-148-1-257; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pelaia G, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/879783; Pettigrew MM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1670-4; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Rogers GB, 2015, ISME J, V9, P217, DOI 10.1038/ismej.2014.124; Rogers GB, 2014, LANCET RESP MED, V2, P988, DOI 10.1016/S2213-2600(14)70213-9; Rogers GB, 2013, TRENDS MICROBIOL, V21, P271, DOI 10.1016/j.tim.2013.03.004; Rogers GB, 2010, J CLIN MICROBIOL, V48, P78, DOI 10.1128/JCM.01324-09; Rossall MRW, 2014, RESP MED, V108, P1566, DOI 10.1016/j.rmed.2014.08.004; Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2016, CHEST, V149, P704, DOI 10.1016/j.chest.2015.12.018; Simpson JL, 2016, EUR RESPIR J, V47, P792, DOI 10.1183/13993003.00405-2015; Simpson JL, 2014, EUR RESPIR J, V43, P1067, DOI 10.1183/09031936.00105013; Suarez-Cuartin G, 2016, ARCH BRONCONEUMOL, V52, P76, DOI 10.1016/j.arbres.2015.03.007; Tarabichi Y, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0133-2; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593; Zhang QL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152724; Zhao JC, 2012, P NATL ACAD SCI USA, V109, P5809, DOI 10.1073/pnas.1120577109	49	158	166	4	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					94	+		10.1016/j.jaci.2017.03.044	http://dx.doi.org/10.1016/j.jaci.2017.03.044			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28479329	hybrid			2022-12-18	WOS:000419312200015
J	Stray-Pedersen, A; Sorte, HS; Samarakoon, P; Gambin, T; Chinn, IK; Akdemir, ZHC; Erichsen, HC; Forbes, LR; Gu, S; Yuan, B; Jhangiani, SN; Muzny, DM; Rodningen, OK; Sheng, Y; Nicholas, SK; Noroski, LM; Seeborg, FO; Davis, CM; Canter, DL; Mace, EM; Vece, TJ; Allen, CE; Abhyankar, HA; Boone, PM; Beck, CR; Wiszniewski, W; Fevang, B; Aukrust, P; Tjonnfjord, GE; Gedde-Dahl, T; Hjorth-Hansen, H; Dybedal, I; Nordoy, I; Jorgensen, SF; Abrahamsen, TG; Overland, T; Bechensteen, AG; Skogen, V; Osnes, LTN; Kulseth, MA; Prescott, TE; Rustad, CF; Heimdal, KR; Belmont, JW; Rider, NL; Chinen, J; Cao, TN; Smith, EA; Caldirola, MS; Bezrodnik, L; Reyes, SOL; Rosales, FJE; Guerrero-Cursaru, ND; Pedroza, LA; Poli, CM; Franco, JL; Vargas, CMT; Becerra, JCA; Wright, N; Issekutz, TB; Issekutz, AC; Abbott, J; Caldwell, JW; Bayer, DK; Chan, AY; Aiuti, A; Cancrini, C; Holmberg, E; West, C; Burstedt, M; Karaca, E; Yesil, G; Artac, H; Bayram, Y; Atik, MM; Eldomery, MK; Ehlayel, MS; Jolles, S; Flato, B; Bertuch, AA; Hanson, IC; Zhang, VW; Wong, LJ; Hu, JH; Walkiewicz, M; Yang, YP; Eng, CM; Boerwinkle, E; Gibbs, RA; Shearer, WT; Lyle, R; Orange, JS; Lupski, JR				Stray-Pedersen, Asbjorg; Sorte, Hanne Sormo; Samarakoon, Pubudu; Gambin, Tomasz; Chinn, Ivan K.; Akdemir, Zeynep H. Coban; Erichsen, Hans Christian; Forbes, Lisa R.; Gu, Shen; Yuan, Bo; Jhangiani, Shalini N.; Muzny, Donna M.; Rodningen, Olaug Kristin; Sheng, Ying; Nicholas, Sarah K.; Noroski, Lenora M.; Seeborg, Filiz O.; Davis, Carla M.; Canter, Debra L.; Mace, Emily M.; Vece, Timothy J.; Allen, Carl E.; Abhyankar, Harshal A.; Boone, Philip M.; Beck, Christine R.; Wiszniewski, Wojciech; Fevang, Borre; Aukrust, Pal; Tjonnfjord, Geir E.; Gedde-Dahl, Tobias; Hjorth-Hansen, Henrik; Dybedal, Ingunn; Nordoy, Ingvild; Jorgensen, Silje F.; Abrahamsen, Tore G.; Overland, Torstein; Bechensteen, Anne Grete; Skogen, Vegard; Osnes, Liv T. N.; Kulseth, Mari Ann; Prescott, Trine E.; Rustad, Cecilie F.; Heimdal, Ketil R.; Belmont, John W.; Rider, Nicholas L.; Chinen, Javier; Cao, Tram N.; Smith, Eric A.; Soledad Caldirola, Maria; Bezrodnik, Liliana; Lugo Reyes, Saul Oswaldo; Espinosa Rosales, Francisco J.; Guerrero-Cursaru, Nina Denisse; Pedroza, Luis Alberto; Poli, Cecilia M.; Franco, Jose L.; Trujillo Vargas, Claudia M.; Aldave Becerra, Juan Carlos; Wright, Nicola; Issekutz, Thomas B.; Issekutz, Andrew C.; Abbott, Jordan; Caldwell, Jason W.; Bayer, Diana K.; Chan, Alice Y.; Aiuti, Alessandro; Cancrini, Caterina; Holmberg, Eva; West, Christina; Burstedt, Magnus; Karaca, Ender; Yesil, Gozde; Artac, Hasibe; Bayram, Yavuz; Atik, Mehmed Musa; Eldomery, Mohammad K.; Ehlayel, Mohammad S.; Jolles, Stephen; Flato, Berit; Bertuch, Alison A.; Hanson, I. Celine; Zhang, Victor W.; Wong, Lee-Jun; Hu, Jianhong; Walkiewicz, Magdalena; Yang, Yaping; Eng, Christine M.; Boerwinkle, Eric; Gibbs, Richard A.; Shearer, William T.; Lyle, Robert; Orange, Jordan S.; Lupski, James R.			Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency disease; whole-exome sequencing; copy number variants	COMMON VARIABLE IMMUNODEFICIENCY; CHRONIC GRANULOMATOUS-DISEASE; SEVERE INTELLECTUAL DISABILITY; WHOLE-GENOME; IMMUNE DYSREGULATION; GERMLINE MUTATIONS; MISSENSE MUTATIONS; PRACTICE PARAMETER; GENETIC-VARIANTS; SEQUENCE	Background: Primary immunodeficiency diseases (PIDDs) are clinically and genetically heterogeneous disorders thus far associated with mutations in more than 300 genes. The clinical phenotypes derived from distinct genotypes can overlap. Genetic etiology can be a prognostic indicator of disease severity and can influence treatment decisions. Objective: We sought to investigate the ability of whole-exome screening methods to detect disease-causing variants in patients with PIDDs. Methods: Patients with PIDDs from 278 families from 22 countries were investigated by using whole-exome sequencing. Computational copy number variant (CNV) prediction pipelines and an exome-tiling chromosomal microarray were also applied to identify intragenic CNVs. Analytic approaches initially focused on 475 known or candidate PIDD genes but were nonexclusive and further tailored based on clinical data, family history, and immunophenotyping. Results: A likely molecular diagnosis was achieved in 110 (40%) unrelated probands. Clinical diagnosis was revised in about half (60/ 110) and management was directly altered in nearly a quarter (26/ 110) of families based on molecular findings. Twelve PIDD-causing CNVs were detected, including 7 smaller than 30 Kb that would not have been detected with conventional diagnostic CNV arrays. Conclusion: This high-throughput genomic approach enabled detection of disease-related variants in unexpected genes; permitted detection of low-grade constitutional, somatic, and revertant mosaicism; and provided evidence of a mutational burden in mixed PIDD immunophenotypes.	[Stray-Pedersen, Asbjorg; Gambin, Tomasz; Akdemir, Zeynep H. Coban; Gu, Shen; Yuan, Bo; Jhangiani, Shalini N.; Muzny, Donna M.; Boone, Philip M.; Beck, Christine R.; Wiszniewski, Wojciech; Karaca, Ender; Yesil, Gozde; Bayram, Yavuz; Atik, Mehmed Musa; Eldomery, Mohammad K.; Boerwinkle, Eric; Gibbs, Richard A.; Lupski, James R.] Baylor Coll Med, Baylor Hopkins Ctr Mendelian Genom, Dept Mol & Human Genet, Houston, TX 77030 USA; [Stray-Pedersen, Asbjorg; Chinn, Ivan K.; Forbes, Lisa R.; Nicholas, Sarah K.; Mace, Emily M.; Rider, Nicholas L.; Cao, Tram N.; Pedroza, Luis Alberto; Poli, Cecilia M.; Hanson, I. Celine; Orange, Jordan S.] Baylor Coll Med, Texas Childrens Hospital, Ctr Human Immunobiol, Dept Pediat, Houston, TX 77030 USA; [Yuan, Bo; Jhangiani, Shalini N.; Muzny, Donna M.; Boone, Philip M.; Beck, Christine R.; Wiszniewski, Wojciech; Belmont, John W.; Zhang, Victor W.; Wong, Lee-Jun; Hu, Jianhong; Walkiewicz, Magdalena; Yang, Yaping; Eng, Christine M.; Gibbs, Richard A.; Lupski, James R.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Jhangiani, Shalini N.; Muzny, Donna M.; Hu, Jianhong; Boerwinkle, Eric; Gibbs, Richard A.; Lupski, James R.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [Allen, Carl E.; Abhyankar, Harshal A.; Bertuch, Alison A.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Smith, Eric A.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Chinn, Ivan K.; Forbes, Lisa R.; Nicholas, Sarah K.; Noroski, Lenora M.; Seeborg, Filiz O.; Davis, Carla M.; Canter, Debra L.; Mace, Emily M.; Rider, Nicholas L.; Chinen, Javier; Cao, Tram N.; Hanson, I. Celine; Shearer, William T.; Orange, Jordan S.] Baylor Coll Med & Texas Childrens Hosp, Div Immunol Allergy & Rheumatol, Dept Pediat, Houston, TX 77030 USA; [Stray-Pedersen, Asbjorg] Univ Oslo, Norwegian Natl Unit Newborn Screening, Oslo, Norway; [Stray-Pedersen, Asbjorg; Erichsen, Hans Christian; Abrahamsen, Tore G.; Overland, Torstein; Bechensteen, Anne Grete] Univ Oslo, Dept Pediat, Oslo, Norway; [Sorte, Hanne Sormo; Samarakoon, Pubudu; Rodningen, Olaug Kristin; Sheng, Ying; Kulseth, Mari Ann; Prescott, Trine E.; Rustad, Cecilie F.; Heimdal, Ketil R.; Lyle, Robert] Univ Oslo, Dept Med Genet, Oslo, Norway; [Tjonnfjord, Geir E.; Gedde-Dahl, Tobias; Dybedal, Ingunn] Univ Oslo, Dept Hematol, Oslo, Norway; [Osnes, Liv T. N.] Univ Oslo, Dept Immunol & Transfus Med, Oslo, Norway; [Flato, Berit] Univ Oslo, Dept Rheumatol, Oslo Univ Hosp, Oslo, Norway; [Sorte, Hanne Sormo; Samarakoon, Pubudu; Fevang, Borre; Aukrust, Pal; Tjonnfjord, Geir E.; Nordoy, Ingvild; Abrahamsen, Tore G.] Univ Oslo, Inst Clin Med, Oslo, Norway; [Gambin, Tomasz] Warsaw Univ Technol, Inst Comp Sci, Warsaw, Poland; [Chinn, Ivan K.; Forbes, Lisa R.; Nicholas, Sarah K.; Noroski, Lenora M.; Seeborg, Filiz O.; Davis, Carla M.; Canter, Debra L.; Vece, Timothy J.; Allen, Carl E.; Abhyankar, Harshal A.; Rider, Nicholas L.; Chinen, Javier; Cao, Tram N.; Bertuch, Alison A.; Hanson, I. Celine; Shearer, William T.; Orange, Jordan S.; Lupski, James R.] Baylor Coll Med & Texas Childrens Hosp, Dept Pediat, Houston, TX 77030 USA; [Allen, Carl E.; Abhyankar, Harshal A.] Texas Childrens Hosp & Baylor Coll Med, Texas Childrens Canc & Hematol Ctr, Dept Pediat, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Fevang, Borre; Aukrust, Pal; Nordoy, Ingvild; Jorgensen, Silje F.] Oslo Univ Hosp, Rikshosp, Sect Clin Immunol & Infect Dis, Oslo, Norway; [Hjorth-Hansen, Henrik] St Olavs Hosp, Dept Hematol, Trondheim, Norway; [Hjorth-Hansen, Henrik; Cancrini, Caterina] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, Trondheim, Norway; [Skogen, Vegard; Flato, Berit] Univ Hosp North Norway, Med Clin, Dept Infect Dis, Tromso, Norway; [Soledad Caldirola, Maria; Bezrodnik, Liliana] Ricardo Gutierrez Childrens Hosp, Serv Immunol, Buenos Aires, DF, Argentina; [Lugo Reyes, Saul Oswaldo; Espinosa Rosales, Francisco J.] Natl Inst Pediat, Immunodeficiencies Res Unit, Mexico City, DF, Mexico; [Guerrero-Cursaru, Nina Denisse; Pedroza, Luis Alberto] Univ San Francisco Quito, Quito, Ecuador; [Poli, Cecilia M.] Univ Chile, Hosp Roberto Rio, Santiago, Chile; [Franco, Jose L.; Trujillo Vargas, Claudia M.] Univ Antioquia UdeA, Fac Med, Dept Microbiol & Parasitol, Grp Inmunodeficiencias Primarias, Medellin, Colombia; [Aldave Becerra, Juan Carlos] Hosp Nacl Edgardo Rebagliati Martins, Allergy & Clin Immunol, Lima, Peru; [Wright, Nicola] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada; [Issekutz, Thomas B.; Issekutz, Andrew C.] Dalhousie Univ, Izaak Walton Killam Hlth Ctr, Dept Pediat, Halifax, NS, Canada; [Abbott, Jordan] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Caldwell, Jason W.] Med Ctr Blvd, Wake Forest Baptist Med Ctr, Sect Pulm Crit Care Allerg & Immunol Dis, Winston Salem, NC USA; [Bayer, Diana K.] Univ Iowa, Carver Coll Med, Dept Pediat, Div Pediatr Allergy Immunol & Pulmonol, Iowa City, IA 52242 USA; [Chan, Alice Y.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Aiuti, Alessandro] San Raffaele Telethon Inst Gene Therapy SR TIGET, Milan, Italy; [Aiuti, Alessandro] Univ Vita Salute San Raffaele, Milan, Italy; [Cancrini, Caterina] Bambino Gesu Pediat Hosp, DPUO, Univ Dept Pediat, Rome, Italy; [Cancrini, Caterina] Tor Vergata Univ, Rome, Italy; [Holmberg, Eva; Burstedt, Magnus] Umea Univ Hosp, Dept Clin Genet, Umea, Sweden; [West, Christina] Umea Univ, Dept Clin Sci, Pediat, Umea, Sweden; [Yesil, Gozde] Bezmi Alem Vakif Univ, Fac Med, Dept Med Genet, Istanbul, Turkey; [Artac, Hasibe] Selcuk Univ, Fac Med, Dept Pediat Immunol & Allergy, Konya, Turkey; [Ehlayel, Mohammad S.] Hamad Med Corp, Sect Pediat Allergy & Immunol, Dept Pediat, Doha, Qatar; [Ehlayel, Mohammad S.] Weill Cornell Med Coll, Dept Paediat, Ar Rayyan, Qatar; [Jolles, Stephen] Univ Wales Hosp, Immunodeficiency Ctr Wales, Cardiff, S Glam, Wales; [Boerwinkle, Eric] Univ Texas Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77004 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; Warsaw University of Technology; Baylor College of Medicine; Texas Children's Cancer Center; University of Oslo; National Hospital Norway; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); UiT The Arctic University of Tromso; University Hospital of North Norway; Hospital de Ninos Doctor Ricardo Gutierrez; Instituto Nacional de Saude Dr. Ricardo Jorge; University of Buenos Aires; Universidad de Chile; Universidad de Antioquia; Seguro Social de Salud del Peru; Alberta Childrens Hospital; University of Calgary; Dalhousie University; National Jewish Health; Wake Forest University; Wake Forest Baptist Medical Center; University of Iowa; University of California System; University of California San Francisco; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Bambino Gesu; University of Rome Tor Vergata; Umea University; Umea University; Bezmialem Vakif University; Selcuk University; Hamad Medical Corporation; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Cardiff University; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Stray-Pedersen, A (corresponding author), Oslo Univ Hosp, Div Pediat & Adolescent Med, Norwegian Natl Unit Newborn Screening, Postbox 4950 Nydalen, N-0424 Oslo, Norway.; Orange, JS (corresponding author), Feigin Ctr, 1102 Bates,Suite 330, Houston, TX 77030 USA.; Lupski, JR (corresponding author), Baylor Coll Med, Mol & Human Genet, Suite 604B,One Baylor Plaza, Houston, TX 77030 USA.	astraype@ous-hf.no; orange@bcm.edu; jlupski@bcm.tmc.edu	St Olav Hospital, Medisinsk Klinikk -/AAD-6414-2022; Tjønnfjord, Geir Erland/AAH-8739-2020; Gu, Shen/AAE-2641-2020; YESIL, GOZDE/ABE-1615-2020; Gambin, Tomasz/HDN-5840-2022; Belmont, John/AAH-6084-2021; AIUTI, ALESSANDRO/K-3918-2016; Reyes, Saul O Lugo/AAS-7621-2021; Belmont, John W/AAI-2494-2019; Heimdal, Ketil Riddervold/H-3038-2019; Reyes, Saul O Lugo/AAP-7951-2021; Abbott, Jordan K/P-2509-2016; Espinosa-Rosales, Francisco Javier/B-9762-2014	Gu, Shen/0000-0003-3107-1218; YESIL, GOZDE/0000-0003-1964-6306; Gambin, Tomasz/0000-0002-0941-4571; AIUTI, ALESSANDRO/0000-0002-5398-1717; Reyes, Saul O Lugo/0000-0002-3730-4150; Belmont, John W/0000-0001-7409-3578; Heimdal, Ketil Riddervold/0000-0002-8911-3508; Reyes, Saul O Lugo/0000-0002-3730-4150; Abbott, Jordan K/0000-0001-6334-5266; orange, jordan/0000-0001-7117-7725; FRANCO, JOSE/0000-0001-5664-6415; Bayer, Diana/0000-0001-7181-7446; Aldave, Juan/0000-0003-3548-0385; Stray-Pedersen, Asbjorg/0000-0002-9168-0878; Mace, Emily/0000-0003-0226-7393; Espinosa-Rosales, Francisco Javier/0000-0002-7629-1647; Issekutz, Thomas/0000-0001-5486-9463; Poli, Maria Cecilia/0000-0001-6817-0573; West, Christina/0000-0001-9599-2580; Shearer, William/0000-0002-2483-2130; Rustad, Cecilie Fremstad/0000-0001-7903-9087; Vece, Timothy/0000-0002-0645-8923; Chinn, Ivan/0000-0001-5684-5457; Hanson, Imelda/0000-0001-9457-0757	South-Eastern Norway Health Authority; American Women's club of Oslo; National Human Genome Research Institute; National Heart, Lung, and Blood [U54HG006542]; Jeffrey Modell Foundation; NIH [AI-120989]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [UM1HG006542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS078056] Funding Source: NIH RePORTER	South-Eastern Norway Health Authority; American Women's club of Oslo; National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Heart, Lung, and Blood(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Jeffrey Modell Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Funding for the work performed in Oslo was provided by the South-Eastern Norway Health Authority, and A. S.-P. received research scholarship from the American Women's club of Oslo. The BHCMG is supported by the National Human Genome Research Institute and the National Heart, Lung, and Blood (U54HG006542). Funding was also provided by the Jeffrey Modell Foundation and NIH AI-120989 (to J.S.O.).	Abina SHB, 2015, JAMA-J AM MED ASSOC, V313, P1550, DOI 10.1001/jama.2015.3253; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Aksentijevich I, 2009, NEW ENGL J MED, V360, P2426, DOI 10.1056/NEJMoa0807865; Al-Herz W, 2010, ASIAN PAC J ALLERGY, V28, P141; Al-Mousa H, 2016, J ALLERGY CLIN IMMUN, V137, P1780, DOI 10.1016/j.jaci.2015.12.1310; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Barrett JH, 2011, NAT GENET, V43, P1108, DOI 10.1038/ng.959; Bayer DK, 2014, CLIN EXP IMMUNOL, V178, P459, DOI 10.1111/cei.12421; Becker-Heck A, 2011, NAT GENET, V43, P79, DOI 10.1038/ng.727; Bernth-Jensen JM, 2016, J ALLERGY CLIN IMMUN, V137, P321, DOI 10.1016/j.jaci.2015.07.047; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, pe1; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Bornholdt D, 2013, HUM MUTAT, V34, P587, DOI 10.1002/humu.22275; Bousfiha A, 2015, J CLIN IMMUNOL, V35, P727, DOI 10.1007/s10875-015-0198-5; Casanova JL, 2014, J EXP MED, V211, P2137, DOI 10.1084/jem.20140520; Chan A, 2011, CLIN IMMUNOL, V138, P3, DOI 10.1016/j.clim.2010.09.010; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405; Corujeira S, 2013, EUR J MED GENET, V56, P603, DOI 10.1016/j.ejmg.2013.09.005; de Ligt J, 2012, NEW ENGL J MED, V367, P1921, DOI 10.1056/NEJMoa1206524; de Pagter APJ, 2015, EUR J PEDIATR, V174, P1183, DOI 10.1007/s00431-015-2518-4; Di Matteo G, 2009, MOL IMMUNOL, V46, P1935, DOI 10.1016/j.molimm.2009.03.016; Duzkale H, 2013, CLIN GENET, V84, P453, DOI 10.1111/cge.12257; Fattahi F, 2011, J CLIN IMMUNOL, V31, P792, DOI 10.1007/s10875-011-9567-x; Fitzgerald TW, 2015, NATURE, V519, P223, DOI 10.1038/nature14135; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Genovese P, 2014, NATURE, V510, P235, DOI 10.1038/nature13420; Ghosh S., 2015, BR J HAEMATOL; Gibbs DC, 2015, CANCER EPIDEM BIOMAR, V24, P992, DOI 10.1158/1055-9965.EPI-14-1426; Gilissen C, 2014, NATURE, V511, P344, DOI [10.1038/nature13394, 10.3389/fnhum.2013.00444]; Gonzaga-Jauregui C, 2015, CELL REP, V12, P1169, DOI 10.1016/j.celrep.2015.07.023; Hayrapetyan A, 2013, BBA-MOL BASIS DIS, V1832, P1662, DOI 10.1016/j.bbadis.2013.05.001; Henderson C, 2010, CURR OPIN RHEUMATOL, V22, P567, DOI 10.1097/BOR.0b013e32833ceff4; HOYERAAL HM, 1970, ACTA PAEDIATR SCAND, V59, P185, DOI 10.1111/j.1651-2227.1970.tb08986.x; HUE YK, 1994, CANCER RES, V54, P2544; Itan Y, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00142; Karaca E, 2015, NEURON, V88, P499, DOI 10.1016/j.neuron.2015.09.048; Koker MY, 2013, J ALLERGY CLIN IMMUN, V132, P1156, DOI 10.1016/j.jaci.2013.05.039; Kuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Liu YW, 2014, J CLIN IMMUNOL, V34, P686, DOI 10.1007/s10875-014-0064-x; Lougaris V, 2015, J ALLERGY CLIN IMMUN, V135, P1641, DOI 10.1016/j.jaci.2014.11.038; Lupski JR, 2013, GENOME MED, V5, DOI 10.1186/gm461; Lupski JR, 2011, CELL, V147, P32, DOI 10.1016/j.cell.2011.09.008; Lupski JR, 2010, NEW ENGL J MED, V362, P1181, DOI 10.1056/NEJMoa0908094; Meynert AM, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-247; Milman N, 2006, APMIS, V114, P912, DOI 10.1111/j.1600-0463.2006.apm_522.x; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Moens LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114901; Montiel-Equihua CA, 2012, CURR GENE THER, V12, P57; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Niemela JE, 2011, BLOOD, V117, P2883, DOI 10.1182/blood-2010-07-295501; Nijman IJ, 2014, J ALLERGY CLIN IMMUN, V133, P529, DOI 10.1016/j.jaci.2013.08.032; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Picard C, 2014, EUR J IMMUNOL, V44, P2854, DOI 10.1002/eji.201444669; Picard C, 2009, EUR J IMMUNOL, V39, P1966, DOI 10.1002/eji.200939385; Platt C, 2014, J ALLERGY CLIN IMMUN, V134, P262, DOI 10.1016/j.jaci.2013.08.021; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Raje N, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0468-y; Rauch A, 2012, LANCET, V380, P1674, DOI 10.1016/S0140-6736(12)61480-9; Reid JG, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-30; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Samarakoon PS, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-661; Sassi A, 2014, J ALLERGY CLIN IMMUN, V133, P1410, DOI 10.1016/j.jaci.2014.02.025; Saunders C, 2015, AM J HUM GENET, V96, P258, DOI 10.1016/j.ajhg.2014.12.020; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Shigemizu D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12742; Siegel AM, 2013, J ALLERGY CLIN IMMUN, V132, P1388, DOI 10.1016/j.jaci.2013.08.045; Stoddard JL, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00531; Stray-Pedersen A, 2000, J CLIN IMMUNOL, V20, P477, DOI 10.1023/A:1026416017763; Stray-Pedersen A, 2014, J CLIN IMMUNOL, V34, P871, DOI 10.1007/s10875-014-0074-8; Stray-Pedersen A, 2014, AM J HUM GENET, V95, P96, DOI 10.1016/j.ajhg.2014.05.007; Sulonen AM, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r94; van Schouwenburg PA, 2015, CLIN IMMUNOL, V160, P301, DOI 10.1016/j.clim.2015.05.020; Vissers LELM, 2010, NAT GENET, V42, P1109, DOI 10.1038/ng.712; Watkin LB, 2015, NAT GENET, V47, P654, DOI 10.1038/ng.3279; Wortmann SB, 2015, AM J HUM GENET, V96, P245, DOI 10.1016/j.ajhg.2014.12.013; Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555; Yu H, 2016, J ALLERGY CLIN IMMUN, V138, P1142, DOI 10.1016/j.jaci.2016.05.035; Zhang Y, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Zhang Y, 2014, J ALLERGY CLIN IMMUN, V133, P1400, DOI 10.1016/j.jaci.2014.02.013	90	158	164	0	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					232	245		10.1016/j.jaci.2016.05.042	http://dx.doi.org/10.1016/j.jaci.2016.05.042			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27577878	Bronze, Green Accepted, Green Submitted			2022-12-18	WOS:000393996800025
J	Baxter, CG; Dunn, G; Jones, AM; Webb, K; Gore, R; Richardson, MD; Denning, DW				Baxter, Caroline G.; Dunn, Graham; Jones, Andrew M.; Webb, Kevin; Gore, Robin; Richardson, Malcolm D.; Denning, David W.			Novel immunologic classification of aspergillosis in adult cystic fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspergillus fumigatus; cystic fibrosis; bronchitis; allergic bronchopulmonary aspergillosis; polymerase chain reaction; galactomannan	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; LUNG-FUNCTION; IGG ANTIBODIES; SPUTUM SAMPLES; FUMIGATUS; SENSITIZATION; STANDARDIZATION; GALACTOMANNAN; PREVALENCE; DIAGNOSIS	Background: Patients with cystic fibrosis (CF) demonstrate a wide range of hypersensitivity responses to Aspergillus, beyond allergic bronchopulmonary aspergillosis, which require classification. Objective: This study integrated 2 new methods of Aspergillus detection-sputum galactomannan (GM) and real-time PCR-alongside established serologic markers, to reclassify aspergillosis in CF. Methods: A total of 146 adult patients with CF had serologic tests (ImmunoCap total IgE, specific Aspergillus fumigatus IgE, and specific A fumigatus IgG), sputum real-time Aspergillus PCR, and sputum GM. Patients were classified by using latent class analysis. Results: Both RT-PCR and GM were more sensitive than culture in detecting Aspergillus in sputum (culture 37%, RT-PCR 74%, and GM 46%). Intraassay and interassay reproducibility of PCR and GM was excellent. Latent class analysis of triazole-naive patients identified a nondiseased group and 3 disease classes: class 1 (n = 49, 37.7%) represented patients with or without positive RT-PCR but no immunologic response to A fumigatus and negative GM (nondiseased); class 2 (n = 23, 17.7%) represented patients with positive RT-PCR, elevated total and specific A fumigatus IgE/IgG, and positive GM (serologic allergic bronchopulmonary aspergillosis); class 3 (n 5 19, 14.6%) represented patients with or without positive RT-PCR, elevated A fumigatus IgE (not IgG), and negative GM (Aspergillus sensitized); and class 4 (n 5 39, 30%) represented patients with positive RT-PCR, elevated A fumigatus IgG (not IgE), and positive GM (Aspergillus bronchitis). Conclusions: Three distinct classes of aspergillosis in CF were identified by latent class analysis by using serologic, RT-PCR, and GM data. This novel classification will facilitate improved phenotyping, pathogenesis studies, and management evaluations.	[Baxter, Caroline G.; Richardson, Malcolm D.; Denning, David W.] Univ S Manchester Hosp, Natl Aspergillosis Ctr, Manchester M20 8LR, Lancs, England; [Baxter, Caroline G.; Jones, Andrew M.; Webb, Kevin] Univ S Manchester Hosp, Manchester Adult Cyst Fibrosis Ctr, Manchester M20 8LR, Lancs, England; [Baxter, Caroline G.; Jones, Andrew M.; Webb, Kevin; Gore, Robin; Richardson, Malcolm D.; Denning, David W.] Univ Manchester, Manchester M13 9PL, Lancs, England; [Baxter, Caroline G.; Jones, Andrew M.; Webb, Kevin; Gore, Robin; Richardson, Malcolm D.; Denning, David W.] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Dunn, Graham] Univ Manchester, Sch Community Based Med, Manchester M13 9PL, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; University of Manchester; University of Manchester	Baxter, CG (corresponding author), Univ S Manchester Hosp, Educ & Res Ctr, Manchester M23 9LT, Lancs, England.	caroline.baxter@manchester.ac.uk	Denning, David/AAC-6931-2019	Denning, David/0000-0001-5626-2251; jones, andrew/0000-0003-3232-1055; Baxter, Caroline/0000-0002-0852-2861; Richardson, Malcolm/0000-0001-5672-9552	National Commissioning Group, National Aspergillosis Centre, University Hospital of South Manchester, United Kingdom; Schering Plough; Pfizer; Merck; F2G; Fungal Research Trust; Wellcome Trust; Moulton Trust; Medical Research Council; Chronic Granulomatous Disease Research Trust; National Institute of Allergy and Infectious Diseases; National Institute of Health Research; European Union; AstraZeneca; Gilead Sciences; Astellas; Novartis; Dainippon; Astellas Pharma; MSD; MRC; NIHR	National Commissioning Group, National Aspergillosis Centre, University Hospital of South Manchester, United Kingdom; Schering Plough(Merck & CompanySchering Plough Corporation); Pfizer(Pfizer); Merck(Merck & Company); F2G; Fungal Research Trust; Wellcome Trust(Wellcome Trust); Moulton Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Chronic Granulomatous Disease Research Trust; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Health Research(National Institute for Health Research (NIHR)); European Union(European Commission); AstraZeneca(AstraZeneca); Gilead Sciences(Gilead Sciences); Astellas(Astellas Pharmaceuticals); Novartis(Novartis); Dainippon; Astellas Pharma(Astellas Pharmaceuticals); MSD; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR(National Institute for Health Research (NIHR))	This study was supported by the National Commissioning Group, National Aspergillosis Centre, University Hospital of South Manchester, United Kingdom.; C. G. Baxter has received one or more payments for lecturing from or is on the speakers' bureau for Astellas and has received one or more payments for travel/accommodations/meeting expenses from Schering Plough, Pfizer, and Merck. D. W. Denning holds founder shares in F2G Ltd, a University of Manchester spin-out company; has received grant support from F2G, the Fungal Research Trust, the Wellcome Trust, the Moulton Trust, The Medical Research Council, The Chronic Granulomatous Disease Research Trust, the National Institute of Allergy and Infectious Diseases, National Institute of Health Research, the European Union, and AstraZeneca; has acted as an advisor/consultant to F2G and Myconostica (now part of the Lab21 group) as well as other companies over the last 5 years including Pfizer, T2Biosystems, Schering Plough (now Merck), Nektar, Astellas, and Gilead; and has been paid for talks on behalf of Merck, Gilead Sciences, Astellas, Novartis, Merck, Dainippon, and Pfizer. M. D. Richardson acts as an advisor/consultant to Astellas Pharma, Merck, and Gilead Sciences and has received grant support and sponsorship from these companies; has consultancy arrangements with and has received one or more payments for the development of educational presentations for Gilead Sciences, Astellas Pharma, and Merck; has received one or more grants from or has one or more grants pending with Gilead Sciences and Astellas; has received one or more payments for lecturing from or is on the speakers' bureau for Gilead Sciences, Astellas, and MSD; and has received royalties from Wiley-Blackwell. G. Dunn has received MRC and NIHR research grants and textbook royalties. The rest of the authors declare that they have no relevant conflicts of interest.	Aaron SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036077; Aimanianda V, 2009, NATURE, V460, P1117, DOI 10.1038/nature08264; Amin R, 2010, CHEST, V137, P171, DOI 10.1378/chest.09-1103; Bakare N, 2003, MYCOSES, V46, P19, DOI 10.1046/j.1439-0507.2003.00830.x; Barton RC, 2008, DIAGN MICR INFEC DIS, V62, P287, DOI 10.1016/j.diagmicrobio.2008.06.018; Baxter CG, 2011, J MICROBIOL METH, V85, P75, DOI 10.1016/j.mimet.2011.01.024; Borman AM, 2010, MED MYCOL, V48, pS88, DOI 10.3109/13693786.2010.511287; Bousquet J, 2012, ALLERGY, V67, P18, DOI 10.1111/j.1398-9995.2011.02728.x; CAMPBELL MJ, 1964, AM REV RESPIR DIS, V89, P186; Chaudhary N, 2012, AM J RESP CRIT CARE, V185, P301, DOI 10.1164/rccm.201106-1027OC; Chrdle A, 2012, ANN NY ACAD SCI, V1272, P73, DOI 10.1111/j.1749-6632.2012.06816.x; de Vrankrijker AMM, 2011, CLIN MICROBIOL INFEC, V17, P1381, DOI 10.1111/j.1469-0691.2010.03429.x; Denning DW, 2011, CLIN INFECT DIS, V52, P1123, DOI 10.1093/cid/cir179; DENNING DW, 1994, CLIN INFECT DIS, V19, P1176, DOI 10.1093/clinids/19.6.1176; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Evaluations and Standards Laboratory Standards Unit Centre for Infections, 2008, 572008 BSOP CTR INF, V57; Fairs A, 2010, AM J RESP CRIT CARE, V182, P1362, DOI 10.1164/rccm.201001-0087OC; FORSYTH KD, 1988, ARCH DIS CHILD, V63, P953, DOI 10.1136/adc.63.8.953; Geller DE, 1999, CHEST, V116, P639, DOI 10.1378/chest.116.3.639; Guo YL, 2010, CHEST, V138, P817, DOI 10.1378/chest.10-0488; Hope WW, 2007, J INFECT DIS, V195, P455, DOI 10.1086/510535; Hope WW, 2005, LANCET INFECT DIS, V5, P609, DOI 10.1016/S1473-3099(05)70238-3; Kanthan SK, 2007, PEDIATR PULM, V42, P785, DOI 10.1002/ppul.20656; Knutsen Alan P, 2011, J Allergy (Cairo), V2011, P785983, DOI 10.1155/2011/785983; Kraemer R, 2006, AM J RESP CRIT CARE, V174, P1211, DOI 10.1164/rccm.200603-423OC; Loussert C, 2010, CELL MICROBIOL, V12, P405, DOI 10.1111/j.1462-5822.2009.01409.x; Maiz L, 2002, CHEST, V121, P782, DOI 10.1378/chest.121.3.782; Mennink-Kersten MASH, 2006, J CLIN MICROBIOL, V44, P1711, DOI 10.1128/JCM.44.5.1711-1718.2006; Menzies D, 2011, ALLERGY, V66, P679, DOI 10.1111/j.1398-9995.2010.02542.x; Milla CE, 1996, PEDIATR PULM, V21, P6, DOI 10.1002/(SICI)1099-0496(199601)21:1&lt;6::AID-PPUL1&gt;3.0.CO;2-R; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Morton CO, 2010, J MED MICROBIOL, V59, P408, DOI 10.1099/jmm.0.017418-0; NICOLAI T, 1990, PEDIATR PULM, V8, P12, DOI 10.1002/ppul.1950080106; Pashley CH, 2012, MED MYCOL, V50, P433, DOI 10.3109/13693786.2011.615762; Shoseyov D, 2006, CHEST, V130, P222, DOI 10.1378/chest.130.1.222; Stevens DA, 2003, CLIN INFECT DIS, V37, pS225, DOI 10.1086/376525; SYMMERS WILLIAM St. CLAIR, 1962, LAB INVEST, V11, P1073; Van Hoeyveld E, 2006, CLIN CHEM, V52, P1785, DOI 10.1373/clinchem.2006.067546; Wojnarowski C, 1997, AM J RESP CRIT CARE, V155, P1902, DOI 10.1164/ajrccm.155.6.9196093; YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002	40	158	162	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					560	+		10.1016/j.jaci.2013.04.007	http://dx.doi.org/10.1016/j.jaci.2013.04.007			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23726262	Bronze			2022-12-18	WOS:000323612000006
J	Lopez-Souza, N; Favoreto, S; Wong, H; Ward, T; Yagi, S; Schnurr, D; Finkbeiner, WE; Dolganov, GM; Widdicombe, JH; Boushey, HA; Avila, PC				Lopez-Souza, Nilceia; Favoreto, Silvio; Wong, Hofer; Ward, Theresa; Yagi, Shigeo; Schnurr, David; Finkbeiner, Walter E.; Dolganov, Gregory M.; Widdicombe, Jonathan H.; Boushey, Homer A.; Avila, Pedro C.			In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human rhinovirus; nasal and bronchial airway epithelial cells; air-liquid interface	HUMAN TRACHEAL EPITHELIUM; BIOELECTRIC PROPERTIES; SITU HYBRIDIZATION; CULTURES; ASTHMA; EXACERBATIONS; EXPRESSION; DIFFERENTIATION; REPLICATION; DISEASE	Background: Human rhinoviruses (HRVs) characteristically cause upper respiratory tract infection, but they also infect the lower airways, causing acute bronchitis and exacerbating asthma. Objective: Our purpose was to study ex vivo the differences in the response to HRV infection of nasal and bronchial epithelial cultures from the same healthy and asthmatic individuals using conditions favoring development of fully differentiated, pseudostratified mucociliary epithelium. Methods: Cells from the inferior turbinates and bronchial tree of 5 healthy and 6 asthmatic individuals were cultured at an air-liquid interface. Cultures were infected with HRV-16, and after 48 hours, the degree of infection was measured. Results: Baseline median transepithelial resistance was lower in human bronchial epithelial (HBE) cell cultures than in human nasal epithelial (HNE) cell cultures (195 Omega.cm(2) [95% CI, 164-252] vs 366 Omega.cm(2) [95% CI, 234-408], respectively; P < .01). Virus replicated more easily in HBE cells than in HNE cells based on virus shedding in apical wash (log tissue culture infective dose of 50%/0.1 mL = 2.0 [95% CI, 1.0-2.5] vs 0.5 [95% CI, 0.5-1.5], P < .01) and on a 20- to 30-fold greater viral load and number of infected cells in HBE cell cultures than in FINE cell cultures. The increases in expression of RANTES and double-stranded RNA-dependent protein kinase were greater in HBE cell cultures than in HNE cell cultures, as were the concentrations of IL-8, IL-1 alpha, RANTES, and IP-10 in basolateral medium. However, no significant differences between asthmatic and healthy subjects (including IFN-beta 1 expression) were found. Conclusions: Differentiated nasal epithelial cells might have mechanisms of increased resistance to rhinovirus infection compared with bronchial epithelial cells. We could not confirm previous reports of increased susceptibility to HRV infection in epithelial cells from asthmatic subjects. (J Allergy Clin Immunol 2009;123:1384-90.)	[Favoreto, Silvio; Avila, Pedro C.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [Lopez-Souza, Nilceia; Wong, Hofer; Ward, Theresa; Boushey, Homer A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Finkbeiner, Walter E.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA; [Boushey, Homer A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Yagi, Shigeo; Schnurr, David] Calif Dept Publ Hlth, Viral & Rickettsial Dis Lab, Richmond, CA USA; [Dolganov, Gregory M.] Stanford Med Sch, Div Infect Dis & Geog Med, Stanford, CA USA; [Widdicombe, Jonathan H.] Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA	Northwestern University; Feinberg School of Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Department of Public Health; Stanford University; University of California System; University of California Davis	Avila, PC (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, 676 N St Clair St,Rm 14-018, Chicago, IL 60611 USA.	pa@northwestern.edu			National Institutes of Health [P01A1050496]; Northwestern University; Cystic Fibrosis Foundation; Cystic Fibrosis Research, Inc; GlaxoSmithKline; Genentech; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050496] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Northwestern University; Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); Cystic Fibrosis Research, Inc; GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant P01A1050496. S. Favoreto and P. C Avila are currently supported by the Ernest S. Bazley Grant to Northwestern University.; W. E. Finkbeiner has received research support from the Cystic Fibrosis Foundation and the National Institutes of Health. G. M. Dolganov has provided legal consultation or expert witness testimony on the topic of gene expression assays. J. H. Widdicombe has received research support from Cystic Fibrosis Research, Inc. H. A. Boushey has received research support from GlaxoSmithKline and honoraria from Genentech and Novartis and has served as a member and chair of the Health Effect's Institute's review committee. P.C. Avila has received research support from Genentech. The rest of the authors have declared that they have no conflict of interest.	ARRUDA E, 1995, J INFECT DIS, V171, P1329, DOI 10.1093/infdis/171.5.1329; BALLARD ST, 1992, J APPL PHYSIOL, V73, P2021, DOI 10.1152/jappl.1992.73.5.2021; BARDIN PG, 1994, AM J RESP CELL MOL, V10, P207, DOI 10.1165/ajrcmb.10.2.8110476; Bianco A, 1998, EUR RESPIR J, V12, P619, DOI 10.1183/09031936.98.12030619; BOUCHER RC, 1981, J APPL PHYSIOL, V51, P706, DOI 10.1152/jappl.1981.51.3.706; Chen Y, 2006, AM J RESP CELL MOL, V34, P192, DOI 10.1165/rcmb.2004-0417OC; COME JM, 2002, LANCET, V359, P831; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; GEM JE, 1997, AM J RESP CRIT CARE, V155, P1159; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; HUNTER CA, 1995, IMMUNOLOGY, V84, P16; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; LENNETTE DA, 1995, DIAGNOSTIC PROCEDURE; Lopez-Souza N, 2004, AM J PHYSIOL-LUNG C, V286, pL373, DOI 10.1152/ajplung.00300.2003; Lopez-Souza N, 2003, IN VITRO CELL DEV-AN, V39, P266; Message SD, 2004, J LEUKOCYTE BIOL, V75, P5, DOI 10.1189/jlb.0703315; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Mosser AG, 2002, J INFECT DIS, V185, P734, DOI 10.1086/339339; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Papadopoulos N G, 2000, Can Respir J, V7, P409; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Proud D, 2004, J IMMUNOL, V172, P4637, DOI 10.4049/jimmunol.172.7.4637; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Seemungal TAR, 2000, EUR RESPIR J, V16, P677, DOI 10.1034/j.1399-3003.2000.16d19.x; SMYTH AR, 1995, ARCH DIS CHILD, V73, P117, DOI 10.1136/adc.73.2.117; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Widdicombe JH, 2003, IN VITRO CELL DEV-AN, V39, P51; WINTHER B, 1986, JAMA-J AM MED ASSOC, V256, P1763, DOI 10.1001/jama.256.13.1763; WINTHER B, 1990, AM REV RESPIR DIS, V141, P839, DOI 10.1164/ajrccm/141.4_Pt_1.839; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; Yoon JH, 2002, DIFFERENTIATION, V70, P77, DOI 10.1046/j.1432-0436.2002.700202.x; 1991, J ALLERGY CLIN IMMUN, V88, P425; 1991, J ALLERGY CLIN IMMUN, V88, P808	37	158	158	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1384	1390		10.1016/j.jaci.2009.03.010	http://dx.doi.org/10.1016/j.jaci.2009.03.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19428098	Green Accepted, Bronze			2022-12-18	WOS:000266799100033
J	Hanson, EP; Monaco-Shawver, L; Solt, LA; Madge, LA; Banerjee, PP; May, MJ; Orange, JS				Hanson, Eric P.; Monaco-Shawver, Linda; Solt, Laura A.; Madge, Lisa A.; Banerjee, Pinaki P.; May, Michael J.; Orange, Jordan S.			Hypomorphic nuclear factor-kappa B essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEMO; immunodeficiency; genetic database; Jurkat reconstitution; NF-kappa B activation; A20	ANHIDROTIC ECTODERMAL DYSPLASIA; INCONTINENTIA PIGMENTI; IMMUNE-DEFICIENCY; FEMALE-PATIENT; NEMO; IMMUNODEFICIENCY; GENE; OSTEOPETROSIS; CYTOTOXICITY; LYMPHEDEMA	Background: Human hypomorphic nuclear factor-kappa B essential modulator (NEMO) mutations cause diverse clinical and immunologic phenotypes, but understanding of their scope and mechanistic links to immune function and genotype is incomplete. Objective: We created and analyzed a database of hypomorphic NEMO mutations to determine the spectrum of phenotypes and their associated genotypes and sought to establish a standardized NEMO reconstitution system to obtain mechanistic insights. Methods: Phenotypes of 72 individuals with NEMO mutations were compiled. NEMO L153R and C417R were investigated further in a reconstitution system. TNF-alpha or Toll-like receptor (TLR)-5 signals were evaluated for nuclear factor-kappa B activation, programmed cell death, and A20 gene expression. Results: Thirty-two different mutations were identified; 53% affect the zinc finger domain. Seventy-seven percent were associated with ectodermal dysplasia, 86% with serious pyogenic infection, 39% with mycobacterial infection, 19% with serious viral infection, and 23% with inflammatory diseases. Thirty-six percent of individuals died at a mean age of 6.4 years. CD40, IL-1, TNF-alpha, TLR, and T-cell receptor signals were impaired in 15 of 16 (94%), 6 of 7 (86%), 9 of 11 (82%), 9 of 14 (64%), and 7 of 18 (39%), respectively. Hypomorphism-reconstituted NEMO-deficient cells demonstrated partial restoration of NEMO functions. Although both L153R and C417R impaired TLR and TNF-alpha-induced NF-kappa B activation, L153R also increased TNF-alpha-induced programmed cell death with decreased A20 expression. Conclusion: Distinct NEMO hypomorphs define specific disease and genetic characteristics. A reconstitution system can identify attributes of hypomorphisms independent of an individual's genetic background. Apoptosis susceptibility in L153R reconstituted cells defines a specific phenotype of this mutation that likely contributes to the excessive inflammation with which it is clinically associated. (J Allergy Clin Immunol 2008; 122:1169-77.)	[Monaco-Shawver, Linda; Banerjee, Pinaki P.; Orange, Jordan S.] Univ Penn, Abramson Res Ctr 1016H, Sch Med,Joseph Stokes Jr Res Inst, Childrens Hosp Philadelphia,Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Hanson, Eric P.] Univ Penn, Div Rheumatol, Sch Med,Joseph Stokes Jr Res Inst, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Solt, Laura A.; Madge, Lisa A.; May, Michael J.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Orange, JS (corresponding author), Univ Penn, Abramson Res Ctr 1016H, Sch Med,Joseph Stokes Jr Res Inst, Childrens Hosp Philadelphia,Div Allergy & Immunol, 615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Orange@mail.med.upenn.edu	Hanson, Eric/AAE-5511-2022; Orange, Jordan S/D-5239-2009	Hanson, Eric/0000-0002-0318-4779; May, Michael/0000-0002-2485-3716; orange, jordan/0000-0001-7117-7725	National Institutes of Health (NIH) [AI079731, HL080612, 5T32CA009140-33]; US Immnodeficiency Network [NIH N01 AI-22070]; Pennsylvania Department of Health; American Academy of Allergy. Asthma Immunology; Penn Center for Clinical Immunology Jackson-Wade Fellowship; NATIONAL CANCER INSTITUTE [T32CA009140] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI055428, R21AI079731, R01AI022070] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Immnodeficiency Network; Pennsylvania Department of Health; American Academy of Allergy. Asthma Immunology; Penn Center for Clinical Immunology Jackson-Wade Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH) AI079731 (J.S.O.), US Immnodeficiency Network Grant NIH N01 AI-22070 (J.S.O., M.J.M.). NIH HL080612 (M.J.M). the Pennsylvania Department of Health (J.S.O.; the Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations or conclusions from this study). a career development award from the American Academy of Allergy. Asthma & Immunology (J.S.O.), NIH 5T32CA009140-33 (E.P.H.). and the Penn Center for Clinical Immunology Jackson-Wade Fellowship (E.P.H.)	Abinun M, 1996, EUR J PEDIATR, V155, P146, DOI 10.1007/s004310050395; Achacoso P., 2001, CURR PROTOC IMMUNOL, V31, P14; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Aradhya S, 2001, HUM MOL GENET, V10, P2557, DOI 10.1093/hmg/10.22.2557; Cordier F, 2008, J MOL BIOL, V377, P1419, DOI 10.1016/j.jmb.2008.01.048; Dai YS, 2004, J AM ACAD DERMATOL, V51, P718, DOI 10.1016/j.jaad.2004.05.032; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dupuis-Girod S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e97; Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20060085; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P1, DOI 10.1016/j.coi.2006.11.018; Kosaki K, 2001, AM J HUM GENET, V69, P664, DOI 10.1086/323003; Mansour S, 2001, AM J MED GENET, V99, P172, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1155>3.0.CO;2-Y; Marienfeld RB, 2006, MOL CELL BIOL, V26, P9209, DOI 10.1128/MCB.00478-06; Martinez-Pomar N, 2005, HUM GENET, V118, P458, DOI 10.1007/s00439-005-0068-y; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Niehues T, 2004, J ALLERGY CLIN IMMUN, V114, P1456, DOI 10.1016/j.jaci.2004.08.047; Nishikomori R, 2004, BLOOD, V103, P4565, DOI 10.1182/blood-2003-10-3655; Orange JS, 2005, IMMUNOL REV, V203, P21, DOI 10.1111/j.0105-2896.2005.00221.x; Orange JS, 2004, J ALLERGY CLIN IMMUN, V114, P650, DOI 10.1016/j.jaci.2004.06.052; Orange JS, 2004, J ALLERGY CLIN IMMUN, V113, P725, DOI 10.1016/j.jaci.2004.01.762; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Orstavik KH, 2006, AM J MED GENET A, V140A, P31, DOI 10.1002/ajmg.a.31026; Pandey R, 2007, J IMMUNOL, V179, P7385, DOI 10.4049/jimmunol.179.11.7385; Risma KA, 2005, CLIN IMMUNOL, V116, P300; Salt BH, 2008, J ALLERGY CLIN IMMUN, V121, P976, DOI 10.1016/j.jaci.2007.11.014; Schmid JMP, 2006, PEDIATRICS, V117, pE1049, DOI 10.1542/peds.2005-2062; Smahi A, 2000, NATURE, V405, P466; Temmerman ST, 2006, BLOOD, V108, P2324, DOI 10.1182/blood-2006-04-017210; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	35	158	166	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1169	1177		10.1016/j.jaci.2008.08.018	http://dx.doi.org/10.1016/j.jaci.2008.08.018			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18851874	Green Accepted			2022-12-18	WOS:000261711800016
J	Antunez, C; Blanca-Lopez, N; Torres, MJ; Mayorga, C; Perez-Inestrosa, E; Montanez, MI; Fernandez, T; Blanca, M				Antunez, C; Blanca-Lopez, N; Torres, MJ; Mayorga, C; Perez-Inestrosa, E; Montanez, MI; Fernandez, T; Blanca, M			Immediate allergic reactions to cephalosporins: Evaluation of cross-reactivity with a panel of penicillins and cephalosporins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; cephalosporin; penicillin; allergic reactions; cross-reactivity	IGE ANTIBODIES; BETA-LACTAMS; HYPERSENSITIVITY; RECOGNITION; SKIN	Background: Allergy to cephalosporins has mainly been evaluated in the context of patients with confirmed penicillin allergy. The problem of studying cross-reactivity in subjects primarily sensitized to cephalosporins and potentially allergic to penicillins has not been sufficiently addressed. Objective: To evaluate the in vitro IgE response and cross-reactivity to betalactams in patients with immediate allergic reactions to cephalosporins. Methods: The study included 24 patients with immediate allergic reactions to cephalosporins and RAST-positive to at least 1 cephalosporin. Skin testing and RAST were performed with a panel of penicillins and cephalosporins. RAST inhibition assay with different monomeric conjugates of penicillin and cephalosporin was performed to establish cross-reactivity. Results: The culprit cephalosporins were cefaclor (N = 7), cefonicid (N = 1), cefotaxime (N = 2), ceftazidime (N 2) ceftriaxone (N = 3), and cefuroxime (N = 9). Two patients had a positive skin test result to penicillin determinants, and 22 patients had a negative result to penicillin determinants and tolerated benzylpenicillin administration. Of these 22, 19 had a positive skin test result to cephalosporins and divided into patients reacting only to the culprit cephalosporin (63.2%) and those reacting to more than 1 cephalosporin (36.8%). RAST and RAST inhibition studies confirmed that the side chain at the RI position is crucial for recognition. Conclusion: The R1 side chain rather than the betalactam structure, shared by penicillins and cephalosporins, seems to play a dominant role in determining the specificity of immunologic reactions to cephalosporins. Thus, penicillin can be administered safely to patients allergic to cephalosporins and with a negative skin test result to penicillin determinants.	Carlos Haya Hosp, Allerg Dis Res Lab, Malaga, Spain; Carlos Haya Hosp, Allergy Serv, Malaga, Spain; Univ Malaga, Dept Organ Chem, Malaga, Spain	Hospital Carlos Haya; Hospital Carlos Haya; Universidad de Malaga	Torres, MJ (corresponding author), Hosp Civil, Allergy Serv, Pl Hosp Civil S-N, Malaga 29009, Spain.	sspa@juntadeandalucia.es	Montanez, Maria I/B-7194-2014; Mayorga, Cristobalina/D-7167-2018; Perez-Inestrosa, Ezequiel/H-9801-2015; Torres, María José/T-3518-2017; Torres, Maria/GVU-3391-2022; Fernández, Tahia Diana/J-2404-2012; Mayorga, Lina/FBO-7730-2022	Montanez, Maria I/0000-0001-6641-5979; Mayorga, Cristobalina/0000-0001-8852-8077; Perez-Inestrosa, Ezequiel/0000-0001-7546-5273; Torres, María José/0000-0001-5228-471X; Fernández, Tahia Diana/0000-0003-0625-2156; 				Atanaskovic-Markovic M, 2003, ALLERGY, V58, P537, DOI 10.1034/j.1398-9995.2003.00146.x; AUDICANA M, 1994, ALLERGY, V49, P108, DOI 10.1111/j.1398-9995.1994.tb00809.x; Baldo BA, 1999, CLIN EXP ALLERGY, V29, P744; Gomez MB, 2004, CURR OPIN ALLERGY CL, V4, P261, DOI 10.1097/01.all.0000136764.74065.15; BLANCA M, 1989, J ALLERGY CLIN IMMUN, V83, P381, DOI 10.1016/0091-6749(89)90122-X; BLANCA M, 1994, CLIN EXP ALLERGY, V24, P407, DOI 10.1111/j.1365-2222.1994.tb00928.x; BLANCA M, 1991, ALLERGY, V46, P632, DOI 10.1111/j.1398-9995.1991.tb00635.x; Daulat S, 2004, J ALLERGY CLIN IMMUN, V113, P1220, DOI 10.1016/j.jaci.2004.03.023; HARLE DG, 1990, INT ARCH ALLER A IMM, V92, P439, DOI 10.1159/000235177; Kanny G, 2005, J ALLERGY CLIN IMMUN, V115, P179, DOI 10.1016/j.jaci.2004.09.012; Kelkar PS, 2001, NEW ENGL J MED, V345, P804, DOI 10.1056/NEJMra993637; Lee CW, 2004, ALLERGY ASTHMA PROC, V25, P23; MANHAS MS, 1971, BETALACTAMS NATURA 1; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; Miranda A, 1996, J ALLERGY CLIN IMMUN, V98, P671, DOI 10.1016/S0091-6749(96)70101-X; MORENO F, 1995, INT ARCH ALLERGY IMM, V108, P74, DOI 10.1159/000237121; NAGAKURA N, 1990, INT ARCH ALLER A IMM, V93, P126, DOI 10.1159/000235291; Novalbos A, 2001, CLIN EXP ALLERGY, V31, P438, DOI 10.1046/j.1365-2222.2001.00992.x; Orhan F, 2004, ALLERGY, V59, P239, DOI 10.1046/j.1398-9995.2003.00376.x; Pham NH, 1996, J MOL RECOGNIT, V9, P287, DOI 10.1002/(SICI)1099-1352(199607)9:4<287::AID-JMR340>3.3.CO;2-C; Romano A, 2004, ANN INTERN MED, V141, P16, DOI 10.7326/0003-4819-141-1-200407060-00010; Romano A, 2000, J ALLERGY CLIN IMMUN, V106, P1177; ROMANO A, 1997, INT J IMMUNOPATHO S2, V10, P187; Sanchez-Sancho F, 2003, J MOL RECOGNIT, V16, P148, DOI 10.1002/jmr.621; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x; Torres MJ, 2002, CLIN EXP ALLERGY, V32, P270, DOI 10.1046/j.1365-2222.2002.01296.x; Torres MJ, 2001, ALLERGY, V56, P850, DOI 10.1034/j.1398-9995.2001.00089.x	27	158	167	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					404	410		10.1016/j.jaci.2005.10.032	http://dx.doi.org/10.1016/j.jaci.2005.10.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461141	Bronze			2022-12-18	WOS:000235687300022
J	Pitchford, SC; Yano, H; Lever, R; Riffo-Vasquez, Y; Ciferri, S; Rose, MJ; Giannini, S; Momi, S; Spina, D; O'Connor, B; Gresele, P; Page, CP				Pitchford, SC; Yano, H; Lever, R; Riffo-Vasquez, Y; Ciferri, S; Rose, MJ; Giannini, S; Momi, S; Spina, D; O'Connor, B; Gresele, P; Page, CP			Platelets are essential for leukocyte recruitment in allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						platelet; leukocyte; platelet-leukocyte interaction; asthma; allergy; eosinophil; lymphocyte; vascular endothelium; CD11b	P-SELECTIN; FLOW-CYTOMETRY; WHOLE-BLOOD; ASTHMA; ADHESION; ACTIVATION; NEUTROPHILS; CELLS; PAF; AGGREGATION	Background: The role of platelets in inflammation is recognized but poorly characterized, and little is known of their interaction with leukocytes. However, platelet-leukocyte interactions have been demonstrated in cardiovascular disease, culminating in enhanced leukocyte recruitment. Objectives: This study was undertaken to assess the possibility and potential role of similar phenomena occurring in asthmatic patients, a murine model of allergic inflammation, and in vitro adhesion studies. Methods: Asthmatic patients had blood taken at various time points to document the degree of leukocyte activation and the presence of platelet-leukocyte aggregates through FACS analysis before and after allergen exposure. Similar studies were carried out in mice exposed to allergen after previous sensitization, with some groups being selectively depleted of platelets through both an immunologic (antiplatelet antiserum) and nonimmunologic (busulfan) method. Additionally, lavage fluid and airway tissue were analyzed to assess the degree of pulmonary leukocyte recruitment. The importance of platelets on leukocyte adhesion to the endothelium was then assessed with in vitro incubation of radiolabeled leukocytes in the presence of activated platelets on cultured human vascular endothelial cells. Results: We have observed circulating platelet-leukocyte aggregates in the blood of allergic asthmatic patients during the allergen-induced late asthmatic response and in sensitized mice after allergen exposure. In platelet-depleted mice infiltration of leukocytes into airways after allergen challenge was significantly reduced and could be restored by means of infusion of platelets from allergic animals, indicating an essential role for platelets in leukocyte recruitment. CD11b expression on leukocytes involved in aggregates with platelets, although not on free leukocytes, was upregulated. Furthermore, the presence of autologous platelets augmented the adhesion of human polymorphonuclear leukocytes to cultured vascular endothelial cells, an effect that was found to be endothelial cell dependent and to involve platelet activation. Conclusion: These results suggest that platelet participation in cell recruitment occurs at the level of the circulation and might involve the priming of leukocytes for subsequent adhesion and transmigration into tissues.	Kings Coll London, GKT Sch Biomed Sci, Sackler Inst Pulm Pharmacol, London SE1 1UL, England; Univ Perugia, Dept Internal Med, Sect Internal & Cardiovasc Med, I-06100 Perugia, Italy; Kings Coll Hosp London, Dept Resp Med & Allergy, London, England	University of London; King's College London; University of Perugia; King's College Hospital NHS Foundation Trust; King's College Hospital	Page, CP (corresponding author), Kings Coll London, GKT Sch Biomed Sci, Sackler Inst Pulm Pharmacol, 5th Floor,Hodgkin Bldg,Guys Campus, London SE1 1UL, England.		gresele, paolo/AAG-8019-2019; Gresele, Paolo/F-6775-2013	Gresele, Paolo/0000-0001-5365-8445; Spina, Domenico/0000-0002-6815-1564; Page, Clive Peter/0000-0002-9358-3799; Pitchford, Simon/0000-0003-3961-0407				Asman B, 1997, INT J CLIN LAB RES, V27, P185, DOI 10.1007/BF02912455; BARNES PJ, 1992, J INTERN MED, V231, P453, DOI 10.1111/j.1365-2796.1992.tb00960.x; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEER JH, 1995, INT ARCH ALLERGY IMM, V106, P291, DOI 10.1159/000236857; BRECHER G, 1950, J APPL PHYSIOL, V3, P365, DOI 10.1152/jappl.1950.3.6.365; Brown KK, 1998, AM J RESP CELL MOL, V18, P100, DOI 10.1165/ajrcmb.18.1.2314; Cerletti C, 1999, THROMB HAEMOSTASIS, V82, P787; Chihara J, 1997, J ALLERGY CLIN IMMUN, V100, pS52, DOI 10.1016/S0091-6749(97)70005-8; Ciferri S, 2000, THROMB HAEMOSTASIS, V83, P157; COYLE AJ, 1990, AM REV RESPIR DIS, V142, P587, DOI 10.1164/ajrccm/142.3.587; DEBRUIJNEADMIRAAL LG, 1992, BLOOD, V80, P134; Diamant Z, 1996, AM J RESP CRIT CARE, V153, P1790, DOI 10.1164/ajrccm.153.6.8665036; El Gendi H., 1999, European Heart Journal, V20, P530; Freedman JE, 2002, CIRCULATION, V105, P2130, DOI 10.1161/01.CIR.0000017140.26466.F5; GRESELE P, 1982, NEW ENGL J MED, V306, P549; GRESELE P, 1993, J ALLERGY CLIN IMMUN, V91, P894, DOI 10.1016/0091-6749(93)90347-I; Harbinson PL, 1997, EUR RESPIR J, V10, P1008, DOI 10.1183/09031936.97.10051008; Herd C.M., 1995, IMMUNOPHARMACOLOGY P, P1; Jawien J, 2002, POL J PHARMACOL, V54, P157; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KARPATKIN S, 1981, ANN INTERN MED, V95, P636, DOI 10.7326/0003-4819-95-5-636; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; Lauener RW, 1999, BBA-MOL CELL RES, V1452, P197, DOI 10.1016/S0167-4889(99)00125-1; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; Lever R, 2000, BRIT J PHARMACOL, V129, P533, DOI 10.1038/sj.bjp.0703099; Lynam E, 1998, J LEUKOCYTE BIOL, V64, P622, DOI 10.1002/jlb.64.5.622; Merhi Y, 1997, ARTERIOSCL THROM VAS, V17, P1185, DOI 10.1161/01.ATV.17.6.1185; Mickelson JK, 1996, J AM COLL CARDIOL, V28, P345, DOI 10.1016/0735-1097(96)00164-7; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; Neumann FJ, 1999, J AM COLL CARDIOL, V34, P1420, DOI 10.1016/S0735-1097(99)00350-2; Ott I, 1996, CIRCULATION, V94, P1239, DOI 10.1161/01.CIR.94.6.1239; PAGE CP, 2000, PLATELETS, P531; PAGE CP, 1993, ALLERGY; Panes J, 1999, BRIT J PHARMACOL, V126, P537, DOI 10.1038/sj.bjp.0702328; Peters MJ, 1997, J IMMUNOL METHODS, V209, P125, DOI 10.1016/S0022-1759(97)00139-7; Powell CC, 1999, J VASC SURG, V30, P844, DOI 10.1016/S0741-5214(99)70009-1; RINDER HM, 1991, BLOOD, V78, P1730; RINDER HM, 1991, BLOOD, V78, P1760; Salter JW, 2001, AM J PHYSIOL-GASTR L, V281, pG1432, DOI 10.1152/ajpgi.2001.281.6.G1432; SCHNEIDER MD, 1974, SCAND J HAEMATOL, V12, P185; SIMON HU, 1994, PEDIATR PULM, V17, P304, DOI 10.1002/ppul.1950170507; Sullivan PJ, 2000, RESPIRATION, V67, P514, DOI 10.1159/000067466; TSICOPOULOS A, 1988, INT J IMMUNOPHARMACO, V10, P227, DOI 10.1016/0192-0561(88)90053-7; WALKER C, 1991, INT ARCH ALLER A IMM, V94, P241, DOI 10.1159/000235370; YAMAMOTO H, 1993, J ALLERGY CLIN IMMUN, V91, P79, DOI 10.1016/0091-6749(93)90299-U; YARON M, 1978, ARTHRITIS RHEUM, V21, P607, DOI 10.1002/art.1780210509	46	158	160	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					109	118		10.1067/mai.2003.1514	http://dx.doi.org/10.1067/mai.2003.1514			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847487				2022-12-18	WOS:000184010600018
J	Hauk, PJ; Hamid, QA; Chrousos, GP; Leung, DYM				Hauk, PJ; Hamid, QA; Chrousos, GP; Leung, DYM			Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						superantigens; dexamethasone; glucocorticoid resistance; glucocorticoid receptor beta; inflammation; human PBMCs	GLUCOCORTICOID RECEPTOR-BETA; STEROID-RESISTANT ASTHMA; INTRAVENOUS IMMUNOGLOBULIN; T-CELLS; EXPRESSION; ACTIVATION; DISEASE; PSORIASIS; ISOFORM	Background: Microbial superantigens have been described to contribute to the pathogenesis of chronic inflammatory diseases often complicated by insensitivity to glucocorticoid therapy. In bronchial asthma glucocorticoid insensitivity has been associated with increased expression of glucocorticoid receptor beta, an endogenous inhibitor of the classic glucocorticoid receptor beta. Objective: To study a potential mechanism by which superantigens could contribute to poor disease control, we examined their capacity to alter steroid sensitivity and expression of glucocorticoid receptor beta. Methods: The capacity of dexamethasone to inhibit stimulation of PBMCs from 7 healthy subjects with the prototypic superantigens, staphylococcal enterotoxin (SE) beta, toxic shock syndrome toxin (TSST)-1 and SEE, versus PHA, was tested. The expression of glucocorticoid receptor beta in normal PBMCs after stimulation with SEE, versus PHA, was assessed by immunocytochemistry. Results: Dexamethasone 10(-6) mol/L caused a 99% inhibition of PNA-induced PBMC proliferation but only a 19% inhibition of the SEE-induced, 26% inhibition of the TSST-1, and 29% inhibition of the SEE-induced PBMC proliferation (P < .01 for all superantigens versus PHA) demonstrating that superantigens can induce steroid insensitivity. Stimulation of normal PBMCs with SEE induced a significant increase of glucocorticoid receptor (beta compared with PHA and unstimulated cells (P < .01). Conclusion: We have demonstrated the capacity of microbial superantigens to induce glucocorticoid insensitivity, which should be considered in the diagnosis and treatment of patients with superantigen-triggered diseases. These data suggest that superantigens may contribute to glucocorticoid insensitivity through induction of glucocorticoid receptor beta.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA; McGill Univ, Dept Pathol, Montreal, PQ, Canada; NICHHD, NIH, Dev Endocrinol Branch, Bethesda, MD 20892 USA; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); McGill University	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Room K926,1400 Jackson St, Denver, CO 80206 USA.				NHLBI NIH HHS [HL37260, HL36577] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000618] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000618] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R37HL037260, P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE J, 1993, J EXP MED, V177, P791, DOI 10.1084/jem.177.3.791; ABECK D, 1991, HDB ATOPIC ECZEMA, P212; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; Corrigan CJ, 1996, EUR RESPIR J, V9, P2077, DOI 10.1183/09031936.96.09102077; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026, DOI 10.1164/ajrccm/144.5.page; deCastro M, 1996, MOL MED, V2, P597, DOI 10.1007/BF03401643; Ezepchuk YV, 1996, J INVEST DERMATOL, V107, P603, DOI 10.1111/1523-1747.ep12583377; HAMID Q, 1992, BLOOD, V80, P1496; Hauk PJ, 1999, J ALLERGY CLIN IMMUN, V104, P37, DOI 10.1016/S0091-6749(99)70111-9; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KRAFT M, 1991, AM RESP J CRIT CARE, V155, pA65; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; LEUNG DYM, 1995, J CLIN INVEST, V96, P2106, DOI 10.1172/JCI118263; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; Neuber K, 1996, ACTA DERM-VENEREOL, V76, P214; Nimmagadda SR, 1997, AM J RESP CRIT CARE, V155, P87, DOI 10.1164/ajrccm.155.1.9001294; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; Oakley RH, 1999, J BIOL CHEM, V274, P27857, DOI 10.1074/jbc.274.39.27857; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; Spahn JD, 1996, J ALLERGY CLIN IMMUN, V98, P1073, DOI 10.1016/S0091-6749(96)80194-1; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; VALDIMARSSON H, 1995, IMMUNOL TODAY, V16, P145, DOI 10.1016/0167-5699(95)80132-4; WACHS GN, 1976, BRIT J DERMATOL, V95, P323, DOI 10.1111/j.1365-2133.1976.tb07021.x	26	158	172	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					782	787		10.1067/mai.2000.105807	http://dx.doi.org/10.1067/mai.2000.105807			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756230	Bronze			2022-12-18	WOS:000086604100018
J	Elberink, JNGO; deMonchy, JGR; Kors, JW; vanDoormaal, JJ; Dubois, AEJ				Elberink, JNGO; deMonchy, JGR; Kors, JW; vanDoormaal, JJ; Dubois, AEJ			Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HYMENOPTERA		UNIV GRONINGEN HOSP,DEPT ALLERGOL,NL-9713 EZ GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT ENDOCRINOL,NL-9700 RB GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen								CHARPIN D, 1994, CLIN EXP ALLERGY, V24, P1010, DOI 10.1111/j.1365-2222.1994.tb02736.x; ENGLER RJM, 1994, J ALLERGY CLIN IMMUN, V94, P556, DOI 10.1016/0091-6749(94)90213-5; KEYZER JJ, 1983, NEW ENGL J MED, V309, P1603, DOI 10.1056/NEJM198312293092603; KORS JW, 1993, J INTERN MED, V233, P255, DOI 10.1111/j.1365-2796.1993.tb00984.x; MULLER U, 1991, CLIN EXP ALLERGY, V21, P281, DOI 10.1111/j.1365-2222.1991.tb01659.x; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001	6	158	160	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				153	154						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003225				2022-12-18	WOS:A1997WD06100022
J	MAK, H; JOHNSTON, P; ABBEY, H; TALAMO, RC				MAK, H; JOHNSTON, P; ABBEY, H; TALAMO, RC			PREVALENCE OF ASTHMA AND HEALTH-SERVICE UTILIZATION OF ASTHMATIC-CHILDREN IN AN INNER-CITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS MED INST,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT BIOSTAT,BALTIMORE,MD 21205; AMER LUNG ASSOC MARYLAND,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NIAID NIH HHS [AI 07007] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARBEITER HI, 1967, CLIN PEDIATR, V6, P140, DOI 10.1177/000992286700600307; BRODER I, 1962, J ALLERGY, V33, P513, DOI 10.1016/0021-8707(62)90019-9; FELDSTEIN MS, 1966, J R STAT SOC SER A-G, V129, P61, DOI 10.2307/2343897; FRANDSEN S, 1958, Acta Allergol, V12, P341, DOI 10.1111/j.1398-9995.1958.tb03090.x; FREEMAN GL, 1964, AM J DIS CHILD, V107, P549, DOI 10.1001/archpedi.1964.02080060551001; German P S, 1976, J Community Health, V2, P92, DOI 10.1007/BF01319087; HILL AE, 1966, J SCHOOL HEALTH, V36, P353, DOI 10.1111/j.1746-1561.1966.tb05591.x; KARETZKY MS, 1977, J ALLERGY CLIN IMMUN, V60, P383, DOI 10.1016/0091-6749(77)90070-7; KRAEPELIEN S, 1954, Acta Paediatr Suppl, V43, P149, DOI 10.1111/j.1651-2227.1954.tb15464.x; MILNE G A, 1969, New Zealand Medical Journal, V70, P27; NATHANSON CA, 1970, SOC SCI MED, V4, P293, DOI 10.1016/0037-7856(70)90002-8; PARCEL GS, 1979, PEDIATRICS, V64, P878; RHYNE MB, 1971, DETERMINATION PREVAL; SCHIFFER CG, 1970, US PHS PUBLICATION, V2074; SHERRY MN, 1968, ANN ALLERGY, V26, P335; SMITH JM, 1961, BRIT MED J, V1, P711, DOI 10.1136/bmj.1.5227.711; STARFIELD B, 1974, MILBANK FUND Q, V52, P39, DOI 10.2307/3349502; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; 1979, DHEW NIH79387 PUBL H; DIRECTORY SCH 1978 1; 1970, SOCIO EC TENTHS AGE	21	158	158	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					367	372		10.1016/0091-6749(82)90026-4	http://dx.doi.org/10.1016/0091-6749(82)90026-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	PQ105	7130552				2022-12-18	WOS:A1982PQ10500008
J	Kolkhir, P; Church, MK; Weller, K; Metz, M; Schmetzer, O; Maurer, M				Kolkhir, Pavel; Church, Martin K.; Weller, Karsten; Metz, Martin; Schmetzer, Oliver; Maurer, Marcus			Autoimmune chronic spontaneous urticaria: What we know and what we do not know	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic spontaneous urticaria; autoimmunity; IgE-anti-self; IgG-anti-Fc epsilon RI/IgE; causality; Hill's criteria of causality	CHRONIC IDIOPATHIC URTICARIA; SERUM SKIN-TEST; FC-EPSILON-RI; ANTI-IGE AUTOANTIBODIES; AUTOLOGOUS SERUM; HISTAMINE-RELEASE; ANTITHYROID ANTIBODIES; CLINICAL-FEATURES; BASOPHIL NUMBERS; IMMUNOGLOBULIN-E	Chronic spontaneous urticaria (CSU) is a mast cell-driven skin disease characterized by the recurrence of transient wheals, angioedema, or both for more than 6 weeks. Autoimmunity is thought to be one of the most frequent causes of CSU. Type I and II autoimmunity (ie, IgE to autoallergens and IgG autoantibodies to IgE or its receptor, respectively) have been implicated in the etiology and pathogenesis of CSU. We analyzed the relevant literature and assessed the existing evidence in support of a role for type I and II autoimmunity inCSUwith the help of Hill's criteria of causality. For each of these criteria (ie, strength of association, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, and analogy), we categorized the strength of evidence as "insufficient," "low," "moderate," or "high" and then assigned levels of causality for type I and II autoimmunity in patients with CSU from level 1 (causal relationship) to level 5 (causality not likely). Based on the evidence in support of Hill's criteria, type I autoimmunity in patients with CSU has level 3 causality (causal relationship suggested), and type II autoimmunity has level 2 causality (causal relationship likely). There are still many aspects of the pathologic mechanisms of CSU that need to be resolved, but it is becoming clear that there are at least 2 distinct pathways, type I and type II autoimmunity, that contribute to the pathogenesis of this complex disease.	[Kolkhir, Pavel] LM Sechenov First Moscow State Med Univ, Dept Dermatol & Venereol, Moscow, Russia; [Kolkhir, Pavel; Church, Martin K.; Weller, Karsten; Metz, Martin; Schmetzer, Oliver; Maurer, Marcus] Charite, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany	Sechenov First Moscow State Medical University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Maurer, M (corresponding author), Charite, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Kolkhir, Pavel V/K-7625-2012; Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020; Kolkhir, Pavel/J-1704-2019	Kolkhir, Pavel V/0000-0001-5380-8132; Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Kolkhir, Pavel/0000-0001-5380-8132; Weller, Karsten/0000-0003-4437-0313; Schmetzer, Oliver/0000-0002-9956-2091	German Academic Exchange Service; European Academy of Allergy and Clinical Immunology; FAES Pharma; Almirall; Menarini; MSD; Novartis; UCB Pharma; Sanofi-Aventis; Uriach; UCB; Moxie; Bayer; Genentech	German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); European Academy of Allergy and Clinical Immunology; FAES Pharma; Almirall(Almirall); Menarini(Menarini Group); MSD; Novartis(Novartis); UCB Pharma(UCB Pharma SA); Sanofi-Aventis(Sanofi-Aventis); Uriach; UCB(UCB Pharma SA); Moxie; Bayer(Bayer AG); Genentech(Roche HoldingGenentech)	P. Kolkhir has received grants from German Academic Exchange Service and European Academy of Allergy and Clinical Immunology. M. K. Church has received consultancy fees and payment for manuscript preparation from FAES Pharma and payment for lectures from Almirall, FAES Pharma, Menarini, MSD, Novartis, UCB Pharma, Sanofi-Aventis, and Uriach. K. Weller has received consultancy fees from Novartis and payment for lectures from Dr. R. Pfleger, Essex pharma (now MSD), Uriach, UCB, and Moxie. M. Metz has received consultancy fees from Bayer and payment for lectures from Novartis. M. Maurer has received board membership, consultancy fees, expert testimony, payment for lectures, payment for development of educational presentations, and travel expenses from Novartis and Genentech, and his institution has received a grant from Uriach. O. Schmetzer declares that he has no relevant conflicts of interest.	Aktar S, 2015, POSTEP DERM ALERGOL, V32, P173, DOI 10.5114/pdia.2015.48057; Altrichter S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014794; Atta AM, 2004, BRAZ J MED BIOL RES, V37, P13, DOI 10.1590/S0100-879X2004000100002; Atwa MA, 2014, J EUR ACAD DERMATOL, V28, P469, DOI 10.1111/jdv.12124; Bar-Sela S, 1999, J ALLERGY CLIN IMMUN, V103, P1216, DOI 10.1016/S0091-6749(99)70204-6; Calamita Z, 2012, AN BRAS DERMATOL, V87, P578, DOI 10.1590/S0365-05962012000400010; Caproni M, 2004, ACTA DERM-VENEREOL, V84, P288, DOI 10.1080/00015550410026939; Chakravarty SD, 2011, J ALLERGY CLIN IMMUN, V128, P1354, DOI 10.1016/j.jaci.2011.08.023; Chang TW, 2015, J ALLERGY CLIN IMMUN, V135, P337, DOI 10.1016/j.jaci.2014.04.036; Cho CB, 2013, ANN ALLERG ASTHMA IM, V110, P29, DOI 10.1016/j.anai.2012.10.020; CIRILLO R, 1990, J IMMUNOL, V144, P3891; Concha LB, 2004, ALLERGY ASTHMA PROC, V25, P293; Confino-Cohen R, 2012, J ALLERGY CLIN IMMUN, V129, P1307, DOI 10.1016/j.jaci.2012.01.043; Deacock SJ, 2008, CLIN EXP IMMUNOL, V153, P151, DOI 10.1111/j.1365-2249.2008.03693.x; Dema B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090424; Di Gioacchino M, 2003, ALLERGY ASTHMA PROC, V24, P285; Dimson OG, 2003, J INVEST DERMATOL, V120, P784, DOI 10.1046/j.1523-1747.2003.12146.x; Eckman JA, 2008, J INVEST DERMATOL, V128, P1956, DOI 10.1038/jid.2008.55; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; Fairley JA, 2007, J INVEST DERMATOL, V127, P2605, DOI 10.1038/sj.jid.5700958; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; Fusari A, 2005, ALLERGY, V60, P256, DOI 10.1111/j.1398-9995.2005.00673.x; Gell PGH, 1968, CLIN ASPECTS IMMUNOL, VSecond, P580; Gimenez-Arnau AM, 2004, ACTAS DERMO-SIFILOGR, V95, P560; Grattan C, 1999, ADV DERMATOLOGY, P311; Grattan CE, 1996, THESIS U CAMBRIDGE; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; Grattan CEH, 1997, CLIN EXP ALLERGY, V27, P1417, DOI 10.1111/j.1365-2222.1997.tb02986.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Grattan CEH, 2003, CLIN EXP ALLERGY, V33, P337, DOI 10.1046/j.1365-2222.2003.01589.x; GRATTAN CEH, 1989, BRIT J DERMATOL, V120, P853, DOI 10.1111/j.1365-2133.1989.tb01387.x; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; Guo J, 1997, CLIN IMMUNOL IMMUNOP, V82, P157, DOI 10.1006/clin.1996.4297; Hatada Y, 2013, INT ARCH ALLERGY IMM, V161, P154, DOI 10.1159/000350388; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Hidvegi B, 2003, INT ARCH ALLERGY IMM, V132, P177, DOI 10.1159/000073719; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hofler M, 2005, EMERG THEMES EPIDEMI, V2, DOI 10.1186/1742-7622-2-11; Hu ZD, 2014, CLIN CHIM ACTA, V437, P14, DOI 10.1016/j.cca.2014.06.015; Kadooka Y, 2000, INT ARCH ALLERGY IMM, V122, P264, DOI 10.1159/000024408; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Kessel A, 2010, INT ARCH ALLERGY IMM, V153, P288, DOI 10.1159/000314370; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2003, J ALLERGY CLIN IMMUN, V112, P218, DOI 10.1067/mai.2003.1605; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; KOJIMA M, 1986, ARCH DERMATOL, V122, P550, DOI 10.1001/archderm.122.5.550; Konstantinou GN, 2013, ALLERGY, V68, P27, DOI 10.1111/all.12056; Kulthanan K, 2007, J DERMATOL, V34, P294, DOI 10.1111/j.1346-8138.2007.00276.x; Kulthanan K, 2006, ASIAN PAC J ALLERGY, V24, P201; Kurt E, 2011, ARCH DERMATOL RES, V303, P643, DOI 10.1007/s00403-011-1144-x; Lee MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109565; Mari A, 2004, INT ARCH ALLERGY IMM, V133, P29, DOI 10.1159/000075251; Marsland AM, 2005, CLIN EXP ALLERGY, V35, P554, DOI 10.1111/j.1365-2222.2005.02242.x; Maurer M, 2011, J ALLERGY CLIN IMMUN, V128, P202, DOI 10.1016/j.jaci.2011.04.038; Metz M, 2014, J INVEST DERMATOL, V134, pS30; Metz M, 2014, J DERMATOL SCI, V73, P57, DOI 10.1016/j.jdermsci.2013.08.011; Mozena JD, 2010, J INVEST DERMATOL, V130, P1860, DOI 10.1038/jid.2010.35; MURPHY GM, 1987, BRIT J DERMATOL, V116, P801, DOI 10.1111/j.1365-2133.1987.tb04898.x; Nettis E, 2002, CLIN EXP DERMATOL, V27, P29, DOI 10.1046/j.0307-6938.2001.00962.x; Neverman L, 2014, J ALLER CL IMM-PRACT, V2, P434, DOI 10.1016/j.jaip.2014.04.011; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; O'Donnell BF, 1998, BRIT J DERMATOL, V138, P101; O'Donnell BF, 1999, BRIT J DERMATOL, V140, P853, DOI 10.1046/j.1365-2133.1999.02815.x; Owens DK, 2008, METHODS GUIDE EFFECT; Pachlopnik JM, 2004, J AUTOIMMUN, V22, P43, DOI 10.1016/j.jaut.2003.09.007; Perez A, 2010, BRIT J DERMATOL, V162, P191, DOI 10.1111/j.1365-2133.2009.09538.x; PERMIN H, 1978, ACTA PATH MICRO IM C, V86, P245; Phalen RF, 2013, INTRO AIR POLLUTION; Prausnitz C., 1921, CENT BAKTERIO, V86, P160; Puccetti A, 2005, CLIN EXP ALLERGY, V35, P1599, DOI 10.1111/j.1365-2222.2005.02380.x; Rajka E., 1942, JOUR ALLERGY, V13, P327, DOI 10.1016/S0021-8707(42)90290-9; RORSMAN H, 1962, ACTA ALLERGOL, V17, P168, DOI 10.1111/j.1398-9995.1962.tb02937.x; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; Sabroe RA, 2002, J ALLERGY CLIN IMMUN, V110, P492, DOI 10.1067/mai.2002.126782; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; Sabroe RA, 1999, J AM ACAD DERMATOL, V40, P443, DOI 10.1016/S0190-9622(99)70495-0; Sanjuan MA, 2016, J ALLERGY CLIN IMMUN, V137, P1651, DOI 10.1016/j.jaci.2016.04.007; Schunemann H, 2011, J EPIDEMIOL COMMUN H, V65, P392, DOI 10.1136/jech.2010.119933; Shin YS, 2015, J KOREAN MED SCI, V30, P705, DOI 10.3346/jkms.2015.30.6.705; Shindo H, 2012, ARCH DERMATOL RES, V304, P647, DOI 10.1007/s00403-012-1236-2; Soundararajan S, 2005, J ALLERGY CLIN IMMUN, V115, P815, DOI 10.1016/j.jaci.2004.12.1120; Staubach P, 2006, DERMATOLOGY, V212, P150, DOI 10.1159/000090656; Sun LW, 2014, ANN DERMATOL, V26, P145, DOI 10.5021/ad.2014.26.2.145; Sun RS, 2011, AUSTRALAS J DERMATOL, V52, pE15, DOI 10.1111/j.1440-0960.2010.00658.x; Tedeschi A, 2001, J ALLERGY CLIN IMMUN, V108, P467; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Toubi E, 2004, ALLERGY, V59, P869, DOI 10.1111/j.1398-9995.2004.00473.x; Vasagar K, 2006, CLIN EXP ALLERGY, V36, P770, DOI 10.1111/j.1365-2222.2006.02494.x; Vonakis BM, 2007, J ALLERGY CLIN IMMUN, V119, P441, DOI 10.1016/j.jaci.2006.09.035; Yasnowsky KM, 2006, J ALLERGY CLIN IMMUN, V117, P1430, DOI 10.1016/j.jaci.2006.02.016; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, P694, DOI 10.1067/mai.2002.123236; Zimmerman AB, 2012, J AM ACAD DERMATOL, V66, P767, DOI 10.1016/j.jaad.2011.06.004; Zuberbier T, 2000, ALLERGY, V55, P951, DOI 10.1034/j.1398-9995.2000.00445.x; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	100	157	174	1	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1772	+		10.1016/j.jaci.2016.08.050	http://dx.doi.org/10.1016/j.jaci.2016.08.050			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27777182	Bronze			2022-12-18	WOS:000402724600005
J	Mullins, RJ; James, H; Platts-Mills, TAE; Commins, S				Mullins, Raymond James; James, Hayley; Platts-Mills, Thomas A. E.; Commins, Scott			Relationship between red meat allergy and sensitization to gelatin and galactose-alpha-1,3-galactose	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; anaphylaxis; red meat; alpha-galactose; gelatin; colloid	IGE ANTIBODIES; FOOD ALLERGY; ANAPHYLACTOID REACTIONS; IMMUNOGLOBULIN-E; RUBELLA VACCINE; RISK-FACTORS; CHILDREN; REACTIVITY; RELEVANCE; CETUXIMAB	Background: We have observed patients clinically allergic to red meat and meat-derived gelatin. Objective: We describe a prospective evaluation of the clinical significance of gelatin sensitization, the predictive value of a positive test result, and an examination of the relationship between allergic reactions to red meat and sensitization to gelatin and galactose-alpha-1,3-galactose (alpha-Gal). Methods: Adult patients evaluated in the 1997-2011 period for suspected allergy/anaphylaxis to medication, insect venom, or food were skin tested with gelatin colloid. In vitro (ImmunoCAP) testing was undertaken where possible. Results: Positive gelatin test results were observed in 40 of 1335 subjects: 30 of 40 patients with red meat allergy (12 also clinically allergic to gelatin), 2 of 2 patients with gelatin colloid-induced anaphylaxis, 4 of 172 patients with idiopathic anaphylaxis (all responded to intravenous gelatin challenge of 0.02-0.4 g), and 4 of 368 patients with drug allergy. Test results were negative in all patients with venom allergy (n = 241), nonmeat food allergy (n = 222), and miscellaneous disorders (n = 290). ImmunoCAP results were positive to a-Gal in 20 of 24 patients with meat allergy and in 20 of 22 patients with positive gelatin skin test results. The results of gelatin skin testing and anti-alpha-Gal IgE measurements were strongly correlated (r = 0.46, P < .01). alpha-Gal was detected in bovine gelatin colloids at concentrations of approximately 0.44 to 0.52 mu g/g gelatin by means of inhibition RIA. Conclusion: Most patients allergic to red meat were sensitized to gelatin, and a subset was clinically allergic to both. The detection of a-Gal in gelatin and correlation between the results of a-Gal and gelatin testing raise the possibility that a-Gal IgE might be the target of reactivity to gelatin. The pathogenic relationship between tick bites and sensitization to red meat, alpha-Gal, and gelatin (with or without clinical reactivity) remains uncertain. (J Allergy Clin Immunol 2012;129:1334-42.)	[Mullins, Raymond James] John James Med Ctr, Deakin, ACT 2600, Australia; [Mullins, Raymond James] Australian Natl Univ, Sch Med, Canberra, ACT, Australia; [Mullins, Raymond James] Univ Canberra, Fac Hlth, Canberra, ACT 2601, Australia; [James, Hayley; Platts-Mills, Thomas A. E.; Commins, Scott] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Australian National University; University of Canberra; University of Virginia	Mullins, RJ (corresponding author), John James Med Ctr, Suite 1,175 Strickland Crescent, Deakin, ACT 2600, Australia.	rmullins@allergycapital.com.au	Mullins, Raymond James/H-8013-2019	Mullins, Raymond James/0000-0002-0267-1591; Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health [RO1 AI-20565, K08 AI085190, R21 AI087985]; Phadia/Thermo-Fisher; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI087985, K08AI085190, R01AI020565] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Phadia/Thermo-Fisher; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by National Institutes of Health grants RO1 AI-20565, K08 AI085190, and R21 AI087985.; Disclosure of potential conflict of interest: T. A. E. Platts-Mills is a consultant for IBT/Viracor and has received honoraria and research support from Phadia/Thermo-Fisher. S. Commins is on the Cornerstone Therapeutics speakers' bureau and has received research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Australian Bureau of Statistics, 1997, APP CONS SEL FOODST; Benito RP, 2002, ALLERGY, V57, P858, DOI 10.1034/j.1398-9995.2002.23575_1.x; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Bogdanovic J, 2009, J ALLERGY CLIN IMMUN, V124, P1108, DOI 10.1016/j.jaci.2009.06.021; Bourne HC, 2005, ALLERGY, V60, P706, DOI 10.1111/j.1398-9995.2005.00760.x; Boyle RJ, 2007, ALLERGY, V62, P209, DOI 10.1111/j.1398-9995.2006.01274.x; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Cahen YD, 1998, CLIN EXP ALLERGY, V28, P1026, DOI 10.1046/j.1365-2222.1998.00356.x; Choi GS, 2010, ALLERGY, V65, P1065, DOI 10.1111/j.1398-9995.2009.02293.x; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Ensminger AH, 1983, FOOD NUTR ENCY; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; HAENEY MR, 1992, BRIT MED J, V305, P870, DOI 10.1136/bmj.305.6858.870-c; Jacquenet S, 2009, J ALLERGY CLIN IMMUN, V124, P603, DOI 10.1016/j.jaci.2009.06.014; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; Konturek PC, 2011, J PHYSIOL PHARMACOL, V62, P139; LAXENAIRE MC, 1994, ANN FR ANESTH, V13, P301, DOI 10.1016/S0750-7658(94)80038-3; LORENZ W, 1976, BRIT J ANAESTH, V48, P151, DOI 10.1093/bja/48.2.151; Moore LM, 2007, ANN ALLERG ASTHMA IM, V98, P92, DOI 10.1016/S1081-1206(10)60866-6; Mullins RJ, 1996, AUST NZ J OPHTHALMOL, V24, P257, DOI 10.1111/j.1442-9071.1996.tb01589.x; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x; Nakayama T, 2000, J ALLERGY CLIN IMMUN, V106, P591, DOI 10.1067/mai.2000.108433; Orhan F, 2003, ALLERGY, V58, P127, DOI 10.1034/j.1398-9995.2003.00021.x; Pasche-Koo F, 1996, Am J Contact Dermat, V7, P56, DOI 10.1016/S1046-199X(96)90035-4; Peters RL, 2011, PEDIAT ALLERGY IMMUN; Pointreau Y, 2012, J CLIN ONCOL, V30, P334, DOI 10.1200/JCO.2011.38.4701; Pool V, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e71; Qian J, 2007, ANAL BIOCHEM, V364, P8, DOI 10.1016/j.ab.2007.01.023; Restani P, 2009, CURR OPIN ALLERGY CL, V9, P265, DOI 10.1097/ACI.0b013e32832aef3d; Sabbah A, 1994, Allerg Immunol (Paris), V26, P173; Sakaguchi M, 1999, J ALLERGY CLIN IMMUN, V104, P695, DOI 10.1016/S0091-6749(99)70344-1; Sakaguchi M, 1999, IMMUNOLOGY, V96, P286, DOI 10.1046/j.1365-2567.1999.00696.x; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Sakaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P1033, DOI 10.1067/mai.2001.119412; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Theler B, 2009, SWISS MED WKLY, V139, P264, DOI smw-12603; Van Nunen S, 2011, INTERN MED J S4, V41, P70; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; Wahr R, 1989, CLIN EXP ALLERGY, V19, P77; Wang J, 2005, ANN ALLERG ASTHMA IM, V94, P530, DOI 10.1016/S1081-1206(10)61128-3; Werfel SJ, 1997, J ALLERGY CLIN IMMUN, V99, P293, DOI 10.1016/S0091-6749(97)70045-9; Wuthrich B, 1996, ALLERGY, V51, P49	46	157	160	2	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1334	U217		10.1016/j.jaci.2012.02.038	http://dx.doi.org/10.1016/j.jaci.2012.02.038			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22480538	Green Accepted			2022-12-18	WOS:000303418000024
J	Hansel, A; Gunther, C; Ingwersen, J; Starke, J; Schmitz, M; Bachmann, M; Meurer, M; Rieber, EP; Schakel, K				Haensel, Anja; Guenther, Claudia; Ingwersen, Jens; Starke, Josephine; Schmitz, Marc; Bachmann, Michael; Meurer, Michael; Rieber, Ernst Peter; Schaekel, Knut			Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong T(H)17/T(H)1 T-cell responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; T cells; T(H)17; slanDC; psoriasis; immunology; chronic inflammation	TH17 CELLS; EPIDERMAL HYPERPLASIA; ANTIMICROBIAL PEPTIDE; INDUCTION; SKIN; TNF; PATHOGENESIS; FRACTALKINE; MECHANISMS; POPULATION	Background: Psoriasis is a chronic inflammatory skin disease that is considered to result from activated T cells stimulated by a population of inflammatory dermal dendritic cells (DCs). The origin and identity of these inflammatory dermal DCs are largely unknown. Objective: We previously identified slanDCs (6-sulfo LacNAc) DCs as a rich source of TNF-alpha and as the early major source of IL-12. Here we studied the relevance of slanDCs as inflammatory dermal DCs in psoriasis. Methods: Psoriasis skin samples were stained for the presence of activated slanDCs. Functional studies were carried out to determine the cytokine production of slanDCs, their T(H)17/T(H)1 T-cell programming, and their migration behavior. Results: Large numbers of IL-23, TNF-alpha, and inducible nitric oxide synthase expressing slanDCs were found in psoriatic skin samples, which can be recruited by C5a, CX3CL1, and CXCL12. SlanDCs isolated from blood produced high levels of IL-1 beta, IL-23, IL-12, and IL-6. Compared with classic CD1c(+) DCs, slanDCs were far more powerful in programming T(H)17/T(H)1 T cells that secrete IL-17, IL-22, TNF-alpha, and IFN-gamma, yet CD1c(+) DCs induced ahigher IL-10 production of T cells. Self-nucleic acids complexed to cathelicidin LL37 trigger endosomal Toll-like receptor (TLR) signaling (TLR7, TLR8, TLR9) and are key factors for the activation of DCs in psoriasis. We show that slanDCs respond particularly well to complexes formed of self-RNA and LL37. Similarly, slanDCs stimulated with a synthetic TLR7/8 ligand produced high levels of proinflammatory cytokines. Conclusion: Our study defines slanDCs as inflammatory dermal DCs in psoriasis and identifies their strong capacity to induce T(H)17/T(H)1 responses. (J Allergy Clin Immunol 2011;127:787-94.)	[Haensel, Anja; Schaekel, Knut] Univ Hosp, Dept Dermatol, D-69120 Heidelberg, Germany; [Guenther, Claudia; Starke, Josephine; Meurer, Michael; Schaekel, Knut] Univ Hosp, Dept Dermatol, Dresden, Germany; [Haensel, Anja; Ingwersen, Jens; Schmitz, Marc; Bachmann, Michael; Rieber, Ernst Peter; Schaekel, Knut] Tech Univ Dresden, Fac Med, Inst Immunol, Dresden, Germany; [Schmitz, Marc; Bachmann, Michael; Schaekel, Knut] Tech Univ Dresden, Ctr Regenerat Therapies Dresden, Dresden, Germany	Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Technische Universitat Dresden	Schakel, K (corresponding author), Univ Hosp, Dept Dermatol, Vossstr 2, D-69120 Heidelberg, Germany.	knut.schaekel@med.uni-heidelberg.de	Bachmann, Michael/AAA-5153-2020; Günther, Claudia/AGG-8982-2022; Bachmann, Michael P/E-8850-2010	Bachmann, Michael/0000-0002-8029-5755; Bachmann, Michael P/0000-0002-8029-5755	Technical University of Dresden; Jurgen Manchot Foundation; Center for Regenerative Therapies Dresden	Technical University of Dresden; Jurgen Manchot Foundation; Center for Regenerative Therapies Dresden	Supported by the MEDDRIVE program of the Medical Faculty of the Technical University of Dresden to C.G. and a grant of the Jurgen Manchot Foundation to K.S. A.H. received a scholarship from the Center for Regenerative Therapies Dresden.	Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Baumeister SHC, 2007, BLOOD, V110, P3078, DOI 10.1182/blood-2006-12-062984; Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; DeVries ME, 2003, J BIOL CHEM, V278, P11985, DOI 10.1074/jbc.M211422200; Dhodapkar KM, 2008, BLOOD, V112, P2878, DOI 10.1182/blood-2008-03-143222; Evans BJ, 2006, BLOOD, V107, P3593, DOI 10.1182/blood-2005-09-3695; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Ganguly D, 2009, J EXP MED, V206, P1983, DOI 10.1084/jem.20090480; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Gombert M, 2005, J IMMUNOL, V174, P5082, DOI 10.4049/jimmunol.174.8.5082; Hamann D, 1996, BLOOD, V88, P3513, DOI 10.1182/blood.V88.9.3513.bloodjournal8893513; Jones J, 2007, J CELL MOL MED, V11, P826, DOI 10.1111/j.1582-4934.2007.00071.x; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Kabashima K, 2007, AM J PATHOL, V171, P1249, DOI 10.2353/ajpath.2007.070225; Kopp T, 2001, J INVEST DERMATOL, V117, P618, DOI 10.1046/j.1523-1747.2001.01441.x; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; Kryczek I, 2008, J IMMUNOL, V181, P4733, DOI 10.4049/jimmunol.181.7.4733; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Martin-Orozco N, 2009, EUR J IMMUNOL, V39, P216, DOI 10.1002/eji.200838475; Mrowietz U, 2001, EXP DERMATOL, V10, P238, DOI 10.1034/j.1600-0625.2001.100403.x; Plant D, 2006, EXP DERMATOL, V15, P900, DOI 10.1111/j.1600-0625.2006.00486.x; Randolph GJ, 2002, J EXP MED, V196, P517, DOI 10.1084/jem.20011608; Raychaudhuri SP, 2001, BRIT J DERMATOL, V144, P1105, DOI 10.1046/j.1365-2133.2001.04219.x; Schakel K, 2009, EXP DERMATOL, V18, P264, DOI 10.1111/j.1600-0625.2008.00823.x; Schakel K, 2006, IMMUNITY, V24, P767, DOI 10.1016/j.immuni.2006.03.020; Schakel K, 1998, EUR J IMMUNOL, V28, P4084, DOI 10.1002/(SICI)1521-4141(199812)28:12<4084::AID-IMMU4084>3.0.CO;2-4; Schakel K, 2002, IMMUNITY, V17, P289, DOI 10.1016/S1074-7613(02)00393-X; Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zaba LC, 2009, J INVEST DERMATOL, V129, P302, DOI 10.1038/jid.2008.225; Zhou XH, 2003, PHYSIOL GENOMICS, V13, P69, DOI 10.1152/physiolgenomics.00157.2002	39	157	166	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					787	U456		10.1016/j.jaci.2010.12.009	http://dx.doi.org/10.1016/j.jaci.2010.12.009			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21377044				2022-12-18	WOS:000288018400034
J	Kaminska, M; Foley, S; Maghni, K; Storness-Bliss, C; Coxson, H; Ghezzo, H; Lemiere, C; Olivenstein, R; Ernst, P; Hamid, Q; Martin, J				Kaminska, Marta; Foley, Susan; Maghni, Karim; Storness-Bliss, Claudine; Coxson, Harvey; Ghezzo, Heberto; Lemiere, Catherine; Olivenstein, Ronald; Ernst, Pierre; Hamid, Qutayba; Martin, James			Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; remodeling; airway smooth muscle; fibrosis; reticular basement membrane; inflammation; cytokines; high-resolution computed tomographic scan; biopsy; sputum	MUSCLE-CELL PROLIFERATION; SMOOTH-MUSCLE; WALL THICKNESS; ORMDL3 EXPRESSION; BASEMENT-MEMBRANE; BRONCHIAL-ASTHMA; MODERATE ASTHMA; TERM TREATMENT; LUNG-FUNCTION; FATAL ASTHMA	Background: The patterns of airway remodeling and the biomarkers that distinguish different subtypes of severe asthma are unknown. Objectives: We sought to characterize subjects with severe asthma with and without chronic persistent airflow obstruction with respect to airway wall remodeling (histopathologic and rachologic) and specific sputum biomarkers. Methods: Subjects with severe asthma with chronic persistent (n = 16) or intermittent (n = 18) obstruction were studied. Endobronchial biopsy specimens were analyzed for airway smooth muscle area, epithelial detachment, basement membrane thickness, and submucosal fibrosis. Levels of eosinophil cationic protein, myeloperoxidase, matrix metalloproteinase 9, tissue inhibitor of matrix metalloproteinase 1 (ELISA), and 27 cytokines (multiplex assay) and differential cell counts were measured in induced sputum. Airway thickness was measured by means of high-resolution computed tomographic scanning. Results: Chronic persistent obstruction was associated with earlier age of onset, longer disease duration, more inflammatory cells in the sputum, and greater smooth muscle area (15.65% +/- 2.69% [n = 10] vs 8.96% +/- 1.99% [n = 14], P = .0325). No differences between groups were found for any of the biomarker molecules measured in sputum individually. However, principal component analysis revealed that the dominant variables in the chronic persistent obstruction group were IL-12, IL-13, and IFN-gamma, whereas IL-9, IL-17, monocyte chemotactic protein 1, and RANTES were dominant in the other group. Airway imaging revealed no differences between groups. Conclusion: Subjects with severe asthma with chronic persistent obstruction have increased airway smooth muscle with ongoing T(H)1 and T(H)2 inflammatory responses. Neither airway measurements on high-resolution computed tomographic scans nor sputum analysis seem able to identify such patients. (J Allergy Clin Immunol 2009;124:45-51.)	[Kaminska, Marta; Foley, Susan; Ghezzo, Heberto; Olivenstein, Ronald; Ernst, Pierre; Hamid, Qutayba; Martin, James] McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; [Maghni, Karim; Lemiere, Catherine] Ctr Rech Hop Sacre Coeur, Montreal, PQ, Canada; [Storness-Bliss, Claudine; Coxson, Harvey] Vancouver Gen Hosp, Dept Radiol, Vancouver, BC V5Z 1M9, Canada; [Storness-Bliss, Claudine; Coxson, Harvey] Vancouver Gen Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V5Z 1M9, Canada	McGill University; Universite de Montreal; University of British Columbia; University of British Columbia	Martin, J (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain, Montreal, PQ H2X 2P2, Canada.	james.martin@mcgill.ca	Coxson, Harvey O/A-9861-2017	Coxson, Harvey O/0000-0001-5750-9711; Martin, James/0000-0001-7574-5363; Kaminska, Marta/0000-0001-6335-0938	Richard and Edith Strauss Canada Foundation; Canadian Institutes of Health Research	Richard and Edith Strauss Canada Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Supported by the Richard and Edith Strauss Canada Foundation, Canadian Institutes of Health Research.	Amrani Y, 2003, AM J PHYSIOL-LUNG C, V284, pL1063, DOI 10.1152/ajplung.00363.2002; Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; Bai TR, 2000, AM J RESP CRIT CARE, V162, P663, DOI 10.1164/ajrccm.162.2.9907151; Bai TR, 2004, J APPL PHYSIOL, V97, P2029, DOI 10.1152/japplphysiol.00884.2004; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bosse Y, 2008, INT ARCH ALLERGY IMM, V146, P138, DOI 10.1159/000113517; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; Brown N, 2007, AM J RESP CRIT CARE, V176, P129, DOI 10.1164/rccm.200609-1317OC; Brown RH, 2001, AM J RESP CRIT CARE, V163, P994, DOI 10.1164/ajrccm.163.4.2007119; Capraz F, 2007, LUNG, V185, P89, DOI 10.1007/s00408-006-0007-2; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chetta A, 2003, AM J RESP CRIT CARE, V167, P751, DOI 10.1164/rccm.200207-710OC; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Elshaw SR, 2004, BRIT J PHARMACOL, V142, P1318, DOI 10.1038/sj.bjp.0705883; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Kelly MM, 2002, EUR RESPIR J, V20, p24S, DOI 10.1183/09031936.02.00002402; LAMBERT RK, 1994, J APPL PHYSIOL, V77, P1206, DOI 10.1152/jappl.1994.77.3.1206; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Liang KC, 2007, J CELL PHYSIOL, V211, P759, DOI 10.1002/jcp.20992; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; Maghni K, 2004, AM J RESP CRIT CARE, V169, P367, DOI 10.1164/rccm.200309-1238OC; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Nakagawa T, 2004, CLIN REV ALLERG IMMU, V27, P1, DOI 10.1385/CRIAI:27:1:001; Nakano Y, 2002, PROC SPIE, V4683, P460, DOI 10.1117/12.463615; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518, DOI 10.1164/ajrccm.162.4.9909044; Niimi A, 2004, AM J MED, V116, P725, DOI 10.1016/j.amjmed.2003.11.026; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Pellegrino R, 1998, EUR RESPIR J, V12, P1219, DOI 10.1183/0903.1936.98.12051219; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; PRATUSEVICH VR, 1995, J GEN PHYSIOL, V105, P73, DOI 10.1085/jgp.105.1.73; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; RCore Team, 2022, R LANG ENV STAT COMP; Saglani S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-46; Shannon J, 2008, CHEST, V133, P420, DOI 10.1378/chest.07-1881; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Tillie-Leblond I, 2008, ALLERGY, V63, P533, DOI 10.1111/j.1398-9995.2008.01656.x; Wang L, 2001, J APPL PHYSIOL, V90, P734, DOI 10.1152/jappl.2001.90.2.734; Ward C, 2001, AM J RESP CRIT CARE, V164, P1718, DOI 10.1164/ajrccm.164.9.2102039; 2005, AM J RESP CRIT CARE, V171, P912	47	157	168	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					45	51		10.1016/j.jaci.2009.03.049	http://dx.doi.org/10.1016/j.jaci.2009.03.049			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19481790				2022-12-18	WOS:000267909700004
J	Finkelman, FD; Rothenberg, ME; Brandt, EB; Morris, SC; Strait, RT				Finkelman, FD; Rothenberg, ME; Brandt, EB; Morris, SC; Strait, RT			Molecular mechanisms of anaphylaxis: Lessons from studies with murine models	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						blocking antibody; Fc epsilon RI; Fc gamma RIIb; Fc gamma RIII; IgE; IL-4 receptor alpha chain	PLATELET-ACTIVATING-FACTOR; FC-EPSILON-RI; MAST-CELLS; IMMUNOGLOBULIN-E; IN-VIVO; SYSTEMIC-ANAPHYLAXIS; RECEPTOR EXPRESSION; CARDIOPULMONARY CHANGES; ACTIVE ANAPHYLAXIS; AFFINITY RECEPTOR	Studies with murine models demonstrate 2 pathways of systemic anaphylaxis: one mediated by IgE, Fc is an element of RI, mast cells, histamine, and platelet-activating factor (PAF), and the other mediated by IgG, Fc gamma RIII, macrophages, and PAF. The former pathway requires much less antibody and antigen than the latter. As a result, IgG antibody can block IgE-mediated anaphylaxis induced by small quantities of antigen without mediating Fc gamma RIII-dependent anaphylaxis. The IgE pathway is most likely responsible for most human anaphylaxis, which generally involves small amounts of antibody and antigen; similarities in the murine and human immune systems suggest that the IgG pathway might mediate disease in persons repeatedly exposed to large quantities of antigen. Mice, like human subjects, can experience IgE/Fc is an element of RI/mast cell-mediated gastrointestinal and systemic anaphylaxis in response to ingested antigen. Gastrointestinal symptoms depend on serotonin and PAF; mediator dependence of systemic symptoms has not been determined. Both local and systemic anaphylaxis induced by ingested antigens might be blocked by IgA and IgG antibodies. IL-4 and IL-13 signaling through the IL-4 receptor a chain, in addition to promoting the mastocytosis and IgE antibody production that mediate most human anaphylaxis, exacerbates the effector phase of anaphylaxis by increasing target cell responsiveness to vasoactive mediators. As a result, IL-4 receptor alpha chain antagonists might be particularly effective suppressors of anaphylaxis.	Univ Cincinnati, Coll Med, Div Immunol, Cincinnati, OH 45267 USA; Cincinnati Childrens Hosp, Med Ctr, Cincinnati Vet Adm Med Ctr, Cincinnati, OH USA; Cincinnati Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH USA; Cincinnati Childrens Hosp, Med Ctr, Div Clin Immunol & Allergy, Cincinnati, OH USA; Cincinnati Childrens Hosp, Med Ctr, Div Emergency Med, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Finkelman, FD (corresponding author), Univ Cincinnati, Coll Med, Div Immunol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	ffinkelman@pol.net		Brandt, Eric/0000-0003-0617-4100	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045898, R01AI052099, R01AI045766, R01AI035987] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL076383] Funding Source: Medline; NIAID NIH HHS [R01 AI45898, R01 AI052099, R01 AI45766, R01 AI35987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD A, 1991, J IMMUNOL, V146, P3563; BERGMAN RK, 1975, J ALLERGY CLIN IMMUN, V55, P378, DOI 10.1016/0091-6749(75)90076-7; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Bircher AJ, 1996, J ALLERGY CLIN IMMUN, V98, P994, DOI 10.1016/S0091-6749(96)80018-2; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Bruschi F, 1999, INT ARCH ALLERGY IMM, V119, P291, DOI 10.1159/000024206; Burks AW, 1999, CLIN REV ALLERG IMMU, V17, P339, DOI 10.1007/BF02737615; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; Choi JH, 2001, J IMMUNOL, V166, P5139, DOI 10.4049/jimmunol.166.8.5139; DAERON M, 1982, CELL IMMUNOL, V70, P27, DOI 10.1016/0008-8749(82)90130-7; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DUPLAY D, 2004, PHYS DESK REF; DVORAK AM, 1994, BLOOD, V83, P3600; Dybendal T, 2003, ACTA ANAESTH SCAND, V47, P1211, DOI 10.1046/j.1399-6576.2003.00237.x; ESHHAR Z, 1980, J IMMUNOL, V124, P775; Faquim-Mauro EL, 1999, J IMMUNOL, V163, P3572; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; FINKELMAN FD, 1987, J IMMUNOL, V138, P2826; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FOX PC, 1982, J IMMUNOL, V129, P314; Golden David B K, 2004, Novartis Found Symp, V257, P101; Gurish MF, 2004, J IMMUNOL, V172, P1139, DOI 10.4049/jimmunol.172.2.1139; GYENES L, 1964, INT ARCH ALLER A IMM, V24, P106, DOI 10.1159/000229449; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; INARREA P, 1983, IMMUNOPHARMACOLOGY, V6, P7, DOI 10.1016/0162-3109(83)90011-5; ISHIZAKA T, 1983, MONOGR ALLERGY, V18, P14; KELEFIOTIS D, 1993, AGENTS ACTIONS, V40, P150, DOI 10.1007/BF01984054; Khodoun MV, 2004, J EXP MED, V200, P857, DOI 10.1084/jem.20040598; Kimura S, 1997, CELL MOL LIFE SCI, V53, P663, DOI 10.1007/s000180050085; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Laroche D, 1999, ALLERGY, V54, P13, DOI 10.1111/j.1398-9995.1999.tb04742.x; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; Liu E, 2002, J CLIN INVEST, V110, P1021, DOI 10.1172/JCI200215488; Lonardoni MVC, 2000, INFECT IMMUN, V68, P6355, DOI 10.1128/IAI.68.11.6355-6361.2000; LUDATSCHER RM, 1986, MICROVASC RES, V31, P345, DOI 10.1016/0026-2862(86)90023-3; MADDEN KB, 1991, J IMMUNOL, V147, P1387; MATSUDA H, 1990, J IMMUNOL, V144, P259; Maurer D, 1996, J IMMUNOL, V157, P607; McKenzie SE, 1999, J IMMUNOL, V162, P4311; MENCIAHUERTA JM, 1979, EUR J IMMUNOL, V9, P409, DOI 10.1002/eji.1830090512; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; NGUER CM, 1992, J IMMUNOL, V149, P2742; Ochiai K, 1996, INT ARCH ALLERGY IMM, V111, P55, DOI 10.1159/000237417; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; PINCKARD RN, 1977, J IMMUNOL, V119, P2185; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Ring Johannes, 2002, Curr Allergy Asthma Rep, V2, P40, DOI 10.1007/s11882-002-0036-8; Serebrisky D, 2000, J IMMUNOL, V165, P5906, DOI 10.4049/jimmunol.165.10.5906; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Soares AC, 2002, BRIT J PHARMACOL, V137, P621, DOI 10.1038/sj.bjp.0704918; SPITZER RH, 1965, NATURE, V206, P1015, DOI 10.1038/2061015a0; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; TAKEISHI T, 1991, J CLIN INVEST, V88, P598, DOI 10.1172/JCI115344; TAKIZAWA F, 1992, J EXP MED, V176, P469, DOI 10.1084/jem.176.2.469; Talvani A, 2003, MICROBES INFECT, V5, P789, DOI 10.1016/S1286-4579(03)00146-1; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Urban JF, 2001, J IMMUNOL, V167, P6078, DOI 10.4049/jimmunol.167.11.6078; WOROBEC A, 2001, SAMTERS IMMUNOLOGIC, P825; Zhang K, 2004, J ALLERGY CLIN IMMUN, V114, P321, DOI 10.1016/j.jaci.2004.03.058; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	68	157	169	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					449	457		10.1016/j.jaci.2004.12.1125	http://dx.doi.org/10.1016/j.jaci.2004.12.1125			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753886				2022-12-18	WOS:000227687000002
J	Bachert, C; Bousquet, J; Canonica, GW; Durham, SR; Klimek, L; Mullol, J; Van Cauwenberge, PB; Van Hammee, G				Bachert, C; Bousquet, J; Canonica, GW; Durham, SR; Klimek, L; Mullol, J; Van Cauwenberge, PB; Van Hammee, G		XPERT Study Grp	Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ARIA; persistent allergic rhinitis; health-related quality of life; levocetirizine; long-term therapy; pharmacoeconomics	HISTAMINE-INDUCED WHEAL; HEALTH-STATUS; DOUBLE-BLIND; CETIRIZINE; EPIDEMIOLOGY; LORATADINE; TRIALS; SINGLE; IMPACT; FLARE	Background: Allergic Rhinitis and its Impact on Asthma in collaboration with the World Health Organization initiative reclassified allergic rhinitis, like asthma, by duration and severity. The Xyzal in Persistent Rhinitis Trial is the first large, long-term clinical trial studying patients with persistent rhinitis as defined by Allergic Rhinitis and its Impact on Asthma. Objectives: Two primary objectives were defined: comparison of the Rhinoconjunctivitis Quality of Life Questionnaire overall score and Total 5 Symptoms Score (rhinorrhea, sneezing, nasal congestion, and nasal and ocular pruritus) over a period of 4 weeks between levocetirizine 5 mg and placebo. Secondary endpoints included similar evaluations at 1 week and 3, 4.5, and 6 months, summary scores for a general health status questionnaire (Medical Outcomes Survey Short Form 36), a pharmacoeconomic assessment, comorbidities, and a safety evaluation. Methods: The Xyzal in Persistent Rhinitis Trial was a 6-month double-blind, placebo-controlled, multicenter, multinational trial in 551 patients. Adults with persistent rhinitis sensitized to both grass pollen and house dust mite were randomized to receive levocetirizine 5 mg/d or placebo. Results: A total of 421 patients completed the full study. Levocetirizine significantly improved both the Rhinoconjunctivitis Quality of Life Questionnaire overall score and the Total 5 Symptoms Score from week 1 to 6 months (all P values < .001). Medical Outcomes Survey Short Form 36 summary scores were also improved in the levocetirizine group compared with the placebo group. Treatment cessation because of lack of effect, comorbidities, and overall costs of disease, and comorbidities per working patient per month (E160.27 vs E108.18) were lower in the levocetirizine group. Conclusion: Levocetirizine was shown to improve quality of life and symptoms and to decrease the overall costs of the disease over the 6-month treatment period.	Ghent Univ Hosp, Dept Otorhinolaryngol, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	Bachert, C (corresponding author), Ghent Univ Hosp, Dept Otorhinolaryngol, Pintelaan 185, B-9000 Ghent, Belgium.	Claus.Bachert@ugent.be	Bachert, Claus/J-8825-2012; Bousquet, Jean/O-4221-2019; canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557				Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; Bellanti JA, 2000, ALLERGY ASTHMA PROC, V21, P367, DOI 10.2500/108854100778249088; Bousquet J., 2002, Allergy (Copenhagen), V57, P841, DOI 10.1034/j.1398-9995.2002.23625.x; Bousquet J, 2003, ALLERGY, V58, P691, DOI 10.1034/j.1398-9995.2003.00105.x; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P309, DOI 10.1016/S0091-6749(96)70155-0; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; Ciprandi G, 2001, ANN ALLERG ASTHMA IM, V87, P222, DOI 10.1016/S1081-1206(10)62230-2; Clough GF, 2001, ALLERGY, V56, P985, DOI 10.1034/j.1398-9995.2001.00204.x; Devalia JL, 2001, ALLERGY, V56, P50, DOI 10.1034/j.1398-9995.2001.00726.x; Fireman P, 1997, AM J RHINOL, V11, P95, DOI 10.2500/105065897782537142; Gandon JM, 2002, BRIT J CLIN PHARMACO, V54, P51, DOI 10.1046/j.1365-2125.2002.01611.x; Grant JA, 2002, ANN ALLERG ASTHMA IM, V88, P190, DOI 10.1016/S1081-1206(10)61995-3; Jones NS, 1998, J LARYNGOL OTOL, V112, P1019, DOI 10.1017/S0022215100142380; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, pS386, DOI 10.1016/S0091-6749(98)70227-1; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Kremer B, 2001, ALLERGY, V56, P957, DOI 10.1034/j.1398-9995.2001.00919.x; Leynadier F, 2001, Acta Otorhinolaryngol Belg, V55, P305; LEYNAERT B, 2000, J ALLERGY CLIN IMMUN, V106, P201; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Majani G, 2001, ALLERGY, V56, P313, DOI 10.1034/j.1398-9995.2001.00852.x; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; Simons FER, 1996, ALLERGY ASTHMA PROC, V17, P185, DOI 10.2500/108854196778996895; Spector SL, 1997, J ALLERGY CLIN IMMUN, V99, pS773, DOI 10.1016/S0091-6749(97)70126-X; Thompson AK, 2000, ANN ALLERG ASTHMA IM, V85, P338, DOI 10.1016/S1081-1206(10)62543-4; Tripathi A, 2001, PHARMACOECONOMICS, V19, P891, DOI 10.2165/00019053-200119090-00001; Vally H, 2002, CLIN EXP ALLERGY, V32, P186, DOI 10.1046/j.1365-2222.2002.01303.x; Ware JE., 1993, SF 36 HLTH SURVEY MA	29	157	175	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					838	844		10.1016/j.jaci.2004.05.070	http://dx.doi.org/10.1016/j.jaci.2004.05.070			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480324				2022-12-18	WOS:000224439100018
J	Matthews, JG; Ito, K; Barnes, PJ; Adcock, IM				Matthews, JG; Ito, K; Barnes, PJ; Adcock, IM			Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; monocytes; chromatin; iniimmunohistochemistry; ELISA	COLONY-STIMULATING FACTOR; INCREASED EXPRESSION; KAPPA-B; BINDING; INHIBITION; ASTHMA; KINASE; PHOSPHORYLATION; SUPPRESSION; MONOCYTES	Background: Most chronic inflammatory diseases are well controlled by glucocorticoids. However, a minority of patients fails to respond adequately to this treatment. Objective: We wished to determine whether glucocorticoid insensitivity in a group of steroid-resistant (SR) and steroid-dependent (SD) asthmatic subjects resulted from an inability of the glucocorticoid receptor (GR) to translocate into the nucleus. Methods: Glucocorticoid receptor nuclear translocation was determined in PBMCs by immunocytochemistry and GR function measured by suppression of TNF-alpha-induced GM-CSF release and effects of dexamethasone on histone acetylation. Results: Glucocorticoid repression of TNF-alpha-induced GM-CSF release was reduced in PBMCs from SD and SR patients. This inhibition correlated with a failure of GR to translocate into the nucleus and induce histone acetylation in response to dexamethasone. In addition, dexamethasone failed to inhibit TNF-alpha-induced histone acetyltransferase activity, which predominantly targeted histone residues lysine (K)8 and K12. However, in a subset of patients, even high levels of GR nuclear translocation failed to produce histone acetylation in response to dexamethasone. Histone H4 K5 acetylation, a marker of dexamethasone transactivation, was specifically reduced in this group. However, cells from this subset of steroid-insensitive subjects were still capable of inhibiting TNF-alpha-induced histone acetylation. Conclusion: We have identified a novel mechanism of glucocorticoid insensitivity in a group of SR and SD subjects. These data suggest that most patients respond to glucocorticoids according to the degree of GR nuclear translocation occurring, but some subjects with steroid resistance have a reduced response because of a failure of steroids to transactivate, rather than transrepress.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London	Adcock, IM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	ian.adcock@imperial.ac.uk	Ito, Kazuhiro/AAF-5994-2019; Adcock, Ian/L-3217-2019	Barnes, Peter/0000-0002-5122-4018; Adcock, Ian/0000-0003-2101-8843				Adcock IM, 1996, AM J RESP CRIT CARE, V154, P771, DOI 10.1164/ajrccm.154.3.8810618; Adcock IM, 2003, J ENDOCRINOL, V178, P347, DOI 10.1677/joe.0.1780347; ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; ADCOCK IM, 1995, J IMMUNOL, V154, P3500; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Bergmann MW, 2004, AM J RESP CELL MOL, V30, P555, DOI 10.1165/rcmb.2003-0295OC; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Galigniana MD, 1999, MOL PHARMACOL, V55, P317, DOI 10.1124/mol.55.2.317; Goleva E, 2002, J IMMUNOL, V169, P5934, DOI 10.4049/jimmunol.169.10.5934; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; KAM JC, 1993, J IMMUNOL, V151, P3460; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Lambert JR, 1998, J BIOL CHEM, V273, P32708, DOI 10.1074/jbc.273.49.32708; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; MUNCK A, 1990, AM REV RESPIR DIS, V141, pS2; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Pariante CM, 1999, ENDOCRINOLOGY, V140, P4359, DOI 10.1210/en.140.9.4359; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; SELDON PM, 1995, MOL PHARMACOL, V48, P747; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Smith PJ, 2001, J IMMUNOL, V167, P2502, DOI 10.4049/jimmunol.167.5.2502; Turlais F, 2001, ANAL BIOCHEM, V298, P62, DOI 10.1006/abio.2001.5340; Yudt MR, 2002, MOL ENDOCRINOL, V16, P1719, DOI 10.1210/me.2002-0106	32	157	169	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1100	1108		10.1016/j.jaci.2004.03.018	http://dx.doi.org/10.1016/j.jaci.2004.03.018			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208591				2022-12-18	WOS:000222091000015
J	Adams, RJ; Fuhlbrigge, AL; Finkelstein, JA; Weiss, ST				Adams, RJ; Fuhlbrigge, AL; Finkelstein, JA; Weiss, ST			Intranasal steroids and the risk of emergency department visits for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; rhinitis; therapeutics; outcome assessment	IGE-MEDIATED HYPERSENSITIVITY; ALLERGIC RHINITIS; OTITIS-MEDIA; NASAL; EFFICACY; CARE; CORTICOSTEROIDS; RESPONSIVENESS; EPIDEMIOLOGY; OBSTRUCTION	Background: In patients with asthma, treatment for associated conditions, such as rhinitis, is recommended. It is unknown whether this treatment can reduce the risk for emergency department (ED) visits for asthma. Objectives: We sought to determine whether treatment with intranasal steroids or prescription antihistamines in persons with asthma is associated with a reduced risk for ED visits caused by asthma. Methods: We performed a retrospective cohort study of members of a managed care organization aged greater than 5 years who were identified during the period of October 1991 to September 1994 as having a diagnosis of asthma by using a computerized medical record system. The main outcome measure was an ED visit for asthma. Results: Of the 13,844, eligible persons, 1031 (7.4%) had an ED visit for asthma. The overall relative risk (RR) for an ED visit among those who received intranasal corticosteroids, adjusted for age, sex, frequency of orally inhaled corticosteroid and beta-agonist dispensing, amount and type of ambulatory care for asthma, and diagnosis of an upper airways condition (rhinitis, sinusitis, or otitis media), was 0.7 (95% confidence interval [CI], 0.59-0.941). For those receiving prescription antihistamines, the risk was indeterminate (RR, 0.9; 95% CI, 0.78-1.11). When different rates of dispensing for intranasal steroids were examined, a reduced risk was seen in ED visits in those with greater than 0 to I (RR, 0.7; 95% Cl, 0.57-0.99) and greater than 3 (RR, 0.5; 95% Cl, 0.23-1.05) dispensed prescriptions per year. Conclusions: Treatment of nasal conditions, particularly with intranasal steroids, confers significant protection against exacerbations of asthma leading to ED visits for asthma. These results support the use of intranasal steroids by individuals with asthma and upper airways conditions.	Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Adelaide, Dept Med, Woodville, SA, Australia; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Pilgrim Hlth Care, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Adelaide; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Fuhlbrigge, AL (corresponding author), Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp, 181 Longwood Ave, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003919] Funding Source: NIH RePORTER; NHLBI NIH HHS [1KO8 HL03919-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUBIER M, 1992, AM REV RESPIR DIS, V146, P122, DOI 10.1164/ajrccm/146.1.122; Bachert C., 1997, EUR RESPIR REV, V7, P294; BERNSTEIN JM, 1985, OTOLARYNG HEAD NECK, V93, P611, DOI 10.1177/019459988509300508; BERNSTEIN JM, 1992, OTOLARYNG CLIN N AM, V25, P197; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; Ciprandi G, 1996, INT ARCH ALLERGY IMM, V111, P279, DOI 10.1159/000237378; Corren J, 1999, J ALLERGY CLIN IMMUN, V104, pS144, DOI 10.1016/S0091-6749(99)70310-6; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; Corren J, 1997, J ALLERGY CLIN IMMUN, V99, pS781, DOI 10.1016/S0091-6749(97)70127-1; Crawford WW, 1998, OTOLARYNG HEAD NECK, V118, P668, DOI 10.1016/S0194-5998(98)70238-4; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; FIREMAN P, 1990, J ALLERGY CLIN IMMUN, V86, P638, DOI 10.1016/S0091-6749(05)80229-5; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; GAMBLE J E, 1992, Ear Nose and Throat Journal, V71, P397; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; Gregory C, 1999, AM J MANAG CARE, V5, P485; Harvey RP, 1996, J ALLERGY CLIN IMMUN, V97, P1233, DOI 10.1016/S0091-6749(96)70190-2; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; Jen A, 2000, J ALLERGY CLIN IMMUN, V105, P732, DOI 10.1067/mai.2000.105225; Kapsali T, 1997, J ALLERGY CLIN IMMUN, V99, P556; Leone FT, 1999, RESP MED, V93, P788, DOI 10.1016/S0954-6111(99)90263-9; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Lumry WR, 1999, J ALLERGY CLIN IMMUN, V104, pS150, DOI 10.1016/S0091-6749(99)70311-8; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; Mygind N., 1997, EUR RESPIR REV, V7, P296; Nash DB, 2000, AM J MANAG CARE, V6, pS3; *NAT ASTH ED PREV, 1997, PUBL NAT ASTH ED PRE; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; PEDERSEN B, 1990, ALLERGY, V45, P451, DOI 10.1111/j.1398-9995.1990.tb01096.x; Ricci J, 1999, AM J RESP CRIT CARE, V159, pA240; Rosner B, 2015, FUNDAMENTALS BIOSTAT, V8th; SAVOLAINEN S, 1989, ALLERGY, V44, P116, DOI 10.1111/j.1398-9995.1989.tb02234.x; Schenkel EJ, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e22; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; Skoner DP, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e23; SKONER DP, 1987, J ALLERGY CLIN IMMUN, V79, P27, DOI 10.1016/S0091-6749(87)80012-X; Spector SL, 1997, J ALLERGY CLIN IMMUN, V99, pS773, DOI 10.1016/S0091-6749(97)70126-X; STROM BL, 1984, AM J MED, V77, P703, DOI 10.1016/0002-9343(84)90369-3; STROM BL, 1985, AM J MED, V78, P475, DOI 10.1016/0002-9343(85)90341-9; SUISSA S, 1994, EUR RESPIR J, V7, P1602, DOI 10.1183/09031936.94.07091602; TOMONAGA K, 1988, ACTA OTO-LARYNGOL, P41; VANCAUWENBERGE P, 1997, EUR RESPIR REV, V7, P288; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Yawn BP, 1999, J ALLERGY CLIN IMMUN, V103, P54, DOI 10.1016/S0091-6749(99)70525-7	49	157	167	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					636	642		10.1067/mai.2002.123237	http://dx.doi.org/10.1067/mai.2002.123237			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941313				2022-12-18	WOS:000175132600011
J	Reed, CE; Milton, DK				Reed, CE; Milton, DK			Endotoxin-stimulated innate immunity: A contributing factor for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						airway inflammation; asthma; cell biology; chronic obstructive pulmonary disease; endotoxin; eosinophils; environmental exposure neutrophils; tolerance	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; CAUSES BRONCHIAL HYPERRESPONSIVENESS; LIPOPOLYSACCHARIDE-BINDING PROTEIN; RESOLUTION COMPUTED-TOMOGRAPHY; DOSE-RESPONSE RELATIONSHIPS; PLATELET-ACTIVATING-FACTOR; HOUSE-DUST ENDOTOXIN; TNF-ALPHA PRODUCTION; INDUCED LUNG INJURY	Exposure to airborne endotoxin in infancy may protect against asthma by promoting enhanced T(H)1 response and tolerance to allergens. On the other hand, later in life, it adversely affects patients with asthma. Endotoxin binding to receptors on macrophages and other cells generates IL-12, which inhibits IgE responses. It also generates cytokines like IL-1, TNF-alpha, and IL-8, which cause inflammation. These signal transduction pathways resemble those leading to the generation of cytokines, such as IL-4, IL-13, and IL-5, which are responsible for the inflammation of IgE-mediated allergic disease. The main difference seems to be that endotoxin recruits neutrophils, but IgE recruits eosinophils, and the details of the tissue injury from these granulocytes differ. Sources of airborne endotoxin include many agricultural dusts, aerosols from contaminated water in many industrial plants, contaminated heating and air-conditioning systems, mist-generating humidifiers, and damp or water-damaged homes. Acute inhalation of high concentrations of endotoxin can cause fever, cough, and dyspnea. Chronic inhalation of lesser amounts causes chronic bronchitis and emphysema and is associated with airway hyperresponsiveness. Airborne endotoxin adversely affects patients with asthma in 3 ways: (1) by increasing the severity of the airway inflammation; (2) by increasing the susceptibility to rhinovirus-induced colds; and (3) by causing chronic bronchitis and emphysema with development of irreversible airway obstruction after chronic exposure of adults. The most effective management is mitigating exposure. The potential of drug treatments requires further clinical investigation.	Mayo Clin, Allerg Dis Res Lab, Rochester, MN USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Mayo Clinic; Harvard University; Harvard T.H. Chan School of Public Health	Reed, CE (corresponding author), POB 158, Boulder Jct, WI 54512 USA.		Milton, Donald K/G-3286-2010	Milton, Donald K/0000-0002-0550-7834				Abrams L, 2000, Appl Occup Environ Hyg, V15, P492; Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Anderson K, 1996, OCCUP ENVIRON MED, V53, P106, DOI 10.1136/oem.53.2.106; BACHWICH PR, 1986, AM J PATHOL, V125, P421; Baykal A, 1999, SURGERY, V125, P403, DOI 10.1016/S0039-6060(99)70008-5; Bellanti JA, 2000, ANN ALLERG ASTHMA IM, V84, P249, DOI 10.1016/S1081-1206(10)62762-7; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; Biernacki W, 1997, EUR RESPIR J, V10, P2455, DOI 10.1183/09031936.97.10112455; Boichot E, 1999, PULM PHARMACOL THER, V12, P285, DOI 10.1006/pupt.1999.0212; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Boulet L P, 1998, Can Respir J, V5, P270; Brauer RB, 2000, INFECT IMMUN, V68, P1626, DOI 10.1128/IAI.68.3.1626-1632.2000; BURRELL R, 1994, CIRC SHOCK, V43, P137; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; Chanez P, 1996, INT ARCH ALLERGY IMM, V111, P83, DOI 10.1159/000237350; CHRISTIANI DC, 1993, AM J IND MED, V23, P333, DOI 10.1002/ajim.4700230210; Christiani DC, 1999, AM J IND MED, V35, P321, DOI 10.1002/(SICI)1097-0274(199904)35:4<321::AID-AJIM1>3.3.CO;2-C; CHRISTIANI DC, 1994, CHEST, V105, P1713, DOI 10.1378/chest.105.6.1713; CLEMENTSEN P, 1990, ALLERGY, V45, P402, DOI 10.1111/j.1398-9995.1990.tb01090.x; CLEMENTSEN P, 1990, ALLERGY, V45, P10, DOI 10.1111/j.1398-9995.1990.tb01078.x; Cowan DB, 2000, AM J PHYSIOL-HEART C, V279, pH619, DOI 10.1152/ajpheart.2000.279.2.H619; Delgado M, 1999, J IMMUNOL, V162, P2358; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146, DOI 10.1165/ajrcmb.23.2.3855; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; DONHAM K, 1989, BRIT J IND MED, V46, P31; Donham KJ, 2000, J OCCUP ENVIRON MED, V42, P260, DOI 10.1097/00043764-200003000-00006; DONHAM KJ, 1995, AM J IND MED, V27, P405, DOI 10.1002/ajim.4700270309; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763, DOI 10.1128/AEM.61.5.1763-1769.1995; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; EDEN E, 1986, IMMUNOPHARMACOLOGY, V12, P81, DOI 10.1016/0162-3109(86)90033-0; Eldridge MW, 2000, J TOXICOL ENV HEAL A, V61, P27, DOI 10.1080/00984100050116762; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Eppihimer MJ, 1999, SHOCK, V11, P93, DOI 10.1097/00024382-199902000-00004; Ertel W, 1996, ARCH SURG-CHICAGO, V131, P51; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Feng WG, 2000, BIOCHEM BIOPH RES CO, V269, P570, DOI 10.1006/bbrc.2000.2341; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; FLAHERTY DK, 1984, INFECT IMMUN, V43, P213, DOI 10.1128/IAI.43.1.213-216.1984; FOLKERTS G, 1988, AM REV RESPIR DIS, V137, P1441, DOI 10.1164/ajrccm/137.6.1441; FORTEZA R, 1994, AM J RESP CRIT CARE, V149, P687, DOI 10.1164/ajrccm.149.3.8118638; Galea E, 1999, FASEB J, V13, P2125, DOI 10.1096/fasebj.13.15.2125; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Ghofrani HA, 1996, AM J PHYSIOL-LUNG C, V270, pL62, DOI 10.1152/ajplung.1996.270.1.L62; Grenier P, 1996, EUR RADIOL, V6, P199; Hakki A, 2000, INT J IMMUNOPHARMACO, V22, P403, DOI 10.1016/S0192-0561(00)00005-9; HARKEMA JR, 1992, AM J PATHOL, V141, P307; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Hasko G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/jimmunol.164.2.1013; Hines CJ, 2000, INDOOR AIR, V10, P2, DOI 10.1034/j.1600-0668.2000.010001002.x; HOFFMANN H, 1991, AM REV RESPIR DIS, V143, P289, DOI 10.1164/ajrccm/143.2.289; HOLLANDER A, 1994, OCCUP ENVIRON MED, V51, P73, DOI 10.1136/oem.51.2.73; Hsuan SL, 1999, MICROB PATHOGENESIS, V26, P263, DOI 10.1006/mpat.1998.0271; HUANG ZB, 1990, CHEST, V98, P576, DOI 10.1378/chest.98.3.576; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471, DOI 10.1164/ajrccm.149.6.8004300; Ingalls RR, 1999, INFECT DIS CLIN N AM, V13, P341, DOI 10.1016/S0891-5520(05)70078-7; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; Jeffery PK, 1997, EUR RESPIR J, V10, P1655, DOI 10.1183/09031936.97.10071655; JORNA THJM, 1994, CHEST, V106, P1050, DOI 10.1378/chest.106.4.1050; Joyce DA, 1997, IMMUNOL CELL BIOL, V75, P345, DOI 10.1038/icb.1997.53; Kamochi M, 1999, AM J PHYSIOL-LUNG C, V277, pL310, DOI 10.1152/ajplung.1999.277.2.L310; Karres I, 1996, ARCH SURG-CHICAGO, V131, P1310; Keicho N, 1999, AM J PHYSIOL-LUNG C, V277, pL523, DOI 10.1152/ajplung.1999.277.3.L523; KENNEDY SM, 1987, AM REV RESPIR DIS, V135, P194; Kimata M, 1998, PHARMACOLOGY, V56, P230, DOI 10.1159/000028202; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; KIPS JC, 1993, CLIN EXP ALLERGY, V23, P518, DOI 10.1111/j.1365-2222.1993.tb03240.x; Kirychuk S, 1998, Can Respir J, V5, P472; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; KONNO S, 1994, INT ARCH ALLERGY IMM, V105, P308, DOI 10.1159/000236773; KUDLACZ EM, 1993, LAB ANIM SCI, V43, P445; Kullman GJ, 1998, AM IND HYG ASSOC J, V59, P403, DOI 10.1080/15428119891010668; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Lahti A, 2000, J PHARMACOL EXP THER, V294, P1188; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099; Larsson BM, 1997, THORAX, V52, P638, DOI 10.1136/thx.52.7.638; Lauw FN, 2000, INFECT IMMUN, V68, P1014, DOI 10.1128/IAI.68.3.1014-1018.2000; Lefort J, 1998, J IMMUNOL, V161, P474; LI D, 1995, OCCUP ENVIRON MED, V52, P328, DOI 10.1136/oem.52.5.328; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Madjdpour C, 2000, AM J PHYSIOL-LUNG C, V278, pL572, DOI 10.1152/ajplung.2000.278.3.L572; Mahar S, 1999, AM IND HYG ASSOC J, V60, P679, DOI 10.1080/00028899908984491; MALMBERG P, 1993, EUR RESPIR J, V6, P400; MAMOLEN M, 1993, AM J IND MED, V23, P483, DOI 10.1002/ajim.4700230311; Mariano F, 1999, NEPHROL DIAL TRANSPL, V14, P1150, DOI 10.1093/ndt/14.5.1150; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; MICHEL O, 1995, INT ARCH ALLERGY IMM, V108, P298, DOI 10.1159/000237168; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; MICHEL O, 1991, ANN ALLERGY, V66, P39; Milanowski J, 1998, J TOXICOL ENV HEAL A, V53, P5, DOI 10.1080/009841098159439; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Milton DK, 1996, AM IND HYG ASSOC J, V57, P889, DOI 10.1202/0002-8894(1996)057<0889:WETEPC>2.0.CO;2; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; MILTON DK, 1990, AM REV RESPIR DIS, V142, P184, DOI 10.1164/ajrccm/142.1.184; Milton DK, 1996, AM J IND MED, V29, P3, DOI 10.1002/(SICI)1097-0274(199601)29:1<3::AID-AJIM2>3.0.CO;2-V; MILTON DK, 1995, AM J IND MED, V28, P469, DOI 10.1002/ajim.4700280404; Miyanohara T, 2000, LARYNGOSCOPE, V110, P126, DOI 10.1097/00005537-200001000-00023; Mochizuki T, 1997, CHEST, V112, P1522, DOI 10.1378/chest.112.6.1522; Nadel JA, 2000, CHEST, V117, p386S, DOI 10.1378/chest.117.5_suppl_2.386S; Nakamura A, 1999, KIDNEY INT, V56, P839, DOI 10.1046/j.1523-1755.1999.00630.x; Nathens AB, 1998, J IMMUNOL, V160, P2959; Neely CF, 1997, AM J PHYSIOL-LUNG C, V272, pL353, DOI 10.1152/ajplung.1997.272.2.L353; Nelson ME, 1999, CHEST, V115, P151, DOI 10.1378/chest.115.1.151; Nicolai T, 1998, THORAX, V53, P1035, DOI 10.1136/thx.53.12.1035; Nightingale JA, 1998, THORAX, V53, P563, DOI 10.1136/thx.53.7.563; Ning YY, 2000, J TOXICOL ENV HEAL A, V59, P165, DOI 10.1080/009841000156952; Niven RM, 1997, THORAX, V52, P22, DOI 10.1136/thx.52.1.22; Nolan B, 1999, SURGERY, V126, P406, DOI 10.1016/S0039-6060(99)70185-6; NOM S, 1987, AGENTS ACTIONS, V20, P29; Nonaka M, 1999, INT ARCH ALLERGY IMM, V119, P314, DOI 10.1159/000024209; OLSON NC, 1990, AM J PHYSIOL, V258, pH1674, DOI 10.1152/ajpheart.1990.258.6.H1674; OLSON NC, 1990, J APPL PHYSIOL, V69, P1315, DOI 10.1152/jappl.1990.69.4.1315; OZESMI M, 1987, BRIT J IND MED, V44, P479; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084, DOI 10.1164/ajrccm/146.4.1084; Pal TM, 1997, AM J IND MED, V31, P682; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; PARK JH, 2001, IN PRESS ENV HLTH PE; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; Pauwels R, 1990, Agents Actions Suppl, V31, P11; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; Prados M, 1995, Allergol Immunopathol (Madr), V23, P24; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; ROSENTHAL GJ, 1992, TOXICOL APPL PHARM, V112, P222, DOI 10.1016/0041-008X(92)90191-T; Ruetten H, 1999, MEDIAT INFLAMM, V8, P77, DOI 10.1080/09629359990568; RYLANDER R, 1993, ANN OCCUP HYG, V37, P57, DOI 10.1093/annhyg/37.1.57; RYLANDER R, 1986, ENVIRON HEALTH PERSP, V66, P83, DOI 10.2307/3430218; RYLANDER R, 1984, CLIN ALLERGY, V14, P109, DOI 10.1111/j.1365-2222.1984.tb02197.x; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981; Rylander R, 1999, EUR RESPIR J, V13, P1151, DOI 10.1034/j.1399-3003.1999.13e35.x; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603, DOI 10.1164/ajrccm.152.2.7633714; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305, DOI 10.1164/ajrccm.163.2.ed2000a; Senthilselvan A, 1997, AM J RESP CRIT CARE, V156, P410, DOI 10.1164/ajrccm.156.2.9612069; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; Shimizu T, 1996, AM J RESP CRIT CARE, V153, P1412, DOI 10.1164/ajrccm.153.4.8616574; SIGSGAARD T, 1994, PHARMACOGENETICS, V4, P135, DOI 10.1097/00008571-199406000-00004; SIGSGAARD T, 1992, AM J IND MED, V22, P163, DOI 10.1002/ajim.4700220204; Silva JRL, 2000, TOXICOLOGY, V152, P31; Simpson JCG, 1998, OCCUP ENVIRON MED, V55, P668, DOI 10.1136/oem.55.10.668; Simpson JCG, 1999, ANN OCCUP HYG, V43, P107, DOI 10.1093/annhyg/43.2.107; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V64, P526, DOI 10.1016/0091-6749(79)90063-0; Skerrett SJ, 1999, AM J PHYSIOL-LUNG C, V276, pL715, DOI 10.1152/ajplung.1999.276.5.L715; SMID T, 1994, AM J IND MED, V25, P877, DOI 10.1002/ajim.4700250611; Spittler A, 1999, FASEB J, V13, P563, DOI 10.1096/fasebj.13.3.563; Steer JH, 1998, ANN RHEUM DIS, V57, P732, DOI 10.1136/ard.57.12.732; STEIGER D, 1995, AM J RESP CELL MOL, V12, P307, DOI 10.1165/ajrcmb.12.3.7873197; Sur S, 1998, J LEUKOCYTE BIOL, V63, P715, DOI 10.1002/jlb.63.6.715; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; TANIZAKI Y, 1993, J ASTHMA, V30, P309, DOI 10.3109/02770909309054531; TAZI A, 1991, AM J RESP CELL MOL, V4, P140, DOI 10.1165/ajrcmb/4.2.140; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339; Thorne PS, 1997, AM IND HYG ASSOC J, V58, P792, DOI 10.1202/0002-8894(1997)058<0792:FEOEAS>2.0.CO;2; Trapp JF, 1998, CHEST, V113, P505, DOI 10.1378/chest.113.2.505; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824, DOI 10.1128/IAI.67.8.3824-3829.1999; VANNIER E, 1991, J CLIN INVEST, V87, P1936, DOI 10.1172/JCI115219; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103, DOI 10.1093/oxfordjournals.aje.a117398; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15, DOI 10.1164/ajrccm.157.1.9703087; Vogelzang PFJ, 2000, CHEST, V117, P1488, DOI 10.1378/chest.117.5.1488; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426; Wang D, 1999, J BIOMED SCI, V6, P28, DOI 10.1159/000025368; Wang Z, 1998, RESP MED, V92, P1022, DOI 10.1016/S0954-6111(98)90349-3; Wang Z, 1999, CLIN EXP IMMUNOL, V115, P6; Wang Z, 1997, EUR RESPIR J, V10, P381, DOI 10.1183/09031936.97.10020381; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; WARREN CPW, 1986, ENVIRON HEALTH PERSP, V66, P55, DOI 10.2307/3430214; Wever-Hess J, 2000, PEDIATR PULM, V29, P250, DOI 10.1002/(SICI)1099-0496(200004)29:4<250::AID-PPUL3>3.0.CO;2-4; Wheeler MD, 1999, AM J PHYSIOL-LUNG C, V277, pL952, DOI 10.1152/ajplung.1999.277.5.L952; White JE, 2000, J CELL PHYSIOL, V182, P381; Wolk K, 2000, BLOOD, V96, P218, DOI 10.1182/blood.V96.1.218.013k04_218_223; Woskie SR, 1996, AM IND HYG ASSOC J, V57, P1154, DOI 10.1202/0002-8894(1996)057<1154:EAFAFI>2.0.CO;2; Wouters IM, 2000, APPL ENVIRON MICROB, V66, P627, DOI 10.1128/AEM.66.2.627-631.2000; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Yamamoto C, 1997, CHEST, V112, P505, DOI 10.1378/chest.112.2.505; Yokota Y, 2000, ARCH BIOCHEM BIOPHYS, V379, P7, DOI 10.1006/abbi.2000.1849; Zhang HB, 1999, AM J RESP CRIT CARE, V160, P1703, DOI 10.1164/ajrccm.160.5.9903068; Zock JP, 1999, AM J RESP CRIT CARE, V159, P137, DOI 10.1164/ajrccm.159.1.9803026	185	157	159	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					157	166		10.1067/mai.2001.116862	http://dx.doi.org/10.1067/mai.2001.116862			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496229				2022-12-18	WOS:000170584600001
J	Pastorello, EA; Farioli, L; Pravettoni, V; Ispano, M; Scibola, E; Trambaioli, C; Giuffrida, MG; Ansaloni, R; Godovac-Zimmermann, J; Conti, A; Fortunato, D; Ortolani, C				Pastorello, EA; Farioli, L; Pravettoni, V; Ispano, M; Scibola, E; Trambaioli, C; Giuffrida, MG; Ansaloni, R; Godovac-Zimmermann, J; Conti, A; Fortunato, D; Ortolani, C			The maize major allergen, which is responsible for food-induced allergic reactions, is a lipid transfer protein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						maize allergens; lipid transfer protein; food allergy	PHOSPHOLIPID TRANSFER PROTEIN; AMINO-ACID-SEQUENCE; CROSS-REACTIVITY; CEREAL-GRAINS; IN-VIVO; HYPERSENSITIVITY; INHIBITOR; CHILDREN; WHEAT; TRYPSIN	Background: Cereals are the most important nutritional component in the human diet. Food-induced allergic reactions to these substances therefore have serious implications, and exhaustive diagnosis Is required. Such diagnosis is still difficult because of the incomplete knowledge about major cereal allergens. In particular, few food-induced allergic reactions to maize have been reported, and no information on the allergenic proteins is available. Objective: Having observed several anaphylactic reactions to maize, we planned a study to identify maize major allergens and cross-reactivity with other cereals, as well as to peach because the majority of patients also reacted to Prunoideae fruits. Methods: Twenty-two patients with systemic symptoms after maize ingestion and positive skin prick test responses and serum-specific IgE antibodies to maize were selected. The IgE-reactivity pattern was identified by SDS-PACE and immunoblotting. The major allergen identified was then purified by HPLC and characterized by mass spectrometry, determination of the isoelectric point value, and N-terminal amino acid sequencing. Results: Sera from 19 (86%) of the 22 patients recognized a 9-kd protein, thus confirming this as the maize major allergen. This protein had an isoelectric point of greater than 9, a molecular mass of 9047.0 d, and no glycosylation. Determination of its N-terminal sequence showed that it was a lipid transfer protein (LTP). By using immunoblotting-inhibition experiments, we demonstrated that the LTP cross-reacts completely with rice and peach LTPs but not with wheat or barley LTPs. N-terminal sequence of the 16-kd allergen (recognized by 36% of patients) showed it to be the maize inhibitor of trypsin, This protein cross-reacts completely with grass, wheat, barley, and rice trypsin inhibitors. Conclusion: The major allergen of maize is an LTP with a molecular weight of 9 kd that is highly homologous with the peach LTP, the major allergen of the Prunoideae subfamily.	Osped Maggiore, IRCCS, Div Gen Med 3, Allergy Ctr, Milan, Italy; ICP, CEMOC, UOOML, Milan, Italy; Osped Niguarda Ca Granda, Bizzozzero Div, Milan, Italy; UCL, Ctr Mol Med, London, England; CNR, Turin, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of London; University College London; Consiglio Nazionale delle Ricerche (CNR)	Pastorello, EA (corresponding author), Padiglione Granelli, Div Gen Med 3, Via Francesco Sforza 35, I-20122 Milan, Italy.		Zimmermann, Jasminka Godovac/E-6863-2010; Giuffrida, Maria Gabriella/AAY-6314-2020; PASTORELLO, ELIDE ANNA/E-3897-2017	Giuffrida, Maria Gabriella/0000-0002-1297-2558; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				ALVAREZ AM, 1995, BBA-PROTEIN STRUCT M, V1251, P201, DOI 10.1016/0167-4838(95)00075-6; BIORKSTEN F, 1980, ALLERGY, V35, P671; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Gomar J, 1996, PROTEIN SCI, V5, P565; Gomar J, 1997, FOLD DES, V2, P183, DOI 10.1016/S1359-0278(97)00025-4; Gomar J, 1998, PROTEINS, V31, P160, DOI 10.1002/(SICI)1097-0134(19980501)31:2<160::AID-PROT6>3.0.CO;2-Q; GROSBOIS M, 1989, PLANT PHYSIOL, V90, P1560, DOI 10.1104/pp.90.4.1560; James JM, 1997, J ALLERGY CLIN IMMUN, V99, P239, DOI 10.1016/S0091-6749(97)70103-9; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; KIVITY S, 1994, CLIN EXP ALLERGY, V24, P19, DOI 10.1111/j.1365-2222.1994.tb00911.x; MAHONEY WC, 1984, J BIOL CHEM, V259, P8412; Nakase M, 1998, ALLERGY, V53, P55, DOI 10.1111/j.1398-9995.1998.tb04962.x; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pauls JD, 1998, J ALLERGY CLIN IMMUN, V101, P853, DOI 10.1016/S0091-6749(98)70317-3; SANDIFORD CP, 1995, CLIN EXP ALLERGY, V25, P340, DOI 10.1111/j.1365-2222.1995.tb01052.x; SHIN DH, 1995, STRUCTURE, V3, P189, DOI 10.1016/S0969-2126(01)00149-6; Tada Y, 1996, FEBS LETT, V391, P341, DOI 10.1016/0014-5793(96)00773-9; TCHANG F, 1988, J BIOL CHEM, V263, P16849; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; URISU A, 1991, INT ARCH ALLER A IMM, V96, P244, DOI 10.1159/000235502	27	157	159	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					744	751		10.1067/mai.2000.108712	http://dx.doi.org/10.1067/mai.2000.108712			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031346				2022-12-18	WOS:000089980600019
J	Hamilos, DL				Hamilos, DL			Chronic sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						sinusitis; inflammation; nasal polyposis; eosinophil; fungal sinusitis	ALLERGIC FUNGAL SINUSITIS; CHRONIC MAXILLARY SINUSITIS; MESSENGER-RNA EXPRESSION; CHRONIC HYPERPLASTIC SINUSITIS; COLONY-STIMULATING FACTOR; VASCULAR ENDOTHELIAL-CELLS; NASAL POLYPS; CHRONIC RHINOSINUSITIS; ASPIRIN DESENSITIZATION; CYTOKINE EXPRESSION	Sinusitis is a very common chronic illness with a substantial health care impact. This review focuses on factors contributing to sinusitis pathogenesis and chronicity, including anatomic factors, disturbances in mucociliary clearance, microbial pathogens, and inflammatory factors. A distinction is made between "infectious" and "noninfectious" types of inflammation in chronic sinusitis, The inflammatory characteristics of noninfectious inflammation are reviewed primarily in the context of chronic hyperplastic sinusitis with nasal polyposis. Key features of this type of inflammation include the presence of chronic inflammatory cells, large numbers of eosinophils, and IL-5-producing T lymphocytes. Allergic fungal sinusitis is discussed as a special type of chronic sinusitis. Published studies on the outcomes of medical management are reviewed. Finally, algorithms for medical management of chronic sinusitis and allergic fungal sinusitis are presented.	Washington Univ, Sch Med, Div Allergy & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Hamilos, DL (corresponding author), Washington Univ, Sch Med, Div Allergy & Immunol, Box 8122,660 S Euclid Ave, St Louis, MO 63110 USA.							ADAMS PF, 1995, VITAL HLTH STAT, V10, P83; Bachert C, 1998, ALLERGY, V53, P2, DOI 10.1111/j.1398-9995.1998.tb03767.x; BEDARD M, 1993, AM J RESP CELL MOL, V9, P455, DOI 10.1165/ajrcmb/9.4.455; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; Braverman I, 1998, J OTOLARYNGOL, V27, P145; Brook I, 1997, J MED MICROBIOL, V46, P430, DOI 10.1099/00222615-46-5-430; BROOK I, 1981, JAMA-J AM MED ASSOC, V246, P967, DOI 10.1001/jama.246.9.967; Brook I, 1996, J MED MICROBIOL, V45, P372, DOI 10.1099/00222615-45-5-372; Brook I, 1996, ARCH OTOLARYNGOL, V122, P418; CANCIANI M, 1988, ACTA PAEDIATR SCAND, V77, P612, DOI 10.1111/j.1651-2227.1988.tb10715.x; Chung SK, 1999, J LARYNGOL OTOL, V113, P865, DOI 10.1017/S002221510014544X; CODY DT, 1994, LARYNGOSCOPE, V104, P1074, DOI 10.1288/00005537-199409000-00005; Dal T, 1997, EUR ARCH OTO-RHINO-L, V254, P205, DOI 10.1007/BF00879275; Danese M, 1997, J RADIOL, V78, P651; Demoly P, 1997, CLIN EXP ALLERGY, V27, P672; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; Elwany S, 1998, EUR ARCH OTO-RHINO-L, V255, P511, DOI 10.1007/s004050050109; Folker RJ, 1998, LARYNGOSCOPE, V108, P1623, DOI 10.1097/00005537-199811000-00007; Gold SM, 1997, LARYNGOSCOPE, V107, P1586, DOI 10.1097/00005537-199712000-00002; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1999, J ALLERGY CLIN IMMUN, V103, P79, DOI 10.1016/S0091-6749(99)70529-4; Hamilos DL, 1999, IMMUNOL ALLERGY CLIN, V19, P799, DOI 10.1016/S0889-8561(05)70123-5; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HAMILOS DL, 2000, IN PRESS ALLERGY CLI; INOUE H, 1994, AM J RESP CELL MOL, V11, P651, DOI 10.1165/ajrcmb.11.6.7946394; Jones NS, 1997, CLIN OTOLARYNGOL, V22, P47, DOI 10.1046/j.1365-2273.1997.00862.x; Kaliner MA, 1997, J ALLERGY CLIN IMMUN, V99, pS829, DOI 10.1016/S0091-6749(97)70041-1; KALINER MA, 1997, J ALLERGY CLIN IMMUN, V100, P510; Kaluskar S K, 1997, Ear Nose Throat J, V76, P884; Kamil A, 1998, OTOLARYNG HEAD NECK, V118, P804, DOI 10.1016/S0194-5998(98)70273-6; KATZENSTEIN ALA, 1983, AM J SURG PATHOL, V7, P439, DOI 10.1097/00000478-198307000-00006; Kennedy D W, 1992, Laryngoscope, V102, P1; Kennedy DW, 1998, LARYNGOSCOPE, V108, P502, DOI 10.1097/00005537-199804000-00008; Khair OA, 1996, EUR RESPIR J, V9, P1913, DOI 10.1183/09031936.96.09091913; Klossek JM, 1998, J LARYNGOL OTOL, V112, P1162, DOI 10.1017/S0022215100142732; Kuhn FA, 1998, ARCH OTOLARYNGOL, V124, P1179, DOI 10.1001/archotol.124.10.1179; Lusk RP, 1996, OTOLARYNG CLIN N AM, V29, P75; Mafee M F, 1994, Ear Nose Throat J, V73, P532; MAFEE MF, 1994, ENT-EAR NOSE THROAT, V73, P540; MAFEE MF, 1994, ENT-EAR NOSE THROAT, V73, P536; Manning SC, 1997, LARYNGOSCOPE, V107, P170, DOI 10.1097/00005537-199702000-00007; Matthews BL, 1997, OTOLARYNG HEAD NECK, V117, P422, DOI 10.1016/S0194-5998(97)70139-6; McNally PA, 1997, ALLERGY ASTHMA PROC, V18, P169, DOI 10.2500/108854197778984374; MILLER CH, 1994, OTOLARYNG HEAD NECK, V111, P51, DOI 10.1177/019459989411100111; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; Mott AE, 1997, ARCH OTOLARYNGOL, V123, P367; Nadel DM, 1998, AM J RHINOL, V12, P233, DOI 10.2500/105065898781390000; Passali D, 1999, EUR ARCH OTO-RHINO-L, V256, P335, DOI 10.1007/s004050050158; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Porter JP, 1999, AM J RHINOL, V13, P203, DOI 10.2500/105065899781389696; RAMADAN HH, 1995, AM J OTOLARYNG, V16, P303, DOI 10.1016/0196-0709(95)90057-8; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; Rhyoo C, 1999, J ALLERGY CLIN IMMUN, V103, P395, DOI 10.1016/S0091-6749(99)70462-8; Rontal M, 1999, AM J RHINOL, V13, P91, DOI 10.2500/105065899782106788; RoweJones JM, 1997, CLIN OTOLARYNGOL, V22, P167, DOI 10.1046/j.1365-2273.1997.00003.x; Sanchez-Segura A, 1998, J ALLERGY CLIN IMMUN, V102, P953, DOI 10.1016/S0091-6749(98)70333-1; Schapowal A. G., 1995, Acta Oto-Rhino-Laryngologica Belgica, V49, P235; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P395, DOI 10.1016/S0091-6749(98)70126-5; Senior BA, 1996, ANN ALLERG ASTHMA IM, V77, P6, DOI 10.1016/S1081-1206(10)63473-4; Setliff RC, 1997, OTOLARYNG CLIN N AM, V30, P341; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P231, DOI 10.2500/108854196778662246; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P269, DOI 10.2500/108854196778662237; Shapiro NL, 1999, ANN OTO RHINOL LARYN, V108, P629, DOI 10.1177/000348949910800701; SHONE G R, 1990, Rhinology (Utrecht), V28, P265; Simon HU, 1997, J IMMUNOL, V158, P3902; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Subramanian H, 1999, J ALLERGY CLIN IMMUN, V103, pS249; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; TAKEUCHI K, 1995, AM J OTOLARYNG, V16, P98, DOI 10.1016/0196-0709(95)90039-X; TEDESCHI A, 1994, J ALLERGY CLIN IMMUN, V93, P526, DOI 10.1016/0091-6749(94)90363-8; THORNHILL MH, 1991, J IMMUNOL, V146, P592; Thornsberry C, 1999, J ANTIMICROB CHEMOTH, V44, P749, DOI 10.1093/jac/44.6.749; Wald ER, 1998, AM J MED SCI, V316, P13, DOI 10.1097/00000441-199807000-00003; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WHITE PS, 1991, J LARYNGOL OTOL, V105, P20, DOI 10.1017/S0022215100114720; WIPPOLD FJ, 1995, ALLERGY PROC, V16, P165, DOI 10.2500/108854195778666801; ZINREICH SJ, 1992, J ALLERGY CLIN IMMUN, V90, P445, DOI 10.1016/0091-6749(92)90167-Z	86	157	169	0	20	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					213	227						15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932063				2022-12-18	WOS:000088708100002
J	Chan, MTS; Leung, DYM; Szefler, SJ; Spahn, JD				Chan, MTS; Leung, DYM; Szefler, SJ; Spahn, JD			Difficult-to-control asthma: Clinical characteristics of steroid-insensitive asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						steroid-sensitive asthma; steroid-insensitive asthma; steroid-resistant asthma; glucocorticoid; inflammation	GLUCOCORTICOID RESISTANCE; HYPERREACTIVITY	Background: Although widely used, little is known regarding the patterns of response that subjects with severe asthma exhibit to oral glucocorticoid (GC) therapy. Methods: We retrospectively reviewed the charts of 164 consecutive adolescents admitted to the National Jewish Medical and Research Center for difficult-to-control asthma, Data collected included medical history, pulmonary function measures by plethysmography, methacholine challenge results, AM cortisol levels, serum IgE, total eosinophil counts (TEC), serum eosinophil cationic protein (ECP), soluble IL-2 receptor (sIL-2R), and spirometry, Results: Eighty-seven patients (53%) required a GC burst during the hospitalization secondary to poor asthma control. Those requiring a GC burst had a significantly longer history of asthma, a greater degree of bronchial hyperresponsiveness, and lower pulmonary function. Twenty-one patients (24%) failed to respond with a greater than 15% improvement in their AM prebronchodilator FEV, after the GC burst and were termed steroid insensitive (SI). Although those with SI asthma had a similar duration of asthma, they required oral GC therapy at a younger age, required a larger maintenance oral GC dose on admission, and were more likely to be African-American, compared with those with steroid-sensitive asthma. Furthermore, two distinct spirometry patterns were noted among the SI asthmatic subjects: "chaotic" and "non-chaotic." Patients with the chaotic pattern were characterized by a significant degree of variability (greater than 30%) in daily pulmonary function, whereas those with nonchaotic, SI asthma were characterized by less than 15% variability in daily lung function. Those with nonchaotic SI were diagnosed with asthma and treated with oral GCs at a later age. Conclusions: This retrospective study suggests that SI asthma is quite common (25%) among adolescents with severe asthma evaluated at a national referral center, In addition, two distinct patterns of SI asthma have been identified that mag constitute different pathophysiologic processes. Finally, the overrepresentation of African-Americans in the SI group supports the need for further epidemiologic studies investigating the prevalence of SI asthma and the impact early asthma intervention may have on this severe form of asthma.	Natl Jewish Med & Res Ctr, Div Clin Pharmacol, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Div Allergy Clin Immunol, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Spahn, JD (corresponding author), Natl Jewish Med & Res Ctr, Div Clin Pharmacol, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, 1400 Jackson St K-926, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00051] Funding Source: Medline; NHLBI NIH HHS [HL-36577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; Boggs PB, 1996, ANN ALLERG ASTHMA IM, V77, P429, DOI 10.1016/S1081-1206(10)63345-5; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026, DOI 10.1164/ajrccm/144.5.page; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; Gainer JV, 1996, J ALLERGY CLIN IMMUN, V98, P283, DOI 10.1016/S0091-6749(96)70151-3; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Lee T, 1996, AM J RESP CRIT CARE, V154, pS1, DOI 10.1164/ajrccm/154.2_Pt_2.S1; POZNANSKY MC, 1984, CLIN SCI, V67, P639, DOI 10.1042/cs0670639; RICHE MF, 1996, WORLD ALMANAC BOOK F, P382; ROCHE WR, 1989, LANCET, V1, P520; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Sly RM, 1997, ANN ALLERG ASTHMA IM, V78, P347, DOI 10.1016/S1081-1206(10)63195-X; SMITH JM, 1988, ALLERGY PRINCIPLES P, P891; SPAHN JD, 1997, ALLERGIC DIS DIAGNOS, P331; TUCHINDA M, 1987, ANN ALLERGY, V59, P207; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; WALKER KB, 1987, CLIN EXP IMMUNOL, V68, P162; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	24	157	164	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					594	601		10.1016/S0091-6749(98)70165-4	http://dx.doi.org/10.1016/S0091-6749(98)70165-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600494				2022-12-18	WOS:000073697400005
J	Strachan, DP; Harkins, LS; Johnston, IDA; Anderson, HR				Strachan, DP; Harkins, LS; Johnston, IDA; Anderson, HR			Childhood antecedents of allergic sensitization in young British adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; skin prick tests; socioeconomic variations; siblings	RISK-FACTORS; HAY-FEVER; ASTHMA	Objective: This study was designed to investigate whether associations of self-reported hay fever with sibship size, birth order, infant feeding, and childhood socioeconomic status reflect variations in sensitization to common aeroallergens. Methods: One thousand three hundred sixty-nine persons born throughout Britain in 1958 were followed up to age 34 to 35 yeats. The cohort included 1050 subjects with a history of asthma, wheezy bronchitis, wheezing, or pneumonia and 319 with no history of wheezing illness at ages 7, 11, 16, 23, ol 33 years. Skin prick tests with extracts of mixed grass pollen, house dust mile (Der p I), and cat fill were performed; and wheal diameters were measured. Results: The prevalence of positive skin test results (greater than or equal to 3 mm wheal) was independently related (p < 0.01) to male sex, reduced numbers of older siblings (but not younger siblings), and higher socioeconomic status in childhood. Current cigarette smoking and maternal smoking during pregnancy were independently associated (p < 0.01) with a reduced prevalence of skin prick test positivity. No significant independent effects (p > 0.10) were found for adult social class, maternal age, birth weight, gestation, breastfeeding, preschool nursery attendance, urban birthplace, or gas stove exposure. Conclusion: Factors related to small families and relative affluence in childhood promote atopic sensitization to a variety of aeroallergens in later life. These observations are consistent with the suggestion that early infection may protect against subsequent allergic disease.	UNIV NOTTINGHAM HOSP, QUEENS MED CTR, DEPT MED, NOTTINGHAM NG7 2UH, ENGLAND	University of Nottingham	Strachan, DP (corresponding author), ST GEORGE HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND.		Anderson, Hugh R/A-7417-2016		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Braback Lennart, 1995, Archives of Disease in Childhood, V72, P487; CHANYEUNG M, 1990, CHEST, V98, pS148, DOI 10.1378/chest.98.5.148S; *DEP HLTH COMM MED, 1995, ASTHM OUTD AIR POLL, P85; DREBORG S, 1989, ALLERGY S10, V44, P52; Drebotg S, 1989, ALLERGY S10, V44, P22; FERRI E, 1993, LIFE 33 5 FOLLOW UP; Francis B., 1993, GLIM SYSTEM RELEASE; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; RONCHETTI R, 1992, ARCH DIS CHILD, V67, P496, DOI 10.1136/adc.67.4.496; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; *SAS SYST INC, 1990, SAS STAT US GUID VER; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1996, BRIT MED J, V312, P1195; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	20	157	159	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				6	12		10.1016/S0091-6749(97)81038-X	http://dx.doi.org/10.1016/S0091-6749(97)81038-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003205	Bronze			2022-12-18	WOS:A1997WD06100002
J	BOUSQUET, J; MAASCH, H; MARTINOT, B; HEJJAOUI, A; WAHL, R; MICHEL, FB				BOUSQUET, J; MAASCH, H; MARTINOT, B; HEJJAOUI, A; WAHL, R; MICHEL, FB			DOUBLE-BLIND, PLACEBO-CONTROLLED IMMUNOTHERAPY WITH MIXED GRASS-POLLEN ALLERGOIDS .2. COMPARISON BETWEEN PARAMETERS ASSESSING THE EFFICACY OF IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGOPHARMA JAOCHIM GANZER KG,REINBECK,FED REP GER	Allergopharma	BOUSQUET, J (corresponding author), CHU MONTPELLIER,CLIN MALAD RESP,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					BERG T, 1980, INT ARCH ALLER A IMM, V63, P266, DOI 10.1159/000232636; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550, DOI 10.1159/000234277; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BROWN HM, 1977, ACTA ALLERGOL, V32, P321; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DEUSCHL H, 1977, CLIN ALLERGY, V7, P315, DOI 10.1111/j.1365-2222.1977.tb01459.x; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; FROSTAD AB, 1980, ALLERGY, V35, P81, DOI 10.1111/j.1398-9995.1980.tb01722.x; IRANDER K, 1979, ACTA OTOLARYNGOL S, V360, P24; KJELLMAN NIM, 1980, ALLERGY, V35, P323, DOI 10.1111/j.1398-9995.1980.tb01774.x; LAWRENCE ID, 1987, J ALLERGY CLIN IMMUN, V79, P179; MACALLEN MK, 1969, ACTA ALLERGOL, V24, P421; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V68, P449, DOI 10.1016/0091-6749(81)90199-8; MERINEY DK, 1986, ANN ALLERGY, V56, P34; MICHEL FB, 1987, J ALLERGY CLIN IMMUN, V79, P247; MOLLER C, 1984, ALLERGY, V39, P291, DOI 10.1111/j.1398-9995.1984.tb00865.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NAGAYA H, 1977, ANN ALLERGY, V39, P246; NORDVALL SL, 1978, INT ARCH ALLER A IMM, V67, P132; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; NORMAN PS, 1981, PROG ALLERGY, V32, P38; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; OSTERBALLE O, 1982, ALLERGY, V37, P491, DOI 10.1111/j.1398-9995.1982.tb02332.x; OSTERBALLE O, 1981, ALLERGY, V36, P183, DOI 10.1111/j.1398-9995.1981.tb01834.x; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; PATTERSON R, 1983, ALLERGY PRINCIPLES P, P1119; Pepys J., 1975, BR J HOSP MED, V14, P412; PUTTONEN E, 1981, INT ARCH ALLER A IMM, V64, P157, DOI 10.1159/000232687; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; ROMAGNANI S, 1976, CLIN EXP IMMUNOL, V19, P83; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; WIHL JA, 1983, EUR J RESPIR DIS, V64, P175	42	157	161	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				439	446		10.1016/0091-6749(88)90017-6	http://dx.doi.org/10.1016/0091-6749(88)90017-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170992				2022-12-18	WOS:A1988Q322900018
J	TAYLOR, WW; OHMAN, JL; LOWELL, FC				TAYLOR, WW; OHMAN, JL; LOWELL, FC			IMMUNOTHERAPY IN CAT-INDUCED ASTHMA - DOUBLE-BLIND TRIAL WITH EVALUATION OF BRONCHIAL RESPONSES TO CAT ALLERGEN AND HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,MED SERV,ALLERGY UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								AAS K, 1970, ARCH DIS CHILD, V45, P221, DOI 10.1136/adc.45.240.221; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; BROWN FR, 1968, ANN ALLERGY, V26, P305; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CITRON K M, 1958, Thorax, V13, P229, DOI 10.1136/thx.13.3.229; Clarke JA, 1927, J AMER MED ASSOC, V89, P866, DOI 10.1001/jama.1927.02690110030010; Cotes JE, 1975, LUNG FUNCTION; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; Freeman J, 1930, LANCET, V1, P744; Hardy W D Jr, 1973, Bibl Haematol, V39, P778; Ipsen J., 1970, BANCROFTS INTRO BIOS; LEVY SB, 1974, NEW ENGL J MED, V290, P513, DOI 10.1056/NEJM197402282900911; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1976, J ALLERGY CLIN IMMUN, V57, P560, DOI 10.1016/0091-6749(76)90007-5; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; OHMAN JL, 1974, J IMMUNOL, V113, P1668; PATTERSON R, 1972, ALLERGIC DISEASES DI, P297; RAJKA G, 1961, ACTA ALLERGOL, V16, P168, DOI 10.1111/j.1398-9995.1961.tb02891.x; RYNES SE, 1937, J ALLERGY, V8, P470; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; TUCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131, DOI 10.1016/0091-6749(73)90018-3; TUFT L, 1967, AM J MED SCI, V253, P19, DOI 10.1097/00000441-196701000-00005	23	157	157	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	5					283	287		10.1016/0091-6749(78)90048-9	http://dx.doi.org/10.1016/0091-6749(78)90048-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EY714	346628				2022-12-18	WOS:A1978EY71400002
J	Finkelman, FD; Khodoun, MV; Strait, R				Finkelman, Fred D.; Khodoun, Marat V.; Strait, Richard			Human IgE-independent systemic anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylatoxin; complement; Fc epsilon R; Fc gamma R; IgE; IgG; mast cell; basophil; mouse	PLATELET-ACTIVATING-FACTOR; MAST-CELL DEGRANULATION; FC-GAMMA RIII; COMPLEMENT ACTIVATION; CARDIOPULMONARY CHANGES; ACTIVE ANAPHYLAXIS; MURINE MODEL; MOUSE; RELEASE; INFLIXIMAB	Anaphylaxis is a rapidly developing, life-threatening, generalized or systemic allergic reaction that is classically elicited by antigen crosslinking of antigen-specific IgE bound to the high-affinity IgE receptor Fc epsilon RI on mast cells and basophils. This initiates signals that induce cellular degranulation with release and secretion of vasoactive mediators, enzymes, and cytokines. However, IgE-independent mechanisms of anaphylaxis have been clearly demonstrated in experimental animals. These include IgG-dependent anaphylaxis, which involves the triggering of mediator release by IgG/antigen complex crosslinking of Fc gamma Rs on macrophages, basophils, and neutrophils; anaphylaxis mediated by binding of the complement-derived peptides C3a and C5a to their receptors on mast cells, basophils, and other myeloid cells; and direct activation of mast cells by drugs that interact with receptors on these cells. Here we review the mechanisms involved in these IgE-independent forms of anaphylaxis and the clinical evidence for their human relevance. We conclude that this evidence supports the existence of all 3 IgE-independent mechanisms as important causes of human disease, although practical and ethical considerations preclude their demonstration to the degree of certainty possible with animal models. Furthermore, we cite evidence that different clinical situations can suggest different mechanisms as having a primal role in anaphylaxis and that IgE-dependent and distinct IgE-independent mechanisms can act together to increase anaphylaxis severity. As specific agents become available that can interfere with mechanisms involved in the different types of anaphylaxis, recognition of specific types of anaphylaxis is likely to become important for optimal prophylaxis and therapy.	[Finkelman, Fred D.; Khodoun, Marat V.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Allergy Immunol & Rheumatol, Cincinnati, OH 45208 USA; [Finkelman, Fred D.; Strait, Richard] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45208 USA; [Finkelman, Fred D.; Khodoun, Marat V.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Strait, Richard] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Finkelman, FD (corresponding author), Univ Cincinnati, Med Ctr, Div Immunol, 3550 Principio Ave, Cincinnati, OH 45208 USA.	finkelfd@ucmail.uc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI103816, R01AI113162] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI103816, R01 AI113162] Funding Source: Medline; Intramural VA [VA999999] Funding Source: Medline; BLRD VA [I01 BX001347] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural VA; BLRD VA		Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; BERGAMASCHINI L, 1995, J LAB CLIN MED, V125, P348; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Farnam K, 2012, INT ARCH ALLERGY IMM, V159, P327, DOI 10.1159/000339690; FUREDER W, 1995, J IMMUNOL, V155, P3152; GREY HM, 1971, J EXP MED, V133, P289, DOI 10.1084/jem.133.2.289; Hedin H, 1980, Dev Biol Stand, V48, P179; HIRAYAMA N, 1982, P NATL ACAD SCI-BIOL, V79, P613, DOI 10.1073/pnas.79.2.613; ISHIZAKA T, 1972, J IMMUNOL, V108, P513; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V132, P1375, DOI 10.1016/j.jaci.2013.09.008; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V131, P1555, DOI 10.1016/j.jaci.2013.02.043; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Kodama T, 2013, IMMUNOBIOLOGY, V218, P844, DOI 10.1016/j.imbio.2012.10.003; Kucuk ZY, 2012, J ALLERGY CLIN IMMUN, V129, P1343, DOI 10.1016/j.jaci.2012.03.004; Lee JJ, 2007, BLOOD, V109, P859, DOI 10.1182/blood-2006-06-027490; Liu E, 2002, J CLIN INVEST, V110, P1021, DOI 10.1172/JCI200215488; Matsuo H, 2013, ALLERGOL INT, V62, P503, DOI 10.2332/allergolint.13-OA-0536; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; MENCIAHUERTA JM, 1979, EUR J IMMUNOL, V9, P409, DOI 10.1002/eji.1830090512; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; Miele E, 2004, J PEDIATR GASTR NUTR, V38, P502, DOI 10.1097/00005176-200405000-00008; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Mushlin N, 2007, SOUTH MED J, V100, P611; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; SANCHEZCRESPO M, 1980, IMMUNOLOGY, V40, P645; Schafer B, 2013, J ALLERGY CLIN IMMUN, V131, P541, DOI 10.1016/j.jaci.2012.05.009; SCHMIDT AP, 1969, NEW ENGL J MED, V280, P188, DOI 10.1056/NEJM196901232800404; Schmidt-Lauber C, 2015, ANN RHEUM DIS, V74, P2062, DOI 10.1136/annrheumdis-2013-204900; Schwartz Lawrence B, 2004, Novartis Found Symp, V257, P65; SCHWARTZ LB, 1987, ANN ALLERGY, V58, P226; Schwartz LB, 2004, NOVART FDN SYMP, V257, P276; Schwartz LB, 2004, NOVART FDN SYMP, V257, P98; Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322; Steenholdt C, 2012, J CROHNS COLITIS, V6, P108, DOI 10.1016/j.crohns.2011.08.001; Strait RT, 2011, J ALLERGY CLIN IMMUN, V127, P982, DOI 10.1016/j.jaci.2011.01.034; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Szebeni J, 2005, TOXICOLOGY, V216, P106, DOI 10.1016/j.tox.2005.07.023; Szebeni J, 2014, MOL IMMUNOL, V61, P163, DOI 10.1016/j.molimm.2014.06.038; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TAKEISHI T, 1991, J CLIN INVEST, V88, P598, DOI 10.1172/JCI115344; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Umeda Y, 2007, Kyobu Geka, V60, P69; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; van der Heijden J, 2013, J ALLERGY CLIN IMMUN, V131, P1408, DOI 10.1016/j.jaci.2013.02.009; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; VANEPPS DE, 1993, J IMMUNOL, V150, P246; VANEPPS DE, 1992, J LEUKOCYTE BIOL, V51, P393, DOI 10.1002/jlb.51.4.393; Veien M, 2000, ANESTHESIOLOGY, V92, P1074, DOI 10.1097/00000542-200004000-00026; Zhao W, 2006, J IMMUNOL, V177, P694, DOI 10.4049/jimmunol.177.1.694	62	156	161	1	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1674	1680		10.1016/j.jaci.2016.02.015	http://dx.doi.org/10.1016/j.jaci.2016.02.015			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27130857	Green Accepted, Bronze			2022-12-18	WOS:000377527200006
J	Jutel, M; Agache, I; Bonini, S; Burks, W; Calderon, M; Canonica, W; Cox, LD; Demoly, P; Frew, AJ; O'Hehir, R; Kleine-Tebbe, J; Muraro, A; Lack, G; Larenas, D; Levin, M; Martin, BL; Nelson, H; Pawankar, R; Pfaar, O; van Ree, R; Sampson, H; Sublett, JL; Sugita, K; Du Toit, G; Werfel, T; van Wijk, RG; Zhang, L; Akdis, M; Akdis, CA				Jutel, Marek; Agache, Ioana; Bonini, Sergio; Burks, Wesley; Calderon, Moises; Canonica, Walter; Cox, Linda; Demoly, Pascal; Frew, Antony J.; O'Hehir, Robyn; Kleine-Tebbe, Joerg; Muraro, Antonella; Lack, Gideon; Larenas, Desiree; Levin, Michael; Martin, Bryan L.; Nelson, Harald; Pawankar, Ruby; Pfaar, Oliver; van Ree, Ronald; Sampson, Hugh; Sublett, James L.; Sugita, Kazunari; Du Toit, George; Werfel, Thomas; van Wijk, Roy Gerth; Zhang, Luo; Akdis, Muebeccel; Akdis, Cezmi A.			International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						International consensus; allergy; immunotherapy; allergen vaccine; allergen standardization; pharmacoeconomics; cost-effectiveness; mechanisms; tolerance; marketing authorization; regulatory authorities; unmet needs	GRASS-POLLEN IMMUNOTHERAPY; REGULATORY T-CELLS; COST-EFFECTIVENESS ANALYSIS; HISTAMINE-RECEPTOR 2; TOLL-LIKE RECEPTORS; ECONOMIC-EVALUATION; SUBLINGUAL IMMUNOTHERAPY; SYMPTOMATIC TREATMENT; IMMUNE-RESPONSES; B-CELLS	This article continues the comprehensive international consensus (ICON) statement on allergen immunotherapy (AIT). The initial article also recently appeared in the Journal. The conclusions below focus on key mechanisms of AIT-triggered tolerance, requirements in allergen standardization, AIT cost-effectiveness, and regulatory guidance. Potential barriers to and facilitators of the use of AIT are described in addition to future directions. International allergy specialists representing the European Academy of Allergy and Clinical Immunology; the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma and Immunology; and the World Allergy Organization critically reviewed the existing literature and prepared this summary of recommendations for best AIT practice. The authors contributed equally and reached consensus on the statements presented herein.	[Jutel, Marek] Wroclaw Med Univ, Dept Clin Immunol, Chalubinskiego 5, PL-50368 Wroclaw, Poland; [Jutel, Marek] ALL MED Med Res Inst, Wroclaw, Poland; [Agache, Ioana] Transylvania Univ, Fac Med, Brasov, Romania; [Bonini, Sergio] Univ Naples 2, Rome, Italy; [Bonini, Sergio] IFT CNR, Rome, Italy; [Bonini, Sergio] Expert On Secondment European Med Agcy, London, England; [Burks, Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Calderon, Moises] Univ London Imperial Coll Sci Technol & Med, Sect Allergy & Clin Immunol, Natl Heart & Lung Inst, Royal Brompton Hosp, London SW7 2AZ, England; [Canonica, Walter] DIMI Univ Genoa, Allergy & Resp Dis Clin, IRCCS AOU San Martino, Genoa, Italy; [Cox, Linda] Ctr Asthma & Allergy, Ft Lauderdale, FL USA; [Demoly, Pascal] Univ Hosp Montpellier, INSERM, U657, Montpellier, France; [Frew, Antony J.] Royal Sussex Cty Hosp, Dept Resp Med, Brighton, E Sussex, England; [O'Hehir, Robyn] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia; [O'Hehir, Robyn] Monash Univ, Melbourne, Vic, Australia; [Kleine-Tebbe, Joerg] Allergy & Asthma Ctr Westend, Berlin, Germany; [Muraro, Antonella] Padua Gen Univ Hosp, Dept Mother & Child Hlth, Padua, Italy; [Lack, Gideon] MRC, Div Asthma Allergy & Lung Biol, London W1N 4AL, England; [Lack, Gideon] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London WC2R 2LS, England; [Lack, Gideon] Guys & St Thomas NHS Fdn Trust, Childrens Allergy Unit, London, England; [Larenas, Desiree] Hosp Med Sur, Mexico City, DF, Mexico; [Levin, Michael] Red Cross War Mem Childrens Hosp, Sch Child & Adolescent Hlth, Div Allergy, Cape Town, South Africa; [Martin, Bryan L.] Walter Reed Army Med Ctr, Dept Allergy & Immunol, Silver Spring, MD USA; [Nelson, Harald] Natl Jewish Hlth, Denver, CO USA; [Pawankar, Ruby] Nippon Med Sch, Dept Pediat, 1-1-5 Sendagi, Tokyo 113, Japan; [Pfaar, Oliver] Univ Hosp Mannheim, Ctr Rhinol & Allergol, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1012 WX Amsterdam, Netherlands; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1012 WX Amsterdam, Netherlands; [Sampson, Hugh] Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy Immunol, New York, NY 10029 USA; [Sampson, Hugh] Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Sublett, James L.] Univ Louisville, Sch Med, Sect Allergy & Immunol, Dept Pediat, Louisville, KY 40292 USA; [Sugita, Kazunari; Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res, CH-8006 Zurich, Switzerland; [Sugita, Kazunari; Akdis, Muebeccel; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Du Toit, George] Kings Coll London, Div Asthma Allergy & Lung Biol, Dept Pediat Allergy, London WC2R 2LS, England; [Du Toit, George] MRC, London W1N 4AL, England; [Du Toit, George] Asthma UK Ctr Allerg Mech Asthma, London, England; [Werfel, Thomas] Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, Hannover, Germany; [van Wijk, Roy Gerth] Erasmus MC, Rotterdam, Netherlands; [Zhang, Luo] Beijing Inst Otolaryngol, Beijing, Peoples R China	Wroclaw Medical University; Transylvania University of Brasov; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Farmacologia Traslazionale (IFT-CNR); University of North Carolina; University of North Carolina Chapel Hill; Imperial College London; Royal Brompton Hospital; University of Genoa; IRCCS AOU San Martino IST; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; University of Brighton; Florey Institute of Neuroscience & Mental Health; Monash University; University of Padua; Azienda Ospedaliera - Universita di Padova; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; United States Department of Defense; United States Army; National Jewish Health; Nippon Medical School; Ruprecht Karls University Heidelberg; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Louisville; Swiss Institute of Allergy & Asthma Research; University of Zurich; University of London; King's College London; University of London; King's College London; Hannover Medical School; Erasmus University Rotterdam; Erasmus MC	Jutel, M (corresponding author), Wroclaw Med Univ, Dept Clin Immunol, Chalubinskiego 5, PL-50368 Wroclaw, Poland.	marek.jutel@umed.wroc.pl	Bonini, Sergio/T-6594-2019; Agache, Ioana/AAP-7403-2020; Demoly, Pascal/Y-9938-2019; Werfel, Thomas/B-6921-2012; Levin, Michael/AAT-2370-2020; O'Hehir, Robyn E/H-3627-2011; canonica, giorgio walter/ABF-2037-2020; Cox, Linda/AAP-1697-2021; Akdis, Cezmi/AAV-4844-2020	Bonini, Sergio/0000-0003-0079-3031; Demoly, Pascal/0000-0001-7827-7964; Levin, Michael/0000-0003-2439-7981; O'Hehir, Robyn E/0000-0002-3489-7595; canonica, giorgio walter/0000-0001-8467-2557; Cox, Linda/0000-0002-5258-6870; Akdis, Cezmi/0000-0001-8020-019X; Kleine-Tebbe, Joerg/0000-0002-2862-7353; Lack, Gideon/0000-0001-7350-4021; JUTEL, MAREK/0000-0003-1555-9379; Du Toit, George/0000-0002-0321-2928; Larenas Linnemann, Desiree/0000-0002-5713-5331; Zhang, Luo/0000-0002-0910-9884; SUBLETT, JAMES L/0000-0003-4696-4609	Anergis; Allergopharma; GLG Research (Gerson Lehrman Group); ActoGeniX; Genentech; Sanofi US Services; Valeant Pharmaceuticals North America; ALK-Abello; Stallergenes; Merck; Greer; Circassia; Stallergenes-Greer; DBV; Thermo Fisher Scientific; Chiesi; Pierre Fabre Medicament; Menarini; MSD; AstraZeneca; NIHR (UK); MEDA; Pfizer; MIT; BI; Novartis Glenmark; Novartis; UCB; GlaxoSmithKline; Astra Zeneca; Senosiain; Sanofi; TEVA; Carnot; Glenmark; Mylan; Pharma Dynamics; INNOVA Pharma; Medical Research Council of South Africa; Thermo Fisher; GlaxoSmithKline/Aspen; Cipla; Astellas; Beiersdorf; Takeda Nycomed; Pearl Therapeutics; Allergopharma (Germany); ALK-Abello (Denmark); Stallergenes (France); HAL-Allergy (Netherlands); Artu Biologicals (Netherlands); Allergy Therapeutics/Bencard (United Kingdom/Germany); Hartington (Spain); Lofarma (Italy); Novartis/Leti (Germany/Spain); GlaxoSmithKline (United Kingdom); Essex-Pharma (Germany); Cytos (Switzerland); Curalogic (Denmark); Roxall (Germany); Biomay (Austria); Thermo Fisher (United States); Circassia (United Kingdom); E.U; Biotech Tools (Belgium); MEDA-Pharma (Sweden); Anergis (Switzerland); Bencard (Germany); Novartis/LETI (Germany); MEDA-Pharma (Germany); GfK Bridgehead (United Kingdom); NAVIGANT-consulting (United States); Sanofi (United States); Guide-point Global Advisors (United States); Pohl-Boskamp (Germany); Mobile Chamber Experts (a GA2LEN partner, Germany); HAL-Allergy (Germany/Netherlands); GlaxoSmithKline (Germany); Thermo-Fisher (Germany); Schattauer (Germany); Springer (Germany); European Academy of Allergy and Clinical Immunology (EAACI); German Society for Allergology and Clinical Immunology (DGAKI); German Respiratory Society (DGP); European Commission; Scientific Advisory Board Chair for HAL Allergy BV; Bayer CropScience; National Institute of Allergy and Infectious Diseases (NIAID) [NO1-AI-15416, UM1AI109565]; Food Allergy and Research Education (FARE); UK Department of Health through NIHR; HAL; Crucell; Emerade; NOW; STW; Biomay; Actelion; Aventis; Circacia; PREDICTA (European Commission's Seventh Framework programme) [260895]; Swiss National Science Foundation; MeDALL (European Commission's Seventh Framework Programme) [261357]; Christine Kuhne-Center	Anergis; Allergopharma; GLG Research (Gerson Lehrman Group); ActoGeniX; Genentech(Roche HoldingGenentech); Sanofi US Services; Valeant Pharmaceuticals North America; ALK-Abello; Stallergenes; Merck(Merck & Company); Greer; Circassia; Stallergenes-Greer; DBV; Thermo Fisher Scientific; Chiesi(Chiesi Pharmaceuticals Inc); Pierre Fabre Medicament; Menarini(Menarini Group); MSD; AstraZeneca(AstraZeneca); NIHR (UK)(National Institute for Health Research (NIHR)); MEDA; Pfizer(Pfizer); MIT; BI; Novartis Glenmark; Novartis(Novartis); UCB(UCB Pharma SA); GlaxoSmithKline(GlaxoSmithKline); Astra Zeneca(AstraZeneca); Senosiain; Sanofi; TEVA(Teva Pharmaceutical Industries); Carnot; Glenmark; Mylan; Pharma Dynamics; INNOVA Pharma; Medical Research Council of South Africa(South African Medical Research Council); Thermo Fisher; GlaxoSmithKline/Aspen; Cipla; Astellas(Astellas Pharmaceuticals); Beiersdorf; Takeda Nycomed; Pearl Therapeutics; Allergopharma (Germany); ALK-Abello (Denmark); Stallergenes (France); HAL-Allergy (Netherlands)(HAL Allergy Group); Artu Biologicals (Netherlands)(Netherlands Government); Allergy Therapeutics/Bencard (United Kingdom/Germany); Hartington (Spain); Lofarma (Italy); Novartis/Leti (Germany/Spain); GlaxoSmithKline (United Kingdom)(GlaxoSmithKline); Essex-Pharma (Germany); Cytos (Switzerland); Curalogic (Denmark); Roxall (Germany); Biomay (Austria); Thermo Fisher (United States); Circassia (United Kingdom); E.U(European Commission); Biotech Tools (Belgium); MEDA-Pharma (Sweden); Anergis (Switzerland); Bencard (Germany); Novartis/LETI (Germany); MEDA-Pharma (Germany); GfK Bridgehead (United Kingdom); NAVIGANT-consulting (United States); Sanofi (United States); Guide-point Global Advisors (United States); Pohl-Boskamp (Germany); Mobile Chamber Experts (a GA2LEN partner, Germany); HAL-Allergy (Germany/Netherlands)(HAL Allergy Group); GlaxoSmithKline (Germany)(GlaxoSmithKline); Thermo-Fisher (Germany); Schattauer (Germany); Springer (Germany); European Academy of Allergy and Clinical Immunology (EAACI); German Society for Allergology and Clinical Immunology (DGAKI); German Respiratory Society (DGP); European Commission(European CommissionEuropean Commission Joint Research Centre); Scientific Advisory Board Chair for HAL Allergy BV(HAL Allergy Group); Bayer CropScience(Bayer AG); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy and Research Education (FARE); UK Department of Health through NIHR; HAL(Horticulture Australia Limited); Crucell; Emerade; NOW; STW(Technologiestichting STW); Biomay; Actelion; Aventis(Sanofi-Aventis); Circacia; PREDICTA (European Commission's Seventh Framework programme); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); MeDALL (European Commission's Seventh Framework Programme); Christine Kuhne-Center	M. Jutel has received consultancy fees from Anergis and has received lecture fees from Allergopharma. S. Bonini has received travel support and is an expert on secondment at the European Medicine Agency. A. W. Burks is on the FARE and World Allergy Organization boards; is on the Murdoch Children's Research Institute Advisory Board; is an unpaid consultant for Dynavax Technologies, Perrigo Company (PBN Nutritionals), and Perosphere; has received consultancy fees from GLG Research (Gerson Lehrman Group), ActoGeniX, Genentech, Sanofi US Services, and Valeant Pharmaceuticals North America; is employed by the University of North Carolina; has patents US5558869, US55973121, US6441142, US6486311, US6835824, US7485708, and US7879977; has received payment for developing educational presentations from Current Views 2012; has stock/stock options in Allertein and Mastcell Pharmaceuticals; and has received travel support for various grand rounds and presentations. M. Calderon is on the boards for ALK-Abello and HAL Allergy, has received consultancy fees from ALK-Abello and Stallergenes, and has received lecture fees from ALK-Abello, Stallergenes, Merck, and Allergopharma. L. Cox has received personal fees from Greer and is the lead author on one of the studies discussed in the correspondence (publication date 2011) but has had no relationship with the sponsoring company in the past 36 months. P. Demoly has received consultancy fees from ALK-Abello, Circassia, Stallergenes-Greer, Allergopharma, DBV, Thermo Fisher Scientific, Chiesi, and Pierre Fabre Medicament and has received lecture fees from Menarini, MSD, and AstraZeneca. A. J. Frew is on the ALK-Abello board and has received research support from NIHR (UK). D. Larenas is on the CMICA board with no financial gain; has received consultancy fees from MEDA, Pfizer, MIT, BI, Novartis Glenmark, and Chiesi; has received research support from Novartis, Pfizer, MEDA, UCB, GlaxoSmithKline, Astra Zeneca, Senosiain, Sanofi, MSD, TEVA, and Carnot; has received lecture fees from Novartis, Pfizer, MEDA, Astra Zeneca, Sanofi, MSD, TEVA, and Chiesi; has received payment for development of educational presentations from Glenmark; and has received travel support from Novartis, Pfizer, MEDA, AstraZeneca, Sanofi, MSD, and Chiesi. M Levin is on the boards for the Allergy Society of South Africa and the Allergy Foundation of South Africa; has received consultancy fees from Mylan, Pharma Dynamics, and INNOVA Pharma; has received research support from Mylan, the Medical Research Council of South Africa, Thermo Fisher, GlaxoSmithKline/Aspen, AstraZeneca, Cipla, Astellas, Pharma Dynamics, and Beiersdorf; and has received lecture fees from Cipla, Takeda Nycomed, Pharma Dynamics, and Novartis. H. Nelson has received research support from Circassia and has received consulting fees from Circassia, Merck, Pearl Therapeutics and AstraZeneca. O. Pfaar has received research grants for his institution from Allergopharma (Germany), ALK-Abello (Denmark), Stallergenes (France), HAL-Allergy (Netherlands), Artu Biologicals (Netherlands), Allergy Therapeutics/Bencard (United Kingdom/Germany), Hartington (Spain), Lofarma (Italy), Novartis/Leti (Germany/Spain), GlaxoSmithKline (United Kingdom), Essex-Pharma (Germany), Cytos (Switzerland), Curalogic (Denmark), Roxall (Germany), Biomay (Austria), Thermo Fisher (United States), Circassia (United Kingdom), E.; U (FP-7-Health-2013-Innovation 1), Biotech Tools (Belgium), and MEDA-Pharma (Sweden); has received personal payments as consultant for Allergopharma (Germany), Anergis (Switzerland), Bencard (Germany), HAL-Allergy (Netherlands), Novartis/LETI (Germany), MEDA-Pharma (Germany), ALK-Abello (Denmark), Biotech Tools (Belgium), GfK Bridgehead (United Kingdom), NAVIGANT-consulting (United States), Sanofi (United States), Guide-point Global Advisors (United States), Pohl-Boskamp (Germany), Stallergenes (France), and Mobile Chamber Experts (a GA2LEN partner, Germany); has received personal payments for lectures, book chapters, or educational presentations from ALK-Abello (Denmark), Allergopharma (Germany), Stallergenes (France), HAL-Allergy (Germany/Netherlands), Allergy Therapeutics/Bencard (United Kingdom/Germany), Hartington (Spain), Lofarma (Italy), Novartis/Leti (Germany/Spain), GlaxoSmithKline (Germany), Roxall (Germany), Thermo-Fisher (Germany), MEDA-Pharma (Germany), Schattauer (Germany), Springer (Germany). and GlaxoSmithKline (Germany); has served as advisor and on the speakers' bureaus for some of the aforementioned companies; has received travel grants from HAL-Allergy (Netherlands), Allergopharma (Germany), the European Academy of Allergy and Clinical Immunology (EAACI), the German Society for Allergology and Clinical Immunology (DGAKI), and the German Respiratory Society (DGP); and is the current chairman of the Immunotherapy Interest Group (IT IG) of the EAACI and is secretary of the ENT section of the DGAKI. R van Ree has received research support from the European Commission; has received consultancy fees as the Scientific Advisory Board Chair for HAL Allergy BV; is Vice President of the EAACI; has received consultancy fees from Bayer CropScience; and has received lecture fees from Thermo Fisher Scientific. H. Sampson, as of November 1, 2015, is a part-time employee of DBV Technologies and serves as their Chief Scientific Officer; DBV Technologies is developing an epicutaneous patch for the treatment of peanut allergy and other disorders. G. Du Toit has received research support from the National Institute of Allergy and Infectious Diseases (NIAID; NO1-AI-15416 [contract] and UM1AI109565 [grant], covering salary); has received contribution to NIAID contract/grant from Food Allergy and Research Education (FARE); has received Contribution to the KCL Division of Asthma, Allergy & Lung Biology (of which Pediatric Allergy Research is a part) from MRC & Asthma UK Centre; has received a BRC award to Guy's and St Thomas' NHS Foundation from the UK Department of Health through NIHR; and has equity holding in FoodMaestro. R Gerth van Wijk has received consultancy fees from MSD, HAL, Crucell, ALK-Abello, Novartis, and Emerade; has received research support from NOW, STW, Novartis, Biomay, and DBV; has received lecture fees from Allergopharma and Thermo Fisher; has received payment for manuscript preparation from Chiesi; and receives royalties from de Tijdstroom and Bohn, Stafleu, van Loghum. C. A. Akdis has received consultancy fees from Actelion, Aventis, Stallergenes, Allergopharma, and Circacia; is employed by the Swiss Institute of Allergy and Asthma Research, University of Zurich, Switzerland; has received research support from Novartis, PREDICTA (European Commission's Seventh Framework programme no. 260895), the Swiss National Science Foundation, MeDALL (European Commission's Seventh Framework Programme no. 261357), and the Christine Kuhne-Center. The rest of the authors declare that they have no relevant conflicts of interest.	Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; Agache I, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0529-x; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Ariano R, 2006, ALLERGY ASTHMA PROC, V27, P159; Ariano R, 2009, ANN ALLERG ASTHMA IM, V103, P254, DOI 10.1016/S1081-1206(10)60190-1; Bachert C, 2007, CLIN EXP ALLERGY, V37, P772, DOI 10.1111/j.1365-2222.2007.02706.x; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Berto P, 2008, CURR MED RES OPIN, V24, P261, DOI 10.1185/030079908X253726; Berto P, 2006, ANN ALLERG ASTHMA IM, V97, P615, DOI 10.1016/S1081-1206(10)61090-3; Bonini S, 2012, WORLD ALLERGY ORGAN, V5, P120, DOI 10.1097/WOX.0b013e318272484e; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Canonica GW, 2007, RESP MED, V101, P1885, DOI 10.1016/j.rmed.2007.05.003; Casale TB, 2014, J ALLERGY CLIN IMMUN, V133, P612, DOI 10.1016/j.jaci.2014.01.007; Chapman MD, 2008, J ALLERGY CLIN IMMUN, V122, P882, DOI 10.1016/j.jaci.2008.07.030; Chapman MD, 2012, CURR ALLERGY ASTHM R, V12, P478, DOI 10.1007/s11882-012-0282-3; Cox L, 2009, ANN ALLERG ASTHMA IM, V103, P451, DOI 10.1016/S1081-1206(10)60259-1; Creticos PS, 2014, J ALLERGY CLIN IMMUN, V133, P751, DOI 10.1016/j.jaci.2013.10.041; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; de Wit J, 2015, J ALLERGY CLIN IMMUN, V135, P1053, DOI 10.1016/j.jaci.2014.08.012; Ferstl R, 2014, J ALLERGY CLIN IMMUN, V134, P744, DOI 10.1016/j.jaci.2014.04.034; Fili L, 2014, IMMUNOL LETT, V161, P207, DOI 10.1016/j.imlet.2013.12.011; Focke-Tejkl M, 2015, J ALLERGY CLIN IMMUN, V135, P1207, DOI 10.1016/j.jaci.2014.09.012; Fox EM, 2015, J ALLERGY CLIN IMMUN, V135, P1341, DOI 10.1016/j.jaci.2014.07.052; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Grundstrom J, 2012, INT ARCH ALLERGY IMM, V157, P136, DOI 10.1159/000327546; Hankin CS, 2008, J ALLERGY CLIN IMMUN, V121, P227, DOI 10.1016/j.jaci.2007.10.026; Hankin CS, 2013, J ALLERGY CLIN IMMUN, V131, P1084, DOI 10.1016/j.jaci.2012.12.662; Hankin CS, 2010, ANN ALLERG ASTHMA IM, V104, P79, DOI 10.1016/j.anai.2009.11.010; Harvima IT, 2014, J ALLERGY CLIN IMMUN, V134, P530, DOI 10.1016/j.jaci.2014.03.007; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Jutel M, 2011, ALLERGY, V66, P725, DOI 10.1111/j.1398-9995.2011.02589.x; Jutel M, 2014, CURR OPIN ALLERGY CL, V14, P557, DOI 10.1097/ACI.0000000000000121; Jutel M, 2013, ALLERGOL INT, V62, P425, DOI 10.2332/allergolint.13-RAI-0608; Jutel M, 2012, HUM VACC IMMUNOTHER, V8, P1534, DOI 10.4161/hv.22064; Kaczorowski M, 2013, ARCH IMMUNOL THER EX, V61, P229, DOI 10.1007/s00005-013-0217-2; Kaul S, 2011, ALLERGY, V66, P753, DOI 10.1111/j.1398-9995.2011.02552.x; Kaul Susanne, 2013, Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess, V97, P45; Keiding H, 2007, CURR MED RES OPIN, V23, P1113, DOI 10.1185/030079907X187865; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Kucuksezer UC, 2013, J ALLERGY CLIN IMMUN, V131, P875, DOI 10.1016/j.jaci.2012.10.051; Kundig TM, 2014, J ALLERGY CLIN IMMUN, V133, P930, DOI 10.1016/j.jaci.2013.11.036; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Larenas-Linnemann D, 2008, ANN ALLERG ASTHMA IM, V100, P137, DOI 10.1016/S1081-1206(10)60422-X; Larenas-Linnemann D, 2014, J ALLERGY CLIN IMMUN, V133, P937, DOI 10.1016/j.jaci.2013.12.1089; Linhart B, 2014, CLIN EXP ALLERGY, V44, P278, DOI 10.1111/cea.12216; Linhart B, 2015, J IMMUNOL, V194, P4008, DOI 10.4049/jimmunol.1400402; Lorenz AR, 2008, INT ARCH ALLERGY IMM, V147, P263, DOI 10.1159/000146074; Lou W, 2012, PEDIAT ALLERG IMM-UK, V23, P141, DOI 10.1111/j.1399-3038.2011.01249.x; Meadows A, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17270; Mehta AK, 2016, J ALLERGY CLIN IMMUN, V137, P278, DOI 10.1016/j.jaci.2015.05.007; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Nagakumar P, 2016, J ALLERGY CLIN IMMUN, V137, P624, DOI 10.1016/j.jaci.2015.06.038; Nasser S, 2008, ALLERGY, V63, P1624, DOI 10.1111/j.1398-9995.2008.01743.x; Neske Florian, 2009, Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess, V96, P12; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135, P1494, DOI 10.1016/j.jaci.2014.12.1911; Noon L, 1911, LANCET, V1, P1572; Novak N, 2012, J ALLERGY CLIN IMMUN, V130, P1153, DOI 10.1016/j.jaci.2012.04.039; Omnes L F, 2007, Eur Ann Allergy Clin Immunol, V39, P148; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Patel P, 2014, J ALLERGY CLIN IMMUN, V133; Patel P, 2014, J ALLERGY CLIN IMMUN, V133, P121, DOI 10.1016/j.jaci.2013.05.032; Petersen K D, 2005, Allergol Immunopathol (Madr), V33, P296, DOI 10.1016/S0301-0546(05)73246-8; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Rosner-Friese K, 2015, J ALLERGY CLIN IMMUN, V135, P636, DOI 10.1016/j.jaci.2014.10.045; Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047; Ruggeri M, 2013, CLIN DRUG INVEST, V33, P343, DOI 10.1007/s40261-013-0067-z; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Schadlich PK, 2000, PHARMACOECONOMICS, V17, P37, DOI 10.2165/00019053-200017010-00003; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2015, J ALLERGY CLIN IMMUN, V135, P913, DOI 10.1016/j.jaci.2014.09.049; Sharma P, 2015, CLIN EXP IMMUNOL, V179, P128, DOI 10.1111/cei.12442; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Suarez-Fueyo A, 2014, J ALLERGY CLIN IMMUN, V133, P130, DOI 10.1016/j.jaci.2013.09.043; Sugita K, 2015, EXP DERMATOL, V24, P554, DOI 10.1111/exd.12711; Tsai YG, 2014, J ALLERGY CLIN IMMUN, V134, P1206, DOI 10.1016/j.jaci.2014.06.005; Turkeltaub P C, 1987, Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M, P169; Uermosi C, 2014, ALLERGY, V69, P338, DOI 10.1111/all.12327; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Van Ree R, 2008, ALLERGY, V63, P310, DOI 10.1111/j.1398-9995.2007.01612.x; Vieths S, 2012, Pharmeur Bio Sci Notes, V2012, P118; von Moos S, 2014, J ALLERGY CLIN IMMUN, V134, P965, DOI 10.1016/j.jaci.2014.07.037; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; Westerhout K Y, 2012, J Med Econ, V15, P906, DOI 10.3111/13696998.2012.688904	88	156	170	1	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					358	368		10.1016/j.jaci.2015.12.1300	http://dx.doi.org/10.1016/j.jaci.2015.12.1300			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26853128	Bronze			2022-12-18	WOS:000369235500003
J	Kuo, IH; Yoshida, T; De Benedetto, A; Beck, LA				Kuo, I-Hsin; Yoshida, Takeshi; De Benedetto, Anna; Beck, Lisa A.			The cutaneous innate immune response in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; tight junction; pattern recognition receptors; single nucleotide polymorphisms; innate immunity	THYMIC STROMAL LYMPHOPOIETIN; TOLL-LIKE RECEPTOR-2; PEPTIDOGLYCAN RECOGNITION PROTEINS; EPIDERMAL DIFFERENTIATION COMPLEX; ALLERGY CLIN IMMUNOL; STAPHYLOCOCCUS-AUREUS; HUMAN KERATINOCYTES; ANTIMICROBIAL PEPTIDES; SKIN BARRIER; EPITHELIAL-CELLS	Orchestrating when and how the cutaneous innate immune system should respond to commensal or pathogenic microbes is a critical function of the epithelium. The cutaneous innate immune system is a key determinant of the physical, chemical, microbial, and immunologic barrier functions of the epidermis. A malfunction in this system can lead to an inadequate host response to a pathogen or a persistent inflammatory state. Atopic dermatitis is the most common inflammatory skin disorder and characterized by abnormalities in both skin barrier structures (stratum corneum and tight junctions), a robust T(H)2 response to environmental antigens, defects in innate immunity, and an altered microbiome. Many of these abnormalities may occur as the consequence of epidermal dysfunction. The epidermis directly interfaces with the environment and, not surprisingly, expresses many pattern recognition receptors that make it a key player in cutaneous innate immune responses to skin infections and injury. This review will discuss the role epidermal innate receptors play in regulation of skin barriers and, where possible, discuss the relevance of these findings for patients with atopic dermatitis. (J Allergy Clin Immunol 2013;131:266-78.)	[Kuo, I-Hsin; Yoshida, Takeshi; De Benedetto, Anna; Beck, Lisa A.] Univ Rochester, Dept Dermatol, Med Ctr, Rochester, NY 14642 USA; [Kuo, I-Hsin] Univ Rochester, Dept Pathol & Lab Med, Med Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Beck, LA (corresponding author), Univ Rochester, Dept Dermatol, Med Ctr, 601 Elmwood Ave,Box 697, Rochester, NY 14642 USA.	lisa_beck@urmc.rochester.edu		Yoshida, Takeshi/0000-0003-0133-5067	Atopic Dermatitis Research Network [HHSN272201000020C, HHSN272201000017C]; DHHS/PHS/NIH [5 T32 AR007472-21]; National Eczema Association; Dermatology Foundation; Atopic Dermatitis Research Network; Regeneron; Genentech; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007472] Funding Source: NIH RePORTER	Atopic Dermatitis Research Network; DHHS/PHS/NIH; National Eczema Association; Dermatology Foundation; Atopic Dermatitis Research Network; Regeneron(Regeneron); Genentech(Roche HoldingGenentech); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Atopic Dermatitis Research Network (contracts HHSN272201000020C and HHSN272201000017C to L. A. B.), DHHS/PHS/NIH 5 T32 AR007472-21 (to A. D. B.), a National Eczema Association research grant (to A. D. B. and L. A. B.), and a Dermatology Foundation research grant (to A.D.B.).; I-H. Kuo has received research and travel support from the Atopic Dermatitis Research Network. T. Yoshida has received research support from the Atopic Dermatitis Research Network. A. De Benedetto has received research support from the National Eczema Association and Dermatology Foundation and has received travel support from the Atopic Dermatitis Research Network. L. A. Beck has received research and travel support from the Atopic Dermatitis Research Network, has received research support from Regeneron and Genentech, is on the Society of Investigative Dermatology Board of Directors, and has received consultancy fees from Regeneron.	Abtin A, 2010, J INVEST DERMATOL, V130, P2423, DOI 10.1038/jid.2010.158; Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Alase A, 2012, BRIT J DERMATOL, V167, P1386, DOI 10.1111/j.1365-2133.2012.11140.x; Albanesi C, 2010, CURR OPIN ALLERGY CL, V10, P452, DOI 10.1097/ACI.0b013e32833e08ae; Allen IC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030612; Angelova-Fischer I, 2010, J INVEST DERMATOL, V130, P2505, DOI 10.1038/jid.2010.143; Arthur JC, 2010, J IMMUNOL, V185, P4515, DOI 10.4049/jimmunol.1002227; Asano S, 2008, BRIT J DERMATOL, V159, P97, DOI 10.1111/j.1365-2133.2008.08613.x; Baroni A, 2006, ARCH DERMATOL RES, V297, P280, DOI 10.1007/s00403-005-0594-4; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Begon E, 2007, EUR J DERMATOL, V17, P497; Benakanakere MR, 2009, J BIOL CHEM, V284, P23107, DOI 10.1074/jbc.M109.013862; Bernard J.J., 2012, NAT MED; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; BRANDTZAEG P, 1995, ADV EXP MED BIOL, V371, P201; Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Cario E, 2004, GASTROENTEROLOGY, V127, P224, DOI 10.1053/j.gastro.2004.04.015; Cario E, 2007, GASTROENTEROLOGY, V132, P1359, DOI 10.1053/j.gastro.2007.02.056; Carmi-Levy I, 2011, CLIN REV ALLERG IMMU, V41, P245, DOI 10.1007/s12016-010-8239-6; Cho KA, 2012, INT IMMUNOL, V24, P147, DOI 10.1093/intimm/dxr110; Cogen AL, 2008, BRIT J DERMATOL, V158, P442, DOI 10.1111/j.1365-2133.2008.08437.x; Cogen AL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008557; Cogen AL, 2010, J INVEST DERMATOL, V130, P192, DOI 10.1038/jid.2009.243; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Craven RR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007446; Dai X, 2011, J ALLERGY CLIN IMMUN, V127, pe1, DOI DOI 10.1016/J.JACI.2010.12.00621272927; Dai XJ, 2011, J ALLERGY CLIN IMMUN, V127, P806, DOI 10.1016/j.jaci.2010.12.006; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2012, J INVEST DERMATOL, V132, P949, DOI 10.1038/jid.2011.435; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V128, P242, DOI 10.1016/j.jaci.2011.02.014; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; de Koning HD, 2010, J INVEST DERMATOL, V130, P2611, DOI 10.1038/jid.2010.196; Deshmukh HS, 2009, INFECT IMMUN, V77, P1376, DOI 10.1128/IAI.00940-08; Dickel H, 2010, CONTACT DERMATITIS, V63, P215, DOI 10.1111/j.1600-0536.2010.01769.x; Elias PM, 2008, J INVEST DERMATOL, V128, P1067, DOI 10.1038/jid.2008.88; Esche C, 2004, CURR ALLERGY ASTHM R, V4, P276, DOI 10.1007/s11882-004-0071-8; Feldmeyer L, 2007, CURR BIOL, V17, P1140, DOI 10.1016/j.cub.2007.05.074; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Furrie E, 2005, IMMUNOLOGY, V115, P565, DOI 10.1111/j.1365-2567.2005.02200.x; Gallo RL, 2012, NAT REV IMMUNOL, V12, P503, DOI 10.1038/nri3228; Gambichler T, 2008, INT ARCH ALLERGY IMM, V147, P17, DOI 10.1159/000128582; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Gariboldi S, 2008, J IMMUNOL, V181, P2103, DOI 10.4049/jimmunol.181.3.2103; Girardin SE, 2004, EUR J IMMUNOL, V34, P1777, DOI 10.1002/eji.200425095; Glaser R, 2009, J INVEST DERMATOL, V129, P641, DOI 10.1038/jid.2008.268; Goldbach-Mansky R, 2009, J ALLERGY CLIN IMMUN, V124, P1141, DOI 10.1016/j.jaci.2009.11.016; Graumann N, 2012, J INVEST DERMATOL, V132, pS110; Grice EA, 2008, GENOME RES, V18, P1043, DOI 10.1101/gr.075549.107; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Grigoryev DN, 2010, J ALLERGY CLIN IMMUN, V125, P153, DOI 10.1016/j.jaci.2009.10.024; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Harder J, 2009, J ALLERGY CLIN IMMUN, V129, P1299; Hasannejad H, 2007, J ALLERGY CLIN IMMUN, V120, P69, DOI 10.1016/j.jaci.2007.04.010; Hata TR, 2010, BRIT J DERMATOL, V163, P659, DOI 10.1111/j.1365-2133.2010.09892.x; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Hau CS, 2011, J INVEST DERMATOL, V131, P2255, DOI 10.1038/jid.2011.201; Heilborn JD, 2003, J INVEST DERMATOL, V120, P379, DOI 10.1046/j.1523-1747.2003.12069.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hirsch T, 2009, J GENE MED, V11, P220, DOI 10.1002/jgm.1287; Hitomi Y, 2009, J ALLERGY CLIN IMMUN, V124, P779, DOI 10.1016/j.jaci.2009.07.044; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2007, J ALLERGY CLIN IMMUN, V119, P1022, DOI 10.1016/j.jaci.2007.01.044; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Hruz P, 2009, P NATL ACAD SCI USA, V106, P12873, DOI 10.1073/pnas.0904958106; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Humphreys NE, 2008, J IMMUNOL, V180, P2443, DOI 10.4049/jimmunol.180.4.2443; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jin HL, 2009, J ALLERGY CLIN IMMUN, V123, P875, DOI 10.1016/j.jaci.2009.02.007; Jurkin J, 2010, J IMMUNOL, V184, P4955, DOI 10.4049/jimmunol.0903021; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kalali BN, 2008, J IMMUNOL, V181, P2694, DOI 10.4049/jimmunol.181.4.2694; Kawai K, 2002, J DERMATOL SCI, V30, P185, DOI 10.1016/S0923-1811(02)00105-6; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kinoshita H, 2009, J ALLERGY CLIN IMMUN, V123, P179, DOI 10.1016/j.jaci.2008.10.008; Kitamura H, 2007, J DERMATOL SCI, V45, P127, DOI 10.1016/j.jdermsci.2006.11.003; Kobayashi M, 2009, BRIT J DERMATOL, V160, P297, DOI 10.1111/j.1365-2133.2008.08897.x; Kollisch G, 2005, IMMUNOLOGY, V114, P531, DOI 10.1111/j.1365-2567.2005.02122.x; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Kumagai Y, 2010, J ALLERGY CLIN IMMUN, V125, P985, DOI 10.1016/j.jaci.2010.01.058; Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006; Kuo IH, 2012, J INVEST DERMATOL; Kvarnhammar AM, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-2; Lai YP, 2012, IMMUNITY, V37, P74, DOI 10.1016/j.immuni.2012.04.010; Lai YP, 2010, J INVEST DERMATOL, V130, P2211, DOI 10.1038/jid.2010.123; Lai YP, 2009, NAT MED, V15, P1377, DOI 10.1038/nm.2062; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Lebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530; Lee HM, 2009, CELL MICROBIOL, V11, P678, DOI 10.1111/j.1462-5822.2009.01285.x; Lee KC, 2007, J INVEST DERMATOL, V127, P945, DOI 10.1038/sj.jid.5700663; Lee KH, 2011, EXP DERMATOL, V20, P149, DOI 10.1111/j.1600-0625.2010.01203.x; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lich JD, 2007, J IMMUNOL, V178, P1256, DOI 10.4049/jimmunol.178.3.1256; Lin Q, 2012, J INVEST DERMATOL, V132, P2085, DOI 10.1038/jid.2012.120; Lin Q, 2011, J IMMUNOL, V186, P3710, DOI 10.4049/jimmunol.1003007; Liu JH, 2010, J IMMUNOL, V184, P5802, DOI 10.4049/jimmunol.0904127; Lu XF, 2006, J BIOL CHEM, V281, P5895, DOI 10.1074/jbc.M511631200; Luci C, 2012, BRIT J DERMATOL, V166, P789, DOI 10.1111/j.1365-2133.2012.10814.x; Macaluso F, 2007, EXP DERMATOL, V16, P692, DOI 10.1111/j.1600-0625.2007.00589.x; Macedo L, 2007, AM J PATHOL, V171, P1774, DOI 10.2353/ajpath.2007.061048; Magalhaes JG, 2011, CURR OPIN IMMUNOL, V23, P29, DOI 10.1016/j.coi.2010.12.003; Mathur P, 2004, GENOMICS, V83, P1151, DOI 10.1016/j.ygeno.2004.01.003; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; McGirt L, 2006, J INVEST DERMATOL, V126, P116; Mempel M, 2003, J INVEST DERMATOL, V121, P1389, DOI 10.1111/j.1523-1747.2003.12630.x; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Moller-Larsen S, 2008, THORAX, V63, P1064, DOI 10.1136/thx.2007.094128; Morizane S, 2012, J INVEST DERMATOL, V132, P135, DOI 10.1038/jid.2011.259; Mork G, 2003, BRIT J DERMATOL, V149, P484, DOI 10.1046/j.1365-2133.2003.05536.x; Mrabet-Dahbi S, 2008, J ALLERGY CLIN IMMUN, V121, P1013, DOI 10.1016/j.jaci.2007.11.029; Munoz-Planillo R, 2009, J IMMUNOL, V183, P3942, DOI 10.4049/jimmunol.0900729; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; Nakatsuji T, 2012, J INVEST DERMATOL, V132, P887, DOI 10.1038/jid.2011.387; Niebuhr M, 2009, ALLERGY, V64, P1580, DOI 10.1111/j.1398-9995.2009.02050.x; Niebuhr M, 2010, EXP DERMATOL, V19, pE296, DOI 10.1111/j.1600-0625.2009.00989.x; Niyonsaba F, 2009, BRIT J DERMATOL, V160, P243, DOI 10.1111/j.1365-2133.2008.08925.x; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Novak N, 2007, ALLERGY, V62, P766, DOI 10.1111/j.1398-9995.2007.01358.x; Nukui T, 2008, J CELL BIOCHEM, V104, P453, DOI 10.1002/jcb.21639; O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Oh DY, 2009, ALLERGY, V64, P1608, DOI 10.1111/j.1398-9995.2009.02066.x; Oh J, 2012, GENOME MED, V4, DOI 10.1186/gm378; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Otte JM, 2004, GASTROENTEROLOGY, V126, P1054, DOI 10.1053/j.gastro.2004.01.007; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024961; Pivarcsi A, 2003, INT IMMUNOL, V15, P721, DOI 10.1093/intimm/dxg068; Potaczek DP, 2011, J EUR ACAD DERMATOL, V25, P715, DOI 10.1111/j.1468-3083.2010.03812.x; Prens EP, 2008, J INVEST DERMATOL, V128, P932, DOI 10.1038/sj.jid.5701087; Rebane A, 2012, J ALLERGY CLIN IMMUN, V129, P1297, DOI 10.1016/j.jaci.2012.02.020; Reid DM, 2009, CURR OPIN IMMUNOL, V21, P30, DOI 10.1016/j.coi.2009.01.003; Rezaee F, 2011, J ALLERGY CLIN IMMUN, V128, P1216, DOI 10.1016/j.jaci.2011.08.035; Rhee SH, 2005, P NATL ACAD SCI USA, V102, P13610, DOI 10.1073/pnas.0502174102; Ribbing C, 2011, ALLERGY, V66, P110, DOI 10.1111/j.1398-9995.2010.02437.x; Rieg S, 2005, J IMMUNOL, V174, P8003, DOI 10.4049/jimmunol.174.12.8003; Rieg S, 2004, BRIT J DERMATOL, V151, P534, DOI 10.1111/j.1365-2133.2004.06081.x; Royet J, 2007, NAT REV MICROBIOL, V5, P264, DOI 10.1038/nrmicro1620; Salpietro C, 2011, INT J IMMUNOPATH PH, V24, P33, DOI 10.1177/03946320110240S408; Sato T, 2010, WOUND REPAIR REGEN, V18, P586, DOI 10.1111/j.1524-475X.2010.00632.x; Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446; Schittek B, 2011, CURR PROBL DERMATOL, V41, P54, DOI 10.1159/000323296; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Sepulveda AR, 2010, GASTROENTEROLOGY, V138, P1836, DOI 10.1053/j.gastro.2009.12.042; Song PI, 2002, J INVEST DERMATOL, V119, P424, DOI 10.1046/j.1523-1747.2002.01847.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spreu J, 2007, IMMUNOGENETICS, V59, P903, DOI 10.1007/s00251-007-0263-1; Spreu J, 2010, P NATL ACAD SCI USA, V107, P5100, DOI 10.1073/pnas.0913108107; Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747; Sumikawa Y, 2006, MICROBES INFECT, V8, P1513, DOI 10.1016/j.micinf.2006.01.008; Sun C, 2006, HUM GENET, V119, P113, DOI 10.1007/s00439-005-0115-8; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Le TA, 2011, INT ARCH ALLERGY IMM, V155, P31, DOI 10.1159/000318679; Voss E, 2006, J BIOL CHEM, V281, P2005, DOI 10.1074/jbc.M511044200; Vu AT, 2011, J INVEST DERMATOL, V131, P2205, DOI 10.1038/jid.2011.185; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Wang HT, 2005, INFECT IMMUN, V73, P7216, DOI 10.1128/IAI.73.11.7216-7225.2005; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Watanabe H, 2007, J INVEST DERMATOL, V127, P1956, DOI 10.1038/sj.jid.5700819; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Yamamoto M, 2011, BIOMATERIALS, V32, P4238, DOI 10.1016/j.biomaterials.2011.02.043; Yuki T, 2011, J IMMUNOL, V187, P3230, DOI 10.4049/jimmunol.1100058; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	188	156	159	0	57	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					266	278		10.1016/j.jaci.2012.12.1563	http://dx.doi.org/10.1016/j.jaci.2012.12.1563			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23374259				2022-12-18	WOS:000314661500001
J	Sykes, A; Edwards, MR; Macintyre, J; del Rosario, A; Bakhsoliani, E; Trujillo-Torralbo, MB; Kon, OM; Mallia, P; McHale, M; Johnston, SL				Sykes, Annemarie; Edwards, Michael R.; Macintyre, Jonathan; del Rosario, Ajerico; Bakhsoliani, Eteri; Trujillo-Torralbo, Maria-Belen; Kon, Onn Min; Mallia, Patrick; McHale, Mark; Johnston, Sebastian L.			Rhinovirus 16-induced IFN-alpha and IFN-beta are deficient in bronchoalveolar lavage cells in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; interferon; rhinovirus; bronchoalveolar lavage cells; peripheral blood mononuclear cells; airway hyperresponsiveness	BRONCHIAL EPITHELIAL-CELLS; TOLL-LIKE RECEPTOR-3; RIG-I; INFECTION; INNATE; RESPONSES; RECOGNITION; REGULATOR; HELICASES; SEVERITY	Background: Asthmatic patients have defective rhinovirus-induced IFN-beta and IFN-lambda production from bronchial epithelial cells and IFN-lambda from bronchoalveolar lavage (BAL) cells. Whether bronchoalveolar lavage cells have defective type I interferon responses to rhinovirus is unknown, as are mechanisms explaining defective rhinovirus interferon induction in asthmatic patients. Objective: We sought to investigate rhinovirus induction of type I interferons in BAL and blood mononuclear cells from asthmatic patients and healthy subjects and to investigate mechanisms of any deficiency observed. Methods: BAL and blood mononuclear cells from atopic asthmatic patients and healthy subjects were infected with rhinovirus ex vivo. Interferon proteins were analyzed by using ELISA. mRNA expression of key components of interferon induction pathways were analyzed by using quantitative PCR. Results: Rhinovirus induction of type I interferon protein was delayed and deficient in BAL cells from asthmatic patients, and lower interferon levels were associated with greater airway hyperresponsiveness and skin prick test response positivity. Expression of Toll-like receptor (TLR) 3, TLR7, TLR8, retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA-5), TIR domain-containing adapter-inducing IFN-beta (TRIF), myeloid differentiation primary response gene 88 (MyD88), caspase recruitment domain adaptor inducing IFN-beta (CARDIF), IL-1 receptor-associated kinase 4 (IRAK4), I kappa B kinase beta (IKKB), IkB kinase iota (IKKI), interferon regulatory factors 3 and 7, and rhinovirus induction of expression of the virus-inducible molecules TLR3, TLR7, RIG-I, and MDA-5 were not impaired in these interferon-deficient BAL cells in asthmatic patients. Defective rhinovirus interferon induction was not observed in blood mononuclear cells. Conclusions: Rhinovirus induction of type I interferons in BAL cells is delayed and deficient and might be a marker of more severe asthma. Defective rhinovirus interferon induction in asthmatic patients was not accompanied by differences in the expression or induction of key molecules implicated in viral induction of interferons. (J Allergy Clin Immunol 2012;129:1506-14.)	[Sykes, Annemarie; Edwards, Michael R.; Macintyre, Jonathan; del Rosario, Ajerico; Bakhsoliani, Eteri; Trujillo-Torralbo, Maria-Belen; Mallia, Patrick; Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London W2 1PG, England; [Sykes, Annemarie; Edwards, Michael R.; Macintyre, Jonathan; del Rosario, Ajerico; Bakhsoliani, Eteri; Trujillo-Torralbo, Maria-Belen; Mallia, Patrick; Johnston, Sebastian L.] MRC & Asthma UK Ctr Allerg Mech Asthma, London, England; [Sykes, Annemarie; Edwards, Michael R.; Macintyre, Jonathan; del Rosario, Ajerico; Bakhsoliani, Eteri; Trujillo-Torralbo, Maria-Belen; Mallia, Patrick; Johnston, Sebastian L.] Ctr Resp Infect, London, England; [Sykes, Annemarie; Macintyre, Jonathan; del Rosario, Ajerico; Trujillo-Torralbo, Maria-Belen; Kon, Onn Min; Johnston, Sebastian L.] Imperial Healthcare NHS Trust, London, England; [McHale, Mark] AstraZeneca R&D, Resp & Inflammat Res Area, Charnwood, England	Imperial College London; University of London; King's College London; AstraZeneca	Sykes, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, St Marys Campus, London W2 1PG, England.	annemarie.sykes@imperial.ac.uk	Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200; Kon, Onn Min/0000-0003-2647-4688; Regis, Eteri/0000-0001-9862-2147; Edwards, Michael Robert/0000-0001-6837-0532	Medical Research Council (MRC) [G0601236, 100758]; British Lung Foundation [P06/3]; Wellcome Trust [083567/Z/07/Z]; Asthma UK [05/067, 08/048, RF07/04]; Asthma UK (ERC) [233015]; AstraZeneca; National Institute of Health Research Biomedical Research Centre; European Research Council (ERS); National Institute of Health Research; Predicta FP7 Collaborative Project; MRC [G0700552, G0601236] Funding Source: UKRI; Medical Research Council [G1000758, G1000758B, G0700552, G0601236] Funding Source: researchfish; National Institute for Health Research [CL-2008-21-014] Funding Source: researchfish	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Lung Foundation; Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK; Asthma UK (ERC); AstraZeneca(AstraZeneca); National Institute of Health Research Biomedical Research Centre(National Institute for Health Research (NIHR)); European Research Council (ERS)(European Research Council (ERC)); National Institute of Health Research(National Institute for Health Research (NIHR)); Predicta FP7 Collaborative Project; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by grants from the Medical Research Council (MRC project grant G0601236 and Centre grant 100758 and an MRC Clinical Research Fellowship [to A. S.]), the British Lung Foundation (grant P06/3), the Wellcome Trust (grant 083567/Z/07/Z for the Centre for Respiratory Infection), Asthma UK (grants 05/067 and 08/048 and Asthma UK Fellowship RF07/04 [to M. R. E.], ERC FP7 Advanced grant 233015 [to S.L.J.]), AstraZeneca, and the National Institute of Health Research Biomedical Research Centre and Clinical Lecturer funding schemes.; A. Sykes receives research support from AstraZeneca. M. McHale is a shareholder in AstraZeneca Pharmaceuticals and is a founder of and a shareholder in ASLAN Pharmaceuticals. S. L. Johnston has consultant arrangements and a share option with Centocor; has consultant arrangements with Sanofi-Pasteur, Synairgen, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Grunenthal, and Novartis; and receives research support from the European Research Council (ERS) FP7, the Medical Research Council Clinical Research Fellowship, the National Institute of Health Research, Asthma UK, the Medical Research Council, Predicta FP7 Collaborative Project, the Wellcome Trust-sponsored Centre for Respiratory Infection, the British Lung Foundation, and AstraZeneca.	Akashi-Takamura S, 2008, CURR OPIN IMMUNOL, V20, P420, DOI 10.1016/j.coi.2008.07.001; Allen IC, 2011, IMMUNITY, V34, P854, DOI 10.1016/j.immuni.2011.03.026; [Anonymous], 1994, RESP MED, V88, P165; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Grayson MH, 2006, ANN ALLERG ASTHMA IM, V96, P643, DOI 10.1016/S1081-1206(10)61061-7; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Iikura K, 2011, INT ARCH ALLERGY IMM, V155, P27, DOI 10.1159/000327262; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2007, J BIOCHEM, V141, P137, DOI 10.1093/jb/mvm032; Khaitov MR, 2009, ALLERGY, V64, P375, DOI 10.1111/j.1398-9995.2008.01826.x; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Mallia P, 2011, AM J RESP CRIT CARE, V183, P734, DOI 10.1164/rccm.201006-0833OC; Matsukura S, 2006, CLIN EXP ALLERGY, V36, P1049, DOI 10.1111/j.1365-2222.2006.02530.x; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Roponen M, 2010, EUR RESPIR J, V35, P64, DOI 10.1183/09031936.00172008; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Satoh T, 2010, P NATL ACAD SCI USA, V107, P1512, DOI 10.1073/pnas.0912986107; Schwindt CD, 2006, J ASTHMA, V43, P439, DOI 10.1080/02770900600758234; Slater L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001178; Sterk P, 1993, EUR RESPIR J, P53; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Thompson AJ, 2007, IMMUNOL CELL BIOL, V85, P435, DOI 10.1038/sj.icb.7100100; Uller L, 2010, THORAX, V65, P626, DOI 10.1136/thx.2009.125930; Vareille M, 2012, THORAX; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2009, RESPIROLOGY, V14, P180, DOI 10.1111/j.1440-1843.2009.01480.x	36	156	157	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1506	+		10.1016/j.jaci.2012.03.044	http://dx.doi.org/10.1016/j.jaci.2012.03.044			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22657407				2022-12-18	WOS:000304764600010
J	Ly, NP; Litonjua, A; Gold, DR; Celedon, JC				Ly, Ngoc P.; Litonjua, Augusto; Gold, Diane R.; Celedon, Juan C.			Gut microbiota, probiotics, and vitamin D: Interrelated exposures influencing allergy, asthma, and obesity?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Microbiota; asthma; obesity; allergic; eczema; vitamin D; probiotics; cytokines	DIET-INDUCED OBESITY; BODY-MASS INDEX; ANTIBIOTIC USE; INTESTINAL MICROFLORA; EARLY-LIFE; 1ST YEAR; DOUBLE-BLIND; CHILDHOOD PREDICTORS; PULMONARY-FUNCTION; PRIMARY PREVENTION	Current evidence supports a role for gut colonization in promoting and maintaining a balanced immune response in early life. An altered or less diverse gut microbiota composition has been associated with atopic diseases, obesity, or both. Moreover, certain gut microbial strains have been shown to inhibit or attenuate immune responses associated with chronic inflammation in experimental models. However, there has been no fully adequate longitudinal study of the relation between the neonatal gut microbiota and the development of allergic diseases (eg, atopic asthma) and obesity. The emergence of promising experimental studies has led to several clinical trials of probiotics (live bacteria given orally that allow for intestinal colonization) in human subjects. Probiotic trials thus far have failed to show a consistent preventive or therapeutic effect on asthma or obesity. Previous trials of probiotics have been limited by small sample size, short duration of follow-up, or lack of state-of-the art analyses of the gut microbiota. Finally, there is emerging evidence that the vitamin D pathway might be important in gut homeostasis and in signaling between the microbiota and the host. Given the complexity of the gut micriobiota, additional research is needed before we can confidently establish whether its manipulation in early life can prevent or treat asthma, obesity, or both. (J Allergy Clin Immunol 2011;127:1087-94.)	[Ly, Ngoc P.] Univ Calif San Francisco, Dept Pediat, Div Pediat Pulm Med, San Francisco, CA 94143 USA; [Litonjua, Augusto; Gold, Diane R.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Litonjua, Augusto; Gold, Diane R.] Harvard Univ, Sch Med, Boston, MA USA; [Celedon, Juan C.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, UPMC, Pittsburgh, PA USA	University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ly, NP (corresponding author), 521 Parnassus Ave,C344, San Francisco, CA 94143 USA.	lyn@peds.ucsf.edu		Litonjua, Augusto/0000-0003-0422-5875	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI035786-17, R01 AI035786] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adlerberth I, 2009, ACTA PAEDIATR, V98, P229, DOI 10.1111/j.1651-2227.2008.01060.x; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Adorini L, 2009, HUM IMMUNOL, V70, P345, DOI 10.1016/j.humimm.2009.01.016; [Anonymous], 2008, ASTHM AM LUNG ASS LU; Antonio MAD, 2005, J INFECT DIS, V192, P394, DOI 10.1086/430926; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; Benyshek DC, 2007, COLLEGIUM ANTROPOL, V31, P11; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V115, P1102, DOI 10.1016/j.jaci.2005.03.018; Beuther DA, 2005, J ALLERGY CLIN IMMUN, V115, P1100, DOI 10.1016/j.jaci.2004.12.1141; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Black PN, 2005, CHEST, V128, P3792, DOI 10.1378/chest.128.6.3792; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Borriello SP, 2003, CLIN INFECT DIS, V36, P775, DOI 10.1086/368080; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Boyle RJ, 2009, CLIN EXP ALLERGY, V39, P1117, DOI 10.1111/j.1365-2222.2009.03305.x; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Cani PD, 2009, CURR PHARM DESIGN, V15, P1546, DOI 10.2174/138161209788168164; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Celedon JC, 2006, CHEST, V130, P1624, DOI 10.1378/chest.130.5.1624; Celedon Juan C, 2004, Treat Respir Med, V3, P291, DOI 10.2165/00151829-200403050-00003; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.1139; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; ELMOHANDES AE, 1993, AM J INFECT CONTROL, V21, P231, DOI 10.1016/0196-6553(93)90414-Y; Feleszko W, 2007, CLIN EXP ALLERGY, V37, P498, DOI 10.1111/j.1365-2222.2006.02629.x; Forno Erick, 2008, Clin Mol Allergy, V6, P11, DOI 10.1186/1476-7961-6-11; Forsythe P, 2007, AM J RESP CRIT CARE, V175, P561, DOI 10.1164/rccm.200606-821OC; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Griffin MD, 2003, ANNU REV NUTR, V23, P117, DOI 10.1146/annurev.nutr.23.011702.073114; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P1235, DOI 10.1016/j.jaci.2005.09.016; Hallstrom M, 2004, EUR J CLIN MICROBIOL, V23, P463, DOI 10.1007/s10096-004-1146-0; Harmsen HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019; Harris JM, 2007, THORAX, V62, P631, DOI 10.1136/thx.2006.072124; Hessle C, 1999, CLIN EXP IMMUNOL, V116, P276; Hildebrandt MA, 2009, GASTROENTEROLOGY, V137, P1716, DOI 10.1053/j.gastro.2009.08.042; Hill G B, 1984, Scand J Urol Nephrol Suppl, V86, P23; HILTON E, 1992, ANN INTERN MED, V116, P353, DOI 10.7326/0003-4819-116-5-353; Holick MF, 2006, MAYO CLIN PROC, V81, P353, DOI 10.4065/81.3.353; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; James WPT, 2008, J INTERN MED, V263, P336, DOI 10.1111/j.1365-2796.2008.01922.x; Jernberg C, 2007, ISME J, V1, P56, DOI 10.1038/ismej.2007.3; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki M, 2008, AM J CLIN NUTR, V87, P534, DOI 10.1093/ajcn/87.3.534; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Karimi K, 2009, AM J RESP CRIT CARE, V179, P186, DOI 10.1164/rccm.200806-951OC; Kelly D, 2007, MUTAT RES-FUND MOL M, V622, P58, DOI 10.1016/j.mrfmmm.2007.03.011; Kero J, 2002, PEDIATR RES, V52, P6, DOI 10.1023/01.PDR.0000017263.01840.F0; Keski-Nisula L, 2009, J ALLERGY CLIN IMMUN, V123, P1305, DOI 10.1016/j.jaci.2009.03.021; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Kumar J, 2009, PEDIATRICS, V124, pE362, DOI 10.1542/peds.2009-0051; Laitinen K, 2009, BRIT J NUTR, V101, P1679, DOI 10.1017/S0007114508111461; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Liu PT, 2007, J IMMUNOL, V179, P2060, DOI 10.4049/jimmunol.179.4.2060; LONG SS, 1977, J PEDIATR-US, V91, P298, DOI 10.1016/S0022-3476(77)80836-6; Lotz M, 2006, J EXP MED, V203, P973, DOI 10.1084/jem.20050625; Luoto R, 2010, INT J OBESITY, V34, P1531, DOI 10.1038/ijo.2010.50; Luoto R, 2010, BRIT J NUTR, V103, P1792, DOI 10.1017/S0007114509993898; Mai V, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-49; Mai XM, 2010, CLIN EXP ALLERGY, V40, P1230, DOI 10.1111/j.1365-2222.2010.03532.x; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; McLachlan CR, 2007, J ALLERGY CLIN IMMUN, V119, P634, DOI 10.1016/j.jaci.2006.10.029; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; Melen E, 2010, J ALLERGY CLIN IMMUN, V126, P631, DOI 10.1016/j.jaci.2010.06.030; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Murphy A, 2009, AM J HUM GENET, V85, P87, DOI 10.1016/j.ajhg.2009.06.011; Murray CS, 2005, CLIN EXP ALLERGY, V35, P741, DOI 10.1111/j.1365-2222.2005.02259.x; Musso G, 2010, CURR OPIN LIPIDOL, V21, P76, DOI 10.1097/MOL.0b013e3283347ebb; Oyama N, 2001, J ALLERGY CLIN IMMUN, V107, P153, DOI 10.1067/mai.2001.111142; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Parikh SJ, 2004, J CLIN ENDOCR METAB, V89, P1196, DOI 10.1210/jc.2003-031398; Parsons TJ, 1999, INT J OBESITY, V23, pS1; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Pistiner M, 2008, J ALLERGY CLIN IMMUN, V122, P274, DOI 10.1016/j.jaci.2008.05.007; Prescott SL, 2005, CLIN EXP ALLERGY, V35, P1557, DOI 10.1111/j.1365-2222.2005.02376.x; Rask C, 2005, SCAND J IMMUNOL, V61, P529, DOI 10.1111/j.1365-3083.2005.01598.x; Reid G, 2001, FEMS IMMUNOL MED MIC, V30, P49, DOI 10.1111/j.1574-695X.2001.tb01549.x; Rusconi F, 2007, AM J RESP CRIT CARE, V175, P16, DOI 10.1164/rccm.200512-1978OC; Salam MT, 2006, ANN EPIDEMIOL, V16, P341, DOI 10.1016/j.annepidem.2005.06.054; Salminen S, 1998, BRIT J NUTR, V80, pS147, DOI 10.1079/BJN19980108; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83, DOI 10.1093/oxfordjournals.aje.a115646; Shida K, 2002, CLIN EXP ALLERGY, V32, P563, DOI 10.1046/j.0954-7894.2002.01354.x; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Sood A, 2005, J ALLERGY CLIN IMMUN, V115, P921, DOI 10.1016/j.jaci.2005.02.033; Su Y, 2010, CLIN EXP ALLERGY, V40, P1222, DOI 10.1111/j.1365-2222.2010.03539.x; Sudo N, 2002, CLIN EXP ALLERGY, V32, P1112, DOI 10.1046/j.1365-2222.2002.01430.x; Sudo N, 1997, J IMMUNOL, V159, P1739; Sutherland ER, 2009, J ALLERGY CLIN IMMUN, V123, P1328, DOI 10.1016/j.jaci.2009.04.005; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Verhulst SL, 2008, J ASTHMA, V45, P828, DOI 10.1080/02770900802339734; Vickers MH, 2007, CURR DRUG TARGETS, V8, P923; Weber G, 2005, J INVEST DERMATOL, V124, P1080, DOI 10.1111/j.0022-202X.2005.23687.x; Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673; Wortsman J, 2000, AM J CLIN NUTR, V72, P690, DOI 10.1093/ajcn/72.3.690; Wu SP, 2010, AM J PATHOL, V177, P686, DOI 10.2353/ajpath.2010.090998; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; Yim S, 2007, J CYST FIBROS, V6, P403, DOI 10.1016/j.jcf.2007.03.003; Yoshioka T, 2001, J INT MED RES, V29, P409, DOI 10.1177/147323000102900505; Young SL, 2004, CLIN DIAGN LAB IMMUN, V11, P686, DOI 10.1128/CDLI.11.4.686-690.2004; Yu SH, 2008, P NATL ACAD SCI USA, V105, P20834, DOI 10.1073/pnas.0808700106; Zoetendal EG, 2006, MOL MICROBIOL, V59, P1639, DOI 10.1111/j.1365-2958.2006.05056.x	128	156	174	5	77	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1087	1094		10.1016/j.jaci.2011.02.015	http://dx.doi.org/10.1016/j.jaci.2011.02.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21419479	Bronze, Green Accepted			2022-12-18	WOS:000290018600001
J	Singh, K; Axelrod, S; Bielory, L				Singh, Kavita; Axelrod, Sara; Bielory, Leonard			The epidemiology of ocular and nasal allergy in the United States, 1988-1994	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ocular allergy; epidemiology; nasal allergy symptoms; seasonal allergic conjunctivitis; perennial allergic conjunctivitis; vernal keratoconjunctivitis; atopic keratoconjunctivitis; giant papillary conjunctivitis	OF-LIFE IMPACT; PHASE-III; CONJUNCTIVITIS; RHINITIS; SYMPTOMS; CHILDREN; DISEASE; ASTHMA; BURDEN; EUROPE	Background: Allergies give rise to the fifth-leading group of chronic diseases. However, the specific prevalence of ocular allergy is poorly described. Objective: We sought to provide a more accurate representation of the epidemiology of ocular allergy in the United States. Methods: The National Health And Nutrition Examination Survey III performed in the United States from 1988-1994 was the source for the data collected. Items from the questionnaire regarding ocular and nasal allergy symptoms in relation to skin prick testing were stratified by age, race, region, and sex. Results: The sample size is 20,010: 1,285 (6.4%) reported ocular symptoms, 3,294 (16.5%) reported nasal symptoms, 5,944 (29.7%) reported both ocular and nasal symptoms, and 9.487 (47.4%) were asymptomatic. Forty percent of the population reported at least 1 occurrence of ocular symptoms in the past 12 months. Those 50 years and older have a higher frequency of isolated ocular symptoms (P < .001). There is an increase in the frequency of symptoms in those younger than 50 years in the populations of subjects with ocular and nasal symptoms combined and isolated nasal symptoms (P < .001). Ocular symptoms are more frequent than nasal symptoms in relation to animals (P < .001), household dust (P < .001), and pollen (P < .001). Conclusion: This analysis provides the first representation of the epidemiology of ocular allergy in the United States. Up to 40% of the population, the highest reported to date, have experienced ocular symptoms at least once in their lifetime, with a peak of symptoms in the months of June and July. (J Allergy Clin Immunol 2010;126:778-83.)	[Singh, Kavita] Cool Springs Internal Med & Pediat, Dept Med Pediat, Brentwood, TN USA; [Axelrod, Sara] Univ Med & Dent New Jersey, Sch Med, Dept Allergy & Immunol, Newark, NJ 07103 USA; [Bielory, Leonard] Rutgers State Univ, Ctr Climate Predict, New Brunswick, NJ 08903 USA; [Bielory, Leonard] STARx Allergy & Asthma Res Ctr, Springfield, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Bielory, L (corresponding author), 400 Mt Ave, Springfield, NJ 07081 USA.	drlbielory@gmail.com			EPA STAR [R834547]	EPA STAR(United States Environmental Protection Agency)	Supported in part by the EPA STAR Grant R834547: Observational, Laboratory, and Modeling Studies of the Impacts of Climate Change on Allergic Airway Disease.	Berdy GJ, 2000, ACTA OPHTHALMOL SCAN, V78, P32, DOI 10.1034/j.1600-0420.2000.078s230032.x; Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Bloch-Michel E, 1996, Allerg Immunol (Paris), V28, P234; Buckley RJ, 1998, CLIN EXP ALLERGY, V28, P39; Burbach GJ, 2009, ALLERGY, V64, P664, DOI 10.1111/j.1398-9995.2009.01975.x; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Fok AOL, 2009, CURR OPIN ALLERGY CL, V9, P116, DOI 10.1097/ACI.0b013e3283292256; Gradman J, 2006, PEDIAT ALLERG IMM-UK, V17, P524, DOI 10.1111/j.1399-3038.2006.00429.x; Hugg T, 2008, EUR J EPIDEMIOL, V23, P123, DOI 10.1007/s10654-007-9217-z; Ibanez MD, 2009, J INVEST ALLERG CLIN, V19, P61; NAVA FV, 2002, REV ALERG MEX, V49, P33; Pitt AD, 2004, OPHTHAL EPIDEMIOL, V11, P17, DOI 10.1076/opep.11.1.17.26437; Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x; *SEPR INC, 2006, ALL AM LANDM SURV NA; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Smith AF, 2005, OPHTHAL EPIDEMIOL, V12, P233, DOI 10.1080/09286580590967781	16	156	164	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					778	U150		10.1016/j.jaci.2010.06.050	http://dx.doi.org/10.1016/j.jaci.2010.06.050			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920769				2022-12-18	WOS:000282510000015
J	Nembrini, C; Marsland, BJ; Kopf, M				Nembrini, Chiara; Marsland, Benjamin J.; Kopf, Manfred			IL-17-producing T cells in lung immunity and inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)17 cells; IL-17; neutrophils; autoimmunity; asthma	GROWTH-FACTOR-BETA; COLONY-STIMULATING FACTOR; AIRWAY SMOOTH-MUSCLE; ROR-GAMMA-T; TH17 CELLS; TGF-BETA; NEUTROPHIL RECRUITMENT; IL-17 PRODUCTION; CUTTING EDGE; HOST-DEFENSE	T(H)17 cells are a recently described effector CD4 T-cell subset characterized by the production of IL-17A, IL-17F, and IL-22, which have been implicated in the pathogenesis of several autoimmune diseases. T(H)17 and other IL-17A-producing T cells, including a population of gamma delta T cells and natural killer T cells, have also been associated with the development of skin, intestinal, and lung inflammatory diseases, such as asthma, granulomatous disease, chronic obstructive pulmonary disease, and cystic fibrosis. On the other hand, IL-17-producing T cells play important roles in protective immunity against some bacterial infections, mainly through the recruitment and activation of neutrophils. Thus, their regulation appears to be critical, and excess or deficient IL-17 elaboration leads either to deficient responses or disease. This review will summarize T(H)17 cell differentiation and discuss the host beneficial and detrimental function of IL-17A and related cytokines produced by different subpopulations of T cells. (J Allergy Clin Immunol 2009;123:986-94.)	[Nembrini, Chiara; Marsland, Benjamin J.; Kopf, Manfred] ETH, Inst Integrat Biol, Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Kopf, M (corresponding author), ETH, Inst Integrat Biol, Zurich, Switzerland.	Manfred.Kopf@ethz.ch	Kopf, Manfred/B-6907-2009	Kopf, Manfred/0000-0002-0628-7140	Swiss National Science Foundation [310030_124922/1]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Supported by the Swiss National Science Foundation (310030_124922/1).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Annunziato F, 2008, INT IMMUNOL, V20, P1361, DOI 10.1093/intimm/dxn106; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Aujla SJ, 2007, EXP LUNG RES, V33, P507, DOI 10.1080/01902140701756604; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1055, DOI 10.1016/j.jaci.2007.01.015; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Born W K, 2000, Respir Res, V1, P151, DOI 10.1186/rr26; Braun RK, 2008, INFLAMMATION, V31, P167, DOI 10.1007/s10753-008-9062-6; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Carding SR, 2000, IMMUNOL REV, V173, P98, DOI 10.1034/j.1600-065X.2000.917302.x; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200; Cheung PFY, 2008, J IMMUNOL, V180, P5625, DOI 10.4049/jimmunol.180.8.5625; Coquet JM, 2008, J IMMUNOL, V180, P7097, DOI 10.4049/jimmunol.180.11.7097; Cosmi L, 2008, J EXP MED, V205, P1903, DOI 10.1084/jem.20080397; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Curtis Jeffrey L, 2007, Proc Am Thorac Soc, V4, P512, DOI 10.1513/pats.200701-002FM; Dardalhon V, 2008, J AUTOIMMUN, V31, P252, DOI 10.1016/j.jaut.2008.04.017; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Dragon S, 2007, AM J PHYSIOL-LUNG C, V292, pL1023, DOI 10.1152/ajplung.00306.2006; Dubin PJ, 2007, INFLAMM RES, V56, P221, DOI 10.1007/s00011-007-6187-2; Dubin PJ, 2008, IMMUNOL REV, V226, P160, DOI 10.1111/j.1600-065X.2008.00703.x; Evans HG, 2007, P NATL ACAD SCI USA, V104, P17034, DOI 10.1073/pnas.0708426104; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Fritz JH, 2007, IMMUNITY, V26, P445, DOI 10.1016/j.immuni.2007.03.009; Fukakusa M, 2005, J ALLERGY CLIN IMMUN, V115, P280, DOI 10.1016/j.jaci.2004.10.036; Furuzawa-Carballeda J, 2007, AUTOIMMUN REV, V6, P169, DOI 10.1016/j.autrev.2006.10.002; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hashimoto T, 2005, INT ARCH ALLERGY IMM, V137, P51, DOI 10.1159/000085432; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Henness S, 2004, J ALLERGY CLIN IMMUN, V114, P958, DOI 10.1016/j.jaci.2004.06.023; Higgins SC, 2006, J IMMUNOL, V177, P7980, DOI 10.4049/jimmunol.177.11.7980; Hizawa N, 2006, CLIN EXP ALLERGY, V36, P1109, DOI 10.1111/j.1365-2222.2006.02550.x; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Hoshino H, 2000, J ALLERGY CLIN IMMUN, V105, P143, DOI 10.1016/S0091-6749(00)90189-1; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Iezzi G, 2009, P NATL ACAD SCI USA, V106, P876, DOI 10.1073/pnas.0810769106; Ishizu T, 2005, BRAIN, V128, P988, DOI 10.1093/brain/awh453; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Jones CE, 2002, AM J RESP CELL MOL, V26, P748, DOI 10.1165/ajrcmb.26.6.4757; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P1265, DOI 10.1016/j.jaci.2004.10.019; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Khader SA, 2008, CYTOKINE, V41, P79, DOI 10.1016/j.cyto.2007.11.022; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; King DP, 1999, J IMMUNOL, V162, P5033; Kirkham BW, 2006, ARTHRITIS RHEUM, V54, P1122, DOI 10.1002/art.21749; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; KORN T, 2009, ANN REV IMMUNOL; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Kroenke MA, 2008, J EXP MED, V205, P1535, DOI 10.1084/jem.20080159; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Liang SC, 2007, J IMMUNOL, V179, P7791, DOI 10.4049/jimmunol.179.11.7791; Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904; Lockhart E, 2006, J IMMUNOL, V177, P4662, DOI 10.4049/jimmunol.177.7.4662; Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258; Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Marsland BJ, 2008, TRENDS IMMUNOL, V29, P179, DOI 10.1016/j.it.2008.01.005; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; McGeachy MJ, 2007, SEMIN IMMUNOL, V19, P372, DOI 10.1016/j.smim.2007.10.012; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Michel ML, 2007, J EXP MED, V204, P995, DOI 10.1084/jem.20061551; Michel ML, 2008, P NATL ACAD SCI USA, V105, P19845, DOI 10.1073/pnas.0806472105; Mills KHG, 2008, EUR J IMMUNOL, V38, P2636, DOI 10.1002/eji.200838535; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; Nakae S, 2007, J LEUKOCYTE BIOL, V81, P1258, DOI 10.1189/jlb.1006610; Nembrini C, 2006, J IMMUNOL, V176, P7180, DOI 10.4049/jimmunol.176.12.7180; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Prause O, 2003, EUR J PHARMACOL, V462, P193, DOI 10.1016/S0014-2999(03)01341-4; Rahman MS, 2006, J IMMUNOL, V177, P4064, DOI 10.4049/jimmunol.177.6.4064; Rohn TA, 2006, EUR J IMMUNOL, V36, P2857, DOI 10.1002/eji.200636658; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; Ruedl C, 2000, EUR J IMMUNOL, V30, P2056, DOI 10.1002/1521-4141(200007)30:7<2056::AID-IMMU2056>3.0.CO;2-S; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Scriba TJ, 2008, J IMMUNOL, V180, P1962, DOI 10.4049/jimmunol.180.3.1962; Sonderegger I, 2008, J EXP MED, V205, P2281, DOI 10.1084/jem.20071119; Sonderegger I, 2008, EUR J IMMUNOL, V38, P1833, DOI 10.1002/eji.200838511; Sonderegger I, 2006, EUR J IMMUNOL, V36, P2849, DOI 10.1002/eji.200636484; Steinman L, 2008, J EXP MED, V205, P1517, DOI 10.1084/jem.20072066; Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285; Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; Umemura M, 2007, J IMMUNOL, V178, P3786, DOI 10.4049/jimmunol.178.6.3786; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; van den Berg A, 2005, AM J RESP CELL MOL, V33, P97, DOI 10.1165/rcmb.2005-0022OC; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Wang JM, 2000, J IMMUNOL, V165, P4051, DOI 10.4049/jimmunol.165.7.4051; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Wright JF, 2007, J BIOL CHEM, V282, P13447, DOI 10.1074/jbc.M700499200; Wu Q, 2007, MICROBES INFECT, V9, P78, DOI 10.1016/j.micinf.2006.10.012; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Zelante T, 2007, EUR J IMMUNOL, V37, P2695, DOI 10.1002/eji.200737409; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	124	156	169	2	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					986	994		10.1016/j.jaci.2009.03.033	http://dx.doi.org/10.1016/j.jaci.2009.03.033			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19410688	Bronze			2022-12-18	WOS:000266309400002
J	Dahl, R; Kapp, A; Colombo, G; De Monchy, JGR; Rak, S; Emminger, W; Riis, B; Gronager, PM; Durham, SR				Dahl, Ronald; Kapp, Alexander; Colombo, Giselda; De Monchy, Jan G. R.; Rak, Sabina; Emminger, Waltraud; Riis, Bente; Gronager, Pernille M.; Durham, Stephen R.			Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; grass pollen; immunotherapy; sublingual; rhinoconjunctivitis; tablet based; double-blind; placebo-controlled; Phleum pratense	POLLEN IMMUNOTHERAPY; FOLLOW-UP; SEASONAL RHINOCONJUNCTIVITIS; EFFICACY; CHILDREN; SAFETY; ASTHMA; PAT	Background: This is an interim analysis of a randomized, double-blind, placebo-controlled phase III trial with 3 years of daily treatment with grass tablet immunotherapy (GRAZAX; ALK-Abello A/S, Horsholm, Denmark) or placebo, followed by 2 years of follow-up to assess the persistent efficacy. Objective: We sought to evaluate the efficacy and safety of specific immunotherapy with grass allergen tablets compared with placebo after treatment covering 2 consecutive grass pollen seasons. Methods: The interim analyses included 351 adult participants with moderate-to-severe allergic rhinoconjunctivitis caused by grass pollen. Participants were treated with active (n = 189) or placebo (n = 162) tablets for an average of 22 months. All participants were allowed to use symptomatic rescue medication. Results: The primary efficacy analysis showed highly significant mean reductions of 36% in rhinoconjunctivitis symptom score (P<.0001; median reduction, 44%) and 46% in rhinoconjunctivitis medication score (P<.0001; median reduction, 73%) in the active group relative to the placebo group. Mean rhinoconjunctivitis quality of life was 33% better (P<.0001; median, 40%). Clinical improvements were paralleled by significant changes in allergen-specific immunoglobulins. The treatment was well tolerated, and adverse events led to withdrawal in less than 1% of participants. There were no serious adverse events related to treatment. Conclusion: Grass allergen tablet immunotherapy showed progressive immunologic changes and highly significant efficacy over 2 years of continued treatment.	[Dahl, Ronald] Aarhus Univ Hosp, Dept Resp Dis, Aarhus, Denmark; [Kapp, Alexander] Hannover Med Sch, Dept Dermatol & Allergol, Hannover, Germany; [Colombo, Giselda] Osped San Raffaele, Med Interna Allergol, Milan, Italy; [De Monchy, Jan G. R.] Univ Groningen, Univ Med Ctr Groningen, Div Allergol, Groningen, Netherlands; [Rak, Sabina] Sahlgrens Univ Hosp, Sect Allerg, Gothenburg, Sweden; [Emminger, Waltraud] Allergie Ambulatorium, Vienna, Austria; [Riis, Bente; Gronager, Pernille M.] Res & Dev, Horsholm, Denmark; [Durham, Stephen R.] Royal Brompton Hosp, Allergy & Clin Immunol Sect, London, England	Aarhus University; Hannover Medical School; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Groningen; Sahlgrenska University Hospital; Royal Brompton Hospital	Durham, SR (corresponding author), Royal Brompton Hosp, Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, Guy Scadding Bldg, Royal Brompton Campus, Doveho, London SW3 6LY, England.	s.durham@imperial.ac.uk	Dahl, Ronahl/F-8170-2013	Kapp, Alexander/0000-0002-1748-6276	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, pS386, DOI 10.1016/S0091-6749(98)70227-1; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Malling HJ, 2006, J INVEST ALLERG CLIN, V16, P162; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Olsson U, 2005, J STAT EDUC, V13, DOI 10.1080/10691898.2005.11910638; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Petersen AB, 2004, CLIN BIOCHEM, V37, P882, DOI 10.1016/j.clinbiochem.2004.06.010; Potter PC, 2006, ANN ALLERG ASTHMA IM, V96, pS22, DOI 10.1016/S1081-1206(10)60898-8; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; White P, 1998, CLIN EXP ALLERGY, V28, P266; World Medical Association, 1964, DECL HELS ETH PRINC	31	156	159	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					512	518		10.1016/j.jaci.2007.10.039	http://dx.doi.org/10.1016/j.jaci.2007.10.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18155284				2022-12-18	WOS:000253337800035
J	Howard, TD; Postma, DS; Jongepier, H; Moore, WC; Koppelman, GH; Zheng, SQL; Xu, JF; Bleecker, ER; Meyers, DA				Howard, TD; Postma, DS; Jongepier, H; Moore, WC; Koppelman, GH; Zheng, SQL; Xu, JF; Bleecker, ER; Meyers, DA			Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; ADAM33; association; haplotype	IDENTIFICATION; SUSCEPTIBILITY; FAMILY; MOUSE; ATOPY; IGE	Background: Asthma is a complex genetic disease characterized by reversible intermittent airway obstruction and respiratory symptoms primarily caused by acute and chronic bronchial inflammation. Recently, a gene potentially involved in airway remodeling, a disintegrin and metalloprotease 33 (ADAM33), was implicated in asthma susceptibility. Objective: We sought to determine whether polymorphisms in ADAM33 are associated with asthma or closely related phenotypes in 4 different asthma populations. Methods: Eight single nucleotide polymorphisms (SNPs) were evaluated in the 3' portion of ADAM33 in 4 unique asthma populations (African American, US white, US Hispanic, and Dutch white). These SNPs were previously reported to be associated with asthma in white populations from the United States and United Kingdom. Results: Significant associations were observed with at least one SNP and asthma in each population (P = .0009-.04). Related phenotypes that included total serum IgE levels and skin test responsiveness were also associated (P = .003-.05). However, no single SNP was associated across all populations. Additionally, haplotype analysis revealed that no single haplotype accounted for asthma susceptibility risk, although potential risk haplotypes existed within some of the populations. Conclusion: Replication of the original ADAM33 findings in these 4 additional asthma populations suggests that this gene (and perhaps others that interact with it) is important in the development and pathogenesis of asthma.	Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Groningen	Bleecker, ER (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.		Koppelman, Gerard/AAG-9187-2020	Koppelman, Gerard/0000-0001-8567-3252	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066393, R01HL048341] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL/66393, R01HL/48341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Drazen JM, 2002, NATURE, V418, P383, DOI 10.1038/418383a; Gunn TM, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-2; Howard TD, 2002, J ALLERGY CLIN IMMUN, V110, P743, DOI 10.1067/mai.2002.128723; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Marsh DG, 1997, NAT GENET, V15, P389; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Shapiro SD, 2002, NEW ENGL J MED, V347, P936, DOI 10.1056/NEJMcibr022144; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6	18	156	175	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					717	722		10.1016/S0091-6749(03)01939-0	http://dx.doi.org/10.1016/S0091-6749(03)01939-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564349	Bronze			2022-12-18	WOS:000185831200010
J	Marotta, A; Klinnert, MD; Price, MR; Larsen, GL; Liu, AH				Marotta, A; Klinnert, MD; Price, MR; Larsen, GL; Liu, AH			Impulse oscillometry provides an effective measure of lung dysfunction in 4-year-old children at risk for persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; children; early intervention; lung function; bronchodilator response; impulse oscillometry; spirometry	FORCED OSCILLATION TECHNIQUE; CHILDHOOD ASTHMA; AIRWAY-OBSTRUCTION; METHACHOLINE RESPONSIVENESS; INTERRUPTER TECHNIQUE; RESPIRATORY SYMPTOMS; PEAK FLOW; COLD-AIR; REVERSIBILITY; HEALTHY	Background: Objective lung function measurements are routinely used to diagnose and manage asthma, but their utility for young children has not been defined. Objective: Bronchodilator responses were measured by means of impulse oscillometry (IOS) and compared with conventional spirometry to determine the value of lung function measures in 4-year-old asthma-prone children. Methods: The study participants were in the Childhood Asthma Prevention Study (National Institute of Health/National Institute of Allergy and Infectious Diseases) and at risk for asthma. At age 4 years, concurrent asthma was determined by using a previously validated modified American Thoracic Society questionnaire. Children performed IOS and spirometry before and after albuterol administration and underwent skin prick testing to 13 common allergens to assess atopy. IOS measures were as follows: airways resistance at 5 Hz and 10 Hz, airways reactance at 5 Hz and 10 Hz, and resonant frequency. Results: Asthmatic patients versus nonasthmatic patients significantly differed in their IOS-assessed bronchodilator responses through Delta resistance at 5 Hz (medians, 27% vs 17%; P = .02) and Delta resistance at 10 Hz (24% vs 16%; P = .03). Because atopic children who have frequent wheezing are at risk for persistent asthma, the data were analyzed in regard to atopic patients with or without asthma. IOS strongly distinguished atopic asthmatic children through A resistance at 5 Hz (36% vs 13 %, P = .007), Delta resistance at 10 Hz (25% vs 11%, P = .02), and Delta reactance at 10 Hz (47 % vs 12 %, P = .03). Conventional spirometry did not establish similar statistically significant findings. Conclusion: IOS bronchodilator responses are remarkably abnormal in 4-year-old children, who are most likely to have persistent asthma. IOS is a useful diagnostic tool in early asthma development and might be a helpful objective outcome measure of early interventions.	Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Pediat Behav Hlth, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Boulder, CO 80309 USA; Natl Jewish Med & Res Ctr, Div Pediat Pulm Med, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; National Jewish Health	Liu, AH (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St,K1023, Denver, CO 80206 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067818, K23HL004272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R18AI041137] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00051] Funding Source: Medline; NHLBI NIH HHS [HL-67818, K23-HL04272] Funding Source: Medline; NIAID NIH HHS [R18-AI41137] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Arets HGM, 2001, EUR RESPIR J, V18, P655, DOI 10.1183/09031936.01.00204301; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; BROOKE AM, 1995, AM J RESP CRIT CARE, V152, P1872, DOI 10.1164/ajrccm.152.6.8520749; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Delacourt C, 2000, AM J RESP CRIT CARE, V161, P730, DOI 10.1164/ajrccm.161.3.9904081; Delacourt C, 2001, AM J RESP CRIT CARE, V164, P965, DOI 10.1164/ajrccm.164.6.2010153; DUIVERMAN EJ, 1986, B EUR PHYSIOPATH RES, V22, P433; Eigen H, 2001, AM J RESP CRIT CARE, V163, P619, DOI 10.1164/ajrccm.163.3.2002054; Gleason M, 2001, P WORLD ASTHM M CHIC; Goodman DC, 1998, PEDIATRICS, V101, P208, DOI 10.1542/peds.101.2.208; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hellinckx J, 1998, EUR RESPIR J, V12, P438, DOI 10.1183/09031936.98.12020438; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Joseph CLM, 1999, J ASTHMA, V36, P565, DOI 10.3109/02770909909087293; Klinnert MD, 2002, AM J PUBLIC HEALTH, V92, P792, DOI 10.2105/AJPH.92.5.792; Klug B, 1999, EUR RESPIR J, V14, P1185, DOI 10.1183/09031936.99.14511859; Klug B, 1996, PEDIATR PULM, V21, P290; KONIG P, 1984, CHEST, V86, P884, DOI 10.1378/chest.86.6.884; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Leone FT, 2001, CHEST, V119, P1027, DOI 10.1378/chest.119.4.1027; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MAZUREK HK, 1995, CHEST, V107, P996, DOI 10.1378/chest.107.4.996; Nielsen KG, 2000, AM J RESP CRIT CARE, V162, P1500, DOI 10.1164/ajrccm.162.4.2002019; Nielsen KG, 2000, AM J RESP CRIT CARE, V161, P1805, DOI 10.1164/ajrccm.161.6.9905098; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37, DOI 10.1164/ajrccm.163.1.2005013; Remes ST, 2002, THORAX, V57, P120, DOI 10.1136/thorax.57.2.120; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; TARGONSKI PV, 1994, AM J PUBLIC HEALTH, V84, P1830, DOI 10.2105/AJPH.84.11.1830; Wolfe R, 2000, AM J RESP CRIT CARE, V162, P2177, DOI 10.1164/ajrccm.162.6.9812019	37	156	163	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					317	322		10.1067/mai.2003.1627	http://dx.doi.org/10.1067/mai.2003.1627			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897737				2022-12-18	WOS:000184650600015
J	Bellinghausen, I; Klostermann, B; Knop, J; Saloga, J				Bellinghausen, I; Klostermann, B; Knop, J; Saloga, J			Human CD4(+)CD25(+) T cells derived from the majority of atopic donors are able to suppress T(H)1 and T(H)2 cytokine production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human regulatory T cells; CD25; T(H)1/T(H)2; allergy; dendritic cells	LYMPHOCYTE-ASSOCIATED ANTIGEN-4; IMMUNOLOGICAL SELF-TOLERANCE; REGULATORY CELLS; IN-VITRO; INTESTINAL INFLAMMATION; PERIPHERAL-BLOOD; MEMORY; POPULATION; RESPONSES; NAIVE	Background: Recently, it has been established that CD4(+)CD25(+) T cells with regulatory capacity are present in human peripheral blood, inhibiting allogeneic proliferation and cytokine production of preactivated CD4(+)CD25(-) responder T cells. Objective: The aim of this study was to analyze in an allergen-specific setting whether such regulatory CD4(+)CD25(+) T cells also exist and function normally in atopic individuals, especially concerning the inhibition of T(H)2 cytokines. Methods: For this purpose, CD4(+)CD25(-) or CD4(+)CD25(+) T cells from donors allergic to grass or birch pollen (mainly with rhinitis) or from healthy nonatopic donors were stimulated in the presence of autologous, mature, monocyte-derived, allergen-pulsed dendritic cells, and the preactivated CD4(+)CD25(+) T cells were added to CD4(+)CD25(-) T cells during restimulation. Results: CD4(+)CD25(+) T cells from the nonatopic donors and from the majority of the patients investigated proliferated poorly, produced fewer cytokines, and inhibited the proliferation and T(H)1 (IFN-gamma) and T(H)2 (IL-4 and IL-5) cytokine production of CD4(+)CD25(-) T cells but not IL-10 production. The suppression of CD4(+)CD25(-) T cells by CD4(+)CD25(+) T cells was at least partially antigen unspecific and not reversible with anti-IL-10, anti-transforming growth factor beta, or anti-cytotoxic T lymphocyte-associated antigen 4 mAb but was reversible with IL-2. In some atopic patients preactivated CD4(+)CD25(+) T cells reproducibly showed strong proliferative responses, produced higher amounts of IL-4 and IL-10 than CD4(+)CD25(-) T cells, and suppressed only the IFN-gamma production of CD4(+)CD25(-) T cells. Conclusion: These data indicate that regulatory CD4(+)CD25(+) T cells are present and functional in most atopic patients with allergic rhinitis and are able to inhibit T(H)1, as well as T(H)2, cytokine production.	Univ Mainz, Dept Dermatol, D-6500 Mainz, Germany	Johannes Gutenberg University of Mainz	Bellinghausen, I (corresponding author), Univ Hautklin, Langenbeckstr 1, D-55131 Mainz, Germany.							Annacker O, 2001, J IMMUNOL, V166, P3008, DOI 10.4049/jimmunol.166.5.3008; Asseman C, 1998, GUT, V42, P157, DOI 10.1136/gut.42.2.157; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Bellinghausen I, 2000, J ALLERGY CLIN IMMUN, V105, P988, DOI 10.1067/mai.2000.105526; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; DosReis GA, 1998, IMMUNOL TODAY, V19, P587, DOI 10.1016/S0167-5699(98)01369-3; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; MAGGI E, 1992, J IMMUNOL, V148, P2142; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Ng WF, 2001, BLOOD, V98, P2736, DOI 10.1182/blood.V98.9.2736; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Sakaguchi S, 1996, J AUTOIMMUN, V9, P211, DOI 10.1006/jaut.1996.0026; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shevach EM, 2001, ADV EXP MED BIOL, V490, P21; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Stephens LA, 2001, EUR J IMMUNOL, V31, P1247, DOI 10.1002/1521-4141(200104)31:4<1247::AID-IMMU1247>3.0.CO;2-M; Suto A, 2001, AM J RESP CRIT CARE, V164, P680, DOI 10.1164/ajrccm.164.4.2010170; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183	25	156	181	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					862	868		10.1067/mai.2003.1412	http://dx.doi.org/10.1067/mai.2003.1412			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704370				2022-12-18	WOS:000182258500030
J	Nel, AE				Nel, AE			T-cell activation through the antigen receptor. Part 1: Signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						T-cell activation; TCR; signal transduction	PROTEIN-KINASE-C; KAPPA-B KINASE; TYROSINE KINASE; IMMUNOLOGICAL SYNAPSE; ACTIN CYTOSKELETON; LYMPHOCYTES-T; TRANSCRIPTIONAL REGULATION; MEMBRANE MICRODOMAINS; IL-2 PROMOTER; IKK COMPLEX	Part 1 of this review will highlight the basic components and signaling pathways by which the T-cell antigen receptor (TCR) activates mature extrathymic T cells. TCR signaling commences with an early wave of protein tyrosine kinase activation, which is mediated by the Src kinases Lck and Fyn. the 70-kd zeta-associated protein kinase, and members of the Tec kinase family. This early wave of protein tyrosine phosphorylation leads to the activation of downstream signaling pathways, including an increase in intracellular free calcium, protein kinase C, nuclear factor kappaB and Ras-mitogen-activated protein kinase activation. These pathways activate transcription factors, such as activator protein 1, nuclear factor of activated T cells, and Rel proteins, which ultimately lead to the expression of genes that control cellular proliferation, differentiation, anergy, or apoptosis. This review also describes how costimulatory receptors assist in signal transduction and assembly of macromolecular complexes at the TCR contact site with the antigen-presenting cell, also known as the immune synapse. These basic concepts of TCR signal transduction will be used in part 2 to explain how T-cell function can be altered by therapeutic targeting of TCR signaling components, as well as to explain modification of TCR signaling during T(H)1/T(H)2 differentiation, tolerance, and immune senescence.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol Allergy, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Nel, AE (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol Allergy, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Nel, Andre E/J-2808-2012		NIAID NIH HHS [P0-1 AI50495] Funding Source: Medline; NIA NIH HHS [R0-1 AG14992] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014992] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Baksh S, 2000, SEMIN IMMUNOL, V12, P405, DOI 10.1006/smim.2000.0221; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BEYERS AD, 1988, J IMMUNOL, V141, P3463; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Bruyns E, 1998, J EXP MED, V188, P561, DOI 10.1084/jem.188.3.561; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Delon J, 1998, EUR J IMMUNOL, V28, P716, DOI 10.1002/(SICI)1521-4141(199802)28:02<716::AID-IMMU716>3.0.CO;2-E; Di Bartolo V, 1999, J BIOL CHEM, V274, P6285, DOI 10.1074/jbc.274.10.6285; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Downward J, 1996, CANCER SURV, V27, P87; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; GUPTA S, 1994, J BIOL CHEM, V269, P17349; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Henning SW, 1998, CURR OPIN IMMUNOL, V10, P322, DOI 10.1016/S0952-7915(98)80171-4; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kaga S, 1998, J IMMUNOL, V160, P24; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kempiak SJ, 1999, J IMMUNOL, V162, P3176; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Khoshnan A, 1999, J IMMUNOL, V163, P5444; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; Krawczyk C, 2001, TRENDS CELL BIOL, V11, P212, DOI 10.1016/S0962-8924(01)01981-X; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Leitenberg D, 2001, SEMIN IMMUNOL, V13, P129, DOI 10.1006/smim.2000.0304; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; Lowin-Kropf B, 1998, J CELL BIOL, V140, P861, DOI 10.1083/jcb.140.4.861; LU YL, 1992, J IMMUNOL, V149, P24; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.immunol.13.1.587; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; NEL AE, 1987, J IMMUNOL, V138, P3519; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; Pelosi M, 1999, J BIOL CHEM, V274, P14229, DOI 10.1074/jbc.274.20.14229; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rincon M, 2000, IMMUNOL CELL BIOL, V78, P166, DOI 10.1046/j.1440-1711.2000.00900.x; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sadra A, 1999, J IMMUNOL, V162, P1966; Schaefer BC, 1999, IMMUNITY, V11, P411, DOI 10.1016/S1074-7613(00)80116-8; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; van der Merwe PA, 2000, SEMIN IMMUNOL, V12, P5, DOI 10.1006/smim.2000.0203; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; van Oers NSC, 1999, SEMIN IMMUNOL, V11, P227, DOI 10.1006/smim.1999.0179; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WANGE RL, 2000, SCI STKE REV LAT LIN, P1; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; WEIL R, 1994, J BIOL CHEM, V269, P22830; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xavier R, 1999, CURR OPIN IMMUNOL, V11, P265, DOI 10.1016/S0952-7915(99)80043-0; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	99	156	165	0	14	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					758	770		10.1067/mai.2002.124259	http://dx.doi.org/10.1067/mai.2002.124259			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994696				2022-12-18	WOS:000175687800002
J	Posadas, SJ; Padial, A; Torres, MJ; Mayorga, C; Leyva, L; Sanchez, E; Alvarez, J; Romano, A; Juarez, C; Blanca, M				Posadas, SJ; Padial, A; Torres, MJ; Mayorga, C; Leyva, L; Sanchez, E; Alvarez, J; Romano, A; Juarez, C; Blanca, M			Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						drugs; allergy; perforin; Fas-l; granzyme B	TOXIC EPIDERMAL NECROLYSIS; NATURAL-KILLER-CELLS; T-CELLS; GENE-EXPRESSION; MESSENGER-RNA; IN-VIVO; ERYTHEMA MULTIFORME; ALLERGIC REACTIONS; RENAL-ALLOGRAFTS; LYMPHOCYTES	Background: Drugs can induce different immunologic reactions; T-cell mediated responses produce the most severe reactions. Although in vitro studies show that T cells recognize drugs or their metabolites and induce an effector cytotoxic response, direct in vivo evidence of involvement is lacking. T lymphocytes produce cytotoxic markers that are responsible for 2 major pathways to cell death: granule-mediated exocytosis (perforin and granzyme B) and Fas/FasL interaction. Objective: The purpose of this investigation was to establish the role of proinflammatory TNF-alpha and cytotoxic markers in subjects with delayed responses to drugs. Methods: We assessed expression levels by quantitative-competitive PCR of TNF-alpha, perforin, granzyme B, and FasL in mononuclear cells from peripheral blood and blister fluid from subjects with delayed reactions to drugs. Samples were obtained within 24 hours of the reaction and 30 days later. Fifteen patients were included and classified according to severity of the reaction, as follows: (A) maculopapular exanthema, (B) desquamative exanthema, (C) Stevens-Johnson syndrome, (D) toxic epidermal necrolysis. Results: At the acute stage, there was a large increase in TNF-alpha (9-fold), perforin (6-fold), and GrB (7-fold) in patients in comparison with control subjects. FasL was expressed in PBMCs only in Stevens-Johnson syndrome and toxic epidermal necrolysis. A high association between cytotoxic markers and disease severity was seen (P < .001). Conclusion: our data show that TNF-alpha, perforin, GrB, and FasL are increased in the early stage of disease, suggesting that a cytotoxic mechanism might be taking part. These findings support the role of T cells in allergic drug reactions and provide further clues pertaining to therapeutic interventions.	Hosp Univ La Paz, Serv Alergia, Madrid 28046, Spain; Carlos Haya Hosp, Res Unit Allergy Dis, Malaga, Spain; IRCCS Oasi Maria SS, Troina, Italy	Hospital Universitario La Paz; Hospital Carlos Haya; IRCCS Oasi Maria SS	Blanca, M (corresponding author), Hosp Univ La Paz, Serv Alergia, Paseo La Castellana 261, Madrid 28046, Spain.		Leyva, Laura/R-2187-2019; Leyva, Laura/B-5574-2019; Torres, Maria/GVU-3391-2022; Romano, Antonino/D-3102-2017; Mayorga, Cristobalina/D-7167-2018; POSADAS, SINFORIANO J/H-8075-2013; Torres, María José/T-3518-2017; Mayorga, Lina/FBO-7730-2022	Leyva, Laura/0000-0003-0620-9625; Leyva, Laura/0000-0003-0620-9625; Romano, Antonino/0000-0001-9742-9898; Mayorga, Cristobalina/0000-0001-8852-8077; POSADAS, SINFORIANO J/0000-0003-0014-1957; Torres, María José/0000-0001-5228-471X; 				AMOS HE, 1976, ALLERGIC DRUG REACTI, P64; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BRANDER C, 1995, J IMMUNOL, V155, P2670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEMENT MV, 1991, INT IMMUNOL, V3, P1175, DOI 10.1093/intimm/3.11.1175; CLEMENT MV, 1990, HUM IMMUNOL, V28, P159, DOI 10.1016/0198-8859(90)90013-F; EIERMAN DF, 1989, J IMMUNOL, V142, P1970; ELIAS PM, 1987, DERMATOLOGY GENERAL, P555; FISHER AA, 1988, CONTACT DERMATITIS, P954; GELL PGH, 1975, CLIN ASPECTS IMMUNOL; Gonzalez FJ, 1997, J ALLERGY CLIN IMMUN, V100, P135, DOI 10.1016/S0091-6749(97)70205-7; Gonzalez FJ, 1997, INT ARCH ALLERGY IMM, V113, P345, DOI 10.1159/000237597; HERSHKOVIZ R, 1994, J IMMUNOL, V153, P554; HERTL M, 1993, J INVEST DERMATOL, V101, P794, DOI 10.1111/1523-1747.ep12371697; HERTL M, 1995, J INVEST DERMATOL, V105, P95; Ikura S, 1999, IMMUNOLOGY, V96, P485; Inachi S, 1997, ARCH DERMATOL, V133, P845, DOI 10.1001/archderm.133.7.845; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; Kivisakk P, 1999, ACTA NEUROL SCAND, V100, P18, DOI 10.1111/j.1600-0404.1999.tb00719.x; Leyva L, 2000, J ALLERGY CLIN IMMUN, V105, P157, DOI 10.1016/S0091-6749(00)90191-X; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175, DOI 10.1111/j.1365-2222.1997.tb00690.x; Padovan E, 1996, EUR J IMMUNOL, V26, P42, DOI 10.1002/eji.1830260107; PODACK E, 1985, P NATL ACAD SCI USA, V2, P8629; Posadas SJ, 2000, J ALLERGY CLIN IMMUN, V106, P769, DOI 10.1067/mai.2000.109828; ROJEAU JC, 1994, NEW ENGL J MED, V331, P1272; Rukavina D, 1998, BLOOD, V92, P2410, DOI 10.1182/blood.V92.7.2410.2410_2410_2420; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; Sloand EM, 1997, BLOOD, V89, P1357, DOI 10.1182/blood.V89.4.1357; Spaeny-Dekking EHA, 1998, J IMMUNOL, V160, P3610; Spaner D, 1998, J IMMUNOL, V160, P2655; Spinozzi F, 1998, ANN INTERN MED, V128, P363, DOI 10.7326/0003-4819-128-5-199803010-00004; Stenger S, 1999, IMMUNOL TODAY, V20, P390, DOI 10.1016/S0167-5699(99)01449-8; Strehlau J, 1997, P NATL ACAD SCI USA, V94, P695, DOI 10.1073/pnas.94.2.695; Sugita Y, 1997, BRIT J DERMATOL, V136, P393, DOI 10.1111/j.1365-2133.1997.tb14952.x; TERRADOS S, 1995, ALLERGY, V50, P563, DOI 10.1111/j.1398-9995.1995.tb01200.x; Vasconcellos LM, 1998, TRANSPLANTATION, V66, P562, DOI 10.1097/00007890-199809150-00002; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; WILKINSON DS, 1970, ACTA DERM-VENEREOL, V50, P287; Yawalkar N, 2000, CLIN EXP ALLERGY, V30, P847	42	156	167	0	21	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					155	161		10.1067/mai.2002.120563	http://dx.doi.org/10.1067/mai.2002.120563			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799383	Bronze			2022-12-18	WOS:000173739300026
J	Ochs, RL; Muro, Y; Si, YZ; Ge, H; Chan, EKL; Tan, EM				Ochs, RL; Muro, Y; Si, YZ; Ge, H; Chan, EKL; Tan, EM			Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; autoantibodies; antinuclear antibodies; asthma; interstitial cystitis; transcription coactivator	INTERSTITIAL CYSTITIS; TRANSCRIPTIONAL ACTIVATION; LENS EPITHELIUM; GENES; PATHOGENESIS; ANTIBODIES; DIAGNOSIS; SEQUENCE; PROTEINS; CLONING	Background: Sera of patients with atopic dermatitis (AD) were found to have autoantibodies that reacted with tissue culture cell substrates in immunohistochemistry to display a characteristic pattern of nuclear distribution of dense fine speckles. The sera also recognized a 70-kd protein on Western immunoblots, and the antigen was termed dense fine speckles 70 kd (DSF70). Objective: Because spontaneously occurring autoantibodies could be immune responses to proteins that might be participating in the disease process, it was of interest to identify the antigens driving the autoimmune antibody response. Methods: A serum containing high-titer antibodies to DFS70 was used to immunoscreen a complementary (c)DNA expression library to isolate cDNA encoding the antigen. After the cDNA was isolated, this was used to express recombinant protein to determine the prevalence of antibody in AD and other conditions. Results: Thirty percent of patients with AD were found to have antibody to recombinant DFS70 in Western immunoblots. Sixteen percent of patients with asthma and 9% of patients with interstitial cystitis had antibodies of the same specificities. The cDNA encoding DFS70 was identical to a transcription coactivator called p75, which had been shown to be required for RNA polymerase II-dependent transcription. Another important finding was that IgE antibodies to DFS70 were also present in AD sera. Conclusion: It is suggested that a common basis for the presence of autoantibodies to DFS70 might be related to AD in asthma, interstitial cystitis, and other conditions. A possible role of this antigen-antibody system in pathogenesis remains to be demonstrated, but it appears to be a marker for a subset of patients with AD.	Scripps Res Inst, WM Keck Autoimmune Dis Ctr, Dept Mol & Expt Med, La Jolla, CA 92037 USA; NICHHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Tan, EM (corresponding author), Scripps Res Inst, WM Keck Autoimmune Dis Ctr, Dept Mol & Expt Med, MEM 131,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Chan, Edward K. L./B-5671-2009; MURO, Yoshinao/M-8883-2014	Chan, Edward K. L./0000-0003-3938-9503; Muro, Yoshinao/0000-0003-2329-8375	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR032063, R01AR032063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049413] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32063] Funding Source: Medline; NIDDK NIH HHS [DK49413] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beltrani VS, 1999, J ALLERGY CLIN IMMUN, V104, pS87, DOI 10.1016/S0091-6749(99)70050-3; CHAN EKL, 1992, MANUAL CLIN LABORATO, P755; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAGERHOLM P, 1984, GRAEF ARCH CLIN EXP, V221, P149, DOI 10.1007/BF02134255; Forrest S, 1999, J ALLERGY CLIN IMMUN, V104, P1066, DOI 10.1016/S0091-6749(99)70090-4; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GILLENWATER JY, 1988, J UROLOGY, V140, P203, DOI 10.1016/S0022-5347(17)41529-1; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HANNO P, 1990, J UROLOGY, V143, P278, DOI 10.1016/S0022-5347(17)39933-0; HOLMBENTZEN M, 1987, J UROLOGY, V138, P500, DOI 10.1016/S0022-5347(17)43240-X; Konstantinov K, 1996, J CLIN INVEST, V98, P1888, DOI 10.1172/JCI118990; KOZIOL JA, 1993, J UROLOGY, V149, P465, DOI 10.1016/S0022-5347(17)36120-7; Leung DYM, 1999, J ALLERGY CLIN IMMUN, V104, pS99, DOI 10.1016/S0091-6749(99)70051-5; Leung DYM, 1993, DERMATOLOGY GEN MED, P1543; Lung CC, 1996, TRENDS GENET, V12, P389, DOI 10.1016/S0168-9525(96)90093-1; MESSING E M, 1978, Urology, V12, P381, DOI 10.1016/0090-4295(78)90286-8; NAKANO E, 1997, J JPN OPHTHALMOL SOC, V101, P64; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Ochs R. L., 1995, Molecular Biology of the Cell, V6, p75A; Ochs RL, 1996, MOL BIOL CELL, V7, P1015, DOI 10.1091/mbc.7.7.1015; OCHS RL, 1994, J UROLOGY, V151, P587, DOI 10.1016/S0022-5347(17)35023-1; Ochs RL, 1997, INTERSTITIAL CYSTITI, P47; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; Singh DP, 1999, INVEST OPHTH VIS SCI, V40, P1444; SINGH DP, 1998, INVEST OPHTHALMOL  S, V39, P3590; TADA J, 1994, DERMATOLOGY, V189, P38, DOI 10.1159/000246756; Tan EM, 1999, IMMUNOLOGIST, V7, P85; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; TANIGUCHI Y, 1992, ACTA DERM-VENEREOL, P62; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	33	156	171	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1211	1220		10.1067/mai.2000.107039	http://dx.doi.org/10.1067/mai.2000.107039			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856157				2022-12-18	WOS:000087781800024
J	Moneret-Vautrin, DA; Guerin, L; Kanny, G; Flabbee, J; Fremont, S; Morisset, M				Moneret-Vautrin, DA; Guerin, L; Kanny, G; Flabbee, J; Fremont, S; Morisset, M			Cross-allergenicity of peanut and lupine: The risk of lupine allergy in patients allergic to peanuts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; legumes; cross-reactivity; lupine allergenicity; double-blind; placebo-controlled food challenge; immunoblot	LEGUME BOTANICAL FAMILY; FOOD HYPERSENSITIVITY; PROTEINS; IDENTIFICATION; CHILDREN; POLYACRYLAMIDE; FEATURES; BINDING; SEED	Background: Peanut allergy is common, but cross-allergy between legumes is rare, Proteins from Lupinus albus are increasingly eaten in the form of seeds or additives to wheat flour, The risk of cross-allergenicity is still insufficiently known, Objective: We sought to study the risk of cross-allergy to lupine in patients allergic to peanut and to study lupine allergenicity, Methods: Twenty-four patients allergic to peanuts were studied by means of skin prick tests with native lupine flour from Lupinus albus. Double-blind oral challenge tests were performed with lupine flour and peanut in 8 of these patients. Specific IgEs were assayed for peanut, lupine flour, and pollen in 6 sera. RAST inhibition tests for lupine pollen by peanut were performed on 4 of these sera. Peanut and lupine flour immunoblots were carried out for 6 sera, and crossed immunoblot inhibitions for peanut by lupine flour and lupine flour by peanut were carried out for 2 sera. Results: The skin prick test responses with lupine flour were positive in 11 (44%) subjects. The challenge test responses mere positive in 7 of 8 subjects at the same doses as with peanut. The major lupine flour allergen (molecular mass, 43 kd) is present in peanuts. The RAST inhibition and immunoblot tests indicated cross-reactivity of peanut with the lupine flour and pollen. Conclusions: The risk of crossed peanut-lupine allergy is high, contrary to the risk with other legumes. The inclusion of 10% lupine flour in wheat flour without mandatory labeling makes lupine a hidden allergen, presenting a major risk of cross-reaction in subjects already allergic to peanut products, A high sensitizing potential can also be postulated for this legume.	Hop Cent, Dept Clin Immunol & Allergol, F-54035 Nancy, France; Lab Allerbio, Varennes En Argonne, France; Fac Med Vandoeuvre Nancy, INSERM, U308, Biochim Lab, F-54505 Vandoeuvre Les Nancy, France	CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Moneret-Vautrin, DA (corresponding author), Hop Cent, Dept Clin Immunol & Allergol, 29 Ave Lattre Tassigny, F-54035 Nancy, France.		Kanny, Gisèle/AHA-8910-2022; Morisset, Martine/A-3084-2017	Morisset, Martine/0000-0002-4028-703X				Bannon GA, 1997, J ALLERGY CLIN IMMUN, V99, P568; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; BURKS AW, 1991, ADV EXP MED BIOL, V289, P295; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; CHANGO A, 1995, FOOD RES INT, V28, P91, DOI 10.1016/0963-9969(95)93337-T; DEPENNA EW, 1987, J FOOD SCI, V52, P1434; DURANTI M, 1995, J PROTEIN CHEM, V14, P107, DOI 10.1007/BF01888368; Eigenmann PA, 1996, J ALLERGY CLIN IMMUN, V98, P969, DOI 10.1016/S0091-6749(96)80014-5; Ewan PW, 1996, BRIT MED J, V312, P1074; Foucard T, 1997, Lakartidningen, V94, P2635; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GUEANT JL, 1995, REV FR ALLERGOL, V35, P312, DOI 10.1016/S0335-7457(05)80521-0; Gutierrez D, 1997, CONTACT DERMATITIS, V36, P311, DOI 10.1111/j.1600-0536.1997.tb00012.x; HEFLE SL, 1994, J ALLERGY CLIN IMMUN, V94, P167, DOI 10.1016/0091-6749(94)90036-1; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Lalles JP, 1996, NUTR REV, V54, P101; Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204; Marrs T, 1996, Health Bull (Edinb), V54, P366; Molvig L, 1997, P NATL ACAD SCI USA, V94, P8393, DOI 10.1073/pnas.94.16.8393; Moneret-Vautrin DA, 1998, CLIN EXP ALLERGY, V28, P1113, DOI 10.1046/j.1365-2222.1998.00370.x; MONERETVAUTRIN DA, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P473; PETTERSON DS, 1994, BRIT J NUTR, V72, P865, DOI 10.1079/BJN19940091; RABILLOUD T, 1992, ELECTROPHORESIS, V13, P264, DOI 10.1002/elps.1150130154; Rance F, 1997, PEDIATR ALLERGY IMMU, V8, P41; ROMANO C, 1997, ALLERGY, V52, P113; Rozan P, 1997, J AGR FOOD CHEM, V45, P1762, DOI 10.1021/jf960723v; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; YANEZ E, 1983, ANN NUTR METAB, V27, P513, DOI 10.1159/000176728; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	41	156	159	2	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				883	888		10.1016/S0091-6749(99)70303-9	http://dx.doi.org/10.1016/S0091-6749(99)70303-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518837	Bronze			2022-12-18	WOS:000083281200024
J	Bollinger, ME; Eggleston, PA; Flanagan, E; Wood, RA				Bollinger, ME; Eggleston, PA; Flanagan, E; Wood, RA			Cat antigen in homes with and without cats may induce allergic symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cat allergen; environmental allergens; animal allergens; antigen challenge	FEL-D-I; HOUSEHOLD-DUST SAMPLES; F-I; CHILDREN; ASTHMA; MITE; DOG; ANTIBODIES; REMOVAL	Although Fel d 1, the major cat allergen, has been found in settled dust samples from homes both with and without cats, the clinical relevance of this allergen has never been studied. In this study we measured airborne concentrations of Fel d 1 in homes both with and without cats and then attempted to relate these levels to those obtained in our experimental cat challenge model to assess their clinical significance. In baseline samples we found measurable levels of airborne Fel d 1 in all 37 homes with cats (range, 1.8 to 578 ng/m(3); median, 45.9 ng/m(3)) and in 10 of the 40 homes without cats (for detectable samples: range, 2.8 to 88.5 ng/m(3); median, 17 ng/m(3)). Fel d 1 was present in the settled dust of 38 of 40 homes without cats (range, 39 to 3750 ng/gm; median, 258 ng/gm), although these levels were only, weakly predictive of airborne levels. Repeat samples obtained weekly from 12 homes without cats yielded measurable airborne Fel d 1 in at least one of the four samples from all homes. When compared with challenges performed in our cat room facility at low levels of airborne Fel d 1 (< 500 ng/m(3)), these home levels are within the range capable of causing upper and lower respiratory symptoms in subjects allergic to cats. We therefore conclude that the low level cat exposure that occurs in many homes without cats is capable of inducing symptoms in some patients who are sensitive to cats. The assessment of cat exposure should not be based solely, on the presence or absence of a cat in the home.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,BALTIMORE,MD 21218	Johns Hopkins University					NCRR NIH HHS [5M01 RR00052] Funding Source: Medline; NIAID NIH HHS [AI-07007, AI-30773] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030773] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAPMAN MD, 1988, J IMMUNOL, V140, P812; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; ENBERG RN, 1993, ANN ALLERGY, V70, P471; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; LINNA O, 1983, ALLERGY, V38, P513, DOI 10.1111/j.1398-9995.1983.tb02360.x; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; MUNIR AKM, 1993, ALLERGY, V48, P158, DOI 10.1111/j.1398-9995.1993.tb00706.x; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; PLATTSMILLS TAE, 1990, ALLERGY PROC, V11, P269, DOI 10.2500/108854190778879729; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; SAKAGUCHI M, 1993, J ALLERGY CLIN IMMUN, V92, P797, DOI 10.1016/0091-6749(93)90056-L; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; VANDERBREMPT X, 1991, J ALLERGY CLIN IMMUN, V87, P595, DOI 10.1016/0091-6749(91)90020-O; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x; 1994, 1994 STAT ABSTR US, P254	18	156	160	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					907	914		10.1016/S0091-6749(96)80064-9	http://dx.doi.org/10.1016/S0091-6749(96)80064-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655885	hybrid			2022-12-18	WOS:A1996UG08600004
J	BOUSQUET, J; CALVAYRAC, P; GUERIN, B; HEJJAOUI, A; DHIVERT, H; HEWITT, B; MICHEL, FB				BOUSQUET, J; CALVAYRAC, P; GUERIN, B; HEJJAOUI, A; DHIVERT, H; HEWITT, B; MICHEL, FB			IMMUNOTHERAPY WITH A STANDARDIZED DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT .1. INVIVO AND INVITRO PARAMETERS AFTER A SHORT COURSE OF TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LABS STALLERGENES, JOINVILLE, FRANCE	Stallergenes Greer	BOUSQUET, J (corresponding author), CLIN AIGUELONGUE, CLIN MALAD RESP, AVE MAJOR FLANDRE, F-34059 MONTPELLIER, FRANCE.							AAS K, 1982, ALLERGY, V37, P1, DOI 10.1111/j.1398-9995.1982.tb04111.x; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; BERG T, 1980, INT ARCH ALLER A IMM, V63, P266, DOI 10.1159/000232636; BERNADOU M, 1983, BORDEAUX MED, V16, P245; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BOUSQUET J, 1985, 3RD P INT P ERHL SEM; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; COLMES A, 1932, J ALLERGY, V3, P449; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DAVIES RJ, 1983, 11 P INT C ALL CLIN, P291; Freeman J, 1930, LANCET, V1, P744; FROSTAD AB, 1980, ALLERGY, V35, P81, DOI 10.1111/j.1398-9995.1980.tb01722.x; GADDIE J, 1976, BRIT MED J, V2, P561, DOI 10.1136/bmj.2.6035.561; GAYRARD P, 1975, AM REV RESPIR DIS, V111, P433; GOLDSTEIN GL, 1981, ANN ALLERGY, V47, P333; Harley D, 1937, J PATHOL BACTERIOL, V44, P589, DOI 10.1002/path.1700440307; HUGGINS KG, 1979, CLIN ALLERGY, V9, P37, DOI 10.1111/j.1365-2222.1979.tb01520.x; KJELLMAN NIM, 1980, ALLERGY, V35, P323, DOI 10.1111/j.1398-9995.1980.tb01774.x; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; MACGLASHAN DW, 1981, J IMMUNOL, V127, P2410; MARYGABRIEL SX, 1977, CLIN ALLERGY, V7, P325; MAUNSELL K, 1971, LANCET, V1, P967; MCALLEN MK, 1969, ACTA ALLERGOL, V24, P421, DOI 10.1111/j.1398-9995.1969.tb03756.x; MENARDO JL, 1982, P ANN M EUROPEAN ACA; NEWTON DAG, 1978, BRIT J DIS CHEST, V72, P21, DOI 10.1016/0007-0971(78)90004-9; NORMAN PS, 1985, 3RD P P EHRL SEM REG; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; PAULI G, 1975, REV FR ALLERGOL, V15, P176; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PIGLOWSKI J, 1976, REV FR MAL RESP S1, V4, P81; PLATTSMILLS TAE, 1983, 12 P C EUR AC ALL CL, P123; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; RAMSDELL JW, 1982, PULMONARY FUNCTION T, P205; ROSENTHAL RR, 1979, J ALLERGY CLIN IMMUN, V64, P564, DOI 10.1016/0091-6749(79)90013-7; RYAN G, 1981, J ALLERGY CLIN IMMUN, V67, P156, DOI 10.1016/0091-6749(81)90012-9; Sherman WB, 1941, J IMMUNOL, V40, P289; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; SMITH J M, 1972, Clinical Allergy, V2, P281, DOI 10.1111/j.1365-2222.1972.tb01291.x; SPECTOR SL, 1983, PROVOCATIVE CHALLENG, P97; SPRECACE GA, 1966, J ALLERGY, V38, P9, DOI 10.1016/0021-8707(66)90068-2; TAYLOR B, 1974, CLIN ALLERGY, V4, P35, DOI 10.1111/j.1365-2222.1974.tb01360.x; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TIPTON WR, 1982, J ALLERGY CLIN IMMUN, V69, P194, DOI 10.1016/0091-6749(82)90099-9; TURNER MW, 1984, CLIN ALLERGY, V14, P221, DOI 10.1111/j.1365-2222.1984.tb02201.x; VANARSDEL P, 1961, J ALLERGY, V32, P348, DOI 10.1016/0021-8707(61)90103-4; VHU JCL, 1981, ANN ALLERGY, V47, P107; WARNER JO, 1978, LANCET, V2, P912; 1979, BR J DIS CHEST, V73, P260	55	156	158	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					734	744		10.1016/0091-6749(85)90680-3	http://dx.doi.org/10.1016/0091-6749(85)90680-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	4056259	Bronze			2022-12-18	WOS:A1985AUU3400014
J	FINK, JN				FINK, JN			HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM MED CTR,RES SERV,MARCUS LAB ALLERGY & IMMUNOL RES,WOOD,WI 53193	US Department of Veterans Affairs; Veterans Health Administration (VHA)	FINK, JN (corresponding author), MED COLL WISCONSIN,DEPT MED,ALLERGY IMMUNOL SECT,MILWAUKEE,WI 53226, USA.				NHLBI NIH HHS [HL 29319, HL 29390] Funding Source: Medline; NIAID NIH HHS [AI 19104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI019104] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN DH, 1975, AM J MED, V59, P505, DOI 10.1016/0002-9343(75)90258-2; ALLEN EM, 1977, J IMMUNOL, V119, P343; AVILA R, 1968, LANCET, V1, P620; BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BARBEE RA, 1968, AM REV RESPIR DIS, V97, P223; BARROWCLIFF DF, 1968, THORAX, V23, P490, DOI 10.1136/thx.23.5.490; BAUR X, 1980, ALLERGY, V35, P383, DOI 10.1111/j.1398-9995.1980.tb01783.x; Benacerraf B., 1975, Immunogenetics and immunodeficiency., P117; BERRENS L, 1974, ANN NY ACAD SCI, V221, P153, DOI 10.1111/j.1749-6632.1974.tb28213.x; BICE DE, 1976, J ALLERGY CLIN IMMUN, V58, P250, DOI 10.1016/0091-6749(76)90130-5; BRENTJENS JR, 1974, J EXP MED, V140, P105, DOI 10.1084/jem.140.1.105; BRINGHURST LS, 1959, JAMA-J AM MED ASSOC, V171, P15, DOI 10.1001/jama.1959.03010190017004; BRYANT DH, 1973, BRIT MED J, V4, P589, DOI 10.1136/bmj.4.5892.589; BUECHNER HA, 1958, AM J MED, V25, P234, DOI 10.1016/0002-9343(58)90030-5; BURRELL R, 1977, INT ARCH ALLER A IMM, V55, P161, DOI 10.1159/000231923; CALVANICO NJ, 1980, J LAB CLIN MED, V96, P129; CAMPBELL JM, 1932, BRIT MED J, V2, P1143; CHMELIK F, 1974, J ALLERGY CLIN IMMUN, V54, P180, DOI 10.1016/0091-6749(74)90055-4; COHEN HI, 1967, AM J MED, V43, P785, DOI 10.1016/0002-9343(67)90121-0; DICKIE HA, 1958, JAMA-J AM MED ASSOC, V167, P1069, DOI 10.1001/jama.1958.02990260011004; EDWARDS JH, 1970, IMMUNOLOGY, V19, P729; EMANUEL DA, 1966, NEW ENGL J MED, V274, P1413, DOI 10.1056/NEJM196606232742504; FINK JN, 1975, INT ARCH ALLER A IMM, V49, P831, DOI 10.1159/000231466; FINK JN, 1976, ANN INTERN MED, V84, P406, DOI 10.7326/0003-4819-84-4-406; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; GHOSE T, 1974, CLIN ALLERGY, V4, P119, DOI 10.1111/j.1365-2222.1974.tb01369.x; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; HARRIS JO, 1976, AM REV RESPIR DIS, V114, P29; JOUBERT J, 1976, AM REV RESPIR DIS, V12, P1619; KELLER R H, 1984, Journal of Allergy and Clinical Immunology, V73, P127; KELLER RH, 1982, J CLIN IMMUNOL, V2, P46, DOI 10.1007/BF00915978; MARKHAM RJF, 1979, IMMUNOL LETT, V1, P79, DOI 10.1016/0165-2478(79)90004-X; MARX JJ, 1977, CLIN IMMUNOL IMMUNOP, V8, P487, DOI 10.1016/0090-1229(77)90012-5; MOORE VL, 1975, J CLIN INVEST, V56, P937, DOI 10.1172/JCI108173; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1113; PATTERSON R, 1976, AM J MED, V60, P144, DOI 10.1016/0002-9343(76)90543-X; PEPYS J, 1969, MONOGR ALLERGY, V4, P44; PETERSON LB, 1979, AM REV RESPIR DIS, V119, P991; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001; REYES CN, 1982, CHEST, V81, P142, DOI 10.1378/chest.81.2.142; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; RICHERSON HB, 1974, ANN NY ACAD SCI, V221, P340, DOI 10.1111/j.1749-6632.1974.tb28236.x; RITTNER C, 1975, LANCET, V2, P1303; ROCKLIN RE, 1976, J CLIN INVEST, V57, P1051, DOI 10.1172/JCI108347; RODEY GE, 1979, AM REV RESPIR DIS, V119, P755; RYLANDER R, 1978, CLIN ALLERGY, V8, P561; SALVAGGIO J, 1975, J ALLERGY CLIN IMMUN, V56, P364, DOI 10.1016/0091-6749(75)90130-X; SCHLUETER DP, 1969, ANN INTERN MED, V70, P457, DOI 10.7326/0003-4819-70-3-457; SCHLUETER DP, 1972, ANN INTERN MED, V77, P907, DOI 10.7326/0003-4819-77-6-907; SCHRIER DJ, 1981, NATURE, V289, P405, DOI 10.1038/289405a0; SPECTOR WG, 1969, J PATHOL, V98, P31, DOI 10.1002/path.1710980105; UNGER JD, 1968, RADIOLOGY, V90, P683, DOI 10.1148/90.4.683; VOISIN C, 1981, LUNG, V159, P17, DOI 10.1007/BF02713892; WARREN WP, 1972, CAN MED ASSOC J, V107, P1196; WENZEL FJ, 1971, J ALLERGY CLIN IMMUN, V48, P224, DOI 10.1016/0091-6749(71)90069-8	55	156	158	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					1	9		10.1016/0091-6749(84)90077-0	http://dx.doi.org/10.1016/0091-6749(84)90077-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6429227	Bronze			2022-12-18	WOS:A1984SZ64800001
J	Chen, RC; Sang, L; Jiang, M; Yang, ZW; Jia, N; Fu, WY; Xie, JX; Guan, WJ; Liang, WH; Ni, ZY; Hu, Y; Liu, L; Shan, H; Lei, CL; Peng, YX; Wei, L; Liu, Y; Hu, YH; Peng, P; Wang, JM; Liu, JY; Chen, Z; Li, G; Zheng, ZJ; Qiu, SQ; Luo, J; Ye, CJ; Zhu, SY; Zheng, JP; Zhang, NF; Li, YM; He, JX; Li, J; Li, SY; Zhong, NS				Chen, Ruchong; Sang, Ling; Jiang, Mei; Yang, Zhaowei; Jia, Nan; Fu, Wanyi; Xie, Jiaxing; Guan, Weijie; Liang, Wenhua; Ni, Zhengyi; Hu, Yu; Liu, Lei; Shan, Hong; Lei, Chunliang; Peng, Yixiang; Wei, Li; Liu, Yong; Hu, Yahua; Peng, Peng; Wang, Jianming; Liu, Jiyang; Chen, Zhong; Li, Gang; Zheng, Zhijian; Qiu, Shaoqin; Luo, Jie; Ye, Changjiang; Zhu, Shaoyong; Zheng, Jinping; Zhang, Nuofu; Li, Yimin; He, Jianxing; Li, Jing; Li, Shiyue; Zhong, Nanshan		Med Treatment Expert Grp COVID-19	Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hematologic indices; immunologic responses; COVID-19; severity; outcome	ACUTE RESPIRATORY SYNDROME; SARS-COV; INFLAMMATORY CYTOKINES; CORONAVIRUS INFECTION; LYMPHOCYTE SUBSETS; EXPRESSION; BLOOD; THROMBOCYTOPENIA; MANIFESTATIONS; CD4(+)	Background: Crucial roles of hematologic and immunologic responses in progression of coronavirus disease 2019 (COVID-19) remain largely unclear. Objective: We sought to address the dynamic changes in hematologic and immunologic biomarkers and their associations with severity and outcomes of COVID-19. Methods: A retrospective study including 548 patients with COVID-19 with clarified outcome (discharged or deceased) from a national cohort in China was performed. Cross-sectional and longitudinal variations were compared and the associations with different severity and outcomes were analyzed. Results: On admission, the counts of lymphocytes, T-cell subsets, eosinophils, and platelets decreased markedly, especially in severe/critical and fatal patients. Increased neutrophil count and neutrophils-to-lymphocytes ratio were predominant in severe/critical cases or nonsurvivors. During hospitalization, eosinophils, lymphocytes, and platelets showed an increasing trend in survivors, but maintained lower levels or dropped significantly afterwards in nonsurvivors. Nonsurvivors kept a high level or showed an upward trend for neutrophils, IL-6, procalcitonin, D-dimer, amyloid A protein, and C-reactive protein, which were kept stable or showed a downward trend in survivors. Positive correlation between CD8(+) T-cell and lymphocytes count was found in survivors but not in nonsurvivors. A multivariate Cox regression model suggested that restored levels of lymphocytes, eosinophils, and platelets could serve as predictors for recovery, whereas progressive increases in neutrophils, basophils, and IL-6 were associated with fatal outcome. Conclusions: Hematologic and immunologic impairment showed a significantly different profile between survivors and nonsurvivors in patients with COVID-19 with different severity. The longitudinal variations in these biomarkers could serve to predict recovery or fatal outcome.	[Chen, Ruchong; Yang, Zhaowei; Jia, Nan; Fu, Wanyi; Xie, Jiaxing; Li, Jing] Guangzhou Med Univ, Affiliated Hosp 1, Dept Allergy & Clin Immunol, Guangzhou, Guangdong, Peoples R China; [Sang, Ling; Jiang, Mei; Guan, Weijie; Liang, Wenhua; Zheng, Jinping; Zhang, Nuofu; Li, Yimin; He, Jianxing; Li, Shiyue; Zhong, Nanshan] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, Natl Clin Res Ctr Resp Dis,State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China; [Ni, Zhengyi] Wuhan Jin Yin Tan Hosp, Wuhan, Peoples R China; [Hu, Yu] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Hubei, Peoples R China; [Liu, Lei] Shenzhen Third Peoples Hosp, Shenzhen, Peoples R China; [Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 1, Zhuhai, Guangdong, Peoples R China; [Lei, Chunliang] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Guangdong, Peoples R China; [Peng, Yixiang] Cent Hosp Wuhan, Wuhan, Hubei, Peoples R China; [Wei, Li] Wuhan Hosp Tradit Chinese & Western Med, Wuhan Hosp 1, Wuhan, Hubei, Peoples R China; [Liu, Yong] Chengdu Publ Hlth Clin Med Ctr, Chengdu, Sichuan, Peoples R China; [Hu, Yahua] Hubei Polytech Univ, Affiliated Hosp, Edong Healthcare Grp, Huangshi Cent Hosp, Huangshi, Hubei, Peoples R China; [Peng, Peng] Wuhan Pulm Hosp, Wuhan, Hubei, Peoples R China; [Wang, Jianming] Wuhan Univ Sci & Technol, Tianyou Hosp, Wuhan, Hubei, Peoples R China; [Liu, Jiyang] First Hosp Changsha, Changsha, Hunan, Peoples R China; [Chen, Zhong] Third Peoples Hosp Hainan Prov, Sanya, Hainan, Peoples R China; [Li, Gang] Huanggang Cent Hosp, Huanggang, Hubei, Peoples R China; [Zheng, Zhijian] Wenling First Peoples Hosp, Wenling, Zhejiang, Peoples R China; [Qiu, Shaoqin] Third Peoples Hosp Yichang, Yichang, Hubei, Peoples R China; [Luo, Jie] Hubei Univ Med, Affiliated Taihe Hosp, Shiyan, Hubei, Peoples R China; [Ye, Changjiang] Xiantao First Peoples Hosp, Xiantao, Peoples R China; [Zhu, Shaoyong] Peoples Hosp Huangpi Dist, Wuhan, Peoples R China	Guangzhou Medical University; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Huazhong University of Science & Technology; Sun Yat Sen University; Guangzhou Medical University; Hubei Polytechnic University; Wuhan University of Science & Technology; Hubei University of Medicine	Li, J; Li, SY; Zhong, NS (corresponding author), Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, StateKey Lab Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, 151 Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China.	lijing@gird.cn; lishiyue@188.com; nanshan@vip.163.com	; Xie, Jiaxing/B-5795-2012	Wenhua, Liang/0000-0002-1391-8238; Yang, Zhaowei/0000-0002-1805-4360; Xie, Jiaxing/0000-0001-6462-6676				Arabi YM, 2017, CRIT CARE MED, V45, P1683, DOI 10.1097/CCM.0000000000002621; Cameron MJ, 2008, VIRUS RES, V133, P13, DOI 10.1016/j.virusres.2007.02.014; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; CholletMartin S, 1996, AM J RESP CRIT CARE, V154, P594, DOI 10.1164/ajrccm.154.3.8810592; Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380; Cowardin CA, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.108, 10.1038/nmicrobiol.2016.108]; Cui W, 2003, CLIN INFECT DIS, V37, P857, DOI 10.1086/378587; De Buck M, 2016, CURR MED CHEM, V23, P1725, DOI 10.2174/0929867323666160418114600; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hassani M, 2020, J LEUKOCYTE BIOL, V108, P1665, DOI 10.1002/JLB.1AB1219-493R; He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067; He Wei-qun, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P336; He ZP, 2005, INT J INFECT DIS, V9, P323, DOI 10.1016/j.ijid.2004.07.014; Hwang SM, 2019, JPN J INFECT DIS, V72, P160, DOI 10.7883/yoken.JJID.2018.187; Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC; Ju XH, 2014, ANIMAL, V8, P1462, DOI 10.1017/S1751731114001268; Kernan KF, 2017, INT IMMUNOL, V29, P401, DOI 10.1093/intimm/dxx031; Lee YS, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-132; Li TS, 2003, CHINESE MED J-PEKING, V116, P985; Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022; Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013; Liu J, 2020, LONGITUDINAL CHARACT, DOI [10.1101/2020.02.16.20023671., DOI 10.1016/J.EBIOM.2020.102763, 10.1016/j.ebiom.2020.102763]; Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0; Liu Xiao-Qing, 2003, Zhonghua Jiehe He Huxi Zazhi, V26, P329; Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8; Mohd HA, 2016, TRAVEL MED INFECT DI, V14, P464, DOI 10.1016/j.tmaid.2016.09.008; National Health Commission & State Administration of Traditional Chinese Medicine, 2020, DIAGN TREATM PROT NO; Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024; Niu PH, 2018, J INFECT DIS, V218, P1249, DOI 10.1093/infdis/jiy311; Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647; Pinto RA, 2006, PEDIATRICS, V117, pE878, DOI 10.1542/peds.2005-2119; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Reis FG, 2012, EXP LUNG RES, V38, P344, DOI 10.3109/01902148.2012.704484; Wang JT, 2004, EMERG INFECT DIS, V10, P818, DOI 10.3201/eid1005.030640; Wang XL, 2020, CELL MOL IMMUNOL, V17, P894, DOI 10.1038/s41423-020-0498-4; Wang YH, 2004, INTENS CARE MED, V30, P1228, DOI 10.1007/s00134-004-2311-8; Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358; World Health Organization, 2019, 92 WHO; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xu XK, 2008, P NATL ACAD SCI USA, V105, P19601, DOI 10.1073/pnas.0806082105; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yang M, 2005, HEMATOLOGY, V10, P101, DOI 10.1080/10245330400026170; Yip TTC, 2005, CLIN CHEM, V51, P47, DOI 10.1373/clinchem.2004.031229; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	54	155	158	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					89	100		10.1016/j.jaci.2020.05.003	http://dx.doi.org/10.1016/j.jaci.2020.05.003			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32407836	Green Published, Bronze			2022-12-18	WOS:000579170500018
J	Bieber, T; D'Erme, AM; Akdis, CA; Traidl-Hoffmann, C; Lauener, R; Schappi, G; Schmid-Grendelmeier, P				Bieber, Thomas; D'Erme, Angelo M.; Akdis, Cezmi A.; Traidl-Hoffmann, Claudia; Lauener, Roger; Schappi, Georg; Schmid-Grendelmeier, Peter			Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; clinical phenotype; endophenotype; biomarkers; stratified medicine; precision medicine	THYMIC STROMAL LYMPHOPOIETIN; ALLERGIC DISEASES; PRECISION MEDICINE; BARRIER IMPAIRMENT; ADULT PATIENTS; SKIN BARRIER; FOOD ALLERGY; BIOMARKERS; ASSOCIATION; FILAGGRIN	Atopic dermatitis (AD) is a paradigmatic chronic inflammatory skin disease characterized by a complex pathophysiology and a wide spectrum of the clinical phenotype. Despite this high degree of heterogeneity, ADis still considered a single disease and usually treated according to the "one-size-fits-all'' approach. Thus more tailored prevention and therapeutic strategies are still lacking. As for other disciplines, such as oncology or rheumatology, we have to approach AD in a more differentiated way (ie, to dissect and stratify the complex clinical phenotype into more homogeneous subgroups based on the endophenotype [panel of biomarkers]) with the aim to refine the management of this condition. Because we are now entering the era of personalized medicine, a systems biology approach merging the numerous clinical phenotypes with robust (ie, relevant and validated) biomarkers will be needed to best exploit their potential significance for the future molecular taxonomy of AD. This approach will not only allow an optimized prevention and treatment with the available drugs but also hopefully help assign newly developed medicinal products to those patients who will have the best benefit/risk ratio.	[Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53105 Bonn, Germany; [Bieber, Thomas; Akdis, Cezmi A.; Traidl-Hoffmann, Claudia; Lauener, Roger; Schappi, Georg; Schmid-Grendelmeier, Peter] Christine Kuhne Ctr Allergy Res & Educ CK CARE Da, Bonn, Germany; [D'Erme, Angelo M.] Livorno Hosp, Unit Dermatol, Livorno, Italy; [D'Erme, Angelo M.] Univ Pisa, Unit Dermatol, Dept Clin & Expt Med, I-56100 Pisa, Italy; [Akdis, Cezmi A.] Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Traidl-Hoffmann, Claudia] Tech Univ Munich, Inst Environm Med, Munich, Germany; [Traidl-Hoffmann, Claudia] Helmholtzzentrum Munchen, Munich, Germany; [Lauener, Roger] Childrens Hosp Eastern Switzerland, St Gallen, Switzerland; [Lauener, Roger] Univ Zurich, CH-8006 Zurich, Switzerland; [Schmid-Grendelmeier, Peter] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland	University of Bonn; University of Pisa; Swiss Institute of Allergy & Asthma Research; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Zurich; University of Zurich; University Zurich Hospital	Bieber, T (corresponding author), Univ Bonn, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53105 Bonn, Germany.	thomas.bieber@ukb.uni-bonn.de	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X	Sanofi/Regeneron; Novartis; PREDICTA: European Commission's Seventh Framework Programme; Swiss National Science Foundation Research; MeDALL: European Commission's Seventh Framework Programme; Christine Kuhne-Center for Allergy Research (CK-CARE); CK-CARE Center of Allergy Research and Education; Kuhne Foundation; Meda; Menarini; Nestle; Vifor; ALK-Abello	Sanofi/Regeneron(Regeneron); Novartis(Novartis); PREDICTA: European Commission's Seventh Framework Programme; Swiss National Science Foundation Research(Swiss National Science Foundation (SNSF)); MeDALL: European Commission's Seventh Framework Programme; Christine Kuhne-Center for Allergy Research (CK-CARE); CK-CARE Center of Allergy Research and Education; Kuhne Foundation; Meda; Menarini(Menarini Group); Nestle(Nestle SA); Vifor; ALK-Abello	T. Bieber serves on the board for Sanofi/Regeneron, serves as a consultant for Sanofi/Regeneron, receives payments for lectures from Sanofi/Regeneron, and receives payment for educational presentation from Sanofi/Regeneron. A. M. D'Erme serves as a consultant for La Roche Posay. C. A. Akdis serves as a consultant form Actellion, Aventis, Stallergenes, Allergopharma, and Circacia; is an employee of the Swiss Institute of Allergy and Asthma Research, University of Zurich; receives grant support from Novartis, PREDICTA: European Commission's Seventh Framework Programme, the Swiss National Science Foundation Research, MeDALL: European Commission's Seventh Framework Programme, and the Christine Kuhne-Center for Allergy Research (CK-CARE). C. Traidl-Hoffmann receives grants support from the CK-CARE Center of Allergy Research and Education. R. Lauener receives grant support and travel support from the Kuhne Foundation; serves as a consultant for AstraZeneca; and receives support from Meda, Menarini, Nestle, Vifor, and ALK-Abello. P. Schmid-Grendelmeier serves as a consultant for Sanofi AG. The rest of the authors declare that they have no relevant conflicts of interest.	Altrichter S, 2008, J INVEST DERMATOL, V128, P2232, DOI 10.1038/jid.2008.80; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bager P, 2016, ALLERGY, V71, P724, DOI 10.1111/all.12849; Bieber T, 2016, ALLERGY, V71, P1662, DOI 10.1111/all.13063; Bieber T, 2016, ALLERGY, V71, P588, DOI 10.1111/all.12857; Bieber T, 2015, ALLERGY, V70, P6, DOI 10.1111/all.12498; Bieber T, 2012, ALLERGY, V67, P969, DOI 10.1111/j.1398-9995.2012.02845.x; Bieber T, 2017, DERMATOL CL IN PRESS; Bieber T, 2012, DERMATOLOGY, P203; Bieber T, 2013, STRATIFIED MED NEW C; Bieber T, 2015, PERSONALIZED TREATME; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Brenninkmeijer EEA, 2008, J AM ACAD DERMATOL, V58, P407, DOI 10.1016/j.jaad.2007.12.002; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; DIEPGEN TL, 1989, ACTA DERM-VENEREOL, P50; Erbas B, 2013, ALLERGY, V68, P58; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Folster-Holst R, 2016, ALLERGY, V71, P1062, DOI 10.1111/all.12916; Folster-Holst R, 2006, ALLERGY, V61, P629, DOI 10.1111/j.1398-9995.2006.01076.x; Garmhausen D, 2013, ALLERGY, V68, P498, DOI 10.1111/all.12112; Glatz M, 2015, ACTA DERM-VENEREOL, V95, P191, DOI 10.2340/00015555-1864; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Hawro T, 2016, ALLERGY, V71, P1745, DOI 10.1111/all.12995; Hon KL, 2011, PEDIAT ALLERG IMM-UK, V22, P704, DOI 10.1111/j.1399-3038.2011.01174.x; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Howell MD, 2015, ALLERGY, V70, P887, DOI 10.1111/all.12632; Irvine AD, 2014, J INVEST DERMATOL, V134, P313, DOI 10.1038/jid.2013.506; Kabashima-Kubo R, 2012, J DERMATOL SCI, V67, P37, DOI 10.1016/j.jdermsci.2012.04.004; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Kim J, 2016, J ALLERGY CLIN IMMUN, V137, P1282, DOI 10.1016/j.jaci.2015.12.1306; Kou K, 2014, BRIT J DERMATOL, V171, P283, DOI 10.1111/bjd.12943; Kou KZ, 2012, ARCH DERMATOL RES, V304, P305, DOI 10.1007/s00403-011-1198-9; Leshem YA, 2015, BRIT J DERMATOL, V172, P1353, DOI 10.1111/bjd.13662; Leung TF, 2012, J EUR ACAD DERMATOL, V26, P518, DOI 10.1111/j.1468-3083.2011.04083.x; Lin JY, 2016, EXP DERMATOL, V25, P548, DOI 10.1111/exd.12998; Mansouri Y, 2015, J CLIN MED, V4, P858, DOI 10.3390/jcm4050858; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; Margolis JS, 2014, JAMA DERMATOL, V150, P593, DOI 10.1001/jamadermatol.2013.10271; Martel BC, 2016, EXP DERMATOL, V25, P453, DOI 10.1111/exd.12967; Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Mortz CG, 2015, ALLERGY, V70, P836, DOI 10.1111/all.12619; Mothes N, 2005, J ALLERGY CLIN IMMUN, V116, P706, DOI 10.1016/j.jaci.2005.06.025; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Namkung JH, 2010, EXP DERMATOL, V19, P1048, DOI 10.1111/j.1600-0625.2010.01142.x; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Nygaard U, 2016, J EUR ACAD DERMATOL, V30, P1930, DOI 10.1111/jdv.13679; Oyoshi MK, 2016, J ALLERGY CLIN IMMUN, V138, P283, DOI 10.1016/j.jaci.2015.12.1304; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park J, 2015, J DERMATOL, V42, P867, DOI 10.1111/1346-8138.12935; Pyun BY, 2015, ALLERGY ASTHMA IMMUN, V7, P101, DOI 10.4168/aair.2015.7.2.101; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; Rabenhorst A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0423-y; Roduit C, 2014, J ALLERGY CLIN IMMUN, V133, P1056, DOI 10.1016/j.jaci.2013.12.1044; Roduit C, 2012, J ALLERGY CLIN IMMUN, V130, P130, DOI 10.1016/j.jaci.2012.02.043; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Saunders SP, 2016, J ALLERGY CLIN IMMUN, V137, P482, DOI 10.1016/j.jaci.2015.06.045; Schmitt J, 2016, J ALLERGY CLIN IMMUN, V137, P130, DOI 10.1016/j.jaci.2015.06.029; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2016, J AM ACAD DERMATOL, V74, P491, DOI 10.1016/j.jaad.2015.10.043; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Staudacher A, 2015, ALLERGY, V70, P1432, DOI 10.1111/all.12699; Tanei R, 2008, J DERMATOL, V35, P562, DOI 10.1111/j.1346-8138.2008.00524.x; Tanei R, 2016, GERIATR GERONTOL INT, V16, P75, DOI 10.1111/ggi.12771; Tang TS, 2012, J ALLERGY CLIN IMMUN, V129, P1209, DOI 10.1016/j.jaci.2012.02.002; Thawer-Esmail F, 2014, J ALLERGY CLIN IMMUN, V133, P280, DOI 10.1016/j.jaci.2013.09.053; Thijs J, 2015, CURR OPIN ALLERGY CL, V15, P453, DOI 10.1097/ACI.0000000000000198; Thijs JL, 2015, J CLIN MED, V4, P479, DOI 10.3390/jcm4030479; Thyssen JP, 2014, ALLERGY, V69, P28, DOI 10.1111/all.12358; Torrelo A, 2014, J EUR ACAD DERMATOL, V28, P2, DOI 10.1111/jdv.12480; Tsakok T, 2016, J ALLERGY CLIN IMMUN, V137, P1071, DOI 10.1016/j.jaci.2015.10.049; Weidinger S, 2014, ALLERGY, V69, P1, DOI 10.1111/all.12359; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Whiteley J, 2016, CURR MED RES OPIN, V21, P1	75	155	160	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4		S			S58	S64		10.1016/j.jaci.2017.01.008	http://dx.doi.org/10.1016/j.jaci.2017.01.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LN	28390478	Green Accepted, Bronze			2022-12-18	WOS:000398771400003
J	Fitzpatrick, AM; Jackson, DJ; Mauger, DT; Boehmer, SJ; Phipatanakul, W; Sheehan, WJ; Moy, JN; Paul, IM; Bacharier, LB; Cabana, MD; Covar, R; Holguin, F; Lemanske, RF; Martinez, FD; Pongracic, JA; Beigelman, A; Baxi, SN; Benson, M; Blake, K; Chmiel, JF; Daines, CL; Daines, MO; Gaffin, JM; Gentile, DA; Gower, WA; Israel, E; Kumar, HV; Lang, JE; Lazarus, SC; Lima, JJ; Ly, N; Marbin, J; Morgan, W; Myers, RE; Olin, JT; Peters, SP; Raissy, HH; Robison, RG; Ross, K; Sorkness, CA; Thyne, SM; Szefler, SJ				Fitzpatrick, Anne M.; Jackson, Daniel J.; Mauger, David T.; Boehmer, Susan J.; Phipatanakul, Wanda; Sheehan, William J.; Moy, James N.; Paul, Ian M.; Bacharier, Leonard B.; Cabana, Michael D.; Covar, Ronina; Holguin, Fernando; Lemanske, Robert F., Jr.; Martinez, Fernando D.; Pongracic, Jacqueline A.; Beigelman, Avraham; Baxi, Sachin N.; Benson, Mindy; Blake, Kathryn; Chmiel, James F.; Daines, Cori L.; Daines, Michael O.; Gaffin, Jonathan M.; Gentile, Deborah Ann; Gower, W. Adam; Israel, Elliot; Kumar, Harsha Vardhan; Lang, Jason E.; Lazarus, Stephen C.; Lima, John J.; Ly, Ngoc; Marbin, Jyothi; Morgan, Wayne; Myers, Ross E.; Olin, J. Tod; Peters, Stephen P.; Raissy, Hengameh H.; Robison, Rachel G.; Ross, Kristie; Sorkness, Christine A.; Thyne, Shannon M.; Szefler, Stanley J.		Natl Inst Hlth; Natl Heart Lung Blood Inst; AsthmaNet	Individualized therapy for persistent asthma in young children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma treatment; asthma biomarkers; asthma phenotype; inhaled corticosteroid; leukotriene receptor antagonist; personalized medicine; treatment response	1ST 6 YEARS; PRESCHOOL-CHILDREN; CHILDHOOD ASTHMA; INHALED CORTICOSTEROIDS; HIGH-RISK; LUNG-FUNCTION; NITRIC-OXIDE; MONTELUKAST; MANAGEMENT; DIAGNOSIS	Background: Phenotypic presentations in young children with asthma are varied and might contribute to differential responses to asthma controller medications. Methods: The Individualized Therapy for Asthma in Toddlers study was a multicenter, randomized, double-blind, double-dummy clinical trial in children aged 12 to 59 months (n = 300) with asthma necessitating treatment with daily controller (Step 2) therapy. Participants completed a 2- to 8-week run-in period followed by 3 crossover periods with daily inhaled corticosteroids (ICSs), daily leukotriene receptor antagonists, and as-needed ICS treatment coadministered with albuterol. The primary outcome was differential response to asthma medication based on a composite measure of asthma control. The primary analysis involved 2 stages: determination of differential response and assessment of whether 3 prespecified features (aeroallergen sensitization, previous exacerbations, and sex) predicted a differential response. Results: Seventy-four percent (170/230) of children with analyzable data had a differential response to the 3 treatment strategies. Within differential responders, the probability of best response was highest for a daily ICS and was predicted by aeroallergen sensitization but not exacerbation history or sex. The probability of best response to daily ICS was further increased in children with both aeroallergen sensitization and blood eosinophil counts of 300/mL or greater. In these children daily ICS use was associated with more asthma control days and fewer exacerbations compared with the other treatments. Conclusions: In young children with asthma necessitating Step 2 treatment, phenotyping with aeroallergen sensitization and blood eosinophil counts is useful for guiding treatment selection and identifies children with a high exacerbation probability for whom treatment with a daily ICS is beneficial despite possible risks of growth suppression.	[Fitzpatrick, Anne M.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Sect Allergy Immunol & Rheumatol, Pediat, Madison, WI 53706 USA; [Mauger, David T.; Boehmer, Susan J.] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA USA; [Paul, Ian M.] Penn State Univ, Coll Med, Dept Pediat, Hershey, PA USA; [Phipatanakul, Wanda; Sheehan, William J.; Baxi, Sachin N.] Harvard Med Sch, Boston Childrens Hosp, Div Allergy Immunol, Boston, MA USA; [Gaffin, Jonathan M.] Harvard Med Sch, Boston Childrens Hosp, Div Resp Dis, Boston, MA USA; [Moy, James N.] Rush Univ, Med Ctr, Dept Pediat, Stroger Hosp Cook Cty, Chicago, IL 60612 USA; [Bacharier, Leonard B.; Beigelman, Avraham] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63130 USA; [Bacharier, Leonard B.; Beigelman, Avraham] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Cabana, Michael D.; Lazarus, Stephen C.] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA; [Holguin, Fernando] Univ Pittsburgh, Asthma Inst, UPMC, UPSOM, Pittsburgh, PA USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Pediat, Madison, WI 53706 USA; [Martinez, Fernando D.; Daines, Cori L.; Daines, Michael O.; Morgan, Wayne] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Pongracic, Jacqueline A.; Robison, Rachel G.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Benson, Mindy; Marbin, Jyothi] Univ Calif San Francisco, Benioff Childrens Hosp Oakland, Oakland, CA USA; [Blake, Kathryn; Lima, John J.] Nemours Childrens Hlth Syst, Jacksonville, FL USA; [Chmiel, James F.; Ross, Kristie] Case Western Reserve Univ, Sch Med, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Covar, Ronina; Olin, J. Tod] Natl Jewish Hlth, Pediat, Denver, CO USA; [Gentile, Deborah Ann] Allegheny Gen Hosp, Dept Pediat, Pittsburgh, PA 15212 USA; [Gower, W. Adam; Peters, Stephen P.] Wake Forest Sch Med, Winston Salem, NC USA; [Israel, Elliot] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA; [Kumar, Harsha Vardhan] Univ Illinois, Chicago, IL USA; [Lang, Jason E.] Univ Cent Florida, Coll Med, Nemours Childrens Hosp, Orlando, FL 32816 USA; [Ly, Ngoc] Univ Calif San Francisco, Airway Clin Res Ctr, San Francisco, CA 94143 USA; [Myers, Ross E.] Rainbow Babies & Childrens Hosp, 2101 Adelbert Rd, Cleveland, OH 44106 USA; [Raissy, Hengameh H.] Univ New Mexico, Pediat Pulm, Albuquerque, NM 87131 USA; [Sorkness, Christine A.] Univ Wisconsin, Madison, WI 53706 USA; [Thyne, Shannon M.] Univ Calif Los Angeles, David Geffen Sch Med, Olive View UCLA Med Ctr, Dept Pediat, Los Angeles, CA 90095 USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Breathing Inst, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Aurora, CO USA	Emory University; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; John H Stroger Junior Hospital Cook County; Rush University; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; University of Arizona; Ann & Robert H. Lurie Children's Hospital of Chicago; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; National Jewish Health; Allegheny General Hospital; Wake Forest University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University System of Florida; University of Central Florida; University of California System; University of California San Francisco; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University of New Mexico; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Szefler, SJ (corresponding author), Childrens Hosp Colorado, Pediat Asthma Res Program, Breathing Inst, 13123 E 16th Ave,Box 395, Aurora, CO 80045 USA.	Stanley.Szefler@childrenscolorado.org	Paul, Ian/AAD-9813-2020	Myers, Ross/0000-0002-9494-3653; Szefler, Stanley/0000-0002-6911-3199; Paul, Ian/0000-0002-6344-8609; GAFFIN, JONATHAN/0000-0003-2213-4504; Robison, Rachel/0000-0003-0160-0529; Fitzpatrick, Anne/0000-0002-2933-5926; Bacharier, Leonard/0000-0003-0432-2704; Gower, William Adam/0000-0001-5863-7379	National Heart, Lung, and Blood Institute as part of AsthmaNet [HL098102, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, HL098103, HL098115, TR001082, TR000439, TR000448, TR000454]; National Heart, Lung, and Blood Institute (NHLBI); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [UG1HD090878] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098107, U10HL098103, U10HL098075, U10HL098090, U10HL098098, U10HL098115, U10HL098102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI104780, K23AI106945] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute as part of AsthmaNet; National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants HL098102, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, HL098103, HL098115, TR001082, TR000439, TR000448, and TR000454 from the National Heart, Lung, and Blood Institute as part of AsthmaNet, a clinical trials network supported by a cooperative agreement with the National Heart, Lung, and Blood Institute (NHLBI). The following were donated: fluticasone propionate and matching placebo by GlaxoSmithKline, Evreux, France; montelukast and matching placebo by Merck and Co, Whitehouse Station, NJ; and albuterol sulfate by GlaxoSmithKline, Research Triangle Park, NC, under a clinical trial agreement with Pennsylvania State University. NHLBI Program Officers participated in study design, conduct, and interpretation of the data. The study was monitored by the AsthmaNet data and safety monitoring board, which also reviewed and approved the final manuscript. INFANT ClinicalTrials.gov number, NCT01606306.	Akinbami Lara, 2006, Adv Data, P1; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; ALLISON PD, 1994, SOCIOL METHODOL, V24, P199, DOI 10.2307/270983; Armstrong M, 2009, J CHROMATOGR B, V877, P3169, DOI 10.1016/j.jchromb.2009.08.011; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bacharier LB, 2007, J ALLERGY CLIN IMMUN, V119, P604, DOI 10.1016/j.jaci.2006.12.607; Bacharier LB, 2009, J ALLERGY CLIN IMMUN, V123, P1077, DOI 10.1016/j.jaci.2008.12.1120; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez JA, 2009, PEDIATRICS, V123, pe519, DOI 10.1542/peds.2008-2867; Chauhan BF, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009611.pub3; Chong J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011032.pub2; Depner M, 2014, AM J RESP CRIT CARE, V189, P129, DOI 10.1164/rccm.201307-1198OC; Ducharme FM, 2014, LANCET, V383, P1593, DOI 10.1016/S0140-6736(14)60615-2; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; Garden FL, 2016, EUR RESPIR J, V47, P499, DOI 10.1183/13993003.00284-2015; Global Initiative for Asthma, 2015, GLOB STRAT ASTHM MAN; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P956, DOI 10.1016/j.jaci.2011.06.027; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, pe1; Hakim F, 2007, CHEST, V131, P180, DOI 10.1378/chest.06-1402; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P921, DOI 10.1016/j.jaci.2009.09.006; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Karaca-Mandic P, 2012, JAMA-J AM MED ASSOC, V307, P1284, DOI 10.1001/jama.2012.340; Kelly HW, 2012, NEW ENGL J MED, V367, P904, DOI 10.1056/NEJMoa1203229; Knuffman JE, 2009, J ALLERGY CLIN IMMUN, V123, P411, DOI 10.1016/j.jaci.2008.11.016; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, P112, DOI 10.1016/j.jaci.2011.10.030; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Levy BD, 2015, AM J RESP CRIT CARE, V192, P1366, DOI 10.1164/rccm.201505-0963WS; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Papi A, 2009, ALLERGY, V64, P1463, DOI 10.1111/j.1398-9995.2009.02134.x; Pedersen SE, 2011, PEDIATR PULM, V46, P1, DOI 10.1002/ppul.21321; Price D, 2011, NEW ENGL J MED, V364, P1695, DOI 10.1056/NEJMoa1010846; Pruteanu AI, 2014, COCHRANE DB SYST REV, DOI [10.1002/ebch.1989, 10.1002/14651858.CD009878.pub2]; Rabinovitch N, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Rabinovitch N, 2014, J ALLERGY CLIN IMMUN, V133, P350, DOI 10.1016/j.jaci.2013.07.039; Rabinovitch N, 2010, J ALLERGY CLIN IMMUN, V126, P545, DOI 10.1016/j.jaci.2010.07.008; Reddel HK, 2015, EUR RESPIR J, V46, P622, DOI 10.1183/13993003.00853-2015; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Sheehan WJ, 2016, NEW ENGL J MED, V375, P619, DOI 10.1056/NEJMoa1515990; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Strid Jennie Maria Christin, 2013, Clin Epidemiol, V5, P345, DOI 10.2147/CLEP.S47679; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Sutherland ER, 2014, J ALLERGY CLIN IMMUN, V133, P34, DOI 10.1016/j.jaci.2013.10.025; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P3, DOI 10.1016/j.jaci.2013.10.018; Szefler SJ, 2013, J ALLER CL IMM-PRACT, V1, P58, DOI 10.1016/j.jaip.2012.08.005; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Szefler SJ, 2011, J ALLERGY CLIN IMMUN, V128, P485, DOI 10.1016/j.jaci.2011.07.010; Triasih R, 2011, ARCH DIS CHILD, V96, P729, DOI 10.1136/adc.2010.205062; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647	57	155	160	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1608	+		10.1016/j.jaci.2016.09.028	http://dx.doi.org/10.1016/j.jaci.2016.09.028			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27777180	Green Accepted, Bronze			2022-12-18	WOS:000390019300017
J	Dhingra, N; Shemer, A; da Rosa, JC; Rozenblit, M; Fuentes-Duculan, J; Gittler, JK; Finney, R; Czarnowicki, T; Zheng, XZ; Xu, H; Estrada, YD; Cardinale, I; Suarez-Farinas, M; Krueger, JG; Guttman-Yassky, E				Dhingra, Nikhil; Shemer, Avner; da Rosa, Joel Correa; Rozenblit, Mariya; Fuentes-Duculan, Judilyn; Gittler, Julia K.; Finney, Robert; Czarnowicki, Tali; Zheng, Xiuzhong; Xu, Hui; Estrada, Yeriel D.; Cardinale, Irma; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma			Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic contact dermatitis; patch testing; T-cell polarization; human skin; allergens; nickel; fragrance; rubber	T-CELL RESPONSES; DELAYED-TYPE HYPERSENSITIVITY; NICKEL-SPECIFIC CD4(+); ATOPIC-DERMATITIS; IN-VITRO; DENDRITIC CELLS; GENE-EXPRESSION; IFN-GAMMA; CYTOKINES; LYMPHOCYTES	Background: Allergic contact dermatitis (ACD) is the most common occupational disease. Although murine contact hypersensitivity provides a framework for understanding ACD, it carries important differences from its human counterpart. Unlike the contact hypersensitivity model, which is induced by potent sensitizers (ie, dinitrofluorobenzene), human ACD is induced by weak-to-moderate sensitizers (ie, nickel), which cannot induce reactions in mice. Distinct hapten-specific immune-polarizing responses to potent inducers were suggested in mice, with unclear relevance to human ACD. Objective: We explored the possibility of distinct T-cell polarization responses in skin to common clinically relevant ACD allergens. Methods: Gene-expression and cellular studies were performed on common allergens (ie, nickel, fragrance, and rubber) compared with petrolatum-occluded skin, using RT-PCR, gene arrays, and immunohistochemistry. Results: Despite similar clinical reactions in all allergen groups, distinct immune polarizations characterized different allergens. Although the common ACD transcriptome consisted of 149 differentially expressed genes across all allergens versus petrolatum, a much larger gene set was uniquely altered by individual allergens. Nickel demonstrated the highest immune activation, with potent inductions of innate immunity, T(H)1/T(H)17 and a T(H)22 component. Fragrance, and to a lesser extent rubber, demonstrated a strong T(H)2 bias, some T(H)22 polarization, and smaller T(H)1/T(H)17 contributions. Conclusions: Our study offers new insights into the pathogenesis of ACD, expanding the understanding of T-cell activation and associated cytokines in allergen-reactive tissues. It is the first study that defines the common transcriptome of clinically relevant sensitizers in human skin and identifies unique pathways preferentially activated by different allergens, suggesting that ACD cannot be considered a single entity.	[Dhingra, Nikhil; Rozenblit, Mariya; Fuentes-Duculan, Judilyn; Gittler, Julia K.; Finney, Robert; Czarnowicki, Tali; Zheng, Xiuzhong; Xu, Hui; Estrada, Yeriel D.; Cardinale, Irma; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, New York, NY 10021 USA; [Dhingra, Nikhil] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Shemer, Avner] Dept Dermatol, Tel Aviv, Israel; [Rozenblit, Mariya; Estrada, Yeriel D.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [da Rosa, Joel Correa; Rozenblit, Mariya; Czarnowicki, Tali; Suarez-Farinas, Mayte; Krueger, James G.] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10021 USA; [Gittler, Julia K.] NYU, Sch Med, Dept Dermatol, New York, NY USA; [Finney, Robert] Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol, Philadelphia, PA 19107 USA	Rockefeller University; Columbia University; Icahn School of Medicine at Mount Sinai; Rockefeller University; New York University; Jefferson University	Guttman-Yassky, E (corresponding author), Mt Sinai Med Ctr, Icahn Sch Med, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	eguttman@rockefeller.edu	Correa da Rosa, Joel/Q-4753-2017; Da Rosa, Joel/AAU-1238-2020; Suarez-Farinas, Mayte/I-3558-2012	Correa da Rosa, Joel/0000-0003-4221-1976; Da Rosa, Joel/0000-0003-4221-1976; Suarez-Farinas, Mayte/0000-0001-8712-3553; Rozenblit, Mariya/0000-0002-8874-6688	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [5UL1RR024143-02]; NIH Roadmap for Medical Research; Dermatology Foundation Physician Scientist Career Development Award	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation Physician Scientist Career Development Award	J. G. K., M. S.-F., J. C. d. R., M. R., T. C., and N. D. were supported by the National Center for Research Resources (NCRR) (grant no. 5UL1RR024143-02), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. E. G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award.	Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Albanesi C, 1999, J IMMUNOL, V162, P494; Almogren A, 2013, CENT EUR J IMMUNOL, V38, P100, DOI 10.5114/ceji.2013.34365; Belsito D V, 1997, Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, P195; Belsito DV, 2005, J AM ACAD DERMATOL, V53, P303, DOI 10.1016/j.jaad.2005.02.045; BERGSTRESSER PR, 1980, J INVEST DERMATOL, V75, P73, DOI 10.1111/1523-1747.ep12521261; Brinkman L, 1997, CLIN EXP ALLERGY, V27, P1043, DOI 10.1111/j.1365-2222.1997.tb01256.x; Buchvald D, 2004, BRIT J DERMATOL, V150, P484, DOI 10.1046/j.1365-2133.2004.05828.x; Cavani A, 2000, J INVEST DERMATOL, V114, P295, DOI 10.1046/j.1523-1747.2000.00881.x; Cavani A, 1998, J INVEST DERMATOL, V111, P621, DOI 10.1046/j.1523-1747.1998.00334.x; Christensen AD, 2012, APMIS, V120, P1, DOI 10.1111/j.1600-0463.2011.02832.x; Czarnobilska E, 2009, ANN AGR ENV MED, V16, P37; Dearman RJ, 1996, TOXICOL APPL PHARM, V138, P308, DOI 10.1006/taap.1996.0129; Dearman RJ, 1999, METHODS, V19, P56, DOI 10.1006/meth.1999.0827; Dhingra N, 2013, J INVEST DERMATOL, V133, P2311, DOI 10.1038/jid.2013.239; Dyring-Andersen B, 2013, CONTACT DERMATITIS, V68, P339, DOI 10.1111/cod.12043; Egawa G, 2011, J INVEST DERMATOL, V131, P2178, DOI 10.1038/jid.2011.198; Giordano-Labadie F, 1999, CONTACT DERMATITIS, V40, P192, DOI 10.1111/j.1600-0536.1999.tb06032.x; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gober Michael D., 2008, V10, P1, DOI 10.1159/000131410; Griffiths CEM, 2005, CYTOKINE, V32, P67, DOI 10.1016/j.cyto.2005.07.011; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hansen MB, 2005, CONTACT DERMATITIS, V53, P100, DOI 10.1111/j.0105-1873.2005.00658.x; Honda T, 2013, J INVEST DERMATOL, V133, P303, DOI 10.1038/jid.2012.284; KALISH RS, 1990, J IMMUNOL, V145, P3706; Kamsteeg M, 2010, BRIT J DERMATOL, V162, P568, DOI 10.1111/j.1365-2133.2009.09547.x; Kaplan DH, 2012, NAT REV IMMUNOL, V12, P114, DOI 10.1038/nri3150; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kimber I, 2002, CONTACT DERMATITIS, V46, P1, DOI 10.1034/j.1600-0536.2002.460101.x; LAMMINTAUSTA K, 1992, CONTACT DERMATITIS, V26, P234, DOI 10.1111/j.1600-0536.1992.tb00235.x; Landheer J, 2013, J ALLERGY CLIN IMMUN, V132, P1252, DOI 10.1016/j.jaci.2013.07.051; Larsen JM, 2009, J ALLERGY CLIN IMMUN, V123, P486, DOI 10.1016/j.jaci.2008.09.036; Larson RP, 2010, J IMMUNOL, V184, P2974, DOI 10.4049/jimmunol.0803478; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Lindemann M, 2008, CLIN EXP ALLERGY, V38, P1468, DOI 10.1111/j.1365-2222.2008.02970.x; Lindemann M, 2003, CLIN EXP ALLERGY, V33, P992, DOI 10.1046/j.1365-2222.2003.01700.x; Liu J, 2014, J INVEST DERMATOL; Marks JG, 1998, J AM ACAD DERMATOL, V38, P911, DOI 10.1016/S0190-9622(98)70587-0; Martin Andrea, 2002, BMC Dermatol, V2, P9, DOI 10.1186/1471-5945-2-9; Mattii M, 2013, EXP DERMATOL, V22, P813, DOI 10.1111/exd.12272; Minang JT, 2006, CLIN EXP IMMUNOL, V146, P417, DOI 10.1111/j.1365-2249.2006.03226.x; Minang JT, 2006, CLIN EXP IMMUNOL, V143, P494, DOI 10.1111/j.1365-2249.2006.03018.x; Minang JT, 2005, SCAND J IMMUNOL, V62, P289, DOI 10.1111/j.1365-3083.2005.01673.x; Moed H, 2005, EXP DERMATOL, V14, P634, DOI 10.1111/j.0906-6705.2005.00344.x; Nasorri F, 2002, J INVEST DERMATOL, V118, P172, DOI 10.1046/j.0022-202x.2001.01574.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nosbaum A, 2009, EUR J DERMATOL, V19, P325, DOI 10.1684/ejd.2009.0686; Oboki Keisuke, 2008, Allergol Int, V57, P121, DOI 10.2332/allergolint.R-07-160; Pedersen MB, 2007, J INVEST DERMATOL, V127, P2585, DOI 10.1038/sj.jid.5700902; Peiser M, 2012, CELL MOL LIFE SCI, V69, P763, DOI 10.1007/s00018-011-0846-8; Peiser M, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/261037; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Pratt Melanie D, 2004, Dermatitis, V15, P176, DOI 10.2310/6620.2004.04038; Qi H, 2003, INFECT IMMUN, V71, P3337, DOI 10.1128/IAI.71.6.3337-3342.2003; Re F, 2004, J IMMUNOL, V173, P7548, DOI 10.4049/jimmunol.173.12.7548; Ricciardi L, 2009, CONTACT DERMATITIS, V60, P57, DOI 10.1111/j.1600-0536.2008.01454.x; Riis JL, 2011, EXP DERMATOL, V20, P789, DOI 10.1111/j.1600-0625.2011.01323.x; Saint-Mezard P, 2004, EUR J DERMATOL, V14, P284; Saint-Mezard P, 2003, J INVEST DERMATOL, V120, P641, DOI 10.1046/j.1523-1747.2003.12093.x; Saripalli YV, 2003, J AM ACAD DERMATOL, V49, P65, DOI 10.1067/mjd.2003.489; Sebastiani S, 2002, J INVEST DERMATOL, V118, P1052, DOI 10.1046/j.1523-1747.2002.01771.x; Shortman K, 2010, IMMUNOL REV, V234, P18, DOI 10.1111/j.0105-2896.2009.00870.x; Sieben S, 2002, J ALLERGY CLIN IMMUN, V109, P1005, DOI 10.1067/mai.2002.123872; Sieben S, 2001, TOXICOL APPL PHARM, V172, P172, DOI 10.1006/taap.2001.9125; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Thyssen JP, 2007, CONTACT DERMATITIS, V57, P287, DOI 10.1111/j.1600-0536.2007.01220.x; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Traidl-Hoffmann C, 2008, CLIN EXP ALLERGY, V38, P1412, DOI 10.1111/j.1365-2222.2008.03065.x; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; Vocanson M, 2006, J INVEST DERMATOL, V126, P815, DOI 10.1038/sj.jid.5700174; Wang Y, 2013, IMMUNOL RES, V55, P83, DOI 10.1007/s12026-012-8351-1; Weinlich G, 1998, J INVEST DERMATOL, V110, P441, DOI 10.1046/j.1523-1747.1998.00161.x; Wentworth AB, 2014, J AM ACAD DERMATOL, V70, P269, DOI 10.1016/j.jaad.2013.09.047; Werfel T, 1997, INT ARCH ALLERGY IMM, V113, P384, DOI 10.1159/000237610; Werfel T, 1997, J IMMUNOL, V158, P2500; Yamaguchi H, 2013, J DERMATOL SCI, V72, P240, DOI 10.1016/j.jdermsci.2013.07.009; Yin L, 2012, P NATL ACAD SCI USA, V109, P18517, DOI 10.1073/pnas.1215928109; Zhao Y, 2009, BRIT J DERMATOL, V161, P1301, DOI 10.1111/j.1365-2133.2009.09400.x; Zug KA, 2009, DERMATITIS, V20, P149, DOI 10.2310/6620.2009.08097	83	155	157	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					362	372		10.1016/j.jaci.2014.03.009	http://dx.doi.org/10.1016/j.jaci.2014.03.009			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24768652				2022-12-18	WOS:000341370800016
J	Lu, TX; Rothenberg, ME				Lu, Thomas X.; Rothenberg, Marc E.			Diagnostic, functional, and therapeutic roles of microRNA in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergy; microRNA; noncoding RNA; asthma; eosinophilic esophagitis; atopic dermatitis; allergic rhinitis; eosinophils; inflammation; biomarkers	T-CELL DIFFERENTIATION; EOSINOPHILIC ESOPHAGITIS; AIRWAY INFLAMMATION; MURINE MODEL; CONSENSUS RECOMMENDATIONS; MEDIATED ACTIVATION; EXPERIMENTAL ASTHMA; EPITHELIAL-CELLS; UP-REGULATION; BONE-MARROW	Allergic inflammation is accompanied by the coordinated expression of a myriad of genes and proteins that initiate, sustain, and propagate immune responses and tissue remodeling. MicroRNAs (miRNAs) are a class of short single-stranded RNA molecules that posttranscriptionally silence gene expression and have been shown to fine-tune gene transcriptional networks because single miRNAs can target hundreds of genes. Considerable attention has been focused on the key role of miRNAs in regulating homeostatic immune architecture and acquired immunity. Recent studies have identified miRNA profiles in multiple allergic inflammatory diseases, including asthma, eosinophilic esophagitis, allergic rhinitis, and atopic dermatitis. Specific miRNAs have been found to have critical roles in regulating key pathogenic mechanisms in allergic inflammation, including polarization of adaptive immune responses and activation of T cells (eg, miR-21 and miR-146), regulation of eosinophil development (eg, miR-21 and miR-223), and modulation of IL-13-driven epithelial responses (eg, miR-375). This review discusses recent advances in our understanding of the expression and function of miRNAs in patients with allergic inflammation, their role as disease biomarkers, and perspectives for future investigation and clinical utility.	[Lu, Thomas X.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45221 USA; [Lu, Thomas X.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Med Scientist Training Program, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,ML7028, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org		Lu, Thomas/0000-0001-9712-180X	National Heart, Lung, and Blood Institute's Ruth L. Kirschstein National Research Service Award [F30HL104892]; National Institutes for Health [R01AI083450, R01 AI045898, R01DK076893, U19 AI070235]; Campaign Urging Research for Eosinophilic Disease; Buckeye Foundation; Food Allergy Research & Education (FARE); Campaign Urging Research for Eosinophilic Disease Foundation; Immune Pharmaceuticals; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL104892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI045898, U19AI070235, R01AI083450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076893] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute's Ruth L. Kirschstein National Research Service Award; National Institutes for Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research for Eosinophilic Disease; Buckeye Foundation; Food Allergy Research & Education (FARE); Campaign Urging Research for Eosinophilic Disease Foundation; Immune Pharmaceuticals; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the National Heart, Lung, and Blood Institute's Ruth L. Kirschstein National Research Service Award for individual predoctoral MD/PhD fellows F30HL104892 (to T.X.L); National Institutes for Health grants R01AI083450 (to M.E.R.), R01 AI045898 (to M.E.R), R01DK076893 (to M.E.R), and U19 AI070235 (to M.E.R); the Campaign Urging Research for Eosinophilic Disease; the Buckeye Foundation; and Food Allergy Research & Education (FARE).; T. X. Lu has received research support from the National Institutes of Health (NIH) and has patents owned by Cincinnati Children's Hospital Medical Center (CCHMC). M. E. Rothenberg has received research support from the NIH; has received funding from Campaign Urging Research for Eosinophilic Disease Foundation, the Buckeye Foundation, and Food Allergy Research & Education; is on the International Eosinophil Society Board and the APFED Medical Panel; has received consultancy fees from Immune Pharmaceuticals; has patents owned by CCHMC; receives royalties from Teva Pharmaceuticals; and has stock/stock options in Immune Pharmaceuticals.	Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bershad SV, 2011, ANN INTERN MED, V155, DOI 10.7326/0003-4819-155-9-201111010-01005; Biton M, 2011, NAT IMMUNOL, V12, P239, DOI 10.1038/ni.1994; Blanchard Carine, 2008, Gastrointest Endosc Clin N Am, V18, P133, DOI 10.1016/j.giec.2007.09.016; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Case SR, 2011, EXP LUNG RES, V37, P500, DOI 10.3109/01902148.2011.596895; Chen RF, 2010, CLIN EXP ALLERGY, V40, P1482, DOI 10.1111/j.1365-2222.2010.03592.x; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Chiba Y, 2010, J PHARMACOL SCI, V114, P264, DOI 10.1254/jphs.10R10FM; Chiba Y, 2009, AM J RESP CRIT CARE, V180, P713, DOI 10.1164/rccm.200903-0325OC; Christodoulou F, 2010, NATURE, V463, P1084, DOI 10.1038/nature08744; Collison A, 2011, J ALLERGY CLIN IMMUN, V128, P160, DOI 10.1016/j.jaci.2011.04.005; Collison A, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-29; Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76; Deshpande DA, 2005, AM J RESP CELL MOL, V32, P149, DOI 10.1165/rcmb.2004-0243OC; Dyer KD, 2008, J IMMUNOL, V181, P4004, DOI 10.4049/jimmunol.181.6.4004; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Fallon PG, 2007, NAT REV IMMUNOL, V7, P220, DOI 10.1038/nri2039; Feng MJ, 2012, INT IMMUNOPHARMACOL, V13, P347, DOI 10.1016/j.intimp.2012.05.001; Feng ZH, 2011, J MOL CELL BIOL, V3, P44, DOI 10.1093/jmcb/mjq040; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; Fulkerson PC, 2006, AM J RESP CELL MOL, V35, P337, DOI 10.1165/rcmb.2005-0474OC; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gallo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030679; Garbacki N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016509; Gelfand EW, 2004, J ALLERGY CLIN IMMUN, V114, pS135, DOI 10.1016/j.jaci.2004.08.043; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Ingram JL, 2012, J ALLERGY CLIN IMMUN, V130, P829, DOI 10.1016/j.jaci.2012.06.034; Iorio MV, 2010, BBA-GENE REGUL MECH, V1799, P694, DOI 10.1016/j.bbagrm.2010.05.005; Ishizaki T, 2011, GENES CELLS, V16, P803, DOI 10.1111/j.1365-2443.2011.01529.x; Iwasaki H, 2005, J EXP MED, V201, P1891, DOI 10.1084/jem.20050548; Jardim MJ, 2012, AM J RESP CELL MOL, V47, P536, DOI 10.1165/rcmb.2011-0160OC; Jude JA, 2012, AM J PHYSIOL-LUNG C, V303, pL460, DOI 10.1152/ajplung.00041.2012; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Konikoff MR, 2006, CLIN GASTROENTEROL H, V4, P1328, DOI 10.1016/j.cgh.2006.08.013; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; KURUP VP, 1994, J LEUKOCYTE BIOL, V56, P593, DOI 10.1002/jlb.56.5.593; Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027; Levanen B, 2013, J ALLERGY CLIN IMMUN, V131, P894, DOI 10.1016/j.jaci.2012.11.039; Li JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053582; Li LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046957; Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Liu F, 2012, MOL MED REP, V6, P1178, DOI 10.3892/mmr.2012.1030; Lu LF, 2010, CELL, V142, P914, DOI 10.1016/j.cell.2010.08.012; Lu SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040676; Lu TX, 2012, MUCOSAL IMMUNOL, V5, P388, DOI 10.1038/mi.2012.16; Lu TX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059397; Lu TX, 2013, J IMMUNOL, V190, P1576, DOI 10.4049/jimmunol.1202897; Lu TX, 2012, J ALLERGY CLIN IMMUN, V129, P1064, DOI 10.1016/j.jaci.2012.01.060; Lu TX, 2011, J IMMUNOL, V187, P3362, DOI 10.4049/jimmunol.1101235; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Maddox L, 2002, ANNU REV MED, V53, P477, DOI 10.1146/annurev.med.53.082901.103921; Martinez I, 2011, CANCER RES, V71, P5370, DOI 10.1158/0008-5472.CAN-11-1044; Martinez-Nunez RT, 2011, J BIOL CHEM, V286, P1786, DOI 10.1074/jbc.M110.169367; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Mayoral RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026133; Mayoral RJ, 2009, J IMMUNOL, V182, P433, DOI 10.4049/jimmunol.182.1.433; Molnar V, 2012, CELL MOL LIFE SCI, V69, P793, DOI 10.1007/s00018-011-0786-3; Muljo SA, 2005, J EXP MED, V202, P261, DOI 10.1084/jem.20050678; Neveu WA, 2009, J IMMUNOL, V183, P1732, DOI 10.4049/jimmunol.0802923; Niwa R, 2007, CURR OPIN GENET DEV, V17, P145, DOI 10.1016/j.gde.2007.02.004; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; Orom UA, 2006, GENE, V372, P137, DOI 10.1016/j.gene.2005.12.031; Ozier Annaig, 2011, J Allergy (Cairo), V2011, P742710, DOI 10.1155/2011/742710; Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060; Patrick DM, 2010, J CLIN INVEST, V120, P3912, DOI 10.1172/JCI43604; Polikepahad S, 2010, J BIOL CHEM, V285, P30139, DOI 10.1074/jbc.M110.145698; Qin HB, 2012, INFLAMMATION, V35, P1595, DOI 10.1007/s10753-012-9474-1; Rabinowits G, 2009, CLIN LUNG CANCER, V10, P42, DOI 10.3816/CLC.2009.n.006; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Rosenwasser LJ, 2011, IMMUNOL ALLERGY CLIN, V31, P433, DOI 10.1016/j.iac.2011.05.009; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Rusca N, 2012, MOL CELL BIOL, V32, P4432, DOI 10.1128/MCB.00824-12; Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Sawant DV, 2013, MOL IMMUNOL, V54, P435, DOI 10.1016/j.molimm.2013.01.006; Sharma A, 2012, J APPL PHYSIOL, V113, P459, DOI 10.1152/japplphysiol.00001.2012; Sharma A, 2009, P NATL ACAD SCI USA, V106, P5761, DOI 10.1073/pnas.0808743106; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Tian TA, 2010, J CELL BIOCHEM, V111, P488, DOI 10.1002/jcb.22733; Tsai CY, 2013, J VIROL, V87, P2348, DOI 10.1128/JVI.01742-12; Tsitsiou E, 2012, J ALLERGY CLIN IMMUN, V129, P95, DOI 10.1016/j.jaci.2011.08.011; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vennegaard MT, 2012, CONTACT DERMATITIS, V67, P298, DOI 10.1111/j.1600-0536.2012.02083.x; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Watford WT, 2003, CYTOKINE GROWTH F R, V14, P361, DOI 10.1016/S1359-6101(03)00043-1; Williams AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005889; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wu F, 2008, GASTROENTEROLOGY, V135, P1624, DOI 10.1053/j.gastro.2008.07.068; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yang LL, 2012, J EXP MED, V209, P1655, DOI 10.1084/jem.20112218; Yao R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046082; Yu SQ, 2011, AM J RHINOL ALLERGY, V25, pE242, DOI 10.2500/ajra.2011.25.3682; Yuan Q, 2006, EUR J IMMUNOL, V36, P2700, DOI 10.1002/eji.200636112; Zen K, 2012, MED RES REV, V32, P326, DOI 10.1002/med.20215; Zhang XH, 2012, AM J RESP CRIT CARE, V185, P140, DOI 10.1164/rccm.201103-0456OC; Zhang X, 2009, J IMMUNOL, V182, P5123, DOI 10.4049/jimmunol.0804276; Zheng YD, 2013, RNA BIOL, V10, P377, DOI 10.4161/rna.23716; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	116	155	164	1	60	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					3	13		10.1016/j.jaci.2013.04.039	http://dx.doi.org/10.1016/j.jaci.2013.04.039			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23735656	Green Accepted			2022-12-18	WOS:000321052300001
J	Hanania, NA; King, MJ; Braman, SS; Saltoun, C; Wise, RA; Enright, P; Falsey, AR; Mathur, SK; Ramsdell, JW; Rogers, L; Stempel, DA; Lima, JJ; Fish, JE; Wilson, SR; Boyd, C; Patel, KV; Irvin, CG; Yawn, BP; Halm, EA; Wasserman, SI; Sands, MF; Ershler, WB; Ledford, DK				Hanania, Nicola A.; King, Monroe J.; Braman, Sidney S.; Saltoun, Carol; Wise, Robert A.; Enright, Paul; Falsey, Ann R.; Mathur, Sameer K.; Ramsdell, Joe W.; Rogers, Linda; Stempel, David A.; Lima, John J.; Fish, James E.; Wilson, Sandra R.; Boyd, Cynthia; Patel, Kushang V.; Irvin, Charles G.; Yawn, Barbara P.; Halm, Ethan A.; Wasserman, Stephen I.; Sands, Mark F.; Ershler, William B.; Ledford, Dennis K.		Asthma Elderly Workshop Participan	Asthma in the elderly: Current understanding and future research needs-a report of a National Institute on Aging (NIA) workshop	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aging; airway; allergy; asthma; elderly; immune mechanisms; immunosenescence	QUALITY-OF-LIFE; EXHALED NITRIC-OXIDE; OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY-TRACT INFECTION; LOWER-EXTREMITY FUNCTION; HEALTH-CARE UTILIZATION; IMMUNOGLOBULIN-E LEVELS; AIR-FLOW OBSTRUCTION; SKIN-TEST REACTIVITY; VIRAL-INFECTIONS	Asthma in the elderly is underdiagnosed and undertreated, and there is a paucity of knowledge on the subject. The National Institute on Aging convened this workshop to identify what is known and what gaps in knowledge remain and suggest research directions needed to improve the understanding and care of asthma in the elderly. Asthma presenting at an advanced age often has similar clinical and physiologic consequences as seen with younger patients, but comorbid illnesses and the psychosocial effects of aging might affect the diagnosis, clinical presentation, and care of asthma in this population. At least 2 phenotypes exist among elderly patients with asthma; those with longstanding asthma have more severe airflow limitation and less complete reversibility than those with late-onset asthma. Many challenges exist in the recognition and treatment of asthma in the elderly. Furthermore, the pathophysiologic mechanisms of asthma in the elderly are likely to be different from those seen in young asthmatic patients, and these differences might influence the clinical course and outcomes of asthma in this population. (J Allergy Clin Immunol 2011;128:S4-24.)	[Hanania, Nicola A.] Baylor Coll Med, Sect Pulm & Crit Care Med, Asthma Clin Res Ctr, Houston, TX 77030 USA; [King, Monroe J.; Ledford, Dennis K.] Univ S Florida, Div Allergy & Immunol, Dept Med, Tampa, FL USA; [Braman, Sidney S.] Brown Univ, Providence, RI 02912 USA; [Saltoun, Carol] Northwestern Univ, Chicago, IL 60611 USA; [Wise, Robert A.; Boyd, Cynthia] Johns Hopkins Univ, Baltimore, MD USA; [Enright, Paul] Univ Arizona, Tucson, AZ USA; [Falsey, Ann R.] Univ Rochester, Rochester, NY 14627 USA; [Mathur, Sameer K.] Univ Wisconsin, Dept Med, Sect Allergy Pulm & Crit Care, Madison, WI 53706 USA; [Ramsdell, Joe W.; Wasserman, Stephen I.] Univ Calif San Diego, San Diego, CA 92103 USA; [Rogers, Linda] NYU, Sch Med, New York, NY USA; [Stempel, David A.] GlaxoSmithKline, Bellevue, WA USA; [Lima, John J.] Nemours Children Clin, Jacksonville, FL USA; [Fish, James E.] Genentech Inc, Gladwyne, England; [Wilson, Sandra R.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Patel, Kushang V.] NIA, Bethesda, MD 20892 USA; [Yawn, Barbara P.] Univ Minnesota, Dept Family & Community Hlth, Rochester, MN USA; [Irvin, Charles G.] Univ Vermont, Burlington, VT 05405 USA; [Halm, Ethan A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Sands, Mark F.] SUNY Buffalo, Dept Veteran Affairs, Med Ctr, Buffalo, NY 14260 USA; [Ershler, William B.] Inst Adv Studies Aging, Gaithersburg, MD USA	Baylor College of Medicine; State University System of Florida; University of South Florida; Brown University; Northwestern University; Johns Hopkins University; University of Arizona; University of Rochester; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Diego; New York University; GlaxoSmithKline; Roche Holding; Genentech; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Minnesota System; University of Minnesota Rochester; University of Vermont; University of Texas System; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	King, MJ (corresponding author), Univ S Florida, Div Allergy & Immunol, Dept Med, 7674 Cumberland Ct, Largo, FL 33777 USA.	m.james.king@me.com	Hanania, Nicola A/C-5875-2016; Camargo, Carlos A./C-2145-2008	Hanania, Nicola A/0000-0003-3087-9530; Camargo, Carlos A./0000-0002-5071-7654; Wise, Robert/0000-0002-8353-2349	National Institute on Aging; GlaxoSmithKline; Genentech; Novartis; Pfizer; Boehringer Ingelheim; Forest; Merck; Sanofi Pasteur; NIH; American Lung Association; National Heart, Lung, and Blood Institute/NIH; Agency for Healthcare Research and Quality; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL074225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG032910] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); Novartis(Novartis); Pfizer(Pfizer); Boehringer Ingelheim(Boehringer Ingelheim); Forest; Merck(Merck & Company); Sanofi Pasteur; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lung Association; National Heart, Lung, and Blood Institute/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Publication of this article was supported by the National Institute on Aging.; N. A. Hanania is on the speakers' bureau for GlaxoSmithKline, AstraZeneca, and Genentech; is on advisory boards for GlaxoSmithKline, Genentech, Novartis, and Pfizer; and receives research support from GlaxoSmithKline, Genentech, Novartis, and Pfizer. M. J. King has consultant arrangements with the National Institutes of Health (NIH). R. A. Wise has consultant arrangements with AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sunovion, and Merck and receives research support from GlaxoSmithKline, Boehringer Ingelheim, Forest, and Merck. A. R. Falsey has consultant arrangements with MedImmune and Sanofi Pasteur and receives research support from Sanofi Pasteur and GlaxoSmithKline. S. K. Mathur receives research support from the NIH and is vice-chair of the American Academy of Allergy, Asthma & Immunology (AAAAI)'s Asthma and Allergic Diseases in the Elderly committee. D. A. Stempel is employed by GlaxoSmithKline. J. J. Lima receives research support from the NIH and the American Lung Association. J. E. Fish is employed by Merck & Co, Inc. S. R. Wilson receives research support from the National Heart, Lung, and Blood Institute/NIH. C. G. Irvin is on the speakers' bureau for Merck and the advisory board for MethaPharm, receives research support from the NIH and the American Lung Association, and is on the advisory board for the Vermont Department of Health. B. P. Yawn has consulted for the American Thoracic Society, receives research support from the Agency for Healthcare Research and Quality, and is the chair of the state coalition for asthma for the American Lung Association. S. I. Wasserman receives research support from the American Lung Association, has provided legal consultation or expert witness testimony in cases related to mold injury and medical malpractice, and is president of the American Board of Allergy and Immunology. The rest of the authors have declared that they have no conflict of interest.	Adcock IM, 2007, CURR OPIN IMMUNOL, V19, P694, DOI 10.1016/j.coi.2007.07.016; Allen SC, 2003, AGE AGEING, V32, P299, DOI 10.1093/ageing/32.3.299; ALLEN SC, 1986, BRIT J DIS CHEST, V80, P45, DOI 10.1016/0007-0971(86)90008-2; Anderson C. Joe, 1996, Comprehensive Therapy, V22, P375; Anderson HR, 2003, EUR RESPIR J, V21, p39S, DOI 10.1183/09031936.03.00402203; ANNEMA JT, 1995, EUR RESPIR J, V8, P62, DOI 10.1183/09031936.95.08010062; [Anonymous], 2000, POPUL DEV REV, V26, P197, DOI [10.1111/j.1728-WNL.0b013e31829a33d1, DOI 10.1111/J.1728-4457.2000.00197.X]; Arias Elizabeth, 2007, Natl Vital Stat Rep, V56, P1; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x; Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262; Banerji A, 2006, J AM GERIATR SOC, V54, P48, DOI 10.1111/j.1532-5415.2005.00563.x; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262, DOI 10.1164/ajrccm.159.1.9804063; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Barr JT, 2000, CLIN THER, V22, P1121, DOI 10.1016/S0149-2918(00)80089-2; Barr RG, 2002, ARCH INTERN MED, V162, P1761, DOI 10.1001/archinte.162.15.1761; Barua P, 2005, DRUG AGING, V22, P1029, DOI 10.2165/00002512-200522120-00004; Bauer BA, 1997, CHEST, V111, P303, DOI 10.1378/chest.111.2.303; Bayliss MS, 2000, QUAL LIFE RES, V9, P451, DOI 10.1023/A:1008939328060; BEGIN R, 1975, J APPL PHYSIOL, V38, P199, DOI 10.1152/jappl.1975.38.2.199; Bellia V, 2004, AM J RESP CRIT CARE, V170, P100, DOI 10.1164/ajrccm.170.1.962; Bellia V, 2000, AM J RESP CRIT CARE, V161, P1094, DOI 10.1164/ajrccm.161.4.9810093; Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877; Blanchette CM, 2008, J MANAGE CARE PHARM, V14, P176, DOI 10.18553/jmcp.2008.14.2.176; Boulet LP, 2002, CHEST, V122, P2217, DOI 10.1378/chest.122.6.2217; Braman S S, 2005, Exp Lung Res, V31 Suppl 1, P6; Braman SS, 2007, CLIN CHEST MED, V28, P685, DOI 10.1016/j.ccm.2007.08.007; Braman SS, 1996, DRUGS, V51, P415, DOI 10.2165/00003495-199651030-00006; BRAMAN SS, 1991, ANN NY ACAD SCI, V629, P449; BRAMAN SS, 1991, AM REV RESPIR DIS, V143, P336, DOI 10.1164/ajrccm/143.2.336; Braman SS, 2003, CLIN GERIATR MED, V19, P57, DOI 10.1016/S0749-0690(02)00052-6; BRAMAN SS, 1989, CLIN CHEST MED, V10, P165; Buist AS, 2006, AM J RESP CRIT CARE, V174, P1075, DOI 10.1164/rccm.200510-1606OC; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; BURROWS B, 1991, J ALLERGY CLIN IMMUN, V88, P870, DOI 10.1016/0091-6749(91)90243-H; Busse PJ, 2007, CLIN EXP ALLERGY, V37, P1392, DOI 10.1111/j.1365-2222.2007.02775.x; Busse PJ, 2007, AM J MED, V120, P498, DOI 10.1016/j.amjmed.2006.03.024; Cassino C, 2000, AM J RESP CRIT CARE, V162, P1423, DOI 10.1164/ajrccm.162.4.9912140; Chang CH, 2007, ANN ALLERG ASTHMA IM, V99, P130, DOI 10.1016/S1081-1206(10)60636-9; CHAPMAN KR, 1993, CHEST, V104, P1332, DOI 10.1378/chest.104.5.1332; Choi JH, 2005, CLIN EXP ALLERGY, V35, P89, DOI 10.1111/j.1365-2222.2004.02006.x; Christensen K, 1996, J INTERN MED, V240, P333, DOI 10.1046/j.1365-2796.1996.d01-2853.x; CONNOLLY MJ, 1992, THORAX, V47, P410, DOI 10.1136/thx.47.6.410; CONNOLLY MJ, 1995, CHEST, V108, P401, DOI 10.1378/chest.108.2.401; CONNOLLY MJ, 1988, AGE AGEING, V17, P123, DOI 10.1093/ageing/17.2.123; Corry DB, 2006, IMMUNOL RES, V35, P279, DOI 10.1385/IR:35:3:279; Craig BM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-144; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Creticos P, 2002, ANN ALLERG ASTHMA IM, V88, P401, DOI 10.1016/S1081-1206(10)62372-1; Cristofalo V J, 1990, Annu Rev Gerontol Geriatr, V10, P1; Cristofalo VJ, 2004, MECH AGEING DEV, V125, P827, DOI 10.1016/j.mad.2004.07.010; Cristofalo VJ, 1999, AGING-CLIN EXP RES, V11, P1; CRISTOFALO VJ, 1994, SURG CLIN N AM, V74, P1; De Filippi F, 2003, ARCH GERONTOL GERIAT, V37, P33, DOI 10.1016/S0167-4943(03)00005-0; de Gouw HWFM, 1998, AM J RESP CRIT CARE, V158, P315, DOI 10.1164/ajrccm.158.1.9703005; DELESPESSE G, 1977, CLIN ALLERGY, V7, P155, DOI 10.1111/j.1365-2222.1977.tb01436.x; DEVOY MAB, 1995, CHEST, V107, P1116, DOI 10.1378/chest.107.4.1116; Diette GB, 2002, ARCH INTERN MED, V162, P1123, DOI 10.1001/archinte.162.10.1123; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DUNN TL, 1986, AM REV RESPIR DIS, V133, P264; Emtner M, 1998, ARCH PHYS MED REHAB, V79, P539, DOI 10.1016/S0003-9993(98)90070-3; Emtner M, 1996, CHEST, V109, P323, DOI 10.1378/chest.109.2.323; Emtner M, 1998, Physiother Res Int, V3, P175, DOI 10.1002/pri.139; Enright PL, 2002, CURR OPIN ALLERGY CL, V2, P175, DOI 10.1097/00130832-200206000-00004; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; ENRIGHT PL, 1994, CHEST, V106, P827, DOI 10.1378/chest.106.3.827; Enright PL, 2001, CHEST, V120, P1861, DOI 10.1378/chest.120.6.1861; Enright PL, 1996, J ASTHMA, V33, P45, DOI 10.3109/02770909609077762; Enright PL, 1997, CHEST, V112, P895, DOI 10.1378/chest.112.4.895; Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Falsey AR, 2008, J AM GERIATR SOC, V56, P1281, DOI 10.1111/j.1532-5415.2008.01775.x; Falsey AR, 2005, DRUG AGING, V22, P577, DOI 10.2165/00002512-200522070-00004; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; FALSEY AR, 1995, J AM GERIATR SOC, V43, P30, DOI 10.1111/j.1532-5415.1995.tb06238.x; Feinberg AP, 2008, JAMA-J AM MED ASSOC, V299, P1345, DOI 10.1001/jama.299.11.1345; Ferrucci L, 2008, RADIOL CLIN N AM, V46, P643, DOI 10.1016/j.rcl.2008.07.005; Finkelman FD, 2008, J ALLERGY CLIN IMMUN, V121, P603, DOI 10.1016/j.jaci.2008.01.008; Fisk WJ, 2007, INDOOR AIR, V17, P284, DOI 10.1111/j.1600-0668.2007.00475.x; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Franceschi C, 2000, VACCINE, V18, P1717, DOI 10.1016/S0264-410X(99)00513-7; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Fried Linda P, 2005, Sci Aging Knowledge Environ, V2005, ppe24, DOI 10.1126/sageke.2005.31.pe24; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Fried LP, 2000, J GERONTOL A-BIOL, V55, pM43; Gelfand EW, 2004, J IMMUNOL, V173, P1298, DOI 10.4049/jimmunol.173.2.1298; Gergen PJ, 2000, CLIN EXP ALLERGY, V30, P1717, DOI 10.1046/j.1365-2222.2000.00971.x; GIBSON GJ, 1976, J APPL PHYSIOL, V41, P20, DOI 10.1152/jappl.1976.41.1.20; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gill TM, 2002, NEW ENGL J MED, V347, P1068, DOI 10.1056/NEJMoa020423; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Griffith KA, 2001, AM J RESP CRIT CARE, V163, P61, DOI 10.1164/ajrccm.163.1.9906089; Griswold SK, 2005, CHEST, V127, P1579, DOI 10.1378/chest.127.5.1579; Gruffydd-Jones K, 2005, BRIT J GEN PRACT, V55, P918; Gupchup GV, 1997, CLIN THER, V19, P1116, DOI 10.1016/S0149-2918(97)80064-1; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Guralnik JM, 2003, AM J PREV MED, V25, P112, DOI 10.1016/S0749-3797(03)00174-0; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; HANNEUSE Y, 1978, CLIN ALLERGY, V8, P165, DOI 10.1111/j.1365-2222.1978.tb00461.x; Hansen EF, 1999, AM J RESP CRIT CARE, V159, P1267, DOI 10.1164/ajrccm.159.4.9807121; HART RW, 1974, P NATL ACAD SCI USA, V71, P2169, DOI 10.1073/pnas.71.6.2169; Hasegawa A, 2006, J IMMUNOL, V176, P2546, DOI 10.4049/jimmunol.176.4.2546; Hayden M L, 2000, Adv Nurse Pract, V8, P30; Hayden ML, 2000, ADV NURSE PRACT, V8, P83; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HIRSCH HR, 1994, EXP GERONTOL, V29, P119, DOI 10.1016/0531-5565(94)90046-9; Huss K, 2001, ANN ALLERG ASTHMA IM, V86, P524, DOI 10.1016/S1081-1206(10)62900-6; Hutchinson AF, 2007, RESP MED, V101, P2472, DOI 10.1016/j.rmed.2007.07.015; Ide K, 1999, J IMMUNOL, V163, P396; Institute of Medicine, CLEAR AIR ASTHM IND; Institute of Medicine, DAMP IND SPAC; Jacoby DB, 2004, J AEROSOL MED, V17, P169, DOI 10.1089/0894268041457156; Janssens JP, 1999, EUR RESPIR J, V13, P197, DOI 10.1034/j.1399-3003.1999.13a36.x; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; Jedrychowski, 1995, Int J Occup Environ Health, V1, P16; JEDRYCHOWSKI W, 1988, EUR J EPIDEMIOL, V4, P335, DOI 10.1007/BF00148921; Jette AM, 2008, J GERONTOL A-BIOL, V63, P1246, DOI 10.1093/gerona/63.11.1246; Johnston Neil W, 2007, Proc Am Thorac Soc, V4, P591, DOI 10.1513/pats.200706-064TH; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Juncal S, 2000, J ASTHMA, V37, P469, DOI 10.3109/02770900009055473; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Katz PP, 1997, AM J RESP CRIT CARE, V155, P577, DOI 10.1164/ajrccm.155.2.9032197; Katz PP, 1999, J CLIN EPIDEMIOL, V52, P667, DOI 10.1016/S0895-4356(99)00026-8; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; King MJ, 2004, ALLERGY ASTHMA PROC, V25, P321; King MJ, 2008, ANN ALLERG ASTHMA IM, V101, P12, DOI 10.1016/S1081-1206(10)60828-9; King MJ, 2010, CURR OPIN PULM MED, V16, P55, DOI 10.1097/MCP.0b013e328333acb0; Kips JC, 2003, EUR RESPIR J, V22, P374, DOI 10.1183/09031936.03.00026403; Kirkwood TBL, 2008, NATURE, V451, P644, DOI 10.1038/451644a; Korenblat PE, 2000, ANN ALLERG ASTHMA IM, V84, P217, DOI 10.1016/S1081-1206(10)62759-7; Kornman KS, 2006, AM J CLIN NUTR, V83, p475S; Krigsman K, 2007, J CLIN PHARM THER, V32, P603, DOI 10.1111/j.1365-2710.2007.00866.x; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1; LEE HY, 1972, BMJ-BRIT MED J, V4, P93, DOI 10.1136/bmj.4.5832.93; Lee HK, 2007, LIFE SCI, V81, P204, DOI 10.1016/j.lfs.2007.05.002; Lehmann S, 2004, RESP MED, V98, P1071, DOI 10.1016/j.rmed.2004.03.019; Leng SX, 2004, AGING CLIN EXP RES, V16, P249, DOI 10.1007/BF03327392; Ling SM, 2007, J GERONTOL A-BIOL, V62, P613, DOI 10.1093/gerona/62.6.613; Litonjua AA, 1997, AM J RESP CRIT CARE, V156, P23, DOI 10.1164/ajrccm.156.1.9608072; Lu Q, 2006, AGEING RES REV, V5, P449, DOI 10.1016/j.arr.2006.07.001; Lutz W, 2008, NATURE, V451, P716, DOI 10.1038/nature06516; Mackenbach JP, 1999, J EPIDEMIOL COMMUN H, V53, P32, DOI 10.1136/jech.53.1.32; Malik A, 2004, ALLERGY ASTHMA PROC, V25, P169; Mallia P, 2006, CHEST, V130, P1203, DOI 10.1378/chest.130.4.1203; MARKS GB, 1993, J CLIN EPIDEMIOL, V46, P1103, DOI 10.1016/0895-4356(93)90109-E; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; Mathias SD, 2000, QUAL LIFE RES, V9, P873, DOI 10.1023/A:1008913209828; Mathur SK, 2008, CHEST, V133, P412, DOI 10.1378/chest.07-2114; Melzer D, 2004, J GERONTOL A-BIOL, V59, P1295, DOI 10.1093/gerona/59.12.1295; Meng YY, 2007, ANN ALLERG ASTHMA IM, V98, P455, DOI 10.1016/S1081-1206(10)60760-0; Meyer KC, 1999, THORAX, V54, P697, DOI 10.1136/thx.54.8.697; Meyer KC, 1998, MECH AGEING DEV, V104, P169, DOI 10.1016/S0047-6374(98)00065-7; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164; Moorman JE, 2001, J ASTHMA, V38, P65, DOI 10.1081/JAS-100000023; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Murakami S, 1996, GENETICS, V143, P1207; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; Narita M, 2004, CELL CYCLE, V3, P244; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Newnham DM, 2001, DRUG SAFETY, V24, P1065, DOI 10.2165/00002018-200124140-00005; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; NIH/NAEPP, 1996, CONS DIAGN MAN ASTHM; NIH NHLB. National Heart Lung and Blood Institute National Institute of Health, 2007, NAT ASTHM ED PREV PR; Nyenhuis Sharmilee M, 2010, Immun Ageing, V7, P8, DOI 10.1186/1742-4933-7-8; OCONNOR GT, 1994, CHEST, V105, P661, DOI 10.1378/chest.105.3.661; Olin AC, 2006, CHEST, V130, P1319, DOI 10.1378/chest.130.5.1319; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Pahor M, 2006, J GERONTOL A-BIOL, V61, P1157; Parameswaran K, 1998, RESP MED, V92, P573, DOI 10.1016/S0954-6111(98)90311-0; Patel R, 2009, J ASTHMA, V46, P30, DOI 10.1080/02770900802460563; PAUWELS R, 1979, IMMUNOLOGY, V36, P145; Pawelec G, 2003, IMMUNOL ALLERGY CLIN, V23, P1, DOI 10.1016/S0889-8561(02)00075-9; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Pezzoli L, 2003, AGE AGEING, V32, P43, DOI 10.1093/ageing/32.1.43; PFEIFER MA, 1983, AM J MED, V75, P249, DOI 10.1016/0002-9343(83)91201-9; Price DB, 2006, RESPIRATION, V73, P285, DOI 10.1159/000090142; PRINCE DS, 1983, CHEST, V84, P640, DOI 10.1378/chest.84.5.640; Proud D, 2006, AM J RESP CELL MOL, V35, P513, DOI 10.1165/rcmb.2006-0199TR; Quadrelli SA, 1998, RESPIRATION, V65, P347, DOI 10.1159/000029294; Quadrelli SA, 2001, J ASTHMA, V38, P377, DOI 10.1081/JAS-100000259; RAIHA I, 1993, SCAND J GASTROENTERO, V28, P1011, DOI 10.3109/00365529309098301; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; Reed CE, 1997, ASTHMA ELDERLY, P33; RICHARDS JM, 1989, J ASTHMA, V26, P99, DOI 10.3109/02770908909073238; RIGGS JE, 1990, MECH AGEING DEV, V55, P235, DOI 10.1016/0047-6374(90)90151-5; Rogers L, 2002, CHEST, V122, P1580, DOI 10.1378/chest.122.5.1580; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; Roth GS, 2007, ANN NY ACAD SCI, V1114, P369, DOI 10.1196/annals.1396.048; Schatz M, 2007, AM J MANAG CARE, V13, P661; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; Scichilone N, 2005, EUR RESPIR J, V25, P364, DOI 10.1183/09031936.05.00080204; Sedivy JM, 2008, EXP CELL RES, V314, P1909, DOI 10.1016/j.yexcr.2008.02.023; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; Sin DD, 2001, CHEST, V119, P720, DOI 10.1378/chest.119.3.720; Slavin RG, 2006, ANN ALLERG ASTHMA IM, V96, P406, DOI 10.1016/S1081-1206(10)60907-6; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Smyrnios NA, 1997, GERIATRICS, V52, P36; STOY PJ, 1981, J ALLERGY CLIN IMMUN, V68, P421, DOI 10.1016/0091-6749(81)90195-0; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; SUN JY, 1994, J BIOL CHEM, V269, P18638; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; Taddei S, 2000, CIRCULATION, V101, P2896, DOI 10.1161/01.CIR.101.25.2896; Tafreshi MJ, 1999, PHARMACOTHERAPY, V19, P974, DOI 10.1592/phco.19.11.974.31575; TAKAYANAGI I, 1990, GEN PHARMACOL-VASC S, V21, P299, DOI 10.1016/0306-3623(90)90826-8; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Tsang KW, 2001, LUNG, V179, P83, DOI 10.1007/s004080000050; TURNER JM, 1968, J APPL PHYSIOL, V25, P664, DOI 10.1152/jappl.1968.25.6.664; ULLAH MI, 1981, THORAX, V36, P523, DOI 10.1136/thx.36.7.523; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; Varkey JB, 2008, CURR OPIN PULM MED, V14, P89, DOI 10.1097/MCP.0b013e3282f4a99f; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Walsh EE, 2008, ARCH INTERN MED, V168, P2489, DOI 10.1001/archinte.168.22.2489; Walsh LJ, 2001, THORAX, V56, P279, DOI 10.1136/thorax.56.4.279; Weindruch R, 1996, SCI AM, V274, P46, DOI 10.1038/scientificamerican0196-46; Weiner P, 1998, EUR RESPIR J, V12, P564, DOI 10.1183/09031936.98.12030564; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; WILLSKARP M, 1991, LIFE SCI, V49, P1039, DOI 10.1016/0024-3205(91)90305-U; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3; Yagi T, 1997, J ALLERGY CLIN IMMUN, V99, P38, DOI 10.1016/S0091-6749(97)70298-7; Yancik R, 2007, J GERONTOL A-BIOL, V62, P275, DOI 10.1093/gerona/62.3.275; Zeiger RS, 2008, J ALLERGY CLIN IMMUN, V121, P885, DOI 10.1016/j.jaci.2007.12.1178; Zosky GR, 2007, CLIN EXP ALLERGY, V37, P973, DOI 10.1111/j.1365-2222.2007.02740.x; Zureik M, 2002, RESPIRATION, V69, P223, DOI 10.1159/000063624	241	155	157	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3		S			S4	S24		10.1016/j.jaci.2011.06.048	http://dx.doi.org/10.1016/j.jaci.2011.06.048			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	828XB	21872730	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000295536500002
J	Massanari, M; Nelson, H; Casale, T; Busse, W; Kianifard, F; Geba, GP; Zeldin, RK				Massanari, Marc; Nelson, Harold; Casale, Thomas; Busse, William; Kianifard, Farid; Geba, Gregory P.; Zeldin, Robert K.			Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Omalizumab; allergic asthma; immunotherapy; systemic allergic reactions; cluster immunotherapy; cat; dog; house dust mines	ANTI-IGE; DOUBLE-BLIND	Background: Although specific immunotherapy is a valuable treatment option for patients with allergic asthma, the potential for systemic allergic reactions has limited its use, especially for patients with symptomatic disease. Objective: To evaluate omalizumab's effect on the tolerability of specific immunotherapy in patients with symptomatic persistent asthma not adequately controlled with inhaled corticosteroids. Methods: This multicenter, double-blind, parallel-group study randomized patients to treatment with omalizumab or placebo, after which they received specific immunotherapy to at least I of 3 perennial aeroallergens (cat, dog, and house dust mite) according to a 4-week, 18-injection cluster regimen, followed by 7 weeks of maintenance therapy. The primary efficacy variable, a systemic allergic reaction after immunotherapy, was analyzed by using the Cochrane-Mantel-Haenszel test. Results: A total of 248 randomized patients (126 omalizumab, 122 placebo) received at least I dose of immunotherapy and were evaluated for efficacy. Patients receiving omalizumab experienced significantly fewer systemic allergic reactions to immunotherapy than those receiving placebo (17/126 [13.5%] vs 32/122 [26.2%]; P = .017; 95% CI, 2.91% to 22.56%) and had fewer respiratory-related (grade 3) systemic allergic reactions (6 vs 24, respectively). Grade 4 reactions were reported in 2 patients in each group. More omalizumab patients were able to reach the target maintenance immunotherapy dose (110 [87.3%] vs 88 [72.1%], respectively; P = .004). Conclusion: Use of omalizumab in patients whose asthma was symptomatic despite use of inhaled corticosteroids was associated with fewer systemic allergic reactions to specific immunotherapy and enabled more patients to achieve the target immunotherapy maintenance dose. (J Allergy, Clin Immunol 2010; 125:383-9.)	[Massanari, Marc; Kianifard, Farid; Geba, Gregory P.; Zeldin, Robert K.] Novartis Pharmaceut, E Hanover, NJ 07936 USA; [Nelson, Harold] Natl Jewish Hlth, Denver, CO USA; [Casale, Thomas] Creighton Univ, Omaha, NE 68178 USA; [Busse, William] Univ Wisconsin, Madison, WI 53706 USA	Novartis; National Jewish Health; Creighton University; University of Wisconsin System; University of Wisconsin Madison	Massanari, M (corresponding author), Novartis Pharmaceut, 1 Hlth Plaza,Bldg 419-2326, E Hanover, NJ 07936 USA.	marc.massanari@novartis.com			Novartis Pharmaceuticals Corp; East Hanover, NJ; Genentech. Inc, South San Francisco, Calif; Schering-Plough; Genentech; Ception; AstraZeneca; Novartis; NIH-NIAID; NIH-NHLB1; Centocor; GlaxoSmithKline; MedImmuen	Novartis Pharmaceuticals Corp(Novartis); East Hanover, NJ; Genentech. Inc, South San Francisco, Calif(Roche HoldingGenentech); Schering-Plough(Merck & CompanySchering Plough Corporation); Genentech(Roche HoldingGenentech); Ception; AstraZeneca(AstraZeneca); Novartis(Novartis); NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH-NHLB1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Centocor; GlaxoSmithKline(GlaxoSmithKline); MedImmuen	Supported by Novartis Pharmaceuticals Corp, East Hanover, NJ, and Genentech. Inc, South San Francisco, Calif.; Disclosure of potential conflict of interest: M. Massanari, F. Kianifard, and R. K. Zeldin are employed by Novartis. H. Nelson has consultant arrangements with Genentech/Novartis, Abbott Laboratories. MediciNova, AstraZeneca. Amgen, GlaxoSmithKline, Schering-Plough, Dyson, and Sepracor: receives research support from Schering-Plough, Genentech. Ception, and AstraZeneca; and is on the speakers' bureau for GlaxoSmithKline. T. Casale receives research support from Novartis and Genentech. W. Busse has consultant arrangements with Altair. GlaxoSmithKline, Merck. Wyeth, Pfizer, Centocor. Amgen, UCB. Johnson & Johnson, Novartis, AstraZeneca, Eisai. TEVA, CompleWare, KaloBios, Boehringer Ingelheim, and Sandoz and receives research support from the NIH-NIAID, NIH-NHLB1, Novartis, Centocor. GlaxoSmithKline, MedImmuen, and Ception. G. P. Geba is a former employee and current stockholder of Novartis.	Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; Adkinson NF, 1999, NEW ENGL J MED, V341, P522, DOI 10.1056/NEJM199908123410710; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Collet D., 2003, MODELLING SURVIVAL D; Cox L, 2008, J ALLERGY CLIN IMMUN, V122, P432, DOI 10.1016/j.jaci.2008.06.007; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; Global Initiative for asthma, GINA REP GLOB STRAT; KAMIN W, 2009, PEDIAT ALLE IN PRESS; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lachin J. M., 2000, WILEY SER PROB STAT; Lockey RF, 2001, J ALLERGY CLIN IMMUN, V108, P497; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MULLER HL, 1966, J ASTHMA RES, V3, P331; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P973, DOI 10.1111/j.1398-9995.2004.00552.x; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Stokes ME., 2000, CATEGORICAL DATA ANA; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027	22	155	163	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					383	389		10.1016/j.jaci.2009.11.022	http://dx.doi.org/10.1016/j.jaci.2009.11.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159249				2022-12-18	WOS:000274764000016
J	De Ravin, SS; Naumann, N; Cowen, EW; Friend, J; Hilligoss, D; Marquesen, M; Balow, JE; Barron, KS; Turner, ML; Gallin, JI; Malech, HL				De Ravin, Suk See; Naumann, Nora; Cowen, Edward W.; Friend, Julia; Hilligoss, Dianne; Marquesen, Martha; Balow, James E.; Barron, Karyl S.; Turner, Maria L.; Gallin, John I.; Malech, Harry L.			Chronic granulomatous disease as a risk factor for autoimmune disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic granulomatous disease; autoimmune; antiphospholipid syndrome; IgA nephropathy; lupus; juvenile idiopathic nephropathy	LUPUS-ERYTHEMATOSUS; PERICARDIAL-EFFUSIONS; CLINICAL-FEATURES; PATIENT; CRITERIA; MODEL	Chronic granulomatous disease (CGD) is characterized by recurrent infections and granuloma formation. In addition, we have observed a number of diverse autoimmune conditions in our CGD population, suggesting that patients with CGD are at an elevated risk for development of autoimmune disorders. In this report, we describe anti phospholipid syndrome, recurrent pericardial effusion, juvenile idiopathic arthritis, IgA nephropathy, cutaneous lupus erythematosus, and autoimmune pulmonary disease in the setting of CGD. The presence and type of autoimmune disease have important treatment implications for patients with CGD. (J Allergy Clin Immunol 2008;122:1097-103.)	[De Ravin, Suk See; Naumann, Nora; Friend, Julia; Hilligoss, Dianne; Marquesen, Martha; Barron, Karyl S.; Gallin, John I.; Malech, Harry L.] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; [Balow, James E.] NIDDKD, Bethesda, MD 20892 USA; [Cowen, Edward W.; Turner, Maria L.] NCI, Dermatol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	De Ravin, SS (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10-CRC,Room 5-3816,10 Ctr Dr, Bethesda, MD 20892 USA.	sderavin@niaid.nih.gov		De Ravin, Suk See/0000-0002-9800-774X; Malech, Harry/0000-0001-5874-5775	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000155, ZIAAI000645] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000645-17, Z01 AI000645-16] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Barese CN, 2004, J PEDIAT HEMATOL ONC, V26, P209, DOI 10.1097/00043426-200403000-00014; Barton L L, 1986, Pediatr Dermatol, V3, P376, DOI 10.1111/j.1525-1470.1986.tb00544.x; Borchers AT, 2006, AUTOIMMUN REV, V5, P279, DOI 10.1016/j.autrev.2005.09.011; Brown JR, 2003, J LEUKOCYTE BIOL, V73, P591, DOI 10.1189/jlb.1202599; Cale CM, 2007, CLIN EXP IMMUNOL, V148, P79, DOI 10.1111/j.1365-2249.2007.03321.x; Cordoba-Guijarro S, 2000, J EUR ACAD DERMATOL, V14, P409, DOI 10.1046/j.1468-3083.2000.00113.x; De Ravin SS, 2006, PEDIATRICS, V117, pE590, DOI 10.1542/peds.2005-1349; Etzioni A, 2003, AUTOIMMUN REV, V2, P364, DOI 10.1016/S1568-9972(03)00052-1; Ferrans V J, 1985, Heart Vessels Suppl, V1, P262, DOI 10.1007/BF02072406; GRUMACH A S, 1987, Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, V42, P30; Haas M, 2005, J NEPHROL, V18, P676; Hartl D, 2004, PEDIATR PULM, V38, P344, DOI 10.1002/ppul.20059; Jackson SH, 2004, NAT IMMUNOL, V5, P818, DOI 10.1038/ni1096; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; LEE BW, 1994, ARTHRITIS RHEUM, V37, P773, DOI 10.1002/art.1780370524; Macedo F, 1999, PEDIATR RADIOL, V29, P820, DOI 10.1007/s002470050704; MANZI S, 1991, ARTHRITIS RHEUM, V34, P101, DOI 10.1002/art.1780340116; Marciano BE, 2004, PEDIATRICS, V114, P462, DOI 10.1542/peds.114.2.462; MATSUURA R, 1980, HIROSHIMA J MED SCI, V29, P83; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Mok GCF, 2003, CARDIOL YOUNG, V13, P131, DOI 10.1017/S104795110300026X; Narsipur SS, 2002, J NEPHROL, V15, P713; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; SATO M, 1983, CLIN NEPHROL, V19, P166; SCHMITT CP, 1995, NEPHROL DIAL TRANSPL, V10, P891; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SMITT JHS, 1990, ARCH DERMATOL, V126, P1656, DOI 10.1001/archderm.1990.01670360124034; Trelinski J, 2005, ANN HEMATOL, V84, P835, DOI 10.1007/s00277-005-1094-5; Turpie AGG, 2002, BMJ-BRIT MED J, V325, P887, DOI 10.1136/bmj.325.7369.887; WITEBSKY E, 1966, ANN NY ACAD SCI, V135, P443, DOI 10.1111/j.1749-6632.1966.tb45493.x	32	155	160	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1097	1103		10.1016/j.jaci.2008.07.050	http://dx.doi.org/10.1016/j.jaci.2008.07.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18823651	Green Accepted, Bronze			2022-12-18	WOS:000261711800008
J	Baurecht, H; Irvine, AD; Novak, N; Illig, T; Buhler, B; Ring, J; Wagenpfeil, S; Weidinger, S				Baurecht, Hansjoerg; Irvine, Alan D.; Novak, Natalija; Illig, Thomas; Buehler, Bettina; Ring, Johannes; Wagenpfeil, Stefan; Weidinger, Stephan			Toward a major risk factor for atopic eczema: Meta-analysis of filaggrin polymorphism data	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic eczema; filaggrin; meta-analysis; atopic dermatitis	OF-FUNCTION MUTATIONS; CAUSE ICHTHYOSIS VULGARIS; STRUCTURAL PROTEINS; FUNCTION VARIANTS; GENE PREDISPOSE; RARE MUTATIONS; EARLY-ONSET; DERMATITIS; ASTHMA; POPULATION	Background: With an impressive series of replication studies, filaggrin (FLG) has become the gene with the most widely replicated association to atopic eczema (AE). However, studies published to date demonstrate differences concerning study design and strength of associations. Objectives: We sought to provide a general and overall estimate of FLG effect sizes and to estimate allele and carrier frequencies. Methods: We searched Medline and Institute for Scientific Information Web of Knowledge databases for relevant studies and abstracts from professional societies that were published through June 30, 2007. Initially, we accounted for different study types and evaluated an overall estimate for case-control and family studies. In a second step, we combined those 2 study types and used a random-effects analysis approach to calculate overall odds ratios (ORs). Tests of asymmetry were applied to detect potential publication bias. Results: Nine studies that met the inclusion criteria were included in the meta-analysis. For the combined genotype (R501X or 2282del4), we found an overall OR of 4.09 (95% CI, 2.64-6.33) from the case-control studies and a summary OR of 2.06 (95% CI, 1.76-2.42) from the family studies. Conclusion: The powerful effect of FLG variation on AE risk exceeds that of any other investigated candidate gene for AE thus far and makes FLG one of the strongest genes known to date for complex diseases. Clinical implications: These results underline the importance of a genetically determined epidermal barrier disruption in AE.	[Ring, Johannes; Weidinger, Stephan] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-80802 Munich, Germany; [Baurecht, Hansjoerg; Wagenpfeil, Stefan] Tech Univ Munich, IMSE, D-80802 Munich, Germany; [Baurecht, Hansjoerg; Buehler, Bettina; Ring, Johannes; Weidinger, Stephan] Tech Univ Munich, GSF, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy, D-80802 Munich, Germany; [Baurecht, Hansjoerg; Buehler, Bettina; Ring, Johannes; Weidinger, Stephan] Tech Univ Munich, ZAUM Ctr Allergy & Environm, D-80802 Munich, Germany; [Irvine, Alan D.] Our Ladus Childrens Hosp, Dept Paediat Dermatol, Dublin, Ireland; [Novak, Natalija] Univ Bonn, Dept Dermatol, D-5300 Bonn, Germany; [Illig, Thomas] GSF, Natl Res Ctr Environm & Hlth, Dept Epidemiol, Neuherberg, Germany	Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; Technical University of Munich; University of Bonn; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Weidinger, S (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.	weidinger@lrz.tum.de	Ring, Johannes/GLN-4341-2022; Baurecht, Hansjoerg/C-4035-2013; Irvine, Alan D/A-3982-2008; Weidinger, Stephan/C-8461-2011	Ring, Johannes/0000-0001-8236-3152; Baurecht, Hansjoerg/0000-0002-9265-5594; Irvine, Alan D/0000-0002-9048-2044; Weidinger, Stephan/0000-0003-3944-252X				Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Blakey J, 2005, THORAX, V60, P274, DOI 10.1136/thx.2004.027227; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cauchi S, 2007, J MOL MED, V85, P777, DOI 10.1007/s00109-007-0203-4; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Gardner TN, 2005, STAT CONFIDENCE CONF; Gruber R, 2007, EUR J HUM GENET, V15, P179, DOI 10.1038/sj.ejhg.5201742; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Huffmeier U, 2007, J INVEST DERMATOL, V127, P1367, DOI 10.1038/sj.jid.5700720; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; McGrath JA, 2006, CLIN EXP DERMATOL, V31, P826, DOI 10.1111/j.1365-2230.2006.02287.x; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; MORRIS J, 2005, STAT CONFIDENCE, V2, P57; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Orwin R.G., 1994, HDB RES SYNTHESIS; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; R Development Core Team, 2006, R LANG ENV STAT COMP; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Schwarzer G., META METAANALYSIS R; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Stemmler S, 2007, J INVEST DERMATOL, V127, P722, DOI 10.1038/sj.jid.5700579; Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184; van Beijsterveldt CEM, 2007, EUR RESPIR J, V29, P516, DOI 10.1183/09031936.00065706; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Zhao Y, 2007, J INVEST DERMATOL, V127, P1878, DOI 10.1038/sj.jid.5700817	38	155	160	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1406	1412		10.1016/j.jaci.2007.08.067	http://dx.doi.org/10.1016/j.jaci.2007.08.067			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17980411				2022-12-18	WOS:000251653800024
J	Hefle, SL; Furlong, TJ; Niemann, L; Lemon-Mule, H; Sicherer, S; Taylor, SL				Hefle, Susan L.; Furlong, Terence J.; Niemann, Lynn; Lemon-Mule, Heather; Sicherer, Scott; Taylor, Steve L.			Consumer attitudes and risks associated with packaged foods having advisory labeling regarding the presence of peanuts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut; peanut allergy; labeling; advisory labeling; avoidance diets; quality of life; consumer behavior	TELEPHONE SURVEY; ALLERGY; CHILDREN; ANAPHYLAXIS; PREVALENCE	Background: Foods with advisory labeling (eg, "may contain") are increasingly prevalent. Consumers with food allergies might ignore advisory labeling advice. Objective: We sought to determine whether consumers with food allergy heeded advisory labels and whether products with advisory labels contained detectable peanut allergen. Methods: Surveys (n = 625 in 2003 and n = 645 in 2006) were conducted at Food Allergy & Anaphylaxis Network patient conferences. Food products bearing advisory statements regarding peanuts were analyzed for the presence of peanut. Results: Consumers were less likely to heed advisory labeling in 2006 (75%) compared with in 2003 (85%, P < .01); behavior varied significantly according to the form of the statement. Peanut protein was detected in 10% (20/200) of total food products bearing advisory statements, although clinically significant levels of peanut (> 1 mg of peanut or > 0.25 mg of peanut protein) were detected in only 13 of 200 such products. Conclusion: Consumers with food allergy are increasingly ignoring advisory labeling. Because food products with advisory labeling do contain detectable levels of peanuts, a risk exists to consumers choosing to eat such foods. The format of the labeling statement did not influence the likelihood of finding detectable peanut, except for products listing peanuts as a minor ingredient, but did influence the choices of consumers with food allergy. Clinical implications: Allergic patients are taking risks by increasingly disregarding advisory labeling.	Univ Nebraska, Dept Food Sci & Technol, Food Allergy Res & Resource Program, Lincoln, NE 68583 USA; Mt Sinai Sch Med, New York, NY 10029 USA; Food Allergy & Anaphylaxis Network, Fairfax, VA USA	University of Nebraska System; University of Nebraska Lincoln; Icahn School of Medicine at Mount Sinai	Taylor, SL (corresponding author), Univ Nebraska, Dept Food Sci & Technol, Food Allergy Res & Resource Program, 255 Food Ind Bldg, Lincoln, NE 68583 USA.	staylor2@unl.edu	Taylor, Steve L./V-1341-2019					*CTR FOOD SAV APPL, 2006, 108282 CTR FOOD SAF; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V117, P448, DOI 10.1016/j.jaci.2005.11.035; Kemp SF, 1996, JAMA-J AM MED ASSOC, V275, P1636, DOI 10.1001/jama.275.21.1636; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Morisset M, 2003, CLIN EXP ALLERGY, V33, P1046, DOI 10.1046/j.1365-2222.2003.01734.x; Nowak-Wegrzyn A, 2006, MED CLIN N AM, V90, P97, DOI 10.1016/j.mcna.2005.08.012; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; TAYLOR SL, 1986, NEW ENGL REG ALLERGY, V7, P527; Taylor SL, 2001, FOOD TECHNOL-CHICAGO, V55, P68; Taylor SL, 2007, COMPR REV FOOD SCI F, V6, P36, DOI 10.1111/j.1541-4337.2007.00016.x; Taylor SL, 2006, COMPR REV FOOD SCI F, V5, P138, DOI 10.1111/j.1541-4337.2006.00012.x; Vierk K, 2002, J ALLERGY CLIN IMMUN, V109, P1022, DOI 10.1067/mai.2002.124500; Whitaker TB, 2005, J AOAC INT, V88, P161; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	18	155	161	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					171	176		10.1016/j.jaci.2007.04.013	http://dx.doi.org/10.1016/j.jaci.2007.04.013			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17544097	Bronze			2022-12-18	WOS:000248066400025
J	Chan-Yeung, M; Ferguson, A; Watson, W; Dimich-Ward, H; Rousseau, R; Lilley, M; DyBuncio, A; Becker, A				Chan-Yeung, M; Ferguson, A; Watson, W; Dimich-Ward, H; Rousseau, R; Lilley, M; DyBuncio, A; Becker, A			The Canadian childhood asthma primary prevention study: Outcomes at 7 years of age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						asthma; primary prevention	FATTY-ACID MODIFICATION; ALLERGEN AVOIDANCE; BRONCHIAL HYPERRESPONSIVENESS; HOUSE-DUST; INFANCY; CHILDREN; REACTIVITY; SYMPTOMS; ATOPY	Background: Avoidance of any one of the individual risk factors associated with childhood asthma has not been successful in preventing its development. Objective: The purpose of this study is to determine the effectiveness of a multifaceted intervention program for the primary prevention of asthma in high-risk infants at 7 years of age. Methods: Five hundred forty-five high-risk infants with an immediate family history of asthma and allergies were prospectively randomized into intervention or control groups prenatally. Intervention measures introduced before birth and during the first year of life included avoidance of house dust, pets, and environmental tobacco smoke and encouragement of breast-feeding with delayed introduction of solid foods. Assessment of outcomes at 7 years consisted of examination by pediatric allergists, methacboline inhalation tests, and allergy skin tests. Results: At 7 years, 469 of the 545 children were contacted, and 380 returned for further assessment. The prevalence of pediatric allergist-diagnosed asthma was significantly lower in the intervention group than in the control group (14.9% vs 23.0%; adjusted risk ratio, 0.44; 95% CI, 0.25-0.79). The prevalence of allergic rhinitis, atopic dermatitis, atopy (defined as positive skin test reactions to any common allergen), and bronchial hyperresponsiveness (defined as the provocative concentration of methacholine that induced a 20% decrease in FEV1 from a postsaline value of less than 7.8 mg/mL) were not significantly different between the 2 groups. The prevalence of asthma (defined as wheeze without colds and the presence of bronchial hyperresponsiveness) was also significantly lower in the intervention group compared with the control group (12.9% vs 25.0%; adjusted risk ratio, 0.39; 95% CI, 0.22-0.71).	Univ British Columbia, Dept Med, Div Resp, Occupat & Environm Lung Dis Unit, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Dept Pediat, Div Allergy, Vancouver, BC V5Z 3J5, Canada; Univ Manitoba, Manitoba Inst Child Hlth, Sect Allergy & Clin Immunol, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada	University of British Columbia; University of British Columbia; University of Manitoba	Chan-Yeung, M (corresponding author), Univ British Columbia, Dept Med, Div Resp, Occupat & Environm Lung Dis Unit, 2775 Heather St, Vancouver, BC V5Z 3J5, Canada.	myeung@interchange.ubc.ca		Ferguson, Alexander C./0000-0002-3143-5619				ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Chan-Yeung M, 2002, ANN ALLERG ASTHMA IM, V88, P52, DOI 10.1016/S1081-1206(10)63592-2; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Ernst P, 2002, EUR RESPIR J, V20, P635, DOI 10.1183/09031936.02.00962002; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; *ISAAC COORD COMM, 1992, MAN INT STUD ASTHM A; Kurukulaaratchy RJ, 2003, J ALLERGY CLIN IMMUN, V112, P311, DOI 10.1067/mai.2003.1623; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057	17	155	161	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					49	55		10.1016/j.jaci.2005.03.029	http://dx.doi.org/10.1016/j.jaci.2005.03.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990772				2022-12-18	WOS:000235686300007
J	Beyer, K; Bardina, L; Grishina, G; Sampson, HA				Beyer, K; Bardina, L; Grishina, G; Sampson, HA			Identification of sesame seed allergens by 2-dimensional proteomics and Edman sequencing: Seed storage proteins as common food allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sesame seed; allergen; 2-dimensional; proteomics; immunolabeling; IgE; seed storage protein; vicilin; 2S albumin; 7S globulin; Ses i 3; Ses i 2	2S ALBUMIN; 11S GLOBULIN; ANAPHYLAXIS; INDICUM; CLONING; PEANUT	Background: Sesame seed allergy is becoming increasingly prevalent, probably because of its use in international fast-food and bakery products. Despite this fact, few studies have focused on the identification of its major allergenic proteins. Objective: The aim of this study was to identify allergenic proteins of sesame seeds (Sesamum indicum). Methods: Extracted sesame seed proteins were separated by means of SDS-PAGE and 2-dimensional (2-D) PAGE. Immunolabeling was performed with individual patient sera from 20 patients with sesame seed allergy. Selected proteins were further analyzed by, means of Edman sequencing. Results: IgE-binding proteins were identified at 78, 52, 45, 34,32, 29, 25, 20, 9, and 7 kd. Analyzing internal sequences, the protein at 45 kd, which was recognized by 75% of the patients, was found to be a 7S vicilin-type globulin, a seed storage protein of sesame and named Ses i 3. The protein at 7 kd was found to be a 2S albumin, another seed storage protein of sesame and named Ses i 2. Seed storage proteins are known food allergens in peanut, walnut, Brazil nut, and soybean. Interestingly, one known IgE-binding epitope of the peanut allergen Ara h 1 has 80% homology with the corresponding area of Ses i 3. The different amino acids were previously shown not to be critical for IgE binding in Ara h 1. In addition, the proteins at 78 and 34 kd were found to be homologous to the embryonic abundant protein nd the seed maturation protein of soybeans, respectively. Conclusion: The identification of 4 sesame seed allergens is the first step toward generating recombinant allergens for use in future immunotherapeutic approaches. In addition, the detection of conserved IgE binding epitopes in common food allergens might be a useful tool for predicting cross-reactivity to certain foods.	Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY 10029 USA; Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Beyer, K (corresponding author), Mt Sinai Sch Med, Div Pediat Allergy & Immunol, Box No 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-00071] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alday E, 1996, ALLERGY, V51, P69, DOI 10.1111/j.1398-9995.1996.tb00019.x; Asero R, 1999, ALLERGY, V54, P526; CHIU JT, 1991, J ALLERGY CLIN IMMUN, V88, P414, DOI 10.1016/0091-6749(91)90106-X; KAGI MK, 1991, LANCET, V338, P582, DOI 10.1016/0140-6736(91)91157-P; KESKINEN H, 1991, CLIN EXP ALLERGY, V21, P623, DOI 10.1111/j.1365-2222.1991.tb00856.x; KOLOPPSARDA MN, 1997, CLIN EXP ALLERGY, V27, P128; Levy Y, 2001, ALLERGY, V56, P193, DOI 10.1034/j.1398-9995.2001.056002193.x; Pajno GB, 2000, ALLERGY, V55, P199, DOI 10.1034/j.1398-9995.2000.00494.x; Pastorello EA, 2001, J CHROMATOGR B, V756, P85, DOI 10.1016/S0378-4347(01)00073-1; Perkins MS, 1996, BRIT MED J, V313, P300, DOI 10.1136/bmj.313.7052.300b; RAJENDRAN S, 1988, J AGR FOOD CHEM, V36, P269, DOI 10.1021/jf00080a008; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Sporik R, 1996, BRIT MED J, V313, P1477, DOI 10.1136/bmj.313.7070.1477c; Stern A, 1998, ALLERGY, V53, P325, DOI 10.1111/j.1398-9995.1998.tb03897.x; Tai SSK, 1999, J AGR FOOD CHEM, V47, P4932, DOI 10.1021/jf990366z; Tai SSK, 2001, PLANT PHYSIOL BIOCH, V39, P981, DOI 10.1016/S0981-9428(01)01314-6; Teuber SS, 1998, J ALLERGY CLIN IMMUN, V101, P807, DOI 10.1016/S0091-6749(98)70308-2; 2001, WORLD MARKET SESAME	18	155	164	4	43	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					154	159		10.1067/mai.2002.125487	http://dx.doi.org/10.1067/mai.2002.125487			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110835				2022-12-18	WOS:000176870300027
J	Rance, F; Abbal, M; Lauwers-Cances, V				Rance, F; Abbal, M; Lauwers-Cances, V			Improved screening for peanut allergy by the combined use of skin prick tests and specific IgE assays	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; double-blind; placebo-controlled food challenge; peanut allergy; skin prick test; specific IgE; performance; characteristic	ADVERSE-REACTIONS; FOOD ALLERGY; DOUBLE-BLIND; ANAPHYLACTIC REACTIONS; CHILDREN; HYPERSENSITIVITY; PREVALENCE	Background: The diagnosis of peanut allergy must be based on reliable, safe criteria. Double-blind, placebo-controlled food challenges (DBPCFCs) are the gold standard but are costly and dangerous because they can trigger severe reactions. Objective: The aim of this study was to develop a new strategy for diagnosing peanut allergy while reducing the need for DBPCFCs. Methods: We studied 363 children referred for an evaluation of suspected food hypersensitivity. They all benefited from the same diagnostic strategy, which included, in order, clinical history, a skin prick test (SPT), and a specific IgE assay. DBPCFCs were performed on all the children by personnel who were unaware of the results of the other tests. To assess the performance characteristics of the SPT (comparing commercial and raw peanut extracts) and the specific IgE assay, we compared the results with those provided by the DBPCFCs. For SPTs and specific IgE assays, we sought to determine the cutoff values required to exclude false-positive and false-negative results. Results: According to DBPCFC results, 177 children were allergic to peanut, and 186 were not. The performance characteristics of the SPTs were superior with the raw extract because the negative predictive value was 100% (95% confidence interval [CI], 97.5-100). If the skin reaction with the raw extract was less than 3 mm, we could be quite certain that the child was not allergic. On the other hand, if the SPT resulted in a wheal diameter of larger than 3 mm, we could only be 74% certain that the children were allergic. Furthermore, if the SPT resulted in a wheal diameter of 16 mm or larger, we could be quite certain that the child was allergic because the positive predictive value was 100% (95% Cl, 86.8-100). Specific IgE concentrations of 57 kU(A)/L or greater were associated with a positive predictive value of 100% (95% CI, 87.2-100). The combined use of the tests resulting in a positive diagnosis if the SPT result was 16 mm or larger or specific IgE concentration was 57 kUA/L or greater and in a negative diagnosis if the SPT result was less than 3 mm and the specific IgE concentration was less than 57 kU(A)/L allowed us to classify subjects with almost complete certainty as being allergic or not because the predictive values were 100%. Conclusion: Commercial extracts could not be used to reliably predict tolerance of peanut. Peanut DBPCFCs can be avoided when SPTs with raw extracts resulted in wheals with a largest diameter of less than 3 mm and a specific IgE concentration of less than 57 kUA/L and also when wheal diameters were 16 mm or larger or specific IgE values were 57 kUA/L or greater. Otherwise, DBPCFCs were indispensable for the unequivocal diagnosis of peanut allergy.	CHU Toulouse, Hop Enfants, F-31026 Toulouse, France	CHU de Toulouse	Rance, F (corresponding author), CHU Toulouse, Hop Enfants, 330 Ave Grande Bretagne, F-31026 Toulouse, France.							[Anonymous], 1989, ALLERGY S10, V10, P1; ATKINS FM, 1985, J ALLERGY CLIN ALLER, V75, P384; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Dreborg S, 2001, ALLERGY, V56, P359, DOI 10.1034/j.1398-9995.2001.056005359.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; ERDREICH LS, 1981, AM J EPIDEMIOL, V114, P649, DOI 10.1093/oxfordjournals.aje.a113236; HEFLE SL, 1995, J ALLERGY CLIN IMMUN, V95, P837, DOI 10.1016/S0091-6749(95)70127-3; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P1240, DOI [10.1111/j.1365-2222.1997.tb01167.x, 10.1046/j.1365-2222.1997.1520954.x]; METCALFE DD, 1990, J ALLERGY CLIN IMMUN, V86, P421, DOI 10.1016/S0091-6749(05)80252-0; Moneret-Vautrin DA, 1998, CLIN EXP ALLERGY, V28, P1113, DOI 10.1046/j.1365-2222.1998.00370.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Noe D, 1998, ALLERGY, V53, P75, DOI 10.1111/j.1398-9995.1998.tb04967.x; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1111/j.1365-2222.1996.tb00537.x; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Rance F, 1997, ALLERGY, V52, P1031, DOI 10.1111/j.1398-9995.1997.tb02427.x; Rance F, 1999, PEDIAT ALLERG IMM-UK, V10, P33, DOI 10.1034/j.1399-3038.1999.101008.x; Rance F, 1999, PEDIATR PULM, P165; RANCE F, 2000, ALLERGY S, V55, P55; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; WULTHRICH B, 2000, INVEST ALLERGOL CLIN, V10, P59; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	39	155	157	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					1027	1033		10.1067/mai.2002.124775	http://dx.doi.org/10.1067/mai.2002.124775			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063536				2022-12-18	WOS:000176442700022
J	Popa, ER; Stegeman, CA; Bos, NA; Kallenberg, CGM; Tervaert, JWC				Popa, ER; Stegeman, CA; Bos, NA; Kallenberg, CGM; Tervaert, JWC			Differential B- and T-cell activation in Wegener's granulomatosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wegener's granulomatosis; immunology; B cells; T cells; activation	SYSTEMIC LUPUS-ERYTHEMATOSUS; CYTOPLASMIC ANTIBODY TITER; INTERLEUKIN-2 RECEPTOR; VASCULITIS; AUTOANTIBODIES; RELAPSES; MARKERS; BLOOD; ANCA; PREVENTION	Background: Autoimmune mechanisms are postulated to play a role in the development and progression of Wegener's granulomatosis (WG), a form of systemic, idiopathic necrotizing vasculitis, Objective: We investigated the relation between lymphocyte activation and disease activity in patients with WG, Methods: B- and T-lymphocyte activation was studied by cytometric assessment of the expression of the activation markers CD38 on B cells and CD25 and HLA-DR on CD4(+) and CD8(+) T-cell subsets, respectively. Activation at the cellular level was related to serum levels of antineutrophil cytoplasmic antibodies and soluble IL-2 receptor, which can be regarded as soluble activation markers of B and T cells. Results: Percentages of CD38(bright) activated B cells were higher in patients with active WG than in patients experiencing disease remission (P < .05) or in healthy control subjects (P < .05), Percentages of activated CD4(+) and CD8(+) T cells were higher in patients with active WG (CD4 subset, P < .0001; CD8 subset, P < .005) than in healthy individuals, An increased percentage of activated T cells of both subsets was also seen in patients whose condition was in remission, as compared with healthy control subjects (CD4 subset, P < .0005; CD8 subset, P < .001). Lymphocyte activation at the cellular level did not correlate with plasma levels of antineutrophil cytoplasmic antibodies or soluble IL-2 receptor. Conclusion: In WG, B-cell activation is related to active disease, whereas T-cell activation persists during remission of the disease, which points to an intrinsic disordered immune system in this disease.	Univ Groningen Hosp, Dept Clin Immunol, NL-9713 GZ Groningen, Netherlands; Univ Groningen Hosp, Dept Nephrol, NL-9713 GZ Groningen, Netherlands; Univ Groningen, Dept Histol & Cell Biol, NL-9700 AB Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Popa, ER (corresponding author), Univ Groningen Hosp, Dept Clin Immunol, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.		tervaert, jan willem cohen/AAB-1111-2019; Bos, Nicolaas/C-1503-2015	Bos, Nicolaas/0000-0002-8649-0455; Stegeman, Coen/0000-0002-0224-0927				ALCOCERVARELA J, 1991, J AUTOIMMUN, V4, P935, DOI 10.1016/0896-8411(91)90056-I; BABSON AL, 1991, J CLIN IMMUNOASSAY, V14, P83; BROUWER E, 1991, CLIN EXP IMMUNOL, V83, P379; BROUWER E, 1991, KIDNEY INT, V39, P1055; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CARRINGTON CB, 1966, AM J MED, V41, P497, DOI 10.1016/0002-9343(66)90214-2; FINK PC, 1989, J CLIN CHEM CLIN BIO, V27, P261; GEPHARDT GN, 1983, AM J MED, V74, P700, DOI 10.1016/0002-9343(83)91030-6; HARADA H, 1993, BLOOD, V81, P2658; Heeringa P, 1998, KIDNEY INT, V53, P253, DOI 10.1046/j.1523-1755.1998.00743.x; IKEDA M, 1993, INT ARCH ALLERGY IMM, V102, P205, DOI 10.1159/000236574; KALLENBERG CGM, 1995, CLIN EXP IMMUNOL, V100, P1; KALLENBERG CGM, 1991, IMMUNOL TODAY, V12, P61, DOI 10.1016/0167-5699(91)90159-Q; KERR GS, 1993, ARTHRITIS RHEUM, V36, P365, DOI 10.1002/art.1780360312; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; LEID RW, 1993, EUR J IMMUNOL, V23, P2939, DOI 10.1002/eji.1830231132; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; LUQMANI RA, 1994, Q J MED, V87, P671; MATHIESON PW, 1992, CLIN IMMUNOL IMMUNOP, V63, P135, DOI 10.1016/0090-1229(92)90005-9; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; RASMUSSEN N, 1988, RHEUMATOL INT, V8, P153, DOI 10.1007/BF00270453; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; Savage COS, 1997, LANCET, V349, P553, DOI 10.1016/S0140-6736(97)80118-3; SCHLESIER M, 1995, RHEUMATOL INT, V14, P213, DOI 10.1007/BF00262300; SCHMITT WH, 1992, ARTHRITIS RHEUM, V35, P1088, DOI 10.1002/art.1780350914; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SPRONK PE, 1993, CLIN EXP IMMUNOL, V93, P39; Stegeman CA, 1996, NEW ENGL J MED, V335, P16, DOI 10.1056/NEJM199607043350103; STEGEMAN CA, 1993, CLIN EXP IMMUNOL, V91, P415; Tervaert JWC, 1996, J NEPHROL, V9, P232; TERVAERT JWC, 1990, LANCET, V336, P709; TERVAERT JWC, 1993, ANN RHEUM DIS, V52, P115, DOI 10.1136/ard.52.2.115; TERVAERT JWC, 1997, J AM SOC NEPHROL, V8, pA533; VILLARREAL GM, 1995, AUTOIMMUNITY, V20, P223, DOI 10.3109/08916939508995699; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; [No title captured]	36	155	160	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				885	894		10.1016/S0091-6749(99)70434-3	http://dx.doi.org/10.1016/S0091-6749(99)70434-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329824				2022-12-18	WOS:000080470200025
J	Umetsu, DT; DeKruyff, RH				Umetsu, DT; DeKruyff, RH			T-H1 and T-H2 CD4(+) cells in human allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTERLEUKIN-12; CYTOKINE				Umetsu, DT (corresponding author), STANFORD UNIV,DEPT PEDIAT,DIV IMMUNOL & TRANSPLANTAT BIOL,RM H307,STANFORD,CA 94305, USA.				NIAID NIH HHS [R0IAI37219, R01AI26322, R01AI24571] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026322, R01AI037219, R01AI024571] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blanas E, 1996, SCIENCE, V274, P1707, DOI 10.1126/science.274.5293.1707; Blotta MH, 1996, J IMMUNOL, V156, P3133; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Gieni RS, 1996, INT IMMUNOL, V8, P1511, DOI 10.1093/intimm/8.10.1511; Guler ML, 1996, SCIENCE, V271, P984, DOI 10.1126/science.271.5251.984; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Kim TS, 1997, J IMMUNOL, V158, P4137; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSHALL JD, 1995, J IMMUNOL, V155, P111; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948	18	155	174	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					1	6		10.1016/S0091-6749(97)70186-6	http://dx.doi.org/10.1016/S0091-6749(97)70186-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257779				2022-12-18	WOS:A1997XP42800001
J	TARLO, SM; SUSSMAN, G; CONTALA, A; SWANSON, MC				TARLO, SM; SUSSMAN, G; CONTALA, A; SWANSON, MC			CONTROL OF AIRBORNE LATEX BY USE OF POWDER-FREE LATEX GLOVES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; OCCUPATIONAL ASTHMA; LATEX; ANAPHYLAXIS	SURGICAL GLOVES; RUBBER; ANAPHYLAXIS; ALLERGENS; ANTIGENS; CONTACT; ASTHMA	Objective: Our objective was to assess airborne latex allergen exposure in the workplace of a hospital laboratory technician with occupational latex sensitization and repeated anaphylactic episodes from this. Her allergic manifestations had cleared only when coworkers changed to powder-free later gloves. Therefore a labolatory still using powdered later gloves was selected for comparative airborne latex sampling. Design: The design was a survey. Setting: We used a hospital hematology laboratory, and a biochemistry laboratory was used for comparison. Participants: The index case with latex allergy is described. An average of 10 employees worked on the day shift in the same laboratory, and 10 employees worked in the biochemistry laboratory studied. Main outcome measure: Airborne latex allergen levels obtained by high airflow area sampling were compared in the laboratory using powder-free latex gloves and in the laboratory using powdered latex gloves. Results: Levels were below the level of detection (<0.02 ng/m(3) of latex allergen) in the laboratory using powder-free latex gloves brit ranged from 39 to 311 ng/m(3) in the laboratory using powdered gloves. Conclusions: Airborne later allergen is produced with use of powdered latex gloves. Such usage by coworkers may provoke respiratory and anaphylactic response to latex in sensitized subjects. Use of powder-free gloves by coworkers may enable such patients to continue work in their trained profession and may prevent measurable airborne latex exposure. Affected patients, however, still need to avoid direct latex contact.	UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905	University of Toronto; Mayo Clinic				Tarlo, Susan/0000-0002-4746-5310				CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; JONES RT, 1992, J ALLERGY CLIN IMMUN, V89, P225; LAGIER F, 1990, LANCET, V335, P517; MAKINENKILJUNEN S, 1992, J ALLERGY CLIN IMMUN, V90, P230, DOI 10.1016/0091-6749(92)90076-E; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; SWANSON MC, 1992, J ALLERGY CLIN IMMUN, V89, P227; SWANSON MC, 1990, AM REV RESPIR DIS, V141, P1578, DOI 10.1164/ajrccm/141.6.1578; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B	15	155	157	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					985	989		10.1016/S0091-6749(94)70045-1	http://dx.doi.org/10.1016/S0091-6749(94)70045-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006320				2022-12-18	WOS:A1994NT17200005
J	GODFREY, S; SILVERMAN, M; ANDERSON, SD				GODFREY, S; SILVERMAN, M; ANDERSON, SD			PROBLEMS OF INTERPRETING EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP, CARDIOTHORAC INST, DEPT PAEDIAT, LONDON, ENGLAND	Royal Brompton Hospital				Anderson, Sandra/0000-0002-6308-8770				ANDERSON SD, 1972, AM REV RESPIR DIS, V106, P30, DOI 10.1164/arrd.1972.106.1.30; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; ANDERSON SD, 1972, THORAX, V27, P718, DOI 10.1136/thx.27.6.718; ANDERSON SD, 1972, THESIS U LONDON; BLACKHALL MI, 1970, DISODIUM CROMOGLYCAT; BRIT MED J, 1968, BRIT MED J, V3, P593; CHANYEUNG MM, 1971, AM REV RESPIR DIS, V104, P915; CONNOLLY N, 1970, Journal of Asthma Research, V8, P31, DOI 10.3109/02770907009105028; CROMPTON GK, 1968, THORAX, V23, P165, DOI 10.1136/thx.23.2.165; EGGLESTON PA, 1972, J ALLERGY CLIN IMMUN, V50, P57, DOI 10.1016/0091-6749(72)90079-6; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; FLOYER JA, 1717, TREATISE ASTHMA; GODFREY S, IN PRESS; HERXHEIMER H, 1972, LANCET, V1, P436; HERXHEIMER H, 1946, LANCET, V250, P83; JONES RS, 1962, BRIT J DIS CHEST, V56, P78, DOI 10.1016/S0007-0971(62)80005-9; JONES RS, 1963, ARCH DIS CHILD, V38, P539, DOI 10.1136/adc.38.202.539; JONES RS, 1966, BRIT MED J, V2, P972, DOI 10.1136/bmj.2.5520.972; KATZ RM, 1971, J ALLERGY, V47, P148, DOI 10.1016/S0091-6749(71)80293-2; MCNEILL RS, 1966, Q J MED, V35, P55; PIERSON WE, 1969, J ALLERGY, V43, P136, DOI 10.1016/S0021-8707(69)80004-3; POPPIUS H, 1970, BRIT MED J, V4, P337, DOI 10.1136/bmj.4.5731.337; REBUCK AS, 1968, LANCET, V2, P429; SCADDING JG, 1966, LANCET, V1, P701; SEATON A, 1969, BRIT MED J, V3, P556, DOI 10.1136/bmj.3.5670.556; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SILVERMAN M, 1972, BMJ-BRIT MED J, V3, P378, DOI 10.1136/bmj.3.5823.378; SILVERMAN M, 1972, BMJ-BRIT MED J, V1, P207, DOI 10.1136/bmj.1.5794.207; SILVERMAN M, IN PRESS; SILVERMAN M, 1972, THESIS U CAMBRIDGE; SIMONSSON BG, 1972, THORAX, V27, P169, DOI 10.1136/thx.27.2.169; SLY RM, 1967, J ALLERGY, V40, P93, DOI 10.1016/0021-8707(67)90102-5; VASSALLO CL, 1972, AM REV RESPIR DIS, V105, P42; WILLIS T, 1679, PHARMACEUTICE RATI	34	155	156	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	4					199	209		10.1016/0091-6749(73)90058-4	http://dx.doi.org/10.1016/0091-6749(73)90058-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q9817	4270245				2022-12-18	WOS:A1973Q981700002
J	Liu, SC; Verma, M; Michalec, L; Liu, WM; Sripada, A; Rollins, D; Good, J; Ito, Y; Chu, HW; Gorska, MM; Martin, RJ; Alam, R				Liu, Sucai; Verma, Mukesh; Michalec, Lidia; Liu, Weimin; Sripada, Anand; Rollins, Donald; Good, James; Ito, Yoko; Chu, HongWei; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul			Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: The role of thymic stromal lymphopoietin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; type 2 innate lymphoid cells; steroid resistance; thymic stromal lymphopoietin; signal transducer and activator of transcription 5; mitogen-activated protein kinase kinase	NUCLEAR TRANSLOCATION; SILENCING MEDIATOR; RECEPTOR; INHIBITION; PROTEIN; SIGNAL; ACTIVATION; MECHANISMS; EXPRESSION; STAT5	Background: Type 2 innate lymphoid cells (ILC2s) represent an important type 2 immune cell. Glucocorticoid regulation of human ILC2s is largely unknown. Objective: We sought to assess steroid resistance of human blood and airway ILC2s from asthmatic patients and to examine its mechanism of induction. Methods: We studied human blood and lung ILC2s from asthmatic patients and control subjects using flow cytometry and ELISA Results: Dexamethasone inhibited (P=.04) chemoattractant receptor homologous molecule expressed on T(H)2 lymphocytes and type 2 cytokine expression by blood ILC2s stimulated with IL-25 and IL-33. However, it did not do so when ILC2s were stimulated with IL-7 and thymic stromal lymphopoietin (TSLP), 2 ligands of IL-7 receptor alpha. Unlike blood ILC2s, bronchoalveolar lavage (BAL) fluid ILC2s from asthmatic patients were resistant to dexamethasone. BAL fluid from asthmatic patients had increased TSLP but not IL-7 levels. BAL fluid TSLP levels correlated (r=0.74) with steroid resistance of ILC2s. TSLP was synergistically induced in epithelial cells by IL-13 and human rhinovirus. Mechanistically, dexamethasone upregulated ILC2 expression of IL-7 receptor alpha, which augmented and sustained signal transducer and activator of transcription (STAT) 5 signaling by TSLP. TSLP induced mitogen-activated protein kinase kinase (MEK), c-Fos, inhibitor of DNA binding 3, phosphorylated signal transducer and activator of transcription (pSTAT) 3, and pSTAT5, molecules linked to steroid resistance. Dexamethasone inhibited c-Fos, inhibitor of DNA binding 3, and pSTAT3 but not pSTAT5 and MEK. The MEK inhibitor trametinib, the Janus kinase STAT inhibitor tofacitinib, and the STAT5 inhibitor pimozide reversed steroid resistance of BAL ILC2s. Conclusions: Dexamethasone inhibited type 2 cytokine production by blood ILC2s. IL-7 and TSLP abrogated this inhibition and induced steroid resistance of ILC2s in a MEK- and STAT5-dependent manner. BAL fluid ILC2s from asthmatic patients with increased TSLP levels were steroid resistant, which was reversed by clinically available inhibitors of MEK and	[Liu, Sucai; Verma, Mukesh; Michalec, Lidia; Liu, Weimin; Sripada, Anand; Rollins, Donald; Good, James; Ito, Yoko; Chu, HongWei; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul] Natl Jewish Hlth, Dept Med, Div Allergy & Immunol, Denver, CO 80206 USA; [Liu, Sucai; Verma, Mukesh; Michalec, Lidia; Liu, Weimin; Sripada, Anand; Rollins, Donald; Good, James; Ito, Yoko; Chu, HongWei; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul] Natl Jewish Hlth, Div Pulm & Crit Care Med, Denver, CO 80206 USA; [Rollins, Donald; Good, James; Chu, HongWei; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul] Univ Colorado, Sch Med, Dept Med, Denver, CO USA; [Michalec, Lidia] Med Univ Lodz, Dept Cytobiol & Prote, Lodz, Poland	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Medical University Lodz	Alam, R (corresponding author), Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	alamr@njhealth.org	verma, mukesh/AAB-9330-2020		National Institutes of Health [RO1 AI091614, HL126895, AI102943]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122995, R01HL126895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091614, R01AI102943] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants RO1 AI091614, HL126895, AI102943, and HL126895.	ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; Barnes PJ, 2006, EUR RESPIR J, V27, P413, DOI 10.1183/09031936.06.00125404; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bertucci PY, 2010, ENDOCRINOLOGY, V151, P5730, DOI 10.1210/en.2010-0517; Bianchi M, 2000, P NATL ACAD SCI USA, V97, P9573, DOI 10.1073/pnas.160099797; Changelian PS, 2003, SCIENCE, V302, P875, DOI 10.1126/science.1087061; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Chu HW, 2007, J IMMUNOL, V179, P3995, DOI 10.4049/jimmunol.179.6.3995; Chuderland D, 2008, MOL CELL, V31, P850, DOI 10.1016/j.molcel.2008.08.007; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Emont MP, 2015, MOL CELL ENDOCRINOL, V407, P52, DOI 10.1016/j.mce.2015.03.002; Falchook GS, 2012, LANCET ONCOL, V13, P782, DOI 10.1016/S1470-2045(12)70269-3; Franchimont D, 2002, J IMMUNOL, V168, P2212, DOI 10.4049/jimmunol.168.5.2212; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Goleva E, 2002, J IMMUNOL, V169, P5934, DOI 10.4049/jimmunol.169.10.5934; Guo L, 2013, J IMMUNOL, V190, P159, DOI 10.4049/jimmunol.1201657; Hu XY, 2003, J IMMUNOL, V170, P4833, DOI 10.4049/jimmunol.170.9.4833; Hua GQ, 2016, P NATL ACAD SCI USA, V113, pE635, DOI 10.1073/pnas.1522826113; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Jones CL, 2015, BLOOD, V126, P2202, DOI 10.1182/blood-2015-04-639138; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Ko M, 2004, J BIOL CHEM, V279, P21916, DOI 10.1074/jbc.M402145200; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Li LB, 2004, J ALLERGY CLIN IMMUN, V114, P1059, DOI 10.1016/j.jaci.2004.08.005; Liang QL, 2010, J IMMUNOL, V185, P5704, DOI 10.4049/jimmunol.1000690; Liu WM, 2010, MOL CELL BIOL, V30, P1783, DOI 10.1128/MCB.01003-09; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Miljkovic D, 2014, ALLERGY, V69, P1154, DOI 10.1111/all.12440; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Shan LY, 2010, J IMMUNOL, V184, P7134, DOI 10.4049/jimmunol.0902515; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Tan AHM, 2010, J IMMUNOL, V184, P1849, DOI 10.4049/jimmunol.0901509; To Y, 2010, AM J RESP CRIT CARE, V182, P897, DOI 10.1164/rccm.200906-0937OC; Verykokakis M, 2013, J IMMUNOL, V191, P5973, DOI 10.4049/jimmunol.1301521; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Wiley RE, 2004, J IMMUNOL, V172, P4995, DOI 10.4049/jimmunol.172.8.4995; Zhong J., 2012, MOL CELL PROTEOMICS, V11, DOI DOI 10.1074/MCP.M112.017764	44	154	158	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					257	+		10.1016/j.jaci.2017.03.032	http://dx.doi.org/10.1016/j.jaci.2017.03.032			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28433687	Green Accepted, Bronze			2022-12-18	WOS:000419312200031
J	Gold, MJ; Antignano, F; Halim, TYF; Hirota, JA; Blanchet, MR; Zaph, C; Takei, F; McNagny, KM				Gold, Matthew J.; Antignano, Frann; Halim, Timotheus Y. F.; Hirota, Jeremy A.; Blanchet, Marie-Renee; Zaph, Colby; Takei, Fumio; McNagny, Kelly M.			Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, T(H)2-einducing allergen exposures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate lymphocytes; allergy; asthma; house dust mite; T(H)2; IgE	HOUSE-DUST MITE; TRANSCRIPTION FACTOR GATA3; HYPERSENSITIVITY PNEUMONITIS; DENDRITIC CELLS; TYPE-2 IMMUNITY; ROR-ALPHA; ASTHMA; RESPONSES; IL-13; INFLAMMATION	Background: Allergic inflammation involves the sensitization of naive CD4(+) T cells to allergens, resulting in a T(H)2-skewed inflammatory response. Although antigen presentation by dendritic cells to T cells in the lymph node is crucial for T(H)2 cell development, the innate signals that initiate adaptive type 2 inflammation and the role of group 2 innate lymphoid cells (ILC2s) are poorly understood. Objective: We sought to investigate the influence of ILC2s and the route of priming on the development of an adaptive type 2 immune response to lung allergens. Methods: Wild-type and ILC2-deficient mice were exposed intranasally or systemically to the T(H)2-inducing antigens house dust mite or ovalbumin in a model of allergic airway inflammation or the T(H)17-inducing bacterial antigen Saccharopolyspora rectivirgula in a model of hypersensitivity pneumonitis. The formation of an adaptive immune response was evaluated based on serum antibody titers and production of T cell-derived cytokines (IL-4, IL-5, IL-13 and IL-17A). Results: We find that lung ILC2s play a critical role in priming the adaptive type 2 immune response to inhaled allergens, including the recruitment of eosinophils, T(H)2 cytokine production and serum IgE levels. Surprisingly, systemic priming with ovalbumin, with or without adjuvants, circumvents the requirement for ILC2s in inducing T(H)2-driven lung inflammation. ILC2s were also found to be dispensable for the sensitization to T(H)1-or T(H)17-inducing antigens. Conclusion: These data highlight a critical role for ILC2s in the development of adaptive type 2 responses to local, but not systemic, antigen exposure.	[Gold, Matthew J.; Antignano, Frann; Zaph, Colby; McNagny, Kelly M.] Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; [Zaph, Colby] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Halim, Timotheus Y. F.; Takei, Fumio] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; [Hirota, Jeremy A.] St Pauls Hosp, UBC James Hogg Res Ctr, Vancouver, BC V6Z 1Y6, Canada; [Blanchet, Marie-Renee] Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada	University of British Columbia; University of British Columbia; British Columbia Cancer Agency; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; Laval University	McNagny, KM (corresponding author), Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	kelly@brc.ubc.ca	McNagny, Kelly/P-5239-2014; Halim, Timotheus/B-3117-2018	McNagny, Kelly/0000-0003-4737-3499; Halim, Timotheus/0000-0001-9773-0023; Zaph, Colby/0000-0002-9889-9848; Antignano, Frann/0000-0003-0502-5330; Takei, Fumio/0000-0002-3620-5046	AllerGen Network Centre of Excellence; Canadian Institute of Health Research [MOP-84545, MOP-106623]; AllerGen CAIDATI; CIHR/Canadian Association of Gastroenterology/Crohn's and Colitis Foundation of Canada; Canadian Institute of Health Research	AllerGen Network Centre of Excellence; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); AllerGen CAIDATI; CIHR/Canadian Association of Gastroenterology/Crohn's and Colitis Foundation of Canada(Canadian Institutes of Health Research (CIHR)); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	Supported by the AllerGen Network Centre of Excellence (K. M. M.) and the Canadian Institute of Health Research (K. M. M. MOP-84545, C.Z. MOP-106623 and F. T.). M.J.G. is the recipient of an AllerGen CAIDATI training award, F. A. is supported by a CIHR/Canadian Association of Gastroenterology/Crohn's and Colitis Foundation of Canada postdoctoral fellowship, and T.Y.F.H. is supported by a Canadian Institute of Health Research-Banting and Best Studentship and Banting Postdoctoral Fellowship. C.Z. is a Michael Smith Foundation for Health Research Career Investigator. K. M. M. is a Michael Smith Foundation for Health Research Senior Scholar.	Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Blanchet MR, 2011, AM J RESP CRIT CARE, V184, P687, DOI 10.1164/rccm.201011-1764OC; Collison A, 2011, J ALLERGY CLIN IMMUN, V128, P160, DOI 10.1016/j.jaci.2011.04.005; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gibson PG, 2007, J ALLERGY CLIN IMMUN, V119, P344, DOI 10.1016/j.jaci.2006.10.043; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Holgate ST, 2011, J ALLERGY CLIN IMMUN, V128, P495, DOI 10.1016/j.jaci.2011.06.052; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Joshi AD, 2009, AM J RESP CRIT CARE, V179, P705, DOI 10.1164/rccm.200811-1700OC; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Post S, 2012, THORAX, V67, P488, DOI 10.1136/thoraxjnl-2011-200606; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Simonian PL, 2009, J IMMUNOL, V182, P657, DOI 10.4049/jimmunol.182.1.657; Spooner CJ, 2013, NAT IMMUNOL, V14, P1229, DOI 10.1038/ni.2743; Webb DC, 2007, J IMMUNOL, V178, P219, DOI 10.4049/jimmunol.178.1.219; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Yang D, 2008, J EXP MED, V205, P79, DOI 10.1084/jem.20062027; Yang Q, 2013, IMMUNITY, V38, P694, DOI 10.1016/j.immuni.2012.12.003; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016	30	154	162	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1142	+		10.1016/j.jaci.2014.02.033	http://dx.doi.org/10.1016/j.jaci.2014.02.033			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24679471				2022-12-18	WOS:000333531700026
J	Salo, PM; Calatroni, A; Gergen, PJ; Hoppin, JA; Sever, ML; Jaramillo, R; Arbes, SJ; Zeldin, DC				Salo, Paeivi M.; Calatroni, Agustin; Gergen, Peter J.; Hoppin, Jane A.; Sever, Michelle L.; Jaramillo, Renee; Arbes, Samuel J., Jr.; Zeldin, Darryl C.			Allergy-related outcomes in relation to serum IgE: Results from the National Health and Nutrition Examination Survey 2005-2006	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; allergy; allergic sensitization; serum IgE	INHALANT ALLERGENS; RISK-FACTORS; DUST-MITE; SKIN-TEST; US HOMES; RHINITIS; PREVALENCE; SENSITIZATION; POPULATION; REACTIVITY	Background: The National Health and Nutrition Examination Survey (NHANES) 2005-2006 was the first population-based study to investigate levels of serum total and allergen-specific IgE in the general US population. Objective: We estimated the prevalence of allergy-related outcomes and examined relationships between serum IgE levels and these outcomes in a representative sample of the US population. Methods: Data for this cross-sectional analysis were obtained from NHANES 2005-2006. Study subjects aged 6 years and older (n = 8086) had blood taken for measurement of total IgE and 19 specific IgE levels against common aeroallergens, including Alternaria alternata, Aspergillus fumigatus, Bermuda grass, birch, oak, ragweed, Russian thistle, rye grass, cat dander, cockroach, dog dander, dust mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus), mouse and rat urine proteins, and selected foods (egg white, cow's milk, peanut, and shrimp). Serum samples were analyzed for total and allergen-specific IgE by using the Pharmacia CAP System. Information on allergy-related outcomes and demographics was collected by questionnaire. Results: In NHANES 2005-2006, 6.6% reported current hay fever, and 23.5% had current allergies. Allergy-related outcomes increased with increasing total IgE levels (adjusted odds ratios for a 10-fold increase in total IgE level of 1.86 [95% CI, 1.44-2.41] for hay fever and 1.64 [ 95% CI, 1.41-1.91] for allergies). Increased levels of plant-, pet-, and mold-specific IgE contributed independently to allergy-related symptoms. The greatest increase in odds was observed for hay fever and plant-specific IgE (adjusted odds ratio, 4.75; 95% CI, 3.83-5.88). Conclusion: In the US population self-reported allergy symptoms are most consistently associated with increased levels of plant-, pet-, and mold-specific IgE. (J Allergy Clin Immunol 2011;127:1226-35.)	[Salo, Paeivi M.; Hoppin, Jane A.; Sever, Michelle L.; Zeldin, Darryl C.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA; [Calatroni, Agustin; Arbes, Samuel J., Jr.] Rho Inc, Chapel Hill, NC USA; [Gergen, Peter J.] NIAID, NIH, Bethesda, MD 20892 USA; [Jaramillo, Renee] SRA Int Inc, Durham, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Rho; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); SRA International	Zeldin, DC (corresponding author), NIEHS, NIH, 111 TW Alexander Dr,Room A222, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Sever, Michelle/0000-0002-2435-1214; Hoppin, Jane/0000-0001-8456-0969	National Institutes of Health, National Institute of Environmental Health Sciences; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025041, ZIAES025041] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences.	Ahlstedt Staffan, 2006, Prim Care Respir J, V15, P228, DOI 10.1016/j.pcrj.2006.05.004; [Anonymous], 2010, NCHS RES ETH REV BOA; [Anonymous], 2008, LAB PROC MAN NHANES; Anto JM, 2010, ALLERGY, V65, P1021, DOI 10.1111/j.1398-9995.2009.02301.x; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Bellanti JA, 2000, ALLERGY ASTHMA PROC, V21, P367, DOI 10.2500/108854100778249088; Bloom Barbara, 2006, Vital Health Stat 10, P1; Bloom Barbara, 2007, Vital Health Stat 10, P1; Burney P, 2010, ALLERGY, V65, P1182, DOI 10.1111/j.1398-9995.2010.02346.x; Bush RK, 2006, J ALLERGY CLIN IMMUN, V117, P326, DOI 10.1016/j.jaci.2005.12.001; Calabria CW, 2009, ALLERGY ASTHMA PROC, V30, P386, DOI 10.2500/aap.2009.30.3258; Calatroni A, 2009, J ALLERGY CLIN IMMUN, V123, pS193, DOI 10.1016/j.jaci.2008.12.732; Callahan KA, 2003, ANN ALLERG ASTHMA IM, V90, P302, DOI 10.1016/S1081-1206(10)61798-X; Crown WH, 2003, VALUE HEALTH, V6, P448, DOI 10.1046/j.1524-4733.2003.64231.x; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Gergen PJ, 2009, J ALLERGY CLIN IMMUN, V124, P447, DOI 10.1016/j.jaci.2009.06.011; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gergen PJ, 2001, J ALLERGY CLIN IMMUN, V107, pS445, DOI 10.1067/mai.2001.114992; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P271, DOI 10.2500/108854198778557728; Heinzerling LM, 2009, ALLERGY, V64, P1498, DOI 10.1111/j.1398-9995.2009.02093.x; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, pe13; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Marinho S, 2007, ALLERGY, V62, P1379, DOI 10.1111/j.1398-9995.2007.01502.x; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Nathan RA, 2008, ALLERGY ASTHMA PROC, V29, P600, DOI 10.2500/aap.2008.29.3179; National Center for Health Statistics, 2005, PUBL DAT GEN REL FIL; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; Phipatanakul W, 2005, IMMUNOL ALLERGY CLIN, V25, P263, DOI 10.1016/j.iac.2005.03.001; Pleis John R, 2006, Vital Health Stat 10, P1; Pleis John R, 2007, Vital Health Stat 10, P1; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, pe7; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Ryan D, 2008, ALLERGY, V63, P981, DOI 10.1111/j.1398-9995.2008.01653.x; Salo PM, 2008, J ALLERGY CLIN IMMUN, V121, pS231, DOI 10.1016/j.jaci.2007.12.915; Scala E, 2010, CLIN EXP ALLERGY, V40, P911, DOI 10.1111/j.1365-2222.2010.03470.x; Settipane RA, 2003, ALLERGY ASTHMA PROC, V24, P147; Settipane RA, 2001, ALLERGY ASTHMA PROC, V22, P185; Sinclair D, 2004, J CLIN PATHOL, V57, P956, DOI 10.1136/jcp.2004.017681; Soeria-Atmadja D, 2007, J ALLERGY CLIN IMMUN, V120, P1433, DOI 10.1016/j.jaci.2007.07.021; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3	47	154	160	0	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1226	U527		10.1016/j.jaci.2010.12.1106	http://dx.doi.org/10.1016/j.jaci.2010.12.1106			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21320720	Green Accepted			2022-12-18	WOS:000290018600018
J	Carroll, KN; Wu, PS; Gebretsadik, T; Griffin, MR; Dupont, WD; Mitchel, EF; Hartert, TV				Carroll, Kecia N.; Wu, Pingsheng; Gebretsadik, Tebeb; Griffin, Marie R.; Dupont, William D.; Mitchel, Edward F.; Hartert, Tina V.			The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchiolitis; asthma	RESPIRATORY-SYNCYTIAL-VIRUS; PREGNANT-WOMEN; EARLY-LIFE; RHINOVIRUS ILLNESSES; TRACT ILLNESS; BIRTH COHORT; 1ST YEAR; AGE 13; CHILDREN; ALLERGY	Background: Infants hospitalized for bronchiolitis have a high rate of early childhood asthma. It is not known whether bronchiolitis severity correlates with the risk of early childhood asthma or with asthma-specific morbidity. Objectives: We sought to determine whether a dose-response relationship exists between severity of infant bronchiolitis and both the odds of early childhood asthma and asthma-specific morbidity. Methods: We conducted a population-based retrospective birth cohort study of term healthy infants born from 1995-2000 and enrolled in a statewide Medicaid program. We defined bronchiolitis severity by categorizing infants into mutually exclusive groups based on the most advanced level of health care for bronchiolitis. Health care visits, asthma-specific medications, and demographics were identified entirely from Medicaid and linked vital records files. Asthma was ascertained at between 4 and 5.5 years of age, and 1-year asthma morbidity (hospitalization, emergency department visit, or oral corticosteroid course) was determined between 4.5 and 5.5 years among children with prevalent asthma. Results: Among 90,341 children, 18% had an infant bronchiolitis visit, and these infants contributed to 31% of early childhood asthma diagnoses. Relative to children with no infant bronchiolitis visit, the adjusted odds ratios for asthma were 1.86 (95% CI, 1.74-1.99), 2.41 (95% CI, 2.21-2.62), and 2.82 (95% CI, 2.61-3.03) in the outpatient, emergency department, and hospitalization groups, respectively. Children hospitalized with bronchiolitis during infancy had increased early childhood asthma morbidity compared with that seen in children with no bronchiolitis visit. Conclusion: To our knowledge, this is the first study to demonstrate the dose-response relationship between the severity of infant bronchiolitis and the increased odds of both early childhood asthma and asthma-specific morbidity. (J Allergy Clin Immunol 2009;123:1055-61.)	[Hartert, Tina V.] Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Ctr Hlth Serv Res, Sch Med,Dept Med, Nashville, TN 37232 USA; [Carroll, Kecia N.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; [Griffin, Marie R.; Dupont, William D.; Mitchel, Edward F.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; [Wu, Pingsheng; Gebretsadik, Tebeb; Dupont, William D.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Carroll, Kecia N.] Vanderbilt Univ, Sch Med, Div Gen Pediat, Nashville, TN 37232 USA; [Griffin, Marie R.] Vanderbilt Univ, Sch Med, Div Gen Internal Med, Nashville, TN 37232 USA; [Griffin, Marie R.] Vanderbilt Univ, Sch Med, Ctr Educ & Res Therapeut, Nashville, TN 37232 USA; [Griffin, Marie R.] Tennessee Valley HealthCare Syst, Vet Affairs, Mid S Geriatr Res Educ & Clin Ctr, Nashville, TN USA; [Griffin, Marie R.] Tennessee Valley HealthCare Syst, Vet Affairs, Clin Res Ctr Excellence, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Hartert, TV (corresponding author), Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Ctr Hlth Serv Res, Sch Med,Dept Med, 6107 MCE, Nashville, TN 37232 USA.	tina.hartert@vanderbilt.edu	Dupont, William D./I-4430-2012		NIH [U01 HL 072471, KO1 AI070808, K24 AI 077930, F32 HL 086048]; Thrasher Research Fund; Parker B. Francis Research Foundation; National Institutes of Health/National Institute of Allergy and Infectious Diseases; MedImmune; Pfizer; Center for Disease Control and Prevention; Agency for Healthcare Research and Quality; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072471, F32HL086048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI070808, K24AI077930] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Thrasher Research Fund; Parker B. Francis Research Foundation; National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MedImmune(AstraZenecaMedimmune); Pfizer(Pfizer); Center for Disease Control and Prevention; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by NIH U01 HL 072471 (T.V.H.), the Thrasher Research Fund ;(T.V.H.). NIH KO1 AI070808 (K.N.C.), NIH K24 AI 077930 (T.V.H.), NIH F32 HL 086048 (P.W., T.V.H.). and the Parker B. Francis Research Foundation (K.N.C.).; Disclosure of potential conflict of interest: K. N. Carroll has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases and the Parker B. Francis Foundation, P. Wu has received research support from the National Institutes of Health and the Thrasher Research Fund. T. Gebretsadik has received research support from the National Institutes of Health/National Institute of Allergy and Infections Diseases, M. R. Griffin has received research support from MedImmune, Pfizer, the Center for Disease Control and Prevention, and the Agency for Healthcare Research and Quality. T V. Hartert has served as a speaker for and on the Advisory Board for Merck and has received research support from the National Institutes of Health and the Thrasher Research Fund. The rest of the authors have declared that they have no conflict of interest.	Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Bradley JP, 2005, PEDIATRICS, V115, pE7, DOI 10.1542/peds.2004-0059; Carroll KN, 2008, PEDIATRICS, V122, P58, DOI 10.1542/peds.2007-2087; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Dombkowski KJ, 2008, ANN EPIDEMIOL, V18, P290, DOI 10.1016/j.annepidem.2007.11.012; DUPONT WD, 2002, STAT MODELING BIOMED, P143; Fjaerli Hans-Olav, 2005, BMC Pediatr, V5, P31, DOI 10.1186/1471-2431-5-31; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Hartert TV, 2003, AM J OBSTET GYNECOL, V189, P1705, DOI 10.1016/S0002-9378(03)00857-3; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Koraka P, 2003, J MED VIROL, V70, P91, DOI 10.1002/jmv.10358; Kotaniemi-Syrjanen A, 2005, ACTA PAEDIATR, V94, P159, DOI 10.1080/08035250410025069; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Legg JP, 2003, AM J RESP CRIT CARE, V168, P633, DOI 10.1164/rccm.200210-1148OC; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; Moore YF, 2004, IMMUNOGENETICS, V56, P1, DOI 10.1007/s00251-004-0661-6; MURRAY M, 1992, ARCH DIS CHILD, V67, P482, DOI 10.1136/adc.67.4.482; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; Noble V, 1997, ARCH DIS CHILD, V76, P315, DOI 10.1136/adc.76.4.315; Openshaw PJM, 2004, J ALLERGY CLIN IMMUN, V114, P1275, DOI 10.1016/j.jaci.2004.08.024; Piippo-Savolainen E, 2004, ARCH PEDIAT ADOL MED, V158, P1070, DOI 10.1001/archpedi.158.11.1070; PIPER JM, 1990, AM J EPIDEMIOL, V132, P561, DOI 10.1093/oxfordjournals.aje.a115692; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Schanzer DL, 2006, PEDIATR INFECT DIS J, V25, P795, DOI 10.1097/01.inf.0000232632.86800.8c; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; van Schaik SM, 1999, J ALLERGY CLIN IMMUN, V103, P630, DOI 10.1016/S0091-6749(99)70235-6; Wakefield DB, 2006, PEDIATR PULM, V41, P962, DOI 10.1002/ppul.20476; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243	42	154	161	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1055	1061		10.1016/j.jaci.2009.02.021	http://dx.doi.org/10.1016/j.jaci.2009.02.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19361850	Green Accepted			2022-12-18	WOS:000266309400011
J	Nizet, V				Nizet, Victor			Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Staphylococcus aureus; group A Streptococcus; innate immunity; virulence factors; antimicrobial peptides; complement; phagocytosis; neutrophil; macrophage	GROUP-A STREPTOCOCCUS; PANTON-VALENTINE LEUKOCIDIN; ANTIMICROBIAL PEPTIDE PROTECTS; NEUTROPHIL EXTRACELLULAR TRAPS; STAPHYLOCOCCUS-AUREUS; CLUMPING FACTOR; STREPTOLYSIN-S; CAPSULAR POLYSACCHARIDE; COMPLEMENT ACTIVATION; HYPERVARIABLE REGION	Staphylococcus aureus (SA) and group A Streptococcus (GAS) are prominent Gram-positive bacterial pathogens, each associated with a variety of mucosal and invasive human infections. SA and GAS systemic disease reflects diverse abilities of these pathogens to resist clearance by the multifaceted defenses of the human innate immune system. Here we review how SA and GAS avoid the bactericidal activities of cationic antimicrobial peptides, delay phagocyte recruitment, escape neutrophil extracellular traps, inhibit complement and antibody opsonization functions, impair phagocytotic uptake, resist oxidative burst killing, and promote phagocyte lysis or apoptosis. Understanding the molecular basis of SA and GAS innate immune resistance reveals novel therapeutic targets for treatment or prevention of invasive human infections. These future therapies envision alternatives to direct microbial killing, such as blocking disease progression by neutralizing specific virulence factors or boosting key innate immune defenses.	Univ Calif San Diego, Sch Med, Div Pediat Pharmacol & Durg Discovery, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Nizet, V (corresponding author), Univ Calif San Diego, Sch Med, Div Pediat Pharmacol & Durg Discovery, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr,Mail Code 0687, La Jolla, CA 92093 USA.	vnizet@ucsd.edu	Nizet, Victor/AAF-3190-2019	Nizet, Victor/0000-0003-3847-0422	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048176, R01AI048694, R01AI060840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052728] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48176, AI48694, AI60840] Funding Source: Medline; NIAMS NIH HHS [AR52728] Funding Source: Medline; NICHD NIH HHS [HD51706] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agniswamy J, 2004, J BIOL CHEM, V279, P52789, DOI 10.1074/jbc.M410698200; Akesson P, 2006, INFECT IMMUN, V74, P497, DOI 10.1128/IAI.74.1.497-503.2006; ANDERSEN BR, 1980, J INFECT DIS, V141, P680, DOI 10.1093/infdis/141.5.680; Aziz RK, 2004, MOL MICROBIOL, V54, P184, DOI 10.1111/j.1365-2958.2004.04255.x; Bader MW, 2003, MOL MICROBIOL, V50, P219, DOI 10.1046/j.1365-2958.2003.03675.x; Bauer S, 2004, J LEUKOCYTE BIOL, V76, P1142, DOI 10.1189/jlb.0404260; Berge A, 1997, J BIOL CHEM, V272, P20774, DOI 10.1074/jbc.272.33.20774; Berggard K, 2001, MOL MICROBIOL, V42, P539, DOI 10.1046/j.1365-2958.2001.02664.x; Bisno AL, 2005, CLIN INFECT DIS, V41, P1150, DOI 10.1086/444505; Brenot A, 2004, INFECT IMMUN, V72, P408, DOI 10.1128/IAI.72.1.408-413.2004; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brouillette E, 2002, VACCINE, V20, P2348, DOI 10.1016/S0264-410X(02)00100-7; Buchanan JT, 2006, CURR BIOL, V16, P396, DOI 10.1016/j.cub.2005.12.039; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carlsson F, 2003, J EXP MED, V198, P1057, DOI 10.1084/jem.20030543; Cho JH, 2005, BLOOD, V106, P2551, DOI 10.1182/blood-2005-02-0530; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Clauditz A, 2006, INFECT IMMUN, V74, P4950, DOI 10.1128/IAI.00204-06; CLEARY PP, 1992, INFECT IMMUN, V60, P5219, DOI 10.1128/IAI.60.12.5219-5223.1992; Cole JN, 2006, FASEB J, V20, P1745, DOI 10.1096/fj.06-5804fje; Collin M, 2002, INFECT IMMUN, V70, P6646, DOI 10.1128/IAI.70.12.6646-6651.2002; Collin M, 2001, INFECT IMMUN, V69, P7187, DOI 10.1128/IAI.69.11.7187-7189.2001; Collins LV, 2002, J INFECT DIS, V186, P214, DOI 10.1086/341454; Courtney HS, 2006, MOL MICROBIOL, V59, P936, DOI 10.1111/j.1365-2958.2005.04977.x; Cunnion KM, 2005, J LAB CLIN MED, V146, P279, DOI 10.1016/j.lab.2005.07.001; Dale JB, 1996, INFECT IMMUN, V64, P1495, DOI 10.1128/IAI.64.5.1495-1501.1996; Datta V, 2005, MOL MICROBIOL, V56, P681, DOI 10.1111/j.1365-2958.2005.04583.x; DeMaster E, 2002, INFECT IMMUN, V70, P350, DOI 10.1128/IAI.70.1.350-359.2002; DiVietro JA, 2001, J IMMUNOL, V167, P4017, DOI 10.4049/jimmunol.167.7.4017; Edwards RJ, 2005, J INFECT DIS, V192, P783, DOI 10.1086/432485; Fernie-King BA, 2004, IMMUNOLOGY, V111, P444, DOI 10.1111/j.0019-2805.2004.01837.x; Fontaine MC, 2003, INFECT IMMUN, V71, P3857, DOI 10.1128/IAI.71.7.3857-3865.2003; Foster TJ, 2005, NAT REV MICROBIOL, V3, P948, DOI 10.1038/nrmicro1289; Ganz T, 2001, J EXP MED, V193, pF31, DOI 10.1084/jem.193.9.F31; Giacometti A, 2004, CRIT CARE MED, V32, P2485, DOI 10.1097/01.CCM.0000148221.09704.22; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Gresham HD, 2000, J IMMUNOL, V164, P3713, DOI 10.4049/jimmunol.164.7.3713; Haggar A, 2004, INFECT IMMUN, V72, P6164, DOI 10.1128/IAI.72.10.6164-6167.2004; Hakansson A, 2005, P NATL ACAD SCI USA, V102, P5192, DOI 10.1073/pnas.0408721102; Hammel M, 2007, NAT IMMUNOL, V8, P430, DOI 10.1038/ni1450; Hidalgo-Grass C, 2004, LANCET, V363, P696, DOI 10.1016/S0140-6736(04)15643-2; Hidalgo-Grass C, 2006, EMBO J, V25, P4628, DOI 10.1038/sj.emboj.7601327; Higgins J, 2006, FEMS MICROBIOL LETT, V258, P290, DOI 10.1111/j.1574-6968.2006.00229.x; JACKSWEIS J, 1982, J IMMUNOL, V128, P1897; Jin T, 2004, J IMMUNOL, V172, P1169, DOI 10.4049/jimmunol.172.2.1169; Johnsson E, 1998, J IMMUNOL, V161, P4894; Jones RN, 2003, SEMIN RESP CRIT CARE, V24, P121, DOI 10.1055/s-2003-37923; Kaneko J, 2004, BIOSCI BIOTECH BIOCH, V68, P981, DOI 10.1271/bbb.68.981; Karavolos MH, 2003, MICROBIOL-SGM, V149, P2749, DOI 10.1099/mic.0.26353-0; Kobayashi SD, 2003, P NATL ACAD SCI USA, V100, P10948, DOI 10.1073/pnas.1833375100; Kristian SA, 2005, J BACTERIOL, V187, P6719, DOI 10.1128/JB.187.19.6719-6725.2005; Kropec A, 2005, INFECT IMMUN, V73, P6868, DOI 10.1128/IAI.73.10.6868-6876.2005; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; Kupferwasser LI, 2003, J CLIN INVEST, V112, P222, DOI 10.1172/JCI200316876; Labandeira-Rey M, 2007, SCIENCE, V315, P1130, DOI 10.1126/science.1137165; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; Lei BF, 2001, NAT MED, V7, P1298, DOI 10.1038/nm1201-1298; Limbago B, 2000, INFECT IMMUN, V68, P6384, DOI 10.1128/IAI.68.11.6384-6390.2000; Liu GY, 2005, J EXP MED, V202, P209, DOI 10.1084/jem.20050846; Luong TT, 2002, INFECT IMMUN, V70, P3389, DOI 10.1128/IAI.70.7.3389-3395.2002; MANDELL GL, 1975, J CLIN INVEST, V55, P561, DOI 10.1172/JCI107963; Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218; McCaig LF, 2006, EMERG INFECT DIS, V12, P1715, DOI 10.3201/eid1211.060190; Medina E, 1999, J IMMUNOL, V163, P3396; Medina E, 2003, J INFECT DIS, V187, P597, DOI 10.1086/373998; Medina E, 2003, INFECT IMMUN, V71, P5376, DOI 10.1128/IAI.71.9.5376-5380.2003; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Miyoshi-Akiyama T, 2005, J INFECT DIS, V192, P107, DOI 10.1086/430617; Morfeldt E, 2001, J IMMUNOL, V167, P3870, DOI 10.4049/jimmunol.167.7.3870; Morrison G, 2002, INFECT IMMUN, V70, P3053, DOI 10.1128/IAI.70.6.3053-3060.2002; Moses AE, 1997, INFECT IMMUN, V65, P64, DOI 10.1128/IAI.65.1.64-71.1997; Nakagawa I, 2004, CELL MICROBIOL, V6, P939, DOI 10.1111/j.1462-5822.2004.00412.x; Nishi H, 2004, ANTIMICROB AGENTS CH, V48, P4800, DOI 10.1128/AAC.48.12.4800-4807.2004; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Nyberg P, 2004, J BIOL CHEM, V279, P52820, DOI 10.1074/jbc.C400485200; O'Riordan K, 2004, CLIN MICROBIOL REV, V17, P218, DOI 10.1128/CMR.17.1.218-234.2004; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Palmqvist N, 2002, MICROB PATHOGENESIS, V33, P239, DOI 10.1006/mpat.2002.0533; Palmqvist N, 2004, MICROBES INFECT, V6, P188, DOI 10.1016/j.micinf.2003.11.005; Pandiripally V, 2002, INFECT IMMUN, V70, P6206, DOI 10.1128/IAI.70.11.6206-6214.2002; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI23865; Postma B, 2004, J IMMUNOL, V172, P6994, DOI 10.4049/jimmunol.172.11.6994; Projan SJ, 2006, CURR OPIN PHARMACOL, V6, P473, DOI 10.1016/j.coph.2006.04.005; PROKESOVA L, 1992, IMMUNOL LETT, V31, P259, DOI 10.1016/0165-2478(92)90124-7; Rooijakkers SHM, 2005, NAT IMMUNOL, V6, P920, DOI 10.1038/ni1235; Rooijakkers SHM, 2005, MICROBES INFECT, V7, P476, DOI 10.1016/j.micinf.2004.12.014; Sandin C, 2006, MOL MICROBIOL, V59, P20, DOI 10.1111/j.1365-2958.2005.04913.x; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Schauber J, 2006, IMMUNOLOGY, V118, P509, DOI 10.1111/j.1365-2567.2006.02399.x; Scott MG, 2007, NAT BIOTECHNOL, V25, P465, DOI 10.1038/nbt1288; Sieprawska-Lupa M, 2004, ANTIMICROB AGENTS CH, V48, P4673, DOI 10.1128/AAC.48.12.4673-4679.2004; Sierig G, 2003, INFECT IMMUN, V71, P446, DOI 10.1128/IAI.71.1.446-455.2003; SPENCER RC, 1995, EUR J CLIN MICROBIOL, V14, pS26; Staali L, 2006, CELL MICROBIOL, V8, P690, DOI 10.1111/j.1462-5822.2005.00662.x; Staubitz P, 2004, FEMS MICROBIOL LETT, V231, P67, DOI 10.1016/S0378-1097(03)00921-2; STERNBERG L, 1992, MOL MICROBIOL, V6, P1185; Sumby P, 2005, P NATL ACAD SCI USA, V102, P1679, DOI 10.1073/pnas.0406641102; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Terao Y, 2006, J BIOL CHEM, V281, P14215, DOI 10.1074/jbc.M513408200; Thakker M, 1998, INFECT IMMUN, V66, P5183, DOI 10.1128/IAI.66.11.5183-5189.1998; THEM A, 1995, J IMMUNOL, V154, P375; *THER NRCCONDITSOA, 2006, TREAT INF DIS MICR W; Tsai PJ, 1999, INFECT IMMUN, V67, P4334, DOI 10.1128/IAI.67.9.4334-4339.1999; Voyich JM, 2006, J INFECT DIS, V194, P1761, DOI 10.1086/509506; Weidenmaier C, 2005, INFECT IMMUN, V73, P8033, DOI 10.1128/IAI.73.12.8033-8038.2005; Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3	108	154	165	2	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					13	22		10.1016/j.jaci.2007.06.005	http://dx.doi.org/10.1016/j.jaci.2007.06.005			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17606031				2022-12-18	WOS:000248066400002
J	Mihrshahi, S; Peat, JK; Marks, GB; Mellis, CM; Tovey, ER; Webb, K; Britton, WJ; Leeder, SR				Mihrshahi, S; Peat, JK; Marks, GB; Mellis, CM; Tovey, ER; Webb, K; Britton, WJ; Leeder, SR		CAPS Team	Eighteen-month outcomes of house dust mite avoidance and dietary fatty acid modification in the Childhood Asthma Prevention Study (CAPS)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen avoidance; asthma; atopy; fatty acids; house dust mite; primary prevention	RANDOMIZED TRIAL; EARLY-LIFE; PREGNANCY; INFANCY	Background: Observational studies have linked house dust mite (HDM) exposure and dietary fatty acid intake with asthma in childhood. However, definitive evidence of their role in the etiology of asthma requires a randomized controlled trial. Objective: We hypothesized that the incidence of asthma and allergy in high-risk children would be reduced by avoidance of HDM allergens, supplementation with omega-3 fatty acids, or the combination of these strategies. We present the results of an interim analysis reporting outcomes assessed at 18 months. Methods: A total of 616 pregnant women were randomized to an HDM avoidance intervention, comprising the use of impermeable mattress covers and an acaricide or control and the use of an oil supplement, margarines, and cooking oils containing high levels of omega-3 fatty acids or control. Atopic status was measured by skin prick testing. Symptoms, diagnoses, and medication histories were elicited by means of parental interviews. Results: The diet intervention resulted in a 9.8% absolute reduction (95% CI, 1.5-18.1; P =.02) in the prevalence of any wheeze and a 7.8% absolute reduction (95% CI, 0.5-15.1, P =.04) in prevalence of wheeze of >1 week, but it had no effect on serum IgE, atopy, or doctors' diagnosis of asthma. The HDM avoidance intervention did not affect these outcomes but was associated with a lower use of oral steroids. Conclusion: Increasing dietary omega-3 fatty acids might have a beneficial effect on the prevalence of wheeze during the first 18 months of life. Follow-up to age 5 years, when the effect of the interventions on asthma risk will be assessed, is underway.	Childrens Hosp, Clin Epidemiol Unit, Westmead, NSW 2145, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Univ Sydney, Centenary Inst Canc Med & Cell Biol, Sydney, NSW 2006, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Cooperat Res Ctr Asthma, Camperdown, NSW, Australia; Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia; Univ Sydney, Dept Child Hlth & Paediat, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; Centenary Institute; University of Sydney; University of Sydney; Woolcock Institute of Medical Research; University of Sydney	Mihrshahi, S (corresponding author), Childrens Hosp, Clin Epidemiol Unit, Locked Bag 4001, Westmead, NSW 2145, Australia.		Tovey, Euan R/G-8604-2017; Marks, Guy B./F-5058-2013; Mihrshahi, Seema/A-9877-2009; Mihrshahi, Seema/AAW-1854-2020	Tovey, Euan R/0000-0002-1802-7266; Marks, Guy B./0000-0002-8976-8053; Mihrshahi, Seema/0000-0001-6567-9884; Mihrshahi, Seema/0000-0002-2394-5432; Britton, Warwick/0000-0001-6721-9646				ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mihrshahi S, 2002, RESPIROLOGY, V7, P147, DOI 10.1046/j.1440-1843.2002.00384.x; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; MIHRSHAHI S, 2003, IN PRESS ALLERGY; PEAT JK, 1992, EUR RESPIR J, V5, P921; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x	16	154	165	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					162	168		10.1067/mai.2003.36	http://dx.doi.org/10.1067/mai.2003.36			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532113	Bronze			2022-12-18	WOS:000180465500025
J	Holzer, K; Anderson, SD; Douglass, J				Holzer, K; Anderson, SD; Douglass, J			Exercise in elite summer athletes: Challenges for diagnosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eucapnic hyperpnea; elite athletes; methacholine challenge	EUCAPNIC VOLUNTARY HYPERVENTILATION; INDUCED ASTHMA; BRONCHIAL RESPONSIVENESS; INDUCED BRONCHOSPASM; HYPERTONIC SALINE; REACTIVITY; CHILDREN; METHACHOLINE; PROVOCATION; SALBUTAMOL	Background: There is a high prevalence of asthma and exercise-induced bronchoconstriction (EIB) in elite athletes when the diagnosis is based on symptoms and medication use. Objective measurements are now required by some sporting bodies to support a diagnosis of asthma or EIB to justify use of beta-agonists. Such measurements could include bronchial provocation with methacholine, with eucapnic voluntary hyperpnea (EVH) of dry air (a surrogate for exercise), or both. Objective: The aim of the study was to investigate the relationship between asthma symptoms and responses to methacholine and the EVH challenge in a group of unselected elite summer-sport athletes. The outcome would be to inform practitioners of a suitable objective approach to identifying those with asthma and EIB. Methods: Fifty elite summer-sport athletes with or without asthma were recruited from sporting teams and sports medicine centers throughout Melbourne, Australia. All subjects completed a respiratory questionnaire and, on separate days, underwent a bronchoprovocation challenge test with methacholine and EVH. Results: Forty-two subjects reported one or more respiratory symptoms in the past year, 9 had positive methacholine challenge results (mean PD20 of 1.69 +/- 2.05 mumol), and 25 had posit e EVH challenge results (mean fall in FEV1 of 25.4% +/- 15%). Although all subjects with positive methacholine challenge results had positive EVH challenge results, methacholine had a negative predictive value of only 61% and a sensitivity of 36% for identifying those responsive to EVH. Conclusion: These findings suggest that the pathogenesis of EIB in elite athletes might be different from that of asthma, and as such, neither symptoms nor the methacholine challenge test should be used exclusively for identifying EIB.	Alfred Hosp, Dept Allergy Asthma & Clin Immunol, Prahran, Vic 3181, Australia; Monash Univ, Prahran, Vic, Australia; Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; University of Sydney	Holzer, K (corresponding author), Alfred Hosp, Dept Allergy Asthma & Clin Immunol, Prahran, Vic 3181, Australia.			Douglass, Jo/0000-0002-1200-8048; Anderson, Sandra/0000-0002-6308-8770				ABRAMSON MJ, 1990, THORAX, V45, P924, DOI 10.1136/thx.45.12.924; Anderson SD, 2001, MED SCI SPORT EXER, V33, P893, DOI 10.1097/00005768-200106000-00007; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; ARGYROS GJ, 1995, CHEST, V108, P419, DOI 10.1378/chest.108.2.419; BACKER V, 1992, CLIN EXP ALLERGY, V22, P741, DOI 10.1111/j.1365-2222.1992.tb02813.x; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120, DOI 10.1164/ajrccm.158.4.9802087; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; ELIASSON AH, 1992, CHEST, V102, P347, DOI 10.1378/chest.102.2.347; Eliasson AH, 1999, CHEST, V115, P608, DOI 10.1378/chest.115.3.608; GRAVETTER FJ, 2000, STAT BEHAV SCI; HABY MM, 1995, EUR RESPIR J, V8, P729; HURWITZ KM, 1995, CHEST, V108, P1240, DOI 10.1378/chest.108.5.1240; *INT OL MED COMM, 2002, BER 2 ADR AG OL WINT; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; PHILLIPS YY, 1985, AM REV RESPIR DIS, V131, P31; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RICE SG, 1985, ANN ALLERGY, V55, P790; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632, DOI 10.1164/ajrccm.150.6.7952626; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; RUPP NT, 1992, AM J DIS CHILD, V146, P941, DOI 10.1001/archpedi.1992.02160200063028; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SMITH CM, 1990, EUR RESPIR J, V3, P144; SMITH CM, 1989, EUR RESPIR J, V2, P36; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P369; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; van Baak MA, 2000, MED SCI SPORT EXER, V32, P1300, DOI 10.1097/00005768-200007000-00018; van Grunsven PM, 1999, THORAX, V54, P316, DOI 10.1136/thx.54.4.316; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	35	154	160	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					374	380		10.1067/mai.2002.127784	http://dx.doi.org/10.1067/mai.2002.127784			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209082				2022-12-18	WOS:000177936900005
J	Trautmann, A; Schmid-Grendelmeier, P; Kruger, K; Crameri, R; Akdis, M; Akkaya, A; Brocker, EB; Blaser, K; Akdis, CA				Trautmann, A; Schmid-Grendelmeier, P; Kruger, K; Crameri, R; Akdis, M; Akkaya, A; Brocker, EB; Blaser, K; Akdis, CA			T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; asthma; bronchial epithelial cell; eosinophil; Fas; interferon-gamma; T cell; tumor necrosis factor	DNA FRAGMENTATION; INTERFERON-GAMMA; CATIONIC PROTEIN; TNF-ALPHA; INFLAMMATION; DEATH; IDENTIFICATION; LYMPHOCYTES; EXPRESSION; ACTIVATION	Background: Asthma is an inflammatory airway disease associated with an infiltration of T cells and eosinophils, increased levels of pro-inflammatory cytokines, and shedding of bronchial epithelial cells (ECs). Objective: Shedding of bronchial ECs is characterized by loss of the normal bronchial pseudostratified epithelium and the maintenance of a few basal cells on a thickened basement membrane. The aim of this study was to investigate whether, and by which mechanism, T cells and eosinophils can cause damage to airway ECs. Methods: Bronchial ECs, cultured and exposed to cytokines, eosinophil cationic protein, activated T cells, and eosinophils were studied for the expression of apoptosis receptors (now cytometry, immunoblotting, and RNA expression) and for the susceptibility for undergoing apoptosis. In addition, bronchial biopsy specimens from patients with asthma were evaluated for EC apoptosis. Results: We demonstrate herein that the respiratory epithelium is an essential target of the inflammatory attack by T cells and eosinophils. Bronchial ECs underwent cytokine-induced cell death with DNA fragmentation and morphologic characteristics of apoptosis mediated by activated T cells and eosinophils. T cell- and eosinophil-induced EC apoptosis was blocked by inhibition of IFN-gamma and TNF-alpha; the Fas ligand-Fas pathway appears to be less important. Recombinant eosinophil cationic protein induced mainly necrosis of ECs. Furthermore, we demonstrated in situ apoptotic features of ECs in bronchial biopsy specimens of asthmatic patients. Conclusion: T cell- and eosinophil-induced apoptosis represents a key pathogenic event leading to EC shedding in asthma.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Suleyman Demiral Univ, Dept Pneumol, Isparta, Turkey; Univ Wurzburg, Dept Dermatol, D-97070 Wurzburg, Germany	Swiss Institute of Allergy & Asthma Research; Suleyman Demirel University; University of Wurzburg	Trautmann, A (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.		Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X				Akdis CA, 2000, FASEB J, V14, P1666; Barnes PJ, 2000, J ALLERGY CLIN IMMUN, V106, P5, DOI 10.1067/mai.2000.107930; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; Boushey HA, 2000, LANCET, V356, P2114, DOI 10.1016/S0140-6736(00)03486-3; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747, DOI 10.1165/ajrcmb.19.5.3166; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gitter AH, 2000, FASEB J, V14, P1749, DOI 10.1096/fj.99-0898com; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; HANSEL TT, 1992, J IMMUNOL, V149, P2130; Haridas V, 1998, J IMMUNOL, V160, P3152; Holtzman MJ, 1996, AM J RESP CELL MOL, V14, P316, DOI 10.1165/ajrcmb.14.4.8600934; HOWARTH PH, 1994, AM J RESP CRIT CARE, V150, pS18, DOI 10.1164/ajrccm/150.5_Pt_2.S18; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Kampf C, 1999, EUR RESPIR J, V14, P84, DOI 10.1034/j.1399-3003.1999.14a15.x; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; MONTEFORT S, 1992, CLIN EXP ALLERGY, V22, P511, DOI 10.1111/j.1365-2222.1992.tb00159.x; MONTEFORT S, 1989, RESP MED, V87, P9; Morishima Y, 2001, AM J RESP CELL MOL, V24, P1; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469, DOI 10.1164/ajrccm/145.6.1469; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; Staley K, 1997, CELL DEATH DIFFER, V4, P66, DOI 10.1038/sj.cdd.4400207; Stirling RG, 2000, EUR RESPIR J, V16, P1158, DOI 10.1034/j.1399-3003.2000.16f24.x; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839, DOI 10.1067/mai.2001.118796; Trautmann A, 2001, J INVEST DERMATOL, V117, P927, DOI 10.1046/j.0022-202x.2001.01474.x; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Weiss T, 1997, J IMMUNOL, V158, P2398; Weller PF, 1997, J ALLERGY CLIN IMMUN, V100, P283, DOI 10.1016/S0091-6749(97)70237-9; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0	38	154	162	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					329	337		10.1067/mai.2002.121460	http://dx.doi.org/10.1067/mai.2002.121460			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842305				2022-12-18	WOS:000174232600020
J	Gereda, JE; Klinnert, MD; Price, MR; Leung, DYM; Liu, AH				Gereda, JE; Klinnert, MD; Price, MR; Leung, DYM; Liu, AH			Metropolitan home living conditions associated with indoor endotoxin levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; prevention; infants; endotoxin; house dust; allergen; animal; cat; dog; air conditioning	IN-HOUSE DUST; HAY-FEVER; ENVIRONMENTAL ENDOTOXIN; BACTERIAL-ENDOTOXIN; INHALED ENDOTOXIN; ASTHMA; EXPOSURE; ALLERGEN; HEALTH; RISK	Background: Household endotoxin exposure in allergy and asthma has been gaining attention for its dual potential to exacerbate these conditions in individuals with established disease and to abrogate atopy before disease onset. Objective: We sought to better understand the home environmental and Lifestyle factors influencing house dust endotoxin levels, Methods: From the homes of 86 infants with wheeze in metropolitan Denver, Colorado, house dust endotoxin (detected with a standardized Limulus Amebocyte Lysate assay) and common indoor allergen (Fel d 1, Can f 1, Her p 1, Her f 1, and Bla g 1) contents were quantified. Comprehensive home environment and lifestyle questionnaires were completed during home visits by trained study staff and parents. Results: House dust endotoxin levels were associated with only 2 home environmental features: animals in the home and the presence of central air conditioning. The strongest positive associations were found with animals in the home, Interestingly,the homes without cats or other animals revealed a negative correlation between house dust Fel d 1 and endotoxin (P = .03), Central air conditioning, especially during months of typical use, was associated with lower house dust endotoxin levels, No significant associations between house dust endotoxin levels and home dampness, number of household inhabitants or young children, cleaning frequency, or presence of tobacco smokers in the home were found, Conclusions: Indoor endotoxin exposure can be increased by the presence of animals in the home and decreased with central air conditioning, In some homes without animals, where allergen exposure adequate for sensitization still occurs, there are lower levels of house dust endotoxin, Therefore in homes without animals, factors that influence allergen and endotoxin levels in house dust probably differ, Households with detectable allergen levels but low endotoxin levels may provide a predisposing environment for animal allergen sensitization.	Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Div Pediat Behav Hlth, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Liu, AH (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, 1400 Jackson St,K1023, Denver, CO 80206 USA.				NCRR NIH HHS [M01-RR00051] Funding Source: Medline; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAID NIH HHS [R18AI41137] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R18AI041137] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Andriessen JW, 1998, CLIN EXP ALLERGY, V28, P1191, DOI 10.1046/j.1365-2222.1998.00322.x; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; Chan-Yeung M, 1999, CLIN EXP ALLERGY, V29, P762; Chun D T, 2000, Appl Occup Environ Hyg, V15, P152; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DONHAM K, 1989, BRIT J IND MED, V46, P31; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348, DOI 10.1164/ajrccm.162.4.9909118; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; Duchaine C, 1999, AM IND HYG ASSOC J, V60, P89, DOI 10.1080/00028899908984426; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Hamilton RG, 1997, METHODS, V13, P53, DOI 10.1006/meth.1997.0495; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; KUEHR J, 1994, CLIN EXP ALLERGY, V24, P229, DOI 10.1111/j.1365-2222.1994.tb00224.x; LE JM, 1986, J IMMUNOL, V136, P4525; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; MICHEL O, 1991, ANN ALLERGY, V66, P39; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Mitchell H, 1997, PEDIATR PULM, V24, P237; Nicolai T, 1998, THORAX, V53, P1035, DOI 10.1136/thx.53.12.1035; OLENCHOCK SA, 1992, SCAND J WORK ENV HEA, V18, P58; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; PLATT SD, 1989, BRIT MED J, V298, P1673, DOI 10.1136/bmj.298.6689.1673; Ponsonby AL, 1999, THORAX, V54, P664, DOI 10.1136/thx.54.8.664; Quinn PJ., 1994, CLIN VET MICROBIOLOG, P254; Reijonen TM, 2000, PEDIATRICS, V106, P1406, DOI 10.1542/peds.106.6.1406; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; THELIN A, 1984, EUR J RESPIR DIS, V65, P266; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Wickens K, 1999, J ALLERGY CLIN IMMUN, V104, P554, DOI 10.1016/S0091-6749(99)70323-4	43	154	155	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					790	796		10.1067/mai.2001.115245	http://dx.doi.org/10.1067/mai.2001.115245			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344344				2022-12-18	WOS:000168812300005
J	Sutas, Y; Soppi, E; Korhonen, H; Syvaoja, EL; Saxelin, M; Rokka, T; Isolauri, E				Sutas, Y; Soppi, E; Korhonen, H; Syvaoja, EL; Saxelin, M; Rokka, T; Isolauri, E			Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG-derived enzymes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk; caseins; infant food; Lactobacillus casei physiology; food hypersensitivity; lymphocyte transformation; immunotherapy	COW MILK ALLERGY; IMMUNE-RESPONSE; FOOD ALLERGY; PROTEIN ANTIGENS; WHOLE-BLOOD; T-CELLS; TOLERANCE; OVALBUMIN; MICE; STIMULATION	Background: Processing of proteins in the gut and activation of T-cell suppression leads to systemic hyporesponsiveness to ingested protein antigens. Objective: The study was designed to determine whether lactobacilli, a major part of human intestinal microflora, can contribute to degradation of food antigens in the gut and modify their immunoactivities. Methods: Lymphocyte transformation tests were carried out in healthy adults to determine the mitogen-induced lymphocyte proliferative responses to bovine caseins hydrolyzed with pepsin and trypsin and to bovine caseins additionally hydrolyzed with enzymes derived from Lactobacillus casei strain GG (ATCC 53103). Results: In experiments done with caseins hydrolyzed with pepsin and trypsin, beta- and alpha(s1)- caseins significantly suppressed the proliferation of lymphocytes at 0.1 and 10 mu g/ml, respectively, when compared with corresponding control cultures without these hydrolysates. In contrast, kappa-casein significantly stimulated the proliferation of lymphocytes at 10 mu g/ml. In experiments done with caseins additionally hydrolyzed with L. casei GG-derived enzymes, there was one consistent effect on lymphocyte proliferation: suppression by alpha(s1-), beta-, and kappa-caseins at 0.1, 10, and 1000 mu g/ml, respectively. Conclusions: Hydrolysis of caseins with L. casei GG-derived enzymes generates molecules with suppressive effects on lymphocyte proliferation. In addition, intestinal bacteria can be beneficial in the down regulation of hypersensitivity reactions to ingested proteins in patients with food allergy.	TAMPERE UNIV,SCH MED,DEPT PEDIAT,FIN-33101 TAMPERE,FINLAND; AGR RES CTR FINLAND,INST FOOD RES,JOKIOINEN,FINLAND; VALIO LTD,CTR RES & DEV,HELSINKI,FINLAND; HELSINKI UNIV,DEPT FOOD TECHNOL,HELSINKI,FINLAND	Tampere University; Natural Resources Institute Finland (Luke); Valio; University of Helsinki			Soppi, Esa/AAN-4191-2020					AGATA H, 1993, J ALLERGY CLIN IMMUN, V91, P668, DOI 10.1016/0091-6749(93)90273-I; ASANTILA T, 1974, J IMMUNOL METHODS, V6, P73, DOI 10.1016/0022-1759(74)90091-X; BOS JD, 1994, LANCET, V343, P1338, DOI 10.1016/S0140-6736(94)92473-2; BRITTON JR, 1991, AM J MED SCI, V301, P124, DOI 10.1097/00000441-199102000-00007; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; DESIMONE C, 1986, NUTR REP INT, V33, P419; ESKOLA J, 1975, IMMUNOL COMMUN, V4, P297, DOI 10.3109/08820137509055781; EXTERKATE FA, 1985, APPL ENVIRON MICROB, V49, P328, DOI 10.1128/AEM.49.2.328-332.1985; HEYMAN M, 1986, AM J PHYSIOL, V14, pG326; ISOLAURI E, 1992, J PEDIATR-US, V120, P9, DOI 10.1016/S0022-3476(05)80589-X; ISOLAURI E, 1993, GASTROENTEROLOGY, V105, P1643, DOI 10.1016/0016-5085(93)91059-Q; Jost R, 1991, Bibl Nutr Dieta, P127; KAILA M, 1992, PEDIATR RES, V32, P141, DOI 10.1203/00006450-199208000-00002; KIM SM, 1993, INT ARCH ALLERGY IMM, V101, P260, DOI 10.1159/000236455; Kleinman REBS., 1991, PEDIAT ALLERG IMM-UK, V2, P146, DOI [DOI 10.1111/J.1399-3038.1991.TB00200.X, 10.1111/j.1399-3038.1991.tb00200.x]; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MOREAU MC, 1988, INFECT IMMUN, V56, P2766, DOI 10.1128/IAI.56.10.2766-2768.1988; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; MOWAT AM, 1986, IMMUNOLOGY, V58, P179; OTANI H, 1992, MILCHWISSENSCHAFT, V47, P512; PENG HJ, 1990, CLIN EXP IMMUNOL, V81, P510; PERDIGON G, 1988, IMMUNOLOGY, V63, P17; PRESS OW, 1977, J EXP MED, V146, P735, DOI 10.1084/jem.146.3.735; SAMPSON HA, 1992, PEDIATRICS, V90, P463; SAMPSON HA, 1991, J PEDIATR-US, V118, P520, DOI 10.1016/S0022-3476(05)90001-2; SAMPSON HA, 1990, CURR OPIN IMMUNOL, V2, P542, DOI 10.1016/0952-7915(90)90008-5; STROBEL S, 1985, IMMUNOLOGY, V56, P57; SYVAOJA EL, 1992, MILCHWISSENSCHAFT, V47, P563; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; VILJANEN MK, 1977, CLIN IMMUNOL IMMUNOP, V8, P28, DOI 10.1016/0090-1229(77)90088-5; WAHN U, 1992, J PEDIATR-US, V121, pS80, DOI 10.1016/S0022-3476(05)81412-X; WALKER WA, 1986, J ALLERGY CLIN IMMUN, V78, P1003, DOI 10.1016/0091-6749(86)90293-9; WOLD AE, 1989, INFECT IMMUN, V57, P2666, DOI 10.1128/IAI.57.9.2666-2673.1989; ZEIGER RS, 1986, J ALLERGY CLIN IMMUN, V78, P224, DOI 10.1016/0091-6749(86)90016-3; 1989, PEDIATRICS, V83, P1068	35	154	157	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					216	224		10.1016/S0091-6749(96)70245-2	http://dx.doi.org/10.1016/S0091-6749(96)70245-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765837	Bronze			2022-12-18	WOS:A1996VA69200026
J	Pauli, G; Oster, JP; Deviller, P; Heiss, S; Bessot, JC; Susani, M; Ferreira, F; Kraft, D; Valenta, R				Pauli, G; Oster, JP; Deviller, P; Heiss, S; Bessot, JC; Susani, M; Ferreira, F; Kraft, D; Valenta, R			Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: Diagnostic value for birch pollen and associated allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birch pollinosis; food allergy; recombinant birch allergen (rBet v 1); recombinant birch profilin (rBet v 2); skin tests	HISTAMINE-RELEASE; IDENTIFICATION; IGE; PURIFICATION; PROTEINS; CELERY; APPLES; PLANTS	Objective: This study assesses the value of two recombinant birch allergens for diagnosis of patients sensitized to birch pollen with or without associated food allergy. Methods: Fifty-one patients with positive skin test responses to Betulaceae and seven nonallergic control subjects were investigated; specific IgE antibodies were evaluated by specific immunoassay and blot immunodetection. Results: Among 51 patients, 47 reacted to rBet v 1 and 10 to rBet v 2. Seven patients reacted to both recombinant allergens. In skin prick tests were found a correlation between the wheal produced by the commercial birch extract and the wheal produced by rBet v 1. Among 47 patients with positive test responses to rBet v 1, 83% had IgE binding to the Bet v 1 protein as determined by immunoblotting. Among 10 patients sensitized to rBet v 2, six had IgE binding to Bet v 2. Eleven patients with negative results, as determined by immunoblotting, had low levels of birch IgE in the sera (<10 kU/L) and low concentrations of IgE to rBet v 1 or rBet v 2 in ELISA. The nonallergic control subjects (n = 7) did not react to rBet v 1 or rBet v 2 in skin prick tests, nor did they have detectable amounts of specific IgE to rBet v 1 or rBet v 2. Histamine release test confirmed sensitization to Bet v 1 in two patients with discordant results; for Bet v 2, one patient had positive results only at a high concentration, and one had results that remained negative. Thirty-four patients had birch pollinosis, and all reacted to rBet v 1. Patients who were monosensitized to birch never reacted to rBet v 2. Sensitization to rBet v 2 was only found in patients who reacted to other pollens (mainly grass). Twenty-nine patients demonstrated allergy to apples, cherries, or hazelnuts; and all reacted to rBet v 1. Among 11 patients with allergy to Umbelliferae, only three reacted to rBet v 2. Conclusions: Use of the two recombinant allergens (rBet v 1 and rBet v 2) always permits the diagnosis of birch sensitization. Sensitization to rBet v 1 is specific for birch and Rosaceae allergies, whereas sensitization to birch profilin, Bet v 2, is encountered in multisensitized subjects and is not always related to Umbelliferae allergy.	FAC MED ALEXIS CARREL,MOL & CELLULAR BIOL LAB,F-69372 LYON,FRANCE; UNIV VIENNA,INST GEN & EXPTL PATHOL,VIENNA,AUSTRIA; INST MOLEC BIOL,SALZBURG,AUSTRIA; INST GEN & DEV BIOL,SALZBURG,AUSTRIA	University of Vienna	Pauli, G (corresponding author), HOP UNIV STRASBOURG,BP 426,PAVILLON LAENNEC,F-67091 STRASBOURG,FRANCE.		Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Valenta, Rudolf/0000-0001-5944-3365				BESSOT JC, 1984, REV FR ALLERGOL, V24, P29, DOI 10.1016/S0335-7457(84)80035-0; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; HOFFMANNSOMMERG.K, 1995, INT S MOL BIOL ALL A; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH NR, 1994, INT ARCH ALLERGY IMM, V105, P70, DOI 10.1159/000236805; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; TANIZAKI Y, 1984, INT ARCH ALLER A IMM, V73, P141, DOI 10.1159/000233454; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171	23	154	160	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1100	1109		10.1016/S0091-6749(96)70264-6	http://dx.doi.org/10.1016/S0091-6749(96)70264-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626988				2022-12-18	WOS:A1996UL26100011
J	Iacono, G; Carroccio, A; Cavataio, F; Montalto, G; Kazmierska, I; Lorello, D; Soresi, M; Notarbartolo, A				Iacono, G; Carroccio, A; Cavataio, F; Montalto, G; Kazmierska, I; Lorello, D; Soresi, M; Notarbartolo, A			Gastroesophageal reflux and cow's milk allergy in infants: A prospective study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk allergy; gastroesophageal reflux; infants; pH monitoring; anti-beta-lactoglobulin; esophagitis	PROTEIN INTOLERANCE; DISTAL ESOPHAGUS; PH; CHILDREN; FORMULA	Background: Recent reports have suggested that gastroesophageal reflux in pediatric patients may be caused by food allergy. Objective: The aim of our study was to determine the frequency of the association of gastroesophageal reflux with cow's milk protein allergy in patients in the first year of life. Methods: We studied 204 consecutive patients (median age, 6.3 months) who had been diagnosed as having gastroesophageal reflux on the basis of 24-hour continuous pH monitoring and histologic examination of the esophageal mucosa. Results: Clinical history suggested diagnosis of cow's milk allergy in 19 infants, arm 93 others had positive test results (serum IgE anti-lactoglobulin, prick tests circulating or fecal or nasal mucus eosinophils) but did nor have symptoms indicating cow's milk allergy. The cow's milk-free diet and two successive blind challenges confirmed the diagnosis of cow's milk allergy in 85 of the 204 patients with gastroesophageal reflux. The clinical presentations of the infants with gastroesophageal reflux alone were different, in view of the greater frequency of diarrhea (p<0.0001) and atopic dermatitis (p<0.0002). In all, gastroesophageal reflux was associated with, and probably caused by COM'S milk allergy, in 85 of 204 cases (41.5%). Conclusions: Considering the frequency of this association, patients younger than 12 months old old with symptoms of gastroesophageal reflux should be carefully examined to determine whether this disorder is primary or caused by cow's milk allergy.	UNIV PALERMO, OSPED G DI CRISTINA, DIV PEDIAT 2, USL 58 PALERMO CATTEDRA MED INTERNA, PALERMO, ITALY	University of Palermo			Soresi, Maurizio/AAY-2045-2020; Carroccio, Antonio/K-4484-2016	Soresi, Maurizio/0000-0001-7850-555X; Carroccio, Antonio/0000-0001-8913-7916; MONTALTO, Giuseppe/0000-0002-8731-8577				ANDRES JM, 1988, DIGEST DIS SCI, V33, P393, DOI 10.1007/BF01536020; BLACK DD, 1990, GASTROENTEROLOGY, V98, P1408, DOI 10.1016/0016-5085(90)91069-I; CARRE IJ, 1959, ARCH DIS CHILD, V34, P344, DOI 10.1136/adc.34.176.344; CARROCCIO A, 1992, SCAND J GASTROENTERO, V27, P799, DOI 10.3109/00365529209011187; CARROCCIO A, 1994, SCAND J GASTROENTERO, V29, P300, DOI 10.3109/00365529409094839; FORGET P, 1985, EUR J PEDIATR, V144, P298, DOI 10.1007/BF00441767; FRIESEN CA, 1992, J PEDIATR GASTR NUTR, V14, P252, DOI 10.1097/00005176-199204000-00002; FRIESEN CA, 1994, PEDIATRICS, V94, P541; IYNGKARAN N, 1978, ARCH DIS CHILD, V53, P20, DOI 10.1136/adc.53.1.20; JAKOBSSON I, 1979, ACTA PAEDIATR SCAND, V68, P853; JOHNSON LF, 1974, AM J GASTROENTEROL, V62, P325; JOLLEY SG, 1987, J PEDIATR SURG, V22, P923, DOI 10.1016/S0022-3468(87)80590-0; JOLLEY SG, 1978, SURGERY, V84, P16; SHINER M, 1975, LANCET, V2, P1060; SONDHEIMER JM, 1980, J PEDIATR-US, V96, P804, DOI 10.1016/S0022-3476(80)80546-4; SONDHEIMER JM, 1985, J PEDIATR GASTR NUTR, V4, P352, DOI 10.1097/00005176-198506000-00005; STINTZING G, 1979, ACTA PAEDIATR SCAND, V68, P383, DOI 10.1111/j.1651-2227.1979.tb05024.x; STROBEL CT, 1979, J PEDIATR-US, V94, P81, DOI 10.1016/S0022-3476(79)80361-3; WALKERSMITH J, 1975, ARCH DIS CHILD, V50, P347, DOI 10.1136/adc.50.5.347; 1993, EUR J PEDIATR, V152, P704	20	154	159	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					822	827						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613639				2022-12-18	WOS:A1996UA97500013
J	KAY, AB; WALSH, GM; MOQBEL, R; MACDONALD, AJ; NAGAKURA, T; CARROLL, MP; RICHERSON, HB				KAY, AB; WALSH, GM; MOQBEL, R; MACDONALD, AJ; NAGAKURA, T; CARROLL, MP; RICHERSON, HB			DISODIUM-CROMOGLYCATE INHIBITS ACTIVATION OF HUMAN INFLAMMATORY CELLS-INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KAY, AB (corresponding author), BROMPTON HOSP,INST CARDIOTHORAC,DEPT ALLERGY & CLIN IMMUNOL,FULHAM RD,LONDON SW3 6HP,ENGLAND.							ANWAR ARE, 1977, J IMMUNOL, V119, P976; ANWAR ARE, 1980, J IMMUNOL, V124, P1122; ASSEM ESK, 1970, INT ARCH ALLER A IMM, V38, P68, DOI 10.1159/000230260; BERGER M, 1984, J CLIN INVEST, V74, P1566, DOI 10.1172/JCI111572; BESWICK PH, 1981, CLIN EXP IMMUNOL, V43, P399; BUTTERWORTH AE, 1979, J EXP MED, V150, P1456, DOI 10.1084/jem.150.6.1456; CARROLL M, 1983, CLIN EXP IMMUNOL, V54, P785; CHURCH MK, 1983, BR J PHARM S, V79, P374; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; DIAZ P, 1986, J ALLERGY CLIN IMMUN, V77, P244; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1985, J ALLERGY CLIN IMMUN, V75, P148, DOI 10.1016/0091-6749(85)90308-2; FEARON DT, 1983, J IMMUNOL, V130, P370; FEARON DT, 1984, IMMUNOL TODAY, V5, P105, DOI 10.1016/0167-5699(84)90044-6; GONZALEZMOLINA A, 1977, J CLIN INVEST, V59, P616, DOI 10.1172/JCI108679; HOLGATE ST, 1984, ASTHMA PHYSL IMMUNOP, P391; KANG B, 1976, BMJ-BRIT MED J, V1, P867, DOI 10.1136/bmj.1.6014.867; KAY AB, 1979, CLIN EXP IMMUNOL, V38, P294; KAY AB, 1984, CLIN EXP IMMUNOL, V57, P729; LACHMANN PJ, 1978, HDB EXPT IMMUNOLOGY, P1; LARSEN GL, 1984, ASTHMA PHYSL IMMUNOP, P245; MAZUREK N, 1983, NATURE, V303, P528, DOI 10.1038/303528a0; MAZUREK N, 1980, NATURE, V286, P722, DOI 10.1038/286722a0; MAZUREK N, 1984, P NATL ACAD SCI-BIOL, V81, P6841, DOI 10.1073/pnas.81.21.6841; MOQBEL R, 1986, AM REV RESPIR DIS, V133, P609; MOQBEL R, 1983, CLIN EXP IMMUNOL, V52, P519; PAPAGEORGIOU N, 1983, LANCET, V2, P1220; PEPYS J, 1968, LANCET, V2, P134; RICHERSON HB, 1985, CLIN EXP IMMUNOL, V62, P442; SELIGMANN B, 1984, J IMMUNOL, V133, P2641; SHEVACH EM, 1972, J CLIN INVEST, V51, P1933, DOI 10.1172/JCI106999; SHOWELL HJ, 1976, J EXP MED, V143, P1154, DOI 10.1084/jem.143.5.1154; VADAS MA, 1979, J IMMUNOL, V122, P1228	35	154	154	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					1	8		10.1016/S0091-6749(87)80183-5	http://dx.doi.org/10.1016/S0091-6749(87)80183-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	3110245	Bronze			2022-12-18	WOS:A1987J219400001
J	SPECTOR, SL; KINSMAN, R; MAWHINNEY, H; SIEGEL, SC; RACHELEFSKY, GS; KATZ, RM; ROHR, AS				SPECTOR, SL; KINSMAN, R; MAWHINNEY, H; SIEGEL, SC; RACHELEFSKY, GS; KATZ, RM; ROHR, AS			COMPLIANCE OF PATIENTS WITH ASTHMA WITH AN EXPERIMENTAL AEROSOLIZED MEDICATION - IMPLICATIONS FOR CONTROLLED CLINICAL-TRIALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV COLORADO, DEPT PSYCHIAT, DENVER, CO 80202 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Colorado System; University of Colorado Denver; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ALLEN E. A., 1964, CAN J PUBLIC HEALTH, V55, P323; BEER S, 1982, ISRAEL J MED SCI, V18, P255; CALDWELL JR, 1970, J CHRON DIS, V22, P579, DOI 10.1016/0021-9681(70)90034-2; DIRKS JF, 1982, CLIN PHARMACOL THER, V31, P413, DOI 10.1038/clpt.1982.53; DUNBAR JM, 1980, NIH81102 PUBL; ENEY RD, 1976, PEDIATRICS, V57, P513; GORDIS L, 1969, J PEDIATR-US, V75, P957, DOI 10.1016/S0022-3476(69)80332-X; GORDIS L, 1979, COMPLIANCE HLTH CARE, P49; HAYNES RB, 1976, LANCET, V1, P1265; HAYNES RB, 1976, COMPLIANCE THERAPEUT; KINSMAN RA, 1980, J PSYCHOSOM RES, V24, P97, DOI 10.1016/0022-3999(80)90059-8; KINSMAN RA, 1981, EFFECTS PARTICULATE; KLEIGER JH, 1979, J ASTHMA RES, V16, P93, DOI 10.3109/02770907909106618; PERRY GB, 1983, AM J PUBLIC HEALTH, V73, P50, DOI 10.2105/AJPH.73.1.50; SACKETT DL, 1975, LANCET, V1, P1205	15	154	162	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				65	70		10.1016/0091-6749(86)90325-8	http://dx.doi.org/10.1016/0091-6749(86)90325-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3511127	Bronze			2022-12-18	WOS:A1986AZD3600013
J	CRETICOS, PS; VANMETRE, TE; MARDINEY, MR; ROSENBERG, GL; NORMAN, PS; ADKINSON, NF				CRETICOS, PS; VANMETRE, TE; MARDINEY, MR; ROSENBERG, GL; NORMAN, PS; ADKINSON, NF			DOSE-RESPONSE OF IGE AND IGG ANTIBODIES DURING RAGWEED IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,ALLERGY CLIN,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00722] Funding Source: Medline; NIAID NIH HHS [AI 11936, AI 10304-0851] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1981, J ALLERGY CLIN IMMUN, V67, P87, DOI 10.1016/0091-6749(81)90001-4; ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; ISHIZAKA T, 1976, J ALLERGY CLIN IMMUN, V58, P523, DOI 10.1016/0091-6749(76)90196-2; JARRETT E, 1974, NATURE, V251, P613, DOI 10.1038/251613a0; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; KISHIMOTO T, 1982, PROG ALLERGY, V32, P265; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; Levine P, 1926, J IMMUNOL, V11, P449; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1973, J CLIN IMMUNOL, V52, P72; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P126; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; NORMAN PS, 1982, PROG ALLERGY, V32, P318; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; Sherman WB, 1941, J IMMUNOL, V40, P289; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	27	154	156	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					94	104		10.1016/0091-6749(84)90490-1	http://dx.doi.org/10.1016/0091-6749(84)90490-1			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6607272				2022-12-18	WOS:A1984SB99000014
J	Schatz, M; Hsu, JWY; Zeiger, RS; Chen, WS; Dorenbaum, A; Chipps, BE; Haselkorn, T				Schatz, Michael; Hsu, Jin-Wen Y.; Zeiger, Robert S.; Chen, Wansu; Dorenbaum, Alejandro; Chipps, Bradley E.; Haselkorn, Tmirah			Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TENOR; severe asthma; difficult-to-treat asthma; phenotype; demographics; atopy; cluster analysis	HEALTH-CARE UTILIZATION; CLINICAL PHENOTYPES; NATURAL-HISTORY; EPIDEMIOLOGY; OUTCOMES; CHILDREN	Background: Asthma phenotyping can facilitate understanding of disease pathogenesis and potential targeted therapies. Objective: To further characterize the distinguishing features of phenotypic groups in difficult-to-treat asthma. Methods: Children ages 6-11 years (n = 518) and adolescents and adults ages >= 12 years (n = 3612) with severe or difficult-to-treat asthma from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study were evaluated in this post hoc cluster analysis. Analyzed variables included sex, race, atopy, age of asthma onset, smoking (adolescents and adults), passive smoke exposure (children), obesity, and aspirin sensitivity. Cluster analysis used the hierarchical clustering algorithm with the Ward minimum variance method. The results were compared among clusters by chi(2) analysis; variables with significant (P < .05) differences among clusters were considered as distinguishing feature candidates. Associations among clusters and asthma-related health outcomes were assessed in multivariable analyses by adjusting for socioeconomic status, environmental exposures, and intensity of therapy. Results: Five clusters were identified in each age stratum. Sex, atopic status, and nonwhite race were distinguishing variables in both strata; passive smoke exposure was distinguishing in children and aspirin sensitivity in adolescents and adults. Clusters were not related to outcomes in children, but 2 adult and adolescent clusters distinguished by nonwhite race and aspirin sensitivity manifested poorer quality of life (P < .0001), and the aspirin-sensitive cluster experienced more frequent asthma exacerbations (P < .0001). Conclusion: Distinct phenotypes appear to exist in patients with severe or difficult-to-treat asthma, which is related to outcomes in adolescents and adults but not in children. The study of the therapeutic implications of these phenotypes is warranted.	[Schatz, Michael; Hsu, Jin-Wen Y.; Zeiger, Robert S.; Chen, Wansu] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA; [Schatz, Michael; Hsu, Jin-Wen Y.; Zeiger, Robert S.; Chen, Wansu] Kaiser Permanente So Calif, Dept Res & Evaluat, San Diego, CA USA; [Schatz, Michael; Hsu, Jin-Wen Y.; Zeiger, Robert S.; Chen, Wansu] Kaiser Permanente So Calif, Dept Allergy, Pasadena, CA 91101 USA; [Schatz, Michael; Hsu, Jin-Wen Y.; Zeiger, Robert S.; Chen, Wansu] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA; [Dorenbaum, Alejandro; Haselkorn, Tmirah] Genentech Inc, US Med Affairs, San Francisco, CA 94080 USA; [Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Roche Holding; Genentech	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	michael.x.schatz@kp.org		Zeiger, Robert/0000-0001-5788-5063	Genentech Inc; Novartis Pharmaceuticals Corporation; Department of Research and Evaluation within the Southern California Permanente Medical Group; Medical Group; Kaiser Permanente Community Benefit Fund; Genentech Inc.	Genentech Inc(Roche HoldingGenentech); Novartis Pharmaceuticals Corporation(Novartis); Department of Research and Evaluation within the Southern California Permanente Medical Group; Medical Group; Kaiser Permanente Community Benefit Fund; Genentech Inc.(Roche HoldingGenentech)	TENOR (The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens) was funded by Genentech Inc and Novartis Pharmaceuticals Corporation. This analysis was partially funded by the Department of Research and Evaluation within the Southern California Permanente Medical Group with funds from the Medical Group and the Kaiser Permanente Community Benefit Fund. Editorial support was provided by CircleScience, funded by Genentech Inc.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Chang JC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/270869; Chang JE, 2012, ALLERGY ASTHMA PROC, V33, P117, DOI 10.2500/aap.2012.33.3541; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; Chipps BE, 2012, J ALLERGY CLIN IMMUN, V130, P332, DOI 10.1016/j.jaci.2012.04.014; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; Maccani Matthew A., 2012, Frontiers in Genetics, V3, P53, DOI 10.3389/fgene.2012.00053; Mahut B, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-65; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Mosen DM, 2010, AM J MANAG CARE, V16, P821; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Ortega H, 2012, J ASTHMA, V49, P158, DOI 10.3109/02770903.2011.649872; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123, DOI 10.1164/ajrccm.157.1.9612063; Pascual RM, 2009, J ALLERGY CLIN IMMUN, V124, P883, DOI 10.1016/j.jaci.2009.09.047; Schatz M, 2003, ANN ALLERG ASTHMA IM, V91, P553, DOI 10.1016/S1081-1206(10)61533-5; Schatz M, 2009, ALLERGY FRONTIERS: DIAGNOSIS AND HEALTH ECONOMICS, VOL 4, P507, DOI 10.1007/978-4-431-98349-1_28; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8	33	153	155	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1549	1556		10.1016/j.jaci.2013.10.006	http://dx.doi.org/10.1016/j.jaci.2013.10.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24315502				2022-12-18	WOS:000336672500005
J	Bryniarski, K; Ptak, W; Jayakumar, A; Pullmann, K; Caplan, MJ; Chairoungdua, A; Lu, J; Adams, BD; Sikora, E; Nazimek, K; Marquez, S; Kleinstein, SH; Sangwung, P; Iwakiri, Y; Delgato, E; Redegeld, F; Blokhuis, BR; Wojcikowski, J; Daniel, WA; Kormelink, TG; Askenase, PW				Bryniarski, Krzysztof; Ptak, Wlodzimierz; Jayakumar, Asha; Puellmann, Kerstin; Caplan, Michael J.; Chairoungdua, Arthit; Lu, Jun; Adams, Brian D.; Sikora, Emilia; Nazimek, Katarzyna; Marquez, Susanna; Kleinstein, Steven H.; Sangwung, Panjamaporn; Iwakiri, Yasuko; Delgato, Eric; Redegeld, Frank; Blokhuis, Bart R.; Wojcikowski, Jacek; Daniel, Wladyslawa Anna; Kormelink, Tom Groot; Askenase, Philip W.			Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exosomes; exosome-like nanovesicles; nanovesicles; T-cell suppression; miRNA; miRNA-150; antibody light chains; allergic cutaneous contact dermatitis; contact sensitivity	FREE LIGHT-CHAINS; REGULATORY CELLS; DOWN-MODULATE; STEM-CELLS; EXPRESSION; MECHANISM; MIR-150; MICE; DIFFERENTIATION; TRANSCRIPTION	Background: T-cell tolerance of allergic cutaneous contact sensitivity (CS) induced in mice by high doses of reactive hapten is mediated by suppressor cells that release antigen-specific suppressive nanovesicles. Objective: We sought to determine the mechanism or mechanisms of immune suppression mediated by the nanovesicles. Methods: T-cell tolerance was induced by means of intravenous injection of hapten conjugated to self-antigens of syngeneic erythrocytes and subsequent contact immunization with the same hapten. Lymph node and spleen cells from tolerized or control donors were harvested and cultured to produce a supernatant containing suppressive nanovesicles that were isolated from the tolerized mice for testing in active and adoptive cell-transfer models of CS. Results: Tolerance was shown due to exosome-like nanovesicles in the supernatants of CD8 1 suppressor T cells that were not regulatory T cells. Antigen specificity of the suppressive nanovesicles was conferred by a surface coat of antibody light chains or possibly whole antibody, allowing targeted delivery of selected inhibitory microRNA (miRNA)-150 to CS effector T cells. Nanovesicles also inhibited CS in actively sensitized mice after systemic injection at the peak of the responses. The role of antibody and miRNA-150 was established by tolerizing either panimmunoglobulin-deficient JH(-/-) or miRNA-150(-/-) mice that produced nonsuppressive nanovesicles. These nanovesicles could be made suppressive by adding antigen-specific antibody light chains or miRNA-150, respectively. Conclusions: This is the first example of T-cell regulation through systemic transit of exosome-like nanovesicles delivering a chosen inhibitory miRNA to target effector T cells in an antigen-specific manner by a surface coating of antibody light chains.	[Bryniarski, Krzysztof; Ptak, Wlodzimierz; Sikora, Emilia; Nazimek, Katarzyna] Jagiellonian Univ, Coll Med, Dept Immunol, Krakow, Poland; [Jayakumar, Asha; Delgato, Eric; Kormelink, Tom Groot; Askenase, Philip W.] Yale Univ, Sch Med, Dept Med, Allergy & Clin Immunol Sect, 333 Cedar St, New Haven, CT 06520 USA; [Lu, Jun; Adams, Brian D.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; [Marquez, Susanna; Kleinstein, Steven H.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Puellmann, Kerstin] Leibniz Univ Hannover, Dept Hematol, Hannover, Germany; [Caplan, Michael J.; Chairoungdua, Arthit] Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; [Kleinstein, Steven H.] Yale Univ, Interdept Program Computat Biol & Bioinformat, New Haven, CT 06520 USA; [Sangwung, Panjamaporn; Iwakiri, Yasuko] Yale Univ, Dept Med, Gastroenterol Sect, New Haven, CT 06520 USA; [Redegeld, Frank; Blokhuis, Bart R.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Fac Sci, Div Pharmacol, NL-3508 TC Utrecht, Netherlands; [Wojcikowski, Jacek; Daniel, Wladyslawa Anna] Polish Acad Sci, Inst Pharmacol, Krakow, Poland	Jagiellonian University; Collegium Medicum Jagiellonian University; Yale University; Yale University; Yale University; Leibniz University Hannover; Yale University; Yale University; Yale University; Utrecht University; Polish Academy of Sciences	Askenase, PW (corresponding author), Yale Univ, Sch Med, Dept Med, Allergy & Clin Immunol Sect, 333 Cedar St, New Haven, CT 06520 USA.	philip.askenase@yale.edu	Bryniarski, Krzysztof/X-8312-2018; Nazimek, Katarzyna/X-8292-2018; Redegeld, Frank A/O-6534-2016; Adams, Brian D./D-9476-2017; Adams, Brian/L-1815-2015	Bryniarski, Krzysztof/0000-0001-8537-9176; Nazimek, Katarzyna/0000-0003-1302-117X; Redegeld, Frank A/0000-0001-8830-7960; Adams, Brian D./0000-0001-8372-2970; Martin, Emilia/0000-0001-9847-9811; Caplan, Michael/0000-0001-5768-4405	Polish Ministry of Science and Higher Education [N401 092 31/2176, K/ZDS/003718]; Lung Foundation Netherlands [3.2.11.09FE]; National Institutes of Health [AI-076366, AI-07174, AI-1053786]; Polish Ministry of Science and Higher Education; National Institutes of Health (NIH); Hannover Medical School; NIH/National Institute of Diabetes and Digestive and Kidney Diseases; Dutch Asthma Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F31AI010537, R21AI076366, R01AI059801, T32AI007174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK082600] Funding Source: NIH RePORTER	Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); Lung Foundation Netherlands; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hannover Medical School; NIH/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Dutch Asthma Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	K.B. was supported by grants from the Polish Ministry of Science and Higher Education: N401 092 31/2176 and K/ZDS/003718. T.G.K. was supported by a grant from Lung Foundation Netherlands; 3.2.11.09FE. P.W.A. was supported by grants AI-076366, AI-07174, and AI-1053786 from the National Institutes of Health.r Disclosure of potential conflict of interest: K. Bryniarski has received research support from the Polish Ministry of Science and Higher Education. A. Jayakumar, M. J. Caplan, A. Chairoungdua, S. Marquez, S. H. Kleinstein, and P. W. Askenase have received research support from the National Institutes of Health (NIH). K. Pullmann has received research support from the Hannover Medical School. Y. Iwakiri has received research support from the NIH/National Institute of Diabetes and Digestive and Kidney Diseases. T. Groot Kormelink has received research support from the Dutch Asthma Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	Accapezzato D, 2004, J CLIN INVEST, V113, P963, DOI [10.1172/JCI200420415, 10.1172/JCI200420515]; Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969; Almqvist N, 2008, IMMUNOLOGY, V125, P21, DOI 10.1111/j.1365-2567.2008.02812.x; Askenase PW, 2004, TRENDS IMMUNOL, V25, P441, DOI 10.1016/j.it.2004.06.003; Bezman NA, 2011, J EXP MED, V208, P2717, DOI 10.1084/jem.20111386; Bruchova-Votavova H, 2010, LEUKEMIA LYMPHOMA, V51, P686, DOI 10.3109/10428191003629362; Buckheit RW, 2012, J VIROL, V86, P13679, DOI 10.1128/JVI.02439-12; Cai ZJ, 2012, J IMMUNOL, V188, P5954, DOI 10.4049/jimmunol.1103466; Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chang CC, 2012, J IMMUNOL, V188, P3042, DOI 10.4049/jimmunol.1102899; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; Chiba T, 2004, BRIT J CANCER, V91, P1711, DOI 10.1038/sj.bjc.6602201; Choudhuri K, 2012, J IMMUNOL, V188; Ciubotariu R, 1998, J IMMUNOL, V161, P5193; Clayton A, 2008, J IMMUNOL, V180, P7249, DOI 10.4049/jimmunol.180.11.7249; Clayton A, 2007, CANCER RES, V67, P7458, DOI 10.1158/0008-5472.CAN-06-3456; Clayton A, 2011, J IMMUNOL, V187, P676, DOI 10.4049/jimmunol.1003884; Eldh M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015353; FERRERI NR, 1993, J IMMUNOL, V150, P2102; Fitzner D, 2011, J CELL SCI, V124, P447, DOI 10.1242/jcs.074088; Ghisi M, 2011, BLOOD, V117, P7053, DOI 10.1182/blood-2010-12-326629; Gilliet M, 2002, J EXP MED, V195, P695, DOI 10.1084/jem.20011603; Hafner M, 2008, METHODS, V44, P3, DOI 10.1016/j.ymeth.2007.09.009; Hao S., 2006, Experimental Oncology, V28, P126; Hedlund M, 2009, J IMMUNOL, V183, P340, DOI 10.4049/jimmunol.0803477; Hergenreider E, 2012, NAT CELL BIOL, V14, P249, DOI 10.1038/ncb2441; Housden NG, 2004, J BIOL CHEM, V279, P9370, DOI 10.1074/jbc.M312938200; Hussein K, 2010, LEUKEMIA RES, V34, P328, DOI 10.1016/j.leukres.2009.06.014; Hutchinson AT, 2012, IMMUNOL LETT, V142, P75, DOI 10.1016/j.imlet.2011.10.013; Ilkovitch D, 2011, J LEUKOCYTE BIOL, V89, P41, DOI 10.1189/jlb.0410229; Jiang H, 2010, J CLIN INVEST, V120, P3641, DOI 10.1172/JCI43522; Jurynczyk M, 2010, ANN NEUROL, V68, P593, DOI 10.1002/ana.22219; KEMENY DM, 1995, ALLERGY, V50, P9, DOI 10.1111/j.1398-9995.1995.tb04268.x; Kim SH, 2007, J IMMUNOL, V179, P2235, DOI 10.4049/jimmunol.179.4.2235; Kim SH, 2006, MOL THER, V13, P289, DOI 10.1016/j.ymthe.2005.09.015; Koles K, 2012, J BIOL CHEM, V287, P16820, DOI 10.1074/jbc.M112.342667; Korkut C, 2009, CELL, V139, P393, DOI 10.1016/j.cell.2009.07.051; Kormelink TG, 2012, ALLERGY, V67, P1165, DOI 10.1111/j.1398-9995.2012.02866.x; Kormelink TG, 2010, ANN RHEUM DIS, V69, P2137, DOI 10.1136/ard.2009.126441; Kormelink TG, 2012, CURR PHARM DESIGN, V18, P2278, DOI 10.2174/138161212800166059; Lachenal G, 2011, MOL CELL NEUROSCI, V46, P409, DOI 10.1016/j.mcn.2010.11.004; Lahl K, 2011, METHODS MOL BIOL, V707, P157, DOI 10.1007/978-1-61737-979-6_10; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee DS, 2011, J DRUGS DERMATOL, V10, P1192; Lu LF, 2009, IMMUNITY, V30, P80, DOI 10.1016/j.immuni.2008.11.010; Martin SF, 2008, J EXP MED, V205, P2151, DOI 10.1084/jem.20070509; Mathivanan S, 2012, NUCLEIC ACIDS RES, V40, pD1241, DOI 10.1093/nar/gkr828; Matsushima H, 2010, J CLIN INVEST, V120, P653, DOI 10.1172/JCI42280; Meckes DG, 2010, P NATL ACAD SCI USA, V107, P20370, DOI 10.1073/pnas.1014194107; Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285; Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004; Olson BM, 2012, J IMMUNOL, V189, P5590, DOI 10.4049/jimmunol.1201744; Paliwal V, 2002, J IMMUNOL, V169, P4113, DOI 10.4049/jimmunol.169.8.4113; Paust S, 2010, NAT IMMUNOL, V11, P1127, DOI 10.1038/ni.1953; Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Powe DG, 2010, J ALLERGY CLIN IMMUN, V125, P139, DOI 10.1016/j.jaci.2009.07.025; Prado N, 2008, J IMMUNOL, V181, P1519, DOI 10.4049/jimmunol.181.2.1519; PTAK W, 1982, P NATL ACAD SCI-BIOL, V79, P2375, DOI 10.1073/pnas.79.7.2375; PTAK W, 1983, J IMMUNOL, V131, P2859; PTAK W, 1980, IMMUNOBIOLOGY, V156, P400, DOI 10.1016/S0171-2985(80)80073-8; Redegeld FA, 2002, NAT MED, V8, P694, DOI 10.1038/nm722; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sabapatha A, 2006, AM J REPROD IMMUNOL, V56, P345, DOI 10.1111/j.1600-0897.2006.00435.x; Sahoo S, 2011, CIRC RES, V109, P724, DOI 10.1161/CIRCRESAHA.111.253286; Simonetta F, 2010, EUR J IMMUNOL, V40, P2528, DOI 10.1002/eji.201040531; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Soo CY, 2012, IMMUNOLOGY, V136, P192, DOI 10.1111/j.1365-2567.2012.03569.x; Suzuki M, 2008, HUM IMMUNOL, V69, P781, DOI 10.1016/j.humimm.2008.08.283; Taylor DD, 2006, J IMMUNOL, V176, P1534, DOI 10.4049/jimmunol.176.3.1534; Tekstra J, 2011, ARTHRITIS RHEUM-US, V63, P4034, DOI 10.1002/art.30632; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Thio M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040986; Tumne A, 2009, J VIROL, V83, P4354, DOI 10.1128/JVI.02629-08; Tutaj M, 2007, J AUTOIMMUN, V28, P208, DOI 10.1016/j.jaut.2007.02.017; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Van Kaer L, 2010, J CLIN INVEST, V120, P3432, DOI 10.1172/JCI44395; Vocanson M, 2006, J INVEST DERMATOL, V126, P815, DOI 10.1038/sj.jid.5700174; Watanabe A, 2011, LEUKEMIA, V25, P1324, DOI 10.1038/leu.2011.81; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Yang CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022517; Zhang J, 2012, INT J ONCOL, V40, P747, DOI 10.3892/ijo.2011.1242; Zhang L, 2012, CELL RES, V22, P107, DOI 10.1038/cr.2011.158; Zheng QH, 2012, J IMMUNOL, V188, P2118, DOI 10.4049/jimmunol.1103342; Zhou BY, 2007, P NATL ACAD SCI USA, V104, P7080, DOI 10.1073/pnas.0702409104	87	153	161	0	62	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					170	+		10.1016/j.jaci.2013.04.048	http://dx.doi.org/10.1016/j.jaci.2013.04.048			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23727037	Green Submitted, Green Accepted			2022-12-18	WOS:000321052300022
J	Haenuki, Y; Matsushita, K; Futatsugi-Yumikura, S; Ishii, KJ; Kawagoe, T; Imoto, Y; Fujieda, S; Yasuda, M; Hisa, Y; Akira, S; Nakanishi, K; Yoshimoto, T				Haenuki, Yoko; Matsushita, Kazufumi; Futatsugi-Yumikura, Shizue; Ishii, Ken J.; Kawagoe, Tatsukata; Imoto, Yoshimasa; Fujieda, Shigeharu; Yasuda, Makoto; Hisa, Yasuo; Akira, Shizuo; Nakanishi, Kenji; Yoshimoto, Tomohiro			A critical role of IL-33 in experimental allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-33; allergic rhinitis; ragweed pollen; epithelial cells; sneezing; eosinophils; basophils; mast cells	CONNECTIVE-TISSUE TYPE; MAST-CELLS; IN-VIVO; AIRWAY INFLAMMATION; ST2 RECEPTOR; NASAL-MUCOSA; TH2 CELLS; T-CELLS; CYTOKINE; BASOPHILS	Background: We reported previously that serum levels of IL-33 are significantly increased in patients with allergic rhinitis (AR). However, very little is known about the role of IL-33 for the development of AR. Objective: We thought to develop a novel murine model of ragweed pollen-specific AR and examined the pathologic role for ragweed-induced IL-33 in the development of AR manifestation using IL-33-deficient (il33(-/-)) mice. Methods: Ragweed-immunized and ragweed-challenged mice were examined for early-and late-phase nasal responses. IL-33 protein expression in the nasal epithelial cells of the AR murine model and patients with AR were assessed by using confocal microscopy. Results: After nasal challenge with ragweed pollen, ragweed-immunized wild-type mice manifested early-phase (sneezing) and late-phase (eosinophilic and basophilic accumulation) responses. In contrast, il33(-/-) and FceRI(-/-) mice did not have both early-and late-phase AR responses. IL-33 protein was constitutively expressed in the nucleus of nasal epithelial cells and was promptly released into nasal fluids in response to nasal exposure to ragweed pollen. In human subjects we revealed constitutive expression of IL-33 protein in the nasal epithelial cells of healthy control subjects and downregulated expression of IL-33 protein in inflamed nasal epithelial cells of patients with AR. IL-33-stimulated mast cells and basophils contributed to the early-and late-phase AR manifestation through increasing histamine release and production of chemoattractants for eosinophils/basophils, respectively. Conclusions: Ragweed pollen-driven endogenous IL-33 contributed to the development of AR responses. IL-33 might present an important therapeutic target for the prevention of AR. (J Allergy Clin Immunol 2012; 130: 184-94.)	[Haenuki, Yoko; Matsushita, Kazufumi; Futatsugi-Yumikura, Shizue; Yoshimoto, Tomohiro] Hyogo Coll Med, Lab Allerg Dis, Inst Adv Med Sci, Nishinomiya, Hyogo 6638501, Japan; [Haenuki, Yoko; Nakanishi, Kenji] Hyogo Coll Med, Dept Immunol & Med Zool, Nishinomiya, Hyogo 6638501, Japan; [Haenuki, Yoko; Yasuda, Makoto; Hisa, Yasuo] Kyoto Prefectural Univ Med, Dept Otolaryngol Head & Neck Surg, Kyoto, Japan; [Ishii, Ken J.] Natl Inst Biomed Innovat, Lab Adjuvant Innovat, Ibaraki, Osaka, Japan; [Ishii, Ken J.; Kawagoe, Tatsukata; Akira, Shizuo] Osaka Univ, Host Def Lab, WPI Immunol Frontier Res Ctr, Suita, Osaka, Japan; [Imoto, Yoshimasa; Fujieda, Shigeharu] Univ Fukui, Fac Med Sci, Dept Otorhinolaryngol, Fukui, Japan	Hyogo College of Medicine; Hyogo College of Medicine; Kyoto Prefectural University of Medicine; National Institute of Health Sciences - Japan; Osaka University; University of Fukui	Yoshimoto, T (corresponding author), Hyogo Coll Med, Lab Allerg Dis, Inst Adv Med Sci, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	tomo@hyo-med.ac.jp	Yoshimoto, Tomohiro/E-2224-2014; Akira, Shizuo/C-3134-2009; Ishii, Ken J/B-1685-2012	Ishii, Ken J/0000-0002-6728-3872	Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan; Japan Society for the Promotion of Science (JSPS) [22659187]; Takeda Science Foundation	Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF))	Supported by a Strategic Program Grant for Research Institute Development in Private Institute from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan; a Grant-in-Aid for Exploratory Research (no. 22659187) from the Japan Society for the Promotion of Science (JSPS); and the Takeda Science Foundation.	ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; Bagarozzi DA, 1998, AM J RESP CELL MOL, V18, P363, DOI 10.1165/ajrcmb.18.3.2825; BARANIUK JN, 1992, J ALLERGY CLIN IMMUN, V90, P1045, DOI 10.1016/0091-6749(92)90121-H; Borish L, 2003, J ALLERGY CLIN IMMUN, V112, P1021, DOI 10.1016/j.jaci.2003.09.015; Bousquet J, 2007, ALLERGY, V62, P216, DOI 10.1111/j.1398-9995.2007.01307.x; Braunstahl GJ, 2001, AM J RESP CRIT CARE, V164, P858, DOI 10.1164/ajrccm.164.5.2006082; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Ho LH, 2007, J LEUKOCYTE BIOL, V82, P1481, DOI 10.1189/jlb.0407200; Howarth PH, 2000, ALLERGY, V55, P7, DOI 10.1034/j.1398-9995.2000.00802.x; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Karimi K, 1999, EXP HEMATOL, V27, P654, DOI 10.1016/S0301-472X(98)00083-6; KleinJan A, 2000, J ALLERGY CLIN IMMUN, V106, P677, DOI 10.1067/mai.2000.109621; Komai-Koma M, 2007, EUR J IMMUNOL, V37, P2779, DOI 10.1002/eji.200737547; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kuna P, 1996, J ALLERGY CLIN IMMUN, V97, P104, DOI 10.1016/S0091-6749(96)70288-9; Kuna P, 1998, AM J RESP CRIT CARE, V157, P873, DOI 10.1164/ajrccm.157.3.9610052; Lamkanfi M, 2009, IMMUNITY, V31, P5, DOI 10.1016/j.immuni.2009.06.011; Lampinen M, 2004, ALLERGY, V59, P793, DOI 10.1111/j.1398-9995.2004.00469.x; Leung BP, 2004, J IMMUNOL, V173, P145, DOI 10.4049/jimmunol.173.1.145; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Louten J, 2011, INT IMMUNOL, V23, P307, DOI 10.1093/intimm/dxr006; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Matsuba-Kitamura S, 2010, INT IMMUNOL, V22, P479, DOI 10.1093/intimm/dxq035; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Sakashita M, 2008, CLIN EXP ALLERGY, V38, P1875, DOI 10.1111/j.1365-2222.2008.03114.x; Sarin S, 2006, J ALLERGY CLIN IMMUN, V118, P999, DOI 10.1016/j.jaci.2006.09.013; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Smith DE, 2010, CLIN EXP ALLERGY, V40, P200, DOI 10.1111/j.1365-2222.2009.03384.x; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Stolarski B, 2010, J IMMUNOL, V185, P3472, DOI 10.4049/jimmunol.1000730; Suzukawa M, 2008, J IMMUNOL, V181, P5981, DOI 10.4049/jimmunol.181.9.5981; Taramarcaz P, 2005, SWISS MED WKLY, V135, P538; Ugajin T, 2009, J LEUKOCYTE BIOL, V86, P1417, DOI 10.1189/jlb.0609400; Vrekoussis T, 2009, ANTICANCER RES, V29, P4995; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Wopfner N, 2005, INT ARCH ALLERGY IMM, V138, P337, DOI 10.1159/000089188; Yasuda K, 2012, P NATL ACAD SCI US; YOSHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P11931, DOI 10.1073/pnas.92.25.11931; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Ziska L, 2011, P NATL ACAD SCI USA, V108, P4248, DOI 10.1073/pnas.1014107108	58	153	166	4	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					184	+		10.1016/j.jaci.2012.02.013	http://dx.doi.org/10.1016/j.jaci.2012.02.013			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22460070				2022-12-18	WOS:000306644800027
J	Bateman, ED; Kornmann, O; Schmidt, P; Pivovarova, A; Engel, M; Fabbri, LM				Bateman, Eric D.; Kornmann, Oliver; Schmidt, Peter; Pivovarova, Anna; Engel, Michael; Fabbri, Leonardo M.			Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Arginine/arginine genotype; beta(2)-agonist receptor; muscarinic receptor; airway obstruction; bronchodilators	ACTING BETA-AGONISTS; FLUTICASONE; BROMIDE; THERAPY; POLYMORPHISMS; COMBINATION; PREVENTION; SAFETY; ADULTS; ADRB2	Background: The efficacy and safety of inhaled long-acting beta(2)-adrenergic agonists in asthmatic patients with the B16-Arg/Arg genotype has been questioned, and the use of antimuscarinics has been proposed as an alternative in patients whose symptoms are not controlled by inhaled corticosteroids (ICSs). Objective: We compared the efficacy and safety of the long-acting anticholinergic tiotropium with salmeterol and placebo added to an ICS in B16-Arg/Arg patients with asthma that was not controlled by ICSs alone. Methods: In a double-blind, double-dummy, placebo-controlled trial, after a 4-week run-in period with 50 mu g of twice-daily salmeterol administered through a metered-dose inhaler, 388 asthmatic patients were randomized 1:1:1 to 16 weeks of treatment with 5 mu g of Respimat tiotropium administered daily in the evening, 50 mu g of salmeterol administered twice daily through a metered-dose inhaler, or placebo. Patients aged 18 to 67 years demonstrated reversibility to bronchodilators, and their symptoms were uncontrolled by regular ICSs (400-1000 mg of budesonide/equivalent). ICS regimens were maintained throughout the trial. The mean weekly morning peak expiratory flow (PEF) before randomization was 358 +/- 115.7 L/min (range, 80.3-733.0 L/min). Results: Changes in weekly PEF from the last week of the run-in period to the last week of treatment (primary end point: change in PEF) were -3.9 +/- 4.87 L/min (n = 128) for tiotropium and -3.2 +/- 4.64 L/min (n = 134) for salmeterol, and these were superior to placebo (-24.6 +/- 4.84 L/min, n = 125, P < .05). Tiotropium was noninferior to salmeterol (estimated difference, -0.78 L/min [95% CI, -13.096 to 11.53]; P = .002; alpha = .025, 1-sided; noninferiority, 20 L/min). Tiotropium and salmeterol were numerically superior to placebo in some patient-reported secondary outcomes. Adverse events were comparable across treatments. Conclusion: Tiotropium was more effective than placebo and as effective as salmeterol in maintaining improved lung function in B16-Arg/Arg patients with moderate persistent asthma. Safety profiles were comparable. (J Allergy Clin Immunol 2011;128:315-22.)	[Fabbri, Leonardo M.] Univ Modena & Reggio Emilia, Sect Resp Dis, Dept Oncol Haematol & Resp Dis, Policlin Modena, I-41124 Modena, Italy; [Bateman, Eric D.] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa; [Kornmann, Oliver] IKF Clin Res Ctr Resp Med, Frankfurt, Germany; [Schmidt, Peter; Pivovarova, Anna; Engel, Michael] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany	Universita di Modena e Reggio Emilia; University of Cape Town; Boehringer Ingelheim	Fabbri, LM (corresponding author), Univ Modena & Reggio Emilia, Sect Resp Dis, Dept Oncol Haematol & Resp Dis, Policlin Modena, Via Pozzo 71, I-41124 Modena, Italy.	leonardo.fabbri@unimore.it	Fabbri, Leonardo M/I-4055-2012	Fabbri, Leonardo M/0000-0001-8894-1689	Boehringer Ingelheim; Pfizer	Boehringer Ingelheim(Boehringer Ingelheim); Pfizer(Pfizer)	Supported by Boehringer Ingelheim and Pfizer.	Bateman ED, 2008, ALLERGY, V63, P932, DOI 10.1111/j.1398-9995.2008.01724.x; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bateman ED, 2010, RESP MED, V104, P1460, DOI 10.1016/j.rmed.2010.06.004; Bateman ED, 2009, PULM PHARMACOL THER, V22, P533, DOI 10.1016/j.pupt.2009.06.002; Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P563, DOI 10.1016/j.jaci.2005.11.036; Bateman Eric, 2010, Int J Chron Obstruct Pulmon Dis, V5, P197; Beasley R, 2009, EUR RESPIR J, V33, P3, DOI 10.1183/09031936.00163408; Bleecker ER, 2007, LANCET, V370, P2118, DOI 10.1016/S0140-6736(07)61906-0; Bleecker ER, 2010, AM J RESP CRIT CARE, V181, P676, DOI [10.1164/rccm.200809-1511OC, 10.1164/200809-1511OC]; Bos IST, 2007, EUR RESPIR J, V30, P653, DOI 10.1183/09031936.00004907; Busse W, 2003, J ALLERGY CLIN IMMUN, V111, P57, DOI 10.1067/mai.2003.38; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Chowdhury BA, 2010, NEW ENGL J MED, V362, P1169, DOI 10.1056/NEJMp1002074; Ducharme FM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005533.pub2; Fardon T, 2007, RESP MED, V101, P1218, DOI 10.1016/j.rmed.2006.11.001; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Godard P, 2008, RESP MED, V102, P1124, DOI 10.1016/j.rmed.2008.03.014; Gosens R, 2005, AM J RESP CRIT CARE, V171, P1096, DOI 10.1164/rccm.200409-1249OC; Gross NJ, 2006, EUR J PHARMACOL, V533, P36, DOI 10.1016/j.ejphar.2005.12.072; Iwamoto H, 2008, EUR RESPIR J, V31, P1379, DOI 10.1183/09031936.00014108; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Kapoor AS, 2009, CAN RESPIR J, V16, P99, DOI 10.1155/2009/206506; Kazani S, 2010, J ALLERGY CLIN IMMUN, V125, P357, DOI 10.1016/j.jaci.2009.12.021; Kerstjens HAM, 2011, J ALLERGY CLIN IMMUN, V128, P308, DOI 10.1016/j.jaci.2011.04.039; Kesten Steven, 2009, Int J Chron Obstruct Pulmon Dis, V4, P397; Magnussen H, 2008, RESP MED, V102, P50, DOI 10.1016/j.rmed.2007.08.003; Michele TM, 2010, NEW ENGL J MED, V363, P1097, DOI 10.1056/NEJMp1008502; *NHLBI, 2007, PUBL NAT HEART LUNG; O'Driscoll BR, 2008, THORAX, V63, DOI 10.1136/thx.2008.102947; Park HW, 2009, ALLERGY, V64, P778, DOI 10.1111/j.1398-9995.2008.01876.x; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Reddel HK, 2010, RESP MED, V104, P1110, DOI 10.1016/j.rmed.2010.04.003; Tashkin DP, 2008, EUR RESPIR J, V31, P742, DOI 10.1183/09031936.00129607; Umeda N, 2008, RESPIROLOGY, V13, P346, DOI 10.1111/j.1440-1843.2008.01259.x; Vogelmeier C, 2011, NEW ENGL J MED, V364, P1093, DOI 10.1056/NEJMoa1008378	36	153	161	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					315	322		10.1016/j.jaci.2011.06.004	http://dx.doi.org/10.1016/j.jaci.2011.06.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21807250	Bronze			2022-12-18	WOS:000293280800010
J	Rueff, F; Przybilla, B; Bilo, MB; Muller, U; Scheipl, F; Aberer, W; Birnbaum, J; Bodzenta-Lukaszyk, A; Bonifazi, F; Bucher, C; Campi, P; Darsow, U; Egger, C; Haeberli, G; Hawranek, T; Kucharewicz, I; Kuchenhoff, H; Lang, R; Quercia, O; Reider, N; Severino, M; Sticherling, M; Sturm, GJ; Wuthrich, B				Rueff, Franziska; Przybilla, Bernhard; Bilo, Maria Beatrice; Mueller, Ulrich; Scheipl, Fabian; Aberer, Werner; Birnbaum, Joelle; Bodzenta-Lukaszyk, Anna; Bonifazi, Floriano; Bucher, Christoph; Campi, Paolo; Darsow, Ulf; Egger, Cornelia; Haeberli, Gabrielle; Hawranek, Thomas; Kucharewicz, Iwona; Kuechenhoff, Helmut; Lang, Roland; Quercia, Oliviero; Reider, Norbert; Severino, Maurizio; Sticherling, Michael; Sturm, Gunter Johannes; Wuethrich, Brunello			Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: The importance of baseline serum tryptase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hymenoptera venom; allergy; venom immunotherapy; tryptase; risk factors; ACE inhibitor; age; sex	MAST-CELL TRYPTASE; HONEYBEE VENOM; ANAPHYLACTIC REACTIONS; RISK-FACTORS; DOUBLE-BLIND; SAFETY; SEVERITY; IGE; MASTOCYTOSIS; EFFICACY	Background: Severe side effects during venom immunotherapy (VIT) are associated with a variety of risk factors. Objective: Our aim was to evaluate the association of baseline serum tryptase concentration (BTC) and of other parameters, which are routinely recorded during patient evaluation, with the frequency of severe reactions requiring an emergency intervention during the buildup phase of VIT. Methods: In this observational prospective multicenter study, we enrolled 680 patients with established honeybee or vespid venom allergy who underwent VIT. Data were collected on tryptase concentration, age, sex, culprit insect, cardiovascular medication, degree of preceding sting reaction, preventive antiallergic medication before therapy, time between last preceding sting reaction and VIT, venom specific IgE concentration, and type of buildup procedure. Relative rates were calculated with generalized additive models. Results: Fifty-seven patients (8.4%) required an emergency intervention during buildup because of a severe systemic reaction. The frequency of interventions increased significantly with higher BTC (log-linear association; adjusted odds ratio, 1.56; 95% CI, 1.15-2.11; P<.005). The predictive power of BTC was markedly greater when VIT was performed for vespid venom allergy than for bee venom (for bee VIT, no significant association; for vespid VII, log-linear association; adjusted odds ratio, 2.33; 95% CI, 1.28-4.26; P = .005). The most important other factor significantly associated with severe reactions during the buildup phase of VII was bee venom allergy. Conclusion: Before vespid VIT, measurement of baseline serum tryptase concentration should be used to identify patients with a high risk for side effects. Patients with bee venom allergy require a particularly high degree of surveillance during VIT. (J Allergy Clin Immunol 2010;126:105-11.)	[Rueff, Franziska] Univ Munich, AllergieZentrum, Klin & Poliklin Dermatol & Allergol, Dept Dermatol & Allergol, D-80337 Munich, Germany; [Scheipl, Fabian; Kuechenhoff, Helmut] Univ Munich, Dept Stat, Stat Consulting Unit, D-80337 Munich, Germany; [Bilo, Maria Beatrice; Bonifazi, Floriano] Azienda Osped Univ, Osped Riuniti Ancona, Dept Internal Med Allergy Immunol & Resp Dis, Allergy Unit, Ancona, Italy; [Mueller, Ulrich; Haeberli, Gabrielle] Spitalnetz Bern, Spital Ziegler, Allergiestn Med Klin, Bern, Switzerland; [Aberer, Werner; Sturm, Gunter Johannes] Med Univ Graz, Dept Dermatol, Graz, Austria; [Birnbaum, Joelle] Hop St Marguerite, Serv Pneumoallergol, Marseille, France; [Bodzenta-Lukaszyk, Anna; Kucharewicz, Iwona] Med Univ Bialystok, Dept Allergol & Internal Med, Bialystok, Poland; [Wuethrich, Brunello] Univ Spital Zurich, Dermatol Klin & Poliklin, Zurich, Switzerland; [Campi, Paolo] Nuovo Osped San Giovanni Dio, Allergy Clin, Florence, Italy; [Darsow, Ulf] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany; [Darsow, Ulf] Tech Univ Munich, Div Environm Dermatol, Munich, Germany; [Darsow, Ulf] Tech Univ Munich, Allergy Helmholtz Ctr, Munich, Germany; [Egger, Cornelia; Reider, Norbert] Med Univ Innsbruck, Dept Dermatol, Innsbruck, Austria; [Hawranek, Thomas; Lang, Roland; Severino, Maurizio] Paracelsus Private Med Univ, Dept Dermatol, Salzburg, Austria; [Quercia, Oliviero] Osped Infermi, Dipartimento Med Interna, Faenza, Italy; [Sticherling, Michael] Univ Klinikum Erlangen, Hautklin, Erlangen, Germany	University of Munich; University of Munich; Medical University of Graz; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Medical University of Bialystok; University of Zurich; University Zurich Hospital; Presidio Ospedaliero San Giovanni di Dio; Technical University of Munich; Technical University of Munich; Technical University of Munich; Medical University of Innsbruck; Paracelsus Private Medical University; Hospital of Rimini; University of Erlangen Nuremberg	Rueff, F (corresponding author), Univ Munich, AllergieZentrum, Klin & Poliklin Dermatol & Allergol, Dept Dermatol & Allergol, Frauenlobstr 9-11, D-80337 Munich, Germany.	Franziska.Rueff@med.uni-muenchen.de	; Bodzenta - Lukaszyk, Anna/V-4795-2018	Scheipl, Fabian/0000-0001-8172-3603; Kuchenhoff, Helmut/0000-0002-6372-2487; Bodzenta - Lukaszyk, Anna/0000-0001-7187-8660	Phadia, Freiburg, Germany; ALK-Abello, Wedel, Germany; Informationsverbund Dermatologischer Kliniken; Jerini	Phadia, Freiburg, Germany; ALK-Abello, Wedel, Germany; Informationsverbund Dermatologischer Kliniken; Jerini	Supported (collection of the data) by Phadia, Freiburg, Germany, and ALK-Abello, Wedel, Germany.; F. Rueff has given paid lectures for and received honoraria for participation in clinical studies from HAL and has received research support from Artu Biologicals and Novartis. B. Przybilla has received honoraria from ALK-Abello, Stallergenes, and Novartis; has received research support from Informationsverbund Dermatologischer Kliniken; and is the treasurer of the German Society of Allergology and Clinical Immunology. M. B. Bilo has received lecture honoraria from Stallergenes. W. Aberer has received research support from Jerini. A. Bodzenta-Lukaszyk has received lecture honoraria from HAL. F. Bonifazi has received lecture honoraria from Phadia. T. Hawranek has given paid lectures for and participated in studies for ALK-Abello. I. Kucharewicz has received lecture honoraria from HAL. The rest of the authors have declared that they have no conflict of interest.	Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; Birnbaum J, 2003, CLIN EXP ALLERGY, V33, P58, DOI 10.1046/j.1365-2222.2003.01564.x; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Brehler R, 2000, J ALLERGY CLIN IMMUN, V105, P1231, DOI 10.1067/mai.2000.105708; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; DAY JH, 1994, J ALLERGY CLIN IMMUN, V93, P691, DOI 10.1016/0091-6749(94)90249-6; Dugas-Breit S, 2010, CLIN EXP ALLERGY, V40, P643, DOI 10.1111/j.1365-2222.2009.03436.x; Gavalas M, 1998, J ACCID EMERG MED, V15, P96; Gelman A., 2008, DATA ANAL USING REGR; Gelman A, 2008, ANN APPL STAT, V2, P1360, DOI 10.1214/08-AOAS191; Gimborn K, 2005, J IMMUNOL, V174, P507, DOI 10.4049/jimmunol.174.1.507; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Kim KT, 1999, J ALLERGY CLIN IMMUN, V103, P671, DOI 10.1016/S0091-6749(99)70241-1; Kucharewicz I, 2007, J INVEST ALLERG CLIN, V17, P65; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Mosbech H, 2000, ALLERGY, V55, P1005, DOI 10.1034/j.1398-9995.2000.00587.x; Muller UR, 2008, J ALLERGY CLIN IMMUN, V122, P1001, DOI 10.1016/j.jaci.2008.08.007; Mueller UR, 2007, CURR OPIN ALLERGY CL, V7, P337, DOI 10.1097/ACI.0b013e328259c328; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Niedoszytko M, 2009, ALLERGY, V64, P1237, DOI 10.1111/j.1398-9995.2009.02118.x; Reimers A, 2000, ALLERGY, V55, P484, DOI 10.1034/j.1398-9995.2000.00520.x; RING J, 1977, LANCET, V1, P466; Roll A, 2006, J INVEST ALLERG CLIN, V16, P79; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Sturm GJ, 2004, ALLERGY, V59, P1110, DOI 10.1111/j.1398-9995.2004.00400.x; White KM, 2008, ANN ALLERG ASTHMA IM, V101, P426, DOI 10.1016/S1081-1206(10)60321-3; Wood SN, 2006, GEN ADDITIVE MODELS, P145; Xiao WB, 2005, J IMMUNOL, V175, P6885, DOI 10.4049/jimmunol.175.10.6885	39	153	154	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					105	111		10.1016/j.jaci.2010.04.025	http://dx.doi.org/10.1016/j.jaci.2010.04.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20542320				2022-12-18	WOS:000280061800018
J	Prescott, SL; Bjorksten, B				Prescott, Susan L.; Bjorksten, Bengt			Probiotics for the prevention or treatment of allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic disease; gut microbiota; probiotics; prebiotics; immune development; allergy prevention; atopic dermatitis; oral tolerance	DOUBLE-BLIND; ATOPIC-DERMATITIS; CHILDREN; IMMUNE; GAMMA; FOOD; SUPPLEMENTATION; MATURATION; MANAGEMENT; INFANTS	This review addresses the effects of probiotic bacteria on immune development and the role in the treatment and prevention of allergic disease. Although there is a sound theoretical basis for anticipating benefits, there are currently insufficient data to recommend probiotics as a part of standard therapy in any allergic conditions. Furthermore, although there have been several studies to show a benefit in prevention of atopic eczema, other studies have failed to support this. None of the studies has shown any clear preventive effect on sensitization, nor any allergic disease other than eczema. The term "probiotic" is often used loosely to include bacterial strains with little documented immunomodulatory capacity or controlled studies to support the claims. It is not known whether effects in experimental systems have any clinical relevance. Finally, very little is known about this large, complex internal ecosystem. Explanations for the varied results between studies include host factors (including genetic differences in microbial responses and allergic predisposition) and other environmental factors, such as general microbial burden, individual microbiota, diet (including consumption of prebiotic substances), and treatment with antibiotics. As more studies are completed, these factors are likely to make robust meta-analyses problematic to perform.	Univ Western Australia, Princess Margaret Hosp, Sch Paediat & Child Hlth Res, Perth, WA 6001, Australia; Natl Inst Environm Med Immunol, Karolinska Inst, Div Physiol, Stockholm, Sweden	University of Western Australia; Karolinska Institutet	Prescott, SL (corresponding author), Univ Western Australia, Princess Margaret Hosp, Sch Paediat & Child Hlth Res, POB D184, Perth, WA 6001, Australia.	sprescott@meddent.uwa.edu.au	Prescott, Susan/H-5665-2014					Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Bell SJ, 2001, J IMMUNOL, V166, P4958, DOI 10.4049/jimmunol.166.8.4958; Benyacoub J, 2003, J NUTR, V133, P1158, DOI 10.1093/jn/133.4.1158; Bjorksten B, 2005, CURR OPIN ALLERGY CL, V5, P249, DOI 10.1097/01.all.0000168790.82206.17; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; BOTTCHER MF, 2007, IN PRESS PED ALLERGY; Brouwer ML, 2006, CLIN EXP ALLERGY, V36, P899, DOI 10.1111/j.1365-2222.2006.02513.x; Di Giacinto C, 2005, J IMMUNOL, V174, P3237, DOI 10.4049/jimmunol.174.6.3237; Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325; Helin T, 2002, ALLERGY, V57, P243, DOI 10.1034/j.1398-9995.2002.1s3299.x; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Lammers KM, 2003, FEMS IMMUNOL MED MIC, V38, P165, DOI 10.1016/S0928-8244(03)00144-5; Lee TTT, 2007, J ALLERGY CLIN IMMUN, V119, P746, DOI 10.1016/j.jaci.2006.11.011; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; MASTRANDREA F, 2004, ALLERG IMMUNOL PARIS, V36, P118; Matricardi PM, 2002, ALLERGY, V57, P185, DOI 10.1034/j.1398-9995.2002.1a3299.x; Newberry RD, 2001, J IMMUNOL, V166, P4465, DOI 10.4049/jimmunol.166.7.4465; Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036; Prescott SL, 2005, CLIN EXP ALLERGY, V35, P1557, DOI 10.1111/j.1365-2222.2005.02376.x; Prescott SL, 2003, CURR OPIN ALLERGY CL, V3, P125, DOI 10.1097/01.all.0000064776.57552.32; Rachmilewitz D, 2004, GASTROENTEROLOGY, V126, P520, DOI 10.1053/j.gastro.2003.11.019; Rehakova Z, 1998, PHYSIOL RES, V47, P357; Riordan SM, 2003, HEPATOLOGY, V37, P1154, DOI 10.1053/jhep.2003.50180; Rosenfeldt V, 2004, J PEDIATR-US, V145, P612, DOI 10.1016/j.jpeds.2004.06.068; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; Vancikova Z, 2003, FOLIA MICROBIOL, V48, P281, DOI 10.1007/BF02930970; Veckman V, 2004, J LEUKOCYTE BIOL, V75, P764, DOI 10.1189/jlb.1003461; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; Wang MF, 2004, PEDIAT ALLERG IMM-UK, V15, P152, DOI 10.1111/j.1399-3038.2004.00156.x; Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673; Wheeler JG, 1997, ANN ALLERG ASTHMA IM, V79, P229, DOI 10.1016/S1081-1206(10)63007-4	37	153	169	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					255	262		10.1016/j.jaci.2007.04.027	http://dx.doi.org/10.1016/j.jaci.2007.04.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17544096	Bronze			2022-12-18	WOS:000248654900004
J	Estelle, F; Simons, R				Estelle, F; Simons, R			Anaphylaxis, killer allergy: Long-term management in the community	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acute systemic allergic reaction; adrenaline; anaphylaxis; antihistamine; epinephrine; food allergy; histamine; insect sting allergy; latex allergy; tryptase	EMERGENCY-DEPARTMENT VISITS; QUALITY-OF-LIFE; IN-VITRO; CLINICAL HISTORY; PEANUT ALLERGY; LATEX ALLERGY; BETA-BLOCKERS; IGE LEVELS; FOOD; EPINEPHRINE	Traditionally, physicians are trained to diagnose and treat anaphylaxis as an acute emergency in a health care setting. In addition to this crucial and time-honored role, we should be cognizant of our wider responsibility to (1) provide a risk assessment for individuals with anaphylaxis, (2) prevent future anaphylaxis episodes by developing long-term personalized risk reduction strategies for affected individuals, and (3) emphasize anaphylaxis education. Risk assessment should include verification of the trigger factor or factors for the anaphylaxis episode by obtaining a comprehensive history and performing relevant investigations, including allergen skin tests and measurement of allergen-specific IgE in serum. In addition, the potential effect of comorbidities and concurrently administered medications on the recognition and emergency treatment of subsequent episodes should be determined. Risk reduction strategies should be personalized to include information about avoidance of specific triggers and initiation of relevant specific preventive treatment (eg, venom immunotherapy). At-risk individuals should be coached in the use of self-injectable epinephrine and equipped with an anaphylaxis emergency action plan and with accurate medical identification. Anaphylaxis education should be provided for these individuals, their families and caregivers, health care professionals, and the general public. Further development of an optimal diagnostic test for anaphylaxis and of tests and algorithms to predict future risk and prevent fatality are urgently needed.	Univ Manitoba, Dept Pediat & Child Hlth, Dept Immunol, Winnipeg, MB, Canada; Univ Manitoba, Natl Training Program Asthma & Allergy, Fac Med, Canadian Inst Hlth Res, Winnipeg, MB, Canada	University of Manitoba; Institute for Work & Health; University of Manitoba	Estelle, F (corresponding author), 820 Sherbrook S, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca						AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; Bansal PJ, 2005, ANN ALLERG ASTHMA IM, V94, P55, DOI 10.1016/S1081-1206(10)61286-0; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Brown RH, 2005, ANESTHESIOLOGY, V102, P496, DOI 10.1097/00000542-200503000-00004; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown Simon G A, 2004, Emerg Med Australas, V16, P120, DOI 10.1111/j.1742-6723.2004.00562.x; CAMARGO C, 2006, ANN ALLERGY ASTHMA I; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; DEBRUYNE JA, 2004, ALLERGY CLIN IMMUNOL, V16, P137; Demoly P, 2005, TOXICOLOGY, V209, P221, DOI 10.1016/j.tox.2004.12.027; Dykewicz MS, 1999, J ALLERGY CLIN IMMUN, V103, pS53; Eberlein-Konig B, 2004, J INVEST ALLERG CLIN, V14, P10; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V109, P162, DOI 10.1067/mai.2002.120552; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Freeman TM, 2004, NEW ENGL J MED, V351, P1978, DOI 10.1056/NEJMcp042013; Fregonese L, 2005, J ALLERGY CLIN IMMUN, V115, P1148, DOI 10.1016/j.jaci.2005.01.068; Gangur V, 2005, ANN ALLERG ASTHMA IM, V95, P4, DOI 10.1016/S1081-1206(10)61181-7; Gillespie C. A., 2004, Journal of Allergy and Clinical Immunology, V113, pS240, DOI 10.1016/j.jaci.2004.01.325; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Grammer LC, 2000, ANN ALLERG ASTHMA IM, V85, P368, DOI 10.1016/S1081-1206(10)62547-1; Hand S, 2004, CLIN EXP ALLERGY, V34, P720, DOI 10.1111/j.1365-2222.2004.1932.x; Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x; Hernandez E, 2005, J INVEST ALLERG CLIN, V15, P158; Hilger C, 2005, J ALLERGY CLIN IMMUN, V115, P617, DOI 10.1016/j.jaci.2004.11.052; JAMES LP, 1964, NEW ENGL J MED, V270, P597, DOI 10.1056/NEJM196403192701202; *JOINT TASK FORC P, 2005, J ALLERGY CLIN IM S2, V0115, pS 483; Kemp SF, 1997, ANN ALLERG ASTHMA IM, V78, P527, DOI 10.1016/S1081-1206(10)63212-7; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; Kimata H, 2004, CLIN EXP ALLERGY, V34, P1910, DOI 10.1111/j.1365-2222.2004.02128.x; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; Kraft S, 2005, J EXP MED, V201, P385, DOI 10.1084/jem.20042085; Krombach JW, 2004, ALLERGY, V59, P1234, DOI 10.1111/j.1398-9995.2004.00603.x; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li M, 2005, J FORENSIC SCI, V50, P169; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; LIEBERMAN P, 2003, MIDDLETONS ALLERGY P, P1497; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jaci.2004.11.012, 10.1016/j.jsci.2004.11.012]; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; Peng ZK, 2004, J ALLERGY CLIN IMMUN, V114, P1189, DOI 10.1016/j.jaci.2004.08.014; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Radcliffe M, 2005, LANCET, V365, P1360, DOI 10.1016/S0140-6736(05)61036-7; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Rawas-Qalaji MM, 2006, J ALLERGY CLIN IMMUN, V117, P398, DOI 10.1016/j.jaci.2005.12.1310; Ring Johannes, 2004, Novartis Found Symp, V257, P6; Ring Johannes, 2002, Curr Allergy Asthma Rep, V2, P40, DOI 10.1007/s11882-002-0036-8; Sainte-Laudy J, 2000, CLIN EXP ALLERGY, V30, P1166, DOI 10.1046/j.1365-2222.2000.00863.x; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sanchez-Borges M, 2005, ANN ALLERG ASTHMA IM, V94, P216, DOI 10.1016/S1081-1206(10)61298-7; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P575, DOI 10.1016/j.jaci.2004.12.1122; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Simons FER, 2001, J ALLERGY CLIN IMMUN, V108, P1040, DOI 10.1067/mai.2001.119916; Simons FER, 2005, ANN ALLERG ASTHMA IM, V94, P534, DOI 10.1016/S1081-1206(10)61129-5; Simons FER, 2000, PEDIATRICS, V106, P1040, DOI 10.1542/peds.106.5.1040; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P622, DOI 10.1016/S1081-1206(10)62289-2; Simons FER, 2004, ALLERGY CLIN IMMUN S, P242; Song TT, 2005, ANN ALLERG ASTHMA IM, V94, P539, DOI 10.1016/S1081-1206(10)61130-1; Sussman GL, 2002, J ALLERGY CLIN IMMUN, V110, pS33, DOI 10.1067/mai.2002.124969; TenBrook JA, 2004, J ALLERGY CLIN IMMUN, V113, P977, DOI 10.1016/j.jaci.2004.02.043; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; VANDERLINDEN PWG, 1993, ANN INTERN MED, V118, P161, DOI 10.7326/0003-4819-118-3-199302010-00001; Zhou X, 2006, J ALLERGY CLIN IMMUN, V117, pS85, DOI 10.1016/j.jaci.2005.12.342	78	153	164	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					367	377		10.1016/j.jaci.2005.12.002	http://dx.doi.org/10.1016/j.jaci.2005.12.002			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461138				2022-12-18	WOS:000235687300020
J	Steinke, JW; Bradley, D; Arango, P; Crouse, CD; Frierson, H; Kountakis, SE; Kraft, M; Borish, L				Steinke, JW; Bradley, D; Arango, P; Crouse, CD; Frierson, H; Kountakis, SE; Kraft, M; Borish, L			Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: Importance to eosinophilia and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; chronic hyperplastic sinusitis; cysteinyl leukotrienes; eosinophiles; leukotriene C4 synthase; nasal polypys; polymorphisms	RECEPTOR ANTAGONISTS; MESSENGER-RNA; TNF-ALPHA; IN-VITRO; INFLAMMATION; RHINOSINUSITIS; INFILTRATION; RHINITIS; AIRWAYS; ALLERGY	Background: Chronic hyperplastic eosinophilic sinusitis (CHS) results from the unregulated proliferation of eosinophils, T(H)2- like lymphocytes, goblet cells, mast cells, and fibroblasts and is present in most patients with asthma. The frequent coexpression of these disorders and their shared pathophysiology suggests that these are similar disorders affecting the upper and lower airways. Objective: We evaluated the expression of cysteinyl leukotrienes (CysLTs) in sinus tissue from subjects with CHS compared with that seen in healthy sinus tissue. Methods: Nasal polyp and sinus tissue was evaluated from 58 individuals undergoing elective functional endoscopic sinus surgery. The diagnosis of CHS was demonstrated through the presence of eosinophilia and activated (EG2(+)) eosinophils, as determined by means of tissue immunohistochemistry. Data were compared with those from both nasal polyp tissue without eosinophilic inflammation and healthy control sinus tissue obtained from the sinus ostiomeatal complex at the time of surgery for unrelated disorders. CysLTs were quantified by means of ELISA in lipid-extracted tissue. Activation of the metabolic pathway leading to CysLT synthesis was demonstrated by ribonuclease protection. Subjects were genotyped for leukotriene C-4 (LTC4) synthase C-to-A promoter polymorphism. Results: CysLT concentrations were significantly higher in tissue obtained from subjects with CHS (776.7 +/- 201.9 pg/g tissue) compared with that seen in healthy sinus tissue (355.7 +/- 101.6 pg/g tissue, P < .03). CysLT concentrations within noneosinophilic nasal polyps (328.0 +/- 116.4 pg/g tissue) were similar to those in control tissue. The presence of CysLTs in CHS was associated with increased expression of LTC4 synthase mRNA. The C-to-A promoter polymorphism was associated with trends toward the increased presence of CHS and CysLTs. Conclusions: CHS is characterized by the increased presence of CysLTs when compared with concentrations seen in tissue from patients with chronic inflammatory sinusitis or healthy sinus tissue. These studies support the use of LT modifiers as anti-inflammatory agents that might have clinical benefit in patients with these disorders.	Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Beirne Carter Ctr Immunol,Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Dept Otolaryngol, Charlottesville, VA 22908 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA	University of Virginia; University of Virginia; University of Virginia; National Jewish Health	Steinke, JW (corresponding author), Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Beirne Carter Ctr Immunol,Dept Med, Box 801355, Charlottesville, VA 22908 USA.				NIAID NIH HHS [AI 01793, K24 AI001793-04, P01 AI050989-03, AI/HL 47737] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Baenkler H. W., 1996, Rhinology (Utrecht), V34, P166; Borish L, 2002, J ALLERGY CLIN IMMUN, V109, P606, DOI 10.1067/mai.2002.123024; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Crawford L, 2002, J ALLERGY CLIN IMMUN, V109, pS296, DOI 10.1016/S0091-6749(02)82041-3; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Denburg JA, 2000, THORAX, V55, pS24, DOI 10.1136/thorax.55.suppl_2.S24; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; FINOTTO S, 1994, J IMMUNOL, V153, P2278; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Jang YJ, 2000, ACTA OTO-LARYNGOL, V120, P531, DOI 10.1080/000164800750046054; Jarjour NN, 2000, J ALLERGY CLIN IMMUN, V105, P1169, DOI 10.1067/mai.2000.106376; Kaliner MA, 1997, J ALLERGY CLIN IMMUN, V99, pS829, DOI 10.1016/S0091-6749(97)70041-1; KAPLAN I, 1995, AM J OTOLARYNG, V6, P395; Kawagishi Y, 2002, J ALLERGY CLIN IMMUN, V109, P936, DOI 10.1067/mai.2002.124466; Kennedy D W, 1992, Laryngoscope, V102, P1; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Lavigne F, 2000, J ALLERGY CLIN IMMUN, V105, P746, DOI 10.1067/mai.2000.105218; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Mygind N, 2000, THORAX, V55, pS79, DOI 10.1136/thorax.55.suppl_2.S79; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; OGINO S, 1993, ACTA OTO-LARYNGOL, P85; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; Parnes S M, 2000, Ear Nose Throat J, V79, P18; Pedersen KE, 1997, J PHARMACOL EXP THER, V281, P655; PFISTER R, 1994, J ALLERGY CLIN IMMUN, V94, P804, DOI 10.1016/0091-6749(94)90146-5; Pinto S, 1997, PROSTAG LEUKOTR ESS, V57, P533, DOI 10.1016/S0952-3278(97)90556-1; Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574; Wald ER, 1998, AM J MED SCI, V316, P13, DOI 10.1097/00000441-199807000-00003; Weller PF, 1997, J ALLERGY CLIN IMMUN, V100, P283, DOI 10.1016/S0091-6749(97)70237-9; Ziroli NE, 2002, OTOLARYNG HEAD NECK, V126, P141, DOI 10.1067/mhn.2002.121913	42	153	165	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					342	349		10.1067/mai.2003.67	http://dx.doi.org/10.1067/mai.2003.67			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589355				2022-12-18	WOS:000180942700019
J	O'Byrne, PM; Inman, MD; Parameswaran, K				O'Byrne, PM; Inman, MD; Parameswaran, K			The trials and tribulations of IL-5, eosinophils, and allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukin-5; eosinophils; allergen; asthma; airway; hyperresponsiveness; late asthmatic responses	RECOMBINANT HUMAN INTERLEUKIN-5; AIRWAY INFLAMMATION; BRONCHIAL HYPERRESPONSIVENESS; ATOPIC ASTHMATICS; MURINE MODEL; BONE-MARROW; BALB/C MICE; RESPONSES; HYPERREACTIVITY; CELLS	Eosinophils have been suggested to be part of the pathologic process that characterizes asthma, and their recruitment into the upper or lower airways appears to be essential for the clinical manifestations of allergen inhalation. IL-5 is a cytokine necessary for the development, differentiation, recruitment, activation, and survival of eosinophils. Allergen inhalation increases the production of IL-5 in the airways as measured in bronchoalveolar lavage cells and induced sputum. The relationship between IL-5 and the development of airway eosinophilia has been firmly established in IL-5 transgenic mice, with allergen challenge models in IL-5-deficient mice, and in mice treated with blocking anti-IL-5 antibodies. In addition, an accumulation of evidence suggests that treating mice with anti-IL-5 blocking antibodies prevents allergen-induced airway hyperresponsiveness. A recently reported study examined the effects of treatment with a humanized anti-IL-5 mAb (SB-240563) on allergen-induced airway responses and inflammation in atopic subjects. The authors of the study concluded that their results call into question the role of eosinophils in mediating the allergen-induced late asthmatic response and airway hyperresponsiveness; however, because of methodologic limitations, the study cannot be used either to support or to refute the concept of an important role for eosinophils in causing allergen-induced changes in airway function.	St Josephs Healthcare, Farestone Inst Resp Hlth, Asthma Res Grp, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Hamilton, ON L8S 4L8, Canada	McMaster University	O'Byrne, PM (corresponding author), St Josephs Healthcare, Farestone Inst Resp Hlth, Asthma Res Grp, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.			O'Byrne, Paul/0000-0003-0979-281X				Avila PC, 2000, AM J RESP CRIT CARE, V161, P2092, DOI 10.1164/ajrccm.161.6.9909056; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CLUTTERBUCK EJ, 1988, BLOOD, V71, P646; COCKCROFT DW, 1989, J ALLERGY CLIN IMMUN, V83, P913, DOI 10.1016/0091-6749(89)90105-X; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; Gauvreau GM, 1999, J ALLERGY CLIN IMMUN, V104, P66, DOI 10.1016/S0091-6749(99)70115-6; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; GIBSON PG, 1989, AM REV RESPIR DIS, V139, P482; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hallden G, 1999, CLIN EXP ALLERGY, V29, P595; Hogan SP, 1997, IMMUNOL CELL BIOL, V75, P284, DOI 10.1038/icb.1997.43; Hogan SP, 1998, J IMMUNOL, V161, P1501; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7; Inman MD, 1998, J ALLERGY CLIN IMMUN, V101, P342, DOI 10.1016/S0091-6749(98)70246-5; Karras JG, 2000, J IMMUNOL, V164, P5409, DOI 10.4049/jimmunol.164.10.5409; KIRBY JG, 1989, J APPL PHYSIOL, V66, P578, DOI 10.1152/jappl.1989.66.2.578; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Mathur M, 1999, AM J RESP CRIT CARE, V159, P580, DOI 10.1164/ajrccm.159.2.9712018; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; Sanderson C J, 1988, Dev Biol Stand, V69, P23; SANDERSON CJ, 1990, INT J CELL CLONING, V8, P147, DOI 10.1002/stem.5530080713; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Shardonofsky FR, 1999, J ALLERGY CLIN IMMUN, V104, P215, DOI 10.1016/S0091-6749(99)70138-7; Singh AD, 1997, THORAX, V52, P483, DOI 10.1136/thx.52.5.483; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Tournoy KG, 2001, J IMMUNOL, V166, P6982, DOI 10.4049/jimmunol.166.11.6982; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125	44	153	158	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					503	508		10.1067/mai.2001.119149	http://dx.doi.org/10.1067/mai.2001.119149			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590372	Bronze			2022-12-18	WOS:000171760300005
J	Helenius, I; Haahtela, T				Helenius, I; Haahtela, T			Allergy and asthma in elite summer sport athletes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; athletes; bronchial hyperresponsiveness; chlorine derivatives; maximal exercise capacity; sports medicine; summer events; swimming	EXERCISE-INDUCED BRONCHOSPASM; CROSS-COUNTRY SKIERS; COLD-AIR; INDUCED BRONCHOCONSTRICTION; BRONCHIAL RESPONSIVENESS; FIGURE SKATERS; MILD ASTHMA; CHILDREN; EXPOSURE; SWIMMERS	Exercise may increase ventilation up to 200 L/min for short periods of time in speed and power athletes, and for longer periods in endurance athletes, such as long-distance runners and swimmers. Therefore highly trained athletes are repeatedly and strongly exposed to cold air during winter training and to many pollen allergens in spring and summer. Competitive swimmers inhale and microaspirate large amounts of air that floats above the water surface, which means exposure to chlorine derivatives from swimming pool disinfectants. In the summer Olympic Games, 4% to 15% of the athletes showed evidence of asthma or used anti-asthmatic medication. Asthma is most commonly found in endurance events, such as cycling, swimming, or long-distance running. The risk of asthma is especially increased among competitive swimmers, of which 36% to 79% show bronchial hyperresponsiveness to methacholine or histamine. The risk of asthma is closely associated with atopy and its severity among athletes. A few studies have investigated occurrence of exercise-induced bronchospasm among highly trained athletes, The occurrences of exercise-induced bronchospasm vary from 3% to 35% and depend on testing environment, type of exercise used, and athlete population tested. Mild eosinophilic airway inflammation has been shown to affect elite swimmers and cross-country skiers. This eosinophilic inflammation correlates with clinical parameters (ie, exercise-induced bronchial symptoms and bronchial hyperresponsiveness). Athletes commonly use antiasthmatic medication to treat their exercise-induced bronchial symptoms. However, controlled studies on their long-term effects on bronchial hyperresponsiveness and airway inflammation in the athletes are lacking. Follow-up studies on asthma in athletes are also lacking. What will happen to bronchial hyperresponsiveness and airway inflammation after discontinuation of competitional career is unclear. In the future, follow-up studies on bronchial responsiveness and airway inflammation, as well as controlled studies on both short- and long-term effects of antiasthmatic drugs in the athletes are needed.	Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, Dept Allergol, Helsinki, Finland; Paijat Hame Cent Hosp, Lahti, Finland	University of Helsinki; Helsinki University Central Hospital; Paijat Hame Central Hospital	Helenius, I (corresponding author), Ohjaajantie 3A 4, Helsinki 00400, Finland.		Helenius, Ilkka/AAM-5803-2020					AGGAZZOTTI G, 1993, ARCH ENVIRON HEALTH, V48, P250, DOI 10.1080/00039896.1993.9940368; ANDERSON SD, 1995, ASTHMA RHINITIS, P1178; Carlsen KH, 1998, PEDIAT ALLERG IMM-UK, V9, P173, DOI 10.1111/j.1399-3038.1998.tb00369.x; Carlson KH, 1989, CHILDREN EXERCISE, P351; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676, DOI 10.1164/ajrccm.149.6.8004329; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; de Benedictis FM, 1998, ANN ALLERG ASTHMA IM, V80, P352, DOI 10.1016/S1081-1206(10)62982-1; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; Dekhuijzen PNR, 1999, THORAX, V54, P1041, DOI 10.1136/thx.54.11.1041; DOSMAN JA, 1991, AM REV RESPIR DIS, V144, P45, DOI 10.1164/ajrccm/144.1.45; Drobnic F, 1996, MED SCI SPORT EXER, V28, P271, DOI 10.1097/00005768-199602000-00018; DROBNIC F, 1994, ARCH BRONCONEUMOL, V8, P419; FITCH KD, 1984, J ALLERGY CLIN IMMUN, V73, P722, DOI 10.1016/0091-6749(84)90314-2; Godfrey S, 1992, ASTHMA, P73; Griffin JW, 1997, LARYNGOSCOPE, V107, P1235, DOI 10.1097/00005537-199709000-00014; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Heir T., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P94; Helbling A, 1991, Schweiz Z Sportmed, V39, P77; HELENIUS I, 1998, THESIS U HELSINKI HE; Helenius IJ, 1996, THORAX, V51, P628, DOI 10.1136/thx.51.6.628; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125, DOI 10.1136/bjsm.32.2.125; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646, DOI 10.1016/S0091-6749(98)70173-3; HENRIKSEN JM, 1986, ALLERGY, V41, P499, DOI 10.1111/j.1398-9995.1986.tb00335.x; Ienna TM, 1997, INT J SPORTS MED, V18, P142, DOI 10.1055/s-2007-972610; Karjalainen EM, 1999, EXERCISE-INDUCED ASTHMA AND SPORTS IN ASTHMA, P81; KOSKELA H, 1997, THESIS U KUOPIO KUOP; Kujala UM, 1996, THORAX, V51, P288, DOI 10.1136/thx.51.3.288; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Larsson K, 1998, EUR RESPIR J, V12, P825, DOI 10.1183/09031936.98.12040825; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564, DOI 10.1152/jappl.1985.58.2.564; MCKENZIE DC, 1994, MED SCI SPORT EXER, V26, P951; *MED COMM INT OL C, 1999, LIST CLASS PROH SUBS; Meltzer EO, 1996, J ALLERGY CLIN IMMUN, V97, P617, DOI 10.1016/S0091-6749(96)70307-X; *MIN SOC AFF HLTH, 1996, CLIN EXP ALLERGY S1, V26, pS1; OCAIN CF, 1980, J APPL PHYSIOL, V49, P875, DOI 10.1152/jappl.1980.49.5.875; Oseid S., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P88; PAPALIA SM, 1996, ASPECTS INHALED BUDE; PAUL DW, 1993, INT J SPORTS MED, V14, P433, DOI 10.1055/s-2007-1021205; PEKKARINEN H, 1989, EUR J APPL PHYSIOL O, V58, P821, DOI 10.1007/BF02332213; PIERSON WE, 1989, ANN ALLERGY, V63, P461; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Potts J, 1996, SPORTS MED, V21, P256, DOI 10.2165/00007256-199621040-00002; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; REED CE, 1988, J ALLERGY CLIN IMMUN, V81, P1042, DOI 10.1016/0091-6749(88)90177-7; RISSER WL, 1994, PEDIATRICS, V94, P129; Sandsund M, 1997, ANN NY ACAD SCI, V813, P751, DOI 10.1111/j.1749-6632.1997.tb51778.x; Schoene RB, 1997, CLIN J SPORT MED, V7, P257, DOI 10.1097/00042752-199710000-00003; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597, DOI 10.1164/ajrccm.158.2.9711012; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; SUZUKI S, 1985, ANN ALLERGY, V54, P136; TIKKANEN HO, 1994, BRIT MED J, V309, P1087, DOI 10.1136/bmj.309.6961.1087; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; ZANCONATO S, 1990, PEDIATR PULM, V8, P240, DOI 10.1002/ppul.1950080406; ZWICK H, 1990, LUNG, V168, P111, DOI 10.1007/BF02719681	63	153	158	0	18	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					444	452		10.1067/mai.2000.107749	http://dx.doi.org/10.1067/mai.2000.107749			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984362				2022-12-18	WOS:000089471900005
J	Sandford, AJ; Chagani, T; Zhu, S; Weir, TD; Bai, TR; Spinelli, JJ; FitzGerald, JM; Behbehani, NA; Tan, WC; Pare, PD				Sandford, AJ; Chagani, T; Zhu, S; Weir, TD; Bai, TR; Spinelli, JJ; FitzGerald, JM; Behbehani, NA; Tan, WC; Pare, PD			Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; severity; IL-4; IL-4 receptor; IgE receptor	FC-EPSILON-RI; STEROID-RESISTANT ASTHMA; IL4-RECEPTOR GENE; ATOPIC ASTHMA; BETA-SUBUNIT; ASSOCIATION; INTERLEUKIN-4; PROMOTER; RECEPTOR; VARIANT	Background: Genetic polymorphisms have been associated with asthma and asthma severity. Objective: We sought to determine whether 3 polymorphisms were associated with severe asthma indicated either by the occurrence of a fatal (or near-fatal) asthma attack or by severe airflow obstruction. Methods: We obtained DNA and clinical data from asthmatic subjects who either died or nearly died during an asthma attack and from a group of subjects with mild-to-moderate asthma who had never experienced a fatal or near-fatal asthma episode. These groups were compared with a group of nonatopic nonasthmatic control subjects. The level of airflow obstruction (FEV1 percent predicted) in the subjects with mild-to-moderate asthma was used as an additional measure of disease severity, The subjects were genotyped for the IL4*C-589T promoter polymorphism and the IL4RA*Q576R and the FCERIB*E237G amino acid substitutions. Results: The results showed that the FCERIB*E237G and IL4RA*Q576R polymorphisms were not associated with fatal or near-fatal asthma. However, the IL4*-589T allele was significantly increased in the subjects with fatal or near-fatal asthma compared with nonasthmatic subjects (odds ratio [OR], 1.8; P = .02) and subjects with mild-to-moderate asthma (OR, 1.9; P = .02). There was no interaction between the IL4*-589T and IL4RA*576R alleles. Of the 3 polymorphisms, only the IL4R4*576R allele was associated with severe airflow obstruction (OR, 8.2; P = .01). Conclusion: These data suggest that the ILA4*-589T allele is a risk factor for life-threatening asthma and that the IL4RA*576R allele is a risk factor for a low level of lung function in asthmatic subjects.	Univ British Columbia, St Pauls Hosp, Pulm Res Lab, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada; St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Vancouver Gen Hosp, Div Resp, Vancouver, BC V5Z 1M9, Canada; Kuwait Univ, Dept Med, Safat, Kuwait; Natl Univ Singapore Hosp, Dept Med, Singapore 117548, Singapore	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; Kuwait University; National University of Singapore	Sandford, AJ (corresponding author), Univ British Columbia, St Pauls Hosp, Pulm Res Lab, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.		Spinelli, John J./B-6210-2013; Pare, Peter D/C-7425-2011	Spinelli, John J./0000-0002-9119-3287; 				*BRIT THOR SOC, 1987, BR J DIS CHEST, V81, P30; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; CALL RS, 1994, J ALLERGY CLIN IMMUN, V94, P1065, DOI 10.1016/0091-6749(94)90125-2; COOPER CS, 1991, METHOD MOL BIOL, V9, P133; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIC; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; KELLY WJW, 1990, J ALLERGY CLIN IMMUN, V85, P548, DOI 10.1016/0091-6749(90)90092-I; LeSon S, 1996, J ASTHMA, V33, P27, DOI 10.3109/02770909609077760; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Sambrook J, 1989, MOL CLONING LAB MANU, V1, P1; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SARAFINO EP, 1995, ARCH DIS CHILD, V73, P112, DOI 10.1136/adc.73.2.112; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SHIRAKAWA T, 1994, CLIN GENET, V46, P228; Shirakawa T, 1996, HUM MOL GENET, V5, P1129, DOI 10.1093/hmg/5.8.1129; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236; Zhu SK, 2000, AM J RESP CRIT CARE, V161, P1655, DOI 10.1164/ajrccm.161.5.9906086; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	35	153	173	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				135	140		10.1067/mai.2000.107926	http://dx.doi.org/10.1067/mai.2000.107926			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887316				2022-12-18	WOS:000088393300018
J	Vignola, AM; Kips, J; Bousquet, J				Vignola, AM; Kips, J; Bousquet, J			Tissue remodeling as a feature of persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; airway remodeling; inflammation; airway obstruction; bronchial hyperresponsiveness	AIRWAY SMOOTH-MUSCLE; BRONCHIAL EPITHELIAL-CELLS; RESOLUTION COMPUTED-TOMOGRAPHY; OBSTRUCTIVE PULMONARY-DISEASE; BRONCHOALVEOLAR LAVAGE FLUID; LONG-TERM TREATMENT; COLONY-STIMULATING FACTOR; DOSE-RESPONSE CURVE; BETA TGF-BETA; INHALED CORTICOSTEROIDS	A chronic inflammatory process is almost invariably associated with tissue damage and healing. Healing results in repair and replacement of dead or damaged cells by viable cells. Repair usually involves 2 distinct processes: regeneration, which is the replacement of injured tissue by parenchymal cells of the same type, and replacement by connective tissue and its eventual maturation into scar tissue. In many instances both processes contribute to the healing response. Chronic inflammatory disease can therefore lead to a wide variety of consequences, from complete or partial restitution of organ structure and function to fibrosis. Asthma is characterized by a chronic inflammatory process of the airways. The ensuing healing process results in structural alterations referred to as a remodeling of the airways. The mechanisms underlying these structural alterations are still largely unknown. They are likely to be heterogeneous, leading-through the highly dynamic process of cell de-differentiation, migration, differentiation, and maturation-to changes in connective tissue deposition and to the altered restitution of airways structure, resulting in mucus gland hyperplasia, neovascularization, fibrosis, and an increase in smooth muscle mass.	Ist Fisiopatol Resp, Palermo, Italy; Ghent Univ Hosp, Dept Resp Dis, Ghent, Belgium; CHU Montpellier, INSERM, U454, Montpellier, France	Ghent University; Ghent University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Bousquet, J (corresponding author), CHU Montpellier, Hop Arnaud Villeneuve, Clin Malad Resp, Montpellier 5, France.		Bousquet, Jean/O-4221-2019					AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Altman GB, 1997, CELL BIOL TOXICOL, V13, P205, DOI 10.1023/A:1007318514715; Altraja A, 1996, AM J RESP CELL MOL, V15, P482, DOI 10.1165/ajrcmb.15.4.8879182; Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907, DOI 10.1164/ajrccm.157.6.9609040; AMITANI R, 1991, AM J RESP CELL MOL, V4, P26, DOI 10.1165/ajrcmb/4.1.26; ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; Arima M, 1999, AM J RESP CELL MOL, V21, P684, DOI 10.1165/ajrcmb.21.6.3671; Backman KS, 1997, CHEST, V112, P1234, DOI 10.1378/chest.112.5.1234; BAI TR, 1990, AM REV RESPIR DIS, V141, P552, DOI 10.1164/ajrccm/141.3.552; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; BEL EH, 1991, AM REV RESPIR DIS, V143, P109, DOI 10.1164/ajrccm/143.1.109; Boulet L P, 1998, Can Respir J, V5, P270; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bousquet J, 1996, AM J RESP CRIT CARE, V153, P1648, DOI 10.1164/ajrccm.153.5.8630616; BRAMLEY AM, 1995, AM J RESP CRIT CARE, V152, P1513, DOI 10.1164/ajrccm.152.5.7582286; Bratton DL, 1999, J ALLERGY CLIN IMMUN, V103, P555, DOI 10.1016/S0091-6749(99)70223-X; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BROWN RH, 1995, J APPL PHYSIOL, V79, P1242, DOI 10.1152/jappl.1995.79.4.1242; Brusasco V, 1999, J APPL PHYSIOL, V87, P567, DOI 10.1152/jappl.1999.87.2.567; Cairns JA, 1997, J CLIN INVEST, V99, P1313, DOI 10.1172/JCI119290; Cameron LA, 1999, EUR RESPIR J, V14, P553, DOI 10.1034/j.1399-3003.1999.14c12.x; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Carroll NG, 2000, AM J RESP CRIT CARE, V161, P244, DOI 10.1164/ajrccm.161.1.9805005; Chakir J, 1996, LAB INVEST, V75, P735; CHANEZ P, 1995, ALLERGY, V50, P878, DOI 10.1111/j.1398-9995.1995.tb02493.x; CHANEZ P, 1993, AM REV RESPIR DIS, V147, P1497, DOI 10.1164/ajrccm/147.6_Pt_1.1497; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; CHETTY A, 1995, EXP LUNG RES, V21, P889, DOI 10.3109/01902149509031769; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; COTRAN R, 1989, INFLAMMATION REPAIR, P39; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; Demoly P, 1999, CLIN EXP ALLERGY, V29, P1390; Djukanovic R, 2000, J ALLERGY CLIN IMMUN, V105, pS522, DOI 10.1016/S0091-6749(00)90055-1; Dolhnikoff M, 1999, AM J RESP CRIT CARE, V160, P1750, DOI 10.1164/ajrccm.160.5.9812040; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; EBINA M, 1990, AM REV RESPIR DIS, V141, P1322, DOI 10.1164/ajrccm/141.5_Pt_1.1322; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Fredberg JJ, 1996, J APPL PHYSIOL, V81, P2703, DOI 10.1152/jappl.1996.81.6.2703; Gillis HL, 1999, J APPL PHYSIOL, V86, P2001, DOI 10.1152/jappl.1999.86.6.2001; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Haahtela T, 1997, CLIN EXP ALLERGY, V27, P351; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Halayko AJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1040, DOI 10.1152/ajplung.1996.270.6.L1040; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; Hirst SJ, 1996, EUR RESPIR J, V9, P808, DOI 10.1183/09031936.96.09040808; Hogg JC, 1996, AM J RESP CRIT CARE, V153, pS16, DOI 10.1164/ajrccm/153.6_Pt_2.S16; Holgate ST, 1999, CLIN EXP ALLERGY, V29, P90, DOI 10.1046/j.1365-2222.1999.00016.x; Holt PG, 1999, J LEUKOCYTE BIOL, V66, P272, DOI 10.1002/jlb.66.2.272; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; HOSSAIN S, 1970, J PATHOL, V101, P171, DOI 10.1002/path.1711010212; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Jeffery PK, 1998, THORAX, V53, P129, DOI 10.1136/thx.53.2.129; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; John M, 1997, J IMMUNOL, V158, P1841; JORDANA M, 1993, AM J RESP CELL MOL, V8, P7, DOI 10.1165/ajrcmb/8.1.7; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; Kay AB, 1997, CIBA F SYMP, V206, P56; Kips JC, 1999, CLIN EXP ALLERGY, V29, P1457; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAMBERT RK, 1994, J APPL PHYSIOL, V77, P1206, DOI 10.1152/jappl.1994.77.3.1206; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lavens SE, 1996, AM J RESP CELL MOL, V14, P95, DOI 10.1165/ajrcmb.14.1.8534491; Lebre MC, 1999, ARCH DERMATOL RES, V291, P447, DOI 10.1007/s004030050436; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260; LESLIE KO, 1992, CELL MOTIL CYTOSKEL, V22, P92, DOI 10.1002/cm.970220203; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Lipscombe RJ, 1998, J LEUKOCYTE BIOL, V63, P342, DOI 10.1002/jlb.63.3.342; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; Low RB, 1999, CURR TOPICS PATHOL, V93, P19; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; Matsukura S, 1999, J IMMUNOL, V163, P6876; Mautino G, 1999, LAB INVEST, V79, P39; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; Mautino G, 1999, J ALLERGY CLIN IMMUN, V104, P530, DOI 10.1016/S0091-6749(99)70319-2; MCGOWAN SE, 1992, FASEB J, V6, P2895, DOI 10.1096/fasebj.6.11.1644255; Meerschaert J, 1999, AM J RESP CRIT CARE, V159, P619, DOI 10.1164/ajrccm.159.2.9806053; Meiss RA, 1999, J APPL PHYSIOL, V86, P5, DOI 10.1152/jappl.1999.86.1.5; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; Minshall E, 2000, J ALLERGY CLIN IMMUN, V105, P232, DOI 10.1016/S0091-6749(00)90070-8; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; MITCHELL RW, 1994, AM J PHYSIOL, V267, pL218, DOI 10.1152/ajplung.1994.267.2.L218; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; NAGATA Y, 1992, J LAB CLIN MED, V120, P707; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; NEELEY SP, 1994, AM J RESP CELL MOL, V11, P206, DOI 10.1165/ajrcmb.11.2.8049081; NOGUCHI H, 1992, AM J PATHOL, V140, P521; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; OHNO KJ, 1995, TOXICOL APPL PHARM, V132, P227, DOI 10.1006/taap.1995.1103; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; Overbeek SE, 1996, CHEST, V110, P35, DOI 10.1378/chest.110.1.35; Overbeek SE, 1996, EUR RESPIR J, V9, P2256, DOI 10.1183/09031936.96.09112256; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084, DOI 10.1164/ajrccm/146.4.1084; Paganin F, 1997, EUR RESPIR J, V10, P2446, DOI 10.1183/09031936.97.10112446; PAGANIN F, 1995, CHEST, V107, pS145, DOI 10.1378/chest.107.3_Supplement.145S; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627, DOI 10.1164/ajrccm.161.2.9902094; Panettieri RA, 1998, AM J RESP CRIT CARE, V158, pS133, DOI 10.1164/ajrccm.158.supplement_2.13tac900; Panhuysen, 1997, AM J RESP CRIT CARE, V156, P674; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267, DOI 10.1164/ajrccm.155.4.9105065; Park CS, 1997, RADIOLOGY, V203, P361, DOI 10.1148/radiology.203.2.9114089; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PHUNEK P, 1997, EUR RESPIR J, V10, P25; Rajah R, 1999, AM J RESP CELL MOL, V20, P199, DOI 10.1165/ajrcmb.20.2.3148; Redington AE, 1998, J PATHOL, V186, P410, DOI 10.1002/(SICI)1096-9896(199812)186:4<410::AID-PATH198>3.0.CO;2-9; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; ROCHE WR, 1989, LANCET, V1, P520; Roman J, 1996, IMMUNOL RES, V15, P163, DOI 10.1007/BF02918505; ROTHE MJ, 1994, CLIN IMMUNOTHER, V1, P282, DOI 10.1007/BF03259254; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160, DOI 10.1164/ajrccm/145.1.160; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169, DOI 10.1164/ajrccm/145.1.169; Salmon M, 1999, EUR RESPIR J, V14, P633, DOI 10.1034/j.1399-3003.1999.14c25.x; Schlick W, 1993, Monaldi Arch Chest Dis, V48, P237; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Shapiro SD, 1999, AM J RESP CELL MOL, V20, P1100, DOI 10.1165/ajrcmb.20.6.f151; SHEPPARD MN, 1992, THORAX, V47, P1064, DOI 10.1136/thx.47.12.1064; Shiels IA, 1999, INFLAMMATION, V23, P321; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Simon HU, 1997, EUR J IMMUNOL, V27, P3536, DOI 10.1002/eji.1830271256; SNIDER GL, 1985, CHEST, V87, pS35, DOI 10.1378/chest.87.1.35S; Solway J, 1997, AM J RESP CELL MOL, V17, P144, DOI 10.1165/ajrcmb.17.2.f137; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; STERK PJ, 1991, AM REV RESPIR DIS, V143, P1433, DOI 10.1164/ajrccm/143.6.1433; Sterk PJ, 1999, EUR RESPIR J, V14, P1435, DOI 10.1183/09031936.99.14614359; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Sun G, 1997, PEPTIDES, V18, P1449, DOI 10.1016/S0196-9781(97)00194-0; THOMPSON HL, 1991, J CLIN INVEST, V87, P619, DOI 10.1172/JCI115038; TOMLINSON PR, 1995, BIOCHEM PHARMACOL, V49, P1809, DOI 10.1016/0006-2952(94)00532-Q; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; ULRIK CS, 1994, EUR RESPIR J, V7, P1003; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; Vanacker NJ, 1999, AM J RESP CRIT CARE, V159, pA115; Vanacker NJ, 1999, AM J RESP CRIT CARE, V159, pA113; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Vignola AM, 1996, CLIN EXP IMMUNOL, V106, P114, DOI 10.1046/j.1365-2249.1996.d01-811.x; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WALZ TM, 1993, LEUKEMIA, V7, P1531; Warshamana GS, 1998, AM J PHYSIOL-LUNG C, V274, pL499, DOI 10.1152/ajplung.1998.274.4.L499; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WERB Z, 1992, MONONUCLEAR PHAGOCYTES, P404; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814, DOI 10.1152/jappl.1997.83.6.1814; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; Ying S, 1999, J IMMUNOL, V163, P6321; YOUNG PG, 1995, EUR J PHARMACOL, V273, P137, DOI 10.1016/0014-2999(94)00679-2; ZAHM JM, 1991, AM J RESP CELL MOL, V5, P242, DOI 10.1165/ajrcmb/5.3.242; Zhang SL, 1999, LAB INVEST, V79, P395	178	153	166	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1041	1053		10.1067/mai.2000.107195	http://dx.doi.org/10.1067/mai.2000.107195			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856134				2022-12-18	WOS:000087781800001
J	Bugajska-Schretter, A; Elfman, L; Fuchs, T; Kapiotis, S; Rumpold, H; Valenta, R; Spitzauer, S				Bugajska-Schretter, A; Elfman, L; Fuchs, T; Kapiotis, S; Rumpold, H; Valenta, R; Spitzauer, S			Parvalbumin, a cross-reactive fish allergen, contains IgE-binding epitopes sensitive to periodate treatment and Ca2+ depletion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fish allergens; immunoblot; cross-reactivity; parvalbumin; Ca2+-binding protein; IgE epitopes	FOOD ALLERGY; PROTEIN; CHILDREN; MUSCLE; INVITRO; POLLEN; COD	Background: Type I allergy to fish is a severe health problem in countries in which a large percentage of the population derive income from fishing. Objective: The aim of the study was to characterize crossreactive IgE-binding components in six different fish species (cod, tuna, salmon, perch, carp, and eel). The effect of reducing extraction conditions, periodate treatment, and depletion of Ca2+ on binding of IgE to the allergens was investigated. Methods: Extracts were prepared under nonreducing and reducing conditions, IgE-binding components were characterized by IgE immunoblotting, and cross-reactive epitopes were studied by IgE-immunoblot inhibition experiments. To reveal calcium-sensitive or carbohydrate-containing epitopes, nitrocellulose-blotted extracts were exposed to ethylene glycol bis(beta-aminoethyl ether) -N,N,N',N'-tetraacetic acid (EGTA) and periodate. Results: Sera from all patients allergic to fish (n = 30) displayed IgE reactivity to parvalbumin, a 12 kd protein present in fish extracts from six different species. Reducing extraction conditions had no effect on IgE binding to parvalbumins, whereas periodate treatment and depletion of protein-bound calcium led to a substantial reduction of IgE binding. Parvalbumins from six different species contained cross-reactive IgE epitopes Conclusion: Parvalbumin represents a cross-reactive fish allergen. It contains IgE epitopes that are sensitive to periodate treatment and Ca2+-depletion.	Univ Vienna, AKH, Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria; Pharmacia & Upjohn Inc, Diagnost, Uppsala, Sweden; Univ Gottingen, Dept Dermatol, D-3400 Gottingen, Germany; Univ Vienna, AKH, Inst Gen & Expt Pathol, A-1090 Vienna, Austria	University of Vienna; Pfizer; Pharmacia Corporation; University of Gottingen; University of Vienna	Valenta, R (corresponding author), Univ Vienna, AKH, Inst Gen & Expt Pathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.			Valenta, Rudolf/0000-0001-5944-3365				AAS K, 1969, J ALLERGY, V44, P333, DOI 10.1016/0021-8707(69)90025-2; Aas K., 1987, FOOD ALLERGY INTOLER, P356; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COFFEE CJ, 1973, J BIOL CHEM, V248, P3305; CRESPO JF, 1992, J ALLERGY CLIN IMMUN, V89, P192; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; de Besche A., 1937, ACTA MED SCAND, V42, P237; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; DEMARTINO M, 1990, J ALLERGY CLIN IMMUN, V86, P909, DOI 10.1016/S0091-6749(05)80154-X; Dreborg S., 1989, ALLERGY S10, V44, P31; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; ELSAYED S, 1971, J ALLERGY, V47, P283, DOI 10.1016/S0091-6749(71)80006-4; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; KAJOSAARI M, 1982, ACTA PAEDIATR SCAND, V71, P815, DOI 10.1111/j.1651-2227.1982.tb09525.x; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindstrom CDV, 1996, SCAND J IMMUNOL, V44, P335, DOI 10.1046/j.1365-3083.1996.d01-314.x; ONEIL C, 1993, CLIN REV ALLERG, V11, P183; PASCUAL C, 1992, J PEDIATR, V121, P29; PECHERE JF, 1971, EUR J BIOCHEM, V23, P421, DOI 10.1111/j.1432-1033.1971.tb01636.x; SEIBERLER S, 1992, INT ARCH ALLERGY IMM, V99, P380, DOI 10.1159/000236290; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; Strynadka NCJ, 1991, CURR OPIN STRUC BIOL, V1, P905, DOI 10.1016/0959-440X(91)90085-8; Suphioglu C, 1997, FEBS LETT, V402, P167, DOI 10.1016/S0014-5793(96)01520-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVE G, 1995, EMBO J, V14, P4922, DOI 10.1002/j.1460-2075.1995.tb00175.x; TUFT L, 1946, J ALLERGY, V17, P329, DOI 10.1016/0021-8707(46)90155-4; TWARDOSZ A, 1997, IN PRESS BIOCH BIOPH; WOODWARD MP, 1985, J IMMUNOL METHODS, V78, P143, DOI 10.1016/0022-1759(85)90337-0	30	153	158	1	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				67	74		10.1016/S0091-6749(98)70195-2	http://dx.doi.org/10.1016/S0091-6749(98)70195-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449503				2022-12-18	WOS:000071539800011
J	Kaliner, MA; Osguthorpe, JD; Fireman, P; Anon, J; Georgitis, JG; Davis, ML; Naclerio, R; Kennedy, D				Kaliner, MA; Osguthorpe, JD; Fireman, P; Anon, J; Georgitis, JG; Davis, ML; Naclerio, R; Kennedy, D			Sinusitis: Bench to bedside - Current findings, future directions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sinusitis; allergy; otolaryngology; sinus surgery; public health, sinusitis	COLONY-STIMULATING FACTOR; ADHESION MOLECULE EXPRESSION; CHRONIC MAXILLARY SINUSITIS; NORMAL HUMAN SKIN; NASAL-MUCOSA; NITRIC-OXIDE; CYTOKINE EXPRESSION; ALLERGIC RHINITIS; RESPIRATORY-TRACT; CHILDREN	Sinusitis, an inflammatory disease of the sinus, is one of the most commonly reported diseases in the United States, affecting an estimated 14% of the population. The prevalence of sinusitis is rising. Between 1990 and 1992, persons with sinusitis reported approximately 73 million restricted activity days-an increase from the 50 million restricted activity days reported between 1986 and 1988. Because critical questions remain unanswered about its cause, pathophysiology, and optimal treatment, sinusitis continues to generate significant health care costs and affects the quality of life of a large segment of the U.S. population. To identify critical directions for research on sinus disease, the American Academy of Allergy, Asthma and Immunology and the American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc., convened a meeting in January 1996 in collaboration with the National Institutes of Allergy and Infectious Disease. This document summarizes the proceedings of that meeting and presents what is intended to be the background for future investigation of the many unanswered questions related to sinusitis.	UNIV PITTSBURGH,CHILDRENS HOSP,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15260; UNIV CHICAGO,CHICAGO,IL 60637; UNIV PENN,PHILADELPHIA,PA 19104; WASHINGTON HOSP CTR,INST ASTHMA & ALLERGY,WASHINGTON,DC 20010; MED UNIV S CAROLINA,CHARLESTON,SC; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Chicago; University of Pennsylvania; MedStar Washington Hospital Center; Medical University of South Carolina; Wake Forest University; Wake Forest Baptist Medical Center	Kaliner, MA (corresponding author), AMER ACAD ALLERGY ASTHMA & IMMUNOL,611 E WELLS ST,MILWAUKEE,WI 53202, USA.		Anon, Jack/S-4468-2019	Anon, Jack/0000-0002-4189-5264				ADINOFF AD, 1989, PEDIATR ANN, V18, P785, DOI 10.3928/0090-4481-19891201-08; BARANIUK JN, 1991, PULM PHARMACOL THER, V4, P20, DOI 10.1016/0952-0600(91)90035-2; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BENSON V, 1994, VITAL HLTH STAT, V10; BERG O, 1986, Rhinology (Utrecht), V24, P223; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOLGER WE, 1994, AM J RHINOL, V8, P279, DOI 10.2500/105065894781874205; BRAUNSTEIN G, 1991, AM REV RESPIR DIS, V144, P630, DOI 10.1164/ajrccm/144.3_Pt_1.630; BREZILLON S, 1995, LAB INVEST, V72, P191; BUSINCO L, 1981, INT J PEDIATR OTORHI, V3, P287, DOI 10.1016/0165-5876(81)90053-7; CERVIN A, 1991, ACTA PHYSIOL SCAND, V143, P405, DOI 10.1111/j.1748-1716.1991.tb09252.x; Collins J G, 1993, Vital Health Stat 10, P1; DENBURG JA, 1991, INT ARCH ALLER A IMM, V94, P127, DOI 10.1159/000235343; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DINGLE JH, 1964, ILLNESS HOME STUDY 2, P347; Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208, DOI 10.1128/AAC.40.5.1208; Dolovich J, 1990, NASAL POLYPS LOCAL I, P233; DRAY A, 1994, TRENDS PHARMACOL SCI, V15, P190, DOI 10.1016/0165-6147(94)90147-3; DRUCE HM, 1990, OTOLARYNG HEAD NECK, V103, P880, DOI 10.1177/01945998901030S508; DURHAM SR, 1992, J IMMUNOL, V148, P2390; ELIAS JA, 1994, J BIOL CHEM, V269, P22261; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FINOTTO S, 1994, J IMMUNOL, V153, P2278; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; GLIKLICH RE, 1995, LARYNGOSCOPE, V105, P387, DOI 10.1288/00005537-199504000-00010; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; GLIKLICH RE, 1995, QUAL LIFE RES, V4, P27, DOI 10.1007/BF00434380; GROVES RW, 1992, J INVEST DERMATOL, V98, P384, DOI 10.1111/1523-1747.ep12499816; GROVES RW, 1995, BRIT J DERMATOL, V132, P345, DOI 10.1111/j.1365-2133.1995.tb08666.x; GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P457, DOI 10.1016/0091-6749(92)90169-3; Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1209, DOI 10.1093/clinids/23.6.1209; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; HAHN B, 1994, AGENCY HLTH CARE POL; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; Hoffman S R, 1993, Ear Nose Throat J, V72, P413; HSU J, IN PRESS AM J RHINOL; IGARASHI Y, 1995, J ALLERGY CLIN IMMUN, V95, P716, DOI 10.1016/S0091-6749(95)70177-X; JAIN B, 1993, BIOCHEM BIOPH RES CO, V191, P83, DOI 10.1006/bbrc.1993.1187; JENEY EVM, 1990, J ALLERGY CLIN IMMUN, V86, P10, DOI 10.1016/S0091-6749(05)80117-4; Juniper EF, 1995, QUALITY LIFE PHARMAC, P49; KARMA P, 1979, ARCH OTOLARYNGOL, V105, P386; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; KENNEDY DW, 1992, LARYNGOSCOPE, V12; KENNEDY DW, 1995, ANN OTOL RHINOL LARY, V104; Lundberg JON, 1995, ACTA PHYSIOL SCAND, V155, P467, DOI 10.1111/j.1748-1716.1995.tb09998.x; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; LUSK RP, 1989, PEDIATR CLIN N AM, V36, P1411; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCNALLY PA, IN PRESS ALLERGY AST; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; MOSS RB, IN PRESS J CLIN LAB; MUNTZ HR, 1991, ARCH OTOLARYNGOL, V117, P179; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; NOAH TL, 1993, AM J PHYSIOL, V265, pL472, DOI 10.1152/ajplung.1993.265.5.L472; OHNO I, 1991, AM J RESP CELL MOL, V5, P505, DOI 10.1165/ajrcmb/5.6.505; OKAMOTO Y, 1993, J IMMUNOL, V151, P4391; OROBELLO PW, 1991, ARCH OTOLARYNGOL, V117, P980; OTTEN FWA, 1988, INT J PEDIATR OTORHI, V15, P269, DOI 10.1016/0165-5876(88)90082-1; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, pS55, DOI 10.1097/00006454-198511001-00003; SHAPIRO GG, 1991, PEDIATRICS, V87, P311; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; SMITH CH, 1993, J IMMUNOL, V151, P3274; STJARNE P, 1991, ACTA PHYSIOL SCAND, V141, P335, DOI 10.1111/j.1748-1716.1991.tb09089.x; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; SYKES DA, 1986, LANCET, V2, P359; TINKELMAN DG, 1989, AM J DIS CHILD, V143, P938, DOI 10.1001/archpedi.1989.02150200098025; TOKUYAMA K, 1990, AM J PHYSL 1, V259, pL408; WALD ER, 1986, PEDIATRICS, V77, P795; WALD ER, 1995, J PEDIATR-US, V127, P339, DOI 10.1016/S0022-3476(95)70061-7; WALTNER W E, 1987, American Review of Respiratory Disease, V135, pA288; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WAWROSE SF, 1992, LARYNGOSCOPE, V102, P1225, DOI 10.1288/00005537-199211000-00004; WELLICOME SM, 1990, J IMMUNOL, V144, P2558; ZIMENT I, 1991, J RESP DIS, V12, P21; ZIMMERMAN B, 1987, J ALLERGY CLIN IMMUN, V80, P268, DOI 10.1016/0091-6749(87)90029-7; ZINREICH SJ, 1987, RADIOLOGY, V163, P764	84	153	162	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	3	S			S829	S848		10.1016/S0091-6749(97)70041-1	http://dx.doi.org/10.1016/S0091-6749(97)70041-1			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XJ364	9212027	Bronze			2022-12-18	WOS:A1997XJ36400001
J	Spector, SL				Spector, SL			Overview of comorbid associations of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; sinusitis; otitis media; respiratory infections; nasal polyposis; antihistamines; decongestants; topical corticosteroids	QUALITY-OF-LIFE; IGE-MEDIATED HYPERSENSITIVITY; RESPIRATORY SYNCYTIAL VIRUS; NASAL STEROID SPRAY; PERENNIAL RHINITIS; ORAL ANTIHISTAMINE; HAY-FEVER; BECLOMETHASONE DIPROPIONATE; BRONCHIAL RESPONSIVENESS; TRIAMCINOLONE ACETONIDE	Allergic rhinitis affects approximately 20% of the U.S. population. An association between allergic rhinitis and conditions including asthma, sinusitis, otitis media, nasal polyposis, respiratory infections, and even orthodontic malocclusions has been observed. Clinical research has identified shared pathogenic mechanisms, epidemiologic correlations, and findings from allergy testing to indicate that these conditions represent long-term physical consequences in allergic individuals. The positive response of patients afflicted with these conditions to antiallergic treatment further enhances the association between allergic rhinitis and other airway diseases. The use of nasal corticosteroids in patients with rhinitis and asthma reduces not only rhinitis symptoms but also asthma symptoms and airway reactivity to methacholine challenge. Similarly, antihistamines, with or without decongestants, result in improvement of objective measurements of pulmonary function. In the treatment of acute sinusitis, the combination of an intranasal corticosteroid and and antibiotic provides greater benefit than an antibiotic alone. Treatment strategies for allergic rhinitis should be directed at controlling the symptoms of allergic rhinitis and reducing the development of physical complications in susceptible persons. Three techniques for the treatment of allergic rhinitis are used, including avoidance of offending allergens, selection of appropriate pharmaceuticals, and allergy immunotherapy. Appropriate treatment may spare some patients of related airway diseases and may also reduce the overall cost of care. The broadened scope of allergic rhinitis and increased prevalence of IgE-mediated diseases have heightened awareness regarding the profound consequences of allergic rhinitis and the importance of effective treatment.			Spector, SL (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, 11620 WILSHIRE BLVD, SUITE 200, LOS ANGELES, CA 90025 USA.							ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; BARANIUK JN, 1996, J RESP DIS S, V17, pS11; BARANIUK JN, 1996, J RESPIR DIS S8, V17, pS34; BERNSTEIN JM, 1985, OTOLARYNG HEAD NECK, V93, P611, DOI 10.1177/019459988509300508; BERNSTEIN JM, 1992, OTOLARYNG CLIN N AM, V25, P197; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P309, DOI 10.1016/S0091-6749(96)70155-0; BRESOLIN D, 1983, AM J ORTHOD DENTOFAC, V83, P334, DOI 10.1016/0002-9416(83)90229-4; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; BUNNAG C, 1992, ALLERGY, V47, P313, DOI 10.1111/j.1398-9995.1992.tb02060.x; CLARKE CH, 1978, BRIT J CLIN PHARMACO, V6, P31, DOI 10.1111/j.1365-2125.1978.tb01678.x; CONNER BL, 1989, ANN ALLERGY, V62, P457; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; CORREN J, 1996, IN PRESS ANN ALLERGY; DAVIS WE, 1991, OTOLARYNG HEAD NECK, V104, P467, DOI 10.1177/019459989110400407; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FARRELL BP, 1993, ENT-EAR NOSE THROAT, V72, P544; FINDLAY S, 1992, ANN ALLERGY, V68, P228; FIREMAN P, 1990, J ALLERGY CLIN IMMUN, V86, P638, DOI 10.1016/S0091-6749(05)80229-5; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; FROLUND L, 1991, CLIN OTOLARYNGOL, V16, P527, DOI 10.1111/j.1365-2273.1991.tb00965.x; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; GURWITZ D, 1980, AM REV RESPIR DIS, V122, P95; HENAUER S, 1991, EUR J CLIN PHARMACOL, V41, P321, DOI 10.1007/BF00314960; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; HURST DS, 1993, OTOLARYNG HEAD NECK, V108, P711, DOI 10.1177/019459989310800614; JORDANA M, 1995, ASTHMA RHINITIS, P156; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; KIM YK, 1996, IN PRESS J CLIN INVE; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; MABRY RL, 1992, SOUTH MED J, V85, P149, DOI 10.1097/00007611-199202000-00008; MARSHALL PS, 1993, ANN ALLERGY, V71, P251; MATERNOWSKI CJ, 1962, J ALLERGY, V33, P130; MCCONNOCHIE KM, 1984, PEDIATRICS, V74, P1; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; *MED LETT INC, 1995, MED LETT DRUGS THER, V37, P5; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; MELTZER EO, 1991, ANN ALLERGY, V67, P625; MELTZER EO, 1995, J ALLERGY CLIN IMMUN, V95, P1097, DOI 10.1016/S0091-6749(95)70213-X; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P613, DOI 10.1016/S0091-6749(05)80225-8; MINOR TE, 1974, J PEDIATR-US, V85, P472, DOI 10.1016/S0022-3476(74)80447-6; Moss AJ, 1985, VITAL HLTH STAT, V10, P1; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MUNCH EP, 1983, ALLERGY, V38, P517, DOI 10.1111/j.1398-9995.1983.tb02361.x; MYGIND N, 1977, CLIN ALLERGY, V7, P69, DOI 10.1111/j.1365-2222.1977.tb01426.x; Mygind N, 1996, CLIN EXP ALLERGY, V26, P2, DOI 10.1111/j.1365-2222.1996.tb00652.x; Mygind N, 1990, AM J RHINOL, V4, P1; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; Nicklas RA, 1996, J ALLERGY CLIN IMMUN, V98, P1001, DOI 10.1016/S0091-6749(96)80183-7; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PORRO E, 1992, INT J PEDIATR OTORHI, V24, P111, DOI 10.1016/0165-5876(92)90137-E; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; RAMAEKERS JG, 1992, EUR J CLIN PHARMACOL, V42, P363; RICKETTI AJ, 1985, ALLERGIC DISEASES DI, P207; ROSS RN, 1996, AM J MANAG CARE, V2, P285; ROTH T, 1987, J ALLERGY CLIN IMMUN, V80, P94, DOI 10.1016/S0091-6749(87)80197-5; SALOMONSSON P, 1988, ALLERGY, V43, P214; SAVOLAINEN S, 1989, ALLERGY, V44, P116, DOI 10.1111/j.1398-9995.1989.tb02234.x; Schwartz H J, 1986, Ear Nose Throat J, V65, P449; SEIDEL WF, 1987, ANN ALLERGY, V59, P58; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; SETTIPANE GA, 1991, RHINITIS, P178; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; SIBBALD B, 1995, ASTHMA RHINITIS, P32; SIMS DG, 1978, BRIT MED J, V1, P11, DOI 10.1136/bmj.1.6104.11; SPECTOR S, 1992, ANN ALLERGY, V69, P212; Spector Sheldon L., 1995, Am J Ther, V2, P290, DOI 10.1097/00045391-199504000-00013; SPECTOR SL, 1995, J ALLERGY CLIN IMMUN, V96, P174, DOI 10.1016/S0091-6749(95)70005-6; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STILLWAGON PK, 1987, ANN ALLERGY, V58, P442; STORMS W, 1991, ANN ALLERGY, V66, P329; TOMONAGA K, 1988, ACTA OTO-LARYNGOL, V458, pS41; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; VAN DISHOECK H A, 1957, Pract Otorhinolaryngol (Basel), V19, P502; VANDERHEIDE S, 1994, J ALLERGY CLIN IMMUN, V93, P470, DOI 10.1016/0091-6749(94)90356-5; VANDISHOECK HAE, 1961, ADV OTORHINOLARYNGOL, V10, P1; VOLLMER R, 1983, NEUROPSYCHOBIOLOGY, V10, P249, DOI 10.1159/000118019; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104; WELLIVER RC, 1986, AM J DIS CHILD, V140, P34, DOI 10.1001/archpedi.1986.02140150036029; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WIHL JA, 1982, EUR J RESPIR DIS, V63, P205; WOOD SF, 1986, CLIN ALLERGY, V16, P195, DOI 10.1111/j.1365-2222.1986.tb00766.x; WRIGHT AL, 1994, PEDIATRICS, V94, P895; WURTZEN PA, IN PRESS J ALLERGY C	95	153	157	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					S773	S780		10.1016/S0091-6749(97)70126-X	http://dx.doi.org/10.1016/S0091-6749(97)70126-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042070				2022-12-18	WOS:A1997WH83100038
J	NIELSON, CP; VESTAL, RE; STURM, RJ; HEASLIP, R				NIELSON, CP; VESTAL, RE; STURM, RJ; HEASLIP, R			EFFECTS OF SELECTIVE PHOSPHODIESTERASE INHIBITORS ON THE POLYMORPHONUCLEAR LEUKOCYTE RESPIRATORY BURST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM MED CTR, CLIN PHARMACOL & GERONTOL RES UNIT, BOISE, ID USA; UNIV WASHINGTON, DEPT MED, DIV GERONTOL & GERIATR MED, SEATTLE, WA 98195 USA; WYETH AYERST RES, DIV IMMUNOPHARMACOL, PRINCETON, NJ USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; Pfizer					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040325] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40325] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P9; CHAN SC, 1985, J ALLERGY CLIN IMMUN, V76, P148, DOI 10.1016/0091-6749(85)90693-1; CRONSTEIN BN, 1988, BIOCHEM J, V252, P709, DOI 10.1042/bj2520709; CRONSTEIN BN, 1985, J IMMUNOL, V135, P1366; DAVIS CW, 1984, BIOCHIM BIOPHYS ACTA, V797, P354, DOI 10.1016/0304-4165(84)90257-5; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DELLABIANCA V, 1986, BIOCHIM BIOPHYS ACTA, V886, P441; GESPACH C, 1982, MOL PHARMACOL, V22, P547; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KUEHL FA, 1987, AM REV RESPIR DIS, V136, P210, DOI 10.1164/ajrccm/136.1.210; LARSEN GL, 1987, FASEB J, V46, P105; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; NADEL JA, 1984, J ALLERGY CLIN IMMUN, V73, P651, DOI 10.1016/0091-6749(84)90299-9; NIELSON CP, 1988, AM REV RESPIR DIS, V137, P25, DOI 10.1164/ajrccm/137.1.25; NIELSON CP, 1987, J IMMUNOL, V139, P2392; NIELSON CP, 1986, J ALLERGY CLIN IMMUN, V78, P660, DOI 10.1016/0091-6749(86)90086-2; OBYRNE PM, 1985, J APPL PHYSIOL, V59, P1941, DOI 10.1152/jappl.1985.59.6.1941; PANG DC, 1988, DRUG DEVELOP RES, V14, P141, DOI 10.1002/ddr.430140205; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PERSSON CGA, 1986, LIFE SCI, V38, P1057, DOI 10.1016/0024-3205(86)90241-9; PERSSON CGA, 1982, LIFE SCI, V31, P2673, DOI 10.1016/0024-3205(82)90711-1; POLSON JB, 1978, CLIN EXP PHARMACOL P, V5, P535; PRIGENT AF, 1984, CLIN CHIM ACTA, V143, P225, DOI 10.1016/0009-8981(84)90072-X; REEVES ML, 1987, BIOCHEM J, V241, P535, DOI 10.1042/bj2410535; SIMCHOWITZ L, 1980, J IMMUNOL, V124, P1482; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; TORPHY T J, 1987, Reviews in Clinical and Basic Pharmacology, V6, P61; TORPHY TJ, 1982, J BIOL CHEM, V257, P1609; WEISHAAR RE, 1987, CIRC RES, V61, P539, DOI 10.1161/01.RES.61.4.539; WEISHAAR RE, 1986, BIOCHEM PHARMACOL, V35, P787, DOI 10.1016/0006-2952(86)90247-9	35	153	157	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					801	808		10.1016/S0091-6749(05)80186-1	http://dx.doi.org/10.1016/S0091-6749(05)80186-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	1977788				2022-12-18	WOS:A1990EJ63100014
J	REID, MJ; MOSS, RB; HSU, YP; KWASNICKI, JM; COMMERFORD, TM; NELSON, BL				REID, MJ; MOSS, RB; HSU, YP; KWASNICKI, JM; COMMERFORD, TM; NELSON, BL			SEASONAL ASTHMA IN NORTHERN CALIFORNIA - ALLERGIC CAUSES AND EFFICACY OF IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DAVID GRANT USAF MED CTR,ALLERGY CLIN,TRAVIS AFB,CA 94535				Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221				AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; BRUUN EGON, 1949, ACTA ALLERGOL, V2, P122, DOI 10.1111/j.1398-9995.1949.tb03295.x; CITRON K M, 1958, Thorax, V13, P229, DOI 10.1136/thx.13.3.229; Cooke R. A, 1918, NY MED J, V107, P577; CRAMPTON B, 1974, GRASSES CALIFORNIA, P31; FORGACS P, 1968, BRIT MED J, V3, P774; HILL DJ, 1982, BRIT MED J, V284, P306, DOI 10.1136/bmj.284.6312.306; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; LEAVENGOOD DC, 1985, J ALLERGY CLIN IMMUN, V76, P789, DOI 10.1016/0091-6749(85)90749-3; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MARTIN BG, 1985, ANN ALLERGY, V54, P99; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; NELSON BL, 1983, 39TH P ANN M AM AC A; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; PATTERSON R, 1977, J ALLERGY CLIN IMMUN, V59, P314, DOI 10.1016/0091-6749(77)90053-7; REID MJ, 1982, J ALLERGY CLIN IMMUN, V70, P191, DOI 10.1016/0091-6749(82)90041-0; REID MJ, 1985, J ALLERGY CLIN IMMUN, V76, P172, DOI 10.1016/0091-6749(85)90697-9; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; Solomon W. R., 1983, ALLERGY PRINCIPLES P, P1143; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TUCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131, DOI 10.1016/0091-6749(73)90018-3; TURKELTAUB PC, 1986, 42ND P ANN M AM AC A; WARNER JO, 1978, LANCET, V2, P912	25	153	157	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				590	600		10.1016/0091-6749(86)90076-X	http://dx.doi.org/10.1016/0091-6749(86)90076-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	3771951				2022-12-18	WOS:A1986E568200007
J	LICORISH, K; NOVEY, HS; KOZAK, P; FAIRSHTER, RD; WILSON, AF				LICORISH, K; NOVEY, HS; KOZAK, P; FAIRSHTER, RD; WILSON, AF			ROLE OF ALTERNARIA AND PENICILLIUM SPORES IN THE PATHOGENESIS OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,DEPT MED,DIV BASIC & CLIN IMMUNOL,101 CITY DR S,ORANGE,CA 92668; UNIV CALIF IRVINE,DIV PULM & CRIT CARE MED,ORANGE,CA 92668	University of California System; University of California Irvine; University of California System; University of California Irvine								BLACKLEY CH, 1959, EXPT RES CAUSES NATU, P57; BOUHUYS A, 1969, J CLIN INVEST, V48, P1159, DOI 10.1172/JCI106073; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHERNIACK RM, 1972, RESPIRATION HLTH DIS, P11; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; FAIRSHTER RD, 1981, CHEST, V79, P50, DOI 10.1378/chest.79.1.50; FEINBERG SM, 1946, ALLERGY PRACTICE, P216; FETTERS LJ, 1984, ARCH INTERN MED, V144, P938, DOI 10.1001/archinte.144.5.938; HABIB MP, 1979, J APPL PHYSIOL, V47, P51, DOI 10.1152/jappl.1979.47.1.51; HARRIS LEONARD H., 1941, JOUR ALLERGY, V12, P279, DOI 10.1016/S0021-8707(41)80011-2; HOFFMAN DR, 1981, ANN ALLERGY, V46, P310; Hopkins JG, 1930, J AMER MED ASSOC, V94, P6, DOI 10.1001/jama.1930.02710270008002; KOZAK PP, 1979, ANN ALLERGY, V43, P88; MINK S, 1979, J APPL PHYSIOL, V47, P490, DOI 10.1152/jappl.1979.47.3.490; OREHEK J, 1981, AM REV RESPIR DIS, V123, P269; PENNINGTON EDNA S., 1941, JOUR ALLERGY, V12, P388, DOI 10.1016/S0021-8707(41)90266-6; PRATTER MR, 1983, CHEST, V84, P42, DOI 10.1378/chest.84.1.42; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; STROHL KP, 1981, J APPL PHYSIOL, V50, P575, DOI 10.1152/jappl.1981.50.3.575; VROOM DA, 1980, MED DEV DIAGN IND, V2, P45; WILSON A F, 1972, Clinical Research, V20, P243; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006	26	153	155	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					819	825		10.1016/0091-6749(85)90755-9	http://dx.doi.org/10.1016/0091-6749(85)90755-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	4067131				2022-12-18	WOS:A1985AWX9300011
J	MENDELSON, LM; RESSLER, C; ROSEN, JP; SELCOW, JE				MENDELSON, LM; RESSLER, C; ROSEN, JP; SELCOW, JE			ROUTINE ELECTIVE PENICILLIN ALLERGY SKIN TESTING IN CHILDREN AND ADOLESCENTS - STUDY OF SENSITIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT PHARMACOL,FARMINGTON,CT 06032	University of Connecticut; University of Connecticut								Adkinson N F Jr, 1976, Med Times, V104, P164; ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; ADKINSON NF, COMMUNICATION; CHANDRA RK, 1980, ARCH DIS CHILD, V55, P857, DOI 10.1136/adc.55.11.857; DOGLIOTTI M, 1968, DERMATOLOGICA, V136, P489, DOI 10.1159/000254145; ERFFMEYER JE, 1981, ANN ALLERGY, V47, P288; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; RYTEL MW, 1963, JAMA-J AM MED ASSOC, V186, P894; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; VANDELLEN RG, 1970, MED CLIN N AM, V54, P997, DOI 10.1016/S0025-7125(16)32617-7	13	153	158	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					76	81		10.1016/0091-6749(84)90487-1	http://dx.doi.org/10.1016/0091-6749(84)90487-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6693670	Bronze			2022-12-18	WOS:A1984SB99000011
J	HOFFMAN, DR				HOFFMAN, DR			IMMUNOCHEMICAL IDENTIFICATION OF THE ALLERGENS IN EGG-WHITE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL & LAB MED,GREENVILLE,NC 27834, USA.							BAZIN H, 1976, IMMUNOLOGY, V30, P679; BLEUMINK E, 1969, INT ARCH ALLER A IMM, V35, P1; BLEUMINK E, 1971, INT ARCH ALLER A IMM, V40, P72, DOI 10.1159/000230396; HICKS R, 1968, INT ARCH ALLER A IMM, V33, P131, DOI 10.1159/000229983; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; HOFFMAN DR, 1975, ADV DIAGNOSIS ALLERG, P165; MILLER HT, 1977, IMMUNOLOGICAL ASPECT, P152; Perlman F., 1977, IMMUNOLOGICAL ASPECT, P279; REGNIER FE, 1980, ANAL BIOCHEM, V103, P1, DOI 10.1016/0003-2697(80)90229-8; SCHUR S, 1974, J ALLERGY CLIN IMMUN, V54, P174, DOI 10.1016/0091-6749(74)90054-2; TAKATSU K, 1975, CELL IMMUNOL, V20, P276, DOI 10.1016/0008-8749(75)90105-7	14	153	167	2	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					481	486		10.1016/0091-6749(83)90465-7	http://dx.doi.org/10.1016/0091-6749(83)90465-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6601671	Bronze			2022-12-18	WOS:A1983QQ74200008
J	ANDERSON, S; SEALE, JP; FERRIS, L; SCHOEFFEL, R; LINDSAY, DA				ANDERSON, S; SEALE, JP; FERRIS, L; SCHOEFFEL, R; LINDSAY, DA			EVALUATION OF PHARMACOTHERAPY FOR EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ANDERSON, S (corresponding author), ROYAL PRINCE ALFRED HOSP,DEPT THORAC MED,CAMPERDOWN 2050,NEW S WALES,AUSTRALIA.			Anderson, Sandra/0000-0002-6308-8770				ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; ANDERSON SD, 1975, AUST NZ J MED, V5, P544, DOI 10.1111/j.1445-5994.1975.tb03860.x; ANDERSON SD, 1972, AM REV RESPIR DIS, V106, P30, DOI 10.1164/arrd.1972.106.1.30; ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; ANDERSON SD, 1972, THORAX, V27, P718, DOI 10.1136/thx.27.6.718; ANDERSON SD, 1977, MED J AUSTRALIA, V2, P825, DOI 10.5694/j.1326-5377.1977.tb99333.x; BIERMAN CW, 1977, PEDIATRICS, V60, P845; BORUT TC, 1977, J ALLERGY CLIN IMMUN, V60, P127, DOI 10.1016/0091-6749(77)90038-0; BROGDEN RN, 1974, DRUGS, V7, P164, DOI 10.2165/00003495-197407030-00002; BURR ML, 1974, ARCH DIS CHILD, V49, P923, DOI 10.1136/adc.49.12.923; CHANYEUNG M, 1977, CHEST, V71, P320, DOI 10.1378/chest.71.3.320; COTES JE, 1968, LUNG FUNCTION, P381; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; EGGLESTON PA, 1976, J ALLERGY CLIN IMMUN, V57, P251; Evans ME, 1971, BRIT J PHARMACOL, V43, P466; FREEDMAN S, 1975, J APPL PHYSIOL, V38, P974, DOI 10.1152/jappl.1975.38.6.974; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1970, British Journal of Diseases of the Chest, V64, P15, DOI 10.1016/S0007-0971(70)80045-6; HARTLEY J, 1978, COMMUNICATION; HARTLEY JPR, 1977, BRIT J DIS CHEST, V71, P253, DOI 10.1016/S0007-0971(77)80022-3; JONES RS, 1963, ARCH DIS CHILD, V38, P539, DOI 10.1136/adc.38.202.539; JONES RS, 1966, BRIT MED J, V2, P972, DOI 10.1136/bmj.2.5520.972; KATTAN M, 1978, J PEDIATR-US, V92, P718, DOI 10.1016/S0022-3476(78)80135-8; KATZ RM, 1971, J ALLERGY, V47, P148, DOI 10.1016/S0091-6749(71)80293-2; KIVILOOG J, 1975, PEDIATRICS, V56, P940; KIVILOOG J, 1975, PEDIATRICS, V56, P908; KONIG P, 1974, THESIS U LONDON; KOYSOOKO R, 1974, CLIN PHARMACOL THER, V15, P454; MARTIN U, 1978, DRUG RES, V28, P770; MELLIS CM, 1978, AM REV RESPIR DIS, V117, P911; MORSE JLC, 1976, AM REV RESPIR DIS, V113, P89; PATEL KR, 1976, J ALLERGY CLIN IMMUN, V57, P285, DOI 10.1016/0091-6749(76)90084-1; PEPYS J, 1968, LANCET, V2, P134; PIERSON WE, 1969, J ALLERGY, V43, P136, DOI 10.1016/S0021-8707(69)80004-3; POLLOCK J, 1977, PEDIATRICS, V60, P840; POPPIUS H, 1977, EUR J CLIN PHARMACOL, V11, P107, DOI 10.1007/BF00562900; POPPIUS H, 1973, SCAND J RESPIR DIS, V54, P142; POPPIUS H, 1970, BRIT MED J, V4, P337, DOI 10.1136/bmj.4.5731.337; RUDOLF M, 1975, LANCET, V1, P450; SEALE JP, 1976, SCAND J RESPIR DIS, V57, P261; SEALE JP, 1977, AUST NZ J MED, V7, P270, DOI 10.1111/j.1445-5994.1977.tb03685.x; SEALE JP, 1975, AUST NZ J MED, V5, P466; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SILVERMAN M, 1972, Clinical Allergy, V2, P137, DOI 10.1111/j.1365-2222.1972.tb01278.x; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P419, DOI 10.1136/adc.47.253.419; SILVERMAN M, 1973, THESIS U CAMBRIDGE; SLY RM, 1975, ANN ALLERGY, V34, P7; SLY RM, 1967, J ALLERGY, V40, P93, DOI 10.1016/0021-8707(67)90102-5; SLY RM, 1969, ANN ALLERGY, V27, P158; SLY RM, 1974, ANN ALLERGY, V33, P138; SMITH AP, 1975, LANCET, V1, P39; Snedecor G.W., 1980, STAT METHODS, V7; SPRENKLE AC, 1975, PEDIATRICS, V56, P937; TINKELMAN DG, 1976, AM REV RESPIR DIS, V114, P87; WALKER SR, 1972, CLIN PHARMACOL THER, V13, P861; WALLACE D, 1976, ANN ALLERGY, V37, P153; ZIELINSKI J, 1977, RESPIRATION, V34, P31, DOI 10.1159/000193773; 1962, AM REV RESPIR DIS, V85, P762	58	153	153	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					612	624		10.1016/0091-6749(79)90024-1	http://dx.doi.org/10.1016/0091-6749(79)90024-1			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	41866				2022-12-18	WOS:A1979HX84300012
J	Paller, AS; Spergel, JM; Mina-Osorio, P; Irvine, AD				Paller, Amy S.; Spergel, Jonathan M.; Mina-Osorio, Paola; Irvine, Alan D.			The atopic march and atopic multimorbidity: Many trajectories, many pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; atopic march; epidermal barrier; asthma; allergic rhinitis; food allergy; endotypes	DUST-MITE ALLERGEN; BARRIER DYSFUNCTION; FILAGGRIN MUTATIONS; EPITHELIAL BARRIER; CHILDHOOD ECZEMA; SKIN BARRIER; BIRTH COHORT; DERMATITIS; ASTHMA; CHILDREN	The atopic march recognizes the increased occurrence of asthma, allergic rhinitis, or both after atopic dermatitis (AD) onset. Mechanisms for developing atopic comorbidities after AD onset are poorly understood but can involve the impaired cutaneous barrier, which facilitates cutaneous sensitization. The association can also be driven or amplified in susceptible subjects by a systemic T(H)2-dominant immune response to cutaneous inflammation. However, these associations might merely involve shared genetic loci and environmental triggers, including microbiome dysregulation, with the temporal sequence reflecting tissue-specific peak time of occurrence of each disease, suggesting more of a clustering of disorders than a march. Prospective longitudinal cohort studies provide an opportunity to explore the relationships between postdermatitis development of atopic disorders and potential predictive phenotypic, genotypic, and environmental factors. Recent investigations implicate disease severity and persistence, age of onset, parental atopic history, filaggrin (FLG) mutations, polysensitization, and the nonrural environment among risk factors for development of multiple atopic comorbidities in young children with AD. Early intervention studies to repair the epidermal barrier or alter exposure to the microbiome or allergens might elucidate the relative roles of barrier defects, genetic locus alterations, and environmental exposures in the risk and sequence of occurrence of T(H)2 activation disorders.	[Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [Paller, Amy S.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Paller, Amy S.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Spergel, Jonathan M.] Childrens Hosp Philadelphia, Dept Pediat, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Mina-Osorio, Paola] Regeneron Pharmaceut, Tarrytown, NY USA; [Irvine, Alan D.] Our Ladys Childrens Hosp Crumlin, Paediat Dermatol, Dublin, Ireland; [Irvine, Alan D.] Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin, Ireland; [Irvine, Alan D.] Trinity Coll Dublin, Med Clin, Dublin, Ireland	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Regeneron; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; Trinity College Dublin	Paller, AS (corresponding author), Dept Dermatol, 676 N St Clair,Suite 1600, Chicago, IL 60611 USA.	apaller@northwestern.edu	Irvine, Alan D/A-3982-2008	Irvine, Alan D/0000-0002-9048-2044; , Paola/0000-0003-2986-9642				Abo-Zaid G, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071415; Asai Y, 2013, J ALLERGY CLIN IMMUN, V132, P239, DOI 10.1016/j.jaci.2013.03.043; Ballardini N, 2013, BRIT J DERMATOL, V168, P588, DOI 10.1111/bjd.12196; Bartsch S, 2017, CAMBRIDGE COMPANION TO THE AGE OF NERO, P1, DOI 10.1111/cea.12988; Belgrave DCM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001748; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Boyle RJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i974; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Byrd AL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4651; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; du Toit G, 2018, J ALLERGY CLIN IMMUN, V141, P1343, DOI 10.1016/j.jaci.2017.09.034; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Fukuoka A, 2018, ALLERGOL INT, V67, P18, DOI 10.1016/j.alit.2017.10.006; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gon Y, 2018, ALLERGOL INT, V67, P12, DOI 10.1016/j.alit.2017.08.011; Gough H, 2015, PEDIAT ALLERG IMM-UK, V26, P431, DOI 10.1111/pai.12410; Grabenhenrich LB, 2015, J ALLERGY CLIN IMMUN, V136, P932, DOI 10.1016/j.jaci.2015.03.040; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Hill DA, 2018, J ALLER CL IMM-PRACT, V6, P1528, DOI 10.1016/j.jaip.2018.05.010; Hill DA, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0673-z; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Hose AJ, 2017, J ALLERGY CLIN IMMUN, V139, P1935, DOI 10.1016/j.jaci.2016.08.046; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000133.pub3; Kristiansen M, 2017, PEDIAT ALLERG IMM-UK, V28, P18, DOI 10.1111/pai.12661; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lowe AJ, 2018, BRIT J DERMATOL, V178, pE19, DOI 10.1111/bjd.15747; Manz J, 2016, J INVEST DERMATOL, V136, P2380, DOI 10.1016/j.jid.2016.07.009; Marenholz I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9804; Martin PE, 2011, J ALLERGY CLIN IMMUN, V127, P1473, DOI 10.1016/j.jaci.2011.02.041; McAleer MA, 2018, BR J DERMATOL; Meylan P, 2017, J INVEST DERMATOL, V137, P2497, DOI 10.1016/j.jid.2017.07.834; Mondoulet Lucie, 2012, Clin Transl Allergy, V2, P22, DOI 10.1186/2045-7022-2-22; Mortz CG, 2015, ALLERGY, V70, P836, DOI 10.1111/all.12619; Myles IA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120608; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V125, P170, DOI 10.1016/j.jaci.2009.10.046; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Paller AS, 2019, J ALLERGY CLIN IMMUN, V143, P26, DOI 10.1016/j.jaci.2018.11.015; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paternoster L, 2018, J ALLERGY CLIN IMMUN, V141, P964, DOI 10.1016/j.jaci.2017.09.044; Pinart M, 2014, LANCET RESP MED, V2, P131, DOI 10.1016/S2213-2600(13)70277-7; Roduit C, 2017, JAMA PEDIATR, V171, P655, DOI 10.1001/jamapediatrics.2017.0556; Saatian B, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24333; Schneider L, 2016, PEDIATR DERMATOL, V33, P388, DOI 10.1111/pde.12867; Silverberg JI, 2013, PEDIAT ALLERG IMM-UK, V24, P476, DOI 10.1111/pai.12095; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Stokholm J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02573-2; Tran MM, 2018, J ALLERGY CLIN IMMUN, V141, P601, DOI 10.1016/j.jaci.2017.08.024; Tsakok T, 2016, J ALLERGY CLIN IMMUN, V137, P1071, DOI 10.1016/j.jaci.2015.10.049; Valovirta E, 2018, J ALLERGY CLIN IMMUN, V141, P529, DOI 10.1016/j.jaci.2017.06.014; van der Hulst AE, 2007, J ALLERGY CLIN IMMUN, V120, P565, DOI 10.1016/j.jaci.2007.05.042; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Williams HC, 1998, BRIT J DERMATOL, V139, P834; Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211; Wise SK, 2014, INT FORUM ALLERGY RH, V4, P361, DOI 10.1002/alr.21298; Zhang GQ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002562; Ziyab AH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21459-x; Zolkipli Z, 2015, J ALLERGY CLIN IMMUN, V136, P1541, DOI 10.1016/j.jaci.2015.04.045	70	152	156	16	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					46	55		10.1016/j.jaci.2018.11.006	http://dx.doi.org/10.1016/j.jaci.2018.11.006			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30458183	Bronze			2022-12-18	WOS:000454918300005
J	Burbank, AJ; Sood, AK; Kesic, MJ; Peden, DB; Hernandez, ML				Burbank, Allison J.; Sood, Amika K.; Kesic, Matthew J.; Peden, David B.; Hernandez, Michelle L.			Environmental determinants of allergy and asthma in early life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Environment; allergy; asthma; exposure; microbiome; infection; endotoxin; allergen; air pollution; tobacco smoke	HOUSE-DUST MITE; AIR-POLLUTION EXPOSURE; RESPIRATORY SYNCYTIAL VIRUS; ATOPIC-DERMATITIS; CHILDHOOD ASTHMA; LUNG-FUNCTION; CORD BLOOD; MOUSE ALLERGEN; SMOKE EXPOSURE; GUT MICROBIOTA	Allergic disease prevalence has increased significantly in recent decades. Primary prevention efforts are being guided by study of the exposome (or collective environmental exposures beginning during the prenatal period) to identify modifiable factors that affect allergic disease risk. In this review we explore the evidence supporting a relationship between key components of the external exposome in the prenatal and early-life periods and their effect on atopy development focused on microbial, allergen, and air pollution exposures. The abundance and diversity of microbial exposures during the first months and years of life have been linked with risk of allergic sensitization and disease. Indoor environmental allergen exposure during early life can also affect disease development, depending on the allergen type, dose, and timing of exposure. Recent evidence supports the role of ambient air pollution in allergic disease inception. The lack of clarity in the literature surrounding the relationship between environment and atopy reflects the complex interplay between cumulative environmental factors and genetic susceptibility, such that no one factor dictates disease development in all subjects. Understanding the effect of the summation of environmental exposures throughout a child's development is needed to identify cost-effective interventions that reduce atopy risk in children.	[Burbank, Allison J.; Sood, Amika K.; Kesic, Matthew J.; Peden, David B.; Hernandez, Michelle L.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Hernandez, ML (corresponding author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.	michelle_hernandez@med.unc.edu		Peden, David/0000-0003-4526-4627	AAAAI ARTrust Gail G. Shapiro Clinical Faculty Development Award;  [2T32GM086330];  [R01ES023349];  [P30ES010126]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES021745, R01ES023349, P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM086330] Funding Source: NIH RePORTER	AAAAI ARTrust Gail G. Shapiro Clinical Faculty Development Award; ; ; ; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	A.J.B. is supported by grant 2T32GM086330. D.B.P. is supported by grants R01ES023349 and P30ES010126. M.L.H. is supported by the AAAAI ARTrust Gail G. Shapiro Clinical Faculty Development Award.	Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P91, DOI 10.1016/j.jaci.2012.02.010; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Baiz N, 2017, J ALLERGY CLIN IMMUN, V139, P369, DOI 10.1016/j.jaci.2016.07.021; Baiz N, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-87; Beck AF, 2015, ANN AM THORAC SOC, V12, P376, DOI 10.1513/AnnalsATS.201408-376OC; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Blanken MO, 2013, NEW ENGL J MED, V369, P782, DOI 10.1056/NEJMc1307429; Boralevi F, 2008, ALLERGY, V63, P205, DOI 10.1111/j.1398-9995.2007.01556.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bowatte G, 2015, ALLERGY, V70, P245, DOI 10.1111/all.12561; Boyce JA, 2012, J ALLERGY CLIN IMMUN, V129, P335, DOI 10.1016/j.jaci.2011.12.968; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brick T, 2016, J ALLERGY CLIN IMMUN, V137, P1699, DOI 10.1016/j.jaci.2015.10.042; Brunekreef B, 2009, ENVIRON HEALTH PERSP, V117, P1791, DOI 10.1289/ehp.0800467; Brunst KJ, 2015, AM J RESP CRIT CARE, V192, P421, DOI 10.1164/rccm.201407-1314OC; Brunst KJ, 2013, J ALLERGY CLIN IMMUN, V131, P592, DOI 10.1016/j.jaci.2012.10.042; Burke H, 2012, PEDIATRICS, V129, P735, DOI 10.1542/peds.2011-2196; Capristo C, 2004, ALLERGY, V59, P53, DOI 10.1111/j.1398-9995.2004.00652.x; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Carter PM, 2003, ANN ALLERG ASTHMA IM, V90, P41, DOI 10.1016/S1081-1206(10)63612-5; Casas L, 2015, ALLERGY, V70, P820, DOI 10.1111/all.12626; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chang HY, 2016, J ALLERGY CLIN IMMUN, V138, P468, DOI 10.1016/j.jaci.2016.01.020; Chen CM, 2010, INT J HYG ENVIR HEAL, V213, P1, DOI 10.1016/j.ijheh.2009.12.003; Chiu YHM, 2014, J ALLERGY CLIN IMMUN, V133, P713, DOI 10.1016/j.jaci.2013.09.023; Cho SH, 2006, ANN ALLERG ASTHMA IM, V97, P539, DOI 10.1016/S1081-1206(10)60947-7; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Codispoti CD, 2015, ANN ALLERG ASTHMA IM, V114, P126, DOI 10.1016/j.anai.2014.10.020; De Vera MJ, 2003, ANN ALLERG ASTHMA IM, V91, P455, DOI 10.1016/S1081-1206(10)61513-X; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Donohue KM, 2008, J ALLERGY CLIN IMMUN, V122, P914, DOI 10.1016/j.jaci.2008.08.034; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Fishbein AB, 2016, ANN ALLERG ASTHMA IM, V117, P43, DOI 10.1016/j.anai.2016.05.004; Fishbein AB, 2012, CURR OPIN PEDIATR, V24, P98, DOI 10.1097/MOP.0b013e32834ee57c; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gehring U, 2015, LANCET RESP MED, V3, P933, DOI 10.1016/S2213-2600(15)00426-9; Gehring U, 2013, ENVIRON HEALTH PERSP, V121, P1357, DOI 10.1289/ehp.1306770; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Gruzieva O, 2017, ENVIRON HEALTH PERSP, V125, P104, DOI 10.1289/EHP36; Gruzieva O, 2012, J ALLERGY CLIN IMMUN, V129, P240, DOI 10.1016/j.jaci.2011.11.001; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Harris JM, 2007, BRIT J DERMATOL, V156, P698, DOI 10.1111/j.1365-2133.2006.07710.x; Herberth G, 2014, J ALLERGY CLIN IMMUN, V133, P543, DOI 10.1016/j.jaci.2013.06.036; Hinz D, 2012, ALLERGY, V67, P380, DOI 10.1111/j.1398-9995.2011.02767.x; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Hollams EM, 2017, J ALLERGY CLIN IMMUN, V139, P472, DOI 10.1016/j.jaci.2016.07.032; Homa DM, 2015, MMWR-MORBID MORTAL W, V64, P103; Hsu HHL, 2015, AM J RESP CRIT CARE, V192, P1052, DOI 10.1164/rccm.201504-0658OC; Huang JL, 2001, PEDIATR ALLERGY IMMU, V12, P11, DOI 10.1034/j.1399-3038.2001.012001011.x; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Iossifova YY, 2007, ALLERGY, V62, P504, DOI 10.1111/j.1398-9995.2007.01340.x; Iossifova YY, 2009, ANN ALLERG ASTHMA IM, V102, P131, DOI 10.1016/S1081-1206(10)60243-8; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jacquet A, 2013, ISRN ALLERGY, V2013, DOI [10.1155/2013/735031, DOI 10.1155/2013/735031]; Jartti T, 2011, EUR J CLIN MICROBIOL, V30, P233, DOI 10.1007/s10096-010-1075-z; Jerrett M, 2008, ENVIRON HEALTH PERSP, V116, P1433, DOI 10.1289/ehp.10968; Jimenez E, 2005, CURR MICROBIOL, V51, P270, DOI 10.1007/s00284-005-0020-3; Jimenez E, 2008, RES MICROBIOL, V159, P187, DOI 10.1016/j.resmic.2007.12.007; Junge KM, 2014, CLIN IMMUNOL, V152, P68, DOI 10.1016/j.clim.2014.02.013; Jutel M, 2011, CURR ALLERGY ASTHM R, V11, P139, DOI 10.1007/s11882-011-0178-7; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Karadag B, 2007, ALLERGY, V62, P1387, DOI 10.1111/j.1398-9995.2007.01505.x; Kim J, 2013, J KOREAN MED SCI, V28, P74, DOI 10.3346/jkms.2013.28.1.74; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Lannero E, 2008, THORAX, V63, P172, DOI 10.1136/thx.2007.079053; Lau MYZ, 2014, ALLERGY, V69, P1440, DOI 10.1111/all.12454; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Liccardi G, 2016, EUR ANN ALLERGY CLIN, V48, P61; Liston A, 2008, J EXP MED, V205, P1993, DOI 10.1084/jem.20081062; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Llanora GV, 2012, ASIA PAC ALLERGY, V2, P181, DOI 10.5415/apallergy.2012.2.3.181; Lluis A, 2014, J ALLERGY CLIN IMMUN, V133, P551, DOI 10.1016/j.jaci.2013.06.034; Lodge CJ, 2011, J ALLERGY CLIN IMMUN, V128, P782, DOI 10.1016/j.jaci.2011.06.038; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Maas T, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006480.pub2; Maheswaran D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098878; Matsui EC, 2010, ALLERGY, V65, P1414, DOI 10.1111/j.1398-9995.2010.02412.x; Matsui EC, 2006, ANN ALLERG ASTHMA IM, V97, P514, DOI 10.1016/S1081-1206(10)60943-X; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; Mendy A, 2016, RESP MED, V114, P61, DOI 10.1016/j.rmed.2016.03.004; Menezes AMB, 2011, CLIN EXP ALLERGY, V41, P218, DOI 10.1111/j.1365-2222.2010.03611.x; Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821; Molter A, 2015, EUR RESPIR J, V45, P610, DOI 10.1183/09031936.00083614; Morales E, 2015, THORAX, V70, P64, DOI 10.1136/thoraxjnl-2014-205413; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nathan AM, 2012, ASIAN PAC J ALLERGY, V30, P204; Nishimura KK, 2016, J ALLERGY CLIN IMMUN, V138, P1703, DOI 10.1016/j.jaci.2016.03.058; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; Park YH, 2010, ALLERGY ASTHMA IMMUN, V2, P28, DOI 10.4168/aair.2010.2.1.28; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Peroni DG, 2008, BRIT J DERMATOL, V158, P539, DOI 10.1111/j.1365-2133.2007.08344.x; Perzanowski MS, 2016, J ALLERGY CLIN IMMUN, V138, P1582, DOI 10.1016/j.jaci.2016.05.017; Phipatanakul W, 2008, ALLERGY, V63, P1512, DOI 10.1111/j.1398-9995.2008.01679.x; Phipatanakul W, 2005, ANN ALLERG ASTHMA IM, V94, P593, DOI 10.1016/S1081-1206(10)61139-8; Pino-Yanes M, 2015, J ALLERGY CLIN IMMUN, V135, P228, DOI 10.1016/j.jaci.2014.07.053; Posa D, 2017, J ALLERGY CLIN IMMUN, V139, P541, DOI 10.1016/j.jaci.2016.08.014; Ranciere F, 2017, ENVIRON HEALTH PERSP, V125, P737, DOI 10.1289/EHP239; Rautava S, 2012, NEONATOLOGY, V102, P178, DOI 10.1159/000339182; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Rice MB, 2016, AM J RESP CRIT CARE, V193, P881, DOI 10.1164/rccm.201506-1058OC; Richgels PK, 2017, J ALLERGY CLIN IMMUN; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Rubner FJ, 2017, J ALLERGY CLIN IMMUN, V139, P501, DOI 10.1016/j.jaci.2016.03.049; Ruokolainen L, 2015, ALLERGY, V70, P195, DOI 10.1111/all.12545; Salo PM, 2008, J ALLERGY CLIN IMMUN, V121, P678, DOI 10.1016/j.jaci.2007.12.1164; Sbihi H, 2015, ENVIRON HEALTH PERSP, V123, P902, DOI 10.1289/ehp.1408700; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Schiavoni G, 2017, ANN ALLERG ASTHMA IM, V118, P269, DOI 10.1016/j.anai.2016.12.019; Schroder PC, 2017, ALLERGY, V72, P604, DOI 10.1111/all.13069; Schultz ES, 2012, AM J RESP CRIT CARE, V186, P1286, DOI 10.1164/rccm.201206-1045OC; Schultzl ES, 2016, AM J RESP CRIT CARE, V193, P171, DOI 10.1164/rccm.201505-0928OC; Schwartz S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-4-r32; Sharpe RA, 2015, CLIN EXP ALLERGY, V45, P1566, DOI 10.1111/cea.12549; Sheehan WJ, 2017, JAMA PEDIATR, V171, P31, DOI 10.1001/jamapediatrics.2016.2543; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Silva JM, 2005, PEDIAT ALLERG IMM-UK, V16, P393, DOI 10.1111/j.1399-3038.2005.00308.x; Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032; Simons E, 2014, J ALLER CL IMM-PRACT, V2, P201, DOI 10.1016/j.jaip.2013.11.014; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Siroux V, 2016, EUR RESPIR REV, V25, P124, DOI 10.1183/16000617.0034-2016; Sordillo JE, 2017, J ALLERGY CLIN IMMUN, V139, P482, DOI 10.1016/j.jaci.2016.08.045; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; Takkouche B, 2008, ALLERGY, V63, P857, DOI 10.1111/j.1398-9995.2008.01732.x; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Thacher JD, 2016, ALLERGY, V71, P239, DOI 10.1111/all.12792; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Tischer C, 2016, ENVIRON HEALTH PERSP, V124, P1919, DOI 10.1289/EHP158; Torjusen EN, 2013, INDOOR AIR, V23, P268, DOI 10.1111/ina.12009; Tovey ER, 2008, J ALLERGY CLIN IMMUN, V122, P114, DOI 10.1016/j.jaci.2008.05.010; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; Vardavas CI, 2016, EUR RESPIR J, V48, P115, DOI 10.1183/13993003.01016-2015; Wegienka G, 2017, CLIN EXP ALLERGY, V47, P97, DOI 10.1111/cea.12804; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; Wu PS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156473; Zahradnik E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00076; Zhang ZH, 2017, J ALLERGY CLIN IMMUN, V139, P54, DOI 10.1016/j.jaci.2016.02.031; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563	152	152	159	2	64	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					1	+		10.1016/j.jaci.2017.05.010	http://dx.doi.org/10.1016/j.jaci.2017.05.010			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28673399	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000404542000001
J	Czarnowicki, T; Krueger, JG; Guttman-Yassky, E				Czarnowicki, Tali; Krueger, James G.; Guttman-Yassky, Emma			Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; atopic march; epidermal barrier; immune dysregulation; microbiome; primary intervention; secondary intervention	THYMIC STROMAL LYMPHOPOIETIN; EPIDERMAL PERMEABILITY BARRIER; OF-FUNCTION VARIANTS; STAPHYLOCOCCUS-AUREUS COLONIZATION; PROTEASE-ACTIVATED RECEPTOR-2; STRATUM-CORNEUM HYDRATION; PLACEBO-CONTROLLED TRIAL; FC-EPSILON-RI; SKIN BARRIER; FILAGGRIN MUTATIONS	Skin barrier abnormalities have been suggested to play an essential role in initiation of early atopic dermatitis (AD). Antigen penetration through a compromised barrier likely leads to increased innate immune responses, antigen-presenting cell stimulation, and priming of overt cutaneous disease. In a T(H)2-promoting environment, T-cell/B-cell interactions occurring in regional lymph nodes lead to excessive IgE switch. Concurrent redistribution of memory T cells into the circulation not only leads to exacerbation of AD through T-cell skin infiltration but also spreads beyond the skin to initiate the atopic march, which includes food allergy, asthma, and allergic rhinitis. Possible primary interventions to prevent AD are focusing on improving skin barrier integrity, including supplementing barrier function with moisturizers. As for secondary prophylaxis in children with established AD, this can be stratified into prevention of disease exacerbations by using proactive approaches (with either topical corticosteroids or topical calcineurin inhibitors) in mild AD cases or the prevention of other atopic disorders that will probably mandate systemic immunosuppression in severe AD cases.	[Czarnowicki, Tali; Krueger, James G.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Czarnowicki, Tali; Krueger, James G.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA; [Czarnowicki, Tali; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org			Pfizer; Janssen; Lilly; Merck; Novartis; Kadmon; Dermira; Boehringer; BMS; Serono; BiogenIdec; Delenex; Abbvie; Sanofi; Baxter; Xenoport; Kineta; Amgen; Innovaderm; Kyowa; Parexel; Regeneron; Celgene; LEO Pharma; NIH	Pfizer(Pfizer); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Lilly(Eli Lilly); Merck(Merck & Company); Novartis(Novartis); Kadmon; Dermira; Boehringer(Boehringer Ingelheim); BMS(Bristol-Myers Squibb); Serono(Merck & Company); BiogenIdec(Biogen); Delenex; Abbvie(AbbVie); Sanofi; Baxter; Xenoport; Kineta; Amgen(Amgen); Innovaderm; Kyowa; Parexel; Regeneron(Regeneron); Celgene(Bristol-Myers SquibbCelgene Corporation); LEO Pharma(LEO Pharma); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	J. G. Krueger has received personal fees from Pfizer, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, BMS, Serono, BiogenIdec, Delenex, Abbvie, Sanofi, Baxter, Xenoport, and Kineta; and has received money to his institution from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, and Parexel. E. Guttman-Yassky is on advisory board for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Celsus, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae and Leo Pharma; has consultant arrangements with Regeneron, Sanofi, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, LEO Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe and Eli Lilly; has received research support from Janssen, Regeneron, Celgene, BMS, Novartis, Merck, LEO Pharma and Dermira; and has received grants from the NIH, Regeneron, Celgene, BMS, Janssen, Dermira, LEO pharma, Merck, Novartis, and Pfizer. T. Czarnowicki declares no relevant conflicts of interest.	Agrawal R, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0433-9; Ali SM, 2013, ACTA DERM-VENEREOL, V93, P261, DOI 10.2340/00015555-1531; Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051; Ballardini N, 2014, J ALLERGY CLIN IMMUN, V133, P594, DOI 10.1016/j.jaci.2013.08.054; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Boguniewicz M, 2007, J ALLERGY CLIN IMMUN, V119, pS209, DOI 10.1016/j.jaci.2006.12.188; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bredo G, 2015, IMMUN INFLAMM DIS, V3, P455, DOI 10.1002/iid3.87; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chamlin SL, 2002, J AM ACAD DERMATOL, V47, P198, DOI 10.1067/mjd.2002.124617; Chang YS, 2016, JAMA PEDIATR, V170, P236, DOI 10.1001/jamapediatrics.2015.3943; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P269, DOI 10.1067/mai.2001.117455; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Cianferoni A, 2014, EXPERT REV CLIN IMMU, V10, P1463, DOI 10.1586/1744666X.2014.967684; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Czarnowicki T, 2016, EXP DERMATOL; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, p[1091, e1]; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P1091, DOI 10.1016/j.jaci.2015.08.013; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2014, J ALLER CL IMM-PRACT, V2, P371, DOI 10.1016/j.jaip.2014.03.006; D'Auria E, 2016, ASIAN PAC J ALLERGY, V34, P98, DOI 10.12932/AP0732.34.2.2016; Darmstadt GL, 2007, PEDIATR RES, V61, P588, DOI 10.1203/pdr.0b013e3180459f75; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Marchi F, 2015, ALLERGY ASTHMA PROC, V36, pE127, DOI 10.2500/aap.2015.36.3872; Dhar S, 2016, INDIAN J DERMATOL, V61, P645, DOI 10.4103/0019-5154.193673; Dharmage SC, 2014, ALLERGY, V69, P17, DOI 10.1111/all.12268; Divekar R, 2015, CURR OPIN ALLERGY CL, V15, P98, DOI 10.1097/ACI.0000000000000133; Dubrac S, 2010, IMMUNOL CELL BIOL, V88, P400, DOI 10.1038/icb.2010.33; Eberlein-Konig B, 2000, ACTA DERM-VENEREOL, V80, P188; Egawa G, 2016, J ALLERGY CLIN IMMUN, V138, P350, DOI 10.1016/j.jaci.2016.06.002; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; ELIAS PM, 1991, ADV LIPID RES, V24, P1; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1473, DOI 10.1016/j.jaci.2016.04.052; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Fujita H, 2013, J DERMATOL SCI, V72, P3, DOI 10.1016/j.jdermsci.2013.04.028; Gaffin JM, 2012, ALLERGY ASTHMA PROC, V33, P282, DOI 10.2500/aap.2012.33.3572; Giam YC, 2016, ASIA PAC ALLERGY, V6, P120, DOI 10.5415/apallergy.2016.6.2.120; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Glatz M, 2015, J INVEST DERMATOL, V135, pS31; Gong JQ, 2006, BRIT J DERMATOL, V155, P680, DOI 10.1111/j.1365-2133.2006.07410.x; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Gruber R, 2015, AM J PATHOL, V185, P2777, DOI 10.1016/j.ajpath.2015.06.021; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Hachem JP, 2003, J INVEST DERMATOL, V121, P345, DOI 10.1046/j.1523-1747.2003.12365.x; Haftek M, 2015, CELL TISSUE RES, V360, P483, DOI 10.1007/s00441-014-2019-1; Hamilton JD, 2015, IMMUNOTHERAPY-UK, V7, P1043, DOI 10.2217/imt.15.69; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hatano Y, 2005, J INVEST DERMATOL, V124, P786, DOI 10.1111/j.0022-202X.2005.23651.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Herberth G, 2010, PEDIAT ALLERG IMM-UK, V21, P5, DOI 10.1111/j.1399-3038.2009.00890.x; Hide DW, 1997, PEDIATR ALLERGY IMMU, V8, P7, DOI 10.1111/j.1399-3038.1997.tb00135.x; Hirasawa Y, 2010, J INVEST DERMATOL, V130, P614, DOI 10.1038/jid.2009.257; Horimukai K, 2016, ALLERGOL INT, V65, P103, DOI 10.1016/j.alit.2015.09.004; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hradetzky S, 2015, ALLERGO J, V24, P32, DOI 10.1007/s15007-015-0737-7; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Irvine AD, 2014, J INVEST DERMATOL, V134, P313, DOI 10.1038/jid.2013.506; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Ishida-Yamamoto A, 2015, CELL TISSUE RES, V360, P477, DOI 10.1007/s00441-014-2037-z; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jacquet A, 2013, ISRN ALLERGY, V2013, DOI [10.1155/2013/735031, DOI 10.1155/2013/735031]; JANEWAY C, 1989, IMMUNOL TODAY, V10, P283, DOI 10.1016/0167-5699(89)90081-9; Jang H, 2016, J INVEST DERMATOL, V136, P127, DOI 10.1038/JID.2015.363; Jones AL, 2016, J ALLERGY CLIN IMMUN, V137, P1247, DOI 10.1016/j.jaci.2016.01.010; Jungersted JM, 2010, ALLERGY, V65, P911, DOI 10.1111/j.1398-9995.2010.02326.x; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kato T, 2009, ALLERGY, V64, P1366, DOI 10.1111/j.1398-9995.2009.02023.x; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Kezic S, 2016, CURR PROBL DERMATOL, V49, P1, DOI 10.1159/000441539; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim H, 2012, BRIT J NUTR, V108, P1726, DOI 10.1017/S0007114511007306; Kim KH, 2006, J KOREAN MED SCI, V21, P315, DOI 10.3346/jkms.2006.21.2.315; Klar J, 2009, AM J HUM GENET, V85, P248, DOI 10.1016/j.ajhg.2009.06.021; Komatsu N, 2007, EXP DERMATOL, V16, P513, DOI 10.1111/j.1600-0625.2007.00562.x; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kramer Michael S, 2014, Evid Based Child Health, V9, P447, DOI 10.1002/ebch.1972; Kuo IH, 2013, J INVEST DERMATOL, V133, P988, DOI 10.1038/jid.2012.437; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Lee HJ, 2014, EXP DERMATOL, V23, P736, DOI 10.1111/exd.12525; Lee HJ, 2014, ALLERGY ASTHMA IMMUN, V6, P276, DOI 10.4168/aair.2014.6.4.276; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Lee SE, 2010, YONSEI MED J, V51, P808, DOI 10.3349/ymj.2010.51.6.808; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564; Leung DYM, 2009, J ALLERGY CLIN IMMUN, V124, P494, DOI 10.1016/j.jaci.2009.07.041; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Loden M, 2003, CLIN DERMATOL, V21, P145, DOI 10.1016/S0738-081X(02)00373-5; Louten J, 2011, INT IMMUNOL, V23, P307, DOI 10.1093/intimm/dxr006; MACHARIA WM, 1991, TROP DOCT, V21, P104, DOI 10.1177/004947559102100305; Margolis DJ, 2014, J INVEST DERMATOL, V134, P2272, DOI 10.1038/jid.2014.126; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Miller DW, 2011, J DRUGS DERMATOL, V10, P531; Miller Lloyd S, 2008, Adv Dermatol, V24, P71; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Morishita Y, 1999, CLIN EXP ALLERGY, V29, P1110; Murakami-Satsutani N, 2014, ALLERGOL INT, V63, P443, DOI 10.2332/allergolint.13-OA-0672; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; Nakamizo S, 2015, SEMIN IMMUNOPATHOL, V37, P73, DOI 10.1007/s00281-014-0452-6; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041; Nissen D, 1997, ANN ALLERG ASTHMA IM, V79, P403, DOI 10.1016/S1081-1206(10)63033-5; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nopper AJ, 1996, J PEDIATR-US, V128, P660, DOI 10.1016/S0022-3476(96)80132-6; Nowrouzian FL, 2017, BRIT J DERMATOL, V176, P439, DOI 10.1111/bjd.15138; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oszukowska M, 2015, POSTEP DERM ALERGOL, V32, P409, DOI 10.5114/pdia.2014.44017; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, P139, DOI 10.1016/j.jaci.2013.07.027; Pabst R C, 1999, J Perinatol, V19, P278, DOI 10.1038/sj.jp.7200157; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Panzer R, 2014, EXP DERMATOL, V23, P364, DOI 10.1111/exd.12383; Park HY, 2013, ANN DERMATOL, V25, P410, DOI 10.5021/ad.2013.25.4.410; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; RIEGER A, 1992, J INVEST DERMATOL, V99, pS30, DOI 10.1111/1523-1747.ep12668293; Riethmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P1573, DOI 10.1016/j.jaci.2015.04.042; Roelandt T, 2008, J INVEST DERMATOL, V128, P1878, DOI 10.1038/jid.2008.168; Rubartelli A, 2007, TRENDS IMMUNOL, V28, P429, DOI 10.1016/j.it.2007.08.004; Runswick S, 2007, RESPIROLOGY, V12, P834, DOI 10.1111/j.1440-1843.2007.01175.x; Sajic D, 2012, Skin Therapy Lett, V17, P6; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Saunders SP, 2016, J ALLERGY CLIN IMMUN, V137, P482, DOI 10.1016/j.jaci.2015.06.045; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Saunes M, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-168; Schmuth M, 2014, BBA-MOL CELL BIOL L, V1841, P463, DOI 10.1016/j.bbalip.2013.11.012; Schneider L, 2016, PEDIATR DERMATOL, V33, P388, DOI 10.1111/pde.12867; Scirica CV, 2007, J ALLERGY CLIN IMMUN, V119, P81, DOI 10.1016/j.jaci.2006.09.002; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2006, DERMATOL THER, V19, P108, DOI 10.1111/j.1529-8019.2006.00059.x; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Simpson EL, 2012, SEMIN CUTAN MED SURG, V31, pS6, DOI 10.1016/j.sder.2012.08.001; Simpson EL, 2010, J AM ACAD DERMATOL, V63, P587, DOI 10.1016/j.jaad.2009.11.011; Son ED, 2014, J DERMATOL SCI, V74, P64, DOI 10.1016/j.jdermsci.2013.12.004; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Steinhoff M, 2003, J NEUROSCI, V23, P6176; Stout TE, 2014, J INVEST DERMATOL, V134, P423, DOI 10.1038/jid.2013.284; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Sugarman JL, 2003, ARCH DERMATOL, V139, P1417, DOI 10.1001/archderm.139.11.1417; Sybilski AJ, 2009, EUR J MED RES, V14, P233, DOI 10.1186/2047-783X-14-S4-233; Szczepanowska J, 2008, PEDIAT ALLERG IMM-UK, V19, P614, DOI 10.1111/j.1399-3038.2007.00706.x; Szegedi A, 2015, BRIT J DERMATOL, V172, P320, DOI 10.1111/bjd.13534; Tawada C, 2014, J INVEST DERMATOL, V134, P712, DOI 10.1038/jid.2013.364; Tesciuba AG, 2008, J IMMUNOL, V181, P1019, DOI 10.4049/jimmunol.181.2.1019; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Tokumasu R, 2016, P NATL ACAD SCI USA, V113, pE4061, DOI 10.1073/pnas.1525474113; Travers JB, 2014, J INVEST DERMATOL, V134, P2069, DOI 10.1038/jid.2014.122; Tsianakas A, 2016, LANCET, V387, P4, DOI 10.1016/S0140-6736(15)00389-X; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; Vieira BL, 2016, AM J CLIN DERMATOL, V17, P557, DOI 10.1007/s40257-016-0209-1; VOLZ A, 1993, GENOMICS, V18, P92, DOI 10.1006/geno.1993.1430; von Kobyletzki LB, 2012, BMC DERMATOL, V12, DOI 10.1186/1471-5945-12-11; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Warner JA, 2009, BRIT J DERMATOL, V160, P183, DOI 10.1111/j.1365-2133.2008.08905.x; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Williams Hywel C, 2012, F1000 Med Rep, V4, P24, DOI 10.3410/M4-24; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Winge MCG, 2011, BRIT J DERMATOL, V165, P1074, DOI 10.1111/j.1365-2133.2011.10475.x; Wuthrich B, 2002, ALLERGY, V57, P267, DOI 10.1034/j.1398-9995.2002.1n3572.x; Yu HS, 2015, J ALLERGY CLIN IMMUN, V135, P827, DOI 10.1016/j.jaci.2014.10.040; Yuki T, 2013, J DERMATOL SCI, V69, P148, DOI 10.1016/j.jdermsci.2012.11.595; Zhang C, 2012, CELLS TISSUES ORGANS, V196, P431, DOI 10.1159/000336268; Zheng T, 2011, ALLERGY ASTHMA IMMUN, V3, P67, DOI 10.4168/aair.2011.3.2.67; Ziegler SF, 2006, NAT IMMUNOL, V7, P709, DOI 10.1038/ni1360	190	152	168	2	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1723	1734		10.1016/j.jaci.2017.04.004	http://dx.doi.org/10.1016/j.jaci.2017.04.004			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28583445				2022-12-18	WOS:000402724600001
J	Narisety, SD; Frischmeyer-Guerrerio, PA; Keet, CA; Gorelik, M; Schroeder, J; Hamilton, RG; Wood, RA				Narisety, Satya D.; Frischmeyer-Guerrerio, Pamela A.; Keet, Corinne A.; Gorelik, Mark; Schroeder, John; Hamilton, Robert G.; Wood, Robert A.			A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; food allergy; immunotherapy; sublingual immunotherapy; oral immunotherapy	NATURAL-HISTORY	Background: Although promising results have emerged regarding oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) for the treatment of peanut allergy (PA), direct comparisons of these approaches are limited. Objective: This study was conducted to compare the safety, efficacy, and mechanistic correlates of peanut OIT and SLIT. Methods: In this double-blind study children with PA were randomized to receive active SLIT/placebo OIT or active OIT/placebo SLIT. Doses were escalated to 3.7 mg/d (SLIT) or 2000 mg/d (OIT), and subjects were rechallenged after 6 and 12 months of maintenance. After unblinding, therapy was modified per protocol to offer an additional 6 months of therapy. Subjects who passed challenges at 12 or 18 months were taken off treatment for 4 weeks and rechallenged. Results: Twenty-one subjects aged 7 to 13 years were randomized. Five discontinued therapy during the blinded phase. Of the remaining 16, all had a greater than 10-fold increase in challenge threshold after 12 months. The increased threshold was significantly greater in the active OIT group (141-vs 22-fold, P = .01). Significant within-group changes in skin test results and peanut-specific IgE and IgG(4) levels were found, with overall greater effects with OIT. Adverse reactions were generally mild but more common with OIT (P < .001), including moderate reactions and doses requiring medication. Four subjects had sustained unresponsiveness at study completion. Conclusion: OIT appeared far more effective than SLIT for the treatment of PA but was also associated with significantly more adverse reactions and early study withdrawal. Sustained unresponsiveness after 4 weeks of avoidance was seen in only a small minority of subjects.	[Narisety, Satya D.] Rutgers State Univ, New Jersey Med Sch, Dept Pediat, Div Allergy Immunol & Infect Dis, Newark, NJ 07102 USA; [Frischmeyer-Guerrerio, Pamela A.; Keet, Corinne A.; Gorelik, Mark; Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Schroeder, John; Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Immunol, Baltimore, MD 21205 USA	Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Medical Center; Johns Hopkins University; Johns Hopkins University	Wood, RA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	rwood@jhmi.edu	Guerrerio, Pamela/S-9360-2019	Keet, Corinne/0000-0002-6585-239X	National Center for Advancing Translational Sciences (NCATS) [UL1 TR 001079]; Research Training in Pediatric Allergy and Immunology [5T32AI007007]; National Institutes of Health (NIH) [K23 AI091869, AI079853]; Winkelstein Fellowship Fund; ARTrust Faculty Development Award; Johns Hopkins University Clinician Scientist Award; National Institute of Health Asthma and Allergic Diseases Cooperative Research Centers grant [U19AI070345-01]; Food Allergy Research and Education (FARE) grant; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; NIH Roadmap for Medical Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD073557] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007, ZIAAI001202, K23AI103187, U19AI070345, R21AI079853] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Research Training in Pediatric Allergy and Immunology; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Winkelstein Fellowship Fund; ARTrust Faculty Development Award; Johns Hopkins University Clinician Scientist Award; National Institute of Health Asthma and Allergic Diseases Cooperative Research Centers grant; Food Allergy Research and Education (FARE) grant; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grant no. UL1 TR 001079 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research, Research Training in Pediatric Allergy and Immunology grant no. 5T32AI007007, National Institutes of Health (NIH) grant K23 AI091869, a Winkelstein Fellowship Fund, an ARTrust Faculty Development Award, a Johns Hopkins University Clinician Scientist Award, an NIH R21 Research Award (AI079853 to J.S.), a National Institute of Health Asthma and Allergic Diseases Cooperative Research Centers grant (U19AI070345-01 to J.S.), and a Food Allergy Research and Education (FARE) grant (to R.A.W). P.A.F.-G. is supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Jackson K, 2013, BFI FILM CLASSICS, P1, DOI 10.1007/978-1-84457-702-6; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Neuman-Sunshine DL, 2012, ANN ALLERG ASTHMA IM, V108, P326, DOI 10.1016/j.anai.2011.11.010; Rinaldi M, 2012, J ALLERGY CLIN IMMUN, V130, P945, DOI 10.1016/j.jaci.2012.07.042; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007	22	152	153	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1275	U698		10.1016/j.jaci.2014.11.005	http://dx.doi.org/10.1016/j.jaci.2014.11.005			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25528358	Green Accepted, Bronze			2022-12-18	WOS:000353980700021
J	Gascon, M; Casas, M; Morales, E; Valvi, D; Ballesteros-Gomez, A; Luque, N; Rubio, S; Monfort, N; Ventura, R; Martinez, D; Sunyer, J; Vrijheid, M				Gascon, Mireia; Casas, Maribel; Morales, Eva; Valvi, Damaskini; Ballesteros-Gomez, Ana; Luque, Noelia; Rubio, Soledad; Monfort, Nuria; Ventura, Rosa; Martinez, David; Sunyer, Jordi; Vrijheid, Martine			Prenatal exposure to bisphenol A and phthalates and childhood respiratory tract infections and allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bisphenol A; phthalates; eczema; wheeze; chest infections; bronchitis; asthma; specific IgE; atopy; children	PRESCHOOL-CHILDREN; ATOPIC-DERMATITIS; RHESUS MACAQUES; URINE SAMPLES; URBAN COHORT; IN-VITRO; ASTHMA; METABOLITES; HEALTH; ASSOCIATION	Background: There is growing concern that prenatal exposure to bisphenol A (BPA) and phthalates, which are widely used in consumer products, might affect susceptibility to infections and the development of allergy and asthma in children, but there are currently very few prospective studies. Objective: We sought to evaluate whether prenatal exposure to BPA and phthalates increases the risk of respiratory and allergic outcomes in children at various ages from birth to 7 years. Methods: We measured BPA and metabolites of high-molecular-weight phthalates, 4 di-(2-ethylhexyl)phthalate (DEHP) metabolites (Sigma 4DEHP) and mono-benzyl phthalate (MBzP), and 3 low-molecular-weight phthalate (LMWP) metabolites (Sigma 3LMWP) in urine samples collected during the first and third trimesters in pregnant women participating in the Infancia y Medio Ambiente-Sabadell birth cohort study. The occurrence of chest infections, bronchitis, wheeze, and eczema in children was assessed at ages 6 and 14 months and 4 and 7 years through questionnaires given to the mothers. Atopy (specific IgE measurement) and asthma (questionnaire) were assessed at ages 4 and 7 years, respectively. Results: The relative risks (RRs) of wheeze (RR, 1.20; 95% CI, 1.03-1.40; P = .02), chest infections (RR, 1.15; 95% CI, 1.00-1.32; P = .05), and bronchitis (RR, 1.18; 95% CI, 1.01-1.37; P = .04) at any age increased for each doubling in concentration of maternal urinary BPA. Sigma 4DEHP metabolites were associated with the same outcomes (wheeze: RR, 1.25; 95% CI, 1.04-1.50, P = .02; chest infections: RR, 1.15; 95% CI, 0.97-1.35; P 5.11; bronchitis: RR, 1.20; 95% CI, 1.01-1.43; P = .04). MBzP was associated with higher risk of wheeze (RR, 1.15; 95% CI, 1.00-1.33;P = .05). The risk of asthma at age 7 years was also increased with increasing prenatal BPA, Sigma 4DEHP, and MBzP exposure. There were no other exposure-outcome associations. Conclusions: Prenatal exposure to BPA and high-molecularweight phthalates might increase the risk of asthma symptoms and respiratory tract infections throughout childhood.	[Gascon, Mireia; Casas, Maribel; Morales, Eva; Valvi, Damaskini; Martinez, David; Sunyer, Jordi; Vrijheid, Martine] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Gascon, Mireia; Casas, Maribel; Morales, Eva; Valvi, Damaskini; Martinez, David; Sunyer, Jordi; Vrijheid, Martine] Univ Pompeu Fabra, Barcelona, Spain; [Gascon, Mireia; Casas, Maribel; Morales, Eva; Valvi, Damaskini; Martinez, David; Sunyer, Jordi; Vrijheid, Martine] CIBER Epidemiol Salud Publ CIBERESP, Barcelona, Spain; [Morales, Eva; Monfort, Nuria; Ventura, Rosa; Sunyer, Jordi] Hosp Mar Med Res Inst, IMIM, Barcelona, Spain; [Ballesteros-Gomez, Ana; Luque, Noelia; Rubio, Soledad] Univ Cordoba, Dept Quim Anal, E-14071 Cordoba, Spain	Pompeu Fabra University; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Universidad de Cordoba	Gascon, M (corresponding author), PRBB, Ctr Res Environm Epidemiol CREAL, Doctor Aiguader 88, Barcelona 08003, Catalonia, Spain.	mgascon@creal.cat	Rubio, Soledad/K-7737-2014; Vrijheid, Martine/H-2702-2014; Gascon, Mireia/G-1275-2016; Valvi, Dania/ABE-6650-2020; Casas, Maribel/T-5643-2017; Ballesteros-Gómez, Ana/K-9526-2013; ventura, rosa/A-6121-2011; Morales, Eva/HHS-0651-2022; martinez, david/GQI-0849-2022; Sunyer, Jordi/G-6909-2014	Rubio, Soledad/0000-0002-9128-4787; Vrijheid, Martine/0000-0002-7090-1758; Gascon, Mireia/0000-0003-4537-8472; Casas, Maribel/0000-0002-2112-6740; Ballesteros-Gómez, Ana/0000-0003-1583-1459; ventura, rosa/0000-0002-1413-8890; Morales, Eva/0000-0003-3145-7022; Sunyer, Jordi/0000-0002-2602-4110; Valvi, Dania/0000-0003-4633-229X; Martinez, David/0000-0001-7001-7674	RecerCaixa [2010ACUP 00349]; Instituto de Salud Carlos III [Red INMA G03/176, CB06/02/0041]; Spanish Ministry of Health [FIS-PI041436, FIS-PI081151]; Generalitat de Catalunya [CIRIT 1999SGR 00241]; Agency for Management of University and Research Grants (AGAUR) [FI-DGR 2012]; Fundacio "La Marato de TV3" [090430]	RecerCaixa(La Caixa Foundation); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); Generalitat de Catalunya(Generalitat de Catalunya); Agency for Management of University and Research Grants (AGAUR)(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Fundacio "La Marato de TV3"	Supported by a research grant from the RecerCaixa (2010ACUP 00349). The Infancia y Medio Ambiente (INMA) project received further funds from the Instituto de Salud Carlos III (Red INMA G03/176, CB06/02/0041), the Spanish Ministry of Health (FIS-PI041436 and FIS-PI081151), Generalitat de Catalunya (CIRIT 1999SGR 00241), the Agency for Management of University and Research Grants (AGAUR; FI-DGR 2012), and Fundacio "La Marato de TV3" (090430).	Anto JM, 2012, J ALLERGY CLIN IMMUN, V129, P943, DOI 10.1016/j.jaci.2012.01.047; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Becker K, 2009, INT J HYG ENVIR HEAL, V212, P685, DOI 10.1016/j.ijheh.2009.08.002; Bertelsen RJ, 2013, ENVIRON HEALTH PERSP, V121, P251, DOI 10.1289/ehp.1205256; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Bonds RS, 2013, CURR OPIN ALLERGY CL, V13, P92, DOI 10.1097/ACI.0b013e32835a6dd6; Bornehag CG, 2010, INT J ANDROL, V33, P333, DOI 10.1111/j.1365-2605.2009.01023.x; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; Braun JM, 2013, CURR OPIN PEDIATR, V25, P247, DOI 10.1097/MOP.0b013e32835e1eb6; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Callesen M, 2014, INDOOR AIR, V24, P136, DOI 10.1111/ina.12060; Callesen M, 2014, INT J HYG ENVIR HEAL, V217, P645, DOI 10.1016/j.ijheh.2013.12.001; Carvajal-Uruena I, 2005, ARCH BRONCONEUMOL, V41, P659, DOI 10.1016/S0300-2896(05)70721-3; Casas M, 2013, ENVIRON INT, V56, P10, DOI 10.1016/j.envint.2013.02.014; Chevrier J, 2013, ENVIRON HEALTH PERSP, V121, P138, DOI 10.1289/ehp.1205092; Christen V, 2010, CHEMOSPHERE, V81, P1245, DOI 10.1016/j.chemosphere.2010.09.031; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Dietert RR, 2010, ENVIRON HEALTH PERSP, V118, P1091, DOI 10.1289/ehp.1001971; Dodson RE, 2012, ENVIRON HEALTH PERSP, V120, P935, DOI 10.1289/ehp.1104052; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, P736, DOI 10.1016/j.jaci.2012.12.1573; Frederiksen H, 2013, INT J HYG ENVIR HEAL, V216, P772, DOI 10.1016/j.ijheh.2013.02.006; Frederiksen H, 2013, ENVIRON SCI TECHNOL, V47, P958, DOI 10.1021/es303640b; Gascon M, 2012, EUR RESPIR J, V39, P1188, DOI 10.1183/09031936.00011711; Guxens M, 2012, INT J EPIDEMIOL, V41, P930, DOI 10.1093/ije/dyr054; Hoppin JA, 2002, ENVIRON HEALTH PERSP, V110, P515, DOI 10.1289/ehp.02110515; Hoppin JA, 2013, ENVIRON HEALTH PERSP, V121, P1129, DOI 10.1289/ehp.1206211; Hsu NY, 2012, INDOOR AIR, V22, P186, DOI 10.1111/j.1600-0668.2011.00753.x; Just AC, 2012, AM J RESP CRIT CARE, V186, P830, DOI 10.1164/rccm.201203-0398OC; Just AC, 2012, ENVIRON HEALTH PERSP, V120, P1475, DOI 10.1289/ehp.1104544; Kimber I, 2010, TOXICOLOGY, V271, P73, DOI 10.1016/j.tox.2010.03.020; Koch HM, 2012, J EXPO SCI ENV EPID, V22, P610, DOI 10.1038/jes.2012.39; Kolarik B, 2008, ENVIRON HEALTH PERSP, V116, P98, DOI 10.1289/ehp.10498; Konkel L, 2013, ENVIRON HEALTH PERSP, V121, pA254, DOI [10.1289/ehp.121-A254, 10.1289/ehp.121-a254]; Kwak Eun Soo, 2009, Open Allergy J, V2, P45; Lewis RC, 2013, CHEMOSPHERE, V93, P2390, DOI 10.1016/j.chemosphere.2013.08.038; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Miller MD, 2010, ENVIRON HEALTH PERSP, V118, P1155, DOI 10.1289/ehp.0901856; Okubo T, 2003, BIOL PHARM BULL, V26, P1219; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Pinkerton KE, 2000, ENVIRON HEALTH PERSP, V108, P457, DOI 10.2307/3454537; Pollack AZ, 2013, AM J EPIDEMIOL, V177, P84, DOI 10.1093/aje/kws209; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Roy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038448; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Saravanabhavan G, 2013, INT J HYG ENVIR HEAL, V216, P652, DOI 10.1016/j.ijheh.2012.12.009; Schafer T, 2008, CURR OPIN ALLERGY CL, V8, P418, DOI 10.1097/ACI.0b013e32830e71a7; Shrier I, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-70; Simpson CR, 2002, CLIN EXP ALLERGY, V32, P37, DOI 10.1046/j.0022-0477.2001.01250.x; Spanier AJ, 2012, ENVIRON HEALTH PERSP, V120, P916, DOI 10.1289/ehp.1104175; Textor J, 2011, EPIDEMIOLOGY, V22, P745, DOI 10.1097/EDE.0b013e318225c2be; Tryphonas H, 2001, ENVIRON HEALTH PERSP, V109, P877, DOI 10.2307/3454650; Vaidya SV, 2012, J ASTHMA, V49, P800, DOI 10.3109/02770903.2012.721041; Van Winkle LS, 2013, ENVIRON HEALTH PERSP, V121, P912, DOI 10.1289/ehp.1206064; van Wonderen KE, 2010, EUR RESPIR J, V36, P48, DOI 10.1183/09031936.00154409; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Volkel W, 2011, ENVIRON RES, V111, P143, DOI 10.1016/j.envres.2010.10.001; Warner JO, 2004, ARCH DIS CHILD, V89, P97, DOI 10.1136/adc.2002.013029; Winans B, 2011, REPROD TOXICOL, V31, P327, DOI 10.1016/j.reprotox.2010.09.004	60	152	158	2	70	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					370	U496		10.1016/j.jaci.2014.09.030	http://dx.doi.org/10.1016/j.jaci.2014.09.030			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25445825				2022-12-18	WOS:000349372300008
J	Roduit, C; Frei, R; Depner, M; Schaub, B; Loss, G; Genuneit, J; Pfefferle, P; Hyvarinen, A; Karvonen, AM; Riedler, J; Dalphin, JC; Pekkanen, J; von Mutius, E; Braun-Fahrlander, C; Lauener, R				Roduit, Caroline; Frei, Remo; Depner, Martin; Schaub, Bianca; Loss, Georg; Genuneit, Jon; Pfefferle, Petra; Hyvarinen, Anne; Karvonen, Anne M.; Riedler, Josef; Dalphin, Jean-Charles; Pekkanen, Juha; von Mutius, Erika; Braun-Fahrlaender, Charlotte; Lauener, Roger		PASTURE Study Grp	Increased food diversity in the first year of life is inversely associated with allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; food allergy and sensitization; food diversity; children	PROSPECTIVE BIRTH COHORT; MICROBIOTA; ECZEMA; CHILDREN; INFANTS; RISK; AGE; SENSITIZATION; EXPOSURE; ASTHMA	Background: The role of dietary factors in the development of allergies is a topic of debate, especially the potential associations between infant feeding practices and allergic diseases. Previously, we reported that increased food diversity introduced during the first year of life reduced the risk of atopic dermatitis. Objective: In this study we investigated the association between the introduction of food during the first year of life and the development of asthma, allergic rhinitis, food allergy, or atopic sensitization, taking precautions to address reverse causality. We further analyzed the association between food diversity and gene expression of T-cell markers and of C epsilon germline transcript, reflecting antibody isotype switching to IgE, measured at 6 years of age. Methods: Eight hundred fifty-six children who participated in a birth cohort study, Protection Against Allergy Study in Rural Environments/EFRAIM, were included. Feeding practices were reported by parents in monthly diaries during the first year of life. Data on environmental factors and allergic diseases were collected from questionnaires administered from birth up to 6 years of age. Results: An increased diversity of complementary food introduced in the first year of life was inversely associated with asthma with a dose-response effect (adjusted odds ratio with each additional food item introduced, 0.74 [95% CI, 0.61-0.89]). A similar effect was observed for food allergy and food sensitization. Furthermore, increased food diversity was significantly associated with an increased expression of forkhead box protein 3 and a decreased expression of C epsilon germline transcript. Conclusion: An increased diversity of food within the first year of life might have a protective effect on asthma, food allergy, and food sensitization and is associated with increased expression of a marker for regulatory T cells.	[Roduit, Caroline] Univ Zurich, Childrens Hosp, Zurich, Switzerland; [Roduit, Caroline; Frei, Remo; Lauener, Roger] Christine Kuhne Ctr Allergy Res & Educ, Zurich, Switzerland; [Frei, Remo] Univ Zurich, Zurich, Switzerland; [Depner, Martin; Schaub, Bianca; von Mutius, Erika] Univ Munich, Dr Von Hauner Childrens Hosp, Munich, Germany; [Loss, Georg; Braun-Fahrlaender, Charlotte] Univ Basel, CH-4003 Basel, Switzerland; [Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Pfefferle, Petra] Univ Marburg, Inst Lab Med Pathobiochem & Mol Diagnost, Marburg, Germany; [Hyvarinen, Anne; Karvonen, Anne M.; Pekkanen, Juha] Natl Inst Hlth & Welf, Dept Environm Hlth, Kuopio, Finland; [Riedler, Josef] Childrens Hosp Schwarzach, Schwarzach, Austria; [Dalphin, Jean-Charles] Univ Hosp Besancon, CNRS, UMR Chrono Environm 6249, Dept Resp Dis, Besancon, France; [Lauener, Roger] Childrens Hosp Eastern Switzerland, St Gallen, Switzerland	University Children's Hospital Zurich; University of Zurich; University of Zurich; University of Munich; University of Basel; Ulm University; Philipps University Marburg; Finland National Institute for Health & Welfare; Centre National de la Recherche Scientifique (CNRS); Universite de Franche-Comte; CHU Besancon	Roduit, C (corresponding author), Kinderspital Zurich, Steinwies Str 75, CH-8032 Zurich, Switzerland.	Caroline.Roduit@kispi.uzh.ch	riedler, josef/AAQ-4666-2020; Roduit, Caroline/S-4928-2017; Ege, Markus/C-1962-2012; Lauener, Roger P/O-8612-2016; Frei, Remo/AAI-9180-2020; Roponen, Marjut/C-2086-2017; Schaub, Bianca/B-9935-2019; Loss, Georg/AAE-7296-2019; Loss, Georg/F-1557-2013; Genuneit, Jon/I-9323-2012	Ege, Markus/0000-0001-6643-3923; Lauener, Roger P/0000-0002-8412-606X; Roponen, Marjut/0000-0002-4442-9090; Schaub, Bianca/0000-0003-1652-8873; Loss, Georg/0000-0003-1090-812X; Genuneit, Jon/0000-0001-5764-1528; Roduit, Caroline/0000-0002-5988-0570; von Mutius, Erika/0000-0002-8893-4515; Hyvarinen, Anne/0000-0002-2823-0866	European Union research grants PASTURE/EFRAIM [QRLT4-CT 2001-00250, KBBE-2-2-06]; Kuhne Foundation; European Research Council; DFG; European Union; Chiesi; Novartis; GlaxoSmithKline; AstraZeneca; Intermune; Boehringer Ingelheim; European Commission; InfectoPharm; Nestle Research; Study Nestec; ALK-Abello	European Union research grants PASTURE/EFRAIM; Kuhne Foundation; European Research Council(European Research Council (ERC)European Commission); DFG(German Research Foundation (DFG)); European Union(European Commission); Chiesi(Chiesi Pharmaceuticals Inc); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Intermune; Boehringer Ingelheim(Boehringer Ingelheim); European Commission(European CommissionEuropean Commission Joint Research Centre); InfectoPharm; Nestle Research(Nestle SA); Study Nestec; ALK-Abello	Supported by European Union research grants PASTURE/EFRAIM (QRLT4-CT 2001-00250, KBBE-2-2-06) and the Kuhne Foundation.; M. Depner has received one or more grants from or has one or more grants pending with the European Research Council. B. Schaub has received one or more grants from or has one or more grants pending with DFG, European Union. J. Genuneit has been supported by one or more grants from the European Union. J.-C. Dalphin has received one or more consulting fees or honoraria from and has received support for travel from Chiesi; has consultancy arrangements with Novartis and Intermune; has received one or more grants from or has one or more grants pending with Novartis; has received one or more payments for lecturing from or is on the speakers' bureau for Novartis, GlaxoSmithKline, AstraZeneca, and Chiesi; has received one or more payments for the development of educational presentations for Novartis, Chiesi, GlaxoSmithKline, AstraZeneca, Intermune, and Boehringer Ingelheim; and has received one or more payments for travel/accommodations/meeting expenses from Novartis, Chiesi, and GlaxoSmithKline. E. von Mutius has been supported by one or more grants from the European Commission; is a Board member for the American Academy of Allergy, Asthma & Immunology; has consultancy arrangements with GlaxoSmithKline, Novartis, Protectimmun, ALK-Abello, and Astellas Pharma Europe; has provided expert testimony for the UK Research Excellence Framework; and has received one or more payments for lecturing from or is on the speakers' bureau for InfectoPharm and for Nestle Research. R. Lauener has been supported by a European Union Research Grant and a Kuhne Foundation Research Grant; has received support for travel from the European Union and from the Kuhne Foundation; has consultancy arrangements with the National Advisory Boards of ALK-Abello, Nestle, Novartis, MSD, MEDA, Allergopharma, and Menarini; has received one or more grants from or has one or more grants pending with Study Nestec; and has received one or more payments for lecturing from or is on the speakers' bureau for ALK-Abello and for Nestle. The rest of the authors declare that they have no relevant conflicts of interest.	Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; Alm B, 2009, ARCH DIS CHILD, V94, P11, DOI 10.1136/adc.2008.140418; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; Depner M, 2013, AM J RESP CRIT CARE; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Frei R, 2012, ALLERGY, V67, P451, DOI 10.1111/j.1398-9995.2011.02783.x; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Kjaer HF, 2009, PEDIAT ALLERG IMM-UK, V20, P726, DOI 10.1111/j.1399-3038.2009.00862.x; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Liu FW, 2011, ARCH TOXICOL, V85, P1383, DOI 10.1007/s00204-011-0673-6; Macia L, 2012, IMMUNOL REV, V245, P164, DOI 10.1111/j.1600-065X.2011.01080.x; Nwaru BI, 2013, J ALLERGY CLIN IMMUN, V131, P78, DOI 10.1016/j.jaci.2012.10.028; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Payne AN, 2012, FEMS MICROBIOL ECOL, V80, P608, DOI 10.1111/j.1574-6941.2012.01330.x; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Roduit C, 2012, J ALLERGY CLIN IMMUN, V130, P130, DOI 10.1016/j.jaci.2012.02.043; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Sariachvili M, 2010, PEDIAT ALLERG IMM-UK, V21, P74, DOI 10.1111/j.1399-3038.2009.00899.x; Sausenthaler S, 2011, AM J CLIN NUTR, V94, p2012S, DOI 10.3945/ajcn.110.001180; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; West CE, 2010, CURR OPIN PEDIATR, V22, P635, DOI 10.1097/MOP.0b013e32833d96ef; Zutavern A, 2008, PEDIATRICS, V121, pE44, DOI 10.1542/peds.2006-3553	30	152	157	1	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1056	+		10.1016/j.jaci.2013.12.1044	http://dx.doi.org/10.1016/j.jaci.2013.12.1044			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24508301	Bronze			2022-12-18	WOS:000333531700016
J	Masthoff, LJN; Mattsson, L; Zuidmeer-Jongejan, L; Lidholm, J; Andersson, K; Akkerdaas, JH; Versteeg, SA; Garino, C; Meijer, Y; Kentie, P; Versluis, A; Jager, CFD; Bruijnzeel-Koomen, CAFM; Knulst, AC; van Ree, R; van Hoffen, E; Pasmans, SGMA				Masthoff, Laury J. N.; Mattsson, Lars; Zuidmeer-Jongejan, Laurian; Lidholm, Jonas; Andersson, Kerstin; Akkerdaas, Jaap H.; Versteeg, Serge A.; Garino, Cristiano; Meijer, Yolanda; Kentie, Petra; Versluis, Astrid; Jager, Constance F. den Hartog; Bruijnzeel-Koomen, Carla A. F. M.; Knulst, Andre C.; van Ree, Ronald; van Hoffen, Els; Pasmans, Suzanne G. M. A.			Sensitization to Cor a 9 and Cor a 14 is highly specific for a hazelnut allergy with objective symptoms in Dutch children and adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Component-resolved diagnosis; diagnostics; double-blind; placebo-controlled food challenge; hazelnut allergy; severity; food allergy	BIRCH-ENDEMIC REGION; ARA H 2; CORYLUS-AVELLANA; DOUBLE-BLIND; CARBOHYDRATE DETERMINANTS; FOOD HYPERSENSITIVITY; DIAGNOSTIC-VALUE; PEANUT ALLERGY; IGE; REACTIVITY	Background: Component-resolved diagnosis has been shown to improve the diagnosis of food allergy. Objective: We sought to evaluate whether component-resolved diagnosis might help to identify patients at risk of objective allergic reactions to hazelnut. Method: A total of 161 hazelnut-sensitized patients were included: 40 children and 15 adults with objective symptoms on double-blind, placebo-controlled food challenges (DBPCFCs) and 24 adults with a convincing objective history were compared with 41 children and 41 adults with no or subjective symptoms on DBPCFCs (grouped together). IgE levels to hazelnut extract and single components were analyzed with ImmunoCAP. Results: IgE levels to hazelnut extract were significantly higher in children with objective than with no or subjective symptoms. In 13% of children and 49% of adults with hazelnut allergy with objective symptoms, only sensitization to rCor a 1.04 was observed and not to other water-soluble allergens. Sensitization to rCor a 8 was rare, which is in contrast to rCor a 1. Sensitization to nCor a 9, rCor a 14, or both was strongly associated with hazelnut allergy with objective symptoms. By using adapted cutoff levels, a diagnostic discrimination between severity groups was obtained. IgE levels to either nCor a 9 of 1 kUA/L or greater or rCor a 14 of 5 kUA/L or greater (children) and IgE levels to either nCor a 9 of 1 kUA/L or greater or rCor a 14 of 1 kUA/L or greater (adults) had a specificity of greater than 90% and accounted for 83% of children and 44% of adults with hazelnut allergy with objective symptoms. Conclusion: Sensitization to Cor a 9 and Cor a 14 is highly specific for patients with objective symptoms in DBPCFCs as a marker for a more severe hazelnut allergic phenotype.	[Masthoff, Laury J. N.; Versluis, Astrid; Jager, Constance F. den Hartog; Bruijnzeel-Koomen, Carla A. F. M.; Knulst, Andre C.; van Hoffen, Els; Pasmans, Suzanne G. M. A.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; [Meijer, Yolanda; Kentie, Petra] Univ Med Ctr Utrecht, Dept Paediat Pulmonol Allergol, NL-3508 GA Utrecht, Netherlands; [Mattsson, Lars; Lidholm, Jonas; Andersson, Kerstin] Thermo Fisher Sci, Uppsala, Sweden; [Zuidmeer-Jongejan, Laurian; Akkerdaas, Jaap H.; Versteeg, Serge A.; van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands; [Garino, Cristiano] Univ Piemonte Orientale, Dept Pharmaceut Sci, Drug & Food Biotechnol Ctr, Novara, Italy; [Meijer, Yolanda; Kentie, Petra; Pasmans, Suzanne G. M. A.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Ctr Paediat Allergol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Thermo Fisher Scientific; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Eastern Piedmont Amedeo Avogadro; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Masthoff, LJN (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol Allergol G02 124, POB 85-500, NL-3508 GA Utrecht, Netherlands.	L.J.N.Masthoff@umcutrecht.nl	Garino, Cristiano/AFX-3764-2022; Pasmans, Suzanne/AAI-6016-2021	Pasmans, Suzanne/0000-0003-1018-4475; Knulst, Andre/0000-0002-1056-3179; Zuidmeer-Jongejan, Laurian/0000-0003-3245-5555; Lidholm, Jonas/0000-0002-7779-3411	Phadia; HAL Allergy BV; Thermo Fisher.; Danone Research BV	Phadia(Phadia); HAL Allergy BV(HAL Allergy Group); Thermo Fisher.; Danone Research BV(Danone Nutricia)	L. Mattsson, J. Lidholm, and K. Andersson are employed by Thermo Fisher Scientific. A. C. Knulst has received research support from Phadia. R. van Ree has received research support and consultancy fees from HAL Allergy BV and has received lecture fees from Thermo Fisher. E. van Hoffen has received research support from HAL Allergy BV and Danone Research BV. S. G. M. A. Pasmans has received research support from Phadia. The rest of the authors declare that they have no relevant conflicts of interest.	Akkerdaas JH, 2006, MOL NUTR FOOD RES, V50, P18, DOI 10.1002/mnfr.200500147; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P517, DOI 10.1067/mai.2002.127434; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; De Knop KJ, 2011, PEDIAT ALLERG IMM-UK, V22, pe139, DOI 10.1111/j.1399-3038.2011.01112.x; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P423, DOI 10.1016/j.jaci.2007.10.009; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V118, P1186, DOI 10.1016/j.jaci.2006.08.017; Garino C, 2010, MOL NUTR FOOD RES, V54, P1257, DOI 10.1002/mnfr.200900456; Hansen KS, 2009, J ALLERGY CLIN IMMUN, V123, P1134, DOI 10.1016/j.jaci.2009.02.005; Klemans RJB, 2013, J ALLERGY CLIN IMMUN, V131, P157, DOI 10.1016/j.jaci.2012.08.010; Lauer I, 2004, BIOCHEM J, V383, P327, DOI 10.1042/BJ20041062; Mari A, 2002, INT ARCH ALLERGY IMM, V129, P286, DOI 10.1159/000067591; Mari A, 2005, CURR OPIN ALLERGY CL, V5, P267, DOI 10.1097/01.all.0000168793.27948.b0; Masthoff LJ, 2012, ALLERGY, V67, P521, DOI 10.1111/j.1398-9995.2011.02766.x; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; Osterballe M, 2005, PEDIAT ALLERG IMM-UK, V16, P567, DOI 10.1111/j.1399-3038.2005.00251.x; Roehr CC, 2004, CLIN EXP ALLERGY, V34, P1534, DOI 10.1111/j.1365-2222.2004.02080.x; Santos A, 2011, INT ARCH ALLERGY IMM, V155, P191, DOI 10.1159/000321178; Schocker F, 2004, J ALLERGY CLIN IMMUN, V113, P141, DOI 10.1016/j.jaci.2003.09.013; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; van Zuuren EJ, 2010, ALLERGY, V65, P1348, DOI 10.1111/j.1398-9995.2010.02357.x; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Verweij MM, 2012, J INVEST ALLERG CLIN, V22, P245; Wensing M, 2002, CLIN EXP ALLERGY, V32, P1757, DOI 10.1046/j.1365-2222.2002.01555.x	26	152	154	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					393	399		10.1016/j.jaci.2013.02.024	http://dx.doi.org/10.1016/j.jaci.2013.02.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23582909				2022-12-18	WOS:000322631700017
J	Rebane, A; Akdis, CA				Rebane, Ana; Akdis, Cezmi A.			MicroRNAs: Essential players in the regulation of inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; atopic; noncoding RNA; T cells; dendritic cells; epithelial cells; extracellular microRNAs	NF-KAPPA-B; ALLERGIC AIRWAYS DISEASE; TOLL-LIKE RECEPTORS; T-CELL-ACTIVATION; DENDRITIC CELLS; IN-VIVO; CIRCULATING MICRORNAS; ATOPIC-DERMATITIS; INDUCED APOPTOSIS; IMMUNE-RESPONSES	Regulation of inflammatory responses is ensured by coordinated control of gene expression in participating immune system and tissue cells. One group of gene expression regulators, the functions of which have recently been started to be uncovered in relation to any type of inflammatory condition, is a class of short single-stranded RNA molecules termed microRNAs (miRNAs). miRNAs function together with partner proteins and mainly cause gene silencing through degradation of target mRNAs or inhibition of translation. A particular miRNA can have hundreds of target genes, and thereby miRNAs together influence the expression of a large proportion of proteins. The role of miRNAs in the immune system has been extensively studied since the discovery of miRNAs in mammalian cells approximately 10 years ago. The purpose of the current review is to provide an overview on the functions of miRNAs in the regulation of inflammation, with a specific focus on the mechanisms of allergic inflammation. Because recent studies clearly demonstrate the presence of extracellular miRNAs in body fluids and propose the involvement of miRNAs in cell-cell communication, we will also highlight findings about functions of extracellular miRNAs. The possible use of miRNAs as biomarkers, as well as miRNA-related novel treatment modalities, might open a new future for the diagnosis and treatment of many inflammatory conditions, including allergic diseases.	[Rebane, Ana; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Rebane, Ana] Univ Tartu, Inst Biomed, EE-50411 Tartu, Estonia	Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Tartu	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	ana.rebane@ut.ee; akdisac@siaf.uzh.ch	Rebane, Ana/D-4279-2013; Akdis, Cezmi/AAV-4844-2020	Rebane, Ana/0000-0001-6051-1361; Akdis, Cezmi/0000-0001-8020-019X	Swiss National Science Foundation [32-132899]; Christine Kuhne-Center for Allergy Research and Education (CK-CARE); Estonian Science Foundation [ESF8350]; Novartis; PREDICTA; Swiss National Science Foundation; MeDALL; Christine Kuhne-Center for Allergy Research and Education	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne-Center for Allergy Research and Education (CK-CARE); Estonian Science Foundation; Novartis(Novartis); PREDICTA; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); MeDALL; Christine Kuhne-Center for Allergy Research and Education	Supported by Swiss National Science Foundation grant 32-132899, the Christine Kuhne-Center for Allergy Research and Education (CK-CARE), and Estonian Science Foundation grant ESF8350.; Disclosure of potential conflict of interest: C. A. Akdis has consultant arrangements with Actellion, Aventis, Stallergenes, Allergopharma, and Circacia; is employed by the Swiss Institute of Allergy and Asthma Research, University of Zurich; and has received grants from Novartis, PREDICTA, the Swiss National Science Foundation, MeDALL, and the Christine Kuhne-Center for Allergy Research and Education. A. Rebane declares no relevant conflicts of interest.	Akbas F, 2012, EXP LUNG RES, V38, P286, DOI 10.3109/01902148.2012.689088; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2012, J ALLERGY CLIN IMMUN, V129, P1438, DOI 10.1016/j.jaci.2012.05.003; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Biton M, 2011, NAT IMMUNOL, V12, P239, DOI 10.1038/ni.1994; Boldin MP, 2012, IMMUNOL REV, V246, P205, DOI 10.1111/j.1600-065X.2011.01089.x; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Boyman O, 2012, J ALLERGY CLIN IMMUN, V129, P160, DOI 10.1016/j.jaci.2011.10.046; Bronevetsky Y, 2013, J EXP MED, V210, P417, DOI 10.1084/jem.20111717; Burge SW, 2013, NUCLEIC ACIDS RES, V41, pD226, DOI 10.1093/nar/gks1005; Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044; Case SR, 2011, EXP LUNG RES, V37, P500, DOI 10.3109/01902148.2011.596895; Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106; Cheloufi S, 2010, NATURE, V465, P584, DOI 10.1038/nature09092; Chen QY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042971, 10.1371/journal.pone.0037149]; Chen RF, 2010, CLIN EXP ALLERGY, V40, P1482, DOI 10.1111/j.1365-2222.2010.03592.x; Chiang HR, 2010, GENE DEV, V24, P992, DOI 10.1101/gad.1884710; Chiba Y, 2010, J PHARMACOL SCI, V114, P264, DOI 10.1254/jphs.10R10FM; Cifuentes D, 2010, SCIENCE, V328, P1694, DOI 10.1126/science.1190809; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Collison A, 2011, J ALLERGY CLIN IMMUN, V128, P160, DOI 10.1016/j.jaci.2011.04.005; Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76; Djuranovic S, 2012, SCIENCE, V336, P237, DOI 10.1126/science.1215691; Djuranovic S, 2011, SCIENCE, V331, P550, DOI 10.1126/science.1191138; Ebert PJR, 2009, NAT IMMUNOL, V10, P1162, DOI 10.1038/ni.1797; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Etzrodt M, 2012, CELL REPORTS, V1, P317, DOI 10.1016/j.celrep.2012.02.009; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Feng MJ, 2012, INT IMMUNOPHARMACOL, V13, P347, DOI 10.1016/j.intimp.2012.05.001; Ghorpade DS, 2012, MOL CELL BIOL, V32, P2239, DOI 10.1128/MCB.06597-11; Griffiths-Jones Sam, 2006, V342, P129, DOI 10.1385/1-59745-123-1:129; Gu S, 2009, NAT STRUCT MOL BIOL, V16, P144, DOI 10.1038/nsmb.1552; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hafner M, 2011, NAT STRUCT MOL BIOL, V18, P1181, DOI 10.1038/nsmb.2170; Haneklaus M, 2012, J IMMUNOL, V189, P3795, DOI 10.4049/jimmunol.1200312; Hanke M, 2010, UROL ONCOL-SEMIN ORI, V28, P655, DOI 10.1016/j.urolonc.2009.01.027; Jardim MJ, 2012, AM J RESP CELL MOL, V47, P536, DOI 10.1165/rcmb.2011-0160OC; Jude JA, 2012, AM J PHYSIOL-LUNG C, V303, pL460, DOI 10.1152/ajplung.00041.2012; Jurkin J, 2010, J IMMUNOL, V184, P4955, DOI 10.4049/jimmunol.0903021; Kanasty RL, 2012, MOL THER, V20, P513, DOI 10.1038/mt.2011.294; Koch M, 2012, P NATL ACAD SCI USA, V109, pE1153, DOI 10.1073/pnas.1116125109; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kucuksezer UC, 2013, J ALLERGY CLIN IMMUN, V131, P875, DOI 10.1016/j.jaci.2012.10.051; Kuipers H, 2010, J IMMUNOL, V185, P400, DOI 10.4049/jimmunol.0903912; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Kundu P, 2012, NUCLEIC ACIDS RES, V40, P5088, DOI 10.1093/nar/gks148; Lamkanfi M, 2011, NAT REV IMMUNOL, V11, P213, DOI 10.1038/nri2936; Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Levanen B, 2013, J ALLERGY CLIN IMMUN, V131, P894, DOI 10.1016/j.jaci.2012.11.039; Li GJ, 2012, NAT MED, V18, P1518, DOI 10.1038/nm.2963; Li LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046957; Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008; Li SQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016956; Liston A, 2008, J EXP MED, V205, P1993, DOI 10.1084/jem.20081062; Liu G, 2009, P NATL ACAD SCI USA, V106, P15819, DOI 10.1073/pnas.0901216106; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lu CM, 2011, BLOOD, V117, P4293, DOI 10.1182/blood-2010-12-322503; Lu LF, 2010, CELL, V142, P914, DOI 10.1016/j.cell.2010.08.012; Lu TX, 2012, MUCOSAL IMMUNOL, V5, P388, DOI 10.1038/mi.2012.16; Lu TX, 2012, J ALLERGY CLIN IMMUN, V129, P1064, DOI 10.1016/j.jaci.2012.01.060; Lu TX, 2011, J IMMUNOL, V187, P3362, DOI 10.4049/jimmunol.1101235; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Makeyev EV, 2008, SCIENCE, V319, P1789, DOI 10.1126/science.1152326; Martinez-Nunez RT, 2011, J BIOL CHEM, V286, P1786, DOI 10.1074/jbc.M110.169367; Martinez-Nunez RT, 2009, J BIOL CHEM, V284, P16334, DOI 10.1074/jbc.M109.011601; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Meunier J, 2013, GENOME RES, V23, P34, DOI 10.1101/gr.140269.112; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Molnar A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2010-11-12-219; Moschos SA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-240; Muljo SA, 2005, J EXP MED, V202, P261, DOI 10.1084/jem.20050678; Nahid MA, 2013, J IMMUNOL, V190, P1250, DOI 10.4049/jimmunol.1103060; Nazari-Jahantigh M, 2012, J CLIN INVEST, V122, P4190, DOI 10.1172/JCI61716; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957; O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014; Park NJ, 2009, CLIN CANCER RES, V15, P5473, DOI 10.1158/1078-0432.CCR-09-0736; Perry MM, 2008, J IMMUNOL, V180, P5689, DOI 10.4049/jimmunol.180.8.5689; Qin HB, 2012, INFLAMMATION, V35, P1595, DOI 10.1007/s10753-012-9474-1; Rebane A, 2012, J ALLERGY CLIN IMMUN, V129, P1297, DOI 10.1016/j.jaci.2012.02.020; Redis RS, 2012, PHARMACOL THERAPEUT, V136, P169, DOI 10.1016/j.pharmthera.2012.08.003; Renz H, 2012, NAT REV IMMUNOL, V12, P9, DOI 10.1038/nri3112; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Rossato M, 2012, P NATL ACAD SCI USA, V109, pE3101, DOI 10.1073/pnas.1209100109; Sharma A, 2012, J APPL PHYSIOL, V113, P459, DOI 10.1152/japplphysiol.00001.2012; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Steiner DF, 2011, IMMUNITY, V35, P169, DOI 10.1016/j.immuni.2011.07.009; Sun XH, 2012, J CLIN INVEST, V122, P1973, DOI 10.1172/JCI61495; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takahashi H, 2012, NAT IMMUNOL, V13, P587, DOI 10.1038/ni.2286; Tan GS, 2012, ACS CHEM BIOL, V7, P402, DOI 10.1021/cb200253h; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Trotta R, 2013, BLOOD, V121, P3126, DOI 10.1182/blood-2012-12-467597; Trotta R, 2012, BLOOD, V119, P3478, DOI 10.1182/blood-2011-12-398099; Tserel L, 2011, J BIOL CHEM, V286, P26487, DOI 10.1074/jbc.M110.213561; Tsitsiou E, 2012, J ALLERGY CLIN IMMUN, V129, P95, DOI 10.1016/j.jaci.2011.08.011; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vennegaard MT, 2012, CONTACT DERMATITIS, V67, P298, DOI 10.1111/j.1600-0536.2012.02083.x; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Wang P, 2010, J IMMUNOL, V185, P6226, DOI 10.4049/jimmunol.1000491; Weiland M, 2012, RNA BIOL, V9, P850, DOI 10.4161/rna.20378; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Williams AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005889; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Xu N, 2011, J INVEST DERMATOL, V131, P1521, DOI 10.1038/jid.2011.55; Xu SL, 2012, BLOOD, V119, P767, DOI 10.1182/blood-2011-05-355412; Xu Z, 2011, J BIOL CHEM, V286, P21401, DOI 10.1074/jbc.M110.198630; Yang LL, 2012, J EXP MED, V209, P1655, DOI 10.1084/jem.20112218; Zekri L, 2013, EMBO J, V32, P1052, DOI 10.1038/emboj.2013.44; Zhang N, 2010, P NATL ACAD SCI USA, V107, P21629, DOI 10.1073/pnas.1016299107; Zhang XH, 2012, AM J RESP CRIT CARE, V185, P140, DOI 10.1164/rccm.201103-0456OC; Zhao JL, 2011, P NATL ACAD SCI USA, V108, P9184, DOI 10.1073/pnas.1105398108; Zhou HB, 2010, BLOOD, V116, P5885, DOI 10.1182/blood-2010-04-280156; Zhou XY, 2008, J EXP MED, V205, P1983, DOI 10.1084/jem.20080707	134	152	163	1	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					15	26		10.1016/j.jaci.2013.04.011	http://dx.doi.org/10.1016/j.jaci.2013.04.011			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23726263				2022-12-18	WOS:000321052300002
J	Fajt, ML; Gelhaus, SL; Freeman, B; Uvalle, CE; Trudeau, JB; Holguin, F; Wenzel, SE				Fajt, Merritt L.; Gelhaus, Stacy L.; Freeman, Bruce; Uvalle, Crystal E.; Trudeau, John B.; Holguin, Fernando; Wenzel, Sally E.			Prostaglandin D-2 pathway upregulation: Relation to asthma severity, control, and T(H)2 inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma control; chemoattractant receptor-homologous molecule expressed on T(H)2 lymphocytes; prostaglandin D-2; severe asthma; T(H)2 inflammation	D SYNTHASE; MAST-CELLS; RECEPTOR ANTAGONIST; DOUBLE-BLIND; ACTIVATION; PHENOTYPE; CRTH2; OC000459; EFFICACY; SAFETY	Background: Bronchoalveolar lavage (BAL) fluid prostaglandin D-2 (PGD(2)) levels are increased in patients with severe, poorly controlled asthma in association with epithelial mast cells (MCs). PGD(2), which is generated by hematopoietic prostaglandin D synthase (HPGDS), acts on 3 G protein-coupled receptors, including chemoattractant receptor-homologous molecule expressed on T(H)2 lymphocytes (CRTH2) and PGD(2) receptor 1 (DP1). However, much remains to be understood regarding the presence and activation of these pathway elements in asthmatic patients. Objective: We sought to compare the expression and activation of PGD(2) pathway elements in bronchoscopically obtained samples from healthy control subjects and asthmatic patients across a range of disease severity and control, as well as in relation to T(H)2 pathway elements. Methods: Epithelial cells and BAL fluid were evaluated for HPGDS (quantitative real-time PCR/immunohistochemistry [IHC]) and PGD(2) (ELISA/liquid chromatography mass spectrometry) in relation to levels of MC proteases. Expression of the 2 inflammatory cell receptors DP1 and CRTH2 was evaluated on luminal cells. These PGD(2) pathway markers were then compared with asthma severity, level of control, and markers of T(H)2 inflammation (blood eosinophils and fraction of exhaled nitric oxide). Results: Confirming previous results, BAL fluid PGD(2) levels were highest in patients with severe asthma (overall P = .0001). Epithelial cell compartment HPGDS mRNA and IHC values differed among groups (P = .008 and P < .0001, respectively) and correlated with MC protease mRNA. CRTH2 mRNA and IHC values were highest in patients with severe asthma (P = .001 and P = .0001, respectively). Asthma exacerbations, poor asthma control, and T(H)2 inflammatory markers were associated with higher PGD(2), HPGDS, and CRTH2 levels. Conclusion: The current study identifies coordinated upregulation of the PGD(2) pathway in patients with severe, poorly controlled, T(H)2-high asthma despite corticosteroid use.	[Fajt, Merritt L.; Uvalle, Crystal E.; Trudeau, John B.; Holguin, Fernando; Wenzel, Sally E.] Univ Pittsburgh, Asthma Inst UPMC, Div Pulm Allergy & Crit Care Med, Sch Med,Dept Med, Pittsburgh, PA 15213 USA; [Gelhaus, Stacy L.; Freeman, Bruce] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fajt, ML (corresponding author), Univ Pittsburgh, Asthma Inst UPMC UPSOM, Div Pulm Allergy & Crit Care Med, Dept Med, 3459 5th Ave,NW 628 Montefiore, Pittsburgh, PA 15213 USA.	fajtml@upmc.edu	Gelhaus, Stacy/AAF-2570-2019	Wenzel, Sally/0000-0002-4242-0164	National Institute of Health/National Heart, Lung, and Blood Institute [HL-69174, HL-109152-01, HL064937-10, NIH-F32 AI085633, CTSI UL1 RR024153]; National Institutes of Health (NIH); Actelion; Merck; Array; Amgen; Genentech MedImmune; Sanofi Aventis; GlaxoSmithKline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109152, R01HL064937, R01HL069174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI085633] Funding Source: NIH RePORTER	National Institute of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Actelion; Merck(Merck & Company); Array; Amgen(Amgen); Genentech MedImmune(AstraZenecaMedimmune); Sanofi Aventis(Sanofi-Aventis); GlaxoSmithKline(GlaxoSmithKline); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institute of Health/National Heart, Lung, and Blood Institute grants HL-69174, HL-109152-01, HL064937-10, NIH-F32 AI085633, and CTSI UL1 RR024153.; Disclosure of potential conflict of interest: M. L. Fajt has received grants from the National Institutes of Health (NIH). S. L. Gelhaus has received grants/has grants pending from the NIH. B. Freeman has received grants from the NIH; has received travel expenses from the NIH; has patents planned, pending, or issued by Complexa; has stock/stock options in Complexa and Nitromega. S. E. Wenzel has received consulting fees or honoraria from Actelion and Merck; has received payment for a Multicenter Study conducted for Array; has consultant arrangements with Amgen, Regeneron, and Novartis; and has grants/grants pending from Amgen, Genentech MedImmune, Sanofi Aventis, GlaxoSmithKline, and Merck. The rest of the authors declare that they have no relevant conflicts of interest.	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Barnes N, 2012, CLIN EXP ALLERGY, V42, P38, DOI 10.1111/j.1365-2222.2011.03813.x; Busse WW, 2013, J ALLERGY CLIN IMMUN, V131, P339, DOI 10.1016/j.jaci.2012.10.013; Chibana K, 2008, CLIN EXP ALLERGY, V38, P936, DOI 10.1111/j.1365-2222.2008.02969.x; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Fajt ML, 2010, AM J RESP CRIT CARE, V181; Fajt ML, 2011, AM J RESP CRIT CARE, V183; Fajt ML, 2010, J ALLERGY CLIN IMMUN, V125, pAB43, DOI 10.1016/j.jaci.2009.12.202; Fujimori K, 2000, J BIOL CHEM, V275, P40511, DOI 10.1074/jbc.M007688200; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gosset P, 2005, EUR J IMMUNOL, V35, P1491, DOI 10.1002/eji.200425319; Herlong JL, 2006, IMMUNOL LETT, V102, P121, DOI 10.1016/j.imlet.2005.10.004; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kanaoka Y, 2000, EUR J BIOCHEM, V267, P3315, DOI 10.1046/j.1432-1327.2000.01362.x; Luna-Gomes T, 2011, J IMMUNOL, V187, P6518, DOI 10.4049/jimmunol.1101806; Mahmud I, 1997, J BIOL CHEM, V272, P28263, DOI 10.1074/jbc.272.45.28263; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2011, J ALLERGY CLIN IMMUN, V128, P328, DOI 10.1016/j.jaci.2011.02.042; Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002; National Asthma Education and Prevention Program, 2007, NIH PUBL, V08-4051; National Asthma Education and Prevention Program National Heart Lung and Blood Institute, 2007, NIH PUBL; Okano M, 2006, AM J RHINOL, V20, P342, DOI 10.2500/ajr.2006.20.2865; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Pettipher R, 2012, J PHARMACOL EXP THER, V340, P473, DOI 10.1124/jpet.111.187203; Philip G, 2009, J ALLERGY CLIN IMMUN, V124, P942, DOI 10.1016/j.jaci.2009.07.006; Singh D, 2013, EUR RESPIR J, V41, P46, DOI 10.1183/09031936.00092111; Stebbins KJ, 2010, EUR J PHARMACOL, V638, P142, DOI 10.1016/j.ejphar.2010.04.031; Tanaka K, 2004, BIOCHEM BIOPH RES CO, V316, P1009, DOI 10.1016/j.bbrc.2004.02.151; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Xue LZ, 2005, J IMMUNOL, V175, P6531, DOI 10.4049/jimmunol.175.10.6531	35	152	156	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1504	+		10.1016/j.jaci.2013.01.035	http://dx.doi.org/10.1016/j.jaci.2013.01.035			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23506843	Bronze, Green Accepted			2022-12-18	WOS:000320532800006
J	Nicolaou, N; Murray, C; Belgrave, D; Poorafshar, M; Simpson, A; Custovic, A				Nicolaou, Nicolaos; Murray, Clare; Belgrave, Danielle; Poorafshar, Maryam; Simpson, Angela; Custovic, Adnan			Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SKIN PRICK; CHILDREN		[Nicolaou, Nicolaos; Murray, Clare; Belgrave, Danielle; Simpson, Angela; Custovic, Adnan] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Univ Hosp S Manchester NHS Fdn Trust, Manchester, Lancs, England; [Belgrave, Danielle] Univ Manchester, Biostat Grp, Sch Community Based Med, Manchester, Lancs, England; [Poorafshar, Maryam] Phadia AB, Uppsala, Sweden	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; University of Manchester; Thermo Fisher Scientific; Phadia	Nicolaou, N (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Univ Hosp S Manchester NHS Fdn Trust, Manchester, Lancs, England.	nic.nicolaou@googlemail.com	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Murray, Clare/0000-0002-8961-8055; Simpson, Angela/0000-0003-2733-6666	Medical Research Council [G0601361] Funding Source: Medline; Department of Health [G0601361] Funding Source: Medline; MRC [G0601361] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Krause S, 2009, J ALLERGY CLIN IMMUN, V124, P771, DOI 10.1016/j.jaci.2009.06.008; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; van Nieuwaal NHG, 2010, J ALLERGY CLIN IMMUN, V125, P1391, DOI 10.1016/j.jaci.2010.01.057; ZWEIG MH, 1993, CLIN CHEM, V39, P561	9	152	154	3	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					684	685		10.1016/j.jaci.2010.12.012	http://dx.doi.org/10.1016/j.jaci.2010.12.012			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21272928				2022-12-18	WOS:000288018400022
J	Khan, DA; Solensky, R				Khan, David A.; Solensky, Roland			Drug allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Drug allergy; adverse drug reactions; drug hypersensitivity; graded challenge; desensitization; tolerance; penicillin; cephalosporin; carbapenem; sulfonamide; local anesthetic; radiocontrast media; angiotensin-converting enzyme inhibitors; nonsteroidal anti-inflammatory drug; biologic modifiers	IGE-MEDIATED HYPERSENSITIVITY; CONVERTING ENZYME-INHIBITORS; CROSS-REACTIVITY; PENICILLIN ALLERGY; ADVERSE-REACTIONS; IMMEDIATE HYPERSENSITIVITY; HOSPITALIZED-PATIENTS; CONTRAST-MEDIA; ABACAVIR HYPERSENSITIVITY; SULFONAMIDE ANTIBIOTICS	Drug allergy is one type of adverse reaction to drugs and encompasses a spectrum of hypersensitivity reactions with heterogeneous mechanisms and clinical presentations. A thorough history is essential to the management of drug allergy. Laboratory testing has a very limited role in the management of drug allergy. Graded dose challenges and procedures to induce drug tolerance might be required in patients with drug allergy when there is a definite need for a particular agent. Management of reactions to specific agents, including beta-lactam antibiotics, sulfonamides, local anesthetics, radiocontrast media, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs, and biologic modifiers, will be discussed in further detail. (J Allergy Clin Immunol 2010;125:S126-37.)	[Khan, David A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Solensky, Roland] Corvallis Clin, Corvallis, OR USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Khan, DA (corresponding author), Univ Texas SW Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	dave.khan@utsouthwestern.edu						Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Apter AJ, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.10.052; Asero R, 1998, ANN ALLERG ASTHMA IM, V80, P185, DOI 10.1016/S1081-1206(10)62953-5; ASSEM ESK, 1974, IMMUNOLOGY, V27, P255; Atanaskovic-Markovic M, 2008, ALLERGY, V63, P237, DOI 10.1111/j.1398-9995.2007.01532.x; AUDICANA M, 1994, ALLERGY, V49, P108, DOI 10.1111/j.1398-9995.1994.tb00809.x; Ballow M, 2007, IMMUNOL RES, V38, P122, DOI 10.1007/s12026-007-0003-5; Banerji A, 2008, ANN ALLERG ASTHMA IM, V100, P327, DOI 10.1016/S1081-1206(10)60594-7; Barbaud A, 2005, TOXICOLOGY, V209, P209, DOI 10.1016/j.tox.2004.12.024; Berkun Y, 2003, ANN ALLERG ASTHMA IM, V91, P342, DOI 10.1016/S1081-1206(10)61680-8; BLANCA M, 1989, J ALLERGY CLIN IMMUN, V83, P381, DOI 10.1016/0091-6749(89)90122-X; BLANCA M, 1990, CLIN EXP ALLERGY, V20, P475, DOI 10.1111/j.1365-2222.1990.tb03139.x; Bonfanti P, 2000, BIOMED PHARMACOTHER, V54, P45, DOI 10.1016/S0753-3322(00)88640-0; Borchers AT, 2007, ANN NY ACAD SCI, V1108, P166, DOI 10.1196/annals.1422.019; Brockow K, 2009, ALLERGY, V64, P234, DOI 10.1111/j.1398-9995.2008.01832.x; Campi P, 2007, CURR OPIN ALLERGY CL, V7, P393, DOI 10.1097/ACI.0b013e3282ef96df; CARO JJ, 1991, AM J ROENTGENOL, V156, P825, DOI 10.2214/ajr.156.4.1825900; Castells MC, 2008, CURR PHARM DESIGN, V14, P2892, DOI 10.2174/138161208786369803; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Cunha BA, 2008, J CHEMOTHERAPY, V20, P233, DOI 10.1179/joc.2008.20.2.233; Dash C H, 1975, J Antimicrob Chemother, V1, P107; Daulat S, 2004, J ALLERGY CLIN IMMUN, V113, P1220, DOI 10.1016/j.jaci.2004.03.023; Davis CM, 2008, J ALLERGY CLIN IMMUN, V121, P826, DOI 10.1016/j.jaci.2007.10.021; Deeren DH, 2005, ANN HEMATOL, V84, P89, DOI 10.1007/s00277-004-0946-8; Dibbern DA, 2008, ANN ALLERG ASTHMA IM, V100, P91, DOI 10.1016/S1081-1206(10)60415-2; Dicpinigaitis PV, 2006, CHEST, V129, p169S, DOI 10.1378/chest.129.1_suppl.169S; Dillman JR, 2008, AM J ROENTGENOL, V190, P187, DOI 10.2214/AJR.07.2718; Dursun AB, 2008, ANN ALLERG ASTHMA IM, V100, P420, DOI 10.1016/S1081-1206(10)60465-6; EISENHAUER EA, 1994, J CLIN ONCOL, V12, P2654, DOI 10.1200/JCO.1994.12.12.2654; Fonacier L, 2005, ALLERGY ASTHMA PROC, V26, P135; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; GIRARD JP, 1968, INT ARCH ALLER A IMM, V33, P428, DOI 10.1159/000230058; Gonzalez-Lopez MA, 2007, CLIN EXP DERMATOL, V32, P672, DOI 10.1111/j.1365-2230.2007.02478.x; Goodman EJ, 2001, J CLIN ANESTH, V13, P561, DOI 10.1016/S0952-8180(01)00329-4; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; GREENBERGER PA, 1985, ARCH INTERN MED, V145, P2197, DOI 10.1001/archinte.145.12.2197; GREENBERGER PA, 2005, J ALLERGY CLIN IMMUN, V115, pS182; Haymore BR, 2008, ANN ALLERG ASTHMA IM, V101, P495, DOI 10.1016/S1081-1206(10)60288-8; Herborn CU, 2007, INVEST RADIOL, V42, P58, DOI 10.1097/01.rli.0000248893.01067.e5; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Hetherington S, 2001, CLIN THER, V23, P1603, DOI 10.1016/S0149-2918(01)80132-6; INCAUDO G, 1978, J ALLERGY CLIN IMMUN, V61, P339, DOI 10.1016/0091-6749(78)90057-X; Jost BC, 2006, ANN ALLERG ASTHMA IM, V97, P807, DOI 10.1016/S1081-1206(10)60973-8; Kanny G, 2005, J ALLERGY CLIN IMMUN, V115, P179, DOI 10.1016/j.jaci.2004.09.012; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; Kim SH, 2008, PHARMACOGENOMICS, V9, P85, DOI 10.2217/14622416.9.1.85; LANG DM, 1995, J ALLERGY CLIN IMMUN, V95, P813, DOI 10.1016/S0091-6749(95)70123-0; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lee CE, 2000, ARCH INTERN MED, V160, P2819, DOI 10.1001/archinte.160.18.2819; Leoung GS, 2001, J INFECT DIS, V184, P992, DOI 10.1086/323353; LopezSerrano MC, 1996, J INVEST ALLERG CLIN, V6, P30; Macy E, 2002, ALLERGY, V57, P1151, DOI 10.1034/j.1398-9995.2002.23700.x; Macy E, 2002, PERM J, V6, P17; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172, DOI 10.1016/S1081-1206(10)60692-8; Malde B, 2007, ANN ALLERG ASTHMA IM, V98, P57, DOI 10.1016/S1081-1206(10)60860-5; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; McConnell SA, 2000, CLIN INFECT DIS, V31, P1512, DOI 10.1086/317507; McKenna JK, 2004, IMMUNOL ALLERGY CLIN, V24, P399, DOI 10.1016/j.iac.2004.03.007; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; Miranda A, 1996, J ALLERGY CLIN IMMUN, V98, P671, DOI 10.1016/S0091-6749(96)70101-X; Novalbos A, 2001, CLIN EXP ALLERGY, V31, P438, DOI 10.1046/j.1365-2222.2001.00992.x; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Park M, 2006, ANN ALLERG ASTHMA IM, V97, P681, DOI 10.1016/S1081-1206(10)61100-3; PARKER CW, 1962, J EXP MED, V115, P803, DOI 10.1084/jem.115.4.803; Paster RZ, 1998, CLIN THER, V20, P978; PETZ LD, 1978, J INFECT DIS, V137, pS74, DOI 10.1093/infdis/137.Supplement.S74; Peyriere H, 2006, BRIT J DERMATOL, V155, P422, DOI 10.1111/j.1365-2133.2006.07284.x; Phillips EJ, 2006, CLIN INFECT DIS, V43, P103, DOI 10.1086/504878; Phillips E, 2009, MOL DIAGN THER, V13, P1, DOI 10.2165/01250444-200913010-00001; Pichichero ME, 1998, J PEDIATR-US, V132, P137, DOI 10.1016/S0022-3476(98)70499-8; Pichler WJ, 2006, ALLERGY, V61, P912, DOI 10.1111/j.1398-9995.2006.01058.x; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Prescott WA, 2004, CLIN INFECT DIS, V38, P1102, DOI 10.1086/382880; Quiralte J, 2007, J INVEST ALLERG CLIN, V17, P182; Ramos-Casals M, 2008, BEST PRACT RES CL RH, V22, P847, DOI 10.1016/j.berh.2008.09.008; Romano A, 2006, NEW ENGL J MED, V354, P2835, DOI 10.1056/NEJMc053529; Romano A, 2004, ANN INTERN MED, V141, P16, DOI 10.7326/0003-4819-141-1-200407060-00010; Romano A, 2007, ANN INTERN MED, V146, P266, DOI 10.7326/0003-4819-146-4-200702200-00005; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Sanz ML, 2008, CURR PHARM DESIGN, V14, P2803, DOI 10.2174/138161208786369722; Sastre J, 1996, ALLERGY, V51, P383, DOI 10.1111/j.1398-9995.1996.tb04634.x; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; Schmid DA, 2006, MOL PHARMACOL, V70, P356, DOI 10.1124/mol.105.021576; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; SHEPHERD GM, 1993, J ALLERGY CLIN IMMUN, V91, P262; Sodhi M, 2004, J ANTIMICROB CHEMOTH, V54, P1155, DOI 10.1093/jac/dkh454; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; Solensky R, 2000, ANN ALLERG ASTHMA IM, V85, P195, DOI 10.1016/S1081-1206(10)62466-0; Solensky R, 2002, ARCH INTERN MED, V162, P822, DOI 10.1001/archinte.162.7.822; Solensky R, 2004, IMMUNOL ALLERGY CLIN, V24, P425, DOI 10.1016/j.iac.2004.03.008; SOLENSKY R, 2010, ANN ALLERGY IN PRESS; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; STARK BJ, 1987, J ALLERGY CLIN IMMUN, V79, P523, DOI 10.1016/0091-6749(87)90371-X; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Stevenson DD, 2009, CURR ALLERGY ASTHM R, V9, P155, DOI 10.1007/s11882-009-0023-4; Strom BL, 2003, NEW ENGL J MED, V349, P1628, DOI 10.1056/NEJMoa022963; Todd Derrick J, 2008, Curr Rheumatol Rep, V10, P195, DOI 10.1007/s11926-008-0033-6; Venemalm L, 2008, J ALLERGY CLIN IMMUN, V121, P1058, DOI 10.1016/j.jaci.2007.12.1154; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; Webb JAW, 2003, EUR RADIOL, V13, P181, DOI 10.1007/s00330-002-1650-5; WOLF GL, 1991, INVEST RADIOL, V26, P404, DOI 10.1097/00004424-199105000-00003; Young B, 2008, AIDS, V22, P1673, DOI 10.1097/QAD.0b013e32830719aa	107	152	162	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S126	U148		10.1016/j.jaci.2009.10.028	http://dx.doi.org/10.1016/j.jaci.2009.10.028			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176256				2022-12-18	WOS:000280170600012
J	Fitch, KD; Sue-Chu, M; Anderson, SD; Boulet, LP; Hancox, RJ; McKenzie, DC; Backer, V; Rundell, KW; Alonso, JM; Kippelen, P; Cummiskey, JM; Garnier, A; Ljungqvist, A				Fitch, Kenneth D.; Sue-Chu, Malcolm; Anderson, Sandra D.; Boulet, Louis-Philippe; Hancox, Robert J.; McKenzie, Donald C.; Backer, Vibeke; Rundell, Kenneth W.; Alonso, Juan M.; Kippelen, Pascale; Cummiskey, Joseph M.; Garnier, Alain; Ljungqvist, Arne			Asthma and the elite athlete: Summary of the International Olympic Committee's Consensus Conference, Lausanne, Switzerland, January 22-24, 2008	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory symptoms; exercise-induced bronchoconstriction; asthma; beta(2)-agonists; airway hyperresponsiveness; bronchial provocation; Olympic Games; endurance training; environment	EXERCISE-INDUCED BRONCHOCONSTRICTION; EUCAPNIC VOLUNTARY HYPERVENTILATION; RESPIRATORY HEALTH SURVEY; FINE PARTICULATE MATTER; CROSS-COUNTRY SKIERS; AIRWAY INFLAMMATION; BRONCHIAL HYPERRESPONSIVENESS; INDUCED BRONCHOSPASM; INHALED CORTICOSTEROIDS; TOLERANCE	Respiratory symptoms cannot be relied on to make a diagnosis of asthma and/or airways hyperresponsiveness (AHR) in elite athletes. For this reason, the diagnosis should be confirmed with bronchial provocation tests. Asthma management in elite athletes should follow established treatment guidelines (eg, Global Initiative for Asthma) and should include education, an. individually tailored treatment plan, minimization of aggravating environmental factors, and appropriate drug therapy that must meet the requirements of the World Anti-Doping Agency. Asthma control can usually be achieved with inhaled corticosteroids and inhaled beta(2)-agonists to minimize exercise-induced bronchoconstriction and to treat intermittent symptoms. The rapid development of tachyphylaxis to beta(2)-agonists after regular daily. use poses a dilemma for athletes. Long-term intense endurance training, particularly in unfavorable environmental conditions, appears to be associated with an increased risk of developing asthma and AHR in elite athletes. Globally, the prevalence of asthma, exercise-induced bronchoconstriction, and AHR in Olympic athletes reflects the known prevalence of asthma symptoms in each country. The policy of requiring Olympic athletes to demonstrate the presence of asthma, exercise-induced bronchoconstriction, or AHR to be approved to inhale beta(2)-agonists will continue.	[Fitch, Kenneth D.] Univ Western Australia, Sch Sports Sci Exercise & Hlth, Fac Life Sci, Crawley, WA, Australia; [Sue-Chu, Malcolm] Univ Trondheim Hosp, Dept Lung Med, St Olays Hosp, Trondheim, Norway; [Sue-Chu, Malcolm] Norwegian Univ Sci & Technol, Dept Circulat & Imaging, Trondheim, Norway; [Anderson, Sandra D.] Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Camperdown, NSW 2050, Australia; [Boulet, Louis-Philippe] Univ Laval, Hop Laval, Inst Cardiol & Pneumol, Quebec City, PQ G1K 7P4, Canada; [Hancox, Robert J.] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Christchurch, New Zealand; [Hancox, Robert J.] Waikato Hosp, Dept Resp Med, Hamilton, New Zealand; [McKenzie, Donald C.] Univ British Columbia, Div Sports Med, Vancouver, BC V5Z 1M9, Canada; [McKenzie, Donald C.] Univ British Columbia, Sch Human Kinet, Vancouver, BC V5Z 1M9, Canada; [Backer, Vibeke] Bispebjerg Hosp, Dept Resp Med L, Copenhagen, Denmark; [Rundell, Kenneth W.] Marywood Univ, Human Physiol Lab, Scranton, PA USA; [Alonso, Juan M.] Int Assoc Athlet Federat, Monaco, Monaco; [Kippelen, Pascale] Univ Aberdeen, Sch Med Sci, Aberdeen AB9 1FX, Scotland; [Cummiskey, Joseph M.] Blackrock Clin, Dublin, Ireland; [Garnier, Alain] World Antidoping Agcy, Lausanne, Switzerland; [Ljungqvist, Arne] Int Olymp Comm, Lausanne, Switzerland	University of Western Australia; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); University of Sydney; Laval University; University of Otago; Waikato Hospital; University of British Columbia; University of British Columbia; University of Copenhagen; Bispebjerg Hospital; University of Aberdeen	Fitch, KD (corresponding author), Univ Western Australia, Sch Sports Sci Exercise & Hlth, Fac Life Sci, M408, Crawley, WA, Australia.	kfitch@cyllene.uwa.edu.au	Hancox, Robert/G-4746-2011; Backer, Vibeke/I-9573-2014; Kippelen, Pascale/ABH-2996-2020; Alonso, Juan-Manuel/GNH-5274-2022; Backer, Vibeke/AAQ-9379-2021; Sue-Chu, Malcolm/D-8671-2016	Backer, Vibeke/0000-0002-7806-7219; Anderson, Sandra/0000-0002-6308-8770; Sue-Chu, Malcolm/0000-0002-3301-1983				Alaranta A, 2004, MED SCI SPORT EXER, V36, P919, DOI 10.1249/01.MSS.0000128250.17793.47; Anderson SD, 2005, EUR RESPIR MONOGR, P48; Anderson SD, 2006, CLIN REV ALLERG IMMU, V31, P163, DOI 10.1385/CRIAI:31:2:163; Anderson Sandra D, 2004, Treat Respir Med, V3, P365, DOI 10.2165/00151829-200403060-00004; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; Anderson SD, 2006, J ALLERGY CLIN IMMUN, V117, P767, DOI 10.1016/j.jaci.2005.12.1355; Anderson SD, 2005, CURR ALLERGY ASTHM R, V5, P116, DOI 10.1007/s11882-005-0084-y; Anderson SD, 2003, J ALLERGY CLIN IMMUN, V111, P45, DOI 10.1067/mai.2003.1; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; Annesi-Maesano I, 2007, RESP MED, V101, P1721, DOI 10.1016/j.rmed.2007.02.022; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Belda J, 2008, BRIT J SPORT MED, V42, P244, DOI 10.1136/bjsm.2007.036335; Berges R, 2000, CLIN CHEM, V46, P1365; BOUGAULT V, 2008, AM J RESP CRIT CARE, V177, pA998; Boulet LP, 2005, CLIN INVEST MED, V28, P15; Brannan JD, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-144; Calderon-Garciduenas L, 2007, ENVIRON HEALTH PERSP, V115, P1248, DOI 10.1289/ehp.9641; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dickinson JW, 2005, THORAX, V60, P629, DOI 10.1136/thx.2004.037499; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; Fitch KD, 2006, CLIN REV ALLERG IMMU, V31, P259, DOI 10.1385/CRIAI:31:2:259; Global Strategy for Asthma Management and Prevention, 2006, GLOB STRAT ASTHM MAN; Hancox RJ, 1999, EUR RESPIR J, V14, P283, DOI 10.1034/j.1399-3003.1999.14b08.x; Hancox RJ, 2002, AM J RESP CRIT CARE, V165, P1068, DOI 10.1164/ajrccm.165.8.200111-091bc; Haney S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-19; Haney S, 2006, CLIN REV ALLERG IMMU, V31, P181, DOI 10.1385/CRIAI:31:2:181; Helenius I, 2005, SPORTS MED, V35, P565, DOI 10.2165/00007256-200535070-00002; Helenius I, 2004, ALLERGY, V59, P39, DOI 10.1046/j.1398-9995.2003.00353.x; Helenius I, 2002, J ALLERGY CLIN IMMUN, V109, P962, DOI 10.1067/mai.2002.124769; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; Holzer KE, 2001, MED SCI SPORT EXER, V33, pS314, DOI 10.1097/00005768-200105001-01766; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Joos GF, 2003, EUR RESPIR J, V21, P1050, DOI 10.1183/09031936.03.00008403; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; Kleinman MT, 2007, INHAL TOXICOL, V19, P117, DOI 10.1080/08958370701495345; Koh MS, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002739.pub3; Koskela HO, 2003, CHEST, V124, P1341, DOI 10.1378/chest.124.4.1341; Kuehn BM, 2007, JAMA-J AM MED ASSOC, V298, P2601, DOI 10.1001/jama.298.22.2601; Kujala UM, 1996, THORAX, V51, P288, DOI 10.1136/thx.51.3.288; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479, DOI 10.1164/ajrccm.161.5.9909008; Langdeau JB, 2001, SPORTS MED, V31, P601, DOI 10.2165/00007256-200131080-00005; Larsson K, 2005, EUR RESPIR MONOGR, P73; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; Lipworth BJ, 1999, J ALLERGY CLIN IMMUN, V103, P88, DOI 10.1016/S0091-6749(99)70530-0; Lumme A, 2003, EUR RESPIR J, V22, P113, DOI 10.1183/09031936.03.00112403; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; MARTINEAU L, 1992, CLIN SCI, V83, P615, DOI 10.1042/cs0830615; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Millqvist E, 2000, ALLERGY, V55, P672, DOI 10.1034/j.1398-9995.2000.00558.x; Nelson JA, 1998, NEW ENGL J MED, V339, P141, DOI 10.1056/NEJM199807163390301; Nystad W, 2000, MED SCI SPORT EXER, V32, P266, DOI 10.1097/00005768-200002000-00003; OByrne PM, 1997, CHEST, V111, pS27, DOI 10.1378/chest.111.2_Supplement.27S; Parsons JP, 2006, J ASTHMA, V43, P379, DOI 10.1080/02770900600709880; Pearce N, 2000, EUR RESPIR J, V16, P420, DOI 10.1183/9031936.00.16337700; Pearlman DS, 2006, ANN ALLERG ASTHMA IM, V97, P98, DOI 10.1016/S1081-1206(10)61377-4; PEDERSEN L, 2008, MED SCI SPO IN PRESS; PHILLIPS YY, 1985, AM REV RESPIR DIS, V131, P31; POPPIUS H, 1986, EUR J RESPIR DIS, V68, P319; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; Rundell KW, 2008, INHAL TOXICOL, V20, P1, DOI 10.1080/08958370701758593 ; Rundell KW, 2008, J STRENGTH COND RES, V22, P2, DOI 10.1519/JSC.0b013e31815ef98b; Rundell KW, 2005, BRIT J SPORT MED, V39, P232, DOI 10.1136/bjsm.2004.014282; Rundell KW, 2005, INHAL TOXICOL, V17, P99, DOI 10.1080/08958370590899479; Rundell KW, 2004, INHAL TOXICOL, V16, P117, DOI 10.1080/08958370490270918; Rundell KW, 2004, CHEST, V125, P909, DOI 10.1378/chest.125.3.909; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; Spooner C H, 2003, Cochrane Database Syst Rev, pCD002307; Sporer BC, 2008, MED SCI SPORT EXER, V40, P149, DOI 10.1249/mss.0b013e3181591df7; Stensrud T, 2006, RESP MED, V100, P1633, DOI 10.1016/j.rmed.2005.12.001; Storms W, 2004, RESP MED, V98, P1051, DOI 10.1016/j.rmed.2004.05.008; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048; Sue-Chu M, 2000, RESPIRATION, V67, P417, DOI 10.1159/000029541; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Sue-Chu M, 1999, RESP MED, V93, P719, DOI 10.1016/S0954-6111(99)90039-2; Tschumperlin DJ, 2006, ANNU REV PHYSIOL, V68, P563, DOI 10.1146/annurev.physiol.68.072304.113102; Turcotte H, 2003, RESP MED, V97, P955, DOI 10.1016/S0954-6111(03)00123-9; Werz O, 2000, EUR J BIOCHEM, V267, P1263, DOI 10.1046/j.1432-1327.2000.01000.x; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; Yates DH, 1996, AM J RESP CRIT CARE, V154, P1603, DOI 10.1164/ajrccm.154.6.8970342; Zielinski H, 1999, AM J PHYSIOL-LUNG C, V277, pL719, DOI 10.1152/ajplung.1999.277.4.L719; 1986, AM REV RESP DIS, V136, P225	92	152	155	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					254	260		10.1016/j.jaci.2008.07.003	http://dx.doi.org/10.1016/j.jaci.2008.07.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18678340	Bronze			2022-12-18	WOS:000258426300006
J	Jenkins, JA; Breiteneder, H; Mills, ENC				Jenkins, John A.; Breiteneder, Heimo; Mills, E. N. Clare			Evolutionary distance from human homologs reflects allergenicity of animal food proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen bioinformatics; protein families; animal food allergen structures; tropomyosin; parvalbumin; casein; evolutionary relatedness; human homology	FISH-ALLERGIC PATIENTS; MAJOR SHRIMP ALLERGEN; COWS MILK ALLERGY; IMMUNOGLOBULIN-E; IMMUNOLOGICAL CHARACTERIZATION; CROSS-REACTIVITY; TROPOMYOSIN; PARVALBUMIN; FAMILIES; CHILDREN	Background: In silico analysis of allergens can identify putative relationships among protein sequence, structure, and allergenic properties. Such systematic analysis reveals that most plant food allergens belong to a restricted number of protein superfamilies, with pollen allergens behaving similarly. Objective: We have investigated the structural relationships of animal food allergens and their evolutionary relatedness to human homologs to define how closely a protein must resemble a human counterpart to lose its allergenic potential. Methods: Profile-based sequence homology methods were used to classify animal food allergens into Pfam families, and in silico analyses of their evolutionary and structural relationships were performed. Results: Animal food allergens could be classified into I main families-tropomyosins, EF-hand proteins, and caseins-along with 14 minor families each composed of I to 3 allergens. The evolutionary relationships of each of these allergen superfamilies; showed that in general, proteins with a sequence identity to a human homolog above approximately 62% were rarely allergenic. Single substitutions in otherwise highly conserved regions containing IgE epitopes in EF-hand parvalbumins may modulate allergenicity. Conclusion: These data support the premise that certain protein structures are more allergenic than others. Contrasting with plant food allergens, animal allergens, such as the highly conserved tropomyosins, challenge the capability of the human immune system to discriminate between foreign and self-proteins. Such immune responses run close to becoming autoimmune responses. Clinical implications: Exploiting the closeness between animal allergens and their human homologs in the development of recombinant allergens for immunotherapy will need to consider the potential for developing unanticipated autoimmune responses.	[Breiteneder, Heimo] Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; [Jenkins, John A.; Mills, E. N. Clare] Inst Food Res, Inst Food Res, Norwich NR4 7UA, Norfolk, England	Medical University of Vienna; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Breiteneder, H (corresponding author), Med Univ Vienna, Dept Pathophysiol, AKH-EBO-3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	heimo.breiteneder@meduniwien.ac.at						Ah-Leung S, 2006, ALLERGY, V61, P1358, DOI 10.1111/j.1398-9995.2006.01193.x; Ayuso R, 1999, ANN ALLERG ASTHMA IM, V83, P399, DOI 10.1016/S1081-1206(10)62837-2; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bellioni-Businco B, 1999, J ALLERGY CLIN IMMUN, V103, P1191, DOI 10.1016/S0091-6749(99)70198-3; Bernard H, 1999, FOOD AGR IMMUNOL, V11, P101, DOI 10.1080/09540109999960; Bernard H, 1998, INT ARCH ALLERGY IMM, V115, P235, DOI 10.1159/000023906; Binder M, 2001, J IMMUNOL, V167, P5470, DOI 10.4049/jimmunol.167.9.5470; Bugajska-Schretter A, 2000, GUT, V46, P661, DOI 10.1136/gut.46.5.661; Businco L, 2000, J ALLERGY CLIN IMMUN, V105, P1031, DOI 10.1067/mai.2000.106377; Elsayed S, 1991, Scand J Clin Lab Invest Suppl, V204, P17; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; Gendel SM, 2006, MOL NUTR FOOD RES, V50, P633, DOI 10.1002/mnfr.200500271; Hamada Y, 2004, FISHERIES SCI, V70, P1137, DOI 10.1111/j.1444-2906.2004.00915.x; Hilger C, 2004, ALLERGY, V59, P653, DOI 10.1111/j.1398-9995.2004.00436.x; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Kanduc D, 2001, PEPTIDES, V22, P1981, DOI 10.1016/S0196-9781(01)00539-3; Koradi R, 1996, J MOL GRAPHICS, V14, P29; LANGELAND T, 1983, ALLERGY, V38, P399, DOI 10.1111/j.1398-9995.1983.tb05083.x; Mantyjarvi R, 2000, BBA-PROTEIN STRUCT M, V1482, P308, DOI 10.1016/S0167-4838(00)00139-4; Natale M, 2004, MOL NUTR FOOD RES, V48, P363, DOI 10.1002/mnfr.200400011; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Perez-Perez J, 2000, INT ARCH ALLERGY IMM, V123, P120, DOI 10.1159/000024442; Poulsen LK, 2001, ALLERGY, V56, P39, DOI 10.1034/j.1398-9995.2001.00912.x; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Reese G, 2005, J IMMUNOL, V175, P8354, DOI 10.4049/jimmunol.175.12.8354; Restani P, 1999, CLIN EXP ALLERGY, V29, P997, DOI 10.1046/j.1365-2222.1999.00563.x; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; Wild LG, 2005, CURR ALLERGY ASTHM R, V5, P74, DOI 10.1007/s11882-005-0059-z	31	152	167	2	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1399	1405		10.1016/j.jaci.2007.08.019	http://dx.doi.org/10.1016/j.jaci.2007.08.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17935767				2022-12-18	WOS:000251653800023
J	Barnes, PJ				Barnes, Peter J.			New molecular targets for the treatment of neutrophilic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						neutrophil; asthma; COPD; phosphodiesterase; nuclear factor-kappa B; p38 MAP kinase; adhesion molecule; chemokine	OBSTRUCTIVE PULMONARY-DISEASE; HISTONE DEACETYLASE ACTIVITY; IN-VIVO EFFICACY; FACTOR-KAPPA-B; AIRWAY INFLAMMATION; INDUCED SPUTUM; PHOSPHODIESTERASE-4 INHIBITOR; BRONCHIAL INFLAMMATION; EXHALED LEUKOTRIENES; MONOCLONAL-ANTIBODY	Increased neutrophils are a feature of airway inflammation in patients with chronic obstructive pulmonary disease and in some patients with asthma, particularly patients with more severe disease, during exacerbations and with cigarette smoking. Because neutrophilic inflammation may be detrimental, there are several new approaches to inhibiting neutrophilic inflammation. Neutrophilic inflammation is resistant or poorly responsive to corticosteroids, so different anti-inflammatory approaches are needed. Blocking neutrophil chemotactic factors such as leukotriene B-4 and IL-8 and related cysteine-X-cysteine chemokines by blocking receptor for leukotriene B4 1 and receptor for cysteine-X-cysteine chemokines 2 receptors is an approach that is currently being investigated. Other approaches include blocking adhesion molecules such as E-selectin. Inhibiting phosphodiesterase-4, nuclear factor-kappa B, or p38 mitogen-activated protein kinase is another approach that inhibits the production of cysteine-X-eysteine chemokines. Antioxidants, long-acting beta(2)-agonists, and activators of histone deacetylase may also be effective.	Imperial Coll Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Imperial Coll Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.	p.j.barnes@imperial.ac.uk		Barnes, Peter/0000-0002-5122-4018				Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8; Baelder R, 2005, J IMMUNOL, V174, P783, DOI 10.4049/jimmunol.174.2.783; Barnes PJ, 2007, EUR RESPIR J, V29, P587, DOI 10.1183/09031936.00080306; Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736; Barnes PJ, 2006, CHEST, V129, P151, DOI 10.1378/chest.129.1.151; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; Beeh KM, 2003, CHEST, V123, P1240, DOI 10.1378/chest.123.4.1240; Biernacki WA, 2003, THORAX, V58, P294, DOI 10.1136/thorax.58.4.294; Birrell MA, 2005, FASEB J, V19, P840, DOI 10.1096/fj.04-2691fje; Bousquet J, 2006, ALLERGY, V61, P72, DOI 10.1111/j.1398-9995.2005.00931.x; Bowler Russell P, 2004, COPD, V1, P255, DOI 10.1081/COPD-200027031; Bowman EP, 2006, CURR OPIN INFECT DIS, V19, P245, DOI 10.1097/01.qco.0000224818.42729.67; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280; Caramori G, 2003, THORAX, V58, P348, DOI 10.1136/thorax.58.4.348; Castro AC, 2003, BIOORG MED CHEM LETT, V13, P2419, DOI 10.1016/S0960-894X(03)00408-6; Castro SM, 2006, AM J RESP CRIT CARE, V174, P1361, DOI 10.1164/rccm.200603-319OC; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; Chung KF, 2006, EUR J PHARMACOL, V533, P110, DOI 10.1016/j.ejphar.2005.12.059; Conese Massimo, 2003, J Cyst Fibros, V2, P129, DOI 10.1016/S1569-1993(03)00063-8; Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416; COX G, 1995, J IMMUNOL, V154, P4719; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Culpitt SV, 2002, AM J RESP CRIT CARE, V165, P1371, DOI 10.1164/rccm.2105106; Culpitt SV, 2003, AM J RESP CRIT CARE, V167, P24, DOI 10.1164/rccm.200204-298OC; Davenpeck KL, 2000, J ALLERGY CLIN IMMUN, V105, P769, DOI 10.1067/mai.2000.105121; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; Donnelly LE, 2006, TRENDS PHARMACOL SCI, V27, P546, DOI 10.1016/j.tips.2006.08.001; Evans DJ, 1996, THORAX, V51, P1178, DOI 10.1136/thx.51.12.1178; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Finan PM, 2004, BIOCHEM SOC T, V32, P378, DOI 10.1042/BST0320378; Gamble E, 2003, AM J RESP CRIT CARE, V168, P976, DOI 10.1164/rccm.200212-1490OC; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gompertz S, 2002, CHEST, V122, P289, DOI 10.1378/chest.122.1.289; Gompertz S, 2001, EUR RESPIR J, V17, P1112, DOI 10.1183/09031936.01.99114901; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Hay Douglas W. P., 2001, Current Opinion in Pharmacology, V1, P242, DOI 10.1016/S1471-4892(01)00043-1; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Hill AT, 1999, AM J RESP CRIT CARE, V160, P893, DOI 10.1164/ajrccm.160.3.9901091; Hizawa N, 2006, CLIN EXP ALLERGY, V36, P1109, DOI 10.1111/j.1365-2222.2006.02550.x; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Jeffery PK, 2002, EUR RESPIR J, V20, P1378, DOI 10.1183/09031936.02.00542001; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Kobayashi M, 2004, RESPIROLOGY, V9, P249, DOI 10.1111/j.1440-1843.2004.00573.x; Kuss H, 2003, J PHARMACOL EXP THER, V307, P373, DOI 10.1124/jpet.103.053942; Lamontagne S, 2001, BRAIN RES, V920, P84, DOI 10.1016/S0006-8993(01)03023-2; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Mahler DA, 2004, CHEST, V126, P926, DOI 10.1378/chest.126.3.926; Maneechotesuwan K, 2005, CHEST, V128, P1936, DOI 10.1378/chest.128.4.1936; Mann BS, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-59; Marc MM, 2004, AM J RESP CELL MOL, V31, P216, DOI 10.1165/rcmb.2003-0394OC; Meagher LC, 1996, J IMMUNOL, V156, P4422; Meja KK, 2000, BRIT J PHARMACOL, V131, P1143, DOI 10.1038/sj.bjp.0703684; Montuschi P, 2003, THORAX, V58, P585, DOI 10.1136/thorax.58.7.585; Montuschi P, 2002, J ALLERGY CLIN IMMUN, V109, P615, DOI 10.1067/mai.2002.122461; MURAHIDY A, 2005, P AM THORAC SOC, V2, pA889; Noguera A, 1998, AM J RESP CRIT CARE, V158, P1664, DOI 10.1164/ajrccm.158.5.9712092; Norzila MZ, 2000, AM J RESP CRIT CARE, V161, P769, DOI 10.1164/ajrccm.161.3.9809071; Qiu YS, 2003, AM J RESP CRIT CARE, V168, P968, DOI 10.1164/rccm.200208-794OC; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Robichaud A, 2002, J CLIN INVEST, V110, P1045, DOI 10.1172/JCI200215506; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503-369OC; Smith SJ, 2006, BRIT J PHARMACOL, V149, P393, DOI 10.1038/sj.bjp.0706885; Sun YC, 2005, CHINESE MED J-PEKING, V118, P953; Traves SL, 2002, THORAX, V57, P590, DOI 10.1136/thorax.57.7.590; Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895, DOI 10.1152/ajplung.2000.279.5.L895; Ward S, 2003, CHEM BIOL, V10, P207, DOI 10.1016/S1074-5521(03)00048-6; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Yamamoto C, 1997, CHEST, V112, P505, DOI 10.1378/chest.112.2.505; Yang XD, 1999, J LEUKOCYTE BIOL, V66, P401, DOI 10.1002/jlb.66.3.401	89	152	158	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1055	1062		10.1016/j.jaci.2007.01.015	http://dx.doi.org/10.1016/j.jaci.2007.01.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17353033				2022-12-18	WOS:000246427200002
J	Mehl, A; Rolinck-Werninghaus, C; Staden, U; Verstege, A; Wahn, U; Beyer, K; Niggemann, B				Mehl, Anne; Rolinck-Werninghaus, Claudia; Staden, Ute; Verstege, Andrea; Wahn, Ulrich; Beyer, Kirsten; Niggemann, Bodo			The atopy patch test in the diagnostic workup of suspected food-related symptoms in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; atopy patch test; atopic dermatitis; children; food; IgE; skin prick test	COWS MILK ALLERGY; SKIN-PRICK TEST; DOUBLE-BLIND; PREDICTIVE-VALUE; IGE LEVELS; ANAPHYLACTIC REACTIONS; CHALLENGES; HYPERSENSITIVITY; DERMATITIS; ACCURACY	Background: There is an increasing need to develop test instruments that make oral food challenges superfluous. Objective: We sought to study the utility of atopy patch tests (APTs) in the diagnostic workup of food allergy. Methods: We investigated 437 children (median age, 13 months; 90% with atopic dermatitis) referred for evaluation of suspected food allergy. Specific serum IgE (sIgE) measurements, skin prick tests (SPTs), APTs, and controlled oral food challenges were performed. Results: We analyzed 873 oral challenges with cow's milk, hen's egg, wheat, and/or soy. One thousand seven hundred single APTs were performed. As a single parameter, the APTs showed the best specificity compared with sIgE measurements, SPTs, or both. Combining the APT with either the SPT or sIgE measurement resulted in improved sensitivity and specificity. Decision points for sIgE measurement and for the SPT showed lower values when combined with a positive APT result. Correctly bypassing an oral food challenge with combined testing, including APTs, only between 0.5% and 7% (99% predicted probability) and between 6% and 14% (using 95% predicted probability) of children would fulfill the criteria for avoiding an oral food challenge. Conclusion: Although the predictive capacity of the APT is improved when combined with sIgE measurement or the SPT, oral food challenges become superfluous in only 0.5% to 14% of study patients. In addition, the APT is time consuming and demands a highly experienced test evaluator. Clinical implications: For daily clinical practice, the APT adds only a small predictive value to the standard SPT and sIgE measurement in the diagnostic workup of suspected food-related symptoms in our study population.	Univ Charite, Childrens Hosp, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Niggemann, B (corresponding author), Univ Charite, Childrens Hosp, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	bodo.niggemann@charite.de						AXEN RE, 1988, NEW ENG REG ALLERGY, V9, P503; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Dreborg S, 2001, ALLERGY, V56, P359, DOI 10.1034/j.1398-9995.2001.056005359.x; Eigenmann PA, 2004, ALLERGY, V59, P895, DOI 10.1111/j.1398-9995.2004.00613.x; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Gellerstedt M, 2004, ALLERGY, V59, P354, DOI 10.1111/j.1398-9995.2003.00437.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hansen TK, 2004, PEDIAT ALLERG IMM-UK, V15, P428, DOI 10.1111/j.1399-3038.2004.00193.x; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; Hughes D A, 2001, Biologist (London), V48, P201; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Kagan R, 2003, ANN ALLERG ASTHMA IM, V90, P640, DOI 10.1016/S1081-1206(10)61869-8; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; Kekki OM, 1997, ALLERGY, V52, P755, DOI 10.1111/j.1398-9995.1997.tb01234.x; Keskin O, 2005, ANN ALLERG ASTHMA IM, V94, P553, DOI 10.1016/S1081-1206(10)61133-7; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; LangeveldWildschut EG, 1996, J ALLERGY CLIN IMMUN, V98, P1019, DOI 10.1016/S0091-6749(96)80186-2; Majamaa H, 1999, ALLERGY, V54, P851, DOI 10.1034/j.1398-9995.1999.00081.x; Majamaa H, 1999, ALLERGY, V54, P346, DOI 10.1034/j.1398-9995.1999.00834.x; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Mehl A, 2005, ALLERGY, V60, P1440, DOI 10.1111/j.1398-9995.2005.00909.x; Mehl A, 2005, ALLERGY, V60, P1034, DOI 10.1111/j.1398-9995.2005.00806.x; Niggemann B, 2005, ALLERGY, V60, P865, DOI 10.1111/j.1398-9995.2005.00828.x; Niggemann B, 2004, ALLERGY, V59, P32, DOI 10.1111/j.1398-9995.2004.00571.x; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91, DOI 10.1046/j.1365-2222.1999.00454.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Niggemann B, 2000, ALLERGY, V55, P281, DOI 10.1034/j.1398-9995.2000.00464.x; Orange AP, 1997, PEDIAT ALLERG IMM-UK, V8, P28, DOI 10.1111/j.1399-3038.1997.tb00139.x; Osterballe M, 2004, J AM ACAD DERMATOL, V51, P556, DOI 10.1016/j.jaad.2004.03.025; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Rance F, 1997, ALLERGY, V52, P1031, DOI 10.1111/j.1398-9995.1997.tb02427.x; Reibel S, 2000, ALLERGY, V55, P940, DOI 10.1034/j.1398-9995.2000.00689.x; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Saarinen KM, 2001, CLIN EXP ALLERGY, V31, P423, DOI 10.1046/j.1365-2222.2001.01015.x; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Stromberg L, 2002, ACTA PAEDIATR, V91, P1044, DOI 10.1080/080352502760311520; Vanto T, 1999, ALLERGY, V54, P837, DOI 10.1034/j.1398-9995.1999.00134.x; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.2324.x; Wistokat-Wulfing A, 1999, CLIN EXP ALLERGY, V29, P513	55	152	155	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					923	929		10.1016/j.jaci.2006.07.003	http://dx.doi.org/10.1016/j.jaci.2006.07.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030247				2022-12-18	WOS:000241434200022
J	Mascia, K; Haselkorn, T; Deniz, YM; Miller, DP; Bleecker, ER; Borish, L				Mascia, K; Haselkorn, T; Deniz, YM; Miller, DP; Bleecker, ER; Borish, L		TENOR Study Grp	Aspirin sensitivity and severity of asthma: Evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sinusitis; rhinosinusitis; rhinitis; eosinophils; functional endoscopic sinus surgery	EXACERBATED RESPIRATORY-DISEASE; LEUKOTRIENE C-4 SYNTHASE; INTOLERANT ASTHMA; CHRONIC SINUSITIS; RHINOSINUSITIS-ASTHMA; BRONCHIAL BIOPSIES; NATURAL-HISTORY; EOSINOPHILIA; OVEREXPRESSION; INFLAMMATION	Background: Patients with aspirin sensitivity experience hyperplastic sinusitis and nasal polyposis. We speculated that similar mechanisms could be acting in the lower airway and that these individuals would demonstrate more severe asthma and irreversible loss of lung function. Objective: We sought to investigate the role of aspirin-exacerbated respiratory disease (AERD) as a risk factor for the development of irreversible airway obstruction. Methods: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study is a multicenter observational study of subjects with severe or difficult-to-treat asthma. Data were compared between subjects who reported asthma exacerbation after aspirin ingestion and those who did not. The primary measure of bronchodilator-resistant obstruction (possible remodeling) was the maximally achieved postbronchodilator spirometry averaged over the 3-year duration of the study. Results: Adult subjects (>= 18 years) with AERD (n = 459) were compared with subjects with non-aspirin-sensitive asthma (n = 2848). Subjects with AERD had significantly lower mean postbronchodilator percent predicted FEVI compared with subjects with non-aspirin-sensitive asthma (75.3% vs 79.9%, P <.001). Differences in spirometry between the 2 cohorts persisted after controlling for potential confounding variables. In addition, subjects with AERD were more likely to have severe asthma by means of physician assessment (66% vs 49%, P <.001), to have been intubated (20% vs 11%, P <.001), to have a steroid burst in the previous 3 months (56% vs 46%, P <.001), and to have required high-dose inhaled corticosteroids (34% vs 26%, P <.001). Conclusions: These data suggest that aspirin sensitivity is associated with increased asthma severity and possible remodeling of both the upper and lower airways.	Univ Virginia, Hlth Syst, Asthma Allerg Dis Ctr, Charlottesville, VA 22908 USA; Genentech Inc, San Francisco, CA 94080 USA; Ovat Res Grp, San Francisco, CA USA	University of Virginia; Roche Holding; Genentech	Borish, L (corresponding author), Univ Virginia, Hlth Syst, Asthma Allerg Dis Ctr, Box 801355, Charlottesville, VA 22908 USA.	lb4m@virginia.edu		Miller, Dave/0000-0003-2947-152X	NIAID NIH HHS [AI50989] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bai TR, 2000, AM J RESP CRIT CARE, V162, P663, DOI 10.1164/ajrccm.162.2.9907151; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Cui TL, 2003, BIOL PHARM BULL, V26, P959; Dahlen B, 2000, AM J RESP CRIT CARE, V161, pS137, DOI 10.1164/ajrccm.161.supplement_1.ltta-27; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; KALINER MA, 1997, J ALLERGY CLIN IMMUN, V99, P829; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; Mascia K, 2005, ANN ALLERG ASTHMA IM, V94, P652, DOI 10.1016/S1081-1206(10)61323-3; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; *NIH NAT HEART LUN, 1997, NIH PUBL; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Peters EJ, 2003, ANN ALLERG ASTHMA IM, V90, P316, DOI 10.1016/S1081-1206(10)61800-5; PFISTER R, 1994, J ALLERGY CLIN IMMUN, V94, P804, DOI 10.1016/0091-6749(94)90146-5; Phipps S, 2002, J IMMUNOL, V169, P4604, DOI 10.4049/jimmunol.169.8.4604; Sampson AP, 1997, INT ARCH ALLERGY IMM, V113, P355, DOI 10.1159/000237600; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szczeklik A, 2000, THORAX, V55, pS42, DOI 10.1136/thorax.55.suppl_2.S42; Szefler S, 2000, NEW ENGL J MED, V343, P1054; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Vally H, 2002, THORAX, V57, P569, DOI 10.1136/thorax.57.7.569	37	152	159	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					970	975		10.1016/j.jaci.2005.08.035	http://dx.doi.org/10.1016/j.jaci.2005.08.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275362				2022-12-18	WOS:000235686700003
J	Foetisch, K; Westphal, S; Lauer, I; Retzek, M; Altmann, F; Kolarich, D; Scheurer, S; Vieths, S				Foetisch, K; Westphal, S; Lauer, I; Retzek, M; Altmann, F; Kolarich, D; Scheurer, S; Vieths, S			Biological activity of IgE specific for cross-reactive carbohydrate determinants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cross-reactive carbohydrate determinant; IgE reactivity; histamine release; clinical relevance	TOMATO LYCOPERSICON-ESCULENTUM; N-LINKED OLIGOSACCHARIDES; HISTAMINE-RELEASE; ALLERGEN; GLYCOPROTEINS; PROTEINS	Background: The clinical relevance of IgE specific for cross-reactive carbohydrate determinants (CCDs) has been a matter of controversy. Until now, no convincing experiments have been performed to test the biologic significance of individual multivalent allergens that carry multiple carbohydrate epitopes. Objective: We sought to contribute to the understanding of the role of CCD-specific IgE antibodies and to study whether CCD-specific IgE antibodies are able to activate basophils using different multivalent glycoproteins as antigens. Methods: Purified natural tomato beta-fructofuranosidase (nLyc e 2) and rLyc e 2.02 expressed in Escherichia coli were compared by means of histamine release tests. In addition, native and deglycosylated horseradish peroxidase and a neoglycoprotein consisting of a defined glycopeptide (Manalpha1-6[XyIbeta1-2]Manbeta1-4GlcNAcbeta1-4[Fucalpha1-3]GlcNAc) coupled to BSA were used in histamine release assays using stripped basophils from normal donors resensitized with IgE from CCD-reactive patients with food allergy to tomato. Results: Ten CCD-positive and 2 CCD-negative sera from patients with tomato allergy underwent histamine release testing by using the glycoproteins and nonglycosylated controls as antigens, respectively. All sera induced histamine release with tomato extract (up to 100%), confirming the allergic status of the donors. Four of the CCD-positive sera induced releases ranging from 12% to 82% with all of the glycoproteins but not with the nonglycosylated or monovalent controls. All other sera showed no response or only very weak response to the glycoproteins. Conclusion: Approximately one third of the CCD-positive sera from patients with tomato allergy have biologically relevant CCD-specific IgE antibodies. Therefore the general claim that CCD-specific IgE is clinically irrelevant has to be reconsidered critically. Hence IgE specific for CCDs should be taken into consideration in the diagnosis and therapy of certain allergies. In the subgroup of patients sensitized to CCDs, the use of natural allergens should be preferred over the use of recombinant allergens expressed in prokaryotic organisms.	Paul Ehrlich Inst, Dept Allergol, D-63225 Langen, Germany; Univ Bodenkultur Wien, Inst Chem, A-1180 Vienna, Austria	Paul Ehrlich Institute; University of Natural Resources & Life Sciences, Vienna	Vieths, S (corresponding author), Paul Ehrlich Inst, Dept Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.		Kolarich, Daniel/B-6893-2012; Scheurer, Stephan/A-6509-2019; Kolarich, Daniel/AAJ-3550-2020	Kolarich, Daniel/0000-0002-8452-1350; Scheurer, Stephan/0000-0002-2859-562X; Kolarich, Daniel/0000-0002-8452-1350; Altmann, Friedrich/0000-0002-0112-7877				BOTELLA MA, 1993, PLANT PHYSIOL, V103, P665, DOI 10.1104/pp.103.2.665; Budde IK, 2001, INT ARCH ALLERGY IMM, V126, P277, DOI 10.1159/000049524; Foetisch K, 2001, EUR FOOD RES TECHNOL, V213, P259, DOI 10.1007/s002170100343; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Fotisch K, 2001, GLYCOCONJUGATE J, V18, P373, DOI 10.1023/A:1014860030380; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; Mita H, 1995, ALLERGY, V50, P952, DOI 10.1111/j.1398-9995.1995.tb02506.x; Mita H, 2000, CLIN EXP ALLERGY, V30, P1582, DOI 10.1046/j.1365-2222.2000.00921.x; Pini C, 2002, ALLERGY, V57, P12; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; STURM A, 1991, EUR J BIOCHEM, V199, P169, DOI 10.1111/j.1432-1033.1991.tb16106.x; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; van Ree R, 1999, J ALLERGY CLIN IMMUN, V103, P1000, DOI 10.1016/S0091-6749(99)70169-7; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; Westphal S, 2003, EUR J BIOCHEM, V270, P1327, DOI 10.1046/j.1432-1033.2003.03503.x; Westphal S, 2002, J ALLERGY CLIN IMMUN, V109, pS308, DOI 10.1016/S0091-6749(02)82082-6; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651	21	152	154	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					889	896		10.1067/mai.2003.173	http://dx.doi.org/10.1067/mai.2003.173			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704374				2022-12-18	WOS:000182258500034
J	Finkelman, FD; Urban, JF				Finkelman, FD; Urban, JF			The other side of the coin: The protective role of the T(H)2 cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; eosinophil; IgE; IL-3; IL-4; IL-5; IL-9; IL-13; mast cell; worm	TRICHINELLA-SPIRALIS INFECTION; PARASITE TRICHURIS-MURIS; T-CELL SUBSETS; INTERLEUKIN-5 TRANSGENIC MICE; NECROSIS-FACTOR-ALPHA; VIRUS TYPE-I; W-WV MICE; MAST-CELL; NIPPOSTRONGYLUS-BRASILIENSIS; SCHISTOSOMA-MANSONI	Although T(H)2 cytokine involvement in allergy makes these cytokines attractive therapeutic targets, they protect against ectoparasites and gastrointestinal worms and suppress inflammation induced by T(H)1 cytokines, T(H)2 cytokines induce mastocytosis, eosinophilia, IgE synthesis, and mucus production. Each element of this response protects against some worms; however, different worms are protected against by different elements of the total response. The induction of the entire response by most parasitic worms suggests that it is safer for the immune system to make a stereotyped worm-protective response than to attempt to match a more specific response to a particular worm, In contrast, the reciprocal antagonism between T(H)1 and T(H)2 cytokines suggests that it is safer for the immune system to Limit immunopathology by suppressing inflammatory effector mechanisms not required for host protection against a particular pathogen class than to make an all-purpose inflammatory response, This, in turn, implies that innate immunity can distinguish different classes of parasites (eg, worms vs protozoa) but has limited ability to distinguish individual parasites within a class (eg, different worms). Although these considerations suggest that T(H)2 cytokine antagonists may increase the risk and severity of worm infections and T(H)1 cytokine-mediated inflammatory disorders, such therapy should be relatively safe if it is restricted to areas in which worm infections are rare and commonsense precautions are taken to minimize the risk of inducing T(H)1 cytokine-related inflammatory disease.	Cincinnati VAMC, Res Serv 151, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; USDA, Beltsville, MD 20705 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; United States Department of Agriculture (USDA)	Finkelman, FD (corresponding author), Cincinnati VAMC, Res Serv 151, 3200 Vine St, Cincinnati, OH 45220 USA.			Urban, Joseph/0000-0002-1590-8869	NIAID NIH HHS [R21 AI46972, R01 AI35987, R01 AI44971, R01 AI45766] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045766, R01AI044971, R21AI046972, R01AI035987] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE T, 1992, IMMUNOLOGY, V76, P10; ABE T, 1993, PARASITE IMMUNOL, V15, P643, DOI 10.1111/j.1365-3024.1993.tb00578.x; ALIZADEH H, 1984, J PARASITOL, V70, P767, DOI 10.2307/3281760; Atkins NS, 1999, PARASITE IMMUNOL, V21, P517, DOI 10.1046/j.1365-3024.1999.00248.x; Bancroft AJ, 2000, EUR J IMMUNOL, V30, P2083, DOI 10.1002/1521-4141(200007)30:7&lt;2083::AID-IMMU2083&gt;3.0.CO;2-3; Betts CJ, 1999, PARASITE IMMUNOL, V21, P45, DOI 10.1046/j.1365-3024.1999.00200.x; Brigandi RA, 1998, J PARASITOL, V84, P440, DOI 10.2307/3284509; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brunet LR, 1997, J IMMUNOL, V159, P777; BUTTERWORTH AE, 1992, IMMUNOL INVEST, V21, P391, DOI 10.3109/08820139209069381; CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; CAPRON M, 1981, J IMMUNOL, V126, P1764; CAPRON M, 1979, J IMMUNOL, V123, P2220; Chan VWF, 1998, J EXP MED, V188, P93, DOI 10.1084/jem.188.1.93; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; Cooper PJ, 2000, J INFECT DIS, V182, P1207, DOI 10.1086/315830; CORREALE J, 1995, J IMMUNOL, V154, P2959; CYPESS RH, 1975, J PARASITOL, V61, P819, DOI 10.2307/3279215; Daly CM, 1999, INFECT IMMUN, V67, P5315, DOI 10.1128/IAI.67.10.5315-5323.1999; DEMEURE CE, 1993, J INFECT DIS, V168, P1000, DOI 10.1093/infdis/168.4.1000; Donaldson LE, 1996, INT IMMUNOL, V8, P559, DOI 10.1093/intimm/8.4.559; Elliott DE, 2000, FASEB J, V14, P1848, DOI 10.1096/fj.99-0885hyp; ELSE KJ, 1992, IMMUNOLOGY, V75, P232; Else KJ, 1996, INFECT IMMUN, V64, P2950, DOI 10.1128/IAI.64.8.2950-2954.1996; ELSE KJ, 1994, J EXP MED, V179, P347, DOI 10.1084/jem.179.1.347; Faulkner H, 1998, INFECT IMMUN, V66, P3832, DOI 10.1128/IAI.66.8.3832-3840.1998; FERNANDEZBOTRAN R, 1988, J EXP MED, V168, P543, DOI 10.1084/jem.168.2.543; Finkelman FD, 1999, CURR OPIN IMMUNOL, V11, P420, DOI 10.1016/S0952-7915(99)80070-3; Finkelman FD, 2000, FASEB J, V14, pA952; FINKELMAN FD, 1991, J EXP MED, V174, P1179, DOI 10.1084/jem.174.5.1179; FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563; Finkelman FD, 1997, ANNU REV IMMUNOL, V15, P505, DOI 10.1146/annurev.immunol.15.1.505; FINKELMAN FD, 1991, IMMUNOL TODAY, V12, P62; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Folkard SG, 1996, PARASITOLOGY, V112, P323, DOI 10.1017/S0031182000065847; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Goldhill J, 1997, AM J PHYSIOL-GASTR L, V272, pG1135, DOI 10.1152/ajpgi.1997.272.5.G1135; GRENCIS RK, 1993, PARASITE IMMUNOL, V15, P55, DOI 10.1111/j.1365-3024.1993.tb00572.x; HA TY, 1983, INFECT IMMUN, V41, P445, DOI 10.1128/IAI.41.1.445-447.1983; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; ISMAIL MM, 1972, EXP PARASITOL, V31, P273, DOI 10.1016/0014-4894(72)90118-X; ITAYAMA H, 1987, JPN J VET RES, V35, P195; Jain-Vora S, 1998, INFECT IMMUN, V66, P4229; KAMIYA M, 1985, J HELMINTHOL, V59, P233, DOI 10.1017/S0022149X00008002; Kang IS, 1997, INFECT IMMUN, V65, P3107, DOI 10.1128/IAI.65.8.3107-3111.1997; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KeaneMyers A, 1996, J IMMUNOL, V156, P2488; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; KORENAGA M, 1991, IMMUNOLOGY, V72, P502; Koyama K, 2000, PARASITE IMMUNOL, V22, P13, DOI 10.1046/j.1365-3024.2000.00270.x; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; LIEW FY, 1994, IMMUNOL LETT, V43, P95, DOI 10.1016/0165-2478(94)00157-X; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MADDEN KB, 1991, J IMMUNOL, V147, P1387; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Martin C, 2000, INFECT IMMUN, V68, P3651, DOI 10.1128/IAI.68.6.3651-3656.2000; MATSUDA H, 1990, J IMMUNOL, V144, P259; McKenzie GJ, 1998, CURR BIOL, V8, P339, DOI 10.1016/S0960-9822(98)70134-4; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; McSharry C, 1999, INFECT IMMUN, V67, P484, DOI 10.1128/IAI.67.2.484-489.1999; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; Mekori YA, 2000, IMMUNOL REV, V173, P131, DOI 10.1034/j.1600-065X.2000.917305.x; MORRIS SC, 1994, J IMMUNOL, V152, P1047; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NACY CA, 1991, CURR OPIN IMMUNOL, V3, P330, DOI 10.1016/0952-7915(91)90033-W; Neva FA, 1998, J INFECT DIS, V178, P1856, DOI 10.1086/314507; NIESSNER M, 1995, CLIN EXP IMMUNOL, V101, P428; OKU Y, 1984, IMMUNOLOGY, V53, P337; Ovington KS, 1998, IMMUNOLOGY, V95, P488, DOI 10.1046/j.1365-2567.1998.00620.x; Ovington KS, 1997, MEM I OSWALDO CRUZ, V92, P93, DOI 10.1590/S0074-02761997000800013; PARSONS JC, 1993, PARASITE IMMUNOL, V15, P501, DOI 10.1111/j.1365-3024.1993.tb00637.x; POND L, 1989, J IMMUNOL, V143, P4232; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; RABINOVITCH A, 1994, DIABETES, V43, P613, DOI 10.2337/diabetes.43.5.613; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; Richard M, 2000, P NATL ACAD SCI USA, V97, P767, DOI 10.1073/pnas.97.2.767; ROBINSON RD, 1994, J INFECT DIS, V169, P692, DOI 10.1093/infdis/169.3.692; Rotman HL, 1996, EXP PARASITOL, V82, P267, DOI 10.1006/expr.1996.0034; RUSSELL DA, 1989, AM J PHYSIOL, V256, pG396, DOI 10.1152/ajpgi.1989.256.2.G396; SASAKI O, 1993, PARASITE IMMUNOL, V15, P349, DOI 10.1111/j.1365-3024.1993.tb00619.x; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1989, IMMUNOL REV, V112, P161, DOI 10.1111/j.1600-065X.1989.tb00557.x; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1990, J IMMUNOL, V145, P3911; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SONE S, 1992, EUR RESPIR J, V5, P174; STEWART GL, 1985, INT J PARASITOL, V15, P327, DOI 10.1016/0020-7519(85)90071-2; STRAIT R, 2001, FASEB J, V15, pA1018; SVETIC A, 1993, J IMMUNOL, V150, P3434; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TUOHY M, 1990, PARASITE IMMUNOL, V12, P675, DOI 10.1111/j.1365-3024.1990.tb00996.x; Urban J, 2000, J IMMUNOL, V164, P4250, DOI 10.4049/jimmunol.164.8.4250; URBAN JF, 1993, J IMMUNOL, V151, P7086; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; Urban JF, 2000, J IMMUNOL, V164, P2046, DOI 10.4049/jimmunol.164.4.2046; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; URBAN JF, 1995, J IMMUNOL, V154, P4675; Urban JF, 2001, FASEB J, V15, pA690; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; Wenner CA, 1996, J IMMUNOL, V156, P1442; WETZEL GD, 1989, EUR J IMMUNOL, V19, P1701, DOI 10.1002/eji.1830190926; WILSON RA, 1993, CURR OPIN IMMUNOL, V5, P538, DOI 10.1016/0952-7915(93)90035-Q; Wilson RA, 1996, IMMUNOLOGY, V87, P275, DOI 10.1046/j.1365-2567.1996.465550.x; WYNN TA, 1995, J IMMUNOL, V154, P4701; ZHANG S, 1990, INT ARCH ALLER A IMM, V93, P272, DOI 10.1159/000235313	115	152	154	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					772	780						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344341				2022-12-18	WOS:000168812300002
J	Liu, X; Nickel, R; Beyer, K; Wahn, U; Ehrlich, E; Freidhoff, LR; Bjorksten, B; Beaty, TH; Huang, SK				Liu, X; Nickel, R; Beyer, K; Wahn, U; Ehrlich, E; Freidhoff, LR; Bjorksten, B; Beaty, TH; Huang, SK		MAS Study Grp	An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German Multicenter Atopy Study (MAS-90)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; polymorphism; IgE level; atopic dermatitis	IL-13 MESSENGER-RNA; BRONCHIAL HYPERRESPONSIVENESS; LINKAGE DISEQUILIBRIUM; PROMOTER POLYMORPHISMS; AUSTRALIAN CHILDREN; ASTHMATIC FAMILIES; ILE50VAL VARIANT; IMMUNOGLOBULIN-E; CHROMOSOME 5Q; GENE MARKERS	Background: Allergic diseases are one of the major causes of morbidity in the developed countries today, and the prevalence of these diseases is increasing steadily. Study of total serum IgE level is important in understanding the genetics of allergic diseases because IgE levels are considered to be a crucial pathogenic component. IL-13 plays an important role in the induction of IgE synthesis and in the pathogenesis of allergic diseases. Objective: We sought to examine potential variation at the IL13 gene and estimate its effect on elevated IgE level and atopic dermatitis (AD), Methods: We conducted mutational analyses of the IL13 gene by using single-stranded conformation polymorphism and DNA sequencing. Case control studies for high-IgE phenotype and AD were performed by using subjects from the German MAS-90 cohort. Results: A novel IL13 coding region variant at 4257 bp (G to A, fourth exon) was identified. Case control studies of a German sample from the MAS-90 cohort showed significant associations between the presence of the A allele and two atopic phenotypes: high IgE (odds ratio, 2.38; 95% confidence interval, 1.35-4.21; P = .0026) and AD (odds ratio, 1.77; 95% confidence interval, 1.06-2.96; P = .03), Conclusion: This IL13 coding region variant may be involved in the pathogenesis of AD and high total serum IgE level in a study population of white subjects.	Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Humboldt Univ, Dept Pediat, Berlin, Germany; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Linkoping Univ, Linkoping, Sweden	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Humboldt University of Berlin; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Linkoping University	Huang, SK (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Huang, Shau-Ku/F-5509-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020059, R01AI040274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031891] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-40274, AI-20059] Funding Source: Medline; NIAMS NIH HHS [AR-31891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adra CN, 1999, CLIN GENET, V55, P431, DOI 10.1034/j.1399-0004.1999.550606.x; ANDERSON KL, 1999, SCIENCE, V284, pA1431; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; CHEN H, 1999, CHENG HUA I HSUEH U, V16, P307; D'Amato M, 1998, AM J RESP CRIT CARE, V158, P1968, DOI 10.1164/ajrccm.158.6.9804126; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; DUFFY DD, ANAL ALLELIC ASS PRI; Gao PS, 1999, CLIN GENET, V56, P164; Gao PS, 1999, BIOCHEM BIOPH RES CO, V263, P425, DOI 10.1006/bbrc.1999.1368; GERGEN PJ, 1992, AM REV RESPIR DIS, V50, P1033; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; HUANG SK, 1995, J IMMUNOL, V155, P2688; Jeannin P, 1998, BLOOD, V91, P1355, DOI 10.1182/blood.V91.4.1355; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; Kawakami Y, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30 Suppl, P1; Koning H, 1997, CYTOKINE, V9, P416, DOI 10.1006/cyto.1996.0184; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Kruse S, 1999, IMMUNOLOGY, V96, P365; Laitinen T, 1997, HUM MOL GENET, V6, P2069, DOI 10.1093/hmg/6.12.2069; Liggett S, 1998, CLIN EXP ALLERGY, V28, P114; Mansur AH, 1998, CLIN EXP ALLERGY, V28, P141; MANSUR AH, 1997, AM J RESP CRIT CARE, V156, pS156; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; NIAN TK, 1992, BRIT MED J, V304, P873; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; Palmer LJ, 1997, AM J HUM GENET, V61, P182, DOI 10.1086/513888; Palmer LJ, 1998, AM J RESP CRIT CARE, V158, P1825, DOI 10.1164/ajrccm.158.6.9804037; Palmer LJ, 1999, CLIN EXP ALLERGY, V29, P1555; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Rosenwasser LJ, 1998, CLIN EXP ALLERGY, V28, P13; Scott WK, 1997, SCIENCE, V275, P1327, DOI 10.1126/science.275.5304.1327; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Trabetti E, 1999, J MED GENET, V36, P323; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; XU J, 1995, AM J HUM GENET, V57, P425	50	152	168	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				167	170		10.1067/mai.2000.107935	http://dx.doi.org/10.1067/mai.2000.107935			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887320	Bronze			2022-12-18	WOS:000088393300022
J	Bacharier, LB; Geha, RS				Bacharier, LB; Geha, RS			Molecular mechanisms of IgE regulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IgE; isotype switching; interleukins	HUMAN B-CELLS; HUMAN INTERLEUKIN-4 RECEPTOR; NF-KAPPA-B; DELETIONAL SWITCH RECOMBINATION; ANTI-CD40 MONOCLONAL-ANTIBODY; EPSILON GERMLINE TRANSCRIPTS; X-LINKED IMMUNODEFICIENCY; PROTEIN-TYROSINE KINASES; C-H TRANSCRIPTION; IN-VIVO TREATMENT	IgE antibody plays an important role in allergic diseases. IgE synthesis by B cells requires two signals. The first signal is delivered by the cytokines IL-4 or IL-13, which target the C epsilon gene for switch recombination. The second signal is delivered by interaction of the B cell surface antigen CD40 with its ligand (CD40L) expressed on activated T cells. This activates deletional switch recombination, We review the molecular mechanisms of IL-4 and CD40 signaling that lead to IgE isotype switching and discuss the implications for intervening to abort or suppress the IgE antibody response.	Harvard Univ, Sch Med, Div Immunol, Childrens Hosp,Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Geha, RS (corresponding author), Harvard Univ, Sch Med, Div Immunol, Childrens Hosp,Dept Pediat, 300 Longwood Ave,Enders 8, Boston, MA 02115 USA.			Bacharier, Leonard/0000-0003-0432-2704	NIAID NIH HHS [AI-31541, AI-31136, AI-35714] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031541, R01AI031136, U01AI031541, P01AI035714] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Atamas SP, 1996, J IMMUNOL, V156, P435; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; Ballantyne J, 1997, INT IMMUNOL, V9, P963, DOI 10.1093/intimm/9.7.963; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; CARBALLIDO JM, 1995, J IMMUNOL, V155, P4162; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Corne J, 1997, J CLIN INVEST, V99, P879, DOI 10.1172/JCI119252; DAVIS FM, 1991, BIO-TECHNOL, V9, P53, DOI 10.1038/nbt0191-53; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DEKRUYFF RH, 1989, J EXP MED, V170, P1477, DOI 10.1084/jem.170.5.1477; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DELPRETE G, 1988, J IMMUNOL, V140, P4193; Devergne O, 1996, MOL CELL BIOL, V16, P7098; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; FARIS M, 1993, T ASSOC AM PHYSICIAN, V106, P187; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1991, INT IMMUNOL, V3, P599, DOI 10.1093/intimm/3.6.599; Fujiwara H, 1997, P NATL ACAD SCI USA, V94, P5866, DOI 10.1073/pnas.94.11.5866; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GARRONE P, 1991, EUR J IMMUNOL, V21, P1365, DOI 10.1002/eji.1830210606; Gauchat JF, 1997, EUR J IMMUNOL, V27, P971, DOI 10.1002/eji.1830270425; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GEHA RS, 1985, NATURE, V315, P577, DOI 10.1038/315577a0; GESSNER A, 1994, INFECT IMMUN, V62, P4112, DOI 10.1128/IAI.62.10.4112-4117.1994; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; HAAKFRENDSCHO M, 1993, J IMMUNOL, V151, P351; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; Iciek LA, 1997, J IMMUNOL, V158, P4769; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; JABARA HH, 1995, J ALLERGY CLIN IMMUN, V95, P893, DOI 10.1016/S0091-6749(95)70134-6; JABARA HH, 1991, J IMMUNOL, V147, P1557; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JABARA HH, 1990, J IMMUNOL, V145, P3468; Janeway C., 1994, IMMUNOBIOLOGY IMMUNE; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LOH RKS, 1994, J ALLERGY CLIN IMMUN, V94, P784, DOI 10.1016/0091-6749(94)90187-2; LOH RKS, 1994, J EXP MED, V180, P663, DOI 10.1084/jem.180.2.663; Loh RKS, 1996, J ALLERGY CLIN IMMUN, V97, P1141, DOI 10.1016/S0091-6749(96)70269-5; LOH RKS, 1995, IMMUNOL LETT, V45, P99, DOI 10.1016/0165-2478(94)00233-H; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Matthews DJ, 1997, EUR J IMMUNOL, V27, P116, DOI 10.1002/eji.1830270118; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Messner B, 1997, J IMMUNOL, V159, P3330; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; NIKAIDO T, 1982, J BIOL CHEM, V257, P7322; PalmerCrocker RL, 1996, J CLIN INVEST, V98, P604, DOI 10.1172/JCI118829; PENE J, 1988, J IMMUNOL, V141, P1218; PRESTA LG, 1993, J IMMUNOL, V151, P2623; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PURKERSON JM, 1992, J EXP MED, V175, P973, DOI 10.1084/jem.175.4.973; REINHOLD U, 1993, J AM ACAD DERMATOL, V29, P58, DOI 10.1016/0190-9622(93)70152-J; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; ROLLING C, 1995, ONCOGENE, V10, P1757; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Ryan JJ, 1997, J ALLERGY CLIN IMMUN, V99, P1; SATO TA, 1993, J IMMUNOL, V150, P2717; SCHIEPEK G, 1995, PSYCHOTHERAPIE FORUM, V3, P1; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Schulte T, 1997, J EXP MED, V186, P1419, DOI 10.1084/jem.186.9.1419; SCHWARTZ RS, 1995, NEW ENGL J MED, V333, P42, DOI 10.1056/NEJM199507063330108; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; SHAPIRA SK, 1991, P NATL ACAD SCI USA, V88, P7528, DOI 10.1073/pnas.88.17.7528; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; SHIKAI Y, 1992, CELL, V68, P855; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Snapper CM, 1996, J IMMUNOL, V156, P183; SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; Takeda K, 1996, J IMMUNOL, V157, P3220; Thienes CP, 1997, J IMMUNOL, V158, P5874; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; VERCELLI D, 1990, J IMMUNOL, V144, P570; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wiegand TW, 1996, J IMMUNOL, V157, P221; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WORM M, 1994, INT IMMUNOL, V6, P1883, DOI 10.1093/intimm/6.12.1883; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948; Zelazowski P, 1997, J IMMUNOL, V159, P3133; Zelazowski P, 1997, J IMMUNOL, V159, P2559; Zhang JG, 1997, J BIOL CHEM, V272, P9474; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	127	152	160	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S547	S558		10.1016/S0091-6749(00)90059-9	http://dx.doi.org/10.1016/S0091-6749(00)90059-9			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669540				2022-12-18	WOS:000085439600017
J	Schafer, T; Heinrich, J; Wjst, M; Adam, H; Ring, J; Wichmann, HE				Schafer, T; Heinrich, J; Wjst, M; Adam, H; Ring, J; Wichmann, HE			Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aeroallergens; atopic eczema; atopic dermatitis; East Germany; epidemiology; IgE-mediated sensitization; disease severity	MITE ALLERGEN AVOIDANCE; CONTACT-DERMATITIS; CHILDREN; GERMANY; BURDEN	Background: A subgroup of patients with atopic eczema exhibits aggravation through contact with aeroallergens. Little is known from population-based studies, however, about the association between the severity of eczematous skin disease and the degree of aeroallergen sensitization. Objective: We sought to investigate the relationship between IgE-mediated allergic sensitization to aeroallergens and severity of atopic eczema in schoolchildren. Methods: A nested case-control analysis on atopic eczema was performed on the basis of a cross-sectional study of 2201 Last German schoolchildren aged 5 to 14 years. Atopic eczema and its severity was identified by dermatologic examination. Total and allergen-specific IgE antibodies to grass and birch pollen, Cladosporium herbarum, Dermatophagoides pteronyssinus, and cat epithelium in serum were determined, and additional information was obtained by means of standardized questionnaire. Results: The overall prevalence of actual atopic eczema was 2.5%. Thirty-seven percent of the children were sensitized to at least one allergen. Children with atopic enema were significantly more often sensitized than those without skin disease (75.0% vs 36.3%; odds ratio. 5.27; 95% confidence interval, 2.54-11.15). This was observed for each single allergen. The prevalence of atopic eczema increased significantly with increasing RAST class (chi(2) trend test for each allergen, P < .0001). Also, the prevalence of sensitization increased with the severity of the disease (chi(2) trend test for each allergen, P < .0001). This association was pronounced for house dust mite and cat allergen. Multiple linear regression analyses showed significant associations between the severity score of atopic eczema and concentrations of allergen-specific IgE to dust mite (P = .032) and cat (P = .014) allergens after adjustment for ses, age, location, and parental predisposition. Conclusions: The degree of sensitization is directly associated with the severity of atopic eczema. We speculate that earl epicutaneous sensitization to aeroallergens may be enhanced by damage of the skin barrier function. The specific IgE response seems to contribute to the severity of the disease in a dose dependent fashion.	Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany; Tech Univ Munich, Div Environm Dermatol & Allergol, GSF, D-80802 Munich, Germany; GSF, Environm & Hlth Res Ctr, Inst Epidemiol, Neuherberg, Germany; Univ Munich, Inst Med Data Proc Biometr & Epidemiol, Munich, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Schafer, T (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy, Biedersteiner Str 29, D-80802 Munich, Germany.		Wichmann, Heinz Erich/AAA-5695-2022; Ring, Johannes/GLN-4341-2022; Heinrich, Joachim/N-1720-2013	Ring, Johannes/0000-0001-8236-3152; Heinrich, Joachim/0000-0002-9620-1629				ADINOFF AD, 1988, J ALLERGY CLIN IMMUN, V81, P736, DOI 10.1016/0091-6749(88)91047-0; ALONSO R, 1995, J INVEST ALLERG CLIN, V5, P156; Behrendt H, 1993, ALLERGO J, V2, P31; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Cabon N, 1996, CONTACT DERMATITIS, V35, P27, DOI 10.1111/j.1600-0536.1996.tb02262.x; Darsow U, 1996, BRIT J DERMATOL, V135, P182, DOI 10.1111/j.1365-2133.1996.tb01144.x; DEMOLY P, 1991, J ALLERGY CLIN IMMUN, V88, P758, DOI 10.1016/0091-6749(91)90183-O; Diepgen T L, 1992, Acta Derm Venereol Suppl (Stockh), V176, P13; GUILLET G, 1992, ARCH DERMATOL, V128, P187, DOI 10.1001/archderm.128.2.187; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Kramer U, 1998, BRIT J DERMATOL, V139, P1040; Meyer I, 1999, ENVIRON RES, V81, P32, DOI 10.1006/enrs.1998.3950; MITCHELL EB, 1982, LANCET, V1, P127; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Mutitts E, 1994, AM J RESP CRIT CARE, V149, P358; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; PRZYBILLA B, 1990, SEMIN DERMATOL, V9, P220; RAJKA G, 1986, INT J DERMATOL, V25, P301, DOI 10.1111/j.1365-4362.1986.tb02249.x; Ring J, 1997, INT ARCH ALLERGY IMM, V113, P7, DOI 10.1159/000237495; Ring J, 1995, PROG ALLER CLIN IMM, V3, P174; RING J, 1991, HDB ATOPIC ECZEMA; RUZICKA T, 1991, HDB ATOPIC ECZEMA; SANDA T, 1992, J ALLERGY CLIN IMMUN, V89, P653, DOI 10.1016/0091-6749(92)90370-H; Schafer T, 1996, ALLERGY, V51, P532; Schafer T, 1998, ALLERGOLOGIE, V21, P259; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; Somos Zsuzsanna, 1993, Orvosi Hetilap, V134, P1359; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Taieb A, 1996, CLIN REV ALLERG IMMU, V14, P209; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Trepka MJ, 1996, SCI TOTAL ENVIRON, V180, P95, DOI 10.1016/0048-9697(95)04945-2; Trepka MJ, 1997, ENVIRON RES, V72, P118, DOI 10.1006/enrs.1996.3720; WILLIAMS HC, 1997, CHALLENGE DERMATOEPI, P125; WUTHRICH B, 1989, THER UMSCH, V46, P633	34	152	161	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1280	1284		10.1016/S0091-6749(99)70025-4	http://dx.doi.org/10.1016/S0091-6749(99)70025-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589013				2022-12-18	WOS:000084289200025
J	Bellioni-Businco, B; Paganelli, R; Lucenti, P; Giampietro, PG; Perborn, H; Businco, L				Bellioni-Businco, B; Paganelli, R; Lucenti, P; Giampietro, PG; Perborn, H; Businco, L			Allergenicity of goat's milk in children with cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk allergy; cross-reactivity; double-blind; placebo-controlled; oral food challenge; goat's milk; immunoblotting	FORMULAS; SHEEPS; CHEESE	Background: Cow's milk allergy (CMA) is a common disease of infancy and childhood. An appropriate cow's milk (CM) substitute is necessary for feeding babies with CMA. CM substitutes are soy formulas and casein- or whey-based extensively hydrolyzed formulas. In several countries, including Italy, goat's milk (GM) formulas are available, and some physicians recommend them for feeding babies with CMA. Objective: We sought to investigate, in vitro and in vivo, the allergenicity of GM in 26 children with proven IgE-mediated CMA. Methods: All the children underwent skin tests with CM and GM; detection of specific serum IgE to CM and GM; and double-blind, placebo-controlled, oral food challenges (DBP-COFCs) with fresh CM, GM, and, as placebo, a soy formula (Isomil, Abbott, Italy), CAP inhibition and immunoblotting inhibition assays were also carried out in 1 of 26 and 4 of 26 children with positive RAST results to both CM and GM, respectively. Results: All the children had positive skin test responses and CAP results to both CM and GM, all had positive DBPCOFC results to CM, and 24 of 26 had positive DBPCOFCs to GM. In CAP inhibition tests, preincubation of serum with CM or GM strongly inhibited IgE either to CM or to GM, In immunoblotting inhibition assays, preincubation with CM completely extinguished reactivity to GM, whereas GM partially inhibited reactivity to CM. Conclusions: These data strongly indicate that GM is not an appropriate CM substitute for children with IgE-mediated CMA. A warning on the lack of safety of GM for children with CMA should be on the label of GM formulas to prevent severe allergic reactions in babies with CMA.	Univ Roma La Sapienza, Dept Pediat, Div Clin Immunol & Allergy, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Clin Med, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Pediat, I-00161 Rome, Italy; Pharmacia & Upjohn Diagnost AB, Dept Allergy & Asthma, Uppsala, Sweden	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Pfizer; Pharmacia Corporation	Businco, L (corresponding author), Univ Roma La Sapienza, Dept Pediat, Div Clin Immunol & Allergy, Viale Regina Elena 324, I-00161 Rome, Italy.							BENGTSSON A, 1986, INT ARCH ALLER A IMM, V80, P383, DOI 10.1159/000234085; Businco L, 1993, Pediatr Allergy Immunol, V4, P101, DOI 10.1111/j.1399-3038.1993.tb00077.x; BUSINCO L, 1993, PEDIATR ASTHMA ALLER, V7, P73, DOI 10.1089/pai.1993.7.73; BUSINCO L, 1993, CLIN EXP ALLERGY, V23, P481, DOI 10.1111/j.1365-2222.1993.tb03234.x; Calvani M, 1998, EUR J PEDIATR, V157, P17, DOI 10.1007/s004310050759; CRAWFORD LV, 1961, J PEDIATR-US, V59, P347, DOI 10.1016/S0022-3476(61)80287-4; FRANCIS DEM, 1987, DIET SICK CHILDREN; FREIER S, 1970, CLIN PEDIATR, V9, P449, DOI 10.1177/000992287000900806; FREIER S, 1969, J PEDIATR-US, V75, P623, DOI 10.1016/S0022-3476(69)80458-0; GJESING B, 1986, ALLERGY, V41, P51, DOI 10.1111/j.1398-9995.1986.tb00275.x; Hill LW, 1939, J PEDIATR-US, V15, P157, DOI 10.1016/S0022-3476(39)80025-7; HOFFMAN KM, 1995, J ALLERGY CLIN IMMUN, V95, P330; Klish WJ, 1998, PEDIATRICS, V101, P148, DOI 10.1542/peds.101.1.148; MCLAUGHLAN P, 1981, ARCH DIS CHILD, V56, P165, DOI 10.1136/adc.56.3.165; PERBORN H, 1995, 16 EUR C ALL CLIN IM; PHILLIPS NI, 1968, J IMMUNOL, V100, P307; POLGAR M, 1998, PEDIAT INTEGRAL, V3, P208; RAGNO V, 1993, EUR J PEDIATR, V152, P760, DOI 10.1007/BF01953996; SAPERSTEIN SIDNEY, 1960, ANN ALLERGY, V18, P765; Spuergin P, 1997, ALLERGY, V52, P293, DOI 10.1111/j.1398-9995.1997.tb00993.x; WUTHRICH B, 1995, J ALLERGY CLIN IMMUN, V96, P270, DOI 10.1016/S0091-6749(95)70021-8	21	152	160	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1191	1194		10.1016/S0091-6749(99)70198-3	http://dx.doi.org/10.1016/S0091-6749(99)70198-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359905	Bronze			2022-12-18	WOS:000080929500032
J	KELLY, KJ; PEARSON, ML; KURUP, VP; HAVENS, PL; BYRD, RS; SETLOCK, MA; BUTLER, JC; SLATER, JE; GRAMMER, LC; RESNICK, A; ROBERTS, M; JARVIS, WR; DAVIS, JP; FINK, JN				KELLY, KJ; PEARSON, ML; KURUP, VP; HAVENS, PL; BYRD, RS; SETLOCK, MA; BUTLER, JC; SLATER, JE; GRAMMER, LC; RESNICK, A; ROBERTS, M; JARVIS, WR; DAVIS, JP; FINK, JN			A CLUSTER OF ANAPHYLACTIC REACTIONS IN CHILDREN WITH SPINA-BIFIDA DURING GENERAL-ANESTHESIA - EPIDEMIOLOGIC FEATURES, RISK-FACTORS, AND LATEX HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX; SPINA BIFIDA; ETHYLENE OXIDE; ANAPHYLAXIS; GENERAL ANESTHESIA; ALLERGY	HUMAN-SERUM-ALBUMIN; CONTACT URTICARIA; ETHYLENE-OXIDE; BARIUM ENEMA; INTRAOPERATIVE ANAPHYLAXIS; ALLERGY; RUBBER; IGE; REACTIVITY; SURGERY	Background: Anaphylactic reactions (ARs) in high-risk pediatric patients undergoing general anesthesia, especially those with spina bifida, have been attributed to anesthetics, muscle relaxants, antimicrobials, ethylene oxide, and latex. Methods: To identify risk factors for AR during general anesthesia and to investigate the role of latex allergy, we studied epidemiologic and immunologic characteristics of patients with ARs during general anesthesia during a 13-month cluster of such reactions at Children's Hospital of Wisconsin (case patients). Patients with AR were compared with patients with spina bifida undergoing uneventful general anesthesia during the same period (control patients). For each case patient and control patient, we conducted a chart review; a parental interview skin prick testing with latex, anesthetics, aeroallergens, and banana extract; ELISA and RAST for latex-specific IgE; a total serum IgE; and an ELISA for IgE antibody to ethylene oxide. Results: Anaphylactic reactions occurred exclusively in patients with spina bifida (n = 10) or patients with a congenital urinary tract anomaly (n = 1). Case-patients were more likely than control patients to have a history of asthma (p = 0.002), rubber contact allergy (p = 0.001), food allergy (p = 0.001), rash caused by adhesive rape (p = 0.05), daily rectal disimpaction (p < 0.001), nine or more prior surgical procedures (p < 0.002), latex-specific IgE (p = 0.027), or elevated total serum IgE levels (p = 0.002). Multivariate analysis identified non-white race, rubber contact allergy, history of food allergy, and nine or more surgical procedures as significant independent risk factors. Logistic model equation identified the predicted probability of AR with a sensitivity, specificity and positive predictive value of 82%, 97%, and 82%, respectively. Conclusions: These findings demonstrate that atopy, especially symptomatic later allergy, is associated with AR during anesthesia in patients with spina bifida. Until a standardized latex test is available, a medical history of immediate rubber contact allergy, non-white race, food allergy, or nine or more prior surgical procedures can identify patients with spina bifida at highest risk for ARs. A complete history, including rubber contact and food allergy, should be compiled on all patients with spina bifida before surgery.	VET ADM MED CTR,CHILDRENS HOSP,DEPT PEDIAT,MILWAUKEE,WI; VET ADM MED CTR,CHILDRENS HOSP,DEPT MED,DIV ALLERGY IMMUNOL,MILWAUKEE,WI; VET ADM MED CTR,CHILDRENS HOSP,DEPT ANESTHESIA,MILWAUKEE,WI; CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,INVEST & PREVENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,OFF SURVEILLANCE & ANAL,ATLANTA,GA 30333; WISCONSIN DEPT HLTH & SOCIAL SERV,BUR PUBL HLTH,MADISON,WI; GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,WASHINGTON,DC; NORTHWESTERN UNIV,SCH MED,ALLERGY IMMUNOL UNIT,CHICAGO,IL	Children's Hospital of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); Children's Hospital of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); Children's Hospital of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Children's National Health System; George Washington University; Northwestern University	KELLY, KJ (corresponding author), MED COLL WISCONSIN,DEPT PEDIAT,DIV ALLERGY IMMUNOL,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.			Grammer, Leslie/0000-0001-6860-2014; Kelly, Kevin/0000-0002-2954-6117				Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P443; FECZKO PJ, 1989, AM J ROENTGENOL, V153, P275, DOI 10.2214/ajr.153.2.275; GERBER AC, 1989, ANESTHESIOLOGY, V71, P800, DOI 10.1097/00000542-198911000-00031; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; GRAMMER LC, 1991, J ALLERGY CLIN IMMUN, V87, P674, DOI 10.1016/0091-6749(91)90387-4; GRAMMER LC, 1985, J ALLERGY CLIN IMMUN, V76, P511, DOI 10.1016/0091-6749(85)90736-5; HOLZMAN RS, 1990, ANESTHESIOLOGY, V73, pA1123; HOSMER DW, 1989, APPLIED LOGISTIC REG, P93; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KURUP VP, 1992, ALLERGY PROC, V13, P329, DOI 10.2500/108854192778816915; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; LOZYNSKY OA, 1986, ANN ALLERGY, V56, P62; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; MEEROPOL E, 1990, NEW ENGL J MED, V323, P1072; MONERETVAUTRIN DA, 1990, ANESTHESIOLOGY, V73, P556, DOI 10.1097/00000542-199009000-00032; MOUDGIL GC, 1986, CAN J ANAESTH, V33, P400, DOI 10.1007/BF03010757; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NGUYEN DH, 1991, J UROLOGY, V146, P571, DOI 10.1016/S0022-5347(17)37858-8; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; SCHWARTZ EE, 1984, AM J ROENTGENOL, V143, P103, DOI 10.2214/ajr.143.1.103; SLATER JE, 1990, ANN ALLERGY, V65, P411; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, BRIT MED J, P297; WAYS ME, 1989, ANESTHESIOLOGY, V71, P483; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x	30	152	156	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					53	61		10.1016/0091-6749(94)90071-X	http://dx.doi.org/10.1016/0091-6749(94)90071-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027499				2022-12-18	WOS:A1994NX39300008
J	WICKMAN, M; NORDVALL, SL; PERSHAGEN, G; SUNDELL, J; SCHWARTZ, B				WICKMAN, M; NORDVALL, SL; PERSHAGEN, G; SUNDELL, J; SCHWARTZ, B			HOUSE DUST MITE SENSITIZATION IN CHILDREN AND RESIDENTIAL CHARACTERISTICS IN A TEMPERATE REGION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHILDHOOD ASTHMA; D-PTERONYSSINUS; STOCKHOLM AREA; GRASS-POLLEN; ALLERGENS; EXPOSURE; DERMATOPHAGOIDES; PREVALENCE; SYMPTOMS; FARINAE	House dust mite (Hdm) infestation used to be rare in Stockholm, but Hdm-sensitized children are now frequently observed, which probably indicates an increased infestation rate. This study was performed to elucidate determinants of Hdm sensitization in children living in the area. In a case-control study, 53 Hdm-sensitized children (cases), a group of non-Hdm-sensitized atopic children (N = 54), and a group of nonallergic neighborhood children (N = 53) were included. Mattress dust was analyzed with ELISA for content of Hdm allergens. Indoor humidity and temperature were measured, and questionnaire data were collected. Asthma was significantly more common in the Hdm-sensitized group than in the atopic control group. Hdm allergens were found in 40%, 19%, and 23% of the dust samples of the case group, atopic group, and neighborhood control groups, respectively. Only 15% of the dust samples of the Hdm-sensitized children contained Hdm allergens above the recommended threshold levels of sensitization of 2000 ng/gm of dust. Inadequate ventilation, which partly appeared to be a consequence of energy saving, appeared to be a risk factor for Hdm sensitization. This result may apply also to other temperate regions and suggests that the problem is preventable.	KAROLINSKA INST,INST ENVIRONM MED,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT ENVIRONM MED,S-10401 STOCKHOLM 60,SWEDEN; ALLERGOL LAB AS,ALK,HORSHOLM,DENMARK; KAROLINSKA HOSP,DEPT CLIN IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA HOSP,DEPT ENVIRONM HLTH & INFECT DIS CONTROL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	WICKMAN, M (corresponding author), ST GORANS CHILDRENS HOSP,DEPT PEDIAT,PB 12500,S-11281 STOCKHOLM,SWEDEN.		Sundell, Jan H/B-2857-2012	Pershagen, Goran/0000-0002-9701-1130				Aas K, 1974, ACTA ALLERGOL, V29, P239; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; CORNFIELD J, 1956, 3RD P BERK S STAT PR; ENGSTROM L, 1987, ENERGY BUILT ENV POS, P109; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; KORSGAARD J, 1983, ALLERGY, V38, P93, DOI 10.1111/j.1398-9995.1983.tb01592.x; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; LINNA O, 1983, ALLERGY, V38, P513, DOI 10.1111/j.1398-9995.1983.tb02360.x; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARSH DG, 1988, CLIN ALLERGY, V18, P201, DOI 10.1111/j.1365-2222.1988.tb02860.x; MARTIN CJ, 1987, BRIT MED J, V294, P1125, DOI 10.1136/bmj.294.6580.1125; MOSBECH H, 1986, ALLERGY, V41, P373, DOI 10.1111/j.1398-9995.1986.tb00315.x; MURRAY AB, 1985, J ALLERGY CLIN IMMUN, V76, P108, DOI 10.1016/0091-6749(85)90812-7; NORDVALL SL, 1988, ACTA PAEDIATR SCAND, V77, P716, DOI 10.1111/j.1651-2227.1988.tb10736.x; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHIBASAKI M, 1988, J ALLERGY CLIN IMMUN, V82, P86, DOI 10.1016/0091-6749(88)90056-5; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRACHAN DP, 1988, BMJ-BRIT MED J, V297, P1223, DOI 10.1136/bmj.297.6658.1223; TUROS M, 1979, ALLERGY, V34, P11, DOI 10.1111/j.1398-9995.1979.tb01995.x; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Voorhorst R., 1969, HOUSE DUST ATOPY HOU; YICHUNG C, 1989, ANN ALLERGY, V62, P101; 1985, SAS USERS GUIDE BASI	32	152	156	0	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					89	95		10.1016/0091-6749(91)90305-8	http://dx.doi.org/10.1016/0091-6749(91)90305-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	2071788				2022-12-18	WOS:A1991FY20400011
J	Poole, A; Urbanek, C; Eng, C; Schageman, J; Jacobson, S; O'Connor, BP; Galanter, JM; Gignoux, CR; Roth, LA; Kumar, R; Lutz, S; Liu, AH; Fingerlin, TE; Setterquist, RA; Burchard, EG; Rodriguez-Santana, J; Seibold, MA				Poole, Alex; Urbanek, Cydney; Eng, Celeste; Schageman, Jeoffrey; Jacobson, Sean; O'Connor, Brian P.; Galanter, Joshua M.; Gignoux, Christopher R.; Roth, Lindsey A.; Kumar, Rajesh; Lutz, Sharon; Liu, Andrew H.; Fingerlin, Tasha E.; Setterquist, Robert A.; Burchard, Esteban G.; Rodriguez-Santana, Jose; Seibold, Max A.			Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal airway epithelium; transcriptome; T(H)2; asthma; bronchial airway epithelium	GENOME-WIDE ASSOCIATION; BRONCHIAL EPITHELIAL-CELLS; BETA(2)-ADRENERGIC RECEPTOR; DIFFERENTIAL EXPRESSION; GENETIC POLYMORPHISMS; GALA II; AIRWAY; CHILDREN; QUANTIFICATION; INFLAMMATION	Background: Bronchial airway expression profiling has identified inflammatory subphenotypes of asthma, but the invasiveness of this technique has limited its application to childhood asthma. Objectives: We sought to determine whether the nasal transcriptome can proxy expression changes in the lung airway transcriptome in asthmatic patients. We also sought to determine whether the nasal transcriptome can distinguish subphenotypes of asthma. Methods: Whole-transcriptome RNA sequencing was performed on nasal airway brushings from 10 control subjects and 10 asthmatic subjects, which were compared with established bronchial and small-airway transcriptomes. Targeted RNA sequencing nasal expression analysis was used to profile 105 genes in 50 asthmatic subjects and 50 control subjects for differential expression and clustering analyses. Results: We found 90.2% overlap in expressed genes and strong correlation in gene expression (rho = .87) between the nasal and bronchial transcriptomes. Previously observed asthmatic bronchial differential expression was strongly correlated with asthmatic nasal differential expression (rho = 0.77, P = 5.6 x 10(-9)). Clustering analysis identified T(H)2-high and T(H)2-low subjects differentiated by expression of 70 genes, including IL13, IL5, periostin (POSTN), calcium-activated chloride channel regulator 1 (CLCA1), and serpin peptidase inhibitor, clade B (SERPINB2). T(H)2-high subjects were more likely to have atopy (odds ratio, 10.3; P = 3.5 x 10(-6)), atopic asthma (odds ratio, 32.6; P = 6.9 x 10(-7)), high blood eosinophil counts (odds ratio, 9.1; P = 2.6 x 10(-6)), and rhinitis (odds ratio, 8.3; P = 4.1 x 10(-6)) compared with T(H)2-low subjects. Nasal IL13 expression levels were 3.9-fold higher in asthmatic participants who experienced an asthma exacerbation in the past year (P = .01). Several differentially expressed nasal genes were specific to asthma and independent of atopic status. Conclusion: Nasal airway gene expression profiles largely recapitulate expression profiles in the lung airways. Nasal expression profiling can be used to identify subjects with IL13-driven asthma and a T(H)2-skewed systemic immune response.	[Poole, Alex; Urbanek, Cydney; O'Connor, Brian P.; Seibold, Max A.] Natl Jewish Hlth, Integrated Ctr Genes Environm & Hlth, Denver, CO 80238 USA; [Liu, Andrew H.; Seibold, Max A.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80238 USA; [Eng, Celeste; Galanter, Joshua M.; Gignoux, Christopher R.; Roth, Lindsey A.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Galanter, Joshua M.; Gignoux, Christopher R.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA USA; [Schageman, Jeoffrey; Setterquist, Robert A.] Life Technol, Res & Dev, Austin, TX USA; [Jacobson, Sean; Fingerlin, Tasha E.] Colorado Sch Publ Hlth, Dept Epidemiol & Biostat, Aurora, CO USA; [O'Connor, Brian P.] Univ Colorado Denver, Denver, CO USA; [Kumar, Rajesh] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA; [Kumar, Rajesh] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Rodriguez-Santana, Jose] Ctr Neumol Pediat, San Juan, PR USA; [Seibold, Max A.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Dept Med, Denver, CO USA	National Jewish Health; National Jewish Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Thermo Fisher Scientific; Colorado School of Public Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Seibold, MA (corresponding author), Natl Jewish Hlth, Integrated Ctr Genes Environm & Hlth, Dept Pediat, 1400 Jackson St, Denver, CO 80238 USA.	seiboldm@njhealth.org		Galanter, Joshua/0000-0002-2561-6384; Kumar, Rajesh/0000-0002-1962-7108	UCSF Dissertation Year Fellowship; National Institutes of Health (NIH) [T32 GM007175]; NIH [ES015794, AI077439, AI079139, AI061774, HL088133, HL078885, HL104608, HL079055, CA113710, DK064695]; Sandler Foundation; American Asthma Foundation; National Institute on Minority Health and Health Disparities of the National Institutes of Health [P60MD006902]; Colorado Career Development in Genetics and Genomics of Lung Diseases [K12HL090147]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL111636, K12HL090147, R01HL088133, R01HL104608, R01HL079055, R01HL117004, R01HL078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079139, U19AI077439, R01AI061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P60MD006902] Funding Source: NIH RePORTER	UCSF Dissertation Year Fellowship; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sandler Foundation; American Asthma Foundation; National Institute on Minority Health and Health Disparities of the National Institutes of Health; Colorado Career Development in Genetics and Genomics of Lung Diseases; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Supported in part by a UCSF Dissertation Year Fellowship and National Institutes of Health (NIH) training grant T32 GM007175 (to C. R. G.); the NIH (ES015794, AI077439, AI079139, AI061774, HL088133, HL078885, HL104608, HL079055, CA113710, and DK064695), the Sandler Foundation, the American Asthma Foundation, and the National Institute on Minority Health and Health Disparities of the National Institutes of Health (P60MD006902; to E. G. B.); and the Colorado Career Development in Genetics and Genomics of Lung Diseases (K12HL090147) and In-kind research support for AmpliSeq assays (sequencing was received from Life Technologies; to M.A.S.).	Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Beane J, 2011, CANCER PREV RES, V4, P803, DOI 10.1158/1940-6207.CAPR-11-0212; Bhakta Nirav R, 2013, Clin Transl Allergy, V3, P24, DOI 10.1186/2045-7022-3-24; Borrell LN, 2013, AM J RESP CRIT CARE, V187, P697, DOI 10.1164/rccm.201211-2116OC; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Galanter JM, 2013, J ALLERGY CLIN IMMUN; Gignoux CR, 2012, AM SOC HUM GEN C SAN; Goff L., CUMMERBUND ANAL EXPL; Goff LA., 2012, R PACKAGE VERSION, V2, P1; Guajardo JR, 2005, J ALLERGY CLIN IMMUN, V115, P243, DOI 10.1016/j.jaci.2004.10.032; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hackett NR, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-82; Hannon G, FASTX TOOLKIT; Harkema JR, 2006, TOXICOL PATHOL, V34, P252, DOI 10.1080/01926230600713475; Himes BE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056179; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Kicic A, 2006, AM J RESP CRIT CARE, V174, P1110, DOI 10.1164/rccm.200603-392OC; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kudo M, 2013, P NATL ACAD SCI USA, V110, P660, DOI 10.1073/pnas.1216673110; Kumar R, 2013, J ALLERGY CLIN IMMUN, V132, P896, DOI 10.1016/j.jaci.2013.02.046; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Li J, 2013, STAT METHODS MED RES, V22, P519, DOI 10.1177/0962280211428386; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Lima JJ, 1999, CLIN PHARMACOL THER, V65, P519, DOI 10.1016/S0009-9236(99)70071-8; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; McDougall CM, 2008, AM J RESP CELL MOL, V39, P560, DOI 10.1165/rcmb.2007-0325OC; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Myers RA, 2012, J ALLERGY CLIN IMMUN, V130, P1294, DOI 10.1016/j.jaci.2012.07.054; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Prevention CfDCa, 2004, NAT HLTH INT SURV 20; Ramskold D, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000598; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Scherf W, 2005, EUR J IMMUNOL, V35, P198, DOI 10.1002/eji.200425209; Silverman EK, 2003, J ALLERGY CLIN IMMUN, V112, P870, DOI 10.1016/S0091-6749(03)02023-2; Simpson JL, 2009, EXP LUNG RES, V35, P781, DOI 10.3109/01902140902906412; Sridhar S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-259; Szefler SJ, 2012, J ALLERGY CLIN IMM S, V129, pS9; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P76, DOI 10.1016/j.jaci.2012.02.040; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wheeler DL, 2008, NUCLEIC ACIDS RES, V36, pD13, DOI 10.1093/nar/gkm1000; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yang IA, 2004, GENES IMMUN, V5, P41, DOI 10.1038/sj.gene.6364037; Yurtsever Z, 2012, J BIOL CHEM, V287, P42138, DOI 10.1074/jbc.M112.410282; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	53	151	155	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					670	+		10.1016/j.jaci.2013.11.025	http://dx.doi.org/10.1016/j.jaci.2013.11.025			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24495433	Green Accepted			2022-12-18	WOS:000332397600007
J	Patel, D; Couroux, P; Hickey, P; Salapatek, AM; Laidler, P; Larche, M; Hafner, RP				Patel, Deepen; Couroux, Peter; Hickey, Pascal; Salapatek, Anne Marie; Laidler, Paul; Larche, Mark; Hafner, Roderick P.			Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; allergic rhinoconjunctivitis; cat allergy; environmental exposure chamber; Fel d 1 peptide immunotherapy; T-cell epitope; immune tolerance; persistence	3RD NATIONAL-HEALTH; QUALITY-OF-LIFE; SUBLINGUAL IMMUNOTHERAPY; EFFICACY; RHINITIS; ALLERGY; SAFETY; POPULATION; SYMPTOMS; TABLETS	Background: Allergic rhinoconjunctivitis is an increasingly common source of morbidity, with sensitivity to cats accounting for 10% to 15% of disease burden. Allergy to cats is also a major risk factor for the development of asthma. Objectives: We sought to probe the persistence of the treatment effect of a novel Fel d 1-derived peptide antigen desensitization (Cat-PAD) 1 year after the start of treatment in subjects with cat allergy-induced rhinoconjunctivitis after standardized allergen challenge. Methods: In a randomized, double-blind, placebo-controlled, parallel-group clinical trial, subjects attended an environmental exposure chamber in which they were exposed to cat allergen before and after treatment with 2 different regimens of Cat-PAD over a 3-month period. Clinical efficacy was assessed as a change in total rhinoconjunctivitis symptom scores 18 to 22 weeks and 50 to 54 weeks after the start of treatment. Results: Treatment with Cat-PAD showed greater efficacy with 4 administrations of a 6-nmol dose 4 weeks apart than with 8 administrations of a 3-nmol dose 2 weeks apart. The treatment effect of 6 nmol persisted 1 year after the start of treatment and was significantly different from that of 3 nmol (P = 5.0342) and placebo (P = 5.0104). The treatment effect was apparent on both nasal and ocular symptoms at 1 year. Conclusions: A short course of Cat-PAD improves the ocular and nasal components of rhinoconjunctivitis symptoms in subjects with cat allergy, with the treatment effect persisting 1 year after the start of treatment. (J Allergy Clin Immunol 2013;131:103-9.)	[Patel, Deepen; Couroux, Peter; Salapatek, Anne Marie] Cetero Res, Mississauga, ON, Canada; [Hickey, Pascal] Adiga Life Sci, Hamilton, ON, Canada; [Laidler, Paul; Hafner, Roderick P.] Circassia Ltd, Magdalen Ctr, Oxford OX4 4GA, England; [Larche, Mark] McMaster Univ, Dept Med, Clin Immunol & Allergy Div, Hamilton, ON, Canada; [Larche, Mark] McMaster Univ, Dept Med, Div Respirol, Hamilton, ON, Canada; [Larche, Mark] McMaster Univ, Firestone Inst Resp Hlth, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University	Hafner, RP (corresponding author), Circassia Ltd, Magdalen Ctr, Oxford Sci Pk, Oxford OX4 4GA, England.	rodhafner@circassia.co.uk		Hafner, Roderick/0000-0002-9082-733X; Larche, Mark/0000-0002-1439-7593	Adiga Life Sciences; Circassia; Canada Research Chairs program; Canadian Foundation for Innovation; McMaster University/GlaxoSmithKline Chair in Lung Immunology at St Joseph's Healthcare; Circassia Research; Canadian Institutes for Health Research; Canadian Lung Association	Adiga Life Sciences; Circassia; Canada Research Chairs program(Canada Research Chairs); Canadian Foundation for Innovation(Canada Foundation for Innovation); McMaster University/GlaxoSmithKline Chair in Lung Immunology at St Joseph's Healthcare; Circassia Research; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Lung Association	Supported by Adiga Life Sciences and Circassia. M.L. is supported by the Canada Research Chairs program, the Canadian Foundation for Innovation, and the McMaster University/GlaxoSmithKline Chair in Lung Immunology at St Joseph's Healthcare.; D. Patel and P. Couroux are employed by Cetero Research. P. Hickey, P. Laidler, and R. P. Hafner are employed by Circassia Limited. A. M. Salapatek was employed by Cetero Research and has received research support from Circassia Research. M. Larche is founder, consultant, and stockholder of Circassia Limited; is scientific founder of Adiga Life Sciences; has consultant arrangements with Boehringer Ingelheim; has received one or more honoraria from MedImmune; has received research support from Adiga Life Sciences, the Canadian Institutes for Health Research, the Canadian Lung Association, the Canada Research Chairs program, and the McMaster University/GlaxoSmithKline Chair in Lung Immunology at St Joseph's Healthcare; and is a member of the American Academy of Allergy, Asthma & Immunology Genetics, Molecular Biology, and Epidemiology Committee.	Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Berkowitz RB, 2006, ANN ALLERG ASTHMA IM, V96, P327, DOI 10.1016/S1081-1206(10)61243-4; Campbell JD, 2009, J EXP MED, V206, P1535, DOI 10.1084/jem.20082901; Chapman MD, 2001, J ALLERGY CLIN IMMUN, V107, pS414, DOI 10.1067/mai.2001.113672; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Day J. H., 2006, Clinical and Experimental Allergy Reviews, V6, P31, DOI 10.1111/j.1365-2222.2005.00099.x; Didier A, 2011, J ALLERGY CLIN IMMUN, V128, P559, DOI 10.1016/j.jaci.2011.06.022; Horak F, 2009, J ALLERGY CLIN IMMUN, V124, P471, DOI 10.1016/j.jaci.2009.06.006; Larche M, 2005, NAT MED, V11, pS69, DOI 10.1038/nm1226; Larche M, SAFETY EFFICACY FELD; Morris DO, 2010, VET DERMATOL, V21, P441, DOI 10.1111/j.1365-3164.2010.00882.x; Nathan RA, 2008, ALLERGY ASTHMA PROC, V29, P600, DOI 10.2500/aap.2008.29.3179; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Patel P, 2007, ANN ALLERG ASTHMA IM, V98, pA19; Salapatek A, 2007, ALLERGY, V62, P118; Schoenwetter WF, 2004, CURR MED RES OPIN, V20, P305, DOI 10.1185/030079903125003053; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029	22	151	156	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					103	U158		10.1016/j.jaci.2012.07.028	http://dx.doi.org/10.1016/j.jaci.2012.07.028			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	22981787	hybrid			2022-12-18	WOS:000312961200012
J	McLoughlin, RM; Mills, KHG				McLoughlin, Rachel M.; Mills, Kingston H. G.			Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mircobiota; immune tolerance; innate immunity; adaptive immunity; dendritic cell; effector T cell; regulatory T cell; immunosuppressive cytokines	REGULATORY T-CELLS; TOLEROGENIC DENDRITIC CELL; GROWTH-FACTOR-BETA; VITAMIN-D; INTESTINAL MICROBIOTA; PROBIOTIC BACTERIA; EPITHELIAL-CELLS; 1,25-DIHYDROXYVITAMIN D-3; HYGIENE HYPOTHESIS; GERM-FREE	The human intestine contains more than 100 trillion microorganisms that maintain a symbiotic relationship with the host. Under normal conditions, these bacteria are not pathogenic and in fact confer health benefits to the host. The microbiota interacts with the innate and adaptive arms of the host's intestinal mucosal immune system and through these mechanisms drives regulatory cell differentiation in the gut that is critically involved in maintaining immune tolerance. Specifically, the microbiota can activate distinct tolerogenic dendritic cells in the gut and through this interaction can drive regulatory T-cell differentiation. In addition, the microbiota is important in driving T(H)1 cell differentiation, which corrects the T(H)2 immune skewing that is thought to occur at birth. If appropriate immune tolerance is not established in early life and maintained throughout life, this represents a risk factor for the development of inflammatory, autoimmune, and allergic diseases. Early-life events are instrumental in establishing the microbiota, the composition of which throughout life is influenced by various environmental and lifestyle pressures. Significant efforts are now being made to establish interventional approaches that can create a healthy microbiota that confers maximum tolerogenic immunomodulatory effects in the gut and that will protect against systemic inflammatory disease pathologies. (J Allergy Clin Immunol 2011;127:1097-107.)	[McLoughlin, Rachel M.; Mills, Kingston H. G.] Trinity Coll Dublin, Sch Biotechnol & Immunol, Dublin 4, Ireland	Trinity College Dublin	McLoughlin, RM (corresponding author), Trinity Coll Dublin, Sch Biotechnol & Immunol, Dublin 4, Ireland.	rachel.mcloughlin@tcd.ie	Mills, Kingston H/F-5684-2013	Mills, Kingston H/0000-0003-3646-8222; McLoughlin, Rachel/0000-0003-4553-018X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abreu MT, 2005, J IMMUNOL, V174, P4453, DOI 10.4049/jimmunol.174.8.4453; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Biasucci G, 2008, J NUTR, V138, p1796S, DOI 10.1093/jn/138.9.1796S; Black PN, 2005, CHEST, V128, P3792, DOI 10.1378/chest.128.6.3792; Borchers AT, 2009, J GASTROENTEROL, V44, P26, DOI 10.1007/s00535-008-2296-0; Cheng G, 2002, AM J RESP CRIT CARE, V166, P409, DOI 10.1164/rccm.2105079; Cong YZ, 2009, EUR J IMMUNOL, V39, P3134, DOI 10.1002/eji.200939052; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; de Roock S, 2010, CLIN EXP ALLERGY, V40, P103, DOI 10.1111/j.1365-2222.2009.03344.x; De Rosa V, 2007, IMMUNITY, V26, P241, DOI 10.1016/j.immuni.2007.01.011; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; DIGNASS AU, 1993, GASTROENTEROLOGY, V105, P1323, DOI 10.1016/0016-5085(93)90136-Z; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Fagarasan S, 2003, NAT REV IMMUNOL, V3, P63, DOI 10.1038/nri982; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; FAO/WHO, 2002, REP JOINT FAO WHO EX; Fohr C, 2005, BRIT J DERMATOL, V152, P202, DOI [10.1111/J.1365-2133.2005.06436.X, 10.1111/j.1365-2133.2004.06436.x]; Foligne B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000313; Forsythe P, 2010, IMMUNOL INVEST, V39, P429, DOI 10.3109/08820131003667978; Furrie E, 2006, GUT, V55, P141, DOI 10.1136/gut.2005.081695; Ghadimi D, 2008, IMMUNOBIOLOGY, V213, P677, DOI 10.1016/j.imbio.2008.02.001; Gibson GR, 1999, J NUTR, V129, p1438S, DOI 10.1093/jn/129.7.1438S; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Ginde AA, 2009, CURR ALLERGY ASTHM R, V9, P81, DOI 10.1007/s11882-009-0012-7; Hall JA, 2008, IMMUNITY, V29, P637, DOI 10.1016/j.immuni.2008.08.009; Hershberg RM, 2000, IMMUNOL TODAY, V21, P123, DOI 10.1016/S0167-5699(99)01575-3; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Holt PG, 2003, VACCINE, V21, P3432, DOI 10.1016/S0264-410X(03)00345-1; Hooper LV, 2009, NAT REV MICROBIOL, V7, P367, DOI 10.1038/nrmicro2114; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Ishikawa H, 2008, CLIN EXP IMMUNOL, V153, P127, DOI 10.1111/j.1365-2249.2008.03668.x; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Kalliomaki M, 2003, CURR OPIN ALLERGY CL, V3, P15, DOI [10.1097/00130832-200302000-00003, 10.1097/01.all.0000053262.39029.a1]; Karlsson H, 2002, INFECT IMMUN, V70, P6688, DOI 10.1128/IAI.70.12.6688-6696.2002; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Khoruts A, 2010, J CLIN GASTROENTEROL, V44, P354, DOI 10.1097/MCG.0b013e3181c87e02; Lagishetty V, 2010, ENDOCRINOLOGY, V151, P2423, DOI 10.1210/en.2010-0089; Lee YK, 2010, SCIENCE, V330, P1768, DOI 10.1126/science.1195568; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Ly Ngoc P, 2006, Clin Mol Allergy, V4, P13; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Maizels RM, 2009, PARASITOLOGY, V136, P1549, DOI 10.1017/S0031182009006106; Manigrasso MR, 2005, J CLIN ENDOCR METAB, V90, P5876, DOI 10.1210/jc.2005-0281; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McAuley JL, 2007, J CLIN INVEST, V117, P2313, DOI 10.1172/JCI26705; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Monteleone I, 2008, EUR J IMMUNOL, V38, P1533, DOI 10.1002/eji.200737909; Morelli L, 2008, J NUTR, V138, p1791S, DOI 10.1093/jn/138.9.1791S; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Niess JH, 2010, J IMMUNOL, V184, P2026, DOI 10.4049/jimmunol.0901936; Noverr MC, 2004, INFECT IMMUN, V72, P4996, DOI 10.1128/IAI.72.9.4996-5003.2004; O'Mahony C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000112; Ochoa-Reparaz J, 2010, J IMMUNOL, V185, P4101, DOI 10.4049/jimmunol.1001443; Ostman S, 2006, EUR J IMMUNOL, V36, P2336, DOI 10.1002/eji.200535244; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Prescott SL, 1998, J IMMUNOL, V160, P4730; Provoost S, 2009, ALLERGY, V64, P1539, DOI 10.1111/j.1398-9995.2009.02056.x; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rescigno M, 2008, CURR DRUG TARGETS, V9, P395, DOI 10.2174/138945008784221125; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Shen L, 2006, AM J PHYSIOL-GASTR L, V290, pG577, DOI 10.1152/ajpgi.00439.2005; Shirai Y, 2004, J CLIN IMMUNOL, V24, P42, DOI 10.1023/B:JOCI.0000018062.01980.ba; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Sierra S, 2010, ANAEROBE, V16, P195, DOI 10.1016/j.anaerobe.2010.02.001; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Smythies LE, 2005, J CLIN INVEST, V115, P66, DOI 10.1172/JCI200519229; Sohn MH, 2007, J PEDIATR-US, V150, P106, DOI 10.1016/j.jpeds.2006.08.065; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Szeles L, 2009, J IMMUNOL, V182, P2074, DOI 10.4049/jimmunol.0803345; Tezuka H, 2007, NATURE, V448, P929, DOI 10.1038/nature06033; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Walton KLW, 2006, IMMUNOL LETT, V102, P16, DOI 10.1016/j.imlet.2005.07.001; Wang TT, 2010, J BIOL CHEM, V285, P2237, DOI 10.1074/jbc.C109.071225; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wei W, 2010, INT ARCH ALLERGY IMM, V153, P19, DOI 10.1159/000301575; Wjst M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-60; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Yao TC, 2010, PEDIAT ALLERG IMM-UK, V21, P900, DOI 10.1111/j.1399-3038.2009.00955.x; Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590; Zhou YF, 2010, NAT MED, V16, P1128, DOI 10.1038/nm.2201	92	151	156	1	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1097	1107		10.1016/j.jaci.2011.02.012	http://dx.doi.org/10.1016/j.jaci.2011.02.012			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21420159				2022-12-18	WOS:000290018600002
J	Wang, J; Lin, J; Bardina, L; Goldis, M; Nowak-Wegrzyn, A; Shreffler, WG; Sampson, HA				Wang, Julie; Lin, Jing; Bardina, Ludmilla; Goldis, Marina; Nowak-Wegrzyn, Anna; Shreffler, Wayne G.; Sampson, Hugh A.			Correlation of IgE/IgG4 milk epitopes and affinity of milk-specific IgE antibodies with different phenotypes of clinical milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Milk allergy; peptide microarray; IgE epitope; IgE affinity; IgG4 epitope	BINDING EPITOPES; MICROARRAY IMMUNOASSAY; PEANUT EPITOPES; COWS; SEVERITY; IDENTIFICATION; ASSOCIATION; PERSISTENT; TOLERANCE; CHILDREN	Background: Results from large-scale epitope mapping with a peptide microarray have been shown to correlate with clinical features of milk allergy. Objectives: We sought to assess IgE and IgG4 epitope diversity and IgE affinity in different clinical phenotypes of milk allergy and identify informative epitopes that might be predictive of clinical outcomes of milk allergy. Methods: Forty-one subjects were recruited from a larger study on the effects of ingesting heat-denatured milk proteins in subjects with milk allergy. Using food challenges, subjects were characterized as being clinically reactive to all forms of milk (n = 17), being tolerant to heated milk (HM) products (n = 16), or having outgrown their milk allergy (n = 8). Eleven healthy volunteers without milk allergy served as control subjects. A peptide microarray was performed by using the previously published protocol. Results: Subjects with milk allergy had increased epitope diversity compared with those who outgrew their allergy. HM-tolerant subjects had IgE-binding patterns similar to those who had outgrown their allergy, but IgG4-binding patterns that were more similar to those of the allergic group. Binding to higher numbers of IgE peptides was associated with more severe allergic reactions during challenge. There was no association between IgG4 peptides and clinical features of milk allergy. Using a competitive peptide microarray assay, allergic patients demonstrated a combination of high- and low-affinity IgE binding, whereas HM-tolerant subjects and those who had outgrown their milk allergy had primarily low-affinity binding. Conclusions: Greater IgE epitope diversity and higher affinity, as determined by using the peptide microarray, were associated with clinical phenotypes and severity of milk allergy. (J Allergy Clin Immunol 2010;125:695-702.)	[Wang, Julie; Lin, Jing; Bardina, Ludmilla; Goldis, Marina; Nowak-Wegrzyn, Anna; Sampson, Hugh A.] Mt Sinai Sch Med, New York, NY 10029 USA; [Shreffler, Wayne G.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; [Shreffler, Wayne G.] Massachusetts Gen Hosp, Food Allergy Res Program, Boston, MA 02114 USA	Icahn School of Medicine at Mount Sinai; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Wang, J (corresponding author), Mt Sinai Sch Med, Box 1198, New York, NY 10029 USA.	julie.wang@mssm.edu	Lin, Jing/C-8877-2010	Nowak-Wegrzyn, Anna/0000-0002-0960-9854	National Institute of Allergy and Infectious Diseases (NIAID) [AI-44236]; National Institutes of Health (NIH)/NIAID [AI083883, AI 059318]; Food Allergy and Anaphylaxis Network; Food Allergy Initiative; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI059318, U19AI044236, K23AI083883] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health (NIH)/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy and Anaphylaxis Network; Food Allergy Initiative; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by a grant from the National Institute of Allergy and Infectious Diseases (NIAID; AI-44236). J.W. is funded in part by a grant from the National Institutes of Health (NIH)/NIAID (AI083883). A.N.-W is supported in part by NIH/NIAID grant AI 059318.; Disclosure of potential conflict of interest: J. Wang is a consultant for Quest Diagnostics. A. Nowak-Wegrzyn is a member of Schering-Plough's Data Safety Monitoring Board. W. G. Shreffler has received research support from the Food Allergy and Anaphylaxis Network. H. A. Sampson is a consultant for Allertein Pharmaceuticals, LLC, and holds shares in that company; has received research support from the Food Allergy Initiative and the National Institutes of Health/National Institute of Allergy and Infectious Diseases; is a consultant and scientific advisor for the Food Allergy Initiative; and is 45% of Herbal Springs, LLC. The rest of the authors have declared that they have no conflict of interest.	Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; El-Khouly F, 2007, PEDIAT ALLERG IMM-UK, V18, P607, DOI 10.1111/j.1399-3038.2007.00542.x; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; LIN J, METHODS MOL BIOL EPI; Lin J, 2009, J ALLERGY CLIN IMMUN, V124, P315, DOI 10.1016/j.jaci.2009.05.024; Mita H, 2000, CLIN EXP ALLERGY, V30, P1582, DOI 10.1046/j.1365-2222.2000.00921.x; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Pecora V, 2009, J ALLERGY CLIN IMMUN, V123, pS178, DOI 10.1016/j.jaci.2008.12.673; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023	19	151	157	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					695	702		10.1016/j.jaci.2009.12.017	http://dx.doi.org/10.1016/j.jaci.2009.12.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226304	Green Accepted			2022-12-18	WOS:000275883200028
J	Kearley, J; Robinson, DS; Lloyd, CM				Kearley, Jennifer; Robinson, Douglas S.; Lloyd, Clare M.			CD4(+)CD25(+) regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						regulatory T cells; T(H)2 cells; eosinophils; TGF-beta; airway remodeling; allergic inflammation	TGF-BETA; FLOW OBSTRUCTION; ASTHMA; EOSINOPHILS; HYPERRESPONSIVENESS; INTERLEUKIN-13; EXPRESSION; COLITIS; HYPERREACTIVITY; SUPPRESSION	Background: CD4(+)CD25(+) regulatory T cells can inhibit excessive T-cell responses in vivo. We have previously demonstrated that prophylactic administration of CD4+CD25+ regulatory T cells suppresses the development of acute allergen-induced airway inflammation in vivo. Objective: We sought to determine the effect of therapeutic transfer of CD4(+)CD25(+) regulatory T cells on established pulmonary inflammation and the subsequent development of airway remodeling. Methods: CD4(+)CD25(+) cells were transferred after the onset of allergic inflammation, and airway challenges were continued to induce chronic inflammation and airway remodeling. Results: Administration of CD4(+)CD25(+) regulatory T cells reduced established lung eosinophilia, T(H)2 infiltration, and expression of IL-5, IL-13, and TGF-beta. Moreover, subsequent mucus hypersecretion and peribronchial collagen deposition were reduced after prolonged challenge. In contrast, transfer of CD4(+)CD25(+) regulatory T cells had no effect on established airway hyperreactivity either 7 days or 4 weeks after transfer. Conclusions: In this study we demonstrate for the first time that therapeutic transfer of CD4(+)CD25(+) regulatory T cells can resolve features of chronic allergen-induced inflammation and prevent development of airway remodeling.	[Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, Fac Med, NHLI, Leukocyte Biol Sect, London SW7 2AZ, England	Imperial College London	Lloyd, CM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, NHLI, Leukocyte Biol Sect, London SW7 2AZ, England.	c.lloyd@imperial.ac.uk		Lloyd, Clare/0000-0001-8977-6726	Wellcome Trust [087618, 057704] Funding Source: Medline; Medical Research Council [G0400503B] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Alcorn JF, 2007, AM J RESP CRIT CARE, V176, P974, DOI 10.1164/rccm.200702-334OC; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Bonniaud P, 2005, J IMMUNOL, V175, P5390, DOI 10.4049/jimmunol.175.8.5390; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Leigh R, 2004, AM J RESP CRIT CARE, V170, P851, DOI 10.1164/rccm.200311-1488OC; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lloyd CM, 2001, J IMMUNOL, V166, P2033, DOI 10.4049/jimmunol.166.3.2033; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x; Morgan ME, 2005, ARTHRITIS RHEUM-US, V52, P2212, DOI 10.1002/art.21195; Mottet C, 2003, J IMMUNOL, V170, P3939, DOI 10.4049/jimmunol.170.8.3939; Munitz A, 2004, ALLERGY, V59, P268, DOI 10.1111/j.1398-9995.2003.00442.x; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Soler D, 2006, J IMMUNOL, V177, P6940, DOI 10.4049/jimmunol.177.10.6940; Suri-Payer E, 2001, J AUTOIMMUN, V16, P115, DOI 10.1006/jaut.2000.0473; Ward C, 2005, CURR OPIN ALLERGY CL, V5, P43, DOI 10.1097/00130832-200502000-00009; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	33	151	165	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					617	624		10.1016/j.jaci.2008.05.048	http://dx.doi.org/10.1016/j.jaci.2008.05.048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18672278	Bronze, Green Accepted			2022-12-18	WOS:000259234000027
J	Kelly, M; Hwang, JM; Kubes, P				Kelly, Margaret; Hwang, John M.; Kubes, Paul			Modulating leukocyte recruitment in inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						selectins; integrins; recruitment; microcirculation; leukocytes; inflammation; endothelium; contact sensitivity; asthma	CELL-ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL-CELLS; SELECTIN GLYCOPROTEIN LIGAND-1; LATE ACTIVATION ANTIGEN-4; CD4(+) T-CELLS; P-SELECTIN; IN-VIVO; ALPHA(4) INTEGRIN; CONTACT HYPERSENSITIVITY; MONOCLONAL-ANTIBODIES	Much information has been obtained regarding how white cells are recruited in the microcirculation to sites of inflammation. In this review we summarize the leukocyte recruitment cascade, highlighting the molecular mechanisms that underlie each of the major steps. Major emphasis is placed on the selectins and integrins and their role in rolling and adhesion. Intraluminal crawling and emigration are also briefly discussed. In addition, we summarize some of the data that implicate these molecules in eosinophil recruitment in animal models of asthma and in lymphocyte recruitment in skin contact sensitivity. There is a growing body of evidence to suggest that leukocyte recruitment could be used as an effective means for future therapeutics, and some of these issues are also raised.	Univ Calgary, Dept Physiol & Biophys, Immunol Res Grp, Inst Infect Immun & Inflammat, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pathol & Lab Med, Immunol Res Grp, Inst Infect Immun & Inflammat, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Surg, Immunol Res Grp, Inst Infect Immun & Inflammat, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Kubes, P (corresponding author), Univ Calgary, Dept Physiol & Biophys, Immunol Res Grp, Inst Infect Immun & Inflammat, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	pkubes@ucalgary.ca	Kelly, Margaret M/G-4128-2012	Kelly, Margaret M/0000-0002-1629-3210				Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; Askenase PW, 2004, TRENDS IMMUNOL, V25, P441, DOI 10.1016/j.it.2004.06.003; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BAGGIOLINI M, 1992, ADV IMMUNOL, V55, P96; Baker DE, 2007, REV GASTROENTEROL DI, V7, P38; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; Bonder CS, 2005, AM J PATHOL, V167, P1647, DOI 10.1016/S0002-9440(10)61248-5; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bowden RA, 2002, CIRC RES, V90, P562, DOI 10.1161/01.RES.0000013835.53611.97; Briskin M, 1997, AM J PATHOL, V151, P97; Broide D, 2001, IMMUNOL REV, V179, P163, DOI 10.1034/j.1600-065X.2001.790116.x; Broide DH, 1998, AM J RESP CELL MOL, V18, P218, DOI 10.1165/ajrcmb.18.2.2829; Campbell DJ, 2002, J EXP MED, V195, P135, DOI 10.1084/jem.20011502; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; CHISHOLM PL, 1993, EUR J IMMUNOL, V23, P682, DOI 10.1002/eji.1830230317; Dang B, 2002, J LEUKOCYTE BIOL, V72, P702; Engelhardt B, 2004, EUR J IMMUNOL, V34, P2955, DOI 10.1002/eji.200425327; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; Fuhlbrigge RC, 2006, BLOOD, V107, P1421, DOI 10.1182/blood-2005-05-2112; Fulkerson PC, 2006, AM J PATHOL, V169, P2117, DOI 10.2353/ajpath.2006.060617; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GALLIN JI, 1999, INFLAMMATION; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Grabbe S, 2002, J CLIN INVEST, V109, P183, DOI 10.1172/JCI11703; Grayson MH, 1998, J EXP MED, V188, P2187, DOI 10.1084/jem.188.11.2187; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Hickey MJ, 1999, J IMMUNOL, V162, P1137; Hidalgo A, 2007, IMMUNITY, V26, P477, DOI 10.1016/j.immuni.2007.03.011; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Hwang JM, 2004, J EXP MED, V199, P1223, DOI 10.1084/jem.20032016; Hyams JS, 2007, J PEDIATR GASTR NUTR, V44, P185, DOI 10.1097/01.mpg.0000252191.05170.e7; Issekutz AC, 2002, J IMMUNOL, V168, P1934, DOI 10.4049/jimmunol.168.4.1934; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; Johnston B, 1999, IMMUNOL TODAY, V20, P545, DOI 10.1016/S0167-5699(99)01544-3; Johnston B, 2000, J IMMUNOL, V164, P3337, DOI 10.4049/jimmunol.164.6.3337; Johnston B, 1996, J EXP MED, V183, P1995, DOI 10.1084/jem.183.5.1995; Johnston B, 2002, SEMIN IMMUNOL, V14, P83, DOI 10.1006/smim.2001.0345; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; JUNG TM, 1990, J IMMUNOL, V144, P3130; Jung U, 1999, J IMMUNOL, V162, P6755; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANWAR S, 1995, CIRC RES, V77, P879, DOI 10.1161/01.RES.77.5.879; Kitayama J, 1997, J IMMUNOL, V159, P3929; KUBES P, 1995, FASEB J, V9, P1103; Kunkel EJ, 1998, CIRC RES, V82, P30; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; Mangan PR, 2005, AM J PATHOL, V167, P1661, DOI 10.1016/S0002-9440(10)61249-7; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; McHale JF, 1999, J IMMUNOL, V162, P1648; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; Mitchell DJ, 2000, BLOOD, V95, P2954, DOI 10.1182/blood.V95.9.2954.009k28_2954_2959; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; Nakamura H, 2001, J ALLERGY CLIN IMMUN, V108, P946, DOI 10.1067/mai.2001.120135; Norman MU, 2003, AM J PATHOL, V163, P1491, DOI 10.1016/S0002-9440(10)63506-7; O'Connor P, 2007, EXPERT OPIN BIOL TH, V7, P123, DOI 10.1517/14712598.7.1.123; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4, DOI 10.1165/ajrcmb.12.1.7529029; Pan JL, 1998, J BIOL CHEM, V273, P10058, DOI 10.1074/jbc.273.16.10058; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; Picarella D, 1997, J IMMUNOL, V158, P2099; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rottman JB, 2001, LAB INVEST, V81, P335, DOI 10.1038/labinvest.3780242; Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Staite ND, 1996, BLOOD, V88, P2973, DOI 10.1182/blood.V88.8.2973.bloodjournal8882973; Steeber DA, 1999, J IMMUNOL, V163, P2176; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; Symon FA, 1996, J IMMUNOL, V157, P1711; ten Hacken NHT, 1998, CLIN EXP ALLERGY, V28, P1518; Tsuji RF, 2000, J IMMUNOL, V165, P1588, DOI 10.4049/jimmunol.165.3.1588; Woltmann G, 2000, BLOOD, V95, P3146; Xia LJ, 2002, J CLIN INVEST, V109, P939; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Yao LB, 1996, J EXP MED, V184, P81, DOI 10.1084/jem.184.1.81; Yu B, 2002, J DERMATOL SCI, V30, P29, DOI 10.1016/S0923-1811(02)00046-4; Zanardo RCO, 2004, BLOOD, V104, P3766, DOI 10.1182/blood-2004-02-0578; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139; Zollner O, 1997, J CELL BIOL, V136, P707, DOI 10.1083/jcb.136.3.707	88	151	156	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					3	10		10.1016/j.jaci.2007.05.017	http://dx.doi.org/10.1016/j.jaci.2007.05.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17559914				2022-12-18	WOS:000248066400001
J	Hartl, D; Griese, M; Kappler, M; Zissel, G; Reinhardt, D; Rebhan, C; Schendel, DJ; Krauss-Etschmann, S				Hartl, D; Griese, M; Kappler, M; Zissel, G; Reinhardt, D; Rebhan, C; Schendel, DJ; Krauss-Etschmann, S			Pulmonary T(H)2 response in Pseudomonas aeruginos-infected patients with cystic fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cystic fibrosis; Pseudomonas aeruginosa; bronchoalveolar lavage fluid; TARC; MDC; CCR4; T(H)1/T(H)2; cytokines	IMMUNE-RESPONSE; CHEMOKINE RECEPTORS; LUNG INFECTION; IN-VIVO; INFLAMMATION; EXPRESSION; CHILDREN; LACTONE; PATHOPHYSIOLOGY; PATHOGENESIS	Background: Pseudomonas aeruginosa infection determines the course of cystic fibrosis (CF) lung disease. Studies in human peripheral blood indicate that P aeruginosa infection is associated with a predominant T(H)2 immune response, whereas T(H)1 responses are accompanied by a better. pulmonary outcome. Objective: Analyses of peripheral blood may not correspond directly with the local pulmonary immune response. Therefore, we asked whether the T(H)1/T(H)2 response is altered in bronchoalveolar lavage fluid from P aerugittosa-infected patients with CF. Methods: Bronchoalveolar lavage fluid was obtained from 12 patients with CF chronically infected with P aeruginosa, 11 noninfected patients with CF, and 8 healthy controls. Pulmonary CXCR3(+) (T(H)1) and CCR4(+) (T(H)2) expressing CD4(+) and CD8(+) lymphocytes were quantified by flow cytometry. Levels of T(H)1-associated (IL-2, IFN-gamma, IFN-gamma inducible T cell-a chemoattractant, Monokine induced by IFN-gamma, IFN-gamma inducible protein of 10 kd) and T(H)2-associated (IL-4, IL-5, IL-10, thymus and activation-regulated chemokine [TARC), macrophage-derived chemokine) cytokines and chemokines and a panel of proinflammatory molecules were quantified at the protein level. Chemokines mRNA levels were assessed by real time RT-PCR. Results: P aeruginosa-infected patients with CF had significantly higher levels of pulmonary CCR4(+)CD4(+) (TH2) cells, IL-4, IL-13, and TARC and lower levels of IFN-gamma compared with noninfected patients with CF and healthy controls. Bronchoalveolar lavage fluid levels of IL-4, IL-13, and TARC correlated inversely with FEV1 in P aeruginosa-infected patients with CF. Conclusion: These results reveal the prevalence of a pulmonary T(H)2 immune response in P aeruginosa-infected patients with CF. The modulation of the pulmonary T(H)2 response in P aeruginosa infection may be an option for the treatment of P aeruginosa lung disease in patients with CF.	Univ Munich, Childrens Hosp, D-80337 Munich, Germany; GSF Natl Res Ctr Environm & Hlth, Clin Cooperat Grp Pediat Immune Regulat, D-80337 Munich, Germany; Univ Hosp, Dept Pneumol, Med Ctr, Freiberg, Germany; GSF Natl Res Ctr Environm & Hlth, Immune Monitoring Platform, Munich, Germany; GSF Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Krauss-Etschmann, S (corresponding author), Univ Munich, Childrens Hosp, Lindwurmstr 2a, D-80337 Munich, Germany.	krauss-etschmann@med.uni-muenchen.de	Zissel, Gernot/B-1208-2010; Krauss-Etschmann, Susanne/H-5198-2018	Zissel, Gernot/0000-0001-8021-9798; Krauss-Etschmann, Susanne/0000-0001-5945-5702				Belperio JA, 2002, J IMMUNOL, V169, P1037, DOI 10.4049/jimmunol.169.2.1037; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; BONFIELD TL, 1995, AM J RESP CRIT CARE, V152, P2111, DOI 10.1164/ajrccm.152.6.8520783; Brazova J, 2005, CLIN IMMUNOL, V115, P210, DOI 10.1016/j.clim.2005.01.013; Chmiel JF, 2002, CLIN REV ALLERG IMMU, V23, P5, DOI 10.1385/CRIAI:23:1:005; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; De Kievit TR, 2001, APPL ENVIRON MICROB, V67, P1865, DOI 10.1128/AEM.67.4.1865-1873.2001; Devine DA, 2003, MOL IMMUNOL, V40, P431, DOI 10.1016/S0161-5890(03)00162-7; DORING G, 1983, ZBL BAKT-INT J MED M, V253, P461; DORING G, 1983, INFECT IMMUN, V42, P197; ELLISON RT, 1991, J CLIN INVEST, V88, P1080, DOI 10.1172/JCI115407; Epelman S, 2000, INFECT IMMUN, V68, P4811, DOI 10.1128/IAI.68.8.4811-4814.2000; FICK RB, 1992, SEMIN RESPIR MED, V13, P205, DOI 10.1055/s-2007-1006272; FICK RB, 1989, CHEST, V95, pS215, DOI 10.1378/chest.95.3_Supplement.215S; FICK RB, 1981, CLIN CHEST MED, V2, P91; FICK RB, 1989, CHEST, V96, P158, DOI 10.1378/chest.96.1.158; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; Griese M, 2004, AM J RESP CRIT CARE, V169, P822, DOI 10.1164/rccm.200308-1104OC; Griese M, 2004, PEDIATR PULM, V37, P356, DOI 10.1002/ppul.10432; Hancock REW, 2000, DRUG RESIST UPDATE, V3, P247, DOI 10.1054/drup.2000.0152; Hartl D, 2005, J ALLERGY CLIN IMMUN, V115, P728, DOI 10.1016/j.jaci.2004.11.049; HOIBY N, 1990, THORAX, V45, P881, DOI 10.1136/thx.45.11.881; HOIBY N, 1974, ACTA PAEDIATR SCAND, V63, P843, DOI 10.1111/j.1651-2227.1974.tb04874.x; Ilyina TS, 2004, RUSS J GENET+, V40, P1189, DOI 10.1023/B:RUGE.0000048660.19958.c3; JONES EM, 1994, J APPL BACTERIOL, V77, P208, DOI 10.1111/j.1365-2672.1994.tb03065.x; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; Moser C, 2002, CLIN EXP IMMUNOL, V127, P206, DOI 10.1046/j.1365-2249.2002.01731.x; Moser C, 2000, APMIS, V108, P329, DOI 10.1034/j.1600-0463.2000.d01-64.x; Moser C, 1999, APMIS, V107, P1093, DOI 10.1111/j.1699-0463.1999.tb01514.x; Motulsky H., 1995, INTUITIVE BIOSTATIST; Parad RB, 1999, INFECT IMMUN, V67, P4744, DOI 10.1128/IAI.67.9.4744-4750.1999; Ritchie AJ, 2003, INFECT IMMUN, V71, P4421, DOI 10.1128/IAI.71.8.4421-4431.2003; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Smith RS, 2002, J BACTERIOL, V184, P1132, DOI 10.1128/jb.184.4.1132-1139.2002; Strieter RM, 1999, CHEST, V116, p103S, DOI 10.1378/chest.116.suppl_1.103S; Tager AM, 1998, AM J RESP CELL MOL, V19, P643, DOI 10.1165/ajrcmb.19.4.3165; Telford G, 1998, INFECT IMMUN, V66, P36, DOI 10.1128/IAI.66.1.36-42.1998; WARREN GH, 1955, J BACTERIOL, V70, P614, DOI 10.1128/JB.70.5.614-619.1955	42	151	156	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					204	211		10.1016/j.jaci.2005.09.023	http://dx.doi.org/10.1016/j.jaci.2005.09.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387607				2022-12-18	WOS:000235687100033
J	Deykin, A; Lazarus, SC; Fahy, JV; Wechsler, ME; Boushey, HA; Chinchilli, VM; Craig, TJ; Dimango, E; Kraft, M; Leone, F; Lemanske, RF; Martin, RJ; Pesola, GR; Peters, SP; Sorkness, CA; Szefler, SJ; Israel, E				Deykin, A; Lazarus, SC; Fahy, JV; Wechsler, ME; Boushey, HA; Chinchilli, VM; Craig, TJ; Dimango, E; Kraft, M; Leone, F; Lemanske, RF; Martin, RJ; Pesola, GR; Peters, SP; Sorkness, CA; Szefler, SJ; Israel, E		Natl Heart Lung and Blood Inst	Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exacerbation; sputum; eosinophils; inhaled corticosteroids; methacholine; nitric oxide	EXHALED NITRIC-OXIDE; FLUTICASONE PROPIONATE AEROSOL; CREATINE-KINASE MB; AIRWAY INFLAMMATION; MARKERS; THERAPY; HYPERRESPONSIVENESS; GLUCOCORTICOIDS; REPRODUCIBILITY; BECLOMETHASONE	Background: Although inhaled corticosteroids (ICSs) are effective in preventing deterioration in asthma control, at least half of subjects with mild-to-moderate asthma will remain stable when these agents are discontinued. Objective: We sought to determine whether noninvasive markers of inflammation predict which individuals maintain asthma control after discontinuation of ICSs. Methods: We analyzed data obtained from 164 subjects with mild-to-moderate asthma who participated in a 16-week trial comparing the effects of continued ICS use with the effects of a switch to salmeterol or placebo. Results: In comparison with continued ICS use, a switch to salmeterol or placebo was associated with increased rates of asthma deterioration over 16 weeks (9.3% vs 24.1% and 37.5%, respectively; P =.04 and P <.001, respectively). We found that neither exhaled nitric oxide nor methacholine PC20, when measured at randomization or 2 weeks after randomization, were significant predictors of subsequent asthma control in subjects who discontinued ICSs. However, both induced sputum eosinophil counts measured 2 weeks after a switch from ICS to placebo and changes in sputum eosinophil counts from before cessation of ICSs to after a switch to placebo predicted subsequent asthma deterioration (area under the receiver-operating characteristic curve, 0.771 [P <.001] and 0.825 [P <.001], respectively). Conclusion: On the basis of a model treatment strategy, we estimate that allocating subjects to ICS therapy on the basis of changes in sputum eosinophil counts after a trial discontinuation could allow 48% of subjects with mild-to-moderate asthma to discontinue ICS therapy without an increased risk of asthma deterioration over a period of at least 14 weeks.	Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Penn State Univ, Coll Med, Hershey, PA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Wisconsin, Madison, WI USA; Harlem Lung Ctr, New York, NY USA; Columbia Univ, New York, NY USA; Natl Jewish Ctr Immunol & Resp Med, Denver, CO 80206 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Wake Forest Univ, Ctr Hlth Sci, Winston Salem, NC 27109 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; Columbia University; National Jewish Health; Jefferson University; Wake Forest University	Deykin, A (corresponding author), Brigham & Womens Hosp, Div Pulm, 75 Francis St, Boston, MA 02115 USA.	adeykin@partners.org	Wechsler, Michael/B-3979-2013; Wechsler, Michael/AAC-5506-2019	Wechsler, Michael/0000-0003-3505-2946; Pesola, Gene/0000-0002-3909-8039	NCRR NIH HHS [M01 RR 03186] Funding Source: Medline; NHLBI NIH HHS [U10 HL 51845, U10 HL 56443, U10 HL 51843, U10 HL 51810, U10 HL 51823, U10 HL 51831, U10 HL 51834] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL051810, U10HL051834, U10HL051831, U10HL051823, U10HL056443, U10HL051845, U10HL051843] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Bray GA, 1999, DIABETES CARE, V22, P623; Brennan M, 2003, NEW ENGL J MED, V349, P1595, DOI 10.1056/NEJMoa035003; Brutsche MH, 2002, J ALLERGY CLIN IMMUN, V109, P271, DOI 10.1067/mai.2002.121530; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Collinson PO, 2003, HEART, V89, P280, DOI 10.1136/heart.89.3.280; Deykin A, 1998, AM J RESP CRIT CARE, V157, P769, DOI 10.1164/ajrccm.157.3.9707114; Deykin A, 2002, AM J RESP CRIT CARE, V165, P1597, DOI 10.1164/rccm.2201081; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; FERGUSON AC, 1989, CHEST, V96, P988, DOI 10.1378/chest.96.5.988; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Garbe E, 1998, JAMA-J AM MED ASSOC, V280, P539, DOI 10.1001/jama.280.6.539; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Israel E, 2002, J ALLERGY CLIN IMMUN, V110, P847, DOI 10.1067/mai.2002.129413; Jatakanon A, 1999, THORAX, V54, P108, DOI 10.1136/thx.54.2.108; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800, DOI 10.1164/ajrccm.152.2.7633745; *NIH, 1997, PUBL; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; Penttila K, 2002, CLIN BIOCHEM, V35, P647, DOI 10.1016/S0009-9120(02)00385-5; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; Romagnoli M, 2002, EUR RESPIR J, V20, P1370, DOI 10.1183/09031936.02.00029202; Sheffer AL, 1996, J FAM PRACTICE, V42, P369; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; ZWEIG MH, 1993, CLIN CHEM, V39, P561; ASTHMA AM SURVEY EXE; FASSTATS A Z ASTHMA	44	151	160	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					720	727		10.1016/j.jaci.2004.12.1129	http://dx.doi.org/10.1016/j.jaci.2004.12.1129			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805990	Bronze			2022-12-18	WOS:000228373400009
J	Weschta, M; Rimek, D; Formanek, M; Polzehl, D; Podbielski, A; Riechelmann, H				Weschta, M; Rimek, D; Formanek, M; Polzehl, D; Podbielski, A; Riechelmann, H			Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: A randomized, double-blind clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyps; amphotericin B; antifungal agents; sinusitis; fungi	ALLERGIC FUNGAL SINUSITIS; AMPHOTERICIN-B; QUALITY	Background: Recently, fungal elements were suspected to be the causative agent of chronic rhinosinusitis, and benefits of topical amphotericin B therapy have been reported. Objective: The effects of amphotericin B versus control nasal spray on chronic rhinosinusitis were compared in a double-blind, randomized clinical trial. Methods: Patients with chronic rhinosinusitis were administered 200 muL per nostril amphotericin B (3 mg/mL) or saline nasal spray 4 times daily over a period of 8 weeks. The response rate, defined as a 50% reduction of pretreatment computed tomography score, was the primary outcome variable. Additional outcome variables included a symptom score, a quality of life score, and an endoscopy score. Before and after treatment, nasal lavages were pretreated with dithiothreitol and examined for fungal elements by PCR and standard culture techniques. Results: Seventy-eight patients were included, and 60 patients finished the study per protocol. In the control group, no positive response (0 of 32) was observed, and 2 of 28 patients responded in the amphotericin B group (P > .2). The symptom scores were distinctly worse after amphotericin B therapy (P < .005). The other parameters investigated did not differ remarkably between the treatment groups. Conclusion: Nasal amphotericin B spray in the described dosing and time schedule is ineffective and deteriorates patient symptoms.	Univ Ulm, Dept Otorhinolaryngol Head & Neck Surg, D-89075 Ulm, Germany; Univ Rostock, Dept Med Microbiol & Hosp Hyg, D-2500 Rostock 1, Germany	Ulm University; University of Rostock	Weschta, M (corresponding author), Univ Ulm, Dept Otorhinolaryngol Head & Neck Surg, Prittwitzstr 43, D-89075 Ulm, Germany.	michael.weschta@medizin.uni-ulm.de						BARON S, 1996, MYCOLOGY; Bent JP, 1996, LARYNGOSCOPE, V106, P1331, DOI 10.1097/00005537-199611000-00005; BONATE PL, 2000, ANAL PRETEST POSTTES; Braun H, 2003, LARYNGOSCOPE, V113, P264, DOI 10.1097/00005537-200302000-00013; Catten MD, 2001, LARYNGOSCOPE, V111, P399, DOI 10.1097/00005537-200103000-00006; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Faure O, 2002, J HOSP INFECT, V50, P155, DOI 10.1053/jhin.2001.1148; Ferguson BJ, 2000, OTOLARYNG CLIN N AM, V33, P441, DOI 10.1016/S0030-6665(00)80018-3; Ferguson BJ, 1998, ARCH OTOLARYNGOL, V124, P1174, DOI 10.1001/archotol.124.10.1174; Ferguson BVJ, 2003, J ALLERGY CLIN IMMUN, V111, P1137, DOI 10.1067/mai.2003.1481; Greenhalgh T, 1997, BRIT MED J, V315, P305, DOI 10.1136/bmj.315.7103.305; Heatley DG, 2001, OTOLARYNG HEAD NECK, V125, P44, DOI 10.1067/mhn.2001.115909; Juniper EF, 2000, CLIN EXP ALLERGY, V30, P132; Kublik H, 1998, ADV DRUG DELIVER REV, V29, P157, DOI 10.1016/S0169-409X(97)00067-7; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Lebowitz RA, 2002, LARYNGOSCOPE, V112, P2189, DOI 10.1097/00005537-200212000-00012; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Lund VJ, 1997, OTOLARYNG HEAD NECK, V117, pS35, DOI 10.1016/S0194-5998(97)70005-6; Malani Preeti N., 2002, Curr Infect Dis Rep, V4, P225, DOI 10.1007/s11908-002-0083-2; Malm L, 1997, ACTA OTO-LARYNGOL, V117, P465, DOI 10.3109/00016489709113422; Ponikau JU, 2002, J ALLERGY CLIN IMMUN, V110, P862, DOI 10.1067/mai.2002.130051; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Rains BM, 2003, AM J RHINOL, V17, P1; Ricchetti A, 2002, J LARYNGOL OTOL, V116, P261, DOI 10.1258/0022215021910708; Rimek D, 1998, MYCOSES, V41, P65, DOI 10.1111/j.1439-0507.1998.tb00605.x; Tomooka LT, 2000, LARYNGOSCOPE, V110, P1189, DOI 10.1097/00005537-200007000-00023; Trigg ME, 1997, BONE MARROW TRANSPL, V19, P43, DOI 10.1038/sj.bmt.1700618; Weschta M, 2003, LARYNGOSCOPE, V113, P1798, DOI 10.1097/00005537-200310000-00026; Wildfeuer A, 1998, MYCOSES, V41, P309, DOI 10.1111/j.1439-0507.1998.tb00344.x	29	151	156	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1122	1128		10.1016/j.jaci.2004.03.038	http://dx.doi.org/10.1016/j.jaci.2004.03.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208594				2022-12-18	WOS:000222091000018
J	Simons, FER				Simons, FER			First-aid treatment of anaphylaxis to food: Focus on epinephrine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acute allergic reaction; adrenaline; adults; anaphylaxis; auto-injector; children; epinephrine; EpiPen; EpiPen Jr; food allergy; peanut allergy; H-1-antihistatnines; activated charcoal	FIRST-AID TREATMENT; YOUNG-CHILDREN; NUT ALLERGY; EPIPEN JR; PEANUT; POPULATION; EPIDEMIOLOGY; MANAGEMENT; INJECTION; INFANTS	Avoiding food triggers for anaphylactic reactions (severe acute systemic allergic reactions) is easier said than done. Most episodes of anaphylaxis to food occur unexpectedly in the community in the absence of a health care professional. All individuals at risk should therefore have an emergency action plan in place. The cornerstone of first-aid treatment of anaphylaxis is epinephrine injected intramuscularly in the vastus lateralis muscle (lateral aspect of the thigh). In this review, we focus on epinephrine. We examine a therapeutic dilemma: the issue of epinephrine dose selection in an individual for whom no optimal fixed-dose auto-injector formulation exists, and a therapeutic controversy: the issue of epinephrine injection versus an oral H-1-antihistamine in anaphylaxis episodes that appear to be mild. The pharmaceutical industry could address the first of these issues by providing a wider range of epinephrine fixed doses in easy-to-use auto-injectors, or by providing adjustable epinephrine doses in auto-injectors. The second issue could be addressed in part by development of alternative routes of epinephrine administration for the first-aid, out-of-hospital treatment of anaphylaxis.	Univ Manitoba, Allergy & Clin Immunol Sect, Dept Pediat & Child Hlth, Winnipeg, MB, Canada; Univ Manitoba, Dept Immunol, Natl Training Program Asthma & Allergy, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba	Simons, FER (corresponding author), Childrens Hosp, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca						AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; American Academy of Pediatrics Committee on Injury Violence and Poison Prevention, 2003, Pediatrics, V112, P1182; Bautista E, 2002, INT ARCH ALLERGY IMM, V128, P151, DOI 10.1159/000059406; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Chowdhury BA, 2002, J ALLERGY CLIN IMMUN, V109, P720, DOI 10.1067/mai.2002.123252; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Gu XC, 2002, BIOPHARM DRUG DISPOS, V23, P213, DOI 10.1002/bdd.312; Hoffman BB, 2001, GOODMAN GILMANS PHAR, P215; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; JAMES LP, 1964, NEW ENGL J MED, V270, P597, DOI 10.1056/NEJM196403192701202; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lieberman P, 2003, CURR OPIN ALLERGY CL, V3, P313, DOI 10.1097/01.all.0000083958.99396.53; LUCIUK GH, 1993, J ALLERGY CLIN IMMUN, V91, P153; McLean-Tooke APC, 2003, BMJ-BRIT MED J, V327, P1332, DOI 10.1136/bmj.327.7427.1332; Pumphrey RSH, 2003, J ALLERGY CLIN IMMUN, V112, P451, DOI 10.1067/mai.2003.1614; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sampson HA, 2003, PEDIATRICS, V111, P1601; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Simons F Estelle R, 2004, Novartis Found Symp, V257, P228; Simons FER, 2001, J ALLERGY CLIN IMMUN, V108, P1040, DOI 10.1067/mai.2001.119916; Simons FER, 2000, PEDIATRICS, V106, P1040, DOI 10.1542/peds.106.5.1040; Simons FER, 2002, J ALLERGY CLIN IMMUN, V110, P647, DOI 10.1067/mai.2002.127860; Simons FER, 2002, J ALLERGY CLIN IMMUN, V109, P171, DOI 10.1067/mai.2002.120758; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P622, DOI 10.1016/S1081-1206(10)62289-2; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Simons FER, 2000, J ALLERGY CLIN IMMUN, V105, P1025, DOI 10.1067/mai.2000.106042; SIMONS FER, 2003, MIDDLETONS ALLERGY P, P834; SIMONS FER, 2003, IN PRESS INT IMMUNOL; Vadas P, 2003, J ALLERGY CLIN IMMUN, V112, P175, DOI 10.1067/mai.2003.1480; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	35	151	163	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					837	844		10.1016/j.jaci.2004.01.079	http://dx.doi.org/10.1016/j.jaci.2004.01.079			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131564	Bronze			2022-12-18	WOS:000221269000004
J	Corren, J; Manning, BE; Thompson, SF; Hennessy, S; Strom, BL				Corren, J; Manning, BE; Thompson, SF; Hennessy, S; Strom, BL			Rhinitis therapy and the prevention of hospital care for asthma: A case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; emergency room; hospitalization; corticosteroid; antihistamine	ALLERGIC RHINITIS; BRONCHIAL RESPONSIVENESS; PROVOCATION; CETIRIZINE; SYMPTOMS; EFFICACY; INCREASE; PLACEBO; RISK	Background: Although clinical trials have demonstrated that rhinitis therapy improves subjective and objective measures of asthma, it is uncertain whether treatment of allergic rhinitis significantly affects the frequency of asthma exacerbations. Objective: The objective of this study was to determine whether treatment with intranasal corticosteroids and/or seeond-generation antihistamines is associated with changes in rates of asthma exacerbations resulting in emergency room visits and/or hospitalizations in patients with asthma and allergic rhinitis. Methods: This was a nested, case-control study. Results: Treatment with either nasal corticosteroids or second-generation antihistamines was associated with a lower risk of asthma-related emergency room treatment and hospitalization (adjusted odds ratio [OR], 0.51; 95% CI, 0.34 to 0.77 and 0.34, 0.18 to 0.62, respectively). Patients who used nasal corticosteroids had a significantly lower risk of both asthma-related emergency room treatment and hospitalization (adjusted OR, 0.75; 95% CI, 0.62 to 0.91 and 0.56, 0.42 to 0.76, respectively), whereas there was a trend toward lower risk of emergency room treatment and hospitalization in patients who used seeond-generation antihistamines (adjusted OR, 0.88; 95% Cl, 0.62 to 1.26 and 0.68, 0.40 to 1.14, respectively). Combined treatment with both medications was associated with a further lowering of the risk of both emergency room treatment and hospitalization (adjusted OR, 0.37; 95% CI, 0.19 to 0.73 and 0.22, 0.07 to 0.63). Conclusions: In patients with asthma, treatment of concomitant allergic rhinitis was associated with significant reductions in risk of emergency room treatment and hospitalization for asthma.	Allergy Res Fdn, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Andover Newton Theol Sch, Newton Ctr, MA USA; Schering Plough Corp, Kenilworth, NJ USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	University of California System; University of California Los Angeles; Merck & Company; Schering Plough Corporation; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Corren, J (corresponding author), Allergy Res Fdn, 11620 Wilshire Blvd,Suite 200, Los Angeles, CA 90025 USA.							Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554; Fontanari P, 1996, J APPL PHYSIOL, V81, P1739, DOI 10.1152/jappl.1996.81.4.1739; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; Greenland S, 1996, INT J EPIDEMIOL, V25, P1107, DOI 10.1093/ije/25.6.1107-a; GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237; Hennessy S, 2001, CONTRACEPTION, V64, P125, DOI 10.1016/S0010-7824(01)00234-7; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Motheral BR, 1997, CLIN THER, V19, P346, DOI 10.1016/S0149-2918(97)80122-1; National institutes of Health National Heart Lung and Blood Institute, 1997, NIH PUBL, V97-4051; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; Simons FER, 1999, CLIN EXP ALLERGY, V29, P98, DOI 10.1046/j.1365-2222.1999.0290s3098.x; SOUT JK, 1999, AM J RESP CRIT CARE, V159, P1043; SPECTOR SL, 1995, J ALLERGY CLIN IMMUN, V96, P174, DOI 10.1016/S0091-6749(95)70005-6; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5	23	151	163	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					415	419		10.1016/j.jaci.2003.11.034	http://dx.doi.org/10.1016/j.jaci.2003.11.034			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007339				2022-12-18	WOS:000220144200010
J	Beyer, K; Grishina, G; Bardina, L; Grishin, A; Sampson, HA				Beyer, K; Grishina, G; Bardina, L; Grishin, A; Sampson, HA			Identification of an 11S globulin as a major hazelnut food allergen in hazelnut-induced systemic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cor a 9; hazelnut; food allergy; tree nut; seed storage protein; peanut	DOUBLE-BLIND; IGE-BINDING; PEANUT; POLLEN	Background: Hazelnuts are a common cause of food allergy. Allergic reactions to hazelnuts range from oral allergy syndrome caused by cross-reactivity between tree pollen and hazelnut proteins to severe anaphylactic reactions. Little, information is available regarding the identification of pollen-independent hazelnut allergens. Objective: The aim of the study was to identify these pollen-independent allergens in patients with hazelnut allergy with systemic reactions. Methods: Extracted hazelnut proteins were separated by means of 2-dimensional PAGE, and immunolabeling was performed with individual sera from 14 patients with hazelnut-induced systemic reactions. Edman sequencing was performed on a 40-kd protein identified as an allergen. In parallel, RNA isolated from hazelnuts was used to construct a cDNA library. By using the peptide sequence data, oligonucleotide primers were synthesized and used to screen the library. Full-length cDNA clones were isolated, sequenced, expressed, and screened with patient sera. Results: By using 2-dimensional proteomics, a protein fraction at 40 kd was recognized by serum IgE from 86% (12/14) of the patients with hazelnut allergy with systemic reactions. Two internal amino acid sequences were determined by means of Edman sequencing. Screening of the prepared hazelnut cDNA library with oligonucleotides based on these internal peptide sequences resulted in isolation of a novel protein cDNA. The new protein, named Cor a 9, belongs to the 11S globulin seed storage protein amily. This family comprises known food allergens in peanut (Ara h 3) and soybean (glycine max). The pairwise homology among these 3 proteins ranges from 45% to 50%. Interestingly, one known IgE-binding epitope of Ara h 3 shares 67% of homologous amino acid residues with the corresponding area of Cor a 9. The amino acids that differ were previously shown not to be critical for IgE binding in Ara h 3. Conclusion: Cor a 9 is the first tree pollen-unrelated hazelnut allergen isolated, sequenced, and cloned. The identification of food allergens is the first step toward generating recombinant allergens for use in future immunotherapeutic approaches. In addition, the detection of conserved IgE epitopes in common food allergens, such as seed storage proteins, might be a useful tool for predicting cross-reactivity to certain foods.	Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY 10029 USA; Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Beyer, K (corresponding author), Mt Sinai Sch Med, Div Pediat Allergy & Immunol, Box No 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-00071] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; Chang S. J., 1993, Plant Molecular Biology Reporter, V11, P113, DOI 10.1007/BF02670468; GROOT H, 1996, ALLERGY, V51, P712; Helm RM, 2000, INT ARCH ALLERGY IMM, V123, P205, DOI 10.1159/000024445; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; Muller U, 2000, EUR FOOD RES TECHNOL, V212, P2, DOI 10.1007/s002170000245; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Pedersen P., 1989, STRUCT OPTIMIZATION, V1, P101, DOI [10.1007/BF01637666, DOI 10.1007/BF01637666]; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Schocker F, 2000, EUR J NUTR, V39, P172, DOI 10.1007/s003940070021; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; TOUS MJ, 2001, WORLD HAZELNUT PRODU; *USDA, 2001, HAZ SIT OUTL 2000; 2002, PROTEIN FAMILIES DAT	17	151	163	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					517	523		10.1067/mai.2002.127434	http://dx.doi.org/10.1067/mai.2002.127434			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209105	Bronze			2022-12-18	WOS:000177936900028
J	Lozano, P; Sullivan, SD; Smith, DH; Weiss, KB				Lozano, P; Sullivan, SD; Smith, DH; Weiss, KB			The economic burden of asthma in US children: Estimates from the National Medical Expenditure Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cost of illness study; health economics; National Center for Health Statistics	CHILDHOOD ASTHMA; UNITED-STATES; HEALTH-SERVICES; PREVALENCE; POVERTY; COST	Background: Asthma is the leading chronic illness of childhood, is responsible for substantial pediatric morbidity, and has a significant impact on use of health resources. Objective: Our purpose was to assess the per capita impact of pediatric asthma on medical care utilization and total expenditures, Methods: A population-based national probability survey, the National Medical Expenditure Survey, was conducted in 1987 to determine the use and cost of health care services in the United States. Ne analyzed the responses for all children aged 1 to 17 pars with (n = 667) and without (n = 6911) asthma. Children with asthma were identified with use of a population-based screening question. Frequency and cost of medications, ambulatory visits, emergency department care, and hospitalizations for all reasons, including asthma, were assessed. Results: The period prevalence of childhood asthma in 1987 was 8.8% and the treated prevalence (any asthma medications) was 4.0%. Forty-one percent of families with asthmatic children were classified as having no primary insurance. Children with asthma used substantially more services in all categories of care: 3.1 times as many prescriptions, 1.9 times as many ambulatory provider visits, 2.2 times as many emergency department visits, and 3.5 times as many hospitalizations. Only 10.7% of children with asthma were defined as chronic users of medications. Children with asthma incurred an average of $1129 (SD $5310) per child per year in total health care expenditures compared with $468 (SD $2960) for children without asthma, a 2.8-fold difference. Conclusion: Asthma has considerable impact on the use and costs of medical care services among US children. Data from the 1987 National Medical Expenditure Survey provide a useful baseline against which more recent, postguideline data should be compared.	Univ Washington, Harborview Med Ctr, Dept Pediat, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Sch Pharm, Seattle, WA 98195 USA; Rush Presbyterian St Lukes Med Ctr, Rush Primary Care Inst, Ctr Hlth Serv Res, Chicago, IL 60612 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Group Health Cooperative; University of Washington; University of Washington Seattle; Rush University	Lozano, P (corresponding author), Univ Washington, Harborview Med Ctr, Dept Pediat, Box 359-774, Seattle, WA 98195 USA.		Lozano, Paula Maria/GPP-4090-2022					CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; FOWLER MG, 1992, PEDIATRICS, V90, P939; GERGEN PJ, 1988, PEDIATRICS, V81, P1; HALFON N, 1993, PEDIATRICS, V91, P56; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; Lozano P, 1997, PEDIATRICS, V99, P757, DOI 10.1542/peds.99.6.757; *NIH, 1991, GUID DIAGN MAN ASTHM; Shah BV, 1997, SOFTWARE STAT ANAL C; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Stempel DA, 1996, ARCH FAM MED, V5, P36, DOI 10.1001/archfami.5.1.36; TAYLOR WR, 1992, PEDIATRICS, V90, P657; *US DEP HHS, 1991, NAT MED EXP SURV SAM; *US DEP HHS, 1992, NAT MED EXP SURV SAM; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777	17	151	155	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					957	963		10.1016/S0091-6749(99)70075-8	http://dx.doi.org/10.1016/S0091-6749(99)70075-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	257JH	10550739				2022-12-18	WOS:000083778400017
J	Fernandez-Rivas, M; van Ree, R; Cuevas, M				Fernandez-Rivas, M; van Ree, R; Cuevas, M			Allergy to Rosaceae fruits without related pollinosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fruit allergy; apple; peach; pollinosis; oral allergy syndrome; anaphylaxis; cross-allergenicity; profilin; Bet v 1	BIRCH POLLEN-ALLERGY; CROSS-REACTIVITY; VEGETABLE FOODS; MAJOR ALLERGEN; IGE ANTIBODIES; APPLE; PROFILIN; PEACH; HYPERSENSITIVITY; IDENTIFICATION	Background: Rosaceae fruit allergy is frequently associated with birch pollinosis in Central and Northern Europe and with grass pollen allergy in Central Spain. The main cross-reactive structures involved for birch pollinosis are Bet v 1 and profilin, and for grass pollinosis they are profilin and carbohydrate determinants. Rosaceae fruit allergy can occasionally be observed in patients without pollinosis. Objective: We investigated the clinical presentation and the allergens involved in allergy to Rosaceae fruit without pollinosis. Methods: Eleven patients from Central Spain allergic to apples, peaches, and/or pears but not to pollens were compared with 22 control subjects with combined grass pollen and fruit allergy. Skin prick tests and RASTs to apple, peach, and pear were performed. Cross-allergenicity was studied by RAST inhibition. Bet v 1 was tested,vith an indirect RAST, and profilin was tested in skin prick tests, histamine release, and RAST. Results: Rosaceae fruit allergy without pollinosis is severe with 82% of patients reporting systemic symptoms, mainly anaphylaxis (73%), whereas oral symptoms are less frequent (64%). Anaphylactic shock was observed in 36% of patients. The fruit allergens involved showed cross-reactivity among Rosaceae species but were not related to profilin or Bet v 1. Ninety-one percent of patients with combined grass pollinosis and fruit allergy reported oral allergy, 45% reported systemic symptoms, 18% reported anaphylaxis, and 9% reported anaphylactic shock. Conclusion: Allergy to Rosaceae fruits in patients without a related pollen allergy is a severe clinical entity. Profilin- and Bet v 1-related structures are not involved in Rosaceae fruit allergy without pollinosis.	Hosp Ntra Sra Sonsoles, Unidad Alergia, Avila 05071, Spain; Netherlands Red Cross, Cent Lab, Dept Allergy, Amsterdam, Netherlands; Univ Amsterdam, Expt & Clin Immunol Lab, Amsterdam, Netherlands; Hosp Ramon y Cajal, Dept Immunol, E-28034 Madrid, Spain	University of Amsterdam; Hospital Universitario Ramon y Cajal	Fernandez-Rivas, M (corresponding author), Hosp Ntra Sra Sonsoles, Unidad Alergia, Carretera Madrid Km 109, Avila 05071, Spain.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AKKERDAAS JH, 1995, ALLERGY, V50, P215, DOI 10.1111/j.1398-9995.1995.tb01136.x; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUESTA J, 1995, ALLERGY S26, V50, P233; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Drebotg S, 1989, ALLERGY S10, V44, P22; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; HERNANDEZ J, 1985, ALLERGOL IMMUNOPATH, V13, P197; LAHTI A, 1988, ALLERGY PRINCIPLES P, P1463; LLEONART R, 1992, ANN ALLERGY, V69, P128; Malling HJ., 2003, ALLERGY, V48, P55; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; SUBIZA J, 1995, J ALLERGY CLIN IMMUN, V96, P15, DOI 10.1016/S0091-6749(95)70028-5; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1989, J ALLERGY CLIN IMMUN, V83, P144, DOI 10.1016/0091-6749(89)90489-2; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VIETHS S, 1994, ALLERGY, V49, P262, DOI 10.1111/j.1398-9995.1994.tb02659.x; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P389; WADEE AA, 1990, J ALLERGY CLIN IMMUN, V85, P801, DOI 10.1016/0091-6749(90)90202-F; Yman L, 1975, Dev Biol Stand, V29, P151	30	151	152	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				728	733		10.1016/S0091-6749(97)70265-3	http://dx.doi.org/10.1016/S0091-6749(97)70265-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438478				2022-12-18	WOS:000071353600002
J	Foresi, A; Leone, C; Pelucchi, A; Mastropasqua, B; Chetta, A; DIppolito, R; Marazzini, L; Olivieri, D; Giovanni, SS				Foresi, A; Leone, C; Pelucchi, A; Mastropasqua, B; Chetta, A; DIppolito, R; Marazzini, L; Olivieri, D; Giovanni, SS			Eosinophils, mast cells, and basophils in induced sputum from patients with seasonal allergic rhinitis and perennial asthma: Relationship to methacholine responsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; allergic asthma; airway inflammation; sputum; mast cells; basophils; eosinophils	NATURAL ANTIGENIC EXPOSURE; BRONCHOALVEOLAR LAVAGE; AIRWAY INFLAMMATION; BRONCHIAL HYPERREACTIVITY; MILD ASTHMA; CHALLENGE; IDENTIFICATION; INDIVIDUALS; IMMEDIATE; MEDIATOR	Objectives: We attempted to determine whether inflammation is present in induced sputum of patients with seasonal allergic rhinitis (NZ) as compared with those with perennial asthma (AS) and examined its relationship with bronchial responsiveness to methacholine. Methods: Sputum was induced in 30 patients with seasonal rhinitis in response to grass pollens only and in 15 patients with stable, asymptomatic asthma. The AR group was divided according to methacholine PD20 value: the AR-group (n = 15) had a methacholine PD20 greater than 24 mu mol; the AR+ group (n = 15) had a methacholine PD20 ranging between 2.2 and 19.6 mu mol. In the AS group, methacholine PD,, ranged between 0.32 and 2.6 mu mol. The percentage of eosinophils and metachromatic cells (alcian blue-positive) was assessed in sputum by light microscopy. Tryptase-positive cells and EG2+ cells were identified by immunocytochemistry with the mouse anti-human mast cell-tryptase monoclonal antibody and the monoclonal anti-eosinophil cationic protein antibody. Results: We found that the number of eosinophils in the AS group was greater than that in the AR+ group (p < 0.05) and in the AR- group (p < 0.01). Moreover, the eosinophil count was lower in the AR- group compared with the AR+ group (p < 0.05). Similarly the number of EG2+ cells was greater in the AS group than in the AR group (p < 0.02) and the AR- group (p < 0.05). Moreover, the EG2+ cell count was lower in the AR- group than in the AR+ group (p < 0.05). The number of mast cells and basophils in the AS group was greater than that in the AR group (p < 0.05 and p < 0.01, respectively). Mast cells in sputum were tryptase-positive. Basophils were present in sputum from 23% of patients with AR and 53% of patients with asthma. There was a significant correlation between methacholine PD20 and eosinophils (p < 0.005) and mast cells (p < 0.02) but not with basophils in those patients showing a measurable methacholine PD20 (AR+ and AS groups). Conclusions: Inflammatory cells are present not only in the airways of patients with asthma but also in airways of patients with seasonal AR, even outside natural exposure. Moreover, we provide evidence for the presence of basophils in sputum of patients with asthma even during clinical remission. The presence of bronchial responsiveness is associated with an increase in the number of eosinophils and metachromatic cells. Our findings are consistent with the hypothesis that eosinophils, as well as mast cells, contribute to bronchial responsiveness not only in AS but also in seasonal AR.	UNIV PARMA, IST CLIN MALATTIE APPARATO RESP, I-43100 PARMA, ITALY	University of Parma	Foresi, A (corresponding author), SERV FISIOPATOL RESP, MODULO ALLERGOL & IMMUNOPATOL POLMONARE, VIALE MATTEOTTI 83, I-20099 SESTO SAN GIOVANNI, ITALY.			Chetta, Alfredo/0000-0002-0416-5334				BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOULET LP, 1990, J ALLERGY CLIN IMMUN, V86, P19, DOI 10.1016/S0091-6749(05)80118-6; BOULET LP, 1993, J ALLERGY CLIN IMMUN, V91, P883, DOI 10.1016/0091-6749(93)90346-H; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; CLAMAN DM, 1994, J ALLERGY CLIN IMMUN, V94, P861, DOI 10.1016/0091-6749(94)90154-6; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; FORESI A, 1990, CHEST, V98, P528, DOI 10.1378/chest.98.3.528; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; HASTIE R, 1979, LAB INVEST, V40, P554; HOLGATE ST, 1991, CLIN EXP ALLERGY, V21, P11, DOI 10.1111/j.1365-2222.1991.tb01758.x; JAHNSEN FL, 1994, LANCET, V344, P1514, DOI 10.1016/S0140-6736(94)90336-0; KIMURA I, 1975, Clinical Allergy, V5, P95, DOI 10.1111/j.1365-2222.1975.tb01840.x; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; LAM S, 1991, J ALLERGY CLIN IMMUN, V87, P842, DOI 10.1016/0091-6749(91)90131-7; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MARUYAMA N, 1994, AM J RESP CRIT CARE, V150, P1086, DOI 10.1164/ajrccm.150.4.7921441; PESCI A, 1993, AM REV RESPIR DIS, V147, P684, DOI 10.1164/ajrccm/147.3.684; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; PLAUT M, 1986, J ALLERGY CLIN IMMUN, V78, P968, DOI 10.1016/0091-6749(86)90287-3; SCHROEDER JT, 1995, ALLERGY, V50, P463, DOI 10.1111/j.1398-9995.1995.tb01180.x; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; STEVENS WJ, 1983, EUR J RESPIR DIS, V64, P72; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	31	151	154	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					58	64		10.1016/S0091-6749(97)70195-7	http://dx.doi.org/10.1016/S0091-6749(97)70195-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257788				2022-12-18	WOS:A1997XP42800010
J	MARTINEZ, FD; STERN, DA; WRIGHT, AL; HOLBERG, CJ; TAUSSIG, LM; HALONEN, M				MARTINEZ, FD; STERN, DA; WRIGHT, AL; HOLBERG, CJ; TAUSSIG, LM; HALONEN, M			ASSOCIATION OF INTERLEUKIN-2 AND INTERFERON-GAMMA PRODUCTION BY BLOOD MONONUCLEAR-CELLS IN INFANCY WITH PARENTAL ALLERGY SKIN-TESTS AND WITH SUBSEQUENT DEVELOPMENT OF ATOPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE; IFN-GAMMA; IL-2; CYTOKINES; IMMEDIATE HYPERSENSITIVITY; ALLERGY SKIN TEST; T-H1 LYMPHOCYTES; T-H2 LYMPHOCYTES; INFANCY	SERUM IGE LEVELS; HOUSE DUST MITE; TEST REACTIVITY; CHILDHOOD ASTHMA; LYMPHOCYTES-T; SENSITIVITY; DERMATITIS; INHIBITION; FREQUENCY; CHILDREN	The mechanisms regulating the onset of atopic sensitization in human beings are not yet fully clarified. We assessed the capacity of mitogen-stimulated umbilical and peripheral blood mononuclear cells to produce interferon-gamma (IFN-gamma) and interleukin-2 (IL-2) at birth and at 9 months of age in 159 infants. Mononuclear cell production of both IFN-gamma and IL-2 al 9 months, but not at birth, was found to be inversely related to parental immediate skin test reactivity to seven local aeroallergens, Skill test reactivity at the age of 6 reals was also inversely related to IFN-gamma and IL-2 production at 9 months of age. However; no relationship was evident between total serum IgE levels at 6 years and production of these cytokines at 9 months. The proportions of circulating lymphocytes and CD4+ or CD8+ cells were also unrelated to skin test reactivity at the age of 6 years. These data suggest that mechanisms regulating skin test reactivity to inhaled allergens may involve deficient IFN-gamma production, deficient IL-2 production, or both during or preceding the time of initial sensitization and that additional mechanisms ale involved in regulating total serum IgE level.	UNIV ARIZONA, HLTH SCI CTR, DEPT PEDIAT, TUCSON, AZ 85724 USA; UNIV ARIZONA, HLTH SCI CTR, DEPT PHARMACOL, TUCSON, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	MARTINEZ, FD (corresponding author), UNIV ARIZONA, ARIZONA HLTH SCI CTR, RESP SCI CTR, WESTEND LABS, TUCSON, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CLAASSEN JL, 1992, CELL IMMUNOL, V140, P357, DOI 10.1016/0008-8749(92)90202-Z; COFFMAN RL, 1986, J IMMUNOL, V136, P949; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; JUJO K, 1993, J ALLERGY CLIN IMMUN, V91, P1206, DOI 10.1016/0091-6749(93)90324-9; KIBLER R, 1985, J CLIN IMMUNOL, V5, P46, DOI 10.1007/BF00915168; KIBLER R, 1986, DIAGN CLIN IMMUNOL, V4, P201; LEUNG DYM, 1993, PEDIATR RES, V33, pS56; LI JTC, 1990, J ALLERGY CLIN IMMUN, V85, P934, DOI 10.1016/0091-6749(90)90080-N; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; MARSH DG, 1993, GENETICS ASTHMA, P201; MIYAWAKI T, 1985, CLIN EXP IMMUNOL, V59, P505; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; REINHOLD U, 1988, INT ARCH ALLER A IMM, V87, P58; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; ROMAGNANI S, 1993, GENETICS ASTHMA, P163; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	33	151	153	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				652	660		10.1016/S0091-6749(95)70264-4	http://dx.doi.org/10.1016/S0091-6749(95)70264-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499682				2022-12-18	WOS:A1995TG52800011
J	GRANT, JA; NICODEMUS, CF; FINDLAY, SR; GLOVSKY, MM; GROSSMAN, J; KAISER, H; MELTZER, EO; MITCHELL, DQ; PEARLMAN, D; SELNER, J; SETTIPANE, G; SILVERS, W				GRANT, JA; NICODEMUS, CF; FINDLAY, SR; GLOVSKY, MM; GROSSMAN, J; KAISER, H; MELTZER, EO; MITCHELL, DQ; PEARLMAN, D; SELNER, J; SETTIPANE, G; SILVERS, W			CETIRIZINE IN PATIENTS WITH SEASONAL RHINITIS AND CONCOMITANT ASTHMA - PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; ASTHMA; ANTIHISTAMINES; CETIRIZINE; HISTAMINE(1) RECEPTOR ANTAGONISTS; HISTAMINE; PLACEBO; PROPHYLAXIS	POLLEN-INDUCED ASTHMA; ALLERGIC RHINITIS; DOUBLE-BLIND; EOSINOPHIL RECRUITMENT; PROPHYLACTIC TREATMENT; BRONCHIAL REACTIVITY; PULMONARY-FUNCTION; ORAL CETIRIZINE; ATOPIC ASTHMA; HISTAMINE	Objective: This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma. Methods: Daily treatment for 6 weeks with cetirizine 10 mg (93 patients) was compared with placebo treatment(93 patients) in a randomized, double-blind parallel study of patients with allergic rhinitis and asthma. This multicenter study was started just-before onset of the fall pollen season. Rhinitis and asthma symptoms were assessed twice daily; spirometry was performed weekly. Results: Placebo-treated patients experienced a worsening of rhinitis symptoms from baseline throughout the study, whereas cetirizine-treated patients had a significant improvement in rhinitis symptoms at week I, which was maintained after onset of the pollen season. Asthma symptoms in the cetirizine group improved from baseline at week 1; symptoms were significantly better than in the placebo group for 5 of 6 weeks of the study. Pulmonary function did not worsen in patients taking cetirizine or placebo; there were no differences between treatments as determined by spirometry. Albuterol use was less frequent in the cetirizine-treated patients for every week of the study but differences did not reach significance. Pseudoephedrine use was similar in both groups. More cetirizine-treated patients (90%) completed the trial than did placebo-treated patients (74%). Both treatments were well tolerated. Conclusion: Cetirizine 10 mg daily is safe;and effective in relieving both upper and lower respiratory tract symptoms in patients with seasonal allergic rhinitis and concomitant asthma.			GRANT, JA (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,CLIN SCI ROOM 409,301 UNIV BLVD,GALVESTON,TX 77555, USA.							ADVENIER C, 1991, J ALLERGY CLIN IMMUN, V88, P104, DOI 10.1016/0091-6749(91)90307-A; BARNES CL, 1993, ANN PHARMACOTHER, V27, P464; BOUSQUET J, 1992, EUR RESPIR J, V5, P1137; BOUSQUET J, 1990, ANN ALLERGY, V65, P504; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; BROIDE DH, 1988, J ALLERGY CLIN IMMUN, V81, P176, DOI 10.1016/0091-6749(88)90268-0; BRUTTMANN G, 1990, ANN ALLERGY, V64, P224; CHARLESWORTH EN, 1992, J PHARMACOL EXP THER, V262, P964; CISTERO A, 1992, ANN ALLERGY, V69, P123; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DAVIES BH, 1989, CLIN TRIALS J, V26, P100; DIJKMAN JH, 1990, CLIN EXP ALLERGY, V20, P483, DOI 10.1111/j.1365-2222.1990.tb03140.x; DIRKSEN A, 1989, ALLERGY, V44, P566, DOI 10.1111/j.1398-9995.1989.tb04201.x; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; EGGLESTON PA, 1988, J ALLERGY CLIN IMMUN, V81, P1036, DOI 10.1016/0091-6749(88)90176-5; Evans R., 1993, ALLERGY PRINCIPLES P, P1109; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FINNERTY JP, 1990, BRIT J CLIN PHARMACO, V29, P79, DOI 10.1111/j.1365-2125.1990.tb03605.x; GHOSH SK, 1991, J ALLERGY CLIN IMMUN, V87, P1010, DOI 10.1016/0091-6749(91)90424-M; HERXHEIMER H, 1949, BMJ-BRIT MED J, V2, P901, DOI 10.1136/bmj.2.4633.901; HOLGATE ST, 1989, J ALLERGY CLIN IMMUN, V83, P537, DOI 10.1016/0091-6749(89)90035-3; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; HOWARTH PH, 1985, J ALLERGY CLIN IMMUN, V75, P166, DOI 10.1016/0091-6749(85)90383-5; HOWARTH PH, 1990, CLIN EXP ALLERGY, V20, P31, DOI 10.1111/j.1365-2222.1990.tb02459.x; JOHNSON HG, 1992, AM REV RESPIR DIS, V146, P621, DOI 10.1164/ajrccm/146.3.621; KAY AB, 1987, ANN ALLERGY, V59, P35; KOPFERSCHMITTKU.MC, 1990, ANN ALLERGY, V65, P501; Kroll V M, 1993, Fortschr Med, V111, P76; KURZEJA A, 1989, LANCET, V1, P556; LINNA O, 1992, ACTA PAEDIATR, V81, P100, DOI 10.1111/j.1651-2227.1992.tb12182.x; LOCKEY RF, 1993, ANN ALLERGY, V70, P311; MELTZER EO, 1990, ANN ALLERGY, V64, P183; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; PECK CC, 1993, JAMA-J AM MED ASSOC, V269, P1550, DOI 10.1001/jama.269.12.1550; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; RAFFERTY P, 1990, BRIT J CLIN PHARMACO, V30, P229, DOI 10.1111/j.1365-2125.1990.tb03769.x; REDIER H, 1992, J ALLERGY CLIN IMMUN, V90, P215, DOI 10.1016/0091-6749(92)90074-C; SCHULLER DE, 1983, J ALLERGY CLIN IMMUN, V71, P147, DOI 10.1016/0091-6749(83)90359-7; SCHULLER DE, 1983, J ALLERGY CLIN IMMUN, V72, P175, DOI 10.1016/0091-6749(83)90526-2; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P481, DOI 10.1016/0091-6749(88)90022-X; SNOWMAN AM, 1990, J ALLERGY CLIN IMMUN, V86, P1025, DOI 10.1016/S0091-6749(05)80248-9; TASHKIN DP, 1987, ANN ALLERGY, V59, P49; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x; VANNESTE D, 1993, DERMATOLOGY, V186, P281, DOI 10.1159/000247376; WASSERFALLEN JB, 1993, J ALLERGY CLIN IMMUN, V91, P1189, DOI 10.1016/0091-6749(93)90322-7; Weeke E R, 1992, Rhinol Suppl, V13, P5; WOODBAKER R, 1993, J ALLERGY CLIN IMMUN, V91, P1005, DOI 10.1016/0091-6749(93)90213-Y; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; WOOSLEY RL, 1993, J ALLERGY CLIN IMMUN, V91, P258; 1993, MED LETT, V35, P71	53	151	157	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				923	932		10.1016/S0091-6749(95)70090-0	http://dx.doi.org/10.1016/S0091-6749(95)70090-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751511				2022-12-18	WOS:A1995QY91700001
J	LEUNG, DYM; RHODES, AR; GEHA, RS				LEUNG, DYM; RHODES, AR; GEHA, RS			ENUMERATION OF T-CELL SUBSETS IN ATOPIC-DERMATITIS USING MONOCLONAL-ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School	LEUNG, DYM (corresponding author), CHILDRENS HOSP MED CTR,DEPT MED,DIV ALLERGY & DERMATOL,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI-05877, 1F32AI06053-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAATHEN LR, 1979, BRIT J DERMATOL, V100, P511, DOI 10.1111/j.1365-2133.1979.tb05576.x; BYROM NA, 1979, BRIT J DERMATOL, V100, P491, DOI 10.1111/j.1365-2133.1979.tb05574.x; EVANS EI, 1952, ANN SURG, V135, P804, DOI 10.1097/00000658-195206000-00006; EVANS RL, 1978, J IMMUNOL, V120, P1423; FISER PM, 1979, J IMMUNOL, V123, P1788; GEHA RS, 1980, J ALLERGY CLIN IMMUN, V66, P78, DOI 10.1016/0091-6749(80)90142-6; GEHA RS, CLIN RES; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KATZ DH, 1974, J IMMUNOL, V113, P974; LEUNG DSP, UNPUBLISHED; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; MARTINEZ JD, 1979, J ALLERGY CLIN IMMUN, V64, P485, DOI 10.1016/0091-6749(79)90057-5; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; OKUMURA K, 1971, J IMMUNOL, V107, P1682; OSBAND M, 1978, J IMMUNOL, V121, P179; PARKMAN R, 1976, J EXP MED, V144, P1520, DOI 10.1084/jem.144.6.1520; REINHERZ EL, 1979, J IMMUNOL, V123, P2894; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; REINHERZ EL, 1980, NEW ENGL J MED, V303, P370, DOI 10.1056/NEJM198008143030704; REINHERZ EL, 1980, J IMMUNOL, V124, P1301; SAXON A, 1980, J CLIN INVEST, V65, P1457, DOI 10.1172/JCI109810; SCHUSTER DL, 1979, J ALLERGY CLIN IMMUN, V64, P139, DOI 10.1016/0091-6749(79)90048-4; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; TADA T, 1971, J IMMUNOL, V106, P1012; THORSBY E, 1970, HISTOCOMPATIBILITY T, P655; WALDMANN TA, 1972, J IMMUNOL, V109, P304	29	151	151	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	6					450	455		10.1016/0091-6749(81)90098-1	http://dx.doi.org/10.1016/0091-6749(81)90098-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LU068	6980906				2022-12-18	WOS:A1981LU06800006
J	Castells, M				Castells, Mariana			Diagnosis and management of anaphylaxis in precision medicine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Anaphylaxis; adverse drug reactions; drug hypersensitivity reactions; hypersensitivity reactions; IgE; mAbs	MAST-CELL ACTIVATION; EXACERBATED RESPIRATORY-DISEASE; EXERCISE-INDUCED ANAPHYLAXIS; IGE ANTIBODIES; CROSS-REACTIVITY; HYPERSENSITIVITY REACTIONS; DRUG HYPERSENSITIVITY; SYSTEMIC-ANAPHYLAXIS; HYMENOPTERA STINGS; ALLERGIC PATIENTS	Anaphylaxis is the most severe and frightening of the allergic reactions, placing patients at high risk and demanding prompt recognition and immediate management by health care providers. Yet because its symptoms imitate those of other diseases, such as asthma and urticaria, current data suggest that its diagnosis is often missed, with underuse of tryptase measurement; its treatment is delayed, with little use of epinephrine; and its underlying cause or causes are poorly investigated. Deaths from anaphylaxis are difficult to investigate because of miscoding. Surprisingly, patients treated with new and powerful chemotherapy agents and humanized mAbs present with nonclassical symptoms of anaphylaxis, and patients may present with unrecognized clonal mast cell disorders with KIT mutations may present as Hymenoptera-induced or idiopathic anaphylaxis. The goal of this review is to recognize the presentations of anaphylaxis with the description of its current phenotypes, to provide new insight and understanding of its mechanisms and causes through its endotypes, and to address its biomarkers for broad clinical use. Ultimately, the aim is to empower allergists and heath care providers with new tools that can help alleviate patients' symptoms, preventing and protecting them against anaphylaxis.	[Castells, Mariana] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Dept Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Castells, M (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, 60 Fenwood Rd,Brigham Transformat Med Bldg, Boston, MA 02115 USA.	mcastells@bwh.harvard.edu						Akin C, 2007, CLIN IMMUNOL, V123, P268, DOI 10.1016/j.clim.2007.02.007; Alvarez-Perea A, 2017, J ALLERGY CLIN IMMUN; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; [Anonymous], 2016, J ALLERGY CLIN IMMUN; [Anonymous], 2015, J ALLERGY CLIN IMMUN; [Anonymous], 2015, J ALLERGY CLIN IMMUN; [Anonymous], 2017, J CLIN DIAGN RES; [Anonymous], 2016, J HUAZHONG U SCI TEC; Antunez C, 2006, J ALLERGY CLIN IMMUN, V117, P404, DOI 10.1016/j.jaci.2005.10.032; Asselin B, 2016, FUTURE ONCOL, V12, P1609, DOI 10.2217/fon-2016-0005; AUSTEN KF, 1974, NEW ENGL J MED, V291, P661, DOI 10.1056/NEJM197409262911306; Banerji A, 2014, J ALLER CL IMM-PRACT, V2, P428, DOI 10.1016/j.jaip.2014.04.010; Banerji A, 2014, J ALLER CL IMM-PRACT, V2, P46, DOI 10.1016/j.jaip.2013.08.012; Beutier H, 2017, J ALLERGY CLIN IMMUN, V139, P269, DOI 10.1016/j.jaci.2016.03.028; Bilo MB, 2011, ALLERGY, V66, P35, DOI 10.1111/j.1398-9995.2011.02630.x; Blumenthal KG, 2015, ANN ALLERG ASTHMA IM, V115, P294, DOI 10.1016/j.anai.2015.05.011; Bonadonna P, 2015, ALLERGY, V70, P755, DOI 10.1111/all.12617; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Bonamichi-Santos R, 2016, CLIN REV ALLERGY IMM; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V118, P447, DOI 10.1016/j.jaci.2006.03.048; Brennan PJ, 2009, J ALLERGY CLIN IMMUN, V124, P1259, DOI 10.1016/j.jaci.2009.09.009; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brown RH, 2004, J ALLERGY CLIN IMMUN, V114, P358, DOI 10.1016/j.jaci.2004.04.003; Caiado J, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0515-3; Caiado J, 2013, J ALLER CL IMM-PRACT, V1, P494, DOI 10.1016/j.jaip.2013.06.002; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Castells M, 2006, IMMUNOL ALLERGY CLIN, V26, P465, DOI 10.1016/j.iac.2006.05.005; Castells MC, 1996, J ALLERGY CLIN IMMUN, V98, P831, DOI 10.1016/S0091-6749(96)70133-1; Castells MC, 2003, CURR ALLERGY ASTHM R, V3, P15, DOI 10.1007/s11882-003-0005-x; Caughey GH, 2006, J ALLERGY CLIN IMMUN, V117, P1411, DOI 10.1016/j.jaci.2006.02.026; Chopra N, 2000, ANN ALLERG ASTHMA IM, V84, P633, DOI 10.1016/S1081-1206(10)62416-7; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Cifuentes L, 2014, J ALLERGY CLIN IMMUN, V133, P909, DOI 10.1016/j.jaci.2013.09.047; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Crespo JF, 2002, ALLERGY, V57, P946, DOI 10.1034/j.1398-9995.2002.23626.x; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; De Olano DG, 2008, J ALLERGY CLIN IMMUN, V121, P519, DOI 10.1016/j.jaci.2007.11.010; Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Eastwood D, 2013, BRIT J CLIN PHARMACO, V76, P299, DOI 10.1111/bcp.12165; Editorial Board, 2017, NY TIMES; Eigenmann PA, 2017, J ALLER CL IMM-PRACT, V5, P296, DOI 10.1016/j.jaip.2016.08.014; Elberink JNGO, 2003, CURR OPIN ALLERGY CL, V3, P287, DOI [10.1097/00130832-200308000-00009, 10.1097/01.all.0000083957.99396.b7]; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Feldweg AM, 2017, J ALLER CL IMM-PRACT, V5, P283, DOI 10.1016/j.jaip.2016.11.022; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Foer D, 2016, J ALLER CL IMM-PRACT, V4, P723, DOI 10.1016/j.jaip.2016.03.003; Fox S, 2011, ANN ALLERG ASTHMA IM, V106, P1, DOI 10.1016/j.anai.2010.05.010; Fregonese L, 2005, J ALLERGY CLIN IMMUN, V115, P1148, DOI 10.1016/j.jaci.2005.01.068; Galvao VR, 2017, J ALLER CL IMM-PRACT, V5, P816, DOI 10.1016/j.jaip.2016.08.012; Galvao VR, 2015, J ALLER CL IMM-PRACT, V3, P175, DOI 10.1016/j.jaip.2014.12.006; Giavina-Bianchi P, 2017, J ALLER CL IMM-PRACT, V5, P728, DOI 10.1016/j.jaip.2016.11.006; Gillis CM, 2017, J ALLERGY CLIN IMMUN, V139, P1253, DOI 10.1016/j.jaci.2016.06.058; Hamilton MJ, 2011, J ALLERGY CLIN IMMUN, V128, P147, DOI 10.1016/j.jaci.2011.04.037; Hansel TT, 2010, NAT REV DRUG DISCOV, V9, P325, DOI 10.1038/nrd3003; Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034; Hesterberg PE, 2009, J ALLERGY CLIN IMMUN, V123, P1262, DOI 10.1016/j.jaci.2009.02.042; Hourihane JO, 2017, J ALLERGY CLIN IMMUN, V139, P1583, DOI 10.1016/j.jaci.2017.01.030; Jensen F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014409; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Kohler J, 2014, J ALLERGY CLIN IMMUN, V133, P1383, DOI 10.1016/j.jaci.2013.10.060; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Laidlaw TM, 2013, IMMUNOL ALLERGY CLIN, V33, P195, DOI 10.1016/j.iac.2012.11.006; Lee CW, 2005, GYNECOL ONCOL, V99, P393, DOI 10.1016/j.ygyno.2005.06.028; Lee CW, 2004, ALLERGY ASTHMA PROC, V25, P23; Legere HJ, 2009, J CYST FIBROS, V8, P418, DOI 10.1016/j.jcf.2009.08.002; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI 10.1016/j.jaci.2010.06.022; Lieberman P, 2003, CURR OPIN ALLERGY CL, V3, P313, DOI 10.1097/01.all.0000083958.99396.53; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Lin E, 2010, INT ARCH ALLERGY IMM, V152, P313, DOI 10.1159/000288284; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172, DOI 10.1016/S1081-1206(10)60692-8; Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; Matsuo H, 2005, FEBS J, V272, P4431, DOI 10.1111/j.1742-4658.2005.04858.x; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; McNeil HP, 2007, J BIOL CHEM, V282, P20785, DOI 10.1074/jbc.R700017200; Moon DH, 2013, BRIT J CANCER, V109, P1072, DOI 10.1038/bjc.2013.389; Murali MR, 2011, NEW ENGL J MED, V364, P1155, DOI 10.1056/NEJMcpc1013929; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Muraro A, 2017, ALLERGY, V72, P1006, DOI 10.1111/all.13132; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Paganelli R, 1998, ALLERGY, V53, P763; Parmar JS, 2005, THORAX, V60, P517, DOI 10.1136/thx.2004.027953; Picard M, 2013, CLIN THER, V35, P548, DOI 10.1016/j.clinthera.2013.04.001; Prieto-Garcia A, 2012, J BIOL CHEM, V287, P7834, DOI 10.1074/jbc.M111.325712; Puxeddu I, 2012, ANN ALLERG ASTHMA IM, V108, P123, DOI 10.1016/j.anai.2011.11.004; Ring Johannes, 2004, Novartis Found Symp, V257, P6; Romano A, 2014, ALLERGY, V69, P806, DOI 10.1111/all.12390; Romano A, 2004, ANN INTERN MED, V141, P16, DOI 10.7326/0003-4819-141-1-200407060-00010; Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sanchez-Monge R, 2006, J ALLERGY CLIN IMMUN, V118, P705, DOI 10.1016/j.jaci.2006.04.058; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; Shadick NA, 1999, J ALLERGY CLIN IMMUN, V104, P123, DOI 10.1016/S0091-6749(99)70123-5; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SHEFFER AL, 1984, NEW ENGL J MED, V311, P1248, DOI 10.1056/NEJM198411083111909; SIMON RA, 1979, J ALLERGY CLIN IMMUN, V63, P281, DOI 10.1016/0091-6749(79)90114-3; Sloane D, 2016, J ALLER CL IMM-PRACT, V4, P497, DOI 10.1016/j.jaip.2015.12.019; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Valent P, 2014, ALLERGY, V69, P1267, DOI 10.1111/all.12436; Vultaggio A, 2010, ALLERGY, V65, P657, DOI 10.1111/j.1398-9995.2009.02280.x; Vultaggio A, 2012, INTERN EMERG MED, V7, pS77, DOI 10.1007/s11739-011-0611-x; Warren CM, 2017, J ALLER CL IMM-PRACT, V5, P381, DOI 10.1016/j.jaip.2016.12.012; Warren CM, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0614-9; Zanotti R, 2015, J ALLERGY CLIN IMMUN, V136, P135, DOI 10.1016/j.jaci.2014.11.035; Zhao YX, 2003, CHINESE MED J-PEKING, V116, P1904	113	150	151	3	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					321	333		10.1016/j.jaci.2017.06.012	http://dx.doi.org/10.1016/j.jaci.2017.06.012			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28780940	Bronze			2022-12-18	WOS:000406855500001
J	Geri, G; Terrier, B; Rosenzwajg, M; Wechsler, B; Touzot, M; Seilhean, D; Tran, TA; Bodaghi, B; Musset, L; Soumelis, V; Klatzmann, D; Cacoub, P; Saadoun, D				Geri, Guillaume; Terrier, Benjamin; Rosenzwajg, Michelle; Wechsler, Bertrand; Touzot, Maxime; Seilhean, Danielle; Tran, Tu-Anh; Bodaghi, Bahram; Musset, Lucile; Soumelis, Vassili; Klatzmann, David; Cacoub, Patrice; Saadoun, David			Critical role of IL-21 in modulating T(H)17 and regulatory T cells in Behcet disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Behcet disease; T(H)17; T(H)1; regulatory T cells; IL-21; vasculitis; autoimmunity	CENTRAL-NERVOUS-SYSTEM; GENOME-WIDE ASSOCIATION; AUTOCRINE REGULATION; MULTIPLE-SCLEROSIS; CHOROID-PLEXUS; T-H-17 CELLS; INTERLEUKIN-21; IL23R-IL12RB2; INVOLVEMENT; GENERATION	Background: Behcet disease (BD) is a chronic systemic inflammatory disorder of unknown etiology. Objective: To determine the nature of T cells driving inflammatory lesions in BD. Methods: T cell homeostasis and cytokines production were analyzed in peripheral blood and brain inflammatory lesions from 45 adult patients with BD (active and untreated BD [n = 25] and patients in remission [n = 20]) and 20 healthy donors, using Luminex, flow cytometry, immunohistochemistry, and immunofluorescence analysis. Results: We found a marked increase in T(H)17 cells and a decrease in the frequency of CD4(+) forkhead box P3(+) regulatory T cells (Tregs) in peripheral blood that were induced by IL-21 production and that correlate with BD activity. The addition of serum from patients with active BD in a sorted CD4(+) T cells culture of healthy donors induced a significant and dose-dependent production of IL-17A and a decrease in forkhead box P3 expression. We demonstrated the presence of IL-21-and IL-17A-producing T cells within the cerebrospinal fluid, brain parenchyma inflammatory infiltrates, and intracerebral blood vessels from patients with active BD and central nervous system involvement. The stimulation of CD4(+) T cells with IL-21 increased T(H)17 and T(H)1 differentiation and decreased the frequency of Treg cells. Conversely, IL-21 blockade with an IL-21R-Fc restored the TH(1)7 and Treg homeostasis in patients with BD. Conclusion: We provided here the first evidence of the critical role of IL-21 in driving inflammatory lesions in BD by promoting T(H)17 effectors and suppressing Treg cells. IL-21 represents a promising target for novel therapy in BD. (J Allergy Clin Immunol 2011; 128: 655-64.)	[Geri, Guillaume; Terrier, Benjamin; Rosenzwajg, Michelle; Klatzmann, David; Cacoub, Patrice; Saadoun, David] Univ Paris 06, Grp Hosp Pitie Salpetriere, Lab I3, F-75013 Paris, France; [Wechsler, Bertrand; Cacoub, Patrice; Saadoun, David] Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Internal Med, F-75013 Paris, France; [Seilhean, Danielle] Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Neuropathol, F-75013 Paris, France; [Bodaghi, Bahram] Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Ophthalmol, F-75013 Paris, France; [Musset, Lucile] Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Immunochem, F-75013 Paris, France; [Touzot, Maxime; Soumelis, Vassili] Inst Curie, Clin Immunol Lab, Paris, France; [Tran, Tu-Anh] Hop Bicetre, Dept Pediat, Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Saadoun, D (corresponding author), Univ Paris 06, Hop La Pitie Salpetriere, INSERM, U959,Dept Internal Med,CNRS,UMR 7211, 47-83 Blvd Hop, F-75013 Paris, France.	david.saadoun@psl.aphp.fr	Rosenzwajg, Michelle/AAF-6276-2019; Seilhean, Danielle D/O-6899-2018; Geri, Guillaume/F-4302-2015; Bodaghi, Bahram/AAS-1160-2021	Rosenzwajg, Michelle/0000-0001-5312-6203; Seilhean, Danielle D/0000-0003-3498-4602; Cacoub, Patrice/0000-0002-6727-4992; Bodaghi, Bahram/0000-0002-0962-5301; Klatzmann, David/0000-0002-0054-3422; touzot, Maxime/0000-0002-0510-2431; TRAN, Tu-Anh/0000-0001-6587-1876; saadoun, david/0000-0003-3628-9996	Direction Regionale des Affaires Sanitaires et Sociales (DRASS); Fondation pour la Recherche Medicale (FRM); Agence Nationale pour la Recherche sur le Sida et les Hepatites (ANRS); Bristol-Myers Squibb; Sanofi-Aventis; Pfizer; Vifor Pharma; Servier; Roche	Direction Regionale des Affaires Sanitaires et Sociales (DRASS); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Agence Nationale pour la Recherche sur le Sida et les Hepatites (ANRS)(ANRSFrench National Research Agency (ANR)); Bristol-Myers Squibb(Bristol-Myers Squibb); Sanofi-Aventis(Sanofi-Aventis); Pfizer(Pfizer); Vifor Pharma; Servier(Servier); Roche(Roche Holding)	Supported by the Direction Regionale des Affaires Sanitaires et Sociales (DRASS) (G.G.). B. T. was supported by the Fondation pour la Recherche Medicale (FRM) and the Agence Nationale pour la Recherche sur le Sida et les Hepatites (ANRS).; Disclosure of potential conflict of interest: P. Cacoub has received consultant fees, speaking fees, and/or honoraria from Bristol-Myers Squibb, Sanofi-Aventis, Pfizer, Vifor Pharma, Servier, and Roche. The rest of the authors have declared that they have no conflict of interest.	Al-Araji A, 2009, LANCET NEUROL, V8, P192, DOI 10.1016/S1474-4422(09)70015-8; Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146/annurev.immunol.23.021704.115643; Brustle A, 2007, NAT IMMUNOL, V8, P958, DOI 10.1038/ni1500; Bucher C, 2009, BLOOD, V114, P5375, DOI 10.1182/blood-2009-05-221135; Caprioli F, 2008, J IMMUNOL, V180, P1800, DOI 10.4049/jimmunol.180.3.1800; Caruso R, 2009, NAT MED, V15, P1013, DOI 10.1038/nm.1995; Chen QZ, 2008, IMMUNITY, V29, P899, DOI 10.1016/j.immuni.2008.10.011; Deng JS, 2010, CIRCULATION, V121, P906, DOI 10.1161/CIRCULATIONAHA.109.872903; Engelhardt B, 2001, MICROSC RES TECHNIQ, V52, P112, DOI 10.1002/1097-0029(20010101)52:1<112::AID-JEMT13>3.0.CO;2-5; Hirohata S, 2008, J NEUROL SCI, V267, P41, DOI 10.1016/j.jns.2007.09.041; Lee JW, 2008, J IMMUNOL, V181, P6536, DOI 10.4049/jimmunol.181.9.6536; LINK J, 1994, ANN NEUROL, V36, P379, DOI 10.1002/ana.410360309; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; McGonagle D, 2006, PLOS MED, V3, P1242, DOI 10.1371/journal.pmed.0030297; Mizuki N, 2010, NAT GENET, V42, P703, DOI 10.1038/ng.624; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; OHNO S, 1982, ARCH OPHTHALMOL-CHIC, V100, P1455; Ozaki K, 2004, J IMMUNOL, V173, P5361, DOI 10.4049/jimmunol.173.9.5361; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; Remmers EF, 2010, NAT GENET, V42, P698, DOI 10.1038/ng.625; Saadoun D, 2010, ARTHRITIS RHEUM-US, V62, P2806, DOI 10.1002/art.27568; Sakane T, 1999, NEW ENGL J MED, V341, P1284, DOI 10.1056/NEJM199910213411707; Sfikakis PP, 2002, ANN RHEUM DIS, V61, P51, DOI 10.1136/ard.61.suppl_2.ii51; SILMAN AJ, 1990, LANCET, V335, P1078	25	150	160	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					655	664		10.1016/j.jaci.2011.05.029	http://dx.doi.org/10.1016/j.jaci.2011.05.029			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21724243				2022-12-18	WOS:000294283400027
J	Burgess, JA; Walters, EH; Byrnes, GB; Matheson, MC; Jenkins, MA; Wharton, CL; Johns, DP; Abramson, MJ; Hopper, JL; Dharmage, SC				Burgess, John A.; Walters, E. Haydn; Byrnes, Graham B.; Matheson, Melanie C.; Jenkins, Mark A.; Wharton, Cathryn L.; Johns, David P.; Abramson, Michael J.; Hopper, John L.; Dharmage, Shyamali C.			Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: A longitudinal study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood allergic rhinitis; incident asthma; persisting asthma; effect modification	INDEPENDENT RISK-FACTOR; ADULT-ONSET ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; CHILDREN; DISEASE; BREAST; AIRWAY; RHINOCONJUNCTIVITIS; QUESTIONNAIRE; EPIDEMIOLOGY	Background: The association between allergic rhinitis and asthma is well documented, but the temporal sequence of this association has not been closely examined. Objective: We sought to assess the associations between childhood allergic rhinitis and (1) asthma incidence from preadolescence to middle age and (2) asthma persistence to middle age. Methods: Data were gathered from the 1968, 1974, and 2004 surveys of the Tasmanian Asthma Study. Cox regression was used to examine the association between childhood allergic rhinitis and asthma incidence in preadolescence, adolescence, and adult life. Binomial regression was used to examine the association between childhood allergic rhinitis and asthma beginning before the age of 7 years and persisting at age 44 years. Results: Childhood allergic rhinitis was associated with a significant 2- to 7-fold increased risk of incident asthma in preadolescence, adolescence, or adult life. Childhood allergic rhinitis was associated with a 3-fold increased risk of childhood asthma persisting compared with remitting by middle age. Conclusions: Childhood allergic rhinitis increased the likelihood of new-onset asthma after childhood and the likelihood of having persisting asthma from childhood into middle age. Clinical implications: Asthma burden in later life might be reduced by more aggressive treatment of allergic rhinitis in early life.	Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Carlton, Vic 3053, Australia; Univ Tasmania, Menzies Res Inst, Resp Res Grp, Hobart, Tas, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	University of Melbourne; University of Tasmania; Menzies Institute for Medical Research; Monash University	Burgess, JA (corresponding author), Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Level 2,723 Swanston St, Carlton, Vic 3053, Australia.	j.burgess@pgrad.unimelb.edu.au	Johns, David P/D-1933-2014; Jenkins, Mark/P-7803-2015; Matheson, Melanie C/O-4721-2015; Burgess, John/H-7555-2019; Abramson, Michael/AAQ-2671-2020; WALTERS, Eugene/AAL-2264-2021	Johns, David P/0000-0002-1575-6850; Jenkins, Mark/0000-0002-8964-6160; Matheson, Melanie C/0000-0002-5822-3499; Burgess, John/0000-0001-7532-5027; Abramson, Michael/0000-0002-9954-0538; Walters, Eugene/0000-0002-0993-4374; Byrnes, Graham/0000-0003-3893-7539				Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Burgess JA, 2006, J ASTHMA, V43, P727, DOI 10.1080/02770900601028587; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Corren J, 1997, J ALLERGY CLIN IMMUN, V99, pS781, DOI 10.1016/S0091-6749(97)70127-1; Corren J, 1998, J ALLERGY CLIN IMMUN, V101, pS352, DOI 10.1016/S0091-6749(98)70218-0; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; Dixon AE, 2006, CHEST, V130, P429, DOI 10.1378/chest.130.2.429; Fontanari P, 1996, J APPL PHYSIOL, V81, P1739, DOI 10.1152/jappl.1996.81.4.1739; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Huurre TM, 2004, J ASTHMA, V41, P311, DOI 10.1081/JAS-120026088; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Kemp A, 2004, J PAEDIATR CHILD H, V40, P337, DOI 10.1111/j.1440-1754.2004.00397.x; KOHI F, 1990, ANN ALLERGY, V65, P228; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; NACLERIO RM, 1991, AM REV RESPIR DIS, V143, pS91, DOI 10.1164/ajrccm/143.5_Pt_2.S91; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; Phipatanakul W, 2005, IMMUNOL ALLERGY CLIN, V25, P263, DOI 10.1016/j.iac.2005.03.001; Remes ST, 2002, THORAX, V57, P120, DOI 10.1136/thorax.57.2.120; Robertson CF, 1998, MED J AUSTRALIA, V168, P434, DOI 10.5694/j.1326-5377.1998.tb139022.x; Roth K., 1998, METHODEN SPORTUNTERR, P27; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P295; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; Silver EJ, 1998, J ASTHMA, V35, P437, DOI 10.3109/02770909809048952; StataCorp, 2005, STAT STAT SOFTW REL; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Vignola AM, 1998, ALLERGY, V53, P833, DOI 10.1111/j.1398-9995.1998.tb03988.x; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; YAN K, 1983, EUR J RESPIR DIS, V64, P105; ZAPLETAL A, 1977, Zeitschrift fuer Erkrankungen der Atmungsorgane, V149, P343	41	150	157	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					863	869		10.1016/j.jaci.2007.07.020	http://dx.doi.org/10.1016/j.jaci.2007.07.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17825896	Green Submitted			2022-12-18	WOS:000250157700021
J	Notarangelo, L; Casanova, JL; Conley, ME; Chapel, H; Fischer, A; Puck, J; Roifman, C; Seger, R; Geha, RS				Notarangelo, L; Casanova, JL; Conley, ME; Chapel, H; Fischer, A; Puck, J; Roifman, C; Seger, R; Geha, RS		Int Union Immunological Soc Primar	Primary immunodeficiency diseases: An update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary immunodeficiency diseases; T cells; B cells; phagocytes; complement; immune dysregulation syndromes; innate immunity		Although relatively rare, primary immunodeficiency diseases (PIDs) provide an excellent window into the functioning of the immune system. In the late 1960s, observations on these diseases, with their associated infections and genetics, bisected the immune system into humoral immunity and cell-mediated immunity. These diseases also represent a challenge in their diagnosis and treatment. Beginning in 1970, a unified nomenclature for the then-known PIDs was created by a committee convoked by the World Health Organization. Since then, and later under the aegis of the International Union of Immunological Societies, an international committee of experts has met every 2 to 3 years to update the classification of PIDs. During the past 15 years, the molecular basis of more than 120 PIDs has been elucidated. This update results from the latest meeting of this committee in Budapest, Hungary, in June 2005, which followed 21/2 days of scientific discussions. As a result of this work, new entities have been included, and the nomenclature of some PIDs (specifically of the various forms of class-switch recombination defects, previously known as hyper-IgM syndromes) has been changed.	Univ Brescia, Spedali Civili, Dept Pediat, I-25121 Brescia, Italy; Hop Necker Enfants Malad, Paris, France; Univ Tennessee, Memphis, TN USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Univ Oxford, Nuffield Dept Med, Oxford OX1 2JD, England; NIH, Bethesda, MD 20892 USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Kinderklin, Zurich, Switzerland; Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Hospital Spedali Civili Brescia; University of Brescia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Oxford; National Institutes of Health (NIH) - USA; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University Children's Hospital Zurich; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Geha, RS (corresponding author), Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016; Casanova, Jean-Laurent/I-3418-2017	Notarangelo, Luigi D/0000-0002-8335-0262; Casanova, Jean-Laurent/0000-0002-7782-4169	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035714] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-35714] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Casanova JL, 2005, J ALLERGY CLIN IMMUN, V116, P426, DOI 10.1016/j.jaci.2005.03.053; FUDENBERG H, 1971, PEDIATRICS, V47, P927; FUDENBERG HH, 1970, NEW ENGL J MED, V283, P656, DOI 10.1056/NEJM197009172831211; Notarangelo L, 2004, J ALLERGY CLIN IMMUN, V114, P677, DOI 10.1016/j.jaci.2004.06.044	4	150	163	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					883	896		10.1016/j.jaci.2005.12.1347	http://dx.doi.org/10.1016/j.jaci.2005.12.1347			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16680902	Bronze			2022-12-18	WOS:000236862800025
J	Bender, BG				Bender, BG			Overcoming barriers to nonadherence in asthma treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; adherence; management; outcomes	MEDICAL-TREATMENT; NONCOMPLIANCE; ADHERENCE; RISK	Inadequate patient adherence to prescribed treatment regimens is a major cause of poor clinical outcomes in the treatment of asthma. Among children with asthma, adherence rates are often below 50%. Multiple treatment-, clinician-, and patient-related barriers prevent the achievement of satisfactory levels of adherence. Treatment-related barriers include prolonged and complex regimens, adverse effects, cost, and delayed onset of action. Clinician-related barriers include difficulty in scheduling, treatment by one different care giver after another, perceived clinician disinterest, and time constraints. Patient-related barriers include mild or severe asthma, poor understanding of the need for treatment, insufficient confidence in the clinician or medication, the presence of psychological problems, and low motivation to change behavior. Although all of these factors must be addressed to maximize adherence, patient motivation may be the most critical. This task falls primarily to clinicians (physicians, nurses, staff), and it requires thorough patient and care giver education, more frequent patient contact, and the development of a patient-clinician partnership dedicated to the effective treatment of asthma.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Bender, BG (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177, DOI 10.1016/S1081-1206(10)63001-3; Bender B, 1996, J ASTHMA, V33, P199, DOI 10.3109/02770909609055360; Bender B, 2000, ANN ALLERG ASTHMA IM, V85, P416, DOI 10.1016/S1081-1206(10)62557-4; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V262, P1472; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; CREER TL, 1993, CHEST, V103, P1316, DOI 10.1378/chest.103.5.1316; DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101; DIMATTEO MR, 1993, HEALTH PSYCHOL, V12, P93, DOI 10.1037/0278-6133.12.2.93; Milgrom H, 1997, PEDIATR ASTHMA ALLER, V11, P3, DOI 10.1089/pai.1997.11.3; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; *NAEPP, 1997, NIH PUBL; PRICE D, 2000, AM J RESP CRIT CARE, V161, pA402; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P47, DOI 10.1037/0278-6133.13.1.47; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Silverman ES, 2000, AM J RESP CRIT CARE, V161, pS77, DOI 10.1164/ajrccm.161.supplement_1.ltta-16; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P472, DOI 10.1016/0091-6749(87)90078-9; Wamboldt FS, 1995, J PSYCHOSOM RES, V39, P995, DOI 10.1016/0022-3999(95)00507-2	17	150	161	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6		S			S554	S559		10.1067/mai.2002.124570	http://dx.doi.org/10.1067/mai.2002.124570			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	568JU	12063512				2022-12-18	WOS:000176539300007
J	Mapp, CE; Fryer, AA; De Marzo, N; Pozzato, V; Padoan, M; Boschetto, P; Strange, RC; Hemmingsen, A; Spiteri, MA				Mapp, CE; Fryer, AA; De Marzo, N; Pozzato, V; Padoan, M; Boschetto, P; Strange, RC; Hemmingsen, A; Spiteri, MA			Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						isocyanates; occupational asthma; airway hyperresponsiveness; genetic markers	TOLUENE DIISOCYANATE TDI; SENSITIZED SUBJECTS; OXIDATIVE STRESS; INFLAMMATION; ASSOCIATION; HYPERRESPONSIVENESS; IDENTIFICATION; LOCALIZATION; POLYMORPHISM; RESPONSES	Background: Polymorphism at the pi class glutathione-S-transferase locus (GSTP1) is associated with allergen-induced asthma and related phenotypes. Objective: We sought to determine whether GSTP1 polymorphism influences susceptibility to asthma induced by toluene diisocyanate (TDI). Methods: The role of GSTP1 was assessed in 131 workers exposed to TDI, 92 with TDI-induced asthma and 39 asymptomatic subjects. The phenotype of the disease was characterized by using detailed clinical history, lung volumes, airway responsiveness to methacholine, and airway responsiveness to TDI. GST genotypes were determined by using PCR-based assays. Results: In patients exposed to TDI for 10 or more years, the frequency of the GSTP1 Val/Val genotype was lower in subjects who had asthma (odds ratio, 0.23; 95% confidence interval, 0.05-1.13; P = .074). Similarly, the frequency of this genotype was significantly lower in subjects with evidence of moderate-to-severe airway hyperresponsiveness to methacholine compared with the frequency in subjects with normal or mild hyperresponsiveness (P = .033). Conclusion: These data suggest that homozygosity for the GSTP1*Val allele confers protection against TDI-induced asthma and airway hyperresponsiveness. This view is supported by the finding that the protective effect increases in proportion to the duration of exposure to TDI.	Univ Ferrara, Dept Clin & Expt Med, Sect Occupat Med, I-44100 Ferrara, Italy; N Staffordshire Hosp Trust, Stoke On Trent, Staffs, England; Keele Univ, Stoke On Trent, Staffs, England; Univ Padua, Dept Environm Med & Publ Hlth, Sect Occupat Med, Padua, Italy	University of Ferrara; Keele University; University Hospital of North Staffordshire NHS Trust; Keele University; University of Padua	Mapp, CE (corresponding author), Dipartimento Med Clin & Sperimentale, Sez Igiene & Med Lavoro, Via Fossato Mortara 64-B, I-44100 Ferrara, Italy.		Boschetto, Piera/AAM-3247-2020	Boschetto, Piera/0000-0003-3889-1681; Fryer, Anthony/0000-0001-8678-0404				ANTTILA S, 1993, CANCER RES, V53, P5643; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; BOARD PG, 1989, ANN HUM GENET, V53, P205, DOI 10.1111/j.1469-1809.1989.tb01786.x; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; *COMM COMM EUR, 1971, TABL REF EX SPIR; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437, DOI 10.1164/ajrccm.161.5.9903006; Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Hemmingsen A, 2001, RESP RES, V2, P250, DOI 10.1186/rr64; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P438; MAESTRELLI P, 1994, CLIN EXP ALLERGY, V24, P29, DOI 10.1111/j.1365-2222.1994.tb00913.x; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; MAPP CE, 1986, EUR J RESPIR DIS, V69, P276; Mapp CE, 1997, AM J RESP CRIT CARE, V156, pS139, DOI 10.1164/ajrccm.156.4.12-t-12; Mapp CE, 2000, CLIN EXP ALLERGY, V30, P651; MAPP CE, 1988, EUR RESPIR J, V1, P273; MAPP CE, 1988, AM REV RESPIR DIS, V137, P1326, DOI 10.1164/ajrccm/137.6.1326; MAPP CE, 1985, J ALLERGY CLIN IMMUN, V75, P568, DOI 10.1016/0091-6749(85)90031-4; MAPP CE, 1999, EUROPEAN RESP MONOGR, V11, P255; Mattey DL, 1999, ANN RHEUM DIS, V58, P164, DOI 10.1136/ard.58.3.164; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Postma DS, 2000, AM J RESP CRIT CARE, V162, pS118, DOI 10.1164/ajrccm.162.supplement_2.ras-13; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; ROWE D, 1997, BIOCHEM J, V235, P481; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160, DOI 10.1164/ajrccm/145.1.160; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169, DOI 10.1164/ajrccm/145.1.169; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; ZOCCA E, 1990, J APPL PHYSIOL, V68, P1576, DOI 10.1152/jappl.1990.68.4.1576	29	150	157	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					867	872		10.1067/mai.2002.123234	http://dx.doi.org/10.1067/mai.2002.123234			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994713	Green Published			2022-12-18	WOS:000175687800019
J	Stevenson, DD; Simon, RA				Stevenson, DD; Simon, RA			Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; aspirin-sensitive asthma; cyclooxygenase enzymes-1 and 2; cyclooxygenase inhibitors; rofecoxib	PROSTAGLANDINS; LEUKOTRIENES; INHIBITOR; SAFETY	Background: Patients with aspirin-sensitive respiratory disease experience cross-reactions to all nonsteroidal anti-inflammatory drugs, which inhibit cyclooxygenase enzymes. With the introduction of antiarthritis drugs, which selectively inhibit cyclooxygenase-2, questions are raised as to whether crossreactivity occurs between aspirin and these new cyclooxygenase-2 inhibitors. Objective: The goal of this study was to determine whether rofecoxib cross-reacts in aspirin-sensitive patients with asthma. Methods: Sixty patients with asthma underwent double-blinded, placebo-controlled oral challenges with rofecoxib (12.5 mg, 25 mg, and 2 placebos) over 48 hours in our General Clinical Research Center. The next day, aspirin sensitivity was proven in each of the 60 patients through use of single-blinded oral aspirin challenges. Results: None of the 60 patients experienced any symptoms, changes in nasal examination findings, or declines in FEV1 values during their challenges with rofecoxib. All 60 patients experienced typical naso-ocular and asthmatic reactions to aspirin with a mean provoking dose of 61 mg. The exact 1-sided C1 for the probability of rofecoxib inducing cross-reactions in aspirin-sensitive patients with asthma is calculated to be between 0% and 0.05%. Conclusion: Given that none of the 60 patients reacted to rofecoxib and given the statistical power of this large sample size, we conclude that cross-reactivity between aspirin and rofecoxib does not occur in patients with aspirin-sensitive respiratory disease. This does not exclude rofecoxib from participating in other types of reactions, including immune recognition after prior treatment with the drug. From the standpoint of the mechanisms involved in aspirin-induced respiratory reactions, this study strongly supports inhibition of cyclooxygenase-1 as the essential initiator of these types of reactions.	Scripps Res Inst, La Jolla, CA 92037 USA	Scripps Research Institute	Stevenson, DD (corresponding author), Scripps Clinic, Dept Med, Div Allergy Asthma & Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCRR NIH HHS [M01RR00833] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDRI L, 1994, ANN ALLERGY, V72, P29; Dahlen B, 2001, NEW ENGL J MED, V344, P142, DOI 10.1056/NEJM200101113440215; Demoly P, 1997, AM J RESP CRIT CARE, V155, P670, DOI 10.1164/ajrccm.155.2.9032211; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Kosnik M, 1998, ALLERGY, V53, P1231, DOI 10.1111/j.1398-9995.1998.tb03854.x; KUEHL FA, 1984, BIOCHEM PHARMACOL, V33, P1, DOI 10.1016/0006-2952(84)90362-9; Lehmann Erich L, 2006, TESTING STAT HYPOTHE; *MED EC CO, 2001, PHYS DRUG REF, P2050; Nasser SMS, 1998, LUNG BIOL HEALTH DIS, V114, P317; NIZANKOWSKA E, 1989, ANN ALLERGY, V63, P159; Pauls JD, 2000, ANN ALLERG ASTHMA IM, V85, P40, DOI 10.1016/S1081-1206(10)62432-5; SETTIPANE RA, 1989, J ALLERGY CLIN IMMUN, V84, P26, DOI 10.1016/0091-6749(89)90174-7; Stevenson DD, 2000, J ALLERGY CLIN IMMUN, V105, pS273, DOI 10.1016/S0091-6749(00)91234-X; Stevenson DD, 2000, ANN ALLERG ASTHMA IM, V85, P477, DOI 10.1016/S1081-1206(10)62575-6; STEVENSON DD, 1990, J ALLERGY CLIN IMMUN, V86, P749, DOI 10.1016/S0091-6749(05)80179-4; STEVENSON DD, 1998, ALLERGY PRINCIPLES P, P1225; SZCZEKLIK A, 1979, THORAX, V34, P654, DOI 10.1136/thx.34.5.654; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1990, EUR RESPIR J, V3, P588; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Yoshida S, 2000, J ALLERGY CLIN IMMUN, V106, P1201, DOI 10.1067/mai.2000.110926	25	150	154	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					47	51		10.1067/mai.2001.116290	http://dx.doi.org/10.1067/mai.2001.116290			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447381				2022-12-18	WOS:000170171200006
J	Goldin, JG; Tashkin, DP; Kleerup, EC; Greaser, LE; Haywood, UM; Sayre, JW; Simmons, MD; Suttorp, M; Colice, GL; Burgt, JAV; Aberle, DR				Goldin, JG; Tashkin, DP; Kleerup, EC; Greaser, LE; Haywood, UM; Sayre, JW; Simmons, MD; Suttorp, M; Colice, GL; Burgt, JAV; Aberle, DR			Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: Assessment with functional helical thin-section computed tomography	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hydrofluoroalkane; chlorofluorocarbon; beclomethasone diproprionate; asthma; small airways; thin-section computed tomography	HIGH-RESOLUTION CT; OBSTRUCTIVE PULMONARY-DISEASE; ASTHMA; LUNG; HYPERREACTIVITY	A double-blind, randomized, parallel-group pilot study compared the relative efficacy of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP [QVAR]; mass median aerodynamic diameter, 0.8-1.2 m) versus cholorofluorocarbon-11/12 BDP (CFC-BDP [Beclovent]; mass median aerodynamic diameter, 3.5-4.0 m) in 31 steroid naive patients with mild to moderate asthma (PC20. 4 mg/mL). Functional high-resolution computed tomography was used to assess the relative efficacy of HFA-BDP and CFC-BDP on regional air trapping, as an indirect measure of small airways function and on regional hyperreactivity Pretreatment functional computed tomography was performed at residual volume before and after methacholine challenge. After 4 weeks of treatment, functional imaging was repeated before and after the same concentration of methacholine that was administered before the treatment (n = 19 patients). Quantitative assessment of changes in distribution of lung attenuation was performed. After 4 weeks of treatment, the HFA-BDP group showed significantly more improvement in air trapping overall (a shift in the lung attenuation curve at residual volume toward more attenuation) on the posttreatment computed tomography scan (P < .05; Fisher's Exact Test). After an equal constrictor stimulus (methacholine concentration), subjects treated with HFA-BDP (n = 10 patients) showed less increase in air trapping overall than subjects treated with CFC-BDP (n = 9 patients) on the posttreatment scans compared with the pretreatment scans (P < .001; Fisher's Exact Test). No significant difference was demonstrated between the 2 treatment groups with respect to improvement in symptoms, spirometry, or methacholine responsiveness assessed by FEV1, except for a greater reduction in breathlessness in the HFA-BDP group (P < .05). We conclude that HFA-BDP may have greater efficacy in the peripheral airways and that this effect is better assessed with functional imaging computed tomography techniques than with conventional physiologic tests.	Univ Calif Los Angeles, Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90095 USA; 3M Pharmaceut, St Paul, MN USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; 3M	Goldin, JG (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA.		Aberle, Denise R./D-5699-2014	Aberle, Denise R./0000-0002-8858-3401; Goldin, Jonathan/0000-0003-3007-9947	NATIONAL CANCER INSTITUTE [P01CA051198] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA51198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABERLE DR, 1995, AM REV RESPIR DIS, V151, P674; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Goldin JG, 1998, RADIOLOGY, V208, P321, DOI 10.1148/radiology.208.2.9680554; GOLDIN JG, 1995, RADIOLOGY, V197, P437; Hoffman EA, 1997, ACAD RADIOL, V4, P758, DOI 10.1016/S1076-6332(97)80080-3; KEE ST, 1994, RADIOLOGY, V193, P367; Kramer SS, 1995, J THORAC IMAG, V10, P280, DOI 10.1097/00005382-199501040-00005; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; LAMERS RJ, 1994, RADIOLOGY, V193, P109, DOI 10.1148/radiology.193.1.8090878; Leach CL, 1998, RESP MED, V92, P3, DOI 10.1016/S0954-6111(98)90211-6; Lehman EL, 1975, NONPARAMETRICS STAT; McNittGray MF, 1997, J COMPUT ASSIST TOMO, V21, P939, DOI 10.1097/00004728-199711000-00017; MCNITTGRAY MF, 1994, MED PHYS, V21, P905; *NAT ASTHM ED PREV, 1997, NIH PUBL; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; NEWMAN SP, 1995, J AEROSOL MED, V8, pS21, DOI 10.1089/jam.1995.8.Suppl_3.S-21; PAGANIN F, 1995, CHEST, V107, pS145, DOI 10.1378/chest.107.3_Supplement.145S; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; RIENMULLER RK, 1991, J COMPUT ASSIST TOMO, V15, P742, DOI 10.1097/00004728-199109000-00003; ROSENBLUM LJ, 1980, RADIOLOGY, V137, P409, DOI 10.1148/radiology.137.2.7433674; Synek M, 1996, AM J RESP CRIT CARE, V154, P224, DOI 10.1164/ajrccm.154.1.8680684; Tashkin DP, 1998, J ALLERGY CLIN IMMUN, V101, pS409, DOI 10.1016/S0091-6749(98)70233-7; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; West JB, 1970, VENTILATION BLOOD FL; Woolcock AJ, 1998, AM J RESP CRIT CARE, V157, pS203, DOI 10.1164/ajrccm.157.5.rsaa-8	28	150	154	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					S258	S267		10.1016/S0091-6749(99)70043-6	http://dx.doi.org/10.1016/S0091-6749(99)70043-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588987				2022-12-18	WOS:000084289200043
J	Nussberger, J; Cugno, M; Cicardi, M; Agostoni, A				Nussberger, J; Cugno, M; Cicardi, M; Agostoni, A			Local bradykinin generation in hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PLASMA; KININ; EDEMA		Univ Lausanne Hosp, Div Hypertens, Lausanne, Switzerland; Univ Milan, Dept Internal Med, Maggiore Hosp, Milan, Italy	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Agostoni, A (corresponding author), Univ Milan, Dept Internal Med, Via Pace 15, I-20122 Milan, Italy.		Cugno, Massimo/K-8106-2016; cicardi, marco/K-9219-2016	Cugno, Massimo/0000-0002-9918-0763; cicardi, marco/0000-0003-1251-225X				Cugno M, 1997, BLOOD, V89, P3213, DOI 10.1182/blood.V89.9.3213; Donaldson V H, 1977, Trans Assoc Am Physicians, V90, P174; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22	5	150	152	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1321	1322		10.1016/S0091-6749(99)70030-8	http://dx.doi.org/10.1016/S0091-6749(99)70030-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589018				2022-12-18	WOS:000084289200030
J	JONES, SM; MAGNOLFI, CF; COOKE, SK; SAMPSON, HA				JONES, SM; MAGNOLFI, CF; COOKE, SK; SAMPSON, HA			IMMUNOLOGICAL CROSS-REACTIVITY AMONG CEREAL-GRAINS AND GRASSES IN CHILDREN WITH FOOD HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CEREAL GRAINS; GRASSES; WHEAT; FOOD CHALLENGES; CROSS-REACTIVITY; IMMUNOBLOT	LEGUME BOTANICAL FAMILY; ATOPIC-DERMATITIS; INGESTION ALLERGY; BAKERS ASTHMA; DOUBLE-BLIND; SKIN-TESTS; WHEAT; FLOUR; DIAGNOSIS; RAST	Background: Because of a lack of clinical data from food challenges, allergists often recommend dietary restriction of all cereal grains in patients with sensitivity to at least one grain. Objectives: The purposes of this study were to assess the degree of intrabotanical cross-reactivity among cereal grains and related grasses, to better define the prevalence of multiple grain hypersensitivity, and to define the protein fractions associated with wheat hypersensitivity. Methods: One hundred forty-five patients evaluated by food challenges and skin prick tests were divided into three groups: group 1, cereal grain and grass allergies; group 2, wheat allergy alone; and group 3, grass allergy alone. Fifteen patients were further selected from groups 1 to 3. Sodium dodecylsulfate-polyacrylamide gel electrophoresis and immunoblot analyses were performed on six grains and four related grasses with sera from these patients. Results: Only 21% of patients had symptomatic reactivity as determined by food challenge; 80% had reactivity to only one grain. As determined by immunoblot analyses, patients in groups 1 and 2 showed extensive cross-reactivity (within each,group) among grains but little cross-reactivity among grasses, whereas patients in group 3 showed cross-reactivity between the grains and grasses. Patients with wheat allergy had specific IgE binding to wheat fractions 47 kd and 20 kd, bands not recognized by patients with grass allergy. Conclusions: Clinically insignificant cross-reactivity exists among cereal grains and grasses; therefore, elimination of all grains from the diet of a patient with grain allergy is unwarranted. Further purification and characterization of the 47 kd and 20 kd wheat fractions is needed to provide move specific in vitro testing.	JOHNS HOPKINS UNIV,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,BALTIMORE,MD 21218; UNIV MILAN,PEDIAT CLIN,MILAN,ITALY	Johns Hopkins University; University of Milan					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439, T32AI007007] Funding Source: NIH RePORTER; NIAID NIH HHS [5 T32 AI07007, R01 AI24439] Funding Source: Medline; PHS HHS [MO1 R00052] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AOKI T, 1987, NEW ENGL REG ALLERGY, V8, P34; ARMENTIA A, 1990, ANN ALLERGY, V65, P149; ARMENTIA A, 1990, ANN ALLERGY, V65, P265; BALDO B, 1982, PROG ALLERGY, V30, P2; BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; BALDO BA, 1980, ALLERGY, V35, P45, DOI 10.1111/j.1398-9995.1980.tb01716.x; BERNHISELBROADB.J, 1989, J ALLERGY CLIN IMMUN, V84, P701; BERNHISELBROADB.J, 1992, J ALLERGY CLIN IMMUN, V89, P730; BERNHISELBROADB.J, 1989, J ALLERGY CLIN IMMUN, V83, P435; BIERMAN CW, 1978, J ALLERGY CLIN IMMUN, V61, P119; BJORKSTEN F, 1977, CLIN ALLERGY, V7, P473, DOI 10.1111/j.1365-2222.1977.tb01478.x; BLANDS J, 1976, INT ARCH ALLER A IMM, V52, P392, DOI 10.1159/000231706; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; DAVID TJ, 1984, ARCH DIS CHILD, V59, P323, DOI 10.1136/adc.59.4.323; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; PFEIL T, 1990, INT ARCH ALLER A IMM, V91, P224, DOI 10.1159/000235121; PRICHARD MG, 1985, CLIN ALLERGY, V15, P203, DOI 10.1111/j.1365-2222.1985.tb02274.x; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V82, P718, DOI 10.1016/0091-6749(88)90070-X; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SAMPSON HA, 1993, ALLERGY PRINCIPLES P, P1661; SUTTON R, 1982, CLIN ALLERGY, V12, P63, DOI 10.1111/j.1365-2222.1982.tb03127.x; WALSH BJ, 1987, NEW ENGL REG ALLERGY, V8, P27; WRAITH DG, 1979, CLIN ALLERGY, V9, P25, DOI 10.1111/j.1365-2222.1979.tb01519.x; 1991, STATE FOOD AGR ROME, P18	31	150	154	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					341	351		10.1016/S0091-6749(95)70053-6	http://dx.doi.org/10.1016/S0091-6749(95)70053-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560636				2022-12-18	WOS:A1995RU66000006
J	WENZEL, SE; WESTCOTT, JY; LARSEN, GL				WENZEL, SE; WESTCOTT, JY; LARSEN, GL			BRONCHOALVEOLAR LAVAGE FLUID MEDIATOR LEVELS 5 MINUTES AFTER ALLERGEN CHALLENGE IN ATOPIC SUBJECTS WITH ASTHMA - RELATIONSHIP TO THE DEVELOPMENT OF LATE ASTHMATIC RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ENZYMATIC ISOTOPIC ASSAY; IMMEDIATE BRONCHOCONSTRICTION; HISTAMINE; RELEASE; ANTIGEN; PLASMA; RADIOIMMUNOASSAY; ANTAGONIST	Inflammatory mediators have been implicated in the pathogenesis of human asthma and have been demonstrated to increase in bronchoalveolar lavage fluid during the time of the immediate asthmatic response (IAR) after allergen instillation in the lungs. However, the relationship of these mediators, measured early to the late asthmatic response (LAR), airway reactivity, and clinical asthma, is unknown. In the present study, we evaluated mediator levels in bronchoalveolar lavage fluid before and 5 minutes after allergen challenge from three subject groups: atopic subjects without asthma (N = 7), atopic subjects with asthma and without LAR ((-)LAR) (N = 6), and atopic subjects with asthma and with LAR ((+)LAR) (N = 6). Subjects with asthma were differentiated into subjects with and without LARs based on at least a 15% decrease in FEV1 between 3 to 8 hours postallergen inhalation. The mediators, prostaglandin D2, thromboxane B2, leukotriene C4 (LTC4), and histamine, were measured both before and after allergen instillation. Baseline prechallenge levels were similar, except in the case of LTC4. LTC4 was detectable at baseline significantly more frequently in the atopic subjects with asthma with and without LAR when these subjects were compared to the atopic subjects without asthma (nine of 12 detectable versus one of seven detectable). In all groups, significant increases in mediator levels were observed in the groups with asthma postallergen challenge, compared to the atopic subjects without asthma. Atopic subjects with asthma and without LAR had significantly higher levels of all four mediators after challenge than atopic subjects with asthma and with LAR and atopic subjects without asthma. No correlation was found between the mediator levels and airway physiology among any of the three groups. Although atopic subjects with asthma and with LAR were more reactive to methacholine than the other two groups, the difference did not reach significance. In addition, no correlation was observed with cell counts, differentials, or proteins. It is hypothesized from these findings that multiple factors are involved in the production of an LAR. These factors most likely include mediator levels and underlying airway reactivity, with the more reactive airways requiring less mediators for bronchoconstriction to occur. This findings implies that therapeutic options in asthma should focus not only on blockage of mediator activity but also on reversal of underlying airway hyperreactivity.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, WEBB WARING LUNG INST, DENVER, CO 80202 USA; UNIV COLORADO, SCH MED, DEPT CARDIOVASC PULM RES, DENVER, CO 80202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WENZEL, SE (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, 1400 JACKSON ST, DENVER, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL007433, P01HL034303, P01HL036577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07433, HL-36577, HL-34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM WM, 1987, AM REV RESPIR DIS, V135, pS49; BERNSTEIN L, 1985, AM REV RESPIR DIS, V132, P180; BRITTON JR, 1987, J ALLERGY CLIN IMMUN, V79, P811, DOI 10.1016/0091-6749(87)90214-4; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CURZEN N, 1987, THORAX, V42, P946, DOI 10.1136/thx.42.12.946; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DORSCH W, 1982, J ALLERGY CLIN IMMUN, V70, P236, DOI 10.1016/0091-6749(82)90059-8; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; FICK RB, 1987, AM REV RESPIR DIS, V135, P1204; HARGREAVE FE, 1983, SEMIN RESPIR MED, V4, P224, DOI 10.1055/s-2007-1012487; HOWARTH PH, 1987, J ALLERGY CLIN IMMUN, V80, P703, DOI 10.1016/0091-6749(87)90291-0; KELLY RW, 1986, PROSTAG LEUKOTR ESS, V24, P1, DOI 10.1016/0262-1746(86)90201-5; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAULS DO, 1986, J ALLERGY CLIN IMMUN, V77, P673, DOI 10.1016/0091-6749(86)90407-0; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SHEPHARD EG, 1985, BRIT J CLIN PHARMACO, V19, P459, DOI 10.1111/j.1365-2125.1985.tb02671.x; SMITH H R, 1989, American Review of Respiratory Disease, V139, pA464; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; WESTCOTT JY, 1990, J APPL PHYSIOL, V68, P2640, DOI 10.1152/jappl.1990.68.6.2640; WESTCOTT JY, UNPUB URINARY LEUKOT	29	150	152	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					540	548		10.1016/0091-6749(91)90013-E	http://dx.doi.org/10.1016/0091-6749(91)90013-E			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993813				2022-12-18	WOS:A1991EX98700012
J	LEBEL, B; BOUSQUET, J; MOREL, A; CHANAL, I; GODARD, P; MICHEL, FB				LEBEL, B; BOUSQUET, J; MOREL, A; CHANAL, I; GODARD, P; MICHEL, FB			CORRELATION BETWEEN SYMPTOMS AND THE THRESHOLD FOR RELEASE OF MEDIATORS IN NASAL SECRETIONS DURING NASAL CHALLENGE WITH GRASS-POLLEN GRAINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP AIGUELONGUE,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE; INSERM,U58,F-34100 MONTPELLIER,FRANCE; IMMUNOTECH,MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			Bousquet, Jean/O-4221-2019					BATAILLE Y, 1986, J ALLERGY CLIN IMMUN, V77, P181; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BLUMSTEIN GI, 1937, J ALLERGY, V8, P321; BORUM P, 1980, J ALLERGY CLIN IMMUN, V66, P25, DOI 10.1016/0091-6749(80)90134-7; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550, DOI 10.1159/000234277; BROWN MS, 1987, ARCH OTOLARYNGOL, V113, P179; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DELUCA HS, 1986, CLIN CHEM, V32, P1075; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LINDER A, 1987, ALLERGY, V42, P126, DOI 10.1111/j.1398-9995.1987.tb02370.x; MACLOUF J, 1986, PROSTAGLANDINS, V31, P123, DOI 10.1016/0090-6980(86)90230-3; MARTINOT B, 1986, J ALLERGY CLIN IMMUN, V77, P214; MCLEAN JA, 1984, RHINITIS, P62; MIADONNA A, 1986, J ALLERGY CLIN IMMUN, V77, P177; MOREL AM, 1985, J ALLERGY CLIN IMMUN, V75, P124, DOI 10.1016/0091-6749(85)90212-X; MYGIND N, 1976, ACTA OTO-LARYNGOL, V82, P219, DOI 10.3109/00016487609120888; MYGIND N, 1975, ACTA ALLERGOL, V30, P298, DOI 10.1111/j.1398-9995.1975.tb00206.x; MYGIND N, 1983, 11 P INT C ALL CLIN, P207; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OKUDA M, 1980, ADV ALLERGOLOGY APPL, P125; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; Pepys J., 1975, BR J HOSP MED, V14, P412; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; SOLOMON WR, 1983, PROVOCATIVE CHALLENG, P134; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; TOGIAS AG, 1986, AM REV RESPIR DIS, V133, P1133; TUFT L, 1950, J ALLERGY, V21, P326, DOI 10.1016/0021-8707(50)90066-9; WACHS M, 1987, J ALLERGY CLIN IMMUN, V79, P253; WIHL JA, 1983, EUR J RESPIR DIS, V64, P175	37	150	153	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				869	877		10.1016/0091-6749(88)90092-9	http://dx.doi.org/10.1016/0091-6749(88)90092-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	2461405				2022-12-18	WOS:A1988R170800023
J	SWANSON, MC; AGARWAL, MK; REED, CE				SWANSON, MC; AGARWAL, MK; REED, CE			AN IMMUNOCHEMICAL APPROACH TO INDOOR AEROALLERGEN QUANTITATION WITH A NEW VOLUMETRIC AIR SAMPLER - STUDIES WITH MITE, ROACH, CAT, MOUSE, AND GUINEA-PIG ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DIV ALLERG DIS,ROCHESTER,MN 55905; MAYO MED SCH,DEPT MED,ROCHESTER,MN 55901; MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55901; ALLERG DIS RES LAB,ROCHESTER,MN	Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016791, P50AI011483] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 16791, AI 11483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PLATTSMILLS TAE, 1983, J ALLERGY CLIN IMMUN, V71, P157, DOI 10.1016/0091-6749(83)90398-6; REED CE, 1983, J OCCUP ENVIRON MED, V25, P207, DOI 10.1097/00043764-198303000-00014; SWANSON MC, 1984, AM REV RESPIR DIS, V129, P844, DOI 10.1164/arrd.1984.129.5.844; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4	6	150	149	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					724	729		10.1016/0091-6749(85)90678-5	http://dx.doi.org/10.1016/0091-6749(85)90678-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	4056257	Bronze			2022-12-18	WOS:A1985AUU3400012
J	Chipps, BE; Zeiger, RS; Borish, L; Wenzel, SE; Yegin, A; Hayden, ML; Miller, DP; Bleecker, ER; Simons, FER; Szefler, SJ; Weiss, ST; Haselkorn, T				Chipps, Bradley E.; Zeiger, Robert S.; Borish, Larry; Wenzel, Sally E.; Yegin, Ashley; Hayden, Mary Lou; Miller, Dave P.; Bleecker, Eugene R.; Simons, F. Estelle R.; Szefler, Stanley J.; Weiss, Scott T.; Haselkorn, Tmirah		TENOR Study Grp	Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TENOR; severe or difficult-to-treat asthma; asthma control; asthma exacerbations; burden; medication; quality of life; allergy; IgE	QUALITY-OF-LIFE; ACTIVITY IMPAIRMENT; HEALTH OUTCOMES; NATIONAL HEART; LARGE COHORT; AIR-FLOW; CHILDREN; ASSOCIATION; SEVERITY; ADULTS	Patients with severe or difficult-to-treat asthma are an understudied population but account for considerable asthma morbidity, mortality, and costs. The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study was a large, 3-year, multicenter, observational cohort study of 4756 patients (n = 3489 adults >= 18 years of age, n = 497 adolescents 13-17 years of age, and n = 770 children 6-12 years of age) with severe or difficult-to-treat asthma. TENOR's primary objective was to characterize the natural history of disease in this cohort. Data assessed semiannually and annually included demographics, medical history, comorbidities, asthma control, asthma-related health care use, medication use, lung function, IgE levels, self-reported asthma triggers, and asthma-related quality of life. We highlight the key findings and clinical implications from more than 25 peer-reviewed TENOR publications. Regardless of age, patients with severe or difficult-to-treat asthma demonstrated high rates of health care use and substantial asthma burden despite receiving multiple long-term controller medications. Recent exacerbation history was the strongest predictor of future asthma exacerbations. Uncontrolled asthma, as defined by the 2007 National Heart, Lung, and Blood Institute guidelines' impairment domain, was highly prevalent and predictive of future asthma exacerbations; this assessment can be used to identify high-risk patients. IgE and allergen sensitization played a role in the majority of severe or difficult-to-treat asthmatic patients. (J Allergy Clin Immunol 2012;130:332-42.)	[Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, Sacramento, CA 95819 USA; [Zeiger, Robert S.] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA; [Borish, Larry] Univ Virginia Hlth Syst, Carter Immunol Ctr, Charlottesville, VA USA; [Wenzel, Sally E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; [Yegin, Ashley; Haselkorn, Tmirah] Genentech Inc, San Francisco, CA 94080 USA; [Hayden, Mary Lou] Univ Virginia, Charlottesville, VA USA; [Miller, Dave P.] ICON Clin Res, San Francisco, CA USA; [Bleecker, Eugene R.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC USA; [Simons, F. Estelle R.] Univ Manitoba, Winnipeg, MB, Canada; [Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Denver, CO USA; [Weiss, Scott T.] Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA	Kaiser Permanente; University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Roche Holding; Genentech; University of Virginia; ICON plc; Wake Forest University; Wake Forest Baptist Medical Center; University of Manitoba; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Harvard Medical School	Chipps, BE (corresponding author), Capital Allergy & Resp Dis Ctr, 5609 J St,Suite C, Sacramento, CA 95819 USA.	bchipps@capitalallergy.com		Miller, Dave/0000-0003-2947-152X; Zeiger, Robert/0000-0001-5788-5063; Szefler, Stanley/0000-0002-6911-3199; Wenzel, Sally/0000-0002-4242-0164	Genentech; AstraZeneca; GlaxoSmithKline; Novartis; Sunovion; Merck-Schering; Alcon; Aerocrine; Merck and Co.; Canadian Institutes of Health Research; Boehringer-Ingelheim; Schering-Plough; National Institutes of Health/National Heart, Lung, and Blood Institute; National Heart, Lung, and Blood Institute's Childhood Asthma Research and Education (CARE); National Institutes of Health/National Heart, Lung, and Blood Institute's Asthma Clinical Research Network (ACRN); National Institutes of Health/National Institutes of Allergy and Infectious Disease's Inner City Asthma Consortium (ICAC); National Institute of Environmental Health Sciences/Environmental Protection Agency's Childhood Environmental Health Center; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076285] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057438] Funding Source: NIH RePORTER	Genentech(Roche HoldingGenentech); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Sunovion; Merck-Schering(Merck & Company); Alcon(Novartis); Aerocrine; Merck and Co.(Merck & Company); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Boehringer-Ingelheim(Boehringer Ingelheim); Schering-Plough(Merck & CompanySchering Plough Corporation); National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Heart, Lung, and Blood Institute's Childhood Asthma Research and Education (CARE); National Institutes of Health/National Heart, Lung, and Blood Institute's Asthma Clinical Research Network (ACRN); National Institutes of Health/National Institutes of Allergy and Infectious Disease's Inner City Asthma Consortium (ICAC); National Institute of Environmental Health Sciences/Environmental Protection Agency's Childhood Environmental Health Center; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	B. E. Chipps has consultant arrangements with Alcon, Genentech, AstraZeneca, GlaxoSmithKline, Meda, Novartis, Sunovion, Merck-Schering, ISTA, Quintiles, and Dey; is on the speakers' bureau for Alcon, Genentech, AstraZeneca, GlaxoSmithKline, Meda, Novartis, Sunovion, Merck-Schering, ISTA, and Dey; has received grants for clinical research from Genentech, AstraZeneca, GlaxoSmithKline, Novartis, Sunovion, and Merck-Schering; and has received grants for education activities from Alcon, Genentech, AstraZeneca, GlaxoSmithKline, and Novartis. R. S. Zeiger has consultant arrangements with AstraZeneca, Aerocrine, Genentech, GlaxoSmithKline, Novartis, Sunovion, Schering-Plough, and MedImmune and has received research support from Aerocrine, Genentech, GlaxoSmithKline, and Merck and Co. L. Borish has received honoraria from Merck; has consultant arrangements with Genentech, Endo Pharmaceuticals, Regeneron, Cephalon, Pfizer, and Hoffman-LaRoche; has received research support from Merck and Genentech; is on committees for the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology; and is a volunteer for the Charlottesville Free Clinic. M. L. Hayden has received speaker's honoraria from TEVA, Merck and Co, and Dey Labs and has consultant arrangements with Sunovion. D. P. Miller's employer has Genentech as a client. E. R. Bleecker has consultant arrangements with Genentech and has received research support from Genentech. F. E. R. Simons has received research support from the Canadian Institutes of Health Research. S. J. Szefler has consultant arrangements with GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from the National Institutes of Health/National Heart, Lung, and Blood Institute's Childhood Management Program (CAMP); the National Heart, Lung, and Blood Institute's Childhood Asthma Research and Education (CARE); the National Institutes of Health/National Heart, Lung, and Blood Institute's Asthma Clinical Research Network (ACRN); the National Institutes of Health/National Institutes of Allergy and Infectious Disease's Inner City Asthma Consortium (ICAC); GlaxoSmithKline; the National Institutes of Health/National Heart, Lung, and Blood Institute's Asthma Net; and a National Institute of Environmental Health Sciences/Environmental Protection Agency's Childhood Environmental Health Center grant. T. Haselkorn has been a paid consultant to Genentech, Inc since 2002. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 1997, ASTH THER ASS QUEST; Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; Aubier M, 1999, RESP MED, V93, P876, DOI 10.1016/S0954-6111(99)90053-7; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Borish L, 2005, ANN ALLERG ASTHMA IM, V95, P247, DOI 10.1016/S1081-1206(10)61221-5; Burgess JA, 2007, EUR RESPIR J, V29, P668, DOI 10.1183/09031936.00080906; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Campbell JD, 2008, EUR RESPIR J, V32, P1237, DOI 10.1183/09031936.00112107; *CDCP, 2009, NAT VIT STAT REP DEA; Chen H, 2008, MAYO CLIN PROC, V83, P786, DOI 10.4065/83.7.786; Chen H, 2008, VALUE HEALTH, V11, P231, DOI 10.1111/j.1524-4733.2007.00229.x; Chen H, 2007, J ALLERGY CLIN IMMUN, V120, P396, DOI 10.1016/j.jaci.2007.04.040; Chinn S, 2003, J ASTHMA, V40, P1, DOI 10.1081/JAS-120017202; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Forno E, 2011, J ALLERGY CLIN IMMUN, V127, P741, DOI 10.1016/j.jaci.2010.12.010; Gamble C, 2010, J ALLERGY CLIN IMMUN, V126, P1149, DOI 10.1016/j.jaci.2010.08.049; [Global Initiative for Asthma (GINA) National Heart Lung and Blood Institute (NHLBI)], 2003, GLOB STRAT ASTHM MAN; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, pe1, DOI DOI 10.1016/J.JACI.2009.07.035.PUBMED; Haselkorn T, 2009, RESP MED, V103, P274, DOI 10.1016/j.rmed.2008.08.010; Haselkorn T, 2008, ANN ALLERG ASTHMA IM, V101, P256, DOI 10.1016/S1081-1206(10)60490-5; Haselkorn T, 2010, PEDIAT ALLERG IMM-UK, V21, P1157, DOI 10.1111/j.1399-3038.2010.01065.x; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P921, DOI 10.1016/j.jaci.2009.09.006; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P895, DOI 10.1016/j.jaci.2009.07.035; Haselkorn T, 2006, J ASTHMA, V43, P745, DOI 10.1080/02770900601031540; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Lee JH, 2006, J ASTHMA, V43, P179, DOI 10.1080/02770900600566405; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; Mathews WC, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-5; Miller MK, 2006, EUR RESPIR J, V28, P1145, DOI 10.1183/09031936.06.00145105; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; National Heart Lung and Blood Institute, 2007, NAT HEART LUNG BLOOD, V08-5846; National Heart Lung Blood Institute, 1997, 2 NAT HEART LUNG BLO; Ownby D, 1998, CLIN SIGNIFICANCE IM; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Reilly MC, 1996, CLIN DRUG INVEST, V11, P278, DOI 10.2165/00044011-199611050-00004; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006; Slavin RG, 2006, ANN ALLERG ASTHMA IM, V96, P406, DOI 10.1016/S1081-1206(10)60907-6; Sullivan SD, 2007, ALLERGY, V62, P655, DOI 10.1111/j.1398-9995.2007.01383.x; Sullivan SD, 2007, ALLERGY, V62, P126, DOI 10.1111/j.1398-9995.2006.01254.x; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2011, ANN ALLERG ASTHMA IM, V107, P110, DOI 10.1016/j.anai.2011.04.008; TAYLOR WR, 1992, PEDIATRICS, V90, P657; Tough SC, 1998, J ASTHMA, V35, P657, DOI 10.3109/02770909809048968; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Zeiger RS, 2012, ANN ALLERG ASTHMA IM, V108, P81, DOI 10.1016/j.anai.2011.12.001; Zeiger RS, 2009, J ALLERGY CLIN IMMUN, V124, P1106, DOI 10.1016/j.jaci.2009.07.052	55	149	154	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					332	+		10.1016/j.jaci.2012.04.014	http://dx.doi.org/10.1016/j.jaci.2012.04.014			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22694932	Green Accepted, Green Published			2022-12-18	WOS:000307002200011
J	Romano, A; Torres, MJ; Castells, M; Sanz, ML; Blanca, M				Romano, Antonino; Torres, Maria J.; Castells, Mariana; Sanz, Maria L.; Blanca, Miguel			Diagnosis and management of drug hypersensitivity reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	4th Drug Hypersensitivity Meeting (DHM4)	APR 22-25, 2010	Rome, ITALY	European Acad Allergy & Clinical Immunol (EAACI)		Anticonvulsants; beta-lactams; desensitization; diagnosis; drugs; hypersensitivity; nonsteroidal anti-inflammatory drugs	IMMEDIATE ALLERGIC REACTIONS; BETA-LACTAM ANTIBIOTICS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EXACERBATED RESPIRATORY-DISEASE; TOXIC EPIDERMAL NECROLYSIS; NEGATIVE PREDICTIVE-VALUE; BASOPHIL ACTIVATION TEST; STEVENS-JOHNSON-SYNDROME; PENICILLIN ALLERGY; CROSS-REACTIVITY	The present article addresses the advances in the diagnosis and management of drug hypersensitivity reactions that were discussed in the 4th Drug Hypersensitivity Meeting held in Rome in April 2010. Such reactions can be classified as immediate or nonimmediate according to the time interval between the last drug administration and onset. Immediate reactions occur within 1 hour, and nonimmediate reactions occur after more than 1 hour. Clinical and immunologic studies suggest that type-I (IgE-mediated) and type-IV (T cell-mediated) pathogenic mechanisms are involved in most immediate and nonimmediate reactions, respectively. In diagnosis prick, patch, and intradermal tests are the most readily available tools. Determination of specific IgE levels is still the most common in vitro method for diagnosing immediate reactions. New diagnostic tools, such as the basophil activation test, the lymphocyte activation test, and enzyme-linked immunospot assays for analysis of the frequency of antigen-specific, cytokine-producing cells, have been developed for evaluating either immediate or nonimmediate reactions. The sensitivity of allergologic tests is not 100%; therefore in selected cases provocation tests are necessary. In the diagnosis of nonallergic hypersensitivity reactions to nonsteroidal anti-inflammatory drugs, the provocation test with the suspected drug still represents the "gold standard." However, there was no consensus regarding the use of this test in subjects with histories of hypersensitivity reactions to 1 (single reactors) or more (multiple reactors) nonsteroidal anti-inflammatory drugs. With regard to management, desensitization allows patients to be treated with irreplaceable chemotherapy agents, such as taxanes, platinum salts, and mAbs, to which they have presented hypersensitivity reactions. Desensitization also permits the use of aspirin in aspirin-sensitive patients undergoing revascularization and in subjects with aspirin-exacerbated respiratory disease. (J Allergy Clin Immunol 2011;127:S67-73.)	[Romano, Antonino] IRCCS Oasi Maria SS, Troina, Italy; [Torres, Maria J.; Blanca, Miguel] Carlos Haya Hosp, Allergy Serv, Malaga, Spain; [Castells, Mariana] Harvard Univ, Brigham & Womens Hosp, Sch Med, Allergy Serv, Boston, MA 02115 USA; [Sanz, Maria L.] Univ Pamplona, Dept Allergy, Allergy Serv, Pamplona, Spain; [Romano, Antonino] Complesso Integrato Columbus, Allergy Unit, I-00168 Rome, Italy	IRCCS Oasi Maria SS; Hospital Carlos Haya; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Romano, A (corresponding author), Complesso Integrato Columbus, Unita Allergol, Via G Moscati 31, I-00168 Rome, Italy.	antoninoromano@h-columbus.it	Torres, Maria/GVU-3391-2022; Romano, Antonino/D-3102-2017; Torres, María José/T-3518-2017	Romano, Antonino/0000-0001-9742-9898; Torres, María José/0000-0001-5228-471X				Aberer W, 2003, ALLERGY, V58, P854, DOI 10.1034/j.1398-9995.2003.00279.x; Cornejo-Garcia JA, 2009, CURR DRUG METAB, V10, P971, DOI 10.2174/138920009790711841; Antunez C, 2006, J ALLERGY CLIN IMMUN, V117, P404, DOI 10.1016/j.jaci.2005.10.032; Asero R, 2002, ANN ALLERG ASTHMA IM, V88, P468, DOI 10.1016/S1081-1206(10)62384-8; Asero R, 2000, ALLERGY, V55, P893, DOI 10.1034/j.1398-9995.2000.00698.x; Beeler A, 2008, ALLERGY, V63, P181, DOI 10.1111/j.1398-9995.2007.01516.x; Benucci M, 2008, ALLERGY, V63, P138, DOI 10.1111/j.1398-9995.2007.01536.x; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Blanca M, 2009, ALLERGY, V64, P183, DOI [10.1111/j.1398-9995.2008.01924.x, 10.1111/j.1398-9995.2008.01916.x]; Blanca M, 2001, ALLERGY, V56, P862, DOI 10.1034/j.1398-9995.2001.00995.x; Bousquet PJ, 2008, CLIN EXP ALLERGY, V38, P185, DOI 10.1111/j.1365-2222.2007.02867.x; Brennan PJ, 2009, J ALLERGY CLIN IMMUN, V124, P1259, DOI 10.1016/j.jaci.2009.09.009; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Castrejon JL, 2010, J ALLERGY CLIN IMMUN, V125, P411, DOI 10.1016/j.jaci.2009.10.031; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Demoly P, 2010, ALLERGY, V65, P327, DOI 10.1111/j.1398-9995.2009.02228.x; Canto MG, 2009, CURR OPIN ALLERGY CL, V9, P293, DOI 10.1097/ACI.0b013e32832db943; Hausmann OV, 2009, IMMUNOL ALLERGY CLIN, V29, P555, DOI 10.1016/j.iac.2009.04.011; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Torres MJ, 2010, J ALLERGY CLIN IMMUN, V125, P502, DOI 10.1016/j.jaci.2009.11.032; KAHN DA, 2010, J ALLERGY CLIN IM S2, V125, pS126; Lin E, 2010, INT ARCH ALLERGY IMM, V152, P313, DOI 10.1159/000288284; Lochmatter P, 2009, ALLERGY, V64, P1269, DOI 10.1111/j.1398-9995.2009.01985.x; Lopez S, 2009, BRIT J DERMATOL, V160, P259, DOI 10.1111/j.1365-2133.2008.08875.x; Lopez S, 2010, J INVEST DERMATOL, V130, P895, DOI 10.1038/jid.2009.308; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172, DOI 10.1016/S1081-1206(10)60692-8; Mayorga C, 2009, CURR OPIN ALLERGY CL, V9, P431, DOI 10.1097/ACI.0b013e3283307abc; Mertes PM, 2005, J INVEST ALLERG CLIN, V15, P91; Mockenhaupt M, 2003, J RHEUMATOL, V30, P2234; Nakamura K, 2006, ANN ALLERG ASTHMA IM, V97, P712, DOI 10.1016/S1081-1206(10)61107-6; Perez-Inestrosa E, 2005, CURR OPIN ALLERGY CL, V5, P323, DOI 10.1097/01.all.0000173788.73401.69; Pichler WJ, 2004, ALLERGY, V59, P809, DOI 10.1111/j.1398-9995.2004.00547.x; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Riemer AB, 2010, CLIN EXP ALLERGY, V40, P486, DOI 10.1111/j.1365-2222.2009.03363.x; Rodriguez-Pena R, 2006, J ALLERGY CLIN IMMUN, V118, P949, DOI 10.1016/j.jaci.2006.07.013; Romano A, 2005, CLIN EXP ALLERGY, V35, P1234, DOI 10.1111/j.1365-2222.2005.02317.x; Romano A, 2004, ALLERGY, V59, P1153, DOI 10.1111/j.1398-9995.2004.00678.x; Romano A, 2000, J ALLERGY CLIN IMMUN, V106, P1177; Romano A, 2008, PEDIATRICS, V122, P521, DOI 10.1542/peds.2007-3178; Romano A, 2010, J ALLERGY CLIN IMMUN, V126, P994, DOI 10.1016/j.jaci.2010.06.052; Romano Antonino, 2008, Allergy Asthma Clin Immunol, V4, P66, DOI 10.1186/1710-1492-4-2-66; Rozieres A, 2009, ALLERGY, V64, P534, DOI 10.1111/j.1398-9995.2008.01674.x; Sanchez-Borges M, 2010, MED CLIN N AM, V94, P853, DOI 10.1016/j.mcna.2010.03.005; Sanchez-Morillas L, 2010, J ALLERGY CLIN IMMUN, V126, P177, DOI 10.1016/j.jaci.2010.03.012; Sanz ML, 2009, CURR OPIN ALLERGY CL, V9, P298, DOI 10.1097/ACI.0b013e32832d5311; Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x; Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177, DOI 10.1016/S1081-1206(10)62221-1; Torres MJ, 2010, ALLERGY, V65, P590, DOI 10.1111/j.1398-9995.2009.02245.x; Torres MJ, 2009, J INVEST ALLERG CLIN, V19, P80; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x; Torres MJ, 2001, ALLERGY, V56, P850, DOI 10.1034/j.1398-9995.2001.00089.x; Waton J, 2009, BRIT J DERMATOL, V160, P786, DOI 10.1111/j.1365-2133.2008.08975.x	52	149	158	1	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3		S			S67	S73		10.1016/j.jaci.2010.11.047	http://dx.doi.org/10.1016/j.jaci.2010.11.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	743NJ	21354502				2022-12-18	WOS:000289024700003
J	Gao, PS; Rafaels, NM; Hand, T; Murray, T; Boguniewicz, M; Hata, T; Schneider, L; Hanifin, JM; Gallo, RL; Gao, L; Beaty, TH; Beck, LA; Barnes, KC; Leung, DYM				Gao, Pei-Song; Rafaels, Nicholas M.; Hand, Tracey; Murray, Tanda; Boguniewicz, Mark; Hata, Tissa; Schneider, Lynda; Hanifin, Jon M.; Gallo, Richard L.; Gao, Li; Beaty, Terri H.; Beck, Lisa A.; Barnes, Kathleen C.; Leung, Donald Y. M.			Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema herpeticum; filaggrin; R501X; 2282del4; single nucleotide polymorphisms	OF-FUNCTION VARIANTS; ICHTHYOSIS VULGARIS; NULL MUTATIONS; GENE; SUSCEPTIBILITY; ASTHMA; POLYMORPHISMS; PREVALENT; SEVERITY; CHILDREN	Background: Loss-of-function null mutations R501X and 2282del4 in the skin barrier gene, filaggrin (FLG), represent the most replicated genetic risk factors for atopic dermatitis ( AD). Associations have not been reported in African ancestry populations. Atopic dermatitis eczema herpeticum (ADEH) is a rare but serious complication of AD resulting from disseminated cutaneous herpes simplex virus infections. Objective: We aimed to determine whether FLG polymorphisms contribute to ADEH susceptibility. Methods: Two common loss-of-function mutations plus 9 FLG single nucleotide polymorphisms were genotyped in 278 European American patients with AD, of whom 112 had ADEH, and 157 nonatopic controls. Replication was performed on 339 African American subjects. Results: Significant associations were observed for both the R501X and 2282del4 mutations and AD among European American subjects (P = 1.46 x 10(-5), 3.87 x 10(-5), respectively), but the frequency of the R501X mutation was 3 times higher (25% vs 9%) for ADEH than for AD without eczema herpeticum (EH) (odds ratio [OR], 3.4; 1.7-6.8; P = .0002). Associations with ADEH were stronger with the combined null mutations (OR, 10.1; 4.7-22.1; P = 1.99 x 10(-11)). Associations with the R501X mutation were replicated in the African American population; the null mutation was absent among healthy African American subjects, but present among patients with AD (3.2%; P = .035) and common among patients with ADEH (9.4%; P = .0049). However, the 2282del4 mutation was absent among African American patients with ADEH and rare (<1%) among healthy individuals. Conclusion: The R501X mutation in the gene encoding filaggrin, one of the strongest genetic predictors of AD, confers an even greater risk for ADEH in both European and African ancestry populations, suggesting a role for defective skin barrier in this devastating condition. (J Allergy Clin Immunol 2009;124:507-13.)	[Gao, Pei-Song; Rafaels, Nicholas M.; Hand, Tracey; Gao, Li; Barnes, Kathleen C.] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; [Murray, Tanda; Beaty, Terri H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Boguniewicz, Mark; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Hata, Tissa; Gallo, Richard L.] Univ Calif San Diego, Div Dermatol, San Diego, CA 92103 USA; [Schneider, Lynda] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Hanifin, Jon M.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Beck, Lisa A.] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14642 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Jewish Health; University of California System; University of California San Diego; Harvard University; Boston Children's Hospital; Oregon Health & Science University; University of Rochester	Barnes, KC (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 3A-62A, Baltimore, MD 21224 USA.	kbarnes@jhmi.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861	National Institute of Allergy and Infectious Diseases; National Institutes of Health; Department of Health and Human Services [HHSN266200400029C, HHSN266200400033C]; Mary Beryl Patch Turnbull Scholar Program	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; Mary Beryl Patch Turnbull Scholar Program	Supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, and the Department of Health and Human Services under contract numbers HHSN266200400029C and HHSN266200400033C. K.C.B. was supported in part by the Mary Beryl Patch Turnbull Scholar Program.	Basu K, 2008, ALLERGY, V63, P1211, DOI 10.1111/j.1398-9995.2008.01660.x; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; de Jongh CM, 2008, BRIT J DERMATOL, V159, P621, DOI 10.1111/j.1365-2133.2008.08730.x; Eichenfield Lawrence F, 2003, J Am Acad Dermatol, V49, P1088, DOI 10.1016/S0190-9622(03)02539-8; Ekelund E, 2008, ACTA DERM-VENEREOL, V88, P15, DOI 10.2340/00015555-0383; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fan JB, 2006, METHOD ENZYMOL, V410, P57, DOI 10.1016/S0076-6879(06)10003-8; Giardina E, 2008, DERMATOLOGY, V216, P83, DOI 10.1159/000109365; Hamada T, 2008, J INVEST DERMATOL, V128, P1323, DOI 10.1038/sj.jid.5701164; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Horii KA, 2007, PEDIATRICS, V120, pE527, DOI 10.1542/peds.2007-0289; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Howie BN, 2006, HUM GENET, V120, P58, DOI 10.1007/s00439-006-0182-5; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Rogers AJ, 2007, J ALLERGY CLIN IMMUN, V120, P1332, DOI 10.1016/j.jaci.2007.09.037; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Tay YK, 1999, ASIAN PAC J ALLERGY, V17, P137; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Xu FJ, 2006, JAMA-J AM MED ASSOC, V296, P964, DOI 10.1001/jama.296.8.964	30	149	155	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					507	U178		10.1016/j.jaci.2009.07.034	http://dx.doi.org/10.1016/j.jaci.2009.07.034			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19733298	Green Accepted			2022-12-18	WOS:000274315900016
J	Narisety, SD; Skripak, JM; Steele, P; Hamilton, RG; Matsui, EC; Burks, AW; Wood, RA				Narisety, Satya D.; Skripak, Justin M.; Steele, Pamela; Hamilton, Robert G.; Matsui, Elizabeth C.; Burks, A. Wesley; Wood, Robert A.			Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TOLERANCE INDUCTION; FOOD ALLERGY; DOUBLE-BLIND; CHILDREN; DESENSITIZATION		[Narisety, Satya D.; Hamilton, Robert G.; Matsui, Elizabeth C.; Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; [Skripak, Justin M.] Mt Sinai Sch Med, New York, NY USA; [Steele, Pamela; Burks, A. Wesley] Duke Univ, Med Ctr, Durham, NC USA	Johns Hopkins University; Icahn School of Medicine at Mount Sinai; Duke University	Narisety, SD (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.	snarise1@jhmi.edu; rwood1@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593	NIAID NIH HHS [T32 AI007007-30, T32 AI007007, 5T32AI007007] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Morisset M, 2007, Eur Ann Allergy Clin Immunol, V39, P12; Patriarca G, 2007, DIGEST DIS SCI, V52, P1662, DOI 10.1007/s10620-006-9245-7; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x	8	149	154	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					610	612		10.1016/j.jaci.2009.06.025	http://dx.doi.org/10.1016/j.jaci.2009.06.025			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19665770	Green Accepted			2022-12-18	WOS:000274315900035
J	Bork, K; Wulff, K; Hardt, J; Witzke, G; Staubach, P				Bork, Konrad; Wulff, Karin; Hardt, Jochen; Witzke, Guenther; Staubach, Petra			Hereditary angioedema caused by missense mutations in the factor XII gene: Clinical features, trigger factors, and therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Angioedema; hereditary angioedema; hereditary angioedema type III; factor XII; coagulation factor XII gene mutation; estrogens; progesterone; danazol; tranexamic acid; C1 esterase inhibitor	NORMAL C1 INHIBITOR; C1-INHIBITOR DEFICIENCY; AFFECTED WOMEN; F12 GENE; EDEMA; ATTACKS; MEN; MECHANISMS; SYMPTOMS; DANAZOL	Background: Hereditary angioedema caused by mutations in the factor XII gene is a recently described disease entity that occurs mainly in women. It differs from hereditary angioedema caused by C1 inhibitor deficiency. Objective: To assess the clinical symptoms, factors triggering acute attacks, and treatments of this disease. Methods: Thirty-five female patients with hereditary angioedema and the factor XII mutations p.Thr309Lys and p.Thr309Arg who came from 13 unrelated families were studied. The observation period was 8.4 years on average (range, 2-26 years). Results: Patients had on average 12.7 +/- 7.9 angioedema attacks per year. Recurrent facial swellings occurred in all patients; skin swellings other than facial, abdominal pain attacks, tongue swellings, and laryngeal edema occurred less frequently. Some factors that triggered angioedema attacks were trauma, physical pressure, and emotional stress. Clinical symptoms started mainly after intake of oral contraceptives (17 women) or pregnancy (3 women). Exacerbation of the symptoms occurred after oral contraceptive use (8 women), pregnancy (7 women), hormone replacement therapy (3 women), intake of angiotensin-converting enzyme inhibitors (2 women), and an angiotensin I receptor blocker (1 woman). Effective treatments included C1 inhibitor concentrate for angioedema attacks (6 women) and, for prophylaxis, progesterone (8 women), danazol (2 women), and tranexamic acid (1 woman). No difference between mutation p.Thr309Arg and p.Thr309Lys was found. Conclusions: Facial swelling is a cardinal symptom of this condition. Estrogens may have a great influence, but this influence is highly variable. Various treatment options are available. (J Allergy Clin Immunol 2009;124:129-34.)	[Bork, Konrad; Witzke, Guenther; Staubach, Petra] Johannes Gutenberg Univ Mainz, Dept Dermatol, D-55131 Mainz, Germany; [Hardt, Jochen] Johannes Gutenberg Univ Mainz, Dept Med Psychol & Med Sociol, D-55131 Mainz, Germany; [Wulff, Karin] Ernst Moritz Arndt Univ Greifswald, Inst Human Genet, Greifswald, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Ernst Moritz Arndt Universitat Greifswald	Bork, K (corresponding author), Johannes Gutenberg Univ Mainz, Dept Dermatol, Langenbeckstr 1, D-55131 Mainz, Germany.	bork@hautklinik.klinik.uni-mainz.de	Bork, Konrad/AAE-4985-2022	Bork, Konrad/0000-0002-6084-4577				AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Amar L, 2004, BRIT J DERMATOL, V151, P713, DOI 10.1111/j.1365-2133.2004.06152.x; Bas M, 2008, J ALLERGY CLIN IMMUN, V121, P969, DOI 10.1016/j.jaci.2008.01.071; Bell CG, 2008, PATHOLOGY, V40, P82, DOI 10.1080/00313020701716433; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Binkley KE, 2001, J ALLERGY CLIN IMMUN, V107, P747, DOI 10.1067/mai.2001.114243; Bork K, 2003, AM J MED, V114, P294, DOI 10.1016/S0002-9343(02)01526-7; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Bork K, 2006, BRIT J DERMATOL, V154, P542, DOI 10.1111/j.1365-2133.2005.07048.x; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; BORK K, 2009, BLOOD COAGU IN PRESS; Bork K, 2008, ANN ALLERG ASTHMA IM, V100, P153, DOI 10.1016/S1081-1206(10)60424-3; Bork K, 2007, AM J MED, V120, P987, DOI 10.1016/j.amjmed.2007.08.021; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; Bouillet L, 2007, BRIT J DERMATOL, V156, P1063, DOI 10.1111/j.1365-2133.2007.07778.x; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; Cugno M, 2009, ALLERGY, V64, P254, DOI 10.1111/j.1398-9995.2008.01859.x; Davis AE, 2008, ANN ALLERG ASTHMA IM, V100, pS7, DOI 10.1016/S1081-1206(10)60580-7; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; Drouet C, 2008, J ALLERGY CLIN IMMUN, V121, P429, DOI 10.1016/j.jaci.2007.10.048; Fiz Matias J, 2007, REV ESP ANESTESIOL R, V54, P253; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Herrmann G, 2004, BRIT J DERMATOL, V150, P157, DOI 10.1111/j.1365-2133.2004.05669.x; Martin L, 2001, J ALLERGY CLIN IMMUN, V107, P747, DOI 10.1067/mai.2001.114242; Martin L, 2007, J ALLERGY CLIN IMMUN, V120, P975, DOI 10.1016/j.jaci.2007.07.002; Osler W, 1888, AM J MED SCI, V95, P362; Quincke H, 1882, MONATSH PRAKT DERMAT, V1, P129; Serrano C, 2008, ALLERGY, V63, P735, DOI 10.1111/j.1398-9995.2007.01579.x	29	149	153	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					129	134		10.1016/j.jaci.2009.03.038	http://dx.doi.org/10.1016/j.jaci.2009.03.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19477491				2022-12-18	WOS:000267909700016
J	Canino, G; McQuaid, EL; Rand, CS				Canino, Glorisa; McQuaid, Elizabeth L.; Rand, Cynthia S.			Addressing asthma health disparities: A multilevel challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma disparities; multi-level model of asthma disparities; clinical recommendations	EMERGENCY-DEPARTMENT VISITS; MANAGED CARE ORGANIZATION; MEDICAID-INSURED CHILDREN; INNER-CITY CHILDREN; CHILDHOOD ASTHMA; RACIAL DISPARITIES; SOCIOECONOMIC-STATUS; PUERTO-RICAN; INHALED STEROIDS; PROVIDERS CONTRIBUTE	Substantial research has documented pervasive disparities in the prevalence, severity, and morbidity of asthma among minority populations compared with non-Latino white subjects. The underlying causes of these disparities are not well understood, and as a result, the leverage points to address them remain unclear. A multilevel framework for integrating research in asthma health disparities is proposed to advance both future research and clinical practice. The components of the proposed model include health care policies and regulations, operation of the health care system, provider/clinician-level factors, social/environmental factors, and individual/family attitudes and behaviors. The body of research suggests that asthma disparities have multiple, complex, and interrelated sources. Disparities occur when individual, environmental, health system, and provider factors interact with one another over time. Given that the causes of asthma disparities are complex and multilevel, clinical strategies to address these disparities must therefore be comparably multilevel and target many aspects of asthma care. Several strategies that could be applied in clinical settings to reduce asthma disparities are described, including the need for routine assessment of the patient's beliefs, financial barriers to disease management, and health literacy and the provision of cultural competence training and communication skills to health care provider groups. (J Allergy Clin Immunol 2009;123:1209-17.)	[Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA; [Canino, Glorisa] Univ Puerto Rico, Dept Pediat, San Juan, PR 00936 USA; [McQuaid, Elizabeth L.] Brown Med Sch, Bradley Hasbro Res Ctr, Providence, RI USA; [Rand, Cynthia S.] Johns Hopkins Sch Med, Baltimore, MD USA	University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; Brown University; Johns Hopkins University; Johns Hopkins Medicine	Canino, G (corresponding author), Univ Puerto Rico, Behav Sci Res Inst, Med Sci Campus,POB 365067, San Juan, PR 00936 USA.	Glorisa.canino@upr.edu			National Institutes of Health [5P60 MD002261-02]; National Center for Minority Health and Health Disparities; National Heart, Lung, and Blood Institute [5 U01 HL 072519-05, 5 U01 HL 072438]; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P60MD002261] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072438, U01HL072519] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant no. 5P60 MD002261-02 funded by the National Center for Minority Health and Health Disparities and 5 U01 HL 072519-05 Canino (PI) and U01 HL 072438 Fritz (PI) from the National Heart, Lung, and Blood Institute.	Akinbami, 2006, STATE CHILDHOOD ASTH, V381; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; ALEGRIA M, COMPREHENSI IN PRESS; Apter AJ, 2006, J ALLERGY CLIN IMMUN, V117, P345, DOI 10.1016/j.jaci.2005.11.026; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Barnes KC, 2006, J ALLERGY CLIN IMMUN, V117, P243, DOI 10.1016/j.jaci.2005.11.030; Bearison DJ, 2002, J PEDIATR PSYCHOL, V27, P385, DOI 10.1093/jpepsy/27.4.385; BENDER B, 2003, ADHERENCE LONG TERM; Bender BG, 2008, ANN ALLERG ASTHMA IM, V101, P382, DOI 10.1016/S1081-1206(10)60314-6; Berman BA, 2003, ADDICT BEHAV, V28, P111, DOI 10.1016/S0306-4603(01)00221-0; Berman S, 2005, PEDIATRICS, V116, P1474, DOI 10.1542/peds.2005-0923; Boudreaux ED, 2003, PEDIATRICS, V111, pE615, DOI 10.1542/peds.111.5.e615; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Burgess DJ, 2004, J GEN INTERN MED, V19, P1154, DOI 10.1111/j.1525-1497.2004.30227.x; Cabana MD, 2000, ARCH PEDIAT ADOL MED, V154, P685, DOI 10.1001/archpedi.154.7.685; Canino G, 2006, SOC SCI MED, V63, P2926, DOI 10.1016/j.socscimed.2006.07.017; *CDCP, 1980, STAT CHILDH ASTHM; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Choudhury AH, 1997, ARCH ENVIRON HEALTH, V52, P113, DOI 10.1080/00039899709602873; Clark NM, 2002, J CLIN EPIDEMIOL, V55, P870, DOI 10.1016/S0895-4356(02)00451-1; Claudio L, 2006, ANN EPIDEMIOL, V16, P332, DOI 10.1016/j.annepidem.2005.06.046; Claudio L, 1999, J ASTHMA, V36, P343, DOI 10.3109/02770909909068227; Conn KM, 2007, PEDIATRICS, V120, pE521, DOI 10.1542/peds.2006-3023; Diette GB, 2001, J PEDIATR-US, V138, P59, DOI 10.1067/mpd.2001.109600; Diette GB, 2007, CHEST, V132, p802S, DOI 10.1378/chest.07-1909; Ellen IG, 2001, J URBAN AFF, V23, P391, DOI 10.1111/0735-2166.00096; Erickson SE, 2007, ARCH INTERN MED, V167, P1846, DOI 10.1001/archinte.167.17.1846; Finkelstein JA, 2000, PEDIATRICS, V106, P886; Finkelstein JA, 2002, ARCH PEDIAT ADOL MED, V156, P562, DOI 10.1001/archpedi.156.6.562; Fisher-Owens Susan A., 2006, Pediatric Asthma Allergy & Immunology, V19, P162, DOI 10.1089/pai.2006.19.162; Flores G, 2000, PEDIATRICS, V105, P496, DOI 10.1542/peds.105.3.496; Flores G, 2000, J PEDIATR-US, V137, P842, DOI 10.1067/mpd.2000.109150; Gazmararian JA, 1999, JAMA-J AM MED ASSOC, V281, P545, DOI 10.1001/jama.281.6.545; George M, 2006, J GEN INTERN MED, V21, P1317, DOI 10.1111/j.1525-1497.2006.00624.x; Ginde AA, 2008, J ALLERGY CLIN IMMUN, V122, P313, DOI 10.1016/j.jaci.2008.04.024; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Halterman JS, 2002, ARCH PEDIAT ADOL MED, V156, P141, DOI 10.1001/archpedi.156.2.141; Haselkorn T, 2008, ANN ALLERG ASTHMA IM, V101, P256, DOI 10.1016/S1081-1206(10)60490-5; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI 10.1001/archpsyc.62.10.1097; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Hudson CG, 2005, AM J ORTHOPSYCHIAT, V75, P3, DOI 10.1037/0002-9432.75.1.3; Hunninghake GM, 2006, AM J RESP CRIT CARE, V173, P143, DOI 10.1164/rccm.200508-1232SO; Joseph CLM, 2006, J ALLERGY CLIN IMMUN, V117, P233, DOI 10.1016/j.jaci.2005.11.004; Joseph CLM, 1998, J ALLERGY CLIN IMMUN, V101, P484, DOI 10.1016/S0091-6749(98)70355-0; Juhn YJ, 2005, SOC SCI MED, V60, P2453, DOI 10.1016/j.socscimed.2004.11.034; Koinis-Mitchell D, 2007, J PEDIATR PSYCHOL, V32, P582, DOI 10.1093/jpepsy/jsl050; Kozyrskyj AL, 2001, ARCH PEDIAT ADOL MED, V155, P1219; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; Kruse LK, 2007, J ASTHMA, V44, P833, DOI 10.1080/02770900701750163; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; Le TT, 2008, J ASTHMA, V45, P33, DOI 10.1080/02770900701815552; Leventhal T, 2000, PSYCHOL BULL, V126, P309, DOI 10.1037/0033-2909.126.2.309; Lieu TA, 2004, PEDIATRICS, V114, pE102, DOI 10.1542/peds.114.1.e102; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; LINK BG, 1995, J HEALTH SOC BEHAV, V35, P80, DOI 10.2307/2626958; Mansour ME, 2000, PEDIATRICS, V106, P512, DOI 10.1542/peds.106.3.512; McCauley E, 2007, GEN HOSP PSYCHIAT, V29, P214, DOI 10.1016/j.genhosppsych.2007.02.003; McGuire TG, 2006, HEALTH SERV RES, V41, P1979, DOI 10.1111/j.1475-6773.2006.00583.x; McQuaid EL, 2003, J PEDIATR PSYCHOL, V28, P323, DOI 10.1093/jpepsy/jsg022; McQuaid EL, 2007, J PEDIATR PSYCHOL, V32, P167, DOI 10.1093/jpepsy/jsj112; MRAZEK DA, 1991, J AM ACAD CHILD PSY, V30, P277, DOI 10.1097/00004583-199103000-00017; National Asthma Education and Prevention Program Third Expert Panel on the Diagnosis and Management of Asthma, 2007, 3 NAT ASTHM ED PREV; Nativel C, 2007, SEIZ SIECLE, V3, P7; Okelo SO, 2007, J GEN INTERN MED, V22, P976, DOI 10.1007/s11606-007-0209-1; Opolski Melissa, 2005, Clin Pract Epidemiol Ment Health, V1, P18, DOI 10.1186/1745-0179-1-18; Paasche-Orlow MK, 2005, AM J RESP CRIT CARE, V172, P980, DOI 10.1164/rccm.200409-1291OC; PACHTER LM, 1995, ARCH PEDIAT ADOL MED, V149, P982, DOI 10.1001/archpedi.1995.02170220048007; PASSEL J, 2008, IMMIGRANT PLAY LEAD; Pearlman DN, 2006, J NATL MED ASSOC, V98, P239; Rand CS, 2000, J ALLERGY CLIN IMMUN, V105, P83, DOI 10.1016/S0091-6749(00)90182-9; Ren Xinhua S., 1999, Ethnicity and Disease, V9, P151; Richardson LD, 2003, ACAD EMERG MED, V10, P1184, DOI 10.1197/S1069-6563(03)00487-1; Riekert KA, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e214; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Saha C, 2005, ARCH PEDIAT ADOL MED, V159, P759, DOI 10.1001/archpedi.159.8.759; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Sawicki GS, 2008, CLIN PEDIATR, V47, P446, DOI 10.1177/0009922807312184; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Shields AE, 2004, PEDIATRICS, V113, P496, DOI 10.1542/peds.113.3.496; Shields AE, 2007, CHEST, V132, p818S, DOI 10.1378/chest.07-1903; Smedley B. D., 2002, COMMITTEE UNDERSTAND; Subramanian SV, 2005, AM J PUBLIC HEALTH, V95, P260, DOI 10.2105/AJPH.2003.034132; ten Brinke A, 2001, AM J RESP CRIT CARE, V163, P1093, DOI 10.1164/ajrccm.163.5.2004020; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; van Ryn M, 2003, AM J PUBLIC HEALTH, V93, P248, DOI 10.2105/AJPH.93.2.248; Wells K, 2008, AM J RESP CRIT CARE, V178, P1194, DOI 10.1164/rccm.200808-1233OC; Williams DR, 2005, HEALTH AFFAIR, V24, P325, DOI 10.1377/hlthaff.24.2.325; Williams LK, 2007, J ALLERGY CLIN IMMUN, V119, P168, DOI 10.1016/j.jaci.2006.09.029; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008; Wolf MS, 2005, ARCH INTERN MED, V165, P1946, DOI 10.1001/archinte.165.17.1946; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625	96	149	149	2	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1209	1217		10.1016/j.jaci.2009.02.043	http://dx.doi.org/10.1016/j.jaci.2009.02.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	455WO	19447484	Green Accepted			2022-12-18	WOS:000266799100008
J	Detoraki, A; Staiano, RI; Granata, F; Giannattasio, G; Prevete, N; de Paulis, A; Ribatti, D; Genovese, A; Triggiani, M; Marone, G				Detoraki, Aikaterini; Staiano, Rosaria I.; Granata, Francescopaolo; Giannattasio, Giorgio; Prevete, Nella; de Paulis, Amato; Ribatti, Domenico; Genovese, Arturo; Triggiani, Massimo; Marone, Gianni			Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human mast cells; vascular endothelial growth factors; vascular endothelial growth factor receptors; angiogenesis; prostaglandin E-2; adenosine; chemotaxis	UP-REGULATION; EXPRESSION; MACROPHAGES; RECEPTORS; AIRWAYS; FLT-1	Background: Angiogenesis and lymphangiogenesis are critical for several allergic, inflammatory, and neoplastic disorders. Mast cells infiltrate the sites of inflammation and tumors. Objective: We sought to characterize the expression and functions of vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) in human mast cells. Methods: VEGF expression was evaluated by means of RT-PCR and Western blotting in primary human lung mast cells and in the mast cell lines LAD-2 and HMC-1. Angiogenic activity of mast cell supernatants was determined by using the chick embryo chorioallantoic membrane assay. VEGFR expression was assessed by means of RT-PCR and flow cytometry. Modified Boyden chambers were used for chemotaxis assay. Results: Human mast cells express VEGF-A, VEGF-B, VEGF-C, and VEGF-D at both the mRNA and protein level. Prostaglandin E-2 (PGE(2)) enhanced the expression of VEGFA, VEGFB, and VEGFC, whereas an adenosine analog (5'[N-ethylcarboxamido] adenosine [NECA]) increased VEGFA, VEGFC, and VEGFD expression. In addition, PGE(2) and NECA enhanced VEGF-A release, and supernatants of PGE(2)- and NECA-activated human lung mast cells induced angiogenic responses in the chorioallantoic membrane assay that were inhibited by an anti-VEGF-A antibody. Mast cells expressed mRNA for VEGFR1 and VEGFR2. These receptors were present on the mast cell surface. VEGF-A(165), VEGF-B-167, VEGF-C, VEGF-D, and placental growth factor I induced mast cell chemotaxis. These chemotactic effects were mediated by the activation of both VEGFR-1 and VEGFR-2. Conclusion: Our data indicate that human mast cells are both a source and a target of angiogenic and lymphangiogenic factors and therefore might play a role in inflammatory and neoplastic angiogenesis through the expression of several forms of VEGFs and their receptors. (J Allergy Clin Immunol 2009;123: 1142-9.)	[Detoraki, Aikaterini; Staiano, Rosaria I.; Granata, Francescopaolo; Giannattasio, Giorgio; Prevete, Nella; de Paulis, Amato; Genovese, Arturo; Triggiani, Massimo; Marone, Gianni] Univ Naples Federico II, Dept Allergy & Clin Immunol, I-80131 Naples, Italy; [Detoraki, Aikaterini; Staiano, Rosaria I.; Granata, Francescopaolo; Giannattasio, Giorgio; Prevete, Nella; de Paulis, Amato; Genovese, Arturo; Triggiani, Massimo; Marone, Gianni] Univ Naples Federico II, Ctr Basic & Clin Immunol Res CISI, I-80131 Naples, Italy; [Ribatti, Domenico] Univ Bari, Dept Anat & Histol, Bari, Italy	University of Naples Federico II; University of Naples Federico II; Universita degli Studi di Bari Aldo Moro	Marone, G (corresponding author), Univ Naples Federico II, Dept Allergy & Clin Immunol, Via S Pansini 5, I-80131 Naples, Italy.	marone@unina.it	Triggiani, Massimo/K-8271-2016; Detoraki, Aikaterini/AAF-1849-2020	Triggiani, Massimo/0000-0001-7318-2093; Detoraki, Aikaterini/0000-0002-3692-1384; de Paulis, Amato/0000-0003-0347-2540	Ministero dell'Universita e della Ricerca; Istituto Superiore di Sanita [40D.57]; Regione Campania	Ministero dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Istituto Superiore di Sanita; Regione Campania(Regione Campania)	Supported in part by grants from the Ministero dell'Universita e della Ricerca, the Istituto Superiore di Sanita (AIDS Project 40D.57), and Regione Campania.	Abdel-Majid RM, 2004, J IMMUNOL, V172, P1227, DOI 10.4049/jimmunol.172.2.1227; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Boesiger J, 1998, J EXP MED, V188, P1135, DOI 10.1084/jem.188.6.1135; BOWERS HM, 1979, CANCER, V43, P568, DOI 10.1002/1097-0142(197902)43:2<568::AID-CNCR2820430225>3.0.CO;2-#; Cao J, 2005, J IMMUNOL, V174, P7665, DOI 10.4049/jimmunol.174.12.7665; Caruso M, 2006, CURR OPIN PHARMACOL, V6, P251, DOI 10.1016/j.coph.2006.02.002; Chetta A, 2005, CLIN EXP ALLERGY, V35, P1437, DOI 10.1111/j.1365-2222.2005.02360.x; de Paulis A, 2000, J IMMUNOL, V165, P7171, DOI 10.4049/jimmunol.165.12.7171; de Paulis A, 2006, J IMMUNOL, V177, P7322, DOI 10.4049/jimmunol.177.10.7322; Feistritzer C, 2004, AM J RESP CELL MOL, V30, P729, DOI 10.1165/rcmb.2003-0314OC; Feoktistov I, 2003, CIRC RES, V92, P485, DOI 10.1161/01.RES.0000061572.10929.2D; di Agraria F, 2007, AESTIMUM, V50, P1; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; LEFEVER A, 1990, CHEST, V98, P1397, DOI 10.1378/chest.98.6.1397; Nakayama T, 2004, J CLIN INVEST, V114, P1317, DOI 10.1172/JCI200422089; Patella V, 1998, CIRCULATION, V97, P971; Profita M, 2003, J ALLERGY CLIN IMMUN, V112, P709, DOI 10.1016/S0091-6749(03)01889-X; Puxeddu I, 2005, J ALLERGY CLIN IMMUN, V116, P531, DOI 10.1016/j.jaci.2005.06.007; Ribatti D, 2001, CLIN EXP ALLERGY, V31, P602, DOI 10.1046/j.1365-2222.2001.00986.x; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Siddiqui S, 2007, J ALLERGY CLIN IMMUN, V120, P813, DOI 10.1016/j.jaci.2007.05.028; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; Triggiani M, 2007, J ALLERGY CLIN IMMUN, V119, P472, DOI 10.1016/j.jaci.2006.09.027; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Walters EH, 2008, CURR OPIN ALLERGY CL, V8, P39, DOI 10.1097/ACI.0b013e3282f42696; Welsh TJ, 2005, J CLIN ONCOL, V23, P8959, DOI 10.1200/JCO.2005.01.4910; Yano Hiroshi, 1999, Gastric Cancer, V2, P26, DOI 10.1007/s101200050017; Zanini A, 2007, J ALLERGY CLIN IMMUN, V120, P329, DOI 10.1016/j.jaci.2007.04.021	35	149	154	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1142	1149		10.1016/j.jaci.2009.01.044	http://dx.doi.org/10.1016/j.jaci.2009.01.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19275959				2022-12-18	WOS:000266309400024
J	Villa, A; Notarangelo, LD; Roifman, CM				Villa, Anna; Notarangelo, Luigi D.; Roifman, Chaim M.			Omenn syndrome: Inflammation in leaky severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunodeficiency; Omenn syndrome; mutation; SCID	CARTILAGE-HAIR HYPOPLASIA; COMBINED IMMUNE-DEFICIENCY; ALLERGEN-SPECIFIC IMMUNOTHERAPY; ADENOSINE-DEAMINASE DEFICIENCY; V(D)J RECOMBINATION ACTIVITY; BONE-MARROW-TRANSPLANTATION; T-CELL REPERTOIRE; RNASE MRP; PLANT HOMEODOMAIN; MUTATIONS	Omenn syndrome (OS) was reported until recently as a distinct form (phenotype and genotype) of severe combined immunodeficiency (SCID). Similar to other patients with SCID, patients with OS present earl), in infancy with viral or fungal pneumonitis, chronic diarrhea, and failure to thrive. Unlike typical SCID, patients with OS have enlarged lymphoid tissue, severe erythroderma, increased IgE levels, and eosinophilia. The inflammation observed in these patients is believed to be triggered by clonally expanded T cells, which are predominantly of the T(H)2 type. These abnormal T cells, in the absence of proper regulation by other components of the immune system, secrete a host of cytokines that promote autoimmune as well as allergic inflammation. The emergence of these T-cell clones occurs in patients with hypomorphic mutations in recombination activating gene 1 or 2, but not in patients with deleterious mutations in these enzymes which render them inactive. Recently, OS was also identified in a growing list of other leaky SCIDs with mutations in RNA component of mitochondrial RNA processing endoribonuclease, adenosine deaminase, IL-2 receptor gamma, IL-7 receptor alpha, ARTEMIS, and DNA ligase 4. This new information revealed CIS is a distinct inflammatory process that can be associated with genetically diverse leaky SCIDS. (J Allergy Clin Immunol 2008;122: 1082-6.)	[Roifman, Chaim M.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Roifman, Chaim M.] Hosp Sick Children, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada; [Villa, Anna] San Raffaele Telethon Ins Gene Therapy, CNR, Ist Tecnol Biomed, Milan, Italy; [Notarangelo, Luigi D.] Harvard Univ, Childrens Hosp Boston, Sch Med, Div Immunol, Cambridge, MA 02138 USA	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Harvard University; Boston Children's Hospital	Roifman, CM (corresponding author), Hosp Sick Children, Div Allergy Immunol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca	Notarangelo, Luigi D/F-9718-2016	Notarangelo, Luigi D/0000-0002-8335-0262; Villa, Anna/0000-0003-4428-9013	Telethon [TGT06A04] Funding Source: Medline	Telethon(Fondazione Telethon)		Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; BARTH RF, 1972, LANCET, V1, P503; Berthet F, 1996, EUR J PEDIATR, V155, P286; BUSINCO L, 1987, CLIN IMMUNOL IMMUNOP, V44, P123, DOI 10.1016/0090-1229(87)90059-6; Cavadini P, 2005, J CLIN INVEST, V115, P728, DOI 10.1172/JCI200523087; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CLAYTON DA, 1994, P NATL ACAD SCI USA, V91, P4615, DOI 10.1073/pnas.91.11.4615; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; DESAINTBASILE G, 1991, J CLIN INVEST, V87, P1352, DOI 10.1172/JCI115139; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Fallon PG, 2007, NAT REV IMMUNOL, V7, P220, DOI 10.1038/nri2039; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Gennery AR, 2008, CLIN EXP IMMUNOL, V153, P75, DOI 10.1111/j.1365-2249.2008.03681.x; Giliani S, 2006, J PEDIATR-US, V148, P272, DOI 10.1016/j.jpeds.2005.10.004; Gill T, 2004, MOL CELL BIOL, V24, P945, DOI 10.1128/MCB.24.3.945-953.2004; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; GRUNEBAUM E, 2008, J ALLERGY CLIN  1010; HAWRYLOWICZ CM, 2007, NAT REV IMMUNOL, V7, P220; KAVADAS FD, 2008, J ALLERGY CLIN  0917; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Khiong K, 2007, J CLIN INVEST, V117, P1270, DOI 10.1172/JCI30513; Krupica T, 2006, CLIN IMMUNOL, V120, P121, DOI 10.1016/j.clim.2006.04.569; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Li X, 2004, NUCLEIC ACIDS RES, V32, P3703, DOI 10.1093/nar/gkh689; Liu Y, 2007, IMMUNITY, V27, P561, DOI 10.1016/j.immuni.2007.09.005; Makitie O, 2000, J PEDIATR-US, V137, P487, DOI 10.1067/mpd.2000.108102; Makitie O, 1998, EUR J PEDIATR, V157, P816, DOI 10.1007/s004310050943; Marrella V, 2008, TRENDS IMMUNOL, V29, P133, DOI 10.1016/j.it.2007.12.001; Marrella V, 2007, J CLIN INVEST, V117, P1260, DOI 10.1172/JCI30928; Matthews AGW, 2007, NATURE, V450, P1106, DOI 10.1038/nature06431; Mazzolari E, 2005, BONE MARROW TRANSPL, V36, P107, DOI 10.1038/sj.bmt.1705017; MCKUSICK VA, 1965, B J HOPKINS HOSP, V116, P231; MELAMED I, 1994, CLIN EXP IMMUNOL, V95, P14; Nakashima E, 2003, AM J MED GENET A, V123A, P253, DOI 10.1002/ajmg.a.20281; OMENN GS, 1965, NEW ENGL J MED, V273, P427, DOI 10.1056/NEJM196508192730806; Pirovano S, 2003, IMMUNOL LETT, V86, P93, DOI 10.1016/S0165-2478(02)00291-2; Ramon-Maiques S, 2007, P NATL ACAD SCI USA, V104, P18993, DOI 10.1073/pnas.0709170104; Ridanpaa M, 2003, AM J MED GENET C, V121C, P81, DOI 10.1002/ajmg.c.20006; Ridanpaa M, 2002, EUR J HUM GENET, V10, P439, DOI 10.1038/sj.ejhg.5200824; Roifman CM, 2008, BONE MARROW TRANSPL, V41, P947, DOI 10.1038/bmt.2008.11; Roifman CM, 2008, J ALLERGY CLIN IMMUN, V121, P1056, DOI 10.1016/j.jaci.2007.12.1148; Roifman CM, 2006, J ALLERGY CLIN IMMUN, V117, P897, DOI 10.1016/j.jaci.2006.01.003; Roifman CM, 2005, IMMUNOL REV, V203, P143, DOI 10.1111/j.0105-2896.2005.00236.x; Santagata S, 2000, P NATL ACAD SCI USA, V97, P14572, DOI 10.1073/pnas.97.26.14572; SANTISTEBAN I, 1993, J CLIN INVEST, V92, P2291, DOI 10.1172/JCI116833; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; Scheimberg I, 2001, PEDIATR DEVEL PATHOL, V4, P237, DOI 10.1007/s100240010171; Shibata F, 2007, EUR J HAEMATOL, V79, P81, DOI 10.1111/j.1600-0609.2007.00874.x; Signorini S, 1999, BLOOD, V94, P3468, DOI 10.1182/blood.V94.10.3468.422k34_3468_3478; Sobacchi C, 2006, HUM MUTAT, V27, P1174, DOI 10.1002/humu.20408; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; West KL, 2005, IMMUNITY, V23, P203, DOI 10.1016/j.immuni.2005.07.004; WIRT DP, 1989, NEW ENGL J MED, V321, P370, DOI 10.1056/NEJM198908103210606; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zhang JY, 2005, PEDIATRICS, V116, pE445, DOI 10.1542/peds.2005-0369	58	149	154	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1082	1086		10.1016/j.jaci.2008.09.037	http://dx.doi.org/10.1016/j.jaci.2008.09.037			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18992930				2022-12-18	WOS:000261711800006
J	Anderson, SD; Kippelen, P				Anderson, Sandra D.; Kippelen, Pascale			Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						epithelial injury; airway smooth muscle; mast cells; microvascular permeability; eicosanoids; beta(2)-agonists	FISH-OIL SUPPLEMENTATION; INDUCED PLASMA EXUDATION; CROSS-COUNTRY SKIERS; MAST-CELL ACTIVATION; SMOOTH-MUSCLE; BRONCHIAL HYPERRESPONSIVENESS; INDUCED ASTHMA; PASSIVE SENSITIZATION; INDUCED BRONCHOSPASM; INDUCED SPUTUM	Exercise-induced bronchoconstriction (EIB) is a consequence of evaporative water loss in conditioning the inspired air. The water loss causes cooling and dehydration of the airway surface. One acute effect of dehydration is the release of mediators, such as prostaglandins, leukotrienes, and histamine, that can stimulate smooth muscle, causing contraction and a change in vascular permeability. Inspiring cold air increases dehydration of the surface area and causes changes in bronchial blood flow. This article proposes that the pathogenesis of EIB in elite athletes relates to the epithelial injury arising from breathing poorly conditioned air at high flows for long periods of time or high volumes of irritant particles or gases. The evidence to support this proposal comes from many markers of injury. The restorative process after injury involves plasma exudation and movement of cells into the airways, a process repeated many times during a season of training. This process has the potential to expose smooth muscle to a wide variety of plasma- and cell-derived substances. The exposure to these substances over time can lead to an alteration in the contractile properties of the smooth muscle, making it more sensitive to mediators of bronchoconstriction. It is proposed that cold-weather athletes have airway hyperresponsiveness (AHR) to pharmacollogic agents as a result of epithelial injury. In those who are allergic, AIIR can also be expressed as EIB. The role of beta(2)-receptor agonists in inhibiting and enhancing the development of AHR and EIB is discussed.	[Anderson, Sandra D.] Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Camperdown, NSW 2050, Australia; Univ Aberdeen, Sch Med Sci, Aberdeen AB9 1FX, Scotland	University of Sydney; University of Aberdeen	Anderson, SD (corresponding author), Royal Prince Alfred Hosp, Dept Resp & Sleep Med, 11 W,50 Missenden Rd, Camperdown, NSW 2050, Australia.	sandya@med.usyd.edu.au	Kippelen, Pascale/ABH-2996-2020	Anderson, Sandra/0000-0002-6308-8770				AITKEN ML, 1985, AM REV RESPIR DIS, V131, P357; Ammit AJ, 1997, AM J RESP CRIT CARE, V155, P1123, DOI 10.1164/ajrccm.155.3.9116997; Ammit AJ, 2000, AM J RESP CRIT CARE, V161, P257, DOI 10.1164/ajrccm.161.1.9901005; Anderson GP, 2006, CLIN REV ALLERG IMMU, V31, P119, DOI 10.1385/CRIAI:31:2:119; Anderson SD, 2006, CLIN REV ALLERG IMMU, V31, P163, DOI 10.1385/CRIAI:31:2:163; Anderson Sandra D, 2004, Paediatr Drugs, V6, P161, DOI 10.2165/00148581-200406030-00003; ANDERSON SD, 1979, LANCET, V2, P629; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; Anderson SD, 2006, J ALLERGY CLIN IMMUN, V117, P767, DOI 10.1016/j.jaci.2005.12.1355; Anderson SD, 2005, CURR ALLERGY ASTHM R, V5, P116, DOI 10.1007/s11882-005-0084-y; Anderson SD, 2003, J ALLERGY CLIN IMMUN, V111, P45, DOI 10.1067/mai.2003.1; ANDERSON SD, 1992, THORAX, V47, P748, DOI 10.1136/thx.47.9.748; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; ANTICEVICH SZ, 1995, EUR J PHARMACOL, V284, P221, DOI 10.1016/0014-2999(95)00463-U; Anticevich SZ, 1996, CLIN EXP ALLERGY, V26, P549, DOI 10.1046/j.1365-2222.1996.d01-341.x; ARGYROS GJ, 1993, AM REV RESPIR DIS, V147, P1419, DOI 10.1164/ajrccm/147.6_Pt_1.1419; BACKER V, 1991, J ALLERGY CLIN IMMUN, V88, P68, DOI 10.1016/0091-6749(91)90302-5; Baki A, 2002, ARCH DIS CHILD, V86, P38, DOI 10.1136/adc.86.1.38; BALUK P, 1994, AM J PHYSIOL, V266, pL461, DOI 10.1152/ajplung.1994.266.4.L461; BANNER AS, 1984, NEW ENGL J MED, V311, P883, DOI 10.1056/NEJM198410043111404; Baraniuk JN, 1999, AM J RESP CRIT CARE, V160, P655, DOI 10.1164/ajrccm.160.2.9805081; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; Berger P, 1998, AM J RESP CRIT CARE, V157, P610, DOI 10.1164/ajrccm.157.2.9707042; Bernard A, 2005, TOXICOL APPL PHARM, V206, P185, DOI 10.1016/j.taap.2004.10.022; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; Bernard A, 2007, PEDIATRICS, V119, P1095, DOI 10.1542/peds.2006-3333; Bernard A, 2006, ENVIRON HEALTH PERSP, V114, P1567, DOI 10.1289/ehp.8461; Bonsignore MR, 2001, AM J PHYSIOL-LUNG C, V281, pL668, DOI 10.1152/ajplung.2001.281.3.L668; Bonsignore MR, 2003, MED SCI SPORT EXER, V35, P1146, DOI 10.1249/01.MSS.0000074581.08023.25; Boulet LP, 2005, CLIN INVEST MED, V28, P15; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Brannan JD, 2006, EUR RESPIR J, V27, P944, DOI 10.1183/09031936.06.00078205; Brannan JD, 2003, EUR RESPIR J, V22, P491, DOI 10.1183/09031936.03.00113403; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Broeckaert F, 2000, ENVIRON HEALTH PERSP, V108, P533, DOI 10.2307/3454615; Button B, 2007, J PHYSIOL-LONDON, V580, P577, DOI 10.1113/jphysiol.2006.126086; Caillaud C, 2003, CAN J APPL PHYSIOL, V28, P793, DOI 10.1139/h03-059; Carbonnelle S, 2002, BIOMARKERS, V7, P464, DOI 10.1080/13547500210166612; Carroll NG, 2002, THORAX, V57, P677, DOI 10.1136/thorax.57.8.677; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Chen BT, 2000, AM J RESP CRIT CARE, V162, P1715, DOI 10.1164/ajrccm.162.5.9912120; Chen BT, 2001, J APPL PHYSIOL, V90, P821, DOI 10.1152/jappl.2001.90.3.821; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; Chetta A, 2007, PULM PHARMACOL THER, V20, P1, DOI 10.1016/j.pupt.2005.10.009; Chimenti L, 2007, AM J RESP CRIT CARE, V175, P442, DOI 10.1164/rccm.200608-1086OC; Cockcroft DW, 1998, J ALLERGY CLIN IMMUN, V102, pS96, DOI 10.1016/S0091-6749(98)70038-7; Coreno A, 2000, J ALLERGY CLIN IMMUN, V106, P500; Crimi N, 2005, J ALLERGY CLIN IMMUN, V115, P870, DOI 10.1016/j.jaci.2005.01.041; Dahlen SE, 2004, THORAX, V59, P453, DOI 10.1136/thx.2004.026641; Davis Beth E, 2003, Can Respir J, V10, P23; DAVISKAS E, 1991, RESP PHYSIOL, V84, P115, DOI 10.1016/0034-5687(91)90023-C; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Duong M, 2008, CHEST, V133, P404, DOI 10.1378/chest.07-2048; Dwyer TM, 1997, AM J PHYSIOL-LUNG C, V272, pL1121, DOI 10.1152/ajplung.1997.272.6.L1121; Ernst P, 2002, EUR RESPIR J, V20, P635, DOI 10.1183/09031936.02.00962002; Evans DW, 1997, THORAX, V52, P136, DOI 10.1136/thx.52.2.136; Fernandes DJ, 2003, J APPL PHYSIOL, V95, P844, DOI 10.1152/japplphysiol.00192.2003; FISCHER AR, 1995, AM J RESP CRIT CARE, V152, P1203, DOI 10.1164/ajrccm.152.4.7551371; Fitch KD, 2006, CLIN REV ALLERG IMMU, V31, P259, DOI 10.1385/CRIAI:31:2:259; Folkesson HG, 1996, J CLIN INVEST, V97, P664, DOI 10.1172/JCI118463; Freed AN, 1997, J APPL PHYSIOL, V83, P1884, DOI 10.1152/jappl.1997.83.6.1884; FROSSARD N, 1989, J PHARMACOL EXP THER, V248, P292; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gleeson M, 2007, J APPL PHYSIOL, V103, P693, DOI 10.1152/japplphysiol.00008.2007; Greiff L, 2003, CLIN PHYSIOL FUNCT I, V23, P301, DOI 10.1046/j.1475-0961.2003.00519.x; Greiff L, 2005, CLIN PHYSIOL FUNCT I, V25, P241, DOI 10.1111/j.1475-097X.2005.00615.x; Greiff L, 1998, THORAX, V53, P1010, DOI 10.1136/thx.53.12.1010; Gulliksson M, 2006, ALLERGY, V61, P1473, DOI 10.1111/j.1398-9995.2006.01213.x; Gulliksson M, 2007, BBA-MOL CELL BIOL L, V1771, P1156, DOI 10.1016/j.bbalip.2007.06.001; HABY MM, 1994, EUR RESPIR J, V7, P43, DOI 10.1183/09031936.94.07010043; Hallstrand TS, 2007, AM J RESP CRIT CARE, V176, P1072, DOI 10.1164/rccm.200707-1088OC; Hallstrand TS, 2007, J ALLERGY CLIN IMMUN, V119, P1092, DOI 10.1016/j.jaci.2007.01.005; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Hancox RJ, 2002, AM J RESP CRIT CARE, V165, P1068, DOI 10.1164/ajrccm.165.8.200111-091bc; Haney S, 2005, RESP MED, V99, P566, DOI 10.1016/j.rmed.2004.10.014; Haney S, 2006, CLIN REV ALLERG IMMU, V31, P181, DOI 10.1385/CRIAI:31:2:181; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; Hashimoto S, 2000, AM J RESP CRIT CARE, V162, P1075, DOI 10.1164/ajrccm.162.3.9911099; Helenius I, 2002, J ALLERGY CLIN IMMUN, V109, P962, DOI 10.1067/mai.2002.124769; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646, DOI 10.1016/S0091-6749(98)70173-3; Hemingson Howard B, 2004, Can Respir J, V11, P399; Hermans C, 1998, EUR RESPIR J, V11, P801, DOI 10.1183/09031936.98.11040801; Hilberg T, 2007, CURR ALLERGY ASTHM R, V7, P27, DOI 10.1007/s11882-007-0027-x; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; Holzer K, 2003, AM J RESP CRIT CARE, V167, P534, DOI 10.1164/rccm.200208-916OC; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Johnson M, 2006, J ALLERGY CLIN IMMUN, V117, P18, DOI 10.1016/j.jaci.2005.11.012; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; Jonasson G, 2000, PEDIATR ALLERGY IMMU, V11, P120, DOI 10.1034/j.1399-3038.2000.00067.x; JONES A, 1994, BRIT J GEN PRACT, V44, P127; Joos GF, 2004, EUR RESPIR J, V23, P76, DOI 10.1183/09031936.03.00101902; Kanazawa H, 2002, CHEST, V122, P166, DOI 10.1378/chest.122.1.166; Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885; KANAZAWA H, 2007, DRUG TARGETS, V6, P133; Kanazawa H, 2008, J ALLERGY CLIN IMMUN, V121, P390, DOI 10.1016/j.jaci.2007.09.026; Kanazawa H, 2007, CHEST, V131, P1035, DOI 10.1378/chest.06-2758; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; Kay LJ, 2007, BRIT J PHARMACOL, V152, P323, DOI 10.1038/sj.bjp.0707400; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Koskela H, 2000, CLIN EXP ALLERGY, V30, P1627; Kujala UM, 2003, ARCH INTERN MED, V163, P1064, DOI 10.1001/archinte.163.9.1064; Lakind JS, 2007, BIOMARKERS, V12, P445, DOI 10.1080/13547500701359327; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479, DOI 10.1164/ajrccm.161.5.9909008; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; Lazarowski ER, 2004, J BIOL CHEM, V279, P36855, DOI 10.1074/jbc.M405367200; Leuppi JD, 1998, EUR RESPIR J, V12, P13, DOI 10.1183/09031936.98.12010013; Mak JCW, 2000, MOL PHARMACOL, V57, P857; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; MCFADDEN ER, 1990, LANCET, V335, P880, DOI 10.1016/0140-6736(90)90478-N; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; McGraw DW, 2007, J CLIN INVEST, V117, P1391, DOI 10.1172/JCI30489; McGraw Dennis W, 2005, Proc Am Thorac Soc, V2, P292, DOI 10.1513/pats.200504-027SR; McGraw DW, 2003, J CLIN INVEST, V112, P619, DOI 10.1172/JCI200318193; McGraw DW, 2005, P AM THORAC SOC, V2, P311; Mickleborough TD, 2006, CHEST, V129, P39, DOI 10.1378/chest.129.1.39; Mickleborough TD, 2003, AM J RESP CRIT CARE, V168, P1181, DOI 10.1164/rccm.200303-373OC; Moloney ED, 2003, RESP MED, V97, P1; Nagase T, 1996, AM J RESP CRIT CARE, V154, P1551, DOI 10.1164/ajrccm.154.5.8912779; NALINE E, 1989, AM REV RESPIR DIS, V140, P679, DOI 10.1164/ajrccm/140.3.679; Nanson CJ, 2001, RESP PHYSIOL, V127, P259, DOI 10.1016/S0034-5687(01)00251-1; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; NIEMAN DC, 1990, J SPORT MED PHYS FIT, V30, P316; Nightingale JA, 1999, THORAX, V54, P1061, DOI 10.1136/thx.54.12.1061; OCAIN CF, 1980, J APPL PHYSIOL, V49, P875, DOI 10.1152/jappl.1980.49.5.875; OMORI C, 1995, J APPL PHYSIOL, V78, P2169, DOI 10.1152/jappl.1995.78.6.2169; OMORI C, 1995, J APPL PHYSIOL, V78, P1043, DOI 10.1152/jappl.1995.78.3.1043; Page S, 2001, AM J PHYSIOL-LUNG C, V281, pL1313, DOI 10.1152/ajplung.2001.281.6.L1313; PERSSON CG, 2008, PULMONARY EPITHELIUM; Persson CGA, 1996, PULM PHARMACOL THER, V9, P129, DOI 10.1006/pulp.1996.0015; PERSSON CGA, 1991, CLIN EXP ALLERGY, V21, P17, DOI 10.1111/j.1365-2222.1991.tb00799.x; Persson CGA, 1998, EUR RESPIR J, V11, P958, DOI 10.1183/09031936.98.11040958; PISARRI TE, 1992, J APPL PHYSIOL, V73, P2305, DOI 10.1152/jappl.1992.73.6.2305; Potts, 1994, THESIS U BRIT COLUMB; Potts J, 1996, SPORTS MED, V21, P256, DOI 10.2165/00007256-199621040-00002; ProvostCraig MA, 1996, J ASTHMA, V33, P67, DOI 10.3109/02770909609077764; Rouadi P, 1999, J APPL PHYSIOL, V87, P400, DOI 10.1152/jappl.1999.87.1.400; Rundell KW, 2005, INHAL TOXICOL, V17, P99, DOI 10.1080/08958370590899479; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; Schmidt D, 1999, EUR RESPIR J, V14, P315, DOI 10.1034/j.1399-3003.1999.14b13.x; SOLWAY J, 1991, J APPL PHYSIOL, V71, P2077, DOI 10.1152/jappl.1991.71.6.2077; SONT JK, 1995, AM J RESP CRIT CARE, V152, P38, DOI 10.1164/ajrccm.152.1.7599850; Stensrud T, 2007, MED SCI SPORT EXER, V39, P1681, DOI 10.1249/mss.0b013e31813738ac; Storms W, 2004, RESP MED, V98, P1051, DOI 10.1016/j.rmed.2004.05.008; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048; Sue-Chu M, 2000, RESPIRATION, V67, P417, DOI 10.1159/000029541; Sue-Chu M, 1999, RESP MED, V93, P719, DOI 10.1016/S0954-6111(99)90039-2; Sue-Chu M, 2002, EUR RESP J S38, V20, p410s; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; Swystun VA, 2000, J ALLERGY CLIN IMMUN, V106, P57; van der Woude HJ, 2001, THORAX, V56, P529, DOI 10.1136/thorax.56.7.529; Van Rensen ELJ, 2002, AM J RESP CRIT CARE, V165, P1275, DOI 10.1164/rccm.2110092; Watson N, 1998, CLIN EXP ALLERGY, V28, P679, DOI 10.1046/j.1365-2222.1998.00269.x; Watson N, 1997, AM J RESP CRIT CARE, V155, P839, DOI 10.1164/ajrccm.155.3.9117014; Weinberger M, 2006, NEW ENGL J MED, V355, P852, DOI 10.1056/NEJMc066282; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879	163	149	151	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					225	235		10.1016/j.jaci.2008.05.001	http://dx.doi.org/10.1016/j.jaci.2008.05.001			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18554705				2022-12-18	WOS:000258426300001
J	Vierk, KA; Koehler, KM; Fein, SB; Street, DA				Vierk, Katherine A.; Koehler, Kathleen M.; Fein, Sara B.; Street, Debra A.			Prevalence of self-reported food allergy in American adults and use of food labels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; food labeling; prevalence	POPULATION	Background: Few population-based studies in the United States have determined the prevalence of food allergy in adults and the problems these individuals might have with reading food labels. Objective: The objectives of this study are to report the prevalence of self-reported food allergy, to identify the characteristics of food allergy reactions, and to describe the use of labels among adults with food allergy. Methods: Questions from the US Food and Drug Administration's 2001 Food Safety Survey were analyzed to determine the prevalence of food allergy and opinions about food labels in the management of food allergy. Results: The prevalence of self-reported food allergy is 9.1% among all survey respondents, with 5.3% of all respondents reporting a doctor-diagnosed food allergy. The prevalence of food allergy to the 8 most common allergens (peanut, tree nuts, egg, milk, wheat, soybeans, fish, and crustacean shellfish) is self-reported as 2.7% among respondents with doctors' diagnoses. Several label issues, such as words on some ingredient lists being too technical or hard to understand and food labels not always alerting persons to new ingredients, were reported as serious or very serious obstacles for managing an allergy. Conclusion: The prevalence of self-reported doctor-diagnosed food allergy among US adults is 5.3%, and a large portion of adults with food allergy found certain label issues a serious problem for managing their food allergy. Clinical implications: The findings provide a needed source of population-based prevalence data of food allergy among US adults. Label issues identified are useful in understanding the difficulties of managing a food allergy.	US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD 20740 USA	US Food & Drug Administration (FDA)	Vierk, KA (corresponding author), US FDA, Ctr Food Safety & Appl Nutr, 5100 Paint Branch Pkwy,HFS 728, College Pk, MD 20740 USA.	katherine.vierk@fda.hhs.gov						Altman DR, 1996, J ALLERGY CLIN IMMUN, V97, P1247, DOI 10.1016/S0091-6749(96)70192-6; Altschul AS, 2001, J ALLERGY CLIN IMMUN, V108, P468, DOI 10.1067/mai.2001.117794; *AM ASS PUBL OP RE, 2000, STAND DEF FIN DISP C; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; Joshi P, 2002, J ALLERGY CLIN IMMUN, V109, P1019, DOI 10.1067/mai.2002.123305; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Schafer T, 2001, ALLERGY, V56, P1172, DOI 10.1034/j.1398-9995.2001.00196.x; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sjoberg O, 1996, ANN ALLERG ASTHMA IM, V77, P327; *US FDA, 2005, SECT 555250 STAT POL; Woods RK, 2001, EUR J CLIN NUTR, V55, P298, DOI 10.1038/sj.ejcn.1601159; Zuberbier T, 2004, ALLERGY, V59, P338, DOI 10.1046/j.1398-9995.2003.00403.x; 2004, FOOD STANDARDS AUSTR; 2007, CURRENT POPULATIONS	17	149	152	1	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1504	1510		10.1016/j.jaci.2007.03.011	http://dx.doi.org/10.1016/j.jaci.2007.03.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17451802				2022-12-18	WOS:000247232800028
J	de Marco, R; Marcon, A; Jarvis, D; Accordini, S; Almar, E; Bugiani, M; Carolei, A; Cazzoletti, L; Corsico, A; Gislason, D; Gulsvik, A; Jogi, R; Marinoni, A; Martinez-Moratalla, J; Pin, I; Janson, C				de Marco, Roberto; Marcon, Alessandro; Jarvis, Deborah; Accordini, Simone; Almar, Enrique; Bugiani, Massimiliano; Carolei, Adriana; Cazzoletti, Lucia; Corsico, Angelo; Gislason, David; Gulsvik, Amund; Jogi, Rain; Marinoni, Alessandra; Martinez-Moratalla, Jesus; Pin, Isabelle; Janson, Christer		European Comm Respiratory Hlth Sur	Prognostic factors of asthma severity: A 9-year international prospective cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; severity; prognostic factors; prospective cohort study; IgE; body mass index; asthma remission; European Community Respiratory Health Survey; ECRHS; global initiative for asthma (GINA) guidelines	SERUM IGE LEVELS; BODY-MASS INDEX; IMMUNOGLOBULIN-E; YOUNG-ADULTS; WEIGHT-LOSS; CHILDHOOD; RESPONSIVENESS; PREVALENCE; EXPOSURES; CHILDREN	Background: The natural history of asthma severity is poorly known. Objective: To investigate prognostic factors of asthma severity. Methods: All current patients with asthma identified in 1991 to 1993 in the European Community Respiratory Health Survey were followed up, and their severity was assessed in 2002 by using the Global Initiative for Asthma categorization (n = 856). Asthma severity (remittent, intermittent, mild, moderate, severe) was related to potential determinants evaluated at baseline and during the follow-up by a multinomial logistic model, using the intermittent group as the reference category for relative risk ratios (RRRs). Results: Asthma severity measured at baseline was a determinant of a patient's severity at the end of the follow-up. At baseline, severe persistent had a poorer FEV1% predicted, a poorer symptom control, higher IgE levels (RRR, 2.06; 95% CI, 1.38-3.06), and a higher prevalence of chronic cough/mucus hypersecretion (RRR, 4.90; 95% CI, 2.18-11.02) than patients with intermittent asthma. Moderate persistent showed the same prognostic factors as severe persistent, even if the associations were weaker. Mild persistent had a distribution of prognostic factors that was similar to patients with intermittent asthma, although the former showed a poorer symptom control than the latter. Remission mainly occurred in patients with less severe asthma and was negatively associated with a change in body mass index (RRR, 0.86; 95% CI, 0.75-0.97). Allergic rhinitis, smoking, and respiratory infections in childhood were not associated with asthma severity. Conclusion: Patients with moderate and severe persistent asthma are characterized by early deterioration of lung function. High IgE levels and persistent cough/mucus hypersecretion are strong markers of moderate/severe asthma, which seems to be a different phenotype from mild persistent or intermittent asthma. Clinical implications: Our results suggest that the evolution of asthma severity is to a large extent predictable.	Univ Verona, Ist Biol 2, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, I-37134 Verona, Italy; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Respirol Epidemiol & Publ Hlth, London, England; Publ Hlth Dept Castilla La Mancha, Epidemiol Unit, Albacete, Spain; Azienda Sanitaria Locale Piemonte 4, Consorzio Provinciale AntiTB, Unit Pneumol, Turin, Italy; Univ Pavia, Fac Med, Dept Appl Hlth Sci, I-27100 Pavia, Italy; Landspitali Univ Hosp, Dept Allergy Resp Med & Sleep, Reykjavik, Iceland; Univ Bergen, Haukeland Univ Hosp, Dept Thorac Med, Bergen, Norway; Fdn Tartu Univ Clin, Lung Clin, Tartu, Estonia; Univ Pavia, San Matteo Hosp, Ist Ricovero & Cura Carattere Sci, Div Resp Dis, I-27100 Pavia, Italy; CHU Grenoble, Dept Pediat, F-38043 Grenoble, France; Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden	University of Verona; Imperial College London; University of Pavia; Landspitali National University Hospital; University of Bergen; Haukeland University Hospital; IRCCS Fondazione San Matteo; University of Pavia; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Uppsala University	de Marco, R (corresponding author), Univ Verona, Ist Biol 2, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, Strada Grazie 8, I-37134 Verona, Italy.	roberto.demarco@univr.it	Carolei, Adriana/AAQ-7656-2021; SESM, SESM/C-1440-2008; Corsico, Angelo Guido/AAC-8138-2019	Carolei, Adriana/0000-0002-5254-8532; Corsico, Angelo Guido/0000-0002-8716-4694; Marcon, Alessandro/0000-0002-2778-658X; Jarvis, Deborah/0000-0002-1753-3896				Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Akerman MJH, 2004, J ASTHMA, V41, P521, DOI 10.1081/JAS-120037651; Backman KS, 1997, CHEST, V112, P1234, DOI 10.1378/chest.112.5.1234; Balzano G, 2001, ALLERGY, V56, P13, DOI 10.1034/j.1398-9995.2001.00128.x; Barnes NC, 2004, AM J RESP CRIT CARE, V170, P830, DOI 10.1164/rccm.2408006; Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Burnham K.P., 2002, MODEL SELECTION MULT, V2nd Edn, DOI 10.1007/b97636; BURROWS B, 1987, AM REV RESPIR DIS, V135, P788, DOI 10.1164/arrd.1987.135.4.788; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Chinn S, 2005, AM J RESP CRIT CARE, V172, P956, DOI 10.1164/rccm.200503-323OC; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Colice GL, 2003, CHEST, V124, P2054, DOI 10.1378/chest.124.6.2054; de Marco R, 1998, EUR RESPIR J, V11, P599; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; de Marco R, 2003, ALLERGY, V58, P221, DOI 10.1034/j.1398-9995.2003.00059.x; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Le Moual N, 2004, AM J EPIDEMIOL, V160, P1108, DOI 10.1093/aje/kwh316; Liard R, 2000, EUR RESPIR J, V16, P615, DOI 10.1034/j.1399-3003.2000.16d08.x; Luder E, 2004, RESP MED, V98, P29, DOI 10.1016/j.rmed.2003.08.004; MACGREGOR AMC, 1993, OBES SURG, V3, P15, DOI 10.1381/096089293765559700; Martinez FD, 2001, J ALLERGY CLIN IMMUN, V107, pS449, DOI 10.1067/mai.2001.114993; *NAT HEART LUNG BL, 1995, GLOB IN ASTHM GLOB S; Olivieri M, 2002, ALLERGY, V57, P600, DOI 10.1034/j.1398-9995.2002.23537.x; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123, DOI 10.1164/ajrccm.157.1.9612063; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Peat JK, 1996, ALLERGY, V51, P804, DOI 10.1111/j.1398-9995.1996.tb00026.x; Prescott E, 1997, THORAX, V52, P287, DOI 10.1136/thx.52.3.287; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Sears MR, 2000, CLIN CHEST MED, V21, P315, DOI 10.1016/S0272-5231(05)70269-0; Shadick NA, 1996, THORAX, V51, P787, DOI 10.1136/thx.51.8.787; SHIMURA S, 1988, CHEST, V94, P1211, DOI 10.1378/chest.94.6.1211; Siroux V, 2003, CLIN EXP ALLERGY, V33, P746, DOI 10.1046/j.1365-2222.2003.01674.x; SLUITER HJ, 1991, EUR RESPIR J, V4, P479; Spivak H, 2005, AM J SURG, V189, P27, DOI 10.1016/j.amjsurg.2004.06.038; Stirling RG, 2001, ALLERGY, V56, P825, DOI 10.1034/j.1398-9995.2001.00143.x; Sullivan Sean D, 2003, J Manag Care Pharm, V9, P3; SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511, DOI 10.1164/ajrccm.163.2.2001038; Thomson CC, 2003, CHEST, V124, P795, DOI 10.1378/chest.124.3.795; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; Wenzel S, 2003, CLIN EXP ALLERGY, V33, P1622, DOI 10.1111/j.1365-2222.2003.01799.x	48	149	149	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1249	1256		10.1016/j.jaci.2006.03.019	http://dx.doi.org/10.1016/j.jaci.2006.03.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750983				2022-12-18	WOS:000238332300008
J	Moffitt, JE; Golden, DBK; Reisman, RE; Lee, R; Nicklas, R; Freeman, T; deShazo, R; Tracy, J; Bernstein, IL; Blessing-Moore, J; Khan, DA; Lang, DM; Portnoy, JM; Schuller, DE; Spector, SL; Tilles, SA				Moffitt, JE; Golden, DBK; Reisman, RE; Lee, R; Nicklas, R; Freeman, T; deShazo, R; Tracy, J; Bernstein, IL; Blessing-Moore, J; Khan, DA; Lang, DM; Portnoy, JM; Schuller, DE; Spector, SL; Tilles, SA			Stinging insect hypersensitivity: A practice parameter update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IMPORTED FIRE ANT; HYMENOPTERA VENOM IMMUNOTHERAPY; WHOLE-BODY EXTRACTS; ANTIGENIC CROSS-REACTIVITY; BETA-BLOCKER DRUGS; SOLENOPSIS-INVICTA; SERUM SICKNESS; YELLOW JACKET; ALLERGIC PATIENTS; NATURAL-HISTORY											BERNSTEIN DI, 1989, J ALLERGY CLIN IMMUN, V84, P951, DOI 10.1016/0091-6749(89)90394-1; BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P944, DOI 10.1016/0091-6749(89)90393-X; Brehler R, 2000, J ALLERGY CLIN IMMUN, V105, P1231, DOI 10.1067/mai.2000.105708; BUTCHER BT, 1988, J ALLERGY CLIN IMMUN, V81, P1096, DOI 10.1016/0091-6749(88)90875-5; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; DeBandt M, 1997, J RHEUMATOL, V24, P1195; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; FRANKEN HH, 1994, J ALLERGY CLIN IMMUN, V93, P431, DOI 10.1016/0091-6749(94)90351-4; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; Goldberg A, 2001, J ALLERGY CLIN IMMUN, V107, P902, DOI 10.1067/mai.2001.114986; Goldberg A, 1997, J ALLERGY CLIN IMMUN, V100, P182, DOI 10.1016/S0091-6749(97)70222-7; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573, DOI 10.1016/S0091-6749(98)70161-7; GRANT DF, 1984, J PEDIATR, V104, P664; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V87, P134, DOI 10.1016/S1081-1206(10)62207-7; HANNAN CJ, 1986, J ALLERGY CLIN IMMUN, V78, P331, DOI 10.1016/S0091-6749(86)80085-9; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; Hermann K, 1997, INT ARCH ALLERGY IMM, V112, P251, DOI 10.1159/000237462; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; Kemp SF, 2000, J ALLERGY CLIN IMMUN, V105, P683, DOI 10.1067/mai.2000.105707; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; LICHTENSTEIN LM, 1983, HOSP PRACT, V18, P36; Light WC, 2001, J ALLERGY CLIN IMMUN, V107, P925, DOI 10.1067/mai.2001.114985; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P391, DOI 10.1016/0091-6749(77)90024-0; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; Moffitt JE, 1997, ANN ALLERG ASTHMA IM, V79, P125, DOI 10.1016/S1081-1206(10)63098-0; MUELLER U, 1991, Journal of Allergy and Clinical Immunology, V87, P702; NICKLAS RA, 1998, J ALLERGY CLIN IMMUN, V101, pS465; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1984, J ALLERGY CLIN IMMUN, V73, P246, DOI 10.1016/S0091-6749(84)80015-9; Reisman RE, 2001, J ALLERGY CLIN IMMUN, V107, P781, DOI 10.1067/mai.2001.115042; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V84, P331, DOI 10.1016/0091-6749(89)90417-X; RHOADES RB, 1977, J FLA MED ASSOC, V64, P247; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; Rueff F, 2001, J ALLERGY CLIN IMMUN, V107, P928; SETTIPANE G, 1970, ACTA ALLERGOL, V25, P292; Simon P, 1996, NEPHROLOGIE, V17, P163; Stafford CT, 1996, ANN ALLERG ASTHMA IM, V77, P87, DOI 10.1016/S1081-1206(10)63493-X; STROM GB, 1983, J ALLERGY CLIN IMMUN, V72, P46, DOI 10.1016/0091-6749(83)90051-9; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TRACY JM, 1995, J ALLERGY CLIN IMMUN, V95, P824, DOI 10.1016/S0091-6749(95)70125-7; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VALENTINE MD, 1993, ANN INTERN MED, V118, P225, DOI 10.7326/0003-4819-118-3-199302010-00013; VALENTINE MD, 1993, ANN ALLERGY, V70, P427; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; Yocum MW, 1996, J ALLERGY CLIN IMMUN, V97, P1424, DOI 10.1016/S0091-6749(96)70217-8	72	149	157	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					869	886		10.1016/j.jaci.2004.07.046	http://dx.doi.org/10.1016/j.jaci.2004.07.046			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480329				2022-12-18	WOS:000224439100023
J	Gelfand, EW				Gelfand, Erwin W.			Inflammatory mediators in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; inflammation; inflammatory mediators; asthma; chronotherapy; chronobiology; unified airway	ANTIGEN CHALLENGE; NASAL SECRETIONS; MAST-CELLS; ASTHMA; EXPOSURE; EXPRESSION; EOSINOPHILS; IMMUNOLOGY; HISTAMINE; AIRWAYS	Allergic rhinitis (AR) is part of a systemic disease complex. There is a close relationship between AR and asthma, which has led to the "one airway, one disease" concept. Both conditions share common immunopathology and pathophysiology. In patients with AR, allergen-triggered early and late responses are mediated by a series of inflammatory cells. Within minutes of contact with allergen, IgE-sensitized mast cells degranulate, releasing both preformed and newly synthesized mediators. Immunologic processes in both nasal and bronchial tissue involve T(H)2 lymphocytes and eosinophils. Eosinophils are the predominant cell in the chronic inflammatory process characteristic of the late-phase allergic response. Eosinophils release an array of proinflammatory mediators, including cysteinyl leukotrienes, cationic proteins, eosinophil peroxidase, and major basic protein, and might serve as a major source of IL-3, IL-5, GM-CSF, and IL-13. Neuropeptides also appear to contribute to the pathophysiology of AR symptoms. Both AR and asthma exhibit marked day-night variation in symptom severity. Acknowledging both the chronobiology of AR and circadian rhythm-dependent attributes of antiallergy medications might enhance the beneficial effects of allergy therapies. (J Allergy Clin Immunol 2004; 114: S135-8.)			Gelfand, EW (corresponding author), Care of Sweetman L, Amer Acad Allergy Asthma & Immunol, 611 E Wells St, Milwaukee, WI 53202 USA.							Adam PJ, 1999, CURRENT ESTIMATES NA, P1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BINDER E, 1982, ALLERGY, V37, P389, DOI 10.1111/j.1398-9995.1982.tb02317.x; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; Bjornsdottir US, 1999, ALLERGY, V54, P55, DOI 10.1111/j.1398-9995.1999.tb04389.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Gelfaned EW, 2002, AM J MED, V113, p2S; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Howarth PH, 1997, ALLERGY, V52, P12, DOI 10.1111/j.1398-9995.1997.tb04878.x; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; LARSEN WJ, 2001, HUMAN EMBRYOLOGY, P351; Ledford DK, 1998, J RESP DIS, V19, P576; MA X, 2000, AM J CRIT CARE MED, V161, P325; MARTIN RJ, 1993, NOCTURNAL ASTHMA MEC; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; OKUDA M, 1988, ANN ALLERGY, V60, P537; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; REINBERG A, 1988, J ALLERGY CLIN IMMUN, V81, P51, DOI 10.1016/0091-6749(88)90220-5; REINBERG A, 1989, CHRONOPHARMACOLOGY C, P115; Reinberg A, 1985, ANN REV CHRONOPHARMA, V3, P441; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; SMOLENSKY MH, 1995, J ALLERGY CLIN IMMUN, V95, P1087; Spada CS, 1997, ADV EXP MED BIOL, V400, P699; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Togias A, 2000, J ALLERGY CLIN IMMUN, V105, pS599, DOI 10.1067/mai.2000.106885; Trousseau A, 1865, CLIN MED HOTEL DIEU, V2, P373; VIEGAS M, 1987, BRIT MED J, V294, P414, DOI 10.1136/bmj.294.6569.414; WANG DY, 1995, INT ARCH ALLERGY IMM, V106, P278, DOI 10.1159/000236855; WANG DY, 1994, ACTA OTO-LARYNGOL, V114, P552, DOI 10.3109/00016489409126103; WHITE MV, 1992, J ALLERGY CLIN IMMUN, V90, P699, DOI 10.1016/0091-6749(92)90155-U; WRIGHT AL, 1994, PEDIATRICS, V94, P895	39	149	158	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		2004	114	5		S			S135	S138		10.1016/j.jaci.2004.08.043	http://dx.doi.org/10.1016/j.jaci.2004.08.043			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V17HV	15536444	Bronze			2022-12-18	WOS:000207929200002
J	Schocker, F; Luttkopf, D; Scheurer, S; Petersen, A; Cistero-Bahima, A; Enrique, E; San Miguel-Moncin, M; Akkerdaas, J; van Ree, R; Vieths, S; Becker, WM				Schocker, F; Luttkopf, D; Scheurer, S; Petersen, A; Cistero-Bahima, A; Enrique, E; San Miguel-Moncin, M; Akkerdaas, J; van Ree, R; Vieths, S; Becker, WM			Recombinant lipid transfer protein Cor a 8 from hazelnut: A new tool for in vitro diagnosis of potentially severe hazelnut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hazelnut allergens; lipid transfer protein; Car a 8; in vitro diagnosis; enzyme allergosorbent test; immunoblot	MAJOR ALLERGEN; DOUBLE-BLIND; IDENTIFICATION; CLEAVAGE; APPLE	Background: Cor a 1.04 has been identified as the major hazelnut allergen in 65 European patients with positive double-blind, placebo-controlled food challenge results to hazelnut. Recently, the 11S globulin Cor a 9 was shown to be a pollen-independent hazelnut allergen in the United States, whereas preliminary data suggest the lipid transfer protein (LTP) as an important birch pollen-unrelated hazelnut allergen in Europe. Objective: We sought to recruit a group of European patients allergic to hazelnut without birch pollen allergy and to identify and clone the major food allergen(s) in this study population. Methods: We recruited 26 such Spanish patients, including 10 patients with anaphylaxis. IgE immunoblotting was performed with hazelnut extract. Hazelnut LTP Cor a 8 was cloned by using a PCR strategy, purified, and subjected to IgE immunoblotting. Recombinant Cor a 8, rCor a 1.0401, and rCor a 2 (profilin) were further investigated by means of enzyme allergosorbent test. Immunoblot inhibition experiments were used to compare the immunologic properties of natural and recombinant LTP. Results: A 9-kd major allergen was identified in hazelnut extract. Cloning, sequencing, heterologous expression, and inhibition experiments identified it as an LTP. The prevalence of specific IgE antibody reactivity to LTP was 62% in hazelnut extract and 77% when recombinant LTP was tested by means of immunoblotting. IgE immunoblot inhibition with hazelnut extract showed that natural Cor a 8 and rCor a 8 shared identical epitopes. Only one patient had positive reactivity to Cor a 1.04, and no patients had positive reactivity to Cor a 2. Two sera bound to high-molecuiar-weight allergens. The LTP was denominated as Cor a 8 and submitted to the allergen database of the World Health Organization/International Union of Immunological Societies Allergen Nomenclature Subcommittee. Conclusions: Cor a 8 is a relevant allergen for a majority of Spanish patients with hazelnut allergy that can cause severe allergic reactions.	Forschungszentrum Borstel, Div Biochem & Mol Allergol, D-23845 Borstel, Germany; Paul Ehrlich Inst, Dept Allergol, D-6070 Langen, Germany; UAB, Dept Allergy, Inst Univ Dexeus, Barcelona, Spain; CLB, Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands	Forschungszentrum Borstel; Paul Ehrlich Institute; Autonomous University of Barcelona	Schocker, F (corresponding author), Forschungszentrum Borstel, Div Biochem & Mol Allergol, Parkallee 22, D-23845 Borstel, Germany.		Scheurer, Stephan/A-6509-2019	Scheurer, Stephan/0000-0002-2859-562X				Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P517, DOI 10.1067/mai.2002.127434; Diaz-Perales A, 2002, J ALLERGY CLIN IMMUN, V110, P790, DOI 10.1067/mai.2002.128242; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Duro G, 1997, INT ARCH ALLERGY IMM, V112, P348, DOI 10.1159/000237479; Enrique E, 2002, ALLERGY, V57, P351, DOI 10.1034/j.1398-9995.2002.1s3509.x; *EUR AC ALL CLIN I, 1989, ALLERGY S, V44, P13; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; GROOT H, 1996, ALLERGY, V51, P712; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; Muller U, 2000, EUR FOOD RES TECHNOL, V212, P2, DOI 10.1007/s002170000245; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V105, P371, DOI 10.1016/S0091-6749(00)90090-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pastorello EA, 2001, ALLERGY, V56, P45, DOI 10.1034/j.1398-9995.2001.00914.x; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; San Miguel-Moncin M, 2003, ALLERGY, V58, P511, DOI 10.1034/j.1398-9995.2003.00097.x; Scheurer S, 2001, J ALLERGY CLIN IMMUN, V107, P724, DOI 10.1067/mai.2001.113864; Schocker F, 2000, EUR J NUTR, V39, P172, DOI 10.1007/s003940070021; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514	26	149	156	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					141	147		10.1016/j.jaci.2003.09.013	http://dx.doi.org/10.1016/j.jaci.2003.09.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713920				2022-12-18	WOS:000187837900019
J	Empedrad, R; Darter, L; Earl, HS; Gruchalla, RS				Empedrad, R; Darter, L; Earl, HS; Gruchalla, RS			Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DESENSITIZATION; ANAPHYLAXIS; IGE		Univ Illinois, Coll Med, Rockford, IL 61107 USA; Univ Texas, SW Med Ctr, Div Allergy & Immunol, Dallas, TX 75230 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Rockford; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Empedrad, R (corresponding author), Univ Illinois, Coll Med, Rockford, IL 61107 USA.							ANNE S, 1994, ANN ALLERGY, V73, P402; Barbaud A, 1998, BRIT J DERMATOL, V139, P49; Bernstein IL, 1999, ANN ALLERG ASTHMA IM, V83, pVIII; BRANDT MA, 1993, J ALLERGY CLIN IMMUN, V91, P263; DAVILA I, 1993, ALLERGY, V48, P388, DOI 10.1111/j.1398-9995.1993.tb02413.x; EARL HS, 1987, J ALLERGY CLIN IMMUN, V79, P477, DOI 10.1016/0091-6749(87)90365-4; HARLE DG, 1988, MOL IMMUNOL, V25, P1347, DOI 10.1016/0161-5890(88)90050-8; Jorro G, 1996, ANN ALLERG ASTHMA IM, V77, P456, DOI 10.1016/S1081-1206(10)63349-2; LIN RY, 1990, ARCH INTERN MED, V150, P2197, DOI 10.1001/archinte.150.10.2197; SCHRETLENDOHERTY JS, 1995, ANN PHARMACOTHER, V29, P704, DOI 10.1177/106002809502907-810	10	149	155	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					629	630		10.1067/mai.2003.1690	http://dx.doi.org/10.1067/mai.2003.1690			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679828				2022-12-18	WOS:000185231200028
J	Espinosa, K; Bosse, Y; Stankova, J; Rola-Pleszczynski, M				Espinosa, K; Bosse, Y; Stankova, J; Rola-Pleszczynski, M			CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial smooth muscle; cysteinyl leukotrienes; leukotriene receptors; leukotriene D-4; airway remodeling; asthma; transforming growth factor-beta; IL-13; IFN-gamma	IN-VITRO; CYSTEINYL LEUKOTRIENES; IFN-GAMMA; EXPRESSION; GROWTH; INTERLEUKIN-13; ASTHMA; CHILDREN; FIBROSIS; ANTIBODY	Background: Airway remodeling is a feature of chronic asthma. It involves a number of structural changes, including bronchi-at smooth muscle cell (BSMC) hyperplasia and hypertrophy. Cysteinyl leukotrienes (cysLTs) have been suggested to play a role in airway remodeling in addition to their numerous other physiopathologic effects. Objectives: This work was aimed at characterizing the potential modulation of CysLT1 receptor expression by cytokines and the eventual functional relevance of this modulation. Methods: Expression of CysLT1 receptor was measured by flow cytometry and immunofluoreseence microscopy. Transcripts were measured by RT-PCR and BSMC proliferation by crystal violet staining. Results: When human BSMC were exposed to transforming growth factor (TGF)-beta, IL-13, or IFN-gamma, their expression of CysLT1 receptor was significantly augmented in a time- and concentration-dependent manner. Interestingly, IL-4 had no significant effect on CysLT1 receptor expression in BSMC. Moreover, IL-13 and IFN-gamma but not TGF-beta were able to increase CysLT1 mRNA levels. Finally, when BSMC were pre-treated with TGF-beta or IL-13 but not IFN-gamma, their responsiveness to LTD4 was markedly enhanced in terms of BSMC proliferation. Whereas TGF-beta, IL-13, or LTD4 alone had little effect on BSMC proliferation, preexposure of the cells to TGF-beta or IL-13 for 24 hours resulted in a significant increase in proliferation in response to LTD4. The enhanced proliferation was totally prevented by pretreating the cytokine-primed BSMC with the selective CysLT1 receptor antagonist Montelukast. Conclusions: Taken together, our findings indicate a synergy between certain cytokines and cysITs, mediated by the augmented expression of the CysLT1 receptor and subsequent LTD4-triggered BSMC proliferation. These findings support a role for cysLTs in the airway remodeling observed in asthmatic patients and may provide a rationale for preventive and therapeutic intervention.	Univ Sherbrooke, Fac Med, Dept Pediat, Div Immunol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Rola-Pleszczynski, M (corresponding author), Univ Sherbrooke, Fac Med, Dept Pediat, Div Immunol, 3001 N 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.							Alcais A, 2001, GENET EPIDEMIOL, V21, pS168, DOI 10.1002/gepi.2001.21.s1.s168; Amrani Y, 2001, AM J RESP CRIT CARE, V164, P2098, DOI 10.1164/ajrccm.164.11.2108005; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Cho SH, 2002, CLIN EXP ALLERGY, V32, P427, DOI 10.1046/j.1365-2222.2002.01281.x; Cohen P, 2000, AM J PHYSIOL-LUNG C, V278, pL545, DOI 10.1152/ajplung.2000.278.3.L545; CORRIN B, 1994, HISTOPATHOLOGY, V24, P145, DOI 10.1111/j.1365-2559.1994.tb01293.x; Elias JA, 2000, AM J RESP CRIT CARE, V161, pS168, DOI 10.1164/ajrccm.161.supplement_2.a1q4-4; Fiorentini S, 2002, SCAND J IMMUNOL, V55, P284, DOI 10.1046/j.1365-3083.2002.01039.x; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Holgate ST, 2000, AM J RESP CRIT CARE, V161, pS147, DOI 10.1164/ajrccm.161.supplement_1.ltta-29; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Kikuchi A, 2001, BRIT J CANCER, V85, P741, DOI 10.1054/bjoc.2001.1973; Kominsky SL, 2000, J INTERF CYTOK RES, V20, P463, DOI 10.1089/10799900050023870; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee JH, 2001, AM J RESP CELL MOL, V25, P474, DOI 10.1165/ajrcmb.25.4.4522; LEE JH, 2000, AM J RESP CRIT CARE, V161, pA699; Lynch KR, 1999, NATURE, V399, P789; MAGNAN A, 1994, THORAX, V49, P789, DOI 10.1136/thx.49.8.789; MALDONADO V, 1999, J BIOCHEM TOXICOL, V11, P183; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; Newman-Tancredi A, 2002, MOL PHARMACOL, V62, P590, DOI 10.1124/mol.62.3.590; Page K, 2000, FRONT BIOSCI-LANDMRK, V5, pD258, DOI 10.2741/Page; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; Salmon M, 1999, BRIT J PHARMACOL, V127, P1151, DOI 10.1038/sj.bjp.0702669; Thivierge M, 2000, J IMMUNOL, V165, P5221, DOI 10.4049/jimmunol.165.9.5221; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Walker TR, 1998, MOL PHARMACOL, V54, P1007, DOI 10.1124/mol.54.6.1007; Wen FQ, 2002, AM J RESP CELL MOL, V26, P484, DOI 10.1165/ajrcmb.26.4.4784; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	39	149	155	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1032	1040		10.1067/mai.2003.1451	http://dx.doi.org/10.1067/mai.2003.1451			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743568				2022-12-18	WOS:000182904500018
J	Phipatanakul, W; Eggleston, PA; Wright, EC; Wood, RA				Phipatanakul, W; Eggleston, PA; Wright, EC; Wood, RA		Natl Cooperative Inner City Asthma	Mouse allergen. I. The prevalence of mouse allergen in inner-city homes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mouse allergen; indoor allergens; inner-city asthma; sensitization	COCKROACH ALLERGEN; HOUSE DUST; ASTHMA; CHILDREN; EXPOSURE; MITE; SENSITIZATION; CAT	Background: Although mouse allergen is a well-defined cause of IgE-mediated hypersensitivity in occupational settings, it has not been web studied in the general population. Objective: We sought to determine the prevalence of mouse allergen in inner-city homes. Methods: A subset of 608 homes from the National Cooperative Inner-City Asthma Study population had dust samples adequate for analysis of mouse allergen. In addition, data regarding the demographics and housing of the subjects were related to the mouse allergen levels. Results: Ninety-five percent of all homes had detectable mouse allergen (Mus m 1) in at least one room, with the highest levels found in kitchens (kitchen: range, 0-618 mug/g; median, 1.60 mug/g; bedroom: range, 0-294 mug/g; median, 0.52 mug/g; television-living room: range, 0-203 mug/g; median, 0.57 mug/g). By city, 100% of the kitchens in Baltimore had detectable mouse allergen, with the lowest percentage (74%) in Cleveland Mouse allergen levels correlated among rooms (R = 0.65-0.75). Forty-nine percent of the homes had reported problems with mice within the last year, and 29% of the homes had evidence of mice in one or more rooms on home inspection and had higher levels of mouse allergen (P = .0001). Higher allergen levels were also associated with evidence of cockroach infestation in any room (P = .006), None of the other subject or housing demographics evaluated were associated with a higher prevalence or level of mouse allergen. Conclusions: We conclude that mouse allergen is widely distributed in inner-city homes and that cockroach infestation is associated with high mouse allergen levels.	Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat,Div Allergy & Immunol, Boston, MA USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; New England Res Inst, Watertown, MA 02172 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Johns Hopkins University; HealthCore, Inc	Wood, RA (corresponding author), Johns Hopkins Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.				NIAID NIH HHS [AI07007] Funding Source: Medline; NIEHS NIH HHS [ES09606] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009606] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BIRKHEAD G, 1989, J ALLERGY CLIN IMMUN, V84, P484, DOI 10.1016/0091-6749(89)90361-8; Bush RK, 1998, J ALLERGY CLIN IMMUN, V102, P99, DOI 10.1016/S0091-6749(98)70060-0; CALL RS, 1992, J PEDIATR, V121, P362; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EVANS R, 1987, CHEST S, V91, P65; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Mitchell H, 1997, PEDIATR PULM, V24, P237; MURRAY AB, 1983, PEDIATRICS, V71, P418; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; WALSHAW MJ, 1986, Q J MED, V58, P199; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	18	149	149	2	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1070	1074						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112888				2022-12-18	WOS:000165930300007
J	Ballmer-Weber, BK; Vieths, S; Luttkopf, D; Heuschmann, P; Wuthrich, B				Ballmer-Weber, BK; Vieths, S; Luttkopf, D; Heuschmann, P; Wuthrich, B			Celery allergy confirmed by double-blind, placebo-controlled food challenge: A clinical study in 32 subjects with a history of adverse reactions to celery root	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; double-blind, placebo-controlled, food; challenge; celery allergy; oral allergy syndrome; systemic reaction	BIRCH POLLEN; CROSS-REACTIVITY; IGE; SENSITIZATION; BINDING; API-G-1; BET-V-1	Background: Celery root is a frequent cause of food allergy in pollen-sensitized patients. Because of problems in blinding challenges with fresh vegetables and the risk of anaphylactic reactions, no double-blind, placebo-controlled, food challenges (DBPCFCs) with celery have been published so far. Objective: The aim of the study was to confirm the clinical relevance of celery as a food allergen by DBPCFCs and to evaluate current diagnostic procedures in patients with true allergy, Methods: DBPCFCs were performed in 32 patients with a history of an allergic reaction to celery. The patients underwent skin prick tests (SPTs) with celery extracts, crude celery, and different pollen extracts. Specific IgE For celery was determined by using the CAP method, Results: Twenty-two of 32 patients had a positive DBPCFC result. Two patients reacted to placebo, and 8 patients did not respond to the challenge. Of the nonresponders, 4 reacted to an open provocation with celery. The sensitivity of CAP determination for specific IgE (greater than or equal to 0.7 kU/L) to celery in patients with a positive DBPCFC result was 73%, 48% to 86% for SPTs (greater than or equal to 3 mm) with commercial extracts, and 96% for prick-to-prick tests with crude celery. The positive predictive value of the SPT and CAP tests was between 87% and 96%, whereas the specificity and negative predictive values were poor, Conclusion: This study confirms the importance of celery as a food allergen for use in DBPCFCs. The SPT and CAP methods proved to be reliable For the diagnosis of a relevant allergy to celery in regard to sensitivity and positive predictive value but not to specificity and negative predictive value.	Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Paul Ehrlich Inst, Dept Allergol, D-6070 Langen, Germany	University of Zurich; University Zurich Hospital; Paul Ehrlich Institute	Ballmer-Weber, BK (corresponding author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.							ANDRE F, 1994, TOXICOLOGY, V93, P77, DOI 10.1016/0300-483X(94)90198-8; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; Bindslev-Jensen C, 1998, ALLERGY, V53, P72, DOI 10.1111/j.1398-9995.1998.tb04966.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Bousquet J, 1998, ALLERGY, V53, P3, DOI 10.1111/j.1398-9995.1998.tb04987.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Etesamifar M, 1998, ALLERGOLOGIE, V21, P451; Goldstein Laurence, 1987, PRINCIPLES INTERNAL, P5; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; *IAO WHO FOOD AGR, 1995, REP FAO TECHN CONS F; JADASSOHN WERNER, 1926, ARCH DERM U SYPH, V151, P93, DOI 10.1007/BF01829529; Jankiewicz A, 1996, INT ARCH ALLERGY IMM, V111, P268, DOI 10.1159/000237377; METCALFE DD, 1990, J ALLERGY CLIN IMMUN, V86, P421, DOI 10.1016/S0091-6749(05)80252-0; MUHLEMANN RJ, 1991, SCHWEIZ MED WSCHR, V121, P1696; Ortolani C, 1999, ALLERGY, V54, P27, DOI 10.1034/j.1398-9995.1999.00913.x; ORTOLANI C, IN PRESS J ALLERGY C; PAULI G, 1988, ANN ALLERGY, V60, P243; WUTHRICH B, 1985, SCHWEIZ MED WSCHR, V115, P358; Wuthrich B, 1997, ALLERGY, V52, P1187, DOI 10.1111/j.1398-9995.1997.tb02522.x; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x; WUTHRICH B, 1993, ALLERGOLOGIE, V16, P280	28	149	152	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					373	378		10.1067/mai.2000.107196	http://dx.doi.org/10.1067/mai.2000.107196			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932083				2022-12-18	WOS:000088708100022
J	Businco, L; Giampietro, PG; Lucenti, P; Lucaroni, F; Pini, C; Di Felice, G; Iacovacci, P; Curadi, C; Orlandi, M				Businco, L; Giampietro, PG; Lucenti, P; Lucaroni, F; Pini, C; Di Felice, G; Iacovacci, P; Curadi, C; Orlandi, M			Allergenicity of mare's milk in children with cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk allergy; cow's milk substitute; mare's milk; mare's milk allergy	FOOD ALLERGY; FORMULAS	Background: Cow's milk allergy is a common disease of infancy and early childhood. If the baby is not breast-fed, a substitute for cow's milk formula is necessary. Objective: The aim of this study was to investigate, in vitro and in vivo, the allergenicity of mare's milk in a population of selected children with severe IgE-mediated cow's milk allergy. Methods: Twenty-five children (17 male and 8 female) aged 19 to 72 months (median age 34 months) with IgE-mediated con's milk allergy were selected for this study. All the children underwent skin prick tests with cow's milk and mare's milk and double-blind placebo-controlled oral food challenge (DBP-COFC) with fresh cow's milk, fresh mare's milk, and, as placebo, a soy formula (Isomil, Abbott. Campoverde, Italy). We performed immunoblotting of cow's and mare's milk developed with IgE from allergic children. Results: All the children showed strong positive skin test responses to cow's milk (4+); 2 children had positive skin test responses to mare's milk (2+). All children had positive DBP-COFCs to cow's milk; one child had a positive DBP-COFC to mare's milk. No children reacted to the placebo (lsomil). In the cow's milk, some proteins are able to strongly react with human IgE; when the sera are tested with mare's milk, the bands corresponding to the same proteins are recognized by a lower percentage of sera. Conclusion: These data suggest that mare's milk can be regarded as a good substitute of cow's milk in most children with severe IgE-mediated cow's milk allergy. It would be prudent, however, to confirm its tolerability by a supervised titrated oral challenge test.	Univ Roma La Sapienza, Dept Pediat, Div Clin Immunol & Allergy, Rome, Italy; Ist Super Sanita, Immunol Lab, Allergy Unit, I-00161 Rome, Italy; Univ Pisa, Fac Anim Sci, Dept Anim Prod, Pisa, Italy	Sapienza University Rome; Istituto Superiore di Sanita (ISS); University of Pisa	Lucenti, P (corresponding author), Via Alessandria 174, I-00198 Rome, Italy.		Di Felice, Gabriella/B-9985-2016	Di Felice, Gabriella/0000-0001-7387-9683				Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; Bellioni-Businco B, 1999, J ALLERGY CLIN IMMUN, V103, P1191, DOI 10.1016/S0091-6749(99)70198-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Businco L, 1993, Pediatr Allergy Immunol, V4, P101, DOI 10.1111/j.1399-3038.1993.tb00077.x; BUSINCO L, 1993, CLIN EXP ALLERGY, V23, P481, DOI 10.1111/j.1365-2222.1993.tb03234.x; GIOVANNINI M, 1994, J AM COLL NUTR, V13, P357, DOI 10.1080/07315724.1994.10718422; GODOVAC-ZIMMERMANN J, 1987, BIOL CHEM H-S, V368, P427, DOI 10.1515/bchm3.1987.368.1.427; IACONO G, 1992, J PEDIATR GASTR NUTR, V14, P177, DOI 10.1097/00005176-199202000-00010; Klish WJ, 1998, PEDIATRICS, V101, P148, DOI 10.1542/peds.101.1.148; Pagliarini E., 1993, Italian Journal of Food Science, V5, P323; RAGNO V, 1993, EUR J PEDIATR, V152, P760, DOI 10.1007/BF01953996; RIGO J, 1989, J PEDIATR-US, V115, P752, DOI 10.1016/S0022-3476(89)80656-0; Solaroli G., 1993, Italian Journal of Food Science, V5, P3	13	149	158	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					1031	1034		10.1067/mai.2000.106377	http://dx.doi.org/10.1067/mai.2000.106377			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808187				2022-12-18	WOS:000087185000025
J	Custovic, A; Simpson, BM; Simpson, A; Hallam, C; Craven, M; Brutsche, M; Woodcock, A				Custovic, A; Simpson, BM; Simpson, A; Hallam, C; Craven, M; Brutsche, M; Woodcock, A			Manchester Asthma and Allergy Study: Low-allergen environment can be achieved and maintained during pregnancy and in early life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary prevention; dust mite; avoidance; atopy; asthma	HOUSE-DUST MITE; RISK FACTOR; P-I; SENSITIZATION; AVOIDANCE; CHILDHOOD; EXPOSURE; INFANCY; POPULATION; DISORDERS	Background: Early exposure to dust mite allergens may be critical for primary sensitization. Reducing exposure may offer a realistic chance for primary prevention of sensitization and asthma, but it is essential to implement measures that can achieve and maintain the low-allergen environment. Objective: Our purpose was to assess the effectiveness of mite allergen avoidance measures in achieving and maintaining a low-allergen environment during pregnancy and in the first year of life. Methods: The Manchester Asthma and Allergy Study is a prospective, prenatally randomized study that follows the development of asthma and atopy in a cohort of infants at high risk (both parents atopic) who are randomly allocated to full mite allergen avoidance or to a normal regimen. Avoidance measures comprise (1) mite-proof covers (mattress, pillow, and quilt) for parental bed, (2) high-filtration vacuum cleaner, (3) vinyl flooring in infant's bedroom, (4) new crib and portable crib mattresses encased in mite-proof material, (5) benzyl benzoate (Acarosan) applied on carpets and soft furniture, (6) bed linens washed in hot water weekly, and (7) washable soft toys. Dust samples from the parental bed, bedroom floor, living room floor, infant's mattress, and nursery floor were collected between the 10th and 14th weeks of pregnancy, immediately after birth, and then at age 6 months and 1 year, and Der p 1 levels were determined by mAb-based ELISA. Results: Recovered Der p 1 from maternal mattress was reduced by 97.25% (95% confidence interval [CI] 95.25%-98.41%) during the second and third trimesters of pregnancy, with the effect persisting for 6 months (98% reduction, 95% CI 97.258-99.1%) and 12 months (97.6% reduction, 95% CI 95.7%-98.6%) after the birth (active vs control, P <.000001). Total Der p 1 from bedroom floor in the active group was reduced by 53.7% (95 % CI 25.7%-71.2%) in samples collected within 4 weeks of the child's birth, with the percentage reduction being 62.8% (95 % CI 39.3%-77.2%) at 6 months and 26.5% (95% CI-24% to 57.1%) at 1 year (active compared vs control, P <.007). Der p 1 levels in crib mattress and nursery floor in the active group were extremely low (crib mattresses geometric mean [95% CI] 2.3 ng [1.6-3.4] at birth, 6.8 ng [4.5-10] at age 6 months, and 15.6 ng [9.8-24.8] at age 1 year [active vs control, P =.001]; nursery 1 ng [0.9-1.1] at birth, 1.7 ng [1.2-2.5] at age 6 months, and 2 ng [1.3-3.5] at age 1 year [active vs control, P <.00001]). The total amount of allergen recovered at age 1 year was 29-fold (95% CI 15.1- to 56.7-fold) higher in the control group than in the active group. Conclusions: The avoidance measures used in this study achieved and maintained a low mite allergen environment during pregnancy and in the first year of life in homes of infants at risk of atopy.	Wythenshawe Hosp, North West Lung Ctr, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Custovic, A (corresponding author), Wythenshawe Hosp, North West Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Brutsche, Martin/0000-0002-1612-3609; Simpson, Angela/0000-0003-2733-6666				ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Asher MI, 1998, EUR RESPIR J, V12, P315; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BROWN T, 1994, IRISH UNIV REV, V24, P38; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Jones CA, 1998, CLIN EXP ALLERGY, V28, P655; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; *NAT ASTHM CAMP, 1999, NAT ASTHM AUD 1999 2; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; *UCB I ALL, 1997, EUR ALL WHIT PAP; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/j.1365-2222.1994.tb01807.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8	27	149	153	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				252	258		10.1016/S0091-6749(00)90073-3	http://dx.doi.org/10.1016/S0091-6749(00)90073-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669844				2022-12-18	WOS:000085402200008
J	Nelson, HS; Bensch, G; Pleskow, WW; DiSantostefano, R; DeGraw, S; Reasner, DS; Rollins, TE; Rubin, PD; Rubin, PD				Nelson, HS; Bensch, G; Pleskow, WW; DiSantostefano, R; DeGraw, S; Reasner, DS; Rollins, TE; Rubin, PD; Rubin, PD			Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Thoracic-Society	APR 24-29, 1998	CHICAGO, IL	Amer Thorac Soc		asthma; levalbuterol; racemic albuterol; bronchodilators; lung function; S-albuterol	TO-MODERATE ASTHMA; RS-ALBUTEROL; AIRWAY HYPERREACTIVITY; INHALED ALBUTEROL; S-ALBUTEROL; GUINEA-PIGS; SALBUTAMOL; SALMETEROL; THERAPY; EXACERBATION	Background: Racemic albuterol is an equal mixture of (R)-albuterol (levalbuterol), which is responsible for the bronchodilator effect, and (S)-albuterol, which provides no benefit and may be detrimental. Objective: We sought to compare 2 doses of a single enantiomer, levalbuterol (0.63 mg and 1.25 mg), and equivalent amounts of levalbuterol administered as racemic albuterol with placebo in patients with moderate-to-severe asthma. Methods: This was a randomized, double-blind, parallel-group trial. Three hundred sixty-two patients 12 years of age or older were treated with study drug administered by means of nebulization 3 times daily for 28 days. The primary endpoint was peak change in FEV1 after 4 weeks. Results: The change in peak FEV1 response to the first dose in the combined levalbuterol group was significantly greater compared with the combined racemic albuterol group (0.92 and 0.82 L, respectively; P = .03), with similar but nonsignificant results after 4 weeks (0.84 and 0.74 L, respectively). Improvement in FEV1 was similar for levalbuterol 0.63 mg and racemic albuterol 2.5 mg and greatest for levalbuterol 1.25 mg. Racemic albuterol 1.25 mg demonstrated the weakest bronchodilator effect, particularly after chronic dosing. The greatest increase in FEV1 was seen after levalbuterol 1.25 mg, especially in subjects with severe asthma. All active treatments were well tolerated, and beta-adrenergic side effects after administration of levalbuterol 0.63 mg were reduced relative to levalbuterol 1.25 mg or racemic albuterol 2.5 mg. At week 4, the predose FEV1 value was greatest in patients who received levalbuterol or placebo when compared with those who received racemic albuterol. The difference was more evident and was statistically significant in patients who were not receiving inhaled corticosteroids. Conclusion: Levalbuterol appears to provide a better therapeutic index than the standard dose of racemic albuterol. These results support the concept that (S)-albuterol may have detrimental effects on pulmonary function.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Allergy Immunol & Astham Grp Inc, Stockton, CA USA; PPD Pharmaco Inc, Wilmington, NC USA; Sepracor Inc, Marlborough, MA USA	National Jewish Health; Dainippon Sumitomo Pharmaceutical Company; Sunovion Pharmaceuticals Inc.	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							[Anonymous], 1992, CHIRALITY, V4, P338; Auclair B, 1998, FASEB J, V12, pA142; Bakale RP, 1996, CLIN REV ALLERG IMMU, V14, P7, DOI 10.1007/BF02772200; Boulet LP, 1997, J ALLERGY CLIN IMMUN, V99, P13, DOI 10.1016/S0091-6749(97)81039-1; Boulton DW, 1996, BRIT J CLIN PHARMACO, V41, P35, DOI 10.1111/j.1365-2125.1996.tb00156.x; Chetham PM, 1997, AM J PHYSIOL-LUNG C, V273, pL22, DOI 10.1152/ajplung.1997.273.1.L22; COCKCROFT DW, 1995, J ALLERGY CLIN IMMUN, V96, P44, DOI 10.1016/S0091-6749(95)70031-5; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Fried KM, 1998, CHIRALITY, V10, P484, DOI 10.1002/(SICI)1520-636X(1998)10:5<484::AID-CHIR11>3.0.CO;2-W; GUMBHIRSHAH K, 1998, IN PRESS J CLIN PHAR; HARTLEY D, 1971, J MED CHEM, V14, P895, DOI 10.1021/jm00291a036; HOSHIKO K, 1993, J ALLERGY CLIN IMMUN, V91, P909, DOI 10.1016/0091-6749(93)90349-K; HOSHIKO K, 1993, JPN J PHARMACOL, V63, P159, DOI 10.1254/jjp.63.159; Jafarian A, 1996, CLIN REV ALLERG IMMU, V14, P91, DOI 10.1007/BF02772205; Johansson F, 1996, CLIN REV ALLERG IMMU, V14, P57, DOI 10.1007/BF02772203; KESTEN S, 1991, AM REV RESPIR DIS, V144, P622, DOI 10.1164/ajrccm/144.3_Pt_1.622; KOCH P, 1997, AM J RESP CRIT CARE, V155, pA279; Mitra S, 1998, MOL PHARMACOL, V53, P347, DOI 10.1124/mol.53.3.347; Morley J, 1996, CLIN REV ALLERG IMMU, V14, P65, DOI 10.1007/BF02772204; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; NELSON HS, 1995, NEW ENGL J MED, V333, P499, DOI 10.1056/NEJM199508243330807; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; Penn RB, 1996, CLIN REV ALLERG IMMU, V14, P37, DOI 10.1007/BF02772201; PerrinFayolle M, 1996, CLIN REV ALLERG IMMU, V14, P139, DOI 10.1007/BF02772208; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Sly RM, 1997, ANN ALLERG ASTHMA IM, V78, P427, DOI 10.1016/S1081-1206(10)63229-2; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; Volcheck GW, 1998, J ALLERGY CLIN IMMUN, V101, pS35; Walle T, 1996, CLIN REV ALLERG IMMU, V14, P101, DOI 10.1007/BF02772206; Yamaguchi H, 1996, CLIN REV ALLERG IMMU, V14, P47, DOI 10.1007/BF02772202	34	149	153	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				943	952		10.1016/S0091-6749(98)70332-X	http://dx.doi.org/10.1016/S0091-6749(98)70332-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	150XE	9847435				2022-12-18	WOS:000077690700012
J	Ferrer, M; Kinet, JP; Kaplan, AP				Ferrer, M; Kinet, JP; Kaplan, AP			Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RI(alpha) (alpha-subunit) in chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						urticaria; mast cells; histamine release; IgE receptor; autoimmunity	CHRONIC IDIOPATHIC URTICARIA; FC-EPSILON-RI; MAST-CELLS; THYROID AUTOIMMUNITY; HUMAN-SKIN; AUTOANTIBODIES; ANGIOEDEMA; CYTOKINES; RECEPTOR; CHAIN	Background: Recent data suggest that a subpopulation of patients with chronic urticaria have an autoimmune disorder that is caused by the presence of antibodies to the IgE receptor. The actual incidence of these antibodies is uncertain. Objective: We sought to assess the incidence of autoimmunity to the IgE receptor in patients with chronic urticaria and to compare functional and binding assays, Methods: We isolated skin mast cells and studied a large number of patient sera (68) for their ability to activate these cells and isolated basophils. We then compared the results with those obtained by immunoblotting using cloned alpha-subunit of the IgE receptor. Results: Sera from patients with chronic urticaria released significant histamine (>15% of basal) on incubation with basophils (48%) and mast cells (46%). By immunoblotting we obtained positive results in 64% of subjects tested and also identified a small subpopulation that is active on cells but does not bind Fc(epsilon)RI(alpha). Conclusion: Our data suggest that approximately 45% to 50% of patients with chronic urticaria have a cutaneous autoimmune disorder. Immunoblotting may provide a rapid screening method for anti-Fc(epsilon)RI(alpha) detection in such patients.	Med Univ S Carolina, Dept Med, Div Pulm Crit Care & Allergy & Clin Immunol, Charleston, SC 29425 USA; Harvard Univ, Sch Med, Dept Pathol, Lab Allergy & Immunol, Boston, MA 02115 USA	Medical University of South Carolina; Harvard University; Harvard Medical School	Kaplan, AP (corresponding author), Med Univ S Carolina, Dept Med, Div Pulm Crit Care & Allergy & Clin Immunol, 171 Ashley Ave, Charleston, SC 29425 USA.		Ferrer, Marta/C-4319-2016	Ferrer, Marta/0000-0001-8495-1302				BENYON RC, 1986, INT ARCH ALLER A IMM, V79, P332; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; CAMPION RH, 1969, BRIT J DERMATOL, V81, P588; Eklund KK, 1997, J IMMUNOL, V158, P4373; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1996, CURR OPIN IMMUNOL, V8, P784, DOI 10.1016/S0952-7915(96)80005-7; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; KAPLAN AP, 1994, ALLERGY, V49, P495, DOI 10.1111/j.1398-9995.1994.tb01119.x; KAPLAN AP, 1995, SAMTERS IMMUNOLOGIC, V2, P1329; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; REIN G, 1992, INT ARCH ALLERGY IMM, V98, P211, DOI 10.1159/000236187; SCHWARTZ LB, 1991, J AM ACAD DERMATOL, V25, P190, DOI 10.1016/S0190-9622(08)80468-9; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	23	149	150	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					672	676		10.1016/S0091-6749(98)70176-9	http://dx.doi.org/10.1016/S0091-6749(98)70176-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600505				2022-12-18	WOS:000073697400016
J	Flemons, WW; Tsai, W				Flemons, WW; Tsai, W			Quality of life consequences of sleep-disordered breathing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sleep-disordered breathing; sleep apnea; quality of life; excessive daytime somnolence	POSITIVE AIRWAY PRESSURE; DAYTIME SLEEPINESS; HEALTH-STATUS; APNOEA/HYPOPNOEA SYNDROME; AUTOMOBILE ACCIDENTS; CLINICAL-TRIALS; LATENCY TEST; OF-LIFE; APNEA; PERFORMANCE	Sleep-disordered breathing occurs in approximately 2% to 4% of the adult population and includes conditions in which patients stop breathing completely (apnea) or have marked reductions in airflow (hypopnea) during sleep. Typical symptoms of sleep apnea include snoring, restless sleep, excessive daytime somnolence, nocturnal enuresis, irritability, depression, memory deficits, inability to concentrate, and decreased alertness. The clinically relevant outcomes of these symptoms include impairment in work efficiency, increased automobile accident rates, and decrements in quality of life. Treatment of sleep apnea, primarily with continuous positive airway pressure, reduces sleepiness and improves mood disturbances, neurocognition, and performance. Traditional measurements of sleep apnea severity do not correlate well with current tests and scales that are used to quantify alterations in alertness, performance, quality of life, or sleepiness. A disease-specific quality of life scale has been developed following patient and physician interviews and literature reviews. The Calgary Sleep Apnea Quality of Life Index is expected to capture aspects of quality of life important to sleep apnea patients, such as cognitive function, performance, and mood, that could be improved with appropriate treatment of sleep-disordered breathing.	UNIV CALGARY, DEPT MED, CALGARY, AB T2N 1N4, CANADA	University of Calgary								*AM THOR SOC, 1996, AM J RESP CRIT CARE, V150, P1463; [Anonymous], [No title captured]; BEARPARK H, 1987, SLEEP RES, V16, P303; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERRY DTR, 1986, J CLIN EXP NEUROPSYC, V8, P229, DOI 10.1080/01688638608401315; BIXLER ED, 1976, SLEEP RES, V5, P160; BRADLEY TD, 1992, CLIN CHEST MED, V13, P493; BROUGHTON R, 1981, CAN J NEUROL SCI, V8, P299, DOI 10.1017/S0317167100043419; BURWELL CS, 1957, AM J MED, V59, P343; CARSKADON MA, 1979, PERCEPT MOTOR SKILL, V48, P495, DOI 10.2466/pms.1979.48.2.495; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; CASSEL W, 1993, SLEEP, V16, pS56, DOI 10.1093/sleep/16.suppl_8.S56; CHESHIRE K, 1992, ARCH INTERN MED, V152, P538, DOI 10.1001/archinte.152.3.538; Colquhoun W., 1971, BIOL RHYTHMS HUMAN P, P39; DERDERIAN SS, 1988, CHEST, V94, P1023, DOI 10.1378/chest.94.5.1023; DINGES DF, 1987, SLEEP, V10, P313; DONNELL JM, 1969, PERCEPT MOTOR SKILL, V29, P711, DOI 10.2466/pms.1969.29.3.711; DOUGLAS NJ, 1994, LANCET, V344, P653, DOI 10.1016/S0140-6736(94)92088-5; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; Ferguson KA, 1996, CHEST, V109, P1269, DOI 10.1378/chest.109.5.1269; FINDLEY L, 1995, CHEST, V108, P619, DOI 10.1378/chest.108.3.619; FINDLEY LJ, 1986, CHEST, V90, P686, DOI 10.1378/chest.90.5.686; FINDLEY LJ, 1989, AM REV RESPIR DIS, V140, P529, DOI 10.1164/ajrccm/140.2.529; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; Finn L., 1996, AM J RESP CRIT CARE, V153, pA358; FLEMONS WW, 1993, SLEEP, V16, pS71, DOI 10.1093/sleep/16.suppl_8.S71; FLEMONS WW, 1994, AM J RESP CRIT CARE, V150, P1279, DOI 10.1164/ajrccm.150.5.7952553; FLEMONS WW, 1996, AM J RESP CRIT CARE, V151, pA748; FLEMONS WW, 1996, AM J RESP CRIT CARE, V153, pA353; GALL R, 1993, SLEEP, V16, pS59, DOI 10.1093/sleep/16.suppl_8.S59; GEORGE CF, 1987, LANCET, V2, P447; George CFP, 1996, AM J RESP CRIT CARE, V154, P175, DOI 10.1164/ajrccm.154.1.8680676; GREENBERG GD, 1987, SLEEP, V10, P254, DOI 10.1093/sleep/10.3.254; GUILLEMINAULT C, 1992, SLEEP, V15, pS13; GUILLEMINAULT C, 1976, ANNU REV MED, V27, P465, DOI 10.1146/annurev.me.27.020176.002341; Guilleminault C., 1994, PRINCIPLES PRACTICE, V2nd ed., P667; GUYATT GH, 1989, J GEN INTERN MED, V4, P101, DOI 10.1007/BF02602348; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; HARDINGE FM, 1995, RESP MED, V89, P617, DOI 10.1016/0954-6111(95)90230-9; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; HORNE JA, 1985, ACTA PSYCHOL, V58, P123, DOI 10.1016/0001-6918(85)90003-4; HUDGEL DW, 1989, INT J PSYCHIAT MED, V19, P11, DOI 10.2190/PPM5-TRTN-A4EA-GVJ1; HUNT SM, 1981, SOC SCI MED-MED SOC, V15, P221, DOI 10.1016/0271-7123(81)90005-5; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; KALES A, 1985, J CHRON DIS, V38, P427, DOI 10.1016/0021-9681(85)90138-9; KLONOFF H, 1987, J NERV MENT DIS, V175, P208, DOI 10.1097/00005053-198704000-00003; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; LARSSON LH, 1994, LARYNGOSCOPE, V104, P1362; LEE S, 1990, J CLIN PSYCHIAT, V51, P309; LIGHT A I, 1989, Current Surgery, V46, P29; Lugaresi E, 1994, PRINCIPLES PRACTICE, P621; MCDOWELL I, 1987, MEASURING HLTH GUIDE, P139; MILLMAN RP, 1989, J CLIN PSYCHIAT, V50, P348; MITLER MM, 1982, ELECTROEN CLIN NEURO, V53, P658, DOI 10.1016/0013-4694(82)90142-0; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; Monk T, 1994, PRINCIPLES PRACTICE, P321; NICHOLSON AN, 1986, EUR J CLIN PHARMACOL, V30, P27, DOI 10.1007/BF00614191; PHILLIPSON EA, 1993, NEW ENGL J MED, V328, P1271, DOI 10.1056/NEJM199304293281712; POLLO O, 1994, LANCET, V344, P655; REYNOLDS CF, 1984, J CLIN PSYCHIAT, V45, P287; RICHARDSON GS, 1978, ELECTROEN CLIN NEURO, V45, P621, DOI 10.1016/0013-4694(78)90162-1; RINGLER J, 1990, J APPL PHYSIOL, V69, P2143, DOI 10.1152/jappl.1990.69.6.2143; SANGAL RB, 1992, CHEST, V101, P898, DOI 10.1378/chest.101.4.898; SHEPARD JW, 1985, MED CLIN N AM, V69, P1243, DOI 10.1016/S0025-7125(16)30985-3; STROHL KP, 1986, AM REV RESPIR DIS, V134, P791; Strohl KP, 1996, AM J RESP CRIT CARE, V154, P279, DOI 10.1164/ajrccm.154.2.8756795; SULLIVAN CE, 1981, LANCET, V1, P862; TELAKIVI T, 1988, SLEEP, V11, P454; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILKINSON RT, 1982, HUM FACTORS, V24, P487, DOI 10.1177/001872088202400409; WILKINSON RT, 1964, ERGONOMICS, V7, P175, DOI 10.1080/00140136408930736; YESAVAGE J, 1985, SLEEP, V8, P30, DOI 10.1093/sleep/8.1.30; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	76	149	152	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					S750	S756		10.1016/S0091-6749(97)70123-4	http://dx.doi.org/10.1016/S0091-6749(97)70123-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	WH831	9042067				2022-12-18	WOS:A1997WH83100035
J	CLAMAN, DM; BOUSHEY, HA; LIU, J; WONG, H; FAHY, JV				CLAMAN, DM; BOUSHEY, HA; LIU, J; WONG, H; FAHY, JV			ANALYSIS OF INDUCED SPUTUM TO EXAMINE THE EFFECTS OF PREDNISONE ON AIRWAY INFLAMMATION IN ASTHMATIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; INDUCED SPUTUM; CORTICOSTEROIDS; EOSINOPHIL; EOSINOPHIL CATIONIC PROTEIN; ALBUMIN; MUCIN-LIKE GLYCOPROTEIN	EOSINOPHILS	To detemine whether induced sputum samples might provide a useful means for evaluating the effects of therapy on airway mucosal inflammation, we examined induced sputum samples obtained before and after 6 days of treatment with prednisone (0.5 mg/kg/day) or placebo in a randomized, double-blind study of 24 asthmatic subjects. Induced sputum was analyzed for total and differential cell counts and for concentrations of eosinophil cationic protein, albumin, and mucin-like glycoprotein. We found that the mean (+/- SEM) percentage of eosinophils in sputum samples from the prednisone-treated group fell from 14.1% +/- 5.0% at baseline to 1.8% +/- 0.8% after treatment, a decrease significantly greater than in the placebo-treated group (from 10.3% +/- 4.9% to 11.1% +/- 4.0%; p = 0.002). The absolute number of eosinophils also decreased significantly more in the prednisone-treated group than in the placebo-treated group (p = 0.04). In addition, eosinophil cationic protein levels in induced sputum fell more in the prednisone-treated group than in the placebo-treated group (from 324 +/- 131 ng/ml to 144 +/- 84 ng/ml vs 173 +/- 50 ng/ml to 188 +/- 47 ng/ml; p = 0.002). Furthermore prednisone treatment was associated with a significant increase in peak expiratory flow an effect chat was significantly correlated with the decrease in. eosinophil percentage in induced sputum (r(s) = 0.64, p = 0.04). Prednisone treatment was not associated with any significant change in the concentrations of albumin or mucin-like glycoprotein. We conclude that analysis of induced sputum is a useful noninvasive method for studying the effects of asthma therapy on airway eosinophilic inflammation.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07185, HL 24136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; BAIGELMAN W, 1983, AM J MED, V75, P929, DOI 10.1016/0002-9343(83)90871-9; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; DUDDRIDGE M, 1993, EUR RESPIR J, V6, P489; FAHY JV, 1994, J ALLERGY CLIN IMMUN, V93, P1031, DOI 10.1016/S0091-6749(94)70052-4; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; FAHY JV, 1993, AM REV RESPIR DIS, V146, P1132; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; SCHLEIMER RP, 1992, INSIGHTS ALLERGY, V7, P1; VIRCHOW JC, 1992, AM REV RESPIR DIS, V146, P604, DOI 10.1164/ajrccm/146.3.604; WALLEN N, 1991, J IMMUNOL, V147, P3490; WELLER PF, 1991, NEW ENGL J MED, V324, P1110	19	149	153	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					861	869		10.1016/0091-6749(94)90154-6	http://dx.doi.org/10.1016/0091-6749(94)90154-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963155				2022-12-18	WOS:A1994PR24000011
J	HAMILOS, DL; LEUNG, DYM; WOOD, R; MEYERS, A; STEPHENS, JK; BARKANS, J; MENG, Q; CUNNINGHAM, L; BEAN, DK; KAY, AB; HAMID, Q				HAMILOS, DL; LEUNG, DYM; WOOD, R; MEYERS, A; STEPHENS, JK; BARKANS, J; MENG, Q; CUNNINGHAM, L; BEAN, DK; KAY, AB; HAMID, Q			CHRONIC HYPERPLASTIC SINUSITIS - ASSOCIATION OF TISSUE EOSINOPHILIA WITH MESSENGER-RNA EXPRESSION OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND INTERLEUKIN-3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SINUSITIS; NASAL POLYPS; EOSINOPHILIA; GM-CSF; IL-3; IN-SITU HYBRIDIZATION; CYTOKINES	LYMPHOCYTE-T ACTIVATION; ACUTE SEVERE ASTHMA; PERIPHERAL-BLOOD; ATOPIC ASTHMA; BRONCHOALVEOLAR LAVAGE; FUNCTIONAL-PROPERTIES; BRONCHIAL BIOPSIES; CELL PROGENITORS; NASAL-MUCOSA; IMMUNOREACTIVITY	Background: We investigated the association among tissue eosinophilia, cellular infiltration, and cytokine mRNA expression in chronic hyperplastic sinusitis (CHS). Methods: Percutaneous biopsies of the maxillary sinuses and nasal polyps were performed in 12 adult patients (six men and six women) of whom seven were nonallergic and 11 were asthmatic. Tissues were compared with biopsy specimens from the inferior and middle turbinates of normal control subjects. Results: Histologically, an eosinophil-predominant inflammatory infiltrate was seen in 10 of 12 patients, whereas a mild to moderate neutrophilic infiltrate was seen in 4 of 12 patients. As determined by immunocytochemistry, diseased tissues and normal control tissues differed significantly in terms of the number of activated (EG2+) eosinophils (p = 0.005) but not in terms of CD3+ or CD4+ T lymphocytes, elastase-positive neutrophils or CD68+ macrophages. The number of eosinophils did not correlate with that of any other cell type. By in situ hybridization, CHS tissues showed significantly higher numbers of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-3 mRNA-positive cells than normal control tissues (p = 0.002 and 0.0005, respectively) per high-powered field. There was a significant correlation between the number of infiltrating EG2+ eosinophils and cells that expressed mRNA for GM-CSF (r = 0.60, p = 0.041) or IL-3 (r = 0.69, p = 0.013). Furthermore, epithelial cells did not show detectable mRNA expression for GM-CSF or IL-3. No significant correlation was found between IL-5 mRNA expression and infiltrating EG2+ eosinophils in diseased tissues. However, the IL-5 density was significantly higher in the five patients with CHS who had positive allergy skin test results than in the seven patients with negative skin test results (p = 0.017) or in normal control subjects. Conclusions: Our data support a role for GM-CSF and IL-3 in the eosinophilia characteristic of CHS and show that IL-5 mRNA expression is not a prominent feature of nonallergic inflammation. The cellular sources of GM-CSF and IL-3 in CHS remain to be definitely determined.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO; NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,LONDON,ENGLAND; NATL HEART & LUNG INST,DEPT LUNG PATHOL,LONDON,ENGLAND; UNIV COLORADO,HLTH SCI CTR,DEPT EAR NOSE & THROAT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT SURG,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262	National Jewish Health; Imperial College London; Imperial College London; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	HAMILOS, DL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206, USA.							AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1988, LANCET, V1, P1129; DENBURG JA, 1985, BLOOD, V66, P312; DENBURG JA, 1985, EXP HEMATOL, V13, P185; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; Denburg JA, 1990, AM J RHINOL, V4, P29; DOLOVICH J, 1990, RHINITIS ASTHMA SIMI, P233; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FREW AJ, 1988, J IMMUNOL, V141, P4158; GAGA M, 1991, J IMMUNOL, V147, P816; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HAMID QA, 1989, CANCER, V63, P266, DOI 10.1002/1097-0142(19890115)63:2<266::AID-CNCR2820630211>3.0.CO;2-D; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; JORDANA M, 1988, AGENTS ACTIONS S, V26, P85; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; OHNISHI M, 1988, AM REV RESPIR DIS, V138, P560, DOI 10.1164/ajrccm/138.3.560; OHNISHI M, 1989, J ALLERGY CLIN IMMUN, V83, P1091, DOI 10.1016/0091-6749(89)90451-X; OHNO I, 1991, AM J RESP CELL MOL, V5, P505, DOI 10.1165/ajrcmb/5.6.505; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; OTSUKA H, 1987, AM REV RESPIR DIS, V136, P710, DOI 10.1164/ajrccm/136.3.710; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; QUINT DJ, 1989, IMMUNOLOGY, V67, P68; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; Sokal Robert R., 1969, BIOMETRY; SPRY CJF, 1985, INT ARCH ALLER A IMM, V77, P252, DOI 10.1159/000233803; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WILSON JW, 1992, AM REV RESPIR DIS, V145, P958, DOI 10.1164/ajrccm/145.4_Pt_1.958	37	149	156	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				39	48		10.1016/0091-6749(93)90035-E	http://dx.doi.org/10.1016/0091-6749(93)90035-E			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8335853				2022-12-18	WOS:A1993LQ35300007
J	NATBONY, SF; PHILLIPS, ME; ELIAS, JM; GODFREY, HP; KAPLAN, AP				NATBONY, SF; PHILLIPS, ME; ELIAS, JM; GODFREY, HP; KAPLAN, AP			HISTOLOGIC-STUDIES OF CHRONIC IDIOPATHIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, HLTH SCI CTR, DEPT MED, DIV ALLERGY RHEUMATOL & CLIN IMMUNOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Godfrey, Henry/0000-0002-7195-6363				GODFREY H P, 1981, Journal of Histotechnology, V4, P80; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1978, ALLERGY PRINCIPLES P, P1080; LEDER LD, 1964, KLIN WOCHENSCHR, V42, P553, DOI 10.1007/BF01486688; LEVER WF, 1975, HISTOPATHOLOGY SKIN, P133; MANDER RJ, 1976, AM J MED, V61, P560; MATHISON DA, 1977, ANN INTERN MED, V86, P534, DOI 10.7326/0003-4819-86-5-534; MCDUFFIE FC, 1973, MAYO CLIN PROC, V48, P340; MONROE EW, 1981, J INVEST DERMATOL, V76, P103, DOI 10.1111/1523-1747.ep12525403; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P436, DOI 10.1016/0091-6749(80)90237-7; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; SISSONS JGP, 1974, LANCET, V2, P1350; SOTER NA, 1974, J INVEST DERMATOL, V63, P485, DOI 10.1111/1523-1747.ep12680443; SOTER NA, 1976, J INVEST DERMATOL, V66, P344, DOI 10.1111/1523-1747.ep12482901; SOTER NA, 1977, NEW ENGL J MED, V296, P1440, DOI 10.1056/NEJM197706232962505; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626; WARREN RP, 1974, URTICARIA, P15	18	149	151	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	2					177	183		10.1016/0091-6749(83)90096-9	http://dx.doi.org/10.1016/0091-6749(83)90096-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC188	6822693				2022-12-18	WOS:A1983QC18800001
J	TOOGOOD, JH; BASKERVILLE, JC; JENNINGS, B; LEFCOE, NM; JOHANSSON, SA				TOOGOOD, JH; BASKERVILLE, JC; JENNINGS, B; LEFCOE, NM; JOHANSSON, SA			INFLUENCE OF DOSING FREQUENCY AND SCHEDULE ON THE RESPONSE OF CHRONIC ASTHMATICS TO THE AEROSOL STEROID, BUDESONIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN ONTARIO,SCH MED,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario)	TOOGOOD, JH (corresponding author), VICTORIA HOSP,DEPT MED,ALLERGY CLIN,LONDON N6A 4G5,ONTARIO,CANADA.		Bjermer, Leif H/I-4899-2014	Bjermer, Leif H/0000-0002-3441-8099				[Anonymous], 1959, Thorax, V14, P286, DOI 10.1136/thx.14.4.286; BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P72, DOI 10.1016/0091-6749(78)90081-7; BJORKANDER J, 1982, EUR J RESPIR DI S122, V63, P108; Blackwell B, 1979, COMPLIANCE HLTH CARE, P144; COSTELLO JF, 1974, THORAX, V29, P571, DOI 10.1136/thx.29.5.571; DAHL R, 1982, EUR J RESPIR DIS, V63, P268; ELLULMICALLEF R, 1980, EUR J RESPIR DIS, V61, P167; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GAMBERTOGLIO JG, 1980, J CLIN ENDOCR METAB, V51, P561, DOI 10.1210/jcem-51-3-561; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GRIECO MH, 1978, ARCH INTERN MED, V138, P1337, DOI 10.1001/archinte.138.9.1337; GWYNN CM, 1977, BR J CLIN PHARM, V4, P2695; JOHANSSON SA, EUR J CLIN PHARM; KOZOWER M, 1974, J CLIN ENDOCR METAB, V38, P407, DOI 10.1210/jcem-38-3-407; KRIZ RJ, 1976, CHEST, V69, P455, DOI 10.1378/chest.69.4.455; LOEB JN, 1976, NEW ENGL J MED, V295, P547, DOI 10.1056/NEJM197609022951007; MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171; Mecoy R J, 1980, Aust Fam Physician, V9, P721; MORRIS HG, 1968, J CLIN INVEST, V47, P436, DOI 10.1172/JCI105740; Morrow-Brown H., 1972, BRIT MED J, V1, P585; MUNCH EP, 1982, EUR J RESPIR DIS, V63, P143; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; MYLES AB, 1971, ANN RHEUM DIS, V30, P149, DOI 10.1136/ard.30.2.149; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; RYRFELDT A, 1982, EUR J RESPIR DIS S, V122, P86; SKALKA HW, 1980, ARCH OPHTHALMOL-CHIC, V98, P1773; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P379, DOI 10.1016/0091-6749(80)90117-7; SOUTHREN AL, 1978, SCIENCE, V200, P1177, DOI 10.1126/science.653363; STIKSA G, 1982, EUR J RESPIR DIS, V63, P266; THALEN A, 1979, ARZNEIMITTEL-FORSCH, V29-2, P1687; TOOGOOD J, 1980, ANN R COLL PHYS SURG, V13, P110; TOOGOOD JH, 1973, CHEST, V63, P881, DOI 10.1378/chest.63.6.881; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TOOGOOD JH, 1978, J ALLERGY CLIN IMMUN, V61, P355, DOI 10.1016/0091-6749(78)90114-8; TOOGOOD JH, 1980, TOPICAL STEROID TREA, P107; WILLEY RF, 1982, BRIT J DIS CHEST, V76, P61, DOI 10.1016/0007-0971(82)90009-2; WILLIAMS MH, 1974, AM REV RESPIR DIS, V109, P538; WILLIAMS MH, 1981, ANN INTERN MED, V95, P464, DOI 10.7326/0003-4819-95-4-464; 1976, BR J DIS CHEST, V70, P95; 1962, AM REV RESPIR DIS, V85, P762	40	149	150	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	4					288	298		10.1016/0091-6749(82)90065-3	http://dx.doi.org/10.1016/0091-6749(82)90065-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PL151	7119301				2022-12-18	WOS:A1982PL15100009
J	Cugno, M; Meroni, PL; Gualtierotti, R; Griffini, S; Grovetti, E; Torri, A; Panigada, M; Aliberti, S; Blasi, F; Tedesco, F; Peyvandi, F				Cugno, Massimo; Meroni, Pier Luigi; Gualtierotti, Roberta; Griffini, Samantha; Grovetti, Elena; Torri, Adriana; Panigada, Mauro; Aliberti, Stefano; Blasi, Francesco; Tedesco, Francesco; Peyvandi, Flora			Complement activation in patients with COVID-19: A novel therapeutic target	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Cugno, Massimo; Gualtierotti, Roberta; Griffini, Samantha; Grovetti, Elena; Aliberti, Stefano; Blasi, Francesco; Peyvandi, Flora] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Cugno, Massimo; Gualtierotti, Roberta; Griffini, Samantha; Grovetti, Elena; Torri, Adriana; Peyvandi, Flora] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy; [Meroni, Pier Luigi; Tedesco, Francesco] IRCCS Ist Auxol Italiano, Immunorheumatol Res Lab, Milan, Italy; [Panigada, Mauro] Fdn IRCCS Ca Granda Osped Maggiore Policlin, UOC Anestesia & Terapia Intens Adulti, Milan, Italy; [Panigada, Mauro; Aliberti, Stefano; Blasi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, UOC Pneumol, Milan, Italy	University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Istituto Auxologico Italiano; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico	Cugno, M (corresponding author), Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.; Cugno, M (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy.	massimo.cugno@unimi.it	Panigada, Mauro/K-4650-2014; Aliberti, Stefano/K-9115-2016; Gualtierotti, Roberta/V-5991-2019; Blasi, Francesco/O-5885-2017	Panigada, Mauro/0000-0003-4841-9794; Aliberti, Stefano/0000-0002-0090-4531; Gualtierotti, Roberta/0000-0001-6465-7624; Blasi, Francesco/0000-0002-2285-9970				BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Diao B., 2020, HUMAN KIDNEY IS TARG, DOI 10.1101/2020.03.04.20031120; Gao T., 2020, HIGHLY PATHOGENIC CO, DOI 10.1101/2020.03.29.20041962; Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Patriquin CJ, 2019, TRANSFUS MED REV, V33, P256, DOI 10.1016/j.tmrv.2019.09.004; Riedl M, 2014, SEMIN THROMB HEMOST, V40, P444, DOI 10.1055/s-0034-1376153; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5	9	148	152	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					215	+		10.1016/j.jaci.2020.05.006	http://dx.doi.org/10.1016/j.jaci.2020.05.006			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32417135	Green Published, Bronze			2022-12-18	WOS:000579170500034
J	Mjosberg, J; Spits, H				Mjosberg, Jenny; Spits, Hergen			Human innate lymphoid cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate lymphoid cells; mucosal immunity; inflammatory bowel disease; allergy; asthma; psoriasis; tumor immunity; graft-versus-host disease	TRANSCRIPTION FACTOR GATA3; NATURAL-KILLER-CELLS; TISSUE-INDUCER CELLS; ROR-GAMMA-T; INTERLEUKIN 22; NK CELLS; LINEAGE; PROGENITOR; FATE; INFLAMMATION	Innate lymphoid cells (ILCs) are increasingly acknowledged as important mediators of immune homeostasis and pathology. ILCs act as early orchestrators of immunity, responding to epithelium-derived signals by expressing an array of cytokines and cell-surface receptors, which shape subsequent immune responses. As such, ILCs make up interesting therapeutic targets for several diseases. In patients with allergy and asthma, group 2 innate lymphoid cells produce high amounts of IL-5 and IL-13, thereby contributing to type 2-mediated inflammation. Group 3 innate lymphoid cells are implicated in intestinal homeostasis and psoriasis pathology through abundant IL-22 production, whereas group 1 innate lymphoid cells are accumulated in chronic inflammation of the gut (inflammatory bowel disease) and lung (chronic obstructive pulmonary disease), where they contribute to IFN-gamma-mediated inflammation. Although the ontogeny of mouse ILCs is slowly unraveling, the development of human ILCs is far from understood. In addition, the growing complexity of the human ILC family in terms of previously unrecognized functional heterogeneity and plasticity has generated confusion within the field. Here we provide an updated view on the function and plasticity of human ILCs in tissue homeostasis and disease.	[Mjosberg, Jenny] Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, Stockholm, Sweden; [Spits, Hergen] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, Amsterdam, Netherlands	Karolinska Institutet; University of Amsterdam; Academic Medical Center Amsterdam	Mjosberg, J (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Dept Med Huddinge, Ctr Infect Med F59, S-14186 Stockholm, Sweden.	jenny.mjosberg@ki.se		Mjosberg, Jenny/0000-0002-1119-0976	Swedish Society for Medical Research; Knut and Alice Wallenberg Foundation; Swedish Research Council; Swedish Cancer Foundation; Swedish Foundation for Strategic Research; European Research Council	Swedish Society for Medical Research; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Foundation; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); European Research Council(European Research Council (ERC)European Commission)	J. Mjosberg has received grants from the Swedish Society for Medical Research, the Knut and Alice Wallenberg Foundation, the Swedish Research Council, the Swedish Cancer Foundation, and the Swedish Foundation for Strategic Research and has consultant arrangements with ONO Pharmaceutical. H. Spits has received a grant from the European Research Council, has consultant arrangements with GlaxoSmithKline and Vaxxilon, is employed by and has patents and stock/stock options with AIMM Therapeutics, and has received royalties from the Netherland Cancer Institute.	Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bar-Ephraim YE, 2016, IMMUNOL REV, V271, P185, DOI 10.1111/imr.12407; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Basu R, 2012, IMMUNITY, V37, P1061, DOI 10.1016/j.immuni.2012.08.024; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Boyd A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108649; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Carrega P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9280; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Constantinides MG, 2015, P NATL ACAD SCI USA, V112, P5123, DOI 10.1073/pnas.1423244112; Constantinides MG, 2014, NATURE, V508, P397, DOI 10.1038/nature13047; Crellin NK, 2010, IMMUNITY, V33, P752, DOI 10.1016/j.immuni.2010.10.012; Crellin NK, 2010, J EXP MED, V207, P281, DOI 10.1084/jem.20091509; Cupedo T, 2009, NAT IMMUNOL, V10, P66, DOI 10.1038/ni.1668; Dadi S, 2016, CELL, V164, P365, DOI 10.1016/j.cell.2016.01.002; Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308; Dyring-Andersen B, 2014, BRIT J DERMATOL, V170, P609, DOI 10.1111/bjd.12658; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Eisenring M, 2010, NAT IMMUNOL, V11, P1030, DOI 10.1038/ni.1947; Facchetti F, 1998, SPRINGER SEMIN IMMUN, V19, P459, DOI 10.1007/BF00792602; Fuchs A, 2013, IMMUNITY, V38, P769, DOI 10.1016/j.immuni.2013.02.010; Gasteiger G, 2015, SCIENCE, V350, P981, DOI 10.1126/science.aac9593; Gentek R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00334; Geremia A, 2011, J EXP MED, V208, P1127, DOI 10.1084/jem.20101712; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1067/MAI.2002.130051; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Ghaedi M, 2016, CELL REP, V15, P471, DOI 10.1016/j.celrep.2016.03.039; Glatzer T, 2013, IMMUNITY, V38, P1223, DOI 10.1016/j.immuni.2013.05.013; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Hanash AM, 2012, IMMUNITY, V37, P339, DOI 10.1016/j.immuni.2012.05.028; Hazenberg MD, 2014, BLOOD, V124, P700, DOI 10.1182/blood-2013-11-427781; Hepworth MR, 2015, SCIENCE, V348, P1031, DOI 10.1126/science.aaa4812; Hepworth MR, 2013, NATURE, V498, P113, DOI 10.1038/nature12240; Hoorweg K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00072; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim HY, 2016, EUR J IMMUNOL, V46, P795, DOI 10.1002/eji.201444557; Kirchberger S, 2013, J EXP MED, V210, P917, DOI 10.1084/jem.20122308; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030; Klose CSN, 2013, NATURE, V494, P261, DOI 10.1038/nature11813; Kloverpris HN, 2016, IMMUNITY, V44, P391, DOI 10.1016/j.immuni.2016.01.006; Knorr DA, 2014, SEMIN IMMUNOL, V26, P161, DOI 10.1016/j.smim.2014.02.002; Konya V, 2016, IMMUNOL LETT, V179, P36, DOI 10.1016/j.imlet.2016.07.006; Lee JS, 2015, IMMUNITY, V43, P727, DOI 10.1016/j.immuni.2015.09.003; Leijten EFA, 2015, ARTHRITIS RHEUMATOL, V67, P2673, DOI 10.1002/art.39261; Li J, 2016, CELL IMMUNOL, V304, P63, DOI 10.1016/j.cellimm.2016.05.001; Li J, 2014, J CLIN INVEST, V124, P3241, DOI 10.1172/JCI73742; Lim AI, 2016, J EXP MED, V213, P569, DOI 10.1084/jem.20151750; Male V, 2014, J EXP MED, V211, P635, DOI 10.1084/jem.20132398; Mannon PJ, 2004, NEW ENGL J MED, V351, P2069, DOI 10.1056/NEJMoa033402; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Montaldo E, 2014, IMMUNITY, V41, P988, DOI 10.1016/j.immuni.2014.11.010; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moretta F, 2016, EUR J IMMUNOL, V46, P1271, DOI 10.1002/eji.201546079; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Munneke JM, 2014, BLOOD, V124, P812, DOI 10.1182/blood-2013-11-536888; Nagakumar P, 2016, J ALLERGY CLIN IMMUN, V137, P624, DOI 10.1016/j.jaci.2015.06.038; Narni-Mancinelli E, 2011, P NATL ACAD SCI USA, V108, P18324, DOI 10.1073/pnas.1112064108; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Rak GD, 2016, J INVEST DERMATOL, V136, P487, DOI 10.1038/JID.2015.406; Rankin LC, 2016, NAT IMMUNOL, V17, P179, DOI 10.1038/ni.3332; Renoux VM, 2015, IMMUNITY, V43, P394, DOI 10.1016/j.immuni.2015.07.011; Richmond JM, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015339; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Roos AB, 2015, AM J RESP CRIT CARE, V192, P428, DOI 10.1164/rccm.201409-1689OC; Salimi M, 2016, J IMMUNOL, V196, P45, DOI 10.4049/jimmunol.1501102; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001; Saunders SP, 2016, J ALLERGY CLIN IMMUN, V137, P482, DOI 10.1016/j.jaci.2015.06.045; Sawa S, 2010, SCIENCE, V330, P665, DOI 10.1126/science.1194597; Scoville SD, 2016, IMMUNITY, V44, P1140, DOI 10.1016/j.immuni.2016.04.007; Seehus CR, 2015, NAT IMMUNOL, V16, P599, DOI 10.1038/ni.3168; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Song C, 2015, J EXP MED, V212, P1869, DOI 10.1084/jem.20151403; Sonnenberg GF, 2015, NAT MED, V21, P698, DOI 10.1038/nm.3892; Sonnenberg GF, 2012, SCIENCE, V336, P1321, DOI 10.1126/science.1222551; Spits H, 2016, NAT IMMUNOL, V17, P758, DOI 10.1038/ni.3482; Takayama T, 2010, GASTROENTEROLOGY, V139, P882, DOI 10.1053/j.gastro.2010.05.040; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2351, DOI 10.1038/jid.2014.146; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; van de Pavert SA, 2014, NATURE, V508, P123, DOI 10.1038/nature13158; van de Pavert SA, 2010, NAT REV IMMUNOL, V10, P664, DOI 10.1038/nri2832; Vely F, 2016, NAT IMMUNOL; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Vivier E, 2016, NAT IMMUNOL, V17, P790, DOI 10.1038/ni.3459; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wojno EDT, 2015, MUCOSAL IMMUNOL, V8, P1313, DOI 10.1038/mi.2015.21; Xu HB, 2015, FASEB J, V29, P5072, DOI 10.1096/fj.15-276477; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Yagi RJ, 2014, IMMUNITY, V40, P378, DOI 10.1016/j.immuni.2014.01.012; Yang Q, 2016, CURR OPIN IMMUNOL, V39, P114, DOI 10.1016/j.coi.2016.01.006; Yang Q, 2015, NAT IMMUNOL, V16, P1044, DOI 10.1038/ni.3248; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Yu XF, 2014, ELIFE, V3, DOI 10.7554/eLife.04406; Yu Y, 2015, J EXP MED, V212, P865, DOI 10.1084/jem.20142318; Zook EC, 2016, NAT IMMUNOL, V17, P775, DOI 10.1038/ni.3481	116	148	152	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1265	1276		10.1016/j.jaci.2016.09.009	http://dx.doi.org/10.1016/j.jaci.2016.09.009			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27677386	Bronze			2022-12-18	WOS:000389542700003
J	Peters, RL; Allen, KJ; Dharmage, SC; Tang, MLK; Koplin, JJ; Ponsonby, AL; Lowe, AJ; Hill, D; Gurrin, LC				Peters, Rachel L.; Allen, Katrina J.; Dharmage, Shyamali C.; Tang, Mimi L. K.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Lowe, Adrian J.; Hill, David; Gurrin, Lyle C.		HealthNuts Study	Skin prick test responses and allergen-specific IgE levels as predictors of peanut, egg, and sesame allergy in infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; skin prick test; serum-specific IgE; oral food challenge; predictive value of tests; egg; baked egg; peanut; sesame	ORAL FOOD CHALLENGES; TREE NUT; CHILDREN; DIAGNOSIS; SERUM; ACCURACY; VALIDITY; MILK	Background: Ninety-five percent positive predictive values (PPVs) provide an invaluable tool for clinicians to avoid unnecessary oral food challenges. However, 95% PPVs specific to infants, the age group most likely to present for diagnosis of food allergy, are limited. Objective: We sought to develop skin prick test (SPT) and allergen-specific IgE (sIgE) thresholds with 95% PPVs for challenge-confirmed food allergy in a large population-based cohort of 1-year-old infants with challenges undertaken irrespective of SPT wheal size or previous history of ingestion. Methods: HealthNuts is a population-based, longitudinal food allergy study with baseline recruitment of 1-year-old infants. Infants were recruited from council-run immunization sessions during which they underwent SPTs to 4 allergens: egg, peanut, sesame, and cow's milk/shrimp. Any infant with a detectable SPT response was invited to undergo oral food challenge and sIgE testing. Results: Five thousand two hundred seventy-six infants participated in the study. Peanut SPT responses of 8 mm or greater (95% CI, 7-9 mm), egg SPT responses of 4 mm or greater (95% CI, 3-5 mm), and sesame SPT responses of 8mm or greater (95% CI, 5-9 mm) had 95% PPVs for challenge-proved food allergy. Peanut sIgE levels of 34 kUA/L or greater (95% CI, 14-48 kUA/L) and egg sIgE levels of 1.7 kUA/L or greater (95% CI, 1-3 kUA/L) had 95% PPVs for challenge-proved food allergy. Results were robust when stratified on established risk factors for food allergy. Egg SPT responses and sIgE levels were poor predictors of allergy to egg in baked goods. Conclusion: These 95% PPVs, which were generated from a unique dataset, are valuable for the diagnosis of food allergy in young infants and were robust when stratified across a number of different risk factors.	[Peters, Rachel L.; Allen, Katrina J.; Dharmage, Shyamali C.; Tang, Mimi L. K.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Lowe, Adrian J.; Hill, David; Gurrin, Lyle C.; HealthNuts Study] Murdoch Childrens Res Inst, Murdoch, WA, Australia; [Peters, Rachel L.; Allen, Katrina J.; Tang, Mimi L. K.; Koplin, Jennifer J.; Ponsonby, Anne-Louise] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Allen, Katrina J.; Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Dharmage, Shyamali C.; Ponsonby, Anne-Louise; Lowe, Adrian J.; Gurrin, Lyle C.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3010, Australia	Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Tang, Mimi/ABD-8350-2020; Ponsonby, Anne-Louise/AAE-4351-2019; Allen, Katrina/I-4361-2018; Matheson, Melanie C/O-4721-2015	Tang, Mimi/0000-0002-3839-5293; Allen, Katrina/0000-0002-1921-4493; Matheson, Melanie C/0000-0002-5822-3499; Ponsonby, Anne-Louise/0000-0002-6581-3657; Gurrin, Lyle/0000-0001-7052-1969; Peters, Rachel/0000-0002-2411-6628; Koplin, Jennifer/0000-0002-7576-5142; Lowe, Adrian/0000-0002-4691-8162	National Health and Medical Research Council (NHMRC) of Australia; Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program	Supported by funding from the National Health and Medical Research Council (NHMRC) of Australia, the Ilhan Food Allergy Foundation, AnaphylaxiStop, the Charles and Sylvia Viertel Medical Research Foundation, and the	Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Cortot CF, 2012, ALLERGY ASTHMA PROC, V33, P275, DOI 10.2500/aap.2012.33.3544; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Dieguez MC, 2009, CLIN EXP ALLERGY, V39, P1575, DOI 10.1111/j.1365-2222.2009.03299.x; FAGAN TJ, 1975, NEW ENGL J MED, V293, P257; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Ho MHK, 2006, J ALLERGY CLIN IMMUN, V117, P1506, DOI 10.1016/j.jaci.2006.03.029; Jarvinen KM, 2012, J IMMUNOL METHODS, V383, P30, DOI 10.1016/j.jim.2012.02.019; Keet CA, 2012, J ALLERGY CLIN IMMUN, V130, P1207, DOI 10.1016/j.jaci.2012.07.020; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Monti G, 2002, CLIN EXP ALLERGY, V32, P1515, DOI 10.1046/j.1365-2745.2002.01454.x; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Permaul P, 2009, ALLERGY ASTHMA PROC, V30, P643, DOI 10.2500/aap.2009.30.3294; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Roberts G, 2000, CLIN EXP ALLERGY, V30, P1495, DOI 10.1046/j.1365-2222.2000.00960.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Venter C, 2007, J HUM NUTR DIET, V20, P565, DOI 10.1111/j.1365-277X.2007.00828.x; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.2324.x; Zavalkoff S, 2008, J ALLERGY CLIN IMMUN, V121, P1508, DOI 10.1016/j.jaci.2008.04.012	25	148	150	2	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					874	880		10.1016/j.jaci.2013.05.038	http://dx.doi.org/10.1016/j.jaci.2013.05.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23891354				2022-12-18	WOS:000325096500014
J	Ziegler, SF				Ziegler, Steven F.			Thymic stromal lymphopoietin and allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; asthma; allergy; atopic dermatitis; inflammation	DENDRITIC CELLS INDUCE; HUMAN EPITHELIAL-CELLS; IGM(+) B-CELLS; ATOPIC-DERMATITIS; T-CELLS; TSLP RECEPTOR; CUTTING EDGE; INCREASED EXPRESSION; MOUSE KERATINOCYTES; AIRWAY INFLAMMATION	The importance of the epithelium in initiating and controlling immune responses is becoming more appreciated. For example, allergen contact first occurs at mucosal sites exposed to the external environment, such as the skin, airways, and gastrointestinal tract. This exposure leads to the production of a variety of cytokines and chemokines that are involved in driving allergic inflammatory responses. One such product is thymic stromal lymphopoietin (TSLP). Recent studies in both human subjects and murine models have implicated TSLP in the development and progression of allergic diseases. This review will highlight recent advances in the understanding of the role of TSLP in these inflammatory diseases. Importantly, these insights into TSLP's multifaceted role could potentially allow for novel therapeutic manipulations of these disorders. (J Allergy Clin Immunol 2012; 130:845-52.)	[Ziegler, Steven F.] Benaroya Res Inst, Program Immunol, Seattle, WA 98101 USA; [Ziegler, Steven F.] Univ Washington, Dept Immunol, Seattle, WA 98195 USA	Benaroya Research Institute; University of Washington; University of Washington Seattle	Ziegler, SF (corresponding author), Benaroya Res Inst, Program Immunol, 1201 9th Ave, Seattle, WA 98101 USA.	sziegler@benaroyaresearch.org			National Institutes of Health [AI068731, AR056113, AR055695, HL098067, HL102708, AR059058]; Asthma and Allergy Foundation of America; National Institutes of Health; American Academy of Allergy, Asthma Immunology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL102708, P01HL098067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056113, R01AR055695, R01AR059058] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Asthma and Allergy Foundation of America; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma Immunology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Support was provided by grants AI068731, AR056113, AR055695, HL098067, HL102708, and AR059058 from the National Institutes of Health and a grant from the Asthma and Allergy Foundation of America.; S.F. Ziegler has received research support from the National Institutes of Health; has received lecture fees from the American Academy of Allergy, Asthma & Immunology; and has received travel support from the Federation of Clinical Immunology Societies.	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Arima K, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000567; Besin G, 2008, DIABETES, V57, P2107, DOI 10.2337/db08-0171; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Blazquez AB, 2010, GASTROENTEROLOGY, V139, P1301, DOI 10.1053/j.gastro.2010.06.055; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Boehme SA, 2009, INT IMMUNOL, V21, P81, DOI 10.1093/intimm/dxn127; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Boita M, 2011, INT J IMMUNOPATH PH, V24, P761, DOI 10.1177/039463201102400322; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Bunyavanich Supinda, 2011, Clin Mol Allergy, V9, P1, DOI 10.1186/1476-7961-9-1; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Corrigan CJ, 2009, ALLERGY, V64, P1014, DOI 10.1111/j.1398-9995.2009.01947.x; Demehri S, 2008, PLOS BIOL, V6, P992, DOI 10.1371/journal.pbio.0060123; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Duan W, 2010, J ALLERGY CLIN IMMUN, V126, P1284, DOI 10.1016/j.jaci.2010.09.021; Dumortier A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009258; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; FRIEND SL, 1994, EXP HEMATOL, V22, P321; Han H, 2012, MUCOSAL IMMUNOL, V5, P468, DOI 10.1038/mi.2012.34; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Headley MB, 2009, J IMMUNOL, V182, P1641, DOI 10.4049/jimmunol.182.3.1641; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Iliev ID, 2009, GUT, V58, P1481, DOI 10.1136/gut.2008.175166; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jessup HK, 2008, J IMMUNOL, V181, P4311, DOI 10.4049/jimmunol.181.6.4311; JUDGE MR, 1994, BRIT J DERMATOL, V131, P615, DOI 10.1111/j.1365-2133.1994.tb04971.x; Kamekura R, 2009, CELL TISSUE RES, V338, P283, DOI 10.1007/s00441-009-0855-1; Kimura S, 2011, ALLERGY ASTHMA IMMUN, V3, P186, DOI 10.4168/aair.2011.3.3.186; Kitajima M, 2011, EUR J IMMUNOL, V41, P1862, DOI 10.1002/eji.201041195; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Larson RP, 2010, J IMMUNOL, V184, P2974, DOI 10.4049/jimmunol.0803478; Lee HC, 2008, J IMMUNOL, V181, P5189, DOI 10.4049/jimmunol.181.8.5189; Lei LY, 2011, J IMMUNOL, V186, P2254, DOI 10.4049/jimmunol.1002503; Leonard WJ, 2002, NAT IMMUNOL, V3, P605, DOI 10.1038/ni0702-605; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Levin SD, 1999, J IMMUNOL, V162, P677; Li DQ, 2011, J ALLERGY CLIN IMMUN, V128, P1318, DOI 10.1016/j.jaci.2011.06.041; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Liu T, 2011, AM J MED SCI, V341, P40, DOI 10.1097/MAJ.0b013e3181f20489; Matsuda A, 2010, INVEST OPHTH VIS SCI, V51, P151, DOI 10.1167/iovs.09-4183; Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809; Miyata M, 2009, EUR J IMMUNOL, V39, P3078, DOI 10.1002/eji.200939302; Mou ZL, 2009, ACTA OTO-LARYNGOL, V129, P297, DOI 10.1080/00016480802225884; Nagata Y, 2007, INT ARCH ALLERGY IMM, V144, P305, DOI 10.1159/000106319; Nguyen Khoa D, 2010, Allergy Asthma Clin Immunol, V6, P4, DOI 10.1186/1710-1492-6-4; Oh MH, 2011, J IMMUNOL, V186, P7232, DOI 10.4049/jimmunol.1100504; Omori M, 2007, J IMMUNOL, V178, P1396, DOI 10.4049/jimmunol.178.3.1396; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Quentmeier H, 2001, LEUKEMIA, V15, P1286, DOI 10.1038/sj.leu.2402175; Ray RJ, 1996, EUR J IMMUNOL, V26, P10, DOI 10.1002/eji.1830260103; Reardon C, 2011, IMMUNITY, V35, P223, DOI 10.1016/j.immuni.2011.05.015; Reche PA, 2001, J IMMUNOL, V167, P336, DOI 10.4049/jimmunol.167.1.336; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Rochman Y, 2010, P NATL ACAD SCI USA, V107, P19455, DOI 10.1073/pnas.1008271107; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Semlali A, 2010, J ALLERGY CLIN IMMUN, V125, P844, DOI 10.1016/j.jaci.2010.01.044; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Shamim Z, 2007, INT J IMMUNOGENET, V34, P149, DOI 10.1111/j.1744-313X.2007.00657.x; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Shi LY, 2008, CLIN IMMUNOL, V129, P202, DOI 10.1016/j.clim.2008.07.015; Shigeno T, 2009, IMMUNOLOGY, V128, pe849, DOI 10.1111/j.1365-2567.2009.03094.x; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Sims JE, 2000, J EXP MED, V192, P671, DOI 10.1084/jem.192.5.671; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Tonozuka Y, 2001, CYTOGENET CELL GENET, V93, P23, DOI 10.1159/000056941; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Watanabe N, 2004, NAT IMMUNOL, V5, P426, DOI 10.1038/ni1048; Watanabe N, 2005, NATURE, V436, P1181, DOI 10.1038/nature03886; Wong CK, 2010, AM J RESP CELL MOL, V43, P305, DOI 10.1165/rcmb.2009-0168OC; Xu G, 2010, ALLERGY, V65, P581, DOI 10.1111/j.1398-9995.2009.02252.x; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhang F, 2011, CLIN EXP IMMUNOL, V164, P256, DOI 10.1111/j.1365-2249.2011.04328.x; Zhang KQ, 2007, AM J PHYSIOL-LUNG C, V293, pL375, DOI 10.1152/ajplung.00045.2007; Zhang Z, 2009, P NATL ACAD SCI USA, V106, P1536, DOI 10.1073/pnas.0812668106; Zheng XF, 2010, INVEST OPHTH VIS SCI, V51, P3076, DOI 10.1167/iovs.09-4122; Zhou BH, 2008, J IMMUNOL, V181, P6557, DOI 10.4049/jimmunol.181.9.6557; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhu DD, 2009, CHINESE MED J-PEKING, V122, P2303, DOI 10.3760/cma.j.issn.0366-6999.2009.19.021; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	91	148	165	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					845	852		10.1016/j.jaci.2012.07.010	http://dx.doi.org/10.1016/j.jaci.2012.07.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22939755	Bronze, Green Accepted			2022-12-18	WOS:000309594800002
J	Canani, RB; Nocerino, R; Terrin, G; Coruzzo, A; Cosenza, L; Leone, L; Troncone, R				Canani, Roberto Berni; Nocerino, Rita; Terrin, Gianluca; Coruzzo, Anna; Cosenza, Linda; Leone, Ludovica; Troncone, Riccardo			Effect of Lactobacillus GG on tolerance acquisition in infants with cow's milk allergy: A randomized trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN; GAMMA		[Canani, Roberto Berni; Nocerino, Rita; Terrin, Gianluca; Coruzzo, Anna; Cosenza, Linda; Leone, Ludovica; Troncone, Riccardo] Univ Naples Federico II, Dept Pediat, Naples, Italy; [Canani, Roberto Berni; Troncone, Riccardo] Univ Naples Federico II, European Lab Investigat Food Induced Dis ELFID, Naples, Italy; [Terrin, Gianluca] Univ Roma La Sapienza, Dept Womens Hlth & Terr Med, Rome, Italy	University of Naples Federico II; University of Naples Federico II; Sapienza University Rome	Canani, RB (corresponding author), Univ Naples Federico II, Dept Pediat, Naples, Italy.	berni@unina.it	Canani, Roberto Berni/AAC-4810-2022; NOCERINO, RITA/AAC-1966-2022; Nocerino, Rita/ABD-8087-2020	Canani, Roberto Berni/0000-0002-5169-9574; NOCERINO, RITA/0000-0003-4681-546X; Terrin, Gianluca/0000-0003-3541-2876; leone, ludovica/0000-0002-4524-0126				Canani RB, 2007, ALLERGY, V62, P738, DOI 10.1111/j.1398-9995.2007.01351.x; Cox MJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0011044, 10.1371/journal.pone.0008745]; Donato KA, 2010, MICROBIOL-SGM, V156, P3288, DOI 10.1099/mic.0.040139-0; Ghadimi D, 2008, IMMUNOBIOLOGY, V213, P677, DOI 10.1016/j.imbio.2008.02.001; Hol J, 2008, J ALLERGY CLIN IMMUN, V121, P1448, DOI 10.1016/j.jaci.2008.03.018; Kankainen M, 2009, P NATL ACAD SCI USA, V106, P17193, DOI 10.1073/pnas.0908876106; Lu RL, 2009, J PEDIATR GASTR NUTR, V49, P23, DOI 10.1097/MPG.0b013e3181924d1e; Mileti E, 2009, PLOS ONE, V16, P4; Mileti E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007056; Mofidi S, 2003, PEDIATRICS, V111, P1645; Pan SJ, 2010, PEDIAT ALLERG IMM-UK, V21, pE659, DOI 10.1111/j.1399-3038.2010.01061.x; Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036; Prescott S, 2011, PEDIAT ALLERG IMM-UK, V22, P155, DOI 10.1111/j.1399-3038.2011.01145.x	13	148	153	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					580	U482		10.1016/j.jaci.2011.10.004	http://dx.doi.org/10.1016/j.jaci.2011.10.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22078573	Green Submitted			2022-12-18	WOS:000299951700049
J	Whitehead, GS; Wilson, RH; Nakano, K; Burch, LH; Nakano, H; Cook, DN				Whitehead, Gregory S.; Wilson, Rhonda H.; Nakano, Keiko; Burch, Lauranell H.; Nakano, Hideki; Cook, Donald N.			IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway hyperresponsiveness; airway hyperresponsiveness; IL-17; T(H)17; T(H)2; IL-35; inducible costimulator; ovalbumin	T(H)17 CELLS; INFLAMMATION; ASTHMA; IL-17; HYPERRESPONSIVENESS; RESPONSES; CD4; HYPERREACTIVITY; INTERLEUKIN-17; CYTOKINE	Background: Recent evidence suggests that IL-17 contributes to airway hyperresponsiveness (AHR); however, the mechanisms that suppress the production of this cytokine remain poorly defined. Objective: We sought to identify the regulatory cells and molecules that suppress IL-17-dependent allergic airways disease. Methods: Mice were sensitized by means of airway instillations of ovalbumin together with low levels of LPS. Leukocyte recruitment to the lung and AHR were assessed after daily challenges with aerosolized ovalbumin. Flow cytometry, quantitative PCR, and gene-targeted mice were used to identify naturally arising subsets of regulatory T (Treg) cells and their cytokines required for the suppression of established allergic airway disease. Results: Allergic sensitization through the airway primed both effector and regulatory responses. Effector responses were initially dominant and led to airway inflammation and IL-17-dependent AHR. However, after multiple daily allergen challenges, IL-17 production and AHR decreased, even though pulmonary levels of T(H)17 cells remained high. This loss of AHR was reversible and required the expansion of a Treg cell subset expressing both forkhead box protein 3 and inducible costimulator. These Treg cells also expressed the regulatory cytokines IL-10, TGF-beta, and IL-35. Whereas IL-10 and TGF-beta were dispensable for suppression of AHR, IL-35 was required. Conclusion: IL-35 production by inducible costimulator-positive Treg cells can suppress IL-17 production and thereby reverse established, IL-17-dependent AHR in mice. Targeting this pathway might therefore be of therapeutic value for treating allergic asthma in human subjects. (J Allergy Clin Immunol 2012;129:207-15.)	[Cook, Donald N.] NIEHS, Lab Resp Biol, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cook, DN (corresponding author), NIEHS, Lab Resp Biol, Div Intramural Res, NIH, 111 TW Alexander Dr,Bldg 101,E244, Res Triangle Pk, NC 27709 USA.	cookd@niehs.nih.gov	Cook, Donald/E-5079-2019	Cook, Donald/0000-0002-0052-3755	National Institutes of Health, National Institute of Environmental Health Sciences; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES102025] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; El-behi M, 2009, J IMMUNOL, V183, P4957, DOI 10.4049/jimmunol.0900735; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Ito T, 2008, IMMUNITY, V28, P870, DOI 10.1016/j.immuni.2008.03.018; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Naundorf S, 2009, EUR J IMMUNOL, V39, P1066, DOI 10.1002/eji.200838773; Niedbala W, 2007, EUR J IMMUNOL, V37, P3021, DOI 10.1002/eji.200737810; O'Byrne PM, 2007, AM J RESP CRIT CARE, V176, P1059, DOI 10.1164/rccm.200708-1264ED; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Ray A, 2010, MUCOSAL IMMUNOL, V3, P216, DOI 10.1038/mi.2010.4; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Song CW, 2008, J IMMUNOL, V181, P6117, DOI 10.4049/jimmunol.181.9.6117; Takahashi N, 2009, J IMMUNOL, V182, P5515, DOI 10.4049/jimmunol.0803256; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Yang JF, 2008, EUR J IMMUNOL, V38, P1204, DOI 10.1002/eji.200838145	35	148	172	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					207	U301		10.1016/j.jaci.2011.08.009	http://dx.doi.org/10.1016/j.jaci.2011.08.009			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	21906794	Green Accepted, Bronze			2022-12-18	WOS:000298634000027
J	Kattan, M; Kumar, R; Bloomberg, GR; Mitchell, HE; Calatroni, A; Gergen, PJ; Kercsmar, CM; Visness, CM; Matsui, EC; Steinbach, SF; Szefler, SJ; Sorkness, CA; Morgan, WJ; Teach, SJ; Gan, VN				Kattan, Meyer; Kumar, Rajesh; Bloomberg, Gordon R.; Mitchell, Herman E.; Calatroni, Agustin; Gergen, Peter J.; Kercsmar, Carolyn M.; Visness, Cynthia M.; Matsui, Elizabeth C.; Steinbach, Suzanne F.; Szefler, Stanley J.; Sorkness, Christine A.; Morgan, Wayne J.; Teach, Stephen J.; Gan, Vanthaya N.			Asthma control, adiposity, and adipokines among inner-city adolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Obesity; asthma; adipokines; leptin; adiponectin	BODY-MASS INDEX; QUALITY-OF-LIFE; CHILDHOOD OBESITY; NONOBESE CHILDREN; INCIDENT ASTHMA; SEX-DIFFERENCES; PLASMA-PROTEIN; ADIPONECTIN; SEVERITY; ASSOCIATION	Background: There is an association between adiposity and asthma prevalence, but the relationship to asthma control is unclear. Objectives: We sought to understand the relationships among adiposity, sex, and asthma control in inner-city adolescents with asthma. Methods: We prospectively followed 368 adolescents with moderate-to-severe asthma (ages 12-20 years) living in 10 urban areas for 1 year. Asthma symptoms and exacerbations were recorded, and pulmonary function and exhaled nitric oxide levels were measured every 6 weeks. Adiposity measures (body mass index [BMI] and dual-energy X-ray absorptiometric scans) were made, and blood was collected for measurement of allergy markers, adiponectin, leptin, TNF-alpha, IL-6, and C-reactive protein levels. Results: More than 60% of female subjects and 50% of male subjects were above the 85th percentile of BMI for age. Higher BMI was associated with more symptom days (R = 0.18, P = .02) and exacerbations (R = 0.18, P = .06) among female subjects only. Adiponectin was inversely related to asthma symptoms (R = 0.18, P < .05) and exacerbations (R = 0.20, P < .05) and positively with FEN/1/forced vital capacity ratio (R = 0.15, P < .05) in male subjects only independent of body size. There was no relationship between adiposity or adipokines and total IgE levels, blood eosinophil counts, and exhaled nitric oxide levels. Dual-energy X-ray absorptiometry provided little additional value in relating adiposity to asthma outcome in this population of adolescents. Conclusion: Adiposity is associated with poorer asthma control in female subjects. Adiponectin is associated with improved asthma control in male subjects. (J Allergy Clin Immunol 2010;125:584-92.)	[Kattan, Meyer] Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Pediat Pulmonol, New York, NY 10032 USA; [Kumar, Rajesh] Childrens Mem Hosp, Div Allergy Immunol, Chicago, IL 60614 USA; [Bloomberg, Gordon R.] Washington Univ, Dept Pediat, Div Allergy Immunol & Pulm Med, St Louis, MO 63130 USA; [Mitchell, Herman E.; Calatroni, Agustin; Visness, Cynthia M.] Rho Fed Syst Div Inc, Chapel Hill, NC USA; [Gergen, Peter J.] NIAID, Div Allergy Immunol & Transplantat, Bethesda, MD 20892 USA; [Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Dept Pediat, Div Pulm Med, Ctr Med, Cincinnati, OH 45229 USA; [Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Steinbach, Suzanne F.] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02215 USA; [Szefler, Stanley J.] Univ Colorado Hlth Sci, Denver, CO USA; [Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Div Allergy & Immunol, Denver, CO USA; [Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Div Pediat Clin Pharmacol, Denver, CO USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Allergy Pulm & Crit Care Med, Madison, WI 53706 USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; [Teach, Stephen J.] Childrens Natl Med Ctr, Div Emergency Med, Washington, DC 20010 USA; [Morgan, Wayne J.] Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ USA; [Gan, Vanthaya N.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA	Columbia University; Ann & Robert H. Lurie Children's Hospital of Chicago; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Cincinnati Children's Hospital Medical Center; Johns Hopkins University; Boston University; University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health; National Jewish Health; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Children's National Health System; University of Arizona; University of Texas System; University of Texas Southwestern Medical Center Dallas	Kattan, M (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Pediat Pulmonol, 3959 Broadway,CHC 7-701, New York, NY 10032 USA.	mk2833@columbia.edu		Matsui, Elizabeth/0000-0001-8134-5593; Kumar, Rajesh/0000-0002-1962-7108	National Institute of Allergy and Infectious Diseases, National Institutes of Health [NO1-AI-25496, NO1-JAI-25482]; National Center for Research Resources, National Institutes of Health [RR00052, M01RR00533, MO1RR00071, 5UL1RR024992-02, 5M01RR020359-04]; National Heart, Lung. and Blood Institute; National Institutes of Health/National Institute of Allergy and Infectious Diseases; Sepracor; NIH/NHLBI Childhood Management Program (CAMP); NHLBI Childhood Asthma Research and Education (CARE); NIH/NHLBI Asthma Clin Res Network (ACRN); NIH/NIAID Inner City Asthma Consortium (ICAC); GlaxoSmithKline; NJH/NHLBI Asthma Net; NEEHS/EPA Childhood Environmental Health Center; Schering Plough; Sanofi; NIH/University of Wisconsin; Novartis; Baylor College of Medicine/Texas Department of State Health Services; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071, UL1RR024992, M01RR000052, M01RR000533, M01RR020359] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL093023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Heart, Lung. and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Sepracor; NIH/NHLBI Childhood Management Program (CAMP)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI Childhood Asthma Research and Education (CARE)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI Asthma Clin Res Network (ACRN)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NIAID Inner City Asthma Consortium (ICAC)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); NJH/NHLBI Asthma Net(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEEHS/EPA Childhood Environmental Health Center; Schering Plough(Merck & CompanySchering Plough Corporation); Sanofi; NIH/University of Wisconsin(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); Baylor College of Medicine/Texas Department of State Health Services; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract numbers NO1-AI-25496 and NO1-JAI-25482 and from the National Center for Research Resources, National Institutes of Health, under grants RR00052, M01RR00533, MO1RR00071, 5UL1RR024992-02, and 5M01RR020359-04.; Disclosure of potential conflict of interest: J. Kumar has received research support from the National Heart, Lung. and Blood Institute; is President of the Illinois Society of Allergy, Asthma. and Immunology; and is a member of the American Thoracic Society. G. R. Bloomberg has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. H. Mitchell has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. C. M. Kercsmar is on the Speakers' Bureau for Merck; and has received research support from Sepracor. E. Matsui has received research support from the National Institutes of Health. S. Steinback has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases; and has served as an expert witness on the topic of bronchiolitis. S. J. Szefler is a Consultant for GlaxoSmithKline, Genentech, Merck, Boeringher-Ingelheim, Novartis, and Schering Plough; has received research support from the NIH/NHLBI Childhood Management Program (CAMP), NHLBI Childhood Asthma Research and Education (CARE), NIH/NHLBI Asthma Clin Res Network (ACRN), NIH/NIAID Inner City Asthma Consortium (ICAC), GlaxoSmithKline, NJH/NHLBI Asthma Net, and NEEHS/EPA Childhood Environmental Health Center Grant. C. A. Sorkness is on the Advisory Board for GlaxoSmithKline, Schering Plough, AstraZeneca, and Novartis; and has received research support from Schering Plough and Sanofi. W. J. Morgan is a consultant for, and Chair of the Data Safety Monitoring Board for the Cystic Fibrosis Foundation; is a Consultant and Chair of the North American Scientific Advisory Group for the Epidemiologic Study of Cystic Fibrosis for Genentech; is a Consultant for Novartis; has received research support from the NIH/University of Wisconsin and Novartis. S. J. Teach has received research support from Novartis; has served as an expert witness on the topics of wheezing, pneumonia, and dehydration; and is a volunteer for the NIAID Food Allergy Guidelines. V. N. Gan has received research support from Baylor College of Medicine/Texas Department of State Health Services. The other authors declare they have no conflicts of interest.	Akerman MJH, 2004, J ASTHMA, V41, P521, DOI 10.1081/JAS-120037651; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Appleton SL, 2008, J ALLERGY CLIN IMMUN, V121, P1285, DOI 10.1016/j.jaci.2008.03.022; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Belamarich PF, 2000, PEDIATRICS, V106, P1436, DOI 10.1542/peds.106.6.1436; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Bibi H, 2004, J ASTHMA, V41, P403, DOI 10.1081/JAS-120026097; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Brenner JS, 2001, J ASTHMA, V38, P509, DOI 10.1081/JAS-100105872; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Carroll CL, 2006, PEDIATR CRIT CARE ME, V7, P527, DOI 10.1097/01.PCC.0000243749.14555.E8; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Chen Y, 2005, CHEST, V128, P3048, DOI 10.1378/chest.128.4.3048; Chinn S, 2006, PAEDIATR RESPIR REV, V7, P223, DOI 10.1016/j.prrv.2006.04.007; Clerisme-Beaty EM, 2009, J ALLERGY CLIN IMMUN, V124, P207, DOI 10.1016/j.jaci.2009.05.034; Daniels SR, 1997, PEDIATRICS, V99, P804, DOI 10.1542/peds.99.6.804; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Doganci A, 2005, CLIN REV ALLERG IMMU, V28, P257, DOI 10.1385/CRIAI:28:3:257; Ellis KJ, 1999, AM J EPIDEMIOL, V150, P939, DOI 10.1093/oxfordjournals.aje.a010102; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hancox RJ, 2004, THORAX, V59, P376, DOI 10.1136/thx.2003.010363; Kattan M, 2009, AM J RESP CRIT CARE, V179; Kobashi C, 2005, CIRC RES, V97, P1245, DOI 10.1161/01.RES.0000194328.57164.36; Kwong KY, 2006, J ASTHMA, V43, P661, DOI 10.1080/02770900600925270; Lavoie KL, 2006, RESP MED, V100, P648, DOI 10.1016/j.rmed.2005.08.001; Lavoie KL, 2005, RESP MED, V99, P1249, DOI 10.1016/j.rmed.2005.03.003; Loerbroks A, 2008, ANN EPIDEMIOL, V18, P283, DOI 10.1016/j.annepidem.2007.11.001; Luder E, 2004, RESP MED, V98, P29, DOI 10.1016/j.rmed.2003.08.004; Maniscalco M, 2008, RESP MED, V102, P102, DOI 10.1016/j.rmed.2007.07.029; Mansell AL, 2006, PEDIATR PULM, V41, P434, DOI 10.1002/ppul.20368; Matricardi PM, 2007, CLIN EXP ALLERGY, V37, P476, DOI 10.1111/j.1365-2222.2007.02664.x; McLachlan CR, 2007, J ALLERGY CLIN IMMUN, V119, P634, DOI 10.1016/j.jaci.2006.10.029; Miech RA, 2006, JAMA-J AM MED ASSOC, V295, P2385, DOI 10.1001/jama.295.20.2385; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; Nagel G, 2009, PEDIAT ALLERG IMM-UK, V20, P81, DOI 10.1111/j.1399-3038.2008.00740.x; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ogden CL, 2008, JAMA-J AM MED ASSOC, V299, P2401, DOI 10.1001/jama.299.20.2401; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Pianosi PT, 2004, PEDIATRICS, V113, pE225, DOI 10.1542/peds.113.3.e225; PISTELLI R, 1992, EUR RESPIR J, V5, P463; Rodrigo GJ, 2007, CHEST, V132, P1513, DOI 10.1378/chest.07-0936; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; Saint-Pierre P, 2006, ALLERGY, V61, P79, DOI 10.1111/j.1398-9995.2005.00953.x; SCHWARTZ JD, 1988, AM REV RESPIR DIS, V138, P1405, DOI 10.1164/ajrccm/138.6.1405; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Shore SA, 2007, J APPL PHYSIOL, V102, P516, DOI 10.1152/japplphysiol.00847.2006; Snijder MB, 2006, INT J EPIDEMIOL, V35, P83, DOI 10.1093/ije/dyi253; Sood A, 2008, THORAX, V63, P877, DOI 10.1136/thx.2007.090803; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Taylor B, 2008, THORAX, V63, P14, DOI 10.1136/thx.2007.082784; Thomas PS, 2002, THORAX, V57, P774, DOI 10.1136/thorax.57.9.774; Thomson CC, 2003, CHEST, V124, P795, DOI 10.1378/chest.124.3.795; Vargas PA, 2007, ANN ALLERG ASTHMA IM, V99, P22, DOI 10.1016/S1081-1206(10)60616-3; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wulster-Radcliffe MC, 2004, BIOCHEM BIOPH RES CO, V316, P924, DOI 10.1016/j.bbrc.2004.02.130	66	148	151	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					584	592		10.1016/j.jaci.2010.01.053	http://dx.doi.org/10.1016/j.jaci.2010.01.053			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226295	Green Accepted			2022-12-18	WOS:000275883200012
J	Levi, M; Choi, G; Picavet, C; Hack, CE				Levi, M; Choi, G; Picavet, C; Hack, CE			Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						C1-inhibitor deficiency; C1-inhibitor concentrate; hereditary angioedema; acquired angiodema	C1 INHIBITOR CONCENTRATE; EDEMA; DANAZOL; ACTIVATION; EPISODES; THERAPY; ACID	Background: Administration of C1-inhibitor concentrate is effective for prophylaxis and treatment of severe angioedema attacks caused by Cl-inhibitor deficiency. The concentrate should be administered intravenously and hence needs to be administered by health care professionals, which might cause considerable delay in treatment and inconvenience for patients. Objective: The aim of this study was to investigate the feasibility, efficacy, and safety of on-demand and prophylactic self-administration of C1-inhibitor concentrate in patients with frequent attacks of angioedema. Methods: Patients with hereditary or acquired Cl-inhibitor deficiency who had very frequent angioedema attacks were trained to self-administer Cl-inhibitor concentrate. The study consisted of 31 patients using on-demand treatment and 12 patients using prophylaxis with C1-inhibitor concentrate. Mean follow-up was 3.5 years. Results: All patients were capable of self-administering the concentrate, with technical failure rates of self-injection being less than 2%. Times between the onset of the attack and the initiation of relief or complete resolution of symptoms in the on-demand group were significantly shortened (2.2 hours and 7.9 hours, respectively) compared with the situation before the start of self-administration. In the prophylaxis group self-administration of Cl-inhibitor concentrate decreased the angioedema attack rate from 4.0 to 0.3 attacks per month. Conclusion: Intravenous self-administration of Cl-inhibitor concentrate is a feasible and safe option and results in more rapid and more effective treatment or prevention of severe angioedema attacks in patients with Cl-inhibitor deficiency. Clinical implications: Self-administration of C1-inhibitor concentrate could be a valuable and convenient treatment modality to prevent or treat angioedema attacks in patients with C1-inhibitor deficiency.	Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands; Netherlands Patient Assoc Hereditary Angioedema &, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Clin Chem, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Hack, CE (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med, F-4,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.m.levi@amc.uva.nl	Levi, Marcel/AAZ-8559-2020					AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Bork K, 2002, J HEPATOL, V36, P707, DOI 10.1016/S0168-8278(02)00035-1; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Cicardi M, 1998, IMMUNOBIOLOGY, V199, P366, DOI 10.1016/S0171-2985(98)80041-7; CICARDI M, 1995, TRANSFUSION, V35, P209, DOI 10.1046/j.1537-2995.1995.35395184276.x; CUGNO M, 1994, J ALLERGY CLIN IMMUN, V93, P870, DOI 10.1016/0091-6749(94)90380-8; Davis AE, 2005, CLIN IMMUNOL, V114, P3, DOI 10.1016/j.clim.2004.05.007; Farkas H, 2002, PEDIAT ALLERG IMM-UK, V13, P153, DOI 10.1034/j.1399-3038.2002.01014.x; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Hack C E, 2000, Methods Mol Biol, V150, P159; Kaplan AP, 2001, J INVEST ALLERG CLIN, V11, P211; Kunschak M, 1998, TRANSFUSION, V38, P540, DOI 10.1046/j.1537-2995.1998.38698326333.x; Szeplaki G, 2005, J ALLERGY CLIN IMMUN, V115, P864, DOI 10.1016/j.jaci.2004.12.1130; TEITEL JM, 1982, BLOOD, V59, P1086; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503	18	148	151	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					904	908		10.1016/j.jaci.2006.01.002	http://dx.doi.org/10.1016/j.jaci.2006.01.002			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630950	Bronze			2022-12-18	WOS:000236862800027
J	Floistrup, H; Swartz, J; Bergstrom, A; Alm, JS; Scheynius, A; van Hage, M; Waser, M; Braun-Fahrlander, C; Schram-Bijkerk, D; Huber, M; Zutavern, A; von Mutius, E; Ublagger, E; Riedler, J; Michaels, KB; Pershagen, G				Floistrup, H; Swartz, J; Bergstrom, A; Alm, JS; Scheynius, A; van Hage, M; Waser, M; Braun-Fahrlander, C; Schram-Bijkerk, D; Huber, M; Zutavern, A; von Mutius, E; Ublagger, E; Riedler, J; Michaels, KB; Pershagen, G		PARSIFAL Study Grp	Allergic disease and sensitization in Steiner school children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; anthroposophic lifestyle; antibiotics; antipyretics; asthma; biodynamic diet; measles; sensitization; vaccination	ANTHROPOSOPHIC LIFE-STYLE; EARLY-CHILDHOOD; INTESTINAL MICROFLORA; ATOPIC SENSITIZATION; ANTIBIOTIC USE; ASTHMA; SYMPTOMS; MEASLES; PREVALENCE; INFECTION	Background: The anthroposophic lifestyle has several features of interest in relation to allergy: for example, a restrictive use of antibiotics and certain vaccinations. In a previous Swedish study, Steiner school children (who often have an anthroposophic lifestyle) showed a reduced risk of atopy, but specific protective factors could not be identified. Objective: To investigate factors that may contribute to the lower risk of allergy among Steiner school children. Methods: Cross-sectional multicenter study including 6630 children age 5 to 13 years (4606 from Steiner schools and 2024 from reference schools) in 5 European countries. Results: The prevalence of several studied outcomes was lower in Steiner school children than in the reference group. Overall, there were statistically significant reduced risks for rhinoconjunctivitis, atopic eczema, and atopic sensitization (allergen-specific IgE >= 0.35 kU/L), with some heterogeneity between the countries. Focusing on doctor-diagnosed disease, use of antibiotics during first year of life was associated with increased risks of rhinoconjunctivitis (odds ratio [OR]. 1.97; 95% CI, 1.26-3.08), asthma (OR, 2.79: 95 % CI, 2.03-3.83), and atopic eczema (OR, 1.63; 95% Cl, 1.22-2.17). Early use of antipyretics was related to an increased risk of asthma (OR, 1.54; 95 % CI, 1.11-2.13) and atopic eczema (OR, 1.32, 95% CI, 1.02-1.71). Children having received measles, mumps, and rubella vaccination showed an increased risk of rhinoconjunctivitis, whereas measles infection was associated with a lower risk of IgE-mediated eczema. Conclusion: Certain features of the anthroposophic lifestyle, such as restrictive use of antibiotics and antipyretics. are associated with a reduced risk of allergic disease in children.	Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden; Karolinska Inst, Ctr Allergy Res, SE-17177 Stockholm, Sweden; Soder Hosp, Sachs Childrens Hosp, Stockholm, Sweden; Vidar Clin, Jarna, Sweden; Karolinska Inst, Dept Med, Clin Allergy Res Unit, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, SE-17177 Stockholm, Sweden; Univ Stockholm, Stockholm, Sweden; Univ Basel, Dept Environm & Hlth, Inst Social & Prevent Med, Basel, Switzerland; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; Louis Bolk Inst, Driebergen, Netherlands; Univ Munich, Dr Von Hauner Childrens Hosp, Munich, Germany; Childrens Hosp, Dept Paediat Pulmonol & Allergol, Salzburg, Austria; Childrens Hosp, Schwarzach, Germany; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Stockholm Cty Council, Dept Occupat & Environm Hlth, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Stockholm University; University of Basel; Utrecht University; University of Munich; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Stockholm County Council	Floistrup, H (corresponding author), Karolinska Inst, Inst Environm Med, Box 210, SE-17177 Stockholm, Sweden.	Helen.Floistrup@ki.se	riedler, josef/AAQ-4666-2020; Lauener, Roger P/O-8612-2016; van Hage, Marianne/A-9678-2017	Lauener, Roger P/0000-0002-8412-606X; van Hage, Marianne/0000-0003-3091-1596; von Mutius, Erika/0000-0002-8893-4515; Pershagen, Goran/0000-0002-9701-1130; Douwes, Jeroen/0000-0003-3599-4036; Ege, Markus/0000-0001-6643-3923; Alm, Johan/0000-0002-9062-4479; brunekreef, bert/0000-0001-9908-0060				ALFVEN T, 2005, ALLERGY; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Alm JS, 2002, PEDIAT ALLERG IMM-UK, V13, P402, DOI 10.1034/j.1399-3038.2002.01062.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Cullinan P, 2004, THORAX, V59, P11; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; Eneli I, 2005, CHEST, V127, P604, DOI 10.1378/chest.127.2.604; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Fukuda S, 2004, J ADOLESCENT HEALTH, V35, P156, DOI 10.1016/j.jadohealth.2003.09.018; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kirjavainen PV, 2001, FEMS IMMUNOL MED MIC, V32, P1, DOI 10.1111/j.1574-695X.2001.tb00526.x; KONDO N, 1993, CLIN EXP ALLERGY, V23, P44, DOI 10.1111/j.1365-2222.1993.tb02483.x; Maziak W, 2003, ALLERGY, V58, P572, DOI 10.1034/j.1398-9995.2003.00161.x; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Olesen AB, 2003, ACTA DERM-VENEREOL, V83, P445, DOI 10.1080/00015550310014997; Paunio M, 2000, JAMA-J AM MED ASSOC, V283, P343, DOI 10.1001/jama.283.3.343; Pershagen G, 1997, ALLERGY, V52, P1045, DOI 10.1111/j.1398-9995.1997.tb00174.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roost HP, 2004, PEDIAT ALLERG IMM-UK, V15, P401, DOI 10.1111/j.1399-3038.2004.00192.x; ROTHMAN K, 2004, META ANAL; Shaheen SO, 1996, BRIT MED J, V313, P969, DOI 10.1136/bmj.313.7063.969; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; VanVlem B, 1996, INFECTION, V24, P275, DOI 10.1007/BF01743360; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766	30	148	151	0	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					59	66		10.1016/j.jaci.2005.09.039	http://dx.doi.org/10.1016/j.jaci.2005.09.039			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387585				2022-12-18	WOS:000235687100010
J	Shreffler, WG; Lencer, DA; Bardina, L; Sampson, HA				Shreffler, WG; Lencer, DA; Bardina, L; Sampson, HA			IgE and IgG(4) epitope mapping by microarray immunoassay reveals the diversity of immune response to the peanut allergen, Ara h 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peptideprotein microarray; Ara h 2; epitope mapping; antibody diversity; IgE; IgG(4); peanut allergy	B-CELL EPITOPES; BINDING EPITOPES; MUTATIONAL ANALYSIS; ANTIBODY-RESPONSES; IDENTIFICATION; PROTEIN; IMMUNOGLOBULIN; MULTIANALYTE; SPECIFICITY; PERSISTENT	Background: Detailed assessment of antibody responses to allergens reveals clinically relevant information about both host response and antigen structure. Microarray technology offers advantages of scale and parallel design over previous methods of epitope mapping. Objective: We designed a redundant peptide microarray for IgE and IgG(4) epitope mapping of the previously characterized peanut allergen, Ara h 2. Methods: Six complete sets of overlapping peptides were commercially synthesized and site-specifically bound to epoxy-derivatized glass slides in triplicate. Peptides were 10, 15, or 20 amino acids in length with an offset of either 2 or 3 amino acids. A total of 10 control and 45 peanut-allergic sera were assayed. Specific IgE and IgG4 were detected by using fluorochrome-labeled monoclonal secondary antibodies. Results: By using 15-mer and 20-mer peptides, we could define 11 antigenic regions, whereas only 5 were identifiable using 10-mers. Controls and patients produced IgG4 recognizing a comparable number of Ara h 2 peptides, although the dominant epitopes were distinct. As expected, patient IgE bound a larger number of Ara h 2 peptides (9.4% vs 0.9%). IgE and IgG4 epitopes recognized by patients were largely the same, and there was a positive association between IgE and IgG4 signal, suggesting coordinate regulation. Cluster analysis of peptide binding patterns confirmed the specificity of antibody-peptide interactions and was used to define 9 core epitopes ranging from 6 to 16 residues in length-7 of which (78%) agreed with previous mapping. Conclusion: Epitope mapping by microarray peptide immunoassay and cluster analysis reveals interpatient heterogeneity and a more detailed map.	Mt Sinai Med Ctr, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst,Mt Sinai Sch Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Shreffler, WG (corresponding author), Mt Sinai Med Ctr, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst,Mt Sinai Sch Med, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	wayne.shreffler@mssm.edu			NCRR NIH HHS [M01-RR-00071] Funding Source: Medline; NIAID NIH HHS [P01-AI44236-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044236] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; BARRE A, 2005, IMMUNOL LETT; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; BURKS AW, 1995, J ALLERGY CLIN IMMUN, V95, P607, DOI 10.1016/S0091-6749(95)70323-3; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; de Vegvar HEN, 2003, J VIROL, V77, P11125, DOI 10.1128/JVI.77.20.11125-11138.2003; EKINS R, 1991, SCAND J CLIN LAB INV, V51, P33, DOI 10.3109/00365519109104600; EKINS R, 1990, ANN BIOL CLIN-PARIS, V48, P655; EKINS RP, 1991, CLIN CHEM, V37, P1955; Elsayed S, 2004, SCAND J IMMUNOL, V60, P486, DOI 10.1111/j.0300-9475.2004.01493.x; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; GETZOFF ED, 1987, SCIENCE, V235, P1191, DOI 10.1126/science.3823879; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; Haab BB, 2001, GENOME BIOL, V2; Hales BJ, 2004, INT ARCH ALLERGY IMM, V135, P101, DOI 10.1159/000080652; James JA, 1998, IMMUNOL REV, V164, P185, DOI 10.1111/j.1600-065X.1998.tb01220.x; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; Kobayashi I, 1996, J ALLERGY CLIN IMMUN, V97, P638, DOI 10.1016/S0091-6749(96)70309-3; Kusnezow W, 2003, J MOL RECOGNIT, V16, P165, DOI 10.1002/jmr.625; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; McCluskey J, 1998, IMMUNOL REV, V164, P209, DOI 10.1111/j.1600-065X.1998.tb01222.x; Mine Y, 2002, BIOCHEM BIOPH RES CO, V292, P1070, DOI 10.1006/bbrc.2002.6725; MOHAPATRA SS, 1994, IMMUNOL TODAY, V15, P596, DOI 10.1016/0167-5699(94)90226-7; Muto A, 2004, NATURE, V429, P566, DOI 10.1038/nature02596; Oyaizu K, 2001, ORAL MICROBIOL IMMUN, V16, P73, DOI 10.1034/j.1399-302x.2001.016002073.x; Petrakou E, 1998, ANTICANCER RES, V18, P4419; Pinilla C, 1999, CURR OPIN IMMUNOL, V11, P193, DOI 10.1016/S0952-7915(99)80033-8; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Ramos JDA, 2003, CLIN EXP ALLERGY, V33, P511, DOI 10.1046/j.1365-2222.2003.01623.x; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Tribbick G, 2002, J IMMUNOL METHODS, V267, P27, DOI 10.1016/S0022-1759(02)00138-2; Viudes A, 2001, INFECT IMMUN, V69, P2909, DOI 10.1128/IAI.69.5.2909-2919.2001; Williams GT, 2000, IMMUNITY, V13, P409, DOI 10.1016/S1074-7613(00)00040-6	38	148	154	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					893	899		10.1016/j.jaci.2005.06.033	http://dx.doi.org/10.1016/j.jaci.2005.06.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210066				2022-12-18	WOS:000235686600026
J	Pastorello, EA; Farioli, L; Pravettoni, V; Ortolani, C; Fortunato, D; Giuffrida, MG; Garoffo, LP; Calamari, AM; Brenna, O; Conti, A				Pastorello, EA; Farioli, L; Pravettoni, V; Ortolani, C; Fortunato, D; Giuffrida, MG; Garoffo, LP; Calamari, AM; Brenna, O; Conti, A			Identification of grape and wine allergens as an endochitinase 4, a lipid-transfer protein, and a thaumatin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; grape; wine; major allergens; minor allergens	ANAPHYLAXIS; CHITINASE; POLLEN; POTATO; PEACH	Background: Few allergic reactions to grape are reported in the literature. In some cases an association with peach and cherry allergy was observed. No IgE-mediated reactions to wine have been described, and no grape major allergens have yet been identified. Objective: We describe several severe reactions to grape or wine. We characterized the grape major allergens and tried to identify the allergen in wine. Methods: We collected documented histories of allergic reactions to grape and wine. Grape allergens were identified by means of SDS-PAGE and immunoblotting and purified by means of HPLC. Using amino acid sequencing and mass spectrometry, we identified the family of proteins to which the allergens belong. Cross-reactivity with peach and cherry was evaluated by means of cross-wise inhibition experiments. Results: Eleven patients with reactions to grape and 3 with anaphylactic reactions to wine were recruited. The major allergens were an endochitinase 4A and a lipid-transfer protein (LTP) that was homologous to and cross-reactive with peach LTP. A 24-kd protein homologous to the cherry thaumatin-like allergen was a minor allergen. Endochitinase 4A is very likely the allergen in vino novello and in vino Fragolino. Conclusions: Grape and wine might cause severe allergic reactions in sensitive patients. The major allergens of grape are endochitinase 4A, which is also the allergen of wine, and an LTP cross-reacting with the peach major allergen.	Osped Maggiore, IRCCS, Div Gen Med 1, Allergy Ctr, I-20122 Milan, Italy; ICP, CEMOC, UOOML, Milan, Italy; Osped Niguarda Ca Granda, Bizzozzero Div, Milan, Italy; ISPA, Natl Res Council, Turin, Italy; Univ Milan, Dept Food Sci & Microbiol, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Consiglio Nazionale delle Ricerche (CNR); Istituto Scienze delle Produzioni Alimentari (ISPA-CNR); University of Milan	Pastorello, EA (corresponding author), Dept Internal Med Padiglione Granelli, Via Francesco Sforza, I-20122 Milan, Italy.		Giuffrida, Maria Gabriella/AAY-6314-2020; Brenna, Oreste V/A-6417-2008; PASTORELLO, ELIDE ANNA/E-3897-2017	Giuffrida, Maria Gabriella/0000-0002-1297-2558; Brenna, Oreste V/0000-0003-4444-3236; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				ANTON E, 1997, ALLERGY S37, V52, P119; BIORKSTEN F, 1980, ALLERGY, V35, P671; Bircher AJ, 1999, J ALLERGY CLIN IMMUN, V104, P1111, DOI 10.1016/S0091-6749(99)70099-0; Brito FF, 1999, J ALLERGY CLIN IMMUN, V103, P262, DOI 10.1016/S0091-6749(99)70500-2; Brouillard R, 1997, BIOFACTORS, V6, P403, DOI 10.1002/biof.5520060406; COUTOSTHEVENOT P, 1993, EUR J BIOCHEM, V217, P885, DOI 10.1111/j.1432-1033.1993.tb18317.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Giannakis C., 1998, Australian Journal of Grape and Wine Research, V4, P14, DOI 10.1111/j.1755-0238.1998.tb00130.x; Giannoccaro F, 1998, ALLERGY, V53, P451, DOI 10.1111/j.1398-9995.1998.tb03923.x; Giuffrida MG, 2001, ELECTROPHORESIS, V22, P1705, DOI 10.1002/1522-2683(200105)22:9<1705::AID-ELPS1705>3.0.CO;2-0; GUINNEPAIN MT, 1997, REV FR ALLERGOL, V37, P400; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYEN M, 1994, AM J ENOL VITICULT, V45, P161; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; PIERPOINT WS, 1990, PHYSIOL MOL PLANT P, V36, P325, DOI 10.1016/0885-5765(90)90062-3; Quaranta S, 2001, ELECTROPHORESIS, V22, P1810, DOI 10.1002/1522-2683(200105)22:9&lt;1810::AID-ELPS1810&gt;3.0.CO;2-M; Robinson SP, 1997, PLANT PHYSIOL, V114, P771, DOI 10.1104/pp.114.3.771; Senna G, 2001, ALLERGY, V56, P1235, DOI 10.1034/j.1398-9995.2001.00352.x; Vaswani SK, 1999, ANN ALLERG ASTHMA IM, V83, P25, DOI 10.1016/S1081-1206(10)63508-9; Warburg O., 1942, BIOCHEM Z, V310, P384; Waters EJ, 1998, J AGR FOOD CHEM, V46, P4950, DOI 10.1021/jf980421o; [No title captured]	23	148	154	1	17	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					350	359		10.1067/mai.2003.35	http://dx.doi.org/10.1067/mai.2003.35			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589356				2022-12-18	WOS:000180942700020
J	Reitamo, S; Van Leent, EJM; Ho, V; Harper, J; Ruzicka, T; Kalimo, K; Cambazard, F; Rustin, M; Taieb, A; Gratton, D; Sauder, D; Sharpe, G; Smith, C; Junger, M; de Prost, Y				Reitamo, S; Van Leent, EJM; Ho, V; Harper, J; Ruzicka, T; Kalimo, K; Cambazard, F; Rustin, M; Taieb, A; Gratton, D; Sauder, D; Sharpe, G; Smith, C; Junger, M; de Prost, Y		European Canadian Tacrolimus Ointm	Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tacrolimus; FK506; atopic dermatitis; efficacy; safety; ointment; topical	ADULT PATIENTS; TRIAL; FK506; FK-506; CELLS	Background: Vehicle-controlled studies have demonstrated the efficacy and safety of tacrolimus ointment in the treatment of patients with atopic dermatitis (AD). Objective: This study was undertaken to compare 0.03% and 0.1% tacrolimus ointment with 1% hydrocortisone acetate ointment in children 2 to 15 years of age with moderate-to-severe AD. Methods: Treatment was twice daily to affected areas for 3 weeks in this multicenter, randomized, double-blind, parallel-group study. The primary endpoint was the modified eczema area and severity index (mEASI) mean area under the curve (mAUC) as a percentage of baseline. Results: Five hundred sixty patients were randomized and received at least one application of ointment. Discontinuations included 21 of 189 patients from the 0.03% tacrolimus group, 13 of 186 patients from the 0.1% tacrolimus group, and 20 of 185 patients from the hydrocortisone acetate group. The median mEASI mAUC as a percentage of baseline showed 0.03% and 0.1 % tacrolimus to be significantly more effective than 1% hydrocortisone acetate (P < .001) and 0.1 % tacrolimus to be more effective than 0.03% tacrolimus (P = .006). The mEASI mAUC as a percentage of baseline was 44.8%, 39.8%, and 64.0% for patients who received 0.03% tacrolimus, 0.1% tacrolimus, and 1% hydrocortisone acetate, respectively. Transient skin burning was the only adverse event to show a higher incidence in the tacrolimus treatment groups than in the hydrocortisone acetate group (P < .05). Laboratory parameters showed no treatment differences and no marked changes over time. Conclusion: Tacrolimus, 0.03% and 0.1%, was significantly more effective than 1% hydrocortisone acetate and 0.1 % tacrolimus was more effective than 0.03% tacrolimus in the treatment of moderate-to-severe AD in children. No safety concerns were identified.	Univ Helsinki, Hosp Skin & Allerg Dis, Dept Dermatol, Helsinki 00250, Finland; Univ Amsterdam, Dept Dermatol, Amsterdam, Netherlands; Div Dermatol, Vancouver, BC, Canada; Great Ormond St Hosp Sick Children, Dept Paediat Dermatol, London WC1N 3JH, England; Univ Dusseldorf, Hautklin, D-4000 Dusseldorf, Germany; Turku Univ Hosp, Dept Dermatol, FIN-20520 Turku, Finland; Hop Nord St Etienne, Serv Dermatol, St Etienne, France; Royal Free Hosp, London NW3 2QG, England; Hop Pellegrin Enfants, Unite Dermatol Pediat, Bordeaux, France; Univ Toronto, Div Dermatol, Toronto, ON, Canada; Univ Liverpool, Dept Dermatol, Liverpool L69 3BX, Merseyside, England; Univ Hosp Lewisham, Dept Dermatol, Skin Therapy Res Unit, London, England; Univ Klinikum Tuebingen, Hautklin, Tubingen, Germany; Hop Necker Enfants Malad, Serv Dermatol, F-75730 Paris, France	University of Helsinki; University of Amsterdam; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Heinrich Heine University Dusseldorf; University of Turku; CHU de St Etienne; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; CHU Bordeaux; University of Toronto; University of Liverpool; University of London; King's College London; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Reitamo, S (corresponding author), Univ Helsinki, Hosp Skin & Allerg Dis, Dept Dermatol, Meilahdentie 2, Helsinki 00250, Finland.		TAIEB, ALAIN/AAB-1085-2021; Smith, Catherine H./G-5268-2012	Smith, Catherine H./0000-0001-9918-1144				Alaiti S, 1998, J AM ACAD DERMATOL, V38, P69, DOI 10.1016/S0190-9622(98)70541-9; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; Bos R, 1996, COLLOID SURFACE B, V7, P101, DOI 10.1016/0927-7765(96)01293-3; *BRIT MED ASS ROYA, 1999, BRIT NAT FORM; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; GOTO T, 1987, TRANSPLANT P, V19, P4; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hanifin JM, 2001, J AM ACAD DERMATOL, V44, pS28, DOI 10.1067/mjd.2001.109810; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HILL HM, 1997, 1997 AAPS ANN M EXP; Kang S, 2001, J AM ACAD DERMATOL, V44, pS58, DOI 10.1067/mjd.2001.109812; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 1997, ANN ALLERG ASTHMA IM, V79, P197, DOI 10.1016/S1081-1206(10)63003-7; MUKAI H, 1990, Journal of Dermatology (Tokyo), V17, P477; Paller A, 2001, J AM ACAD DERMATOL, V44, pS47, DOI 10.1067/mjd.2001.109813; Panhans-Gross A, 2001, J ALLERGY CLIN IMMUN, V107, P345, DOI 10.1067/mai.2001.112600; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Reitamo S, 2000, ARCH DERMATOL, V136, P999, DOI 10.1001/archderm.136.8.999; Reitamo S, 1998, J INVEST DERMATOL, V111, P396, DOI 10.1046/j.1523-1747.1998.00323.x; Reitamo S, 2001, J ALLERGY CLIN IMMUN, V107, P445, DOI 10.1067/mai.2001.113521; Remitz A, 2001, J ALLERGY CLIN IMMUN, V107, P196, DOI 10.1067/mai.2001.112131; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Soter NA, 2001, J AM ACAD DERMATOL, V44, pS39, DOI 10.1067/mjd.2001.109817; Taieb A, 2000, CUTANEOUS BIOMETRICS, P93; TOCCI MJ, 1989, J IMMUNOL, V143, P718	25	148	161	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					539	546		10.1067/mai.2002.121831	http://dx.doi.org/10.1067/mai.2002.121831			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11898004				2022-12-18	WOS:000174586400024
J	Kaur, R; Chupp, G				Kaur, Ravdeep; Chupp, Geoffrey			Phenotypes and endotypes of adult asthma: Moving toward precision medicine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; heterogeneity; phenotypes; endotypes; biologics	INNATE LYMPHOID-CELLS; EXHALED NITRIC-OXIDE; INDUCED SPUTUM; INFLAMMATORY SUBTYPES; AIRWAY INFLAMMATION; CLUSTER-ANALYSIS; NASAL POLYPS; DOUBLE-BLIND; BENRALIZUMAB; OMALIZUMAB	Asthma is a chronic inflammatory disease of the airways that is challenging to dissect into subgroups because of the heterogeneity present across the spectrum of the disease. Efforts to subclassify asthma using advanced computational methods have identified a number of different phenotypes that suggest that multiple pathobiologically driven clusters of disease exist. The main phenotypes that have been identified include (1) early-onset allergic asthma, (2) early-onset allergic moderate-to-severe remodeled asthma, (3) late-onset nonallergic eosinophilic asthma, and (4) late-onset nonallergic noneosinophilic asthma. Subgroups of these phenotypes also exist but have not been as consistently identified. Advances in our understanding of the diverse immunologic perturbations that drive airway inflammation are consistent with clinical traits associated with these phenotypes and their response to biologic therapies. This has improved the clinician's approach to characterizing asthmatic patients in the clinic. Being able to define asthma endotypes using clinical characteristics and biomarkers will move physicians toward even more personalized management of asthma and precision-based care in the future. Here we will review the most prominent phenotypes and immunologic advances that suggest these disease subtypes represent asthma endotypes.	[Kaur, Ravdeep] Yale Sch Med, Dept Internal Med, Div Rheumatol Allergy & Clin Immunol, New Haven, CT USA; [Chupp, Geoffrey] Yale Sch Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, 300 Cedar St,S441 TAC, New Haven, CT 06520 USA	Yale University; Yale University	Chupp, G (corresponding author), Yale Sch Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, 300 Cedar St,S441 TAC, New Haven, CT 06520 USA.	geoffrey.chupp@yale.edu						Agache I, 2012, ALLERGY, V67, P835, DOI 10.1111/j.1398-9995.2012.02832.x; Agache I, 2019, J CLIN INVEST, V129, P1493, DOI 10.1172/JCI124611; Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Agumadu VC, 2018, CUREUS, V10, DOI 10.7759/cureus.3216; Akinbami LJ, 2001, NCHS DATA BRIEF, V2012, P1; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Barnes PJ, 2010, CHEST, V138, P682, DOI 10.1378/chest.09-2090; Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; Bellini A, 2012, MUCOSAL IMMUNOL, V5, P140, DOI 10.1038/mi.2011.60; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Borish L, 2016, ANN ALLERG ASTHMA IM, V117, P108, DOI 10.1016/j.anai.2016.04.022; Boudier A, 2019, ALLERGY, V74, P953, DOI 10.1111/all.13697; Boudier A, 2013, AM J RESP CRIT CARE, V188, P550, DOI 10.1164/rccm.201301-0156OC; Buhl R, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00634-2017; Busse W, 2019, J ALLERGY CLIN IMMUN, V143, P190, DOI 10.1016/j.jaci.2018.08.031; Busse W, 2012, J ALLERGY CLIN IMMUN, V129, P983, DOI 10.1016/j.jaci.2012.01.033; Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092; Chambers ES, 2015, J ALLERGY CLIN IMMUN, V136, P628, DOI 10.1016/j.jaci.2015.01.026; Chen JH, 2016, RESP MED, V121, P48, DOI 10.1016/j.rmed.2016.10.018; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Chupp GL, 1998, J IMMUNOL, V161, P3114; Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064; Coumou H, 2016, EXPERT REV RESP MED, V10, P1093, DOI 10.1080/17476348.2017.1236688; Culic O, 2001, EUR J PHARMACOL, V429, P209, DOI 10.1016/S0014-2999(01)01321-8; de Groot JC, 2015, ERJ OPEN RES, V1; de Groot JC, 2016, ERJ OPEN RES, V2, P1; Domingo C, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0893-x; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Eisner MD, 2012, J ASTHMA, V49, P642, DOI 10.3109/02770903.2012.690477; Endo Y, 2014, TRENDS IMMUNOL, V35, P69, DOI 10.1016/j.it.2013.11.003; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Gabryelska A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00692; Gandhi NA, 2017, EXPERT REV CLIN IMMU, V13, P425, DOI 10.1080/1744666X.2017.1298443; Gao J, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0248-7; Ghazi A, 2012, EXPERT OPIN BIOL TH, V12, P113, DOI 10.1517/14712598.2012.642359; Gomez JL, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00800-2017; Grob NM, 2008, CHEST, V133, P837, DOI 10.1378/chest.07-2743; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Han JK, 2019, J ALLERGY CLIN IMMUN, V143, pAB422, DOI 10.1016/j.jaci.2018.12.948; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Holgate S, 2009, RESP MED, V103, P1098, DOI 10.1016/j.rmed.2009.03.008; Ianaro A, 2000, J PHARMACOL EXP THER, V292, P156; Jia Y, 2016, AM J RESP CELL MOL, V55, P675, DOI 10.1165/rcmb.2016-0099OC; Kabata H, 2015, ALLERGOL INT, V64, P227, DOI 10.1016/j.alit.2015.03.004; Kim HY, 2016, EUR J IMMUNOL, V46, P795, DOI 10.1002/eji.201444557; Komi DEA, 2019, CLIN REV ALLERG IMMU, V56, P234, DOI 10.1007/s12016-018-8720-1; Kubo M, 2017, IMMUNOL REV, V278, P162, DOI 10.1111/imr.12557; Kuruvilla ME, 2019, CLIN REV ALLERG IMMU, V56, P219, DOI 10.1007/s12016-018-8712-1; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lefaudeux D, 2017, J ALLERGY CLIN IMMUN, V139, P1797, DOI 10.1016/j.jaci.2016.08.048; Lim HF, 2018, SEMIN RESP CRIT CARE, V39, P56, DOI 10.1055/s-0037-1606217; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; MacDonald KM, 2019, EXPERT REV CLIN IMMU, V15, P553, DOI 10.1080/1744666X.2019.1574571; Miljkovic D, 2014, ALLERGY, V69, P1154, DOI 10.1111/all.12440; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Opina MTD, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0678-1; Ortega Hector, 2014, Ann Am Thorac Soc, V11, P1011, DOI 10.1513/AnnalsATS.201312-454OC; Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5; Pavlidis S, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00938-2018; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Peebles RS, 2019, CLIN CHEST MED, V40, P29, DOI 10.1016/j.ccm.2018.10.014; Pelaia C, 2018, DRUG DES DEV THER, V12, P619, DOI 10.2147/DDDT.S155307; Peters MC, 2016, LANCET RESP MED, V4, P574, DOI 10.1016/S2213-2600(16)30048-0; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Samitas K, 2017, CURR OPIN PULM MED, V23, P48, DOI 10.1097/MCP.0000000000000342; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Svenningsen S, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00158; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Torabi M, 2018, GEOSPAT HLTH, V13; Tran TN, 2016, ANN ALLERG ASTHMA IM, V116, P37, DOI 10.1016/j.anai.2015.10.027; Wan XC, 2016, IMMUNOL ALLERGY CLIN, V36, P547, DOI 10.1016/j.iac.2016.03.004; Wang FP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166833; Weinstein SF, 2018, J ALLERGY CLIN IMMUN, V142, P171, DOI 10.1016/j.jaci.2017.11.051; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Yan XT, 2015, AM J RESP CRIT CARE, V191, P1116, DOI 10.1164/rccm.201408-1440OC	82	147	151	8	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					1	12		10.1016/j.jaci.2019.05.031	http://dx.doi.org/10.1016/j.jaci.2019.05.031			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	31277742				2022-12-18	WOS:000473432800001
J	Durack, J; Lynch, SV; Nariya, S; Bhakta, NR; Beigelman, A; Castro, M; Dyer, AM; Israel, E; Kraft, M; Martin, RJ; Mauger, DT; Rosenberg, SR; Sharp-King, T; White, SR; Woodruff, PG; Avila, PC; Denlinger, LC; Holguin, F; Lazarus, SC; Lugogo, N; Moore, WC; Peters, SP; Que, L; Smith, LJ; Sorkness, CA; Wechsler, ME; Wenzel, SE; Boushey, HA; Huang, YJ				Durack, Juliana; Lynch, Susan V.; Nariya, Snehal; Bhakta, Nirav R.; Beigelman, Avraham; Castro, Mario; Dyer, Anne-Marie; Israel, Elliot; Kraft, Monica; Martin, Richard J.; Mauger, David T.; Rosenberg, Sharon R.; Sharp-King, Tonya; White, Steven R.; Woodruff, Prescott G.; Avila, Pedro C.; Denlinger, Loren C.; Holguin, Fernando; Lazarus, Stephen C.; Lugogo, Njira; Moore, Wendy C.; Peters, Stephen P.; Que, Loretta; Smith, Lewis J.; Sorkness, Christine A.; Wechsler, Michael E.; Wenzel, Sally E.; Boushey, Homer A.; Huang, Yvonne J.		Natl Heart Lung Blood Inst AsthmaN	Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; microbiome; corticosteroids; 16S ribosomal RNA; bacteria; T(H)2 inflammation; three-gene mean; metabolic pathways; short-chain fatty acids	HAEMOPHILUS-INFLUENZAE; AIRWAY MICROBIOME; EXPRESSION; INFECTION; EOSINOPHILS; COMMUNITIES; DIVERSITY; SECRETION; DISEASE; MODELS	Background: Compositional differences in the bronchial bacterial microbiota have been associated with asthma, but it remains unclear whether the findings are attributable to asthma, to aeroallergen sensitization, or to inhaled corticosteroid treatment. Objectives: We sought to compare the bronchial bacterial microbiota in adults with steroid-naive atopic asthma, subjects with atopy but no asthma, and nonatopic healthy control subjects and to determine relationships of the bronchial microbiota to phenotypic features of asthma. Methods: Bacterial communities in protected bronchial brushings from 42 atopic asthmatic subjects, 21 subjects with atopy but no asthma, and 21 healthy control subjects were profiled by using 16S rRNA gene sequencing. Bacterial composition and communitylevel functions inferred from sequence profiles were analyzed for between-group differences. Associations with clinical and inflammatory variables were examined, including markers of type 2-related inflammation and change in airway hyperresponsiveness after 6 weeks of fluticasone treatment. Results: The bronchial microbiome differed significantly among the 3 groups. Asthmatic subjects were uniquely enriched inmembers of the Haemophilus, Neisseria, Fusobacterium, and Porphyromonas species and the Sphingomonodaceae family and depleted in members of the Mogibacteriaceae family and Lactobacillales order. Asthma-associated differences in predicted bacterial functions included involvement of amino acid and short-chain fatty acid metabolism pathways. Subjects with type 2-high asthma harbored significantly lower bronchial bacterial burden. Distinct changes in specific microbiota members were seen after fluticasone treatment. Steroid responsiveness was linked to differences in baseline compositional and functional features of the bacterial microbiome. Conclusion: Even in subjects with mild steroid-naive asthma, differences in the bronchial microbiome are associated with immunologic and clinical features of the disease. The specific differences identified suggest possible microbiome targets for future approaches to asthma treatment or prevention.	[Durack, Juliana; Lynch, Susan V.] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA USA; [Nariya, Snehal; Huang, Yvonne J.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA; [Bhakta, Nirav R.; Woodruff, Prescott G.; Lazarus, Stephen C.; Boushey, Homer A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Beigelman, Avraham; Castro, Mario] Washington Univ, Div Pediat, Sch Med, St Louis, MO 63130 USA; [Castro, Mario] Washington Univ, Div Pulm & Crit Care Med, Sch Med, St Louis, MO 63130 USA; [Dyer, Anne-Marie; Mauger, David T.; Sharp-King, Tonya] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Israel, Elliot] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Kraft, Monica] Univ Arizona, Hlth Sci, Tucson, AZ USA; [Martin, Richard J.; Wechsler, Michael E.] Natl Jewish Hosp, Dept Med, Denver, CO USA; [Rosenberg, Sharon R.; Avila, Pedro C.; Smith, Lewis J.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [White, Steven R.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Denlinger, Loren C.; Sorkness, Christine A.] Univ Wisconsin Madison, Dept Med, Madison, WI USA; [Holguin, Fernando; Wenzel, Sally E.] Univ Pittsburgh, Asthma Inst, UPMC UPSOM, Pittsburgh, PA USA; [Lugogo, Njira; Que, Loretta] Duke Univ, Sch Med, Duke Asthma Allergy & Airway Ctr, Durham, NC 27706 USA; [Moore, Wendy C.; Peters, Stephen P.] Wake Forest Sch Med, Winston Salem, NC USA	University of California System; University of California San Francisco; University of Michigan System; University of Michigan; University of California System; University of California San Francisco; Washington University (WUSTL); Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Brigham & Women's Hospital; University of Arizona; University of Arizona Health Sciences; National Jewish Health; Northwestern University; University of Chicago; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Duke University; Wake Forest University	Boushey, HA (corresponding author), Univ Calif San Francisco, Div Pulm Crit Care Med, 505 Parnassus Ave,M1292,Box 0130, San Francisco, CA 94143 USA.	homer.boushey@ucsf.edu	Durack, Juliana/B-3400-2010; Wechsler, Michael/AAC-5506-2019	Durack, Juliana/0000-0002-8916-9376; Smith, Lewis J/0000-0002-4728-1562; Wenzel, Sally/0000-0002-4242-0164; Huang, Yvonne/0000-0002-7497-6597	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (MAID) [AI113916, AI089473-01, AI097172]; Janssen; Broad Foundation; Sloan Foundation; Pfizer; NIH/National Institute of Child Health and Human Development [HD082147-01]; NIH/National Heart, Lung, and Blood Institute (NHLBI) [HL098107, HL098964]; NIH/National Institute of Diabetes and Digestive and Kidney Diseases [DK104664]; NHLBI; National Institute of Allergy and Infectious Disease (NIAID); NIH/NHLBI; Roche/Genentech; Boston Scientific; Holaira; Genentech; Teva; GlaxoSmithKline; Boehringer Ingelheim; Elsevier; Neostem; Amgen; Novartis; Sanofi-Aventis; Vectura; Medlmmune; Invion; AstraZeneca; Philips Respironics; Regeneron Pharmaceuticals; Campbell; Edwards Conroy; Crammer; Bishop O'Brien; Fox Rothschild; Ryan Deluca LLP; TEVA Specialty Pharmaceuticals; UpToDate; Cowen Co; Bird Rock Bio; Nuvelution Pharmaceuticals; Vitaeris; Sanofi; Sunovion; Respiratory Effectiveness Group; Pearl Therapeutics; Insmed; NIAID [U19-AI-095230]; Marathon Pharmaceuticals; Johnson Johnson; Roche; Respiratory Disease Young Investigators' Research Forum; NIH; MAID; Sepracor/Sunovion; Asthmatx/BSCI; Merck; Regeneron; Ambitbio; Mylan; Meda; Theravance; Tunitas; Gliacure; Aerocrine; Actelion; NIH/NIAID; McGraw-Hill Companies; NHLBI [K23HL105572]; Michigan Institute of Health and Clinical Research; American Academy of Allergy, Asthma Immunology; Massachusetts Institute of Technology; European Respiratory Society; Microbiome R&D Business Forum; European Academy of Allergy, Asthma, and Clinical Immunology; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001422] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098090, U10HL098115, U10HL098177, U10HL098098, U10HL109257, U10HL098096, K23HL116657, U10HL098102, U10HL098075, K23HL105572, U10HL098107, U10HL098103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI129958] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (MAID); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Broad Foundation; Sloan Foundation(Alfred P. Sloan Foundation); Pfizer(Pfizer); NIH/National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Disease (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Roche/Genentech(Roche HoldingGenentech); Boston Scientific(Boston Scientific); Holaira; Genentech(Roche HoldingGenentech); Teva(Teva Pharmaceutical Industries); GlaxoSmithKline(GlaxoSmithKline); Boehringer Ingelheim(Boehringer Ingelheim); Elsevier; Neostem; Amgen(Amgen); Novartis(Novartis); Sanofi-Aventis(Sanofi-Aventis); Vectura; Medlmmune; Invion; AstraZeneca(AstraZeneca); Philips Respironics; Regeneron Pharmaceuticals(Regeneron); Campbell; Edwards Conroy; Crammer; Bishop O'Brien; Fox Rothschild; Ryan Deluca LLP; TEVA Specialty Pharmaceuticals(Teva Pharmaceutical Industries); UpToDate; Cowen Co; Bird Rock Bio; Nuvelution Pharmaceuticals; Vitaeris; Sanofi; Sunovion; Respiratory Effectiveness Group; Pearl Therapeutics; Insmed; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Marathon Pharmaceuticals; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Roche(Roche Holding); Respiratory Disease Young Investigators' Research Forum; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MAID; Sepracor/Sunovion; Asthmatx/BSCI; Merck(Merck & Company); Regeneron(Regeneron); Ambitbio; Mylan; Meda; Theravance; Tunitas; Gliacure; Aerocrine; Actelion; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); McGraw-Hill Companies; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Michigan Institute of Health and Clinical Research; American Academy of Allergy, Asthma Immunology; Massachusetts Institute of Technology; European Respiratory Society; Microbiome R&D Business Forum; European Academy of Allergy, Asthma, and Clinical Immunology; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S. V. Lynch has received grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (MAID; AI113916, AI089473-01, and AI097172), Janssen, the Broad Foundation, the Sloan Foundation, Pfizer, the NIH/National Institute of Child Health and Human Development (HD082147-01), the NIH/National Heart, Lung, and Blood Institute (NHLBI; HL098107 and HL098964), and the NIH/National Institute of Diabetes and Digestive and Kidney Diseases (DK104664); has a patent Stan449-PRV REDUCTIVE PRODRUG CANCER CHEMOTHERA issued, a patent Combination antibiotic and antibody therapy for the treatment of Pseudomonas aeruginosa infection with royalties paid, a patent provisional filing for use of Lactobacillus sakei and other lactic acid bacteria as a therapeutic strategy for chronic rhinosinusitis issued, a patent provisional filing for claims associated with use of PhyloChip as a diagnostic and prognostic clinical tool issued, and a patent Bacterial Therapeutic Consortium for induction of Immune Tolerance pending. S. Nariya has received a grant from the NHLBI and the National Institute of Allergy and Infectious Disease (NIAID). N. R. Bhakta has received a grant from the NIH/NHLBI and has received personal fees from Roche/Genentech. M. Castro has received personal fees from Boston Scientific, Holaira, Genentech, Teva, GlaxoSmithKline, Boehringer Ingelheim, Elsevier, and Neostem; has received grants from Amgen, Teva, Novartis, GlaxoSmithKline, Sanofi-Aventis, Vectura, Boehringer Ingelheim, Medlmmune, Invion, and Pfizer; and owns stock in Sparo. A.-.M. Dyer has received a grant from the NHLBI. E. Israel has received personal fees from AstraZeneca, Novartis, Philips Respironics, Regeneron Pharmaceuticals, Campbell, Campbell, Edwards & Conroy, Crammer, Bishop & O'Brien, Fox Rothschild, Ryan Deluca LLP, TEVA Specialty Pharmaceuticals, UpToDate, Cowen & Co, Bird Rock Bio, Nuvelution Pharmaceuticals, and Vitaeris; has received a grant from Genentech and Sanofi; has received nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, and TEVA; and has received other compensation from Novartis, Research in Real Life, and TEVA Specialty Pharmaceuticals. R.J. Martin has received a grant from Medlmmune; has received personal fees from Teva, AstraZeneca, and Genentech; and has received travel support from the Respiratory Effectiveness Group. D. T. Mauger has received a grant from the NHLBI and has received nonfinancial support from GlaxoSmithKline, Merck, Boehringer Ingelheim, Teva, and Sunovion. S. R. Rosenberg has received grants from AstraZeneca and Boehringer Ingelheim. T. Sharp-King has received a grant from the NHLBI and has received personal fees from Pearl Therapeutics and Insmed. S. R. White has received grants from the NIAID (U19-AI-095230) and AstraZeneca and has received personal fees from Marathon Pharmaceuticals. P. G. Woodruff has received personal fees from Genentech, Johnson & Johnson, Roche, and Neostem and has a patent pending related to asthma biomarkers with Genentech. P. C. Avila has received grants from the NIH/NHLBI, Genentech, AstraZeneca, and Novartis. L. C. Denlinger has received a grant from the NIH/NHLBI and has received personal fees from Novartis and GlaxoSmithKline. S. C. Lazarus has received a grant from the NIH/NHLBI and has received personal fees from Respiratory Disease Young Investigators' Research Forum. N. Lugogo has received a grant from the NIH. W. C. Moore has received a grant from the NHLBI. S. P. Peters has received a grant from the NIH/NHLBI. C. A.; Sorkness has received grants from the NHLBI and the MAID. M. E. Wechsler has received personal fees from Sepracor/Sunovion, Asthmatx/BSCI, Merck, Regeneron, Medlmmune, Ambitbio, Vectura, Sanofi, Teva, Mylan, AstraZeneca, Genentech, Meda, Theravance, Novartis, Boehringer Ingelheim, GlaxoSmithKline, Tunitas, and Gliacure. S. E. Wenzel has received grants from Sanofi, Genentech, AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim and has received personal fees from AstraZeneca, Aerocrine, GlaxoSmithKline, Actelion, and Boehringer Ingelheim. H. A. Boushey has received grants from the NIH/NHBI and the NIH/NIAID and has received personal fees from the McGraw-Hill Companies. Y. J. Huang has received grants from the NHLBI (K23HL105572) and the Michigan Institute of Health and Clinical Research, has received travel and lodging compensation from the NIH, and has received payment for lectures from the American Academy of Allergy, Asthma & Immunology; the Massachusetts Institute of Technology; the European Respiratory Society; the Microbiome R&D Business Forum; and the European Academy of Allergy, Asthma, and Clinical Immunology. The rest of the authors declare that they have no relevant conflicts of interest.	Abreu NA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003783; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; Araki N, 2010, EUR J PHARMACOL, V644, P209, DOI 10.1016/j.ejphar.2010.06.056; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Bhakta Nirav R, 2013, Clin Transl Allergy, V3, P24, DOI 10.1186/2045-7022-3-24; Bostanci N, 2011, CYTOKINE, V56, P656, DOI 10.1016/j.cyto.2011.08.039; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Denner DR, 2016, J ALLERGY CLIN IMMUN, V137, P1398, DOI 10.1016/j.jaci.2015.10.017; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dollive S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071806; FAITH DP, 1992, BIOL CONSERV, V61, P1, DOI 10.1016/0006-3207(92)91201-3; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Gerber GK, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002624; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hirose M, 2001, J PERIODONTOL, V72, P590, DOI 10.1902/jop.2001.72.5.590; Hogan SP, 2013, CURR OPIN GASTROEN, V29, P7, DOI 10.1097/MOG.0b013e32835ab29a; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Iwai S, 2012, J CLIN MICROBIOL, V50, P2995, DOI 10.1128/JCM.00278-12; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kariyawasam HH, 2013, CURR OPIN OTOLARYNGO, V21, P79, DOI 10.1097/MOO.0b013e32835ac640; Kassahun W, 2014, STAT MED, V33, P4402, DOI 10.1002/sim.6237; Kelly CJ, 2015, CELL HOST MICROBE, V17, P662, DOI 10.1016/j.chom.2015.03.005; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; McMurdie PJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003531; Min YY, 2005, STAT MODEL, V5, P1, DOI 10.1191/1471082X05st084oa; Nagaoka K, 2013, ANTIMICROB AGENTS CH, V57, P1844, DOI 10.1128/AAC.02466-12; Ozdemir O, 2010, CLIN EXP IMMUNOL, V160, P295, DOI 10.1111/j.1365-2249.2010.04109.x; Pana Y, 2008, MICROB PATHOG, V46, P73; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Peleg AY, 2010, NAT REV MICROBIOL, V8, P340, DOI 10.1038/nrmicro2313; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Pinheiro JC, 2005, LINEAR MIXED EFFECTS; Price MN, 2009, MOL BIOL EVOL, V26, P1641, DOI 10.1093/molbev/msp077; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Simpson JL, 2016, EUR RESPIR J, V47, P792, DOI 10.1183/13993003.00405-2015; Tarkka MT, 2009, CURR GENET, V55, P233, DOI 10.1007/s00294-009-0241-2; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Tomazic PV, 2014, J ALLERGY CLIN IMMUN, V133, P741, DOI 10.1016/j.jaci.2013.09.040; Travers J, 2015, MUCOSAL IMMUNOL, V8, P464, DOI 10.1038/mi.2015.2; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Ursell LK, 2012, J ALLERGY CLIN IMMUN, V129, P1204, DOI 10.1016/j.jaci.2012.03.010; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zajonc DM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00400	52	147	155	3	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					63	75		10.1016/j.jaci.2016.08.055	http://dx.doi.org/10.1016/j.jaci.2016.08.055			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27838347	Bronze, Green Accepted			2022-12-18	WOS:000404542000007
J	Castanhinha, S; Sherburn, R; Walker, S; Gupta, A; Bossley, CJ; Buckley, J; Ullmann, N; Grychtol, R; Campbell, G; Maglione, M; Koo, S; Fleming, L; Gregory, L; Snelgrove, RJ; Bush, A; Lloyd, CM; Saglani, S				Castanhinha, Susana; Sherburn, Rebekah; Walker, Simone; Gupta, Atul; Bossley, Cara J.; Buckley, James; Ullmann, Nicola; Grychtol, Ruth; Campbell, Gaynor; Maglione, Marco; Koo, Sergio; Fleming, Louise; Gregory, Lisa; Snelgrove, Robert J.; Bush, Andrew; Lloyd, Clare M.; Saglani, Sejal			Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; fungal sensitization; pediatric; IL-33; innate immunity; steroid resistance	LUNG INFLAMMATION; INNATE; ITRACONAZOLE; EXPOSURE; CHILDREN; EXACERBATIONS; VORICONAZOLE; ALLERGENS; IMMUNITY; MOLDS	Background: The mechanism underlying severe asthma with fungal sensitization (SAFS) is unknown. IL-33 is important in fungus-induced asthma exacerbations, but its role in fungal sensitization is unexplored. Objective: We sought to determine whether fungal sensitization in children with severe therapy-resistant asthma is mediated by IL-33. Methods: Eighty-two children (median age, 11.7 years; 63% male) with severe therapy-resistant asthma were included. SAFS (n = 38) was defined as specific IgE or skin prick test response positivity to Aspergillus fumigatus, Alternaria alternata, or Cladosporium herbarum. Clinical features and airway immunopathology were assessed. Chronic exposure to house dust mite and A alternata were compared in a neonatal mouse model. Results: Children with SAFS had earlier symptom onset (0.5 vs 1.5 years, P = .006), higher total IgE levels (637 vs 177 IU/mL, P = .002), and nonfungal inhalant allergen-specific IgE. Significantly more children with SAFS were prescribed maintenance oral steroids (42% vs 14%, P = .02). SAFS was associated with higher airway IL-33 levels. In neonatal mice A alternata exposure induced higher serum IgE levels, pulmonary IL-33 levels, and IL-13(+) innate lymphoid cell (ILC) and T(H)2 cell numbers but similar airway hyperresponsiveness (AHR) compared with those after house dust mite exposure. Lung IL-33 levels, IL-13(+) ILC numbers, T(H)2 cell numbers, IL-13 levels, and AHR remained increased with inhaled budesonide during A alternata exposure, but all features were significantly reduced in ST2(-/-) mice lacking a functional receptor for IL-33. Conclusion: Pediatric SAFS was associated with more oral steroid therapy and higher IL-33 levels. A alternata exposure resulted in increased IL-33-mediated ILC2 numbers, T(H)2 cell numbers, and steroid-resistant AHR. IL-33 might be a novel therapeutic target for SAFS.	[Castanhinha, Susana; Ullmann, Nicola; Maglione, Marco; Koo, Sergio; Fleming, Louise; Bush, Andrew; Saglani, Sejal] Royal Brompton Hosp, Dept Resp Paediat, London, England; [Sherburn, Rebekah; Walker, Simone; Buckley, James; Grychtol, Ruth; Campbell, Gaynor; Gregory, Lisa; Snelgrove, Robert J.; Lloyd, Clare M.; Saglani, Sejal] Imperial Coll London, NHLI, Leukocyte Biol, London, England; [Fleming, Louise; Bush, Andrew] Imperial Coll London, NHLI, Airways Dis, London, England; [Gupta, Atul; Bossley, Cara J.] Kings Coll Hosp London, Dept Resp Paediat, London, England	Royal Brompton Hospital; Imperial College London; Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital	Saglani, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Resp Paediat, NHLI, 368 Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	s.saglani@imperial.ac.uk	ULLMANN, NICOLA/K-6140-2016; Fleming, Louise/ABD-7452-2020; Maglione, Marco/AAC-6848-2022; Saglani, Sejal/AAE-5072-2019; Sherburn, Rebekah/AAB-5414-2022; Castanhinha, Susana/S-3275-2018	Sherburn, Rebekah/0000-0002-1683-3977; Ullmann, Nicola/0000-0003-1111-5690; Lloyd, Clare/0000-0001-8977-6726; Fleming, Louise/0000-0002-7268-7433; Buckley, James/0000-0001-9567-1621; MAGLIONE, MARCO/0000-0001-8181-2219; Castanhinha, Susana/0000-0003-0762-7730; Gregory, Lisa/0000-0003-2199-5417	Wellcome Trust UK [086718/Z/08/Z, 095707/Z/11/Z]; MRC New Investigator Research Grant [MR/J010529/1]; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; Imperial College London; German Research Foundation [GR 4379/1 1]; MRC [MR/J010529/1] Funding Source: UKRI; Medical Research Council [MR/J010529/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10192] Funding Source: researchfish; Asthma UK [AUK-AC-2012-01, 10/058] Funding Source: researchfish	Wellcome Trust UK(Wellcome Trust); MRC New Investigator Research Grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; Imperial College London(General Electric); German Research Foundation(German Research Foundation (DFG)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	C.M.L. and R.J.S. were funded by the Wellcome Trust UK (grants 086718/Z/08/Z and 095707/Z/11/Z). S.S. was funded by the MRC New Investigator Research Grant (grant MR/J010529/1). A.B. is an NIHR Senior Investigator and was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. S.S., C.M.L., and A.B. are investigators in the MRC Asthma UK Centre for Allergic Mechanisms of Disease. R.G. was funded by the German Research Foundation (GR 4379/1 1).	Agarwal R, 2011, CURR ALLERGY ASTHM R, V11, P403, DOI 10.1007/s11882-011-0217-4; Agbetile J, 2014, J ALLERGY CLIN IMMUN, V134, P33, DOI 10.1016/j.jaci.2013.09.050; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Blatter Joshua, 2014, Ann Am Thorac Soc, V11, P925, DOI 10.1513/AnnalsATS.201402-077OC; Blondin MC, 2013, ENDOCR PRACT, V19, pE138, DOI 10.4158/EP13122.CR; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bracken M, 2009, ARCH DIS CHILD, V94, P780, DOI 10.1136/adc.2008.152140; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Chishimba L, 2012, J ASTHMA, V49, P423, DOI 10.3109/02770903.2012.662568; Denning DW, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-14; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Desai D, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-17; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Flaczyk A, 2013, J IMMUNOL, V191, P2503, DOI 10.4049/jimmunol.1300426; Gent JF, 2012, ENVIRON RES, V118, P86, DOI 10.1016/j.envres.2012.07.005; Kim HK, 2014, INT ARCH ALLERGY IMM, V163, P92, DOI 10.1159/000356341; Knutsen AP, 2012, J ALLERGY CLIN IMMUN, V129, P280, DOI 10.1016/j.jaci.2011.12.970; Le HT, 2012, J IMMUNOL, V189, P287, DOI 10.4049/jimmunol.1103564; Marinho S, 2007, ALLERGY, V62, P1379, DOI 10.1111/j.1398-9995.2007.01502.x; Matsuse H, 2013, RESPIRATION, V85, P429, DOI 10.1159/000345861; Mattos W, 2002, CHEST, V122, P1543, DOI 10.1378/chest.122.5.1543; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; O'Driscoll B Ronan, 2005, BMC Pulm Med, V5, P4, DOI 10.1186/1471-2466-5-4; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Saglani S, 2009, AM J RESP CELL MOL, V41, P281, DOI 10.1165/rcmb.2008-0396OC; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Vicencio AG, 2014, PEDIATR PULM, V49, P8, DOI 10.1002/ppul.22779; Vicencio AG, 2010, PEDIATRICS, V125, pE1255, DOI 10.1542/peds.2009-2443; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	36	147	148	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					312	+		10.1016/j.jaci.2015.01.016	http://dx.doi.org/10.1016/j.jaci.2015.01.016			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25746970	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000359004900012
J	Molina-Infante, J; Arias, A; Barrio, J; Rodriguez-Sanchez, J; Sanchez-Cazalilla, M; Lucendo, AJ				Molina-Infante, Javier; Arias, Angel; Barrio, Jesus; Rodriguez-Sanchez, Joaquin; Sanchez-Cazalilla, Marta; Lucendo, Alfredo J.			Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; four-food elimination diet; six-food elimination diet; diet; treatment	FOOD ALLERGY; SKIN PRICK; FOLLOW-UP; CHILDREN; REMISSION; IDENTIFICATION; DIAGNOSIS; DISEASE	Background: Eosinophilic esophagitis (EoE) is an esophageal disorder predominantly triggered by food antigens. A six-food group elimination diet (SFGED) achieves remission in more than 70% of adult patients with EoE. After individual food reintroduction, just 1 or 2 food triggers for EoE can be identified in 65% to 85% of the patients, so some dietary restrictions and endoscopies after food challenge may be unnecessary. Objective: To evaluate the efficacy of a four-food group elimination diet (FFGED) (dairy products, wheat, egg, and legumes) for adult patients with EoE. Methods: Prospective multicenter study. All patients were reevaluated after 6 weeks on an FFGED. Response to the FFGED was defined by clinical and histologic (<15 eos/hpf) remission. Responders underwent reintroduction of each individual food over 6 weeks followed by endoscopy and esophageal biopsies. Nonresponders were offered a rescue SFGED. Results: A total of 52 adult patients were included, of whom 12 patients (23%) had previous failure to topical steroid therapy. Twenty-eight of the 52 patients (54%) achieved clinicopathologic remission on the FFGED and 6 of the 19 (31%) nonresponders to the FFGED were successfully rescued with the SFGED. Twenty-two of 28 responders to the FFGED (78%) finished the individual food reintroduction challenge. Milk was identified as an EoE trigger in 11 patients (50%), egg in 8 (36%), wheat in 7 (31%), and legumes in 4 (18%). All patients had just 1 or 2 food triggers, with milk being the only causative food in 27% of the patients. Conclusions: An FFGED achieved clinicopathologic remission in 54% of adult patients with EoE. An SFGED was effective in almost a third of FFGED nonresponders, resulting in a combined efficacy of 72% of both strategies.	[Molina-Infante, Javier] Hosp San Pedro Alcantara, Dept Gastroenterol, Caceres 10003, Spain; [Arias, Angel] Gen Hosp, Res Support Unit, Mancha Ctr, Ciudad Real, Spain; [Barrio, Jesus] Hosp Rio Hortega, Dept Gastroenterol, Valladolid, Spain; [Rodriguez-Sanchez, Joaquin] Hosp Gen Univ, Dept Gastroenterol, Ciudad Real, Spain; [Sanchez-Cazalilla, Marta; Lucendo, Alfredo J.] Hosp Gen Tomelloso, Dept Gastroenterol, Ciudad Real, Spain	Hospital del Rio Hortega	Molina-Infante, J (corresponding author), Hosp San Pedro Alcantara, Dept Gastroenterol, C Pablo Naranjo S-N, Caceres 10003, Spain.	xavi_molina@hotmail.com	Arias, Ángel J/E-5885-2016; Lucendo, Alfredo J/C-1958-2009	Arias, Ángel J/0000-0003-1006-0958; Lucendo, Alfredo J/0000-0003-1183-1072; BARRIO, JESUS/0000-0001-7087-3921				Almansa C, 2009, AM J GASTROENTEROL, V104, P828, DOI 10.1038/ajg.2008.169; Arias A, 2014, GASTROENTEROLOGY, V146, P1639, DOI 10.1053/j.gastro.2014.02.006; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Dellon ES, 2014, GASTROINTEST ENDOSC, V79, P577, DOI 10.1016/j.gie.2013.10.027; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Gonsalves N, 2013, GASTROENTEROLOGY, V144, pS154; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Greenhawt M, 2013, J ALLER CL IMM-PRACT, V1, P332, DOI 10.1016/j.jaip.2013.05.009; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Hirano I, 2013, GUT, V62, P489, DOI 10.1136/gutjnl-2011-301817; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kagalwalla AF, 2012, J PEDIATR GASTR NUTR, V55, P711, DOI 10.1097/MPG.0b013e318268da40; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Lack G, 2008, NEW ENGL J MED, V359, P1252, DOI 10.1056/NEJMcp0800871; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2013, J ALLERGY CLIN IMMUN, V131, P797, DOI 10.1016/j.jaci.2012.12.664; Moawad FJ, 2010, ALIMENT PHARM THER, V31, P509, DOI 10.1111/j.1365-2036.2009.04199.x; Molina Infante J, 2012, J ALLERGY CLIN IMMUN, V130, P1200; Paquet B, 2013, J ALLERGY CLIN IMMUN, V131, P613, DOI 10.1016/j.jaci.2012.10.053; Pascual JMR, 2011, J INVEST ALLERG CLIN, V21, P59; Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015; Shadish WR, 2002, EXPT QUASIEXPERIMENT; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Simon D, 2006, ALLERGY, V61, P1480, DOI 10.1111/j.1398-9995.2006.01224.x; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9; Spergel JM, 2007, J ALLERGY CLIN IMMUN, V119, P509, DOI 10.1016/j.jaci.2006.11.016; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Wolf WA, 2014, CLIN GASTROENTEROL H, V12, P1272, DOI 10.1016/j.cgh.2013.12.034	30	147	155	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1093	+		10.1016/j.jaci.2014.07.023	http://dx.doi.org/10.1016/j.jaci.2014.07.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25174868				2022-12-18	WOS:000344938900014
J	Yamada, T; Saito, H; Fujieda, S				Yamada, Takechiyo; Saito, Hirohisa; Fujieda, Shigeharu			Present state of Japanese cedar pollinosis: The national affliction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Seasonal allergic rhinitis; Japanese cedar; global climate change; prophylactic treatment; alternative complementary treatments	SEASONAL ALLERGIC RHINITIS; EARLY INTERVENTIONAL TREATMENT; GENOME-WIDE ASSOCIATION; BALB/C MOUSE MODEL; ASIAN SAND DUST; DOUBLE-BLIND; SYMPTOMS; PREVALENCE; RISK; IMMUNOTHERAPY	Seasonal allergic rhinitis (SAR) caused by Japanese cedar pollen (JCP; ie, sugi-pollinosis) is the most common disease in Japan and has been considered a national affliction. More than one third of all Japanese persons have sugi-pollinosis, and this number has significantly increased in the last 2 decades. In our opinion the reason why sugi-pollinosis became a common disease in the last half century is the increased number of cedar pollens, with global climate change and forest growth caused by the tree-planting program of the Japanese government after World War II playing substantial roles; dust storms containing small particulate matter from China might also contribute to the increased incidence of sugi-pollinosis. To help minimize their symptoms, many Japanese wear facemasks and eyeglasses at all times between February and April to prevent exposure to JCP and aerosol pollutants. Forecasts for JCP levels typically follow the weather forecast in mass media broadcasts, and real-time information regarding JCP levels is also available on the Internet. Because a large amount of JCP is produced over several months, it can induce severe symptoms. Japanese guidelines for allergic rhinitis recommend prophylactic treatment with antihistamines or antileukotrienes before the start of JCP dispersion. Additionally, sublingual immunotherapy will be supported by health insurance in the summer of 2014. However, many patients with sugi-pollinosis do not find satisfactory symptom relief with currently available therapies. Collaboration between scientists and pharmaceutical companies to produce new therapeutics for the control of sugi-pollinosis symptoms is necessary.	[Yamada, Takechiyo; Fujieda, Shigeharu] Univ Fukui, Dept Otorhinolaryngol Head & Neck Surg, Yoshida, Fukui 9101193, Japan; [Saito, Hirohisa] Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo, Japan	University of Fukui; National Center for Child Health & Development - Japan	Fujieda, S (corresponding author), Univ Fukui, Dept Otorhinolaryngol Head & Neck Surg, 23-3 Matsuoka Shimoaizuki, Yoshida, Fukui 9101193, Japan.	sfujieda@u-fukui.ac.jp		Saito, Hirohisa/0000-0002-6630-8337	Japanese Ministry of Health, Labour and Welfare [H23-Immunology-general-006]; Japanese Ministry of Education, Culture, Sports, Science and Technology [23390397, 22659306]	Japanese Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported by Grants-in-Aid for Scientific Research from the Japanese Ministry of Health, Labour and Welfare (H23-Immunology-general-006) and from the Japanese Ministry of Education, Culture, Sports, Science and Technology (23390397, 22659306).	Bajin MD, 2013, EUR ARCH OTO-RHINO-L, V270, P27, DOI 10.1007/s00405-012-2073-9; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Chang CC, 2006, J TOXICOL ENV HEAL A, V69, P229, DOI 10.1080/15287390500227415; DUCE RA, 1980, SCIENCE, V209, P1522, DOI 10.1126/science.209.4464.1522; Fuertes E, 2013, J ALLERGY CLIN IMMUN, V132, P342, DOI 10.1016/j.jaci.2013.03.007; Fujieda S, 2012, AURIS NASUS LARYNX, V39, P553, DOI 10.1016/j.anl.2011.12.006; Fujimura Takashi, 2010, Allergology International, V59, P21, DOI 10.2332/allergolint.09-RAI-0151; Futamura Masaki, 2011, Allergology International, V60, P509, DOI 10.2332/allergolint.10-OA-0293; Gotoh M, 2005, RHINOLOGY, V43, P266; Gotoh M, 2013, ALLERGOL INT, V62, P181, DOI 10.2332/allergolint.12-OA-0498; Gotoh Minoru, 2011, Allergology International, V60, P483, DOI 10.2332/allergolint.10-OA-0285; Gotoh M, 2009, BIOSCI BIOTECH BIOCH, V73, P1971, DOI 10.1271/bbb.90144; Higaki T, 2012, ANN ALLERG ASTHMA IM, V109, P458, DOI 10.1016/j.anai.2012.08.016; Hirano Toru, 2009, Allergology International, V58, P373, DOI 10.2332/allergolint.08-OA-0070; Honda K, 2013, ALLERGOL INT, V62, P375, DOI 10.2332/allergolint.12-OA-0526; HORIGUCHI S, 1964, JPN J ALLERGOL, V13, P16, DOI DOI 10.15036/ARERUGI.13.16; Ichinose T, 2008, ARCH ENVIRON CON TOX, V55, P348, DOI 10.1007/s00244-007-9128-8; Ichinose T, 2009, INHAL TOXICOL, V21, P985, DOI 10.1080/08958370802672883; Inoue H, 2012, J HUM GENET, V57, P176, DOI 10.1038/jhg.2011.148; Ito Yukiko, 2008, Allergol Int, V57, P321, DOI 10.2332/allergolint.O-07-520; Kaneko Y, 2005, INT ARCH ALLERGY IMM, V136, P365, DOI 10.1159/000084256; Kawai Mari, 2007, Allergol Int, V56, P113; Kawai T, 2009, CLIN EXP ALLERGY, V39, P1508, DOI 10.1111/j.1365-2222.2009.03316.x; Kawamoto S, 2006, INT ARCH ALLERGY IMM, V141, P313, DOI 10.1159/000095457; Kawashima S, 2007, ATMOS ENVIRON, V41, P7987, DOI 10.1016/j.atmosenv.2007.09.019; Kurosaka Fumitake, 2011, Allergology International, V60, P317, DOI 10.2332/allergolint.10-OA-0246; Makihara S, 2012, ALLERGOL INT, V61, P295, DOI 10.2332/allergolint.11-OA-0382; Makino Y, 2010, J ALLERGY CLIN IMMUN, V126, P1163, DOI 10.1016/j.jaci.2010.06.031; Masuyama Keisuke, 2009, Allergology International, V58, P63, DOI 10.2332/allergolint.08-OA-0008; Matsumoto Yuri, 2011, Allergology International, V60, P87, DOI 10.2332/allergolint.10-OA-0230; Mosges R, 2013, ALLERGOL INT, V62, P215, DOI 10.2332/allergolint.12-OA-0486; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Ogino S, 2009, INT ARCH ALLERGY IMM, V149, P239, DOI 10.1159/000199719; Okamoto Yoshitaka, 2009, Allergology International, V58, P155, DOI 10.2332/allergolint.08-RAI-0074; Okubo Kimihiro, 2006, Allergol Int, V55, P379, DOI 10.2332/allergolint.55.379; Okubo Kimihiro, 2011, Allergology International, V60, P171, DOI [10.2332/allergolint.11-RAI-0334, 10.2332/allergolint. 11-RAI-0334]; Okubo Kimihiro, 2008, Allergol Int, V57, P265, DOI 10.2332/allergolint.O-07-514; Okuda M, 2003, ANN ALLERG ASTHMA IM, V91, P288, DOI 10.1016/S1081-1206(10)63532-6; Sakaguchi M, 2011, AURIS NASUS LARYNX, V38, P431, DOI 10.1016/j.anl.2010.12.002; Sakashita M, 2008, CLIN EXP ALLERGY, V38, P1875, DOI 10.1111/j.1365-2222.2008.03114.x; Sakashita M, 2010, INT ARCH ALLERGY IMM, V151, P255, DOI 10.1159/000242363; Schouten B, 2011, PEDIAT ALLERG IMM-UK, V22, P537, DOI 10.1111/j.1399-3038.2010.01132.x; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Takahashi G, 2012, ALLERGOL INT, V61, P155, DOI 10.2332/allergolint.11-OA-0342; Tamari M, 2013, ALLERGOL INT, V62, P21, DOI 10.2332/allergolint.13-RAI-0539; Tamari Mayumi, 2011, Allergology International, V60, P247, DOI 10.2332/allergolint.11-RAI-0320; Tanaka T, 2012, ALLERGOL INT, V61, P57, DOI 10.2332/allergolint.10-OA-0302; Terada Tetsuya, 2009, Allergology International, V58, P255, DOI 10.2332/allergolint.08-OA-0043; Tomita K, 2013, ALLERGY, V68, P92, DOI 10.1111/all.12066; Tsunematsu Masako, 2007, Allergol Int, V56, P465, DOI 10.2332/allergolint.O-07-495; Watanabe Masanari, 2011, Allergology International, V60, P517, DOI 10.2332/allergolint.10-OA-0298; Xiao JZ, 2006, CLIN EXP ALLERGY, V36, P1425, DOI 10.1111/j.1365-2222.2006.02575.x; Xiao Jin-zhong, 2007, Allergol Int, V56, P67, DOI 10.2332/allergolint.O-06-455; Yamada P, 2012, ECOTOX ENVIRON SAFE, V84, P9, DOI 10.1016/j.ecoenv.2012.05.021; Yamamoto H, 2010, ALLERGY ASTHMA PROC, V31, P296, DOI 10.2500/aap.2010.31.3355; Yamanaka Kei-ichi, 2011, Allergology International, V60, P45, DOI 10.2332/allergolint.10-OA-0198; Yang CB, 2013, ALLERGOL INT, V62, P53, DOI 10.2332/allergolint.12-OA-0452; Yang CB, 2013, ALLERGOL INT, V62, P65, DOI 10.2332/allergolint.12-OA-0473; Yonekura S, 2011, AURIS NASUS LARYNX, V38, P600, DOI 10.1016/j.anl.2010.11.017; Yonekura S, 2009, ALLERGY ASTHMA PROC, V30, P397, DOI 10.2500/aap.2009.30.3256; Yuki Ayumi, 2011, Allergology International, V60, P533, DOI 10.2332/allergolint.10-OA-0264; Ziska L, 2011, P NATL ACAD SCI USA, V108, P4248, DOI 10.1073/pnas.1014107108	63	147	150	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					632	+		10.1016/j.jaci.2013.11.002	http://dx.doi.org/10.1016/j.jaci.2013.11.002			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24361081				2022-12-18	WOS:000332397600003
J	Vadas, P; Perelman, B; Liss, G				Vadas, Peter; Perelman, Boris; Liss, Gary			Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Platelet-activating factor; histamine; tryptase; anaphylaxis; emergency department	SYSTEMIC-ANAPHYLAXIS; PLASMA HISTAMINE; ALLERGY; BASOPHILS; MODELS; ACETYLHYDROLASE; EMERGENCY; LESSONS; ASTHMA; MICE	Background: Platelet-activating factor (PAF) is an important mediator and correlates with anaphylaxis severity. How well PAF correlates with severity relative to histamine or tryptase is not known. Objective: To analyze the levels of PAF, histamine, and tryptase as a function of severity in patients with acute allergic reactions. Methods: PAF, histamine, and tryptase levels were measured in blood samples collected from 23 healthy volunteers and from 41 patients during acute allergic reactions. Reactions were stratified by severity from grade 1 (least severe) to grade 3 (most severe). Results: Among the 3 reaction grades, there were significant differences by ANOVA for PAF (P < .0001). The proportion of elevated PAF values increased across severity groups (P = .0009). Increased PAF levels were observed in 20%, 66.7%, and 100% of the patients with grades 1, 2, and 3 allergic reactions, respectively. While the proportion of elevated histamine values increased from 40% to 57% to 70% across grades 1, 2, and 3, respectively, these were not significantly different (P = .40). For tryptase, the proportion of elevated values increased monotonically from 0 in grade 1 to 4.8% in grade 2 to 60% in grade 3 (P = .0002). Conclusions: The PAF level was significantly elevated in proportion to the severity of acute allergic reactions. Whereas the PAF level was elevated in all patients with severe anaphylaxis, this was not true for either histamine or tryptase. Neither histamine nor tryptase showed as good correlations with severity scores as did PAF. These data are consistent with a pivotal role for PAF as a mediator of anaphylaxis. (J Allergy Clin Immunol 2013;131:144-9.)	[Vadas, Peter; Perelman, Boris] Univ Toronto, St Michaels Hosp, Dept Med, Div Allergy & Clin Immunol, Toronto, ON M5B 1W8, Canada; [Liss, Gary] Univ Toronto, Dalla Lama Sch Publ Hlth, Gage Occupat & Environm Hlth Unit, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Vadas, P (corresponding author), Univ Toronto, St Michaels Hosp, Dept Med, Div Allergy & Clin Immunol, Carter Wing 8-161,30 Bond St, Toronto, ON M5B 1W8, Canada.	vadasp@smh.ca			National Peanut Board; Ganz Family Foundation	National Peanut Board; Ganz Family Foundation	This study was supported by grants-in-aid from the National Peanut Board and the Ganz Family Foundation.	Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Brown Simon G A, 2004, Emerg Med Australas, V16, P120, DOI 10.1111/j.1742-6723.2004.00562.x; Cauwels A, 2006, J CLIN INVEST, V116, P2244, DOI 10.1172/JCI25426; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Fukuda Y, 2000, EUR J PHARMACOL, V390, P203, DOI 10.1016/S0014-2999(99)00920-6; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Karasuyama H, 2010, CHEM IMMUNOL ALLERGY, V95, P85, DOI 10.1159/000315939; LAROCHE D, 1991, ANESTHESIOLOGY, V75, P945, DOI 10.1097/00000542-199112000-00004; Lie WJ, 2003, CLIN EXP ALLERGY, V33, P1125, DOI 10.1046/j.1365-2222.2003.01726.x; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; Marone G, 2005, TRENDS IMMUNOL, V26, P25, DOI 10.1016/j.it.2004.10.010; Montrucchio G, 2000, PHYSIOL REV, V80, P1669, DOI 10.1152/physrev.2000.80.4.1669; OHTSUKA T, 1993, ANN ALLERGY, V71, P139; Okunuki H, 2000, IMMUNOL LETT, V74, P233, DOI 10.1016/S0165-2478(00)00264-9; Ordoqui E, 1997, ALLERGY, V52, P1102, DOI 10.1111/j.1398-9995.1997.tb00182.x; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Sarchielli P, 2004, CEPHALALGIA, V24, P623, DOI 10.1111/j.1468-2982.2003.00717.x; Schwartz Lawrence B, 2004, Novartis Found Symp, V257, P65; Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693; Stone SF, 2009, J ALLERGY CLIN IMMUN, V124, P786, DOI 10.1016/j.jaci.2009.07.055; Strait Richard, 2004, Novartis Found Symp, V257, P80; Triggiani M, 2008, CLIN EXP IMMUNOL, V153, P7, DOI 10.1111/j.1365-2249.2008.03714.x; Vadas P., 2003, Journal of Allergy and Clinical Immunology, V111, pS206, DOI 10.1016/S0091-6749(03)80712-1; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1	29	147	155	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					144	149		10.1016/j.jaci.2012.08.016	http://dx.doi.org/10.1016/j.jaci.2012.08.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23040367				2022-12-18	WOS:000312961200018
J	Illi, S; Depner, M; Genuneit, J; Horak, E; Loss, G; Strunz-Lehner, C; Buchele, G; Boznanski, A; Danielewicz, H; Cullinan, P; Heederik, D; Braun-Fahrlander, C; von Mutius, E				Illi, Sabina; Depner, Martin; Genuneit, Jon; Horak, Elisabeth; Loss, Georg; Strunz-Lehner, Christine; Buechele, Gisela; Boznanski, Andrzej; Danielewicz, Hanna; Cullinan, Paul; Heederik, Dick; Braun-Fahrlaender, Charlotte; von Mutius, Erika		GABRIELA Study Grp	Protection from childhood asthma and allergy in Alpine farm environments-the GABRIEL Advanced Studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; hay fever; atopic dermatitis; atopic sensitization; childhood; farming; farm milk; early life	ATOPIC SENSITIZATION; MILK CONSUMPTION; LIFE-STYLE; EXPOSURE; CHILDREN; ASSOCIATION; DISEASES	Background: Studies on the association of farm environments with asthma and atopy have repeatedly observed a protective effect of farming. However, no single specific farm-related exposure explaining this protective farm effect has consistently been identified. Objective: We sought to determine distinct farm exposures that account for the protective effect of farming on asthma and atopy. Methods: In rural regions of Austria, Germany, and Switzerland, 79,888 school-aged children answered a recruiting questionnaire (phase I). In phase II a stratified random subsample of 8,419 children answered a detailed questionnaire on farming environment. Blood samples and specific IgE levels were available for 7,682 of these children. A broad asthma definition was used, comprising symptoms, diagnosis, or treatment ever. Results: Children living on a farm were at significantly reduced risk of asthma (adjusted odds ratio [aOR], 0.68; 95% CI, 0.59-0.78; P < .001), hay fever (aOR, 0.43; 95% CI, 0.36-0.52; P < .001), atopic dermatitis (aOR, 0.80; 95% CI, 0.69-0.93; P = .004), and atopic sensitization (aOR, 0.54; 95% CI, 0.48-0.61; P <. 001) compared with nonfarm children. Whereas this overall farm effect could be explained by specific exposures to cows, straw, and farm milk for asthma and exposure to fodder storage rooms and manure for atopic dermatitis, the farm effect on hay fever and atopic sensitization could not be completely explained by the questionnaire items themselves or their diversity. Conclusion: A specific type of farm typical for traditional farming (ie, with cows and cultivation) was protective against asthma, hay fever, and atopy. However, whereas the farm effect on asthma could be explained by specific farm characteristics, there is a link still missing for hay fever and atopy. (J Allergy Clin Immunol 2012;129:1470-7.)	[Illi, Sabina; Depner, Martin; Strunz-Lehner, Christine; von Mutius, Erika] Univ Childrens Hosp, Asthma & Allergy Res Grp, D-80337 Munich, Germany; [Genuneit, Jon; Buechele, Gisela] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Horak, Elisabeth] Innsbruck Med Univ, Dept Paediat & Adolescents, Innsbruck, Austria; [Loss, Georg; Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Loss, Georg; Braun-Fahrlaender, Charlotte] Univ Basel, CH-4003 Basel, Switzerland; [Boznanski, Andrzej; Danielewicz, Hanna] Wroclaw Med Univ, Dept Paediat Allergol & Cardiol, Wroclaw, Poland; [Cullinan, Paul] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Heederik, Dick] Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, NL-3508 TC Utrecht, Netherlands	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Ulm University; Medical University of Innsbruck; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Wroclaw Medical University; Imperial College London; Utrecht University	Illi, S (corresponding author), Univ Childrens Hosp, Asthma & Allergy Res Grp, Lindwurmstr 4, D-80337 Munich, Germany.	sabina.illi@med.uni-muenchen.de	Genuneit, Jon/I-9323-2012; Strunz, Celia Maria Cassaro/L-4117-2019; Loss, Georg/F-1557-2013; Danielewicz, Hanna/AAY-6014-2020; Ege, Markus/C-1962-2012; Loss, Georg/AAE-7296-2019; Normand, Anne-Cécile/V-4271-2018; Latzin, Philipp/F-2206-2017	Genuneit, Jon/0000-0001-5764-1528; Strunz, Celia Maria Cassaro/0000-0002-9766-1184; Danielewicz, Hanna/0000-0001-7999-8923; Ege, Markus/0000-0001-6643-3923; Loss, Georg/0000-0003-1090-812X; Normand, Anne-Cécile/0000-0002-9589-4603; Wouters, Inge M./0000-0001-7834-9390; Frey, Urs/0000-0003-3773-2822; von Mutius, Erika/0000-0002-8893-4515; Heederik, Dick/0000-0002-4550-1437; Latzin, Philipp/0000-0002-5239-1571; piarroux, renaud/0000-0002-4151-4134	European Commission as part of GABRIEL [018996, LSH-2004-1.2.5-1]; European Commission/European Research Council; European Commission; InfectoPharm; Airsonnett AB; Medical Research Council [G1000758B, G1000758, G0801056B] Funding Source: researchfish	European Commission as part of GABRIEL; European Commission/European Research Council(European CommissionEuropean Commission Joint Research CentreEuropean Research Council (ERC)); European Commission(European CommissionEuropean Commission Joint Research Centre); InfectoPharm; Airsonnett AB(HOGANAS ABStatisticon AB); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the European Commission as part of GABRIEL (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community), contract no. 018996 under the Integrated Program LSH-2004-1.2.5-1.; M. Depner has received research support from the European Commission/European Research Council. A. Boznanski, H. Danielewicz, and D. Heederik have received research support from the European Commission. E. von Mutius has consulted for Novartis, GlaxoSmithKline, ALK-Abello, and Protectimmune; has received a speaker's fee from InfectoPharm; has received research support from Airsonnett AB; and has served as a member of the Expert Panel for the UK Research Excellence Framework. The rest of the authors declare that they have no relevant conflicts of interest.	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Genuneit J, 2011, PAEDIATR PERINAT EP, V25, P436, DOI 10.1111/j.1365-3016.2011.01223.x; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; McCutcheon A.C, 1987, LATENT CLASS ANAL; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Muralikrishna G, 2007, CRIT REV FOOD SCI, V47, P599, DOI 10.1080/10408390600919056; Normand AC, 2011, OCCUP ENVIRON MED, V68, P849, DOI 10.1136/oem.2010.061879; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Peters M, 2010, J ALLERGY CLIN IMMUN, V126, P648, DOI 10.1016/j.jaci.2010.05.011; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Pfender WF, 1996, APPL SOIL ECOL, V3, P69, DOI 10.1016/0929-1393(95)00068-2; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Zutavern A, 2005, CLIN EXP ALLERGY, V35, P1301, DOI 10.1111/j.1365-2222.2005.02350.x	24	147	152	0	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1470	+		10.1016/j.jaci.2012.03.013	http://dx.doi.org/10.1016/j.jaci.2012.03.013			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22534534	Green Submitted			2022-12-18	WOS:000304764600005
J	Shi, YX; Aledia, AS; Tatavoosian, AV; Vijayalakshmi, S; Galant, SP; George, SC				Shi, Yixin; Aledia, Anna S.; Tatavoosian, Ahramahzd V.; Vijayalakshmi, Shruthi; Galant, Stanley P.; George, Steven C.			Relating small airways to asthma control by using impulse oscillometry in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Reactance; resistance; control; pediatric; lung function	EXHALED NITRIC-OXIDE; LUNG-FUNCTION; REFERENCE VALUES; BRONCHIAL HYPERRESPONSIVENESS; OSCILLATION TECHNIQUE; FORCED OSCILLATION; PRESCHOOL-CHILDREN; CHILDHOOD ASTHMA; HEALTHY-CHILDREN; OBSTRUCTION	Background: Previous reports suggest that the peripheral airways are associated with asthma control. Patient history, although subjective, is used largely to assess asthma control in children because spirometric results are many times normal values. Impulse oscillometry (IOS) is an objective and noninvasive measurement of lung function that has the potential to examine independently both small-and large-airway obstruction. Objective: We sought to determine the utility of IOS in assessing asthma control in children. Methods: Asthmatic and healthy children (6-17 years) were enrolled in the study. Spirometric and IOS (resistance of the respiratory system at 5 Hz [R5] and 20 Hz [R20], reactance of the respiratory system at 5 Hz [X5], resonant frequency of reactance [Fres], and area under the reactance curve between 5 Hz and Fres [reactance area {AX}]) values were collected in triplicate before and after a bronchodilator was administered. The physicians were blinded to the IOS measurements and assessed asthma control using American Thoracic Society guidelines. Results: Small-airway IOS measurements, including the difference of R5 and R20 [R5-20], X5, Fres, and AX, of children with uncontrolled asthma (n = 44) were significantly different from those of children with controlled asthma (n 5 57) and healthy children (n 5 14), especially before the administration of a bronchodilator. However, there was no difference in large-airway IOS values (R20). No differences were found between children with controlled asthma and healthy children in any of the end points. Receiver operating characteristic analysis showed cut points for baseline R5-20 (1.5 cm H2O . L-1 . s) and AX (9.5 cm H2O . L-1) that effectively discriminated controlled versus uncontrolled asthma (area under the curve, 0.86 and 0.84) and correctly classified more than 80% of the population. Conclusion: Uncontrolled asthma is associated with small-airways dysfunction, and IOS might be a reliable and noninvasive method to assess asthma control in children. (J Allergy Clin Immunol 2012; 129: 671-8.)	[Shi, Yixin; Aledia, Anna S.; Tatavoosian, Ahramahzd V.; Vijayalakshmi, Shruthi; George, Steven C.] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA; [George, Steven C.] Univ Calif Irvine, Dept Chem Engn & Mat Sci, Irvine, CA 92697 USA; [Aledia, Anna S.; George, Steven C.] Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; [George, Steven C.] Univ Calif Irvine, Edwards Life Sci Ctr Adv Cardiovasc Technol, Irvine, CA 92697 USA; [Galant, Stanley P.] Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA; [Galant, Stanley P.] Childrens Hosp Orange Cty, Orange, CA 92668 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Childrens Hospital of Orange County	George, SC (corresponding author), Univ Calif Irvine, Dept Biomed Engn, 2420 Engn Hall, Irvine, CA 92697 USA.	scgeorge@uci.edu	George, Steven/K-9359-2015	George, Steven/0000-0003-2263-1914	National Institutes of Health [HL070645]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070645] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant HL070645.	ANNESI I, 1992, EUR RESPIR J, V5, P1104; [Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Carroll WD, 2011, EUR RESP J; Cirillo I, 2006, ANN ALLERG ASTHMA IM, V96, P692, DOI 10.1016/S1081-1206(10)61067-8; Cohen J, 2008, EUR RESPIR J, V31, P1213, DOI 10.1183/09031936.00082407; Davis KJ, 2011, PEDIAT ALLERG IMM-UK, V22, P31, DOI 10.1111/j.1399-3038.2010.01016.x; Dencker M, 2006, CLIN PHYSIOL FUNCT I, V26, P247, DOI 10.1111/j.1475-097X.2006.00682.x; Frei J, 2005, CHEST, V128, P1266, DOI 10.1378/chest.128.3.1266; Galant SP, 2011, J PEDIATR-US, V158, P953, DOI 10.1016/j.jpeds.2010.11.029; Gaylor P., 2003, Journal of Allergy and Clinical Immunology, V111, pS135, DOI 10.1016/S0091-6749(03)80423-2; GELB AF, 1977, CHEST, V71, P396, DOI 10.1378/chest.71.3.396; Goldman MD, 2005, RESP PHYSIOL NEUROBI, V148, P179, DOI 10.1016/j.resp.2005.05.026; Goldman MD, 2002, PEDIATR PULM, V34, P312, DOI 10.1002/ppul.10168; GRIMBY G, 1968, J CLIN INVEST, V47, P1455, DOI 10.1172/JCI105837; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Horsman TA, 2009, J ASTHMA, V46, P600, DOI 10.1080/02770900903006265; Hozawa S, 2011, PULM PHARMACOL THER, V24, P571, DOI 10.1016/j.pupt.2011.05.004; Jee HM, 2010, J ASTHMA, V47, P227, DOI 10.3109/02770901003624259; Larsen GL, 2009, J ALLERGY CLIN IMMUN, V123, P861, DOI 10.1016/j.jaci.2008.10.036; Liao O, 2006, J SCHOOL HEALTH, V76, P313, DOI 10.1111/j.1746-1561.2006.00119.x; Malmberg LP, 2003, THORAX, V58, P494, DOI 10.1136/thorax.58.6.494; Marotta A, 2003, J ALLERGY CLIN IMMUN, V112, P317, DOI 10.1067/mai.2003.1627; Marseglia GL, 2007, ALLERGY ASTHMA PROC, V28, P74, DOI 10.2500/aap.2007.28.2920; Martin RJ, 2002, J ALLERGY CLIN IMMUN, V109, pS447, DOI 10.1067/mai.2002.121409; Meraz EG, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-43; Meraz EG, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-21; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; Nakajima Naoki, 2011, Allergology International, V60, P53, DOI 10.2332/allergolint.10-OA-0215; Nielsen KG, 2001, AM J RESP CRIT CARE, V164, P554, DOI 10.1164/ajrccm.164.4.2006119; Nowowiejska B, 2008, PEDIATR PULM, V43, P1193, DOI 10.1002/ppul.20926; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P102; Oostveen E, 2003, EUR RESPIR J, V22, P1026, DOI 10.1183/09031936.03.00089403; Paredi P, 2010, THORAX, V65, P263, DOI 10.1136/thx.2009.120790; Park Jye Hae, 2011, Korean J Pediatr, V54, P64, DOI 10.3345/kjp.2011.54.2.64; PFITZNER J, 1976, ANAESTHESIA, V31, P273, DOI 10.1111/j.1365-2044.1976.tb11804.x; Saadeh C. K., 2003, Journal of Allergy and Clinical Immunology, V111, pS136, DOI 10.1016/S0091-6749(03)80425-6; SACKNER MA, 1972, CHEST, V62, P414, DOI 10.1378/chest.62.4.414; Smith HJ, 2005, EUROPEAN RESP MONOGR, V31, P72, DOI [DOI 10.1183/1025448X.00031005, 10.1183/1025448x.00031005]; Song TW, 2008, ACTA PAEDIATR, V97, P51, DOI 10.1111/j.1651-2227.2007.00526.x; Song TW, 2008, PEDIAT ALLERG IMM-UK, V19, P763, DOI 10.1111/j.1399-3038.2008.00734.x; Spahn JD, 2004, AM J RESP CRIT CARE, V169, P784, DOI 10.1164/rccm.200309-1234OE; Studnicka M, 1998, PEDIATR PULM, V25, P238, DOI 10.1002/(SICI)1099-0496(199804)25:4<238::AID-PPUL4>3.3.CO;2-9; Takeda T, 2010, RESPIRATION, V80, P120, DOI 10.1159/000242113; Teeter JG, 1998, CHEST, V113, P272, DOI 10.1378/chest.113.2.272; VANNOORD JA, 1989, AM REV RESPIR DIS, V139, P921, DOI 10.1164/ajrccm/139.4.921; Vink GR, 2003, PEDIATR PULM, V35, P214, DOI 10.1002/ppul.10235; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502, DOI 10.1164/ajrccm/148.6_Pt_1.1502	49	147	155	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					671	678		10.1016/j.jaci.2011.11.002	http://dx.doi.org/10.1016/j.jaci.2011.11.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22178635	Green Accepted, Green Published			2022-12-18	WOS:000301189300010
J	Vink, NM; Postma, DS; Schouten, JP; Rosmalen, JGM; Boezen, HM				Vink, Nienke M.; Postma, Dirkje S.; Schouten, Jan P.; Rosmalen, Judith G. M.; Boezen, H. Marike			Gender differences in asthma development and remission during transition through puberty: The TRacking Adolescents' Individual Lives Survey (TRAILS) study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Longitudinal study; adolescents; asthma prevalence; total IgE; peak expiratory flow fall; pubertal stage	AIRWAY INFLAMMATION; CHILDHOOD ASTHMA; YOUNG-WOMEN; SEX; GIRLS; DETERMINANTS; PREVALENCE; PREDICTORS; ADULTHOOD; CHILDREN	Background: During puberty, a gender shift in asthma prevalence occurs, with a preponderance of boys before puberty. The mechanisms underlying this gender shift are unclear. Objectives: We assessed associations of pubertal stages and transition through puberty with (1) the prevalence, incidence, and remission of asthma in male and female subjects; (2) total IgE levels; and (3) peak expiratory flow (PEF) fall during a shuttle run test (SRT). Methods: In the TRacking Adolescents' Individual Lives Survey study (n = 2,230; 51% female subjects), associations between pubertal stages and the prevalence, incidence, and remission of asthma were tested by using logistic regression and generalized estimating equations at a mean age of 11.1 (SD, 0.6), 13.6 (SD, 0.5), and 16.3 (SD, 0.7) years. Multiple linear regression analyses were used to study log-transformed total IgE levels and PEF fall during a SRT dependent on early versus late pubertal stages at a mean age of 16.3 years. Results: The prevalence of asthma was similar in boys (7.7%) and girls (7.4%) at a mean age of 11.1 years. The prevalence of asthma was significantly higher in female (6.2%) than male (4.3%) subjects at 16.3 years of age. There were no significant associations between transition of pubertal stages and the presence of asthma, either cross-sectionally or longitudinally. Pubertal stages and log-transformed total IgE levels or PEF fall during a SRT at age 16.3 years were not correlated. Conclusions: A shift in the prevalence of asthma occurs between 11.1 and 16.3 years, which is due to both an increased incidence and decreased remission of asthma in female compared with male subjects. Pubertal stages could not be proved to explain the gender shift in asthma prevalence. (J Allergy Clin Immunol 2010;126:498-504.)	[Vink, Nienke M.; Schouten, Jan P.; Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 RD Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9700 RD Groningen, Netherlands; [Rosmalen, Judith G. M.] Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychiat Epidemiol, NL-9700 RD Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Boezen, HM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, E3-29,Hanzepl 1,POB 30001, NL-9700 RD Groningen, Netherlands.	h.m.boezen@epi.umcg.nl	Rosmalen, Judith G.M./F-5375-2011	Rosmalen, Judith G.M./0000-0002-6393-0032	Netherlands Asthma Foundation [3.4.07.034]; Netherlands Organization for Scientific Research [GB-MW 940-38-011, GB-MAG 480-01-006, ZonMw 100.001.001, NWO 175.010.2003.005]; Department of Justice	Netherlands Asthma Foundation; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Department of Justice	This research was funded by a grant of the Netherlands Asthma Foundation (grant no. 3.4.07.034). This research is embedded in TRAILS. Centers participating in TRAILS include various Departments of the University of Groningen, the Erasmus Medical Center of Rotterdam, the University of Nijmegen, the Trimbos Institute, and the University of Utrecht, The Netherlands. TRAILS is financially supported by grants from the Netherlands Organization for Scientific Research (GB-MW 940-38-011, GB-MAG 480-01-006, ZonMw 100.001.001; NWO 175.010.2003.005), the Department of Justice, and by the participating centers.	Agarwal AK, 1997, J ASTHMA, V34, P539, DOI 10.3109/02770909709055398; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; APTER D, 1989, INT J CANCER, V44, P783, DOI 10.1002/ijc.2910440506; BROOKSGUNN J, 1987, CHILD DEV, V58, P829, DOI 10.2307/1130220; Carey MA, 2007, TRENDS ENDOCRIN MET, V18, P308, DOI 10.1016/j.tem.2007.08.003; CARSKADON MA, 1993, J ADOLESCENT HEALTH, V14, P190, DOI 10.1016/1054-139X(93)90004-9; Castro-Rodriguez JA, 2007, ARCH BRONCONEUMOL, V43, P171, DOI 10.1157/13099535; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chen W, 2008, ALLERGY, V63, P1418, DOI 10.1111/j.1398-9995.2008.01880.x; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68, DOI 10.1164/ajrccm.162.1.9907008; de Winter AF, 2005, EUR J EPIDEMIOL, V20, P173, DOI 10.1007/s10654-004-4948-6; Forbes L, 1999, THORAX, V54, P265, DOI 10.1136/thx.54.3.265; FREEMAN W, 1990, RESP MED, V84, P31, DOI 10.1016/S0954-6111(08)80091-1; GEYSEL J, 20 METER SHUTTLE RUN, P117; Gluck LC, 2004, CLIN REV ALLERG IMMU, V26, P171, DOI 10.1385/CRIAI:26:3:171; Hayashi T, 2003, SCAND J IMMUNOL, V57, P562, DOI 10.1046/j.1365-3083.2003.01269.x; Hellings PW, 2003, CLIN EXP ALLERGY, V33, P1457, DOI 10.1046/j.1365-2222.2003.01743.x; Huisman M, 2008, INT J EPIDEMIOL, V37, P1227, DOI 10.1093/ije/dym273; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Jenkins MA, 2006, CLIN EXP ALLERGY, V36, P609, DOI 10.1111/j.1365-2222.2006.02475.x; Kumar R, 2008, CURR OPIN PEDIATR, V20, P682, DOI 10.1097/MOP.0b013e3283154f26; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; Melgert BN, 2007, CURR ALLERGY ASTHM R, V7, P143, DOI 10.1007/s11882-007-0012-4; Melgert BN, 2005, CLIN EXP ALLERGY, V35, P1496, DOI 10.1111/j.1365-2222.2005.02362.x; Murugan A T, 2008, Chron Respir Dis, V5, P233, DOI 10.1177/1479972308096978; Nicolai T, 2003, PEDIATR ALLERGY IMMU, V14, P280, DOI 10.1034/j.1399-3038.2003.00047.x; Nicolai T, 2001, PEDIATR ALLERGY IMMU, V12, P142, DOI 10.1034/j.1399-3038.2001.0007.x; Norris SA, 2008, J ADOLESCENT HEALTH, V42, P259, DOI 10.1016/j.jadohealth.2007.08.009; Osman M, 2007, PEDIATR PULM, V42, P60, DOI 10.1002/ppul.20545; PETERSEN AC, 1988, J YOUTH ADOLESCENCE, V17, P117, DOI 10.1007/BF01537962; Postma DS, 2007, GENDER MED, V4, pS133, DOI 10.1016/S1550-8579(07)80054-4; Rosmalen JGM, 2005, PSYCHONEUROENDOCRINO, V30, P483, DOI 10.1016/j.psyneuen.2004.12.007; Salam MT, 2006, J ALLERGY CLIN IMMUN, V117, P1001, DOI 10.1016/j.jaci.2006.02.004; Schatz M, 2006, CHEST, V129, P50, DOI 10.1378/chest.129.1.50; Schatz M, 2003, ANN ALLERG ASTHMA IM, V91, P553, DOI 10.1016/S1081-1206(10)61533-5; Tantisira KG, 2008, AM J RESP CRIT CARE, V178, P325, DOI 10.1164/rccm.200708-1174OC; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; VANMECHELEN W, 1986, EUR J APPL PHYSIOL O, V55, P503, DOI 10.1007/BF00421645; Vrieze A, 2003, J ALLERGY CLIN IMMUN, V112, P271, DOI 10.1067/mai.2003.1676; Watson L, 2006, EUR RESPIR J, V28, P311, DOI 10.1183/09031936.06.00055805; Watson L, 2003, EUR RESP MON, V8, P50	43	147	148	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					498	U162		10.1016/j.jaci.2010.06.018	http://dx.doi.org/10.1016/j.jaci.2010.06.018			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	646CF	20816186				2022-12-18	WOS:000281512500014
J	Hitomi, Y; Ebisawa, M; Tomikawa, M; Imai, T; Komata, T; Hirota, T; Harada, M; Sakashita, M; Suzuki, Y; Shimojo, N; Kohno, Y; Fujita, K; Miyatake, A; Doi, S; Enomoto, T; Taniguchi, M; Higashi, N; Nakamura, Y; Tamari, M				Hitomi, Yuki; Ebisawa, Motohiro; Tomikawa, Morimitsu; Imai, Takanori; Komata, Takatsugu; Hirota, Tomomitsu; Harada, Michishige; Sakashita, Masafumi; Suzuki, Yoichi; Shimojo, Naoki; Kohno, Yoichi; Fujita, Kimie; Miyatake, Akihiko; Doi, Satoru; Enomoto, Tadao; Taniguchi, Masami; Higashi, Noritaka; Nakamura, Yusuke; Tamari, Mayumi			Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NLR family; pyrin domain containing 3; gene polymorphism; association study; food allergy; hypersensitivity; anaphylaxis; aspirin-induced asthma; enhancer activity; mRNA stability	PEANUT ALLERGY; EXERCISE; DANGER; INNATE; RISK	Background: NLR family, pyrin domain containing 3 (NLRP3), controls the activity of inflammatory caspase-1 by forming inflammasomes, which leads to cleavage of the procytokines IL-1 beta and IL-18. Recent studies have shown associations of human NLRP3 polymorphisms with susceptibility to various inflammatory diseases; however, the association with allergic diseases remains unclear. Objective: We sought to examine whether NLRP3 polymorphisms are associated with susceptibility to food allergy, food-induced anaphylaxis, and aspirin-induced asthma (AIA). Methods: We selected 15 tag single nucleotide polymorphisms (SNPs) of NLRP3 and conducted association analyses of NLRP3 using 574 and 1279 samples for food allergy and AIA, respectively. We further performed functional analyses of the susceptible SNPs. Results: Two NLRP3 SNPs (rs4612666 and rs10754558) were significantly associated with susceptibility to food-induced anaphylaxis (P = .00086 and P = .00068, respectively). The NLRP3 haplotype of the 2 SNPs also showed a significant association (P = .000098). We could confirm the association with susceptibility to another hypersensitivity phenotype, AIA (rs4612666, P = .0096). Functional analysis revealed that the risk alleles of rs4612666 and rs10754558 increased the enhancer activity of NLRP3 expression and NLRP3 mRNA stability, respectively. Conclusion: Our results indicate that the NLRP3 SNPs might play an important role in the development of food-induced anaphylaxis and AIA in a gain-of-function manner. Further research on the NLRP3 inflammasome will contribute to the development of novel diagnostic and therapeutic methods for food-induced anaphylaxis and AIA. (J Allergy Clin Immunol 2009;124:779-85.)	[Tamari, Mayumi] RIKEN, Inst Phys & Chem Res, Ctr Genom Med, Lab Resp Dis,Tsurumi Ku, Kanagawa 2300045, Japan; [Ebisawa, Motohiro; Tomikawa, Morimitsu; Imai, Takanori; Komata, Takatsugu; Taniguchi, Masami; Higashi, Noritaka] Natl Hosp Org, Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Shimojo, Naoki; Kohno, Yoichi] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan; [Suzuki, Yoichi] Chiba Univ, Dept Publ Hlth, Chiba, Japan; [Fujita, Kimie] Univ Shiga Prefecture, Sch Human Nursing, Shiga, Japan; [Miyatake, Akihiko] Miyatake Asthma Clin, Osaka, Japan; [Doi, Satoru] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Pediat Allergy, Osaka, Japan; [Enomoto, Tadao] NPO Japan Hlth Promot Supporting Network, Wakayama, Japan; [Nakamura, Yusuke] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo 1138654, Japan	RIKEN; Chiba University; Chiba University; University Shiga Prefecture; Osaka Prefectural Medical Center Respiratory & Allergic Diseases; University of Tokyo	Tamari, M (corresponding author), RIKEN, Inst Phys & Chem Res, Ctr Genom Med, Lab Resp Dis,Tsurumi Ku, 1-7-22 Suehiro, Kanagawa 2300045, Japan.	tamari@src.riken.jp	Hitomi, Yuki/V-8236-2019; Tamari, Mayumi/N-5378-2015	Ebisawa, Motohiro/0000-0003-4117-558X	Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labor and Welfare of Japan	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	Supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labor and Welfare of Japan.	Adkinson NF Jr, 2003, MIDDLETONS ALLERGY P, V6th; Akahoshi M, 2005, HUM GENET, V117, P16, DOI 10.1007/s00439-005-1285-0; Alberto EJC, 2008, PEDIAT ALLERG IMM-UK, V19, P716, DOI 10.1111/j.1399-3038.2007.00709.x; Amoli MM, 2002, GENES IMMUN, V3, P220, DOI 10.1038/sj.gene.6363872; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Day JJ, 2008, NEURON, V58, P6, DOI 10.1016/j.neuron.2008.03.014; Estelle F, 2008, J ALLERGY CLIN IMMUN, V121, pS402, DOI 10.1016/j.jaci.2007.08.061; Fremont S, 2002, ANN BIOL CLIN-PARIS, V60, P405; Harada M, 2007, AM J RESP CELL MOL, V36, P491, DOI 10.1165/rcmb.2006-0090OC; Harada S, 2001, BRIT J DERMATOL, V145, P336, DOI 10.1046/j.1365-2133.2001.04329.x; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hysi P, 2005, HUM MOL GENET, V14, P935, DOI 10.1093/hmg/ddi087; Jin Y, 2007, NEW ENGL J MED, V356, P1216, DOI 10.1056/NEJMoa061592; Kusunoki T, 2005, J ALLERGY CLIN IMMUN, V115, P636, DOI 10.1016/j.jaci.2004.12.1114; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; McGovern DPB, 2005, HUM MOL GENET, V14, P1245, DOI 10.1093/hmg/ddi135; Morita E, 2007, J DERMATOL SCI, V47, P109, DOI 10.1016/j.jdermsci.2007.03.004; Mukoyama Tokuko, 2007, Allergol Int, V56, P349, DOI 10.2332/allergolint.R-06-138; Omi T, 2006, EUR J HUM GENET, V14, P1295, DOI 10.1038/sj.ejhg.5201698; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Skripak JM, 2008, CURR OPIN IMMUNOL, V20, P690, DOI 10.1016/j.coi.2008.09.002; Smith HR, 2002, CLIN EXP DERMATOL, V27, P138, DOI 10.1046/j.1365-2230.2002.00997.x; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Szczeklik A, 2006, EUR J PHARMACOL, V533, P145, DOI 10.1016/j.ejphar.2005.12.053; SZCZEKLIK A, 1995, AM J RESP CRIT CARE, V152, P1753, DOI 10.1164/ajrccm.152.6.8520733; Ting JPY, 2008, NAT REV IMMUNOL, V8, P372, DOI 10.1038/nri2296; Villani AC, 2009, NAT GENET, V41, P71, DOI 10.1038/ng.285; Wang JL, 2007, CLIN EXP ALLERGY, V37, P651, DOI 10.1111/j.1365-2222.2007.02682.x; Willart MAM, 2009, CLIN EXP ALLERGY, V39, P12, DOI 10.1111/j.1365-2222.2008.03118.x; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634	37	147	160	0	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					779	785		10.1016/j.jaci.2009.07.044	http://dx.doi.org/10.1016/j.jaci.2009.07.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767079	Bronze			2022-12-18	WOS:000270802800024
J	Cerecedo, I; Zamora, J; Shreffler, WG; Lin, J; Bardina, L; Dieguez, MC; Wang, J; Muriel, A; de la Hoz, B; Sampson, HA				Cerecedo, Inmaculada; Zamora, Javier; Shreffler, Wayne G.; Lin, Jing; Bardina, Ludmilla; Carmen Dieguez, Ma; Wang, Julie; Muriel, Alfonso; de la Hoz, Belen; Sampson, Hugh A.			Mapping of the IgE and IgG4 sequential epitopes of milk allergens with a peptide microarray-based immunoassay	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						milk allergy; peptide; microarray; cow's milk proteins; oral tolerance; natural history; children; casein; alpha-lactalbumin; beta-lactoglobulin; lactoglobuline	BOVINE BETA-LACTOGLOBULIN; COWS-MILK; BINDING EPITOPES; SYNTHETIC PEPTIDES; NATURAL-HISTORY; FOOD ALLERGY; ALPHA-LACTALBUMIN; PEANUT EPITOPES; CLINICAL-COURSE; KAPPA-CASEIN	Background: Peptide microarray analysis is a novel method that can provide useful information on the nature of specific allergies. Objective: We sought to determine the specificity and diversity of IgE and IgG4 antibodies binding to sequential epitopes of alpha(s1)-, (alpha(s2)-, beta-, and kappa-caseins and beta-lactoglobulin by using a peptide microarray-based immunoassay. Methods: A microarray immunoassay was performed with sera from 31 children with IgE-mediated milk allergy (16 with positive oral milk challenge results [ie, the reactive group] and 15 with negative oral milk challenge results [ie, the tolerant group]). A library of peptides, consisting of 20 amino acids (AAs) overlapping by 17 (3-offset), corresponding to the primary sequences of alpha(s1)-, alpha(s2)-, beta-, and kappa-caseins and beta-lactoglobulin was printed on epoxy-coated slides. A region was defined as an epitope if it was statistically associated with reactive groups and recognized by at least 75% of reactive patients. Results: By using this method, a total of 10 epitopes were identified: alpha(s1), AAs 28 to 50, 75% reactive and 26.7% tolerant; a,2, AAs I to 20, 75% reactive and 13.3% tolerant; AAs 13 to 32, 75% reactive and 26.7% tolerant; AAs 67 to 86, 75% reactive and 33.3% tolerant, and AAs 181 to 207, 75% reactive and 20% tolerant; beta-casein, AAs 25 to 50, 75% reactive and 33.3% tolerant, AAs 52 to 74, 81.3% reactive and 26.7% tolerant; and AAs 154 to 173, 75% reactive and 33.3% tolerant; beta-lactoglobulin, AAs 58 to 77, 81.3% reactive and 40% tolerant; and kappa-casein, AAs 34 to 53, 87.5% reactive and 40% tolerant. Conclusion: Several regions have been defined as epitopes, which showed differential recognition patterns between reactive and tolerant patients. Further studies are needed to validate the utility of this assay in clinical practice.	[Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy, New York, NY 10029 USA; [Shreffler, Wayne G.; Lin, Jing; Bardina, Ludmilla; Wang, Julie] Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA; [Cerecedo, Inmaculada; de la Hoz, Belen] Hosp Univ Ramon Cajal, Serv Alergol, Madrid, Spain; [Zamora, Javier; Muriel, Alfonso] Hosp Univ Ramon Cajal, Unidad Biostadist Clin, Epidemiol & Salud Publ CIBERESP, Madrid, Spain; [Carmen Dieguez, Ma] Hosp Sureste, Unidad Alergol, Arganda Del Rey, Spain	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Hospital Universitario Ramon y Cajal; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Hospital Universitario Ramon y Cajal	Sampson, HA (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	hugh.sampson@mssm.edu	del Carmen Diéguez, Maria/AAB-1704-2019; Lin, Jing/C-8877-2010; Zamora, Javier/AEO-0608-2022; Muriel, Alfonso AM/F-9948-2015; de la Hoz, Belen/AAA-8067-2019; Zamora, Javier/B-1722-2009	del Carmen Diéguez, Maria/0000-0001-8363-5172; Zamora, Javier/0000-0003-4901-588X; Muriel, Alfonso AM/0000-0002-4805-4011; de la Hoz, Belen/0000-0002-5127-8702; Zamora, Javier/0000-0003-4901-588X	Fundacion I-AIR (Madrid, Spain); National Institutes of Health(NIH)/National Institute of Allergy and Infectious Diseases [AI-066738, AI-067722]; NIH-LRP; Food Allergy Initiative; NIH/NIAID [AI-066738, AI-44236]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI067722, U19AI066738] Funding Source: NIH RePORTER	Fundacion I-AIR (Madrid, Spain); National Institutes of Health(NIH)/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH-LRP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Initiative; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Dr Cerecedo was supported by the Fundacion I-AIR (Madrid, Spain). Dr Shreffler was supported in part by grants front the National Institutes of Health(NIH)/National Institute of Allergy and Infectious Diseases (NIAID: nos. AI-066738 and AI-067722). the NIH-LRP. and the Food Allergy Initiative. Dr Sampson was Supported in pan by grants from the NIH/NIAID (nos. AI-44236 and AI-066738).	Adams JJ, 2006, J STRUCT BIOL, V154, P246, DOI 10.1016/j.jsb.2005.12.010; ADAMS SL, 1991, IMMUNOL CELL BIOL, V69, P191, DOI 10.1038/icb.1991.28; Asero R, 2007, MOL NUTR FOOD RES, V51, P135, DOI 10.1002/mnfr.200600132; BALL G, 1994, CLIN EXP ALLERGY, V24, P758, DOI 10.1111/j.1365-2222.1994.tb00987.x; Bernard H, 1998, INT ARCH ALLERGY IMM, V115, P235, DOI 10.1159/000023906; BISHOP JM, 1990, J PEDIATR-US, V116, P862, DOI 10.1016/S0022-3476(05)80641-9; Busse PJ, 2002, INT ARCH ALLERGY IMM, V129, P93, DOI 10.1159/000065178; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Clement G, 2002, J IMMUNOL METHODS, V266, P67, DOI 10.1016/S0022-1759(02)00149-7; CREAMER LK, 1981, ARCH BIOCHEM BIOPHYS, V211, P689, DOI 10.1016/0003-9861(81)90505-1; Elsayed S, 2004, SCAND J IMMUNOL, V60, P486, DOI 10.1111/j.0300-9475.2004.01493.x; Farrell HM, 2004, J DAIRY SCI, V87, P1641, DOI 10.3168/jds.S0022-0302(04)73319-6; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Frank R, 1996, Methods Mol Biol, V66, P149; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Garcia-Ara MC, 2004, CLIN EXP ALLERGY, V34, P866, DOI 10.1111/j.1365-2222.2004.01976.x; Heinzmann A, 1999, INT ARCH ALLERGY IMM, V120, P280, DOI 10.1159/000024280; HILL DJ, 1993, CLIN EXP ALLERGY, V23, P124, DOI 10.1111/j.1365-2222.1993.tb00307.x; HILL DJ, 1994, CLIN EXP ALLERGY, V24, P1137, DOI 10.1111/j.1365-2222.1994.tb03319.x; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; HOST A, 1995, EUR J CLIN NUTR S1, V49, P13; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; KUMOSINSKI TF, 1991, J DAIRY SCI, V74, P2879, DOI 10.3168/jds.S0022-0302(91)78469-5; KUMOSINSKI TF, 1991, J DAIRY SCI, V74, P2889, DOI 10.3168/jds.S0022-0302(91)78470-1; Nakajima-Adachi H, 1998, J ALLERGY CLIN IMMUN, V101, P660, DOI 10.1016/S0091-6749(98)70175-7; Niggemann B, 2005, ALLERGY, V60, P865, DOI 10.1111/j.1398-9995.2005.00828.x; Osterballe M, 2005, PEDIAT ALLERG IMM-UK, V16, P567, DOI 10.1111/j.1399-3038.2005.00251.x; Ruiter B, 2007, CLIN EXP ALLERGY, V37, P1103, DOI 10.1111/j.1365-2222.2007.02749.x; Saarinen KM, 2005, J ALLERGY CLIN IMMUN, V116, P869, DOI 10.1016/j.jaci.2005.06.018; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Spuergin P, 1996, ALLERGY, V51, P306, DOI 10.1111/j.1398-9995.1996.tb00090.x; TOMICIC S, 2008, PEDIAT ALLE IN PRESS; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Wal JM, 2004, ANN ALLERG ASTHMA IM, V93, pS2, DOI 10.1016/S1081-1206(10)61726-7; Wal JM, 2002, ANN ALLERG ASTHMA IM, V89, P3, DOI 10.1016/S1081-1206(10)62115-1; Wal JM, 1998, ALLERGY, V53, P114, DOI 10.1111/j.1398-9995.1998.tb04979.x; Williams SC, 1998, J IMMUNOL METHODS, V213, P1, DOI 10.1016/S0022-1759(98)00022-2	42	147	158	1	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					589	594		10.1016/j.jaci.2008.06.040	http://dx.doi.org/10.1016/j.jaci.2008.06.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774394	Bronze			2022-12-18	WOS:000259234000023
J	Palmer, CNA; Ismail, T; Lee, SP; Terron-Kwiatkowski, A; Zhao, YW; Liao, HH; Smith, FJD; McLean, WHI; Mukhopadhyay, S				Palmer, Colin N. A.; Ismail, Tahmina; Lee, Simon P.; Terron-Kwiatkowski, Ana; Zhao, Yiwei; Liao, Haihui; Smith, Frances J. D.; McLean, W. H. Irwin; Mukhopadhyay, Somnath			Filaggrin null mutations are associated with increased asthma severity in children and young adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin barrier; asthma; atopy; eczema; keratinization; treatment; control; lung function	OF-FUNCTION MUTATIONS; ATOPIC-DERMATITIS; GENE; SENSITIZATION; PREDISPOSE; EXPRESSION; IGE	Background: Filaggrin is a key protein involved in skin barrier function. Filaggrin (FLG) null mutations are important genetic predisposing factors for atopic disease. Objective: To study the role of FLG null alleles in the clinical phenotype in children and young adults with asthma. Methods: FLG mutations R501X and 2282del4 were assayed in 874 subjects 3 to 22 years old with asthma from Tayside. Lung function and disease severity were also studied. Results: The filaggrin mutations were significantly associated with greater disease severity for asthma. Independent of eczema, mean FEV1/forced vital capacity of FLG wild-type individuals differed from those carrying either FLG null allele (0.89 vs 0.86; P =.012). Individuals bearing FLG null alleles were more likely to be prescribed increased medication (chi(2) = 10.3; P =.001), with the homozygote null individuals having an odds ratio of 6.68 (95% CI, 1.7-27.0; P =.008) for being prescribed long-acting P-agonists in addition to inhaled steroids. FLG null alleles were also associated with increased rescue medication use (P =.004). Individuals with asthma and with FLG null alleles were more likely to have eczema, and individuals with eczema tended to have more severe asthma; however, the association of FLG null alleles with all markers of asthma disease severity was similar in children with and without eczema. Conclusion: FLG mutations are associated not only with eczema-associated asthma susceptibility but also with asthma severity independent of eczema status. Clinical implications: FLG status influences controller and reliever medication requirements in children and young adults with asthma.	Univ Dundee, Populat Pharmacogenet Grp, Biomed Res Ctr, Dundee DD1 4HN, Scotland; Univ Dundee, Childrens Asthma & Allergy Res Unit, Tayside Childrens Hosp, Dundee DD1 4HN, Scotland; Univ Dundee, Royal Perth Infirm, Dundee DD1 4HN, Scotland; Univ Dundee, Epithelial Genet Grp, Human Genet Unit, Div Pathol & Neurosci, Dundee DD1 4HN, Scotland	University of Dundee; University of Dundee; University of Dundee; University of Dundee	Mukhopadhyay, S (corresponding author), Ninewells Hosp, Tayside Childrens Hosp, Dundee DD1 9SY, Scotland.	s.mukhopadhyay@dundee.ac.uk	McLean, William HI/C-6352-2009; Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560; McLean, William Henry Irwin/0000-0001-5539-5757	Medical Research Council [G0700314] Funding Source: Medline; MRC [G0700314] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arshad SH, 2005, J ALLERGY CLIN IMMUN, V116, P3, DOI 10.1016/j.jaci.2005.03.043; Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; CORBO GM, 1988, J ALLERGY CLIN IMMUN, V81, P41, DOI 10.1016/0091-6749(88)90218-7; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; GILBERT R, 1985, ARCH INTERN MED, V145, P1635, DOI 10.1001/archinte.145.9.1635; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Kondo H, 1998, EUR J IMMUNOL, V28, P769, DOI 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H; KOPFERSCHMITTKUBLER MC, 1987, J ALLERGY CLIN IMMUN, V80, P730, DOI 10.1016/0091-6749(87)90295-8; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; MORAR N, 2007, J INVEST DERMAT 0215; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2006, PEDIATRICS, V118, P710, DOI 10.1542/peds.2005-3030; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; Segre JA, 2006, J CLIN INVEST, V116, P1150, DOI 10.1172/JCI28521; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Stemmler S, 2007, J INVEST DERMATOL, V127, P722, DOI 10.1038/sj.jid.5700579; Strid Jessica, 2005, Current Drug Targets - Inflammation and Allergy, V4, P531, DOI 10.2174/156801005774322199; TIMONEN KL, 1995, EUR RESPIR J, V8, P1155, DOI 10.1183/09031936.95.08071155; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yamaguchi M, 1999, J IMMUNOL, V162, P5455	25	147	154	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					64	68		10.1016/j.jaci.2007.04.001	http://dx.doi.org/10.1016/j.jaci.2007.04.001			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17531295				2022-12-18	WOS:000248066400009
J	Ebbens, FA; Scadding, GK; Badia, L; Hellings, PW; Jorissen, M; Mullol, J; Cardesin, A; Bachert, C; van Zele, TPJ; Dijkgraaf, MGW; Lund, V; Fokkens, WJ				Ebbens, Fenna A.; Scadding, Glenis K.; Badia, Lydia; Hellings, Peter W.; Jorissen, Mark; Mullol, Joaquim; Cardesin, Alda; Bachert, Claus; van Zele, Thibaut P. J.; Dijkgraaf, Marcel G. W.; Lund, Valerie; Fokkens, Wytske J.			Amphotericin B nasal lavages: Not a solution for patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						randomized controlled trial; prospective study; double-blind method; human; amphotericin B; intranasal administration; rhinosinusitis; nasal polyps; chronic disease; fungi	ANTIFUNGAL TREATMENT; DOUBLE-BLIND; BLADDER IRRIGATION; ORAL FLUCONAZOLE; POLYPOSIS; FUNGURIA; SINUSITIS; TRIAL	Background: Chronic rhinosinusitis (CRS) is one of the most common chronic diseases. Recently, it has been suggested that an exaggerated immune response to fungi is crucial in the pathogenesis of the disease. On the basis of this hypothesis, intranasal treatment with amphotericin B should benefit patients with CRS. Data from 2 uncontrolled and 2 controlled trials are conflicting, however. Objective: To clarify the role of intranasal antifungal drugs in the treatment of CRS, we conducted a large, double-blind, placebo-controlled, multicenter study comparing the effectiveness of amphotericin B nasal lavages with placebo. Methods: A total of 116 randomly selected patients with CRS were instructed to instill 25 mL amphotericin B (100 mu g/mL) or placebo to each nostril twice daily for 3 months. Primary outcomes included a reduction in total visual analog scale (VAS) score and nasal endoscopy score. Secondary outcome measures included peak nasal inspiratory flow, polyp score, quality of life (Short Form-36, Rhinosinusitis Outcome Measure-31), and individual VAS scores. Results: Analysis was based on intention to treat and involved all patients randomly assigned. Mean VAS scores, Short Form-36 and Rhinosinusitis Outcome Measure-31 data, peak nasal inspiratory flow values, nasal endoscopy scores, and polyp scores were similar in both treatment groups at the time of randomization, and no significant differences were observed after 13 weeks of treatment. Conclusion: Amphotericin B nasal lavages in the described dosing and time schedule do not reduce clinical signs and symptoms in patients with CRS. Clinical implications: Amphotericin B nasal lavages in the described dosing and time schedule are ineffective and therefore not advised in the treatment of patients with CRS.	Acad Med Ctr, Dept Otolaryngol Head & Neck Surg, NL-1105 AZ Amsterdam, Netherlands; Royal Natl Throat Nose & Ear Hosp, Dept Rhinol, London WC1X 8DA, England; Univ Hosp St Rafael, Dept Otorhinolaryngol, Louvain, Belgium; Hosp Clin Barcelona, Rhinol Unit, Dept Otorhinolaryngol, Inst Invest Biomed August Pi Sunyer, Barcelona, Spain; Univ Hosp Ghent, Dept Otorhinolaryngol, Ghent, Belgium; Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Ghent University; Ghent University Hospital; University of Amsterdam; Academic Medical Center Amsterdam	Ebbens, FA (corresponding author), Acad Med Ctr, Dept Otolaryngol Head & Neck Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	f.a.ebbens@amc.uva.nl	Fokkens, Wytske WJ/ABF-2185-2020; Hellings, Peter W/I-4068-2018; Bachert, Claus/J-8825-2012; Dijkgraaf, Marcel GW/G-6663-2011	Hellings, Peter W/0000-0001-6898-688X; Van Zele, Thibaut/0000-0002-6031-4293				Bhattacharyya T, 1997, ARCH OTOLARYNGOL, V123, P1189; Bossler AD, 2003, J CLIN MICROBIOL, V41, P4779, DOI 10.1128/JCM.41.10.4779-4782.2003; Braun H, 2003, LARYNGOSCOPE, V113, P264, DOI 10.1097/00005537-200302000-00013; FANHAVARD P, 1995, CLIN INFECT DIS, V21, P960, DOI 10.1093/clinids/21.4.960; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; GLEESON MJ, 1986, CLIN OTOLARYNGOL, V11, P99, DOI 10.1111/j.1365-2273.1986.tb00114.x; Heatley DG, 2001, OTOLARYNG HEAD NECK, V125, P44, DOI 10.1067/mhn.2001.115909; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Jacobs LG, 1996, CLIN INFECT DIS, V22, P30, DOI 10.1093/clinids/22.1.30; Johansson L, 2000, ACTA OTO-LARYNGOL, V120, P72; Kauffman CA, 2000, CLIN INFECT DIS, V30, P14, DOI 10.1086/313583; Kennedy DW, 2005, LARYNGOSCOPE, V115, P1793, DOI 10.1097/01.mlg.0000175683.81260.26; Kfoury AG, 1997, CLIN TRANSPLANT, V11, P608; KINTZEL PE, 1992, AM J HOSP PHARM, V49, P1156, DOI 10.1093/ajhp/49.5.1156; LEU HS, 1995, CLIN INFECT DIS, V20, P1152, DOI 10.1093/clinids/20.5.1152; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; LUND VJ, 1992, OTOLARYNG CLIN N AM, V25, P803; Malani Preeti N., 2002, Curr Infect Dis Rep, V4, P225, DOI 10.1007/s11908-002-0083-2; Piccirillo JF, 1995, AM J RHINOL, V9, P297, DOI 10.2500/105065895781808711; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V115, P125, DOI 10.1016/j.jaci.2004.09.037; Ponikau JU, 2002, J ALLERGY CLIN IMMUN, V110, P862, DOI 10.1067/mai.2002.130051; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Ricchetti A, 2002, J LARYNGOL OTOL, V116, P261, DOI 10.1258/0022215021910708; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P231, DOI 10.2500/108854196778662246; STRUIJK DG, 1987, AM J KIDNEY DIS, V9, P66, DOI 10.1016/S0272-6386(87)80164-6; Tomooka LT, 2000, LARYNGOSCOPE, V110, P1189, DOI 10.1097/00005537-200007000-00023; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weschta M, 2004, J ALLERGY CLIN IMMUN, V113, P1122, DOI 10.1016/j.jaci.2004.03.038; WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405; Wildfeuer A, 1998, MYCOSES, V41, P309, DOI 10.1111/j.1439-0507.1998.tb00344.x; [No title captured]	31	147	153	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1149	1156		10.1016/j.jaci.2006.07.058	http://dx.doi.org/10.1016/j.jaci.2006.07.058			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088142				2022-12-18	WOS:000244282300022
J	Weidinger, S; Klopp, N; Rummler, L; Wagenpfeil, S; Novak, N; Baurecht, HJ; Groer, W; Darsow, U; Heinrich, J; Gauger, A; Schafer, T; Jakob, T; Behrendt, H; Wichmann, HE; Ring, J; Illig, T				Weidinger, S; Klopp, N; Rummler, L; Wagenpfeil, S; Novak, N; Baurecht, HJ; Groer, W; Darsow, U; Heinrich, J; Gauger, A; Schafer, T; Jakob, T; Behrendt, H; Wichmann, HE; Ring, J; Illig, T			Association of NOD1 polymorphisms with atopic eczema and related phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic eczema; asthma; allergic rhinoconjunctivitis; IgE; CARD4; NOD1; SNP; haplotype; association	HOUSE-DUST ENDOTOXIN; TOLL-LIKE RECEPTOR-2; LINKAGE DISEQUILIBRIUM; INNATE IMMUNITY; SUSCEPTIBILITY; ALLERGY; ASTHMA; SENSITIZATION; HAPLOTYPE; EXPOSURE	Background: Interactions with microbial pathogens are crucial for the maturation of the immune system. The nucleotide-binding oligomerization domain protein 1 (NOD1) is a cytosolic receptor sensing a muropeptide found mostly in gram-negative bacterial peptidoglycans. NOD1 is located on chromosome 7p14-p15, a region that has been linked with atopy. Recently, polymorphisms of the closely related NOD2 have been associated with atopy-related traits. Objectives: Within a large population-based cohort of German adults (n = 1417), a case-control population for atopic eczema (n = 454), and a large cohort of parent-offspring trios for atopic eczema (189 trios), we evaluated 11 NOD1 polymorphisms for associations with atopic phenotypes. Methods: Subjects were phenotyped by standardized questionnaires and interviews, skin examination, and serum IgE measurements. Genotyping was performed by using matrix-assisted laser desorption ionization-time of flight mass spectrometry. Results: Analyses revealed significant association of one NOD1 haplotype with atopic eczema in the population-based cohort (P = .004) and the case-control population (P = .003). Another NOD1 haplotype was associated with decreased total IgE (P = .008). In addition, significant associations with total serum IgE levels were observed for polymorphisms rs2907748 (P = .006), rs2907749 (P = .012), and rs2075822 (P = .018). These polymorphisms were significantly associated with atopic eczema and asthma in the family-based association analyses (P = .001-043). Seven polymorphisms showed significant transmission distortion for total IgE levels (P values < .0001-.029). Conclusion: These data indicate that genetic variants within NOD1 are important determinants of atopy susceptibility.	Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany; GSF, Inst Epidemiol, Natl Res Ctr Environm & Hlth, Neuherberg, Germany; Tech Univ Munich, Inst Med Stat & Epidemiol, D-80802 Munich, Germany; Univ Bonn, Dept Dermatol & Allergy, D-5300 Bonn, Germany; Med Univ Lubeck, Inst Social Med, Lubeck, Germany; Tech Univ Munich, Div Environm Dermatol & Allergy, GSF, D-80802 Munich, Germany; Tech Univ Munich, ZAUM Ctr Allergy & Environm, D-80802 Munich, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Bonn; University of Lubeck; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich	Weidinger, S (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy, Biedersteiner St 29, D-80802 Munich, Germany.	weidinger@lrz.turn.de	Heinrich, Joachim/N-1720-2013; Weidinger, Stephan/C-8461-2011; Baurecht, Hansjorg/C-4035-2013	Heinrich, Joachim/0000-0002-9620-1629; Weidinger, Stephan/0000-0003-3944-252X; Baurecht, Hansjorg/0000-0002-9265-5594				Abecasis GR, 2000, EUR J HUM GENET, V8, P545, DOI 10.1038/sj.ejhg.5200494; Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Ciacci C, 2004, J ALLERGY CLIN IMMUN, V113, P1199, DOI 10.1016/j.jaci.2004.03.012; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eder W, 2004, CURR OPIN ALLERGY CL, V4, P113, DOI 10.1097/01.all.0000123970.96233.fc; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Hampe J, 2002, LANCET, V359, P1661, DOI 10.1016/S0140-6736(02)08590-2; Heine H, 2003, INT ARCH ALLERGY IMM, V130, P180, DOI 10.1159/000069517; Holt PG, 2002, EUR RESPIR J, V19, P538, DOI 10.1183/09031936.02.00229302; Homma T, 2004, AM J RESP CELL MOL, V31, P463, DOI 10.1165/rcmb.2004-0161OC; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Illig T, 2003, DIABETES, V52, P2861, DOI 10.2337/diabetes.52.11.2861; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Leung DYM, 2003, CURR OPIN IMMUNOL, V15, P634, DOI 10.1016/j.coi.2003.09.009; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Matsubara M, 2004, FEBS LETT, V566, P195, DOI 10.1016/j.febslet.2004.04.028; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Powrie F, 2003, SCIENCE, V299, P1030, DOI 10.1126/science.1082031; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Simpson CR, 2002, CLIN EXP ALLERGY, V32, P37, DOI 10.1046/j.0022-0477.2001.01250.x; Slatkin M, 1996, HEREDITY, V76, P377, DOI 10.1038/hdy.1996.55; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Wallin J, 1996, DEVELOPMENT, V122, P23; Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yoo NJ, 2002, BIOCHEM BIOPH RES CO, V299, P652, DOI 10.1016/S0006-291X(02)02714-6	48	147	153	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					177	184		10.1016/j.jaci.2005.02.034	http://dx.doi.org/10.1016/j.jaci.2005.02.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990792				2022-12-18	WOS:000235686300027
J	Binstadt, BA; Geha, RS; Bonilla, FA				Binstadt, BA; Geha, RS; Bonilla, FA			IgG Fc receptor polymorphisms in human disease: Implications for intravenous immunoglobulin therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						autoimmune; Fc receptor; Guillain-Barre; intravenous immunoglobulin; ITP lupus; multiple sclerosis; polymorphism; vasculitis	SYSTEMIC-LUPUS-ERYTHEMATOSUS; GUILLAIN-BARRE-SYNDROME; IMMUNE THROMBOCYTOPENIC PURPURA; MULTIPLE-SCLEROSIS; GAMMA-RIIA; AUTOIMMUNE-DISEASE; RISK-FACTORS; FC-GAMMA-RIIIA-158F ALLELE; WEGENERS-GRANULOMATOSIS; GENE POLYMORPHISMS	Polymorphisms of human Fc receptors (FcRs) have been described that are associated with the development or progression of autoimmune diseases. The FcR polymorphisms affect the affinity with which FcRs interact with immunoglobulin molecules. Intravenous immunoglobulin is administered as therapy for many autoimmune diseases and might exert its effects by interacting with FcRs. Thus, FcR polymorphisms might influence the efficacy of intravenous immunoglobulin therapy for patients with certain autoimmune diseases. In this article we review FcR polymorphisms in relation to autoimmune diseases for which intravenous immunoglobulin is used therapeutically.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Bonilla, FA (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.		Binstadt, Bryce/N-1305-2013	Binstadt, Bryce/0000-0003-3127-3856	NIAID NIH HHS [T32-AI-07512] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHIRON A, 1994, J CLIN INVEST, V93, P600, DOI 10.1172/JCI117012; Achiron A, 1998, NEUROLOGY, V50, P398, DOI 10.1212/WNL.50.2.398; AMAL C, 2002, J RHEUMATOL, V29, P75; BIEBER A, 2000, MULT SCLER S, V2, pS1; Bottto M, 1996, CLIN EXP IMMUNOL, V104, P264, DOI 10.1046/j.1365-2249.1996.33740.x; Buchwald B, 2002, ANN NEUROL, V51, P673, DOI 10.1002/ana.10205; BURDACH SEG, 1986, J PEDIATR-US, V109, P770, DOI 10.1016/S0022-3476(86)80691-6; Cines DB, 2002, NEW ENGL J MED, V346, P995, DOI 10.1056/NEJMra010501; Clynes R, 1998, SCIENCE, V279, P1052, DOI 10.1126/science.279.5353.1052; Davies KA, 2002, ARTHRITIS RHEUM-US, V46, P1028, DOI 10.1002/art.10189; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; Dijstelbloem HM, 1999, ARTHRITIS RHEUM, V42, P1823, DOI 10.1002/1529-0131(199909)42:9<1823::AID-ANR5>3.0.CO;2-X; Dijstelbloem HM, 2000, ARTHRITIS RHEUM, V43, P2793, DOI 10.1002/1529-0131(200012)43:12<2793::AID-ANR20>3.0.CO;2-6; Duits AJ, 1995, ARTHRITIS RHEUM, V38, P1832, DOI 10.1002/art.1780381217; Edberg JC, 1997, EXP CLIN IMMUNOGENET, V14, P183; Ericson SG, 1996, BRIT J HAEMATOL, V92, P718, DOI 10.1046/j.1365-2141.1996.393931.x; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; Foster CB, 2001, BRIT J HAEMATOL, V113, P596, DOI 10.1046/j.1365-2141.2001.02807.x; FRANCIONI C, 1994, CLIN EXP RHEUMATOL, V12, P163; Francis GS, 1997, MULT SCLER J, V3, P370, DOI 10.1177/135245859700300602; Fujimoto TT, 2001, BRIT J HAEMATOL, V115, P125, DOI 10.1046/j.1365-2141.2001.03109.x; Gomez-Guerrero C, 2000, J IMMUNOL, V164, P2092, DOI 10.4049/jimmunol.164.4.2092; GURSES N, 1995, SCAND J INFECT DIS, V27, P241, DOI 10.3109/00365549509019016; Hatta Y, 1999, GENES IMMUN, V1, P53, DOI 10.1038/sj.gene.6363639; Hughes R A, 1997, Ther Apher, V1, P129, DOI 10.1111/j.1744-9987.1997.tb00027.x; Hughes RAC, 1997, LANCET, V349, P225; JACKSON MC, 1993, J NEUROL, V240, P51, DOI 10.1007/BF00838447; Jayne DRW, 2000, QJM-INT J MED, V93, P433, DOI 10.1093/qjmed/93.7.433; Jayne DRW, 1996, BRIT J RHEUMATOL, V35, P1150; JUNGI TW, 1990, CLIN EXP IMMUNOL, V82, P163; Karassa FB, 2002, ARTHRITIS RHEUM-US, V46, P1563, DOI 10.1002/art.10306; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; KIMBERLY RP, 1984, J IMMUNOL, V132, P745; Koene HR, 1998, ARTHRITIS RHEUM, V41, P1813, DOI 10.1002/1529-0131(199810)41:10<1813::AID-ART13>3.3.CO;2-Y; Kohl J, 1999, MOL IMMUNOL, V36, P893, DOI 10.1016/S0161-5890(99)00111-X; KRAUSE I, 1995, J RHEUMATOL, V22, P1068; Kuwabara S, 2001, J NEUROL NEUROSUR PS, V70, P560, DOI 10.1136/jnnp.70.4.560; Kyogoku C, 2002, ARTHRITIS RHEUM, V46, P1242, DOI 10.1002/art.10257; Lehrnbecher T, 1999, BLOOD, V94, P4220, DOI 10.1182/blood.V94.12.4220.424k08_4220_4232; Levy Y, 1999, INT ARCH ALLERGY IMM, V119, P231, DOI 10.1159/000024199; Levy Y, 2000, SEMIN ARTHRITIS RHEU, V29, P321, DOI 10.1016/S0049-0172(00)80018-9; MAIER WP, 1990, ARTHRITIS RHEUM, V33, P1233; Manger K, 2002, ANN RHEUM DIS, V61, P786, DOI 10.1136/ard.61.9.786; Manger K, 1998, ARTHRITIS RHEUM, V41, P1181, DOI 10.1002/1529-0131(199807)41:7<1181::AID-ART6>3.0.CO;2-C; McKenzie SE, 1999, J IMMUNOL, V162, P4311; Myhr KM, 1999, NEUROLOGY, V52, P1771, DOI 10.1212/WNL.52.9.1771; Oh M, 1999, J RHEUMATOL, V26, P1486; Ott VL, 2001, J ALLERGY CLIN IMMUN, V108, pS95, DOI 10.1067/mai.2001.117822; PORGES AJ, 1994, J IMMUNOL, V153, P1271; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; RICHTER C, 1995, CLIN EXP IMMUNOL, V101, P2; SALMON JE, 1992, J CLIN INVEST, V89, P1274, DOI 10.1172/JCI115712; Salmon JE, 1996, J CLIN INVEST, V97, P1348, DOI 10.1172/JCI118552; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Schroeder JO, 1996, J RHEUMATOL, V23, P71; Schuller E, 1996, PATHOL BIOL, V44, P710; Song YW, 1998, ARTHRITIS RHEUM, V41, P421, DOI 10.1002/1529-0131(199803)41:3<421::AID-ART7>3.3.CO;2-J; Sorensen PS, 1998, NEUROLOGY, V50, P1273, DOI 10.1212/WNL.50.5.1273; Stangel M, 2000, J NEUROL NEUROSUR PS, V68, P89, DOI 10.1136/jnnp.68.1.89; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; Teeling JL, 2001, BLOOD, V98, P1095, DOI 10.1182/blood.V98.4.1095; TIJHUIS GJ, 1991, BRIT J HAEMATOL, V77, P93, DOI 10.1111/j.1365-2141.1991.tb07954.x; Tse WY, 1999, CLIN EXP IMMUNOL, V117, P198; Tse WY, 2000, CLIN EXP IMMUNOL, V119, P574, DOI 10.1046/j.1365-2249.2000.01182.x; van der Pol WL, 1998, IMMUNOGENETICS, V48, P222, DOI 10.1007/s002510050426; van der Pol WL, 2000, NEUROLOGY, V54, P1661, DOI 10.1212/WNL.54.8.1661; Vedeler CA, 2001, J NEUROIMMUNOL, V118, P187, DOI 10.1016/S0165-5728(01)00344-7; Vedeler CA, 2000, NEUROLOGY, V55, P705, DOI 10.1212/WNL.55.5.705; Wainstein E., 1996, Arthritis and Rheumatism, V39, pS210; Williams JD, 1998, INT J ANTIMICROB AG, V10, P1; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616; Zhuang QL, 2002, J ALLERGY CLIN IMMUN, V110, P480, DOI 10.1067/mai.2002.127284	72	147	174	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					697	703		10.1067/mai.2003.1380	http://dx.doi.org/10.1067/mai.2003.1380			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12592303				2022-12-18	WOS:000182258500005
J	Diaz-Sanchez, D; Penichet-Garcia, M; Saxon, A				Diaz-Sanchez, D; Penichet-Garcia, M; Saxon, A			Diesel exhaust particles directly induce activated mast cells to degranulate and increase histamine levels and symptom severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; pollution; mediators; clinical outcomes; hypersensitivity	IN-VIVO; IGE PRODUCTION; CYTOKINE PRODUCTION; RAGWEED ALLERGEN; NASAL CHALLENGE; MESSENGER-RNA; DRY AIR; RELEASE; IL-4; HEXOSAMINIDASE	Background: The ability of combustion products, such as diesel exhaust particles (DEPs), to modulate the immune system has now been firmly established. DEPs can synergize with allergen at the human upper respiratory mucosa to enhance allergen-specific IgE production, initiate a T(H)2 cytokine environment, and even promote primary allergic sensitization. Experiments suggest that these effects result from the initial activation of mast cells to produce IL-4. Objective: We sought to demonstrate that in vivo mast cell activation by DEPs plus allergen will also affect the release of classic mast cell mediators and consequently enhance the immediate-phase response. Methods: Dust mite-sensitive subjects were challenged intranasally with allergen, and symptom scores and histamine levels in nasal wash samples were compared after prechallenge with 0.3 mg of DEPs, Results: If the subjects were first sprayed with DEPs, mean symptom scores rose from 3.7 to 9.9; additionally, only one fifth of the amount of intranasal dust mite allergen was required to induce clinical symptoms. DEPs alone had no effect. The changes in symptoms correlated with histamine levels measured in nasal lavage specimens from these subjects, Although challenge with DEPs alone did not induce histamine release, challenge with both DEPs and allergen resulted in 3-fold higher histamine concentrations than those seen with allergen alone. In contrast, carbon black particles (elemental carbon devoid of chemicals) had no effect. The role of chemicals was confirmed because degranulation of a murine mast cell fine by Fc epsilon RI cross-linking was increased significantly (by 72%) by the soluble organic chemicals extracted from DEPs. Conclusions: Overall, these results suggest that exposure to DEPs can enhance the severity of clinical symptoms to allergen by enhancing mast cell degranulation.	Univ Calif Los Angeles, Sch Med, Hart & Louise Lyon Lab, Div Clin Immunol Allergy,Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Diaz-Sanchez, D (corresponding author), Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci 52 175, Div Clin Immunol Allergy,Dept Med, Los Angeles, CA 90095 USA.				NIAID NIH HHS [AI-15251, AI-34567] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015251, U01AI034567, U19AI034567, R21AI015251] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEASLEY R, 1920, J ALLERGY CLIN IMMUN, V105, P466; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; *CENS TRANSP, 1995, US BUR CENS PUBL; CHURCH MK, 1983, BRIT J PHARMACOL, V80, P719, DOI 10.1111/j.1476-5381.1983.tb10063.x; Dastych J, 1999, J ALLERGY CLIN IMMUN, V103, P1108, DOI 10.1016/S0091-6749(99)70186-7; Diaz-Sanchez D, 1999, CLIN IMMUNOL, V90, P313, DOI 10.1006/clim.1998.4676; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Diaz-Sanchez D, 2000, IMMUNOLOGY, V101, P11, DOI 10.1046/j.1365-2567.2000.00108.x; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; *FED HIGHW ADM, 1995, US DEP TRANSP PUBL; Fujieda S, 1998, CLIN CANCER RES, V4, P1583; Hiura TS, 1999, J IMMUNOL, V163, P5582; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; Kittelson DB, 1998, J AEROSOL SCI, V29, P575, DOI 10.1016/S0021-8502(97)10037-4; Kumagai Y, 1997, FREE RADICAL BIO MED, V22, P479, DOI 10.1016/S0891-5849(96)00341-3; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138, DOI 10.1164/ajrccm.157.4.9708066; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Ng D, 1998, J IMMUNOL, V161, P942; OCHEL M, 1991, J IMMUNOL, V146, P3006; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; Polosa R, 1999, THORAX, V54, P230, DOI 10.1136/thx.54.3.230; PROUD D, 1992, J ALLERGY CLIN IMMUN, V89, P1098, DOI 10.1016/0091-6749(92)90293-B; PROUVOSTDANON A, 1981, J IMMUNOL, V126, P699; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702, DOI 10.1164/ajrccm.159.3.9709083; Saneyoshi K, 1997, INT ARCH ALLERGY IMM, V114, P237, DOI 10.1159/000237674; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; Suzuki Takahito, 1993, Japanese Journal of Allergology, V42, P963; Terada N, 1999, CLIN EXP ALLERGY, V29, P52; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOGIAS A, 1990, AM REV RESPIR DIS, V141, P1428, DOI 10.1164/ajrccm/141.6.1428; Toru H, 1998, J ALLERGY CLIN IMMUN, V102, P491, DOI 10.1016/S0091-6749(98)70140-X; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628	38	147	151	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1140	1146		10.1067/mai.2000.111144	http://dx.doi.org/10.1067/mai.2000.111144			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112898				2022-12-18	WOS:000165930300017
J	Perzanowski, MS; Ronmark, E; Nold, B; Lundback, B; Platts-Mills, TAE				Perzanowski, MS; Ronmark, E; Nold, B; Lundback, B; Platts-Mills, TAE			Relevance of allergens from cats and dogs to asthma in the northernmost province of Sweden: Schools as a major site of exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; cat allergen; dog allergen; school	FEL-D-I; INNER-CITY CHILDREN; F-I; COCKROACH ALLERGENS; CHILDHOOD ASTHMA; INDOOR ALLERGENS; MITE ALLERGEN; RISK FACTOR; P-I; DUST	Background: The prevalence of asthma in the northernmost region of Sweden has been estimated at 6% to 8% in spite of the very dry climate. The causes of the increase in asthma are not clear, but conditions are unfavorable for dust mite growth, and domestic animals are thought to be the primary source of indoor allergens. Objectives: We sought to investigate the relationship between asthma, exposure, and sensitization in Northern Sweden, with a focus on the role of schools. Methods: Serum was collected from 110 asthmatic children, 55 children with symptoms of asthma but no established diagnosis, and 63 control children (age, 7 and 8 years). Total IgE and specific IgE to 7 allergens were measured. Dust samples were collected from the classrooms of 7- and 8-year-old children in 22 schools from Kiruna and Lulea, Sweden. For comparison,. dust was also collected from 24 homes in Kiruna and 2 schools: in Virginia in the United States. Results: Serum IgE antibody assays on 165 children with respiratory symptoms confirmed that there was a high degree of sensitization to cat, dog, and birch in Northern Sweden. Cat and dog allergens were present in almost all of the school samples in Sweden. By contrast, dust mite and cockroach allergens were generally unmeasurable. The highest levels of cat and dog allergens were found in samples from desks and chairs. Cat and dog allergen levels in the schools were comparable with but higher than those in the homes without pets, The schools in Virginia had similar allergen levels, except that samples from this humid region also had significant mite allergen. Conclusions: In this climate the primary sensitization associated with asthma is to cat dander and dog dander but also to birch pollen. Mite and cockroach allergens were not present in the dust samples, and sensitization to these allergens was not significant, The schools appear to be a major site of exposure to cat and dog allergens. These results are relevant both to an understanding of the reasons for the increase in asthma in this region and to any proposal to reduce exposure to allergens.	Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Natl Inst Working Life, Dept Occupat Med, Resp Epidemiol Unit, Stockholm, Sweden; Cent Hosp Norrbotten, Dept Med, OLIN Study Grp, Lulea, Sweden; Natl Inst Working Life, Dept Occupat Med, Resp Epidemiol Unit, Umea, Sweden	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Box 225, Charlottesville, VA 22908 USA.			Perzanowski, Matthew/0000-0003-1300-0985; Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, R37AI020565, U19AI034607, R01AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, AI-34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; Almqvist C, 1998, J ALLERGY CLIN IMMUN, V101, pS48; Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; DEANDRADE AD, 1994, J ALLERGY CLIN IMMUN, V93, P255; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)70307-5; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; Dotterud LK, 1997, CLIN EXP ALLERGY, V27, P252, DOI 10.1111/j.1365-2222.1997.tb00703.x; DYBENDAL T, 1992, CLIN EXP ALLERGY, V22, P1100, DOI 10.1111/j.1365-2222.1992.tb00136.x; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Lundback B, 1992, Nord Med, V107, P112; Mollet JA, 1997, J MED ENTOMOL, V34, P307, DOI 10.1093/jmedent/34.3.307; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; PEAT JK, 1995, MED J AUSTRALIA, V163, P22, DOI 10.5694/j.1326-5377.1995.tb126083.x; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; Perzanowski MS, 1997, J ALLERGY CLIN IMMUN, V100, P428, DOI 10.1016/S0091-6749(97)70261-6; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; RONMARK E, IN PRESS DIFFERENT P; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1997, J ALLERGY CLIN IMMUN, V99, P486, DOI 10.1016/S0091-6749(97)70074-5; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; Warner AM, 1996, PEDIAT ALLERG IMM-UK, V7, P61, DOI 10.1111/j.1399-3038.1996.tb00108.x; Wood RA, 1997, J ALLERGY CLIN IMMUN, V100, P290, DOI 10.1016/S0091-6749(97)70239-2; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110; Woolcock AJ, 1997, CIBA F SYMP, V206, P122	36	147	148	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1018	1024		10.1016/S0091-6749(99)70173-9	http://dx.doi.org/10.1016/S0091-6749(99)70173-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359880				2022-12-18	WOS:000080929500007
J	Valenta, R; Kraft, D				Valenta, R; Kraft, D			Type I allergic reactions to plant-derived food: A consequence of primary sensitization to pollen allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BIRCH POLLEN; CROSS-REACTIVITY; VEGETABLE FOODS; GRASS-POLLEN; IDENTIFICATION; PROFILIN; SENSITIVITY; ANTIBODIES; PROTEIN; APPLE		UNIV VIENNA,INST GEN & EXPTL PATHOL,AKH,A-1090 VIENNA,AUSTRIA	University of Vienna				Valenta, Rudolf/0000-0001-5944-3365				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; DREBORG S, 1983, ALLERGY, V38, P162; DROBAK BK, 1994, PLANT J, V6, P389, DOI 10.1046/j.1365-313X.1994.06030389.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; FERREIRA F, 1993, ALLERGY, V48, P53; FERREIRA F, IN PRESS J ALLERGY C; HALMEPURO L, 1985, ALLERGY, V40, P264, DOI 10.1111/j.1398-9995.1985.tb00231.x; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; HEISS S, 1994, ACI NEWS S, V2, P73; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; LAHTI A, 1980, ALLERGY, V35, P297, DOI 10.1111/j.1398-9995.1980.tb01770.x; LOEWENSTEIN H, 1983, ALLERGY, V38, P577; MITTERMANN I, 1995, PLANT MOL BIOL, V27, P137, DOI 10.1007/BF00019185; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; PETTENBURGER K, 1992, MOL IMMUNOL, V29, P1401, DOI 10.1016/0161-5890(92)90177-Y; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SWOBODA I, IN PRESS PROTOPLASMA; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VRTALA S, 1993, ALLERGY, V48, P53	29	147	152	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					893	895		10.1016/S0091-6749(96)80062-5	http://dx.doi.org/10.1016/S0091-6749(96)80062-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655883	Bronze			2022-12-18	WOS:A1996UG08600002
J	Petersen, LJ; Mosbech, H; Skov, PS				Petersen, LJ; Mosbech, H; Skov, PS			Allergen-induced histamine release in intact human skin in vivo assessed by skin microdialysis technique: Characterization of factors influencing histamine releasability	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hypersensitivity; histamine liberation; microdialysis; mast cells; skin test methods	CELL DE-GRANULATION; MAST-CELL; BRONCHOALVEOLAR LAVAGE; MEDIATOR RELEASE; URTICARIA; INVIVO; ASTHMA; CHALLENGE; IGE	Background: The purposes of the study were to characterize allergen-induced histamine release in intact human skin in vivo by using a novel microdialysis technique and to study covariates influencing histamine releasability. Methods: Hollow microdialysis fibers were inserted in to the upper dermis in 15 timothy-sensitive subjects. Up to 12 fibers were inserted in each subject. Each fiber was perfused with Krebs-Ringer's solution at a rate of 3.0 mu l/min. Three to four serial dilutions of allergen were applied to the skin by intracutaneous injections or skin prick test above individual fibers. Samples were collected in two 2-minute fractions before skin challenge and in 10 consecutive samples for 20 minutes after skin challenge. Histamine was assayed spectrofluorometrically. Results: A significant dose-response relationship for histamine release was demonstrated with intracutaneous tests and skin prick tests. The time to reach peak histamine release after an intracutaneous test was 4 to 8 minutes, compared with 12 to 14 minutes for a skin prick test. Histamine release correlated significantly with wheal size. Intrasubject coefficient of variation on histamine release was about 20%. A substantial intersubject variation in histamine releasability was observed. Seventy to seventy-five percent of the variation could be accounted for by a combination of gender, total and allergen-specific IgE, and an in vitro basophil histamine release test. Conclusion: Using a skin microdialysis technique, we have described in detail histamine release in intact human skin by allergen. The microdialysis method proved to be a reproducible technique for monitoring histamine release in allergic skin reactions and for studying histamine releasability of skin mast cells in vivo.	UNIV COPENHAGEN,NATL UNIV HOSP,REFERENCE LAB,COPENHAGEN,DENMARK; BISPEBJERG HOSP,DEPT PULM MED,DK-2400 COPENHAGEN NV,DENMARK	University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Petersen, LJ (corresponding author), BISPEBJERG HOSP,DEPT DERMATOL,DK-2400 COPENHAGEN NV,DENMARK.							ANDERSSON M, 1990, J ALLERGY CLIN IMMUN, V86, P815, DOI 10.1016/S0091-6749(05)80188-5; [Anonymous], 1991, MICRODIALYSIS NEUROS; ATKINS PC, 1993, J ALLERGY CLIN IMMUN, V91, P1031, DOI 10.1016/0091-6749(93)90216-3; ATKINS PC, 1990, J ALLERGY CLIN IMMUN, V86, P371, DOI 10.1016/S0091-6749(05)80100-9; Barret K. E., 1993, IMMUNOPHARMACOLOGY M, P29; BEDARD PM, 1983, J ALLERGY CLIN IMMUN, V71, P394, DOI 10.1016/0091-6749(83)90068-4; BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; CASOLARO V, 1990, AM REV RESPIR DIS, V142, P1108, DOI 10.1164/ajrccm/142.5.1108; CASOLARO V, 1989, AM REV RESPIR DIS, V139, P1375, DOI 10.1164/ajrccm/139.6.1375; CHURCH MK, 1991, SKIN PHARMACOL, V4, P15; CONROY MC, 1977, J IMMUNOL, V118, P1317; FLINT KC, 1986, RESPIRATION, V50, P31, DOI 10.1159/000195099; GREAVES MW, 1970, J INVEST DERMATOL, V54, P365, DOI 10.1111/1523-1747.ep12259058; HEAVEY DJ, 1984, BRIT J CLIN PHARMACO, V18, P915, DOI 10.1111/j.1365-2125.1984.tb02564.x; IND PW, 1984, AGENTS ACTIONS, V14, P417, DOI 10.1007/BF01973841; JACQUES P, 1992, J ALLERGY CLIN IMMUN, V89, P1139, DOI 10.1016/0091-6749(92)90297-F; LEBEL B, 1988, CLIN ALLERGY, V18, P605, DOI 10.1111/j.1365-2222.1988.tb02912.x; LONNROTH P, 1990, J INTERN MED, V227, P295; MCBRIDE P, 1989, J ALLERGY CLIN IMMUN, V83, P374, DOI 10.1016/0091-6749(89)90121-8; MOSBECH H, 1987, ALLERGY, V42, P456, DOI 10.1111/j.1398-9995.1987.tb00363.x; NEITTAANMAKI H, 1984, ARCH DERMATOL RES, V276, P317, DOI 10.1007/BF00404624; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; PETERSEN LJ, 1992, ALLERGY, V47, P635, DOI 10.1111/j.1398-9995.1992.tb02387.x; PETERSEN LJ, 1992, J INVEST DERMATOL, V99, P357, DOI 10.1111/1523-1747.ep12616676; PETERSEN LJ, 1994, J ALLERGY CLIN IMMUN, V94, P773, DOI 10.1016/0091-6749(94)90186-4; PETERSEN LJ, 1995, J ALLERGY CLIN IMMUN, V95, P225; PETERSEN LJ, 1995, IN PRESS CLIN EXP AL; PETERSEN LJ, 1995, HDB NONINVASIVE METH, P641; RESHEF A, 1989, J ALLERGY CLIN IMMUN, V84, P678, DOI 10.1016/0091-6749(89)90296-0; SCHWARZENBACH HR, 1982, CLIN ALLERGY, V12, P465, DOI 10.1111/j.1365-2222.1982.tb01645.x; SHALIT M, 1990, J ALLERGY CLIN IMMUN, V86, P117, DOI 10.1016/S0091-6749(05)80131-9; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SKOV PS, 1984, AGENTS ACTIONS, V14, P414, DOI 10.1007/BF01973840; SOTER NA, 1991, J AM ACAD DERMATOL, V24, P1084, DOI 10.1016/0190-9622(91)70161-T; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; VOLUND A, 1978, BIOMETRICS, V34, P357, DOI 10.2307/2530598; VOLUND A, 1994, HDB LAB ANIMAL SCI, V1, P203; WEISS ME, 1989, J ALLERGY CLIN IMMUN, V83, P1040, DOI 10.1016/0091-6749(89)90445-4; Young A M, 1993, Rev Neurosci, V4, P373	42	147	149	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					672	679		10.1016/S0091-6749(96)70313-5	http://dx.doi.org/10.1016/S0091-6749(96)70313-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621853				2022-12-18	WOS:A1996TW08700013
J	BERNARDBONNIN, AC; STACHENKO, S; BONIN, D; CHARETTE, C; ROUSSEAU, E				BERNARDBONNIN, AC; STACHENKO, S; BONIN, D; CHARETTE, C; ROUSSEAU, E			SELF-MANAGEMENT TEACHING PROGRAMS AND MORBIDITY OF PEDIATRIC ASTHMA - A METAANALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PEDIATRIC ASTHMA; MORBIDITY; SELF-MANAGEMENT; TEACHING PROGRAMS; METAANALYSIS	CHILDHOOD ASTHMA; EDUCATION-PROGRAM; HEALTH-EDUCATION; CHILDREN; IMPACT; TRIAL; INTERVENTION; NEED	Background: Self-management teaching programs are becoming an important asset in the management of pediatric asthma. Objective: The study was designed to evaluate the impact of self-management teaching programs on the morbidity of pediatric asthma. Methods: The meta-analysis included randomized clinical trials, published between 1970 and 1991, addressing the outcome of morbidity. Studies were retrieved from searches of MEDLINE, American Journal of Nursing International Index, and Dissertation Abstracts Online Database. The quality of studies was assessed with the scale of Chalmers. The pooled effect size was calculated by the method of Hedges. Results: The literature search retrieved 23 randomized clinical trials, but 12 studies had to be excluded. Global score of quality of studies (Chalmers' scale) was fair, 51.6% +/- 9.9%. As indicated by the effect size (ES) of the pooled studies, self-management teaching did not reduce school absenteeism (ES: 0.04 +/- 0.08), asthma attacks (ES: 0.09 +/- 0.14), hospitalizations (ES: 0.06 +/- 0.08), hospital days (ES: -0.11 +/- 0.08), or emergency visits (0.14 +/- 0.09). Conclusion: Self-management teaching programs do not seem to reduce morbidity and future programs should focus more on intermediate outcomes such as behavior.	UNIV MONTREAL, DEPT PEDIAT, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT SOCIAL & PREVENT MED, MONTREAL, PQ, CANADA	Universite de Montreal; Universite de Montreal	BERNARDBONNIN, AC (corresponding author), UNIV MONTREAL, HOP ST JUSTINE, DEPT PEDIAT, 3175 COTE ST CATHERINE, MONTREAL, PQ H3T 1C5, CANADA.							Alexander J S, 1988, J Pediatr Nurs, V3, P312; BRUHN JG, 1983, J ALLERGY CLIN IMMUN, V72, P561, DOI 10.1016/0091-6749(83)90483-9; Carson D K, 1991, Child Health Care, V20, P114, DOI 10.1207/s15326888chc2002_7; Carswell F, 1989, Bristol Med Chir J, V104, P11; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CLARK NM, 1989, CHEST, V95, P1110, DOI 10.1378/chest.95.5.1110; COHEN J, 1977, STATISTICAL POWER AN, P184; CREER T L, 1990, Pediatric Asthma Allergy and Immunology, V4, P41, DOI 10.1089/pai.1990.4.41; EVANS D, 1987, HEALTH EDUC QUART, V14, P267, DOI 10.1177/109019818701400302; FIREMAN P, 1981, PEDIATRICS, V68, P341; FOWLER MG, 1992, PEDIATRICS, V90, P939; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GOLD R, 1986, THESIS RUTGERS U NEW; Hedges L, 1985, STAT METHODS METAANA, P108; HOWLAND J, 1988, CHEST, V94, P964, DOI 10.1378/chest.94.5.964; HUGHES DM, 1991, PEDIATRICS, V87, P54; INDINNIMEO L, 1987, HEALTH EDUC QUART, V14, P291, DOI 10.1177/109019818701400304; KLINGELHOFER EL, 1988, J ASTHMA, V25, P89, DOI 10.3109/02770908809071359; KUBLY SL, 1984, ISSUES COMP PEDIATR, V7, P121; LEWIS CE, 1984, PEDIATRICS, V74, P478; MCNABB W, 1984, THESIS U DENVER DENV; MITCHELL EA, 1986, ARCH DIS CHILD, V61, P1184, DOI 10.1136/adc.61.12.1184; OXMAN AD, 1992, ASSESSING INTERVENTI, P191; Parcel G S, 1980, J Dev Behav Pediatr, V1, P128; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; RACHELEFSKY GS, 1987, J ALLERGY CLIN IMMUN, V80, P506, DOI 10.1016/0091-6749(87)90087-X; RAKOS RF, 1985, J PSYCHOSOM RES, V29, P101, DOI 10.1016/0022-3999(85)90014-5; RUBIN DH, 1986, PEDIATRICS, V77, P1; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SCHWARTZ PL, 1990, THESIS TEXAS WOMENS; SHIELDS MC, 1990, AM J PUBLIC HEALTH, V80, P36, DOI 10.2105/AJPH.80.1.36; SLY RM, 1975, ANN ALLERGY, V34, P94; SMITH NA, 1986, MED J AUSTRALIA, V144, P119, DOI 10.5694/j.1326-5377.1986.tb112234.x; SPECTOR TD, 1991, J EPIDEMIOL COMMUN H, V45, P89, DOI 10.1136/jech.45.2.89; TAYLOR WR, 1992, PEDIATRICS, V90, P657; THORESEN CE, 1983, J ALLERGY CLIN IMMUN, V72, P596, DOI 10.1016/0091-6749(83)90487-6; VANASPEREN P, 1986, AUST PAEDIATR J, V22, P49; WEISS JH, 1987, PREVENT HLTH, V5, P57; WHITMAN N, 1985, HEALTH EDUC QUART, V12, P333, DOI 10.1177/109019818501200312; WIGAL J K, 1990, Pediatric Asthma Allergy and Immunology, V4, P17, DOI 10.1089/pai.1990.4.17; WILKINS K, 1993, CAN MED ASSOC J, V148, P185; WILSONPESSANO SR, 1987, J ALLERGY CLIN IMMUN, V80, P487, DOI 10.1016/0091-6749(87)90081-9	43	147	148	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				34	41		10.1016/S0091-6749(95)70150-8	http://dx.doi.org/10.1016/S0091-6749(95)70150-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	QC312	7822662				2022-12-18	WOS:A1995QC31200006
J	GOLD, M; SWARTZ, JS; BRAUDE, BM; DOLOVICH, J; SHANDLING, B; GILMOUR, RF				GOLD, M; SWARTZ, JS; BRAUDE, BM; DOLOVICH, J; SHANDLING, B; GILMOUR, RF			INTRAOPERATIVE ANAPHYLAXIS - AN ASSOCIATION WITH LATEX SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CONTACT URTICARIA; SURGICAL GLOVES; ANESTHETIC DRUGS; NATURAL LATEX; ALLERGY; RUBBER; PENICILLIN; CHILDREN	Latex products have recently been identified as the cause of severe intraoperative anaphylactic reactions. We have identified a group of pediatric patients who appear to be at increased risk for such reactions. Fifteen patients with either spina bifida or congenital urologic abnormalities experienced 19 intraoperative anaphylactic reactions. All patients had frequent previous exposures to rubber materials since infancy as part of their management and/or investigative procedures. Seven of 15 patients had a previous history of local skin reactions to rubber. Only four patients were atopic. All patients had undergone multiple (two to 26) operative procedures before their reactions, the onset of which ranged from 40 to 290 minutes after induction of anesthesia. The reactions varied in intensity from urticaria to severe cardiorespiratory collapse. All these patients subsequently had positive allergy skin tests and positive RAST to latex antigen. We conclude that this group is at risk when they are exposed to latex intraoperatively as a result of frequent past exposure to these materials. Allergic evaluation for latex allergy may assist in the preoperative evaluation of similar patients. In sensitized patients, appropriate prophylactic measures, particularly the avoidance of lates, is required.	HOSP SICK CHILDREN,DEPT ANAESTHESIA,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA; MCMASTER UNIV,DEPT PAEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT SURG,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT MED ENGN,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	GOLD, M (corresponding author), HOSP SICK CHILDREN,DEPT PAEDIAT,DIV IMMUNOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.							AXELSSON IGK, 1988, ACTA PAEDIATR SCAND, V77, P314, DOI 10.1111/j.1651-2227.1988.tb10652.x; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; DESWARTE RD, 1985, ALLERGIC DISEASES, P505; FISHER M, 1984, ANAESTH INTENS CARE, V12, P115, DOI 10.1177/0310057X8401200205; FISHER MM, 1987, BRIT J ANAESTH, V59, P690, DOI 10.1093/bja/59.6.690; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P33, DOI 10.1111/j.1600-0536.1980.tb03887.x; FROSCH PJ, 1986, CONTACT DERMATITIS, V14, P241, DOI 10.1111/j.1600-0536.1986.tb01233.x; GERBER AC, 1989, ANESTHESIOLOGY, V71, P800, DOI 10.1097/00000542-198911000-00031; GOLD M, 1988, ALLERGY CAN CLIN REV, V1, P7; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; LOZYNSKY OA, 1986, ANN ALLERGY, V56, P62; MARSH DG, 1980, J ALLERGY CLIN IMMUN, V65, P322, DOI 10.1016/0091-6749(80)90208-0; MEDING B, 1984, CONTACT DERMATITIS, V10, P52, DOI 10.1111/j.1600-0536.1984.tb00071.x; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; MYERS GE, 1981, CATHETER CARDIO DIAG, V7, P65, DOI 10.1002/ccd.1810070109; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; Pepys J., 1975, BR J HOSP MED, V14, P412; REISMAN RE, 1988, ALLERGY PRINCIPLES P, P1345; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; STOELTING RK, 1983, ANESTH ANALG, V62, P341; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029	27	147	149	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					662	666		10.1016/0091-6749(91)90385-2	http://dx.doi.org/10.1016/0091-6749(91)90385-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005317				2022-12-18	WOS:A1991FB80100009
J	PROUD, D; SWEET, J; STEIN, P; SETTIPANE, RA; KAGEYSOBOTKA, A; FRIEDLAENDER, MH; LICHTENSTEIN, LM				PROUD, D; SWEET, J; STEIN, P; SETTIPANE, RA; KAGEYSOBOTKA, A; FRIEDLAENDER, MH; LICHTENSTEIN, LM			INFLAMMATORY MEDIATOR RELEASE ON CONJUNCTIVAL PROVOCATION OF ALLERGIC SUBJECTS WITH ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, SCH MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA; SCRIPPS CLIN & RES FDN, DIV ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA; SCRIPPS CLIN & RES FDN, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; SCRIPPS CLIN & RES FDN, DIV OPHTHALMOL, LA JOLLA, CA 92037 USA	Johns Hopkins University; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute				Settipane, Russell/0000-0002-6328-8780	NATIONAL EYE INSTITUTE [R01EY002502] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032272] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02502] Funding Source: Medline; NHLBI NIH HHS [HL 32272] Funding Source: Medline; NIAID NIH HHS [AI 07290] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELSON MB, 1980, OPHTHALMOLOGY, V87, P812; ADKINSON NF, 1980, AM REV RESPIR DIS, V121, P911; ALLANSMITH MR, 1978, AM J OPHTHALMOL, V86, P250, DOI 10.1016/S0002-9394(14)76821-7; ALLANSMITH MR, 1988, CLIN ALLERGY, V18, P1, DOI 10.1111/j.1365-2222.1988.tb02837.x; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BEDARD PM, 1983, J ALLERGY CLIN IMMUN, V71, P394, DOI 10.1016/0091-6749(83)90068-4; BISGAARD H, 1984, PROSTAGLANDINS, V27, P369, DOI 10.1016/0090-6980(84)90196-5; BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6; BOWSHER RR, 1983, J BIOL CHEM, V258, P2215; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; Friedlander MH, 1988, ALLERGY PRINCIPLES P, P1469; HAYES EC, 1983, J IMMUNOL, V131, P429; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Ishizaka T, 1988, ALLERGY PRINCIPLES P, P71; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LICHTENSTEIN LM, 1986, MAST CELL DIFFERENTI, P331; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, 1986, J ALLERGY CLIN IMMUN, V78, P874, DOI 10.1016/0091-6749(86)90233-2; Peters S P, 1982, Trans Assoc Am Physicians, V95, P221; PIENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P95, DOI 10.1016/0091-6749(88)90057-7; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; WEBSTER ME, 1963, ANN NY ACAD SCI, V104, P91, DOI 10.1111/j.1749-6632.1963.tb17655.x; WEBSTER ME, 1970, HDB EXPERIMENTAL PHA, V25, P131; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450	38	147	150	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					896	905		10.1016/0091-6749(90)90075-F	http://dx.doi.org/10.1016/0091-6749(90)90075-F			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	1692049				2022-12-18	WOS:A1990DD95900013
J	PLATTSMILLS, TAE; HEYMANN, PW; LONGBOTTOM, JL; WILKINS, SR				PLATTSMILLS, TAE; HEYMANN, PW; LONGBOTTOM, JL; WILKINS, SR			AIRBORNE ALLERGENS ASSOCIATED WITH ASTHMA - PARTICLE SIZES CARRYING DUST MITE AND RAT ALLERGENS MEASURED WITH A CASCADE IMPACTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CARDIOTHORAC INST, LONDON SW3 6HP, ENGLAND		PLATTSMILLS, TAE (corresponding author), UNIV VIRGINIA, MED CTR, DIV ALLERGY & CLIN IMMUNOL, BOX 225, CHARLOTTESVILLE, VA 22908 USA.				NIAID NIH HHS [AI20565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R37AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; Blackley CH., 1873, EXPT RES CAUSES NATU; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; CAVANAUGH MJ, 1977, J ALLERGY CLIN IMMUN, V59, P41, DOI 10.1016/0091-6749(77)90175-0; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; COCKCROFT A, 1981, LANCET, V1, P827; FINDLAY S, 1983, J ALLERGY CLIN IMMUN, V71, P160, DOI 10.1016/0091-6749(83)90412-8; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; HARGREAVE FE, 1984, ASTHMA PHYSL IMMUNOP, P263; HARPER GJ, 1953, J HYG-CAMBRIDGE, V51, P372, DOI 10.1017/S0022172400015801; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; LEVY D A, 1982, Journal of Allergy and Clinical Immunology, V69, P158; LONGBOTTOM JL, 1983, 11 P INT C ALL CLIN, P525; LUTSKY II, 1983, J OCCUP ENVIRON MED, V25, P372; MICHEL FB, 1977, AM REV RESPIR DIS, V115, P609; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P21, DOI 10.1016/0091-6749(83)90542-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; ROSENBERG GL, 1975, J ALLERGY CLIN IMMUN, V55, P126; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; SOLOMON WR, 1984, NEW ENGLAND REGIONAL, V5, P142; SOLOMON WR, 1978, ALLERGY PRINCIPLES P, P899; STEVENSON DD, 1975, ARCH INTERN MED, V135, P777, DOI 10.1001/archinte.135.6.777; SWANSON MC, 1984, AM REV RESPIR DIS, V129, P844, DOI 10.1164/arrd.1984.129.5.844; TATTERSFIELD AE, 1983, ASTHMA, P301; TAYLOR AN, 1977, LANCET, V2, P847; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; 1969, HDB CHEM PHYSICS	35	147	147	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					850	857		10.1016/0091-6749(86)90383-0	http://dx.doi.org/10.1016/0091-6749(86)90383-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3711552				2022-12-18	WOS:A1986C869400010
J	BERNSTEIN, IL				BERNSTEIN, IL			ISOCYANATE-INDUCED PULMONARY-DISEASES - A CURRENT PERSPECTIVE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BERNSTEIN, IL (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267, USA.				NIOSH CDC HHS [OH 773-01] Funding Source: Medline	NIOSH CDC HHS		ADAMS WGF, 1975, BRIT J IND MED, V32, P72; AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; AXFORD AT, 1976, BRIT J IND MED, V33, P65; BAUR V, 1981, CHEST S, V80, P73; BLAKE BL, 1965, J COLL RADIOL AUSTRA, V9, P45; BRUGSCH HG, 1963, NEW ENGL J MED, V268, P353, DOI 10.1056/NEJM196302142680705; BUTCHER BT, 1977, J ALLERGY CLIN IMMUN, V59, P223, DOI 10.1016/0091-6749(77)90153-1; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; CHARLES J, 1976, THORAX, V31, P127, DOI 10.1136/thx.31.2.127; CHEN S E, 1982, Journal of Allergy and Clinical Immunology, V69, P123; CHESTER EH, 1979, CHEST, V75, P229, DOI 10.1378/chest.75.2_Supplement.229; Cirla A M, 1975, Med Lav, V66, P5; DANKS JM, 1981, CLIN ALLERGY, V11, P161, DOI 10.1111/j.1365-2222.1981.tb01580.x; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P223, DOI 10.1016/0091-6749(77)90134-8; Duncan B., 1962, AMER INDUS HYG ASSOC, V23, P447; FINK JN, 1978, AM REV RESPIR DIS, V118, P955; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; KAROL MH, 1979, J OCCUP ENVIRON MED, V21, P354; KAROL MH, 1980, TOXICOL APPL PHARM, V53, P260, DOI 10.1016/0041-008X(80)90425-1; KAROL MH, 1979, TOXICOL APPL PHARM, V51, P73, DOI 10.1016/0041-008X(79)90009-7; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P546, DOI 10.1080/0002889778507807; MCKAY R T, 1981, American Review of Respiratory Disease, V123, P132; McKay R T, 1981, Chest, V80, P61; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; OBRIEN IM, 1979, CLIN ALLERGY, V9, P7, DOI 10.1111/j.1365-2222.1979.tb01517.x; PAIN MCF, 1972, MED J AUSTRALIA, V1, P522, DOI 10.5694/j.1326-5377.1972.tb46926.x; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; PHAM QT, 1978, ANN OCCUP HYG, V21, P121, DOI 10.1093/annhyg/21.2.121; SCHEEL L D, 1964, Am Ind Hyg Assoc J, V25, P179, DOI 10.1080/00028896409342574; SCHUR E, 1959, Med Klin, V54, P168; SMITH AB, 1980, J OCCUP ENVIRON MED, V22, P327, DOI 10.1097/00043764-198005000-00005; STEVENS MA, 1970, P ROY SOC MED, V63, P380, DOI 10.1177/003591577006300422; TREVISAN A, 1981, INT ARCH OCC ENV HEA, V49, P129, DOI 10.1007/BF00377666; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; TSE CST, 1979, AM REV RESPIR DIS, V120, P829; VANERT M, 1975, ANN ALLERGY, V35, P142; WEGMAN DH, 1977, BRIT J IND MED, V34, P196; WOODBURY JW, 1956, IND MED, V24, P540; ZEDDA S, 1976, RESPIRATION, V33, P14, DOI 10.1159/000193684; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0; 1973, DHEW HSM7311022 PUBL	45	147	147	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	1					24	31		10.1016/0091-6749(82)90197-X	http://dx.doi.org/10.1016/0091-6749(82)90197-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NY715	6282949				2022-12-18	WOS:A1982NY71500008
J	VERVLOET, D; PENAUD, A; RAZZOUK, H; SENFT, M; ARNAUD, A; BOUTIN, C; CHARPIN, J				VERVLOET, D; PENAUD, A; RAZZOUK, H; SENFT, M; ARNAUD, A; BOUTIN, C; CHARPIN, J			ALTITUDE AND HOUSE DUST MITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INST J PAOLI I CALMETTES, INSERM, U174, DEPT CHEST DIS, F-13009 MARSEILLE, FRANCE; HOP NORD, PARASITOL LAB, F-13326 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	VERVLOET, D (corresponding author), HOP ST MARGUERITE, DEPT CHEST DIS, F-13277 MARSEILLE 9, FRANCE.							ASSEM E S K, 1973, Clinical Allergy, V3, P161, DOI 10.1111/j.1365-2222.1973.tb01319.x; BERNSTEIN C, 1952, J Fla Med Assoc, V39, P38; BERRENS L, 1971, ACTA ALLERGOL, V26, P200, DOI 10.1111/j.1398-9995.1971.tb01296.x; BRANDT RL, 1976, J MED ENTOMOL, V13, P327, DOI 10.1093/jmedent/13.3.327; CABANIEU G, 1974, REV FR ALLERGOL, V14, P63, DOI 10.1016/S0335-7457(74)80011-0; CABANIEU G, 1977, ALLERGOL IMMUNOPATHO, V5; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DOMROW R, 1970, MED J AUSTRALIA, V2, P1248, DOI 10.5694/j.1326-5377.1970.tb63454.x; FAIN A, 1967, Acarologia (Paris), V9, P179; Fain A., 1965, Revue de Zoologie et de Botanique Africaines, V72, P257; Fain A., 1964, Revue de Zoologie et de Botanique Africaines, V69, P201; Fain A., 1966, Bulletin Acad R Med Belge (7), V6, P479; Fain A., 1966, Acarologia, V8, P302; FISH JE, 1977, AM REV RESPIR DIS, V115, P371; GITOHO F, 1971, BRIT MED J, V3, P475, DOI 10.1136/bmj.3.5772.475; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GRIFFITHS D A, 1970, Bulletin of the British Museum (Natural History) Zoology, V19, P85; HUGHES A M, 1973, Clinical Allergy, V3, P127, DOI 10.1111/j.1365-2222.1973.tb01316.x; HUGHES AM, 1961, FISHERIES FOOD, V9, P142; LANG JD, 1977, ENVIRON ENTOMOL, V6, P643, DOI 10.1093/ee/6.5.643; LARSON DG, 1969, J MED ENTOMOL, V6, P295, DOI 10.1093/jmedent/6.3.295; LARSON DG, 1969, THESIS OHIO STATE U; LASCAUD D, 1978, ANN PARASIT HUM COMP, V53, P675, DOI 10.1051/parasite/1978536675; LEES LJ, 1974, BRIT J CLIN PRACT, V28, P343; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1977, ASTHMA PHYSL IMMUNOP, P414; MAUNSELL K, 1968, LANCET, V1, P1267; Miyamoto J., 1976, Japanese J Sanit Zool, V27, P251; MULLA MS, 1975, J MED ENTOMOL, V12, P5, DOI 10.1093/jmedent/12.1.5; MUMCUOGLU Y, 1977, ACTA ALLERGOL, V32, P333; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; NADCHATRAM M, 1981, ANN ALLERGY, V46, P197; ORDMAN D, 1971, South African Medical Journal, V45, P739; PENAUD A, 1972, Annales de Parasitologie Humaine et Comparee, V47, P631; ROBERTSON PHYLLIS L., 1959, AUSTRALIAN JOUR ZOOL, V7, P146, DOI 10.1071/ZO9590146; RUFLI M, 1969, MED HYG, V887, P1139; SCHUTZBANK FB, 1949, JAMA-J AM MED ASSOC, V139, P1260, DOI 10.1001/jama.1949.02900350022006; SHAMIYEH NB, 1971, J ECON ENTOMOL, V64, P53, DOI 10.1093/jee/64.1.53; SHARP JL, 1970, P HAWAII ENTOMOL SOC, V20, P583; Spieksma F. Th. M., 1967, Acarologia, V9, P226; SPIEKSMA FT, 1971, BMJ-BRIT MED J, V1, P82, DOI 10.1136/bmj.1.5740.82; Spieksma FTM, 1967, THESIS U LEIDEN NETH; Summers FM., 1970, REV MITE FAMILY CHEY; Van Bronswijk J.E.M.H., 1972, Netherlands J Zool, V22, P207, DOI 10.1163/002829672X00077; VANBRONS.JE, 1973, J MED ENTOMOL, V10, P63, DOI 10.1093/jmedent/10.1.63; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; VOORHORST R, 1969, ACTA ALLERGOL, V24, P115, DOI 10.1111/j.1398-9995.1969.tb03761.x; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577; WHARTON GW, 1970, SCIENCE, V167, P1382, DOI 10.1126/science.167.3923.1382; [No title captured]	53	147	151	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	3					290	296		10.1016/S0091-6749(82)80006-7	http://dx.doi.org/10.1016/S0091-6749(82)80006-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NF697	7061770				2022-12-18	WOS:A1982NF69700006
J	Paller, AS; Kabashima, K; Bieber, T				Paller, Amy S.; Kabashima, Kenji; Bieber, Thomas			Therapeutic pipeline for atopic dermatitis: End of the drought?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Biologics; small molecule inhibitors; topical therapy; cytokines; mAbs; precision medicine	DEFICIT HYPERACTIVITY DISORDER; ARYL-HYDROCARBON RECEPTOR; HEALTH-CARE UTILIZATION; PROOF-OF-CONCEPT; SKIN BARRIER; DOUBLE-BLIND; PHASE 2A; SCRATCHING BEHAVIOR; TOPICAL WBI-1001; TYPE-2 IMMUNITY	Until the past year, our therapeutic armamentarium for treating atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, systemic immunosuppressants. The pipeline of more targeted topical and systemic therapies is expanding based on our growing understanding of the mechanism for AD and is particularly focused on suppressing the skewed immune activation. Most agents are in phase 2 clinical trials. Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became available in late 2016 in the United States for mild-to-moderate AD, with other PDE4 inhibitors, an agonist of the aryl hydrocarbon receptor, Janus kinase inhibitors, and commensal organisms also in trials for topical application. The first highly effective mAb for AD, dupilumab, targets the IL-4/IL-13 receptor and was approved in early 2017 in the United States for moderate-tosevere adult AD. Other biologics similarly inhibit TH2 cytokines (thymic stromal lymphopoietin, IL-4, IL-5, IL-13, and the itch-specific cytokine IL-31 and their receptors) or T(H)22/T(H)17 cytokines, levels of which are increased in lesional skin. Orally administered small-molecule inhibitors that suppress inflammation (targeting chemoattractant receptor-homologous molecules expressed on TH2 lymphocytes, PDE4, the histamine 4 receptor, and Janus kinase) or specifically itching (eg, NK1R inhibitors) are also being studied. Comparing biomarkers with individual responses to experimental agents will help to determine subphenotypes within AD that predict prognosis and treatment responses.	[Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol & Pediat, Chicago, IL 60208 USA; [Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Kabashima, Kenji] Singapore Immunol Network SIgN, Singapore, Singapore; [Kabashima, Kenji] ASTAR, Biopolis, Singapore, Singapore; [Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany; [Bieber, Thomas] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland	Northwestern University; Feinberg School of Medicine; Kyoto University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR); University of Bonn	Paller, AS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, 676 North St Clair St,Suite 1600, Chicago, IL 60611 USA.	apaller@northwestern.edu	Kabashima, Kenji/G-2521-2014	Kabashima, Kenji/0000-0002-0773-0554	AbbVie; Celgene; LEO; Novartis; Japan Tobacco; Astellas; Pfizer; Sanofi; Sanofi/Regeneron	AbbVie(AbbVie); Celgene(Bristol-Myers SquibbCelgene Corporation); LEO(LEO Pharma); Novartis(Novartis); Japan Tobacco; Astellas(Astellas Pharmaceuticals); Pfizer(Pfizer); Sanofi; Sanofi/Regeneron(Regeneron)	A. S. Paller has consultant arrangements with Dermira, Eli Lilly, Galderma, GlaxoSmithKline-Stiefel, Novartis, Pfizer, Regeneron/Sanofi, Roivant, and Valeant and has received grants from AbbVie, Celgene, LEO, and Novartis. K. Kabashima has consultant arrangements with Chugai and Maruho and has received grants from Japan Tobacco. T. Bieber has consultant arrangements with Astellas, Sanofi/Regeneron, Pfizer, Novartis, Lilly, Galderma, Roivant, Menlo TX, GlaxoSmithKline, and Daiichi-Sankyo; has received payment for lectures including Astellas, Pfizer and Sanofi; and has received payment for manuscript preparation from Sanofi/Regeneron. S. Weidinger disclosed no relevant financial relationships.	Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051; Apfelbacher CJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007770.pub2; Bangert C, 2016, EXP DERMATOL, V25, P37; Bissonnette R, 2016, BRIT J DERMATOL, V175, P902, DOI 10.1111/bjd.14871; Bissonnette R, 2012, BRIT J DERMATOL, V166, P853, DOI 10.1111/j.1365-2133.2011.10775.x; Bissonnette R, 2010, ARCH DERMATOL, V146, P446, DOI 10.1001/archdermatol.2010.34; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Brunner PM, 2017, J INVEST DERMATOL, V137, P18, DOI 10.1016/j.jid.2016.08.022; Buffie CG, 2015, NATURE, V517, P205, DOI 10.1038/nature13828; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Drucker AM, 2016, ALLERGY, V71, P1496, DOI 10.1111/all.12957; Drucker AM, 2017, J INVEST DERMATOL, V137, P26, DOI 10.1016/j.jid.2016.07.012; Drucker AM, 2017, BRIT J DERMATOL; Dunford PJ, 2007, J ALLERGY CLIN IMMUN, V119, P176, DOI 10.1016/j.jaci.2006.08.034; Egawa G, 2016, J ALLERGY CLIN IMMUN, V138, P350, DOI 10.1016/j.jaci.2016.06.002; Egeberg A, 2017, ALLERGY, V72, P783, DOI 10.1111/all.13085; Eichenfield LF, 2017, J ALLERGY CLIN IMMUN, V139, pS49, DOI 10.1016/j.jaci.2017.01.009; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Gause WC, 2013, NAT REV IMMUNOL, V13, P607, DOI 10.1038/nri3476; Gonzalez ME, 2016, J AM ACAD DERMATOL, V75, P481, DOI 10.1016/j.jaad.2016.04.066; Gueniche A, 2008, BRIT J DERMATOL, V159, P1357, DOI 10.1111/j.1365-2133.2008.08836.x; Guttman-Yassky E, 2017, J INVEST DERMATOL, V137, pS53, DOI 10.1016/j.jid.2017.02.329; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Haarmann-Stemmann T, 2015, J INVEST DERMATOL, V135, P2572, DOI 10.1038/jid.2015.285; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hjuler KF, 2015, AM J MED, V128, P1325, DOI 10.1016/j.amjmed.2015.05.041; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Hotze M, 2014, ALLERGY, V69, P132, DOI 10.1111/all.12234; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Huang JT, 2009, PEDIATRICS, V123, pE808, DOI 10.1542/peds.2008-2217; Kabashima K, 2017, NAT IMMUNOL, V18, P5, DOI 10.1038/ni.3615; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Kennedy EA, 2017, J ALLERGY CLIN IMMUN, V139, P166, DOI 10.1016/j.jaci.2016.07.029; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Kim HO, 2014, EXP DERMATOL, V23, P278, DOI 10.1111/exd.12350; Knowlden SA, 2017, J INVEST DERMATOL, V137, pS50, DOI 10.1016/j.jid.2017.02.312; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Legendre L, 2015, J AM ACAD DERMATOL, V72; Leung TH, 2013, J CLIN INVEST, V123, P5361, DOI 10.1172/JCI70895; Liu Q, 2009, CELL, V139, P1353, DOI 10.1016/j.cell.2009.11.034; Meng J, 2016, CURR RES TRANSL MED, V64, P203, DOI 10.1016/j.retram.2016.08.006; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Miyazaki C, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1281-7; Mizutani N, 2015, IMMUNOLOGY, V146, P568, DOI 10.1111/imm.12528; Murata Y, 2015, J DERMATOL, V42, P129, DOI 10.1111/1346-8138.12726; Murota H, 2012, J ALLERGY CLIN IMMUN, V130, P671, DOI 10.1016/j.jaci.2012.05.027; Myles IA, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86955; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Negi O, 2012, J DERMATOL SCI, V66, P37, DOI 10.1016/j.jdermsci.2012.01.007; Nic Dhonncha E, 2016, BR J DERMATOL; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Oetjen L, 2017, J INVEST DERMATOL, V137, pS100, DOI 10.1016/j.jid.2017.02.602; Ohmura T, 2004, EUR J PHARMACOL, V491, P191, DOI 10.1016/j.ejphar.2004.03.047; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Paller AS, 2016, J AM ACAD DERMATOL, V75, P494, DOI 10.1016/j.jaad.2016.05.046; Ricci Giampaolo, 2006, J Pediatr Health Care, V20, P311, DOI 10.1016/j.pedhc.2006.04.009; Ruzicka T, 2017, NEW ENGL J MED, V376, P826, DOI 10.1056/NEJMoa1606490; Saeki H, 2017, BR J DERMATOL; Samrao A, 2012, ARCH DERMATOL, V148, P890, DOI 10.1001/archdermatol.2012.812; Schmitt J, 2009, JAMA-J AM MED ASSOC, V301, P724, DOI 10.1001/jama.2009.136; Seltmann J, 2015, J ALLERGY CLIN IMMUN, V135, P1659, DOI 10.1016/j.jaci.2015.01.048; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Shiratori-Hayashi M, 2015, NAT MED, V21, P927, DOI 10.1038/nm.3912; Silverberg JI, 2015, JAMA DERMATOL, V151, P743, DOI 10.1001/jamadermatol.2014.5432; Silverberg JI, 2014, DERMATITIS, V25, P107, DOI 10.1097/DER.0000000000000034; Silverberg JI, 2013, PEDIAT ALLERG IMM-UK, V24, P476, DOI 10.1111/pai.12095; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Standl M, 2017, J INVEST DERMATOL, V137, P1074, DOI 10.1016/j.jid.2016.11.031; Strom MA, 2016, BRIT J DERMATOL, V175, P920, DOI 10.1111/bjd.14697; Suh DC, 2007, J MANAGE CARE PHARM, V13, P778, DOI 10.18553/jmcp.2007.13.9.778; Sun YG, 2007, NATURE, V448, P700, DOI 10.1038/nature06029; Thyssen JP, 2017, ALLERGY; Tominaga M, 2007, J DERMATOL SCI, V48, P103, DOI 10.1016/j.jdermsci.2007.06.003; Toyoda M, 2002, BRIT J DERMATOL, V147, P71, DOI 10.1046/j.1365-2133.2002.04803.x; van den Bogaard EH, 2013, J CLIN INVEST, V123, P917, DOI 10.1172/JCI65642; Verstraete K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14937; Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691; Werfel T, 2016, ALLERGY, V71, P95; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Williams MR, 2017, J INVEST DERMATOL, V137, P377, DOI 10.1016/j.jid.2016.10.008; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Yu SH, 2015, J INVEST DERMATOL, V135, P3183, DOI 10.1038/jid.2015.337; Zane LT, 2016, IMMUNOTHERAPY-UK, V8, P853, DOI 10.2217/imt-2016-0023; Zhang A, 2015, J AM ACAD DERMATOL, V72, P606, DOI 10.1016/j.jaad.2014.12.013; Zink A, 2016, ACTA DERM-VENEREOL, V96, P72, DOI 10.2340/00015555-2165	92	146	148	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					633	643		10.1016/j.jaci.2017.07.006	http://dx.doi.org/10.1016/j.jaci.2017.07.006			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28887947	Bronze			2022-12-18	WOS:000409241500001
J	Wood, RA				Wood, Robert A.			Food allergen immunotherapy: Current status and prospects for the future	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Food allergy; peanut allergy; egg allergy; milk allergy; immunotherapy; oral immunotherapy; sublingual immunotherapy; epicutaneous immunotherapy; omalizumab	ORAL TOLERANCE INDUCTION; COWS MILK ALLERGY; SEVERE EGG ALLERGY; ARA H 1; PEANUT ALLERGY; DOUBLE-BLIND; EPICUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; RUSH DESENSITIZATION; NATURAL-HISTORY	Food allergy is a common condition for which the only currently approved treatments are avoidance of the allergenic food and administration of emergency medications on accidental exposure. Over the past 10 years, significant advances have been made in the field of food immunotherapy, including oral immunotherapy, sublingual immunotherapy, and, more recently, epicutaneous immunotherapy. Each of these approaches are intended to induce some level of desensitization with chronic or repeated exposure to the allergenic food protein, although the risks and potential benefits of each treatment differ significantly. Although new data are emerging at a rapid pace and progress has been substantial, a number of important issues need to be addressed before introduction of these therapies into clinical practice. Furthermore, it is entirely possible that advances in this field will render these current approaches obsolete over the next 20 to 30 years as new and better therapies are developed.	[Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, 600 N Wolfe St, Baltimore, MD 21287 USA	Johns Hopkins University	Wood, RA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, 600 N Wolfe St, Baltimore, MD 21287 USA.	rwood@jhmi.edu						Akdis CA, 2006, ALLERGY, V61, P11, DOI 10.1111/j.1398-9995.2006.01159.x; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Alvaro M, 2012, EUR J PEDIATR, V171, P1389, DOI 10.1007/s00431-012-1739-z; Anagnostou K, 2011, CLIN EXP ALLERGY, V41, P1273, DOI 10.1111/j.1365-2222.2011.03699.x; Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Atkins D, 2009, CURR ALLERGY ASTHM R, V9, P179, DOI 10.1007/s11882-009-0027-0; Bauer A, 1999, ALLERGY, V54, P894, DOI 10.1034/j.1398-9995.1999.00228.x; Beeh KM, 2013, J ALLERGY CLIN IMMUN, V131, P866, DOI 10.1016/j.jaci.2012.12.1561; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-1; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-7; Berin M Cecilia, 2014, Curr Pediatr Rep, V2, P119; Berin MC, 2011, CURR OPIN IMMUNOL, V23, P794, DOI 10.1016/j.coi.2011.08.010; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Boyce JA, 2011, J AM ACAD DERMATOL, V64, P175, DOI [10.1016/j.jaad.2010.11.020, 10.1016/j.nutres.2011.01.001]; Brozek JL, 2012, CLIN EXP ALLERGY, V42, P363, DOI 10.1111/j.1365-2222.2011.03948.x; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Caminiti L, 2015, J ALLER CL IMM-PRACT, V3, P532, DOI 10.1016/j.jaip.2015.01.017; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Cox LS, 2014, J ALLER CL IMM-PRACT, V2, P156, DOI 10.1016/j.jaip.2014.01.010; Dello Iacono I, 2013, PEDIAT ALLERG IMM-UK, V24, P66, DOI 10.1111/j.1399-3038.2012.01349.x; Dioszeghy V, 2014, CLIN EXP ALLERGY, V44, P867, DOI 10.1111/cea.12312; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Edwards HE, 1940, CAN MED ASSOC J, V43, P234; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Rodriguez RG, 2011, CLIN EXP ALLERGY, V41, P1289, DOI 10.1111/j.1365-2222.2011.03722.x; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Itoh Naoka, 2010, Allergology International, V59, P43, DOI 10.2332/allergolint.09-OA-0107; Jagdis A, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-36; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2014, J CLIN INVEST, V124, P1880, DOI 10.1172/JCI72061; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Mansfield L, 2006, ANN ALLERG ASTHMA IM, V97, P266, DOI 10.1016/S1081-1206(10)60026-9; Martorell A, 2011, CLIN EXP ALLERGY, V41, P1297, DOI 10.1111/j.1365-2222.2011.03749.x; Massanari M, 2010, J ALLERGY CLIN IMMUN, V125, P383, DOI 10.1016/j.jaci.2009.11.022; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Meglio P, 2008, PEDIAT ALLERG IMM-UK, V19, P412, DOI 10.1111/j.1399-3038.2007.00670.x; Meglio P, 2013, PEDIAT ALLERG IMM-UK, V24, P75, DOI 10.1111/j.1399-3038.2012.01341.x; Mondoulet L, 2010, CLIN EXP ALLERGY, V40, P659, DOI 10.1111/j.1365-2222.2009.03430.x; Mondoulet L, 2015, IMMUNOTHERAPY-UK, V7, P1293, DOI 10.2217/imt.15.86; Morisset M, 2007, Eur Ann Allergy Clin Immunol, V39, P12; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Noh G, 2009, J INTERF CYTOK RES, V29, P667, DOI 10.1089/jir.2009.0001; Nurmatov U, 2014, BRIT J NUTR, V111, P12, DOI 10.1017/S0007114513002353; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Pajno GB, 2010, ANN ALLERG ASTHMA IM, V105, P376, DOI 10.1016/j.anai.2010.03.015; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; PATRIARCA C, 1984, ALLERGOL IMMUNOPATH, V12, P275; Patriarca G, 2006, DIGEST DIS SCI, V51, P471, DOI 10.1007/s10620-006-3157-4; Patriarca G, 2003, ALIMENT PHARM THER, V17, P459, DOI 10.1046/j.1365-2036.2003.01468.x; Patriarca G, 1998, HEPATO-GASTROENTEROL, V45, P52; Pelaia G, 2012, NAT REV DRUG DISCOV, V11, P958, DOI 10.1038/nrd3792; Potemkina A M, 1982, Pediatriia, P38; Prickett SR, 2013, CLIN EXP ALLERGY, V43, P684, DOI 10.1111/cea.12113; Ridolo E, 2011, ANN ALLERG ASTHMA IM, V106, P73, DOI 10.1016/j.anai.2010.10.010; Robbins KA, 2014, J ALLERGY CLIN IMMUN, V134, P1466, DOI 10.1016/j.jaci.2014.08.037; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Sanchez-Garcia S, 2012, J ALLERGY CLIN IMMUN, V129, P1155, DOI 10.1016/j.jaci.2011.11.042; Sanchez-Garcia S, 2012, ISR MED ASSOC J, V14, P43; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Swoboda I, 2013, J ALLERGY CLIN IMMUN, V132, P979, DOI 10.1016/j.jaci.2013.04.027; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Takahashi M, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-3; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Traister RS, 2012, ANN ALLERG ASTHMA IM, V109, P319, DOI 10.1016/j.anai.2012.08.012; Untersmayr E, 2008, J ALLERGY CLIN IMMUN, V121, P1301, DOI 10.1016/j.jaci.2008.04.025; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Vickery BP, 2010, ANN ALLERG ASTHMA IM, V105, P444, DOI 10.1016/j.anai.2010.09.030; Wang JL, 2010, ANN ALLERG ASTHMA IM, V105, P75, DOI 10.1016/j.anai.2010.05.005; Wasserman RL, 2014, J ALLER CL IMM-PRACT, V2, P91, DOI 10.1016/j.jaip.2013.10.001; Wood RA, 2013, ALLERGY, V68, P803, DOI 10.1111/all.12158; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005; Wood RA, 2014, J ALLER CL IMM-PRACT, V2, P97, DOI 10.1016/j.jaip.2013.11.010; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029; Yang M, 2010, CLIN EXP ALLERGY, V40, P668, DOI 10.1111/j.1365-2222.2009.03442.x; Yeung JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009542.pub2; Zapatero L, 2008, J INVEST ALLERG CLIN, V18, P389	99	146	148	3	51	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					973	982		10.1016/j.jaci.2016.01.001	http://dx.doi.org/10.1016/j.jaci.2016.01.001			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	27059725	Bronze			2022-12-18	WOS:000373351200001
J	Silverberg, JI; Greenland, P				Silverberg, Jonathan I.; Greenland, Philip			Eczema and cardiovascular risk factors in 2 US adult population studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema; obesity; body mass index; BMI; hypertension; diabetes; prediabetes; insulin resistance; high cholesterol; smoking; alcohol; physical activity; fatigue; sleepiness; insomnia	CHILDHOOD ATOPIC-DERMATITIS; HAND ECZEMA; DIABETES-MELLITUS; ALCOHOL-CONSUMPTION; ALLERGIC DISEASES; CIGARETTE-SMOKING; TOBACCO SMOKING; PREVALENCE; PSORIASIS; ASSOCIATION	Background: Eczema is associated with high rates of sleep disturbance and quality-of-life impairment. These factors might have a negative impact on psychosocial development and behavior and could increase cardiovascular risk. Objective: We sought to determine whether adults with eczema have increased cardiovascular risk factors. Methods: We analyzed data for 27,157 and 34,525 adults aged 18 to 85 years from the 2010 and 2012 National Health Interview Survey. Results: Adults with eczema had higher odds of ever smoking 100 cigarettes in their lifetime (survey logistic regression; adjusted odds ratio [aOR], 1.32; 95% CI, 1.18-1.47) and current smoking history (aOR, 1.28; 95% CI, 1.12-1.45), with significantly younger age of onset (survey linear regression; adjusted beta, -0.58; 95% CI, -0.95 to -0.21). Eczema was also associated with greater odds of ever drinking 12 or more alcoholic beverages annually (aOR, 1.16; 95% CI, 1.03-1.31), including current intake of moderate (aOR, 1.33; 95% CI, 1.09-1.62) and heavier (aOR, 1.58; 95% CI, 1.23-2.03) amounts. Adults with a history of eczema had lower odds of daily vigorous activity (aOR, 0.79; 95% CI, 0.63-0.99) and lower frequency of vigorous activity in the past week (adjusted beta, -0.46; 95% CI, -0.72 to -0.21) than did adults without a history of eczema. Those with eczema had a higher body mass index than did those without eczema (adjusted beta, 0.86; 95% CI, 0.37-1.36), particularly a body mass index of 35 or more (aOR, 1.54; 95% CI, 1.16-2.05), and higher odds of hypertension (aOR, 1.48; 95% CI, 1.18-1.85), hypertension on 2 visits (aOR, 1.56; 1.22-1.99), and lifetime prediabetes (aOR, 1.71; 95% CI, 1.19-2.45). Finally, there were significant interactions between eczema and sleep disturbances such that eczema associated with fatigue, daytime sleepiness, or insomnia was associated with even higher odds of obesity, hypertension, hypertension on 2 visits, prediabetes, diabetes, and high cholesterol than eczema alone. Conclusions: We found that eczema in adults is a marker for cardiovascular risk, emphasizing the importance of behavioral modification and perhaps more aggressive interventions to better manage eczema.	[Silverberg, Jonathan I.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol Prevent Med & Med Social Sci, Chicago, IL 60611 USA; [Greenland, Philip] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med & Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Silverberg, JI (corresponding author), Northwestern Univ, Dept Dermatol, Ste 1400,680 Lakeshore Dr, Chicago, IL 60611 USA.	JonathanISilverberg@gmail.com	Greenland, Philip/ABD-5528-2021; silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805				Abramovits W, 2003, BRIT J DERMATOL, V148, P380, DOI 10.1046/j.1365-2133.2003.05097_15.x; Ali Z, 2013, RESP MED, V107, P1287, DOI 10.1016/j.rmed.2013.03.019; Annesi-Maesano I, 2004, CLIN EXP ALLERGY, V34, P1017, DOI 10.1111/j.1365-2222.2004.02002.x; Armesto S, 2012, J EUR ACAD DERMATOL, V26, P785, DOI 10.1111/j.1468-3083.2011.04108.x; Armstrong AW, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2012.26; Berglind IA, 2011, BRIT J DERMATOL, V165, P568, DOI 10.1111/j.1365-2133.2011.10394.x; Bo K, 2008, DERMATOLOGY, V216, P40, DOI 10.1159/000109357; Brenaut E, 2013, J EUR ACAD DERMATOL, V27, P30, DOI 10.1111/jdv.12164; Brenninkmeijer EEA, 2009, PEDIATR DERMATOL, V26, P14, DOI 10.1111/j.1525-1470.2008.00745.x; Coto-Segura P, 2013, BRIT J DERMATOL, V169, P783, DOI 10.1111/bjd.12473; Dahlquist G, 2000, J PEDIATR-US, V137, P470, DOI 10.1067/mpd.2000.109109; Du Vivier A, 2002, ATLAS CLIN DERMATOLO, P748; Ellis CN, 2002, J AM ACAD DERMATOL, V46, P361, DOI 10.1067/mjd.2002.120528; Flohr C, 2009, BRIT J DERMATOL, V161, P846, DOI 10.1111/j.1365-2133.2009.09261.x; Fsadni P, 2012, CLIN RESPIR J, V6, P18, DOI 10.1111/j.1752-699X.2011.00239.x; Garg N, 2014, ANN ALLERG ASTHMA IM, V112, P525, DOI 10.1016/j.anai.2014.03.006; Garmendia JV, 2014, RECENT PATENTS ENDOC, V8, P60, DOI 10.2174/1872214807666140107151023; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kupetsky EA, 2013, CYTOKINE, V61, P704, DOI 10.1016/j.cyto.2012.12.027; Kusunoki T, 2008, PEDIAT ALLERG IMM-UK, V19, P527, DOI 10.1111/j.1399-3038.2007.00686.x; Lee CH, 2011, BRIT J DERMATOL, V164, P483, DOI 10.1111/j.1365-2133.2010.10116.x; Lin L, 2012, J INVEST DERMATOL, V132, pS46; Lonne-Rahm SB, 2014, ACTA DERM-VENEREOL, V94, P185, DOI 10.2340/00015555-1556; Margolis JS, 2014, JAMA DERMATOL, V150, P593, DOI 10.1001/jamadermatol.2013.10271; Meding B, 2010, BRIT J DERMATOL, V163, P752, DOI 10.1111/j.1365-2133.2010.09991.x; Meerwaldt R, 2002, CLIN EXP ALLERGY, V32, P254, DOI 10.1046/j.1365-2222.2002.01311.x; MILLS CM, 1994, INT J DERMATOL, V33, P33, DOI 10.1111/j.1365-4362.1994.tb01489.x; Suarez-Varela MM, 2010, J INVEST ALLERG CLIN, V20, P469; Olesen AB, 2001, LANCET, V357, P1749, DOI 10.1016/S0140-6736(00)04896-0; Orita K, 2010, EXP DERMATOL, V19, P1067, DOI 10.1111/j.1600-0625.2010.01130.x; Ronmark EP, 2012, BRIT J DERMATOL, V166, P1301, DOI 10.1111/j.1365-2133.2012.10904.x; Rosenbauer J, 2003, DIABETOLOGIA, V46, P784, DOI 10.1007/s00125-003-1108-6; Silverberg J, 2014, JAMA DERMATOL, DOI [10.1001/jamadermatol.2014.3059, DOI 10.1001/JAMADERMAT0L.2014.3059]; Silverberg JI, 2014, DERMATITIS, V25, P172, DOI 10.1097/DER.0000000000000047; Silverberg JI, 2014, JAMA DERMATOL, V150, P591, DOI 10.1001/jamadermatol.2013.10267; Silverberg JI, 2014, J ALLERGY CLIN IMMUN, V133, P1041, DOI 10.1016/j.jaci.2013.08.012; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; Silverberg JI, 2013, PEDIAT ALLERG IMM-UK, V24, P476, DOI 10.1111/pai.12095; Silverberg JI, 2011, J ALLERGY CLIN IMMUN, V127, P1180, DOI 10.1016/j.jaci.2011.01.063; Stern UM, 1998, HAUTARZT, V49, P209, DOI 10.1007/s001050050729; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; SUSITAIVAL P, 1995, SCAND J WORK ENV HEA, V21, P30, DOI 10.5271/sjweh.5; Tay YK, 2002, BRIT J DERMATOL, V146, P101, DOI 10.1046/j.1365-2133.2002.04566.x; Thomsen SF, 2011, ALLERGY, V66, P645, DOI 10.1111/j.1398-9995.2010.02517.x; Thyssen JP, 2010, BRIT J DERMATOL, V162, P619, DOI 10.1111/j.1365-2133.2009.09378.x; Thyssen JP, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000062; Uehara M, 2002, BRIT J DERMATOL, V146, P631, DOI 10.1046/j.1365-2133.2002.04717.x; Vena GA, 2010, DERMATOL THER, V23, P144, DOI 10.1111/j.1529-8019.2010.01308.x; Williams JR, 2004, BRIT J DERMATOL, V150, P1154, DOI 10.1111/j.1365-2133.2004.05869.x; Yao TC, 2011, J ASTHMA, V48, P503, DOI 10.3109/02770903.2011.576743; Zhu KJ, 2011, J DERMATOL SCI, V63, P126, DOI 10.1016/j.jdermsci.2011.04.013	51	146	147	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					721	U219		10.1016/j.jaci.2014.11.023	http://dx.doi.org/10.1016/j.jaci.2014.11.023			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25579484				2022-12-18	WOS:000351065000019
J	Ma, L; Danoff, TM; Borish, L				Ma, Larry; Danoff, Theodore M.; Borish, Larry			Case fatality and population mortality associated with anaphylaxis in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; mortality; case fatality; epidemiology; hospitalization; emergency department presentation; death certificate	WORLD-ALLERGY-ORGANIZATION; EPIDEMIOLOGIC ANALYSIS; HOSPITALIZATIONS; MANAGEMENT; CHILDREN; FLORIDA; DEATHS; LIFE	Background: Anaphylaxis is a serious allergic reaction that can cause death; however, the actual risk of death is unclear. Objective: We sought to estimate the case fatality rate among hospitalizations or emergency department (ED) presentations for anaphylaxis and the mortality rate associated with anaphylaxis for the general population. Methods: This was a population-based epidemiologic study using 3 national databases: the Nationwide Inpatient Sample (NIS; 1999-2009), the Nationwide Emergency Department Sample (NEDS; 2006-2009), and Multiple Cause of Death Data (MCDD; 1999-2009). Sources for these databases are hospital and ED discharge records and death certificates, respectively. Results: Case fatality rates were between 0.25% and 0.33% among hospitalizations or ED presentations with anaphylaxis as the principal diagnosis (NIS+NEDS, 2006-2009). These rates represent 63 to 99 deaths per year in the United States, approximately 77% of which occurred in hospitalized patients. The rate of anaphylaxis-related hospitalizations increased from 21.0 to 25.1 per million population between 1999 and 2009 (annual percentage change, 2.23%; 95% CI, 1.52% to 2.94%), contrasting with a decreasing case fatality rate among hospitalizations (annual percentage change, -2.35%; 95% CI, -4.98% to 0.34%). Overall mortality rates ranged from 0.63 to 0.76 per million population (186-225 deaths per year, MCDD) and appeared stable in the last decade (annual percentage change, -0.31%; 95% CI, -1.54% to 0.93%). Conclusion: From 2006 to 2009, the overwhelming majority of hospitalizations or ED presentations for anaphylaxis did not result in death, with an average case fatality rate of 0.3%. Anaphylaxis-related hospitalizations increased steadily in the last decade (1999-2009), but this increase was offset by the decreasing case fatality rate among those hospitalized; both inpatient and overall mortality rates associated with anaphylaxis appeared stable and were well under 1 per million population. Although anaphylactic reactions are potentially life-threatening, the probability of dying is actually very low. With the prevalence of anaphylaxis on the increase, practitioners need to stay vigilant and follow the treatment guidelines to further reduce anaphylaxis-related deaths.	[Ma, Larry; Danoff, Theodore M.] Endo Pharmaceut Inc, Malvern, PA 19355 USA; [Borish, Larry] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Endo Pharmaceuticals Inc.; University of Virginia	Ma, L (corresponding author), Endo Pharmaceut Inc, Clin Dev & Med Sci, 1400 Atwater Dr, Malvern, PA 19355 USA.	ma.larry@endo.com			Endo Pharmaceuticals Inc (Malvern, Pa); National Institutes of Health [RO1 AI1057438, UO1 AI100799]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057438, U01AI100799] Funding Source: NIH RePORTER	Endo Pharmaceuticals Inc (Malvern, Pa); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by Endo Pharmaceuticals Inc (Malvern, Pa). L. B. receives his salary from the National Institutes of Health (RO1 AI1057438 and UO1 AI100799).	Agency for Healthcare Research and Quality, HCUP METH SER 2007 H; Agency for Healthcare Research and Quality, 2006, HCUP NAT EM DEP SAMP; Agency for Healthcare Research and Quality, 1999, HCUP NAT INP SAMPL N; ANDERSON RN, 1998, NATL VITAL STAT REP, V47, P20; Ben-Shoshan M, 2011, ALLERGY, V66, P1, DOI 10.1111/j.1398-9995.2010.02422.x; Blanton Lenee, 2011, Morbidity and Mortality Weekly Report, V60, P1233; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Centers for Disease Control and Prevention, INSTR CLASS UND CAUS; Centers for Disease Control and Prevention National Center for Health Statistics, 1999, MULT CAUS DEATH CDC; Centers for Disease Control and Prevention National Center for Health Statistics, VIT STAT US MORT 199; Dibs S D, 1997, Pediatrics, V99, pE7, DOI 10.1542/peds.99.1.e7; Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; Kim Harold, 2011, Allergy Asthma Clin Immunol, V7 Suppl 1, pS6, DOI 10.1186/1710-1492-7-S1-S6; Lee JK, 2011, CLIN EXP ALLERGY, V41, P923, DOI 10.1111/j.1365-2222.2011.03779.x; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI 10.1016/j.jaci.2010.06.022; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P185, DOI 10.1016/S1081-1206(10)60208-6; Ma LY, 2009, AM J PUBLIC HEALTH, V99, pS398, DOI 10.2105/AJPH.2008.148494; Matasar MJ, 2003, CURR ALLERGY ASTHM R, V3, P30, DOI 10.1007/s11882-003-0007-8; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Moneret-Vautrin DA, 2005, ALLERGY, V60, P443, DOI 10.1111/j.1398-9995.2005.00785.x; Mulla ZD, 2007, INT ARCH ALLERGY IMM, V144, P128, DOI 10.1159/000103224; Mulla ZD, 2011, CURR ALLERGY ASTHM R, V11, P37, DOI 10.1007/s11882-010-0154-7; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; Owens PL, 2010, ANN EMERG MED, V56, P150, DOI 10.1016/j.annemergmed.2009.11.022; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3rd ed; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Schneider G, 2012, PHARMACOEPIDEM DR S, V21, P240, DOI 10.1002/pds.2327; Simon MR, 2008, ALLERGY, V63, P1077, DOI 10.1111/j.1398-9995.2008.01737.x; Simons FER, 2012, CURR OPIN ALLERGY CL, V12, P389, DOI 10.1097/ACI.0b013e328355b7e4; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Tang MLK, 2009, CURR OPIN ALLERGY CL, V9, P351, DOI 10.1097/ACI.0b013e32832db95a; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	39	146	149	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1075	1083		10.1016/j.jaci.2013.10.029	http://dx.doi.org/10.1016/j.jaci.2013.10.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24332862	Green Accepted			2022-12-18	WOS:000333531700018
J	Sampaio, EP; Hsu, AP; Pechacek, J; Bax, HI; Dias, DL; Paulson, ML; Chandrasekaran, P; Rosen, LB; Carvalho, DS; Ding, L; Vinh, DC; Browne, SK; Datta, S; Milner, JD; Kuhns, DB; Priel, DAL; Sadat, MA; Shiloh, M; De Marco, B; Alvares, M; Gillman, JW; Ramarathnam, V; de la Morena, M; Bezrodnik, L; Moreira, I; Uzel, G; Johnson, D; Spalding, C; Zerbe, CS; Wiley, H; Greenberg, DE; Hoover, SE; Rosenzweig, SD; Galgiani, JN; Holland, SM				Sampaio, Elizabeth P.; Hsu, Amy P.; Pechacek, Joseph; Bax, Hannelore I.; Dias, Dalton L.; Paulson, Michelle L.; Chandrasekaran, Prabha; Rosen, Lindsey B.; Carvalho, Daniel S.; Ding, Li; Vinh, Donald C.; Browne, Sarah K.; Datta, Shrimati; Milner, Joshua D.; Kuhns, Douglas B.; Priel, Debra A. Long; Sadat, Mohammed A.; Shiloh, Michael; De Marco, Brendan; Alvares, Michael; Gillman, Jason W.; Ramarathnam, Vivek; de la Morena, Maite; Bezrodnik, Liliana; Moreira, Ileana; Uzel, Gulbu; Johnson, Daniel; Spalding, Christine; Zerbe, Christa S.; Wiley, Henry; Greenberg, David E.; Hoover, Susan E.; Rosenzweig, Sergio D.; Galgiani, John N.; Holland, Steven M.			Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Signal transducer and activator of transcription 1; IFN-gamma; progressive multifocal leukoencephalopathy; Histoplasma capsulatum; Coccidioides immitis; thrush	CHRONIC MUCOCUTANEOUS CANDIDIASIS; PIAS PROTEINS; ARGININE METHYLATION; IN-VIVO; DEFICIENCY; IMMUNITY; GAMMA; MYCOBACTERIAL; PATHWAYS; DISEASE	Background: Impaired signaling in the IFN-gamma/IL-12 pathway causes susceptibility to severe disseminated infections with mycobacteria and dimorphic yeasts. Dominant gain-of-function mutations in signal transducer and activator of transcription 1 (STAT1) have been associated with chronic mucocutaneous candidiasis. Objective: We sought to identify the molecular defect in patients with disseminated dimorphic yeast infections. Methods: PBMCs, EBV-transformed B cells, and transfected U3A cell lines were studied for IFN-gamma/IL-12 pathway function. STAT1 was sequenced in probands and available relatives. Interferon-induced STAT1 phosphorylation, transcriptional responses, protein-protein interactions, target gene activation, and function were investigated. Results: We identified 5 patients with disseminated Coccidioides immitis or Histoplasma capsulatum with heterozygous missense mutations in the STAT1 coiled-coil or DNA-binding domains. These are dominant gain-of-function mutations causing enhanced STAT1 phosphorylation, delayed dephosphorylation, enhanced DNA binding and transactivation, and enhanced interaction with protein inhibitor of activated STAT1. The mutations caused enhanced IFN-gamma-induced gene expression, but we found impaired responses to IFN-gamma restimulation. Conclusion: Gain-of-function mutations in STAT1 predispose to invasive, severe, disseminated dimorphic yeast infections, likely through aberrant regulation of IFN-gamma-mediated inflammation.	[Sampaio, Elizabeth P.; Hsu, Amy P.; Pechacek, Joseph; Bax, Hannelore I.; Dias, Dalton L.; Chandrasekaran, Prabha; Rosen, Lindsey B.; Carvalho, Daniel S.; Ding, Li; Browne, Sarah K.; Uzel, Gulbu; Spalding, Christine; Zerbe, Christa S.; Holland, Steven M.] NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Datta, Shrimati; Milner, Joshua D.] NIAID, Allerg Inflammat Unit, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Sadat, Mohammed A.; Rosenzweig, Sergio D.] NIAID, Infect Dis Susceptibil Unit, Lab Host Def, NIH, Bethesda, MD 20892 USA; [Rosenzweig, Sergio D.] NIAID, Primary Immunodeficiency Clin, NIH, Bethesda, MD 20892 USA; [Sampaio, Elizabeth P.; Carvalho, Daniel S.] Fiocruz MS, Inst Oswaldo Cruz, Leprosy Lab, BR-21045900 Rio De Janeiro, Brazil; [Bax, Hannelore I.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands; [Bax, Hannelore I.] Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands; [Paulson, Michelle L.] NCI, Clin Res Directorate CMRP, SAIC Frederick, Frederick, MD 21701 USA; [Paulson, Michelle L.] NCI, Clin Serv Program, SAIC Frederick, Frederick, MD 21701 USA; [Vinh, Donald C.] McGill Univ, Ctr Hlth, Div Infect Dis, Montreal, PQ, Canada; [Shiloh, Michael; De Marco, Brendan; Gillman, Jason W.; Ramarathnam, Vivek; Greenberg, David E.] Univ Texas SW Med Ctr Dallas, Div Infect Dis, Dallas, TX USA; [Alvares, Michael; de la Morena, Maite] Univ Texas SW Med Ctr Dallas, Div Allergy & Immunol, Dallas, TX USA; [Bezrodnik, Liliana; Moreira, Ileana] Pediat Hosp R Gutierrez, Immunol Unit, Buenos Aires, DF, Argentina; [Johnson, Daniel] Univ Chicago, Comer Childrens Hosp, Chicago, IL 60637 USA; [Wiley, Henry] NEI, Clin Trials Branch, NIH, Bethesda, MD 20892 USA; [Hoover, Susan E.; Galgiani, John N.] Univ Arizona, Valley Fever Ctr Excellence, Coll Med, Tucson, AZ 85721 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Fundacao Oswaldo Cruz; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; McGill University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Chicago; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Arizona	Holland, SM (corresponding author), CRC B3-4141 MSC 1684, Bethesda, MD 20892 USA.	smh@nih.gov	Hoover, Susan/F-8580-2015; Shiloh, Michael/AAS-8883-2020; Galgiani, John/GLT-7012-2022	Shiloh, Michael/0000-0003-4329-2253; Hsu, Amy/0000-0001-6841-2122; VINH, DONALD/0000-0003-1347-7767	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; Canadian Institutes of Health Research; CSL Behring Canada; Astellas Canada; Sunovion/Sepracor; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001069, R01AI099439, ZIAAI001122, ZIAAI001183, ZIAAI000647] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); CSL Behring Canada; Astellas Canada(Astellas Pharmaceuticals); Sunovion/Sepracor; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, and funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.; Disclosure of potential conflict of interest: D. C. Vinh has received research support from the Canadian Institutes of Health Research Post-doctoral Fellowship, CSL Behring Canada, and Astellas Canada; has consultant arrangements with CSL Behring Canada and Pfizer Canada; and has received payment for lectures from CSL Behring Canada and Sunovion/Sepracor. D. B. Kuhns and D. A. Long Priel have received grants from the National Cancer Institute/National Institutes of Health. V. Ramarathnam is employed by Private Practice ID. S. D. Rosenzweig receives royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	Adam RD, 2009, AM J MED, V122, P770, DOI 10.1016/j.amjmed.2008.12.024; Al-Muhsen S, 2008, J ALLERGY CLIN IMMUN, V122, P1043, DOI 10.1016/j.jaci.2008.10.037; Anstee QM, 2012, J HEPATOL, V57, P1097, DOI 10.1016/j.jhep.2012.04.041; Averbuch D, 2011, PEDIATR INFECT DIS J, V30, P352, DOI 10.1097/INF.0b013e3181fdff4a; Begitt A, 2011, BLOOD, V118, P1002, DOI 10.1182/blood-2011-04-347930; Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016; Chapgier A, 2006, J IMMUNOL, V176, P5078, DOI 10.4049/jimmunol.176.8.5078; de Moraes-Vasconcelos D, 2005, CLIN INFECT DIS, V41, pE31, DOI 10.1086/432119; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Feld JJ, 2011, GASTROENTEROLOGY, V140, P830, DOI 10.1053/j.gastro.2010.09.010; Filipowicz M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015492; Haverkamp MH, 2006, MICROBES INFECT, V8, P1157, DOI 10.1016/j.micinf.2005.10.029; Hector RF, 2011, INT J ENV RES PUB HE, V8, P1150, DOI 10.3390/ijerph8041150; HOSTOFFER RW, 1994, PEDIATRICS, V94, P234; Iwasaki H, 2010, CIRC RES, V107, P992, DOI 10.1161/CIRCRESAHA.110.225326; Li J, 2010, ANTIVIR RES, V85, P463, DOI 10.1016/j.antiviral.2009.10.011; Liu B, 2004, NAT IMMUNOL, V5, P891, DOI 10.1038/ni1104; Liu B, 2005, MOL CELL BIOL, V25, P1113, DOI 10.1128/MCB.25.3.1113-1123.2005; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(01)00269-0; Palvimo JJ, 2007, BIOCHEM SOC T, V35, P1405, DOI 10.1042/BST0351405; Powers AE, 2009, PEDIATR INFECT DIS J, V28, P664, DOI 10.1097/INF.0b013e31819866ec; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Shuai K, 2006, CELL RES, V16, P196, DOI 10.1038/sj.cr.7310027; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Tamiya T, 2011, ARTERIOSCL THROM VAS, V31, P980, DOI 10.1161/ATVBAHA.110.207464; Toth B, 2012, LANCET, V379, P2500, DOI 10.1016/S0140-6736(12)60365-1; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Vinh DC, 2011, CLIN INFECT DIS, V52, pE99, DOI 10.1093/cid/ciq215; Vinh DC, 2010, J ALLERGY CLIN IMMUN, V125, P1389, DOI 10.1016/j.jaci.2010.01.047; Vinh DC, 2009, CLIN INFECT DIS, V49, pE62, DOI 10.1086/605532; Wolf SS, 2009, CELL MOL LIFE SCI, V66, P2109, DOI 10.1007/s00018-009-0010-x; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Zerbe CS, 2005, CLIN INFECT DIS, V41, pE38, DOI 10.1086/432120; Zhong MH, 2005, P NATL ACAD SCI USA, V102, P3966, DOI 10.1073/pnas.0501063102; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200	36	146	149	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1624	+		10.1016/j.jaci.2013.01.052	http://dx.doi.org/10.1016/j.jaci.2013.01.052			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23541320	Green Published, Bronze, Green Accepted			2022-12-18	WOS:000320532800023
J	Huang, F; Chawla, K; Jarvinen, KM; Nowak-Wegrzyn, A				Huang, Faith; Chawla, Kanwaljit; Jaervinen, Kirsi M.; Nowak-Wegrzyn, Anna			Anaphylaxis in a New York City pediatric emergency department: Triggers, treatments, and outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Children; anaphylaxis; food allergy; autoinjectable epinephrine; pediatric emergency department; food-induced anaphylaxis; peanut allergy; seafood allergy	REPEAT EPINEPHRINE TREATMENTS; FOOD-INDUCED ANAPHYLAXIS; ALLERGIC REACTIONS; EPIDEMIOLOGY; CHILDREN	Background: Anaphylaxis incidence is increasing. Objective: We sought to characterize anaphylaxis in children in an urban pediatric emergency department (PED). Methods: We performed a review of PED records for anaphylactic reactions over 5 years. Results: We identified 213 anaphylactic reactions in 192 children (97 male patients): 6 were infants, 20 had multiple reactions, and the median age was 8 years (age range, 4 months to 18 years). Sixty-two reactions were coded as anaphylaxis; 151 additional reactions met the second symposium anaphylaxis criteria. There was no increase in incidence over 5 years. The triggers included the following: foods, 71%; unknown, 15%; drugs, 9%; and "other," 5%. Food was more likely to be a trigger in multiple PED visits (P = .03). Epinephrine was administered in 169 (79%) reactions; in 58 (27%) reactions epinephrine was administered before arrival in the PED. Patients with Medicaid were less likely to receive epinephrine before arrival in the PED (P < .001). Twenty-eight (14.6%) patients were hospitalized, 9 in the intensive care unit. For 13 (6%) of the reactions, 2 doses of epinephrine were administered; 69% of the patients treated with 2 doses of epinephrine were hospitalized compared with 12% of the patients treated with a single dose (P < .001). Administration of both epinephrine doses before arrival to the PED was associated with a lower rate of hospitalization compared with epinephrine administration in the PED (P = .05). Conclusions: Food is the main anaphylaxis trigger in the urban PED, although the International Classification of Diseases-ninth revision code for anaphylaxis is underused. Treatment with 2 doses of epinephrine is associated with a higher risk of hospitalization; epinephrine treatment before arrival to the PED is associated with a decreased risk. Children with Medicaid are less likely to receive epinephrine before arrival in the PED. (J Allergy Clin Immunol 2012; 129: 162-8.)	[Nowak-Wegrzyn, Anna] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Nowak-Wegrzyn, A (corresponding author), Mt Sinai Sch Med, Dept Pediat, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	anna.nowak-wegrzyn@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854	National Institutes of Health [K12 HD052890]; Food Allergy Initiative; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD052890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI091655] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Initiative; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	K.M.J. was supported in part by National Institutes of Health grant K12 HD052890. A.N.-W. was supported in part by an Food Allergy Initiative research grant.	Atkins D, 2009, CURR ALLERGY ASTHM R, V9, P179, DOI 10.1007/s11882-009-0027-0; Banerji A, 2011, ANN ALLERG ASTHMA IM, V106, P42, DOI 10.1016/j.anai.2010.10.011; Banerji A, 2010, ALLERGY ASTHMA PROC, V31, P308, DOI 10.2500/aap.2010.31.3375; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Furlong TJ, 2001, J ALLERGY CLIN IMMUN, V108, P867, DOI 10.1067/mai.2001.119157; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Hompes S, 2011, PEDIAT ALLERG IMM-UK, V22, P568, DOI 10.1111/j.1399-3038.2011.01154.x; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Joint Task Force on Practice Parameters, 2005, J Allergy Clin Immunol, V115, pS483; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Oren E, 2007, ANN ALLERG ASTHMA IM, V99, P429, DOI 10.1016/S1081-1206(10)60568-6; Rudders SA, 2010, J ALLERGY CLIN IMMUN, V126, P385, DOI 10.1016/j.jaci.2010.05.018; Rudders SA, 2010, PEDIATRICS, V125, pE711, DOI 10.1542/peds.2009-2832; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Simons FER, 2008, J ALLERGY CLIN IMMUN, V122, P1166, DOI 10.1016/j.jaci.2008.10.019; Treudler R, 2008, J INVEST ALLERG CLIN, V18, P52; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	20	146	152	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					162	U232		10.1016/j.jaci.2011.09.018	http://dx.doi.org/10.1016/j.jaci.2011.09.018			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22018905	Bronze, Green Accepted			2022-12-18	WOS:000298634000021
J	Tintle, S; Shemer, A; Suarez-Farinas, M; Fujita, H; Gilleaudeau, P; Sullivan-Whalen, M; Johnson-Huang, L; Chiricozzi, A; Cardinale, I; Duan, S; Bowcock, A; Krueger, JG; Guttman-Yassky, E				Tintle, Suzanne; Shemer, Avner; Suarez-Farinas, Mayte; Fujita, Hideki; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Johnson-Huang, Leanne; Chiricozzi, Andrea; Cardinale, Irma; Duan, Shenghui; Bowcock, Anne; Krueger, James G.; Guttman-Yassky, Emma			Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; phototherapy; narrow-band UVB; T(H)2; T22; biomarker; skin	PSORIATIC LESIONAL SKIN; T-CELLS; GENE-EXPRESSION; ULTRAVIOLET-B; DENDRITIC CELLS; DOWN-REGULATION; CYCLOSPORINE-A; TH2 CYTOKINES; UP-REGULATION; IFN-GAMMA	Background: Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly T(H)2/"T22'' immune activation and a defective epidermal barrier. Narrow-band UVB (NB-UVB) is considered an efficient treatment for moderate-to-severe AD. In patients with psoriasis, NB-UVB has been found to suppress T(H)1/T(H)17 polarization, with subsequent reversal of epidermal hyperplasia. The immunomodulatory effects of this treatment are largely unknown in patients with AD. Objective: We sought to evaluate the effects of NB-UVB on immune and barrier abnormalities in patients with AD, aiming to establish reversibility of disease and biomarkers of therapeutic response. Methods: Twelve patients with moderate-to-severe chronic AD received NB-UVB phototherapy 3 times weekly for up to 12 weeks. Lesional and nonlesional skin biopsy specimens were obtained before and after treatment and evaluated by using gene expression and immunohistochemistry studies. Results: All patients had at least a 50% reduction in SCORAD index scores with NB-UVB phototherapy. The T(H)2, T22, and T(H)1 immune pathways were suppressed, and measures of epidermal hyperplasia and differentiation normalized. The reversal of disease activity was associated with elimination of inflammatory leukocytes and T(H)2/T22-associated cytokines and chemokines and normalized expression of barrier proteins. Conclusions: Our study shows that resolution of clinical disease in patients with chronic AD is accompanied by reversal of both the epidermal defects and the underlying immune activation. We have defined a set of biomarkers of disease response that associate resolved T(H)2 and T22 inflammation in patients with chronic AD with reversal of barrier pathology. By showing reversal of the AD epidermal phenotype with a broad immune-targeted therapy, our data argue against a fixed genetic phenotype. (J Allergy Clin Immunol 2011;128:583-93.)	[Tintle, Suzanne; Suarez-Farinas, Mayte; Fujita, Hideki; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Johnson-Huang, Leanne; Chiricozzi, Andrea; Cardinale, Irma; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10065 USA; [Tintle, Suzanne] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Shemer, Avner] Tel Hashomer Hosp, Dept Dermatol, Tel Aviv, Israel; [Shemer, Avner] Tel Aviv Univ, IL-69978 Tel Aviv, Israel; [Chiricozzi, Andrea] Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy; [Duan, Shenghui; Bowcock, Anne] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63130 USA; [Guttman-Yassky, Emma] Cornell Univ, Weill Cornell Med Coll, Dept Dermatol, New York, NY 10021 USA	Rockefeller University; Columbia University; Tel Aviv University; University of Rome Tor Vergata; Washington University (WUSTL); Cornell University	Guttman-Yassky, E (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10065 USA.	eguttman@rockefeller.edu	Suarez-Farinas, Mayte/I-3558-2012	Suarez-Farinas, Mayte/0000-0001-8712-3553; Bowcock, Anne/0000-0001-8691-9090	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [5UL1RR024143-02]; NIH Roadmap for Medical Research; Clinical and Translational Science Award grant; Women's Dermatology Society; Dermatology Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clinical and Translational Science Award grant; Women's Dermatology Society; Dermatology Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. S. T. and E. G.-Y. were supported by a Clinical and Translational Science Award grant, and E. G.-Y. was also supported by a Women's Dermatology Society grant and a physician scientist career development award from the Dermatology Foundation.	Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Aufiero BM, 2006, J PHOTOCH PHOTOBIO B, V82, P132, DOI 10.1016/j.jphotobiol.2005.08.011; Baumgrass R, 2010, J ALLERGY CLIN IMMUN, V126, P183, DOI 10.1016/j.jaci.2010.04.032; Bieber T, 2009, CURR ALLERGY ASTHM R, V9, P291, DOI 10.1007/s11882-009-0041-2; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bowcock AM, 2004, HUM MOL GENET, V13, pR43, DOI 10.1093/hmg/ddh094; Breuckmann F, 2003, J EUR ACAD DERMATOL, V17, P418, DOI 10.1046/j.1468-3083.2003.00761.x; Bunikowski R, 2001, PEDIAT ALLERG IMM-UK, V12, P216, DOI 10.1034/j.1399-3038.2001.012004216.x; Caproni M, 2007, BRIT J DERMATOL, V156, P312, DOI 10.1111/j.1365-2133.2006.07609.x; Caproni M, 2006, CLIN EXP DERMATOL, V31, P813, DOI 10.1111/j.1365-2230.2006.02214.x; Cooper KD, 1996, PHOTOCHEM PHOTOBIOL, V63, P400, DOI 10.1111/j.1751-1097.1996.tb03055.x; Coven TR, 1997, ARCH DERMATOL, V133, P1514, DOI 10.1001/archderm.133.12.1514; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2010, CLIN REV ALLERGY IMM; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Farrell AM, 2001, BRIT J DERMATOL, V144, P24, DOI 10.1046/j.1365-2133.2001.03948.x; FARTASCH M, 1994, J INVEST DERMATOL, V102, P366, DOI 10.1111/1523-1747.ep12371797; Fujita H, 2009, P NATL ACAD SCI USA, V106, P21795, DOI 10.1073/pnas.0911472106; Gambichler T, 2008, BRIT J DERMATOL, V158, P1117, DOI 10.1111/j.1365-2133.2008.08498.x; Gambichler T, 2006, BRIT J DERMATOL, V155, P1275, DOI 10.1111/j.1365-2133.2006.07481.x; Gambichler T, 2009, ARCH DERMATOL RES, V301, P197, DOI 10.1007/s00403-008-0923-5; GOTTLIEB AB, 1992, J INVEST DERMATOL, V98, P302, DOI 10.1111/1523-1747.ep12499782; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hashimoto S, 2006, J DERMATOL SCI, V44, P93, DOI 10.1016/j.jdermsci.2006.08.004; Hayashida S, 2011, J DERMATOL SCI, V61, P78, DOI 10.1016/j.jdermsci.2010.08.013; Hijnen D, 2009, J ALLERGY CLIN IMMUN, V124, P856, DOI 10.1016/j.jaci.2009.07.056; Hong SP, 2008, J INVEST DERMATOL, V128, P2880, DOI 10.1038/jid.2008.169; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Hubiche T, 2007, ACTA DERM-VENEREOL, V87, P499, DOI 10.2340/00015555-0329; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Krutmann J, 1999, J INVEST DERM SYMP P, V4, P70, DOI 10.1038/sj.jidsp.5640185; Krutmann J, 2000, METHOD ENZYMOL, V319, P296; Kwakkel-van Erp Johanna M, 2010, J Am Acad Dermatol, V63, pe70, DOI 10.1016/j.jaad.2010.02.015; Lee SY, 2004, ALLERGY, V59, P1129, DOI 10.1111/j.1398-9995.2004.00639.x; Levy ML, 2007, CURR MED RES OPIN, V23, P3091, DOI 10.1185/030079907X242593; Majoie IML, 2009, J AM ACAD DERMATOL, V60, P77, DOI 10.1016/j.jaad.2008.08.048; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Muschen A, 1999, INFLAMM RES, V48, P539, DOI 10.1007/s000110050500; Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Ong PY, 2008, ANN ALLERG ASTHMA IM, V100, P286, DOI 10.1016/S1081-1206(10)60458-9; Oranje AP, 2007, BRIT J DERMATOL, V157, P645, DOI 10.1111/j.1365-2133.2007.08112.x; Ozawa M, 1999, J EXP MED, V189, P711, DOI 10.1084/jem.189.4.711; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Schmitt J, 2011, J INVEST DERMATOL, V131, P623, DOI 10.1038/jid.2010.303; Schnopp C, 2007, PHOTODERMATOL PHOTO, V23, P81, DOI 10.1111/j.1600-0781.2007.00284.x; SIMON JC, 1992, J INVEST DERMATOL, V98, P66; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; ten Berge O, 2009, AM J CLIN DERMATOL, V10, P119, DOI 10.2165/00128071-200910020-00004; Walters IB, 2003, ARCH DERMATOL, V139, P155, DOI 10.1001/archderm.139.2.155; Walters IB, 1999, J AM ACAD DERMATOL, V40, P893, DOI 10.1016/S0190-9622(99)70076-9; Wang YH, 2009, CLIN EXP ALLERGY, V39, P798, DOI 10.1111/j.1365-2222.2009.03241.x; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, pe4; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Yamada H, 1999, INT ARCH ALLERGY IMM, V120, P100, DOI 10.1159/000053605; Zaba LC, 2010, J ALLERGY CLIN IMMUN, V125, P1261, DOI 10.1016/j.jaci.2010.03.018	72	146	155	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					583	U231		10.1016/j.jaci.2011.05.042	http://dx.doi.org/10.1016/j.jaci.2011.05.042			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21762976	Green Accepted			2022-12-18	WOS:000294283400018
J	Siebenhaar, F; Degener, F; Zuberbier, T; Martus, P; Maurer, M				Siebenhaar, Frank; Degener, Franziska; Zuberbier, Torsten; Martus, Peter; Maurer, Marcus			High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Urticaria; cold; chronic; objective; antihistamine; desloratadine	CHRONIC IDIOPATHIC URTICARIA; DOUBLE-BLIND; EAACI/GA(2)LEN/EDF GUIDELINE; MULTICENTER; DIAGNOSIS; EFFICACY; SAFETY; ADULTS; TRIAL	Background: Increased dosing of nonsedating antihistamines is recommended by the current European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum guidelines on patients with acquired cold urticaria (ACU) who do not respond satisfactorily to the standard dose. Prospective data supporting this recommendation are scant. Objective: We sought to assess the effects of 5 and 20 mg of desloratadine and placebo on cold-induced urticarial reactions in patients with ACU. Methods: In this prospective, randomized, double-blind, 3-way crossover trial, patients with ACU (n = 30) received placebo, 5 mg of desloratadine, and 20 mg of desloratadine every day each for 7 days separated by 14-day washout periods. At the end of each treatment, patients underwent cold provocation with the TempTest 2.0/2.1 system, and urticarial reactions were assessed by using digital 3-dimensional time-lapse photography and thermography; the critical temperature threshold (CTT) and critical stimulation time threshold (CSTT) were measured. Adverse events (AEs) reported during the study were assessed. Results: Compared with placebo, 7 days of desloratadine at 5 and 20 mg/d significantly reduced the volume of cold-induced wheals and areas of hyperthermic skin and improved CTT and CSTT results. Desloratadine at 20 mg/d significantly reduced cold-induced wheal volume and CTT and CSTT values versus desloratadine at 5 mg/d. Desloratadine was well tolerated, with no increased rate of somnolence or other AEs with 20 mg of desloratadine. Conclusions: Desloratadine at standard and high doses significantly improved objective signs of ACU provoked by cold exposure. Desloratadine at 4 times the standard dose significantly reduced ACU lesion severity versus 5 mg of desloratadine without an increase in AEs. This study supports current guidelines that increased desloratadine dosing might benefit patients with urticaria who do not respond to standard doses. (J Allergy Clin Immunol 2009;123:672-9.)	[Siebenhaar, Frank; Degener, Franziska; Zuberbier, Torsten; Maurer, Marcus] Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, D-10117 Berlin, Germany; [Martus, Peter] Charite Univ Med Berlin, Inst Biostat & Clin Epidemiol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Maurer, M (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Beldar, Sagar V/C-8542-2011; Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X; Siebenhaar, Frank/0000-0003-4532-1644	DFG; Schering-Plough; Novartis; Leti; Stallergenes; Bayer Schering; Ansell; Kryolan; UCB; MSD; Proctor Gamble	DFG(German Research Foundation (DFG)); Schering-Plough(Merck & CompanySchering Plough Corporation); Novartis(Novartis); Leti; Stallergenes; Bayer Schering(Bayer AG); Ansell; Kryolan; UCB(UCB Pharma SA); MSD; Proctor Gamble(Procter & Gamble)	F Siebenhaar has received research support from DFG and Schering-Plough. T. Zuberbier has received research grants from Schering-Plough, Novartis, Leti, Stallergenes, Bayer Schering, Ansell, Kryolan, UCB, MSD, and Proctor & Gamble; has been affiliated with the Editorial Board of the Journal of Allergy, the Scientific Advisory Board of the German Society for Allergy and Clinical Immunology, and the Expert Commission "Novel Food" of the German Federal Ministry of Consumer Protection; has served as the Chairman of the European Academy of Allergology and Clinical Immunology Dermatology Section, the Head of the European Centre for Allergy Research Foundation, a committee member of the World Health Organization Initiative Allergic Rhinitis and its Impact on Asthma, a member of the World Allergy Organisation Communications Council, and Secretary General of the Global Allergy and Asthma European Network and has provided expert testimony for the US Food and Drug Administration. M. Maurer is or recently was an investigator, speaker, and/or advisor for Almirall Hermal, Bayer Schering Pharma, Biofrontera, Essex Pharma, Genentech, JADO Technologies, Jerini, Novartis, Schering-Plough, Symbiopharm, UCB, and Uriach. The rest of the authors have declared that they have no conflict of interest.	Boyce JA, 2006, J ALLERGY CLIN IMMUN, V117, P1415, DOI 10.1016/j.jaci.2006.04.003; Grob JJ, 2008, J EUR ACAD DERMATOL, V22, P87, DOI 10.1111/j.1468-3083.2007.02385.x; Henz BM, 2001, ALLERGY, V56, P7, DOI 10.1034/j.1398-9995.2001.00101.x; Juhlin L, 2004, J Dermatolog Treat, V15, P51; Lippert U, 1995, Exp Dermatol, V4, P272, DOI 10.1111/j.1600-0625.1995.tb00257.x; Monroe E, 2003, J AM ACAD DERMATOL, V48, P535, DOI 10.1067/mjd.2003.143; Neven B, 2004, BLOOD, V103, P2809, DOI 10.1182/blood-2003-07-2531; Ortonne JP, 2007, AM J CLIN DERMATOL, V8, P37, DOI 10.2165/00128071-200708010-00005; Ring J, 2001, INT J DERMATOL, V40, P72, DOI 10.1046/j.1365-4362.2001.00186.x; Siebenhaar F, 2007, CLIN EXP DERMATOL, V32, P241, DOI 10.1111/j.1365-2230.2007.02376.x; Siebenhaar F, 2004, J ALLERGY CLIN IMMUN, V114, P1224, DOI 10.1016/j.jaci.2004.07.018; Wanderer AA, 2004, IMMUNOL ALLERGY CLIN, V24, P259, DOI 10.1016/j.iac.2004.01.001; Wang YH, 2005, ALLERGY, V60, P117, DOI 10.1111/j.1398-9995.2004.00641.x; Zhao Y, 2004, INFLAMM RES, V53, P664, DOI 10.1007/s00011-004-1309-6; Zuberbier T, 2006, ALLERGY, V61, P321, DOI 10.1111/j.1398-9995.2006.00962.x; Zuberbier T, 2006, ALLERGY, V61, P316, DOI 10.1111/j.1398-9995.2005.00964.x	16	146	153	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					672	679		10.1016/j.jaci.2008.12.008	http://dx.doi.org/10.1016/j.jaci.2008.12.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19201016	Bronze			2022-12-18	WOS:000264731200029
J	Jacobsen, EA; Taranova, AG; Lee, NA; Lee, JJ				Jacobsen, Elizabeth A.; Taranova, Anna G.; Lee, Nancy A.; Lee, James J.			Eosinophils: Singularly destructive effector cells or purveyors of immunoregulation?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; immunoregulation; inflammation; innate; antigen presentation; granulocyte	SMOOTH-MUSCLE-CELLS; MAST-CELLS; CHEMOTACTIC ACTIVITIES; AIRWAY INFLAMMATION; LYMPH-NODES; T-CELLS; EXPRESSION; IL-4; ANTIGEN; ASTHMA	Eosinophils are granulocytes typically associated with immune responses to a limited number of specific insults, including helminth infection and exposure to various allergens. Moreover, the overwhelming consensus from the literature is that eosinophils evolved as uniquely destructive leukocytes with cytotoxic activities as an adaptation for host defense. However, recent studies now suggest that the parochial caricature of eosinophils as effector cells with nonspecific killing abilities that evolved as a host defense mechanism against large nonphagotizable parasites is incomplete. A new paradigm has emerged describing eosinophils as initial responders to cell death/tissue damage that are a part of remodeling/repair processes and, more importantly, significant contributors to localized innate and acquired immune responses as well as systemic adaptive immunity. Significantly, this new paradigm does not preclude roles for cosinophils in host defense leading to tissue damage but instead suggests the equal importance of eosinophil-associated regulatory mechanisms modulating local tissue immune responses. The goal of this review is to summarize the data in support of this new paradigm. In turn, we believe that this expanded role provides a probable explanation for the presence of eosinophils in diverse disease settings such as asthma, allergy, cancer, transplant rejection, gastrointestinal inflammation, and viral or helminth infection.	Mayo Clin, Coll Med, Div Pulm Med, Scottsdale, AZ 85259 USA; Mayo Clin, Coll Med, Div Hematol & Oncol, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Lee, JJ (corresponding author), Mayo Clin, Coll Med, Div Pulm Med, SC Johnson Med Res Bldg,13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	jjlee@mayo.edu		Jacobsen, Elizabeth A./0000-0003-2956-753X	NATIONAL CANCER INSTITUTE [R01CA112442] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL085014, R01HL058723, R56HL058723, R01HL065228, F32HL083718] Funding Source: NIH RePORTER; NCI NIH HHS [CA112442] Funding Source: Medline; NHLBI NIH HHS [HL07897, HL65228, F32HL085014, F32 HL083718, HL58723] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen LQ, 2004, J IMMUNOL, V172, P2059, DOI 10.4049/jimmunol.172.4.2059; Cormier SA, 2006, J LEUKOCYTE BIOL, V79, P1131, DOI 10.1189/jlb.0106027; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; DELPOZO V, 1992, EUR J IMMUNOL, V22, P1919; Duez C, 2004, J ALLERGY CLIN IMMUN, V114, P820, DOI 10.1016/j.jaci.2004.08.011; Fryer AD, 2006, J CLIN INVEST, V116, P228, DOI 10.1172/JCI25423; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; Fulkerson PC, 2005, CLIN EXP ALLERGY, V35, P1251, DOI 10.1111/j.1365-2222.2005.02354.x; Gessner A, 2005, J IMMUNOL, V174, P1063, DOI 10.4049/jimmunol.174.2.1063; Gharaee-Kermani M, 1998, INT J MOL MED, V1, P43; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X; Gutierrez-Ramos JC, 2000, IMMUNOL REV, V177, P31, DOI 10.1034/j.1600-065X.2000.17713.x; Joubert P, 2005, J IMMUNOL, V175, P2702, DOI 10.4049/jimmunol.175.4.2702; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL302, DOI 10.1152/ajplung.00158.2001; Lamkhioued B, 1996, ANN NY ACAD SCI, V796, P203, DOI 10.1111/j.1749-6632.1996.tb32582.x; Lampinen M, 2004, ALLERGY, V59, P793, DOI 10.1111/j.1398-9995.2004.00469.x; LEE I, 1995, PATHOL INT, V45, P655, DOI 10.1111/j.1440-1827.1995.tb03518.x; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; Miyahara N, 2005, J IMMUNOL, V174, P4979, DOI 10.4049/jimmunol.174.8.4979; MULLER E, 1977, HISTOCHEMISTRY, V52, P273, DOI 10.1007/BF00495862; Nagase H, 2003, J IMMUNOL, V171, P3977, DOI 10.4049/jimmunol.171.8.3977; Odemuyiwa SO, 2004, J IMMUNOL, V173, P5909, DOI 10.4049/jimmunol.173.10.5909; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Padigel UM, 2006, INFECT IMMUN, V74, P3232, DOI 10.1128/IAI.02067-05; Pang LH, 2006, J IMMUNOL, V176, P3788, DOI 10.4049/jimmunol.176.6.3788; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Puxeddu I, 2005, J ALLERGY CLIN IMMUN, V116, P531, DOI 10.1016/j.jaci.2005.06.007; Raines EW, 2005, J LIPID RES, V46, P1081, DOI 10.1194/jlr.R500004-JLR200; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Sabin EA, 1996, J EXP MED, V184, P1871, DOI 10.1084/jem.184.5.1871; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Shakoory B, 2004, J INTERF CYTOK RES, V24, P271, DOI 10.1089/107999004323065057; Shi HZ, 2004, ALLERGY, V59, P428, DOI 10.1046/j.1398-9995.2003.00405.x; Spina D, 2002, TRENDS PHARMACOL SCI, V23, P311, DOI 10.1016/S0165-6147(02)02022-9; Spoelstra FM, 2001, CLIN EXP ALLERGY, V31, P808, DOI 10.1046/j.1365-2222.2001.01111.x; Stellato C, 2000, CHEM IMMUNOL, V76, P156; Sur S, 1998, J LEUKOCYTE BIOL, V63, P715, DOI 10.1002/jlb.63.6.715; Surquin M, 2002, J IMMUNOL, V169, P500, DOI 10.4049/jimmunol.169.1.500; Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933; Tachimoto H, 2000, CHEM IMMUNOL, V76, P45; Throsby M, 2000, J IMMUNOL, V165, P1965, DOI 10.4049/jimmunol.165.4.1965; van Rijt LS, 2003, J IMMUNOL, V171, P3372, DOI 10.4049/jimmunol.171.7.3372; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Walsh GM, 2001, CLIN EXP ALLERGY, V31, P351, DOI 10.1046/j.1365-2222.2001.01032.x; Watt A. P., 2005, Current Drug Targets - Inflammation and Allergy, V4, P415, DOI 10.2174/1568010054526313; Yang D, 2003, BLOOD, V102, P3396, DOI 10.1182/blood-2003-01-0151	48	146	154	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1313	1320		10.1016/j.jaci.2007.03.043	http://dx.doi.org/10.1016/j.jaci.2007.03.043			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17481717				2022-12-18	WOS:000247232800003
J	Marshall, JS; Jawdat, DM				Marshall, JS; Jawdat, DM			Mast cells in innate immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; innate immunity; effector cells; mediators; histamine; proteases	TOLL-LIKE RECEPTOR-2; NECROSIS-FACTOR-ALPHA; CUTTING EDGE; PSEUDOMONAS-AERUGINOSA; CHEMOKINE PRODUCTION; BACTERIAL CLEARANCE; SIGNAL-TRANSDUCTION; HISTAMINE-RELEASE; DENDRITIC CELLS; HIV-1 INFECTION	Mast cells have been most extensively studied in their traditional role as an early effector cell of allergic disease. However, in the majority of individuals, it might be the role of this cell as a sentinel in host defense that is most important. Mast cells have been repeatedly demonstrated to play a critical role in defense against bacterial infections, and evidence for their involvement in early responses to viral and fungal pathogens is growing. Mast cells are activated during innate immune responses by multiple mechanisms, including well-established responses to complement components. In addition, novel mechanisms have emerged as a result of the explosion of knowledge in our understanding of pattern-recognition receptors. The mast cell shares many features with other innate immune effector cells, such as neutrophils and macrophages. However, a unique role for mast cells is defined not only by their extensive mediator profile but also by their ability to interact with the vasculature, to expedite selective cell recruitment, and to set the stage for an appropriate acquired response.	Dalhousie Univ, Dept Microbiol & Immunol, Dalhousie Inflammat Grp, Halifax, NS B3H 1E2, Canada; Dalhousie Univ, Dept Pathol, Dalhousie Inflammat Grp, Halifax, NS B3H 1E2, Canada	Dalhousie University; Dalhousie University	Marshall, JS (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, Dalhousie Inflammat Grp, Sir Charles Tupper Med Bldg,Coll St, Halifax, NS B3H 1E2, Canada.	jean.marshall@dal.ca	; Jawdat, Dunia/Q-3422-2018	Marshall, Jean S./0000-0002-5642-1379; Jawdat, Dunia/0000-0002-3615-2909				Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arock M, 1998, INFECT IMMUN, V66, P6030, DOI 10.1128/IAI.66.12.6030-6034.1998; Burns AR, 1999, J LEUKOCYTE BIOL, V65, P299, DOI 10.1002/jlb.65.3.299; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; CASTLEMAN WL, 1990, AM J PATHOL, V137, P821; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Coelho-Castelo AAM, 2002, INT J PARASITOL, V32, P1747, DOI 10.1016/S0020-7519(02)00211-4; de Paulis A, 2002, J IMMUNOL, V169, P4559, DOI 10.4049/jimmunol.169.8.4559; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Genovese A, 2003, INT ARCH ALLERGY IMM, V132, P336, DOI 10.1159/000074901; Genovese A, 2000, INFECT IMMUN, V68, P5517, DOI 10.1128/IAI.68.10.5517-5524.2000; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Huang CF, 1998, J IMMUNOL, V160, P1910; KIMMAN TG, 1989, AM J VET RES, V50, P694; King CA, 2002, J VIROL, V76, P8408, DOI 10.1128/JVI.76.16.8408-8419.2002; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; Lin TJ, 2003, INFECT IMMUN, V71, P365, DOI 10.1128/IAI.71.1.365-373.2003; Lin TJ, 2002, J IMMUNOL, V169, P4522, DOI 10.4049/jimmunol.169.8.4522; Malaviya R, 2000, J LEUKOCYTE BIOL, V67, P841, DOI 10.1002/jlb.67.6.841; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; Marone G, 2001, TRENDS IMMUNOL, V22, P229, DOI 10.1016/S1471-4906(01)01903-2; Marone G, 2001, INT ARCH ALLERGY IMM, V125, P89, DOI 10.1159/000053802; Marshall JS, 2003, CURR PHARM DESIGN, V9, P11, DOI 10.2174/1381612033392413; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; McCurdy JD, 2001, J LEUKOCYTE BIOL, V70, P977; McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Nilsson G, 1996, J IMMUNOL, V157, P1693; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; Niyonsaba F, 2002, IMMUNOLOGY, V106, P20, DOI 10.1046/j.1365-2567.2002.01398.x; Okumura S, 2003, BLOOD, V102, P2547, DOI 10.1182/blood-2002-12-3929; OKUMURA S, 2003, BLOOD; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Skokos D, 2003, J IMMUNOL, V170, P3037, DOI 10.4049/jimmunol.170.6.3037; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Supajatura V, 2001, J IMMUNOL, V167, P2250, DOI 10.4049/jimmunol.167.4.2250; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; van Schaik SM, 1999, J ALLERGY CLIN IMMUN, V103, P630, DOI 10.1016/S0091-6749(99)70235-6; Varadaradjalou S, 2003, EUR J IMMUNOL, V33, P899, DOI 10.1002/eji.200323830; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Woolhiser MR, 2001, EUR J IMMUNOL, V31, P3298, DOI 10.1002/1521-4141(200111)31:11<3298::AID-IMMU3298>3.0.CO;2-U	56	146	162	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					21	27		10.1016/j.jaci.2004.04.045	http://dx.doi.org/10.1016/j.jaci.2004.04.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241339				2022-12-18	WOS:000222534300003
J	Kainulainen, L; Varpula, M; Liippo, K; Svedstrom, E; Nikoskelainen, J; Ruuskanen, O				Kainulainen, L; Varpula, M; Liippo, K; Svedstrom, E; Nikoskelainen, J; Ruuskanen, O			Pulmonary abnormalities in patients with primary hypogammaglobulinemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hypogammaglobulinemia; common variable immunodeficiency; X-linked agammaglobulinemia; bronchiectasis; high-resolution computed tomography; immunoglobulin replacement therapy	COMMON VARIABLE IMMUNODEFICIENCY; COMPUTED-TOMOGRAPHY; CYSTIC-FIBROSIS; DRUG-THERAPY; LUNG-DISEASE; BRONCHIECTASIS; DISORDERS	Background: Pulmonary complications are common in patients with primary hypogammaglobulinemia. Intravenous immunoglobulin replacement therapy has been thought to reduce the occurrence of pulmonary complications, yet they do occur. Objective: The purpose of this study was to evaluate pulmonary abnormalities in 22 patients with primary hypogammaglobulinemia (18 with common variable immunodeficiency; 4 with X-linked agammaglobulinemia) and to conduct a prospective 3-year follow-up study to assess the possible progression of pulmonary abnormalities. Methods: Pulmonary changes were evaluated with use of pulmonary imaging (chest radiographs, high-resolution computed tomography), and pulmonary function testing. Results: High-resolution computed tomography revealed pulmonary abnormalities in 21 patients. Bronchiectasis was present in 16 patients, whereas chest radiographs revealed bronchiectasis in only 3 patients. Pulmonary function testing showed obstruction in 5 patients. zi prospective 3-year follow-up was conducted in IJ patients. It showed silent progression of bronchiectasis in 5 of the 14 patients, all of whom were receiving intravenous immunoglobulin replacement therapy and had preinfusion serum IgG concentrations of 5 gn or more. Conclusions: Pulmonary abnormalities develop in most patients with primary hypogammaglobulinemia. A new finding is that silent and asymptomatic progression of pulmonary changes may occur in patients despite an adequate immunoglobulin replacement therapy. High-resolution computed tomography is the method of choice in monitoring pulmonary changes.	Turku Univ Hosp, Dept Pediat, Turku 20500, Finland; Turku Univ Hosp, Dept Diagnost Radiol, Turku 20500, Finland; Turku Univ Hosp, Dept Pulm Dis, Turku 20500, Finland; Turku Univ Hosp, Dept Med, Turku 20500, Finland	University of Turku; University of Turku; University of Turku; University of Turku	Kainulainen, L (corresponding author), Turku Univ Hosp, Dept Pediat, Vaha Hameenkatu 1 A 3, Turku 20500, Finland.			Kainulainen, Leena/0000-0002-7776-3626				ASTON C, 1995, AM J RESP CRIT CARE, V151, P1597, DOI 10.1164/ajrccm.151.5.7537587; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BRODY AR, 1981, EXP LUNG RES, V2, P207, DOI 10.3109/01902148109052316; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; CHAPMAN HA, 1986, AM REV RESPIR DIS, V133, P437; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CURTIN JJ, 1991, CLIN RADIOL, V44, P82, DOI 10.1016/S0009-9260(05)80501-X; DUKES RJ, 1978, THORAX, V33, P603, DOI 10.1136/thx.33.5.603; ESKOLA J, 1989, J CLIN LAB IMMUNOL, V28, P55; IP M, 1993, RESP MED, V87, P449, DOI 10.1016/0954-6111(93)90072-8; JONES CGL, 1995, EUR RESPIR J, V8, P1479; Kainulainen L, 1999, AM J RESP CRIT CARE, V159, P1199, DOI 10.1164/ajrccm.159.4.9807067; KONSTAN MW, 1995, NEW ENGL J MED, V332, P848, DOI 10.1056/NEJM199503303321303; Kotilainen P, 1996, J INTERN MED, V240, P103, DOI 10.1046/j.1365-2796.1996.497838000.x; Manson D, 1997, PEDIATR RADIOL, V27, P794, DOI 10.1007/s002470050235; NAIDICH DP, 1982, J COMPUT ASSIST TOMO, V6, P437, DOI 10.1097/00004728-198206000-00001; OBREGON RG, 1994, CHEST, V106, P490, DOI 10.1378/chest.106.2.490; Punnonen J, 1997, SCAND J IMMUNOL, V45, P203, DOI 10.1046/j.1365-3083.1997.d01-381.x; RAMSEY BW, 1993, NEW ENGL J MED, V328, P1740, DOI 10.1056/NEJM199306173282403; ROIFMAN CM, 1987, LANCET, V1, P1075; Rosen FS, 1997, CLIN EXP IMMUNOL, V109, P1; STOCKLEY RA, 1987, CLIN CHEST MED, V8, P481; SWEINBERG SK, 1991, J ALLERGY CLIN IMMUN, V88, P96, DOI 10.1016/0091-6749(91)90306-9; TUDDENHAM WJ, 1984, AM J ROENTGENOL, V143, P509, DOI 10.2214/ajr.143.3.509; VILJANEN AA, 1982, SCAND J CLIN INVES S, V159, P1; WATTS WJ, 1986, AM REV RESPIR DIS, V134, P699	26	146	149	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1031	1036		10.1016/S0091-6749(99)70085-0	http://dx.doi.org/10.1016/S0091-6749(99)70085-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550749				2022-12-18	WOS:000083778400027
